<SEC-DOCUMENT>0001641172-25-001011.txt : 20250328
<SEC-HEADER>0001641172-25-001011.hdr.sgml : 20250328
<ACCEPTANCE-DATETIME>20250327210617
ACCESSION NUMBER:		0001641172-25-001011
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250328
DATE AS OF CHANGE:		20250327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioRestorative Therapies, Inc.
		CENTRAL INDEX KEY:			0001505497
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				301341024
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37603
		FILM NUMBER:		25781182

	BUSINESS ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
		BUSINESS PHONE:		(631) 760-8100

	MAIL ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stem Cell Assurance, Inc.
		DATE OF NAME CHANGE:	20101110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:BRTX="http://biorestorative.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_BRTX_biorestorative.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001505497 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001505497</ix:nonNumeric>
  <ix:nonFraction name="BRTX:DeferredOfferingCost" contextRef="AsOf2023-12-31" id="xdx2ixbrl0087" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0125" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0126" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0195" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GrantIncome" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GainOnExchangeOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0228" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GainOnExchangeOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:PaymentsForProceedsFromDeferredOfferingCosts" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:IssuanceOfCommonStockHeldInAbeyance" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_us-gaap_ProductMember" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2024-12-31_srt_MinimumMember" id="xdx2ixbrl0595" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl0645" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2024-12-31_custom_PatentsAndTrademarksMember" id="xdx2ixbrl0738" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xs:nil="true"></ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31_custom_PatentsAndTrademarkMember" id="xdx2ixbrl0750" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_custom_PatentsAndTrademarkMember" id="xdx2ixbrl0762" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1001" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl1013" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-12-31" id="xdx2ixbrl1021" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember29066796" id="xdx2ixbrl1085" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember29066796" id="xdx2ixbrl1089" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1091" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:DeferredTaxAssetsRightOfUseAsset" contextRef="AsOf2024-12-31" id="xdx2ixbrl1144" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="AsOf2024-12-31" id="xdx2ixbrl1162" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1177" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1178" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1189" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1190" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1199" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1231" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="xdx2ixbrl1266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl1270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2023-12-31" id="xdx2ixbrl1273" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-12-31" id="xdx2ixbrl1274" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl1276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl1278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="brtx-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-062024-11-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-06</xbrli:startDate>
        <xbrli:endDate>2024-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RoyaltyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RoyaltyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ComputerSoftwareAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ComputerSoftwareAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ManufacturingEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ManufacturingEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PatentsAndTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PatentsAndTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PatentsAndTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-082022-09-08_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-08</xbrli:startDate>
        <xbrli:endDate>2022-09-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-082022-09-08_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-08</xbrli:startDate>
        <xbrli:endDate>2022-09-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-242022-10-25_us-gaap_CommonClassBMember_custom_AuctusFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-24</xbrli:startDate>
        <xbrli:endDate>2022-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-242022-10-25_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-24</xbrli:startDate>
        <xbrli:endDate>2022-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-04_custom_AuctusFundLLCMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-04_custom_AuctusFundLLCMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-18_custom_TwoThousandTwentyOneStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-22_custom_TwoThousandAndTwentyOneStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-23_custom_TwoThousandAndTwentyOneStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-04-30_us-gaap_CommonStockMember_custom_DemandSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:DemandSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-122023-07-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-12</xbrli:startDate>
        <xbrli:endDate>2023-07-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_ATMProgramMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-06_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-062024-02-06_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-06</xbrli:startDate>
        <xbrli:endDate>2024-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-062024-02-06_us-gaap_CommonStockMember_custom_AuctusFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-06</xbrli:startDate>
        <xbrli:endDate>2024-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-062024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-06</xbrli:startDate>
        <xbrli:endDate>2024-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-052024-02-05_us-gaap_CommonStockMember_custom_RothCapitalPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-05</xbrli:startDate>
        <xbrli:endDate>2024-02-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember_custom_RothCapitalPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExistingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_NewWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:NewWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:NewWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember29065375">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember29065765">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember29066796">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SectionThreeHundredAndEightyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:SectionThreeHundredAndEightyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MelvilleLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_custom_ExistingWarrantMember_custom_BlackScholesOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BlackScholesOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BlackScholesOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_BlackScholesOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_BlackScholesOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ExistingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_custom_ExistingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_custom_ExistingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_custom_ExistingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ExistingWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-27_us-gaap_SubsequentEventMember_custom_AuctusFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="xdx2ixbrl0337" toRefs="Footnote000406"/>
  <ix:relationship fromRefs="Fact000338" toRefs="Footnote000406"/>
  <ix:relationship fromRefs="Fact000339" toRefs="Footnote000406"/>
  <ix:relationship fromRefs="xdx2ixbrl0340" toRefs="Footnote000406"/>
  <ix:relationship fromRefs="Fact000341" toRefs="Footnote000406"/>
  <ix:relationship fromRefs="Fact000343" toRefs="Footnote000406"/>
  <ix:relationship fromRefs="Fact000486" toRefs="Footnote000524"/>
  <ix:relationship fromRefs="xdx2ixbrl0487" toRefs="Footnote000524"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_900_edei--DocumentType_c20240101__20241231_zky6jP080sj2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000012" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--DocumentAnnualReport_c20240101__20241231_zsRy74xKyK7l"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000013" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE FISCAL YEAR ENDED <span id="xdx_90A_edei--DocumentPeriodEndDate_c20240101__20241231_z1e3D6CoQMX7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000014" name="dei:DocumentPeriodEndDate"><span id="xdx_903_edei--CurrentFiscalYearEndDate_c20240101__20241231_zRWzDHZ9VPy8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000015" name="dei:CurrentFiscalYearEndDate">DECEMBER 31</ix:nonNumeric></span>, <span id="xdx_90F_edei--DocumentFiscalYearFocus_c20240101__20241231_z59Z4I4m4Zi1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000016" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--DocumentTransitionReport_c20240101__20241231_zQPRYlvSXSR8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000017" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE TRANSITION PERIOD FROM__________ TO__________</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number <b><span style="text-decoration: underline"><span id="xdx_901_edei--EntityFileNumber_c20240101__20241231_zdTAojULNM16"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000018" name="dei:EntityFileNumber">001-37603</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_901_edei--EntityRegistrantName_c20240101__20241231_zLHl91vum1o8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000019" name="dei:EntityRegistrantName">BIORESTORATIVE
THERAPIES, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20240101__20241231_zLEJn9PVfDv9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20240101__20241231_zaYmBCnpjlM8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityTaxIdentificationNumber">30-1341024</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction <br/>
    of incorporation or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer <br/>
    Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20240101__20241231_z10ztI1L5Bt6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000022" name="dei:EntityAddressAddressLine1">40
    Marcus Drive</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressAddressLine2_c20240101__20241231_zTBVrASbpUo4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000023" name="dei:EntityAddressAddressLine2">Suite 1</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressCityOrTown_c20240101__20241231_zK3IOOn8Iedk"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000024" name="dei:EntityAddressCityOrTown">Melville</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20240101__20241231_zPQinQSGWqql"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000025" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressPostalZipCode_c20240101__20241231_zdFdjX891z98"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:EntityAddressPostalZipCode">11747</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90C_edei--CityAreaCode_c20240101__20241231_zO9r1MaJLvWb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:CityAreaCode">(631)</ix:nonNumeric></span>
<span id="xdx_903_edei--LocalPhoneNumber_c20240101__20241231_zCXbPwbOTH36"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000028" name="dei:LocalPhoneNumber">760-8100</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--Security12bTitle_c20240101__20241231_zqcGfLvD8iyg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000029" name="dei:Security12bTitle">Common
    Stock $0.0001 par value</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--TradingSymbol_c20240101__20241231_zqYqs7VUueSb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000030" name="dei:TradingSymbol">BRTX</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--SecurityExchangeName_c20240101__20241231_zBeaROmrOtmj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of Class)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;&#9744;&#160;<span id="xdx_907_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_zCHFUIxhBtT4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000032" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes&#160;&#9744;&#160;<span id="xdx_906_edei--EntityVoluntaryFilers_c20240101__20241231_zIwQilC4vTm6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000033" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_906_edei--EntityCurrentReportingStatus_c20240101__20241231_zN1zPLpdsSOh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000034" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#9746;&#160;No&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
<span id="xdx_90A_edei--EntityInteractiveDataCurrent_c20240101__20241231_zAfvxwHU6Pr5"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000035" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#9746;&#160;No&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer&#160;&#9744;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
filer&#160;&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityFilerCategory_c20240101__20241231_zGvmLijfwqW8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000036" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span>&#160;&#9746;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
reporting company&#160;<span id="xdx_901_edei--EntitySmallBusiness_c20240101__20241231_zj66YXrgHF15"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000037" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&#160;<span id="xdx_908_edei--EntityEmergingGrowthCompany_c20240101__20241231_zXUp94BjF6Zh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_90C_edei--IcfrAuditorAttestationFlag_c20240101__20241231_zYtzCIafWim5"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000039" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.<span id="xdx_90E_edei--DocumentFinStmtErrorCorrectionFlag_c20240101__20241231_zzEo5yeaXiXj"> <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000040" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based
compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to
&#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; No <span id="xdx_908_edei--EntityShellCompany_dbF_c20240101__20241231_zFh62oXKLY65"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000041" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which
the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s
most recently completed second fiscal quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2024, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was $<span id="xdx_90B_edei--EntityPublicFloat_iI_c20240630_zLa7UArvQORe"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-30" id="Fact000042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,463,696</ix:nonFraction></span>
based on the closing sale price as reported on the Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLICABLE
ONLY TO REGISTRANTS INVOLVED IN BANKRUPTCY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROCEEDINGS
DURING THE PRECEDING FIVE YEARS:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the
Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. <span id="xdx_903_edei--EntityBankruptcyProceedingsReportingCurrent_c20240101__20241231_zmuQtCz8RzH6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000043" name="dei:EntityBankruptcyProceedingsReportingCurrent">Yes</ix:nonNumeric></span>
&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 26, 2025, there were <span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_c20250326_zVa3RWOcutV6"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-03-26" id="Fact000044" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,504,780</ix:nonFraction></span> shares of common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS
INCORPORATED BY REFERENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--DocumentsIncorporatedByReferenceTextBlock_c20240101__20241231_z8ZuyQBNzV1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000045" name="dei:DocumentsIncorporatedByReferenceTextBlock">None</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 0.1in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_001">Forward-Looking Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#me_002">PART I</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_003">Business.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_004">Risk Factors.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#aa_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved].</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>Other Information.</span></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#aa_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART III</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#aa_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART IV</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits and Financial Statement Schedules.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#aa_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K Summary.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#aa_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signatures</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="me_002"></span>PART
I</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="me_001"></span>Forward-Looking
Statements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking
statements contained in this Annual Report may not occur. Generally, these statements relate to business plans or strategies, projected
or anticipated benefits or other consequences of our plans or strategies, projected or anticipated benefits from acquisitions to be made
by us, or projections involving anticipated revenues, earnings or other aspects of our operating results. The words &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221;
&#8220;intend,&#8221; &#8220;estimate,&#8221; and &#8220;continue,&#8221; and their opposites and similar expressions are intended to
identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are
subject to a number of uncertainties, risks and other influences, many of which are beyond our control, that may influence the accuracy
of the statements and the projections upon which the statements are based. Factors which may affect our results include, but are not
limited to, the risks and uncertainties discussed in Item 1A of this Annual Report (&#8220;Risk Factors&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking
statements made by us ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from
those expressed or implied in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking
statements, whether from new information, future events or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Intellectual
Property</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report includes references to our federally registered trademarks, <i>BioRestorative Therapies</i> and <i>Dragonfly</i> design,
<i>BRTX-100</i>, <i>ThermoStem</i> and <i>BRTX</i>. The <i>Dragonfly </i>logo is also registered with the U.S. Copyright Office. This
Annual Report also includes references to trademarks, trade names and service marks that are the property of other organizations. Solely
for convenience, trademarks and trade names referred to in this Annual Report appear without the &#174;, SM or &#8482; symbols, and copyrighted
content appears without the use of the symbol &#169;, but the absence of use of these symbols does not reflect upon the validity or enforceability
of the intellectual property owned by us or third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_003"></span>ITEM
    1.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BUSINESS</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
<span style="text-decoration: underline">Business Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Annual Report on Form 10-K, or the Annual Report, references to the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;,
or &#8220;our&#8221; refer to BioRestorative Therapies, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in Nevada on June 13, 1997. On August 15, 2011, we changed our name from &#8220;Stem Cell Assurance, Inc.&#8221; to
&#8220;BioRestorative Therapies, Inc.&#8221; Effective January 1, 2015, we reincorporated in Delaware. Effective December 31, 2022, we
reincorporated in Nevada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
develop therapeutic products using cell and tissue protocols, primarily involving adult stem cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently pursuing our <i>Disc/Spine Program</i> with our initial investigational therapeutic product being called <i>BRTX-100</i>.
In March 2022, a United States patent issued in our <i>Disc/Spine Program</i>. We submitted an investigational new drug, or IND, application
to the U.S. Food and Drug Administration, or the FDA, to obtain authorization to commence a Phase 2 clinical trial investigating the
use of <i>BRTX-100</i> in the treatment of chronic lower back pain arising from degenerative disc disease. We have received such authorization
from the FDA and have commenced such clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have obtained an exclusive license to use technology for investigational adult stem cell treatment of disc and spine conditions, including
protruding and bulging lumbar discs. The technology is an advanced stem cell injection procedure that may offer relief from lower back
pain, buttock and leg pain, and numbness and tingling in the leg and foot.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also developing our <i>ThermoStem Program</i>. This pre-clinical program involves the use of brown adipose (fat) in connection with
the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
Patents related to the <i>ThermoStem Program</i> have been issued in the United States and other jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we operate a commercial biocosmeceuticals business. Our current commercial product, formulated and manufactured as a third party contract manufacturer using our cGMP ISO-7
certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has
been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness.
We also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic
products and therapeutics via IND-enabling studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
Events During 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2024, we issued 2,000,000 shares of our common stock pursuant to the exercise of warrants. In connection with the issuance,
we issued warrants for the purchase of 2,513,686 shares of our common stock and are obligated to issue an additional 1,138,055 shares
of our common stock, which additional shares have been fully paid for but have not yet been issued due to a maximum beneficial ownership
limitation for one of the warrant holders. We received gross proceeds of approximately $8,100,000 from the warrant exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2024, we announced that the FDA cleared an important amendment to the protocol of our ongoing Phase 2 study investigating the use
of <i>BRTX-100</i>. The protocol amendment removes saline injection in the control arm of the study and replaces it with a sham injection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2024, we announced that we entered into a five-year exclusive supply agreement with Cartessa Aesthetics, LLC, or Cartessa, a leading
North American based aesthetic company. The agreement provides for the supply by us of pre-set minimum quantities of finished vials of
a proprietary cell-based biologic serum to Cartessa annually as private label under Cartessa&#8217;s Chronos ExoCR mark.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2024, we announced our development of a novel exosome-based biologic program targeting obesity. The new therapeutic candidate, developed
using our patented <i>ThermoStem</i> platform, has the potential to serve as an adjuvant to existing pharmaceuticals that are FDA approved
and marketed towards weight loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2024, a Japanese patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, we announced that we received a provisional license from the New York State Department of Health, or the NYSDOH, for the
processing of allogeneic (non-autologous) donor tissue material for the isolation, expansion and cryopreservation of various cell types,
including stem cells, for medical research. Previously, we were licensed by the NYSDOH to act as a tissue bank for the processing of
mesenchymal stem cells derived from autologous donors only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, we announced new preliminary 26&#8211;52 week blinded data from the first 10 patients with chronic lumbar disc disease,
or cLDD, enrolled in our ongoing Phase 2 clinical trial of <i>BRTX-100</i>. No serious adverse events were reported in any of the 10
safety run-in subjects. In addition, there was no dose limiting toxicity at 26-52 weeks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, we entered into an At The Market Offering Agreement, or the Offering Agreement, with Rodman &amp; Renshaw LLC, or Rodman,
pursuant to which we may offer and sell, from time to time, through or to Rodman, shares of our common stock having an aggregate offering
price of up to approximately $3.6 million. To date, we have sold approximately $1.1 million of our shares pursuant to the Offering Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
Events During 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2025, we announced new preliminary 26&#8211;52 week blinded data from the first 15 patients with cLDD enrolled in our ongoing
Phase 2 clinical trial of <i>BRTX-100</i>. No serious adverse events were reported in any of the 15 subjects. In addition, there was
no dose limiting toxicity at 26-52 weeks. Further, we announced certain positive preliminary data analyses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">In February 2025, a European patent related to our
<i>ThermoStem Program </i>was issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">In March 2025, an Israeli patent related to our <i>ThermoStem
Program</i> was issued.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
<span style="text-decoration: underline">Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
develop therapeutic products, using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described
below, relate to the treatment of disc/spine disease and metabolic disorders:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disc/Spine
    Program (brtxDisc). </i></b>Our lead cell therapy candidate, <i>BRTX-100</i>, is a product formulated from autologous (or a person&#8217;s
    own) cultured mesenchymal stem cells, or MSCs, collected from the patient&#8217;s bone marrow. We intend that the product will be
    used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure.
    The <i>BRTX-100</i> production process utilizes proprietary technology and involves collecting a patient&#8217;s bone marrow, isolating
    and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, <i>BRTX-100 </i>is to be
    injected by a physician into the patient&#8217;s damaged disc. The treatment is intended for patients whose pain has not been alleviated
    by non-surgical procedures and who potentially face the prospect of surgery. We have received authorization from the FDA to commence
    a Phase 2 clinical trial using <i>BRTX-100</i> to treat chronic lower back pain arising from degenerative disc disease. We have commenced
    such clinical trial through the execution of a CRO agreement with PRC Clinical, the execution of clinical trial site agreements,
    patient enrollment, the commencement of patient procedures, the purchase of manufacturing equipment and the expansion of our laboratory
    to include capabilities for clinical production. In March 2022, a United States patent related to our <i>Disc/Spine Program </i>was
    issued. We have been granted exclusive license rights with regard to the patent. See &#8220;Disc/Spine Program&#8221; below.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Metabolic
    Program (ThermoStem)</i></b>. We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown
    adipose (fat) derived stem cells, or BADSC, to generate brown adipose tissue, or BAT. We refer to this as our <i>ThermoStem Program</i>.
    BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical
    research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced
    glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity
    and diabetes. Patents related to the <i>ThermoStem Program</i> have been issued in the United States and other jurisdictions. See
    &#8220;Metabolic Brown Adipose (Fat) Program&#8221; below.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>BioCosmeceuticals</i></b>:
    We operate a commercial biocosmeceutical platform. Our current commercial product, formulated and manufactured as a third party contract manufacturer using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors.
    This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring
    forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial
    offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the
    aim of pioneering FDA approvals in the emerging biocosmeceuticals space.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to
the spine and discs (and other parts of the body). We anticipate that FDA approval or clearance will be necessary for this device prior
to commercialization. We do not intend to utilize this device in connection with our Phase 2 clinical trial with regard to <i>BRTX-100</i>.
See &#8220;Curved Needle Device&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patents and patent applications for the <i>Disc/Spine Program</i>, the <i>ThermoStem Program</i> and the curved needle device are listed
below under &#8220;Technology; Research and Development.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
human being has stem cells in his or her body. These cells exist from the early stages of human development until the end of a person&#8217;s
life. Throughout our lives, our body continues to produce stem cells that regenerate to produce differentiated cells that make up various
aspects of the body such as skin, blood, muscle and nerves. These are generally referred to as adult (non-embryonic) stem cells. These
cells are important for the purpose of medical therapies aiming to replace lost or damaged cells or tissues or to otherwise treat disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regenerative
cell therapy relies on replacing diseased, damaged or dysfunctional cells with healthy, functioning ones or repairing damaged or diseased
tissue. A great range of cells can serve in cell therapy, including cells found in peripheral and umbilical cord blood, bone marrow and
adipose (fat) tissue. Physicians have been using adult stem cells from bone marrow to treat various blood cancers for more than 65 years
(the first successful bone marrow transplant was performed in 1956). Recently, physicians have begun to use stem cells to treat various
other diseases. We intend to develop cell and tissue products and regenerative therapy protocols, primarily involving adult stem cells,
to allow patients to undergo cellular-based treatments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are concentrating initially on therapeutic areas in which risk to the patient is low, recovery is relatively easy, results can be demonstrated
through sufficient clinical data, and patients and physicians will be comfortable with the procedure. We believe that there will be readily
identifiable groups of patients who will benefit from these procedures. We also believe that these procedures will be significantly less
expensive than the most common surgical procedure alternatives and will compare favorably, over the long-term, to conservative treatment
costs which may persist for years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
we have focused our initial developmental efforts on cellular-based therapeutic products and clinical development programs in selective
areas of medicine for which the treatment protocol is minimally invasive. Such areas include the treatment of the disc and spine and
metabolic-related disorders. Upon regulatory approval, we will seek to obtain third party reimbursement for our products and procedures;
however; if we are not successful, patients may be required to pay for our products and procedures out of pocket in full and without
the ability to be reimbursed by any governmental and other third party payers, which would adversely impact our prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have undertaken research and development efforts in connection with the development of investigational therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. See &#8220;Disc/Spine Program,&#8221; &#8220;Metabolic
Brown Adipose (Fat) Program&#8221; and &#8220;Curved Needle Device&#8221; below. As a result of these programs, we have seven United
States patents, sixteen foreign patents, one United States patent application, and two foreign patent applications related to research
regarding our <i>ThermoStem Program.</i> We have also obtained licenses for two United States patent applications related to our <i>Disc/Spine
Program, </i>one United States patent related to our <i>Disc/Spine Program,</i> and a license for one United States patent related to
a curved needle device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a research laboratory facility with current Good Manufacturing Practice, or cGMP, capabilities to produce clinical grade
products and we will seek to further develop cellular-based treatments, products and protocols, stem cell-related intellectual property,
or IP, and translational research applications. See &#8220;Laboratory&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated any significant revenues to date. In November 2021, we completed a $23,000,000 public offering of our securities.
In 2023, we raised approximately $2,680,000 in additional gross proceeds through public offerings of our securities. In February
2024, we also received approximately $8,100,000 in gross proceeds pursuant to the exercise of warrants and in February 2025, we
received approximately $1,084,000 of gross proceeds pursuant to what is commonly is referred to as an &#8220;at-the-market&#8221;
program with Rodman &amp; Renshaw, LLC (the &#8220;2024 ATM&#8221;). As of the date of this filing, we have the ability to raise an
additional approximately $2,530,000 under the 2024 ATM. Our BRTX-100 program has been granted a fast track designation by the FDA
which may result in a reduction in the length of time required to complete our Phase 2 clinical trial and consequently a reduction
in the costs involved. However, notwithstanding the above, we believe that our current funds may not be sufficient for us to complete our Phase 2 clinical trial investigating the use of <i>BRTX</i>-<i>100</i>
in the treatment of chronic lower back pain arising from degenerative disc disease, as further described in this section, continue
our pre-clinical research and development efforts with respect to our <i>ThermoStem Program</i> and satisfy our current working
capital needs through the end of the 12 month period following the date of the financial statements included in this Annual Report.
In addition, the implementation of our business plan, as discussed below, will require the receipt of significant additional
financing to fund our research and development efforts, including our contemplated Phase 3 clinical trial with regard to <i>BRTX-100</i>
and our contemplated clinical trials relating to our <i>ThermoStem Program</i>, and otherwise fund our operations. We intend to seek
to raise capital through our 2024 ATM and warrant exercises as well as through investment bankers and from biotech funds, strategic
partners and other financial institutions. No assurance can be given that the amount of funding that we anticipate may be required
for the above purposes is correct or that we will be able to accomplish our goals within the timeframes projected. In addition, no
assurance can be given that we will be able to obtain any required financing on commercially reasonable terms or otherwise. If we
are unable to obtain adequate funding, we may be required to significantly curtail or discontinue our proposed
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disc/Spine
Program</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the initiatives that we are currently pursuing is our <i>Disc/Spine Program</i>, with our initial product candidate being called <i>BRTX-100</i>.
We have obtained an exclusive license (see &#8220;<i>Exclusive License</i>&#8221; below) that permits us to use technology for adult
stem cell treatment of disc and spine conditions. The technology is an advanced stem cell culture and injection procedure into the intervertebral
disc, or IVD, that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower
back pain is the most common, most disabling, and most costly musculoskeletal ailment faced worldwide. According to a 2016 market report
from Trinity Partners, a global life sciences consulting firm, of the 250 million American adults, nearly 25 million have chronic lower
back pain of which approximately 12 million have been diagnosed with and treated for disc degeneration and approximately 5.6 million
have pain caused by a protruding or injured disc. We believe that between 500,000 and one million invasive surgical procedures are performed
each year to try to alleviate the pain associated with these lower back conditions and that such procedures cost approximately $40 billion.
Clinical studies have documented that the source of the pain is most frequently damage to the IVD. This can occur when forces, whether
a single load or repetitive microtrauma, exceed the IVD&#8217;s inherent capacity to resist those loads. Aging, obesity, smoking, lifestyle,
and certain genetic factors may predispose one to an IVD injury. Current surgical approaches to back pain are extremely invasive (often
altering the spine&#8217;s biomechanics unfavorably and predisposing it to further disc degeneration) and are associated with unacceptably
low success rates (with a second operation occurring 10% to 20% of the time). In addition, current surgical approaches are costly with
spinal fusion surgery costing approximately $110,000, discectomy costing approximately $20,000 to $50,000 and disc replacement surgery
costing approximately $80,000 to $150,000. Even conservative treatments can be costly, with oral medications costing between $1,000 and
$2,000 per year, injection treatments costing approximately $8,000 per year and physical therapy costing approximately $20,000 annually.
We anticipate that the cost of a single treatment using <i>BRTX-100</i> will compare favorably to conservative treatments which may continue
for years and will be less expensive than the most common surgical procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
once thought to be benign, the natural history of lower back pain is often one of chronic recurrent episodes of pain leading to progressive
disability. This is believed to be a direct result of the IVD&#8217;s poor healing capacity after injury. The IVD is the largest avascular
(having few or no blood vessels) structure in the body and is low in cellularity. Therefore, its inherent capacity to heal after injury
is poor. The clinical rationale of <i>BRTX-100</i> is to deliver a high concentration of the patient&#8217;s own cultured MSCs into the
site of pathology to promote healing and relieve pain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed a mesenchymal stem cell product candidate, <i>BRTX-100, </i>derived from autologous (or a person&#8217;s own) human bone
marrow, cultured and formulated, in a proprietary method, specifically for introduction into a painful lumbar disc. The product candidate
was developed utilizing in part the exclusive license described below under &#8220;<i>Exclusive License</i>.&#8221; As described below
under &#8220;<i>BRTX-100</i>&#8221; and &#8220;<i>Production and Delivery</i>,&#8221; <i>BRTX-100</i> is a hypoxic (low oxygen) stem
cell product developed through a culturing process. In order to enhance the survivability of our bone marrow-derived MSCs in the avascular
environment of the damaged disc, <i>BRTX-100 </i>is designed to expand under hypoxic conditions. This process is intended to result in
a large cell count population with enhanced viability and therapeutic potential following injection into the injured disc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2017, pursuant to an IND application, we received authorization from the FDA to commence a Phase 2 clinical trial investigating
the use of <i>BRTX-100</i>, our lead cell therapy candidate, in the treatment of chronic lower back pain arising from degenerative disc
disease. We have commenced our Phase 2 clinical trial through the execution of a CRO agreement with PRC Clinical, the execution of clinical
trial site agreements, patient enrollment, the commencement of patient procedures, the purchase of manufacturing equipment and the expansion
of our laboratory to include capabilities for clinical production. We believe that, based upon our periodic reports to the FDA as to
the commencement of the clinical trial, the existing IND remains effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to developing <i>BRTX-100</i>, we may also seek to sublicense the technology to a strategic third party, who may assist in gaining
FDA approval for a lumbar disc indication, or third parties for use in connection with cellular-based developmental programs with regard
to disc and spine related conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a laboratory, which includes a clean room facility, to perform the production of cell products (including <i>BRTX-100</i>)
for use in our clinical trials, for third party cell products or for general research purposes. We may also use this laboratory to develop
our pipeline of future products and expand our stem cell-related IP. See &#8220;Laboratory&#8221; and &#8220;Technology; Research and
Development&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, a United States patent related to <i>BRTX-100</i> was issued. We have been granted exclusive license rights with respect
to the patent. See &#8220;<i>Exclusive License</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>BRTX-100</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead product candidate<i>, BRTX-100,</i> is an autologous hypoxic (low oxygen) cultured mesenchymal stem cell product derived from a
patient&#8217;s own bone marrow and formulated with a proprietary biomaterial carrier (platelet lysate) to increase potency, viability
and survivability. We have designed the cryopreserved sterile cellular product candidate to be provided in vials for injection into painful
lumbar discs. We anticipate the product candidate will be delivered using a standard 20 gauge 3.5 inch introducer needle and a 25 gauge
6 inch needle that will extend into the disc center upon delivery. Upon regulatory approval, we plan to provide training to medical practitioners
with regard to the approved injection procedure. It is anticipated that the delivery of the product candidate will be a 30 minute procedure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mesenchymal
stem cells used in <i>BRTX-100 </i>are similar to other MSCs under development by others; however, in order to enhance the survivability
of our bone marrow-derived MSCs in the avascular environment of the damaged disc, <i>BRTX-100 </i>is designed to expand under hypoxic
conditions for a period of approximately three weeks. This process is intended to result in an approximate 40 million cell count population
with enhanced viability and therapeutic potential following injection locally into injured spinal discs. Publications and scientific
literature have indicated that MSCs preconditioned in hypoxic environment show enhanced skeletal muscle regeneration properties and improved
impacts upon circulation and vascular formation compared to MSCs cultured under normoxic (normal oxygen) conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the <i>Journal of Translational Medicine</i> published the results of our study evaluating the benefits of long-term hypoxic
culturing of human bone marrow-derived MSCs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2021, we were awarded a National Institutes of Health Small Business Technology Transfer (STTR) Phase 1 grant for $256,000
to evaluate the therapeutic effects on our hypoxic cultured bone marrow derived mesenchymal stem cells (<i>BRTX-100</i>) after encapsulation
with a PEG-peptide hydrogel. The work is being done in collaboration with Washington University of St. Louis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
June 2022, we have entered into clinical trial agreements with 16 sites to conduct our Phase 2 clinical trial targeting chronic lumbar
disc disease. See &#8220;<i>Clinical Trial</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Production
and Delivery</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production of our product candidate, <i>BRTX-100, </i>begins with the physician collecting bone marrow from the patient under local anesthesia.
Peripheral blood is also collected from the patient. The physician will then send the patient&#8217;s bone marrow and blood samples to
our laboratory (or a contract laboratory) for culturing and formulation. The hypoxic culturing process is intended to result in the selection
of a cell population that is suitable for an improved possibility of survival in the internal disc environment. We anticipate that the
cell culturing process and product formulation will take approximately three weeks, with an additional two weeks required for quality
control testing required to meet product release criteria. We will then send the therapeutic cryopreserved stem cells (<i>BRTX-100</i>)
in a sterile vial back to the physician&#8217;s offices where it will undergo a controlled thaw prior to the procedure. The price structure
for the procedure and our services has not been determined and no assurances can be given as to the effect that such price structure
will have on the marketability of such procedure and services. The following illustrates the process:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="form10-k_001.jpg" alt=""/>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exclusive
License</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our license agreement with Regenerative Sciences, LLC, or Regenerative, that became effective in April 2012, or the Regenerative License
Agreement, we have obtained, among other things, a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license from
Regenerative to utilize or sublicense a certain method for culturing cells for use in our developmental program involving disc and spine
conditions, including protruding or painful discs and the treatment of avascular zones. The investigational technology that has been
licensed is an advanced stem cell culture and injection procedure that may offer relief from lower back pain, buttock and leg pain, and
numbness and tingling in the leg and foot. Pursuant to the Regenerative License Agreement, we have also obtained a worldwide, exclusive,
royalty-bearing license from Regenerative to utilize or sublicense a certain investigational curved needle device for the administration
of specific cells and/or cell products to the disc and/or spine (and other parts of the body). It will be necessary to advance the design
of this investigational device to facilitate the delivery of substances, including living cells, to specific locations within the body
and minimize the potential for damage to nearby structures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patents that are the subject of the Regenerative License Agreement have been assigned to Regenexx, LLC which we have been advised by
Regenerative is an affiliate of Regenerative.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Animal
Study</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
efficacy and safety of our product candidate, <i>BRTX-100,</i> has been tested in a degenerative intervertebral rabbit disc model. In
this study, 80 rabbits underwent surgery to create a puncture in the discs. Four weeks post-surgery, each rabbit had either contrast,
a biomaterial carrier or <i>BRTX-100</i> injected into the discs. In order to study the biodistribution and efficacy of <i>BRTX-100</i>,
the rabbits were evaluated at day 56 and day 120.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key safety findings of the animal study are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    was no evidence or observation of gross toxicity related to the administration of <i>BRTX-100</i> at either time point. The clinical
    pathology across both groups and time points were within expected normal historical ranges and under the conditions of the test.
    No abnormalities (including fractures or overt signs of lumbar disc disease) were identified after review of the radiographic images
    taken at both endpoints for both groups. No toxicity or adverse finding was evident in the systemic tissues or the discs of animals
    receiving <i>BRTX-100</i>.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    was no detectable presence of human cells (<i>BRTX-100</i>) observed at the day 56 interim time point. This is consistent with the
    proposed mechanism of action that <i>BRTX-100</i> acts through a paracrine effect of secreted growth and immunomodulation factors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key efficacy findings of the animal study are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>BRTX-100
    </i>showed a statistically significant DHI (disc height increase) over the control group at day 120.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>BRTX-100
    </i>showed a statistically significant improvement in disc histology over the control group at day 120 as graded by a validated histology
    scale. <i>BRTX-100</i> showed a significant improvement in the cellularity and matrix of the disc when compared to the control at
    day 120.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to an IND application we submitted to the FDA, we have obtained authorization to undertake a Phase 2 clinical trial investigating the
use of <i>BRTX-100</i>, our lead cell therapy candidate, in the treatment of chronic lower back pain arising from degenerative disc disease.
We have commenced our Phase 2 clinical trial through the execution of a CRO agreement with PRC Clinical, the execution of clinical trial
agreements with 16 sites, patient enrollment, the commencement of patient procedures, the purchase of manufacturing equipment and the
expansion of our laboratory to include capabilities for clinical production.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following describes the Phase 2 clinical trial authorized by the FDA:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Phase 2 Prospective, Double-Blinded, Placebo Controlled, Randomized Study</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99
    patients; randomized 2:1, <i>BRTX-100</i> to control, 40 million cells/dose</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-20
    clinical trial sites (we intend to utilize 15 clinical trial sites)</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
    efficacy endpoint at 12 months</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
    safety and efficacy follow up at 24 months</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
    subjects must have only one symptomatic diseased disc</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
    subjects must have current diagnosis of chronic lumbar disc disease typical pain with degeneration of a single disc confirmed by
    history, exam, radiography, or other acceptable means</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
    subjects must have exhausted previous conservative non-operative therapies</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
    Efficacy Endpoint</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Responder
    endpoint - percentage of patients that meet the improvement in function and reduction in pain threshold</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improvement
    in function defined as at least a 30% increase in function based on the Oswestry questionnaires (ODI)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction
    of pain defined as at least a 30% decrease in pain as measured using the Visual Analogue Scale (VAS)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    or Secondary Endpoints</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    response at 12 months</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline in pain as assessed with the VAS score and ODI at weeks 2, 12, 26, 52 and 104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline in function as assessed with the ODI at weeks 2, 12, 26, 52 and 104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline in function as assessed by Roland Morris Disability Questionnaire (RMDQ) at weeks 26, 52 and 104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline function as assessed by Functional Rating Index (FRI) at weeks 12, 52 and 104</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    from baseline Quality of Life assessment (SF-12 questionnaire) scores at weeks 2, 12, 26, 52 and 104</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021, we entered into a Master Service Agreement with Professional Research Consulting Inc. d/b/a PRC Clinical, a contract research
organization, or CRO, specializing in clinical trial management, to conduct our Phase 2 clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, we announced that we had completed enrollment for the safety run-in component of our Phase 2 clinical study of <i>BRTX-100</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, we announced that we had signed a clinical trial agreement with Northwell Health, New York State&#8217;s largest health care
provider and private employer, pursuant to which Northwell Health is participating in our Phase 2 clinical study of <i>BRTX-100</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, we announced that the final subject in our <i>BRTX-100</i> Phase 2 clinical trial safety cohort had been dosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, we announced that the independent Data Safety Monitoring Board, which is overseeing our Phase 2 clinical trial, unanimously
recommended the continuation of our study in accordance with the version of the protocol with no changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2024, we announced that the FDA cleared an important amendment to the protocol of our ongoing Phase 2 study investigating the use
of <i>BRTX-100</i>. The protocol amendment removes saline injection in the control arm of the study and replaces it with a sham injection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, we announced new preliminary 26&#8211;52 week blinded data from the first 10 patients with cLDD enrolled in our ongoing
Phase 2 clinical trial of <i>BRTX-100</i>. No serious adverse events were reported in any of the 10 safety run-in subjects. In addition,
there was no dose limiting toxicity at 26-52 weeks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2025, we announced new preliminary 26&#8211;52 week blinded data from the first 15 patients with cLDD enrolled in our ongoing
Phase 2 clinical trial of <i>BRTX-100</i>. No serious adverse events were reported in any of the 15 subjects. In addition, there was
no dose limiting toxicity at 26-52 weeks. Further, we announced certain positive preliminary data analyses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA approval process can be lengthy, expensive and uncertain and there is no guarantee that the clinical trial(s) will be completed or
that the product will ultimately receive approval or clearance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an alternative to undertaking any necessary clinical trials ourselves, we may explore the licensing of our rights with respect to our
product candidate, <i>BRTX-100,</i> to a strategic partner. Such an arrangement could possibly eliminate or significantly reduce the
need to raise the substantial capital needed to commence and complete the clinical trials and undertake the commercialization of <i>BRTX-100
</i>and would provide licensing-related revenue to us in lieu of product sales revenue. No assurance can be given that any licensing
agreement will be entered into, whether upon commercially reasonable terms or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Defined
Health Report</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2018, we engaged Defined Health, a business development and strategy consulting firm, to conduct an independent review of <i>BRTX-100</i>.
Defined Health has worked with many of the leading companies in the pharmaceutical, biotech and healthcare industries for over 25 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
review was intended to collect informed, independent opinions regarding <i>BRTX-100</i> among key opinion leaders, or KOLs (i.e., orthopedic
surgeons specializing in back and spine surgery with experience in stem cell therapy), who, upon studying applicable clinical material,
could offer opinions regarding the future therapeutic potential of <i>BRTX-100</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted in the Defined Health report, the KOLs indicated that stem cell therapies have great potential to treat chronic lumbar disc disease
and other therapeutic areas. The KOLs reacted positively to the value proposition of our product candidate, <i>BRTX-100, </i>and were
optimistic that the clinical data presented to date is likely to be mirrored in future clinical investigations. Given the opportunity,
the KOLs indicated that they would likely participate in a clinical trial should it be offered at their center and that they would recommend
the study to appropriately eligible patients. The report indicated that, if <i>BRTX-100</i> were to be granted FDA approval, the KOLs
anticipate that it would be integrated into the standard of care for eligible chronic lumbar disc disease patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Similar
Therapies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
data from studies of therapies comparative to <i>BRTX-100</i> have shown reduced pain, increased function, and an absence of significant
safety issues with a durable response, as shown below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_002.jpg" alt=""/>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impact
on Public Health</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States is the world&#8217;s leading consumer of hydrocodone (99%) and oxycodone (83%) and leads the world in per capital consumption
of such drugs (twice as much as second ranked Canada). In 2020, 91,000 persons in the United States died from overdoses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
annual healthcare and lost productivity costs in the United States related to pain, including headache, back pain and neck pain, are
estimated to be $600 billion, which is twice the annual costs related to heart disease and greater than the combined annual costs related
to cancer and diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Metabolic
Brown Adipose (Fat) Program</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
June 2011, we have been engaging in pre-clinical research efforts with respect to an investigational platform technology utilizing brown
adipose (fat) derived stem cells, or BADSCs, for therapeutic purposes. We have labeled this initiative our <i>ThermoStem Program</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brown
fat is a specialized adipose (fat) tissue found in the human body that plays a key role in the evolutionarily conserved mechanisms underlying
thermogenesis (generation of non-shivering body heat) and energy homeostasis in mammals - long known to be present at high levels in
hibernating mammals and human newborns. Recent studies have demonstrated that brown fat is present in the adult human body and may be
correlated with the maintenance and regulation of healthy metabolism, thus potentially being involved in caloric regulation. The pre-clinical
<i>ThermoStem Program</i> involves the use of a cell-based (brown adipose tissue construct) treatment for metabolic disease, such as
type 2 diabetes, obesity, hypertension and other metabolic disorders, as well as cardiac deficiencies. The diseases, disorders and syndromes
that may be targeted by our <i>ThermoStem Program</i> are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_003.jpg" alt=""/>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have had initial success in transplanting the brown adipose tissue construct in animals, and we are currently exploring ways to deliver
into humans. Even though present, BAT mass is very low in healthy adults and even lower in obese populations. Therefore, it may not be
sufficient to either naturally impact whole body metabolism, or to be targeted by drugs intended to increase its activity in the majority
of the population. Increasing BAT mass is crucial in order to benefit from its metabolic activity and this is what our <i>ThermoStem
Program</i> seeks to accomplish. We may also identify other naturally occurring biologics and chemically engineered molecules that may
enhance brown adipose tissue performance and activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obesity,
the abnormal accumulation of white fat tissue, leads to a number of metabolic disorders and is the driving force behind the rise of type
2 diabetes and cardiovascular diseases worldwide. Pharmacological efforts to alter metabolic homeostasis through modulating central control
of appetite and satiety have had limited market penetration due to significant psychological and physiological safety concerns directly
attributed to modulating these brain centers. Adipose tissue is one of the largest organs in the human body and plays a key role in central
energy balance and lipid homeostasis. White and brown adipose tissues are found in mammals. White adipose tissue&#8217;s function is
to store energy, whereas BAT specializes in energy expenditure. As discussed in a 2020 article published in the <i>International Journal
of Molecular Sciences</i>, recent advancements in unraveling the mechanisms that control the induction, differentiation, proliferation,
and thermogenic activity of BAT, along with the application of imaging technologies for human BAT visualization, have generated optimism
that these advances may provide novel strategies for targeting BAT activation/thermogenesis, leading to efficacious and safe obesity
targeted therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing a cell-based product candidate to target obesity and metabolic disorders using BADSCs. Our goal is to develop a bioengineered
implantable brown adipose tissue construct intended to mimic ones naturally occurring in the human body. We have isolated and characterized
a human multipotent stem cell population that resides within BAT depots. We have expanded these stem cells to clinically relevant numbers
and successfully differentiated them into functional brown adipocytes. We intend to use adult stem cells that may be differentiated into
progenitor or fully differentiated brown adipocytes, or a related cell type, which can be used therapeutically in patients. We are focusing
on the development of treatment protocols that utilize allogeneic cells (i.e., stem cells from a genetically similar but not identical
donor).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to deliver these differentiated cells into target locations <i>in vivo</i>, we seeded BADSCs onto 3-dimensional biological scaffolds.
Pre-clinical animal models of diet-induced obesity, that were transplanted with differentiated BADSCs supported by a biological scaffold,
presented significant reductions in weight and blood glucose levels compared to scaffold only controls. We are identifying technology
for <i>in vivo</i> delivery in small animal models. Having completed our proof of concept using our BAT in small animals, we are currently
developing our next generation BAT. It is anticipated that this next version will contain a higher purity of BADSC and a greater percent
of functional brown adipocytes, which is expected to increase the therapeutic effect compared to our first generation product. In addition,
we are exploring the delivery of the therapeutic using encapsulation technology, which will only allow for reciprocal exchange of small
molecules between the host circulation and the BAT implant. We expect that encapsulation may present several advantages over our current
biological scaffolds, including prevention of any immune response or implant rejection that might occur in an immunocompetent host and
an increase in safety by preventing the implanted cells from invading the host tissues. We have developed promising data on the loading
of human stem cell-derived tissue engineered brown fat into an encapsulation device to be used as a cell delivery system for our metabolic
platform program for the treatment of type 2 diabetes, obesity, hyperlipidemia and hypertension. This advancement may lead to successful
transplantation of brown fat in humans. We are evaluating the next generation of BAT constructs that will first be tested in small animal
models. No assurance can be given that this delivery system will be effective <i>in vivo</i> in animals or humans. Our allogeneic brown
adipose derived stem cell platform potentially provides a therapeutic and commercial model for the cell-based treatment of obesity and
related metabolic disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2014, our research with regard to the identification of a population of brown adipose derived stem cells was published in <i>Stem
Cells</i>, a respected stem cell journal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2014, we entered into a Research Agreement with Pfizer Inc., a global pharmaceutical company. Pursuant to the Research Agreement
with Pfizer, we were engaged to provide research and development services with regard to a joint study of the development and validation
of a human brown adipose cell model. The Research Agreement with Pfizer provided for an initial payment to us of $250,000 and the payment
of up to an additional $525,000 during the two-year term of the Agreement, all of which has been received. The Research Agreement expired
upon completion of the services provided for therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2015, we entered into a one year research collaboration agreement with the University of Pennsylvania with regard to the understanding
of brown adipose biology and its role in metabolic disorders. In September 2018, we entered into a one year research collaboration agreement
with the University of Pennsylvania pursuant to which the university was provided access to our proprietary brown adipose tissue cells
for research purposes. No amounts were payable by or to us pursuant to either agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2015, a United States patent related to the <i>ThermoStem Program </i>was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2017, an Australian patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2017, a Japanese patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2019, a United States patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, an Australian patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2019, an Israeli patent related to the <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, a United States patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, our collaboration with the University of Pennsylvania resulted in a publication in <i>Cell Reports</i>, a respected peer
reviewed journal, with regard to our <i>ThermoStem Program</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, a European patent related to our <i>ThermoStem Program</i> was issued to us. This European patent was validated in Belgium,
France, Germany, Italy, Poland, Spain, Sweden, Switzerland, and the United Kingdom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, an Israeli patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2021, a European patent related to our <i>ThermoStem Program</i> was issued to us. This European patent was validated in France,
Germany, Italy, Spain, and the United Kingdom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, a United States patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2021, a Japanese patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2021, a United States patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2021, an Australian patent related to our <i>ThermoStem Program </i>was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, a Japanese patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, an Israeli patent related to our <i>ThermoStem Program</i> was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2022, we announced that we were awarded a Small Business Innovation Research (SBIR) Phase 1 grant from Eunice Kennedy Shriver
National Institute of Child Health &amp; Human Development of the National Institutes of Health to enable the development and the evaluation
of our <i>ThermoStem Program</i> for the treatment of polycystic ovary syndrome (PCOS). The work is to be done in collaboration with
Dr. Sheng Wu, Associate Professor, Center for Metabolic Disease Research at Temple University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, a Japanese patent related to our <i>ThermoStem Program </i>was issued to us<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, a United States patent related to our <i>ThermoStem Program </i>was issued to us<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, a European patent related to our <i>ThermoStem Program </i>was issued to us<i>. </i>This European patent was validated in
France, Germany, Italy, Spain, and the United Kingdom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, a United States patent related to our <i>ThermoStem Program </i>was issued to us<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2024, a Japanese patent related to our <i>ThermoStem</i> program was issued to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2025, a European patent related to our <i>ThermoStem Program was issued.</i> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, an Israeli patent related to our <i>ThermoStem Program was issued.</i> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have completed proof of concept preclinical animal studies using our first generation brown adipose derived stem cells. We intend to
undertake additional preclinical animal studies in order to optimize delivery and explore the feasibility of targeting additional indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that much of our development work in this area will take place at our laboratory facility, outside core facilities at academic,
research or medical institutions, or contractors. See &#8220;Laboratory&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioCosmeceuticals</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate a commercial biocosmeceutical platform. Our current commercial product, formulated and manufactured as a third party contract manufacturer using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors.
This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring
forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial
offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the
aim of pioneering FDA approvals in the emerging biocosmeceuticals space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2024, we announced that we entered into a five-year exclusive supply agreement with Cartessa Aesthetics, LLC, or Cartessa, a leading
North American based aesthetic company. The agreement provides for the supply by us of pre-set minimum quantities of finished vials of
a proprietary cell-based biologic serum to Cartessa annually as private label under Cartessa&#8217;s Chronos ExoCR mark.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Curved
Needle Device</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Regenerative License Agreement discussed under &#8220;Disc/Spine Program-<i>Exclusive License</i>&#8221; above, we have licensed
and further developed an investigational curved needle device, or CND, that is a needle system with a curved inner cannula to allow access
to difficult-to-locate regions for the delivery or removal of fluids and other substances. The investigational CND is intended to deliver
stem cells and/or other therapeutic products or material to the interior of a human intervertebral disc, the spine region, or potentially
other areas of the body. The device is designed to rely on the use of pre-curved nested cannulae that allow the cells or material to
be deposited in the posterior and lateral aspects of the disc to which direct access is not possible due to outlying structures such
as vertebra, spinal cord and spinal nerves. We anticipate that the use of the investigational CND will facilitate the delivery of substances,
including living cells, to specific locations within the body and minimize the potential for damage to nearby structures. The investigational
device may also have more general use applications. In August 2015, a United States patent for the CND was issued to the licensor, Regenerative.
We anticipate that FDA approval or clearance will be necessary for the investigational CND prior to commercialization. We do not intend
to utilize the CND in connection with our Phase 2 clinical trial with regard to <i>BRTX-100</i>. The FDA review and approval process
can be lengthy, expensive and uncertain and there is no guarantee of ultimate approval or clearance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Laboratory</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a laboratory in Melville, New York for research purposes and have built a cleanroom within the laboratory for the production
of cell-based product candidates, such as <i>BRTX-100</i>, for use in a clinical trial, for third party cell products or for general
research purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have expanded our laboratory to include capabilities for the clinical production of our pipeline of clinical and investigational cell
therapy candidates. Our expanded cGMP facility includes process development space, ISO 7 cleanrooms and state-of-the-art equipment. We
have expanded our research and development operations to include clinical manufacturing, a necessary step for our Phase 2 clinical trial
for <i>BRTX-100</i>. The new facility has been designed to provide cGMP manufacturing according to FDA and European Medicines Agency
regulations and guidelines to support clinical grade cell production. In May 2023, we announced that we had received a license from the
New York State Department of Health, or the NYSDOH, to act as a tissue bank for the processing of mesenchymal stem cells from autologous
donors. In November 2024, we announced that we received a provisional license from the NYSDOH for the processing of allogeneic (non-autologous)
donor tissue material for the isolation, expansion and cryopreservation of various cell types, including stem cells, for medical research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we develop our business and our stem cell product candidates, and we obtain regulatory approval, we will seek to establish ourselves
as a key provider of adult stem cells for therapies and expand to provide cells in other market areas for stem cell therapy. We may also
use outside laboratories specializing in cell therapy services and manufacturing of cell products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Technology;
Research and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to utilize our laboratory or a third party laboratory in connection with cellular research activities. We also intend to obtain
cellular-based therapeutic technology licenses and increase our IP portfolio. We intend to seek to develop potential stem cell delivery
systems or devices. The goal of these specialized delivery systems or devices is to deliver cells into specific areas of the body, control
the rate, amount and types of cells used in a treatment, and populate these areas of the body with sufficient stem cells so that there
is a successful therapeutic result.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also intend to perform research to develop certain stem cell optimization compounds, media designed to enhance cellular growth and regeneration
for the purpose of improving pre-treatment and post-treatment outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our <i>Disc/Spine Program</i>, thirteen patent applications have been filed with regard to technology that is the subject of the Regenerative
License Agreement (see &#8220;Disc/Spine Program-<i>Exclusive License</i>&#8221; above). Regenerative has been issued a patent from one
of these applications with regard to its curved needle therapeutic delivery device. This patent expires in March 2031. In addition, in
March 2022, a United States patent related to <i>BRTX-</i>100 was issued. This patent expires in December 2029. Of the other eleven applications
that were filed, two applications remain pending. The patents that are the subject of the Regenerative License Agreement have been assigned
to Regenexx, LLC which we have been advised is an affiliate of Regenerative.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our <i>ThermoStem Program</i>, we have one pending United States patent application and seven United States patents within three
patent families. Four of the patents expire in June 2032 and three of the patents expire in April 2034. With regard to the first
patent family in the <i>ThermoStem Program, </i>patent applications have been filed in five foreign jurisdictions (of which four
applications have been granted as foreign patents and one application has lapsed). The patents expire in June 2032. With regard to
the second patent family in the <i>ThermoStem Program,</i> patent applications have been filed in four foreign jurisdictions (of
which four applications have been granted as foreign patents). The patents expire in April 2034. With regard to the third patent
family in the <i>ThermoStem Program</i>, patent applications have been filed in four foreign jurisdictions (of which three
applications have been granted as a foreign patents).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patent applications and those of Regenexx, LLC are currently in prosecution (i.e., we and Regenexx, LLC are seeking issued patents).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2014, we entered into a Research and Development Agreement with Rohto Pharmaceutical Co., Ltd., a Japanese pharmaceutical company,
or Rohto. Pursuant to the Research and Development Agreement with Rohto, we were engaged to provide research and development services
with regard to stem cells. The agreement with Rohto expired upon the completion of the services provided for therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have secured registrations in the U.S. Patent and Trademark Office for the following trademarks:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><img src="form10-k_004.jpg" alt=""/></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRTX-100</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>
<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THERMOSTEM</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRTX</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<i>Dragonfly Logo</i> is also registered with the U.S. Copyright Office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have federal common law rights in the trademark <i>BioRestorative Therapies</i> and other trademarks and trade names used in the
conduct of our business that are not registered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in large part on our ability to develop and protect our proprietary technology. We intend to rely on a combination
of patent, trade secret and know-how, copyright and trademark laws, as well as confidentiality agreements, licensing agreements, non-compete
agreements and other agreements, to establish and protect our proprietary rights. Our success will also depend upon our ability to avoid
infringing upon the proprietary rights of others, for if we are judicially determined to have infringed such rights, we may be required
to pay damages, alter our services, products or processes, obtain licenses or cease certain activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, we incurred $5,348,709 and $4,034,591, respectively, in research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scientific
Advisors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a Scientific Advisory Board whose purpose is to provide advice and guidance in connection with scientific matters relating
to our business. The Scientific Advisory Board has established a Disc Advisory Committee which focuses on matters relating to our <i>Disc/Spine
Program</i>. Our Scientific Advisory Board members are Dr. Wayne Marasco (Chairman), Dr. Jason Lipetz, Dr. Wayne Olan, Dr. Joy Cavagnaro,
Dr. Harvinder Sandhu and Dr. Christopher Plastaras. The Disc Advisory Committee members are Dr. Lipetz (Chairman), Dr. Olan, Dr. Sandhu
and Dr. Plastaras. See Item 10 of this Annual Report (&#8220;Directors, Executive Officers and Corporate Governance &#8211; Scientific
Advisory Board&#8221;) for a listing of the principal positions for Drs. Marasco, Lipetz, Olan, Cavagnaro, Sandhu and Plastaras.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will compete with many pharmaceutical, biotechnology and medical device companies, as well as other private and public stem cell companies
involved in the development and commercialization of cell-based medical technologies and therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regenerative
medicine is rapidly progressing, in large part through the development of cell-based therapies or devices designed to isolate cells from
human tissues. Most efforts involve cell sources, such as bone marrow, adipose tissue, embryonic and fetal tissue, umbilical cord and
peripheral blood and skeletal muscle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies
working in the area of regenerative medicine with regard to the disc and spine include, among others, Mesoblast, Fibrogenesis, DiscGenics
and Isto Biologics. Companies that are developing products and therapies to combat obesity and diabetes include Novo Nordisk, Sanofi,
Merck, Eli Lilly, Roche, Pfizer, Regeneron and Altimmune. The recent extensive use of both FDA-approved and compounded versions of glucagon-like
peptide-1 (GLP-1) receptor agonist drug products, such as Wegovy and Ozempic (semaglutide) for the treatment of obesity has significantly
increased the competition in the obesity market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors and potential competitors have substantially greater financial, technological, research and development, marketing
and personnel resources than we do. We cannot, with any accuracy, forecast when or if these companies are likely to bring their products
and therapies to market in competition with those that we are pursuing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biologics Price Competition and Innovation Act, or the BPCIA, sets forth an abbreviated pathway for the approval of biosimilar and interchangeable
biological products that could be used by future competitors, if any, of our product candidates that are approved by the FDA as a biologic.
For the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product
and the proposed biosimilar product. Interchangeability requires that a product is biosimilar to the reference product, and the product
must be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic
and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished
efficacy relative to exclusive use of the reference biologic. Under the BPCIA, an application for a biosimilar product cannot be submitted
to the FDA until four years following approval of the reference product, and it may not be approved by the FDA until 12 years after the
original branded product is approved under a biologics license application, or BLA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that, if any of our product candidates are approved as a biological product under a BLA, it should qualify for the 12-year period
of exclusivity. However, there is a risk that the FDA could permit biosimilar applicants to reference approved biologics other than our
therapeutic candidates, thus circumventing our exclusivity and potentially creating the opportunity for competition sooner than anticipated.
Additionally, this period of regulatory exclusivity does not apply to companies pursuing regulatory approval via their own traditional
BLA, rather than via the abbreviated pathway. Moreover, it is possible that a biosimilar product could be approved as &#8220;interchangeable&#8221;
with our product and therefore substitutable for our product by a healthcare professional under applicable state laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also face increased competition from stem cell therapies performed by treatment centers that do not require FDA premarket approval.
In August 2022, a federal District Court in the case of <i>United States v. California Stem Cell Treatment Center, Inc.</i> (&#8220;<i>California
Stem Cell&#8221;) </i>held that certain autologous adipose stem cell treatments were not &#8220;biological products&#8221; and therefore
did not require FDA approval. The FDA appealed the decision and it was reversed by the U.S. Court of Appeals for the Ninth Circuit, which
held that the FDA has jurisdiction to regulate the stem cell therapy as a drug under the FDCA. However, the California Stem Cell Treatment
Center has until May 19, 2025 to request review of the decision by the U.S. Supreme Court. Additionally, the U.S. Supreme Court&#8217;s
decision in <i>Loper Bright Enterprises v. Raimondo</i> overruled the landmark <i>Chevron </i>decision, which required that federal courts
defer to federal agency interpretations of ambiguous statutory provisions. <i>Loper Bright </i>may increase the likelihood of challenges
under the Administrative Procedure Act, or APA, of the FDA&#8217;s interpretation of the HCT/P statutory provisions. If those APA challenges
result in the FDA&#8217;s HCT/P Regulations being modified or struck down, or the U.S. Supreme Court reverses the Court of Appeals decision
in the <i>California Stem Cell </i>case, we could face competition from stem cell clinics that would not be required to undergo the costly
and time-consuming FDA approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a comparison of <i>BRTX-100</i> to Mesoblast&#8217;s adult stem cell biologic:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_005.jpg" alt=""/>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that <i>BRTX-100</i> has competitive advantages to Mesoblast&#8217;s product for the following reasons:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    use of autologous cells results in low to no risk of rejection, greater safety profile (introduction of viral/genetic) and a streamlined
    regulatory path</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hypoxic
    culturing creates increased cell proliferation, greater plasticity, increased paracrine effect and increased cell survival after
    application</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Autologous
    platelet lysate provides growth factors that interact with the cells, allowing for better cell survival</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
    to no risk of safety concerns related to immunological and zoonotic (animal to human) transmission</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Customers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
regulatory approval, our cell product candidates are intended to be marketed to physicians, other health care professionals, hospitals,
research institutions, pharmaceutical companies and the military. It is anticipated that physicians who are trained and skilled in performing
spinal injections will be the physicians most likely to treat discs with injections of <i>BRTX-100</i> upon regulatory approval. These
physicians would include interventional physiatrists (physical medicine physicians), pain management anesthesiologists, interventional
radiologists and neurosurgeons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governmental
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Government Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
health care industry is highly regulated in the United States. The federal government, through various departments and agencies, state
and local governments, and private third-party accreditation organizations, regulate and monitor the health care industry, associated
products, and operations. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose
substantial requirements upon the clinical development, approval, manufacture, distribution and marketing of medical products, including
drugs, biologics, and medical devices. These agencies and other federal, state and local entities regulate research and development activities
and the testing, manufacture, quality control, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval,
post-approval monitoring, advertising, promotion, sampling and import and export of medical products. The following is a general overview
of the laws and regulations pertaining to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>FDA
Regulation of Stem Cell Treatment and Products</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA regulates the manufacture of human stem cell treatments and associated products under the authority of the Public Health Service
Act, or PHSA, and the Federal Food, Drug, and Cosmetic Act, or FDCA. Stem cells can be regulated under the FDA&#8217;s Human Cells, Tissues,
and Cellular and Tissue-Based Products Regulations, or HCT/Ps, or may also be subject to the FDA&#8217;s drug, biologic, or medical device
regulations, each as discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Human
Cells, Tissues, and Cellular and Tissue-Based Products Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 361 of the PHSA, the FDA issued specific regulations governing the use of HCT/Ps in humans. Pursuant to Part 1271 of Title 21
of the Code of Federal Regulations, or CFR, or the HCT/P Regulations, the FDA established a unified registration and listing system for
establishments that manufacture and process HCT/Ps. The regulations also include provisions pertaining to donor eligibility determinations;
current good tissue practices covering all stages of production, including harvesting, processing, manufacture, storage, labeling, packaging,
and distribution; and other procedures to prevent the introduction, transmission, and spread of communicable diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
HCT/P Regulations define HCT/Ps as articles &#8220;containing or consisting of human cells or tissues that are intended for implantation,
transplantation, infusion or transfer into a human recipient.&#8221; The HCT/P Regulations strictly constrain the types of products that
may be regulated solely as HCT/P. Factors considered include the degree of manipulation, whether the product is intended for a homologous
function, whether the product has been combined with noncellular or non-tissue components, and the product&#8217;s effect or dependence
on the body&#8217;s metabolic function. In those instances where cells, tissues, and cellular and tissue-based products have been only
minimally manipulated, are intended strictly for homologous use, have not been combined with noncellular or nontissue substances, and
do not depend on or have any effect on the body&#8217;s metabolism, the manufacturer is only required to register with the FDA, submit
a list of manufactured products, and adopt and implement procedures for the control of communicable diseases. If one or more of the above
factors has been exceeded, the product would be regulated as a drug, biological product, or medical device rather than an HCT/P.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are an enterprise in the early stages of operations and have not generated significant revenues from operations, it is difficult to
anticipate the likely regulatory status of the array of products and services that we may offer. We believe that some of the adult autologous
(self-derived) stem cells that will be used in our cellular therapy products and services, including the brown adipose (fat) tissue that
we intend to use in our <i>ThermoStem Program</i>, may be regulated by the FDA as HCT/Ps under the HCT/P Regulations. However, the FDA
may disagree with this position or conclude that some or all of our stem cell therapy products or services do not meet the applicable
definitions and exemptions to the regulation. In July 2020, the FDA issued an updated guidance document entitled &#8220;Regulatory Considerations
for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use&#8221; that provides additional
guidance on how FDA interprets the HCT/P Regulations, particularly the definition of the terms &#8220;minimally manipulated&#8221; and
&#8220;homologous use.&#8221; In the guidance, the FDA stated it would exercise enforcement discretion until May 31, 2021 for products
that do not comply with the HCT/P Regulations. As of that date, manufacturers of products marketed as HCT/Ps that do not comply with
the HCT/P Regulations are subject to immediate FDA enforcement action. If we are not regulated solely under the HCT/P Regulations, we
would need to expend significant resources to comply with the FDA&#8217;s broad regulatory authority under the FDCA. Historically, the
U.S. federal courts have upheld the FDA&#8217;s authority to regulate stem cell products under the FDCA that do not comply with the FDA&#8217;s
interpretations of the HCT/P Regulations. However, the U.S. Supreme Court&#8217;s 2024 decision in <i>Loper Bright Enterprises v. Raimondo
</i>overruled the landmark <i>Chevron </i>decision, which required that federal courts defer to federal agency interpretations of ambiguous
statutory provisions. <i>Loper Bright </i>may make it easier to successfully challenge the FDA&#8217;s interpretation of the HCT/P statutory
provisions in the HCT/P Regulations under the APA. In August 2022, a federal District Court in the case of <i>United States v. California
Stem Cell Treatment Center, Inc.</i> held that certain autologous adipose stem cell treatments that the FDA alleged were biological products
were instead within the HCT/P definition and therefore did not require FDA approval. The FDA appealed the decision and it was reversed
by the U.S. Court of Appeals for the Ninth Circuit. The California Stem Cell Treatment Center has until May 19, 2025 to request review
of the decision by the U.S. Supreme Court. Should the Supreme Court reverse the Court of Appeals decision, or the HCT/P Regulations be
modified or struck down by a court applying <i>Loper Bright </i>in an APA case, it could expand the types of stem cell products that
are regulated solely as HCT/Ps.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulated solely under the FDA&#8217;s HCT/P statutory and regulatory provisions, once our laboratory in the United States becomes operational,
it will need to satisfy the following requirements, among others, to process and store stem cells:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">registration
    and listing of HCT/Ps with the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">donor
    eligibility determinations, including donor screening and donor testing requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">current
    good tissue practices, specifically including requirements for the facilities, environmental controls, equipment, supplies and reagents,
    recovery of HCT/Ps from the patient, processing, storage, labeling and document controls, and distribution and shipment of the HCT/Ps
    to the laboratory, storage, or other facility;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tracking
    and traceability of HCT/Ps and equipment, supplies, and reagents used in the manufacture of HCT/Ps;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    event reporting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    inspection; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abiding
    by any FDA order of retention, recall, destruction, and cessation of manufacturing of HCT/Ps.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-reproductive
HCT/Ps and non-peripheral blood stem/progenitor cells that are offered for import into the United States and regulated solely under Section
361 of the PHSA must also satisfy the requirements under 21 C.F.R. &#167; 1271.420. Section 1271.420 requires that the importer of record
of HCT/Ps notify the FDA prior to, or at the time of, importation and provide sufficient information for the FDA to make an admissibility
decision. In addition, the importer must hold the HCT/P intact and under conditions necessary to prevent transmission of communicable
disease until an admissibility decision is made by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions
including public warning letters, fines, consent decrees, orders of retention, recall or destruction of product, orders to cease manufacturing,
and criminal prosecution. If any of these events were to occur, it could materially adversely affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that our cellular therapy activities are limited to developing products and services outside the United States, as described
in detail below, the products and services would not be subject to FDA regulation, but will be subject to the applicable requirements
of the foreign jurisdiction. We intend to comply with all applicable foreign governmental requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Drug
and Biological Product Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
HCT/P product that does not meet the criteria for being solely regulated under Section 361 of the PHSA will be regulated as a drug, device
or biological product under the FDCA and/or Section 351 of the PHSA, and applicable FDA regulations. The FDA has broad regulatory authority
over drugs and biologics marketed for sale in the United States. The FDA regulates the research, clinical testing, manufacturing, safety,
effectiveness, labeling, storage, recordkeeping, promotion, distribution, and production of drugs and biological products. The FDA also
regulates the export of drugs and biological products manufactured in the United States to international markets in certain situations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug or biologic may be marketed in the United States generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
completion of non-clinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practice,
or GLP, or other applicable regulations;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
submission of an IND, which allows clinical trials to begin unless the FDA objects within 30 days;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug or biologic
for its intended use or uses conducted in accordance with FDA regulations and Good Clinical Practices, or GCP, which are international
ethical and scientific quality standards meant to ensure that the rights, safety and well-being of trial participants are protected and
that the integrity of the data is maintained;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
registration of clinical trials of FDA-regulated products and certain clinical trial information;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
preparation and submission to the FDA of a new drug application, or NDA, in the case of a drug or BLA in the case of a biologic;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
review of the product by an FDA advisory committee, where appropriate or if applicable;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
satisfactory completion of pre-approval inspection of manufacturing facilities and clinical trial sites at which the product, or components
thereof, are produced to assess compliance with cGMP requirements and of selected clinical trial sites to assess compliance with GCP
requirements; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
FDA approval of an NDA or BLA which must occur before a drug or biologic can be marketed or sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
of an NDA requires a showing that the drug is safe and effective for its intended use and that the methods, facilities, and controls
used for the manufacturing, processing, and packaging of the drug are adequate to preserve its identity, strength, quality, and purity.
To obtain a BLA, a manufacturer must show that the proposed product is safe, pure, and potent and that the facility in which the product
is manufactured, processed, packed, or held meets established quality control standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of an NDA or BLA approval by the FDA, human clinical trials are typically conducted in the following phases (which may overlap):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Phase 1: The investigational product is initially given to healthy human subjects or patients and tested for safety, dosage tolerance,
absorption, metabolism, distribution and excretion. These trials may also provide early evidence on effectiveness. During Phase 1 clinical
trials, sufficient information about the investigational product&#8217;s pharmacokinetics and pharmacologic effects may be obtained to
permit the design of well-controlled and scientifically valid Phase 2 clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Phase 2: These clinical trials are conducted in a limited number of human subjects in the target population to identify possible adverse
effects and safety risks, to determine the efficacy of the investigational product for specific targeted diseases and to determine dosage
tolerance and dosage levels. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning
larger and more costly Phase 3 clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Phase 3: Phase 3 clinical trials are undertaken after Phase 2 clinical trials demonstrate that a dosage range of the investigational
product appears effective and has a tolerable safety profile. The Phase 2 clinical trials must also provide sufficient information for
the design of Phase 3 clinical trials. Phase 3 clinical trials are conducted to provide statistically significant evidence of clinical
efficacy and to further test for safety risks in an expanded human subject population at multiple clinical trial sites. These clinical
trials are intended to further evaluate dosage, effectiveness and safety, to establish the overall benefit-risk profile of the investigational
product and to provide an adequate basis for product labeling and approval by the FDA. In most cases, the FDA requires two adequate and
well-controlled Phase 3 clinical trials to demonstrate the efficacy of an investigational drug or biologic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
clinical trials must be conducted in accordance with FDA regulations, GCP requirements and their protocols in order for the data to be
considered reliable for regulatory purposes. Progress reports detailing the results of the clinical trials must be submitted at least
annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed
successfully within any specified period, or at all. These government regulations may delay or prevent approval of product candidates
for a considerable period of time and impose costly procedures upon our business operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may require, or companies may pursue, additional clinical trials, referred to as Phase 4 clinical trials, after a product is approved.
Such trials may be made a condition to be satisfied for continuing drug approval. The results of Phase 4 clinical trials can confirm
the effectiveness of a product candidate and can provide important safety information. In addition, the FDA has authority to require
sponsors to conduct post-marketing trials to specifically address safety issues identified by the agency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Pediatric Research Equity Act, or PREA, certain NDAs and BLAs and certain supplements to an NDA or BLA must contain data to assess
the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration
for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric
data or full or partial waivers. A sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient,
new indication, new dosage form, new dosing regimen, or new route of administration submit an initial Pediatric Study Plan, or PSP, to
the FDA within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of
the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct,
including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including
such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to
provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A
sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based
on data collected from preclinical studies, early phase clinical trials, and/or other clinical development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to some of the conditions established in an approved application, including changes in indications, labeling, manufacturing processes
or facilities, require submission and FDA approval of a new NDA or BLA, or an NDA or BLA supplement, before the change can be implemented.
An NDA or BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA
uses the same procedures and actions in reviewing NDA and BLA supplements as it does in reviewing NDAs and BLAs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
and biological products must also comply with applicable requirements, including monitoring and recordkeeping activities, manufacturing
requirements, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities
with updated safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising
requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting drugs for uses or
in patient populations that are not described in the drug&#8217;s approved labeling, or off-label use, limitations on industry-sponsored
scientific and educational activities and requirements for promotional activities involving the internet. Although physicians may, in
their independent professional medical judgment, prescribe legally available drugs for off-label uses, manufacturers typically may not
market or promote such off-label uses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have determined that, under the FDA&#8217;s current interpretation of the applicable law, our <i>BRTX-100</i> product candidate will
be regulated as a biological product under the PHSA. Therefore, we will need to expend significant resources to ensure regulatory compliance.
There is no assurance as to whether or when we will receive FDA approval of the <i>BRTX-100 </i>product candidate. The process of designing,
conducting, compiling and submitting the non-clinical and clinical studies required for BLA approval is time-consuming, expensive and
unpredictable. The process can take many years, depending on the product and the FDA&#8217;s requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if a product candidate receives regulatory approval, the approval may be limited to specific disease states, patient populations
and dosages, or might contain significant limitations on use in the form of warnings, precautions or contraindications, or in the form
of onerous risk management plans, restrictions on distribution or use, or post-marketing trial requirements. Further, even after regulatory
approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product, including
safety labeling or imposition of a Risk Evaluation and Mitigation Strategy, or REMS, the requirement to conduct post-market studies or
clinical trials or even complete withdrawal of the product from the market. Delay in obtaining, or failure to obtain, regulatory approval
for our products, or obtaining approval but for significantly limited use, would harm our business. Further, we cannot predict what adverse
governmental regulations may arise from future United States or foreign governmental action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions
from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals,
seizure of our products, total or partial shutdown of our production, withdrawal of approvals, and criminal prosecutions. If any of these
events were to occur, it could materially adversely affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>FDA
Expedited Review Programs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA is authorized to expedite the review of NDAs and BLAs in several ways. Under the Fast Track program, the sponsor of a drug or biologic
product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after
the filing of the IND. Drug and biologic products are eligible for Fast Track designation if they are intended to treat a serious or
life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies
to the combination of the product candidate and the specific indication for which it is being studied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of
a Fast Track NDA or BLA before the application is complete, a process known as rolling review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product submitted to the FDA for marketing, including under a Fast Track program, may also be eligible for the following other types
of FDA programs intended to expedite development and review:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Breakthrough therapy designation. To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious
or life-threatening disease or condition, and preliminary clinical evidence must indicate that such product candidates may demonstrate
substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor
of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement
of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review, and rolling review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Priority review. A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a
significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious condition compared to marketed
products. The FDA aims to complete its review of priority review applications within six months as opposed to ten months for standard
review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Accelerated approval. Drug or biologic products studied for their safety and effectiveness in treating serious or life-threatening illnesses
and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means
that a product candidate may be approved on the basis of adequate and well-controlled clinical trials establishing that the product candidate
has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical
endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity
and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require
that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well-controlled post-marketing
clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials.
As a result of the FDA&#8217;s controversial use of the accelerated approval pathway for an Alzheimer&#8217;s drug (aducanumab), Congress
revised the accelerated approval process as a part of the Food and Drug Omnibus Reform Act of 2022 to provide the FDA with additional
authorities to enforce the post-approval study requirements and to withdraw approvals when those requirements are not met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
Track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval
but may expedite the development or approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the FDA is authorized to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible
for this designation if it is a regenerative medicine advanced therapy, or RMAT (which may include a cell therapy), that is intended
to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that
the drug has the potential to address unmet medical needs for such disease or condition. The benefits of a RMAT designation include early
interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for
priority review and accelerated approval based on surrogate or intermediate endpoints.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Medical
Device Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also has broad authority over the regulation of medical devices marketed for sale in the United States. The FDA regulates the research,
clinical testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, promotion, distribution,
and production of medical devices. The FDA also regulates the export of medical devices manufactured in the United States to international
markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDCA, medical devices are classified into one of three classes, Class I, Class II, or Class III, depending upon the degree of risk
associated with the medical device and the extent of control needed to ensure safety and effectiveness. Class I devices are subject to
the lowest degree of regulatory scrutiny because they are considered low risk devices and need only comply with the FDA&#8217;s General
Controls. The General Controls include compliance with the registration, listing, adverse event reporting requirements, and applicable
portions of the Quality System Regulation as well as the general misbranding and adulteration prohibitions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
II devices are subject to the General Controls as well as certain Special Controls such as 510(k) premarket notification. Class III devices
are subject to the highest degree of regulatory scrutiny and typically include life supporting and life sustaining devices and implants.
They are subject to the General Controls and Special Controls that include a premarket approval application, or PMA. &#8220;New&#8221;
devices are automatically regulated as Class III devices unless they are shown to be low risk, in which case they may be subject to de
novo review to be moved to Class I or Class II. Clinical research of an investigational device is subject to the FDA&#8217;s Investigational
Device Exemption, or IDE, regulations. Nonsignificant risk devices are subject to abbreviated requirements that do not require a submission
to the FDA but must have Institutional Review Board (IRB) approval and comply with other requirements pertaining to informed consent,
labeling, recordkeeping, reporting, and monitoring. Significant risk devices require the submission of an IDE application to the FDA
and the FDA&#8217;s approval of the IDE application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA premarket clearance and approval process can be lengthy, expensive and uncertain. It generally takes three to twelve months from
submission to obtain 510(k) premarket clearance, although it may take longer. Approval of a PMA could take one to four years, or more,
from the time the application is submitted and there is no guarantee of ultimate clearance or approval. Securing FDA clearances and approvals
may require the submission of extensive clinical data and supporting information to the FDA. Additionally, the FDA actively enforces
regulations prohibiting marketing and promotion of devices for indications or uses that have not been cleared or approved by the FDA.
In addition, modifications or enhancements of products that could affect the safety or effectiveness or effect a major change in the
intended use of a device that was either cleared through the 510(k) process or approved through the PMA process may require further FDA
review through new 510(k) or PMA submissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event we develop processes, products or services which qualify as medical devices subject to FDA regulation, we intend to comply
with such regulations. If the FDA determines that our products are regulated as medical devices and we have failed to comply with applicable
regulatory requirements, it can impose a variety of enforcement actions from public warning letters, application integrity proceedings,
fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure of our products, total
or partial shutdown of our production, withdrawal of approvals, and criminal prosecutions. If any of these events were to occur, it could
materially adversely affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Current
Good Manufacturing Practices and other FDA Regulations of Cellular Therapy Products</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products
that fall outside of the HCT/P regulations and are regulated as drugs, biological products, or devices must comply with applicable cGMP
regulations. These cGMPs and related quality standards are designed to ensure the products that are processed at a facility meet the
FDA&#8217;s applicable requirements for identity, strength, quality, sterility, purity, and safety. In the event that our domestic United
States operations are subject to the FDA&#8217;s drug, biological product, or device regulations, we intend to comply with the applicable
cGMPs and quality regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions
from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals,
seizure of our products, total or partial shutdown of our production, withdrawal of approvals, and criminal prosecutions. If any of these
events were to occur, it could materially adversely affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Promotion
of Foreign-Based Cellular Therapy Treatment&#8212; &#8220;Medical Tourism&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may establish, or license technology to third parties in connection with their establishment of, adult stem cell therapy facilities outside
the United States. We also intend to work with hospitals and physicians to make the stem cell-based therapies available for patients
who travel outside the United States for treatment. &#8220;Medical tourism&#8221; is defined as the practice of traveling across international
borders to obtain health care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Federal Trade Commission, or the FTC, has the authority to regulate and police advertising of medical treatments, procedures, and regimens
in the United States under the Federal Trade Commission Act, or the FTCA. The FTC has regulatory authority to prevent unfair and deceptive
practices and false advertising. Specifically, the FTC requires advertisers and promoters to have a reasonable basis to substantiate
and support claims. The FTC has many enforcement powers, one of which is the power to order disgorgement by promoters deemed in violation
of the FTCA of any profits made from the promoted business and can order injunctions from further violative promotion. Advertising that
we may utilize in connection with our medical tourism operations will be subject to FTC regulatory authority, and we intend to comply
with such regulatory r&#233;gime. Similar laws and requirements are likely to exist in other countries and we intend to comply with
such requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Federal
Regulation of Clinical Laboratories</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Clinical Laboratory Improvement Amendments, or CLIA, provides the Centers for Medicare and Medicaid Services, or CMS, authority
over all laboratory testing, except research, that is performed on humans in the United States. The Division of Laboratory Services,
within the Survey and Certification Group, under the Center for Medicaid and State Operations, or CMSO, has the responsibility for implementing
the CLIA program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CLIA program is designed to establish quality laboratory testing by ensuring the accuracy, reliability, and timeliness of patient test
results. Under CLIA, a laboratory is a facility that does laboratory testing on specimens derived from humans and used to provide information
for the diagnosis, prevention, treatment of disease, or impairment of, or assessment of health. Laboratories that handle stem cells and
other biologic matter are, therefore, included under the CLIA program. Under the CLIA program, laboratories must be certified by the
government, satisfy governmental quality and personnel standards, undergo proficiency testing, be subject to inspections, and pay fees.
To the extent that our business activities require CLIA certification, we intend to obtain and maintain such certification. If we are
subject to CLIA, the failure to comply with CLIA standards could result in suspension, revocation, or limitation of a laboratory&#8217;s
CLIA certificate. In addition, fines or criminal penalties could also be levied. If any of these events were to occur, it could impact
our business operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Health
Insurance Portability and Accountability Act&#8212;Protection of Patient Health Information</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business.
The Health Insurance Portability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health
Act, or HITECH, and their respective implementing regulations imposes specified requirements relating to the privacy, security and transmission
of individually identifiable health information on certain types of individuals and organizations. In addition, certain state laws govern
the privacy and security of health information in certain circumstances, many of which differ from each other and from HIPAA in significant
ways and may not have the same effect, thus complicating compliance efforts. Further, we may need to also comply with additional federal
or state privacy laws and regulations that may apply to certain diagnoses, such as HIV/AIDS, to the extent that they apply to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Department of Health and Human Services, or HHS, through its Office for Civil Rights, investigates breach reports and determines whether
administrative or technical modifications are required and whether civil or criminal sanctions should be imposed. Companies failing to
comply with HIPAA and the implementing regulations may also be subject to civil money penalties or in the case of knowing violations,
potential criminal penalties, including monetary fines, imprisonment, or both. In some cases, the State Attorneys General may seek enforcement
and appropriate sanctions in federal court.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Applicable U.S. Laws</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the above-described regulation by United States federal and state government, the following are other federal and state laws
and regulations that could directly or indirectly affect our ability to operate the business:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and local licensure, registration, and regulation of the development of pharmaceuticals and biologics;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and local licensure of medical professionals;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    statutes and regulations related to the corporate practice of medicine;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">laws
    and regulations administered by U.S. Customs and Border Protection related to the importation of biological material into the United
    States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    laws and regulations administered by the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    laws and regulations administered by HHS;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and local laws and regulations governing human subject research and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal physician self-referral prohibition, also known as Stark Law, and any state equivalents to Stark Law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal False Claims Act, or FCA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, or AKS, and any state equivalent statutes and regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    and state coverage and reimbursement laws and regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and local laws and regulations for the disposal and handling of medical waste and biohazardous material;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Occupational
    Safety and Health Administration, or OSHA, regulations and requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Intermediate Sanctions rules of the IRS providing for potential financial sanctions with respect to &#8220;excess benefit transactions&#8221;
    with tax-exempt organizations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Physician Payments Sunshine Act (in the event that our products are classified as drugs, biologics, devices or medical supplies and
    are reimbursed by Medicare, Medicaid or the Children&#8217;s Health Insurance Program);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and other federal laws addressing the privacy of health information; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items
    or services reimbursed by any third-party payer, including commercial insurers, state laws that require pharmaceutical companies
    to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated
    by the federal government or otherwise restrict payments that may be made to healthcare professionals and other potential referral
    sources, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians
    and other healthcare professionals or marketing expenditures, and state laws governing the privacy and security of health information
    in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating
    compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violation
of any of the laws described above or any other governmental laws and regulations may result in penalties, including civil and criminal
penalties, damages, fines, the curtailment or restructuring of operations, the exclusion from participation in federal and state healthcare
programs and imprisonment. Furthermore, efforts to ensure that business activities and business arrangements comply with applicable healthcare
laws and regulations can be costly for manufacturers of branded prescription products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
Government Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, we will need to comply with the government regulations of each individual country in which our therapy centers are located and
products are to be distributed and sold. These regulations vary in complexity and can be as stringent, and on occasion even more stringent,
than FDA regulations in the United States. Due to the fact that there are new and emerging cell therapy regulations that have recently
been drafted and/or implemented in various countries around the world, the application and subsequent implementation of these new and
emerging regulations have little to no precedence. Therefore, the level of complexity and stringency is not always precisely understood
for each country, creating greater uncertainty for the international regulatory process. Furthermore, government regulations can change
with little to no notice and may result in up-regulation of our product(s), thereby creating a greater regulatory burden for our cell
processing technology products. We have not yet thoroughly explored the applicable laws and regulations that we will need to comply with
in foreign jurisdictions. It is possible that we may not be permitted to expand our business into one or more foreign jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any definitive plans or arrangements with respect to the establishment by us of stem cell therapy clinics in any country.
We intend to explore any such opportunities as they arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Offices</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 40 Marcus Drive, Suite One, Melville, New York, and our telephone number is (631) 760-8100.
Our website is www.biorestorative.com. Our internet website and the information contained therein or connected thereto are not intended
to be incorporated by reference into this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have 11 employees, all of whom are full-time employees. We believe that our employee relations are good.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_004"></span>ITEM
    1A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK
    FACTORS.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk factors listed in this section provide examples of risks, uncertainties and events that may cause our actual results to differ materially
from the expectations we describe in our forward-looking statements. Readers should be aware that the occurrence of any of the events
described in these risk factors could have a material adverse effect on our business, results of operations and financial condition.
We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future
events, or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preceding
the full risk factors is a list of certain of the risk factors that follow. Reference is made to the complete risk factors for a full
description of the risks involved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Business Generally</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have a limited operating history; we have incurred substantial losses since inception; we expect to continue to incur losses for
    the near term; there is substantial doubt about our ability to continue as a going concern within the next twelve months from the
    date of this filing; the report of our independent registered public accounting firm contains an explanatory paragraph that expresses
    substantial doubt about our ability to continue as a going concern.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will need to obtain a significant amount of financing to complete our clinical trials and implement our business plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will need to enter into agreements in order to implement our business strategy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend on our executive officers and on our ability to attract and retain additional qualified personnel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Relating to Late Filing of our Periodic Report</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Our failure to prepare and timely file our Quarterly Report on Form 10-Q for the period ended March 31, 2024 with the SEC limits our access to the public markets to raise debt or equity capital.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Cell Therapy Product Development Efforts</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    future success is significantly dependent on the timely and successful development and commercialization of <i>BRTX-100</i>, our
    lead product candidate for the treatment of chronic lumbar disc disease; if we encounter delays or difficulties in the development
    of this product candidate, as well as any other product candidates, our business prospects would be significantly harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may experience delays and other difficulties in enrolling a sufficient number of patients in our clinical trials which could delay
    or prevent the receipt of necessary regulatory approvals.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    development of our cell therapy product candidates is subject to uncertainty because autologous cell therapy is inherently variable.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    disruption to our access to the media (including cell culture media) and reagents we are using in the clinical development of our
    cell therapy product candidates could adversely affect our ability to perform clinical trials and seek future regulatory submissions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates, which would prevent or delay
    regulatory approval and commercialization.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize
    a product candidate, and the approval may be for a narrower indication than we seek.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may never obtain FDA approval for any of our product candidates in the United States and, even if we do, we may never obtain approval
    for or commercialize any of our product candidates in any foreign jurisdiction, which would limit our ability to realize our full
    market potential.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    presently lack manufacturing capabilities to produce our product candidates at commercial scale quantities and do not have an alternate
    manufacturing supply at this time, which could negatively impact our ability to meet any future demand for the products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    commercial potential and profitability of our products are unknown and subject to significant risk and uncertainty.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may have difficulties in sourcing brown adipose (fat) tissue.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    safety problems are encountered by us or others developing new stem cell-based therapies, our stem cell initiatives could be materially
    and adversely affected.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are vulnerable to competition and technological change, and also to physicians&#8217; inertia.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have limited experience in the development and marketing of cell therapies and may be unsuccessful in our efforts to establish a
    profitable business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    cell therapy business is based on novel technologies that are inherently expensive, risky and may not be understood by or accepted
    in the marketplace, which could adversely affect our future value.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    cell therapy product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject to significant product liability claims and litigation, including potential exposure from the use of our product candidates
    in human subjects, and our insurance may be inadequate to cover claims that may arise.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    internal computer systems, or those that are expected to be used by our clinical investigators, clinical research organizations or
    other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of development
    programs for our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    inability to obtain reimbursement for our products and services from private and governmental insurers could negatively impact demand
    for our products and services.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our activity as a contract manufacturer of biologic-based cosmetics could
result in FDA enforcement for reasons outside of our control, which could disrupt the development of our own product candidates or harm
our reputation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Intellectual Property</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to protect our proprietary rights.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    to United States patent law may have a material adverse effect on our intellectual property rights.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    certain countries, patent holders may be required to grant compulsory licenses, which would likely have a significant and detrimental
    effect on any future revenues in such country.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Government Regulation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory oversight.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information
    privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    failure to receive regulatory approvals for our cell therapy product candidates would likely have a material and adverse effect on
    our business and prospects.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to conduct clinical studies in accordance with regulations and accepted standards, we may be delayed in receiving,
    or may never receive, regulatory approvals of our product candidates from the FDA and other regulatory authorities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
    care companies have been the subjects of federal and state investigations, and we could become subject to investigations in the future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    is uncertain to what extent the government, private health insurers and third-party payors will approve coverage or provide reimbursement
    for the therapies and products to which our services relate. Availability for such reimbursement may be further limited by reductions
    in Medicare, Medicaid and other federal healthcare program funding in the United States.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitor
    companies or hospitals in the EU may be able to take advantage of EU rules permitting sales of unlicensed medicines for individual
    patients to sell competing products without a marketing authorization.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    pay no dividends.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
    who hold unregistered shares of our common stock are subject to resale restrictions pursuant to Rule 144 due to our former status
    as a &#8220;shell company.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
    weaknesses in our internal control over financial reporting may cause us to fail to timely and accurately report our financial results
    or result in a material misstatement of our consolidated financial statements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    may be significant future issuances or resales of our common stock which may materially and adversely dilute stockholders&#8217;
    ownership interest and affect the market price of our securities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-takeover
    provisions and the regulations to which we may be subject may make it more difficult for a third party to acquire control of us,
    even if the change in control would be beneficial to our securityholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Associated with Our Nasdaq Listing</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    cannot assure you that we will be able to continue to comply with the minimum bid price requirement of Nasdaq.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    market price of our common stock may not attract new investors, including institutional investors, and may not satisfy the investing
    requirements of those investors. Consequently, the trading liquidity of our common stock may not improve.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Business Generally</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history; we have incurred substantial losses since inception; we expect to continue to incur losses for the
near term; there is substantial doubt about our ability to continue as a going concern within the next twelve months from the date of
this filing; the report of our independent registered public accounting firm contains an explanatory paragraph that expresses substantial
doubt about our ability to continue as a going concern.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a limited operating history. Since our inception, we have incurred net losses. As of December 31, 2024, our accumulated deficit
was $155,678,715. Our consolidated financial statements as of December 31, 2024 and 2023 and for the years then ended which are included
in this Annual Report following Item 16 (&#8220;Form 10-K Summary&#8221;) have been prepared on the basis that we will continue as a
going concern, which contemplates realization of assets and satisfying liabilities in the normal course of business. For the year ended
December 31, 2024, we had a net loss of $9.0 million and a negative cash flows from operations of $8.2 million and as of December 31,
2024, we had working capital of $7.4 million. We anticipate that we will continue to incur net losses and negative cash flows from operations
as we execute our development plans for 2025 and beyond, as well as other potential strategic and business development initiatives. These
conditions raise substantial doubt about our ability to continue as a going concern for at least twelve months after the issuance date
of the financial statements included herein. Our current funds will not be sufficient to enable us to fully complete our development
activities or attain profitable operations. If we are unable to obtain such needed additional financing on a timely basis, we may have
to curtail our development, marketing and promotional activities, which would have a material adverse effect on our business, financial
condition and results of operations, and ultimately we could be forced to discontinue our operations and liquidate. The report of our
independent registered public accounting firm with respect to our financial statements as of December 31, 2024 and 2023 and for the years
then ended indicates that our financial statements have been prepared assuming that we will continue as a going concern. The report states
that, as of December 31, 2024 there is substantial doubt about our ability to continue as a going concern within one year after the issuance
date of such financial statements. Our plans in regard to these matters are described in footnote 1 to such financial statements. Our
financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to obtain a significant amount of financing to complete our clinical trials and implement our business plan.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have not generated revenues from our operations and have funded our operations through the sale of our equity securities
and debt securities. The implementation of our business plan, as discussed in this Annual Report under Item 1 (&#8220;Business&#8221;),
will require the receipt of sufficient equity and/or debt financing to purchase necessary equipment, technology and materials, fund our
clinical trials and other research and development efforts and otherwise fund our operations. We will require significant additional
funding to complete our clinical trials using <i>BRTX-100</i>. We will also require a substantial amount of additional funding to implement
our other programs described in this Annual Report under Item 1 (&#8220;Business&#8221;), including our metabolic <i>ThermoStem Program,
</i>and fund general operations. No assurance can be given that the amount of funding that we anticipate may be required for such purposes
is correct or that we will be able to accomplish our goals within the timeframes projected. In addition, no assurance can be given that
we will be able to obtain any required financing on commercially reasonable terms or otherwise. In the event we do not obtain the financing
required for the above purposes, we may have to curtail our development, marketing and promotional activities, which would have a material
adverse effect on our business, financial condition and results of operations, and ultimately we could be forced to discontinue our operations
and liquidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business strategy is high risk.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focusing our resources and efforts primarily on the development of cellular-based products and services which will require extensive
cash for research, development and commercialization activities. This is a high-risk strategy because there is no assurance that our
products and services, including our <i>Disc/Spine Program</i> and our <i>ThermoStem</i> metabolic brown fat research initiative, will
ever become commercially viable (commercial risk), that we will prevent other companies from depriving us of market share and profit
margins by offering services and products based on our inventions and developments (legal risk), that we will successfully manage a company
in a new area of business, regenerative medicine, and on a different scale than we have operated in the past (operational risk), that
we will be able to achieve the desired therapeutic results using stem and regenerative cells (scientific risk), or that our cash resources
will be adequate to develop our products and services until we become profitable, if ever (financial risk). We are using our cash in
one of the riskiest industries in the economy (strategic risk). This may make our securities an unsuitable investment for many investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to enter into agreements in order to implement our business strategy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for a certain license agreement with Regenerative Sciences, LLC, a product manufacturing agreement with Cartessa Aesthetics, LLC, and agreements relating
to the conduct of our Phase 2 clinical trial, we do not have any material agreements or understandings in place with respect to the implementation
of our business strategy. No assurances can be given that we will be able to enter into any necessary agreements with respect to the
development of our business. Our inability to enter into any such agreements would have a material adverse effect on our results of operations
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on our executive officers and on our ability to attract and retain additional qualified personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
performance is substantially dependent on the performance of Lance Alstodt, our Chief Executive Officer. We rely upon him for strategic
business decisions and guidance. We are also dependent on the performance of Francisco Silva, our Vice President of Research and Development.
Each of Messrs. Alstodt and Silva is subject to an employment agreement with us. We do not have any key-man insurance policies on the
lives of either of our executive officers. We believe that our future success in developing marketable products and services and achieving
a competitive position will depend in large part upon whether we can attract and retain additional qualified management and scientific
personnel. Competition for such personnel is intense, and there can be no assurance that we will be able to attract and retain such personnel.
The loss of the services of Mr. Alstodt and/or Mr. Silva or the inability to attract and retain additional personnel and develop expertise
as needed would have a substantial negative effect on our results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Relating to Late Filing of our Periodic Report</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to prepare and timely file our Quarterly Report on Form 10-Q for the period ended March 31, 2024 with the SEC limits our access
to the public markets to raise debt or equity capital for a period of time.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
filed our Quarterly Report on Form 10-Q for the period ended March 31, 2024 with the SEC late on June 11, 2024; therefore, at such time,
we were not current in our reporting requirements with the SEC. We are not currently eligible, without receiving a waiver from the SEC,
to register our securities pursuant to a short-form registration statement on Form S-3 or a &#8220;shelf&#8221; registration statement
until June 2025. After such date, we must maintain status as a current filer. If we wish to pursue an offering now, we would be required
to conduct the offering on an exempt basis or file a registration statement on Form S-1. Using a Form S-1 registration statement for
a public offering could take significantly longer than using a registration statement on Form S-3 and increase our transaction costs,
and could, to the extent we are not able to conduct offerings using alternative methods, adversely impact our ability to raise capital
or complete acquisitions of other companies in a timely manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Cell Therapy Product Development Efforts</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future success is significantly dependent on the timely and successful development and commercialization of BRTX-100, our lead product
candidate for the treatment of chronic lumbar disc disease; if we encounter delays or difficulties in the development of this product
candidate, as well as any other product candidates, our business prospects would be significantly harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent upon the successful development, approval and commercialization of our product candidates. Before we are able to seek regulatory
approval of our product candidates, we must conduct and complete extensive clinical trials to demonstrate their safety and efficacy in
humans. Our lead product candidate, <i>BRTX-100</i>, is in early stages of development and we have just recently commenced a Phase 2
clinical trial using <i>BRTX-100</i> to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging
discs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive, difficult to design and implement, and can take many years to complete. Importantly, a failure of one or more of
these or any other clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result
of, clinical trials that could delay or prevent our ability to complete our clinical studies, receive regulatory approval or commercialize
our cell therapy product candidates, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspensions,
    delays or changes in the design, initiation, enrollment, implementation or completion of required clinical trials; adverse changes
    in our financial position or significant and unexpected increases in the cost of our clinical development program; changes or uncertainties
    in, or additions to, the regulatory approval process that require us to alter our current development strategy; clinical trial results
    that are negative, inconclusive or less than desired as to safety and/or efficacy, which could result in the need for additional
    clinical studies or the termination of the product&#8217;s development; delays in our ability to manufacture the product in quantities
    or in a form that is suitable for any required clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intellectual
    property constraints that prevent us from making, using, or commercializing any of our cell therapy product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    supply or quality of our product candidates or other materials necessary to conduct clinical trials of these product candidates may
    be insufficient or inadequate; the inability to generate sufficient pre-clinical, toxicology, or other in vivo or in vitro data,
    to support the initiation of clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching agreement on acceptable terms with prospective clinical study sites, the terms of which can be subject to extensive negotiation
    and may vary significantly among different clinical study sites;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining required Institutional Review Board, or IRB, approval at each clinical study site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND application
    or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical
    trial participants; a negative finding from an inspection of our clinical study operations or study sites; developments on trials
    conducted by competitors or approved products post-market for related technology that raise FDA concerns about risk to patients of
    the technology broadly; or if the FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    collaborating with patient groups and investigators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by our CRO, other third parties, or us to adhere to clinical study requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to perform in accordance with the FDA&#8217;s current Good Clinical Practices, or GCP, requirements, or applicable regulatory guidelines
    in other countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in having patients qualify for or complete participation in a study or return for post-treatment follow-up;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    dropping out of a study;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
    of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfer
    of manufacturing processes from any academic collaborators to larger-scale facilities operated by either a contract manufacturing
    organization, or CMO, or by us, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in our clinical trials caused by health emergencies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for
    use in clinical studies or the inability to do any of the foregoing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA not accepting clinical data from trials that are conducted at clinical sites in countries where the standard of care is potentially
    different from the United States; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to raise sufficient funds to complete our clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
inability to successfully complete pre-clinical and clinical development could result in additional costs to us or impair our ability
to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required, or we
may elect, to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical study delays could also
shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before
we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we are able to successfully complete our clinical development program for our product candidates, and ultimately receive regulatory
approval to market one or more of the products, we may, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    approval for indications that are not as broad as the indications we sought;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
    the product removed from the market after obtaining marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">encounter
    issues with respect to the manufacturing of commercial supplies;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    subject to additional post-marketing testing requirements; and/or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    subject to restrictions on how the product is distributed or used.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we will not be able to commercialize our <i>BRTX-100</i> product candidate for at least five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may experience delays and other difficulties in enrolling a sufficient number of patients in our clinical trials which could delay or
prevent the receipt of necessary regulatory approvals.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to initiate or complete as planned any clinical trials if we are unable to identify and enroll a sufficient number of
eligible patients to participate in the clinical trials required by the FDA or other regulatory authorities. We also may be unable to
engage a sufficient number of clinical trial sites to conduct our trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may face challenges in enrolling patients to participate in our clinical trials due to the novelty of our cell-based therapies, the size
of the patient populations and the eligibility criteria for enrollment in the trial. In addition, some patients may have concerns regarding
cell therapy that may negatively affect their perception of therapies under development and their decision to enroll in the trials. Furthermore,
patients suffering from diseases within target indications may enroll in competing clinical trials, which could negatively affect our
ability to complete enrollment of our trials. Enrollment challenges in clinical trials often result in increased development costs for
a product candidate, significant delays and potentially the abandonment of the clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may have other delays in completing our clinical trials and we may not complete them at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have just recently commenced the clinical trials necessary to obtain FDA approval to market our product candidate, <i>BRTX-100</i>. Since
we lack significant experience in completing clinical trials and bringing a drug through commercialization, we have hired outside consultants
with such experience. Clinical trials for <i>BRTX-100 </i>and other product candidates in development may be delayed or terminated as
a result of many factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    failing to complete clinical trials due to dissatisfaction with the treatment, side effects, or other reasons;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by regulators to authorize us to commence a clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or termination by regulators of clinical research for many reasons, including concerns about patient safety, the failure of study
    sites and/or investigators in our clinical research program to comply with GCP requirements, or our failure, or the failure of our
    contract manufacturers, to comply with current cGMP requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or failure to obtain clinical supply for our products necessary to conduct clinical trials from contract manufacturers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">treatment
    candidates demonstrating a lack of efficacy during clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">treatment
    candidates demonstrating significant safety signals; and/or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to continue to fund clinical trials or to find a partner to fund the clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay or failure to complete clinical trials and obtain FDA approval for our product candidates could have a material adverse effect
on our cost to develop and commercialize, and our ability to generate revenue from, a particular product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
development of our cell therapy product candidates is subject to uncertainty because autologous cell therapy is inherently variable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
manufacturing an autologous cell therapy, the number and composition of the cell population varies from patient to patient. Such variability
in the number and composition of these cells could adversely affect our ability to manufacture autologous cell therapies in a cost-effective
or profitable manner and meet acceptable product release specifications for use in a clinical trial or, if approved, for commercial sale.
As a consequence, the development and regulatory approval process for autologous cell therapy products could be delayed or may never
be completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
disruption to our access to the media (including cell culture media) and reagents we are using in the clinical development of our cell
therapy product candidates could adversely affect our ability to perform clinical trials and seek future regulatory submissions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
media (including cell culture media) and reagents, as well as devices, materials and systems, that we intend to use in our clinical trials,
and that we may need or use in commercial production, are provided by unaffiliated third parties. Any lack of continued availability
of these media, reagents, devices, materials and systems for any reason would have a material adverse effect on our ability to complete
these studies and could adversely impact our ability to achieve commercial manufacture of our planned therapeutic products. Although
other available sources for these media, reagents, devices, materials and systems may exist in the marketplace, we have not evaluated
their cost, effectiveness, or intellectual property foundation and therefore cannot guarantee the suitability or availability of such
other potential sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Products
that appear promising in research and development may be delayed or may fail to reach later stages of clinical development.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful development of cellular based products is highly uncertain. Product candidates that appear promising in preclinical and early
research and development may be delayed or fail to reach later stages of development. Decisions regarding the further development of
product candidates must be made with limited and incomplete data, which makes it difficult to ensure or even accurately predict whether
the allocation of limited resources and the expenditure of additional capital on specific product candidates will result in desired outcomes.
Pre-clinical and clinical data can be interpreted in different ways, and negative or inconclusive results or adverse events during a
clinical trial could delay, limit or prevent the development of a product candidate. Positive preclinical data may not continue or occur
for future subjects in our clinical studies and may not be repeated or observed in ongoing or future studies involving our product candidates.
Furthermore, our product candidates may also fail to show the desired safety and efficacy in later stages of clinical development despite
having successfully advanced through initial clinical studies. In addition, regulatory delays or rejections may be encountered as a result
of many factors, including changes in regulatory policy during the period of product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates, which would prevent or delay regulatory
approval and commercialization.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trials of our product candidates are, and the manufacturing and marketing of our products will be, subject to extensive and
rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test
and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we
must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both
safe and effective for use in each target indication. In particular, because some of our product candidates are subject to regulation
as biological drug products, we will need to demonstrate that those products are safe, pure, and potent for use in their target indications.
Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended
use. The risk/benefit profile required for product licensure will vary depending on these factors and may include decrease or elimination
of pain, adequate duration of response, a delay in the progression of the disease, an improvement in function and/or decrease in disability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if such trials are successfully completed, we cannot guarantee that the FDA will interpret the results as we do or that the FDA will apply the policies and standards that we expect due to rapid and unpredictable regulatory policy
changes associated with the Trump Administration, and
more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are
not satisfactory to the FDA for support of a marketing application, we may be required to expend significant resources, which may
not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product
candidate, and the approval may be for a narrower indication than we seek.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate.
Even if our product candidates meet their safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete
their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA
Advisory Committee or other regulatory authority recommends non-approval or restrictions or conditions on approval. In addition, we may
experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes
in regulatory authority policy during the period of product development, clinical trials and the review process. For example, executive
orders and other government cost-saving measures may result in reductions in the number of FDA personnel available to review our applications
or conduct necessary pre-approval inspections of our manufacturing sites resulting in delays in the approvals of our product candidates.
Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant
limitations in the form of narrow indications, contraindications or a Risk Evaluation and Mitigation Strategy, or REMS. These regulatory
authorities may require warnings or precautions with respect to conditions of use or they may grant approval subject to the performance
of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims or allow the promotional
claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios
could materially harm the commercial prospects for our product candidates and materially and adversely affect our business, financial
condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may never obtain FDA approval for any of our product candidates in the United States and, even if we do, we may never obtain approval
for or commercialize any of our product candidates in any foreign jurisdiction, which would limit our ability to realize our full market
potential.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to eventually market any of our product candidates in any particular foreign jurisdiction, we must establish and comply with numerous
and varying regulatory requirements regarding safety and efficacy on a jurisdiction-by-jurisdiction basis. Approval by the FDA in the
United States, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. In addition, preclinical
studies and clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory
approval in one country does not guarantee regulatory approval in any other country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
processes vary among countries and can involve additional product testing and validation and additional administrative review periods.
Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical
trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent
the introduction of our product candidates in those countries. The foreign regulatory approval process involves similar risks to those
associated with FDA approval. We do not have any product candidates approved for sale in any jurisdiction, including international markets,
nor have we attempted to obtain such approval. If we fail to comply with regulatory requirements in international markets or to obtain
and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and
our ability to realize the full market potential of our products may be unrealized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
presently lack manufacturing capabilities to produce our product candidates at commercial scale quantities and do not have an alternate
manufacturing supply at this time, which could negatively impact our ability to meet any future demand for the products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have utilized our laboratory to provide the cell processing services necessary for clinical production of <i>BRTX-100 </i>for our Phase
2 disc clinical trial. We believe that we have sufficient laboratory capacity to provide such services with regard to the balance of
the Phase 2 trial; however, we would need to significantly expand our manufacturing capabilities to provide such cell processing services
to meet potential commercial demand for <i>BRTX-100</i> and any other of our product candidates, if approved, as well as any of our other
product candidates that might attain regulatory approval. Such expansion would require additional regulatory approvals. Even if we increase
our manufacturing capabilities, it is possible that we may still lack sufficient capacity to meet demand. Ultimately, if we are unable
to supply our products to meet commercial demand, whether because of processing constraints or other disruptions, delays or difficulties
that we experience, sales of the products and their long-term commercial prospects could be significantly damaged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek to utilize a third-party manufacturer for <i>BRTX-100</i> or any of our other product candidates; however, we do not have any
arrangements in place with a third-party manufacturer. If our facilities at which these product candidates would be manufactured or our
equipment were significantly damaged or destroyed, or if there were other disruptions, delays or difficulties affecting manufacturing
capacity, our planned and future clinical studies and commercial production for these product candidates would likely be significantly
disrupted and delayed. It would be both time consuming and expensive to replace this capacity with third parties, particularly since
any new facility would need to comply with the regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ultimately,
if we are unable to supply our cell therapy product candidates to meet commercial demand (assuming commercial approval is obtained),
whether because of processing constraints or other disruptions, delays or difficulties that we experience, our production costs could
dramatically increase and sales of the product and its long-term commercial prospects could be significantly damaged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
commercial potential and profitability of our products are unknown and subject to significant risk and uncertainty.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we successfully develop and obtain regulatory approval for our cell therapy product candidates, the market may not understand or accept
the products, which could adversely affect both the timing and level of future sales. Ultimately, the degree of market acceptance of
our product candidates (or any of our future product candidates) will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical effectiveness, safety and convenience of the product particularly in relation to alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to distinguish our products (which involve adult cells) from any ethical and political controversies associated with stem
    cell products derived from human embryonic or fetal tissue; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of the product, the reimbursement policies of government and third-party payors and our ability to obtain sufficient third-party
    coverage or reimbursement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we are successful in achieving sales of our product candidates, it is not clear to what extent, if any, the products will be profitable.
The costs of goods associated with production of cell therapy products are significant. In addition, some changes in manufacturing processes
or procedures generally require FDA or foreign regulatory authority review and approval prior to implementation. We may need to conduct
additional pre-clinical studies and clinical trials to support approval of any such changes. Furthermore, this review process could be
costly and time-consuming and could delay or prevent the commercialization of product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may have difficulties in sourcing brown adipose (fat) tissue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use brown adipose (fat) tissue to identify and characterize brown adipose derived stem cells for use in our pre-clinical <i>ThermoStem
Program. </i>There is no certainty that we will be able to continue to collect brown adipose samples through any relationships that we
have, have had or may establish with potential sources of brown adipose tissue. The inability to procure brown fat tissue would have
a material adverse effect upon our ability to advance our <i>ThermoStem Program.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
safety problems are encountered by us or others developing new stem cell-based therapies, our stem cell initiatives could be materially
and adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of stem cells for therapeutic indications is still in the very early stages of development. If an adverse event occurs during clinical
trials related to one of our proposed products and/or services or those of others, the FDA and other regulatory authorities may halt
clinical trials or require additional studies. The occurrence of any of these events would delay, and increase the cost of, our development
efforts and may render the commercialization of our proposed products and/or services impractical or impossible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are vulnerable to competition and technological change, and also to physicians&#8217; inertia.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will compete with many domestic and foreign companies in developing our technology and products, including biotechnology, medical device
and pharmaceutical companies. Many current and potential competitors have substantially greater financial, technological, research and
development, marketing, and personnel resources. There is no assurance that our competitors will not succeed in developing alternative
products and/or services that are more effective, easier to use, or more economical than those which we may develop, or that would render
our products and/or services obsolete and non-competitive. In general, we may not be able to prevent others from developing and marketing
competitive products and/or services similar to ours or which perform similar functions or which are marketed before ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may have greater experience in developing products, therapies or devices, conducting clinical trials, obtaining regulatory clearances
or approvals, manufacturing and commercialization. It is possible that competitors may obtain patent protection, approval or clearance
from the FDA or achieve commercialization earlier than we can, any of which could have a substantial negative effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will compete against cell-based therapies derived from alternate sources, such as bone marrow, adipose tissue, umbilical cord blood and
potentially embryos. Doctors historically are slow to adopt new technologies like ours, whatever the merits, when older technologies
continue to be supported by established providers. Overcoming such inertia often requires very significant marketing expenditures or
definitive product performance and/or pricing superiority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that physicians&#8217; inertia and skepticism will also be a significant barrier as we attempt to gain market penetration with
our future products and services. We may need to finance lengthy time-consuming clinical studies (so as to provide convincing evidence
of the medical benefit) in order to overcome this inertia and skepticism.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not
realize the benefits of such alliances or licensing arrangements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may form or seek strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third
parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates
and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges,
increase our near and long-term expenditures, issue securities that dilute the shares of our existing stockholders, or disrupt our management
and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming
and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements
for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third
parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. To date, such efforts
have not been successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
collaborations involving our product candidates, such as our collaborations with third-party research institutions, are subject to numerous
risks, which may include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    have significant discretion in determining the efforts and resources that they will apply to a collaboration;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization
    programs based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability
    of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate,
    repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing
    and distribution;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information
    in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary
    information or expose us to potential liability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of
    our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations
    may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization
    of the applicable product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we
    would not have the exclusive right to commercialize such intellectual property.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, if we enter into collaboration agreements and strategic partnerships or license our products or businesses, we may not be able
to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company
culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic
transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into
new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization
of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition,
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited experience in the development and marketing of cell therapies and may be unsuccessful in our efforts to establish a profitable
business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business plan has been focused historically on capturing a piece of the burgeoning field of cell therapy. We have limited experience
in the areas of cell therapy product development and marketing, and in the related regulatory issues and processes. Although we have
recruited a team that has experience with designing and conducting clinical trials and have hired FDA consultants, as a company, we have
limited experience in conducting clinical trials and no experience in conducting clinical trials through to regulatory approval of any
product candidate. In part because of this lack of experience, we cannot be certain that planned clinical trials will begin or be completed
on time, if at all. We cannot assure that we will successfully achieve our clinical development goals or fulfill our plans to capture
a piece of the cell therapy market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
cell therapy business is based on novel technologies that are inherently expensive, risky and may not be understood by or accepted in
the marketplace, which could adversely affect our future value.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical development, commercialization and marketing of cell and tissue-based therapies are at an early-stage, substantially research-oriented,
and financially speculative. To date, very few companies have been successful in their efforts to develop and commercialize a cell therapy
product. In general, cell-based or tissue-based products may be susceptible to various risks, including undesirable and unintended side
effects, unintended immune system responses, inadequate therapeutic efficacy, or other characteristics that may prevent or limit their
approval or commercial use. In addition, <i>BRTX-100</i> is a cell-based candidate that is produced by using a patient&#8217;s own stem
cells derived from bone marrow. Regulatory approval of novel product candidates such as <i>BRTX-100</i>, which is manufactured using
novel manufacturing processes, can be more complex and expensive and take longer than other, more well-known or extensively studied pharmaceutical
or biopharmaceutical products, due to the FDA&#8217;s lack of experience with them. To our knowledge, the FDA has not yet approved a
disc related stem cell therapy product. This lack of experience may lengthen the regulatory review process, require us to conduct additional
studies or clinical trials, which would increase our development costs, lead to changes in regulatory positions and interpretations,
delay or prevent approval and commercialization of these product candidates or lead to significant post-approval limitations or restrictions.
Furthermore, the number of people who may use cell or tissue-based therapies is difficult to forecast with accuracy. Our future success
is dependent on the establishment of a large global market for cell- and tissue-based therapies and our ability to capture a share of
this market with our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
cell therapy product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
enactment of the Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated regulatory pathway for the
approval of products demonstrated to be biosimilar, or &#8220;highly similar,&#8221; to or &#8220;interchangeable&#8221; with an FDA-approved
innovator (original) biologic product. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve
biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to
an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years
after the original branded product is approved under a biologics license application, or BLA. The FDA has developed considerable experience
with the biosimilar and interchangeable biosimilar processes since the enactment of the BPCIA in 2009. Should any of our product candidates
be approved via the BLA pathway, we expect that biosimilar applicants will seek approval of biosimilar, and/or interchangeable, versions
of our product that could result in lower prices for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that, if any of our product candidates are approved as a biological product under a BLA, it should qualify for the 12-year period
of exclusivity. However, there is a risk that the FDA could approve biosimilar applicants for other reference products that no longer
have such exclusivity, thus potentially creating the opportunity for greater competition sooner than anticipated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also face increased competition from stem cell therapies performed by treatment centers that do not require FDA premarket approval.
In August 2022, a federal District Court in the case of <i>United States v. California Stem Cell Treatment Center, Inc.</i> held that
certain autologous adipose stem cell treatments were not &#8220;biological products&#8221; and therefore did not require FDA approval.
The decision was reversed by the U.S. Court of Appeals for the Ninth Circuit, but may be appealed to the U.S. Supreme Court. Should it
be reversed by the Supreme Court, we could face competition from stem cell clinics that would not be required to undergo the costly and
time-consuming FDA approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA&#8217;s regulation of regenerative medicine products remains unpredictable and we are not certain what impact this will have on the
potential approval of our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s regulation of therapies derived from stem cell products and technologies is evolving and may continue to evolve. In December
2016, the 21st Century Cures Act, or the Cures Act, was signed into law in the United States to advance access to medical innovations.
Among other things, the Cures Act established a new FDA regenerative medicine advanced therapy, or RMAT, designation. This designation
offers a variety of benefits to product candidates, including enhanced FDA support during clinical development, priority review on application
filing, accelerated approval based on potential surrogate endpoints, and the potential use of patient registry data and other forms of
real world evidence for post-approval confirmatory studies. There is no certainty that any of our product candidates will receive RMAT
designation or any other type of expedited review program designation from the FDA. In any event, the receipt of an FDA RMAT designation
or other expedited review program designation may not result in a faster development process, review or approval compared to products
considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to significant product liability claims and litigation, including potential exposure from the use of our product candidates
in human subjects, and our insurance may be inadequate to cover claims that may arise.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to potential product liability risks inherent in the testing, processing and marketing of cell therapy products.
Such liability claims may be expensive to defend and result in large judgments against us. We face an inherent risk of product liability
exposure related to the testing of our current and any future product candidates in human clinical trials and will face an even greater
risk with respect to any commercial sales of our products should they be approved. No product candidate has been widely used over an
extended period of time, and therefore safety data is limited. Cell therapy companies derive the raw materials for manufacturing of product
candidates from human cell sources, and therefore the manufacturing process and handling requirements are extensive, which increases
the risk of quality failures and subsequent product liability claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to maintain insurance coverage adequate to cover our clinical trials and increase that coverage before commercializing product
candidates, if ever. At any time during our clinical trials or after commercialization, if that occurs, we may not be able to obtain
or maintain product liability insurance on acceptable terms with adequate coverage or at all, or if claims against us substantially exceed
our coverage, then our financial position could be significantly impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not we are ultimately successful in any product liability litigation that may arise, such litigation could consume substantial amounts
of our financial and managerial resources, result in decreased demand for our products and injure our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to maintain errors and omissions, directors and officers, workers&#8217; compensation and other insurance at levels we believe to
be appropriate to our business activities. If, however, we were subject to a claim in excess of this coverage or to a claim not covered
by our insurance and the claim succeeded, we would be required to pay the claim from our own limited resources, which could have a material
adverse effect on our financial condition, results of operations and business. Additionally, liability or alleged liability could harm
our business by diverting the attention and resources of our management and damaging our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those that are expected to be used by our clinical investigators, clinical research organizations or other
contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of development programs
for our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on information technology systems to keep financial records, maintain laboratory and corporate records, communicate with staff and
external parties and operate other critical functions. Any significant degradation or failure of these computer systems could cause us
to inaccurately calculate or lose data. Despite the implementation of security measures, these internal computer systems and those used
by our clinical investigators, clinical research organizations, and other contractors and consultants are vulnerable to damage from computer
viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures. The techniques that could
be used by criminal elements or foreign governments to attack these computer systems are sophisticated, change frequently and may originate
from less regulated and remote areas of the world. While we have not experienced any such system failure, theft of information, accident
or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption
of our clinical development activities. For example, the loss of clinical trial data from historical or future clinical trials could
result in delays in regulatory approval efforts and significantly increase costs to recover or reproduce the data. To the extent that
any disruption, theft of information, or security breach were to result in a loss of or damage to data or applications, or inappropriate
disclosure of confidential or proprietary information, we could incur liability and the clinical development and the future development
of our product candidates could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
operate and sell in international markets carries great risk.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to market our products and services both domestically and in foreign markets. A number of risks are inherent in international
transactions. In order for us to market our products and services in non-U.S. jurisdictions, we need to obtain and maintain required
regulatory approvals or clearances in these countries and must comply with the country specific regulations regarding safety, manufacturing
processes and quality. These regulations, including the requirements for approvals or clearances to market, may differ from the FDA regulatory
scheme. International operations and sales also may be limited or disrupted by political instability, price controls, trade restrictions
and changes in tariffs. Additionally, fluctuations in currency exchange rates may adversely affect demand for our services and products
by increasing the price of our products and services in the currency of the countries in which the products and services are offered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that we will obtain regulatory approvals or clearances in all of the countries where we intend to market our products
and services, that we will not incur significant costs in obtaining or maintaining foreign regulatory approvals or clearances, or that
we will be able to successfully commercialize our products and services in various foreign markets. Delays in receipt of approvals or
clearances to market our products and services in foreign countries, failure to receive such approvals or clearances or the future loss
of previously received approvals or clearances could have a substantial negative effect on our results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
inability to obtain reimbursement for our products and services from private and governmental insurers could negatively impact demand
for our products and services.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
acceptance and sales of our product candidates may depend on coverage and reimbursement policies and health care reform measures. Decisions
about formulary coverage as well as levels at which government authorities and third-party payors, such as private health insurers and
health maintenance organizations, reimburse patients for the price they pay for our product candidates, as well as levels at which these
payors pay directly for our product candidates, where applicable, could affect whether we are able to successfully commercialize these
products. We cannot guarantee that reimbursement will be available for any of our product candidates. We also cannot guarantee that coverage
or reimbursement amounts will not reduce the demand for, or the price of, our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
coverage and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize
our products. The Patient Protection and Affordable Care Act, or PPACA, as well as the Inflation Reduction Act, passed in August 2022,
and other health reforms include measures that would limit or prohibit payments for certain medical treatments or subject the pricing
of drugs and biologics to government control. In addition, in many foreign countries, particularly the countries of the European Union,
or the EU, the pricing of drugs and biologics is subject to government control. If our products are or become subject to government regulation
that limits or prohibits payment for our products, or that subjects the price of our products to government control, we may not be able
to generate revenue, attain profitability or commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, third-party payors are increasingly limiting both coverage and the level of reimbursement of new drugs and biologics. They
may also impose strict prior authorization requirements and/or refuse to provide any coverage of uses of approved products for medical
indications other than those for which the FDA has granted market approvals. As a result, significant uncertainty exists as to whether
and how much third-party payors will reimburse patients for their use of newly-approved drugs and biologics. If we are unable to obtain
adequate levels of reimbursement for our product candidates, our ability to successfully market and sell our product candidates will
be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
activity as a contract manufacturer of biologic-based cosmetics could result in FDA enforcement for reasons outside of our control, which
could disrupt the development of our own product candidates or harm our reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
manufacture a commercial product as a contract manufacturer for a third-party company, Cartessa. While we believe the product we manufacture
for Cartessa is intended for cosmetic uses, we (as the contract manufacturer) do not ultimately have control over how the product is
marketed. It is possible that the FDA could determine, based on how the product is marketed (among other considerations), that it is
intended for unapproved therapeutic use(s), which could result in the temporary or permanent suspension of manufacturing and/or commercialization
of the product and/or a wide range of enforcement actions, such as warning letters, recall, &#8216;dear doctor&#8217; letters, and others.
If the FDA takes enforcement action against Cartessa or us in connection with this product, it could have an adverse impact on our operations
and/or harm our reputation as a biologics company.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Intellectual Property</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our proprietary rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend in large part upon our ability to protect our proprietary rights. There is no assurance, for example,
that any additional patents will be issued based on our or our licensor&#8217;s pending applications or, if issued, that such patents
will not become the subject of a re-examination, will provide us with competitive advantages, will not be challenged by any third parties,
or that the patents of others will not prevent the commercialization of products and services incorporating our technology. Furthermore,
there can be no guarantee that others will not independently develop similar products and services, duplicate any of our products and
services, or design around any patents we obtain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will also depend upon our ability to avoid infringing patents issued to others. If we were judicially determined to
be infringing on any third-party patent, we could be required to pay damages, alter our products, services or processes, obtain licenses,
or cease certain activities. If we are required in the future to obtain any licenses from third parties for some of our products and/or
services, there can be no guarantee that we would be able to do so on commercially favorable terms, if at all. United States and foreign
patent applications are not immediately made public, so we might be surprised by the grant to someone else of a patent on a technology
we are actively using. Although we conducted a freedom to operate, or FTO, search years ago on the licensed technology associated with
our <i>Disc/Spine Program</i>, modifications made, and/or further developments that may be made, to that technology may not be covered
by the initial FTO. No FTO has been undertaken with respect to our <i>ThermoStem </i>brown fat initiative.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation,
which would result in substantial costs to us and the diversion of effort on our part, may be necessary to enforce or confirm the ownership
of any patents issued or licensed to us, or to determine the scope and validity of third-party proprietary rights. If our competitors
claim technology also claimed by us and prepare and file patent applications in the United States, we may have to participate in interference
proceedings declared by the U.S. Patent and Trademark Office, or the Patent Office, or a foreign patent office to determine priority
of invention, which could result in substantial costs and diversion of effort, even if the eventual outcome is favorable to us. Any such
litigation or interference proceeding, regardless of outcome, could be expensive and time-consuming.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
challenges to our patents through oppositions, re-examination proceedings or interference proceedings could result in a loss of patent
rights in the relevant jurisdiction. If we are unsuccessful in actions we bring against the patents of other parties, and it is determined
that we infringe upon the patents of third parties, we may be subject to litigation, or otherwise prevented from commercializing potential
products and/or services in the relevant jurisdiction, or may be required to obtain licenses to those patents or develop or obtain alternative
technologies, any of which could harm our business. Furthermore, if such challenges to our patent rights are not resolved in our favor,
we could be delayed or prevented from entering into new collaborations or from commercializing certain products and/or services, which
could adversely affect our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of our confidential or sensitive information could be compromised by disclosure in the event of litigation. In addition, during the course
of litigation there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If
securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on unpatented trade secrets and proprietary technological expertise. Some of our intended future cell-related
therapeutic products and/or services may fit into this category. We also rely, in part, on confidentiality agreements with our partners,
employees, advisors, vendors, and consultants to protect our trade secrets and proprietary technological expertise. There can be no guarantee
that these agreements will not be breached, or that we will have adequate remedies for any breach, or that our unpatented trade secrets
and proprietary technological expertise will not otherwise become known or be independently discovered by competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to obtain or maintain patent protection, failure to protect trade secrets, third-party claims against our patents, trade secrets, or
proprietary rights or our involvement in disputes over our patents, trade secrets, or proprietary rights, including involvement in litigation,
could divert our efforts and attention from other aspects of our business and have a substantial negative effect on our results of operations
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property in countries outside of the United States.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
property law outside the United States is uncertain and, in many countries, is currently undergoing review and revisions. The laws of
some countries do not protect our patent and other intellectual property rights to the same extent as United States laws. Third parties
may attempt to oppose the issuance of patents to us in foreign countries by initiating opposition proceedings. Opposition proceedings
against any of our patent filings in a foreign country could have an adverse effect on our corresponding patents that are issued or pending
in the United States. It may be necessary or useful for us to participate in proceedings to determine the validity of our patents or
our competitors&#8217; patents that have been issued in countries other than the United States. This could result in substantial costs,
divert our efforts and attention from other aspects of our business, and could have a material adverse effect on our results of operations
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
to United States patent law may have a material adverse effect on our intellectual property rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Leahy-Smith America Invents Act, or AIA, which was signed into law in 2011, significantly changes United States patent law. It may take
some time to establish what the law means, since it is just being interpreted by the lower courts, Federal Circuit Courts of Appeal,
and the Supreme Court. The effects of these decisions are still not known. The first major change is that AIA switches the United States
patent system from a &#8220;first to invent&#8221; system to a &#8220;first to file&#8221; system. Now that the first to file system
is in effect, there is a risk that another company may independently develop identical or similar patents at approximately the same time,
and be awarded the patents instead of us. Further, for the second major change, AIA abolished interference proceedings, and establishes
derivation proceedings to replace interference proceedings in all cases in which the time period for instituting an interference proceeding
has not lapsed where an inventor named in an earlier application derived the claimed invention from a named inventor. Now that the derivation
proceedings are in effect, there is a risk that the inventorship of any pending patent application can be challenged for reasons of derivation.
The third major change is that AIA established post-grant opposition proceedings that will apply only to patent applications filed after
&#8220;first to file&#8221; became effective. Post-grant opposition will enable a person who is not the patent owner to initiate proceedings
in the Patent Office within nine months after the grant of a patent that can result in cancellation of a patent as invalid. In addition
to AIA, recent court decisions have created uncertainty with regard to our ability to obtain and maintain patents. Therefore there is
a risk that any of our patents once granted may be subject to post-grant opposition, which will increase uncertainty on the validity
of any newly granted patent or may ultimately result in cancellation of the patent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Supreme Court has recently taken more limiting positions as to what constitutes patentable subject matter. As a result,
many patents covering what were previously patentable inventions are now determined to cover inventions which are deemed non-statutory
subject matter and are now invalid. As a result of this and subsequent opinions by the Court of Appeals for the Federal Circuit, the
Patent Office is now applying more stringent limitations to claims in patent applications and is refusing to grant patents in areas of
technology where patents were previously deemed available. Therefore there is a risk that we will be unable to acquire patents to cover
our products and if such patents are granted they may subsequently be found to be invalid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
certain countries, patent holders may be required to grant compulsory licenses, which would likely have a significant and detrimental
effect on any future revenues in such country.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries, including some countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses
to third parties. In addition, most countries limit the enforceability of patents against government agencies or government contractors.
In these countries, the patent owner may be limited to monetary relief and may be unable to enjoin infringement, which could materially
diminish the value of the patent. Compulsory licensing of life-saving products is also becoming increasingly common in developing countries,
either through direct legislation or international initiatives. Such compulsory licenses could be extended to our product candidates,
which may limit our potential revenue opportunities, including with respect to any future revenues that may result from our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Government Regulation</span></i></b> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory oversight.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates for which we obtain regulatory approval will be subject to ongoing regulatory requirements for manufacturing, labeling,
packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information. Any regulatory
approvals that we receive for our product candidates also may be subject to a REMS or the specific obligations imposed as a condition
for marketing authorization by equivalent authorities in a foreign jurisdiction, limitations on the approved indicated uses for which
the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing,
including Phase 4 clinical trials, and surveillance to monitor the quality, safety and efficacy of the product. For example, in the United
States, the holder of an approved new drug application, or NDA, or BLA is obligated to monitor and report adverse events and any failure
of a product to meet the specifications in the NDA or BLA. The holder of an approved NDA or BLA also must submit new or supplemental
applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising
and promotional materials must comply with the Federal Food, Drug and Cosmetic Act, or FDCA, and implementing regulations and are subject
to FDA oversight and post-marketing reporting obligations, in addition to other potentially applicable federal and state laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, product manufacturers and their facilities may be subject to payment of application and program fees and are subject to continual
review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments
made in the NDA, BLA or foreign marketing application. If we or a regulatory authority discover previously unknown problems with a product,
such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or if
a regulatory authority disagrees with the promotion, marketing or labeling of our product, a regulatory authority may impose restrictions
relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or
suspension of manufacturing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with applicable regulatory requirements for any product candidate following approval, a regulatory authority may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    a warning or untitled letter asserting that we are in violation of the law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    an injunction or impose administrative, civil or criminal penalties or monetary fines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or withdraw regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any ongoing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic
    partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrict
    the marketing or manufacturing of the product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain the product or otherwise demand or require the withdrawal or recall of the product from the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to permit the import or export of products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">request
    and publicize a voluntary recall of the product; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to allow us to enter into supply contracts, including government contracts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
government enforcement action or investigation of alleged violations of law could require us to expend significant time and resources
in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to
commercialize our product candidates and adversely affect our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information
privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the research, manufacturing, distribution, sale, and promotion of drugs and biologic products are subject to regulation
by various federal, state, and local authorities, including the FDA, the Centers for Medicare and Medicaid Services, or CMS, other divisions
the Department of Health and Human Services, or HHS (e.g., the Office of Inspector General), the United States Department of Justice
offices of the United States Attorney, the Federal Trade Commission and state and local governments. Our operations are directly, or
indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations,
including the federal Anti-Kickback Statute, or AKS, the federal civil and criminal False Claims Act, or FCA, the Physician Payments
Sunshine Act and regulations and equivalent provisions in other countries. In addition, we may be subject to patient privacy laws by
both the federal government and the states in which we conduct our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
and federal regulatory and enforcement agencies continue actively to investigate violations of health care laws and regulations, and
the United States Congress continues to strengthen the arsenal of enforcement tools. For example, the Bipartisan Budget Act of 2018 increased
the criminal and civil penalties that can be imposed for violating certain federal health care laws, including the AKS. Enforcement agencies
also continue to pursue novel theories of liability under these laws. Government agencies have recently increased regulatory scrutiny
and enforcement activity with respect to programs supported or sponsored by pharmaceutical companies, including reimbursement and co-pay
support, funding of independent charitable foundations and other programs that offer benefits for patients. Several investigations into
these programs have resulted in significant civil and criminal settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any
of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and
criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment
and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our
results of operations. Even if we are not determined to have violated these laws, government investigations into these issues typically
require the expenditure of significant resources and generate negative publicity, which could harm our financial condition and divert
the attention of our management from operating our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
in the event we determine to operate in foreign jurisdictions, including conducting clinical trials, we will need to comply with the
United States Foreign Corrupt Practices Act of 1977, or the FCPA. The FCPA prohibits a corporation, including its subsidiaries, third-party
contractors, distributors, consultants and employees, from corruptly making or offering to make payments to foreign officials for the
purpose of obtaining or enhancing business. Under the law, &#8220;foreign officials&#8221; include employees of health systems operated
by government entities. The FCPA also establishes specific record-keeping and internal accounting controls. Violations of the FCPA can
result in the imposition of civil penalties or criminal prosecution. Failure to comply with the FCPA will adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the FCPA, we will also need to comply with the foreign government laws and regulations of each individual country in which
any therapy centers that we may establish are located and products are to be distributed and sold. These regulations vary in complexity
and can be as stringent, and on occasion even more stringent, than FDA regulations in the United States. Due to the fact that there are
new and emerging stem cell and cell therapy regulations that have recently been drafted and/or implemented in various countries around
the world, the application and subsequent implementation of these new and emerging regulations have little to no precedence. Therefore,
the level of complexity and stringency is not always precisely understood today for each country, creating greater uncertainty for the
international regulatory process. Furthermore, there can be no guarantee that laws and regulations will not be implemented, amended and/or
reinterpreted in a way that will negatively affect our business. Likewise, there can be no assurance that we will be able, or will have
the resources, to maintain compliance with all such healthcare laws and regulations. Failure to comply with such healthcare laws and
regulations, as well as the costs associated with such compliance or with enforcement of such healthcare laws and regulations, may have
a material adverse effect on our operations or may require restructuring of our operations or impair our ability to operate profitably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current and future employees, consultants and advisors and our future principal investigators, medical institutions and commercial partners
may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of fraud or other misconduct by our current and future employees, consultants, advisors, principal investigators,
medical institutions and commercial partners, including contract laboratories, and CROs. Misconduct by these parties could include intentional
failures to comply with FDA regulations or the regulations applicable in other jurisdictions, provide accurate information to the FDA
and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report
financial information or data accurately or disclose unauthorized activities to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not and in the future may not independently conduct all aspects of our product candidate research and preclinical and clinical
testing and product candidate manufacturing. If we rely on third parties, including CROs, medical institutions, and contract laboratories
to monitor and manage data for our ongoing preclinical and clinical programs, we will still maintain responsibility for ensuring their
activities are conducted in accordance with the applicable study protocol, legal, regulatory and scientific standards. We and our third-party
vendors will be required to comply with current cGMP, GCP, and Good Laboratory Practice, or GLP, requirements, which are a collection
of laws and regulations enforced by the FDA, the EU and comparable foreign authorities for all of our product candidates in clinical
development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended
to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a
wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.
Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the
FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
precautions we take to detect and prevent employee and third-party misconduct may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with
these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting
our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects,
including the imposition of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
failure to receive regulatory approvals for our cell therapy product candidates would likely have a material and adverse effect on our
business and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not received regulatory approval to market any of our product candidates in any jurisdiction. If we seek approval of any
of our cell therapy product candidates, we will be required to submit to the FDA and potentially other regulatory authorities extensive
pre-clinical and clinical data supporting its safety and efficacy, as well as information about the manufacturing process and to undergo
inspection of our manufacturing facility or other contract manufacturing facilities, if utilized, among other things. The process of
obtaining FDA and other regulatory approvals is expensive, generally takes many years and is subject to numerous risks and uncertainties,
particularly with complex and/or novel product candidates such as our cell-based product candidates. Changes in regulatory approval requirements,
policies, or court decisions may cause delays in the approval or rejection of an application, make it easier for our competitors to gain
regulatory approval to enter the marketplace, or allow competitors to enter the market without having to obtain FDA approval. Executive
orders and other government cost-saving measures may result in reductions in the number of FDA personnel available to review our applications
or conduct necessary pre-approval inspections of our manufacturing sites resulting in delays in the approvals of our product candidates.
Ultimately, the FDA and other regulatory agencies have substantial discretion in the approval process and may refuse to accept any application
or may decide that our product candidate data are insufficient for approval without the submission of additional preclinical, clinical
or other studies. In addition, varying agency interpretations of the data obtained from preclinical and clinical testing could delay,
limit or prevent regulatory approval of a product candidate. Any difficulties or failures that we encounter in securing regulatory approval
for our product candidates would likely have a substantial adverse impact on our ability to generate product sales, and could make any
search for a collaborative partner more difficult. Similarly, any regulatory approval we ultimately obtain may be limited or subject
to restrictions or post-approval commitments that render the approved product not commercially viable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to conduct clinical studies in accordance with regulations and accepted standards, we may be delayed in receiving, or may
never receive, regulatory approvals of our product candidates from the FDA and other regulatory authorities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain marketing approvals for our product candidates in the United States and abroad, we must, among other requirements, complete adequate
and well-controlled clinical trials sufficient to demonstrate to the FDA and other regulatory bodies that the product candidate is safe
and effective for each indication for which approval is sought. If the FDA finds that patients enrolled in the trial are or would be
exposed to an unreasonable and significant risk of illness or injury, due to, among other things, occurrence of a serious adverse event
in an ongoing clinical trial, the FDA can place one or more of our clinical trials on hold. If safety concerns develop, we may, or the
FDA or an institutional review board may require us to, stop the affected trials before completion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
completion of our clinical trials also may be delayed or terminated for a number of other reasons, including if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.55in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    clinical investigators do not perform the clinical trials on the anticipated schedule or consistent with the clinical trial protocol,
    good clinical practices required by the FDA and other regulatory requirements, or other third parties do not perform data collection
    and analysis in a timely or accurate manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspections
    of clinical trial sites by the FDA or other regulatory authorities reveal violations that require us to undertake corrective action,
    suspend or terminate one or more sites, or prohibit use of some or all of the data in support of marketing applications; or</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or one or more institutional review boards suspends or terminates the trial at an investigational site, or precludes enrollment
    of additional subjects.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
development costs will increase if there are material delays in our clinical trials, or if we are required to modify, suspend, terminate
or repeat a clinical trial. If we are unable to conduct our clinical trials properly, we may never receive regulatory approval to market
our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Health
care companies have been the subjects of federal and state investigations, and we could become subject to investigations in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
federal and state government agencies have heightened civil and criminal enforcement efforts. There are numerous ongoing investigations
of health care companies, as well as their executives and managers. In addition, amendments to the federal FCA, including under healthcare
reform legislation, have made it easier for private parties to bring &#8220;<i>qui tam</i>&#8221; (or whistleblower) lawsuits against
companies under which the whistleblower may be entitled to receive a percentage of any money paid to the government. The FCA provides,
in part, that an action can be brought against any person or entity that has knowingly presented, or caused to be presented, a false
or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim
approved. The government has taken the position that claims presented in violation of the federal AKS, Stark Law or other healthcare-related
laws, including laws enforced by the FDA, may be considered a violation of the FCA. Penalties include substantial fines for each false
claim, plus three times the amount of damages that the federal government sustained because of the act of that person or entity and/or
exclusion from the Medicare and Medicaid programs. In addition, a majority of states have adopted similar state whistleblower and false
claims provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any government investigations involving any of our facilities or management. While we believe that we are in compliance
with applicable governmental healthcare laws and regulations, any future investigations of our business or executives could cause us
to incur substantial costs, and result in significant liabilities or penalties, as well as damage to our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
is uncertain to what extent the government, private health insurers and third-party payors will approve coverage or provide reimbursement
for the therapies and products to which our services relate. Availability for such reimbursement may be further limited by reductions
in Medicare, Medicaid and other federal healthcare program funding in the United States.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that health care providers cannot obtain coverage or reimbursement for our products and therapies, they may elect not to provide
such products and therapies to their patients and, thus, may not need our services. Further, as cost containment pressures are increasing
in the health care industry, government and private payors may adopt strategies designed to limit the amount of reimbursement paid to
health care providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
the trend toward managed health care and bundled pricing for health care services in the United States, could significantly influence
the purchase of healthcare products and services, resulting in lower prices and reduced demand for our therapeutic products under development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may directly or indirectly receive revenues from federal health care programs, such as Medicare. Federal health care programs are subject
to changes in coverage and reimbursement rules and procedures, including retroactive rate adjustments. These contingencies could materially
decrease the range of services covered by such programs or the reimbursement rates paid directly or indirectly for our products and services.
To the extent that any health care reform favors the reimbursement of other therapies over our therapeutic products under development,
such reform could affect our ability to sell our services, which may have a material adverse effect on our revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
limitation on reimbursement available from private and government payors may reduce the demand for, or the price of, our products and
services, which could have a material adverse effect on our revenues. Additional legislation or regulation relating to the health care
industry or third-party coverage and reimbursement may be enacted in the future which could adversely affect the revenues generated from
the sale of our products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
there has been a trend in recent years towards reductions in overall funding for Medicare, Medicaid and other federal health care programs.
The reduced funding of governmental programs could have a negative impact on the demand for our services to the extent it relates to
products and services which are reimbursed by government and private payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unintended
consequences of healthcare reform in the United States may adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
healthcare industry is undergoing fundamental changes resulting from political, economic and regulatory influences. In the United States,
the PPACA was signed into law in 2010 under the Obama administration. By implementing comprehensive reforms, the law seeks to, among
other things, increase access to healthcare for the uninsured and control the escalation of healthcare expenditures within the economy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been adopted since the PPACA was enacted. These changes include aggregate reductions in Medicare
payments to providers of 2% per fiscal year, which went into effect in April 2013 and, following passage of the Bipartisan Budget Act
of 2018, will remain in effect through 2030 unless additional Congressional action is taken. In January 2013, President Obama signed
into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several types of providers
and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Congress
has since considered additional reductions in Medicare reimbursement for drugs and devices as part of legislation to reduce the budget
deficit. Similar legislation could be enacted in the future. The Medicare regulations and interpretive determinations that determine
how drugs, devices and services are covered and reimbursed also are subject to change. These laws, regulations, and interpretive determinations
may result in additional reductions in Medicare and other health care funding, which could impact our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2022, President Biden signed the Inflation Reduction Act, or the IRA, which provides for (i) the government to set or negotiate
prices for select high-cost Medicare Part D (beginning in 2026) and Medicare Part B drugs (beginning in 2028) that are more than nine
years (for small-molecule drugs) or 13 years (for biological products) from their FDA approval, (ii) manufacturers to pay a rebate for
Medicare Part B and Part D drugs when prices increase faster than inflation beginning in 2022 for Medicare Part D and 2023 for Medicare
Part B drugs, and (iii) Medicare Part D redesign which replaces the current coverage gap provisions and establishes a $2,000 cap for
out-of-pocket limits costs for Medicare beneficiaries beginning in 2025, with manufacturers being responsible for 10% of costs up to
the $2,000 cap and 20% after that cap is reached. Implementation of the IRA is expected to be carried out through upcoming actions by
regulatory authorities, the outcome of which is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
reform measures that may be adopted in the future, may result in more rigorous coverage criteria and decreased reimbursement. The implementation
of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or
commercialize our product candidates. It is difficult to predict how enforcement initiatives under the PPACA, the IRA, and/or additional
legislation or regulation enacted in the future may impact our business. If the PPACA, the IRA, and/or additional legislation or regulation
enacted in the future cause such unintended consequences or indirect impact, they could have a material adverse effect on our business,
financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Competitor
companies or hospitals in the EU may be able to take advantage of EU rules permitting sales of unlicensed medicines for individual patients
to sell competing products without a marketing authorization.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU medicines rules allow individual member states to permit the supply of a medicinal product without a marketing authorization to fulfill
special needs, where the product is supplied in response to a bona fide unsolicited order, formulated in accordance with the specifications
of a healthcare professional and for use by an individual patient under his direct personal responsibility. This may, in certain countries,
also apply to products manufactured in a country outside the EU and imported to treat specific patients or small groups of patients.
In addition, advanced therapy medicinal products do not need a marketing authorization if they are prepared on a non-routine basis and
are used within the same EU member state in a hospital in accordance with a medical prescription for an individual patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
exemptions could allow our competitors to make sales in the EU without having obtained a marketing authorization and without undergoing
the expense of clinical trials, especially if those competitors have cell processing facilities in the relevant EU member state. Similarly,
certain hospitals may be able to compete with us on the basis of these rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Related to Our Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
pay no dividends.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid cash dividends in the past, and currently do not intend to pay any cash dividends in the foreseeable future. We intend
to retain earnings, if any, to finance the development and expansion of our business. Our future dividend policy will be subject to the
discretion of our Board of Directors and will be contingent upon future earnings, if any, our financial condition, capital requirements,
general business conditions, and other factors. Therefore, we can give no assurance that any dividends of any kind will ever be paid
to holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is no assurance that an active trading market for our common stock will be sustained.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on Nasdaq. However, no assurance can be given that an active market for our common stock will be sustained. In
addition, although there have been market makers in our common stock, we cannot assure that these market makers will continue to make
a market in our securities or that other factors outside of our control will not cause them to stop market making in our securities.
Making a market in securities involves maintaining bid and ask quotations and being able to effect transactions in reasonable quantities
at those quoted prices, subject to various securities laws and other regulatory requirements. Furthermore, the development and maintenance
of a public trading market depends upon the existence of willing buyers and sellers, the presence of which is not within our control
or that of any market maker. Market makers are not required to maintain a continuous two-sided market, are required to honor firm quotations
for only a limited number of securities, and are free to withdraw firm quotations at any time. Even with a market maker, factors such
as our past losses from operations and the small size of our company mean that there can be no assurance of an active and liquid market
for our securities developing in the foreseeable future. Even if there is a market for our securities, we cannot assure that securityholders
will be able to resell their securities at any price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stockholders
who hold unregistered shares of our common stock are subject to resale restrictions pursuant to Rule 144 due to our former status as
a &#8220;shell company.&#8221;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
previously were a &#8220;shell company&#8221; pursuant to Rule 144, promulgated under the Securities Act, or Rule 144, and, as such,
sales of our securities pursuant to Rule 144 cannot be made unless, among other things, we continue to remain subject to Section 13 or
15(d) of the Exchange Act, and we file all of our required periodic reports with the SEC under the Exchange Act. Because our unregistered
securities cannot be sold pursuant to Rule 144 unless we continue to meet such requirements, any unregistered securities we sell in the
future or issue to consultants or employees, in consideration for services rendered or for any other purpose, will have no liquidity
unless we continue to comply with such requirements. As a result, it may be more difficult for us to obtain financing to fund our operations
and pay our consultants and employees with our securities instead of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred, and will continue to incur, increased costs as a result of being an SEC reporting company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as a variety of related rules implemented by the SEC, have required changes
in corporate governance practices and generally increased the disclosure requirements of public companies. As a reporting company, we
incur significant legal, accounting and other expenses in connection with our public disclosure and other obligations. Based upon SEC
regulations currently in effect, we are required to establish, evaluate and report on our internal control over financial reporting.
We believe that compliance with the myriad of rules and regulations applicable to reporting companies and related compliance issues will
continue to require a significant amount of time and attention from our management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Material
weaknesses in our internal control over financial reporting have caused and may cause us to fail to timely and accurately report our
financial results or result in a material misstatement of our consolidated financial statements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
identified control deficiencies in the design and operation of our internal control over financial reporting that constituted material
weaknesses, as further described in Item 9A of this Annual Report (&#8220;Controls and Procedures&#8221;). A material weakness is a deficiency,
or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material
misstatement of our consolidated financial statements will not be prevented or detected on a timely basis. Our material weaknesses related
to the following control deficiencies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of adherence to formal policies and procedures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of risk assessment procedures on internal controls to detect financial reporting risks on a timely manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Lack of design and implementation of effective controls to achieve complete
and accurate financial reporting and disclosures, including documented controls over the preparation and review of journal entries, account
reconciliations and income taxes.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of design and implementation of effective controls over the accounting for warrants issued in connection with equity financings.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
deficiencies described above resulted in a past misstatement and, if not remedied, could result in a misstatement of one or more
account balances or disclosures in our annual or interim consolidated financial statements that would not be prevented or detected, and,
accordingly, we determined that these control deficiencies constituted material weaknesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address our material weaknesses, we have engaged an external financial consulting firm to assist us with implementing enhancements and
controls within our accounting systems, and further evolving our accounting and quarterly and annual close processes. We will not be
able to remediate these control deficiencies until these steps have been completed and have been operating effectively for a sufficient
period of time and Management has concluded, through testing, that the controls are operating effectively. The redesign and implementation
of improvements to our accounting and proprietary systems and controls may be costly and time consuming and the cost to remediate may
impair our results of operations in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to remediate our material weakness, identify future material weaknesses in our internal control over financial reporting or fail
to meet the demands that have been placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act, we may be
unable to accurately report our financial results or report them within the timeframes required by law or stock exchange regulations.
Failure to comply with Section 404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the
SEC or other regulatory authorities. If additional material weaknesses exist or are discovered in the future, and we are unable to remediate
any such material weakness, our reputation, results of operations and financial condition could suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
stock price may fluctuate significantly and be highly volatile and this may make it difficult for a securityholder to resell our securities
at the volume, prices and times the securityholder finds attractive.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock may be subject to significant fluctuations and be highly volatile, which may make it difficult for a
securityholder to resell our securities at the volume, prices and times the securityholder finds attractive. There are many factors that
will impact our stock price and trading volume, including, but not limited to, the factors listed above under &#8220;Risks Related to
Our Business Generally,&#8221; &#8220;Risks Related to Our Cell Therapy Product Development Efforts,&#8221; &#8220;Risks Related to Our
Intellectual Property,&#8221; &#8220;Risks Related to Government Regulation,&#8221; &#8220;Risks Related to Our Common Stock&#8221; and
&#8220;Risks Associated with Our Nasdaq Listing.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
markets, in general, experience significant price and volume volatility, and the market price of our securities may continue to be subject
to such market fluctuations that may be unrelated to our operating performance and prospects. Increased market volatility and fluctuations
could result in a substantial decline in the market price of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
may be significant future issuances or resales of our common stock which may materially and adversely dilute stockholders&#8217; ownership
interest and affect the market price of our securities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have authorization to issue up to 75,000,000 shares of common stock of which, as of March 26, 2025, 7,504,780 shares were issued
and outstanding. In addition, as discussed in Item 1 (&#8220;Business &#8211; Business Development &#8211; Material Events During 2024&#8221;),
we are obligated to issue an additional 1,138,055 shares of common stock. We are not restricted from issuing additional shares of our
common stock in the future, including securities convertible into, or exchangeable or exercisable for, shares of our common stock. In
addition, there are 1,398,158 shares of Series B preferred stock issued and outstanding. Such shares are convertible under certain circumstances
into an equal number of shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our November 2021 public offering of securities, we issued warrants for the purchase of an aggregate of 2,645,000 shares of common
stock (of which warrants for the purchase of an aggregate of 1,675,000 shares of common stock have been exercised) as well as underwriter
warrants for the purchase of 235,970 shares of common stock. We have an effective registration statement on Form S-3 under the Securities
Act registering the issuance of such shares. The shares issuable pursuant to the registration statement on Form S-3 will be freely tradable
in the public market, except for shares held by affiliates. In addition, in connection with the public offering and pursuant to exchange
agreements entered into with holders of convertible notes and warrants, we issued an aggregate of 313,789 shares of common stock and
warrants for the purchase of an aggregate of 1,856,938 shares of common stock (of which warrants for the purchase of an aggregate of
1,676,580 shares of common stock have been exercised). The shares of common stock issued to such holders are eligible for resale in the
open market (subject to Rule 144 volume limitations applicable to affiliates), potentially causing sales in the market to increase and
our stock price to decline. We have registered the resale of the shares of common stock issuable upon exercise of such warrants. The
issuance of shares of common stock upon exercise of the above warrants would dilute the ownership of our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in February 2024, in connection with the warrant exercises discussed in Item 1 (&#8220;Business &#8211; Business Development
&#8211; Material Events During 2024&#8221;), we issued warrants for the purchase of an aggregate of 2,513,686 shares of common stock.
We have registered the resale of the shares of common stock underlying such warrants. The issuance of shares of common stock upon exercise
of the above warrants would dilute the ownership of our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have effective registration statements on Form S-8 under the Securities Act registering an aggregate of 6,850,000 shares of our
common stock issuable under our 2021 Stock Incentive Plan, or the 2021 Plan (of which 319,797 shares have been issued). As of March 27,
2025, options to purchase 5,237,973 shares of our common stock were outstanding under the 2021 Plan. The shares issued and issuable pursuant
to the registration statements on Form S-8 will be freely tradable in the public market, except for shares held by affiliates. We may
include a resale prospectus in a registration statement on Form S-8 with regard to the 2021 Plan covering the resale of the shares issuable
to Messrs. Alstodt and Silva (and other affiliates) upon their exercise of options held by them and shares issued to them upon the vesting
of restricted stock units, or RSUs, issued to them. The resale of such shares will be currently subject to the volume limitations imposed
by Rule 144.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we have an effective shelf registration statement on Form S-3 under the Securities Act registering $75,000,000 of our equity and debt
securities. Pursuant to the requirements of Form S-3, we currently may sell pursuant to such Form S-3, during any 12 month period, securities
having an aggregate market value of no more than one-third of the aggregate market value of the shares of our common stock held by non-affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sale of a substantial number of shares of our common stock or securities convertible into, or exchangeable or exercisable for, shares
of our common stock, whether directly by us in future offerings or by our existing stockholders in the secondary market, the perception
that such issuances or resales could occur or the availability for future issuances or resale of shares of our common stock or securities
convertible into, or exchangeable or exercisable for, shares of our common stock could materially and adversely affect the market price
of our securities and our ability to raise capital through future offerings of equity or equity-related securities on attractive terms
or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our Board of Directors is authorized to designate and issue 18,456,842 shares of preferred stock without further stockholder
approval, containing such rights and preferences as our Board of Directors shall determine. We may also issue other equity and equity-related
securities that are senior to our common stock in the future for a number of reasons, including, without limitation, to support operations
and growth, and to comply with any future changes in regulatory standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions and the regulations to which we may be subject may make it more difficult for a third party to acquire control of us, even
if the change in control would be beneficial to our securityholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated in Nevada. Anti-takeover provisions in Nevada law and our articles of incorporation and bylaws could make it more difficult
for a third party to acquire control of us and may prevent stockholders from receiving a premium for their securities. Our certificate
of incorporation provides that our Board of Directors may issue up to 20,000,000 shares of preferred stock, in one or more series, without
stockholder approval and with such terms, preferences, rights and privileges as the Board of Directors may deem appropriate. Of such
20,000,000 authorized shares, 1,398,158 shares of Series B preferred stock are issued and outstanding. These provisions and other factors
may hinder or prevent a change in control, even if the change in control would be perceived as beneficial to, or sought by, our other
stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Risks
Associated with Our Nasdaq Listing</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
cannot assure you that we will be able to continue to comply with the minimum bid price requirement of Nasdaq</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the market price of our common stock satisfied the initial listing minimum bid price requirement for Nasdaq, there can be no assurance
that the market price of our common stock will remain at the $1.00 per share level required for continuing compliance with that requirement.
There are many factors, such as negative financial or operational results, that could adversely affect the market price of our common
stock and jeopardize our ability to maintain Nasdaq&#8217;s minimum bid price requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our common stock may not attract new investors, including institutional investors, and may not satisfy the investing
requirements of those investors. Consequently, the trading liquidity of our common stock may not improve</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that our Nasdaq listing has helped generate greater and broader investor interest, including institutional investors, there
can be no assurances in that regard. In addition, there can be no assurance that the market price of our common stock will satisfy the
investing requirements of those investors. As a result, the trading liquidity of our common stock may not necessarily improve.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_001"></span>ITEM
    1B</b>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNRESOLVED
    STAFF COMMENTS</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_002"></span>ITEM
    1C</b>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYBERSECURITY</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>We
recognize the critical importance of cybersecurity in safeguarding sensitive information, maintaining operational resilience, and protecting
stakeholders&#8217; interests.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information
Technology and Cybersecurity Governance</b></span></span></span></p>

<div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_986_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_iB_c20240101__20241231_gBFCRBODOTB-RVBGSK_zCLEFDgCKPI3" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000048-01" escape="true" id="Fact000048" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate IT infrastructure, communication networks, and related systems are essential operational components. These systems manage product
development, internal and external communications, accounting functions, data storage, and other critical operations. Our business depends
on secure handling of proprietary, confidential, and sensitive data.</span></ix:nonNumeric></p>

<div id="xdx_C0E_gBFCRBODOTB-RVBGSK_zhLhw6kXuJJg"><ix:continuation continuedAt="ConU000048-02" id="ConU000048-01"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zzwvf59E06n5" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000049" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Our
Chief Financial Officer oversees information security efforts in conjunction with a <span id="xdx_909_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zhfkuwQnkeg1" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000050" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">third-party</ix:nonNumeric></span> IT services company and reports material
cybersecurity matters to the Chief Executive Officer and Board of Directors</ix:nonNumeric></span>.</span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0F_gBFCRBODOTB-RVBGSK_zsa7Dvh3ixq4"><ix:continuation id="ConU000048-02">&#160;</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Management and Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_98C_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPFAIAMT-BZSW_zQxUcfvEFC8b" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000053-01" escape="true" id="Fact000053" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
<span id="xdx_903_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zWCGyXxRAmw" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000054" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">recognize the importance of assessing, <span id="xdx_90B_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zrUEszxx1fJa" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000055" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">identifying</ix:nonNumeric></span>, and managing cybersecurity risks. These include operational vulnerabilities, intellectual
property theft, fraud, extortion, potential harm to stakeholders, regulatory compliance issues, and associated legal, financial, and
reputational consequences</ix:nonNumeric></span>.</span></ix:nonNumeric></p>

<div id="xdx_C0D_gBFCRMPFAIAMT-BZSW_zs9i4xR8arz"><ix:continuation continuedAt="ConU000053-02" id="ConU000053-01"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>In
partnership with external consultants, we maintain comprehensive information security processes to identify and mitigate material cybersecurity
risks. Our protective measures include:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technical,
                                            physical, and organizational safeguards</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaster
                                            recovery and business continuity planning</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
                                            encryption and network security controls</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access
                                            restrictions and physical security measures</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
                                            asset management</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuous
                                            systems monitoring</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
                                            security training</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
assessment to date shows that cybersecurity incidents and vulnerabilities have <span id="xdx_90F_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240101__20241231_zcRFntJBGU59" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000056" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">not</ix:nonNumeric></span> materially impacted our business operations, financial
performance, or strategic direction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ongoing monitoring and evaluation have not identified any cybersecurity risks that are expected to significantly affect our operational
capabilities, financial condition, or business objectives in the foreseeable future.</span></p>

</ix:continuation></div></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span><span><span id="xdx_C0A_gBFCRMPFAIAMT-BZSW_z6iu9i9fNkni"><ix:continuation id="ConU000053-02">&#160;</ix:continuation></span></span></span></span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
    2.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_003"></span>PROPERTIES</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices and laboratory are located at 40 Marcus Drive, Suite One, Melville, New York. We occupy 6,800 square feet
of space at the premises pursuant to a lease that expired in December 2024. The lease provided for a current annual base rental of $173,060.
We currently occupy the premises on a month-to-month basis at a monthly rental of $14,422 and are negotiating an extension of the term
of the lease. Our premises are suitable and adequate for our current operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_004"></span>ITEM
    3.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEGAL
    PROCEEDINGS</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_005"></span>ITEM
    4.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MINE
    SAFETY DISCLOSURES.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="aa_006"></span>PART
II</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_007"></span>ITEM
    5.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MARKET
    FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
in our common stock are currently reported under the symbol &#8220;BRTX&#8221; on the Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 20, 2025, there were 530 record holders of our shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer
Purchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_008"></span>ITEM
    6</b>.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[RESERVED]</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_009"></span>ITEM
    7.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGEMENT&#8217;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion and analysis of the consolidated results of operations and financial condition of BioRestorative Therapies, Inc.
as of December 31, 2024 and 2023 and for the years ended December 31, 2024 and 2023 should be read in conjunction with our financial
statements and the notes to those financial statements that are included elsewhere in this Annual Report following Item 16 (&#8220;Form
10-K Summary&#8221;). References in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
to &#8220;us,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and similar terms refer to BioRestorative Therapies, Inc. This Annual Report
contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements
contained in this Annual Report may not occur. Generally, these statements relate to business plans or strategies, projected or anticipated
benefits or other consequences of our plans or strategies, projected or anticipated benefits from acquisitions that may be made by us,
or projections involving anticipated revenues, earnings or other aspects of our operating results. The words &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221;
&#8220;estimate,&#8221; and &#8220;continue,&#8221; and their opposites and similar expressions, are intended to identify forward-looking
statements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties,
risks and other influences, many of which are beyond our control, which may influence the accuracy of the statements and the projections
upon which the statements are based. Reference is made to Item 1A of this Annual Report (&#8220;Risk Factors&#8221;) for a discussion
of some of the uncertainties, risks and assumptions associated with these statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
develop therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently pursuing our <i>Disc/Spine Program</i> with our initial investigational therapeutic product being called <i>BRTX-100</i>.
In March 2022, a United States patent issued in our <i>Disc/Spine Program</i>. We have received authorization from the FDA to commence
a Phase 2 clinical trial investigating the use of <i>BRTX-100</i> in the treatment of chronic lower back pain arising from degenerative
disc disease. We have commenced such clinical trial through the execution of a CRO agreement with PRC Clinical, the execution of clinical
trial site agreements, patient enrollment, the commencement of patient procedures, the purchase of manufacturing equipment and the expansion
of our laboratory to include capabilities for clinical production. We have obtained an exclusive license to use technology for investigational
adult stem cell treatment of disc and spine conditions, including protruding and bulging lumbar discs. The technology is an advanced
stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg
and foot.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also developing our <i>ThermoStem Program</i>. This pre-clinical program involves the use of brown adipose (fat) in connection with
the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
United States patents related to the <i>ThermoStem Program</i> were issued in September 2015, January 2019, March 2020, March 2021, July
2021, June 2023 and December 2023; Australian patents related to the <i>ThermoStem Program</i> were issued in April 2017, October 2019
and August 2021; Japanese patents related to the <i>ThermoStem Program</i> were issued in December 2017, June 2021, February 2022 June
2023, and July 2024; Israeli patents related to our <i>ThermoStem Program</i> were issued in October 2019, May 2020, March 2022 and March 2025; and
European patents related to the <i>ThermoStem Program </i>were issued in April 2020, January 2021, July 2023 and February 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate a commercial biocosmeceutical platform. Our current commercial product, formulated and manufactured as a third party contract manufacturer using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors.
This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring
forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial
offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the
aim of pioneering FDA approvals in the emerging biocosmeceuticals space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also licensed a patented curved needle device that is a needle system designed to deliver cells and/or other therapeutic products
or materials to the spine and discs or other potential sites. We anticipate that FDA approval or clearance will be necessary for this
device prior to commercialization. We do not intend to utilize this device in connection with our Phase 2 clinical trial with regard
to <i>BRTX-100</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
offices are located in Melville, New York where we have established a laboratory facility in order to increase our capabilities for the
further development of possible cellular-based treatments, products and protocols, stem cell-related intellectual property and translational
research applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, our accumulated deficit was $155,678,715. We have historically only generated a modest amount of revenue, and our
losses have principally been operating expenses incurred in research and development, marketing and promotional activities in order to
commercialize our products and services, plus costs associated with meeting the requirements of being a public company. We expect to
continue to incur substantial costs for these activities over at least the next year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, we entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, under
which we had the ability to issue and sell shares of our common stock, from time to time, through JonesTrading, up to an aggregate offering
price of approximately $6,109,000 in what is commonly referred to as an &#8220;at-the-market&#8221;, or ATM, program. During the year
ended December 31, 2023, we sold 132,827 shares of our common stock under the ATM program with JonesTrading at a weighted-average gross
price of approximately $4.68 per share and raised approximately $622,000 of gross proceeds. The total commissions and related legal fees
were approximately $127,000, and we received net proceeds of approximately $495,000. No shares were sold during the year ended December
31, 2024 pursuant to the ATM program with JonesTrading. In connection with the ATM program with Rodman &amp; Renshaw, LLC, or Rodman,
discussed below, in November 2024, we terminated the Capital on Demand Sales Agreement with JonesTrading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, we sold an aggregate of 685,033 shares of our common stock in a registered direct public offering. We received net proceeds
of approximately $1,854,000 from the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, we entered into an At The Market Offering Agreement with Rodman, under which we currently have the ability to issue and
sell shares of our common stock, from time to time, through Rodman, up to an aggregate offering price of approximately $3,614,000 in
an ATM program. Subsequent to the year ended December 31, 2024, we sold 492,000 shares of our common stock under the ATM program with
Rodman at a weighted-average gross price of approximately $2.20 per share and raised approximately $1,084,000 of gross proceeds. The
total commissions and related legal fees were approximately $178,000, and we received net proceeds of approximately $906,000. As of March
24, 2025, we had remaining capacity to sell up to an additional $2,530,000 of common stock under the ATM program with Rodman.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, we had a net loss of $9.0 million and negative cash flows from operations of $8.2 million and as of
December 31, 2024, we had working capital of $7.4 million. We anticipate that we will continue to incur net losses and negative cash
flows from operations as we execute our development plans for 2025 and beyond, as well as other potential strategic and business development
initiatives. These conditions raise substantial doubt about our ability to continue as a going concern for at least twelve months after
the issuance date of the financial statements included in this Annual Report. We will require significant additional funding to complete
our clinical trials using <i>BRTX-100. </i>We will require a substantial amount of additional funding to implement our other programs
as discussed in this Annual Report under the caption Item 1 (&#8220;Business&#8221;), including our metabolic <i>ThermoStem Program</i>,
and fund general operations. No assurance can be given that the amount of funding that we anticipate may be required for such purposes
is correct or that we will be able to accomplish our goals within the timeframes projected. In addition, no assurance can be given that
we will be able to obtain any required financing on commercially reasonable terms or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
Ended December 31, 2024 Compared with Year Ended December 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents selected items in our consolidated statements of operations for the years ended December 31, 2024 and 2023,
respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td colspan="2" style="font-size: 12pt; text-align: center">&#160;</td><td style="font-size: 12pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"/><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">401,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">145,800</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of goods sold</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">28,072</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">372,928</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Expenses:</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,348,709</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,034,591</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,579,413</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,331,983</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Total Operating Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,928,122</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,366,574</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Loss From Operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(11,555,194</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(15,220,774</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other Income:</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">616,077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">552,293</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Grant income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,664</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Gain on exchange of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,711,698</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Change in fair value of warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">97,188</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,997,780</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Total Other Income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,575,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,803,070</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 20pt">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,979,381</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(10,417,404</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenues</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and 2023, we generated $401,000 and $145,800, respectively, of royalty revenue in connection with our
sublicense agreement and sales revenue in connection with our cosmeceuticals business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include cash and non-cash compensation of (a) our Vice President of Research and Development; (b) our Scientific
Advisory Board members; and (c) laboratory staff and costs related to our brown fat and disc/spine initiatives. Research and development
expenses are expensed as they are incurred. For the year ended December 31, 2024, research and development expenses increased by $1,314,118,
or 33%, to $5,348,709 compared to $4,034,591 for the year ended December 31, 2023. The increase was primarily driven by headcount costs
of $323,025 and general lab supplies expense of $1,041,952, partially offset by the reversal of a 2023 bonus accrual of $257,873.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our research and development expenses will continue to increase with the continuation of the aforementioned initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and administrative</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries, bonuses, payroll taxes and stock-based compensation to employees (excluding
any cash or non-cash compensation of our Vice President of Research and Development and our laboratory staff), as well as corporate expenses
such as legal and professional fees, investor relations and occupancy related expenses. For the year ended December 31, 2024, general
and administrative expenses decreased by $4,752,570, or 42% to $6,579,413 from $11,331,983 for the year ended December 31, 2023. The
decrease was primarily driven by a decrease in stock-based compensation expense of $4,970,401 and a decrease in headcount costs of $111,363,
offset by an increase in professional fees of $229,273.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our general and administrative expenses related to operations will increase as we expand our staff, develop our infrastructure
and incur additional costs to support the growth of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
income</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, interest income increased $63,784, or 12%, to $616,077 from $552,293 for the year ended December 31,
2023. The increase was due to the interest and dividend income of the investments held in marketable securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Grant
income</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no grant income for the year ended December 31, 2024. Grant income of $83,333 during the year ended December 31, 2023 consisted of
funding received under a National Institutes of Health Small Business Technology Transfer (STTR) Phase 1 grant, offset by related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
income</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, other income of $150,850 primarily related to investment dividend income and other miscellaneous income.
For the year ended December 31, 2023, other income of $169,664 primarily related to an Employee Retention Tax Credit, gains from settlements
of certain accrued expenses and realized and unrealized gain on investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Gain
on Exchange of Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, we recognized a gain on exchange of $1,711,698 related to the issuance of warrants and common stock
in exchange for the cancellation of existing warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in fair value of derivative liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, we recognized a gain on the change in fair value of warrant liabilities of $97,188 related to the reduction
in the fair value of the warrants that are accounted for as warrant liabilities. For the year ended December 31, 2023, we recognized
a gain on the change in fair value of warrant liabilities of $3,997,780 related to the reduction in the fair value of the warrants that
are accounted for as warrant liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure our liquidity in a number of ways, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">547,890</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">884,377</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Investments held in marketable securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,184,701</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,181,618</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Working capital</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,395,815</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,783,181</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Availability
of Additional Funds</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, we had a net loss of $9.0 million and negative cash flows from operations of $8.2 million and as of
December 31, 2024, we had working capital of $7.4 million. We anticipate that we will continue to incur net losses and negative cash
flows from operations as we execute our development plans for 2025 and beyond, as well as other potential strategic and business development
initiatives. Based on these conditions, we believe we may not have sufficient cash for at least twelve months after
the issuance date of the financial statements included in this Annual Report which raises substantial doubt about our ability to continue as a going concern. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating needs include the planned costs to operate our business, including amounts required to fund our clinical trials, working capital
and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including
our ability to successfully commercialize our products and services, competing technological and market developments, and the need to
enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service
offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to raise sufficient additional capital when we need it or raise capital on favorable terms. Future financing may require
us to pledge certain assets and enter into covenants that could restrict certain business activities or our ability to incur further
indebtedness and may contain other terms that are not favorable to our stockholders or us. If we are unable to obtain adequate funds
on reasonable terms, we may be required to significantly curtail or discontinue operations or obtain funds by entering into financing
agreements on unattractive terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#8220;At-the-Market&#8221;
Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, we entered into an At The Market Offering Agreement with Rodman, under which we currently have the ability to issue and
sell shares of our common stock, from time to time, through Rodman, up to an aggregate offering price of approximately $3,614,000 in
an ATM, program. Subsequent to the year ended December 31, 2024, we sold 492,000 shares of our common stock under the ATM program with
Rodman at a weighted-average gross price of approximately $2.20 per share and raised approximately $1,084,000 of gross proceeds. The
total commissions and related legal and accounting fees were approximately $178,000 and we received net proceeds of approximately $906,000.
As of March 26, 2025, we had remaining capacity to sell up to an additional $2,530,000 of common stock under the ATM program with Rodman.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrant
Exercises</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2024, we received gross proceeds of approximately $8,100,000 pursuant to the exercise of outstanding warrants. See Item 1 (&#8220;Business
&#8211; Business Development &#8211; Material Events During 2024&#8221;) for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, our sources and uses of cash were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Cash Used In Operating Activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,230,346</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,430,211</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Cash Provided By Investing Activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">514,529</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,252,043</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Cash Provided By Financing Activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,379,330</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,348,773</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Decrease in Cash</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(336,487</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(829,395</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Used in Operating Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $8,230,346 for the year ended December 31, 2024, primarily due to cash used to fund the net loss
of $8,979,381 which gives effect to net non-cash expenses of $720,382, partially offset by $28,653 of cash provided by changes in operating
assets and liabilities. Net cash used in operating activities was $6,430,211 for the year ended December 31, 2023, primarily due to cash
used to fund the net loss of $10,417,704 which gives effect to net non-cash expenses of $3,472,167, partially offset by $515,326 of cash
provided by changes in our operating assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Provided by Investing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by investing activities decreased by $2,737,514 for the year ended December 31, 2024 compared to the year ended December
31, 2023, primarily due to the purchase of marketable securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Cash Provided by Financing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities increased by $5,030,557 for the year ended December 31, 2024 compared to the year ended December
31, 2023 due to the gross proceeds from the exchange and issuance of warrants of $8,123,391, less issuance costs of $595,364, all partially
offset by $2,348,773 of gross proceeds from the sale of common stock pursuant to an ATM and direct offering undertaken
during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effects
of Inflation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not believe that inflation had a material impact on our business, revenues or operating results during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
prepare our consolidated financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, which require
our management to make estimates that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities
at the balance sheet dates, as well as the reported amounts of revenues and expenses during the reporting periods. To the extent that
there are material differences between these estimates and actual results, our financial condition or results of operations would be
affected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking account
of our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were
highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from
period to period or the use of different estimates that we reasonably could have used in the current period would have a material impact
on our financial condition or results of operations. There are items within our financial statements that require estimation but are
not deemed critical, as defined above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a detailed discussion of our significant accounting policies and related judgments, see Note 2 of the Notes to Consolidated Financial
Statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2 to our consolidated financial statements for the years ended December 31, 2024 and 2023 included elsewhere in this Annual Report
following Item 16 (&#8220;Form 10-K Summary&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that
is material to investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_010"></span>ITEM
    7A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUANTITATIVE
    AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 71.3pt; text-align: justify; text-indent: -71.3pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_011"></span>ITEM
    8.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL
    STATEMENTS AND SUPPLEMENTARY DATA</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements required by this Item 8 of this Annual Report are included in this Annual Report following Item 16 (&#8220;Form
10-K Summary&#8221;). As a smaller reporting company, we are not required to provide supplementary financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_012"></span>ITEM
    9.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CHANGES
    IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_013"></span>ITEM
    9A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTROLS
    AND PROCEDURES</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934, as amended, or the Exchange Act), that are designed to ensure that information required to be disclosed in our reports under
the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms,
and that such information is accumulated and communicated to our management, including our principal executive officer and principal
financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures,
our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls
and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future
conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance
of achieving the desired control objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of our management, including our principal executive officer and principal financial officer,
we are required to perform an evaluation of our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the
Exchange Act, as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has completed such evaluation and has concluded that our disclosure controls and procedures were not effective to provide reasonable
assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is appropriate to allow
timely decisions regarding required disclosures. As a result of the material weakness in internal controls over financial reporting described
below, we concluded that our disclosure controls and procedures as of December 31, 2024 were not effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Annual Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial
reporting is a process designed under the supervision of our principal executive and principal financial officer and effected by our
Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of our consolidated financial statements for external reporting purposes in accordance with GAAP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections
of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in
conditions or that the degree of compliance with the policies or procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
Weaknesses in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assessed the effectiveness of our internal control over financial reporting as of December 31, 2024 based on the framework established
in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on this assessment, management has determined that our internal control over financial reporting as of December 31, 2024 was not
effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
material weakness, as defined in the standards established by the Sarbanes-Oxley is a deficiency, or a combination of deficiencies, in
internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim
consolidated financial statements will not be prevented or detected on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ineffectiveness of our internal control over financial reporting was due to the following material weaknesses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of adherence to formal policies and procedures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of risk assessment procedures on internal controls to detect financial reporting risks in a timely manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Lack of design and implementation of effective controls to achieve complete
and accurate financial reporting and disclosures, including documented controls over the preparation and review of journal entries, account
reconciliations and income taxes.</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of design and implementation of effective controls over the accounting for warrants issued in connection with equity financings.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -35.6pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Plan to Remediate the Material Weaknesses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weaknesses
are remediated, such that these controls are designed, implemented, and are operating effectively. The remediation actions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    personnel, including our Chief Financial Officer, are overseeing the financial reporting process and implementation of enhanced controls
    and governance;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engagement
    of external financial consulting firm with expertise in accounting for significant and complex non-routine transactions to continue
    to enhance financial reporting, financial operations and internal controls; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documentation
    of key procedures and controls using a risk-based approach.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -35.6pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is committed to maintaining a strong internal controls environment and implementing measures designed to help ensure that control deficiencies
contributing to the material weakness are remediated as soon as possible. We have documented key procedures and controls using a risk-based
approach and have, therefore, made progress toward remediation. We continue to implement our remediation plan, which includes continued
engagement of an external financial consulting firm to enhance financial reporting and operations as well as design and implementation
of controls. We will consider the material weakness remediated after the applicable controls operate for a sufficient period of time,
and management has concluded, through testing, that the controls are operating effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting on an ongoing
basis and we are committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds
allow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control
over financial reporting. Management&#8217;s report was not subject to attestation by our independent registered public accounting firm
pursuant to rules of the Securities and Exchange Commission that exempt smaller reporting companies from this requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than described above, there have been no changes in our internal control over financial reporting that occurred during our fourth quarter
of 2024 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_014"></span>ITEM
    9B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER
    INFORMATION</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--NoInsiderTradingFlag_dbT_c20240101__20241231_zDO20kUJHtPd" title="No insider trading flag" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000058" name="BRTX:NoInsiderTradingFlag">None</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_015"></span>ITEM
    9C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DISCLOSURE
    REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="aa_016"></span>PART
III</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_017"></span>ITEM
    10.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DIRECTORS,
    EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding our directors and executive officers is set forth below. Each of our officers devotes his full business time in providing services
on our behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 61%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Positions
    Held</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President and Chairman of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    Silva</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President of Research and Development, Secretary and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    E. Kristal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay
    Kukekov, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Compensation Committee Chair</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    F. Williams</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Audit Committee Chair</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Rosa</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Nominating Committee Chair</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lance
Alstodt</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
Alstodt has served as our Chief Executive Officer, President and Chairman of the Board since November 2020. He served as our Executive
Vice President and Chief Strategy Officer from October 2018 to February 2020. Since 2013, Mr. Alstodt has served as Chief Executive Officer
of MedVest Consulting Corporation, an advisory and capital firm that focuses exclusively on the healthcare industry. Prior to MedVest,
he was an investment banker with over 23 years of experience with respect to healthcare investment banking, including mergers and acquisitions.
From 2011 to 2013, Mr. Alstodt was a Managing Director at Leerink Partners where he helped lead its medical technology sector. From 2009
to 2011, he was a Managing Director and Head of Medical Technology at Oppenheimer &amp; Co. From 2000 to 2009, Mr. Alstodt was a Managing
Director in the Healthcare Group and Global Mergers and Acquisitions Group at Bank of America Merrill Lynch. He previously spent seven
years as a Vice President in the Global Mergers and Acquisitions Group at J.P. Morgan Chase, where he worked extensively on acquisitions,
leveraged buyouts, private and public financings, exclusive sales and general advisory assignments. Mr. Alstodt received a degree in
Economics from the State University of New York at Albany, with a secondary concentration in Finance and Marketing. We believe that Mr.
Alstodt&#8217;s executive-level management experience with us and other healthcare businesses and his extensive experience in the investment
banking field relating to the healthcare sector give him the qualifications to serve as one of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Francisco
Silva</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
Silva has served as our Vice President of Research and Development since March 2013, having also previously served in such position from
April 2011 until March 2012. Mr. Silva was elected our Secretary and a director in November 2020. He served as our Research Scientist
from March 2012 to June 2012 and as our Chief Scientist from June 2012 to March 2013. From 2007 to 2011, Mr. Silva served as Chief Executive
Officer of DV Biologics LLC, and as President of DaVinci Biosciences, LLC, companies engaged in the commercialization of human based
biologics for both research and therapeutic applications. From 2003 to 2007, Mr. Silva served as Vice President of Research and Development
for PrimeGen Biotech LLC, a company engaged in the development of cell based platforms. From 2002 to 2003, he was a Research Scientist
with PrimeGen Biotech and was responsible for the development of experimental designs that focused on germ line reprogramming stem cell
platforms. Mr. Silva has taught courses in biology, anatomy and advanced tissue culture at California State Polytechnic University. He
has obtained a number of patents relating to stem cells and has had numerous articles published with regard to stem cell research. Mr.
Silva graduated from California State Polytechnic University with a degree in Biology. He also obtained a Graduate Presidential Fellowship
and MBRS Fellowship from California State Polytechnic University. We believe that Mr. Silva&#8217;s executive-level management experience
with us since April 2011 and his extensive knowledge of the science related to our business give him the qualifications to serve as one
of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Robert
E. Kristal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
E. Kristal has served as our Chief Financial Officer since November 2021. Mr. Kristal is an experienced Wall Street and Bay Street professional
who has served in various management roles within multiple business lines of investment banks. From 2016 to 2020, he was Head of Equity
Research at H.C. Wainwright. Mr. Kristal provided investment banking and merchant banking services from 2013 to 2016 at H.C. Wainwright
and T.R. Winston. He is a Charted Financial Analyst. Mr. Kristal received a Bachelor of Arts degree in Economics from Wilfrid Laurier
University and a Bachelor of Commerce (Honors) degree in Finance from the University of Windsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nickolay
Kukekov, Ph.D.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay
Kukekov, Ph.D. has served as one of our directors since March 2021 and Chair of our Board&#8217;s Compensation Committee since November
2021. For more than the past fifteen years, Dr. Kukekov has held a number of healthcare investment banking positions. He has served as
Senior Managing Director of Paulson Investment Company, LLC since 2020. From 2012 to 2020, Dr. Kukekov was a founding partner of Highline
Research Advisors LLC. He served as a Managing Director of Summer Street Research Partners from 2010 to 2012. From 2007 to 2009, Dr.
Kukekov was a Managing Director of Paramount Capital. He served as a Vice President of Rodmen &amp; Renshaw from 2006 to 2007. He serves
as a director of Brain Scientific, Inc. and Omnia Wellness Inc. whose shares are publicly traded. Dr. Kukekov received a Bachelor of
Arts degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and a Ph.D. in neuroscience from
Columbia University College of Physicians and Surgeons. We believe that Dr. Kukekov&#8217;s extensive experience in the investment banking
field relating to the healthcare sector and his strong background in regenerative medicine give him the qualifications to serve as one
of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patrick
F. Williams</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
F. Williams has served as one of our directors and Chair of our Board&#8217;s Audit Committee since November 2021. Mr. Williams has more
than 20 years of experience across medical device, consumer product goods and technology sectors. Mr. Williams served as Chief Financial
Officer of STAAR Surgical Company, or STAAR, from July 2020 to March 2025 and is currently serving as a consultant to STAAR. From 2016
to 2019, he served as the Chief Financial Officer of Sientra, Inc. before transitioning to General Manager for its miraDry&#174; business
unit. From 2012 to 2016, Mr. Williams served as Chief Financial Officer of ZELTIQ Aesthetics, Inc., a publicly-traded medical device
company that was acquired by Allergan. Previously, he served as Vice President in finance, strategy and investor relations roles from
2007 to 2012 at NuVasive, Inc., a San-Diego based medical device company servicing the spine sector. He has also held finance roles with
Callaway Golf and Kyocera Wireless. Mr. Williams received an MBA in Finance and Management from San Diego State University and a Bachelor
of Arts in Economics from the University of California, San Diego. We believe that Mr. Williams&#8217; executive-level management experience
with healthcare-related businesses, including his financial management expertise, give him the qualifications to serve as one of our
directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>David
Rosa</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Rosa has served as one of our directors and Chair of our Board&#8217;s Nominating Committee since November 2021. Mr. Rosa has served
as the Chief Executive Officer, President and a director of NeuroOne Medical Technologies Corporation, or NeuroOne (Nasdaq: NMTC), since
July 2017 and served as Chief Executive Officer and a director of NeuroOne, Inc., formerly its wholly-owned subsidiary, from October
2016 until December 2019, when NeuroOne, Inc. merged with and into NeuroOne. NeuroOne is committed to providing minimally invasive and
hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#8217;s
disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve
patient outcomes and reduce procedural costs. From November 2009 to November 2015, Mr. Rosa served as the Chief Executive Officer and
President of Sunshine Heart, Inc., n/k/a CHF Solutions, Inc. (Nasdaq: CHFS), a publicly-held early-stage medical device company. From
2008 to November 2009, he served as Chief Executive Officer of Milksmart, Inc., a company that specializes in medical devices for animals.
From 2004 to 2008, Mr. Rosa served as the Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical,
Inc. He serves as a director on the board of directors of Biotricity Inc. (Nasdaq:BTCY) and Healthcare Triangle, Inc. (Nasdaq:HCTI).
Mr. Rosa is Chairman of Neuro Event Labs, a privately-held company in Finland, and an Advisory Board member of SYNAPS Dx, a privately-held
company in Bethesda, Maryland. We believe that Mr. Rosa&#8217;s senior leadership experience in the medical device industry and his strong
technical, strategic, and operational expertise give him the qualifications to serve as one of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scientific
Advisory Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following persons are the members of our Scientific Advisory Board:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    Positions</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wayne
    Marasco, M.D., Ph.D.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professor,
    Department of Cancer Immunology &amp; AIDS, Dana-Farber Cancer Institute;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professor
    of Medicine, Harvard Medical School;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Faculty Member, Harvard Stem Cell Institute</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jason
    Lipetz, M.D.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    Disc Advisory Committee</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founder,
    Long Island Spine Rehabilitation Medicine;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    of Spine Medicine, Northwell Health Spine Center;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Assistant Professor, Department of Physical Medicine and Rehabilitation, Zucker School of Medicine at Hofstra/Northwell</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wayne
    J. Olan, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Interventional and Endovascular Neurosurgery;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Associate
    Professor, Neurosurgery and Radiology, George Washington University Medical Center;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting
    Physician, Department of Radiology, National Institutes of Health</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 34%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joy
    Cavagnaro, Ph.D.,</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DABT,
    RAC</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Founder, Access BIO, L.C.; Fellow, Academy of Toxicological Sciences and the Regulatory Professional Society;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formerly
    Senior Pharmacologist and Director of Quality Assurance, Food and Drug Administration&#8217;s Center for Biologics Evaluation and
    Research</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harvinder
    Sandhu, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orthopedic
    Spine Surgeon, Hospital for Special Surgery;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formerly
    Chief of Spinal Surgery Service, UCLA Medical Center</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Plastaras, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Director of Musculoskeletal Spine and Sports Rehabilitation Medicine and Physiatrist, MossRehab;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formerly
    Director of The Penn Spine and Rehabilitation Center;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formerly
    Director of Spine, Sports and Musculoskeletal Medicine Fellowship, University of Pennsylvania</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our executive officers, directors and Scientific Advisory Board members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term
of Office</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a classified Board of Directors. The directors will hold office until the respective annual meetings of stockholders indicated below
and until their respective successors are elected and qualified or until their earlier resignation or removal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    Expires</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    Silva</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay
    Kukekov</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    F. Williams</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Rosa</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
executive officer will hold office until the initial meeting of the Board of Directors following the next annual meeting of stockholders
and until his successor is elected and qualified or until his or her earlier resignation or removal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee of the Board of Directors is responsible for overseeing our accounting and financial reporting processes and the audits
of our financial statements. The members of the Audit Committee are Mr. Williams (Chair), Dr. Kukekov and Mr. Rosa.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee Financial Expert</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has determined that Mr. Williams qualifies as an &#8220;audit committee financial expert,&#8221; as that term is defined in Item
407(d)(5) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delinquent
Section 16(a) Beneficial Ownership Reports</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16 of the Exchange Act requires that reports of beneficial ownership of common stock and changes in such ownership be filed with the
Securities and Exchange Commission by Section 16 &#8220;reporting persons,&#8221; including directors, certain officers, holders of more
than 10% of the outstanding common stock and certain trusts of which reporting persons are trustees. We are required to disclose in this
Annual Report each reporting person whom we know to have failed to file any required reports under Section 16 on a timely basis during
the fiscal year ended December 31, 2024. To our knowledge, based solely on a review of copies of Forms 3, 4 and 5 filed with the Securities
and Exchange Commission, during the fiscal year ended December 31, 2024, our officers, directors and 10% stockholders complied with all
Section 16(a) filing requirements applicable to them, except that Dale Broadrick, a 10% stockholder, filed a Form 4 late (reporting one
transaction).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics for Senior Financial Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has adopted a Code of Ethics for our principal executive officer, principal financial officer, principal accounting
officer or controller, or persons performing similar functions. A copy of the Code of Ethics is posted on our website, www.biorestorative.com.
We intend to satisfy the disclosure requirement under Item 5.05(c) of Form 8-K regarding an amendment to, or a waiver from, our Code
of Ethics by posting such information on our website, <span style="text-decoration: underline">www.biorestorative.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have <span id="xdx_908_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbT_c20241001__20241231_zF5n70CZCwY" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleantrue" id="Fact000059" name="ecd:InsiderTrdPoliciesProcAdoptedFlag">adopted</ix:nonNumeric></span> an insider trading policy governing the purchase, sale and/or other disposition of our company&#8217;s securities by directors,
officers and employees that is designed to promote compliance with insider trading laws, rules and regulations, as well as procedures
designed to further the foregoing purposes. A copy of our insider trading policy is filed as an exhibit to this Annual Report on Form
10-K. In addition, from time to time, we may engage in transactions in our company&#8217;s securities. It is our intent to comply with
applicable laws and regulations relating to insider trading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_018"></span>ITEM
    11.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXECUTIVE
    COMPENSATION</b>. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following Summary Compensation Table sets forth all compensation earned in all capacities during the fiscal years ended December 31,
2024 and 2023 by (i) our principal executive officer, and (ii) our two most highly compensated executive officers, other than our principal
executive officer, who were serving as an executive officer as of December 31, 2024 and whose total compensation for the 2024 fiscal
year, as determined by Regulation S-K, Item 402, exceeded $100,000 (the individuals falling within categories (i) and (ii) are collectively
referred to as the Named Executive Officers):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Salary</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bonus</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Awards<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other Compensation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Lance Alstodt</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">593,583</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">275,000</td><td style="width: 1%; text-align: left"><sup>(2)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">1,314,583</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chief Executive Officer</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">479,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">475,000</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,254,167</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">514,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">262,500</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,227,083</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">VP, Research and Development</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">454,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">450,000</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,204,167</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Kristal</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">293,752</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">90,000</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">683,752</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">240,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">127,500</td><td style="text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">618,124</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    reflect the aggregate grant date fair value of grants made in the fiscal year computed in accordance with stock-based accounting
    rules (FASB ASC Topic 718-Stock Compensation). Assumptions used in the calculations of these amounts are included in Note 8 to our
    consolidated financial statements included in this Annual Report.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 85; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    2024 Bonus amount represents a discretionary bonus in consideration of 2024 services which was paid in 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    2023 Bonus amount represents (a) a discretionary bonus is the amount of $250,000 in consideration of 2023 services which was paid
    in 2024 and (b) a discretionary bonus in the amount of $225,000 in consideration of 2022 services which was paid in 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    2023 Bonus amount represents (a) a discretionary bonus in the amount of $237,500 in consideration of 2023 services which was paid
    in 2024 and (b) a discretionary bonus in the amount of $212,500 in consideration of 2022 services which was paid in 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    2023 Bonus amount represents (a) a discretionary bonus in the amount of $75,000 in consideration of 2023 services which was paid
    in 2024 and (b) a discretionary bonus in the amount of $52,500 in consideration of 2022 services which was paid in 2023.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information on outstanding equity awards as of December 31, 2024 to the Named Executive Officers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="17" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities underlying unexercised options exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities underlying unexercised options unexercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity incentive plan awards: Number of securities underlying unexercised unearned options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option exercise price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option expiration date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares or units of stock that have not vested</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Market value of shares of units that have not vested</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity incentive plan awards: Number of unearned shares, units or other rights that have not vested</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: left">Lance Alstodt</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">293,479</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">5.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">3/18/31</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lance Alstodt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,059</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">11/4/31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lance Alstodt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,072</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,690</td><td style="text-align: left">(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/17/33</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lance Alstodt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219,298</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219,298</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/13/34</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">9/4/25</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">6/10/26</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">7/12/27</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">10/29/28</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">293,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">3/18/31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,059</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">11/4/31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,072</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,690</td><td style="text-align: left">(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/17/33</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Francisco Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,369</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,368</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/13/34</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Kristal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,490</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">11/4/31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Kristal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,726</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,242</td><td style="text-align: left">(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/17/33</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Kristal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131,579</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131,579</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/13/34</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    becomes exercisable in four nearly equal quarterly installments beginning on February 17, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    becomes exercisable in eight nearly equal quarterly installments beginning on February 13, 2025.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 86; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lance
Alstodt</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
November 16, 2020, Mr. Alstodt was elected our Chief Executive Officer, President and Chairman of the Board. On March 18, 2021, we entered
into an employment agreement with Mr. Alstodt which provides for a term ending on March 18, 2026. Pursuant to the employment agreement,
Mr. Alstodt currently is entitled to receive an annual salary of $600,000 (giving effect to a $150,000 performance salary increase received
in November 2021 and $50,000 annual increases in salary pursuant to his employment agreement). Concurrently with the execution of the
employment agreement, we granted to Mr. Alstodt pursuant to the 2021 Plan (i) a ten year option for the purchase of 293,479 shares of
our common stock at an exercise price of $47.60 per share (which exercise price was subsequently reduced to $13.50 per share and further
reduced to $5.08 per share) and (ii) 146,740 RSUs. The option vested to the extent of 50% thereof on the date of grant, 12.5% on November
4, 2021 and the balance in six equal quarterly installments commencing on December 18, 2021. The RSUs vested in three equal annual installments
on the first, second and third anniversaries of the date of grant. In the event that Mr. Alstodt&#8217;s employment is terminated by
us without &#8220;cause&#8221;, or Mr. Alstodt terminates his employment for &#8220;good reason&#8221; (each as defined in the employment
agreement), Mr. Alstodt will be entitled to receive severance in an amount up to one time his then annual base salary. If Mr. Alstodt&#8217;s
employment with us is terminated without cause, the option granted to Mr. Alstodt will remain exercisable until its expiration date notwithstanding
such termination of employment with us. In March 2022, we and Mr. Alstodt agreed that, in lieu of a $50,000 increase in his annual salary
(as provided for in his employment agreement), we issued to Mr. Alstodt 12,438 RSUs (having a value of $50,000), which RSUs vested in
twelve equal monthly installments. Such grant was in consideration of Mr. Alstodt deferring his right to receive the $50,000 increase
in his salary for one year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Francisco
Silva</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, we and Mr. Silva entered into an employment agreement which provides for a term ending on March 18, 2026. Pursuant to
the employment agreement, Mr. Silva is currently entitled to receive an annual salary of $575,000 (giving effect to a $150,000 performance
salary increase received in November 2021 and $50,000 annual increases in salary pursuant to his employment agreement). Concurrently
with the execution of the employment agreement, we granted to Mr. Silva pursuant to the 2021 Plan (i) a ten year option for the purchase
of 293,479 shares of our common stock at an exercise price of $47.60 per share (which exercise price was subsequently reduced to $13.50
per share and further reduced to $5.08 per share) and (ii) 146,740 RSUs. The option vested to the extent of 50% thereof on the date of
grant, 12.5% on November 4, 2021 and the balance in six equal quarterly installments commencing on December 18, 2021. The RSUs vested
in three equal annual installments on the first, second and third anniversaries of the date of grant. In the event that Mr. Silva&#8217;s
employment is terminated by us without &#8220;cause&#8221;, or Mr. Silva terminates his employment for &#8220;good reason&#8221; (each
as defined in the employment agreement), Mr. Silva will be entitled to receive severance in an amount up to one time his then annual
base salary. If Mr. Silva&#8217;s employment with us is terminated without cause, the option granted to Mr. Silva will remain exercisable
until its expiration date notwithstanding such termination of employment with us. In March 2022, we and Mr. Silva agreed that, in lieu
of a $50,000 increase in his annual salary (as provided for in his employment agreement), we issued to Mr. Silva 12,438 RSUs (having
a value of $50,000), which RSUs vested in twelve equal monthly installments. Such grant was in consideration of Mr. Silva deferring his
right to receive the $50,000 increase in his salary for one year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information concerning the compensation of our non-employee directors for the fiscal year ended December
31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fees Earned or Paid in Cash</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards</td><td style="padding-bottom: 0.06in; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-Equity Incentive Plan Compensation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nonqualified Deferred Compensation Earnings</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other Compensation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Nickolay Kukekov</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">35,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">90,000</td><td style="padding-bottom: 0.06in; width: 1%; text-align: left"><sup>(1)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">125,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patrick F. Williams</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">90,000</td><td style="padding-bottom: 0.06in; text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">125,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">David Rosa</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">90,000</td><td style="padding-bottom: 0.06in; text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">125,000</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, Dr. Kukekov held options for the purchase of 136,910 shares of common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, Mr. Williams held options for the purchase of 122,164 shares of common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, Mr. Rosa held options for the purchase of 122,164 shares of common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Kukekov and Messrs. Williams and Rosa, our non-employee directors, as compensation for their services as a director, are entitled to
receive per annum $35,000 in cash and $90,000 in option grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Award Grant Practices</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
awards are discretionary and are generally granted to our named executive officers in the second or third week of February each year.
In certain circumstances, including the hiring or promotion of an officer, the Compensation Committee may approve grants to be effective
at other times. The Compensation Committee did not take material nonpublic information into account when determining the timing and terms
of equity awards in 2024, and we do not time the disclosure of material nonpublic information for the purpose of affecting the value
of executive compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_019"></span>ITEM
    12.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITY
    OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.15in; text-align: justify; text-indent: -1.15in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.15in; text-align: justify; text-indent: -1.15in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.15in; text-align: justify; text-indent: -1.15in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information regarding the beneficial ownership of our common stock, as of March 20, 2025, known by
us, through transfer agent records and reports filed with the SEC, to be held by: (i) each person who beneficially owns 5% or more of
the shares of common stock then outstanding; (ii) each of our directors; (iii) each of our Named Executive Officers (as defined above);
and (iv) all of our directors and executive officers as a group. The following table also sets forth certain information regarding the
beneficial ownership of our Series B preferred stock as of March 20, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this table reflects &#8220;beneficial ownership&#8221; as defined in Rule 13d-3 of the Exchange Act. To our knowledge,
and unless otherwise indicated, each stockholder has sole voting power and investment power over the shares listed as beneficially owned
by such stockholder, subject to community property laws where applicable. Percentage ownership is based on 7,504,780 shares of common
stock (exclusive of the shares of common stock issuable to Auctus Fund, LLC, or Auctus, as discussed in footnote (10) to the following
table) and 1,398,158 shares of Series B preferred stock outstanding as of March 20, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and Address of Beneficial</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owner</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Shares of<br/> Common Stock<br/> Beneficially</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></p></td><td style="padding-bottom: 0.05in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Approximate<br/> Percent of<br/> Class</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares of Series<br/> B Preferred<br/> Stock<br/> Beneficially<br/> Owned</td><td style="padding-bottom: 0.05in; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Approximate<br/> Percent of Class</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Directors and Executive Officers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance Alstodt<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">1,270,893</td><td style="padding-bottom: 0.05in; width: 1%; text-align: left"><sup>(2)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">14.8</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-</td><td style="padding-bottom: 0.05in; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco Silva<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,228,117</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Kristal<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">344,051</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nickolay Kukekov</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,068</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patrick F. Williams</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135,322</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">David Rosa</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135,322</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">All directors and executive officers as a group (6 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,263,773</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Certain Beneficial Owners</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dale Broadrick<sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">923,905</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Todd Hale Morrison</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">645,000</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(9)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Auctus Fund, LLC<sup>(10)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auctus Fund Management LLC<sup>(10)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alfred Sollami<sup>(10)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 0.05in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Louis Posner<sup>(10)</sup></span></p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">758,997</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(11)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.99</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,398,158</td><td style="padding-bottom: 0.05in; text-align: left"><sup>(12)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than 1%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    is c/o BioRestorative Therapies, Inc., 40 Marcus Drive, Suite One, Melville, New York 11747.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    1,099,021 shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    1,060,222 shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days and 12,136
    shares of common stock held by Mr. Silva in a retirement account.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    336,057 shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    2,916,012 shares of common stock issuable upon the exercise of options that are exercisable currently or within 60 days.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    is 3003 Brick Church Pike, Nashville, Tennessee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    upon Amendment No. 9 to Schedule 13D and Forms 4 filed with the SEC. Includes 477,972 shares of common stock held by Fleetco Inc.
    of which Mr. Broadrick is a 93% stockholder.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    upon Schedule 13G, as amended, filed with the SEC, Mr. Morrison has shared voting and dispositive power with respect to the 645,000
    shares of common stock. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    is 545 Boylston Street, 2<sup>nd</sup> Floor, Boston, Massachusetts 02116.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    upon Amendment No. 3 to Schedule 13G filed with the SEC and other filings made with the SEC. Auctus holds warrants for the purchase
    of up to 1,426,185 shares of our common stock. In addition, Auctus&#8217; shares of Series B preferred stock are convertible into
    an aggregate of 1,398,158 shares of our common stock. In connection with the transaction in which the above warrants were issued,
    we issued to Auctus certain shares of our common stock and have agreed to issue to Auctus, upon receipt of notice from Auctus, subject
    to the limitation discussed below, 1,138,055 shares of our common stock, or the Additional Shares. However, such warrants are not
    exercisable for the purchase of our common stock, such Series B preferred stock is not convertible into shares of our common stock
    and the Additional Shares are not issuable to the extent Auctus would beneficially own, after such exercise, conversion or issuance,
    more than 9.99% of our outstanding shares of common stock. Auctus has advised that, as of March 20, 2025, it owned 666,200 shares
    of common stock, which represented approximately 8.9% of the then 7,504,780 outstanding shares of common stock, and that the Additional
    Shares are issuable to it, upon notice from it, to the extent that such issuances would not result in Auctus beneficially owning
    after such issuances more than 9.99% of our outstanding shares of common stock. Based upon the foregoing, as of March 20, 2025, 92,797
    Additional Shares are issuable to Auctus (to comply with the 9.99% beneficial ownership limitation), the remaining Additional Shares
    are not issuable, Auctus&#8217; warrants are not currently exercisable for the purchase of shares of common stock and its Series
    B preferred stock is not currently convertible into shares of common stock. The number of shares of common stock beneficially owned
    by Auctus includes the 92,797 Additional Shares currently issuable to it. Without the 9.99% limitation discussed above, Auctus would
    have beneficial ownership of 4,628,598 shares of common stock.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
    to the Certificate of Designations of Preferred Stock with regard to the Series B preferred stock, Auctus, as the sole holder of
    the 1,398,158 outstanding shares of Series B preferred stock, is entitled to vote such shares based on the number of shares of common
    stock into which such shares are convertible (currently 1,398,158); however, pursuant to such Certificate of Designations of Preferred
    Stock, as indicated in footnote (10), such Series B preferred stock is not convertible into shares of common stock to the extent
    Auctus would beneficially own, after such conversion, more than 9.99% of our then outstanding shares of common stock. Since Auctus
    has advised that, as of March 20, 2025, it owned 666,200 shares of common stock, which represented approximately 8.9% of the outstanding
    shares of common stock, and, as indicated in footnote (10) above, 92,797 Additional Shares are issuable to it, Auctus&#8217; Series
    B preferred stock is not currently convertible into shares of common stock. Accordingly, as of March 20, 2025, Auctus, as the sole
    holder of the Series B preferred stock, is not entitled to any votes for such shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance Under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information as of December 31, 2024 with respect to compensation plans (including individual compensation
arrangements) under which our common stock are authorized for issuance, aggregated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    compensation plans previously approved by security holders; and</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>
<!-- Field: Page; Sequence: 89; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    compensation plans not previously approved by security holders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY
COMPENSATION PLAN INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> securities to be<br/> issued upon<br/> exercise of<br/> outstanding<br/> options (a)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-average<br/> exercise price of<br/> outstanding options<br/> (b)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> securities<br/> remaining<br/> available for future<br/> issuance under<br/> equity<br/> compensation<br/> plans (excluding<br/> securities reflected<br/> in column (a))</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Equity compensation plans approved by security holders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3,263,467</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2.63</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3,266,736</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"/><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_020"></span>ITEM
    13.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTAIN
    RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors is comprised of Lance Alstodt (Chair), Francisco Silva, Nickolay Kukekov, Patrick F. Williams and David Rosa. Each
of Dr. Kukekov, Mr. Williams and Mr. Rosa is an &#8220;independent director&#8221; based on the definition of independence in Listing
Rule 5605(a)(2) of The Nasdaq Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.3pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Williams (Chair), Dr. Kukekov and Mr. Rosa are the members of our Board&#8217;s Audit Committee. Each of Mr. Williams, Dr. Kukekov and
Mr. Rosa is an &#8220;independent director&#8221; based on the definition of independence in Listing Rule 5605(a)(2) of The Nasdaq Stock
Market and Rule 10A-3(b)(1) under the Exchange Act. Our Board of Directors has determined that Mr. Williams qualifies as an &#8220;audit
committee financial expert,&#8221; as that term is defined in Item 407(d)(5) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Rosa (Chair), Dr. Kukekov and Mr. Williams are the members of our Board&#8217;s Nominating Committee. Each of Mr. Rosa, Dr. Kukekov and
Mr. Williams is an &#8220;independent director&#8221; based on the definition of independence in Listing Rule 5605(a)(2) of The Nasdaq
Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Kukekov (Chair), Mr. Williams and Mr. Rosa are the members of our Board&#8217;s Compensation Committee. Each of Dr. Kukekov, Mr. Williams
and Mr. Rosa is an &#8220;independent director&#8221; based on the definition of independence in Listing Rule 5605(a)(2) of The Nasdaq
Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 90; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_021"></span>ITEM
    14.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PRINCIPAL
    ACCOUNTANT FEES AND SERVICES</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
LLP served as our independent registered public accountants for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the fees billed or expected to be billed to us by Marcum LLP, our independent registered public accountants,
for professional services rendered with respect to the fiscal years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Marcum LLP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Marcum LLP</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Audit Fees (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">138,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">101,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Audit-Related Fees (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Tax Fees (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">All Other Fees (4)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">173,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">138,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    Fees consist of fees billed and expected to be billed for services rendered for the audit of our consolidated financial statements
    for the fiscal years ended December 31, 2024 and 2023, and the review of our condensed consolidated financial statements included
    in our Quarterly Reports on Form 10-Q.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-Related
    Fees consist of fees billed for assurance and related services that are reasonably related to the performance of the audit of our
    financial statements and in connection with the filing of Forms S-1, S-3 and S-8 registration statements and are not reported under
    &#8220;Audit Fees.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    Fees consist of fees billed for professional services related to preparation of our U.S. federal and state income tax returns and
    tax advice.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Other Fees consist of fees billed for products and services provided by our independent registered public accountants, other than
    those disclosed above.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee is responsible for the appointment, compensation and oversight of the work of the independent registered public accountants,
and approves in advance any services to be performed by the independent registered public accountants, whether audit-related or not.
The Audit Committee reviews each proposed engagement to determine whether the provision of services is compatible with maintaining the
independence of the independent registered public accountants. The fees shown above were pre-approved either by our Board or our Audit
Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="aa_022"></span>PART
IV</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_023"></span>ITEM
    15.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBITS
    AND FINANCIAL STATEMENT SCHEDULES</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 0.75in"><span style="font-size: 10pt">Exhibit No.</span></td>
    <td style="padding-bottom: 1pt; width: 0.1in"/>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"/></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt; color: #212529">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex3_3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Articles of Incorporation, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated December 29, 2022, wherein such document is identified as Exhibit 3.3</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex3_4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designations of Series B Preferred Stock, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated December 29, 2022, wherein such document is identified as Exhibit 3.4</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex3_5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated December 29, 2022, wherein such document is identified as Exhibit 3.5</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224043839/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934, incorporated by reference to the registrant&#8217;s Amendment No. 2 to Annual Report on Form 10-K/A for the year ended December 31, 2023, wherein such document is identified as Exhibit 4.1</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000114420412021914/v308966_ex10-44.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement, dated as of January 27, 2012, between Regenerative Sciences, LLC and BioRestorative Therapies, Inc. (&#8220;License Agreement&#8221;), incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011, wherein such document is identified as Exhibit 10.44</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000114420412021914/v308966_ex10-45.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to License Agreement, dated March 21, 2012, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011, wherein such document is identified as Exhibit 10.45</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000114420416091575/v434828_ex10-20.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to License Agreement, dated November 30, 2015, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2015, wherein such document is identified as Exhibit 10.20</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315223008960/ex10-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter agreement, dated November 21, 2022, by and among BioRestorative Therapies, Inc., Regenerative Sciences, LLC and Regenexx, LLC with regard to License Agreement, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.4</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177114000054/ex99_1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease, dated as of August 25, 2014, between BioRestorative Therapies, Inc. and 50 Republic Road, LLC, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated August 25, 2014, wherein such document is identified as Exhibit 99.1</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315221006285/ex10-37.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Amendment, dated as of June 4, 2019, between 50 Republic Road, LLC and BioRestorative Therapies, Inc., incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, wherein such document is identified as Exhibit 10.37</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.7</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-7.htm">BioRestorative Therapies, Inc. 2021 Stock Incentive Plan, as amended*</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.8</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000020/ex99_2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement, dated as of March 18, 2021, by and between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated March 18, 2021, wherein such document is identified as Exhibit 99.2</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000020/ex99_3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement, dated as of March 18, 2021, by and between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated March 18, 2021, wherein such document is identified as Exhibit 99.3</span></a></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 92; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 0.75in"><span style="font-size: 10pt">10.10</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000020/ex99_4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of March 18, 2021, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated March 18, 2021, wherein such document is identified as Exhibit 99.4</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000020/ex99_5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of March 18, 2021, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated March 18, 2021, wherein such document is identified as Exhibit 99.5</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-12.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Robert Kristal, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 10.12</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.13</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/ex99_1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated November 4, 2021, wherein such document is identified as Exhibit 99.1</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/ex99_2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated November 4, wherein such document is identified as Exhibit 99.2</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.15</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-15.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Nickolay Kukekov, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.15</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.16</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-16.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Patrick F. Williams, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.16</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.17</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-17.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and David Rosa, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.17</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.18</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-18.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.18</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.19</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-19.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of November 4, 2021, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.19</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.20</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-20.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Purchase Warrant, dated November 9, 2021, issued by BioRestorative Therapies, Inc. pursuant to public offering, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.20</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.21</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-21.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Purchase Warrant, dated November 9, 2021, issued by BioRestorative Therapies, Inc. to Auctus Fund, LLC, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.21</span></a></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 93; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: center; width: 0.75in"><span style="font-size: 10pt">10.22</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-22.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 2 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.22</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.23</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-23.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 2 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.23</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.24</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-24.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and Nickolay Kukekov, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.24</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.25</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-25.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and Patrick F. Williams, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.25</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.26</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315222008184/ex10-26.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Non-Qualified Stock Option Award Agreement, dated as of December 10, 2021, between BioRestorative Therapies, Inc. and David Rosa, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, wherein such document is identified as Exhibit 10.26</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.27</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315223008960/ex10-28.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.28</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.28</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315223008960/ex10-29.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.29</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.29</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315223008960/ex10-30.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Robert Kristal, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.30</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.30</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315223008960/ex10-32.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Nickolay Kukekov, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.32</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.31</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315223008960/ex10-33.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and Patrick F. Williams, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.33</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.32</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315223008960/ex10-34.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of February 17, 2023, between BioRestorative Therapies, Inc. and David Rosa, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, wherein such document is identified as Exhibit 10.34</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.33</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-36.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive Stock Option Award Agreement, dated as of February 13, 2024, between BioRestorative Therapies, Inc. and Lance Alstodt, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 10.36</span></a></td></tr>
</table>
<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 94; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 0.75in"><span style="font-size: 10pt">10.34</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-37.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive Stock Option Award Agreement, dated as of February 13, 2024, between BioRestorative Therapies, Inc. and Francisco Silva, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 10.37</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.35</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-38.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive Stock Option Award Agreement, dated as of February 13, 2024, between BioRestorative Therapies, Inc. and Robert Kristal, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 10.38</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.36</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-40.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of February 13, 2024, between BioRestorative Therapies, Inc. and Nickolay Kukekov, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 10.40</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.37</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-41.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of February 13, 2024, between BioRestorative Therapies, Inc. and Patrick F. Williams, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 10.41</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.38</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex10-42.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Award Agreement, dated as of February 13, 2024, between BioRestorative Therapies, Inc. and David Rosa, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 10.42</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.39</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177124000188/ex1_1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the Market Offering Agreement, dated as of November 6, 2024, by and between BioRestorative Therapies, Inc. and Rodman &amp; Renshaw, LLC, incorporated by reference to the registrant&#8217;s Current Report on Form 8-K for an event dated November 1, 2024, wherein such document is identified as Exhibit 1.1</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.40</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-40.htm">Incentive Stock Option Award Agreement, dated as of February 14, 2025, between BioRestorative Therapies, Inc. and Lance Alstodt*</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.41</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-41.htm">Incentive Stock Option Award Agreement, dated as of February 14, 2025, between BioRestorative Therapies, Inc. and Francisco Silva*</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.42</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-42.htm">Incentive Stock Option Award Agreement, dated as of February 14, 2025, between BioRestorative Therapies, Inc. and Robert Kristal*</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.43</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-43.htm">Non-Qualified Stock Option Award Agreement, dated as of February 14, 2025, between BioRestorative Therapies, Inc. and Nickolay Kukekov*</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.44</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-44.htm">Non-Qualified Stock Option Award Agreement, dated as of February 14, 2025 between BioRestorative Therapies, Inc. and Patrick F. Williams*</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">10.45</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-45.htm">Non-Qualified Stock Option Award Agreement, dated as of February 14, 2025, between BioRestorative Therapies, Inc. and David Rosa*</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">14</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000114420412021914/v308966_ex14.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011, wherein such document is identified as Exhibit 14</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">19</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex19.htm">Insider Trading Policy*</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">21</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315219004292/ex21.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, wherein such document is identified as Exhibit 21</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">23</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex-23.htm">Independent Registered Public Accounting Firm&#8217;s Consent*</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">31.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Principal Executive Officer Certification*</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">31.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Principal Financial Officer Certification*</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">32</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32.htm">Section 1350 Certification**</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">97</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000149315224012056/ex97.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clawback Policy, incorporated by reference to the registrant&#8217;s Annual Report on Form 10-K/A (Amendment No. 1) for the year ended December 31, 2023, wherein such document is identified as Exhibit 97</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document *</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Schema Document *</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Calculation Linkbase Document*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Definition Linkbase Document*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Label Linkbase Document*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Presentation Linkbase Document*</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Furnished herewith</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_024"></span>ITEM
    16.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
    10-K SUMMARY</b>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="aa_025"></span>SIGNATURES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIORESTORATIVE
    THERAPIES, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 27, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><p style="border-bottom: Black 0.25pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Lance Alstodt</i></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"><p style="border-bottom: Black 0.25pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><p style="border-bottom: Black 0.25pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capacity</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%"><p style="border-bottom: Black 0.25pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President, Chairman of the Board and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    27, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President, Research and Development and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    27, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    Silva</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    27, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    E. Kristal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and Principal Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    27, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay
    Kukekov</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    27, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    F. Williams</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    27, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Rosa</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ar_007"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIORESTORATIVE
THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aud_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID <span id="xdx_906_edei--AuditorFirmId_c20240101__20241231_zuLNtyEaWJx8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000060" name="dei:AuditorFirmId">688</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_002">Consolidated Balance Sheets as of December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_003">Consolidated Statements of Operations for the Years Ended December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_004">Consolidated Statements of Changes in Stockholders&#8217; Equity for the Years Ended December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_005">Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_006">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-7</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 97; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aud_001"></span>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_988_edei--AuditorOpinionTextBlock_c20240101__20241231_zaa8SEFjmBaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000061" name="dei:AuditorOpinionTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of BioRestorative Therapies, Inc. (the &#8220;Company&#8221;) as of December
31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders&#8217; equity and cash flows for each of
the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024,
in conformity with accounting principles generally accepted in the United States of America.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Explanatory
Paragraph &#8211; Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described
in Note 1, the Company has incurred significant losses and negative cash flows from operations, and needs to raise additional funds to
meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue
as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be
communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and
(2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_90F_edei--AuditorName_c20240101__20241231_zJ2eqZWzjCuc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000062" name="dei:AuditorName">Marcum LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
<span style="font-variant: small-caps">llp</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2020<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--AuditorLocation_c20240101__20241231_zvu9CbRpHHqb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000063" name="dei:AuditorLocation">Marlton,
New Jersey</ix:nonNumeric></span> <b><br/>
</b>March 27, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 98 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_002"></span>BIORESTORATIVE
THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_111_zGbBWymdMx26" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zRnHsXd3yrQd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zUEVmUdVKkyc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsAbstract_iB_zDSsPwnj9rXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B_ze0DUS58I7xh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzsph_zsEnleEGRZW3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">547,890</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">884,377</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--MarketableSecuritiesCurrent_i02I_maACzsph_zq8Q31ZsQFq2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Investments held in marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2024-12-31" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,184,701</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,181,618</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzsph_ztPo8LKdcsCb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzsph_z0VhC7dpoJ6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,230</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">305,231</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrent_i02TI_mtACzsph_maAzhZI_z2rVgeQfjRyl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,144,221</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,390,526</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredOfferingCost_i01I_maAzhZI_ziYlXCxuVN87" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:DeferredOfferingCost" contextRef="AsOf2024-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,697</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0087">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzhZI_zxbYyldgcuqe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362,936</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,055</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzhZI_z1gomklKRuej" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0092">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,447</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_maAzhZI_zBxOQ1phT8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Intangible assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">623,945</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">713,692</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Assets_i01TI_mtAzhZI_zoUZpfVqO1Dh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,279,799</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,611,720</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zt1rUKRiO51" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_z10K0Vup0Jy" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableCurrent_i02I_maLCzrOD_zxFPwUTxyP42" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">483,070</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,389</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzrOD_zGwuPvzhL3xf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">744,485</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">711,686</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzrOD_zjAAOIWPGGX6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0113">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLCzrOD_zTHLxwXlvtM3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,543,953</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzrOD_maLzD8l_zJtfYJVndVN4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 20pt; text-align: left">Total Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,748,406</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,607,345</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Liabilities_i01TI_mtLzD8l_maLASEzs12_z7RTc5kTUPQi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,748,406</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,607,345</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzs12_zaUJMflTtF36" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0125">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0126">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockholdersEquityAbstract_i01B_zWYM1UKzKJ76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PreferredStockValue_i02I_maSEz26Y_zyOrEtj1q6Af" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Preferred stock, $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zDNpUwygRo96" title="Preferred stock, par value"><span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_zrIr3SmvVRNa" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000136" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zKdbU8aGSSt9" title="Preferred stock, shares authorized"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zMzKIZylfd7k" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000138" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_maSEz26Y_zoNoUO7BYn0h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Series B Convertible Preferred Stock; <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zN8SuJv6KtX3" title="Preferred stock, shares authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zH6fgkv6TVDh" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000147" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></ix:nonFraction></span></span> shares designated, <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zA825q7V8Fa" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zJxEfqM41Gha" title="Preferred stock, shares outstanding"><span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zKMET9bPze25" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zydQGuNWewM7" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000151" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000153" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000155" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and
    outstanding at December 31, 2024 and 2023.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_maSEz26Y_zgMBQ2EOp3Z4" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Preferred
    stock, value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--CommonStockValue_i02I_maSEz26Y_zQYc2Tcm4SOj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">Common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241231_zFm0V3LTdr23" title="Common stock, par value"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zL7OOj1B52Je" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000163" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000165" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_z2d75Oj11Boi" title="Common stock, shares authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zQ87Ire8gRQl" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000167" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000169" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20241231_zcbBZiwlpngb" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_z5HONaabprKa" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,919,919</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20231231_zyLgarnuuFh2" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zK5FEWlcjvR" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000175" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000177" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,706,917</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December
    31, 2024 and 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">471</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdditionalPaidInCapital_i02I_maSEz26Y_zm3vO3HMr8cl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,195,434</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,689,256</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEz26Y_zxMS8h5BEQM9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">155,678,715</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000183" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">146,699,334</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockholdersEquity_i02TI_mtSEz26Y_maLASEzs12_zPjMroRvCKGc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,531,393</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,004,375</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzs12_z8HKn2q9Ph7g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,279,799</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,611,720</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 99 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_003"></span>BIORESTORATIVE
THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_113_zhVyYadUk4Cl" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zWAXQb9ZXtph" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231_zSd3HTxBuaEf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzOBw_zFobw5cMTBXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; text-align: left">Revenues, net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,800</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CostOfGoodsAndServicesSold_msGPzOBw_zaAhDlwom7u1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2024-01-01to2024-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,072</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0195">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GrossProfit_iT_maOILzbGU_mtGPzOBw_zNY1L2NcVVqh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-01to2024-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,928</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_zBj1zYDdC85k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzRcV_zGEWwOA6Uh2j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,348,709</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,034,591</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzRcV_z99qcsmMOUP3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,579,413</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,331,983</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingExpenses_i01T_mtOEzRcV_msOILzbGU_zuKiWqtdKO4i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Operating Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,928,122</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,366,574</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingIncomeLoss_iT_maNILzy4a_mtOILzbGU_z81TdTWzZbEl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Loss From Operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,555,194</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,220,774</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z0YwF9Li7o34" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other Income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestIncomeExpenseNet_i01_maNIEzqv3_ztJgA8MBDKu5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-01-01to2024-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">616,077</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-012023-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">552,293</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--GrantIncome_i01_maNIEzqv3_zzZQegAAXNBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Grant income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0221">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:GrantIncome" contextRef="From2023-01-012023-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEzqv3_zrmRpER1mZE7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,850</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,664</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--GainOnExchangeOfWarrants_i01_maNIEzqv3_zH50GWR1HCAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on exchange of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:GainOnExchangeOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,711,698</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0228">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maNIEzqv3_zv37knrD4RQg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-01to2024-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,188</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-12-31" id="Fact000231" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,997,780</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpense_i01T_maNILzy4a_mtNIEzqv3_zahjYij8Zsp9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Other Income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,575,813</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,803,070</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_iT_mtNILzy4a_zt5495q7mG5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,979,381</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000237" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,417,704</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20240101__20241231_zx7lZSohTgp9" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zLj6LcJouhig" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000239" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000241" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.16</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zPLGKuYYSvC4" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zZRmyr5CTU22" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000243" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000245" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.47</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Weighted Average Common Shares Outstanding - Basic and
    Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20241231_za8Cmo1ZWCye" title="Weighted Average Common Shares Outstanding - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_zXS19XgulEe4" title="Weighted Average Common Shares Outstanding - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,763,932</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zMigcXFGyzpe" title="Weighted Average Common Shares Outstanding - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_z3lQfJevERSa" title="Weighted Average Common Shares Outstanding - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000253" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,218,347</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 100 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_004"></span>BIORESTORATIVE
THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEARS ENDED DECEMBER 31, 2024 AND 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_114_z24egwdDMku1" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesBConvertiblePreferredStockMember_zCWtvGLnERYa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z11Oq97jYAJ3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z1rfTKea0u64" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zxnmAzKkmWI3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_zJtSgYde18Ea" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Series B Convertible</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Paid-In</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_431_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zrYq7BMo5aF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; font-weight: bold">Balance - January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z6HzOyv4WxBi" title="Balance, shares" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000261" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,518,158</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,182</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znJLm3vMxCnb" title="Balance, shares" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000263" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,677,775</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,556,418</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000258" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">136,281,630</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000259" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,290,339</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodSharebasedCompensationAbstract_iB_z2DhzwOPs6l3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_i01_zV7JzU6iTTq4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Restricted share units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_i01_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zffQnoPFWndd" title="Restricted share units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000277" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">89,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,633,655</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31" id="Fact000275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,633,664</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_i01_z4BE4HMD7nNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,141,803</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000283" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,141,803</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_i01_zMrncSKXz0rk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD9oR1aXO9zh" title="Common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,442</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zlJhyCxMpRP6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of Series B Convertible Preferred Stock into common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zZkB2halxbAc" title="Conversion of Series B Convertible Preferred Stock into common stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000299" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">120,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000293" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,200</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhuTJ0UAr6J5" title="Conversion of Series B Convertible Preferred Stock into common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000301" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000295" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,188</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zDiUd7SVTk71" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance and sale of common stock, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFGeLQJ8sOH9" title="Issuance and sale of common stock, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000309" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">817,860</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000305" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,348,692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31" id="Fact000307" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,348,773</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_z8xDBTopIfc6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000314" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,417,704</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000315" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,417,704</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zKAKi9vhRKk1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance - December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z5omHEyqboh6" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000323" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000317" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znofUx98zZZ" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000325" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,706,917</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">471</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,689,256</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000320" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">146,699,334</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,004,375</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zn3dL5AxdHd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zKjqErvyBoJk" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000333" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000327" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ3U6n8CBsLl" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000335" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,706,917</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">471</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,689,256</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000330" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">146,699,334</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000331" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,004,375</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueOther_zExUNccJBOji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issued in connection with warrant exchange <span id="xdx_F4C_zO0cSBHnFjw3">[1]</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fWzFd_zwPXlgsagB8" title="Common stock issued in connection with warrant exchange, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000343" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,742,043</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0340">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-01to2024-12-31" id="Fact000341" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,742,243</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_zFxlw1UkW3Zh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Return and cancellation of shares in lieu of payroll tax withholding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxbphkG8Aolk" title="Return and cancellation of shares in lieu of payroll tax withholding, shares" style="text-align: right">(<ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000351" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">34,825</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000346" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000347" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,406</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-01to2024-12-31" id="Fact000349" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,410</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_z2tFPLKdny3h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issued in connection with abeyance shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3KsVehr3Y0c" title="Common stock issued in connection with abeyance shares, shares" style="text-align: right"><ix:nonFraction name="BRTX:StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000359" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000355" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodSharebasedCompensationAbstract_iB_z1IfqdkKB1R" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_i01_zyYrmdUCZFwc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Restricted share units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_i01_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZXBSFl6l1Dc" title="Restricted share units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000373" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,827</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">985,028</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-01to2024-12-31" id="Fact000371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">985,038</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_i01_zkfNBgnXCrd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827,528</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827,528</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zlC0xEuLjEf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000384" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,979,381</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000385" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,979,381</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zkN8cQHR5G5l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance - December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zPq9ihANYwG7" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000393" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRbgdjEOLUTi" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000395" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,919,919</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000389" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,195,434</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000390" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">155,678,715</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,531,393</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zrC65x1lKA65" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zHGxLKNXCn09" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000403" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztGDk9tm3rI7" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000405" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,919,919</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000398" format="ixt:numdotdecimal" decimals="0" unitRef="USD">692</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,195,434</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000400" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">155,678,715</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000401" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,531,393</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F07_zxTxnGYXRYGl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[1]</span></td><td style="text-align: justify"><span id="xdx_F1A_zBpz89dKwW8k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000406" xml:lang="en-US">Represents the
aggregate fair value of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpPD4xdmm3mj" title="Aggregate fair value of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000408" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,351,580</ix:nonFraction></span> shares of common stock, which includes <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5nhgzoqroak" title="Warrants exercisable"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000410" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,150,000</ix:nonFraction></span> shares that have been issued and <span id="xdx_908_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zTAiLGZkPyDe" title="Shares held in abeyance"><ix:nonFraction name="BRTX:SharesHeldInAbeyance" contextRef="AsOf2024-12-31" id="Fact000412" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,201,580</ix:nonFraction></span> shares
held in abeyance. See Note 6 - Stockholders&#8217; Equity - Warrant Exercise and Issuance and Note 9 - Fair Value Measurement for additional
details.</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_005"></span>BIORESTORATIVE
THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_112_z9rvBaFbYQ13" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_zHJEwn56X6L4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_z6h0uZN4ZNhi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zECibvoL6D8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_i01_maNCPBUzfaZ_zPkClOuah3D2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000417" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,979,381</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000418" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,417,704</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zRw9CvelFmgf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DepreciationAndAmortization_i02_maNCPBUzfaZ_zD8dTtLhRyWi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact000424" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,735</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InterestAndDividendIncomeOperating_i02N_di_msNCPBUzfaZ_zrt2EHvq4ms7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Dividend and interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestAndDividendIncomeOperating" contextRef="From2024-01-01to2024-12-31" id="Fact000426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">623,801</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestAndDividendIncomeOperating" contextRef="From2023-01-012023-12-31" id="Fact000427" format="ixt:numdotdecimal" decimals="0" unitRef="USD">569,068</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--ShareBasedCompensation_i02_maNCPBUzfaZ_zc90Ji4TPbR1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,812,566</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,782,967</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--NoncashLeaseExpense_i02_maNCPBUzfaZ_zgVMt6nV2MF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Non-cash lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:NoncashLeaseExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000432" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,447</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:NoncashLeaseExpense" contextRef="From2023-01-012023-12-31" id="Fact000433" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,313</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--GainOnExchangeOfWarrants_i02N_di_msNCPBUzfaZ_zwer4O1njJo6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gain on exchange of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:GainOnExchangeOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,711,698</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_msNCPBUzfaZ_zXL1P4RxfEk4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-01to2024-12-31" id="Fact000438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,188</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-12-31" id="Fact000439" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,997,780</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zVlOLHMTHrC3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUzfaZ_zMZdsTjyHwH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-01to2024-12-31" id="Fact000444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,100</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-12-31" id="Fact000445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,300</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzfaZ_ziNS6VQ9eeKh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,591</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000448" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,851</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzfaZ_zC8J4eD4d253" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000450" format="ixt:numdotdecimal" decimals="0" unitRef="USD">293,680</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-12-31" id="Fact000451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,487</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_i03_maNCPBUzfaZ_zfgBmo7sBVbk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,799</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000454" format="ixt:numdotdecimal" decimals="0" unitRef="USD">581,616</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzfaZ_zeIqgoV5NLa8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000456" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">162,317</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact000457" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">139,328</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_maCCERCzjE7_mtNCPBUzfaZ_zkcurDWtm6j1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Used In Operating Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000459" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,230,346</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000460" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,430,211</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zdUsCVewWmzg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_i01_maNCPBUziM9_zJmAWL3uA7sa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Sale of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2024-01-01to2024-12-31" id="Fact000465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,508,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2023-01-012023-12-31" id="Fact000466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,964,373</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentsToAcquireMarketableSecurities_i01N_di_msNCPBUziM9_z73fQ1w1dqEe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Purchase of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2024-01-01to2024-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,887,923</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2023-01-012023-12-31" id="Fact000469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,541,287</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUziM9_zO37IGbl1Pwl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; padding-bottom: 1pt">Purchases of equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,189</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000472" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,043</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_maCCERCzjE7_mtNCPBUziM9_z3ypdsqYTFRa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Provided By Investing Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">514,529</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,252,043</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zI41P0G7Wf8b" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzIrP_z7vuPG6lRaKg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Net proceeds from issuance of common stock in at-the-market offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0480">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000481" format="ixt:numdotdecimal" decimals="0" unitRef="USD">494,783</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_i01_maNCPBUzIrP_z0obSQvSuDI6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Net proceeds from issuance of common stock in direct-offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-01-012023-12-31" id="Fact000484" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,853,990</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ProceedsFromExchangeAndIssuanceOfWarrantsNet1_i01_maNCPBUzIrP_zChsXfDjeoE2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Proceeds from exchange and issuance of warrants, net <span id="xdx_F4A_zTTsmaN2uOg1">[1]</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1" contextRef="From2024-01-01to2024-12-31" id="Fact000486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,528,027</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PaymentsForProceedsFromDeferredOfferingCosts_i01N_di_msNCPBUzIrP_zMiocy9E3kfd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Deferred offering costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BRTX:PaymentsForProceedsFromDeferredOfferingCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,697</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCCERCzjE7_mtNCPBUzIrP_zOcNJNC14NPc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Provided By Financing Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,379,330</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000493" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,348,773</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzjE7_z7zt3AfmF0L9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left">Net Decrease In Cash and Cash Equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000495" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">336,487</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000496" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">829,395</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_z0K5VwwO4aeh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and Cash Equivalents - Beginning of the Year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="0" unitRef="USD">884,377</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000499" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,713,772</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zSj3hKr7vDic" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and Cash Equivalents - End of the Year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">547,890</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">884,377</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zHO7DehfCmfe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplemental Disclosures of Cash Flow Information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--SupplementalCashFlowInformationRelatedText_i01B_zYrk6Tb1wuZk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cash paid during the year for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestPaidNet_i02_zCXUlgTr6pu" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">Interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxesPaidNet_i02_zvKeEpXwG0Yh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0513">-</span></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zO43AMsp65Td" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--IssuanceOfCommonStockHeldInAbeyance_i01_z80rKykqNmm4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Issuance of common stock held in abeyance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:IssuanceOfCommonStockHeldInAbeyance" contextRef="From2024-01-01to2024-12-31" id="Fact000519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0520">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_i01_zAYEe9V9PIz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Return and cancellation of shares in lieu of payroll tax withholding</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2024-01-01to2024-12-31" id="Fact000522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,410</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" contextRef="From2023-01-012023-12-31" id="Fact000523" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,308</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F0F_zjqAxJSjdgh2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[1]</span></td><td style="text-align: justify"><span id="xdx_F17_zuzQmrhsdySd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000524" xml:lang="en-US">Includes gross
proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_c20240101__20241231_zSqmWfzB3Fwf" title="Proceeds from debt issuance costs"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000526" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,123,391</ix:nonFraction></span>, less issuance costs of $<span id="xdx_908_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231_zFrZALfkTkQg" title="Issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000528" format="ixt:numdotdecimal" decimals="0" unitRef="USD">595,364</ix:nonFraction></span>.</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 102 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_006"></span>BIORESTORATIVE
THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000530" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zad1yrVgoFC6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
1 - <span id="xdx_82E_zTWJIhlVH5wj">ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#8220;Stem Pearls&#8221;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#8220;BRT&#8221; or the &#8220;Company&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 23, 2022, the Company reincorporated from Delaware to Nevada by filing Articles of Incorporation with the state of Nevada. The
reincorporation was structured as a statutory merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and Going Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which
contemplates realization of assets and satisfying liabilities in the normal course of business. For the year ended December 31, 2024,
the Company had a net loss of $<span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zpyfxt7l3Ml4" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000532" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">9.0</ix:nonFraction></span> million, negative cash flows from operations of $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zbxaUj3RB9Eg" title="Cash flows from operations"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000534" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">8.2</ix:nonFraction></span> million and working capital of $<span id="xdx_905_ecustom--WorkingCapital_iI_pn5n6_c20241231_zuIvnxRVR3fg" title="Working capital"><ix:nonFraction name="BRTX:WorkingCapital" contextRef="AsOf2024-12-31" id="Fact000536" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.4</ix:nonFraction></span> million.
The Company anticipates that it will continue to incur net losses and negative cash flows from operations as it executes its development
plans for 2025 and beyond, as well as other potential strategic and business development initiatives. These conditions raise substantial
doubt about the Company&#8217;s ability to continue as a going concern for at least twelve months after the issuance date of these financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has previously funded, and plans to continue funding, these losses primarily through current cash on hand, investments in marketable
securities and additional infusions of cash from equity and debt financing. During the year ended December 31, 2024, the Company raised
net proceeds of approximately $<span id="xdx_906_ecustom--ProceedsFromWarrantExercisesNet_pn5n6_c20240101__20241231_zPQQMtfHNcL1" title="Proceeds from warrant exercises, net"><ix:nonFraction name="BRTX:ProceedsFromWarrantExercisesNet" contextRef="From2024-01-01to2024-12-31" id="Fact000538" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.5</ix:nonFraction></span> million in connection with a warrant exercise program which is further discussed in Note 6 &#8211;
Stockholders&#8217; Equity. On November 6, 2024, the Company entered into an at-the-market offering agreement (the &#8220;2024 ATM&#8221;)
pursuant to which the Company has an ability to issue and sell shares of its common stock up to an aggregate offering price of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241106__20241106_zicrnDnE8Hjb" title="Offering price"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-11-062024-11-06" id="Fact000540" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,614,170</ix:nonFraction></span>.
Subsequent to December 31, 2024, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zD3UaD052txg" title="Sold shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember" id="Fact000542" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">492,000</ix:nonFraction></span> shares of its common stock under the 2024 ATM and raised approximately $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z22hnIqNkwu3" title="Offering price"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember" id="Fact000544" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,084,000</ix:nonFraction></span>
of gross proceeds See Note 10 &#8211; Subsequent Events for additional details regarding sales of the Company&#8217;s common under the
2024 ATM subsequent to December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s current funds will not be sufficient to enable the Company to fully complete its development activities or attain profitable
operations. If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its
development, marketing and promotional activities, which would have a material adverse effect on the Company&#8217;s business, financial
condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;), which contemplate continuation of the Company as a going concern and the realization
of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented
in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying consolidated
financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#8217;s
website is at www.biorestorative.com. The information contained in the website or connected thereto is not intended to be incorporated
by reference into this Annual Report. BRT is currently developing a Disc/Spine Program referred to as &#8220;brtxDISC&#8221;. Its lead
cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person&#8217;s own) cultured mesenchymal stem cells collected
from the patient&#8217;s bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral disc disorders
or as a complimentary therapeutic to a surgical procedure. BRT is also engaging in research efforts with respect to a platform technology
utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders and has labeled
this initiative its ThermoStem Program. In addition, in continuation of BRT&#8217;s mission of developing and commercializing cell-based
biologics, it is seeking to develop a biologics-based cosmetic products business. Pursuant to such business, BRT would formulate, manufacture
and sell products designed for cosmetic and aesthetic uses. Further, BRT has licensed a patented curved needle device that is a needle
system designed to deliver cells and/or other therapeutic products or material to the spine and discs or other potential sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 103 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000546" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_80B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zKzKY88P6szc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
2 - <span id="xdx_828_zMyXsBBEEUzi">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000548" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zntv9Aiyyqwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zdk4PxG1qrLi">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#8217;s consolidated financial statements. Such consolidated
financial statements and accompanying notes are the representations of Company&#8217;s management, who is responsible for their integrity
and objectivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000550" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zxDKCiAlpgg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_z0fNjlbqN8zj">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stem Pearls. All intercompany
accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000552" name="us-gaap:UseOfEstimates"><p id="xdx_842_eus-gaap--UseOfEstimates_zEU1sFsNaugc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z4poG7D1ldXh">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related
notes to the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#8217;s future results to be affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000554" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkkM4rTKhXL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z3GH9BVMoxqk">Segment
Reporting</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has one operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#8217;s Chief Executive Officer, serves
as the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial
performance. The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated
expense data beyond what is included in the consolidated statements of operations is not provided to the CODM. Since the Company&#8217;s
operations consist of a single reporting segment, the segment assets are presented on the accompanying consolidated balance sheet as
total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000556" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zutuEXoDmQC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zLcOVvLUxfTa">Revenue
Recognition</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue in accordance with ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;).
The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC
606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required
within the revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable
consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company
recognizes revenue primarily from the following different types of contracts:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
    sales</b> - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Royalty
    revenue</b> - Revenue is recognized as a usage-based royalty from customers&#8217; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 104 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#8217;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    reason for the bill-and-hold arrangement is substantive</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    customer has requested the product be warehoused</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product has been identified as separately belonging to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product is currently ready for physical transfer to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company does not have the ability to use the product or direct it to another customer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s revenue recognized in its consolidated statements of operations:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000558" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcIh7pV1dQj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z7tV6GJV8wQe" style="display: none">SCHEDULE
OF REVENUE RECOGNIZED</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_z6bGTQxxirwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_zcNhTDyKdqYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zNRTnoVTmbne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Product revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_us-gaap_ProductMember" id="Fact000560" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ziVx2XrSPJPj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_us-gaap_RoyaltyMember" id="Fact000563" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_us-gaap_RoyaltyMember" id="Fact000564" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,800</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zvWAylJpLPRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="Fact000566" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact000567" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zucK4GFra5g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000569" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z82RXuAQ9m83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zPY8JAe2pUG9">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#8220;FDIC&#8221;) coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zd4LGIJOhtt9" title="FDIC insured limit"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-12-31" id="Fact000571" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> per banking institution. The Company had deposits in excess of FDIC coverage of $<span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zkZR8JFpwxA1" title="FDIC amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-12-31" id="Fact000573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,801</ix:nonFraction></span> and
$<span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_c20231231_zuUVXiGB8vo1" title="FDIC amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2023-12-31" id="Fact000575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">604,226</ix:nonFraction></span> as of December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company has not experienced losses on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000577" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zrHslI4Q5v9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zMa1AmFIfaIk">Customer
and Revenue Concentrations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s royalty revenue is derived from one customer. Additionally, all of the Company&#8217;s product sales revenue is
derived from one customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000579" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z96cN1ak7Q7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zjqSBcHeCS88">Accounts
Receivable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of December 31, 2024 and 2023, no allowances
for credit losses were determined to be necessary. Management estimates the allowance for credit losses based on existing economic conditions,
the financial conditions of the customers, and the amount and age of past due accounts. Receivables are considered past due if full payment
is not received by the contractual due date. Past due accounts are generally written off against the allowance for credit losses only
after all collection attempts have been exhausted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000581" name="BRTX:DeferredContractCostsPolicyTextBlock"><p id="xdx_84B_ecustom--DeferredContractCostsPolicyTextBlock_zPwiT9fl58tj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_z9v0S1hZqQUi">Deferred
Contract Costs</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs
relate directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying
performance obligations in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as
cost of revenues in the period when the related revenue is recognized. Deferred contract costs consist of consumables and labor
costs and are included within prepaid &amp; other current assets in the consolidated balance sheets. The Company had $<span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zZfVwr6cQXkb" title="Deferred contract costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2024-12-31" id="Fact000583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,250</ix:nonFraction></span>
and $<span id="xdx_905_eus-gaap--DeferredCosts_iI_c20231231_zdJ4p8ov21Hk" title="Deferred contract costs"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-12-31" id="Fact000585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> </span>deferred contract
costs as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000587" name="BRTX:DeferredOfferingCostsPolicyTextBlock"><p id="xdx_842_ecustom--DeferredOfferingCostsPolicyTextBlock_zzmFBpKtS7Q4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_zv1g22C3EyB3">Deferred Offering Costs</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Deferred offering costs, which
primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized as non-current assets
on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the offering proceeds. If
the completion of a contemplated financing was no longer probable, the related deferred offering costs would be charged to general and
administrative expense in the consolidated financial statements. The Company had $<span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_c20241231_zRqgz5xgN36j" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-12-31" id="Fact000589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,697</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_c20231231_zQ0rJYVdgKF6" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31" id="Fact000591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> deferred offering costs as of December
31, 2024 and 2023, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 105 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000593" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrNWYT5nz4ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zheceqDJFsi8">Property
and Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember_zz0rpqtMCv35" title="Property plant and equipment estimated useful lives::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0595">three</span></span> to <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_z9lXBJdFqlhj" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MaximumMember" format="ixt-sec:durwordsen" id="Fact000597" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">fifteen years</ix:nonNumeric></span>. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfnq9MSy6d45" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear" id="Fact000599" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> years. Medical equipment costs
are capitalized and depreciated over <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zZ4jRpsDJgA6" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_MedicalEquipmentMember" format="ixt-sec:duryear" id="Fact000601" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years, while furniture and fixtures are depreciated over <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zjMrGwd0Prad" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact000603" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span> years. Office equipment is depreciated
over a period of <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zFxufD0aVXDh" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000605" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> to <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcK9bTYPatcf" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000607" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years, and manufacturing equipment over <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRGoTgdUsUR5" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000609" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MaximumMember_zNoLqgQf3lLh" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000611" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000613" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zvYszRC8Li8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zEt2msSsRFC2">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records its intangible assets at cost in accordance with ASC 350, <i>Intangibles - Goodwill and Other</i>. Definite lived intangible
assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over
which the cash flows from the asset are expected to be generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000615" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhNRS1Aqq6jc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zFhYORrqYOJc">Impairment
of Long-Lived Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2024 and 2023, the Company determined that
there was <span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20240101__20241231_zkUKhwWoBDvg" title="Impairment of long-lived assets"><span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20230101__20231231_zJwaUYA1d6li" title="Impairment of long-lived assets"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2024-01-01to2024-12-31" id="Fact000617" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2023-01-012023-12-31" id="Fact000619" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> impairment charge for its long-lived assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000621" name="BRTX:WarrantAndOptionValuationPolicyTextBlock"><p id="xdx_849_ecustom--WarrantAndOptionValuationPolicyTextBlock_zIkk7Kjs9Gzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zUd3lVu9E2Sd">Warrant
and Option Valuation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#8220;simplified&#8221;
method to develop an estimate of the expected term of &#8220;plain vanilla&#8221; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry blended with the Company&#8217;s historical
volatility. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining
term consistent with the expected term of the instrument being valued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000623" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zQ9biVqlTD72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_86F_z6RhMrU5RzF3">Derivative
Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option pricing model to value the
derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether
such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 106 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000625" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGbcb7LJWe47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zhJEhRPQrt7k">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of December 31, 2024 and 2023, the carrying amount of cash and cash equivalents,
investments held in marketable securities, accounts receivable, and accounts payable approximate their fair value due to the relatively
short period of time between their origination and their expected realization or payment. The warrant liabilities are measured at fair
value (see Note 9 &#8211; Fair Value Measurement for additional details).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company recognized aggregate dividend and interest income of $<span id="xdx_90C_eus-gaap--InterestAndDividendIncomeOperating_c20240101__20241231_zg5oD0W09dNe" title="Dividend and interest income"><ix:nonFraction name="us-gaap:InterestAndDividendIncomeOperating" contextRef="From2024-01-01to2024-12-31" id="Fact000627" format="ixt:numdotdecimal" decimals="0" unitRef="USD">623,801</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--InterestAndDividendIncomeOperating_c20230101__20231231_zU0r2WazoLE7" title="Dividend and interest income"><ix:nonFraction name="us-gaap:InterestAndDividendIncomeOperating" contextRef="From2023-01-012023-12-31" id="Fact000629" format="ixt:numdotdecimal" decimals="0" unitRef="USD">569,068</ix:nonFraction></span> respectively,
on its marketable securities, which was included within other income on its consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000631" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zV62cxfcykAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zSfIv1elO46k">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The Company has <span id="xdx_90D_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zZu0Wr23kU3b" title="Shares held in abeyance"><ix:nonFraction name="BRTX:SharesHeldInAbeyance" contextRef="AsOf2024-12-31" id="Fact000633" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,201,580</ix:nonFraction></span> shares held in abeyance included
in basic loss per share given that they are issuable for no additional consideration (see Note 6 &#8211; Stockholders&#8217; Equity for
additional details). The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding
convertible preferred stock is considered common stock at the beginning of the period or at the time of issuance, if later, pursuant
to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, options, warrants,
restricted stock units (&#8220;RSUs&#8221;) and convertible preferred stock have been excluded from the Company&#8217;s computation of
diluted net loss per common share for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000635" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zTOISYbdZzv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z1GIc8cffMY8" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zvW4VkuXWp01" title="Total" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000637" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,263,467</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNj7qEzjGEDh" title="Total" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000639" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,466,892</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsnSJJFV0i21" title="Total potentially dilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000641" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,634</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zNev5ZVPtlKh" title="Total potentially dilutive shares" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000643" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,791,019</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unvested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zeme8xsmLW02" title="Unvested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zigFx6OtpUFa" title="Unvested" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000647" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,827</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zr441Bl9Y3b4" title="Convertible notes" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000649" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_znmyQsqEKWl1" title="Convertible notes" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000651" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zfF2OKgWsyX5" title="Anti-dilutive securities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-12-31" id="Fact000653" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,613,259</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zRJKPmUwTj02" title="Anti-dilutive securities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact000655" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,753,896</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zh9UmzbEuc23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000657" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4rqRiibYMW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zXmhvArh15nb">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The
fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be
provided in exchange for the award, usually the vesting period, on a straight-line basis. The Company computes the fair value of equity-classified
warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are recorded as incurred as a reduction
of amounts previously expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 107 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000659" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zyorW7NGWskg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zwBN5Q5WlHH">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes ASC 740, &#8220;Income Taxes,&#8221; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#8220;more likely-than-not&#8221;
that a deferred tax asset will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000661" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zUyYKWUBRBq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zvsoDK4W79Yj">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;)
assets and operating lease liabilities in our consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value
of lease payments over the lease term. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental
borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement
date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company&#8217;s lease terms
may include options to extend or terminate the lease when it is reasonably certain that it will exercise the option. Lease expense for
lease payments is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000663" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zXTkrjpty3U9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zpKTHgzD4l67">Recently
Adopted Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07,
&#8220;Improvements to Reportable Segments Disclosures (Topic 280)&#8221; (&#8220;ASU 2023-07&#8221;), which updates reportable segment
disclosure requirements, primarily through enhanced disclosures about significant segment expenses on both an annual and interim basis.
The guidance becomes effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after
December 15, 2024, with early adoption permitted. The adoption of this accounting standard on a retrospective basis did not have a material
impact on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000665" name="BRTX:RecentlyIssuedAccountingPronouncementsPolicyTextBlock"><p id="xdx_847_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zqqRwAf1WA26" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zNfZlr2uXiec">Recently
Issued Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; (&#8220;ASU
2023-09&#8221;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the impact of this update on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 108 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; (&#8220;ASU 2024-03&#8221;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.</span></p>

</ix:nonNumeric><p id="xdx_850_zSD8QCfCQlbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000667" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zEvV1FTo67xk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
3 - <span id="xdx_829_zsg9IrEIAfo9">PROPERTY AND EQUIPMENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000669" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z2ZdwaDNWsb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zRiW19Duyqmj" style="display: none">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zcvb0j2Mshvj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zCrUODQYb0Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zLOXDxjVNdhb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_MedicalEquipmentMember" id="Fact000671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352,133</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_MedicalEquipmentMember" id="Fact000672" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352,133</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zHKi6c2fM66c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000674" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,486</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000675" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,486</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zTPXuLfpmrf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_ComputerSoftwareAndEquipmentMember" id="Fact000677" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,205</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_ComputerSoftwareAndEquipmentMember" id="Fact000678" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,205</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zdSPeVh24a7d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember" id="Fact000680" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_OfficeEquipmentMember" id="Fact000681" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,779</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zHLEEhyimZOi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Manufacturing equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_ManufacturingEquipmentMember" id="Fact000683" format="ixt:numdotdecimal" decimals="0" unitRef="USD">501,421</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_ManufacturingEquipmentMember" id="Fact000684" format="ixt:numdotdecimal" decimals="0" unitRef="USD">395,232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zb0uKt79Uwyg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000686" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,048</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000687" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,048</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzKiZ_z4su14VN8qy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    plant and equipment gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000689" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,474,072</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,367,883</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzKiZ_zeJSxm1HRBa4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000692" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,111,136</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,011,828</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzKiZ_zPMObeOSxMXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000695" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362,936</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,055</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zZiYqaFLPewe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
depreciation expense for the years ended December 31, 2024 and 2023 was $<span id="xdx_908_eus-gaap--Depreciation_pp0p0_c20240101__20241231_zvtQEHghKRO7" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact000698" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,309</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--Depreciation_pp0p0_c20230101__20231231_zi5SeumhaRl8" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000700" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,989</ix:nonFraction></span>, respectively. Depreciation expense is reflected
in general and administrative expenses and research and development expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000702" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--IntangibleAssetsDisclosureTextBlock_z7XcTOpi2I3c" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
4 - <span id="xdx_82E_z8jFnJ0P8vsc">INTANGIBLE ASSETS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a license agreement with the SCTC (as amended) (the &#8220;SCTC Agreement&#8221;). Pursuant to the SCTC Agreement,
the Company obtained, among other things, a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license from the SCTC
to utilize or sublicense a certain method for culturing cells and a worldwide, exclusive, royalty-bearing license from the SCTC to utilize
or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or spine
(and other parts of the body).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2017, the Company received authorization from the Food and Drug Administration (the &#8220;FDA&#8221;) to proceed with a Phase
2 clinical trial. In February 2022, the Company announced that the United States Patent and Trademark Office issued a notice of allowance
for a patent application relating to the Company&#8217;s BRTX-100 clinical program. This patent was issued in March 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 109 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000704" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zdsSzvPsMxw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zovX5FmRjKn8" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Balance as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zMa8DpLEhmyh" title="Finite Lived Intangible Assets, Gross, beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_custom_PatentsAndTrademarksMember" id="Fact000706" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,676</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgkIpLlGFbo2" title="Finite Lived Intangible Assets, gross, beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_us-gaap_LicenseMember" id="Fact000708" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,593,530</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zqY3dA0k41Sl" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance" style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember" id="Fact000710" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">793,768</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20230101__20231231_z6h1cAws7Od" title="Finite Lived Intangible Assets, Net, beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-12-31" id="Fact000712" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">803,438</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zDUNrjLtHqbj" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31_custom_AccumulatedAmortizationMember" id="Fact000714" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,746</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231_zRrGfdmJ09Eb" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact000716" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,746</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zTRGfffLeNbf" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_custom_PatentsAndTrademarksMember" id="Fact000718" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,676</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBVozX7VDJlj" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_LicenseMember" id="Fact000720" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,593,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXRYXWxN8sRe" title="Beginning Balance" style="text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_custom_AccumulatedAmortizationMember" id="Fact000722" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">883,514</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20240101__20241231_zqwLjk2xJY0j" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31" id="Fact000724" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">713,692</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zytthitOTw2k" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_custom_AccumulatedAmortizationMember" id="Fact000726" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231_zAM5NMN8yS06" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000728" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zQuRKUBmR8mh" title="Finite Lived Intangible Assets, Gross, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_custom_PatentsAndTrademarksMember" id="Fact000730" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,676</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zoYjoWDb33X3" title="Finite Lived Intangible Assets, Gross, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_us-gaap_LicenseMember" id="Fact000732" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,593,530</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_ztG665tY4AIa" title="Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_custom_AccumulatedAmortizationMember" id="Fact000734" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">973,261</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iE_pp0p0_c20240101__20241231_zjzg3CCnlNxd" title="Finite Lived Intangible Assets, Net, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31" id="Fact000736" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">623,945</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average remaining amortization period at December 31, 2024 (in years)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zFTAQg0U6qf8" title="Finite Lived Intangible Assets, weighted average amortization period"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zWn6aGIbVlz8" title="Finite Lived Intangible Assets, weighted average amortization period"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_LicenseMember" format="ixt-sec:duryear" id="Fact000740" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">10.3</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zQnJWoLGRUxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000742" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zyr8t0Ym6OWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of intangible assets consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_zIE3bG4EPzp9" style="display: none">SCHEDULE OF FINITE LIVED
INTANGIBLE ASSETS AMORTIZATION EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Balance as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zAQRVTNxCnRa" title="Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_custom_PatentsAndTrademarkMember" id="Fact000744" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,676</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zTV1EfXZQxkj" title="Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_us-gaap_LicenseMember" id="Fact000746" format="ixt:numdotdecimal" decimals="0" unitRef="USD">790,092</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zuMtebEZOmgf" title="Beginning Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember" id="Fact000748" format="ixt:numdotdecimal" decimals="0" unitRef="USD">793,768</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zY8aapJwfbif" title="Amortization expense" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0750">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgEjKj6jTWI5" title="Amortization expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31_us-gaap_LicenseMember" id="Fact000752" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,746</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2rXVJBGP7il" title="Amortization expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31_custom_AccumulatedAmortizationMember" id="Fact000754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,746</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zgRAH3stiYi7" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_custom_PatentsAndTrademarkMember" id="Fact000756" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,676</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zDe9KaWcOYI7" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_LicenseMember" id="Fact000758" format="ixt:numdotdecimal" decimals="0" unitRef="USD">879,838</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXVvp6oFTRTa" title="Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_custom_AccumulatedAmortizationMember" id="Fact000760" format="ixt:numdotdecimal" decimals="0" unitRef="USD">883,514</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zuHhehAQNkik" title="Amortization expense" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0762">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z6qgnUqvdCNe" title="Amortization expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_us-gaap_LicenseMember" id="Fact000764" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zygSxwRoDT8e" title="Amortization expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_custom_AccumulatedAmortizationMember" id="Fact000766" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zpDaKpFlcUXl" title="Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_custom_PatentsAndTrademarkMember" id="Fact000768" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,676</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_ziQYvOYoF2Vh" title="Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_us-gaap_LicenseMember" id="Fact000770" format="ixt:numdotdecimal" decimals="0" unitRef="USD">969,585</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z21atXqH7Mrd" title="Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_custom_AccumulatedAmortizationMember" id="Fact000772" format="ixt:numdotdecimal" decimals="0" unitRef="USD">973,261</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zXJeZ8EsBx54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000774" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zO5E84hy3qC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense for the next five years is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zDxhPMghSJb7" style="display: none">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom">For the Years Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zLqGmLhSvkA" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz89Q_z1vNDKxW98G5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact000776" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,746</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz89Q_za7zLx3utHS9" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2024-12-31" id="Fact000778" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,746</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz89Q_z9FWK80aZ1L8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2024-12-31" id="Fact000780" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,746</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz89Q_zCZfaJK7po9f" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2024-12-31" id="Fact000782" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,746</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz89Q_zlr2Quf6AHf9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2024-12-31" id="Fact000784" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,746</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz89Q_zivgdmaXPRBi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact000786" format="ixt:numdotdecimal" decimals="0" unitRef="USD">448,730</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zRFY1LD10kBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000788" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zcCzM4pARQo3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
5 - <span id="xdx_820_zMsUx2ILh5Tl">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000790" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z7ve0gvNg4Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z3T5qunqNukl" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zEWk23Yc0nC" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zeM88DjmnpU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zg5ydVfCG0I2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accrued bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact000792" format="ixt:numdotdecimal" decimals="0" unitRef="USD">704,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact000793" format="ixt:numdotdecimal" decimals="0" unitRef="USD">638,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_z5sQM90mCxFd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BRTX:AccruedGeneralAndAdministrativeExpenses" contextRef="AsOf2024-12-31" id="Fact000795" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,485</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BRTX:AccruedGeneralAndAdministrativeExpenses" contextRef="AsOf2023-12-31" id="Fact000796" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,686</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zJIAosR1rmQf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2024-12-31" id="Fact000798" format="ixt:numdotdecimal" decimals="0" unitRef="USD">744,485</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31" id="Fact000799" format="ixt:numdotdecimal" decimals="0" unitRef="USD">711,686</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_ziyjOByjOsNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000801" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zJPEBtlN7YIk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
6 - <span id="xdx_82B_zUgzUG841pcg">STOCKHOLDERS&#8217; EQUITY</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
A Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2021, in connection with the Company&#8217;s public offering, the Company&#8217;s Board of Directors adopted a resolution
allowing for the designation and issuance of <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAv4O5ACYYm2" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" id="Fact000803" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></span> shares of the Company&#8217;s Preferred Stock, $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQNlJEUEDcQa" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" id="Fact000805" decimals="INF" unitRef="USDPShares">.01</ix:nonFraction></span> par value per share, designated
as Series A Preferred Stock (&#8220;Series A&#8221;). The Series A had a liquidation preference of $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3hczMMtKpU8" title="Preferred stock, liquidation preference"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" id="Fact000807" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. On September 8,
2022, the Company issued <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zo0GcvUNCdN2" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember" id="Fact000809" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></span> shares of Series B Preferred Stock (&#8220;Series B&#8221;) to Auctus Fund, LLC (&#8220;Auctus&#8221;)
in exchange for an equal number of shares of the Company&#8217;s outstanding Series A. Simultaneously, the stock certificate representing
the Series A shares was being returned to the Company for cancellation. On such date and upon such exchange, the Company&#8217;s Board
of Directors cancelled the Series A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 110 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
B Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 8, 2022, the Company issued <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYC3O1qRrCy6" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember" id="Fact000811" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></span> shares of Series B to Auctus in exchange for an equal number of shares of the Company&#8217;s
outstanding Series A. The terms of the Series B are substantially identical to those of the Series A, except that, among other things,
the limitation on beneficial ownership of common stock of the Company upon a conversion of the Series B into Common Stock, and the limitation
on the number of votes attributable to the Series B, is <span id="xdx_90D_eus-gaap--PreferredStockVotingRights_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKAmHWfyKJBh" title="Preferred stock voting rights"><ix:nonNumeric contextRef="From2022-09-082022-09-08_us-gaap_SeriesBPreferredStockMember" id="Fact000813" name="us-gaap:PreferredStockVotingRights">9.99</ix:nonNumeric></span>% of the then outstanding Common Stock of the Company instead of <span id="xdx_90C_eus-gaap--PreferredStockVotingRights_pid_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuT87XMZHkJ6" title="Preferred stock voting rights"><ix:nonNumeric contextRef="From2022-09-082022-09-08_us-gaap_SeriesAPreferredStockMember" id="Fact000815" name="us-gaap:PreferredStockVotingRights">4.99</ix:nonNumeric></span>% as
provided for the Series A. The Company is required, at all times, to reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of Common Stock upon the full conversion of the Series B. The Series B is not subject to
redemption by the Company or any Series B holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders
of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Voting
Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders
of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes
for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares
of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law.
The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares
of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled
to vote more than <span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7GqZ3KTuVV4" title="Preferred stock voting percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000817" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% of the then outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conversion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optional
Conversion - <span id="xdx_902_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zL2VXQ8WU4De" title="Preferred stock conversion term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000819" name="us-gaap:ConvertiblePreferredStockTermsOfConversion">Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock;</ix:nonNumeric></span> provided, however, that in no event shall a Series B holder be entitled to convert any shares of Series B
to the extent that such conversion would result in beneficial ownership by such Series B holder of more than <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_znCDeplQWuW5" title="Preferred stock voting percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000821" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% of the outstanding
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automatic
Conversion - From time to time, in the event that an event occurs which has the effect of reducing a Series B holder&#8217;s beneficial
ownership of shares of Common Stock to less than <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zphxO48CaFTi" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember" id="Fact000823" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.5</ix:nonFraction></span>% of the then publicly disclosed outstanding shares of Common Stock, then, within
five business days, the Series B holder is required to provide notice to the Company to such effect, which notice shall state the number
of shares of Common Stock beneficially owned by the Series B holder and shall provide reasonable detail with regard thereto, including
the number of derivative securities compromising a portion of such beneficial share amount. Such notice shall have the effect of a notice
of conversion with respect to the conversion of such number of shares of Series B as would increase the Series B holder&#8217;s beneficial
ownership of Common Stock to <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zf50yJldC0Qg" title="Preferred stock voting percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember" id="Fact000825" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% of the then publicly disclosed outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 25, 2022, Auctus converted <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_z5AXhJwz8bFi" title="Debt conversion, converted instrument, shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember_custom_AuctusFundLLCMember" id="Fact000827" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of Series B into <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zlLsZqLS1tRe" title="Debt conversion, converted instrument, shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember" id="Fact000829" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of Common Stock. The number of shares of Series B remaining
outstanding after this conversion was <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zLoD9gwPh8vg" title="Conversion of stock shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember" id="Fact000831" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,518,158</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 4, 2023, Auctus converted <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zFD1ODMs5Buk" title="Number of shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-04-032023-04-04_custom_AuctusFundLLCMember_custom_SeriesBConvertiblePreferredStockMember" id="Fact000833" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span> shares of Series B into <span id="xdx_90D_eus-gaap--ConversionOfStockSharesIssued1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zUB0LKFisLvh" title="Number of shares issued in conversion"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2023-04-032023-04-04_custom_AuctusFundLLCMember_us-gaap_CommonStockMember" id="Fact000835" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span> shares of Common Stock. As of December 31, 2024, the number of
shares of Series B remaining outstanding after giving effect to such conversion was <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zveV0mvbGEcl" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000837" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Stock Incentive Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, the Company&#8217;s Board of Directors adopted the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &#8220;2021
Plan&#8221;). The 2021 Plan was approved by the Company&#8217;s stockholders on August 17, 2021. Pursuant to the 2021 Plan, a total of
<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210318__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember_zQB2Po9BLkKg" title="Number of shares of common stock authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2021-03-18_custom_TwoThousandTwentyOneStockIncentivePlanMember" id="Fact000839" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,175,000</ix:nonFraction></span> shares of common stock were initially authorized to be issued pursuant to the grant of stock options, restricted stock units,
restricted stock, stock appreciation rights and other incentive awards. On December 10, 2021, the Company&#8217;s Board of Directors
approved an amendment to increase the number of shares of Common Stock authorized to be issued from <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20211210__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zVPMbYgrWnQ2" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember" id="Fact000841" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,175,000</ix:nonFraction></span> to <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20211210__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zncC5eiUPWt1" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember" id="Fact000843" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span>. Such amendment
was approved by the Company&#8217;s stockholders on November 3, 2022. On July 13, 2023, the Company&#8217;s Board of Directors approved
an amendment to the 2021 Plan to increase the number of shares of Common Stock authorized to be issued from <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20230713__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zo1X1po4yASk" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember" id="Fact000845" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span> to <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20230713__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zVCTDa6pQi4" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember" id="Fact000847" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,850,000</ix:nonFraction></span>. Such
amendment was approved by the Company&#8217;s stockholders on September 13, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 111 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 23, 2024, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s 2021 Plan to increase the number of
shares of common stock authorized to be issued under the 2021 Plan from <span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240722__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zVT1EXT7QkA9" title="Common stock authorized to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-07-22_custom_TwoThousandAndTwentyOneStockIncentivePlanMember" id="Fact000849" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,850,000</ix:nonFraction></span> to <span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240723__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_z0fNr8c0ddHb" title="Common stock authorized to issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-07-23_custom_TwoThousandAndTwentyOneStockIncentivePlanMember" id="Fact000851" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,850,000</ix:nonFraction></span>. Such amendment was approved by the Company&#8217;s
stockholders on September 19, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensatory
Common Stock Issuance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company issued <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20230101__20231231_ztpy3rsk930e" title="Vested common stock, shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-01-012023-12-31" id="Fact000853" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,442</ix:nonFraction></span> shares of immediately vested common stock with a value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20231231_zKuKeGD0i2fd" title="Aggregate common stock services rendered"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-12-31" id="Fact000855" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,500</ix:nonFraction></span> to a consultant
for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales
of Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, the Company entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (&#8220;JonesTrading&#8221;)
under which the Company had the ability to issue and sell shares of its Common Stock, from time to time, through JonesTrading, up to
an aggregate offering price of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230401__20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--DemandSalesAgreementMember_z2vE6NAiKWPj"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-04-012023-04-30_us-gaap_CommonStockMember_custom_DemandSalesAgreementMember" id="Fact000856" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,109,000</ix:nonFraction></span> in what is commonly referred to as an &#8220;at-the-market&#8221; (&#8220;ATM&#8221;)
program. During the year ended December 31, 2023, the Company sold <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zXplo7pD9iOk" title="Sold shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember" id="Fact000858" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">132,827</ix:nonFraction></span> shares of its Common Stock at a weighted average price of
$<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zpEUTC3wNX2l" title="Weighted average price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember" id="Fact000860" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.68</ix:nonFraction></span> per share and raised $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zunGcHy30dsd"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember" id="Fact000861" format="ixt:numdotdecimal" decimals="0" unitRef="USD">494,782</ix:nonFraction></span> in net proceeds under the JonesTrading ATM program. In November 2024, in connection with the ATM
program with Rodman &amp; Renshaw LLC (&#8220;Rodman&#8221;) discussed below, the Company terminated the Capital on Demand Sales Agreement
with JonesTrading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 13, 2023, the Company sold an aggregate of 	<span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230712__20230713_zGeXKDbsQOZf" title="Sale of aggregate shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-07-122023-07-13" id="Fact000863" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">685,033</ix:nonFraction></span> shares of Common Stock to several institutional buyers and accredited investors
in a registered direct offering at an offering price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230713_zcVAT4OtM4yi" title="Offering price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-07-13" id="Fact000865" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.03</ix:nonFraction></span> per share. The offering closed on July 13, 2023 with net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230712__20230713_zP7zaht68Fhf" title="Net proceeds offering price"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-07-122023-07-13" id="Fact000867" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,853,990</ix:nonFraction></span>.
The Company intends to use the net proceeds from the offering in connection with its clinical trials with respect to its lead cell therapy
candidate, BRTX-100, pre-clinical research and development with respect to its metabolic ThermoStem Program and for general corporate
purposes and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the Company entered into an At The Market Offering Agreement with Rodman, under which the Company currently has the ability
to issue and sell shares of its Common Stock, from time to time, through Rodman, up to an aggregate offering price of approximately $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zH6H9vwuMDQa" title="Sold value of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_ATMProgramMember" id="Fact000869" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,614,000</ix:nonFraction></span>
in an ATM program. See Note 10 - Subsequent Events &#8211; Common Stock Sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Exercise and Issuance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2024, the Company entered into agreements with certain holders of its existing warrants exercisable for an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJLLRuKcXiXh" title="Warrants exercisable"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember" id="Fact000871" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,351,580</ix:nonFraction></span>
shares of its Common Stock (collectively, the &#8220;Existing Warrants&#8221;), to exercise their warrants at a reduced exercise price
of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWIprX6rqLng" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember" id="Fact000873" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.33</ix:nonFraction></span> per share, in exchange for the issuance of new warrants (the &#8220;New Warrants&#8221;) as described below (the &#8220;Warrant
Exercise and Issuance&#8221;). The aggregate gross proceeds from the exercise of the Existing Warrants and the payment of the New Warrants,
as described below, was approximately $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLxbdAHUuGN7" title="Proceeds from exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember" id="Fact000875" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.1</ix:nonFraction></span> million, before deducting cash issuance costs in the amount of $<span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAFNeSFqflDl" title="Cash issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember" id="Fact000877" format="ixt:numdotdecimal" decimals="0" unitRef="USD">595,364</ix:nonFraction></span>. The reduction of
the exercise price of the Existing Warrants and the issuance of the New Warrants was structured as an at-market transaction under Nasdaq
rules. Of the <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzsKaWfvjyT2" title="Warrants exercisable"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember" id="Fact000879" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,351,580</ix:nonFraction></span> shares of Common Stock issuable upon the exercise of the Existing Warrants, through December 31, 2024, the Company
had issued an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z68Q6vqjUh11" title="Warrants exercisable"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember" id="Fact000881" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,150,000</ix:nonFraction></span> shares of Common Stock. The remaining <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember_zvVWO1PSwBY4" title="Warrants exercisable"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember_custom_AuctusFundLLCMember" id="Fact000883" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,201,580</ix:nonFraction></span> shares of Common Stock, which are issuable to Auctus
Fund, LLC (&#8220;Auctus&#8221;), are being held in abeyance due to Auctus&#8217; maximum beneficial ownership limitation (the &#8220;Abeyance
Shares&#8221;). Such Abeyance Shares have been fully paid for and are issuable upon notice from Auctus to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the immediate exercise of the Existing Warrants for cash and the payment of $<span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zBxG29Eh8Uv" title="Warrants for cash and the payment"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember" id="Fact000885" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.125</ix:nonFraction></span> per share underlying the New Warrants,
the exercising holders received the New Warrants to purchase shares of Common Stock in a private placement pursuant to Section 4(a)(2)
of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The New Warrants will be exercisable for a period of five
years into an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNlyN1DFbIFj" title="Warrants exercisable"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember" id="Fact000887" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,513,686</ix:nonFraction></span> shares of Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zRsdklXiIqW9" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember" id="Fact000889" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.43</ix:nonFraction></span> per share. The securities offered in the private
placement have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not
be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration
requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company agreed to file
a resale registration statement with the SEC to register the resale of the shares of Common Stock underlying the New Warrants issued
in the private placement. Such resale registration statement was filed and was declared effective by the SEC on April 18, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 112 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the transaction described above, the Company entered into a financial advisory services agreement, dated February 5,
2024, with Roth Capital Partners, LLC (&#8220;Roth&#8221;), pursuant to which the Company has paid Roth a cash fee of approximately $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240205__20240205__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zzl7n2lB0Vtl" title="Cash fee for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-02-052024-02-05_us-gaap_CommonStockMember_custom_RothCapitalPartnersLLCMember" id="Fact000891" format="ixt:numdotdecimal" decimals="0" unitRef="USD">528,000</ix:nonFraction></span>
for its services, in addition to reimbursement for certain expense. During the year ended December 31, 2024, the Company incurred an
aggregate of $<span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zT0D139u7t1a" title="Issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember_custom_RothCapitalPartnersLLCMember" id="Fact000893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">595,364</ix:nonFraction></span> of cash issuance costs related to the Warrant Exercise and Issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Warrant Exercise and Issuance, the Existing Warrants were classified as derivative liabilities. Additionally, the Company analyzed
the form of the New Warrants and determined that they should be classified as derivative liabilities in accordance with ASC 815-40, Derivatives
and Hedging &#8212; Contracts in Entity&#8217;s Own Equity. Under the New Warrants, the Company does not control the occurrence of events,
such as a tender offer or exchange, that may trigger cash settlement of the New Warrants and not result in a change of control of the
Company. As a result, such New Warrants do not meet the criteria for equity treatment. Additionally, certain New Warrants contain adjustments
to the settlement amount based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option as defined
under ASC 815-40 and, accordingly, such New Warrants are not considered indexed to the Company&#8217;s own stock and are not eligible
for an exception from derivative accounting. See Note 9&#8211; Fair Value Measurement for details regarding the valuation of the Existing
Warrants and New Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the Warrant Exercise and Issuance to be an exchange by investors of Existing Warrants with an aggregate fair value
of $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zwsYJKgpvCMb" title="Fair value of adjustment"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember" id="Fact000895" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,115,334</ix:nonFraction></span> along with aggregate cash consideration of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zfFm1YZsZXZc" title="Proceeds from issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember" id="Fact000897" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,123,392</ix:nonFraction></span> (consisting of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zCSVqe8YkOf2" title="Proceeds from issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-12-31_custom_ExistingWarrantMember" id="Fact000899" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,809,181</ix:nonFraction></span> paid to exercise the Existing Warrants
and $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_zbHEcEn03OHl" title="Proceeds from issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember" id="Fact000901" format="ixt:numdotdecimal" decimals="0" unitRef="USD">314,211</ix:nonFraction></span> paid for the New Warrants) for an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zF7lId3Nr2Q7" title="Stock issued during period shares new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember" id="Fact000903" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,351,580</ix:nonFraction></span> shares of common stock with an aggregate fair value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zefA77ZQfLn9" title="Stock issued during period value new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember" id="Fact000905" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,742,244</ix:nonFraction></span>,
New Warrants with an aggregate fair value of $<span id="xdx_909_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zk6OWlB7V2rb" title="Stock issued during period value warrants"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember" id="Fact000907" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,189,420</ix:nonFraction></span> and aggregate cash issuance costs of $<span id="xdx_909_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zWjJHU1kOYy9" title="Issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember" id="Fact000909" format="ixt:numdotdecimal" decimals="0" unitRef="USD">595,364</ix:nonFraction></span> and, accordingly, the Company recorded
a gain on exchange of warrants of $<span id="xdx_90D_ecustom--GainOnExchangeOfWarrants_c20240101__20241231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_z8JamcJ6mWz2" title="Gain on exchange of warrants"><ix:nonFraction name="BRTX:GainOnExchangeOfWarrants" contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember" id="Fact000911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,711,698</ix:nonFraction></span> during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Activity Summary</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000913" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zSZin8yUZKs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the warrant activity during the year ended December 31, 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zGJJPKtZyAE5" style="display: none">SCHEDULE OF WARRANT ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Outstanding, January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znAqvvT4Qbx9" title="Number of Warrants, Outstanding Beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000915" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,791,019</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z87TDq6moIv1" title="Weighted Average Exercise Price,  Outstanding beginning balance" style="width: 14%; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000917" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.57</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdjrTKuhx9z6" title="Number of Warrants, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765" id="Fact000919" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">2,513,686</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAkun9Fl9f26" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765" id="Fact000921" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzgG1cCZ4vr1" title="Number of Warrants, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765" id="Fact000923" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,351,580</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEztUrDWikmi" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765" id="Fact000925" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOsoduSVUaRk" title="Number of Warrants, Expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765" id="Fact000927" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,491</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5TDR39mHj08" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765" id="Fact000929" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,770</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfvfXo0Eesnl" title="Number of Warrants, Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000931" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,634</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsOAZv5WGZd9" title="Weighted Average Exercise Price, Outstanding ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000933" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.22</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYsjitrPloab" title="Weighted Average Remaining Life In Years, Outstanding"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765" format="ixt-sec:duryear" id="Fact000935" name="BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.30</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq1vHs0qwAbb" title="Number of Warrants, Exercisable Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000937" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,634</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zegEmgi5jNK" title="Weighted Average Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000939" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.22</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwG8bbAgSYD7" title="Weighted Average Remaining Life In Years, Exercisable"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765" format="ixt-sec:duryear" id="Fact000941" name="BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1">3.30</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zXSUQ9QnVqc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average estimated fair value of the warrants granted during the year ended December 31, 2024 was $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDO6RUoak3l1" title="Weighted average estimated fair value of warrants granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065375" id="Fact000943" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.87</ix:nonFraction> </span>per warrant. See Note
9 &#8211; Fair Value Measurement &#8211; for details regarding the fair value estimates of the Warrants that are classified as derivative
liabilities. The Company did not issue any warrants during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 113 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000945" name="BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock"><p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zMwHHKdVRuS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock warrants at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zJhgTLHPR6Ie" style="display: none">SCHEDULE
OF STOCK WARRANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBIP5ZD4QC56" title="Warrants outstanding, exercise price" style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember" id="Fact000947" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.43</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zl2Jku2lXkle" title="Warrants outstanding, number of warrants" style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember" id="Fact000949" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,513,686</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zU6Nhvq6d4e2" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember" format="ixt-sec:duryear" id="Fact000951" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.1</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zC60jbXs1afd" title="Warrants exercisable, exercisable number of warrants" style="width: 21%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember" id="Fact000953" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,513,686</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z17wx76SisWa" title="Warrants outstanding, exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember" id="Fact000955" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUseg3QpPL84" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember" id="Fact000957" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zyTCTVYqM8Mh" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember" format="ixt-sec:duryear" id="Fact000959" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.9</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zwoRloxfJKD9" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember" id="Fact000961" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuBvZFdF9pE2" title="Warrants outstanding, exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember" id="Fact000963" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWunI15vUYcb" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember" id="Fact000965" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,150,358</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOE3aHbPJii4" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember" format="ixt-sec:duryear" id="Fact000967" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.9</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCyYxBCsyVJe" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember" id="Fact000969" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,150,358</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zroKiGu0kyKh" title="Warrants outstanding, exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember" id="Fact000971" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvBqal267Qf4" title="Warrants outstanding, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember" id="Fact000973" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">235,970</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zsRzI4SStm05" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember" format="ixt-sec:duryear" id="Fact000975" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.9</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zjlWnxsI3Tue" title="Warrants exercisable, exercisable number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember" id="Fact000977" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">235,970</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcUo7cIEyFd6" title="Warrants outstanding, exercise price" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember" id="Fact000979" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4H9FGqoOWtj" title="Warrants outstanding, number of warrants" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember" id="Fact000981" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zlijR7PFbo2l" title="Warrants exercisable, weighted average remaining life in years"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember" format="ixt-sec:duryear" id="Fact000983" name="us-gaap:WarrantsAndRightsOutstandingTerm">0.0</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zJksqF3ibGo6" title="Warrants exercisable, exercisable number of warrants" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember" id="Fact000985" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zMTGD0WHNxH" title="Warrants outstanding, number of warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31" id="Fact000987" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,634</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zfJ2T3TGfPA7" title="Warrants exercisable, exercisable number of warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31" id="Fact000989" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,634</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_za7feX7DXOtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000991" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfNfCP9eNvD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the option activity during the year ended December 31, 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zrN9b2GV9bbk" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding, January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTvM4oSXln82" title="Number of Options, Outstanding beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact000993" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,466,892</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zoDROm8SpfK" title="Weighted Average Exercise Price, Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact000995" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.11</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z1Abs0lPnAC2" title="Number of Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-01to2024-12-31" id="Fact000997" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,934,716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zf56QyHtDan2" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="Fact000999" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_zBqFaBP2hRrg" title="Number of Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zQdf2naQfNwc" title="Number of Options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-01to2024-12-31" id="Fact001003" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">138,141</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zPDXmZhZIG01" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="Fact001005" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.76</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zcyRTNE1DYVe" title="Number of Options, Outstanding ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact001007" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,263,467</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z6AUvmyFe4hl" title="Weighted Average Exercise Price, Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001009" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.63</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zTVIyvLVQU9e" title="Weighted Average Remaining Life in Years Outstanding Ending"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001011" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.5</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231_z0jhmSrRb99" title="Intrinsic Value, Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z6OaUmtzPBzj" title="Number of Options, Exercisable Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact001015" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,499,132</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zLxmZKqE199h" title="Weighted Average Exercise Price Exercisable Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001017" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.95</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zv88ELOpOHR9" title="Weighted Average Remaining Life in Years Exercisable Ending"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001019" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.1</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231_z0nAmGqFN17c" title="Intrinsic Value, Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zoAlkje3gnuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of the stock options granted during the years ended December 31, 2024 and 2023 was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zHbmqifX8bie" title="Weighted average grant date fair value of stock options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-01to2024-12-31" id="Fact001023" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.45</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zRFePEuvUmbe" title="Weighted average grant date fair value of stock options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31" id="Fact001025" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001027" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zRtaMfXkznRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock options at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_ztcIUlTEysz5" style="display: none">SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zeGpMtvcx146" title="Options Outstanding, Exercise Price" style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_RangeOneMember" id="Fact001029" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.45</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFR9VoHQVghd" title="Options Outstanding, Outstanding Number of Options" style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_RangeOneMember" id="Fact001031" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,825,067</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBesCUmhfgB8" title="Options Exercisable Weighted Average Remaining Life In Years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeOneMember" format="ixt-sec:duryear" id="Fact001033" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">8.1</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zOElztZCIEXk" title="Options Exercisable, Exercisable Number of Options" style="width: 21%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_RangeOneMember" id="Fact001035" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,138,579</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zlN1nxbD5Qm7" title="Options Outstanding, Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_RangeTwoMember" id="Fact001037" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.91</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z5su5TfUL9I1" title="Options Outstanding, Outstanding Number of Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_RangeTwoMember" id="Fact001039" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">626,215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmxifRgIyVvh" title="Options Exercisable Weighted Average Remaining Life In Years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact001041" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">6.7</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrvHndT1tcGc" title="Options Exercisable, Exercisable Number of Options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_RangeTwoMember" id="Fact001043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">548,368</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGAMtsYhR5eh" title="Options Outstanding, Exercise Price" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-12-31_custom_RangeThreeMember" id="Fact001045" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.08</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zoR8Y98253Y8" title="Options Outstanding, Outstanding Number of Options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_RangeThreeMember" id="Fact001047" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">812,185</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1xz1zj7zjja" title="Options Exercisable Weighted Average Remaining Life In Years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact001049" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.9</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIZKhcRWSsw5" title="Options Exercisable, Exercisable Number of Options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_RangeThreeMember" id="Fact001051" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">812,185</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231_zbocWCIXa5Vc" title="Options Outstanding, Outstanding Number of Options" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact001053" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,263,467</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_ziXBWM6T6LZ" title="Options Exercisable, Exercisable Number of Options" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact001055" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,499,132</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zrKbEgsvNC01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 114 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001057" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zzhvGPbrfrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zZxbFDb2dxqf" style="display: none">SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zGOcrqNV9u6b" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember" id="Fact001059" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.14</ix:nonFraction></span> -<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zlS2vh9EUFd4" title="Risk free interest rate"> <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember" id="Fact001061" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.30</ix:nonFraction></span>%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoHTrUNaM9yc" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember" id="Fact001063" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.22</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z1KylLmbD0Dj" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001065" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.77</ix:nonNumeric></span> - <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zar0bL5bcuah" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001067" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.38</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx5RjK2kIGab" title="Expected term (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact001069" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zWWPgchvXA8e" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember" id="Fact001071" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">101</ix:nonFraction></span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_znbbAp1dPtUe" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember" id="Fact001073" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">102</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEkATAdzvs76" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember" id="Fact001075" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">175.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zauNMGbqKima" title="Expected dividends" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember" id="Fact001077" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0OQS4xjFub7" title="Expected dividends" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember" id="Fact001079" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zjeFEbC9TUoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the 2021 Plan, the Company may grant restricted stock units (&#8220;RSUs&#8221;) to employees, consultants or non-employee directors
(&#8220;Eligible Recipients&#8221;). The number, terms and conditions of the RSUs that are granted to Eligible Recipients are determined
on an individual basis by the 2021 Plan administrator. On the distribution date, the Company shall issue to the Eligible Recipient one
unrestricted, fully transferable share of the Company&#8217;s common stock (or the fair market value of one such share in cash) for each
vested and nonforfeitable RSU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001081" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zbjCRCDfsw47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the unvested RSUs as of December 31, 2024 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z7qX6TjqzmYg" style="display: none">SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%">Non-vested at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z54caD9t4qNf" title="Number of shares outstanding beginning" style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001083" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,827</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7rNzZRrwG7c" title="Number of shares granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1085">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE6DHLnyY2Zc" title="Number of shares forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember29066796" id="Fact001087" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,827</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVJwCiRoFDV8" title="Number of shares forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z984AZuQj4Zh" title="Number of shares outstanding ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1091">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zHAVwHeWUTFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001093" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zKMX8JsmytWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock-based compensation expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zNmDZQdJkQIj" style="display: none">SCHEDULE OF STOCK OPTION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unrecognized at December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Weighted Average Remaining
    Amortization Period</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8mg1PWdtnvh" title="Stock-based compensation expense" style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" id="Fact001095" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,812,566</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0lPbAx67Oo4" title="Stock-based compensation expense" style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" id="Fact001097" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,782,967</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAfZqmoXHmha" title="Unrecognized expense" style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">774,470</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbb2sY1Dla3" title="Weighted average remaining amortization period (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001101" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">0.95</ix:nonNumeric></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231_zbrAVj7QZ22e" title="Stock-based compensation expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001103" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,812,566</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231_zf5gaaCKHH4l" title="Stock-based compensation expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31" id="Fact001105" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,782,967</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231_zZzUIJJBw2k1" title="Unrecognized expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2024-12-31" id="Fact001107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">774,470</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zOzUVTj3znM8" title="Weighted average remaining amortization period (years)"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001109" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">0.95</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zFWRUvqoB1Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001111" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zVozmWE0SJyc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
7 - <span id="xdx_826_zR22wSIZcwLf">INCOME TAXES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company identified its federal and New York tax returns as its &#8220;major&#8221; tax jurisdictions. The Company is no longer subject
to income tax income examinations by these tax authorities for taxable years ended December 31, 2020, and prior. The Company reviewed
the prior New York state income tax filings and concluded that the prior year return will be amended to change the apportionment from
zero to <span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_c20240101__20241231_zUkrmcjJv7h4" title="Prior year income taxes, percentage"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact001113" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>%. The Company believes its income tax filing positions and deductions will be sustained on audit, and it does not anticipate
any adjustments that would result in a material change to its financial position. Therefore, no liabilities for uncertain tax positions
have been recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the Company had approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zePnVp7cedXh" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember" id="Fact001115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,200,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zRa5IkvBOzVf" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,800,000</ix:nonFraction></span>, respectively, of federal and state net operating losses
that may be available to offset future taxable income. As a result of the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;),
certain future carryforwards do not expire. At December 31, 2024, approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_c20241231__srt--StatementScenarioAxis__custom--ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_zDqomiSyERfd" title="Operating loss carry-forwards subject to expiration"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" contextRef="AsOf2024-12-31_custom_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" id="Fact001119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,800,000</ix:nonFraction></span> of federal net operating losses will expire
from 2030 to 2038 and approximately $<span id="xdx_908_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_c20241231_zXc6BzRqcNMd" title="Operating loss carry-forwards not subject to expiration"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" contextRef="AsOf2024-12-31" id="Fact001121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,400,000</ix:nonFraction></span> have no expiration but are subject to a utilization limit equal to 80% of current taxable
income. <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseDescription_c20240101__20241231_z84EZ3UauGO9" title="Net operating loss description"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact001123" name="us-gaap:LesseeOperatingLeaseDescription">The state net operating losses have a 20 year carryforward period and will begin to expire beginning 2035.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 115 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zywpKWkgXOba" title="Income tax examination, description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SectionThreeHundredAndEightyTwoMember" id="Fact001125" name="us-gaap:IncomeTaxExaminationDescription">In
accordance with Section 382 of the Internal Revenue Code, the usage of the Company&#8217;s net operating loss carryforwards are subject
to annual limitations due to several greater than 50% ownership changes.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not performed a formal analysis for the year ended December 31, 2024, but it believes its ability to use such net operating
losses and tax credit carryforwards in the future is subject to annual limitations due to change of control provisions under Sections
382 and 383 of the Internal Revenue Code, which will significantly impact its ability to realize these deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit
use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred
over the three-year period ended December 31, 2024. For the period ended December 31, 2024, the Company has recorded a full valuation
allowance against the gross deferred tax asset balance as management believes that it is more likely than not that the results of operations
will not generate sufficient taxable income to realize any of the deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this filing, the Company has not filed its 2024 federal and state corporate income tax returns. The Company expects to
file these documents as soon as practicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001127" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOmgaPOBaQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2024 and 2023 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zZUwWPmupGV3" style="display: none">SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_zL9QFC7L3Yig" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zhbF1s19zvl7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zEjIVolmYEU6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred Tax Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGzcBK_zW8G8vTtyQJk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001132" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,004,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001133" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,311,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGzcBK_zFIFQbADeNHb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact001135" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,695,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact001136" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,788,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTAGzcBK_zdxqp5f1BD88" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact001138" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,694,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact001139" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,676,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGzcBK_zOXQBzh1v0Wa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2024-12-31" id="Fact001141" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">330,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-12-31" id="Fact001142" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">330,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsRightOfUseAsset_i01I_maDTAGzcBK_zBysCmdOR9Q" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1144">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:DeferredTaxAssetsRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact001145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcBK_zwScf9aTi8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact001147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact001148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGzcBK_maDTALNz6jW_zRxljnsv5rrj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Deferred Tax Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001150" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,724,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact001151" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,134,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zlws6xNcz8z3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred Tax Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxLiabilitiesDepreciation_i01NI_pp0p0_di_maDITLz8iB_zLKFtT22d6Pg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:DeferredTaxLiabilitiesDepreciation" contextRef="AsOf2024-12-31" id="Fact001156" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">153,200</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BRTX:DeferredTaxLiabilitiesDepreciation" contextRef="AsOf2023-12-31" id="Fact001157" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">122,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_pp0p0_di_maDITLz8iB_zMvdEk1EX2Mf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2024-12-31" id="Fact001159" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,700</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2023-12-31" id="Fact001160" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_i01NI_pp0p0_di_maDITLz8iB_z5JN7o7R2Nk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="AsOf2023-12-31" id="Fact001163" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_di_maDITLz8iB_z626f9pOcRZd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2024-12-31" id="Fact001165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2023-12-31" id="Fact001166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pp0p0_di_mtDITLz8iB_msDTALNz6jW_z5ov3kRZfdYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Deferred Tax Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2024-12-31" id="Fact001168" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">289,900</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2023-12-31" id="Fact001169" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">294,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNz6jW_zDuuMmzJjzh4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Deferred Tax Asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="Fact001171" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,434,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-12-31" id="Fact001172" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,840,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8Hs2v6wALU5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001174" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,434,100</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001175" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,840,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_z8GkK0NwV2Ph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred Tax Asset, Net of Valuation Allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1178">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Change in valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20240101__20241231_zmS2WbGfj5n6" title="Change in valuation allowance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2024-01-01to2024-12-31" id="Fact001180" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,405,900</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"/><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20230101__20231231_zc9ckzJO7A9f" title="Change in valuation allowance" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-01-012023-12-31" id="Fact001182" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,064,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zgRHuIkbL9D3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 116 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001184" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zltwcQOflIb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision (benefit) as of December 31, 2024 and 2023 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zewWuR64PcD5" style="display: none">SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zRwhUVQspGih" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zxkSMrPCvzR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"/><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zlI2aJg7XIZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maDFSALzNuk_zO5ShPfW6jN4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1189">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1190">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zk51qR840bie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%">Deferred</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,567,000</ix:nonFraction></td><td style="width: 1%; text-align: left"/><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001193" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,090,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zTDgkAmF6Uzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">State &amp; Local:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maDFSALzNuk_z2FcUaberu53" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1198">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zRDQK8KB7bX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Deferred</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001201" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,161,100</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001202" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">974,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_maITEBz5Bf_mtDFSALzNuk_zPjhdL5jZTtd" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,405,900</ix:nonFraction></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001205" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,064,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--ChangeInValuationAllowance_i01N_di_msITEBz5Bf_zUa8lJUQV31j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BRTX:ChangeInValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact001207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,405,900</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BRTX:ChangeInValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001208" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,064,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz5Bf_zTflNXI3Iww2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision (benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1210">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zE62j2LkqvZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001213" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbnotrZxBuda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2024 and 2023 is as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zkPZz0PDfa4f" style="display: none">SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zIN1SWuTCKCd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zYoEk77mdqyd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"/><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR_zoD8GqfTv0Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001215" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001216" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR_zBasGeNwUdq5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax, net of valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact001218" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact001219" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.7</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maETR_ztCkHqhYvo49" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2024-01-01to2024-12-31" id="Fact001221" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2023-01-012023-12-31" id="Fact001222" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40D_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_maETR_zPZ9svXk5zz5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax return to provision adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" contextRef="From2024-01-01to2024-12-31" id="Fact001224" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.4</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" contextRef="From2023-01-012023-12-31" id="Fact001225" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maETR_zu0T4TNCIfFa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in federal valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact001227" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39.7</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001228" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">29.7</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_pid_dp_uPure_maETR_zY3qcJ2Patwj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Adjustment for stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">-<ix:nonFraction name="BRTX:EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact001230" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">62.1</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1231">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR_z9fAJvH2U32l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    tax rate</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-01to2024-12-31" id="Fact001233" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-012023-12-31" id="Fact001234" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zWRkjNmqbrWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001236" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zgcg9trQLw4b" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
8 &#8211; <span id="xdx_82A_zZqO5mhrGS0j">LEASES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a lease for <span id="xdx_902_eus-gaap--AreaOfLand_iI_usqft_c20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_z8CRWSAIBAK3" title="Area of land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2024-12-31_custom_MelvilleLeaseMember" id="Fact001238" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">6,800</ix:nonFraction></span> square feet of space located in Melville, New York (the &#8220;Melville Lease&#8221;) with respect
to its corporate and laboratory operations. The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option
of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zmpZ4l7IQSC6" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MinimumMember" id="Fact001240" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">132,600</ix:nonFraction></span> and
$<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zOjbIvPdVbN8" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MaximumMember" id="Fact001242" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">149,260</ix:nonFraction></span>. In June 2019, <span id="xdx_908_eus-gaap--LessorOperatingLeaseOptionToExtend_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_z4SYxbAeZm8h" title="Lease extension description"><ix:nonNumeric contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember" id="Fact001244" name="us-gaap:LessorOperatingLeaseOptionToExtend">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zIdUhKaj4omk" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember" id="Fact001246" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">153,748</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zAvMxkpiKrlg" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember" id="Fact001248" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">173,060</ix:nonFraction></span>.</ix:nonNumeric></span> The lease
expired on December 31, 2024 and the Company is currently leasing the premises on a month-to-month basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zrQlabrxcXu" title="Weighted average incremental borrowing rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact001250" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 117 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001252" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zfhOXOmxfDS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents net lease cost and other supplemental lease information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_8BA_zYd7fINKNxyl" style="display: none">SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zAim7KPlS8Vd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_zJY5zkeqo6Qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease Costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCzEnl_zdxX3SOKOhwd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left; padding-bottom: 1pt">Operating lease cost (cost resulting from lease payments)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact001254" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,060</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact001255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,028</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zNJI74DdZmgh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact001257" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">173,060</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-12-31" id="Fact001258" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">168,028</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zaVUvxrI8Xgk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease - operating cash flows (fixed payments)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-01to2024-12-31" id="Fact001260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,060</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-12-31" id="Fact001261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,028</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--OperatingLeaseLiabilityReduction_zHFwZpsBCS1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease - operating cash flows (liability reduction)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:OperatingLeaseLiabilityReduction" contextRef="From2024-01-01to2024-12-31" id="Fact001263" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="BRTX:OperatingLeaseLiabilityReduction" contextRef="From2023-01-012023-12-31" id="Fact001264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,328</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current leases - right of use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20241231_zlGR7yPRwte5" title="Non-current leases - right of use assets" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1266">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_z3Cs3WdUJgzk" title="Non-current leases - right of use assets" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact001268" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">151,447</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities - operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20241231_zait734oCTT3" title="Current liabilities - operating lease liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1270">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20231231_z5SMTMDgFzqf" title="Current liabilities - operating lease liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact001272" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">162,317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_zZt6kWMqb8m5" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseLiabilityCurrent"><span id="xdx_903_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_ztGyISFv9IYe" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl1273"><span style="-sec-ix-hidden: xdx2ixbrl1274">Non-current liabilities - operating lease liabilities</span></span></span></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20241231_zqhxJYXaknKk" title="Non-current liabilities - operating lease liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1276">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20231231_zSdrEeHsTO37" title="Non-current liabilities - operating lease liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zHFgvhk3iHe6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no future minimum payments under non-cancelable leases following the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001280" name="us-gaap:FinancialInstrumentsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zltmBzWqEc73" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
9 &#8211; <span id="xdx_822_zkzDTDJn5Zsa">FAIR VALUE MEASUREMENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the Warrants as liabilities in accordance with the guidance contained in ASC 815-40, Derivatives and Hedging &#8212;
Contracts in Entity&#8217;s Own Equity. For certain Warrants, the Company does not control the occurrence of events, such as a tender
offer or exchange, that may trigger cash settlement of the Warrants and not result in a change of control of the Company. As a result,
such Warrants do not meet the criteria for equity treatment and the Warrants must be recorded as a derivative liability. Additionally,
certain other Warrants contain adjustments to the settlement amount based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221;
option as defined under ASC 815-40 and, accordingly, such Warrants are not considered indexed to the Company&#8217;s own stock and are
not eligible for an exception from derivative accounting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2024, in connection with the Warrant Exercise and Issuance, the Company estimated the aggregate fair value of the Existing
Warrants (see Note 6- Stockholders&#8217; Equity for details) to be $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20240208__20240208__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_ziBScYzZ13xb" title="Fair value of adjustment"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-02-082024-02-08_custom_ExistingWarrantMember_custom_BlackScholesOptionMember" id="Fact001282" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,115,334</ix:nonFraction></span> using the Black-Scholes option pricing model (Level 3
inputs). The following table shows the detail of the valuation assumptions used:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU001289-01" escape="true" id="Fact001289" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-ZMNRFLS_zGWiyj8eGB08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zy4Lx3EQdX9j" style="display: none">SCHEDULE
OF FAIR VALUE VALUATION ASSUMPTIONS</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">February 8, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_z3vjeUokVdy1" title="Risk free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ExistingWarrantMember" id="Fact001291" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.20</ix:nonFraction></span> - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zsQwgnRfo9ne" title="Risk free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ExistingWarrantMember" id="Fact001293" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.28</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zqcGcNRJo4Xb" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_custom_ExistingWarrantMember" format="ixt-sec:duryear" id="Fact001295" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.75</ix:nonNumeric></span> - <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zMr7mo2LgO82" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_custom_ExistingWarrantMember" format="ixt-sec:duryear" id="Fact001297" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.76</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zT7MOzpWsO63" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_custom_ExistingWarrantMember" id="Fact001299" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">102</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zByUcEfDP6Vl" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ExistingWarrantMember" id="Fact001301" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zWTVHDTVNATa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2024, the Company estimated the aggregate issuance date fair value of the warrant liability related to the New Warrants (see
Note 4 - Stockholders&#8217; Equity for details) as $<span id="xdx_909_eus-gaap--DerivativeLiabilities_iI_c20240208_zaZ4oNIOeEXf" title="Derivative liabilities"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-02-08" id="Fact001303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,189,420</ix:nonFraction></span> using the Black-Scholes option pricing model (Level 3 inputs). The following
table shows the detail of the valuation assumptions used:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_C0F_gL3FVAALMORAN-ZMNRFLS_zFEXuwxSsfh3"><ix:continuation continuedAt="ConU001289-02" id="ConU001289-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<div id="xdx_C07_gL3FVAALMORAN-ZMNRFLS_z9jIJ08bBYOb"><ix:continuation continuedAt="ConU001289-03" id="ConU001289-02"><table cellpadding="0" cellspacing="0" id="xdx_300_zBSJWV5SGvha" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">February 8, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zD3oN4V56Q5b" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member" id="Fact001305" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.12</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8SRKjJEIcZ3" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member" format="ixt-sec:duryear" id="Fact001307" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.00</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0OvHJjsBvog" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member" id="Fact001309" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">101</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmGV2nd8un74" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_FairValueInputsLevel3Member" id="Fact001311" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C04_gL3FVAALMORAN-ZMNRFLS_zRoWvOb3mFlc"><ix:continuation continuedAt="ConU001289-04" id="ConU001289-03">&#160;</ix:continuation></span></span></p>


<ix:exclude><!-- Field: Page; Sequence: 118 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2024 and 2023, the Company estimated the aggregate fair value of the warrants classified as derivative liabilities to purchase
an aggregate of <span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zLLHtFGQXIk2" title="Fair value of adjustment"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_custom_BlackScholesOptionMember" id="Fact001313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,900,014</ix:nonFraction></span> and <span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_z5RerJc1v6T2" title="Fair value of adjustment"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_custom_BlackScholesOptionMember" id="Fact001315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,737,908</ix:nonFraction></span> shares of common stock, respectively, to be $<span id="xdx_907_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zC0D4h0jC5k6" title="Fair value of derivative liabilitiy"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeNet" contextRef="AsOf2024-12-31_custom_BlackScholesOptionMember" id="Fact001317" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zSAOIQsG5Qm9" title="Fair value of derivative liabilitiy"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeNet" contextRef="AsOf2023-12-31_custom_BlackScholesOptionMember" id="Fact001319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,543,953</ix:nonFraction></span>, respectively, using the
Black-Scholes option pricing model (Level 3 inputs) using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div id="xdx_C0F_gL3FVAALMORAN-ZMNRFLS_z6Jk0lFnAFsd"><ix:continuation continuedAt="ConU001289-05" id="ConU001289-04"><table cellpadding="0" cellspacing="0" id="xdx_307_zKLVcIhIzVE2" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zv7eKFqVeiu7" title="Risk free interest rate, Minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001321" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.12</ix:nonFraction>%</span> - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBHAeic1Mmv" title="Risk free interest rate, Maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001323" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.34</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zvyycNHmduL7" title="Risk free interest rate, Minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001325" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.04</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zA8LVCxdYpp9" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001327" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">1.86</ix:nonNumeric></span> - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zMhtVWrrmuYj" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001329" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.11</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z570pw5hpvj8" title="Expected term (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact001331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.86</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zCRrHeM4Aqyi" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember" id="Fact001333" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">97</ix:nonFraction></span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zQRlaizdtMj2" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember" id="Fact001335" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">110</ix:nonFraction></span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmLHGhk0izj8" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">87.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1AoHDe9wf58" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001339" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4BAeX5Y6SXd" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001341" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_C01_gL3FVAALMORAN-ZMNRFLS_zQgLe4Ufswxb"><ix:continuation id="ConU001289-05">&#160;</ix:continuation></span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001343" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zMC0qycoxwah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zKAQQdINnHu1" style="display: none">SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance, January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231_zzGF2dcRpRfi" title="Balance, January 1, 2023" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact001345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,541,733</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ChangeInFairValueOfDerivativeLiability_c20230101__20231231_zBJbF8pUGFtc" title="Change in fair value of derivative liability" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BRTX:ChangeInFairValueOfDerivativeLiability" contextRef="From2023-01-012023-12-31" id="Fact001347" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,997,780</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20240101__20241231_zaG0GkTdbKLk" title="Balance, January 1, 2024" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001349" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,543,953</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231_zKGDn9WG9Bhf" title="Issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact001351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,189,420</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_iN_di_c20240101__20241231_zGBz4IkSBmC9" title="Exercise of warrants">(<ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-01to2024-12-31" id="Fact001353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,115,334</ix:nonFraction></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ChangeInFairValueOfDerivativeLiability_c20240101__20241231_zz1OQhkUhksg" title="Change in fair value of derivative liability" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BRTX:ChangeInFairValueOfDerivativeLiability" contextRef="From2024-01-01to2024-12-31" id="Fact001355" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">97,188</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20240101__20241231_zDiXGX0BNwLc" title="Balance, december 30, 2024" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_z3mL6NzRpPKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities measured at fair value on a recurring basis are as follows:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001359" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6tGfwS6kgK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z5r5D5GaLK3d" style="display: none"><span>SCHEDULE
OF FAIR VALUE RECURRING BASIS</span></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities (Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%">Marketable securities as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4WzJJjC4wS1" title="Marketable securities, fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact001361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,184,701</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxeusrZDKjP6" title="Marketable securities, fair value" style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1363">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2rpFzeBYrv1" title="Marketable securities, fair value" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_c20241231_zmKh1dwd0rfe" title="Marketable securities" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2024-12-31" id="Fact001367" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,184,701</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Marketable securities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zC3pfJMA2Vod" title="Marketable securities, fair value" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact001369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,181,618</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFxBE74S8NCj" title="Marketable securities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUaeaX3Cxbrj" title="Marketable securities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1373">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zkPmSxUWuL6e" title="Marketable securities" style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact001375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,181,618</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrant liabilities as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaDiGqMl6dni" title="Warrant liabilities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZUD9addK6D7" title="Warrant liabilities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1379">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlzurmG7ynm" title="Warrant liabilities, fair value" style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_ziSFoXIxNsge" title="Warrant liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001383" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,520,851</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrant liabilities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRXvDdOz7IR8" title="Warrant liabilities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1385">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWQ1XwDflpwh" title="Warrant liabilities, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1387">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzV5BGldJR4" title="Warrant liabilities, fair value" style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001389" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,543,953</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231_zyQUQAE5wWT5" title="Warrant liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,543,953</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zHZFVjyZEVW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001393" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zQwk95xqwdn2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
10 - <span id="xdx_827_z8pGpu2YREya">SUBSEQUENT EVENTS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to the year ended December 31, 2024, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKg7Zk2AAER1" title="Sold shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember" id="Fact001395" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">492,000</ix:nonFraction></span> shares of its common stock under the Rodman ATM program with a weighted-average
gross price of approximately $<span id="xdx_906_eus-gaap--SharePrice_iI_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFw7mnG04Qni" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember" id="Fact001397" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.20</ix:nonFraction></span> per share and raised approximately $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zus5kgmQYQ7" title="Gross proceeds"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember" id="Fact001399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,084,000</ix:nonFraction></span> of gross proceeds. The total commissions and related
legal and accounting fees were approximately $<span id="xdx_904_eus-gaap--PaymentsForLegalSettlements_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuIqcQVJa93f" title="Legal settlements paid"><ix:nonFraction name="us-gaap:PaymentsForLegalSettlements" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember" id="Fact001401" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,000</ix:nonFraction></span> and the Company received net proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zfCSxkZoeUo1" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember" id="Fact001403" format="ixt:numdotdecimal" decimals="0" unitRef="USD">906,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Option
Grants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to December 31, 2024, the Company granted options to purchase an aggregate <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9OxoGbvnv17" title="Grant options shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001405" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,152,908</ix:nonFraction></span> shares of the Company&#8217;s common stock at an
exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8mtyATWWQi7" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001407" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.46</ix:nonFraction></span> per share to employees, the Company&#8217;s board of directors and a member of the Company&#8217;s scientific
advisory board. The options had an aggregate grant date fair value of $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zP0528XPAvEi" title="Grant options shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001409" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">4,044,250</ix:nonFraction></span> and vest as follows: (i) options to purchase an aggregate
<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zA3ysS42tju2" title="Options to purchase shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001411" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">323,459</ix:nonFraction></span> shares of common stock vest monthly over one year, and (ii) options to purchase an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoMpjuVT8AZf" title="Purchase of common shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001413" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,829,449</ix:nonFraction></span> shares of common stock
vest <span id="xdx_90E_ecustom--CommonStockVestRemainderPercentage_iI_pid_dp_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2ckuWuDozG7" title="Purchase of common shares"><ix:nonFraction name="BRTX:CommonStockVestRemainderPercentage" contextRef="AsOf2025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001415" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% immediately with the remainder vesting quarterly over two years commencing one year from the date of grant. The Company will
recognize the grant date fair value of the options proportionate to the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Common Stock Issuance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to the year ended December 31, 2024, the
Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_zn754CUGeFkd" title="Number of shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-03-27_us-gaap_SubsequentEventMember_custom_AuctusFundLLCMember" id="Fact001417" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,525</ix:nonFraction></span> shares of common stock to Auctus Fund, LLC in partial satisfaction of shares held by abeyance.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><p id="xdx_814_zwydxQb5pRWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 119; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>ex10-7.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Exhibit
10.7</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>As
Amended</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>September
19, 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>BIORESTORATIVE
THERAPIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>2021
STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ARTICLE
1</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><BR>&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">PURPOSE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
purpose of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;) is to promote the success and
enhance the value of BioRestorative Therapies, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and its Subsidiaries
(as defined below) by linking the individual interests of Employees, Consultants and members of the Board to those of the Company&rsquo;s
stockholders and by providing such individuals with an incentive for outstanding performance to generate superior returns to the Company&rsquo;s
stockholders. The Plan is further intended to provide flexibility to the Company and its Subsidiaries in their ability to motivate, attract,
and retain the services of those individuals upon whose judgment, interest, and special effort the successful conduct of the Company&rsquo;s
operation is largely dependent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ARTICLE
2<BR></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">DEFINITIONS AND CONSTRUCTION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Wherever
the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise.
The singular pronoun shall include the plural where the context so indicates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.1
&ldquo;<U>Administrator</U>&rdquo; shall mean the entity that conducts the general administration of the Plan as provided in Article
10 hereof. With reference to the duties of the Administrator under the Plan which have been delegated to one or more persons pursuant
to Section 10.6 hereof, or which the Board has assumed, the term &ldquo;Administrator&rdquo; shall refer to such person(s) unless the
Committee or the Board has revoked such delegation or the Board has terminated the assumption of such duties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.2
&ldquo;<U>Applicable Accounting Standards</U>&rdquo; shall mean Generally Accepted Accounting Principles in the United States, International
Financial Reporting Standards or such other accounting principles or standards as may apply to the Company&rsquo;s financial statements
under United States federal securities and other applicable laws from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.3
&ldquo;<U>Applicable Law</U>&rdquo; shall mean any applicable law, including without limitation, (a) provisions of the Code, the Securities
Act, the Exchange Act and any rules or regulations thereunder; (b) corporate, securities, tax or other laws, statutes, rules, requirements
or regulations, whether federal, state, local or foreign; and (c) rules of any securities exchange or automated quotation system on which
the Shares are listed, quoted or traded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.4
&ldquo;<U>Award</U>&rdquo; shall mean an Option, a Restricted Stock award, a Dividend Equivalent award, a Stock Payment award, a Restricted
Stock Unit award, a Performance Share award, an Other Incentive Award, or a Stock Appreciation Right, which may be awarded or granted
under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.5
&ldquo;<U>Award Agreement</U>&rdquo; shall mean any written notice, agreement, contract or other instrument or document evidencing an
Award, including through electronic medium, which shall contain such terms and conditions with respect to an Award as the Administrator
shall determine, consistent with the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.6
&ldquo;<U>Board</U>&rdquo; shall mean the Board of Directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.7
&ldquo;<U>Cause</U>&rdquo; shall mean (a) the Administrator&rsquo;s determination that the Participant failed to substantially perform
the Participant&rsquo;s duties (other than any such failure resulting from the Participant&rsquo;s Disability); (b) the Administrator&rsquo;s
determination that the Participant failed to carry out, or comply with, any lawful and reasonable directive of the Board or the Participant&rsquo;s
immediate supervisor; (c) the Participant&rsquo;s commission of any act which, if the Participant were convicted would constitute, or
the Participant&rsquo;s conviction, plea of no contest, plea of nolo contendere, or imposition of unadjudicated probation for, any (i)
felony, (ii) indictable offense or (iii) crime involving moral turpitude; (d) the Participant&rsquo;s unlawful use (including being under
the influence) or possession of illegal drugs on the premises of the Company or any of its Subsidiaries or while performing the Participant&rsquo;s
duties and responsibilities; or (e) the Participant&rsquo;s commission of an act of fraud, embezzlement, misappropriation, willful or
gross misconduct, or breach of fiduciary duty against the Company or any of its Subsidiaries. Notwithstanding the foregoing, if the Participant
is a party to a written employment, consulting, or other agreement with the Company or any of its Subsidiaries in which the term &ldquo;cause&rdquo;
is defined, then &ldquo;Cause&rdquo; shall be as such term is defined in the applicable written employment or consulting agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.8
&ldquo;<U>Change in Control</U>&rdquo; shall mean the occurrence of any of the following events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
A &ldquo;change in ownership,&rdquo; as described in Section 1.409A-3(i)(5)(v) of the Treasury Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
A &ldquo;change in effective control,&rdquo; as described in Section 1.409A-3(i)(5)(vi) of the Treasury Regulations (but substituting
&ldquo;50 percent&rdquo; for &ldquo;30 percent&rdquo; in the first sentence of Section 1.409A-3(i)(5)(vi)(A)(1)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
A &ldquo;change in ownership of a substantial portion of the assets,&rdquo; as described in Section 1.409A-3(i)(5)(vii) of the Treasury
Regulations (but substituting &ldquo;50 percent&rdquo; for &ldquo;40 percent&rdquo; in the first sentence thereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.9
&ldquo;<U>Code</U>&rdquo; shall mean the Internal Revenue Code of 1986, as amended from time to time, together with the regulations and
official guidance promulgated thereunder, whether issued prior or subsequent to the grant of any Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.10
&ldquo;<U>Committee</U>&rdquo; shall mean the committee appointed by the Board to administer the Plan or the Board if no committee is
appointed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.11
&ldquo;<U>Common Stock</U>&rdquo; shall mean the common stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.12
&ldquo;<U>Company</U>&rdquo; shall mean BioRestorative Therapies, Inc., a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.13
&ldquo;<U>Consultant</U>&rdquo; shall mean any consultant or advisor to the Company or any Subsidiary who provides consulting or advisory
services, other than as an Employee or Director, and such consultant or advisor (a) is a natural person (or an entity wholly-owned, directly
or indirectly, by a natural person), (b) has provided and/or will provide bona fide services to the Company, and (c) such services are
not in connection with the offer or sale of securities in a capital-raising transaction and do not directly or indirectly promote or
maintain a market for the Company&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.14
&ldquo;<U>Director</U>&rdquo; shall mean a member of the Board, as constituted from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.15
&ldquo;<U>Disability</U>,&rdquo; unless otherwise specified in an Award Agreement or under the terms of a Program, shall mean total and
permanent disability as defined in Section 22(e)(3) of the Code. For purposes of the Plan, a Participant shall be deemed to have incurred
a Disability if the Participant is determined to be totally disabled by the Social Security Administration or in accordance with the
applicable disability insurance program of the Company. Notwithstanding the foregoing, if the Participant is a party to a written employment,
consulting, or other agreement with the Company or any of its Subsidiaries in which the term &ldquo;disability&rdquo; is defined, then
&ldquo;Disability&rdquo; shall be as such term is defined in the applicable written employment or consulting agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.16
&ldquo;<U>Dividend Equivalent</U>&rdquo; shall mean a right to receive the equivalent value (in cash or Shares) of dividends paid on
Shares, awarded under Section 8.1 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.17
&ldquo;<U>Effective Date</U>&rdquo; shall mean the date the Plan is approved by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.18
&ldquo;<U>Eligible Individual</U>&rdquo; shall mean any person who is an Employee, a Consultant or a Non-Employee Director, as determined
by the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.19
&ldquo;<U>Employee</U>&rdquo; shall mean any officer or other employee (within the meaning of Section 3401(c) of the Code) of the Company
or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.20
&ldquo;<U>Equity Restructuring</U>&rdquo; shall mean a nonreciprocal transaction between the Company and its stockholders, such as a
stock dividend, stock split, reverse stock split, spin-off, rights offering or recapitalization through a large, nonrecurring cash dividend,
that affects the number or kind of Shares (or other securities of the Company) or the share price of Common Stock (or other securities)
and causes a change in the per share value of the Common Stock underlying outstanding stock-based Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.21
&ldquo;<U>Exchange Act</U>&rdquo; shall mean the Securities Exchange Act of 1934, as amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.22
&ldquo;<U>Expiration Date</U>&rdquo; shall have the meaning given to such term in Section 11.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.23
&ldquo;<U>Fair Market Value</U>&rdquo; shall mean, as of any given date, the value of a Share, determined as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
if the Common Stock is listed on any established stock exchange or a national market system, including, without limitation, Nasdaq, its
Fair Market Value shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange
or system on the day immediately preceding the day of determination (or, if the determination is made after the close of business for
trading, then on the day of determination) (or, if no closing sales price or closing bid was reported on that date, as applicable, on
the last trading date such closing sales price or closing bid was reported), as reported in The Wall Street Journal or such other source
as the Administrator deems reliable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
if the Common Stock is regularly quoted on an automated quotation system (including the OTCQB market) or by a recognized securities dealer,
its Fair Market Value shall be the closing sales price for such stock (or the mean between the high bid and low asked prices for the
Common Stock, if selling prices are not reported), as quoted on such system or by such securities dealer on the day immediately preceding
the day of determination (or, if the determination is made after the close of business for trading, then on the day of determination)
(or, if no such prices were reported on that date, as applicable, on the last date such prices were reported), as reported in The Wall
Street Journal or such other source as the Administrator deems reliable; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
in the absence of an established market for the Common Stock, the Fair Market Value shall be determined by the Administrator in good
faith, using such criteria as it shall determine, in its sole discretion, to be appropriate for valuation, provided that the determination
shall be consistent with the requirements of Sections 422 and 409A of the Code, if applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.24
&ldquo;<U>Greater Than 10% Stockholder</U>&rdquo; shall mean an individual then-owning (within the meaning of Section 424(d) of the Code)
more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any &ldquo;parent corporation&rdquo;
or &ldquo;subsidiary corporation&rdquo; (as defined in Sections 424(e) and 424(f) of the Code, respectively).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.25
&ldquo;<U>Incentive Stock Option</U>&rdquo; shall mean an Option that is intended to qualify as an incentive stock option and conforms
to the applicable provisions of Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.26
&ldquo;<U>Non-Employee Director</U>&rdquo; shall mean a Director of the Company who is not an Employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.27
&ldquo;<U>Non-Qualified Stock Option</U>&rdquo; shall mean an Option that is not an Incentive Stock Option or which is designated as
an Incentive Stock Option but does not meet the applicable requirements of Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.28
&ldquo;<U>Option</U>&rdquo; shall mean a right to purchase Shares at a specified exercise price, granted under Article 5 hereof. An Option
shall be either a Non-Qualified Stock Option or an Incentive Stock Option; <U>provided</U>, <U>however</U>, that Options granted to Non-Employee
Directors and Consultants shall only be Non-Qualified Stock Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.29
&ldquo;<U>Organizational Documents</U>&rdquo; shall mean, collectively, (a) the Company&rsquo;s articles of incorporation, certificate
of incorporation, bylaws or other similar organizational documents relating to the creation and governance of the Company, and (b) the
Committee&rsquo;s charter or other similar organizational documentation relating to the creation and governance of the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.30
&ldquo;<U>Other Incentive Award</U>&rdquo; shall mean an Award denominated in, linked to or derived from Shares or value metrics related
to Shares, granted pursuant to Section 8.5 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.31
&ldquo;<U>Participant</U>&rdquo; shall mean a person who has been granted an Award pursuant to the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.32
&ldquo;<U>Performance Share</U>&rdquo; shall mean a contractual right awarded under Section 8.4 hereof to receive a number of Shares
or the Fair Market Value of such number of Shares in cash based on the attainment of specified performance goals or other criteria determined
by the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.33
&ldquo;<U>Plan</U>&rdquo; shall mean this BioRestorative Therapies, Inc. 2021 Stock Incentive Plan, as it may be amended, supplemented,
and restated from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.34
&ldquo;<U>Program</U>&rdquo; shall mean any program adopted by the Administrator pursuant to the Plan containing the terms and conditions
intended to govern a specified type of Award granted under the Plan and pursuant to which such type of Award may be granted under the
Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.35
&ldquo;<U>Restricted Stock</U>&rdquo; shall mean an award of Shares made under Article 7 hereof that is subject to certain restrictions
and may be subject to risk of forfeiture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.36
&ldquo;<U>Restricted Stock Unit</U>&rdquo; shall mean a contractual right awarded under Section 8.3 hereof to receive in the future a
Share or the Fair Market Value of a Share in cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.37
&ldquo;<U>Securities Act</U>&rdquo; shall mean the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.38
&ldquo;<U>Share Limit</U>&rdquo; shall have the meaning provided in Section 3.1(a) hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.39
&ldquo;<U>Shares</U>&rdquo; shall mean shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.40
&ldquo;<U>Stock Appreciation Right</U>&rdquo; shall mean an Award entitling the Participant (or other person entitled to exercise pursuant
to the Plan) to exercise all or a specified portion thereof (to the extent then exercisable pursuant to its terms) and to receive from
the Company an amount determined by multiplying the difference obtained by subtracting the exercise price per share of such Award from
the Fair Market Value on the date of exercise of such Award by the number of Shares with respect to which such Award shall have been
exercised, subject to any limitations the Administrator may impose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.41
&ldquo;<U>Stock Payment</U>&rdquo; shall mean a payment in the form of Shares awarded under Section 8.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.42
&ldquo;<U>Subsidiary</U>&rdquo; shall mean (a) a corporation, association or other business entity of which fifty percent (50%) or more
of the total combined voting power of all classes of capital stock is owned, directly or indirectly, by the Company and/or by one or
more Subsidiaries, (b) any partnership or limited liability company of which fifty percent (50%) or more of the equity interests are
owned, directly or indirectly, by the Company and/or by one or more Subsidiaries, and (c) any other entity not described in clauses (a)
or (b) above of which fifty percent (50%) or more of the ownership or the power (whether voting interests or otherwise), pursuant to
a written contract or agreement, to direct the policies and management or the financial and the other affairs thereof, are owned or controlled
by the Company and/or by one or more Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.43
&ldquo;<U>Substitute Award</U>&rdquo; shall mean an Award granted under the Plan in connection with a corporate transaction, such as
a merger, combination, consolidation or acquisition of property or stock, in any case, upon the assumption of, or in substitution for,
an outstanding equity award previously granted by a company or other entity that is a party to such transaction; <U>provided</U>, <U>however</U>,
that in no event shall the term &ldquo;Substitute Award&rdquo; be construed to refer to an award made in connection with the cancellation
and repricing of an Option or Stock Appreciation Right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.44
&ldquo;<U>Termination of Service</U>&rdquo; shall mean, unless otherwise determined by the Administrator:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
As to a Consultant, the time when the engagement of a Participant as a Consultant to the Company and its Subsidiaries is terminated for
any reason, with or without cause, including, without limitation, by resignation, discharge, death, Disability or retirement, but excluding
terminations where the Consultant simultaneously commences or remains in employment and/or service as an Employee and/or Director of
the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
As to a Non-Employee Director, the time when a Participant who is a Non-Employee Director ceases to be a Director for any reason, including,
without limitation, a termination by resignation, failure to be elected, removal, death, Disability or retirement, but excluding terminations
where the Participant simultaneously commences or remains in employment and/or service as an Employee of and/or Consultant to the Company
or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
As to an Employee, the time when the employee-employer relationship between a Participant and the Company and its Subsidiaries is terminated
for any reason, including, without limitation, a termination by resignation, discharge, death, Disability or retirement, but excluding
terminations where the Participant simultaneously commences or remains in service as a Consultant to and/or Director of the Company or
any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Administrator, in its sole discretion, shall determine the effect of all matters and questions relating to any Termination of Service,
including, without limitation, whether a Termination of Service has occurred, whether any Termination of Service resulted from a discharge
for Cause and whether any particular leave of absence constitutes a Termination of Service; <U>provided</U>, <U>however</U>, that, with
respect to Incentive Stock Options, unless the Administrator otherwise provides in the terms of any Program, Award Agreement or otherwise,
or as otherwise required by Applicable Law, a leave of absence, change in status from an employee to an independent contractor or other
change in the employee-employer relationship shall constitute a Termination of Service only if, and to the extent that, such leave of
absence, change in status or other change interrupts employment for the purposes of Section 422(a)(2) of the Code. For purposes of the
Plan, a Participant&rsquo;s employee-employer relationship or consultancy relationship shall be deemed to be terminated in the event
that the Subsidiary employing or contracting with such Participant ceases to remain a Subsidiary following any merger, sale of stock
or other corporate transaction or event (including, without limitation, a spin-off).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ARTICLE
3<BR></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">SHARES SUBJECT TO THE PLAN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3.1
<U>Number of Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
Subject to Sections 3.1(b) and 11.2 hereof, the aggregate number of Shares which may be issued or transferred pursuant to Awards under
the Plan is Six Million Eight Hundred Fifty Thousand (6,850,000) Shares (the &ldquo;<U>Share Limit</U>&rdquo;). No more than Six Million
Eight Hundred Fifty Thousand (6,850,000) Shares may be issued upon the exercise of Incentive Stock Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
If any Shares subject to an Award are forfeited or expire or such Award is settled for cash (in whole or in part), the Shares subject
to such Award shall, to the extent of such forfeiture, expiration or cash settlement, again be available for future grants of Awards
under the Plan and shall be added back to the Share Limit in the same number of Shares as were debited from the Share Limit in respect
of the grant of such Award (as may be adjusted in accordance with Section 11.2 hereof). In addition, the following Shares shall be added
back to the Share Limit and will be available for future grants of Awards: (i) Shares tendered by a Participant or withheld by the Company
in payment of the exercise price of an Option or Stock Appreciation Right; (ii) Shares tendered by the Participant or withheld by the
Company to satisfy any tax withholding obligation with respect to an Award; and (iii) Shares subject to a Stock Appreciation Right that
are not issued in connection with the stock settlement of the stock appreciation right on exercise thereof. Any Shares forfeited by the
Participant or repurchased by the Company under Section 7.4 hereof at the same price paid by the Participant so that such Shares are
returned to the Company will again be available for Awards. The payment of Dividend Equivalents in cash in conjunction with any outstanding
Awards shall not be counted against the Shares available for issuance under the Plan. Notwithstanding the provisions of this Section
3.1(b), no Shares may again be optioned, granted or awarded if such action would cause an Incentive Stock Option to fail to qualify as
an incentive stock option under Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
Substitute Awards shall not reduce the Shares authorized for grant under the Plan, except to the extent required by reason of Section
422 of the Code. Additionally, in the event that a company acquired by the Company or any Subsidiary, or with which the Company or any
Subsidiary combines, has shares available under a pre-existing plan approved by its stockholders and not adopted in contemplation of
such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the
extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination
to determine the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be
used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan to the extent that grants of Awards
using such available shares are (i) permitted without stockholder approval under the rules of the principal securities exchange on which
the Common Stock is then listed, if applicable, and (ii) made only to individuals who were not employed by or providing services to the
Company or its Subsidiaries immediately prior to such acquisition or combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ARTICLE
4</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">GRANTING OF AWARDs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4.1
<U>Participation.</U> The Administrator may, from time to time, select from among all Eligible Individuals, those to whom one or more
Awards shall be granted and shall determine the nature and amount of each Award, which shall not be inconsistent with the requirements
of the Plan. No Eligible Individual or other Person shall have any right to be granted an Award pursuant to the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4.2
<U>Award Agreement</U>. Each Award shall be evidenced by an Award Agreement stating the terms and conditions applicable to such Award,
consistent with the requirements of the Plan and any applicable Program. Award Agreements evidencing Incentive Stock Options shall contain
such terms and conditions as may be necessary to meet the applicable provisions of Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4.3
<U>At-Will Service</U>. Nothing in the Plan or in any Program or Award Agreement hereunder shall confer upon any Participant any right
to continue as an Employee, Director or Consultant of the Company or any Subsidiary, or shall interfere with or restrict in any way the
rights of the Company or any Subsidiary, which rights are hereby expressly reserved, to discharge any Participant at any time for any
reason whatsoever, with or without Cause, and with or without notice, or to terminate or change all other terms and conditions of any
Participant&rsquo;s employment or engagement, except to the extent expressly provided otherwise in a written agreement between the Participant
and the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4.4
<U>Stand-Alone and Tandem Awards</U>. Awards granted pursuant to the Plan may, in the sole discretion of the Administrator, be granted
either alone, in addition to, or in tandem with, any other Award granted pursuant to the Plan. Awards granted in addition to or in tandem
with other Awards may be granted either at the same time as or at a different time from the grant of such other Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ARTICLE
5</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">granting OF OPTIONS and stock appreciation rights</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.1
<U>Granting of Options and Stock Appreciation Rights to Eligible Individuals</U>. The Administrator is authorized to grant Options and
Stock Appreciation Rights to Eligible Individuals from time to time, in its sole discretion, on such terms and conditions as it may determine
which shall not be inconsistent with the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.2
<U>Qualification of Incentive Stock Options</U>. No Incentive Stock Option shall be granted to any person who is not an Employee of the
Company or any &ldquo;parent corporation&rdquo; or &ldquo;subsidiary corporation&rdquo; of the Company (as defined in Sections 424(e)
and 424(f) of the Code, respectively). No person who qualifies as a Greater Than 10% Stockholder may be granted an Incentive Stock Option
unless such Incentive Stock Option conforms to the applicable provisions of Section 422 of the Code. Any Incentive Stock Option granted
under the Plan may be modified by the Administrator, with the consent of the Participant, to disqualify such Option from treatment as
an &ldquo;incentive stock option&rdquo; under Section 422 of the Code. To the extent that the aggregate fair market value of stock with
respect to which &ldquo;incentive stock options&rdquo; (within the meaning of Section 422 of the Code, but without regard to Section
422(d) of the Code) are exercisable for the first time by a Participant during any calendar year under the Plan and all other plans of
the Company or any &ldquo;parent corporation&rdquo; or &ldquo;subsidiary corporation&rdquo; of the Company (as defined in Section 424(e)
and 424(f) of the Code, respectively) exceeds one hundred thousand dollars ($100,000), the Options shall be treated as Non-Qualified
Stock Options to the extent required by Section 422 of the Code. The rule set forth in the preceding sentence shall be applied by taking
Options and other &ldquo;incentive stock options&rdquo; into account in the order in which they were granted and the fair market value
of stock shall be determined as of the time the respective options were granted. In addition, to the extent that any Options otherwise
fail to qualify as Incentive Stock Options, such Options shall be treated as Nonqualified Stock Options. Any interpretations and rules
under the Plan with respect to Incentive Stock Options shall be consistent with the provisions of Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.3
<U>Option and Stock Appreciation Right Exercise Price</U>. The exercise price per Share subject to each Option and Stock Appreciation
Right shall be set by the Administrator, but shall not be less than one hundred percent (100%) of the Fair Market Value of a Share on
the date the Option or Stock Appreciation Right, as applicable, is granted (or, as to Incentive Stock Options, on the date the Option
is modified, extended or renewed for purposes of Section 424(h) of the Code). In addition, in the case of Incentive Stock Options granted
to a Greater Than 10% Stockholder, such price shall not be less than one hundred ten percent (110%) of the Fair Market Value of a Share
on the date the Option is granted (or the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code).
Notwithstanding the foregoing, in the case of an Option or Stock Appreciation Right that is a Substitute Award, the exercise price per
share of the Shares subject to such Option or Stock Appreciation Right, as applicable, may be less than the Fair Market Value per share
on the date of grant; <U>provided</U> that the exercise price of any Substitute Award shall be determined in accordance with the applicable
requirements of Sections 424 and 409A of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.4
<U>Option and SAR Term</U>. The term of each Option and the term of each Stock Appreciation Right shall be set by the Administrator in
its sole discretion; <U>provided</U>, <U>however</U>, that the term shall not be more than ten (10) years from the date the Option or
Stock Appreciation Right, as applicable, is granted, or five (5) years from the date an Incentive Stock Option is granted to a Greater
Than 10% Stockholder. Except as limited by the requirements of Section 409A or Section 422 of the Code, and subject to the limitations
set forth in the previous sentence, the Administrator may extend the term of any outstanding Option or Stock Appreciation Right, and
may extend the time period during which vested Options or Stock Appreciation Rights may be exercised, in connection with any Termination
of Service of the Participant or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.5
<U>Termination of Services</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
Unless otherwise provided in an Award Agreement, if a Participant has a Termination of Service for any reason other than for Cause or
due to death or Disability, the Participant may exercise any vested outstanding Option or Stock Appreciation Right, to the extent exercisable
on the date of Termination of Service, at any time within three months after the date of such Termination of Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
Unless otherwise provided in an Award Agreement, if a Participant has a Termination of Service due to death or Disability, the Participant
(or in the case of death, the Participant&rsquo;s estate or the beneficiary who acquired the right to exercise the Option or Stock Appreciation
Right by bequest or inheritance or otherwise by reason of the death of the Participant) may exercise any vested outstanding Option or
Stock Appreciation Right, to the extent exercisable on the date of Termination of Service, at any time within twelve months after the
date of such Termination of Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
Unless otherwise provided in an Award Agreement, if a Participant has a Termination of Service for Cause, any Option or Stock Appreciation
Right held by the Participant under the Plan, to the extent not exercised prior to the Termination of Service, and whether or not vested,
will terminate immediately.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d)
Notwithstanding the foregoing, nothing in this Section 5.5 will extend the exercise period for any Option or Stock Appreciation Right
beyond the stated term of the Option or Stock Appreciation Right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.6
<U>Option and SAR Vesting</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
The terms and conditions pursuant to which an Option or Stock Appreciation Right vests in the Participant and becomes exercisable shall
be determined by the Administrator and set forth in the applicable Award Agreement. Such vesting may be based on service with the Company
or any Subsidiary, specified performance goals, or any other criteria selected by the Administrator. At any time after the grant of an
Option or Stock Appreciation Right, the Administrator may, in its sole discretion and subject to whatever terms and conditions it selects,
accelerate the vesting of the Option or Stock Appreciation Right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
Unless otherwise permitted by the Plan, no portion of an Option or Stock Appreciation Right which is unexercisable at a Participant&rsquo;s
Termination of Service shall thereafter become exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">5.7
<U>Substitution of Stock Appreciation Rights</U>. The Administrator may, in its sole discretion, substitute an Award of Stock Appreciation
Rights for an outstanding Option at any time prior to or upon exercise of such Option; <U>provided</U><I>,</I> <U>however</U>, that such
Stock Appreciation Rights shall be exercisable with respect to the same number of Shares for which such substituted Option would have
been exercisable, and shall also have the same exercise price and remaining term as the substituted Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ARTICLE
6</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT>EXERCISE OF OPTIONS and stock appreciation rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.1
<U>Exercise and Payment</U>. An exercisable Option or Stock Appreciation Right may be exercised in whole or in part. However, an Option
or Stock Appreciation Right shall not be exercisable with respect to fractional shares and the Administrator may require that, by the
terms of the Option or Stock Appreciation Right, a partial exercise must be with respect to a minimum number of Shares. Payment of the
amounts payable with respect to Stock Appreciation Rights pursuant to this Article 6 shall be in cash, Shares (based on its Fair Market
Value as of the date the Stock Appreciation Right is exercised), or a combination of both, as determined by the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.2
<U>Manner of Exercise</U>. All or a portion of an exercisable Option or Stock Appreciation Right shall be deemed exercised upon delivery
of all of the following to the Secretary of the Company, the Administrator or such other person or entity designated by the Administrator,
or his, her or its office, as applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
A written or electronic notice complying with the applicable rules established by the Administrator stating that the Option or Stock
Appreciation Right, or a portion thereof, is exercised. The notice shall be signed by the Participant or other person then entitled to
exercise the Option or Stock Appreciation Right or such portion thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
Such representations and documents as the Administrator, in its sole discretion, deems necessary or advisable to effect compliance with
Applicable Law. The Administrator may, in its sole discretion, also take such additional actions as it deems appropriate to effect such
compliance including, without limitation, placing legends on share certificates and issuing stop-transfer notices to agents and registrars;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
In the event that the Option or Stock Appreciation Right shall be exercised pursuant to Section 9.3 hereof by any person or persons other
than the Participant, appropriate proof of the right of such person or persons to exercise the Option or Stock Appreciation Right, as
determined in the sole discretion of the Administrator; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d)
Full payment of the exercise price and applicable withholding taxes for the Shares with respect to which the Option or Stock Appreciation
Right, or portion thereof, is exercised, in a manner permitted by the Administrator in accordance with Sections 9.1 and 9.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">6.3
<U>Notification Regarding Disposition</U>. The Participant shall give the Company prompt written or electronic notice of any disposition
of Shares acquired by exercise of an Incentive Stock Option which occurs within (a) two (2) years after the date of granting (including
the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code) of such Option to such Participant,
or (b) one (1) year after the date of transfer of such Shares to such Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ARTICLE
7</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT>RESTRICTED STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.1
<U>Award of Restricted Stock</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
The Administrator is authorized to grant Restricted Stock to Eligible Individuals, and shall determine the terms and conditions, including
the restrictions applicable to each award of Restricted Stock, which terms and conditions shall not be inconsistent with the Plan or
any applicable Program, and may impose such conditions on the issuance of such Restricted Stock as it deems appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
The Administrator shall establish the purchase price, if any, and form of payment for Restricted Stock; <U>provided</U>, <U>however</U>,
that if a purchase price is charged, such purchase price shall be no less than the par value of the Shares to be purchased, unless otherwise
permitted by Applicable Law. In all cases, legal consideration shall be required for each issuance of Restricted Stock to the extent
required by Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.2
<U>Rights as Stockholders</U>. Subject to Section 7.4 hereof, upon issuance of Restricted Stock, the Participant shall have, unless otherwise
provided by the Administrator, all the rights of a stockholder with respect to the Shares, subject to the restrictions in the Plan, an
applicable Program or in the applicable Award Agreement, including the right to receive all dividends and other distributions paid or
made with respect to the Shares; <U>provided</U>, <U>however</U>, that, in the sole discretion of the Administrator, any extraordinary
distributions with respect to the Shares may be subject to the restrictions set forth in Section 7.3 hereof. In addition, with respect
to Restricted Stock that is subject to performance-based vesting (including the continuation of services for a specified period of time),
dividends which are paid prior to vesting shall only be paid out to the Participant to the extent that the performance-based vesting
conditions are subsequently satisfied and the share of Restricted Stock vests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.3
<U>Restrictions</U>. All shares of Restricted Stock (including any shares received by Participants thereof with respect to shares of
Restricted Stock as a result of stock dividends, stock splits or any other form of recapitalization) shall be subject to such restrictions
and vesting requirements as the Administrator shall provide in the applicable Program or Award Agreement. By action taken after the Restricted
Stock is issued, the Administrator may, on such terms and conditions as it may determine to be appropriate, accelerate the vesting of
such Restricted Stock by removing any or all of the restrictions imposed by the terms of any Program or by the applicable Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.4
<U>Repurchase or Forfeiture of Restricted Stock</U>. Except as otherwise determined by the Administrator, if no purchase price was paid
by the Participant for the Restricted Stock, upon a Termination of Service, the Participant&rsquo;s rights in unvested Restricted Stock
then subject to restrictions shall lapse and be forfeited, and such Restricted Stock shall be surrendered to the Company and cancelled
without consideration on the date of such Termination of Service. If a purchase price was paid by the Participant for the Restricted
Stock, upon a Termination of Service the Company shall have the right to repurchase from the Participant the unvested Restricted Stock
then-subject to restrictions at a cash price per share equal to the price paid by the Participant for such Restricted Stock or such other
amount as may be specified in an applicable Program or the applicable Award Agreement. The Administrator in its sole discretion may provide
that, upon certain events, including without limitation a Change in Control, the Participant&rsquo;s death, retirement or Disability,
any other specified Termination of Service or any other event, the Participant&rsquo;s rights in unvested Restricted Stock shall not
terminate, such Restricted Stock shall vest and cease to be forfeitable and, if applicable, the Company shall cease to have a right of
repurchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.5
<U>Certificates/Book Entries for Restricted Stock</U>. Restricted Stock granted pursuant to the Plan may be evidenced in such manner
as the Administrator shall determine. Certificates or book entries evidencing shares of Restricted Stock must include an appropriate
legend referring to the terms, conditions, and restrictions applicable to such Restricted Stock, and the Company may, in its sole discretion,
retain physical possession of any stock certificate until such time as all applicable restrictions lapse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">7.6
<U>Section 83(b) Election</U>. If a Participant makes an election under Section 83(b) of the Code to be taxed with respect to the Restricted
Stock as of the date of transfer of the Restricted Stock rather than as of the date or dates upon which the Participant would otherwise
be taxable under Section 83(a) of the Code, the Participant shall be required to deliver a copy of such election to the Company promptly
after filing such election with the Internal Revenue Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ARTICLE
8</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">DIVIDEND EQUIVALENTS; STOCK PAYMENTS; RESTRICTED STOCK UNITS; PERFORMANCE SHARES; OTHER INCENTIVE AWARDS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8.1
<U>Dividend Equivalents</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
Subject to Section 8.1(b) hereof, Dividend Equivalents may be granted by the Administrator, either alone or in tandem with another Award,
based on dividends declared on Common Stock, to be credited as of dividend payment dates during the period between the date the Dividend
Equivalents are granted to a Participant and the date such Dividend Equivalents terminate or expire, as determined by the Administrator.
Such Dividend Equivalents shall be converted to cash or additional Shares by such formula and at such time and subject to such limitations
as may be determined by the Administrator. In addition, Dividend Equivalents with respect to an Award that is subject to performance-based
vesting that are based on dividends paid prior to the vesting of such Award shall only be paid out to the Participant to the extent that
the performance-based vesting conditions are subsequently satisfied and the Award vests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
Notwithstanding the foregoing, no Dividend Equivalents shall be payable with respect to Options or Stock Appreciation Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8.2
<U>Stock Payments</U>. The Administrator is authorized to make one or more Stock Payments to any Eligible Individual. The number or value
of Shares of any Stock Payment shall be determined by the Administrator and may be based upon one or more specific performance criteria
or any other specific criteria, including service to the Company or any Subsidiary, determined by the Administrator. Stock Payments may,
but are not required to, be made in lieu of base salary, bonus, fees or other cash compensation otherwise payable to such Eligible Individual.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8.3
<U>Restricted Stock Units</U>. The Administrator is authorized to grant Restricted Stock Units to any Eligible Individual. The number
and terms and conditions of Restricted Stock Units shall be determined by the Administrator. The Administrator shall specify the date
or dates on which the Restricted Stock Units shall become fully vested and nonforfeitable, and may specify such conditions to vesting
as it deems appropriate, including conditions based on one or more specific performance criteria or other specific criteria, including
service to the Company or any Subsidiary, in each case, on a specified date or dates or over any period or periods, as determined by
the Administrator. The Administrator shall specify, or may permit the Participant to elect, the conditions and dates upon which the Shares
underlying the Restricted Stock Units shall be issued, which dates shall not be earlier than the date as of which the Restricted Stock
Units vest and become nonforfeitable and which conditions and dates shall be consistent with the applicable provisions of Section 409A
of the Code or an exemption therefrom. On the distribution dates, the Company shall issue to the Participant one unrestricted, fully
transferable Share (or the Fair Market Value of one such Share in cash) for each vested and nonforfeitable Restricted Stock Unit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8.4
<U>Performance Share Awards</U>. Any Eligible Individual selected by the Administrator may be granted one or more Performance Share awards
which shall be denominated in a number or range of Shares and the vesting of which may be linked to any specific performance criteria
(in each case on a specified date or dates or over any period or periods determined by the Administrator) and/or time-vesting or other
criteria, as determined by the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8.5
<U>Other Incentive Awards</U>. The Administrator is authorized to grant Other Incentive Awards to any Eligible Individual, which Awards
may cover Shares or the right to purchase Shares or have a value derived from the value of, or an exercise or conversion privilege at
a price related to, or that are otherwise payable in or based on, Shares, stockholder value or stockholder return, in each case, on a
specified date or dates or over any period or periods determined by the Administrator. Other Incentive Awards may be linked to such specific
performance criteria as determined appropriate by the Administrator. Other Incentive Awards may be paid in cash, Shares, or a combination
of cash and Shares, as determined by the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8.6
<U>Other Terms and Conditions</U>. All applicable terms and conditions of each Award described in this Article 8, including without limitation,
as applicable, the term, vesting conditions and exercise/purchase price applicable to the Award, shall be set by the Administrator in
its sole discretion, <U>provided</U>, <U>however</U>, that the value of the consideration paid by a Participant for an Award, if any,
shall not be less than the par value of a Share, unless otherwise permitted by Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">8.7
<U>Exercise upon Termination of Service</U>. Awards described in this Article 8 are exercisable or distributable, as applicable, only
while the Participant is an Employee, Director or Consultant, as applicable. Except as otherwise provided in the Plan, the Administrator,
however, in its sole discretion may provide that such Award may be exercised or distributed subsequent to a Termination of Service as
provided under an applicable Program, Award Agreement, payment deferral election and/or in certain events, including without limitation,
a Change in Control, the Participant&rsquo;s death, retirement or Disability or any other specified Termination of Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ARTICLE
9</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Additional terms of awards</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.1
<U>Payment</U>. The Administrator shall determine the method or methods by which payments by any Participant with respect to any Awards
granted under the Plan shall be made, including, without limitation: (a) cash or check, (b) Shares (including, in the case of payment
of the exercise price of an Award, Shares issuable pursuant to the exercise of the Award) held for such minimum period of time as may
be established by the Administrator, in each case, having a Fair Market Value on the date of delivery equal to the aggregate payments
required, (c) other form of legal consideration acceptable to the Administrator, or (d) any combination of the foregoing. The Administrator
shall also determine the methods by which Shares shall be delivered or deemed to be delivered to Participants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.2
<U>Tax Withholding and Tax Bonuses</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
The Company and its Subsidiaries shall have the authority and the right to deduct or withhold, or require a Participant to remit to the
Company or a Subsidiary, an amount sufficient to satisfy federal, state, local and foreign taxes (including the Participant&rsquo;s social
security, Medicare and any other employment tax obligation) required by law to be withheld with respect to any taxable event concerning
a Participant arising in connection with any Award. The Administrator may in its sole discretion and in satisfaction of the foregoing
requirement allow a Participant to satisfy such obligations by any payment means described in Section 9.1 hereof, including without limitation,
by allowing such Participant to elect to have the Company or a Subsidiary withhold Shares otherwise issuable under an Award (or allow
the surrender of Shares). Notwithstanding anything in this Section 9.2 to the contrary, the Company shall not allow a Participant to
make any such election if the election would cause a violation of Section 409A of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
The Committee, in its discretion, shall have the authority, at the time of grant of any Award under the Plan or at any time thereafter,
to approve cash bonuses to designated Participants to be paid upon their exercise or receipt of (or the lapse of restrictions relating
to) Awards in order to provide funds to pay all or a portion of federal and state taxes due as a result of such exercise or receipt (or
the lapse of such restrictions). The Committee shall have full authority in its discretion to determine the amount of any such tax bonus.
Notwithstanding the foregoing, tax bonuses shall not be granted with respect to Awards that are Stock Appreciation Rights or Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.3
<U>Transferability of Awards</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
No Award under the Plan may be sold, pledged, assigned or transferred in any manner other than by will or the laws of descent and distribution,
unless and until such Award has been exercised, or the Shares underlying such Award have been issued, and all restrictions applicable
to such Shares have lapsed. No Award or interest or right therein shall be liable for or otherwise subject to the debts, contracts or
engagements of the Participant or the Participant&rsquo;s successors in interest or shall be subject to disposition by transfer, alienation,
anticipation, pledge, hypothecation, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary
or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy)
unless and until such Award has been exercised, or the Shares underlying such Award have been issued, and all restrictions applicable
to such Shares have lapsed, and any attempted disposition of an Award prior to the satisfaction of these conditions shall be null and
void and of no effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
During the lifetime of the Participant, only the Participant may exercise any exercisable portion of an Award granted to him under the
Plan. Notwithstanding the foregoing, a Non-Qualified Stock Option granted under the Plan may be transferred, in whole or in part, during
a Participant&rsquo;s lifetime, upon the approval of the Administrator, to a Participant&rsquo;s &ldquo;family members&rdquo; (as such
term is defined in Rule 701(c)(3) of the Securities Act and General Instructions A(1)(a)(5) to Form S-8) through a gift or domestic relations
order. The transferred portion of a Non-Qualified Stock Option may only be exercised by the person or entity who acquires a proprietary
interest in such Option pursuant to the transfer. The terms applicable to the transferred portion shall be the same as those in effect
for the Option immediately prior to such transfer and shall be set forth in such documents issued to the transferee as the Administrator
may deem appropriate. After the death of the Participant, any exercisable portion of an Award may, prior to the time when such portion
becomes unexercisable under the Plan or the applicable Program or Award Agreement, be exercised by the Participant&rsquo;s personal representative
or by any person empowered to do so under the deceased Participant&rsquo;s will or under the then-applicable laws of descent and distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
Notwithstanding Section 9.3(a) hereof, a Participant may, in the manner determined by the Administrator, designate a beneficiary to exercise
the rights of the Participant and to receive any distribution with respect to any Award upon the Participant&rsquo;s death. A beneficiary,
legal guardian, legal representative, or other person claiming any rights pursuant to the Plan is subject to all terms and conditions
of the Plan and any Program or Award Agreement applicable to the Participant, and to any additional restrictions deemed necessary or
appropriate by the Administrator. If the Participant is married or a domestic partner in a domestic partnership qualified under Applicable
Law and resides in a &ldquo;community property&rdquo; state, a designation of a person other than the Participant&rsquo;s spouse or domestic
partner, as applicable, as his or her beneficiary with respect to more than fifty percent (50%) of the Participant&rsquo;s interest in
the Award shall not be effective without the prior written or electronic consent of the Participant&rsquo;s spouse or domestic partner.
If no beneficiary has been designated or survives the Participant, payment shall be made to the person entitled thereto pursuant to the
Participant&rsquo;s will or the laws of descent and distribution. Subject to the foregoing, a beneficiary designation may be changed
or revoked by a Participant at any time provided the change or revocation is delivered to the Administrator in writing prior to the Participant&rsquo;s
death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.4
<U>Conditions to Issuance of Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
The Administrator shall determine the methods by which Shares shall be delivered or deemed to be delivered to Participants. Notwithstanding
anything herein to the contrary, neither the Company nor its Subsidiaries shall be required to issue or deliver any certificates or make
any book entries evidencing Shares pursuant to the exercise of any Award, unless and until the Administrator has determined, with advice
of counsel, that the issuance of such Shares is in compliance with Applicable Law, and the Shares are covered by an effective registration
statement or applicable exemption from registration. In addition to the terms and conditions provided herein, the Administrator may require
that a Participant make such reasonable covenants, agreements, and representations as the Administrator, in its discretion, deems advisable
in order to comply with any such Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
All Share certificates delivered pursuant to the Plan and all Shares issued pursuant to book entry procedures are subject to any stop-transfer
orders and other restrictions as the Administrator deems necessary or advisable to comply with Applicable Law. The Administrator may
place legends on any Share certificate or book entry to reference restrictions applicable to the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
The Administrator shall have the right to require any Participant to comply with any timing or other restrictions with respect to the
settlement, distribution or exercise of any Award, including a window-period limitation, as may be imposed in the sole discretion of
the Administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d)
No fractional Shares shall be issued and the Administrator shall determine, in its sole discretion, whether cash shall be given in lieu
of fractional Shares or whether such fractional Shares shall be eliminated by rounding down.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(e)
The Company, in its sole discretion, may (i) retain physical possession of any stock certificate evidencing Shares until any restrictions
thereon shall have lapsed and/or (ii) require that the stock certificates evidencing such Shares be held in custody by a designated escrow
agent (which may but need not be the Company) until the restrictions thereon shall have lapsed, and that the Participant deliver a stock
power, endorsed in blank, relating to such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(f)
Notwithstanding any other provision of the Plan, unless otherwise determined by the Administrator or required by Applicable Law, the
Company and/or its Subsidiaries may, in lieu of delivering to any Participant certificates evidencing Shares issued in connection with
any Award, record the issuance of Shares in the books of the Company (or, as applicable, its transfer agent or stock plan administrator).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.5
<U>Market Stand-Off</U>. In connection with any underwritten public offering by the Company of its equity securities pursuant to an effective
registration statement filed under the Securities Act, including the Company&rsquo;s initial public offering, the Participant will not
directly or indirectly sell, make any short sale of, loan, hypothecate, pledge, offer, grant or sell any Option or other contract for
the purchase of, any Option or other contract for the sale of, or otherwise dispose of or transfer, or agree to engage in any of the
foregoing transactions with respect to, any Shares acquired under this Plan or any Award issued under this Plan without the prior written
consent of the Company or its underwriters. Such restriction (the &ldquo;<B>Market Stand-Off</B>&rdquo;) will be in effect for such period
of time following the date of the final prospectus for the offering as may be requested by the Company or such underwriters. In no event,
however, will such period exceed a) 180 days or b) such other period as may be requested by the Company or the underwriters to accommodate
regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions,
including, but not limited to, the restrictions contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions
or amendments thereto). In the event of the declaration of a stock dividend, a spin-off, a stock split, an adjustment in conversion ratio,
a recapitalization or a similar transaction affecting the Company&rsquo;s outstanding securities without receipt of consideration, any
new, substituted or additional securities which are by reason of such transaction distributed with respect to any Stock shall be subject
to the Market Stand-Off. The Company may impose stop-transfer instructions with respect to any and all Stock or Options previously referred
to in this Section until the end of the applicable stand-off period. The Company&rsquo;s underwriters will be beneficiaries of the agreement
set forth in this Section. A Participant will be subject to this Section only if the directors and officers of the Company are subject
to similar arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.6
<U>Forfeiture and Claw-Back Provisions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
Unless otherwise provided in an Award Agreement: (i) any proceeds, gains or other economic benefit actually or constructively received
by the Participant upon any receipt or exercise of the Award, or upon the receipt or resale of any Shares underlying the Award, must
be paid to the Company, and (ii) the Award shall terminate and any unexercised portion of the Award (whether or not vested) shall be
forfeited, if (x) a Termination of Service occurs within six months following receipt or exercise of the Award, (y) the Participant at
any time engages in any activity in competition with the Company, or which is inimical, contrary or harmful to the interests of the Company,
as further defined by the Administrator or (z) the Participant incurs a Termination of Service for Cause; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
All Awards (including any proceeds, gains or other economic benefit actually or constructively received by a Participant upon any receipt
or exercise of any Award or upon the receipt or resale of any Shares underlying the Award) shall be subject to the applicable provisions
of any claw-back policy implemented by the Company, whether implemented prior to or after the grant of such Award, including without
limitation, any claw-back policy adopted to comply with the requirements of Applicable Law, to the extent set forth in such claw-back
policy and/or in the applicable Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">9.7
<U>Leave of Absence</U>. Unless the Administrator provides otherwise, vesting of Awards granted hereunder shall not be suspended during
any unpaid leave of absence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ARTICLE
10</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ADMINISTRATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10.1
<U>Administrator</U>. The Committee (or another committee or a subcommittee of the Board assuming the functions of the Committee under
the Plan) shall administer the Plan (except as otherwise permitted herein) unless otherwise determined by the Board. Except as may otherwise
be provided in the Organizational Documents, appointment of Committee members shall be effective upon acceptance of appointment, Committee
members may resign at any time by delivering written or electronic notice to the Board, and vacancies in the Committee may only be filled
by the Board. Notwithstanding the foregoing, (a) the full Board, acting by a majority of its members in office, shall conduct the general
administration of the Plan with respect to Awards granted to Non-Employee Directors of the Company and (b) the Board or Committee may
delegate its authority hereunder to the extent permitted by Section 10.6 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10.2
<U>Duties and Powers of Administrator</U>. It shall be the duty of the Administrator to conduct the general administration of the Plan
in accordance with its provisions. The Administrator shall have the power to interpret the Plan and all Programs and Award Agreements,
and to adopt such rules for the administration, interpretation and application of the Plan and any Program as are not inconsistent with
the Plan, to interpret, amend or revoke any such rules and to amend any Program or Award Agreement provided that the rights or obligations
of the holder of the Award that is the subject of any such Program or Award Agreement are not materially adversely affected by such amendment,
unless the consent of the Participant is obtained or such amendment is otherwise permitted under Section 9.5, Section 11.2, Section 11.7,
or Section 11.10 hereof. Without limiting the generality of the foregoing, the Administrator shall have the power to reduce the exercise
price of an Option granted pursuant to the Plan (either directly or pursuant to the cancellation of the Option and the regrant of an
Option) to an exercise price equal to the Fair Market Value of a Share at the time of the exercise price reduction or Option regrant.
Any such interpretations and rules with respect to Incentive Stock Options shall be consistent with the provisions of Section 422 of
the Code. In its sole discretion, the Board may at any time and from time to time exercise any and all rights and duties of the Committee
in its capacity as the Administrator under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10.3
<U>Action by the Committee</U>. Unless otherwise established by the Board or in the Organizational Documents or as required by Applicable
Law, a majority of the Administrator shall constitute a quorum and the acts of a majority of the members present at any meeting at which
a quorum is present, and acts approved in writing by a majority of the members of the Administrator in lieu of a meeting, shall be deemed
the acts of the Administrator. Each member of the Administrator is entitled to, in good faith, rely or act upon any report or other information
furnished to that member by any officer or other employee of the Company or any Subsidiary, the Company&rsquo;s independent certified
public accountants, or any executive compensation consultant or other professional retained by the Company to assist in the administration
of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10.4
<U>Authority of Administrator</U>. Subject to any specific designation in the Plan and Applicable Law, the Administrator has the exclusive
power, authority and sole discretion to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
Designate Eligible Individuals to receive Awards;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
Determine the type or types of Awards to be granted to each Eligible Individual;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
Determine the number of Awards to be granted and the number of Shares to which an Award will relate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d)
Determine the terms and conditions of any Award granted pursuant to the Plan, including, but not limited to, the exercise price, grant
price, or purchase price, any specific performance criteria, any restrictions or limitations on the Award, any schedule for vesting,
lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations or waivers thereof, and any provisions
related to non-competition and recapture of gain on an Award, based in each case on such considerations as the Administrator in its sole
discretion determines;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(e)
Determine whether, to what extent, and under what circumstances an Award may be settled in, or the exercise price of an Award may be
paid in cash, Shares, other Awards, or other property, or an Award may be canceled, forfeited, or surrendered;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(f)
Prescribe the form of each Award Agreement, which need not be identical for each Participant;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(g)
Decide all other matters that must be determined in connection with an Award;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(h)
Establish, adopt, or revise any Programs, rules and regulations as it may deem necessary or advisable to administer the Plan;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(i)
Interpret the terms of, and any matter arising pursuant to, the Plan, any Program or any Award Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(j)
Make all other decisions and determinations that may be required pursuant to the Plan or as the Administrator deems necessary or advisable
to administer the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10.5
<U>Decisions Binding</U>. The Administrator&rsquo;s interpretation of the Plan, any Awards granted pursuant to the Plan, any Program,
any Award Agreement and all decisions and determinations by the Administrator with respect to the Plan are final, binding, and conclusive
on all parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10.6
<U>Delegation of Authority</U>. To the extent permitted by Applicable Law, the Board or Committee may from time to time delegate to a
committee of one or more members of the Board or one or more officers of the Company the authority to grant or amend Awards or to take
other administrative actions pursuant to this Article 10; <U>provided</U>, <U>however</U>, that in no event shall an officer of the Company
be delegated the authority to grant Awards to, or amend Awards held by, officers of the Company (or Directors) to whom authority to grant
or amend Awards has been delegated hereunder; <U>provided</U>, <U>further</U>, that any delegation of administrative authority shall
only be permitted to the extent it is permissible under the Organizational Documents, and other Applicable Law. Any delegation hereunder
shall be subject to the restrictions and limits that the Board or Committee specifies at the time of such delegation or that are otherwise
included in the applicable Organizational Documents, and the Board or Committee, as applicable, may at any time rescind the authority
so delegated or appoint a new delegatee. At all times, the delegatee appointed under this Section 10.6 shall serve in such capacity at
the pleasure of the Board or the Committee, as applicable, and the Board or the Committee may abolish any committee at any time and re-vest
in itself any previously delegated authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">ARTICLE
11</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">MISCELLANEOUS PROVISIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.1
<U>Amendment, Suspension or Termination of the Plan</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
Except as otherwise provided in this Section 11.1, the Plan may be wholly or partially amended or otherwise modified, suspended or terminated
at any time or from time to time by the Board; provided that, except as provided in Section 9.5, Section 11.2, Section 11.7, or Section
11.10 hereof, no amendment, suspension or termination of the Plan shall, without the consent of the Participant, impair any rights or
obligations under any Award theretofore granted or awarded, unless the Award itself otherwise expressly so provides.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
No Awards may be granted or awarded during any period of suspension or after termination of the Plan, and notwithstanding anything herein
to the contrary, in no event may any Award be granted under the Plan after the tenth (10<SUP>th</SUP>) anniversary of the date on which
the Plan was adopted by the Board (the &ldquo;<U>Expiration Date</U>&rdquo;). Any Awards that are outstanding on the Expiration Date
shall remain in force according to the terms of the Plan, the applicable Program and the applicable Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
A Participant shall not have the right to a change in the exercise price of an Option, an increase in the exercise period for exercise
of an Option, or a change to the number of securities received on exercise of an Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.2
<U>Changes in Common Stock or Assets of the Company, Acquisition or Liquidation of the Company and Other Corporate Events</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
In the event of any stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other
than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of the Company&rsquo;s stock
or the share price of the Company&rsquo;s stock other than an Equity Restructuring, the Administrator may make equitable adjustments,
if any, to reflect such change with respect to (i) the aggregate number and kind of shares that may be issued under the Plan; (ii) the
number and kind of Shares (or other securities or property) subject to outstanding Awards; (iii) the terms and conditions of any outstanding
Awards (including, without limitation, any applicable performance targets or criteria with respect thereto); and/or (iv) the grant or
exercise price per share for any outstanding Awards under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
In the event of any transaction or event described in Section 11.2(a) hereof or any unusual or nonrecurring transactions or events affecting
the Company, any Subsidiary, or the financial statements of the Company or any Subsidiary, or of changes in Applicable Law or Applicable
Accounting Standards, the Administrator, in its sole discretion, and on such terms and conditions as it deems appropriate, either by
the terms of the Award or by action taken prior to the occurrence of such transaction or event, is hereby authorized to take any one
or more of the following actions whenever the Administrator determines that such action is appropriate in order to prevent dilution or
enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any Award under the
Plan, to facilitate such transactions or events or to give effect to such changes in Applicable Law or Applicable Accounting Standards:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(i)
To provide for the termination of any such Award in exchange for an amount of cash and/or other property, if any, equal to the amount
that would have been attained upon the exercise of such Award or realization of the Participant&rsquo;s rights (and, for the avoidance
of doubt, if as of the date of the occurrence of the transaction or event described in this Section 11.2, the Administrator determines
in good faith that no amount would have been attained upon the exercise of such Award or realization of the Participant&rsquo;s rights,
then such Award may be terminated by the Company without payment);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(ii)
To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted
for by similar options, rights or awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof,
with appropriate adjustments as to the number and kind of shares and applicable exercise or purchase price;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(iii)
To make adjustments in the number and type of securities subject to outstanding Awards and Awards which may be granted in the future
and/or in the terms, conditions and criteria included in such Awards (including the grant or exercise price, as applicable);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(iv)
To provide that such Award shall be exercisable or payable or fully vested with respect to all securities covered thereby, notwithstanding
anything to the contrary in the Plan or an applicable Program or Award Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(v)
To replace such Award with other rights or property selected by the Administrator in its sole discretion; and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(vi)
To provide that the Award cannot vest, be exercised or become payable after such event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
In connection with the occurrence of any Equity Restructuring, and notwithstanding anything to the contrary in Sections 11.2(a) and 11.2(b)
hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(i)
The number and type of securities subject to each outstanding Award and the exercise price or grant price thereof, if applicable, shall
be equitably adjusted; and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(ii)
The Administrator shall make such equitable adjustments, if any, as the Administrator in its discretion may deem appropriate to reflect
such Equity Restructuring with respect to the aggregate number and kind of shares that may be issued under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
adjustments provided under this Section 11.2(c) shall be nondiscretionary and shall be final and binding on the affected Participant
and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d)
Except as may otherwise be provided in any applicable Award Agreement or other written agreement entered into between the Company (or
a Subsidiary) and a Participant, if a Change in Control occurs and a Participant&rsquo;s outstanding Awards are not continued, converted,
assumed, or replaced by the surviving or successor entity in such Change in Control, then, immediately prior to the Change in Control,
such outstanding Awards, to the extent not continued, converted, assumed, or replaced, shall become fully vested and, as applicable,
exercisable, and all forfeiture, repurchase and other restrictions on such Awards shall lapse. Upon, or in anticipation of, a Change
in Control, the Administrator may cause any and all Awards outstanding hereunder to terminate at a specific time in the future, including
but not limited to the date of such Change in Control, and shall give each Participant the right to exercise such Awards during a period
of time as the Administrator, in its sole and absolute discretion, shall determine. For the avoidance of doubt, if the value of an Award
that is terminated in connection with this Section 11.2(d) is zero or negative at the time of such Change in Control, such Award shall
be terminated upon the Change in Control without payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(e)
The Administrator may, in its sole discretion, include such further provisions and limitations in any Award, agreement or certificate,
as it may deem equitable and in the best interests of the Company that are not inconsistent with the provisions of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(f)
Unless otherwise determined by the Administrator, no adjustment or action described in this Section 11.2 or in any other provision of
the Plan shall be authorized to the extent it would (i) cause the Plan to violate Section 422(b)(1) of the Code or (ii) cause an Award
to fail to be exempt from or fail to comply with Section 409A of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(g)
The existence of the Plan, any Program, any Award Agreement and/or any Award granted hereunder shall not affect or restrict in any way
the right or power of the Company or the stockholders of the Company or any Subsidiary to make or authorize any adjustment, recapitalization,
reorganization or other change in the Company&rsquo;s or such Subsidiary&rsquo;s capital structure or its business, any merger or consolidation
of the Company or any Subsidiary, any issue of stock or of options, warrants or rights to purchase stock or of bonds, debentures, preferred
or prior preference stocks whose rights are superior to or affect the Common Stock, the securities of any Subsidiary, or the rights thereof
or which are convertible into or exchangeable for Common Stock or securities of any Subsidiary, or any sale or transfer of all or any
part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(h)
In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution
(other than normal cash dividends) of Company assets to stockholders, or any other change affecting the Shares or the share price of
the Common Stock including any Equity Restructuring, for reasons of administrative convenience, the Company in its sole discretion may
refuse to permit the exercise of any Award during a period of thirty (30) days prior to the consummation of any such transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.3
<U>Approval of Plan by Stockholders</U>. The Plan shall be submitted for the approval of the Company&rsquo;s stockholders within twelve
(12) months after the date of the Board&rsquo;s initial adoption of the Plan. Awards may be granted or awarded prior to such stockholder
approval; and, <U>provided</U> that if such approval has not been obtained at the end of said 12-month period, no Options previously
granted or awarded under the Plan shall qualify as Incentive Stock Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.4
<U>No Stockholders Rights</U>. Except as otherwise provided herein or in an applicable Program or Award Agreement, a Participant shall
have none of the rights of a stockholder with respect to Shares covered by any Award until the Participant becomes the record owner of
such Shares, including the right to participate in any new issues of stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.5
<U>Paperless Administration</U>. In the event that the Company establishes, for itself or using the services of a third party, an automated
system for the documentation, granting or exercise of Awards, such as a system using an internet website or interactive voice response,
then the paperless documentation, granting or exercise of Awards by a Participant may be permitted through the use of such an automated
system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.6
<U>Effect of Plan upon Other Compensation Plans</U>. The adoption of the Plan shall not affect any other compensation or incentive plans
in effect for the Company or any Subsidiary. Nothing in the Plan shall be construed to limit the right of the Company or any Subsidiary:
(a) to establish any other forms of incentives or compensation for Employees, Directors or Consultants of the Company or any Subsidiary
or (b) to grant or assume options or other rights or awards otherwise than under the Plan in connection with any proper corporate purpose
including without limitation, the grant or assumption of options in connection with the acquisition by purchase, lease, merger, consolidation
or otherwise, of the business, stock or assets of any corporation, partnership, limited liability company, firm or association.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.7
<U>Compliance with Laws</U>. The Plan, the granting and vesting of Awards under the Plan, the issuance and delivery of Shares and the
payment of money under the Plan or under Awards granted or awarded hereunder are subject to compliance with all Applicable Law and to
such approvals by any listing, regulatory or governmental authority as may, in the opinion of counsel for the Company, be necessary or
advisable in connection therewith. Any securities delivered under the Plan shall be subject to such restrictions, and the person acquiring
such securities shall, if requested by the Company, provide such assurances and representations to the Company as the Company may deem
necessary or desirable to assure compliance with all Applicable Law. The Administrator, in its sole discretion, may take whatever actions
it deems necessary or appropriate to effect compliance with Applicable Law, including, without limitation, placing legends on share certificates
and issuing stop-transfer notices to agents and registrars. Notwithstanding anything to the contrary herein, the Administrator may not
take any actions hereunder, and no Awards shall be granted, that would violate Applicable Law. To the extent permitted by Applicable
Law, the Plan and Awards granted or awarded hereunder shall be deemed amended to the extent necessary to conform to such Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.8
<U>Titles and Headings, References to Sections of the Code or Exchange Act</U>. The titles and headings of the sections in the Plan are
for convenience of reference only and, in the event of any conflict, the text of the Plan, rather than such titles or headings, shall
control. References to sections of the Code or the Exchange Act shall include any amendment or successor thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.9
<U>Governing Law</U>. The Plan and any Programs or Award Agreements hereunder shall be administered, interpreted and enforced under the
internal laws of the State of Delaware without regard to conflicts of laws thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.10
<U>Section 409A</U>. To the extent that the Administrator determines that any Award granted under the Plan is subject to Section 409A
of the Code, the Plan, any applicable Program and the Award Agreement covering such Award shall be interpreted in accordance with Section
409A of the Code. Notwithstanding any provision of the Plan to the contrary, in the event that, following the Effective Date, the Administrator
determines that any Award may be subject to Section 409A of the Code, the Administrator may adopt such amendments to the Plan, any applicable
Program and the Award Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive
effect), or take any other actions, that the Administrator determines are necessary or appropriate to avoid the imposition of taxes on
the Award under Section 409A of the Code, either through compliance with the requirements of Section 409A of the Code or with an available
exemption therefrom. The Company makes no representations or warranties as to the tax treatment of any Award under Section 409A of the
Code or otherwise. The Company shall have no obligation under this Section 11.10 or otherwise to take any action (whether or not described
herein) to avoid the imposition of taxes, penalties or interest under Section 409A of the Code with respect to any Award and shall have
no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute
non-compliant, &ldquo;nonqualified deferred compensation&rdquo; subject to the imposition of taxes, penalties and/or interest under Section
409A of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.11
<U>No Rights to Awards</U>. No Eligible Individual or other person shall have any claim to be granted any Award pursuant to the Plan,
and neither the Company nor the Administrator is obligated to treat Eligible Individuals, Participants or any other persons uniformly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.12
<U>Unfunded Status of Awards</U>. The Plan is intended to be an &ldquo;unfunded&rdquo; plan for incentive compensation. With respect
to any payments not yet made to a Participant pursuant to an Award, nothing contained in the Plan or any Program or Award Agreement shall
give the Participant any rights that are greater than those of a general creditor of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.13
<U>Indemnification</U>. To the extent allowable pursuant to Applicable Law and the Organizational Documents, each member of the Board
and any officer or other employee to whom authority to administer any component of the Plan is delegated shall be indemnified and held
harmless by the Company from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by such member in
connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may
be involved by reason of any action or failure to act pursuant to the Plan and against and from any and all amounts paid by him or her
in satisfaction of judgment in such action, suit, or proceeding against him or her; <U>provided</U>, <U>however</U>, that he or she gives
the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on
his or her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which
such persons may be entitled pursuant to the Organizational Documents, as a matter of law, or otherwise, or any power that the Company
may have to indemnify them or hold them harmless.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.14
<U>Relationship to other Benefits</U>. No payment pursuant to the Plan shall be taken into account in determining any benefits under
any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except
to the extent otherwise expressly provided in writing in such other plan or an agreement thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">11.15
<U>Expenses</U>. The expenses of administering the Plan shall be borne by the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>3
<FILENAME>ex10-40.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.40</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INCENTIVE
STOCK OPTION AWARD AGREEMENT<BR>
UNDER THE<BR>
BIORESTORATIVE THERAPIES, INC.<BR>
2021 STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Incentive Stock Option Award Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of February 14, 2025 by and
between BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and Lance Alstodt (the &ldquo;<B>Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
  Date</B>:</FONT></TD>
  <TD STYLE="text-align: justify; width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 14, 2025</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
  Price per Share</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.46</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Option
  Shares</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">791,885</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
  Date</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 14, 2035</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
1. <B>Grant of Option</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
 <B>Grant; Type of Option</B>. The Company hereby grants to the Participant an option (the &ldquo;<B>Option</B>&rdquo;)
to purchase the number of Shares of Common Stock of the Company equal to the number of Option Shares set forth above. The Option is being
granted pursuant to the terms of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;). The Option
is intended to be an Incentive Stock Option within the meaning of Section 422 of the Code to the maximum extent permitted by Applicable
Law, although the Company makes no representation or guarantee that the Option will qualify as an Incentive Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
 <B>Consideration; Subject to Plan</B>. The grant of the Option is made in consideration of
the services to be rendered by the Participant to the Company and is subject to the terms and conditions of the Plan. Capitalized terms
used but not otherwise defined herein have the meanings given to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2. Exercise
Period; Vesting</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1 <B>Vesting
Schedule</B>. The Option will become vested and exercisable with respect to 50% of the Option Shares on the Grant Date, with the remainder
vesting quarterly in eight nearly equal installments (at a rate of 1/16 per quarter) with the first quarterly installment vesting on
the one-year anniversary of the Grant Date and continuing every three months thereafter until fully vested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of the Participant&rsquo;s involuntary Termination of Service by the Company without Cause, 100% of the Shares subject to the
Option shall become immediately vested and exercisable. Upon the Participant&rsquo;s Termination of Service for any other reason, the
unvested portion of the Option will be forfeited and will not be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2 <B>Expiration</B>.
The Option will expire on the Expiration Date set forth above, or earlier as provided in this Agreement or the Plan. The Expiration Date
shall not be more than ten years from the Grant Date (or, if the Option is being granted to a Greater Than 10% Stockholder, not more
than five years from the Grant Date). To the extent the Expiration Date listed above is inconsistent with this paragraph, this paragraph
shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3 The
Option shall not be subject to Section 9.6(a) of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3. Termination
of Service</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 <B>Termination
for Reasons Other Than Cause, Death, Disability</B>. If the Participant has a Termination of Service for any reason other than Cause,
death or Disability, the Participant may exercise the vested portion of the Option at any time until the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2 <B>Termination
for Cause</B>. If the Participant has a Termination of Service for Cause, the Participant may exercise the vested portion of the Option,
but only within such period of time ending on the earlier of: (a) the date 12 months following the Participant&rsquo;s Termination of
Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3 <B>Termination
due to Disability</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s Disability, the Participant
may exercise the vested portion of the Option, but only within such period of time ending on the earlier of: (a) the date 24 months following
the Participant&rsquo;s Termination of Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4 <B>Termination
due to Death</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s death, the vested portion of
the Option may be exercised by the Participant&rsquo;s estate, by a person who acquired the right to exercise the Option by bequest or
inheritance or by the person designated to exercise the Option upon the Participant&rsquo;s death, but only within the time period ending
on the earlier of: (a) the date 24 months following the Participant&rsquo;s Termination of Service, or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4. Manner
of Exercise</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 <B>Election
to Exercise</B>. To exercise the Option, the Participant (or in the case of exercise after the Participant&rsquo;s death or incapacity,
the Participant&rsquo;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed stock option
exercise agreement in such form as is approved by the Committee from time to time (the &ldquo;<B>Exercise Agreement</B>&rdquo;), which
shall set forth, inter alia:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) the
Participant&rsquo;s election to exercise the Option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) the
number of Shares of Common Stock being purchased;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) any
restrictions imposed on the Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) any
representations, warranties and agreements regarding the Participant&rsquo;s investment intent and access to information as may be required
by the Company to comply with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the Company
verifying that such person has the legal right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 <B>Payment
of Exercise Price</B>. The entire Exercise Price of the Option shall be payable in full at the time of exercise to the extent permitted
by applicable statutes and regulations, either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) in
cash or by certified or bank check at the time the Option is exercised;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) by
delivery to the Company of other Shares of Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the date
of delivery equal to the Exercise Price (or portion thereof) due for the number of Shares being acquired, or by means of attestation
whereby the Participant identifies for delivery specific Shares that have a Fair Market Value on the date of attestation equal to the
Exercise Price (or portion thereof) and receives a number of Shares equal to the difference between the number of Shares thereby purchased
and the number of identified attestation Shares (a &ldquo;<B>Stock for Stock Exchange</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) through
a &ldquo;cashless exercise program&rdquo; established with a broker;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) by
reduction in the number of Shares otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate
Exercise Price at the time of exercise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) by
any combination of the foregoing methods; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) in
any other form of legal consideration that may be acceptable to the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <B>Withholding</B>.
Prior to the issuance of Shares upon the exercise of the Option, the Participant must make arrangements satisfactory to the Company to
pay or provide for any applicable federal, state and local withholding obligations of the Company. The Participant may satisfy any federal,
state or local tax withholding obligation relating to the exercise of the Option by any of the following means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) tendering
a cash payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) authorizing
the Company to withhold Shares of Common Stock from the Shares of Common Stock otherwise issuable to the Participant as a result of the
exercise of the Option; provided, however, that no Shares of Common Stock are withheld with a value exceeding the maximum amount of tax
required to be withheld by law; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) delivering
to the Company previously owned and unencumbered Shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to withhold from any compensation paid to the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4 <B>Issuance
of Shares</B>. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the Company shall
issue the Shares of Common Stock registered in the name of the Participant, the Participant&rsquo;s authorized assignee, or the Participant&rsquo;s
legal representative which shall be evidenced by stock certificates representing the Shares with the appropriate legends affixed thereto,
appropriate entry on the books of the Company or of a duly authorized transfer agent, or other appropriate means as determined by the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5. No
Right to Continued Employment; No Rights as Shareholder</B>. Neither the Plan nor this Agreement shall confer upon the Participant any
right to be retained in any position, as an Employee, Consultant or Director of the Company. Further, nothing in the Plan or this Agreement
shall be construed to limit the discretion of the Company to terminate the Participant&rsquo;s employment or service with the Company
at any time, with or without Cause. The Participant shall not have any rights as a shareholder with respect to any Shares of Common Stock
subject to the Option unless and until certificates representing the Shares have been issued by the Company to the holder of such Shares,
or the Shares have otherwise been recorded on the books of the Company or of a duly authorized transfer agent as owned by such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6. Transferability</B>.
The Option is only transferable by will or the laws of descent and distribution or in accordance with the limited conditions set forth
in Section 9.3(b) of the Plan. No assignment or transfer of the Option, or the rights represented thereby, whether voluntary or involuntary,
by operation of law or otherwise (except to a designated beneficiary, upon death, by will or the laws of descent or distribution or pursuant
to Section 9.3(b) of the Plan) will vest in the assignee or transferee any interest or right herein whatsoever, but immediately upon
such assignment or transfer the Option will terminate and become of no further effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7. Change
in Control</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1 <B>Acceleration
of Vesting</B>. Notwithstanding any provision of the Plan or this Agreement to the contrary, in the event of a Change in Control prior
to the date that the Option is fully vested and exercisable, the Option shall become immediately vested and exercisable with respect
to 100% of the Shares in each remaining vesting tranche. To the extent practicable, such acceleration of vesting and exercisability shall
occur in a manner and at a time which allows the Participant the ability to participate in the Change in Control with respect to the
Shares of Common Stock received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2 <B>Cash-Out</B>.
In the event of a Change in Control, the Committee may, in its discretion and upon at least ten (10) days&rsquo; advance notice to the
Participant, cancel the Option and pay to the Participant the value of the Option based upon the price per Share of Common Stock received
or to be received by other shareholders of the Company in the event. Notwithstanding the foregoing, if at the time of a Change in Control
the Exercise Price of the Option equals or exceeds the price paid for a Share of Common Stock in connection with the Change in Control,
the Committee may cancel the Option without the payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8. Adjustments</B>.
The Shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9. Tax
Liability and Withholding</B>. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance,
payroll tax, or other tax-related withholding (&ldquo;<B>Tax-Related Items</B>&rdquo;), the ultimate liability for all Tax-Related Items
is and remains the Participant&rsquo;s responsibility and the Company (a) makes no representation or undertakings regarding the treatment
of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent sale of any Shares acquired
on exercise; and (b) does not commit to structure the Option to reduce or eliminate the Participant&rsquo;s liability for Tax-Related
Items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10. Qualification
as an Incentive Stock Option</B>. It is understood that this Option is intended to qualify as an incentive stock option as defined in
Section 422 of the Code to the extent permitted under Applicable Law. Accordingly, the Participant understands that in order to obtain
the benefits of an incentive stock option, no sale or other disposition may be made of Shares for which incentive stock option treatment
is desired within one (1) year following the date of exercise of the Option or within two (2) years from the Grant Date. The Participant
understands and agrees that the Company shall not be liable or responsible for any additional tax liability the Participant incurs in
the event that the Internal Revenue Service for any reason determines that this Option does not qualify as an incentive stock option
within the meaning of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11. Disqualifying
Disposition</B>. If the Participant disposes of the Shares of Common Stock prior to the expiration of either two (2) years from the Grant
Date or one (1) year from the date the Shares are transferred to the Participant pursuant to the exercise of the Option (a &ldquo;<B>Disqualifying
Disposition</B>&rdquo;), the Participant shall notify the Company in writing within thirty (30) days after such disposition of the date
and terms of such disposition. The Participant also agrees to provide the Company with any information concerning any such dispositions
as the Company requires for tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12. Compliance
with Law</B>. The exercise of the Option and the issuance and transfer of Shares of Common Stock shall be subject to compliance by the
Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable requirements
of any stock exchange on which the Company&rsquo;s Shares of Common Stock may be listed. No Shares of Common Stock shall be issued pursuant
to this Option unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied
with to the satisfaction of the Company and its counsel. The Participant understands that the Company is under no obligation to register
the Shares with the Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13. Notices</B>.
Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary of the Company
at the Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Participant under this Agreement shall
be in writing and addressed to the Participant at the Participant&rsquo;s address as shown in the records of the Company. Either party
may designate another address in writing (or by such other method approved by the Company) from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14. Governing
Law</B>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard to conflict
of law principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15. Interpretation</B>.
Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to the Committee for
review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16. Options
Subject to Plan</B>. This Agreement is subject to the Plan as approved by the Company&rsquo;s shareholders. The terms and provisions
of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any
term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and
prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17. Successors
and Assigns</B>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the
benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be
binding upon the Participant and the Participant&rsquo;s beneficiaries, executors, administrators and the person(s) to whom this Agreement
may be transferred by will or the laws of descent or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18. Severability</B>.
The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability of
any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable
to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19. Discretionary
Nature of Plan</B>. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion.
The grant of the Option in this Agreement does not create any contractual right or other right to receive any Options or other Awards
in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the
Plan shall not constitute a change or impairment of the terms and conditions of the Participant&rsquo;s employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20. Amendment</B>.
The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively; provided, that,
no such amendment shall adversely affect the Participant&rsquo;s material rights under this Agreement without the Participant&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21. No
Impact on Other Benefits</B>. The value of the Participant&rsquo;s Option is not part of his or her normal or expected compensation for
purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22. Counterparts</B>.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one
and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable
document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document,
will have the same effect as physical delivery of the paper document bearing an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23. Acceptance</B>.
The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands the terms
and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this Agreement. The Participant
acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the underlying Shares and that
the Participant should consult a tax advisor prior to such exercise or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Follow***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Incentive Stock Option Agreement***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE THERAPIES, INC.</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Kristal</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">CFO</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alstodt</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.41
<SEQUENCE>4
<FILENAME>ex10-41.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.41</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INCENTIVE
STOCK OPTION AWARD AGREEMENT<BR>
UNDER THE<BR>
BIORESTORATIVE THERAPIES, INC.<BR>
2021 STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Incentive Stock Option Award Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of February 14, 2025 by and
between BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and Francisco Silva (the &ldquo;<B>Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
  Date</B>:</FONT></TD>
  <TD STYLE="text-align: justify; width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 14, 2025</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
  Price per Share</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.46</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Option
  Shares</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">768,979</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
  Date</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 14, 2035</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
1. <B>Grant of Option</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
 <B>Grant; Type of Option</B>. The Company hereby grants to the Participant an option (the &ldquo;<B>Option</B>&rdquo;)
to purchase the number of Shares of Common Stock of the Company equal to the number of Option Shares set forth above. The Option is being
granted pursuant to the terms of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;). The Option
is intended to be an Incentive Stock Option within the meaning of Section 422 of the Code to the maximum extent permitted by Applicable
Law, although the Company makes no representation or guarantee that the Option will qualify as an Incentive Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
 <B>Consideration; Subject to Plan</B>. The grant of the Option is made in consideration of
the services to be rendered by the Participant to the Company and is subject to the terms and conditions of the Plan. Capitalized terms
used but not otherwise defined herein have the meanings given to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2. Exercise
Period; Vesting</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1 <B>Vesting
Schedule</B>. The Option will become vested and exercisable with respect to 50% of the Option Shares on the Grant Date, with the remainder
vesting quarterly in eight nearly equal installments (at a rate of 1/16 per quarter) with the first quarterly installment vesting on
the one-year anniversary of the Grant Date and continuing every three months thereafter until fully vested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of the Participant&rsquo;s involuntary Termination of Service by the Company without Cause, 100% of the Shares subject to the
Option shall become immediately vested and exercisable. Upon the Participant&rsquo;s Termination of Service for any other reason, the
unvested portion of the Option will be forfeited and will not be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2 <B>Expiration</B>.
The Option will expire on the Expiration Date set forth above, or earlier as provided in this Agreement or the Plan. The Expiration Date
shall not be more than ten years from the Grant Date (or, if the Option is being granted to a Greater Than 10% Stockholder, not more
than five years from the Grant Date). To the extent the Expiration Date listed above is inconsistent with this paragraph, this paragraph
shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3 The
Option shall not be subject to Section 9.6(a) of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3. Termination
of Service</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 <B>Termination
for Reasons Other Than Cause, Death, Disability</B>. If the Participant has a Termination of Service for any reason other than Cause,
death or Disability, the Participant may exercise the vested portion of the Option at any time until the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2 <B>Termination
for Cause</B>. If the Participant has a Termination of Service for Cause, the Participant may exercise the vested portion of the Option,
but only within such period of time ending on the earlier of: (a) the date 12 months following the Participant&rsquo;s Termination of
Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3 <B>Termination
due to Disability</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s Disability, the Participant
may exercise the vested portion of the Option, but only within such period of time ending on the earlier of: (a) the date 24 months following
the Participant&rsquo;s Termination of Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4 <B>Termination
due to Death</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s death, the vested portion of
the Option may be exercised by the Participant&rsquo;s estate, by a person who acquired the right to exercise the Option by bequest or
inheritance or by the person designated to exercise the Option upon the Participant&rsquo;s death, but only within the time period ending
on the earlier of: (a) the date 24 months following the Participant&rsquo;s Termination of Service, or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4. Manner
of Exercise</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 <B>Election
to Exercise</B>. To exercise the Option, the Participant (or in the case of exercise after the Participant&rsquo;s death or incapacity,
the Participant&rsquo;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed stock option
exercise agreement in such form as is approved by the Committee from time to time (the &ldquo;<B>Exercise Agreement</B>&rdquo;), which
shall set forth, inter alia:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) the
Participant&rsquo;s election to exercise the Option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) the
number of Shares of Common Stock being purchased;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) any
restrictions imposed on the Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) any
representations, warranties and agreements regarding the Participant&rsquo;s investment intent and access to information as may be required
by the Company to comply with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the Company
verifying that such person has the legal right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 <B>Payment
of Exercise Price</B>. The entire Exercise Price of the Option shall be payable in full at the time of exercise to the extent permitted
by applicable statutes and regulations, either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) in
cash or by certified or bank check at the time the Option is exercised;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) by
delivery to the Company of other Shares of Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the date
of delivery equal to the Exercise Price (or portion thereof) due for the number of Shares being acquired, or by means of attestation
whereby the Participant identifies for delivery specific Shares that have a Fair Market Value on the date of attestation equal to the
Exercise Price (or portion thereof) and receives a number of Shares equal to the difference between the number of Shares thereby purchased
and the number of identified attestation Shares (a &ldquo;<B>Stock for Stock Exchange</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) through
a &ldquo;cashless exercise program&rdquo; established with a broker;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) by
reduction in the number of Shares otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate
Exercise Price at the time of exercise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) by
any combination of the foregoing methods; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) in
any other form of legal consideration that may be acceptable to the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <B>Withholding</B>.
Prior to the issuance of Shares upon the exercise of the Option, the Participant must make arrangements satisfactory to the Company to
pay or provide for any applicable federal, state and local withholding obligations of the Company. The Participant may satisfy any federal,
state or local tax withholding obligation relating to the exercise of the Option by any of the following means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) tendering
a cash payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) authorizing
the Company to withhold Shares of Common Stock from the Shares of Common Stock otherwise issuable to the Participant as a result of the
exercise of the Option; provided, however, that no Shares of Common Stock are withheld with a value exceeding the maximum amount of tax
required to be withheld by law; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) delivering
to the Company previously owned and unencumbered Shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to withhold from any compensation paid to the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4 <B>Issuance
of Shares</B>. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the Company shall
issue the Shares of Common Stock registered in the name of the Participant, the Participant&rsquo;s authorized assignee, or the Participant&rsquo;s
legal representative which shall be evidenced by stock certificates representing the Shares with the appropriate legends affixed thereto,
appropriate entry on the books of the Company or of a duly authorized transfer agent, or other appropriate means as determined by the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5. No
Right to Continued Employment; No Rights as Shareholder</B>. Neither the Plan nor this Agreement shall confer upon the Participant any
right to be retained in any position, as an Employee, Consultant or Director of the Company. Further, nothing in the Plan or this Agreement
shall be construed to limit the discretion of the Company to terminate the Participant&rsquo;s employment or service with the Company
at any time, with or without Cause. The Participant shall not have any rights as a shareholder with respect to any Shares of Common Stock
subject to the Option unless and until certificates representing the Shares have been issued by the Company to the holder of such Shares,
or the Shares have otherwise been recorded on the books of the Company or of a duly authorized transfer agent as owned by such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6. Transferability</B>.
The Option is only transferable by will or the laws of descent and distribution or in accordance with the limited conditions set forth
in Section 9.3(b) of the Plan. No assignment or transfer of the Option, or the rights represented thereby, whether voluntary or involuntary,
by operation of law or otherwise (except to a designated beneficiary, upon death, by will or the laws of descent or distribution or pursuant
to Section 9.3(b) of the Plan) will vest in the assignee or transferee any interest or right herein whatsoever, but immediately upon
such assignment or transfer the Option will terminate and become of no further effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7. Change
in Control</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1 <B>Acceleration
of Vesting</B>. Notwithstanding any provision of the Plan or this Agreement to the contrary, in the event of a Change in Control prior
to the date that the Option is fully vested and exercisable, the Option shall become immediately vested and exercisable with respect
to 100% of the Shares in each remaining vesting tranche. To the extent practicable, such acceleration of vesting and exercisability shall
occur in a manner and at a time which allows the Participant the ability to participate in the Change in Control with respect to the
Shares of Common Stock received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2 <B>Cash-Out</B>.
In the event of a Change in Control, the Committee may, in its discretion and upon at least ten (10) days&rsquo; advance notice to the
Participant, cancel the Option and pay to the Participant the value of the Option based upon the price per Share of Common Stock received
or to be received by other shareholders of the Company in the event. Notwithstanding the foregoing, if at the time of a Change in Control
the Exercise Price of the Option equals or exceeds the price paid for a Share of Common Stock in connection with the Change in Control,
the Committee may cancel the Option without the payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8. Adjustments</B>.
The Shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9. Tax
Liability and Withholding</B>. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance,
payroll tax, or other tax-related withholding (&ldquo;<B>Tax-Related Items</B>&rdquo;), the ultimate liability for all Tax-Related Items
is and remains the Participant&rsquo;s responsibility and the Company (a) makes no representation or undertakings regarding the treatment
of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent sale of any Shares acquired
on exercise; and (b) does not commit to structure the Option to reduce or eliminate the Participant&rsquo;s liability for Tax-Related
Items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10. Qualification
as an Incentive Stock Option</B>. It is understood that this Option is intended to qualify as an incentive stock option as defined in
Section 422 of the Code to the extent permitted under Applicable Law. Accordingly, the Participant understands that in order to obtain
the benefits of an incentive stock option, no sale or other disposition may be made of Shares for which incentive stock option treatment
is desired within one (1) year following the date of exercise of the Option or within two (2) years from the Grant Date. The Participant
understands and agrees that the Company shall not be liable or responsible for any additional tax liability the Participant incurs in
the event that the Internal Revenue Service for any reason determines that this Option does not qualify as an incentive stock option
within the meaning of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11. Disqualifying
Disposition</B>. If the Participant disposes of the Shares of Common Stock prior to the expiration of either two (2) years from the Grant
Date or one (1) year from the date the Shares are transferred to the Participant pursuant to the exercise of the Option (a &ldquo;<B>Disqualifying
Disposition</B>&rdquo;), the Participant shall notify the Company in writing within thirty (30) days after such disposition of the date
and terms of such disposition. The Participant also agrees to provide the Company with any information concerning any such dispositions
as the Company requires for tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12. Compliance
with Law</B>. The exercise of the Option and the issuance and transfer of Shares of Common Stock shall be subject to compliance by the
Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable requirements
of any stock exchange on which the Company&rsquo;s Shares of Common Stock may be listed. No Shares of Common Stock shall be issued pursuant
to this Option unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied
with to the satisfaction of the Company and its counsel. The Participant understands that the Company is under no obligation to register
the Shares with the Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13. Notices</B>.
Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary of the Company
at the Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Participant under this Agreement shall
be in writing and addressed to the Participant at the Participant&rsquo;s address as shown in the records of the Company. Either party
may designate another address in writing (or by such other method approved by the Company) from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14. Governing
Law</B>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard to conflict
of law principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15. Interpretation</B>.
Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to the Committee for
review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16. Options
Subject to Plan</B>. This Agreement is subject to the Plan as approved by the Company&rsquo;s shareholders. The terms and provisions
of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any
term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and
prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17. Successors
and Assigns</B>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the
benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be
binding upon the Participant and the Participant&rsquo;s beneficiaries, executors, administrators and the person(s) to whom this Agreement
may be transferred by will or the laws of descent or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18. Severability</B>.
The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability of
any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable
to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19. Discretionary
Nature of Plan</B>. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion.
The grant of the Option in this Agreement does not create any contractual right or other right to receive any Options or other Awards
in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the
Plan shall not constitute a change or impairment of the terms and conditions of the Participant&rsquo;s employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20. Amendment</B>.
The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively; provided, that,
no such amendment shall adversely affect the Participant&rsquo;s material rights under this Agreement without the Participant&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21. No
Impact on Other Benefits</B>. The value of the Participant&rsquo;s Option is not part of his or her normal or expected compensation for
purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22. Counterparts</B>.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one
and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable
document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document,
will have the same effect as physical delivery of the paper document bearing an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23. Acceptance</B>.
The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands the terms
and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this Agreement. The Participant
acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the underlying Shares and that
the Participant should consult a tax advisor prior to such exercise or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Follow***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Incentive Stock Option Agreement***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE THERAPIES, INC.</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Kristal</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">CFO</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco Silva</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>5
<FILENAME>ex10-42.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.42</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INCENTIVE
STOCK OPTION AWARD AGREEMENT<BR>
UNDER THE<BR>
BIORESTORATIVE THERAPIES, INC.<BR>
2021 STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Incentive Stock Option Award Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of February 14, 2025 by and
between BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and Robert Kristal (the &ldquo;<B>Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
  Date</B>:</FONT></TD>
  <TD STYLE="text-align: justify; width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 14, 2025</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
  Price per Share</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.46</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Option
  Shares</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">166,492</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
  Date</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 14, 2035</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
1. <B>Grant of Option</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
 <B>Grant; Type of Option</B>. The Company hereby grants to the Participant an option (the &ldquo;<B>Option</B>&rdquo;)
to purchase the number of Shares of Common Stock of the Company equal to the number of Option Shares set forth above. The Option is being
granted pursuant to the terms of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;). The Option
is intended to be an Incentive Stock Option within the meaning of Section 422 of the Code to the maximum extent permitted by Applicable
Law, although the Company makes no representation or guarantee that the Option will qualify as an Incentive Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
 <B>Consideration; Subject to Plan</B>. The grant of the Option is made in consideration of
the services to be rendered by the Participant to the Company and is subject to the terms and conditions of the Plan. Capitalized terms
used but not otherwise defined herein have the meanings given to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2. Exercise
Period; Vesting</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1 <B>Vesting
Schedule</B>. The Option will become vested and exercisable with respect to 50% of the Option Shares on the Grant Date, with the remainder
vesting quarterly in eight nearly equal installments (at a rate of 1/16 per quarter) with the first quarterly installment vesting on
the one-year anniversary of the Grant Date and continuing every three months thereafter until fully vested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Upon the Participant&rsquo;s
Termination of Service for any  reason, the unvested portion of the Option will be forfeited and will not be exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2 <B>Expiration</B>.
The Option will expire on the Expiration Date set forth above, or earlier as provided in this Agreement or the Plan. The Expiration Date
shall not be more than ten years from the Grant Date (or, if the Option is being granted to a Greater Than 10% Stockholder, not more
than five years from the Grant Date). To the extent the Expiration Date listed above is inconsistent with this paragraph, this paragraph
shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3. Termination
of Service</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 <B>Termination
for Reasons Other Than Cause, Death, Disability</B>. If the Participant has a Termination of Service for any reason other than Cause,
death or Disability, the Participant may exercise the vested portion of the Option, but only within such period of time ending on the earlier of: (a) the date three months following the Participant&rsquo;s
Termination of Service, or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2 <B>Termination
for Cause</B>. If the Participant has a Termination of Service for Cause, the Option (whether vested or unvested) shall immediately terminate and cease to be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3 <B>Termination
due to Disability</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s Disability, the Participant
may exercise the vested portion of the Option, but only within such period of time ending on the earlier of: (a) the date 12 months following
the Participant&rsquo;s Termination of Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4 <B>Termination
due to Death</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s death, the vested portion of
the Option may be exercised by the Participant&rsquo;s estate, by a person who acquired the right to exercise the Option by bequest or
inheritance or by the person designated to exercise the Option upon the Participant&rsquo;s death, but only within the time period ending
on the earlier of: (a) the date 12 months following the Participant&rsquo;s Termination of Service, or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4. Manner
of Exercise</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 <B>Election
to Exercise</B>. To exercise the Option, the Participant (or in the case of exercise after the Participant&rsquo;s death or incapacity,
the Participant&rsquo;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed stock option
exercise agreement in such form as is approved by the Committee from time to time (the &ldquo;<B>Exercise Agreement</B>&rdquo;), which
shall set forth, inter alia:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) the
Participant&rsquo;s election to exercise the Option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) the
number of Shares of Common Stock being purchased;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) any
restrictions imposed on the Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) any
representations, warranties and agreements regarding the Participant&rsquo;s investment intent and access to information as may be required
by the Company to comply with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the Company
verifying that such person has the legal right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 <B>Payment
of Exercise Price</B>. The entire Exercise Price of the Option shall be payable in full at the time of exercise to the extent permitted
by applicable statutes and regulations, either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) in
cash or by certified or bank check at the time the Option is exercised;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) by
delivery to the Company of other Shares of Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the date
of delivery equal to the Exercise Price (or portion thereof) due for the number of Shares being acquired, or by means of attestation
whereby the Participant identifies for delivery specific Shares that have a Fair Market Value on the date of attestation equal to the
Exercise Price (or portion thereof) and receives a number of Shares equal to the difference between the number of Shares thereby purchased
and the number of identified attestation Shares (a &ldquo;<B>Stock for Stock Exchange</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) through
a &ldquo;cashless exercise program&rdquo; established with a broker;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) by
reduction in the number of Shares otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate
Exercise Price at the time of exercise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) by
any combination of the foregoing methods; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) in
any other form of legal consideration that may be acceptable to the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <B>Withholding</B>.
Prior to the issuance of Shares upon the exercise of the Option, the Participant must make arrangements satisfactory to the Company to
pay or provide for any applicable federal, state and local withholding obligations of the Company. The Participant may satisfy any federal,
state or local tax withholding obligation relating to the exercise of the Option by any of the following means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) tendering
a cash payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) authorizing
the Company to withhold Shares of Common Stock from the Shares of Common Stock otherwise issuable to the Participant as a result of the
exercise of the Option; provided, however, that no Shares of Common Stock are withheld with a value exceeding the maximum amount of tax
required to be withheld by law; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) delivering
to the Company previously owned and unencumbered Shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to withhold from any compensation paid to the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4 <B>Issuance
of Shares</B>. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the Company shall
issue the Shares of Common Stock registered in the name of the Participant, the Participant&rsquo;s authorized assignee, or the Participant&rsquo;s
legal representative which shall be evidenced by stock certificates representing the Shares with the appropriate legends affixed thereto,
appropriate entry on the books of the Company or of a duly authorized transfer agent, or other appropriate means as determined by the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5. No
Right to Continued Employment; No Rights as Shareholder</B>. Neither the Plan nor this Agreement shall confer upon the Participant any
right to be retained in any position, as an Employee, Consultant or Director of the Company. Further, nothing in the Plan or this Agreement
shall be construed to limit the discretion of the Company to terminate the Participant&rsquo;s employment or service with the Company
at any time, with or without Cause. The Participant shall not have any rights as a shareholder with respect to any Shares of Common Stock
subject to the Option unless and until certificates representing the Shares have been issued by the Company to the holder of such Shares,
or the Shares have otherwise been recorded on the books of the Company or of a duly authorized transfer agent as owned by such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6. Transferability</B>.
The Option is only transferable by will or the laws of descent and distribution or in accordance with the limited conditions set forth
in Section 9.3(b) of the Plan. No assignment or transfer of the Option, or the rights represented thereby, whether voluntary or involuntary,
by operation of law or otherwise (except to a designated beneficiary, upon death, by will or the laws of descent or distribution or pursuant
to Section 9.3(b) of the Plan) will vest in the assignee or transferee any interest or right herein whatsoever, but immediately upon
such assignment or transfer the Option will terminate and become of no further effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7. Change
in Control</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1 <B>Acceleration
of Vesting</B>. Notwithstanding any provision of the Plan or this Agreement to the contrary, in the event of a Change in Control prior
to the date that the Option is fully vested and exercisable, the Option shall become immediately vested and exercisable with respect
to 100% of the Shares in each remaining vesting tranche. To the extent practicable, such acceleration of vesting and exercisability shall
occur in a manner and at a time which allows the Participant the ability to participate in the Change in Control with respect to the
Shares of Common Stock received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2 <B>Cash
Out</B>. In the event of a Change in Control, the Committee may, in its discretion and upon at least ten (10) days&rsquo; advance
notice to the Participant, cancel the Option and pay to the Participant the value of the Option based upon the price per Share of
Common Stock received or to be received by other shareholders of the Company in the event. Notwithstanding the foregoing, if at the
time of a Change in Control the Exercise Price of the Option equals or exceeds the price paid for a Share of Common Stock in
connection with the Change in Control, the Committee may cancel the Option without the payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8. Adjustments</B>.
The Shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9. Tax
Liability and Withholding</B>. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance,
payroll tax, or other tax-related withholding (&ldquo;<B>Tax-Related Items</B>&rdquo;), the ultimate liability for all Tax-Related Items
is and remains the Participant&rsquo;s responsibility and the Company (a) makes no representation or undertakings regarding the treatment
of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent sale of any Shares acquired
on exercise; and (b) does not commit to structure the Option to reduce or eliminate the Participant&rsquo;s liability for Tax-Related
Items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10. Qualification
as an Incentive Stock Option</B>. It is understood that this Option is intended to qualify as an incentive stock option as defined in
Section 422 of the Code to the extent permitted under Applicable Law. Accordingly, the Participant understands that in order to obtain
the benefits of an incentive stock option, no sale or other disposition may be made of Shares for which incentive stock option treatment
is desired within one (1) year following the date of exercise of the Option or within two (2) years from the Grant Date. The Participant
understands and agrees that the Company shall not be liable or responsible for any additional tax liability the Participant incurs in
the event that the Internal Revenue Service for any reason determines that this Option does not qualify as an incentive stock option
within the meaning of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11. Disqualifying
Disposition</B>. If the Participant disposes of the Shares of Common Stock prior to the expiration of either two (2) years from the Grant
Date or one (1) year from the date the Shares are transferred to the Participant pursuant to the exercise of the Option (a &ldquo;<B>Disqualifying
Disposition</B>&rdquo;), the Participant shall notify the Company in writing within thirty (30) days after such disposition of the date
and terms of such disposition. The Participant also agrees to provide the Company with any information concerning any such dispositions
as the Company requires for tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12. Compliance
with Law</B>. The exercise of the Option and the issuance and transfer of Shares of Common Stock shall be subject to compliance by the
Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable requirements
of any stock exchange on which the Company&rsquo;s Shares of Common Stock may be listed. No Shares of Common Stock shall be issued pursuant
to this Option unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied
with to the satisfaction of the Company and its counsel. The Participant understands that the Company is under no obligation to register
the Shares with the Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13. Notices</B>.
Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary of the Company
at the Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Participant under this Agreement shall
be in writing and addressed to the Participant at the Participant&rsquo;s address as shown in the records of the Company. Either party
may designate another address in writing (or by such other method approved by the Company) from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14. Governing
Law</B>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard to conflict
of law principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15. Interpretation</B>.
Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to the Committee for
review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16. Options
Subject to Plan</B>. This Agreement is subject to the Plan as approved by the Company&rsquo;s shareholders. The terms and provisions
of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any
term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and
prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17. Successors
and Assigns</B>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the
benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be
binding upon the Participant and the Participant&rsquo;s beneficiaries, executors, administrators and the person(s) to whom this Agreement
may be transferred by will or the laws of descent or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18. Severability</B>.
The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability of
any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable
to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19. Discretionary
Nature of Plan</B>. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion.
The grant of the Option in this Agreement does not create any contractual right or other right to receive any Options or other Awards
in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the
Plan shall not constitute a change or impairment of the terms and conditions of the Participant&rsquo;s employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20. Amendment</B>.
The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively; provided, that,
no such amendment shall adversely affect the Participant&rsquo;s material rights under this Agreement without the Participant&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21. No
Impact on Other Benefits</B>. The value of the Participant&rsquo;s Option is not part of his or her normal or expected compensation for
purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22. Counterparts</B>.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one
and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable
document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document,
will have the same effect as physical delivery of the paper document bearing an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23. Acceptance</B>.
The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands the terms
and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this Agreement. The Participant
acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the underlying Shares and that
the Participant should consult a tax advisor prior to such exercise or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Incentive Stock Option Agreement***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE THERAPIES, INC.</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance Alstodt</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><P STYLE="margin: 0">President and CEO</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Kristal</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.43
<SEQUENCE>6
<FILENAME>ex10-43.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.43</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NON-QUALIFIED
STOCK OPTION AWARD AGREEMENT<BR>
UNDER THE<BR>
BIORESTORATIVE THERAPIES, INC.<BR>
2021 STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Non-Qualified Stock Option Award Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of February 14, 2025 by and
between BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and Nickolay Kukekov (the &ldquo;<B>Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
  Date</B>:</FONT></TD>
  <TD STYLE="text-align: justify; width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 14, 2025</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
  Price per Share</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.46</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Option
  Shares</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,632</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
  Date</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 14, 2035</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
1. <B>Grant of Option</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1. <B>Grant;
Type of Option</B>. The Company hereby grants to the Participant an option (the &ldquo;<B>Option</B>&rdquo;) to purchase the number
of Shares of Common Stock of the Company equal to the number of Option Shares set forth above. The Option is being granted pursuant
to the terms of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;). The Option is intended
to be a Non-Qualified Stock Option and <I>not </I> an Incentive Stock Option within the meaning of Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
 <B>Consideration; Subject to Plan</B>. The grant of the Option is made in consideration of
the services to be rendered by the Participant to the Company and is subject to the terms and conditions of the Plan. Capitalized terms
used but not otherwise defined herein have the meanings given to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2. Exercise
Period; Vesting</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1 <B>Vesting
Schedule</B>. The Option will become vested and exercisable <FONT STYLE="letter-spacing: 0.05pt">in
twelve equal monthly installments (at a rate of 1/12 per month) with the first installment vesting on the one-month anniversary of the
Grant Date and continuing every month thereafter until fully vested.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the Participant&rsquo;s Termination of Service for any reason, the
unvested portion of the Option will be forfeited and will not be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<B>Expiration</B>. The Option will expire on the Expiration Date set forth above, or earlier as provided in this Agreement or the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3. Termination
of Service</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 <B>Termination
for Reasons Other Than Cause, Death, Disability</B>. If the Participant has a Termination of Service for any reason other than
Cause, death or Disability, the Participant may exercise the vested portion of the Option, but only within such period of time
ending on the earlier of: (a) the date three months following the Participant&rsquo;s Termination of Service, or (b) the Expiration
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<B>Termination for Cause</B>. If the Participant has a Termination of Service for Cause, the Option (whether vested or unvested) shall
immediately terminate and cease to be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3 <B>Termination
due to Disability</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s Disability, the Participant
may exercise the vested portion of the Option, but only within such period of time ending on the earlier of: (a) the date 12 months following
the Participant&rsquo;s Termination of Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4 <B>Termination
due to Death</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s death, the vested portion of
the Option may be exercised by the Participant&rsquo;s estate, by a person who acquired the right to exercise the Option by bequest or
inheritance or by the person designated to exercise the Option upon the Participant&rsquo;s death, but only within the time period ending
on the earlier of: (a) the date 12 months following the Participant&rsquo;s Termination of Service, or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4. Manner
of Exercise</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 <B>Election
to Exercise</B>. To exercise the Option, the Participant (or in the case of exercise after the Participant&rsquo;s death or incapacity,
the Participant&rsquo;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed stock option
exercise agreement in such form as is approved by the Committee from time to time (the &ldquo;<B>Exercise Agreement</B>&rdquo;), which
shall set forth, inter alia:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) the
Participant&rsquo;s election to exercise the Option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) the
number of Shares of Common Stock being purchased;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) any
restrictions imposed on the Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) any
representations, warranties and agreements regarding the Participant&rsquo;s investment intent and access to information as may be required
by the Company to comply with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the Company
verifying that such person has the legal right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 <B>Payment
of Exercise Price</B>. The entire Exercise Price of the Option shall be payable in full at the time of exercise to the extent permitted
by applicable statutes and regulations, either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) in
cash or by certified or bank check at the time the Option is exercised;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) by
delivery to the Company of other Shares of Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the date
of delivery equal to the Exercise Price (or portion thereof) due for the number of Shares being acquired, or by means of attestation
whereby the Participant identifies for delivery specific Shares that have a Fair Market Value on the date of attestation equal to the
Exercise Price (or portion thereof) and receives a number of Shares equal to the difference between the number of Shares thereby purchased
and the number of identified attestation Shares (a &ldquo;<B>Stock for Stock Exchange</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) through
a &ldquo;cashless exercise program&rdquo; established with a broker;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) by
reduction in the number of Shares otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate
Exercise Price at the time of exercise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) by
any combination of the foregoing methods; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) in
any other form of legal consideration that may be acceptable to the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <B>Withholding</B>.
Prior to the issuance of Shares upon the exercise of the Option, the Participant must make arrangements satisfactory to the Company to
pay or provide for any applicable federal, state and local withholding obligations of the Company. The Participant may satisfy any federal,
state or local tax withholding obligation relating to the exercise of the Option by any of the following means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) tendering
a cash payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) authorizing
the Company to withhold Shares of Common Stock from the Shares of Common Stock otherwise issuable to the Participant as a result of the
exercise of the Option; provided, however, that no Shares of Common Stock are withheld with a value exceeding the maximum amount of tax
required to be withheld by law; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) delivering
to the Company previously owned and unencumbered Shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to withhold from any compensation paid to the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4 <B>Issuance
of Shares</B>. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the Company shall
issue the Shares of Common Stock registered in the name of the Participant, the Participant&rsquo;s authorized assignee, or the Participant&rsquo;s
legal representative which shall be evidenced by stock certificates representing the Shares with the appropriate legends affixed thereto,
appropriate entry on the books of the Company or of a duly authorized transfer agent, or other appropriate means as determined by the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5. No
Right to Continued Employment; No Rights as Shareholder</B>. Neither the Plan nor this Agreement shall confer upon the Participant any
right to be retained in any position, as an Employee, Consultant or Director of the Company. Further, nothing in the Plan or this Agreement
shall be construed to limit the discretion of the Company to terminate the Participant&rsquo;s employment or service with the Company
at any time, with or without Cause. The Participant shall not have any rights as a shareholder with respect to any Shares of Common Stock
subject to the Option unless and until certificates representing the Shares have been issued by the Company to the holder of such Shares,
or the Shares have otherwise been recorded on the books of the Company or of a duly authorized transfer agent as owned by such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6. Transferability</B>.
The Option is only transferable by will or the laws of descent and distribution or in accordance with the limited conditions set forth
in Section 9.3(b) of the Plan. No assignment or transfer of the Option, or the rights represented thereby, whether voluntary or involuntary,
by operation of law or otherwise (except to a designated beneficiary, upon death, by will or the laws of descent or distribution or pursuant
to Section 9.3(b) of the Plan) will vest in the assignee or transferee any interest or right herein whatsoever, but immediately upon
such assignment or transfer the Option will terminate and become of no further effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7. Change
in Control</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1 <B>Acceleration
of Vesting</B>. Notwithstanding any provision of the Plan or this Agreement to the contrary, in the event of a Change in Control prior
to the date that the Option is fully vested and exercisable, the Option shall become immediately vested and exercisable with respect
to 100% of the Shares in each remaining vesting tranche. To the extent practicable, such acceleration of vesting and exercisability shall
occur in a manner and at a time which allows the Participant the ability to participate in the Change in Control with respect to the
Shares of Common Stock received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2 <B>Cash
Out</B>. In the event of a Change in Control, the Committee may, in its discretion and upon at least ten (10) days&rsquo; advance
notice to the Participant, cancel the Option and pay to the Participant the value of the Option based upon the price per Share of
Common Stock received or to be received by other shareholders of the Company in the event. Notwithstanding the foregoing, if at the
time of a Change in Control the Exercise Price of the Option equals or exceeds the price paid for a Share of Common Stock in
connection with the Change in Control, the Committee may cancel the Option without the payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8. Adjustments</B>.
The Shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9. Tax
Liability and Withholding</B>. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance,
payroll tax, or other tax-related withholding (&ldquo;<B>Tax-Related Items</B>&rdquo;), the ultimate liability for all Tax-Related Items
is and remains the Participant&rsquo;s responsibility and the Company (a) makes no representation or undertakings regarding the treatment
of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent sale of any Shares acquired
on exercise; and (b) does not commit to structure the Option to reduce or eliminate the Participant&rsquo;s liability for Tax-Related
Items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Compliance with Law</B>. The exercise of the Option and the issuance and transfer of Shares of Common Stock shall be subject to compliance
by the Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable requirements
of any stock exchange on which the Company&rsquo;s Shares of Common Stock may be listed. No Shares of Common Stock shall be issued pursuant
to this Option unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied
with to the satisfaction of the Company and its counsel. The Participant understands that the Company is under no obligation to register
the Shares with the Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11. Notices</B>.
Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary of the Company
at the Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Participant under this Agreement shall
be in writing and addressed to the Participant at the Participant&rsquo;s address as shown in the records of the Company. Either party
may designate another address in writing (or by such other method approved by the Company) from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12. Governing
Law</B>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard to conflict
of law principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13. Interpretation</B>.
Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to the Committee for
review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14. Options
Subject to Plan</B>. This Agreement is subject to the Plan as approved by the Company&rsquo;s shareholders. The terms and provisions
of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any
term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and
prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15. Successors
and Assigns</B>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the
benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be
binding upon the Participant and the Participant&rsquo;s beneficiaries, executors, administrators and the person(s) to whom this Agreement
may be transferred by will or the laws of descent or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16. Severability</B>.
The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability of
any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable
to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17. Discretionary
Nature of Plan</B>. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion.
The grant of the Option in this Agreement does not create any contractual right or other right to receive any Options or other Awards
in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the
Plan shall not constitute a change or impairment of the terms and conditions of the Participant&rsquo;s employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18. Amendment</B>.
The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively; provided, that,
no such amendment shall adversely affect the Participant&rsquo;s material rights under this Agreement without the Participant&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19. No
Impact on Other Benefits</B>. The value of the Participant&rsquo;s Option is not part of his or her normal or expected compensation for
purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20. Counterparts</B>.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one
and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable
document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document,
will have the same effect as physical delivery of the paper document bearing an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21. Acceptance</B>.
The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands the terms
and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this Agreement. The Participant
acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the underlying Shares and that
the Participant should consult a tax advisor prior to such exercise or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Follow***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Non-Qualified Stock Option Agreement***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE THERAPIES, INC.</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance Alstodt</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><P STYLE="margin: 0">President and CEO</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nickolay Kukekov</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.44
<SEQUENCE>7
<FILENAME>ex10-44.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.44</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NON-QUALIFIED
STOCK OPTION AWARD AGREEMENT<BR>
UNDER THE<BR>
BIORESTORATIVE THERAPIES, INC.<BR>
2021 STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Non-Qualified Stock Option Award Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of February 14, 2025 by
and between BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and Patrick F. Williams (the
&ldquo;<B>Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
  Date</B>:</FONT></TD>
  <TD STYLE="text-align: justify; width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 14, 2025</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
  Price per Share</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.46</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Option
  Shares</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,632</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
  Date</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 14, 2035</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
1. <B>Grant of Option</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1. <B>Grant;
Type of Option</B>. The Company hereby grants to the Participant an option (the &ldquo;<B>Option</B>&rdquo;) to purchase the number
of Shares of Common Stock of the Company equal to the number of Option Shares set forth above. The Option is being granted pursuant
to the terms of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;). The Option is intended
to be a Non-Qualified Stock Option and <I>not </I> an Incentive Stock Option within the meaning of Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
 <B>Consideration; Subject to Plan</B>. The grant of the Option is made in consideration of
the services to be rendered by the Participant to the Company and is subject to the terms and conditions of the Plan. Capitalized terms
used but not otherwise defined herein have the meanings given to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2. Exercise
Period; Vesting</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1 <B>Vesting
Schedule</B>. The Option will become vested and exercisable <FONT STYLE="letter-spacing: 0.05pt">in
twelve equal monthly installments (at a rate of 1/12 per month) with the first installment vesting on the one-month anniversary of the
Grant Date and continuing every month thereafter until fully vested.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the Participant&rsquo;s Termination of Service for any reason, the
unvested portion of the Option will be forfeited and will not be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<B>Expiration</B>. The Option will expire on the Expiration Date set forth above, or earlier as provided in this Agreement or the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3. Termination
of Service</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 <B>Termination
for Reasons Other Than Cause, Death, Disability</B>. If the Participant has a Termination of Service for any reason other than
Cause, death or Disability, the Participant may exercise the vested portion of the Option, but only within such period of time
ending on the earlier of: (a) the date three months following the Participant&rsquo;s Termination of Service, or (b) the Expiration
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<B>Termination for Cause</B>. If the Participant has a Termination of Service for Cause, the Option (whether vested or unvested) shall
immediately terminate and cease to be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3 <B>Termination
due to Disability</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s Disability, the Participant
may exercise the vested portion of the Option, but only within such period of time ending on the earlier of: (a) the date 12 months following
the Participant&rsquo;s Termination of Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4 <B>Termination
due to Death</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s death, the vested portion of
the Option may be exercised by the Participant&rsquo;s estate, by a person who acquired the right to exercise the Option by bequest or
inheritance or by the person designated to exercise the Option upon the Participant&rsquo;s death, but only within the time period ending
on the earlier of: (a) the date 12 months following the Participant&rsquo;s Termination of Service, or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4. Manner
of Exercise</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 <B>Election
to Exercise</B>. To exercise the Option, the Participant (or in the case of exercise after the Participant&rsquo;s death or incapacity,
the Participant&rsquo;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed stock option
exercise agreement in such form as is approved by the Committee from time to time (the &ldquo;<B>Exercise Agreement</B>&rdquo;), which
shall set forth, inter alia:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) the
Participant&rsquo;s election to exercise the Option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) the
number of Shares of Common Stock being purchased;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) any
restrictions imposed on the Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) any
representations, warranties and agreements regarding the Participant&rsquo;s investment intent and access to information as may be required
by the Company to comply with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the Company
verifying that such person has the legal right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 <B>Payment
of Exercise Price</B>. The entire Exercise Price of the Option shall be payable in full at the time of exercise to the extent permitted
by applicable statutes and regulations, either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) in
cash or by certified or bank check at the time the Option is exercised;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) by
delivery to the Company of other Shares of Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the date
of delivery equal to the Exercise Price (or portion thereof) due for the number of Shares being acquired, or by means of attestation
whereby the Participant identifies for delivery specific Shares that have a Fair Market Value on the date of attestation equal to the
Exercise Price (or portion thereof) and receives a number of Shares equal to the difference between the number of Shares thereby purchased
and the number of identified attestation Shares (a &ldquo;<B>Stock for Stock Exchange</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) through
a &ldquo;cashless exercise program&rdquo; established with a broker;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) by
reduction in the number of Shares otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate
Exercise Price at the time of exercise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) by
any combination of the foregoing methods; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) in
any other form of legal consideration that may be acceptable to the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <B>Withholding</B>.
Prior to the issuance of Shares upon the exercise of the Option, the Participant must make arrangements satisfactory to the Company to
pay or provide for any applicable federal, state and local withholding obligations of the Company. The Participant may satisfy any federal,
state or local tax withholding obligation relating to the exercise of the Option by any of the following means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) tendering
a cash payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) authorizing
the Company to withhold Shares of Common Stock from the Shares of Common Stock otherwise issuable to the Participant as a result of the
exercise of the Option; provided, however, that no Shares of Common Stock are withheld with a value exceeding the maximum amount of tax
required to be withheld by law; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) delivering
to the Company previously owned and unencumbered Shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to withhold from any compensation paid to the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4 <B>Issuance
of Shares</B>. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the Company shall
issue the Shares of Common Stock registered in the name of the Participant, the Participant&rsquo;s authorized assignee, or the Participant&rsquo;s
legal representative which shall be evidenced by stock certificates representing the Shares with the appropriate legends affixed thereto,
appropriate entry on the books of the Company or of a duly authorized transfer agent, or other appropriate means as determined by the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5. No
Right to Continued Employment; No Rights as Shareholder</B>. Neither the Plan nor this Agreement shall confer upon the Participant any
right to be retained in any position, as an Employee, Consultant or Director of the Company. Further, nothing in the Plan or this Agreement
shall be construed to limit the discretion of the Company to terminate the Participant&rsquo;s employment or service with the Company
at any time, with or without Cause. The Participant shall not have any rights as a shareholder with respect to any Shares of Common Stock
subject to the Option unless and until certificates representing the Shares have been issued by the Company to the holder of such Shares,
or the Shares have otherwise been recorded on the books of the Company or of a duly authorized transfer agent as owned by such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6. Transferability</B>.
The Option is only transferable by will or the laws of descent and distribution or in accordance with the limited conditions set forth
in Section 9.3(b) of the Plan. No assignment or transfer of the Option, or the rights represented thereby, whether voluntary or involuntary,
by operation of law or otherwise (except to a designated beneficiary, upon death, by will or the laws of descent or distribution or pursuant
to Section 9.3(b) of the Plan) will vest in the assignee or transferee any interest or right herein whatsoever, but immediately upon
such assignment or transfer the Option will terminate and become of no further effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7. Change
in Control</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1 <B>Acceleration
of Vesting</B>. Notwithstanding any provision of the Plan or this Agreement to the contrary, in the event of a Change in Control prior
to the date that the Option is fully vested and exercisable, the Option shall become immediately vested and exercisable with respect
to 100% of the Shares in each remaining vesting tranche. To the extent practicable, such acceleration of vesting and exercisability shall
occur in a manner and at a time which allows the Participant the ability to participate in the Change in Control with respect to the
Shares of Common Stock received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2 <B>Cash
Out</B>. In the event of a Change in Control, the Committee may, in its discretion and upon at least ten (10) days&rsquo; advance
notice to the Participant, cancel the Option and pay to the Participant the value of the Option based upon the price per Share of
Common Stock received or to be received by other shareholders of the Company in the event. Notwithstanding the foregoing, if at the
time of a Change in Control the Exercise Price of the Option equals or exceeds the price paid for a Share of Common Stock in
connection with the Change in Control, the Committee may cancel the Option without the payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8. Adjustments</B>.
The Shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9. Tax
Liability and Withholding</B>. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance,
payroll tax, or other tax-related withholding (&ldquo;<B>Tax-Related Items</B>&rdquo;), the ultimate liability for all Tax-Related Items
is and remains the Participant&rsquo;s responsibility and the Company (a) makes no representation or undertakings regarding the treatment
of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent sale of any Shares acquired
on exercise; and (b) does not commit to structure the Option to reduce or eliminate the Participant&rsquo;s liability for Tax-Related
Items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Compliance with Law</B>. The exercise of the Option and the issuance and transfer of Shares of Common Stock shall be subject to compliance
by the Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable requirements
of any stock exchange on which the Company&rsquo;s Shares of Common Stock may be listed. No Shares of Common Stock shall be issued pursuant
to this Option unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied
with to the satisfaction of the Company and its counsel. The Participant understands that the Company is under no obligation to register
the Shares with the Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11. Notices</B>.
Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary of the Company
at the Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Participant under this Agreement shall
be in writing and addressed to the Participant at the Participant&rsquo;s address as shown in the records of the Company. Either party
may designate another address in writing (or by such other method approved by the Company) from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12. Governing
Law</B>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard to conflict
of law principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13. Interpretation</B>.
Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to the Committee for
review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14. Options
Subject to Plan</B>. This Agreement is subject to the Plan as approved by the Company&rsquo;s shareholders. The terms and provisions
of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any
term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and
prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15. Successors
and Assigns</B>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the
benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be
binding upon the Participant and the Participant&rsquo;s beneficiaries, executors, administrators and the person(s) to whom this Agreement
may be transferred by will or the laws of descent or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16. Severability</B>.
The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability of
any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable
to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17. Discretionary
Nature of Plan</B>. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion.
The grant of the Option in this Agreement does not create any contractual right or other right to receive any Options or other Awards
in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the
Plan shall not constitute a change or impairment of the terms and conditions of the Participant&rsquo;s employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18. Amendment</B>.
The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively; provided, that,
no such amendment shall adversely affect the Participant&rsquo;s material rights under this Agreement without the Participant&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19. No
Impact on Other Benefits</B>. The value of the Participant&rsquo;s Option is not part of his or her normal or expected compensation for
purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20. Counterparts</B>.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one
and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable
document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document,
will have the same effect as physical delivery of the paper document bearing an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21. Acceptance</B>.
The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands the terms
and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this Agreement. The Participant
acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the underlying Shares and that
the Participant should consult a tax advisor prior to such exercise or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Follow***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Non-Qualified Stock Option Agreement***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE THERAPIES, INC.</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance Alstodt</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><P STYLE="margin: 0">President and CEO</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><P STYLE="margin: 0">Patrick F. Williams</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.45
<SEQUENCE>8
<FILENAME>ex10-45.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.45</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NON-QUALIFIED
STOCK OPTION AWARD AGREEMENT<BR>
UNDER THE<BR>
BIORESTORATIVE THERAPIES, INC.<BR>
2021 STOCK INCENTIVE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Non-Qualified Stock Option Award Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of February 14, 2025 by and
between BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), and David Rosa (the &ldquo;<B>Participant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
  Date</B>:</FONT></TD>
  <TD STYLE="text-align: justify; width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 14, 2025</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
  Price per Share</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.46</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Option
  Shares</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,632</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
  Date</B>:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 14, 2035</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
1. <B>Grant of Option</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1. <B>Grant;
Type of Option</B>. The Company hereby grants to the Participant an option (the &ldquo;<B>Option</B>&rdquo;) to purchase the number
of Shares of Common Stock of the Company equal to the number of Option Shares set forth above. The Option is being granted pursuant
to the terms of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;). The Option is intended
to be a Non-Qualified Stock Option and <I>not </I> an Incentive Stock Option within the meaning of Section 422 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
 <B>Consideration; Subject to Plan</B>. The grant of the Option is made in consideration of
the services to be rendered by the Participant to the Company and is subject to the terms and conditions of the Plan. Capitalized terms
used but not otherwise defined herein have the meanings given to them in the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2. Exercise
Period; Vesting</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1 <B>Vesting
Schedule</B>. The Option will become vested and exercisable <FONT STYLE="letter-spacing: 0.05pt">in
twelve equal monthly installments (at a rate of 1/12 per month) with the first installment vesting on the one-month anniversary of the
Grant Date and continuing every month thereafter until fully vested.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the Participant&rsquo;s Termination of Service for any reason, the
unvested portion of the Option will be forfeited and will not be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<B>Expiration</B>. The Option will expire on the Expiration Date set forth above, or earlier as provided in this Agreement or the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3. Termination
of Service</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 <B>Termination
for Reasons Other Than Cause, Death, Disability</B>. If the Participant has a Termination of Service for any reason other than
Cause, death or Disability, the Participant may exercise the vested portion of the Option, but only within such period of time
ending on the earlier of: (a) the date three months following the Participant&rsquo;s Termination of Service, or (b) the Expiration
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<B>Termination for Cause</B>. If the Participant has a Termination of Service for Cause, the Option (whether vested or unvested) shall
immediately terminate and cease to be exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3 <B>Termination
due to Disability</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s Disability, the Participant
may exercise the vested portion of the Option, but only within such period of time ending on the earlier of: (a) the date 12 months following
the Participant&rsquo;s Termination of Service or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4 <B>Termination
due to Death</B>. If the Participant has a Termination of Service as a result of the Participant&rsquo;s death, the vested portion of
the Option may be exercised by the Participant&rsquo;s estate, by a person who acquired the right to exercise the Option by bequest or
inheritance or by the person designated to exercise the Option upon the Participant&rsquo;s death, but only within the time period ending
on the earlier of: (a) the date 12 months following the Participant&rsquo;s Termination of Service, or (b) the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4. Manner
of Exercise</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 <B>Election
to Exercise</B>. To exercise the Option, the Participant (or in the case of exercise after the Participant&rsquo;s death or incapacity,
the Participant&rsquo;s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed stock option
exercise agreement in such form as is approved by the Committee from time to time (the &ldquo;<B>Exercise Agreement</B>&rdquo;), which
shall set forth, inter alia:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) the
Participant&rsquo;s election to exercise the Option;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) the
number of Shares of Common Stock being purchased;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) any
restrictions imposed on the Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) any
representations, warranties and agreements regarding the Participant&rsquo;s investment intent and access to information as may be required
by the Company to comply with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the Company
verifying that such person has the legal right to exercise the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 <B>Payment
of Exercise Price</B>. The entire Exercise Price of the Option shall be payable in full at the time of exercise to the extent permitted
by applicable statutes and regulations, either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) in
cash or by certified or bank check at the time the Option is exercised;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) by
delivery to the Company of other Shares of Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the date
of delivery equal to the Exercise Price (or portion thereof) due for the number of Shares being acquired, or by means of attestation
whereby the Participant identifies for delivery specific Shares that have a Fair Market Value on the date of attestation equal to the
Exercise Price (or portion thereof) and receives a number of Shares equal to the difference between the number of Shares thereby purchased
and the number of identified attestation Shares (a &ldquo;<B>Stock for Stock Exchange</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) through
a &ldquo;cashless exercise program&rdquo; established with a broker;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) by
reduction in the number of Shares otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate
Exercise Price at the time of exercise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) by
any combination of the foregoing methods; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) in
any other form of legal consideration that may be acceptable to the Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <B>Withholding</B>.
Prior to the issuance of Shares upon the exercise of the Option, the Participant must make arrangements satisfactory to the Company to
pay or provide for any applicable federal, state and local withholding obligations of the Company. The Participant may satisfy any federal,
state or local tax withholding obligation relating to the exercise of the Option by any of the following means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) tendering
a cash payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) authorizing
the Company to withhold Shares of Common Stock from the Shares of Common Stock otherwise issuable to the Participant as a result of the
exercise of the Option; provided, however, that no Shares of Common Stock are withheld with a value exceeding the maximum amount of tax
required to be withheld by law; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) delivering
to the Company previously owned and unencumbered Shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to withhold from any compensation paid to the Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4 <B>Issuance
of Shares</B>. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the Company shall
issue the Shares of Common Stock registered in the name of the Participant, the Participant&rsquo;s authorized assignee, or the Participant&rsquo;s
legal representative which shall be evidenced by stock certificates representing the Shares with the appropriate legends affixed thereto,
appropriate entry on the books of the Company or of a duly authorized transfer agent, or other appropriate means as determined by the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5. No
Right to Continued Employment; No Rights as Shareholder</B>. Neither the Plan nor this Agreement shall confer upon the Participant any
right to be retained in any position, as an Employee, Consultant or Director of the Company. Further, nothing in the Plan or this Agreement
shall be construed to limit the discretion of the Company to terminate the Participant&rsquo;s employment or service with the Company
at any time, with or without Cause. The Participant shall not have any rights as a shareholder with respect to any Shares of Common Stock
subject to the Option unless and until certificates representing the Shares have been issued by the Company to the holder of such Shares,
or the Shares have otherwise been recorded on the books of the Company or of a duly authorized transfer agent as owned by such holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6. Transferability</B>.
The Option is only transferable by will or the laws of descent and distribution or in accordance with the limited conditions set forth
in Section 9.3(b) of the Plan. No assignment or transfer of the Option, or the rights represented thereby, whether voluntary or involuntary,
by operation of law or otherwise (except to a designated beneficiary, upon death, by will or the laws of descent or distribution or pursuant
to Section 9.3(b) of the Plan) will vest in the assignee or transferee any interest or right herein whatsoever, but immediately upon
such assignment or transfer the Option will terminate and become of no further effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7. Change
in Control</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1 <B>Acceleration
of Vesting</B>. Notwithstanding any provision of the Plan or this Agreement to the contrary, in the event of a Change in Control prior
to the date that the Option is fully vested and exercisable, the Option shall become immediately vested and exercisable with respect
to 100% of the Shares in each remaining vesting tranche. To the extent practicable, such acceleration of vesting and exercisability shall
occur in a manner and at a time which allows the Participant the ability to participate in the Change in Control with respect to the
Shares of Common Stock received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2 <B>Cash
Out</B>. In the event of a Change in Control, the Committee may, in its discretion and upon at least ten (10) days&rsquo; advance
notice to the Participant, cancel the Option and pay to the Participant the value of the Option based upon the price per Share of
Common Stock received or to be received by other shareholders of the Company in the event. Notwithstanding the foregoing, if at the
time of a Change in Control the Exercise Price of the Option equals or exceeds the price paid for a Share of Common Stock in
connection with the Change in Control, the Committee may cancel the Option without the payment of consideration therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8. Adjustments</B>.
The Shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9. Tax
Liability and Withholding</B>. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance,
payroll tax, or other tax-related withholding (&ldquo;<B>Tax-Related Items</B>&rdquo;), the ultimate liability for all Tax-Related Items
is and remains the Participant&rsquo;s responsibility and the Company (a) makes no representation or undertakings regarding the treatment
of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent sale of any Shares acquired
on exercise; and (b) does not commit to structure the Option to reduce or eliminate the Participant&rsquo;s liability for Tax-Related
Items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Compliance with Law</B>. The exercise of the Option and the issuance and transfer of Shares of Common Stock shall be subject to compliance
by the Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable requirements
of any stock exchange on which the Company&rsquo;s Shares of Common Stock may be listed. No Shares of Common Stock shall be issued pursuant
to this Option unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied
with to the satisfaction of the Company and its counsel. The Participant understands that the Company is under no obligation to register
the Shares with the Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11. Notices</B>.
Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary of the Company
at the Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Participant under this Agreement shall
be in writing and addressed to the Participant at the Participant&rsquo;s address as shown in the records of the Company. Either party
may designate another address in writing (or by such other method approved by the Company) from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12. Governing
Law</B>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard to conflict
of law principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13. Interpretation</B>.
Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to the Committee for
review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14. Options
Subject to Plan</B>. This Agreement is subject to the Plan as approved by the Company&rsquo;s shareholders. The terms and provisions
of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any
term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and
prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15. Successors
and Assigns</B>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the
benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be
binding upon the Participant and the Participant&rsquo;s beneficiaries, executors, administrators and the person(s) to whom this Agreement
may be transferred by will or the laws of descent or distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16. Severability</B>.
The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability of
any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable
to the extent permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17. Discretionary
Nature of Plan</B>. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion.
The grant of the Option in this Agreement does not create any contractual right or other right to receive any Options or other Awards
in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the
Plan shall not constitute a change or impairment of the terms and conditions of the Participant&rsquo;s employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18. Amendment</B>.
The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively; provided, that,
no such amendment shall adversely affect the Participant&rsquo;s material rights under this Agreement without the Participant&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19. No
Impact on Other Benefits</B>. The value of the Participant&rsquo;s Option is not part of his or her normal or expected compensation for
purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20. Counterparts</B>.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one
and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable
document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document,
will have the same effect as physical delivery of the paper document bearing an original signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21. Acceptance</B>.
The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands the terms
and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this Agreement. The Participant
acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the underlying Shares and that
the Participant should consult a tax advisor prior to such exercise or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Follow***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***<I>Signature
Page to Non-Qualified Stock Option Agreement***</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE THERAPIES, INC.</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance Alstodt</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><P STYLE="margin: 0">President and CEO</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTICIPANT:</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Rosa</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>9
<FILENAME>ex19.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
19</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
THERAPIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INSIDER
TRADING POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effective
March 27, 2025 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.5pt; text-indent: -36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>I.
Introduction</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.5pt; text-indent: -36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of this Insider Trading Policy (the &ldquo;<U>Policy</U>&rdquo;) is to promote compliance with applicable securities laws by
BioRestorative Therapies, Inc. and its subsidiaries (the &ldquo;<U>Company</U>&rdquo;) and all directors, officers and employees thereof,
and consultants thereto, in order to preserve the reputation and integrity of the Company as well as that of all persons affiliated with
it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.5pt; text-align: justify; text-indent: -36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>II.
Applicability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.5pt; text-align: justify; text-indent: -36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Policy is applicable to all directors, officers and employees of, and consultants to, the Company in all jurisdictions in which the Company
operates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Questions
regarding this Policy should be directed to Lance Alstodt, the Company&rsquo;s Chief Executive Officer, at (631) 760-8100. Reporting
Insiders (as defined below) are also encouraged to seek independent legal advice for matters other than routine reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.5pt; text-align: justify; text-indent: -36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>III.
Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.5pt; text-align: justify; text-indent: -36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a director, officer or employee of the Company, or any consultant to the Company, has material nonpublic information relating to the
Company, that person will be considered an insider. It is the Company&rsquo;s policy that neither that person nor any Related Person
(as defined below) may buy or sell securities of the Company (&ldquo;<U>Company Securities</U>&rdquo;) or engage in any other action
to take advantage of, or pass on to others, that information. This Policy also applies to material nonpublic information relating to
any other company with publicly traded securities, including, but not limited to, the Company&rsquo;s customers or suppliers, obtained
in the course of employment by or association with the Company. Any questions with respect to whether certain information is considered
material nonpublic information should be referred to the Chief Executive Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
avoid even the appearance of impropriety, additional restrictions on trading Company Securities apply to Reporting Insiders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy in no way reduces the obligations imposed by law on an insider. Compliance with the insider trading and disclosure requirements
remains the personal responsibility of each insider.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.5pt; text-align: justify; text-indent: -36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IV.
Definitions/Explanations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.5pt; text-align: justify; text-indent: -36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<U>What is &ldquo;Material Nonpublic Information?&rdquo;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
is material if there is a substantial likelihood that a reasonable investor would consider it important in deciding whether to buy, hold
or sell a security. Any information that could reasonably be expected to affect the price of Company Securities is material. Common examples
of material information are the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Projections of future earnings or losses or other earnings guidance</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings that are inconsistent with the consensus expectations of the investment community</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A pending or proposed merger, tender offer, joint venture or acquisition or disposition of significant assets</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A change in management</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major events regarding the Company Securities, including, but not limited to, the declaration of a stock split or a reverse stock
    split, the offering of additional securities or change in dividend policy</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severe financial liquidity problems</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual or threatened material litigation, or the resolution of such litigation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New material contracts, orders, suppliers, customers or finance sources, or the loss thereof</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant changes in corporate objectives</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company restructuring</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank borrowing or other financing transactions out of the ordinary course</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in auditors or notification that the auditors&rsquo; reports may no longer be relied upon</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development of a significant new product, process or service.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
positive and negative information can be material. Because trading that receives scrutiny will be evaluated after the fact with the benefit
of hindsight, questions concerning the materiality of particular information should be resolved in favor of materiality, and trading
should be avoided. <B>If you are unsure whether information is material, you should consult the Chief Executive Officer before making
any decision to disclose such information or to trade in or recommend Company Securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonpublic
information is information that is not generally known or available to the public. One common misconception is that material information
loses its &ldquo;nonpublic&rdquo; status as soon as a press release is issued disclosing the information. In fact, information is considered
to be available to the public only when it has been released broadly to the marketplace (such as by a press release or by filings with
the Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;)) <I>and the investing public has had time to absorb the information
fully</I>. As a general rule, information is considered nonpublic until the second full trading day after the information is released.
For example, if the Company announces financial earnings <I>before</I> trading begins on Tuesday, the first time you can buy or sell
Company Securities is the opening of the market on Thursday (assuming that, at that time, you are not aware of other material nonpublic
information and there is no event-specific blackout in place). However, if the Company announces earnings <I>after</I> trading begins
on that Tuesday, the first time you can buy or sell Company Securities is the opening of the market on Friday. <B>As with questions of
materiality, if you are not sure whether information is considered public, you should either consult with the Chief Executive Officer
or assume that the information is &ldquo;non-public&rdquo; and treat it as confidential.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<U>Who is a &ldquo;Related Person?&rdquo;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Policy, a Related Person includes your spouse, minor children and anyone else living in your household or who does not
live in your household but whose transactions in Company Securities are directed by you or are subject to your influence or control;
partnerships in which you are a general partner; trusts of which you are a trustee; and estates of which you are an executor. Although
a person&rsquo;s parent or sibling may not be considered a Related Person (unless living in the same household or under the person&rsquo;s
influence or control), a parent or sibling may be a &ldquo;tippee&rdquo; for securities laws purposes. See <U>Section V</U> below for
a discussion on the prohibition on &ldquo;tipping.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
<U>Who is a &ldquo;Reporting Insider?&rdquo;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
directors and officers of the Company and certain designated employees of the Company (as listed on <U>Schedule I</U> attached to this
Policy) are considered Reporting Insiders, are governed by the terms and conditions of this Policy applicable to Reporting Insiders and
may be subject to the reporting obligations stipulated in the securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.5pt; text-align: justify; text-indent: -36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>V.
Guidelines</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.5pt; text-align: justify; text-indent: -36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.8pt; text-align: justify; text-indent: -34.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<U>Non-Disclosure of Material Nonpublic Information</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.8pt; text-align: justify; text-indent: -34.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintaining
the confidentiality of Company information is essential for competitive, security and other business reasons, as well as to comply with
securities laws. You should treat all information you learn about the Company or its business plans in connection with your employment
or association as confidential and proprietary to the Company. Inadvertent disclosure of confidential or inside information may expose
the Company and you to significant risk of investigation and litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timing and nature of the Company&rsquo;s disclosure of material information to outsiders is subject to legal rules, the breach of which
could result in substantial liability to you, the Company and its management. Accordingly, material nonpublic information must not be
disclosed to anyone, except to persons within the Company or third party agents of the Company (such as investment banking advisors or
outside legal counsel) whose positions require them to know it, until such information has been publicly released by the Company. The
responsibility for determining whether you are in possession of material nonpublic information rests with you and any action on the part
of the Company, the Chief Executive Officer of any other employee or director pursuant to this Policy (or otherwise) does not in any
way constitute legal advice or insulate you from liability under applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.8pt; text-align: justify; text-indent: -34.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<U>Prohibited Trading in Company Securities</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.8pt; text-align: justify; text-indent: -34.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
person may place a purchase or sell order or recommend that another person place a purchase or sell order in Company Securities (including,
but not limited to, initial elections, changes in elections or reallocations of funds relating to 401(k) plan accounts) when he or she
has knowledge of material information concerning the Company that has not been disclosed to the public. This rule does not apply to the
purchase of stock under, or upon exercise of securities issued under, the Company&rsquo;s 2021 Stock Incentive Plan, as amended, or any
other stock option, equity participation plan or similar plan hereafter adopted by the Company (collectively, the &ldquo;<U>Plans</U>&rdquo;).
However, stock that is acquired through or under the Plans is subject to this Policy and may not be sold by a director, officer, employee
or consultant who is in possession of material nonpublic information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
&ldquo;<U>Tipping&rdquo; Information to Others</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insiders
may be liable for communicating or tipping material nonpublic information to any third party (&ldquo;<U>tippee</U>&rdquo;), not limited
to just Related Persons. Further, insider trading violations are not limited to trading or tipping by insiders. Persons other than insiders
also can be liable for insider trading, including, but not limited to, tippees who trade on material information which has been misappropriated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tippees
inherit an insider&rsquo;s duties and generally are liable for trading on material nonpublic information illegally tipped to them by
an insider. Similarly, just as insiders are liable for the insider trading of their tippees, so are tippees who pass the information
along to others who trade. In other words, a tippee&rsquo;s liability for insider trading is generally no different from that of the
insider from whom he or she obtained the information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
<U>Avoid Speculation</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors,
officers, employees and consultants, and their Related Persons, may not trade in options, warrants, puts and calls or similar instruments
on Company Securities or sell Company Securities &ldquo;short.&rdquo; In addition, directors, officers, employees and consultants, and
their Related Persons, may not hold Company Securities in margin accounts. Investing in Company Securities provides an opportunity to
share in the future growth of the Company. Investment in the Company and sharing in the growth of the Company, however, does not mean
short-range speculation based on fluctuations in the market. Such activities may put the personal gain of the director, officer, employee
or consultant in conflict with the best interests of the Company and its securityholders. Anyone may, of course, exercise options granted
to him or her by the Company and, subject to the restrictions discussed in this Policy and any other applicable Company policies, sell
shares acquired through the exercise of options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
circumstances related to the trading activities described above that do not involve short-range speculation may be reviewed and approved
by the Company&rsquo;s Board of Directors or a committee thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.8pt; text-align: justify; text-indent: -34.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.
<U>Trading in Other Securities</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.8pt; text-align: justify; text-indent: -34.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
director, officer, employee or consultant may place purchase or sell orders or recommend that another person place a purchase or sell
order in the securities of another corporation if the person learns of material nonpublic information about the other corporation in
the course of his or her employment or association with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VI.
Trading Restrictions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<U>Event-Specific Blackouts</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may on occasion disclose material information by means of a press release, SEC filing on Form 8-K or other means designed to
achieve widespread dissemination of the information. All Reporting Insiders and those employees and consultants with knowledge of the
material nonpublic information should anticipate that trading will be blacked out while the Company is in the process of assembling the
information to be released and until the information has been released and fully absorbed by the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, an event may occur that is material to the Company and is known by only a few directors, officers or employees of the Company.
So long as the event remains material and nonpublic, the persons who are aware of the event may not trade in Company Securities. The
existence of an event-specific blackout will not be announced, other than to those who are aware of the event giving rise to the blackout.
If, however, a person whose trades are subject to the pre-clearance procedures outlined below requests permission to trade in Company
Securities during an event-specific blackout, the Chief Executive Officer will inform the requesting person of the existence of a blackout
period, without disclosing the reason for the blackout. Any person made aware of the existence of an event-specific blackout should not
disclose the existence of the blackout to any other person. The failure of the Chief Executive Officer to designate a person as being
subject to an event-specific blackout will not relieve that person of the obligation not to trade while aware of material nonpublic information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<U>Quarterly Blackouts</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s announcement of its quarterly financial results almost always has the potential to have a material effect on the market
for Company Securities. Therefore, to avoid even the appearance of trading on the basis of material nonpublic information, Reporting
Insiders may not trade in Company Securities during the period beginning on the day following the end of a fiscal quarter and ending
after the second full business day following the release of the Company&rsquo;s earnings for that quarter (or, in the case of the last
quarter of a fiscal year, for that year).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
<U>Pension Plan Blackouts</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting
Insiders may also be subject to event-specific blackouts which prohibit certain sales and other transfers by insiders during certain
pension plan blackout periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
<U>Hardship Exceptions</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Reporting Insider who is subject to a quarterly earnings blackout period and who has an unexpected and urgent need to sell Company Securities
in order to generate cash may, in appropriate circumstances, be permitted to sell Company Securities even during the quarterly blackout
period. Hardship exceptions may be granted only by the Chief Executive Officer and must be requested at least two days in advance of
the proposed trade. A hardship exception may be granted only if the Chief Executive Officer concludes that the Company&rsquo;s earnings
information for the applicable quarter does not constitute material nonpublic information and there exists no event-specific blackout
at that time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.
<U>Pre-Clearance Requirements for Reporting Insiders</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Reporting Insiders must obtain prior clearance from the Company&rsquo;s Chief Executive Officer, or his or her designee, before he, she
or a Related Person makes any purchases or sales of Company Securities. Prior clearance is required for all purchases or sales of Company
Securities (if an available investment option) in any Company 401(k) plan. Each proposed transaction will be evaluated to determine whether
it raises insider trading concerns or other concerns under federal or state securities laws and regulations. Any advice will relate solely
to the restraints imposed by law and will not constitute advice regarding the investment aspects of any transaction. Clearance of a transaction
is valid only for a 48-hour period. If the transaction order is not placed within that 48-hour period, clearance of the transaction must
be re-requested. If clearance is denied, the fact of such denial must be kept confidential by the person requesting such clearance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.
<U>Pre-Arranged Trading Plan under SEC Rule 10b5-1</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Reporting Insider who wishes to establish or modify a pre-arranged trading plan under SEC Rule 10b5-1 must first obtain approval of the
plan or modification from the Chief Executive Officer. The following requirements, restrictions and limitations, among others, are applicable
to all pre-arranged trading plans entered into or modified by a Reporting Insider subsequent to the effective date of this Policy:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Reporting Insider may enter into a pre-arranged trading plan only when he or she is not in possession of material nonpublic information.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Reporting Insider may not enter into a pre-arranged trading plan during a blackout period.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The first trade pursuant to an approved pre-arranged trading plan may not be executed until the later of (i) 90 days after the adoption
    or modification of the plan and (ii) two business days following the filing of the Form 10-Q or Form 10-K for the fiscal quarter
    in which the plan was adopted or modified (but not to exceed 120 days after the plan was adopted or modified).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
transaction effected pursuant to an approved pre-arranged trading plan will not require pre-clearance at the time of the transaction;
however, Reporting Insiders must immediately notify the Chief Executive Officer and the Company&rsquo;s outside counsel when any such
transaction has been completed for Section 16 reporting purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VII.
Reporting of Insider Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
officers and directors must promptly report their ownership and trading in securities of the Company to the SEC. This Policy requires
officers and directors to notify the Company of their ownership and trades in Company Securities and provides for the Company or its
counsel to file reports with the SEC on their behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.5pt; text-align: justify; text-indent: -34.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<U>Initial Form 3</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.5pt; text-align: justify; text-indent: -34.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
person who becomes an officer or director of the Company must file with the SEC an Initial Statement of Beneficial Ownership of Securities
on Form 3 within ten (10) days of becoming such. The report must disclose the beneficial ownership of Company Securities by the officer
or director. The Form 3 must be filed whether or not the officer or director beneficially owns any Company Securities.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.5pt; text-align: justify; text-indent: -34.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<U>Subsequent Forms 4 and 5</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.5pt; text-align: justify; text-indent: -34.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
comply with applicable federal securities laws, subsequent Statements of Changes in Beneficial Ownership of Securities on Form 4 must
be filed with the SEC within two (2) business days after the date of any change in the beneficial ownership of Company Securities by
an officer or director, including the grant and exercise of options and gifts. In addition, an Annual Statement of Beneficial Ownership
of Securities on Form 5 must be filed with the SEC within 45 days after the end of the fiscal year to disclose certain transactions that
were not required to be reported on a Form 4 and certain transactions after a person ceases to be an officer or director of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ownership
is deemed to pass on the date of trade (i.e., the date the offer to buy or sell is accepted) and not on the settlement date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
should be noted that the sale and purchase or purchase and sale of Company Securities by an officer or director within a six (6) month
period of time could result in liability on the part of the officer or director to the Company for short-swing profits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.55pt; text-align: justify; text-indent: -34.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
<U>Reporting Procedures</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.55pt; text-align: justify; text-indent: -34.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s counsel will assist each officer and director in preparing and filing his/her Forms 3, 4 and 5 with the SEC. The Company&rsquo;s
counsel will have the authority to execute the Forms 3, 4 and 5 provided the officer or director has signed a Power of Attorney authorizing
such counsel to sign and file such forms on his/her behalf. The reporting procedure will be as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All trades,
    including the grant and exercise of options, must be reported immediately to the Chief Executive Officer and the Company&rsquo;s
    counsel in order to meet the two (2) business day filing requirement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s counsel
    will complete and file the Form 3, 4 or 5 on behalf of the officer or director with the SEC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s counsel
    will notify the officer or director that the Form 3, 4 or 5 has been filed on his/her behalf.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
should be noted that the timely filing of the Forms 3, 4 and 5 is the personal responsibility of the officer or director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VIII.
Other Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<U>Company Assistance</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
compliance with this Policy is of the utmost importance both for you and for the Company. If you have any questions about this Policy
or its application to any proposed transaction, you may obtain additional guidance from the Chief Executive Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 65.2pt; text-align: justify; text-indent: -28.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<U>Certification</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 65.2pt; text-align: justify; text-indent: -28.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Reporting Insiders as well as other employees or consultants determined from time to time by the Chief Executive Officer to be subject
to the procedures set forth in this Policy must certify their understanding of, and intent to comply with, this Policy on the Company&rsquo;s
form of Insider Trading Policy Certification which is attached to this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 65.2pt; text-align: justify; text-indent: -28.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
<U>Insider Liability</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 65.2pt; text-align: justify; text-indent: -28.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person who fails to comply with insider trading laws is exposed to significant financial and legal liability including fines and imprisonment,
in addition to general embarrassment and damage to his or her reputation. Further, the reputation of the Company may be damaged, and
it may be exposed to liability. A breach of the Company&rsquo;s Insider Trading Policy is considered a breach of any employment contract
with the Company and, as such, violators may be immediately dismissed for cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
THERAPIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INSIDER
TRADING POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Chief Executive Officer:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
_________________________ (name), have received and read a copy of the Insider Trading Policy of BioRestorative Therapies, Inc. (the
&ldquo;<U>Company</U>&rdquo;), effective March 27, 2025 (the &ldquo;<U>Policy</U>&rdquo;). I hereby agree to comply with the specific
requirements of the Policy in all respects during my employment or other association with the Company. I understand that my failure to
comply in all respects with the Policy is a basis for termination for cause of my employment or other association.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 55%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name - Please Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Date)</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULE
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>REPORTING
INSIDERS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Designated
Employees</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>10
<FILENAME>ex-23.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statement of BioRestorative Therapies, Inc. on Form S-1 (File No. 333-278488),
Form S-3 (File Nos. 333-269631, 333-265052 and 333-258611) and S-8 (File Nos. 333-255681, 333-196299, 333-203310, 333-210555, 333-214621,
333-228434, 333-233309, 333-270909, 333-275571 and 333-283197) of our report dated March 27, 2025, which includes an explanatory paragraph
as to the Company&rsquo;s ability to continue as a going concern, with respect to our audits of the consolidated financial statements
of BioRestorative Therapies, Inc. as of December 31, 2024 and 2023 and for the years ended December 31, 2024 and 2023, which report is
included in this Annual Report on Form 10-K of BioRestorative Therapies, Inc. for the year ended December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
<FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marlton,
New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
27, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>11
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
302 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Lance Alstodt, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of BioRestorative Therapies, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Lance Alstodt</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 27, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>12
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 CERTIFICATION OF PRINCIPAL FINANCIAL
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Robert Kristal, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this Annual Report on Form 10-K of BioRestorative Therapies, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom; width: 49%; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; width: 2%; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; width: 49%; text-align: justify"><FONT STYLE="font-size: 10pt"><I>/s/
    Robert Kristal</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date: March 27, 2025</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Robert Kristal</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Principal Financial Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>13
<FILENAME>ex32.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AND
PRINCIPAL FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to 18 U.S.C. &sect; 1350, the undersigned officers of BioRestorative Therapies, Inc. (the &ldquo;Company&rdquo;) hereby certify that
the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2024 (the &ldquo;Report&rdquo;) fully complies with the
requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the
Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Lance Alstodt</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 27, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Robert Kristal</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Kristal</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing certification is being furnished solely pursuant to 18 U.S.C. &sect; 1350 and is not being filed as part of the Report or as
a separate disclosure document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'Y X0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HKCK/XA^ -1\;ZU\,]/\ ''A"^^)'AO1-*\2^
M(OA_9^)=%NO&^@^&]=N+FUT3Q#K7A2"^?7M*T/6+JSO+;2M6OK""PU">UN8;
M2>:2"55[&KJ4JM)Q56E5I.=.G6@JM.I2<Z-:+G1K056G3<Z-:"<Z56"G2JP3
ME2JU(IR4QE&:;A*,U&4H2<)1DE.#M.#<922G!Z3@VI1>DHQ>@4445!04444
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MB#QU\+OA-X;^''@7Q1?V=[\.%UK2]#\0^)_&UWI^B7OB#4&MK"..QTUM0O\
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M/2;WQMX*\0V)NK*_DTKQ!IUMJFG7PU+1M9U2SO #]\*^/OV"/VK7_;=_9/\
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M43H3CB:52JJ483J3<FE#&T^:"^KP=1P_;'QO^UI^RO\ #/X@6/PG^(_[2WP
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M$>F:O+!?,0EE,EF8[MR$MVD8@'\^_%VBZ9X5_P""RG[-&@>#= TC1])\.?\
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MC?$#XIZI!K&M7VNW+^+_ (F>([OQ5XKN8;N_DDF@L;G6+VXFM-/0_9[&)A!
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M_=A)/NI*7Y.+ZO1KS"BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%%
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MUM\=?^&H(/V;_@9#^T@7NI1\>(_A7X(3XN+=WWAC_A![[45^(*Z(/%":M?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH X#XC>!X?'/A^2RC>*UUJR9KS0=1D# 6U\J\P3NBO)_9]^JBWOD5)-J^5
M=I#)=6=L5^2O"'C"[TK4I])U2*6QU+3KF:RO[.X*B6UN[=S%/$_+(2K [9$+
MQ31E)89'B=';[TKY1_:,^&]S/;/\3_"\!.KZ);+_ ,)386T9\W6-#M5.-3B2
M-29M3T.')E! EO-%1X1)++IFFV<H![EX:U^&^@A=9 0RYZYQP"0<Y('7('?^
M+N?G7]HC]LWP7^SC\:?V3/@QXF\#?%7Q1??M9>//&W@+P_XB^'GPK^*?Q(TC
MP5>^#O!5YXL%_P"+G^''@3QA!I=EJ=S'96$D^LWFAVVAZ"?$GQ%UBYM_ ?@#
MQQK>A<U\+/B LR6P:8,CA!G<#D$ Y#9[Y!&.H[GJ=;XY_ ?Q7\:OB)^R;\7/
MAY\2?#?@#Q?^S'\8M=\?/:^,_AYJGQ)\->/? ?CWX6>-/A)\0_!HL=$^(GPR
MU3PKXLNO#WC)M3\%^/?[9\1Z/X:UG3%_MSX>^,;"]:UMEK>/;F7-=VNN6IU2
M;7O>SNTFTKNSM:0]I6WY7R_XKQMZZ<^CLF[)M7NHOA'_ ,%$/V2/CE\2="^%
MOPW^('BC4==\:KXU;X6>)O$'P5^./@+X0?'5/AX\S>+W_9T^/7C_ .&_ACX(
M?M%)INEVM_XJM&^"/Q!\>KK_ ("TG6_B)X<.K^!-$U;Q'9<KX[_:Z^.>L?$C
MXS^!/V2_V6=(_:-T_P#9FUO3/"'QSU[Q3^T!H'P+FOOB3JGP\\'?%M?@W\ M
M,U'P%X^L/B5\4=,^'?Q!\!ZSKEQ\4_$'[/?P8T_5/''A[PO'\:+O7M+^(]I\
M/?*?V?/^">WQC^%.K?L=>"OB#^TUX2^(G[-7_!/5+Y?V4? 7ASX"7'P_^,.H
M2:7\"O'W[+7PLN/VB_C#=?%[QKX4^(S_  Y_9Z^*7CGPUJ4?PP^#/P/A^(/Q
M"N]%^)&H+X?TW1Y?A]J?HOB[]D_]IWP=\4/V@/'?[('[4'PI^"V@_M/^(=%^
M(?Q+\)?&7]E[4OCZW@_XQ:7\-/!_P@O_ (H?!O5_"G[07P!CT*3Q/X#^''P^
M7Q%X*^(VD_%#PU/XY\/2>.[#^SQKOB_PSXJ;M9;M\K?2W.G'ENI*W*USW2EI
M)0O+E;NNKTLKQMNVU[_/ML[^SY79WBYV2DHFYXA_X*5?LL>!9M%T_P")-_\
M%SX>:Z?AW\-OB=\4-,UG]GCXY^(-*_9C\._%+3GU308_VN/B1\._ 'C;X/\
M[,.H:39PWE_XQC^,OQ%\)6?A'P[87WCG7+ZT^'UL_BRN5_9\_;WU/XW_ +0N
MC? V[^%EAX9@U:Y_X*9P+XDM_&-QK,T,?_!/C]L?X)?LJZ9(=+E\,:7&S_%:
MS^+TGCF]B&H >"KK0H_#L$OBB+4&UNT^5/C/_P $9Y_B7\4?B/XPL?CKX2\1
MZ)^T'X0^%7AW]H?7/V@O@7)\6_C-XB\1> /A)X5^ 7BWXB>!M:\%?%7X+_L]
MZ3KWQ8^$'@;PKI_B+PG\1/V8OBC\*](^(-OJOC.V\!ZIX-UK4/A+/]9?L_\
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MJWQ#MO@5K \8:)!X-^->I>%[+X7_ !#OGOM-^'_BKQ/J.EZC:VT7PG_X)H?
MWX8W_P"TW\09/!?P5UO]HG]HGXC?M.>+T_:5B^ W@S2?C+X5\*?M#ZOK5]9_
M#V]\?BXU#QWXHT;P/IFK0:"7?Q?HMAK^G:=;P0Z+X?LQ#8VW%>'/V"/V@?@?
M+\$/$_[+G[3/PK\&?$/P5^Q7\!?V)OC#>_&G]FSQ)\7_  )\3/"G[-H\2WWP
MC^(_@WPGX/\ VBO@MXD^&?C#PUXA^)7Q?O=1T>\^('COPWXLT/QOIV@ZI;VN
MH>$-*\42UIRO^;DC:R;O/D;DGK%64XJ#>EE4O&ZA=SK=6VO).[M9*:2:2C)Z
MP;DD[WE'7E<VEU'[0O\ P59_91^#'@#XA^)O!_BK6?C=XA\'_LW6W[2U@/A'
M\,_C7\4OA-:>!?&'@CQ-XU^#^N_%G]H#X0_"[XC_  D^!'@[XJZ=X:N-6T+Q
M?\4O$WAZQC\$M+\0C!-X/@;5F]K\,_MQ? 6^^#_B7XM>+?%#>%[3X9^*O@C\
M+_C+86_AGQYK_P#PKWXP?'GP9\!?&G@CP#$^G^$/[0\6QW^G_M*_!\CQ3X8T
MO4?#5E'XJW:YJ.CSZ#XKMM!^ K;_ ()(_%3X2?![XO\ [-7[*G[5_A3X>? +
M]HO]F[X?? ?XR6/QJ_9WN_C7\4K?Q/X$_9NT/]D^]^,_PN\;^$_C=\$?"_AK
MQ+XZ^#/@OX?6FO>$/%WP[\>^!]&\;^$H_&'AK2;#3-9UWP7J75>,?^"8GQOO
MM$^(7PS^'O[4GPP\(?!GXT_&+]DGX^_%K2_$G[,_B;QK\4)OB'^ROX3_ &2_
M [Z7\._'MK^TKX1\)>%? ?Q-\/\ ['_P^-[IOB3X6^.O$O@[4-=\=SZ=XIUM
M-;\-+X$<5%M<TFKSIINVD8<W[VUKZ*%^66LIR5.\(+G%*_V5>T:EMES.R=.Z
M?PN3T<4W&-Y>_+1OZI\1_P#!2']E;P[XE\3^#UUSXHZOKN@ZI\7?"6C:AHW[
M.'[2.J?#SXE?%#X&>'?'?B3XG?!?X/\ Q>TOX1W_ ,+/C!\9_#$'PP^(FE7'
MPH^%WBWQA\0=0\4^ O'G@S0_#>K>,/ OC#0=$\.^"'_!5SX1_%GPAX/^,?B2
M&7X5_"?Q7^Q[\"OVE)O"GB_X>_M(P?M!Z;XJ^.?Q-U#X6^%/!'A[X<W/P%T_
M2_BWHOC'QHND^ ?@OJ/PB\0^,?&_QW\<ZAIP^%_P]\0^$_%G@/Q+XG] ^$?[
M&OQ_^$%[9?"OPY^T]X.T[]CO2?B-\=_'MM\*=%_9]\OXY>(M"^.FN?%/QA)\
M(?&GQ[\5?%GQEX5G\ ^ /&_Q3N]=T#7O!GP*\$_%'7M+\'?#SPWXA\<R'3?B
M-K?Q;^7/ G_!(OXDZ!X!^#>C^*OVHO NO?$C]G/]G+]C3X'?!GQQH/[.?B#P
MYX7M/$7["/QVU'XO_!7X@>/_ (>ZA^T7XGO?%VF^*M!DTWX?_&/P/HWCWP9+
MXAM9_%/B+X?>,OAAK.J>&&\$S&W*G+=QBVM+IVESJ,?ANI-6O-J2BI7BW*+<
MK\S4=DY);ZJ\>6[Z72?-[JY7)QM*RD?8<G_!3W]CR'0;?5I?$_QACUZ?XO6_
MP$_X5*W[*/[5P_:$M/B[??"+Q)\>M)\&ZI^SE_PI3_A>FCOK_P 'O"'B7X@^
M&?$6J_#ZS\(>)_#>D7.H>'_$.I1&(R6/BY_P4%^%O@[]ASXJ?MR_"/PYXN^.
MGA/X9VGBJV'PWT_PYXN^&GQ.UCQSX(^(DWPJ\6?"S4O WQ&\)Z-X]\#_ !*T
M#Q]9:IX4U7P5XQ\%Z7XFL/$.G2:1=Z1!<2QFO*/!O_!/;XFWO[2?@/\ :_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<VH:C?W9\ZYO+V[E:XNKNXE/WYIYI'ED; RS'  P!]V>%M AT^WA18P  O\
M".<+DDYXP#@X)/IS@U\X>X;^C:8EG @"@84#D=N.!R>V1CH,YZUT%-50@PHP
M,D_B:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN;>[U33O%WBWQOI&HQ:5IOXJV/DP1I%&B1QQHB11Q(J1HB<HJ*NU$50"H48
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M\,*PH%48X&>G4>^!U[_2JUA:);1!0!G@<8ZKU/3U'TR">A%7Z_EP_?@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#-UK6-
M+\/:/JNOZY?VNE:+H>G7NL:QJE],EO9:;I6FVTE[J-_>3R%4@M;.SAFN+B9R
M%CBC=VX4U_#)^U)^T!K'[37QY^(/QCU1[F*P\1ZLUGX,TJ^W))X>^'^CE['P
M;HA@,DD=K<II2KJ>MQ6[_9YO$^J:]?H%:]?/](?_  6/^/K_  G_ &6F^'&C
M7_V;Q3^T!K1\"B.&8Q7L?@#3(H]7^(UY&N"D]C?6)TCP+JL+ EK/QTQ4*RB2
M/^2T2#ON7MR-V1UXX;&/;'L>./[P^B;P3#"9/G''V,H)XG-J]3(LEG.%Y4LL
MP%2G/-,32<K6^OYFZ.#YXVYL/EE2'-*+DC^2?I#<42Q.9Y;PCAJE\/EU*&:Y
MG&+;53,,7"<,#1J*+2?U3 ^TQ'+*[C6QU.5DU%FGOY. 1T/R\C/;IWQCGID'
MGI4HD./E8$\D]!CZ=#_/..*RUD;L1DYY4X.#R>F1UQSQGV-2>;_>P2,YR#CM
MS\O3CU'J?K_8:E??[O/T]U6WZ_(_FVR=O+9/5?=ITO\ :9],_LU_'G4/@7X[
MAU.9KF?P9KKVMEXRTV$-*ZVT;N+3Q!86XYDU30C+-,D2!FU#39M0TL!9[FTN
M[3^F_P"#GQ,M=0M-,O['4(+ZPU"UM+VQO;6XCN+2^LKR%+FTO+6>,E)[6ZMY
M([BWE1BDL,B2(2K G^/M9>!@E0,Y&0PP<<@=QW[\].<9^Y?V;?VYM&_9O\$^
M+K+XI2:WJ'@OPAHFK>*O"KZ)92ZEK8N[8-=7/@>S@&(HX->O)3/HFHW\MIHV
M@7\VH2:W?VNC7"7.E_RA](WP:Q'%=*EQKPCE\L3Q-A5A\'G.5X.$7B,^P'/2
MPV$QE"FI053-<KE6I4:J<U+%Y1)N4W5RB,G_ $-X)>)-/(J[X3S_ !4:62XN
M=6ME.-KSDJ>5XZ7-5K82I)\WLL!F/+*=*UX8;,K6BJ>92BOZ3OVN?V^_@E^P
MY\$;CXN?%O4Y+Z^U%KG2?AQ\.M%FMSXR^)WBR"U2X_L'PY:SNJ6]C81SVUUX
MH\47VW1/"VG3V]SJ$LE_?Z-I>J_P+_MJ_MW?'?\ ;O\ BFWQ,^-OB!(M,TA]
M0M?AM\+M#N;I/A_\*]!OFC,^G>&M.G*F_P!=U-+>T;Q;XXU6)O$?BNXM;6.X
M?3_#FD^&O#'A[A/C]^T+^T'^W_\ M&0^(M3T?Q1\0?B5XVNO^$5^$_P?\!Z?
MK/BR7PMX9MWNK_3/ 'P\\.:?;3:C=6NFVRW>K^(M7BT^&YUO46UOQKXD-NUQ
M=RVW[Z_L/_\ !M3XW\60Z-X__;Y\=W/@#2W\J]C_ &>?A+K.E:EXQF17C<67
MQ'^+%H-6\-Z&',4]KJ/A_P"&4?B2XGL;FWN],^*.AZBDUG#OP9P]X<?1MR.A
MG_&^98#%^(69824Y^QA',<=@*=6#C5RCAG TW*MR1;^K9EGTE@Z>.K1JT:>.
MP^61AA,9^@9WC^(_$;'5,OR3#UZ/#^'K))S;PU&O*$KPQ>95Y6C>27M<-@$Z
MTJ$7"<J-3%.56C_,KX>AUSQ;XATGP?X+\/>(/&?C'79C;:%X1\'Z'JGBGQ9K
MERJ[C;:+X;T*VU#6=5N-H+^186-Q*!DA" *_6OX$_P#!#W_@I=\=(;/4IO@[
MH7P*\.W]LES::[^T'XPM_!EQ+$VXO')X&\+6/CKXGZ1>J%4"S\3^!]!9I'C6
M2:-/,FA_NA_9V_9*_9K_ &3/"X\'_LY_!?P)\)](D@@@U.Y\-:.C>)O$OV4M
M]GNO&?C?4WO_ !IXXU&$.435?%^OZWJ8C6.+[7Y<4:+]$U^:\7?2ZXBQU6K1
MX0R'!93AN:2IXW.Y/,L=.-VE-8'"U,)EV';234*N(QLH_#*3:;/>RKP>RRE&
M,\XS"OBZFCE0P2CA:"?6+KU(U<1473FC3HII)I(_DB^''_!L3XC>&TN_B[^V
M596TK@?;_#OPQ^#DLZ0'Y686?C7Q;X^C^TJQ+JIG^'UL4VI)ABQC3ZUT3_@V
MJ_8[LH8CK7QY_:SU>[7F<VGB?X+Z/ITQ(.1'9K\#]0OH5S@X.KRMP 'P#N_H
MHHK\7Q_CIXLYA4=2IQIF6&U;5/+L/EF I)._N\E'+*K:2=DY5)2T3<VU<^PH
M>'G!F'CRK(<+6>EYXJIBL3-M6UYJF*A9Z7TBE?9+8_G\E_X-P_V)RJBV^+W[
M6MDP;)DM_'GP@D8\8^9;WX%7<> >?E16)XW;?EKRSQ=_P;=_#.1&_P"%9_M8
M_%3PW+_RR;XA^ ?!7Q$C4 \++'X6N_A*\N  "8YH,G)& 2M?TK45S8?QI\5<
M-4C4AQQG51QVABG@,72>MWS4J^5.,D^J<K6T5EH.OX><$XF+A4X<R])_:I+$
MT9]M)TL:FODOQ/XVOB;_ ,$$?VU_A_%>:A\,_&OP:^-VFV:@V^G6^LZS\,_&
MVI-EF M]#\565]X)@'RC=]M^)MMB2157S(PTD?YH?%CX+?M _LWWZZ=\?_@U
M\1/A2TEX--M=7\4Z!.?!^IWYVG[%H7C[2Y-2\"^(;D#;NBT#Q+J9571B,2(7
M_P!%2L_5M)TK7M,O]%US3=/UG1]4M9K'4])U6SMM1TS4;*Y0QW%G?V%Y%-:7
MEK/&S1S6]Q#)%*C,CHRDBOTOASZ4W'>65*<,^P65<0X5.*J2ITI9-C^563E&
MKA7B,!.I:[_>X"G"3T?*CX7._ OAC'PJ2RK%8[**[3Y(RG',<'S.]E*G75'%
M1CJE^[Q4I127*F]_\YC3-9MKA%V2*3P0>N,CV+' QD'D9)X[#L[699!D,#D
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MR21_:XZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT[3K/^9?&[QRP_ M&?#_  _*AC.*\31NU/EJX;),/6B_9XS'4U*U7%58/VF
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MO!7PK\+ZI/9$7=EH_B?XE^)?">@:QJ5L'GTO3-1N]1BBF>U6)Y&?,'_!3_\
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M^.K328O$_B[1=*TG0]%TO3=+U_5+^QL=.TG3;*U@BMK*VBCT?A'\%_@]\ /
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M1\1>%-%UKQ1^S-\&_C-X_P#$'A+PUXB\::)'X&\0>'O GAOQC9>)Y_A_K_\
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M 7'B#XI?$K7/B5X>\!^#)=>^('[4?QA\?_&#X>^#OV9?'=AX^^%/ASX/^/\
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MKFK^*IOCW\3?C_X9\#?$/XF_$WQ%JFO:OXWG\ >%_#FM1S^#QKOA[7-_5?\
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M-X(^.WA3XP_%O]I&U\%>/[?2_P!ESPA^S+X%^(&I?$+X:?";P=\/M;U+5O\
MA9WQ?\!?%.U_JCQQC_/^?Z\T8[\_F?Y9Q3DVU)12@I>UO;7E=1R<7!-OE=%R
M7(Y.;DE:3:21,5RN+;<W'V>LK7ER**ESV2O[3E]Y1Y$FVXQ5[K^2#X5?%37K
M7QE\9_%?CKX_ZGK_ ,>?C/\ M'_\&_\ \5+?X&_$C_A3>N:=XI^%WQ;\??\
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M-YX5^VW^P1^U1_P4Z_;/G\&_&S3->^ G[!7P+^&_C:W^$'B;3O%7PX\2:_\
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M1:6&B:I9^'/"%I>>))!I'[?V/[:/[/\ XFT;]IR^^&?BRZ^,?B+]D.S\7?\
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M?H4=GJOBK0;W3=1LO#WB*\\(G5]-\._%N*^\/>'_  IXJTBVT+Q3/KGA\?T
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M&<WA?XE>(_$G@YU\*:])IE_JMUJVBZC'!X9'B 0P_P!H-97-M<CM5&/ER1R
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M (-_$/PROB+X57.L:O\ J'112_X';LD]DET_S;=VZ_X/]?U]R"BBB@ HHHH
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M*W\H>(>2O*>,,;*,.7#9I.&:X>2ORMXF5\5%=+TL;3K\R3=E7BVES(_TG_\
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MOVS-<\%WEY^T7\-_ 4_PR\&^.D\8^-K2RTKP3<CQN)](E\%67B*W\":I(_\
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M)\*>)-9T+Q[XUTCQEH\B7OB"^TF3Q;X.N_V.^#G_  3/_8?^ FG?&W0_A=\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.I/FC"C3<JU6<*4)SC]R:Y\9OF<1W'!R55#DG&<D =2>N >Y'I7R?\3?VO\
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M,L=4HXBO0]GC*5"DL/A(*AC\/+#8RG%SHUY)1Q$Z:FI25*]V_P"1;QS^P_\
M'3P:9IM,TG2_'&GQ;F\_PSJ"0ZFL(!^:;1=;73+J29B#_HVD3ZTX!7#/\VWY
M:UC1M:\.7[Z3XBT75_#VJQ ^9IFNZ;>:1J"!3M+&SU&&VN"F1@.(RC<%6((S
M_9GKWP<BD#LD"L2"1A<9!R3VZC\^3U&*\"\<?L_:1X@L9=,U_P /:5KVF2%C
M+INMZ79ZM8.3QO-G?P7%N7QP&$88<888Y\KAGZ6_%&"]E0XMX>RO/Z,;1J8[
M*JD\BS-QT3F\/-9AD]:I:[LJ>!C*7\B;Y?#S[Z.60XOGJ\/9WF&457=PPN8Q
M6<8%-ZJ*K)X/,J4;V2O/%.*M\5M?Y-)0?*E)VX6-VP#GHIZGT]" >>I&*_NP
M_9IM#8?LX_ "Q.<V7P3^%5H<]<V_@3083GD\_)SR?J>M?A'\2_\ @G1\*]>2
M[ET*PUKP'?3++B?PU?R3Z;YK*RJTNB:VNIV<< !'^C:3)HR'8-CQL6+?K/\
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M<:E?2VFEV=Y>V_Y8^-/^"H2-?3V_P_\ A+')I<<K"WU+QKK[K?7L/&V270M
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MGM'/7!%Q"/\ @:!)?4Y-NHP.N<@*^CQ9.U0/0]",$\$9[<YZ<XSCI0FE*F,
M$=1A3D]2,GD#D\\\\X)H Z"*XAG :*1'!&< \@'U4X8?B!4U4K. 1!B!SPO7
M/^T?Y@'/)VY// NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&[K@,/4U:FNHY$+HZNK $,K!P?E/(93AO48.,X8'G:<2XF!ZGI@=<\],<8!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+)%D\:?M-?M#:VH!,B>$]-^%?A%W94).R36_!OCU(@3G:7CN-H(!#8K4O?\
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M)^W1^W]^WK_P64_9&_X)$?\ "?\ @W]EJP\(?M0_\%"/$'P/UCX/Z-J'Q_\
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MYH27,GS=4Y\T5K9ITYJ>SC&-7VLHZVY>><X-MVE%I-.+/Y+_ -J3_@CUX/\
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M%'X[\*VMOXJUG0?#_AC1/!MW<>%Y_P!*_B!_P53_ &&O!_PK_:1^*'AGX]>
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M:^'?PGTT>,M.3Q%X\^(_AGQ/X2\&>*?AOX?\+2NGB6Z^(WA/Q+XZ\*Z9XM\
MMI,?B_PLVJ?:=?T;3K*QU*YL[DY3E*33<IRE)VB]93G*3LDNLINR7DE>Q,5&
M,8Q3TC%15VGI"*6KTU48IRVMJW9;?8U%?(7A;]O[]B7QK>?$BR\,_M3_  -U
M,_"/PCXQ^(/Q"OO^%A^';/1- ^'OPYU9?#_Q(^(*^(=0O;30=8\!?#;Q&\7A
MGXB^-=!U+5/#'@/Q//;>'/%FJZ/K=S!821+_ ,% ?V+W^&(^,"?M&_#5_ I^
M(=Q\(A<)JTS^)3\6[30QXKNOA4/A^MJ?B ?B9:^#&7QY<^ ?^$8_X2V#X?$>
M/Y=(3P;_ ,3RHYEW73JOM7Y>OVK.W>SM<NS[/KT?3?ITZ]MG9Z'V%17Q7XJ_
MX*/?L%>"AX-/B;]KS]G_ $Y/B'X TGXL^!I5^)GAG4(/%?PHUH^+!9_%/0Y]
M,O[R&_\ AG ? _BI=7\?PNWA+P^VD2+KVL::;FR%SZ;\7?VM/V:_@)/K]G\9
M/C3X"^'E_P"&=,^'>JZOI?B/6HK75T@^+WB'QMX2^%-I8:1&LNIZUKGQ+\3?
M#;X@:%X"\-Z+::AXA\7:GX,\2VN@Z7?R:/?"%O3?2[:5]+M;I7M=ZK17>JTU
M0OU7,O--7OZ6UOM;6]DVOH>BOSQU+_@JA^P_%XR_9^\&>%_C7X?^)D_[1OQJ
M\5?L_>#]=^%]U8>-/#7ASXG>#O@S9?'#6= \>ZEIM_YOA^\A\+Z_X&T>32K:
MTU7Q#I_BSXA^%-*UG1=+M$\2:EX>F\-_\%,OV2]/^'?P*\3_ !W^._P!^"/C
M3XW_  K\$_%RT\&2_&_PGXXT+0?"'CZ_DT/PUXKN?B/I4&E^'O\ A6WB#Q/!
M=>%?"7Q3UVV\,>"_&'B2SN]#T&_NM7MI[",2;5TKJ]KK6[NE96O=W:6E[W5K
MAL[.Z=KZIK2S=]4NB;^6MC]"**^2YOV\?V-;?XR6_P"SY<?M*_"*'XSW'CD_
M"X_#Z3Q?IR:Y9_$Y]/&JZ?\ #;5<R?8M&^(.OZ6)=2\)^"=6N[+Q-XPL+2_O
M/"VEZQ;Z??26_P!:4)W2:U3V:V?H]G\F 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 '/:OPE^+G_!-K]HGXG?%OXR^(_#6E_LI_ NV\<>'?VOM.\2
M?&CX)^(?B]X#\:_M@Z-\?_@K\6?A?\)_AI^UQ^SUX?\ !ND?"::^^#_B#XA^
M!/'>M?M(ZM\1/C[\1_%&N_ O2)/ W@+X2Z1\4?$_AWPW^[5%)Q4DT[VE&4'9
MM>[-.,M59IM-JZ?JG96:;5FNDE):)ZQ::T=UHUU7>S5W?\9?VFO^";_Q4^,D
M/[(5MX*\1?"OP]#^SS^S;H7P4\3#4YO$-BFH:KH7[8W_  3 _:)M7\,0Z1X3
MO5D\,P>#?V)?BEHMD-0?2KBS\2>*O ]O'I0TK4?$>J>'O#_V;O@5^U1\>_AG
M>?#(67[/7A?]E_3_ /@L%^UM^TYKGQ,N=4^)'_#0\<7[-?\ P67^.W[0&@_"
MC3/A&/!Y^'FL7/COXF?"3PL;C]H*\^-6B#1?A'XLU+P79_L_ZUK_ (;T[XC>
M)/TV_;2^,?Q7^'>G_L]?"WX&:CX)\+?%K]K']HG3OV>O"/Q)^(NBWOBSPA\*
MK.R^#?QG_:&\?>.;KP1IVL^&[KQOXC3X8? +QOX8^&_AN7Q'HVCS_%'Q-X*U
M#Q1-?^%-.US1-4^5OCIXA_;N_97\+Z')XD_:3\(_%[P%XL_; _X)L_#?P)\1
M[SX5>#_!WQXM]"^-O[:?PN^$/[1_PQ^)NB:'X=D^"OB;PEXE^'/BN&W^'_Q$
M\">%/AIX^\+'7/$.EW>FWFN:+X>^(TS2;G*5TW5K2G*+2495:M6,I2L[I14I
MIQBO=;C96E%<TKELHZ?NZ?*M=8TU"2LNMW&#5[WMY-VWO@G^P1\1OAA\,_\
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M?%CQ9X<\>']K&TT[5?'?BGXI3>*/B#XMTGQ-XMG\%_#/2+OPUX+T'S'X;?\
M!./]LCX<>&OA!\>O$/QB^#_QZ_;P^$_[2VB_%SQ->^/]1\?>%/A!\=_AMX#_
M &1/%G[ G@WP=K'Q L_"'CGQ[\)/&>L?"'Q+K?[3>L>*-'^&OQ+T#PA^TW\5
M?CMX0\.^$M8^''Q&N_$</[O44KO36UDDDDK:2E*]GS).\Y*^K<6XMO1Q;UW[
MWOU^%1M?>UHQ=KVYHJ22>_XA^ ?V#OVO/#'Q;L?VC=?N/V8;_P"(UQ_P4_\
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MFW:VR_NI*[204444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<?&WP;K%Y\</&G[1WA37/ _[0GQE\-:M\)OB_P#%"Z\;:C\7=>^$-U9^,B/
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MDI.+:79-QBVK6]U::(/\^;YV:OZVE+7^\^[N4444 %%%% %.] ,+ ]-C^O\
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MN[---N]V[QB[MMWBG=M)K\^?!'_!+W]CKP1X1^)G@@^#_B3X[T/XI_#GP?\
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M]<YKLJYKP?'Y7AO2X^/ECG''_7U.?Z\^_3BNEH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** (Y1E#Z\ 9Z9/R\^O!/%<=JUOYBDC
M!&#DD@]MO7'!X(!.0Q)./3M&&Y2/4<?7L?P/-9-S:EQP&Z\@9X.1CV( R W0
M[0,]* $T"/R=(LH_[J2_K/*?;U_QR>:V*JV<9BMHXR,;=_!&#@R,1Q]#5J@
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MZ/\ A"- ]==_\*WQ9_\ +NNMHH Y+_A"- ]==_\ "M\6?_+NC_A"- ]==_\
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M&@>NN_\ A6^+/_EW76T4 <E_PA&@>NN_^%;XL_\ EW1_PA&@>NN_^%;XL_\
MEW76T4 <E_PA&@>NN_\ A6^+/_EW1_PA&@>NN_\ A6^+/_EW76T4 <E_PA&@
M>NN_^%;XL_\ EW1_PA&@>NN_^%;XL_\ EW76T4 <E_PA&@>NN_\ A6^+/_EW
M1_PA&@>NN_\ A6^+/_EW76T4 <E_PA&@>NN_^%;XL_\ EW1_PA&@>NN_^%;X
ML_\ EW76T4 <E_PA&@>NN_\ A6^+/_EW1_PA&@>NN_\ A6^+/_EW76T4 <E_
MPA&@>NN_^%;XL_\ EW1_PA&@>NN_^%;XL_\ EW76T4 <E_PA&@>NN_\ A6^+
M/_EW1_PA&@>NN_\ A6^+/_EW76T4 <E_PA&@>NN_^%;XL_\ EW1_PA&@>NN_
M^%;XL_\ EW76T4 <E_PA&@>NN_\ A6^+/_EW1_PA&@>NN_\ A6^+/_EW76T4
M <E_PA&@>NN_^%;XL_\ EW1_PA&@>NN_^%;XL_\ EW76T4 <E_PA&@>NN_\
MA6^+/_EW1_PA&@>NN_\ A6^+/_EW76T4 <E_PA&@>NN_^%;XL_\ EW1_PA&@
M>NN_^%;XL_\ EW76T4 <E_PA&@>NN_\ A6^+/_EW1_PA&@>NN_\ A6^+/_EW
M76T4 <E_PA&@>NN_^%;XL_\ EW1_PA&@>NN_^%;XL_\ EW76T4 <E_PA&@>N
MN_\ A6^+/_EW1_PA&@>NN_\ A6^+/_EW76T4 <E_PA&@>NN_^%;XL_\ EW1_
MPA&@>NN_^%;XL_\ EW76T4 <E_PA&@>NN_\ A6^+/_EW1_PA&@>NN_\ A6^+
M/_EW76T4 <E_PA&@>NN_^%;XL_\ EW1_PA&@>NN_^%;XL_\ EW76T4 <E_PA
M&@>NN_\ A6^+/_EW1_PA&@>NN_\ A6^+/_EW76T4 <E_PA&@>NN_^%;XL_\
MEW1_PA&@>NN_^%;XL_\ EW76T4 <E_PA&@>NN_\ A6^+/_EW1_PA&@>NN_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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:P^=,7D\J*./=L10+5%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '2 X0# 2(  A$! Q$!_\0
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M%=%%^S+>6W@.Y\-^-/C!XL>Z@M4@L]=M[_R452!LDE4QAV;=C?M(+ '[PQD
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M&$DC8!=HTD"D$X)49]/&Q^Q!_P (MX[N_$Z_M ^*++0-6D/V#3+W5I)YI&+
M[1)@JPP0J[6(RQ&<G) /T=?4--MX_M)U&Q!!*RM->VJ!&4\ %I5!Z8;!/&[/
M0X#>Z7=!+R;4[-%4;H]M[;$,,#&")#UXP<DD9. *_/WXC?L7R^)M,L=.'QU\
M2:)>&X22U9-1(^T1LY=FE50&VA=W(!7L3C(/10?L>HNF:+I%A\7_ !1--I,,
M2WUY+JI=+THK I&N25+%LEEX XR",  ^XX]6LKKS;FRU.SDCC&V0F[M]@90<
MDD/M&!DDD\$D8&*JVNI6=U!]HM=2TLS1S/YA6\MI%V!L,KD2-M+'IQ@\<\U\
MI3?LKZ1;^#]3T>3XF>+;*YNR\:ZNFI@V\,TJ$A3@;B ,\'!;J,]!X%X6_8^7
MPG9K]C_:'UB[UK6]5%E9?VK?3/87+>8)3:1)\@-R0KA2.-JDAN10!^G"E(Y5
M5+-$DO2K^=&V^)B"&5]RX4C(W9&<@UMQ*P1 [;W"X+=<],\]\X!)[GI7GG@\
MVUEI]CX>&OV^K:EX5MDTW66\X"9[E(02Q!.59@H&#DJOWL UO7'BO0=,DM;*
M[OK>&]NT#VMB)5DN)07900%8C' &>!W[B@#JJ*QEUNRS&'FB5IE8Q9FC;.U2
M[>85;"';R P'?' )$D>JV[V[799$MU)7S&D7:6&> 02!]&()YP.E &K144,J
MS1I*OW7 93Z@C((]CVJ6@ HHHH **** "BBB@ HHHH **** "BBB@#&UB]L[
M"W>^OW6*UM"C/(Y 4,[*HQDCG#9Z_P (/0&G0O!=;HH"K030QW<4BYP5<@[L
MC@YR1UZG':O /VL]0O\ 2_@IXDN=+G^S7@FTY4G.20#< $9&3R...GN*]!^%
MMS=77P_\*ZA<R>==S^'-.+L<_.Q+YR3W+<= !@'CF@#U$1@8Y)P01SQP!V^H
MS56XA4&)U3=(F41R?]7G)W=L=3R!V'' (JK<,UR+17RYC:1GVMA=O0,.,[B3
MD*>@!R.I^0OA;^VS\-?BM^T3\1OV;M"TOQ#:^+?AO;13:KJE[;-'I%YYS2(B
M64QB.\_NSNRS8;!!'S  'UWL,++"EU*TDI((7Y@@8YR#TSSGKUS]0X"XMR5C
M6**//SNZYWY(RQ<=2<DGG()YY&*^?_VG?B=K_P %?V?OB;\4/#]BEWK7@CP]
M=:Y'ILK(LNH+!Y:BVMYWQ$DSF48+%0,=5S@_F=\*O^"E/Q'^'6I>$M'_ &Q?
M"^F>$=*^(GPYG^)WA7Q'IVH6=_;G2=EM/::-=)92.Z:E);W"[BP*AAR<D"@#
M]LPG):5[=(\966+!8L>-IY)*]SC (R#ZT]Y8GMY5-RW0Y<')YSZ#@9QG&,=B
M17YAZ/\ \%4?V==>\*>"O$6FZ;XAA;QKXL/AF&RNK2:!=*S( NJW^H.D=HED
MT9,RX;"J!DY(6K.O_P#!4;]G[P[I7Q$\4W.GZ[=_#KX<36.D:OX_L;;[1HE]
MXJU"YAMK?PM8",2RS7TDEQ&OF!_* ?)RS** /TL!6&"$*Y57#!F!X)(&23CD
MC&0>,D8!SQ2[$V".W+R2N!F8 D*"<N-V,9SC@^QZ=?R2TW_@IAX+\.W7B'6O
M%.F:[=6,^IM;Z+X(M;!D\065@VF+J4=Y*6CV2Q26[1R;0#A95RXVD#G=5_X*
MS^"O%7B_PKX&^%W@[Q%J%OXO\):KXJN/%+H(K#PI'HMLUYJ%CJL,H5VNDCA8
M854'S$+DEB0#]E!MCD^SEV5%0DO_ +6W !/J,G &23R>N:0AR?)CG FBY:1O
M^>9(95/X\ XQ@X-?E#X6_P""IGP4CD\%^&;^[U?Q'<^*M-BU;4_$^G:;<+I7
MA6&^>2"QAU97C\R22XN(&BC^SG&9%+J1DKU'A?\ X*H_LR^+/BK??"NP/B*3
M6?,&E:)K LK@Z=XHUBW*Q7>F:>?*^2:W=\2-(0N,!>1A0#]-L-Y@9%$\A^22
M5-N(VVX.#GC&!GKDG'M4/F&XDD@B26%8S_I#E2"P/'!QR",DC![D9.#7S'\?
M_B/XX\&?!77_ (B^"K)]*O=#TF[U.ZT?4XP]V#;Q^9\[,"A!4MG#+RN?E R?
MB;Q#^W'\4K3X<?L]?%)="MUTGXDZU!H5_ID,T!O#=K<&UDGFD!"QQRMAE60@
M@CH&YH _8"T$:K(MLY*H^&#*?O$ \=S[D_H.KWDE#<$\C(&#_3UP<#KT!ZU\
MD_&O]KKPC\"6\%6'BO1]5U77O&MO;7QT?0XC(^C:8T,1N]2U"YP\;10LY7:C
M%CQT7[WG?BS]OSX1>&[/2[R&+5=9.O:+=ZMX?@LXF275;FW#[=+AC.TQSO,H
MC#O\JEE;<%)H ^^9)H598O,=3U( ).1QSQSZ'L I[ TUY8-KQ>>79E^Z.2#V
M/ QU^O8BOS7TG]O+PQ:^"_#WQ$^)EA??#M?$:7$UIX2U6-KO4XHK>>6*,33P
M H&N5B5XR&R%D SU WI?^"C_ ,"H- T3Q']CU\G7+ZXL(K%-/F>:&"WC=S?L
M0A$EN4(8[ 'VY)& : /T#9XF$0>0GR@2^%.0" 0/IGCDYX_*>01RH%\UV\Q_
M,3 );;C;Q@'(7/ X/:OS8\+_ /!13P9K,OCG57\$>*8_#/A#3M-U4:U]F9X=
M4T_5YFAMYXHPNZ!%*#_7 $#<22 37TAXR_:>\(>$?A+I_P 3)4EF;Q+8_:O"
M^C6P\V\O?-!$$.Y!Y<4F QVDD@CG&10!]+/;PR-&LT;2;$.QRI R#G'(P">
M 1V!]ZF4HJ&.+"  @Y//RG ''?D\]QGGJ1^:WP+_ &R-4\?6&OZOK5B]A>:=
M)<,G@NZDBAUB18V8H8[EV6!050D<E<$$LQ&:NZO_ ,%*?@5IGA72=?\ LFMZ
MIJU]J=WI.H^&-.4S:AHUU:3K!()Y4W17$;N^X-"V-D;9P"* /T>+%8R&;<W4
M\\[>I&>1D@$  GK[$TP284R8VA S'..0ORD#MR6P.>HKX1D_X* _ K3_ !K+
MX0U>75]*T:QTFQN[_P <WUI<+X?L]<U2S6_LO#!9(I'DU.:%]B^67B\S:'
M+#*;_@HK\%[;2-3GUG1?%6C:O#YMSI7A^XL99+O7=#6Z,*ZY831IY:V<@V2[
M9!F-9$!.210!^@7VP?W#^1JM-)YLMLP1PPDQYH!V*H/W2W'S$G! /UY&*^']
M0_;X^!VG>*?!?A"6YO[C5_&=DE^ALD:ZM="@D4L1J]Q#E(74@[D9AM"@-C!Q
MQ-M^VM:^-_VBM&^$_@;2-0D\*2Z==3W7BN90;*;5+)!--:6L&TSS>:@:..2(
MG]XOF8"GD _1)I(U2XWW9D19%RO!*#@X'N1U!ZXXYY%E Q65F)9)5S",'IL.
M,C'N <>F1TS7PU+^WS\ -.\5Z=X'N]0DL_$M_=ZS;:M:W VKH[:%&TK_ &TR
M'*R7K*8K2+"MYA"O\Q5:\O\ $7[>!TV\B?P?HEYXUTOQ1<6MG8W-F%LAX4EO
M9S;H^I1W6QIO)(#L$.65SA>6( /TB\J)U:REW17,JF=VVY#K&0-H)'3 XQG!
M';FIUEAN[<319-N-T$V<YD*;EX_A8 ]>W&!T%? '[,G[:-C\9?$FL_#7Q'I5
M[HWC33-2UC3=+U>\A"V&IIITJ1W,L!VJ-F7!CP>=I/*YKSOXQ?M\Z!X9^*'@
M+P;X7@ND\(V'B"^L/'OBW,3Z3I@TNX%O=M<' =EWK)N&_N"0 <T ?JDMRD:J
MB(P5,H 5(^5?E7\=H&?>D:X#E1M"_,.6!Z YQDX].G?MS7YV:A_P4H_9_P!.
MT+Q;XBN!KPM_#TQAT^&*VEN#XF=W5;?^S9(P43SU??$)6QM !&<"K*_\%&/@
M0=.\%76H+KNE:AXPA_M!M'N+25K_ $'2!P^K7ZH")+:%BJ,J(6+2+NPJL* /
MT29H]N0PR"2#_O-DCTP<_P CVJNET$4+C=@=1SQV'']?KTQ7P'H7_!0OX(:W
MXAU_2;D:UHGAO2+=Y=-\<ZE;21Z-XAG42,+.QC""6.4[>?,P 7" #!VTX/\
M@HQ\"KBPTV2VM_$$^JZOXD'AK2M$CM)C/?2&5474(;G#0FV()8@L6&0"<E5
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M^?;IO\P AOE;!V[: /O&=KDLGDOD94L.AQN!( )[8/ID'OP:F:12V5QR>,=
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M]::<L%W6R':XD0G&%D''F9SG.,<] 1D@FDJLWM2E_P" O\MPUWL[?UTO<_)
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MWS2&>3SDCV.(E^1I/,&UEP%W')P3QGECG..G79J/\WX,CW_Y/N:9\[?M?_\
M)$/$?_7QIOZ7//Y5Z)\*%W?#'PBI)7=X:T]21PP!,@.WD?-C.WD'..<UY?\
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MCQ#X,73/$W@#Q!XE2TO+/5[E)8]$TE%,KMIN6'EL(P5CV;F*C 4@5] ^,O\
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M:;<7]V;J34#(6)5U:0@R#:55  >./MKX/^/D^(W@;2?%4MC%IVJZK;M=7&F
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MDTCXP_#/7+2RFT_Q9ILNGZLDKZ-.DD@345@<QW'V=2FXB-_W;EE4 AB,KDT
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M^V+\&_@I\/-/^)5[XETOQ&GB1[:/P1IED[W,NKB\/EPS010(S1(\F%1KD19
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M/ J&;]HOX+V.I:-INH>.M#LG\2*&T"*>Y=)M04(#_J\;X %&"+E82<8&2<D
M]P+73<QE%3L,K_5A^>.>M%?*/B7]L[]FGPWK%YHNJ?%+1+:_L7\FY@6WU>Y$
M4JDAD\ZUM9H&((.=DC#W/4E 'CG[7/[9WA7]GG3_ !-X.T;1=9^(/Q7'AJ;Q
M$ND:'&';2D)DMUNKL(/,6.,Q.[.%QC[Q7)(^<_A'_P %'O#>C^!O"/BSXO37
M]SX@\6:;INGZ)I%K &&GZI?ZHUK;1:HP8""&-_+621P5 4Y&017LG[3'[$?C
M/XM?%;4?B_\ "CXAVW@[Q#XH\'#P-X@BU"#S(9=(EFD>>2V1UWK?K#-* P7
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MM=W9_P#!/&PMOV2IOV7=<\7W'BO5-5\91>-O$NO?9##'=Z@=5MM7*0*ZB*)
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MZ5!I^LZSX4UKP+KEI:&2XL=2\.6L=O:/JLL+%+F*1%D:5H6!W[2N!P:?PO\
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MO[9\'P9^,?@'PA/87&I?#[QKX3_MJ37HHF)TNWC@5H[JR?8T8D*'+JYSAB4
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M;JYF\G#'YY6*(JE6P>OVQ^U+^WUJWP/_ &I/!/PO\"ZEIOC+0=4U"WT;QEX
M\G?J&B22Z$]\DL<CDEF$X7.US\S_ 'L=/N2V_8Q_9OL_B':_&C3/AEX>O/%K
MW2:^VNVS6[0'5$8O]MM N82]U(YE+(,N&QNXP/,OCE\(OV0O!?CW1?CI\8_#
M6D:!X_\ $WC+3+?0=2CD@;4]3U VR6=K$Z';N61$_>C&<, 1AB* /@#XB?\
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M\0_"+PYJ&N>-]>NI(+/2?&<]A$3:VOAZ6<^5?SR^64%M9[G+' 4,_'9>&_\
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MXR\7_L\:%K$6KZ#:_%#Q!X"M[RYFL[F&.$>)Y+".98[B8$K!B1F5BX!!R-M
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M-]Y"#E5&.BU?_@HG_P (E;_$BR\5>&U^U^%M1L+7P7);*I3Q-_:ZSO9:Q,P
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M=&"2'3E)R4<K*C[0.RMN K>^*_[;?BSP3\0/'6@Z#X5T)_!N@ZY<>&9]2%[
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MHWA""7P=JM^;R^BOW^UWUQ=X#G5KN:1%8^6R)&9)5  SW )2R^#/P3BE\/\
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MO'NL^-]:UR#XR26NA7<2V]AIUM=Q(T< 0*Z2KY^Q0.<>6 1NR* /LD:KI5A
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MWPK\?_ACJ7BGXP^(;?4?BGIZ^!KN32O $B3W,4UY]@E5;>ZMM[X61D"NH4,
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MQ(Q(F9P&7!^[EJ>N^+_V>O#\O@GQ??W'P^T:;Q?;0)\+]<DTW39KS54D5?\
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M &EKWXC>$M U/QWX['AN'0])U+2[PQSK?7.J1RVU[>6NLKO*1VXA)@C.<D@
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M1F#/-;/LW0R,0IWJ0P(!W8R*=J?@CPS=:9<Z"WA[1GT6^=9=7MAIMH8;R9%
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M0F)4L!TS+^!/U/?-?<A 8$'H:15"# Z9S_G\J /AG_AC)?\ HI/B[_P8S_\
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MPMX_,0-@Y5MF1DX/''UQ6J\$+[ \:L(V#("/NL.,@=!T%*L$2L[JBJTC!I&
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MLY(]QBNA,,9C:/:-C9XYP,C'8@X XZ]*:+>($X4 %2N.2<''KG&,'CITXZT
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M5LY4CN[55"WIB3S'X_>J6*]P1USQD@=36X(8PI 1.<\E0>OX4HAC!R$4<8X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4LF=C8&3C@>OM]/7VZ4 .#*>01^=&1ZC\Q5 ^;W7GW0?X^E'[S^[_P".+_\
M%4 7\CU'YBC(]1^8JA^\_N_^.+_\502X'W>?3R\=\=>GY9H OY'J/S%&1ZC\
MQ6>688)  /3* 9/7'7Z\]/PI0S@'*J1Z[< >^2/<8Z@T"NMKFA15?='W;![\
MKC/^>F>M/1D)^4Y]#G.>1_7CCCCKUIM-=_FFA<\-E)7O;^M62T444B@HHHH
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M98UW9<#9G?S]W"EB3Z8 /\NM-6Y@=VC26-W159U5U+(K E689RJD \GCC'7
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M;'3O0!G_ &2/UF_[Z;_&C[)'ZS?]]-_C6H74$ D!CR%)&<#'.!GU'YBFF6,
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MO?UHHHK7\34**** "BBB@ HHHH **** "BBB@ HHJ.1F1<J 6.0 >YP2!^)
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M0T2\\0_#GQ7XL7Q/'J7D0:?J-[?&&333O\Z[+-*Q$D:#<L6&)^Z0"PJ'X?\
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M:_!C7/@5\:? ?PW^&VHZ[JWCOQ5I.K0WMYXATVSU+4GO[36=264:(MWME++
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MOBK7M0G\CQ#<>/;G7-5MM4\,VKE8;CPO;VJN4N+2<%Y3<2R[]S8V]00#]T-
M\3>%M;;44T77+.ZBTN9]-U</J"E[._BW,\1RXP4"E2%Q@'(P1D;7]J65^6EM
MIK/4([6(W4,MCJ$;J85./,N"C,/+!!SN^4X/)YS^#'AO]F+XPMKVM^$K;3/B
M-H,-UXGN?$>KZW8ZGJ4BZM!<Z2T)5U:=%56OF5B"2,C*GC @U/\ 9^_:U^&7
M@MH_AEXA\9O%?:-=6FM#5;V^GOU"2R2M:VOF7$C+&T$K!77!&?N+M% '[T/J
MNFP11ZHVH:7!:73"".Y^W1K9>>P(4,V=C2;RH[_,?NBLG3_'WA+4M8N?#FF>
M)-(O_%-H"USIUG,KR)C;D,JJ2-VX#@#KT&>?Q8\-?L__ !L\6>!_AK8+XJ\<
M/H%\QO?$UG-/>JVF:U"QDB,<[3*[1O.51@>2K'( &VO9OV.?A3XN^%'QX\:W
M?Q!T'7;V\U?>NG^)KJ2XE0-(8PIVRG;AL#D/DXQCC( /UXCPR W"2I+_ !*C
M,J^W"E1T[D9]R,44RT^T01&.XE>XD#LWF#:"$8[D1AO'**0#VZ8QTHH _A5_
MX*#ZD_P]_P""N_Q"\9^)/@/XF^(?P^T_PN-'&MQ:%?:G:C793+-&89$LYXGD
MVR0J"N\#;'QR:\+D^*OP!\7_ !2\.Z=J/[%GQ4\/>'KFV_L_Q?XU@\+:A';Z
MDP=IG@MS_9X5&C20$#:=VQMV <C^_>\\&>#=2=Y-2\'Z%?S.R^9/?Z)IM]/*
MP& [S7%M)+(V /F=B<$#(Z"B/AC\.V!4^!_"I0,6\N3P_H^Q6)^^$%MC=GY2
M?O<8/%?IF1^(>,R>E&E.DL2HQ4$Y5$M%'E6FFRTOU['YKFG"']H3<Z=;V*T;
MBH.>CTWW_JY_ K\6O'G[)&C:@/ GPU_8_P#B]XB\.W,JKJ.OGPOJ FM"VT,Z
M2#35*89F8=06' !!)P-9^,'[/'A]?A[IWPH_8I^)]LG@J:XN?&^M:CX4U*9[
MD7(7[-(Q.F(),*N3MW@' P._^@2GPP^&L6Y4\!>#4W?> \.:,@9N2"V+4YR2
M<DG/)S@5*OPZ^'BJZ+X$\(JCX614\,Z-LDQ@D/FS'FJ#@J#D ]*[?^(H8SVL
MZGU6+C)? ZRM>][^G97WZG/0X#A&+53%2E9W7[IKMVWW_#Y'\"3?'/X$R>&+
M_2]9_8G^)WB.^UC5)]3N-3M/">H&Y@A=R]I$C+IORILP-IP000>, \T_CO\
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M=P(QZC=UQC:<=3E%&1K>L:;X>L;_ %C5=0ATW2-(MGNKYG\M81"L?F-YTC9
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MD"L)F7.2,C YYSG.3W .!>\M/[HI] &3/IBS3,Q;Y)@?.8LQD("X"+V",?O
M8.,X.3FJD>ESL$25X8X;<?NX;?S41R&8;I6X9OE R.<G!&,9/0D@#)( ]3P*
M* ,C[)-%;SQ6LB"1SB)W#GRTP5QSN/)./O8"GZFA;=[6*,G,TQ3RW)YB8C&X
MLN.!GA>"3SDX QKTUG51GD\X.T;B#Z8&3]: ,*!)(KB6X,>UI#L(A4!?+!!C
M4@@892&)P#C/!YX;+8BXE9I8$\J>W,4C[G68Y!#. OR^8<$@G#>AYK:\P?\
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MOP/X%O?%.I_9-$\8^/K1+6VN_&U];W#$7EV\D,UR)ANBP"&0=_DCXI_MV?\
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MAI/Q7^#7[*TFK7VI:EXBTJV\8OXIE,K2R>&[:0171OIV):WN6$3!K:1B1N;
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MT!/^SUX:GU?Q5=^$/"?Q:TG59]7EMKVVF\<>')$ADNK'582^ZWC2900)FEX
M#)M8[@#^@Z&ZCU&".?34D:*1-T$D1 MKA)!E'8?QA@PP<[,$X[&L+4/$_A[2
M]1M] UGQ+H5E=ZD$M['2FECAOY]0)#A?ODD,"%53C/0'@9_+?]JS]IGXB?#S
MX^_#/X9_"E?$":='?Z)9:CI@TZX@T_RWGACF0WBMY3*$5B3MP0<$<5#^W?XC
M\&:K\3OA#\/K"P\3Z+\6=2N_#_B>Y\7:3;W!TO3["00K+;3W4,B 3 L9&1L
MJ Q&,F@#]3(/&/A62^G\/-K.GWOB.QN?]+TBWF5[BPE8[3 47[C1#)1<Y5R
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M< "OPS\3_M(?'_P_\.OA1H'A/Q/XE\:+X_M9=4\8^+[RQO+.\\+>()KN)O\
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M^N_V<OC]\5O$?[0UGX0^)@U6VC\5^#K>_AL([>:?28VBLUEDEGO=_DV\NX8
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MCW]KS6/AUXE\3-XLU:+6G\9_8["W2PNW,>A)9)/D2=8S#)YB&-5PQ16!P3D
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M+7@3X:>!O!=I/XB\)^&K^[\)Z;K7CP6=S/?1&&9@?.A1DE*SA DLADP-X)#
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M-:*W4HA\\&06J++</<3 PQQI]XK(D@5E$84DX^7!YP.O\^?P3^+W[4&C^*?
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M<$D[LCCC@[@00<8JO=K;W!MFDW3- ZW5K#;R! CQA<"1D8[P,@[7P"5;/'-
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M_P +_#[Q#X1M-?UWPZ/%D>IZK=:E>Z\NF:6]G>7MK=74SRVD-U<*)@L+H%7
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M?VCM _9A^+.B>('U'PWXNU&26;PO#<W!NI;OSGF:;3(FF=VB;)")("&W$$'
M(H _4#1QX',LR:++X4U?4Y&DCN[B&XL99&N#_J[1VC,C9;#*$8YSPVTYQ@6=
M]\.]$\0RV)L/#VBZGJ5M<W^I7;FS2. 6CE9HFD?"H)'&XC<-Q)!!.,_@K\+/
M"7QOT;Q'\0M*\#^!O&^AZYX"U3PAXCU;1-2UW4K\ZX,RRZPME<74S[/M31$I
M%$0J955P %KUWQ;\)?VIO%?A*/QA<^'=<M'O)=1U+7=%6[=+U]':\#+I\,RR
M&6-C /+\Q'#\<%N#0!^MT7Q*^&?_  GDGP_BFT*ZUB71WO?M#-;&"XT9W42J
ML@&R41NP48=QQ\V&-:\7PV^$VB_$2Q\90VNEV?CFWL#I6FRW<D,$ILI3)*J6
M@=!(T9+Y)1F&T# Q@U^1OB7X ?&C5OBY\!/BWX!\+ZMX;^$^@^%[?POX^\)7
M5[-<:YJD-S+:W%[(+Z=S>C-Q&S;]Q(7Y00#S[+^UKX+_ &B?B)\;OANWP[\'
MZCI7A_0+6WG_ .$GMM5EACM+10I2SO+?S-D\R.BY>4$MC''2@#].-G@^[UBX
MEB;PG+XML58ZG</+9R7UM;R;@S2?,98U*NHPX PIXP:X+P]\5?A/XQ\::_\
M#OPU/I&LZWX<LY1X@NHD@FMM/2-&+-*Z%E15?DY;"G 85^6=]^RC^T+I5UJO
MCCP=>Z\/'6KV[+XMN)M<N+FVU6SC&!#:V$S&"U9T50#"%.!DCDX[C]AKX&>-
MO!WB/X[:UXF\(ZCX5T[Q]X5N],OM0O=1FNM3U/76%PTKZ:TDDDT )$C%(2%!
MQ@X(P ?I,=?\!:0FE>'M/@\/75KXA:>UU.6QEMDMI20J2++)&"&#;B&7.1D
M 9(JZ'^%-S9Q&W@\$3Z;X=NC:[9KBP\NUF/R@#<6RP<L<$$DDY'!!_#6+X7_
M +3_ (1^%WBB_N/#VN:5H'A+7?$5W!JEUJ$\VM:WI-S&PTY;:$NTD0A?YMT:
MI]T@[E)(\X^!'P7\5?&RPN/"-MJOCNUU.]D_X2+6B^LZA9AIA*\WE%PR; -R
MED#$' P>6  /W,^,WQ8^#_P\\%ZM=_$!]"FT1'MDLK"U6"0;KI7,4\+1DCY%
M7(8!0H8 9!YTH+KX2?%+X8HEX-$LO"'CS0X='M[N6:*&^OT1$B^SJSD2280!
M"J(22S#!!-?F!XG_ &7/C;XY\)R^$O$'ABYU_P /Z3JVG168GU!UN[BPTYW3
M:UP93)*60+N+/N(W'*YY@L_@A\:O#&N?" ^.M"UWQ-\/+"_U+2M%\&Z1=3Z8
M-#UN2Y9=$O+V[M'626W@PBNLK%7Y=AG (!^O/A?2_ &A^&K?P)X>NO#D'A7P
M]:06EYX>E>V2*QMHXV8R2AB-B7,@\_<4&6?D\Y%6;QI\)/!VG>&1?ZEX6TZ+
M7-3_ +*T 6\]D5?4))"MO' 4;.\@Q(H Y)]>*_%O7O@_^UWXW^)?Q&ETOP_K
M7A/POKNDSV5_9KJ4XDNY+.YAMH7M;DREX0UJA!,)&20Y.XMBQK'[(GQ2T[6?
M $U_H7B35? /@/QUX=UZPTB7Q#>SW\1AMH7O'DG,OGSJ;E'<(Q(0$A6. M '
M[3:KJWP];Q(8?$VG:'/X@TBV6]34KU8%>-!NE@D\R7D H1L8@GC .!5R+3_A
M]XGU&#4;@>%M<UAHQ=J/M=I<SVMI&-B%74EXXT4 \A?0@8!K\_OVD_@_\7OB
M)\4=-U+PYIVJ6O@G7/#%K9^(=/M+AX+F0QQ;(T6YCD66W=%\M=R,""",8&:^
M4[/]EKXZ?!JP\1>,?#\WBR-E@U=;J*]UZ\OFDT-;266"Q@CFE?RW694PXP^2
M0#C:0 ?M3:6'PXLCJ.LZ=_PBMIJ,4PAEOY;JUD:+J#"6WG!_A"G<QP">U2:A
M:?#[Q5I\]I?:?X3ULP)#<'36EL@TMQ&0XN#;<.V"%=7V'GOGK^"OP2^"'QL^
M*3^$-9T[0O&OA[X>ZI/H6K>,[;4O$5_-/J^K#4BVH3V\UQ(\UM%/&)<PQE4P
MX7:JJ2?6]>_9H^/&H?&/7O#.DP^)=#\47&MWNJ>$OB'#XANU\/67@FV1)+7P
MY=:69397%VR+/";J:/SB7XS@9 /V7NM,\"SBSO-7TSPO!-IUE%%:W,\UHK:8
MI0""&*5WS&=J9"C!&XDY(.=.;Q%H21V>G7VO>';1I,BXL[N]M=EW:E4'(D=$
M=3'CJ>."3D C\*=>^ G[7/C+P&UYXHU+Q!I<>D_$ Z9<Z;87DL=WJVF:?=SP
MPWSR1.'6&9!NRNU2' QBNY\0?L@?%/Q3K5SJ6M7GC"Z33+CPQ9Z +?6KNS%I
MIES#)_:"3B)U\]G*(6D=BR%C[B@#]?K/1_AE'HTVRU\*'PI<7<C6-RT]GY/V
MF60?:A;R'/(N,86,CD 8YYU;N^\(:"L:"\\,V5Y9:>UY:7=S<V:72!1B%45B
M)@&@!Q@8&#@8SG\.?%?[-G[1FE3^$?"Z7?BJW^%.DZE+;'3UU"XDN5O[R^\^
M*\FO5D^T2Q*50LCG'4+D'GU?QI^R3\6O%D_B'5DU+Q+?^(7TVS3PG=-J]Q:V
M,&F6MB(9[&2W63RKF>0@$2N!(5#-N#<4 ?I^GBKX4:E9R?$BV30M6A6==,U?
M6%6">*VNPVU?-F(:-&9BQPQ7'8YK:M(?A[%([65CX6.NZ^JO#903VK7>MVL@
M4&22"/+A3&V#E>B'GG _-WX2_ ;XH:'^Q]XO^$VB>'K_ $/QS<Z[+J>KSZEJ
M,M[<ZG<"3S#);R7#R"!?,0D+&H0$X53R:\R^&_[+_P"T%H/Q,\#>/-:77DUV
M;7H8;B:76[I["TT.WC"&RCLA*((20I+.%W,#NXP!0!^MGB"?X?Z'9-;:I=>'
MK,:!:3ZO#H+?98[FV%K$9KEHEW+(Q"J[%@"<GCC%1>&_&OPV\;^'/#NO6>HZ
M$]I?SO<Z'#JD]N)FFE.QOL23LL@)*J5,:L/E4DXR:_*W]K;P3^T1\1/C[I5O
MX$\%ZB-#TRVNM(OM4L[F007,&H6<5K<>=M=5F,A=E5Y,F,G[W!8?(?BO1_$N
MD_&;PI\,]6O?&&@_\*V\.Z/I?@S1=,%TME)XTU.=H;6XOKF'"WJ17;1F2.9M
MFS&\X)R ?T7-!X"UVY;38[/POJEYI]YF73X?L<KPW%RP:6X\I,;920&8\OM)
MS@D9\?\ "?QA^%.M_%_Q5\*O"NG:9'XN\&P"34+QO(5W)(8Z?')Q(&=F"B'>
M!V"G%?!'[.7PB^.5I\5UU!+76/ FJZ9:WX\:ZKK=_/JNG>*M>$++97]K:7<D
MD-G'(9$)M[<*F26&2Q%5=:_9I^+?@7Q;\0?B]X?TJ[O_ !K?^)K'6_$36MXZ
M2:_8P^8T\%JD;*+5+B1U*^0$*J ,@4 ?J5?P>";75$O-0N?#%OKVI1M+<7\X
MLT-U:6Y$;:8RR2Y:;)923E@200<@57F\0_#OP5H[+J>J>&?"6C1Q2Z@NDYLX
MOL\4LVZ:\DP<A)Y.5=U7 ("G!R/QCT']G#]I'XM7$/BKXA6/B/18AI?BK4O#
M>CQ:[=64MGK#W1ET4S[9LS^0J1YBE&U\#ECG&W'\$_BAK^D_%CX>_%/P'XE\
M4^,/$OA"!O"WB./7+VWM-+TZQ>S\RR2&"5(!+)) 7#,N\*W!))H _833_&7P
M]OH?+TS5O#CV&J&.^,CO;+%)I!C5OM18[5\IV90),\F0<YQ71/J_A6R@M)(K
M_P *66@WTKPG?<6*137; IA6+!#(\7;(;8R'/>OQ:USX&_'RW\-^ K[0_"VH
M?\(AH'@1/"/C30(]3FCU#4;))+<QB"Y67SX9TEA1Y9HSN(!4X4*:;HG[)?QN
M\::%;VVL'Q,FBZ9=W&NZ-IG_  D-W;31WP@_T??-YK23)&(HD:)QM;8-Q/)H
M _7KQ9XK\!^%-+UJ:\DT'4;72-'_ +7UJS8VK22^'7'[EK8;BLJ^9S^[9@>3
MR.!@>&O$?PCU;PSX+U;3=&TV/0?'B2G04O8D6",(A>5L,I1% ^^00<Y'J#^.
MUW\(?VN_%_C+3-'U7PIJ5M9:-X7O=$N]0^UN+?6M(\J6/3K*Y16,<S0O(DC2
M$;F.\D\"OLSX@?!GXTW/P3^ GA3PAI@TK6/!WA[5K?71#,@D2_FT_P NWE'S
M+Y16X8R<$[FR!G"X /ON&7P1+HVIV-U+X7OO#NB^;<W<(GM);:V\I6D;<A9E
MA" !<' RW45Y?X,^-OP@\:ZC<Z5X-BT*YETUY!=LJVR6=M:6SA)[ABB+'^X!
MS@MD9.><BOS O?V8?CCX(\/VD_AN+Q'?:;K>@1GXCZ!-KUW<S:SJ4Z,E[);2
MO+YMBD@ "B';M!P%QT\P\!_LM?M/Z%X*\8VGP\\*7'A+3_$,SRV=I>ZC)<ZJ
MUC+(K7\27\\K7 :?YUP#QDD*.E '[IHGP^M;@>([2Z\)6-U<E8],\3I<60-P
M['#V\<F\KWVG#,&!SCM3;^Q\!ZAXB34;FWTBZ\7V$"SR26KPS&6#8-@O&CS\
MD@!D!?IRP/RBOQ(\9_!+XKZU_P *=DT;2_&OA7X<VLT6@>)M&CU*^U&8^*T,
M<$NK>=--)*D#2I,\<28APV!C -?6_P"SE\,_BYX"_:"\=:/J,.K^(OAKXCTB
M.&3Q'KEQ(+O3IEL)8!% 97W(4D="@  )+$@\9 /T?#Z")1?7<_ABVNI+4I&_
MFVBQ/:$X=V.>?*8F DG ?<N2>*Q=='@*ZL7TOQ!-X0_LG4V\FP:*6RS+<Q@S
M8W*2,AF(X(SSD@]/QI\1_L^_M>ZGK/QS\+B[U?\ X1[P;IE[)\,=3MKMS<ZW
M:7^HQWLEC#B0-/*L<DAC8CY0 N3R5O\ PL_9;^(FI:[\.[SQJ_Q,N_ .G6$]
MYJUA<W-W!J5OXC%IY;-;*LF^>$3+*$1B8RH4]Q@ _8NTLO DAL-6LK;PO=7C
M6ZZ=:LAM&*R(568#YW.?*3!((( !YSDW;T^%-2C;PX)O#VJFY$AL=*22SE,-
MP599V2)"[+MWN2",]?NM7XCV'PZ_:H\(:;K7B+PKHGB6^TK2/&&K6^C:7JTT
MJZC+:7%NT%O</!)(7\LAU,9P.5?'S?*/0?@S\+OVB/!/QI^$'BCQ#X=U>ZMM
M<DU#4?&44VKSRPZ?!=PLJNT+3,(Q 2K*H"Y"C)/ H _7FT3PC;W4VCNV@0>(
M+728[6_M7F@6==&C#8,D;$2BV" C)7;@MT'(P_$$W@&X\/S&8^$[SPDD+VUT
MBS612&\5E6Q*,IQ&R.0 0.,\XVU^87Q&^%GQGU/XX?'BYT_3=<U'Q'JGA&%O
M 'BR#4[BUTJRTAUG$^GO8QS+:3W+QF-!)(I;S(P5*]3X!X<_9L^._BK3%TM?
M#_B_0/ $Z:)!K>E2>(;Z:ZUO6\G^T=0@NY;@S6D1G",(XF">6@557F@#]J'U
M_P"$V@^)?#6CQZAX9M/%&H:/$MEI8:V>672C"K/<RN"<QJHR'/!S@MWK#\1_
M#SX&^)V-MJ4OAF*-?$=IXDCMTO+ 6LNK:;@K(BNPC><29R(R7)8  D<?DW8?
MLR?'+PQXR;6;_P -^(->\1R^&M;\,>$M6FU6>7^Q]&D98;5)5\P++.ELN!<2
MGS,J"&!R:S/%'[-'Q:^'K^%M'?0/%WB/4M9MY+O1+Z'Q)J$B:+XJE<,MQ>B.
M;%Q;H[C=:RL\14-D&@#]BO"/Q7^''C:TU&Q34=(EN/#%\^D3:9J;6P07RL$M
M&A2?:"1%PC*2VWA2#Q7<3Z;HTND7%IK>AZ9*L4A.([2)A,ZHUPLJ@*<$QY7<
MO\(8CCBOQ/N_V</VC_!UGI'BB?1;C6?%%SXWT[7->AL+LVR7-G:11(W[B*0+
M@;2'#??(*D "OV:^%_BK7_%WAZTN/$_A4^'+J.UMX9[>Z<R-*ZQ+;L$WL6!9
M=S#J?Q)% 'FMO\3_ ('W-JGB2#7/#6F7EIKC>&$U&58%N]"U"VV-/H:L,21S
M,BN<'!(*DKR,<O>_M&?LT:_I?Q"N=2\0>&+GP]\-)K=?$^GWD%N&CU>:9%M9
MD>1=KS/(T8CV@R;V#'(KX4^(G[.'QCTGX]>/-,\!>#X[WX2>(9[GQYH^FSS"
M?[+\1[CS8CK<ES(?-\ED$3)9.YA+Q@$!26KRBR_9%^-_P]E\6P?%?P)'\6/A
MY\2M%FU7Q#H/A:"*RU>U\:[672[N:[LFCFEM[*XCM)&MMQB 0ESG=0!^RGAO
M7OAW\0?#>@_$J/2]-M;*VM!%I%]KT$<$!M2FR$6<DP5=I6/",N1@''*@UVDM
MUX&FT5KN\?P['8ZC!,'^WW=F$D@==MR;?S2=ZLOF *G)^0#  )_-WP#H?[0'
MAS]BK6?#GB_PIJ/B?Q,NI7&G^$O#\-JEGJNA:([W*V$)BA=9)9+6#R4$CMEC
MN9OF:ODOP'^RA^TIXM\*^$--^)%YXR>SL7\<:O:6EUJ]UI-Y823Q^=H]K=+#
M(1+;6TB*(HY!AU."QW-0!^R?C?XA?!WX5Z)HT'BK5M"6PU>]M+72+2,VK7CW
M%P1]C\N-&\UD!)*# ! 9ATP>0^,7QK^"GPKM_#&H_$EK/4]6N7CFT#2=,LH[
MB\TZQNBCK>W$,8>2!$0[VED4 DE-IP*_)+5/V;_CYJWC#X?CQ[X/U7Q3XAT;
MQ)X:N=+\0_VE,NDZ5H>FRCRGN]-246EPT,1?S9)49I&(W CE?L']H/PQ\3?A
M[^T WQ+T'X36OQLT;QC\.H_"<VES"-K31M6,<$0O;:%BT-LJLC#,2!@A#(T;
M$-0![]XH_:@_9;T/6/#FGWEYI^HZKXCT_P"T6E[':QSO9:?,ZF6:YF48B\@O
M\S,R[#D,P VU[?X3^)OPT\9,NG>"M8T#7]+L7C.H3>;;SQ:8_E'$DK-\L+",
M(O.TDE><'!_(72?@)\8_A7J^GF[^#=CX]A^('A'5K74+201W$W@JZU.;=!9P
M7)<O"8=X8$$,A7(; KZ!_8__ &8?B#\)=+^,ND^,H)-*;XCZ9?W6FR^:672Y
MF1I;"TBE/^J(<1PD(RY X5R0: /TNFT[PW.MU';:5X<U:QNKC[5>"WEL@UM'
M*AB^ULJ;]K, 4\P%<D =>!B0^'? 5KIVI:.R^%;OPY<W,D^IVTES9LVG;PI
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M$D\ID<A7GCCE_P!2G5U"%0"N N.#]V)#&%C5<XB7RQN.YL!0N&/<@=>HSZT
M<I;V4VAPII_AG2K2UTF,;XH8%$<:R/S)\H;@\+GN2,DGK175Q6T<2E4+X+,Q
MRQZL>:* /S;^+O@[XNS>/M:U+X:^/M.TK4X7\JZO]9NDMX()"?E60"1NH RI
M'/88KG;CX5?MGZBFBZGJWQ1\)ZOH]C<I+?/:WQAB2)R$9@ZMF0*& (.,,,^N
M>?\ V@/@[\*O%_COX@W]U\='\ ^*H=2CDCT"76!;02RJJ,-T+3!2"V!@J206
M /IS%G\"/$7B;X:ZCX<U']IW3-"T.XD"G4;+68OM$$4>9<NWVH8#J"6)&,A0
M.K!@#ZM\'Z'XG\$>,+^R\0ZM9S/XHT-K#1]9?424-Q/'&IDM6+\LA8,I5Q]T
M'M7D,?P/_:N\)>+->D\ _&73[CP7>01MJ,FL7*3-!=D.\R6QEG8AHTVX8%<$
MG)'?!U7X-_"_4_#OPY\,W'[4<1E\&6RF/6AJL1EO#%$J;_,:7D<%A@@X/)R,
MUYC\0OV?-0BUZRUGQ-^T@="^&EQ:3WME?VVN&"+5C;J[(3BZ$>9@@3:?FR<G
M?RM '3ZWX;_:Y\&Z[/<0_%S3O%6EO-IW]H6MO<Q&ZT^6Y5?LI8-,Q%KDC)&$
M"D=1U]N\)^$_VA=>\&^/_!7Q?^(NB:5K6NR6MYX O[*[A18HG5GRSK(FQ0QC
M)^;<3D#&0:\W\5? ;X2>.+3PWJ-E^T5:Z"VJ>'K338BFNI&-5N;5%6"YD4S@
MEPQ &Y6)VKR2"3@^'?V-=$U.PTS3-<_:(N];\1QZGY.FF#7@TLMK&0/(B'VC
M=@*G ! 88QR<D LZ!\&OVB?AYXXTO7_&'Q$T[Q5KM[?64^CZ<VL3BTN[.R5;
M=K:RA,K1 R*=[@!<N226&<^Y^//V>?B'XT\5WOB+3OBC+X3U\R1:S9Z?8:S<
M-902BR6W?3[N!)X@\32'S&4H8]WS]"37DGB?PW\"M6\51?#K7OC5JN@Z[X/T
MN>UL9I-0;SK6_ *JZSLS\LXR,.#CN#S7#Q_ 70'^%EYK>B_&OQ9XFU?2M>F?
M5OL6H227D^E/<-!MC$<C2M\KCE0?E7H 6! /?_@?\+?BKX2O]/L_'?B>Y\0Z
M3>75[>:Q=O+Y]O-"DLNY@WF2#R05;KG"J,87I-XM\#>*K77_ !)XW\-_&/1[
M"./3[@^"="%W$8\A7 ?R1*I#!U QLR"JEB5&%P/ACX-\'_";5-)BD_:,AETS
M4=!E@O\ 0?$>I(U[:O>19("32_(\:3.I#@$,J@G)R?(D_9@^%0U^;Q['\>3J
M4MOJUY#%:WNMI'8P6TP:50D1G50A=R RJ,@_>.1M .N\+:#^U'X7\(SZO\1_
MC9H6GZCXXU&1?#\LDR"-HV<R1(&+J5*PQIO( &&X(!%36-A^U#H-S+'J_P 4
MM$U2&;FT^SZAYZW +;CY(C<D@_*%!((4_-C%>HZY\'_AUX\TGP=IGC;X@Z7J
MVF:!#J$]A;:5K$;7#H8''[M4FD8S/&6(8+DMGD#Y1Y?X,^#/P_\ #NOP^+M+
M^,%MH_A[3KE(X-%\5:O']IV(Y/EHES+&Y+JNTL$ZA201U .N\3>#OVA?&R^!
M[_P]\3=$T&_\.F\&JZ9<7KPS:LER'6*5%+#S%MLY.<D$<E1G-*^^%/[7VCW=
M_=6WQ1T:Y3485#JM^%^RF1"0&5Y0?X&VE5V'G#<@GL_CEX$\ _%6ST"RT'XL
MV/@+5K)9(H[NQU*&,^(EO" KPE91N\H[MI#C(R, X)^7?&'P$T'PWXIN?!^L
M?M(Z_HTIL=(N)]2N=3<V^P01R.VYIMACD!;;ELJ3G)P: /HCP7H'Q_:S\;>
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MM@K65F!(P2!1&RQH@Q@8],@'W)XQ_:D^$?A3X7_$3XI6&OW?C3PK\'4DNO$
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MUK<?$[Q;XJU32=;\2ZKXQTCQ'IOA^:..72Y);2!%DOK:-BRBZ8J\H<?/YH#
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M>M(T:R/-:1YAA>175C'<$!2C,00<<G->H?LZ_LP^//#-C\;D^)-AI6GM\2O
M=QX6BL]/CCC_ +5,-I=0BXNU',CL)B290<[R. 2* /1K/]NSX':KK'P]TR]U
ME+/PQ\3;2Z;PUXPN";>VU76=.,AD2VDSN>)I(66/=Y> %   &?I4?%CX>3^+
M$\ CQWHL'BW5=/L+[3=.DNHVNM1M!"K2/;1Y_>@;UW#(.YCRV0*_.OPG^PGK
M^K^%/"'A7QWIFDQV_@^UUR'PM>0".--%CN_,^QR0*"!#.P?+.FUOF//.!C_#
M?]@?QGX*^./A_P >>(->O-=BT"2)K#5'N?-80LRLMH7\PG;L&" %#'/RKC
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ME:'>>*-1%UXAO=3>*6]$,<ZA1$6D4[A'@*#U9%)R-PH ^RK']K7X0:_XWO\
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M^1_PK;PB"0"/#>G(>>C$,NT^A!X(ZCJ>#0!ZS5>X5G"JKLA)(W+CCC.3D$]
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M_P""=FF>/?'?@?Q%J?Q!UYO#/AI;4?\ "%H=MC'>0V;01W.Q)%BVQ.0S#!Z
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M^(/^"=6AZ]XPN9CXVUFQ^&T>GSRV'@J!8UQK-Y:+!->%P$ /FF24X.[)&""
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MESJMD-,\<:E9>'DQ%JGAAH(2KP7#+)(3)@JZE@& ;D,BD@E15GQM^PEINO\
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MJ/LUO_SR3\J /CC_ (4=\;>?^+Q:ASZ-C^1'_P"OFD_X4;\;/^BQZC_WV?\
M'G\?QK[(^S6__/)/RH^S6_\ SR3\J /CC_A1OQL_Z+%J ^AQ_(BC_A1OQL_Z
M+'J/3'WSZYZYR/P/L:^Q_LUO_P \D_*C[-;_ //)/RH ^.#\#?C81C_A<>H?
M@QS_ #__ %]Z/^%&_&W_ *+'J'_?7Z]:^Q_LUO\ \\D_*C[-;_\ /)/RH ^.
M?^%'?&W_ *+%J'I]X_7U[GFD'P1^-BDX^,NH*0,']X<XP.N6..!^-?8_V:W_
M .>2?E1]GA ^6- ?H<<9QT/')Z\XYXH ^.O^%*_&[&/^%SW_ *<N#QZ=>GM^
M'2C_ (4K\;>WQFOAQCAE''Y_3\A7V)Y(_P"><?\ WT_^%'DC_GG'_P!]/_A0
M!\=CX*_&T=/C-?8!R!O'OWSGOZ_RI/\ A2GQMSG_ (7/?Y!SGS!UX]_8?E7V
M+Y(_YYQ_]]/_ (4>2/\ GG'_ -]/_A0!\>?\*6^-W.?C/?'/JX/K_M>]-/P4
M^-I))^,U\<\\N"/U)K[%\D?\\X_^^G_PH\D?\\X_^^G_ ,* /CH?!3XV@Y_X
M7->\<_>7_&G?\*6^-O\ T66]_P"^Q_\ %5]A^2/^><?_ 'T_^%'DC_GG'_WT
M_P#A0!\=GX*_&TC'_"Y;WU^\/ZDTH^"WQM Q_P +EO>/]H?T.*^P_)'_ #SC
M_P"^G_PH\D?\\X_^^G_PH ^//^%+?&W_ *++>_\ ?8_^*H_X4M\;?^BRWO\
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MQCZG-/484 ]@!^0H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0<T :U%11#Y%;/!4\=N23]<CI4M !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4UG"XSGGI@9Z8_Q%5O.?T;'4G:,?S[=2<^V,TY
M)@V0PSGH"!DXYSCN.XQGH?;(!+YJ^C?]\FG@AAD=#^'3@_K4/F0J>5"GJ,J
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M<MP< @@\_*N,\Y.??@8DCNHRJC>')7.X$8([GC@#/ YY]: ()(H>/W00$@#
M)YQT8<8!.>?;KZ30Q1-R%X3 &>,\'GJ<C!XY]0<XJPVPC+!2.V>_'3\\^WK3
M3*B#@849&>V0<'&,Y]<T 2@   = ,4M,#@H' )! ( Y."<9_+FHGF*@G  R
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MP3TOP+_X*7_"GXQ:3=ZAKL-[\/9UM]?N_#J:W$;2Q\3P^&;?[3J,=A-<JGG
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M_!JZ\8:A9W7B2Q>PU;Q.@83:AHMQ\MW;P31C"S-$=J'(*OP#O.!\[)_P3Z\
MSR?#Z*Y\7:^+7P'ISZ-J)M+J=;?Q3;1R8L[;5XU<?:_(_<HQ<.B^7@DG(H [
M7XK_ +:&A?"+1_ABL_AK7?%GB#XA:#I?B26.TMV$6CZ9JMK%>W)N6 (5K$SQ
MQ0ASC;R3P0.4\8_\%"_AUX7TO1M3M=(U#5QXFT:YU'0(+=UDN+F\MQ)&+)XD
MYPUPJHRX# L1QBI_VC/V5/&'QA\>?"B;PMXJM/"7A/P)HLFB>)DMU@EFU;2Q
MY<<-O%&(Y)D,=K&4Q\N&#?*<\9%K_P $ZO@E8^*-"\2CQ'K<NEZ1H]UIFCZ;
M>W6([>ZNI)1)=Q)*47>)G#1Y0?.J@9V9(!3TO]OFUT[P;H/Q$^*VB:CX :^M
M[G=X*38]S>PB29+.ZMGF#R-+=E80JAB07V(.0*T+K_@I%\.5T'0-4M/!_BR;
M5/$%_=)_PCUW:.FI6UA;1O,]S%&L(\R%8$$A;D+N#XSP-#6_V"/AOX@\-OX9
M\>:YKWBN#2&>;PUJXFQJ5@99GFM;:78=FVTE:-TR2"BH3P"#T_AS]BOP19Z?
MX3;5]9;4?%OA*TU&+3-8Q&"]KJ-K)9;+R/:(W:.!HTX0DLA8'J* /(_#?_!1
MF+48OB/XJU'X=ZFWPU\*Z7I>H:5KUJI-Y-<:O.\,-I?1_<BCCD3#-L1P"<\+
MQ]0>)_VG/"W@WX:^$/B;K[F+0?$NGMJ0N+=XY(+9V5C%I]Q*I,:3 X5E+ @K
M@#@BO&-*_8*\&Z#HWBGPMX?\3ZQ9^'/&WAI-$\3:9>MNAFNX3-+::A9!PX5U
MEF+IM*L #D9!"]V/V/?!%_\ L_6/[.>H:KJ^K:'I5S9WTVOWLI:[::.XDN)H
M(W)$D<3+,5P-JA02",#(!Y7)_P %#?AOXL\$_P!M^$+](_$%O?W(N]*F(-O'
M963NQ61^"MU=QJHMT9@S-N4*2V*^>;C_ (*4_$'4O"G@[X@V_P .KKP]HUWX
MQO/#?]CW\<C7'BN"VNEA:\@"[G1?*8.I7C>2I)(./ICPW_P3R_9_\!V_BR"W
MMKZ[T[Q1<Z%>0VB232SQW&CJP:.UE1RJ/>2.=PWJKY&_.!73>"/V*?A_X4=-
M+O+K4/$.@M+=ZIH.FZ_)&TWA34+T%XX;6.)CA\ME9'+$,    #0!I:_^V)X5
MT?X4>$OBR^F:M-'X]UJW\,^#_!NC(LNN2ZY)+/%=+JT<@*1117$$@CVHC&'R
MR<L>/"-5_;P\3^!OCM=>#O'WA#4(?#QT."ZU31+&(R:AX9AD1)!J5TV612&R
MLJ,RKP0,$ U[YXK_ &.?!6N?#+2OAQ::WJ^B2>$O$<OB[PSXMLYDBU*UUR:Y
MFN?)NS< VYC,LSI&L?W8BBMR*M7_ .Q[X-U[2M0/B'7;S4/%_BG2H-$\4^,4
MVR:O?V<05GAA?YDADDVOF1!$"6R.* /*H_\ @H?X%O=1GL?#?A'7O%C7>H/8
M^';?3(B;S4+*WMOM5_J-P'4Q[K1!.2(PRA8MHY RV[_X*0_"&34M.L?#FBZ[
MK-D8HSKNM>2QM=$O_.$+Z;=OM*K<)<!X7P0 <LHQBN@O_P!AWP+J7A'3-)\$
MZY>^!==\/ZTUSI^O:9M.JVNG/!':7]CJ+-YJEKN 3%C\V3.<,#N%6](_8/\
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M:>&6QM8H(ETXHR_9V0CG<RX; V@$%F(4<],:KWMNTLZ^8";,"2YW!E,:G;R
M<!E;@#&>C?2@#8HJFMY"$0N_+H'!56P5).#T/I_6B@#\9/%'_!0YOA/X]^*?
M@*/PQXF^*/B;2O&USH2V-EJ,4J6MA8V@N[F2%!YP53&L@+*BA=N[>?,PFM\-
M?^"H>C^-[V^U'Q5\'/%?@;P1;>'=4UW1=6O[J #4=8T>&2>ZTH,\2 N_DNBK
MYJ@9QM/?TZ;_ ()T_#G3?B[XK^+]CXJU"Q\0>*;Z_O?W;(--L/M]C+9327T3
MJ2\GESXC)9 6VY'R@5QOQ._8,T6V^%-WX1\%>*I_$_B[2=!\1WWA70]:OK:T
MAOM6U>TNTDG2*18GN;5?. 6*-BP;C^'- 'RQ\;O^"E7C/QI\&=%CL_A]XG^!
M>K?$KQ+H6I_#+Q#<W\2/XLTZ?4C'(T!B6/$=U$%9FRP(<9W8KZG\4?\ !1;P
MW\'/%^E?#CXH^%[J75#\/+7Q3I&K:/=65[<W=WIUM)<:O;3W!21H);M8C'("
MR[069D 8J?"_@7_P3%U[QI\-OAG-^U#XSU#7/$7@[PU8V7AOPBUQ$]KX6FMY
M2T;:+M&;>2-414)+E5 SG@UU^H?\$CO#.H>+;K7=>^*VIWF@#3M?TRSNI&5]
M:T]M=@DMYK>>]<-'((MVV,"-0 ^W&.0 8_C;_@JQX@L? 7Q#U+1?@/KFE^/K
M3PS'XT^&EI=W5L(/$VF-Y+%YB(@3Y<3L2N6P-S!@!S[?XO\ ^"@P^$^D?LZ0
M?&'X>&S\0?'KP7H6N^(+>QU"W \/ZCK&F0W<%NR[4,:&27 9@#@9!(4;MKQW
M_P $^O"'B_1/!.AGQA>6-U\._AIJ'P^LM0$(-WJD&JV_EV-V[!!YLL"A,LBX
MR,+\IQ7C'B/_ ()63^./%?P^U?Q=\5;SQ/:>'M+TC3O$D-VI^TZ>OA^UCM-'
M_L%')-H7@$@G5HMTC(A5N<  X_P]_P %$_&OB+PIKGBWXS>$-2^%?@GPM\2)
M-%T[4K>_MHO^$GT.WDC2UMH HMR_VT>6KJ"Z2%BQ*DD5ZT?^"G_A_0;2+7OB
M%\)?$W@WP5>Z!-XH^%VKR7T.?&BVD[:;;VK (AS<2EG/#*X W8!&ZMJW_!,3
MP3XLT[Q#X*\6_$;4-:^'M[XEL?$N@>&KV9$U2$:9#Y<RV:G9(L9DC5P1#(&=
M,@^M;_AUUH_BR.\TKXB?$[5]<^'?AC1(O#/P:T*=-M]X1TL7\.I3W%S<!=LU
MREU&\4;!%3RL!P"!@ ]R_90_;AM_VF?&VM^!-3^'VO\ PY\2:7H2^*K&74+A
M%&I:-)-LAE5&"%B8I(_F92@W=2 "?,O&_P#P4@\/>%/%?CAV^&7B:[^#'@_5
M[KP?XE^,D5W"+'1_B2L2_9M SC"()I;8@>>,^> 4 (KZ4\ _LL^#/ /QHC^-
MUAXBN-3O[/X=6?PR@T"*6%K1K&UV1_:Y((QE+YUBW-([ %SD ?+CYN\8?\$W
M-!\4>//'-DGQ#UJT^ _Q%U*+Q'XN^$"SPBWN/B!:S"^D\2VSE Z3,(8(LG<"
MJ'.<8 !R'_!.3XH?%7XJ6'[07Q_^.=]JL6FZ?XRU^QT2%[T/IUMX'T:%KS3[
MY(V*QB06<!+L &\Q2V?F)'<Z7_P47@N/!GB;XP^(_AGXCTSX?6GB2;PA\(+P
M7UNW_"T]5N9S96?EDKD&XD2$(!YN1+@!RV*^F?@?^SQX3^"GPW\1_"Z74UN_
M!?CW4M:C-I?N(]1>VU:T:UELH[DE5:);<E(TV%PS'G#'/R=X9_X)M3Z)X ^(
M?P8UCXH3:U\(&\2Q^,_A'97Y6XUOX;^(X+B>ZC&GW<:H(+:&5X62-XRR[ "Q
MP30!4U__ (*;6'@W0[C0OB%\"_%MC\7H]2T>&\^&4-Y#_:2PZZY/AR:-UA!\
MBZ;(D41X !&'52:\ZL/^"H<_C_0/&%BOP?\ %_PSDU#2_$.F:-XEO[V&*'0?
M&.@.;:WLI&\N(KY\T;(41@QQ@C:26]=\(?\ !.NWMM>\._%?XN?%+4?&_P 6
M-)UFTEG\3Q*#_:6D:<P3P];3Q%&9Y=.1WW%5"J7XQ@Y[K4_^">/@77/"&H^$
M=:\3:Q<6L_CO4_'5RQEC::X.KWD]Y<AXDC$GE!I_W0 &%7YNHP ?$WPI_P""
MBGB_3?@'X+TO]H#PAXC^&^O?$K5=>L/"?Q0L9[:*RU^^TB_6TC:X"Q0$O=,4
M92['S-^X[BI)]=M_^"HNDV&N:'X8D^&_B[4? _AO4;3PM\4OB#?SK)96=Q=0
M"X@UN.6),F$((F+-,FX2;>  ALV7_!)W3-9MX?"OQ'^+FM^+OAKH<^HWWP[T
M.ZG1H_#%_?7*7,+6D;1J4CA\N+<H8MYB8R <GUV3_@GCX&M_ 7B_P;+X[U.7
MP[X@UG3-5UY(EB)O186D-DNGLVTXB>$+WW;@L@.5& #S<?\ !6;X.#Q9XPTF
MYT:[E^%^G6D</A/QI;J_E^)=2(C\NP+(67,CED7)(RHW=!G ^!W[5?QL^.?[
M<'A_PQK?A74_AU\(KCX6IX@T#1YKM0=;=[QU@O1%B,9EB6)PQ+L%?;@;<GN_
M!?\ P33\">$(/%?P]FUW0+SX.ZS;--I&EZQ8Y\6:-XDF@,D-YH^I%X@D<,LA
M;RMC.RHBA&.6'4_LU_L)ZM\'OBA9?&/X@_%75/B;XD\(:#_P@_@ZQMY/LUAI
MVCFX9K9=2A9&:::*V:%/,!4$Q%L#- &W^T=^WCX;_9<^+WA3P%XRT;4M>\*^
M++'=>ZUIUU%+)X3!\Q ;D+EE\\*8N&0$L, YXYCQQ_P4(\,:;\&[OXD:#X.N
M;[2-3U/6M*^&EO(QCN]:U/P]$]Q(]U$ I:*9$9&7# \,0>_(?&W_ ()D>'?C
M%\9=6^)_B'XJ:U:>$M7O8$UO0H7#W %O,MQ#::5*R.L/F3G9(NV1C&YQ@+D-
MT+_@EQI=CX[M=5O/B_K&H?#[PU%J=YX&^'U\!(=#U76(D@N+[4BJ@70>(N0J
MI&5+@Y&>0#G/ W_!2WX@ZIX%T>XUGX'WFK_%N&T'BWQCX<TM_P#1_#OPRXGN
M=5<QQ_+<0V*R2,-H7"DLWR[3Q/A3_@H=-IGQ4^*/B71KVZ\>_#[QA!X2TGX(
M?#*VF4:K/XMUNTC-]I4C2&1$?[0)$0A6RH' [^K/_P $X]:TNRO+?PK\?9]*
M\2Z\U[I7C35;:6!+^X\ WX\B]T2&)B9(8([%I43,>8P0,Y.*W!_P2Y^&-I9:
MRWPZUS4_#VO6-SX0U;P-XH9LRZ3K7AR*,'4XW"'S)+F5&>4@99CD[1P0"J?^
M"F1CMT\!:7\']<G^/^C:A!;>*?A,;NV271K4+(UQ<%E7AX2@&3"C;\DC!R,Z
MP_X*=Z-XOT*Y_P"$%^&&O:KXI\"PW>M?$'0YY8KBYT>ST^Y,=_$SQ([$QXG)
MC?&=BC: *\8^.7[%5S\$_ 5]\9M&G\<_$3]JWQ%K)CU7QAX=F*37-S()4BN+
MZW\F5OL#;E>XQE7#%<@C)E^ G_!,[XCZ;\']'\1WGQ"N?A]\;/B+->2_&2:"
M$2:=KGA#5)UGN[*SMPNZTU1X9IT:665E9GW&,!,$ ^NO"'_!1CX4>,O#?B_Q
M9X6\/:DVB^"M!MM<\5WEV^%TNYN+B"TFLD!!!*R3; %< LH.%.%'2?LX?MGV
M'[1WQ,\8> _#GA^3PIIOA>WBDM(]2"QSZQ#.H<7L"D!I4.48R!'&'7#%F /S
M9XN_X)6^&]4U!+#X<?%O6_!_@34K&RL?B%H#E1/KBV5Q%>/=3D1H,W=Y$K*S
M+@"3;]??/AW^Q=#X$_:+\/\ [0-SXZ66T\/^#X/!>C^#/#EJ=,M9[>WBC@BU
M/Q$CLWV^\\NWC_>_)EW8D'<N #]#+80GRGC1F8.8FN3D^;A0,AB0=H/3(YVG
M XK5F<JRDY/=<8X.1GJ>2<# XR"17)O?V>FW,9N=7L+33X+=RJW-U;Q>?DL^
M(UDD5BZ[AEQNSD #BM*VOTU)8Y5<%)+8S)*H_=!6)V$,?EDW#)PIS[YQ0!T2
MG(!]0#^E+@=<<^M5+:4ND1#*ZLI^< @,>N5!['G P,#Z<2B1O,"$ 9#9]B,<
M#G)ZYSSD=AV+=>WZ@.<?*2>>5QQT^8=_T_"HB,\X'\OIR.>,=/\  588!@0<
MX/IUX.:C\H?WG_,?X4"M_5W?[QB#YD^IR.WW3CCU&!S@?0<8L5&L84@[F.,]
M2".01Z>]24#/EW]L3_DA?B/_ *_-+_\ 2FO6_A+_ ,D_\-?]@RU_]%+7DG[8
MG_)"_$?_ %^:7_Z4UZW\)?\ DG_AK_L&6O\ Z*6@#T>J=TL+%/-;A>=G=RH+
M <'L<'I\I(/1JN'H<<GL.F:JSB-629_X=P4\X#L ,L.AZ* "1W- 'C'QN^)<
M_P )OA5XN^(D-@^HW&CVQEM[9%8R']X(5 4!MI4DMR .K'D8/Y ^$OVX_BKX
M%\6^//%_B_3X_%TOB:'2/^$<T6TU*$6VDPW\$$T*/'C9'+'&%5T&7SN '6OV
MU\7>&]+\8:%=^$]?M)+_ $W7%>"\%N501P' # L&4$C)!(.&R-I.37S./V*/
MV?+70=;\,CPK)$^L7UOJ)U>5VFUA9;7(A2WNPH18ANYC"D[< [3Q0!\AW/[<
MOQ)\7S>(K&[^'O\ PBG@_P -^&;?5O$^L&[2:=Y9RL<20&*(.&,I)9RP&U1P
M<DK5U[_@HY+\//#>I^&;CPZNI_$7P18V6L:C:JK,EQX3U!D%M=#:C$RJDRF0
MLIY!?.3@?HCI_P !_AEIVEO;?\(7%<PWUE;Z3K"W&U8[RSM-@CDNHV7?(A>)
M99-N,G<">3G$O_@;^S]:>-+Z^U[PQX:;QEXYT'_A'W2\CC(N]'MT:*&WMT<;
M08XUPK MM<*5P10!\"W_ .W[XZ\3^"@GAKP38^'O%7BRWU/2O"?C[7)!%X?M
MC'IDUW&\[ND<882A OS[@=QR2H-><^-/C9\=K;]@CP?XZ\/^)],T[XY7OBN/
M3?$OB'2I6FM-6EL[Q95\AD=F,4S;(_E  7(P<C'Z17G[)/PDU'X>_P#"M]9\
M/76H:%!J]UK&DV$ES$)(&DCD5X;.>,(8X%BE*JAP0!@G!Q72:1\&?@OI/A?P
M_P#"^T\+:7!I'AZ2.[TGPM.OFR_;8Y"S3WC/S.^[_EH,!=H[ ;@#\L[C]KSX
ML_%GXG? >P^&7CV#0M-TOPGJGA_XKR7B2I:S_%,:=<1Q0,,*I66Z>V ."2SA
MMK$#/*VO[1GQ,,4GP1\6_$W6/#/Q.U#QMJ%A\2O'\%UL\/Z3HD\\B6,5I(SJ
M8Y(TDC+\QCA@!P:_7BS_ &9_@O8:/J&EV7@'2M&_MKQ)+XDO[B)HX=1M]6E:
M-Q=6]RN&9P$C*;,D=P2H*\5_PQO\!;SP[XJ\,:QX6U#48/'&HW5QJ5[K-P)_
M$%S=(0RS:??[!]DBP245_56)VY% '@5K\<K[]G[XE_#WX#^+=>F\9?#KQ%96
M%WH_Q1FU*WGO+Z^N<%+)KA7?S59EC+;9I -VT ;@1^@4,LL?A?4+?2+Z&\OO
MLE_=Z3<->PMYTTZ%[9)"3D/$[KC<?X<@\UX=H_[)/P7'_")-J/A>YN(/ L*V
M^AZ;K\PO_LGE!5MKPW"!%9T"J%VDA61?;'J&D^'/"'@/1;/P_J31VMSKFJWU
MIIXN+G-U*]Z\GEQ6DK-A=D8S$@W<#N.: /R<^''[3'B;X3:I\:=!^*GCV&R^
M).DWNH>(/#EOJ=Y]HLKG0+:YG:2RB+2!%8EU54(VC"KVP?*_%'[=WC7Q?XV^
M$?QENM):T^#?AG2KL^,?#]FSI)K>HP3L;:X2)#L:-[@*27&57IE< _J=JO[%
M7P!O;3Q/%KGA!=?O_$=RUYJ6O:U=176MV-I-(6ELM.G4!HK9F9\QLK#H7)Z#
MJK']E[X+:+H\.EVGP\L[G2=/T]M$T_2[D1_9Y;&>,N]VZE06N8SE@Y(R5'R\
MF@#\ZI?V]?CSX[U+X67G@OP9H7A7P_XI\4WNFZC=Z@^Z/4;&*UN'MH$9E.)O
M)6#@'"N&5>17U5\"/VL_^%N?$3Q?\.[;PC86MW\,=+FNO&VJ/<KY-G<6[2?O
M%.X[(Y74A5X(#@$,#@^TZ/\ LM_"*P\,>%]*&A//IWA?Q!=^+-*\Y<RVU],)
M5%N0JINMXVD9 F/F0+A@,8YOX*?LQ^$?@QXB^+_B=+>.ZU+XU:SJ.IZS<.=M
MG9:3-%)MLGC8DI:QQ@-L) #*",$9 !\=7G_!275K36O'_AO3="T7Q?J.A3;O
M#%S9N"DCW4CV]I!,0&!:.56R #@Y' 45B>//V]_BS>_"GQ?HEEX9T/PQ\6=*
MT.+4]3_M"3R[<:7/AS):GRT#3")XU4#D;B0< FOM/X=?LO?LU:>+C5/!/AG1
M=?-]K$D6L7UG+%<"VOK219Q$KHQ$7DNXRI8G!8[LG)Z[QC^S7\$/B&XLO$7@
MP2SW5V8I=0CC9+_9:\"SOIPNR33750D46!CY?F*Y6@#Y.T[]JWQ#\*OV8/@K
MXGC6'Q=X_P#BQ<VUO9F\G\O2;%IU5KMIKN4D+)$S@01NV6("B,BO*KS]HKQ]
M\+O'?Q#F\87NH>(?&MWK'A*;PWH$>J1-HXM;F!3<11;FV!%=FY"  #!(SD?I
M7XE^!'PA\5_#VU^&6L^#K)/!WAJ>UN="T:S@9+K3Y-,V@75G*H+))+E2'7*D
MEB<@**RI?V;O@HT.GQ7WA"#4C+Y,EGJUS&TVJPO;+^[6[F&U749*XV@\,N">
M0 ?GKXG_ &\/%=RKV'Q+\(OX6M9+N"]T2VT25YY+EK=0ICN[B$8*2-S@L H
M'/.WNM'_ &T?&&H_#3Q?\5KR/P=X.T+P_:BVT#0WNHCJNO2P<LDH+ J\\49
M4 D,X)89Q7W9=_LZ_!S5?+:Y\)6DBQLHCC$*^4K1J4;8CJS!6R2PW'^$C@@U
MPFJ_L6_L[:E;ZA!?>"O,M;YQ+-9B5A;(X8$/%" BJ200<Y!!/  - 'R#^SU^
MU-K'QJ^-%GXM@U*X\/>$+CP!J&L7O@PJ?LVHZGI\%\_[K!$1\Z2 !3C/S)P0
MYJ.S_P""@WB^Q$^LZEX-M[_PQ>ZJ;*VM=&N(%O\ 0FCOY+=Y-4@R94MUBC,C
MR%4C (!)R37WSX,^ 7PH\!W]KJGA?PO!8W-E9FPMX]J&&.V=#&\6P1C<CHS9
M!QR3UYKG=+_93^!6D>(/%'B.W\*+]L\96\T&M6DS;]/,5T1YPM[;9MC=CE@P
MR,YXR> #X!^*/[>GQ U/Q)H.A?"R.QND_P"$D$^N:I;ZG;2:*GAZ!H)+K3Y)
MD!4WSQ^9##'N#O)B,8.<=OJ/[<WQ#_X1:_\ %4&A^';+1=5U_P#X1KP?91.L
ME]IEY&\2"XUY6)-M&)90K[@F K-D#!/UEX?_ &./V</"N@S^'- \!6EEIUQJ
ML&N2(AW2'5+>=;F*7S'7<5$R_,@(#(<9JJ?V/?@;-IGB;3)]$OX;?Q9JK:WJ
MWDW2H6OW\L/]F#(PB0B-0<9/)).230!\=Z]^WY\3-(T5+73/ 6C:[\1-.L[F
M/49K.5Y-%U$1\PR6DB!EDF4E?.VLVW#*>#QSME_P4B\6Z/X8UB/QQX"L+/XA
MRI8_8K!'Q8H;J,E0P(5=P9L+\N<@MP37Z2Z!^SU\)=&T.PT#3_!VGP6.CP3P
M6%R(_P#3F6Z!\Z6:=PYDE()*DY&0.,5A>+?V8O@MXMTF]TG5_!EH[WWV02:M
M"BIJL(LEVPF"=E(0D;BYQC)4@8(R ?'W@;]MSQEJOB/X5:-XP\)6G@KP[XO%
MS%-J-RW%]K[.\=I:0J0"(YQRN20> 0"H!L?M'?M\V7[,/C^'X9ZWX(DGTF_>
M+5+>Y@WM+_PC=X%>_P!70J1LBCNY?*1P-J*X.[*K7UD_[+OP?N[[PM?ZGI^H
MZK_PAQMIO#]C?3))9V5S:8\BZ$*1JPF7@A]V<\COGHOB#\ OA-\4=6DU[QKX
M5L]9U=O#$W@Z*ZGBW-:Z'//%=216^X$++YT**'(_U>X=^ #\_-3_ ."DNJMX
M@\/Z-X$^&WVRRUQ+?6=+FN4=3>^$?W8N+TML)-PC,Z@@DCRVQG<:SM?_ ."C
M/CWP[H'B/Q]K7PRTZ#PK:^*7\->"0"QOM1D6&-GN;A2@*DRNT?&%"H^.6+']
M ;C]F/X3W]]X*U"#03I<_@+2UT;01I>R"*72_P!V3:WZE3Y\<AB#.H*\M)M(
M.<W?$7[.OPA\2Z WA;6_"EI+IJZI_:Z(D>);>_(&6@9D953@'!&2<G@_,0#Y
M-^(/[<^K> _V<? WQC\0^#/LWB/Q[K7]DZ9I2+(;.&)$EN)WNF*[4WP(4C+G
M=ELGTKCI?^"@5QX?T?2M1^*?P\M?#.J>*DB;X0Z8)'9]=NI HBDEX4-$9'B^
M15=<9.3DU]RZ]\ ?A?XE^'9^%VO:/+J_A))1/907Q22ZTN95,:OITVQ1 P4D
MH<-@G8W!!J#4_P!G#X/^)+?X=6_B7PC9Z^?A2ZGP9=:HBR75ILVLJ7$@4"1!
MM&!@'(X;!(H _,;QA^W/X^^(*>(_AAI!T?3_ !5:VNG:P-=TAB9[)XW%Q>Z+
M/Y(W(0BB)@"A8'<W (KV?PU^W?IMDG@S1]970=*U6_L8](U'46EBE:VO(HEB
MEO\ 4(Q(QCB>1-\C/T/S,P+#/UWH/[(WP"\,ZYKWB31_ UI9ZUXEOWU'5;I5
M&6EE&)([<;2(X& VE.<JQ&2"0,Z__8P_9RU'Q!J?B:X\ VG]H:M8MI]Y"I*V
M9BD&))8HB%,<S_>9M_+8VA<MD _-B\_X*#>/_&/CSPKX2\,6NB6W@S0?&TL7
MCOQ LC*GB*PMYW806;*!E+B-&$8+#.5X( 6O6O"__!1CQ3KFG^+O$J?"]H=&
MTW4[O3O#KP!S EI:SM9MJ>I,L7R(LY#!GP F.3R*^S=(_8R_9XT/3;/2M-\!
MVD-I8ZI#K%ORIE-U  $BDDR"]L0!N3.YB22QX(W=%_98^$.BVGC#3K#3;ZVT
MKQE:2V>K:4)XAI\<4[I+-]BB,3>0[L@R=[?+U!/- 'YX?#WXZ?%W6OA)^UCX
MR\0^+=)_MS3'AD^'NOZ1*\EIHB7<;30V<Z[BJD*PBE*\ !FRNW;65\-O^"BO
MC#P!X)T.#XI>$= UB;1M MI]4\5>&;E9[1Y;J8P1/-)R$FE+ R!B27!4H"HS
M^FOAC]F[X+^"O!_BCP)X?\'VMOX;\98?Q#9R#>;TK 8%._Y3D+N8=&Y('!KQ
M#QI^PM\%M0^$VJ?"CPAH$?AO0_$L]HNLSVC@ZQ%#:WJ7@-E=,,P!W!23<K#8
M2,<D@ I^*/VH'\.?L^/\=]:BTSPP=0NI19:GK#XM9M*$)E@0PD[Y/,  4Q Y
M.&)XQ7C7@']OW6_B7=^'[.U\+:18Z9J?A:[U;3'N721?&ES! )4CT! NZSDG
M7F,SY +#YB<JOVEX@_9Q^%_CKX<^'/A5XYT.+7?"OA/1X;+3[!MH16B@,!N9
M< I)<,O)?&W<2P4$FJ&F?LF? W36\)S:;X4&G2>!M,FT?PZUJR(UI:31"+>P
M*X>X"*I5PH"X/RDDF@#X.US_ (*0ZOHND^#]$T[P?I6O>*-;U/4[36/"HF!N
M?#UO8;<6,LJ%D>\<..2BR.^"""V!VFI_MU>/M)US4M G^'^DZ!<6OA>T\4:+
MH=U*?MFIVDULLUW,0P!V619P5"9^5=QYW#ZD@_8O_9[@TF'2[+PF]OJ4/B,>
M*'\4QRQ'Q+/JBW"W$L<NH&(![.8QJDMN(@IC 53DDGH-:_9F^%VO^)/^$L\0
M:-)>:K'I[Z5'?%@)X-.E41R6438V>0Z*J%64Y'<#  !^?$G[?=Q(;7QAH_AC
M3]<UBZM_LUII4+%8+;4F 4ATQRRR,2IQE0<#/6JWC;_@I-XX\%^&AH.L^"H;
MOXOMJ>G)::5IT8^QK!J4D1MT4^7R1%O\["DGN1V_0[0OV7/@)HVGV]CIG@:Q
MM8[*\-VDD:?O9)CF1O-<@AE8G) ..QZ9KP/]HG]A#PI\:;K2=?\ "=]<^%]=
M@NK:>ZNK&6*.95M908W1GR4*@#!P>2%X!S0!S/QZ_: ^+7PK\)?!WXX>))(/
M#/ARYMH+GX@^'AGR4M=2MUM[>.4855W7<UO+M<C!QCEA7QAX]_;(^+G@WQ%\
M*=-L/&MZT.FZFGQ6^*2V44DMI;?#76+J.&RL"^&C"Q13;Q&Q"@-D'*_-^P\G
MP%\'^)O@_I/P<^)[-X_TR"TM+*]EU1TN+RX2TECGB5I5554)+#&00HP%P3C%
M7[?]G[X1:;!J=O'X$T6]BUG0[?PWJ/VZU6X:;0[5!%;Z<?E'[B-0!M)/S*#\
MI R ?GAX(^/WBK1_VMK63XE^,+NZ^$?Q#T"RU#X'C3=11-&2TN0 +G6+9I W
MVE;@E')# H&'.W ]E_;,^(/C6PU'X,_";PQXOO\ X=:9\4O$EPOB+XQ:5>QV
M&FZ)96\3S6EO)<^8N([@>4K?O4#$8+C.:]*\1?L3?!C7[&5CIVHVL\5M'IFD
MS0782Y\-V<;&2.'0'</]E".QY*G.]OE!&3ZCX@^ /PV\9_"C1?A1\0M+F\4^
M&M#M[2#3[C4IA)JZ26C%K>X:\7:?M'(#L@ 91C'% 'Y$S_&_XWZMXNT_X&_\
M+;U+3-!T'QU?:1)\:SJ:1Z=K%G:3JD1\\N5=)(RS??).1@L< >J_"C]ICXIW
M/QC\(_#W6O%5_K'A'1/%&N:-<>+KB[C:R\7QB39%+$S.8S]E< J79BN, ?-D
M??=[^QS^S_JWA#1? USX29-"T'57U>U2&=8KJ>\D(:1;N?RW>>(E4(!(8Y.6
MYR+7B7]E#X2ZWX1TWP3HVA1^'M,TF^FU.UU+2G$&M6ES,VYS;7A1L>:>)-RD
MGJ=IS0!\_?M^>)OB7X,T7X<>*O!?C&32O .F>)X+CX@Q65W''?:GIQ\]TB#Q
M.C2(4,97<6#",\9P1\K_  [_ &S_ (A>$_B+X^\3?V=J?CG]G>^U70=.T6[O
M+^,W&GWU_93S2PJ)#)Y:QL8@5#$C83MX&/T\\2_LV_#_ ,:^%/#_ (,\7IJ>
MIZ/X<FMYH ;H?:=1: .%35'*E;B,JV'550/QDC K;M/V<?@II>F3:/I_@+28
MM&GOK;4I=&6+&G27=I$T44CQ$%B64GS,/@,<]J /SBC_ ."A'BK2=.N]0NOA
MU8ZU::@9[GPE!;WT4U[%J']HBTLS>I'\ZPK&R$AN$.X<]:]4_9^^//[0WCS]
MHGQSX,^(H\):?X3MOA_!XFL/#B'_ $BW>86978N=Y8BX;S'Y.&8GH2?I#1/V
M0O@3I-YJC6/@V.U;4E=O-5R'M%:Y6Z,5H3N6&+>HXV$\X.<XKT.'X&_##3/B
M'-\4;'05A\77'AR/PM<7*L#;SZ5$(D02PJJDSF.&,&3H&&>"22 ?DW\*OVF/
MB'HU_P#M%_$'Q7=>*+_2_"'Q)O\ PO\ "WP3#= ^%KR[ F6V&IW$O[N" W!B
M&2PQ'EB<"O5[#]OWXG:A<>&_!*?#[3;CXK7WVO4-<TG3;^&[\/V.EI$TMNTD
MJ>83,J(C$DKB3G!R2/T)G^!OPPNO!7B/P(OABRA\/>+KN?5-=M8U"27.HS\-
M>[P 1-_$'))7('()-<KX._9A^#?P[CL%\,^#;*TGT\78_MB13+J]W#=Q/ \%
MY=MN,D<:,/(50 K  EN20#\_-3_;\^/;W<46C?"G2Y+60ZC!J<\A<"%M#C$M
M[(A$;*!,"RJ"<9QAFQBOHOQ%\>V^+?P(\5CPU'KG@KQ7%X(7Q%;ZMI5PNGVL
M>J3V;O% +J;8CM',OS1HS./F90K##_2D/P"^%7V:2V31)(8Y4O4D\LJ&<7ZA
M+MV.P@.Z\D]0&Z8&6N^)?@EX \0> HOAF; Z7X1@AMH1#I;);7THMAM!EN-O
M[Q90!YN1@Y8@CF@#\0+?]KGXNZY\/OA1HNO>+K^'_A%[_5[[Q]K&CW_]G>(;
M[2M/N7Q"E_<,D,]VR;/+^<[L\>A^Z_C7\8=6\5ZC^RYX7^'/B'4M,T_XDVB:
MKHVKZI<>7/?7]K#&L-CKLRL&O#,Q1G$9*.S%MN6P?H'5_P!CW]GK6/#6C>%=
M3\#K_9.A7B7T5W;,L-Y=;)%=XM1E"_OH),?.!@L#R#6Y\3?V;O WQ#B^'<D%
MLVD6WPOEBE\%_P!DN+9M',2A$$;'>"-F,XYRH+9[@'X_>/OVCOC)X'\/?$CX
M?^+O&?B]?CL/B?9Z>=!\+:FDMM)I#RHEJ^E2(V-.A,9;?#)MSPP'&T_I7X0^
M(US<?#*/X?:T_P 0]'^(^L>$?[2.NW,X34(;N.R-U"3J4G[E29%"L<X^89'&
MZO6?#'[*/P7T34=0\27GARUUWQ;KNHQ:SJ_B/4=EQJ=[?PKOCEFF8$ QRY"H
MB@;.N.:]R\5^$]$\7:'=>']5B:*UO+,Z<;FRV0WT-JZB(I!.0VP/&"I7!(R=
MHP. #^>C3/VQOCA;:'8_#_7?'&KZGJ)^)E_#X@U&TU!(O$ \/6)F"07&L8%E
M-&\<.WRHW)R-I(V9/Z"_ _XS:QK7Q\TNUAU"ZN_AQXH\$6=W_P 3:\5OL&K&
M1XIE(RH64LHW2KM4J5"C))'T,O[&G[-\/A:V\"-X+6'3K?5(]:2^FF4:I->B
M0RR&>\*$RPS2$M*A4$[L;AD9YS5_V,O!FK>.KGQ/IFL:AH$,MG:V<>FZ!=+:
MV-C;6C;H#;1'(1Y%4+,P)W?-A@#M !QW[6G[6\O[.FO^"=#L]4TO5KOQ-JVF
MVC:9'MEOUTVXGPP#KO8 QECGA" "< \>*M^W=XSL-=UO6-2^&%K9_"FU?7UT
M^V"M+=7VJ:,!*UTS>41&)B 0=ZA1U#]:^XO&/[,?P5\=:WX7U;Q;X?CUG7O"
M]G:VNG:G(0T_^BX6.6=VWAYP<#(5<\G' %=7/\!/A<MG::<WANWN-/MYM2G:
MSF"O;W,FK )=FY78"R;?NA2O+%LD$@@'YS?LW?M"?%7XH?M!?%V[\7:UIR^"
MY?AI9^)?!WA[PU<J);:+[%/-=1WC;A&)H5"ET?)8$\<\\E:_\% OBEI\6M:'
M\._A9/XNBTS4)X);O6+^%64)+Y;,I.5(X& 5'&TC. :_2WX9?LQ?!;X3S:_J
M'@WPM%IU[XDMIK+4KB1O-D6RN5:.2SMBPW1PXW!4)8A2>E6M-_9O^"^E07$%
MCX-LXOM4QN+B0*"\TK.';S'"C>I;)SQR>P H ^"6_;P\46OP3\:>,=8T30O#
M'Q#\/ZI8POX)>Z66[U:VEC#O%92QD!BPR"$5@"P!'S9'/:-_P4(\3^._&/AO
MPCX*\ Z5/H&J>'&F\;:>\\0O/#<OV:1Y;]PN#N+@@%RIRHX7 K[_ /&7[*GP
M%\=Q6UOJ_@;3K*6WVO!?V&;:X:15"*TCL&5V&T$D@Y] <$?*VG?\$[_"ND?&
MK3?B+X6UW^RM-L9@NLZ=;NJ_VWIY5HVL-0 9O,1E8'"[<'JQR* /*-,_;]\:
M>&KAK6/X?6.H>$['4KJWU?6)IF+VUO&\R$AN<KM10"Y !!'(Q7KW[+_[8GBO
M]H?XD^,]('@6PA^&OA]9I-'\20S+NL-4A60NTC ']TBQL[;&XP,8VU].ZE^S
M%\(;KPWK_A*VT&WA_P"$@BF%P\0P%DE\P!HB2<%6)P.N,'.<X\&_9L_8CB^
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MK:.\L(;Z[@^QM/;^863>K+D!>!R1DC H^#O^";7[._A7QA>>+M4M]>\175Q
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MBC2? [WSIH=GJ9D"+J:VY8Q&>%PT@=8E/S#:Q)KWWQ]^SS\,_BYXRF\9^)]
MFA\16'AV[\,ZAJ,T(!O-*O(6B6&*5B2ZH@<$\@G!/!H _)G1/^"J?Q+\(^%M
M:U[XM?#:UTRQ\4:)!JOPK&E)'<3Q7.IHWG+J"0DD)#(IVL^0H7*[B<MJ6?\
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M@# RI' Z5I;1NW8Y/?)]ATZ=A5:U9WC5I $D;YF3C<N %*D^@('/<C'05:H
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MSXO[U %'^S\DY"D=L]O7ICVZY]L=*8^G,"-A Y&2/3GCD?3KGH*U=Z'^-?\
MOH?XT;T_O+_WT/\ &@"E!:O%CYL8&,Y]B!G'7 [=/S.6/9>9)([;6+-GOQ\J
M@ \CGC/XUH;T_O+_ -]#_&H7GCB))9>?FSN [8P.O]W)]!^&0"BUBJ8(5=PY
M4<G.,9XS@_C^%2)%[;1GG/4G&23U"@CT'7TJY'.D@)!&![Y]?;CI].1S1(8B
M"S.HX /(Y&<<@D<Y/7J* (BB$Y^]P.1E1G)R.",X]^>>32&-,=/S9L?4\]!_
M]8<U(GDA0-\1Y/WL9ZGCEC@>W3OWI28B/O1]^5*@@]NA)/K[8S0! 8(LG+)G
M//7K3_LP QD '/'(ZC![^G^1UJ,F)&8[@6;(SG^]R"?KC/'3I5AFA?!+ X'8
M\^I&/7_&@"@]J=P(Y Q@ Y .3SU)([XR1D].HJ(V@6Y-W-$0&78%4[BN 5)]
M2&X()R<=>IQH_N?]K]:L;T_O+_WT/\: *$<3@RH80JE,HZ8^;<I&QB0.!P<#
M^(]<9P^&)%1P1M.TD<Y.-H&[C@XZ Y]<C/-6))XX]N64[CC[P_S_ )[T/+%$
MC293@=01DY/MU]?>@"LD"Y)& 3@DGCJ<X&.N<')[C@GD8B^RR,6\ULPE2,9!
MR?X3D -R??'.!UYMB2$@,2#N .!T!QSCZY&?7KWIZSPG@.!@>HXQQCK0!4@L
MXTB;Y,$ALY49)((SQGMP.^,U5^Q1%2D2>4[%S(0Y#,FXD  '&.#GOGVQG2DN
MHH^I!''.<#G/4^@P>?8U&':0[TC1E/*O@'/X@$'GGUX^IH @AM5M6C$5J&+'
M=+*S D$#&0>3G.,#(!&2<8%7FB5LYZ$] ..O&,<CL3SC.3T-(9U0'S"%8#.T
MG'8?CU/IR!FFQW,;DC.,=\Y';O@?3ZC% %&XTZ&2179W4KR5!;:P)/8< \8)
MZXS]0KVT,L8C PHX&2V"5 VE0"1S[#OVSS?-Q&'";EY .=P'!.._X_E@9-(\
MZ18R4"D@?> QEMHZ#O\ H!Z\4 58;9MH.0""<\Y^;:0<CMU' !Y/<8P2689E
MW/M&XD!<@EAT)QW_ $&<@9X-SSXAGYAU[8Y]Z8TL99#O&!_"?J#QCG/ /IP.
MQ- $(M6CRRL",=6R2!QG.<'M[XQQBI([<<G=D$DKWY.,GGKR#U]2:>\\>QOF
M'3'Y\$_A_/%)'/'M/S#AC]>>?TSC\J (Y(OF.W&0""2,$C:K?P@X YSP..^<
M&H?LF_G@$<<%N#U[X/?W'YFK:2(TK$,/N]_HO/Y#]/>IMZ?WE_[Z'^- &2+(
MA]JN!R2%W98#' SUP,9QGV//-7!;%LJ^"AP!@GH#D<9Y)P,D]/UH::VWL#C?
MDY/J<9YY!Q_4#O2J[@@[AL SCKP>%''NPQGDXSW(  HM(5& /Q//]>><GG/6
MJEQ:VQE)*OO*C  .PX!/\.!D=3@<=N:O^?'_ 'OY?XU%YT9D/S8X!R#SQD<\
M^Y[<#IRS4 46MYF_=JB&)@ ZG 8J2 0"V>JX! /WL=^:M);P^4(! BPA=N"1
MQG.2.<Y!S[^_>I7FC?8 PP3D]^G! QGG!/XX^M*?)SU8^X)/^<=* *R6$*'$
M(*)D[@3D$^W)/3 )X)]<&G268(SP #NP"3@@<,,@#*\_GSD9JVC1@':P S_$
M0#G ]>U/+I@_,O3^\* .<DTJV\SS;B2>X;^$XW@ 'D GA<%A_".G%3Q6-M%(
M98TPI15*LV& ZC(SD+EAP<'J.HK26>.3B,JHY) X)//<=,>G'8$BHV>*,JQ(
MRV0W7[HRW3/\77)]>Y)H K/;QEO-M[=1(.I8@ G[P]LYV]?QZ582-W5?,!$G
M<<;<[>H.,8 RH[$ 8 /-3(T+X!(ST!#9Y]#Z=L8XR2!TIW/0,P&2!@\8!XP>
M3C&.YS0!7DB;[@^52RGH#T.<'M\Q)P0>IY]A;8L<9Z8#=LC)P,#' YZ8ST)/
M03$%R4#G(P?F8\=, CH<YS],\''*@,H'S$G!!(ZG:>,YXYSP?KDGK0!2ELD,
MFZ4L\:@8C)."<X !X4#)Q]>HQ34M(4<&&Q18Y\K/*KGS%]P-QXSU'3(R<\U=
MEE7RB&89!!^N.?Q.,9X&.I]*6":/R^#D[FX'N20/;I0!62)9HW"6WEM&=BR-
M@$XQ\RDY(R"3D8QD8]S["75?,+.0 QW-D[@>@W' !&>1C&>.*O></3_QY?\
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M))-/DA2REDV1AFM%*1,9'=4(\LL S8!+GKG% 'XR_%__ (*7_%BW^%G@G4/
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M8D,#P>F??C&.>IY[UPOAVT;3-,\.17VI)?3:9HEII%RR$,7NH(HX7<@="=C
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MIXZ^/>F?M0W7CT^+;W2-9GU?P//IS6$EA!J,\!AFM-4DAB<F-%Q^[++*-Q+
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M;BSMP;A'\E8)6BE4&X+.5:.0"3)*A0"*T]0'PG\4VUSX>UJ'P;J(\6PQ7_\
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M"[><$9%:-]H4%X+--1M+*[BCE286\\22PVCQY,8LHI T896&X;@6!52K @4
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M%2?MW^$K/3M/^)>JQ1-H&J^#=5\21^&[%TN+U[W2YEMXK<!EW+.,@#:N<KL
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M8?\ #&O?#\Z1X/U"?0?$36^JZ%:^(;E@)[+2->OQ=W[;XE'S<#RR"!AN>HP
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M4^(O"WA"TT/4K+4;Z\GL-<U9HTBL_"^K):237-J2H D$)W @<$IG@D&N/O\
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M%!' (K:;_P %*?@L;#Q9<1Z%JVG:9HNIQ:=X1<Q*P\<WZ1R,;:&8H K"01Q
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MO%/@OXL_$OPE\4O!GP3UCQQ\-O#]KX?M;R]MM;UB[2QDBU)# DL<DT<\Z_.
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MK]-+;]D']G.PTV^TK3OAOX>MEUY;DJ([(*UM)=EI+BXC< 21O*S,S%&4$\
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M"VM=#N4O?#<S6T;OH-Q;OYXEM9V7S\[B1MEE< #A1MP #\8?BCX\_:H\4_%
M^(T\6R>$_#D7CVTTVZT.UN$C>2.66,M"(D1"<D$!>,ABH( X^RO"?[57C"\\
M2:3\(_!2VVF7KW'BW^T]6\7-'#;7;:3;1-(;26YX:2,$NRQ\_P!\'?S]]?\
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M "T;=G@C/0YQCTZ#''3G&<#D59,!ST0_4MG_ #_^NK-% %;R6'0(/Q:BK-%
M'YPZQ\ /VA],ODU7PW\6IM1%Z1%J<*@[+=#M!9#NPQ"L20N <8/'0O\ X)?M
M3Z=?Z%:Z7\4$;05NFNM6NIKE+>1%D"*81&[AFVL<8; ] 3BK4/PH_:?TL3IX
M3^(6GZG#YJ[S<7<!P. 5&8O[HP3ZYYP<UJ:G\/OVE=7,D?B#Q3ID#66G-<0Q
MPW<*F\N5'[N- N"_[P#( 7G  (X( [5O@=\7[KPIJ6CZI\3%.OW7B*UO]+BD
MN4@6ZTZ*>,S/#*S@/+AE A3+M@\= 9]0^%7[16JZHTLOCZ/1M.L+;[/IMN]P
MJI?2(N4N7?[JL['E7(8D#(PU5/#?PP^.WBGP)YWQ!\06]IXUT;52W@^*&X1#
M<6T4F85NL +M9$C.61P0!QPV6>#_ (.?M*W/A+QAI?Q#\?V=WXBU+5+JZ\-/
M!<1A-/M&*FW@#1Q@;8^JACD,?E4#+4 =)\*/@]\38;/7]0_: \2)XAL[.Z:[
MT:T^U1B*)(2#;S-=[S''$J_*5W#)QD ]8_&OPV\>^/)X-?\  NN0^'+2U8QV
M,ZZG&;:81DE4,@=48Y   9ER3@=QY2O@#XAZ L.@_&KXW&VTHHROHUE<;IKY
M-V8XPT<:,2PP0I8%1G.!P?5_BK\(/'OCSX=^%/"?P@\3?\(1X<L$AN8KRYN3
M'?ZFX5 K2.PDD(EVEB#N #%2.P ,W0_@Y^T9=SZA%KWQ#^RVT\>VTFA<7&\*
MA )"-E!@J QR#G(XZ<M_PHS]JFPNV31?B:1:-=(3+/*(BD8=-[;&.YPR;DP,
MCG/; HZ=\)OVM=#\.:XB_%&RE\1Q"&VL8C-$R["J"-US;D%G4G(XR5.<G&2^
M^$?[4]WI'AZRUCXN:?:^(TD^T30QW,2LQ88P5$"Y&#R .N.": .Y^(_P<^,U
M_J6DZOX>^)IT?4+:PAMUE>?R;?5;Q$030DEE$;-(/^6A ;>>=H->F^#OAC_P
MC>C7>W;J7CS7-(FB\270OHV>#4)E=&N80-Q==I!S&3DY.3S7F,?PF^.)^'<V
MB:[XNMM5\4Z?XDL[^$I.$>33%='EP5VDJROC+*.,EF %8?Q^^'WQ*TWQGHGQ
M-\+^/?\ A%8;/P]8^'I?"\,XDCU"]B<M)J;1A&!:3>T>X[N!EF*[20!]C\&_
MVD;>RA\-:-XU_LWP\VM/J$]])+F\2/SA(+8*6$A0CY&VIMSG.,<:'Q!^'_QQ
MN?%7AS3=-\?QQQ>4OVTO<)$40[<MM;;P<$'#$G/&<"O,O^$(_;&U3R-2T3QP
MHM[]$*+)Y:E0WS"3:8E "X+,<9]00:^BOAA\*/B#H#_:OB;KC^)]<O;;;!=Q
M2%EM9<,/FVA57!9#G'\+<<XH \[T;P7^T'IOCJ.PN/$D>I>$EM9_/OGD66*.
MZ",80[*Q";W*@Y]2#TK-U/X4_M2ZSXLTF:U\?66E>&I=0(U*UBD695T_<S%B
MFXC)C)7 PQ('!YH\2_!W]HZ[UF]_L?QRFB^%QJUNT\'F(TMW9M*"T:,T3N B
M@*Q!' )!S@5VOC/X3_'&6ZLM,\&>+7M; Z9&D^H/(H;SQ$ S?.KDN7W9P"&Y
MX! H ]*7P=9?#?0M6TKPEH[+8:LC?:]=-XC32ZM*K"XG6V#%U1KALCC R0">
M*\G\)_#[XU1^)(IM>\;0VGA.6*1K1C?1O<1RNV$_<;P^%)7D@*N?:E\'? +X
MS:#J-M/XA^(SZ[9"47$MF9/EW'[Z8"+P>F??  XKI/B3\+_'GBS4EM=$U";P
M^ALTBCOTF95:8 ;4XR/3 *G!Y([T >:>,_V>OVAKCQ+=:EX1^)\HLIV\ZW9Y
M0D; @LO)8*#G##&0<DCBNC\2_ KXP>(?#WA74+WQS(/&.@11Q2S&Y%M%=7,<
MB'<&/RR\I@$%BW0YQS2N/AI^U#;:=#HEIXQB:VT>VWQW9F4R7/EJ2(U;8"Q)
M#8  W$ Y((JCHGPT_:#^(7AGSM8\<2Z1?Z7<,E@@=8_.>)V!+[8V&,HA!((.
M1GDD4 )X0_9V^,=]XHGU[XW>-I/$WAY);:6+P]8S9:[EMI%:SC.TG'E31K(Y
M[C!(VEJZ?XO_  V^/?CGQCHVK^ O$L7A7P[H$4=HNFPWT,GF111Q@>:JLI1L
M1DE64#G@]JL> _AO^T:GB..]\:^.HUT[3(Y[>W561EG$L7EQ,X\O:7)* $XY
M Z8W#BH?@1^T/8^(-7U+3_BH]CI.H:N_VFPD=3Y\$CL"L0:-F&4QLVL >A*@
M8 !DZEX/^.>DV;^*?"OQ1M=?\0PZE%8ZYH@NXA':10.@9@V\QEL;R0'RO([<
M;GC'X._M :U:Z%XQ\-?$)X]:^U6-U?Z=#-NC4(27$C*VQEX&[.2N!NYKT6?X
M27GA30-?TK1(KN75=5:)WU%Y69'O[E<22H6;Y0'^?Y2%!)SVKS'PW\#?VGO#
MIUZY'Q)AD@OK<_V5IDDZ2*LK$>7%CRP%PN-Q+Y&T\'.& .]\/?#W]H+4/&>G
M:[XM\3"+3-,C99]*CFQ!J ^4#+C(+'!)&<CC' XX_P 1? 7XW7GC/Q#XC\'>
M/)M%_MF\66"Q%QOM]-@4D.O#;8RP8[54Y)Y P3G UCP5^UEHNC:!K&I^,(]2
MN(M5A2\T6W*;X[,LRLQ*("5VX7 )+#L> =?Q'\(OVG;2ZUG4O!OC_?9>*_LU
M_):,X+:1*ENJM;1>;&Q"Y/.#T7)Y' !WW@?X&>.-$U)?$OQ,\07'Q(U"P9%L
MK."78L8=BA9C\X+1!RVTGHJL<XS7'?%/X,?'>/Q+>ZS\)_%8\/:;<RQ7=REQ
M>J/*M!\TJ[9-HW1+E#ZX! ^Z1FZ)\+OVM?#6@7+Q^.(K_4I@[".1HF*EEXZ1
MJ.&+<G(QCCDD:WPJ^'_[0NHR>(M)^*?B%T-UIEP+2:$@ %V8)L9$&!M8=-I!
MY'7D SO$?P7^/FJZQX=\3^$/BE;:ND.GP1ZRWVE!''=1MND01F1> 5;)R0<<
M#()/::'X7^/MCJD.N>,?&FG:;X?TPB6[O;J1$C\N-E9F^=U#J0'P1G<3CH,G
MR74/V<_VD-&T1M)\!_$*2U&LW4D-]<S3AC;68.8Y$$JL QQ@LO! &<<FM_0?
M@1\>]3_LKP_\1/'C>*/">F,%UBU@G$,MW'DM)")$6.1LJQSAB=WIUH CN_V?
M_C?X@\9:OXK\*?&%QX9U2275M/*LQ@EFN&WI' G.V$@N%;E=I5BQ&*^D?AO\
M.=6\*W.GW?B&XDU;Q7+;W"WVH[P4$97:1DX'SDOM.2,<XQBO4?"NE0Z9IT.F
M:=#)::7IT45I86[[B\-I;J(TCDW$MD+DEB2Q^7).[%=BL<:RPMC+F-AO]1@$
M@CT(![9Z=3DT /5',2[@ X7&WC'(7(STZ@D?@*F4L1\P .>QSQZTZB@ HHHH
M ^7?VQ/^2%^(_P#K\TO_ -*:];^$O_)/_#7_ &#+7_T4M>2?MB?\D+\1_P#7
MYI?_ *4UZW\)?^2?^&O^P9:_^BEH ]'J.1&< !BH!R<'!/\ /W_.I** *KQ^
M82'3(4@@JV">.IR?89]1U Y%0&*1266*,M*Y$_ !9!D)DXP20!D#[Q.<YK1P
M/3KU]Z* ,MH;B.5I%1&&?*B(P#'$W4X.>N2N%Y]QR#*UO(<&(B,J<LP4!I0.
M@+9Y!'&3G@=/6_10!519L'Y(T QL7&=HQSSGJ3UZ=AVH(G!X"].H!&.3Z'KT
M/IT]ZM44 5=CR;=\:@Y!)X/L<C/MQZX^M++"7(8"(LA)3*#\ <GMQR/K@]*L
MT4 5#'*VPE8P^2DA4#(0]U.>&P>/PQUI[0MMPLCY!]O8'MZ>N?P/-6** *L:
M3!>'QU'[Q=S=N<@CCVS[U)MG/62/'_7,_P!6(_2IJ* (2)API3 '/RX^;OQG
MIC&#SFF21R8#!8F93G&P MVP"<XP#QQ^O-6:* *@A!Q*4!?!W(/E#'&&![9#
M#(^F>O-1BU21C*\")(I^3&.<<C/0<D#G//.>:OT4 5 LA'F&*/SE.%. 3M(Y
MYX(STXYZCIG!Y3EQ, JNR;7&<X'KGCGMWQDU;HH SH[=[;'EH)-SLYS@%2WH
M?0'GCDXZU8:,M(I*AAN4MD<# QP3UP,9'(.2!R*LT4 4HX9E=@Q4Q%L@$ X4
M'. .V[]/QP'&*17,@>1R=RA%(1 ,D<CN>>HZ$ ^@JW10!12.0-DB0YXPS*0,
M\9]\#/.*D6%TQC:V,]5QW'4D]AP../RJU10!3=9V.4$:,NX*60'=W!!YVCMU
M)Z>II3:[\ER-S !BG&>03CC/( '45;HH KA'; < J..@!P,=?7. /EXQD@]*
M:P8,2L6"RD;E(!'../0X .1TXXSS5JB@"@ENZJTA>4N2Q"%QCT'\/ []^F>^
M:(8G5D8!E=AF52=W).,Y&,Y5<8XQC@9-7Z* *X2<L2[1%01M'E\X^N<C!Y'K
MT-1$3B3;Y49CS]_ W'J>GOQW..<@BKM% %5H2)/, W$A0<@8P&R1CZ=.QR03
MTRLJNH011(2Q D!P %Z$YX.?F//4]STJS10!3=&5E$4,>#M\QB%)Q],9)X&?
M44R2VDE7;YCQH)E==AVMM  Q\PW?+@[>02.<9P1?HH SVMG\R63<[ Y"Q;AA
MS@ ,<\?*23R""1GGK2K;/M$;2RE<9\P,!QD$ 9!8^G)Z9]!B_10!1BBDC#(V
M^0'HTKAQNZ''/ ('&.<]:!',C8"(01S(>H^7_'DG(//?%7J* *[1,ZJN4&!R
M-N?U))[4U(73=C8"3]XJ"3C&![>OH/3I5JB@"';-T\R/'_7,_P#Q0'Z?7-5+
MBSDN&423#8.2@7 ..,8'7K^'IS6C10!3DA=5CBM]L49/[PJ IP >A[=!D<Y&
M14:Q2B%U)?>3A267./E"\$<<\<=3R.:T*,#TH STAD10WF2,^/F5NF<DYR1Z
M=^F0/X3BI3&S;7.\,.RNN.#GG''.<8P>!TP:MT8 Z#% %.6.:1QT4=<C@@9)
M )SAB..H]QBI%C9.$5!DC>V.7SU)Y!XR?Z#H*L44 5GC89/EQR$@\8QCGZY.
M2??'7V($GY),0!'"*@X/'5CUP,C\L=.;-% %95F#99EVXVA N1DX^8D<YXZD
M\ X)J0I)V,8_X!G^H_K]:EHH IE'C)?YY&?YF^8!!TX52,\=L=CC&:50ZD@J
M[*<Y+LO;)4@X!&2 #DCKDY-6\ ]110!4*N<[8T Z9&">G7N3C/ 'X<T%))"8
MVW*H (D0@!NN!CJ !U&>21D=Q;P!T&** ,T6TK.5:2147[I###<\A@03@\$=
MQZC!R^6&8!=A7 Z\8 YR3R>/4DY''0<5?HH K/'(8U1&V..2PQP1C@9P?_K#
MD]*8()8XMJNK2 CYR#V[DEO7DC'7GDU<HH I[+B2/)*QR$D9 YVY')SC!Z_I
MVIPCEC0#<97'\0^7G '/U&?;CL235JB@"F!=L3G8J\8W#<?KCVZY]?7K2NLA
M(38K(2 QV[<DD;B <9!Y/''4\@5;HH J;)(L+"B@L>3@D 8!V_>  !R!^!'>
MES=^D?Y?_9U:HH K[9\$GRB<\?)STZY+'Z8_7M0$ESSLQSGCVQTSC]*L44 5
M'CDR=C#ID*" !SS@8SCT_ 9J6'>$PX4-DX &,CCDC\?PX!J:B@ HHHH ****
M /@*^^"7[0&FZH6\)^.38:/*RF6)IS++[XD:0L.#@$ 'D]N#2\1_L\?'*^>'
MQ"OQ)O)-;L9+1K!/MTPMU8S*LWVB$N4F4QX&&8X=G89(6MUOV4OB'(^7^.7B
M;R\$[-QP20/^F@ P?8'&!D#(+/\ AE3X@L'C7XV^*O+DV'&XX1U.0^=V<':
M.<]^@((!R&M?"/\ :;T=M6\01>.5O+]FM[:U&[S(HK9I%21H8O,_=2!0O[Q
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M_P#AE?XHMR?CEXAZ>K?T./\ /UH'[*?Q(V+O^-_B,O@;L,_7'LW3&.I)YZ]
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M?Q&_Z+=XE_.7_P"+H_X93^(W_1;O$OYR_P#Q= 'W1YC^D7_?S_ZU'F/Z1?\
M?S_ZU?"__#*?Q&_Z+=XE_.7_ .+H_P"&4_B-_P!%N\2_G+_\70!Z9^UR99O@
MEXFB\F*4M)I[0J+C8YE2XR"%QEE #%L#D#@UZ9\)+B9OA[X5:5!;9T&Q+G)<
MFX((; ]P$4#/ ([DBOEO4OV1?%&KVMMI6O\ Q2U[7;.6ZCEN$FE956*-B0I4
MGD+NSCDD@#DC%?9OA[P[9>&]'TWP[ \\T&GVL<*SR G<8MK(6." 3M+'@\X!
MYY(!UHSCGVY]>!SCMSGBEI  !Q[<^O &?R I: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M K8'H/R%21]6^B_S:BB@"6JQ RW ^\W;_:-%% #T^_\ \!/\UJ:BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** *;?\?B_]<Q_Z$:FE[?[K_\ LM%% $U%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (W X0# 2(  A$! Q$!_\0
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M: "BFLVT X)R<<?0G/Z4WS5]&_[Y- $E%%% !112$@=:5U>UU?M=7^Z]_P
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M!^?%,4H YC,;IQD;E^4XP<GYL$XS@C'.?:FH\9=F@>)SQO&X80D=L$X).>"
M1DCIQ02Y).SO]P\SJIP5&?\ =X_ ]Q[T\3QJ &(4L>PXYSCGUP/KQTQ4;&4G
M(2$CG)R"<@G(Y!Z8_,X],U3Y/E$M-;BW#?-)O&1)G[G+8& 0<;L\G(/0 U)/
M8T6E10"2<'H0,@_0]_\ ]>*<K!QD=/\ ZP/\B*J(S;4\OR)(=H(?>2, =5ZC
M)[CUS[U/',C D84<$= "&Q@GW)/Z'K@T#)J*80^3AE [ C)HI77=?>O\P(]S
M_P!X?]\__7H#/DX^?/7/ '7IVYYX[8I*K3W:VB^85RN&)SQM55+$YZ8/&,X
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M6@:E_P 76_9^L#IDTB!(;+^T(M1M(BWS27$*S9$.T@!MH)8,,8 K]P?V,O\
M@X+_ &*OVL-1T;P7JWB1/AC\2M8V1:=H6M220:;=W#\".:^N$6.W0,,%I)3M
M ?)R:_)WQA^RA^S;XTLKTW?PET*RN+B P:AJYC!U&ZM&R%B@@(*(R$,^]<,7
M '*5^9G[2?\ P2#\'1^#M0^)'[+NIZII'B&R#R7NFS3S6FO1MN)D30S"3*I+
M; C1M$<M\I9=V/>XB\'<NEAV\'1A1J.#LZ/NM.,'+7EEKS6MMI=GSW"7T@\-
MB,5&.)Q-6JI3Y6JKA4C9S48V4FFE%/75N5NA_HU6&K_;[>TN$O=/^RZA9QRV
M-[IUQ'>V$YE =9;>X3<LT<BG?&ZGRV4,.< ULV\LBJ4D8O-;$"9CP')((8$
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M^'E*7,VVX]/UZ=_D>W)VFXV\TR6BDR/4?F*,CU'YBND!:*3(]1^8HR/4?F*
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M,EP(_.S$Y*D=<*^$+;L\D;CCGCJ.0!6@\D+;96EP550,'#,A)8Y'4$D =/\
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MP:CUT_X"*CG&%JPJQIR=Y4W!I:W3U[+J:ODQ1":>--YV,9%SPP) (&>_TXZ
M9ZUQOB[4H/#WAW4]:O[B*WM;.SN)(QA4\HK%(P(;'4]<$Y'7[HYZZXN8;6VD
M,CAU=&**G)?<%*E2.""3@9(YYZ\U\M?M6IXQ\1?"#4=!\'V,Z:_?)+Y<1**R
MVYA<&=G9PBHHE!8M(IQG )P#678:^;4HWM&4MO\ $U&W2_IIY'D9W4E'AC,*
M5"')5E1FH\BO)S<9*]DKJR;_ ,S\9]'G_P"%JW'[0%C),\M]JVL"UT/$[-J.
MH75S="WBMX;3)9K> OYAE*E"<D\$9_%S_@OA\=[KX5?";X0?L&^$91;3'3=,
M\4?&^YTZ?_2YGNH6GLK.YD@/[B..YN(O.@*MY@^1PH(K[^^.?[8W[-/_  3#
M\)^(_&?B#QSHGQ<_:QUS09+?PMX!\/WR:C;^')[AYH[.ZUF!7-K#=V]RWFR.
M=T@6,9W8 K^-[XV_&CXI?M(?&7Q5\</BWKKZAXQ^(MRU[J,4TA>SM--WHUC8
MP+R(U@ABAC545 NSGYN*_J3AG)\;FF)R[#_5)/+*45I*+5.K*\(RDXV2E!\K
MT;=]7'2*;_E# 8667U,;BL7%SQ*G.5&K47OPL^91BVVT[V=_.W6QK?LY?'SQ
MW^RE\8O!_P >?AI:6RZK\/;JRFU&[N;<7*-X=M98I)[>SMF=/L["")E66,[E
M<[@V,U_J0_L(_ME> /VVOV:O W[07@F]MY;;6K&"Q\1:9$Z&[TO5K01+="[
M;SDWLX>(2 Y!.&(!K_*&N);>6VO;Z7S8X0K:;<:1;[?].M) 4>3;D*XVDD;B
MV1U-?TV_\&O_ .U9<?#S]H7X@?LG:]JRQ_#OXBZ4FJ^#K:]G;R+76;.U:2>U
MMPQ(CGO)D*JJ[ <@8KO\:^ \-3RFEF&#<*<L#1O&C1C#E5*7*ZU*,=914DDW
MNKQ:LG*Z_3/#/B.4*]3"UZDG6Q=6*YY36DDYR32:UT:25[+5G]ZSF0R"!+H*
M9U2:V( .(LJQ!!4]CR<Y&3P0:VLE65>&P%3/'S'J3@< 9/ /0$8[US-F$<))
ML?=;/<V"MG)5D(2./JH!P 1UPO4C%=,I("#G*! V1S\H4'OU].H///K_ "-B
M9PO&A2<7-+WK))KEU=UJTK6Z]6?T9.?/AJ,X-Q;Y;M.W,W:]_4\X^+'CNT^&
MW@;Q3XZU W+:?X5TB_U6:SM87EEO6AM'\BW'EJ717F*LS '"J><\#\XOV-_$
M?QS\?^%KG]J_XK_&M1\//$#Z]KFB?#73],LVL=&\,V-Y<Q01ZOJZRR3VMQ$D
M$<C1R,C\.I&3S^G_ (JAT6?1M<M_$D=I+X<FTF]CUT7H5K1-,FMY5N'E5@R
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M<? CP%\8[CP=\-OC/JJ:CH7AZRO3J46K6-TR3M;::))9)O(90%,K! H(S\W
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M_9X^"OP1\?1?#B[^+.NZEI^K^*+JRMKZ6V$$B?8'MH;J6.*14(?S-P*@;"Y
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MES7DURVE?O:SV75[66YI2;19AB1C"@L<XQDDDCH?E)[?CZ?N;_P;@:G/I/\
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MDS4_AQX-U34K#7;KP_I/]O:3#]FT?5C8V[7&D1*?D%@C)Y$(4 @*(CPQ!.
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MY#%3SM)&?7!(SCWP?R]^+EN26)&.1P3GD#?@]!UX/T/'6JS1_O)""3\[ \=
M&R<'=@9SQ@=??FOV.,HR5XN+2M>S3M?O;;70_)ZCE[6I&=ER))=EJUH_P_X)
M'GD #.?3U_E[?SQCE<C.._<'VZBIU^4*5Z#GGCJ#R?Q.3^-022C.#G );(!/
M)+ \^@Y'J<9X'6A)7T2>B_K3]!:0_P"?\?PZTU6+*&P!USD],$CT]NM*PW+@
MY&<?4<Y[_J*!6L]>]GU DXZ9_D?\ 1SD\#OFI$5BIP0,8;+#A5;;MW-U&3E>
MA&>"3D57*N!A,LN>FTMCC)YZ'GWZFK4 ?RYVN%=;/RI!=OM(QL#21'J""9,*
MV#R<8Y()::B^9J_+[W_@.NGW>1I&'.U%-7DTOO:6J^>W7;8M))';3*;E"[Q#
MSXD +.BJH/F,.JQ$[L/C;GOQFO[*?^#3[]GN;2_#7QR_:2U6V8/XLUJ7P]IU
MU+$RQM#8+ S"UG=<.K;V4(C</NR!D$_QR^&/#7BGXI^(_ OPJ\$Z=<ZE\2_B
MSKUCX;TN*UMY9Y;;P_=W4=K(Y6-68?NI&;E22451A@N/]6O_ ()Z_LK:%^QK
M^R)\(O@996VR31-#L]3\1D(JR-XBO88+J]$F 6)$X$;%\L2I!Q@U_,'CMQ51
MJ0_L^,HRE.48*THOECHI/NDM$V_O/WWPRX9Y*M'&5;J-HR:L];/FCY6YE=)7
M3]#[DMY(VR$R&;8[@C'4CC&!CYB3T'&,=\:T8Y?/0A>/;YAS]:SUVDLP&&*Q
MLQZC&>@/\)!SP<$^^:T8^K?1?YM7\K244WR[;[WNW=MW/Z(DHKE4;62Z?(3;
M&0=@P23ZC.TX.<\8Y_7(J*".59',ARN"H!YSD@Y^G!&/Z8S;I"0!DTB2"1 .
MP*]<= #C&,GH#G/OR.]5S;HQ)P.3G) ;.>_(],#W(_$W\C('<]*9Y:\Y)'7&
M#@ >GIQ_GB@"HD"(P(P#SAL  <'=D#!Y X(J*8A0<X7(4G)QG!!)!)X Y!R>
MHXYS5R8Q1QLQ*KDJN1V+' QCH>N#QTK'O)HD<6DR><SX=>IVACP"3G!7(QR<
M9ZXI:-6Z-/YJVOX$5)J$7-J]D9UU ]U(?+.TJI._I\I.%Y]N#W  Z<M7%^.?
M&OAKP+H$FL^)+A#;11LQ_>)NNGC1V%M;EF"RSR$86&-][\_+C JK\0OB#X<^
M'7AC4/$'B;48["UM(V/V#S(UN[TDK'!!91EUDD:61@K"-6/)4#N?EWP'X5\1
M_'+45^)WQ)TN?2/ MA/_ &AX$\"2K)'Y\T>3::W<1ML)8)B1%*MDL#M.T52P
MEW&=MFI+35VL[7WZ?\,?.8O,959>S@W:_*K)-+R:O^>VG70L^!_#/C7XZZ[H
MWQ*^(-S/HOA#3Y=1_P"$4\)1^9"+^U19?L[ZE;LJKNV%23-O&4( .3C%_8%L
MDD\*_%B=8_LAN?BAKJFRCX@M4M[F952V7=L1)4"L54+SM8X88K[KTV.%[+%K
M;F >2Y*[50 O Q)50%VC+9Z9)QG) KXG_P""?\;CPA\4@S;BOQ1\1=0& S?7
M(/J,9SCL!R#7H*M^[G9]%II>/D]-_7\V<U' .K5A.2=US<TG>SO:R71\M]NV
M^A]WQ"TC*Q*"\XYR0>AY^\>/7&3P3D]R;]G+G*E2,?*#@ 'Y]I(XSR<$^O4]
M@*YA)G(&!W.0""O."!VX'3KQG%64QGCCY&88['*G^?->5&?/5JO_  _G+Y'U
MT(0ITJ4(._+!)Z6Z*WKU]#0HHHK084444 %%%% #)%+1NH[J168;4!^AQD%N
MI& ISGG.<=NG.> 1C6H(R"#T/!H>S]'^0',ZGIZW/G+Y$,RS0&&X6YC6>UNK
M=@";::"3*2*ZL?O#!)YR!Q_/)_P4-_X-\?V:OVN]3U3XF_"NVMO@;\:;\W-Q
M=:MHL3VFE:I>/"Z*]S:6>(@TLK%G81%6/(P<5_1O(HW$'&/E*C., #'7GH0>
M,?0\D&)U5Q\RGD$!AA3@^Y(S@<CG/L>M=N49QF628J6+PN,G2_E@I.R=X_%%
M:M:>JZ-*YXN;9%A<UI*-2"D[-2NDW9]G+17:WU7E<_S5OC5_P;S?\%)O@SY[
M^#[/PY\9+ "4":W8^<JK@*T:2VS.NY6#D!E8 $C@<?J!_P $&O\ @C=^TO\
M 3]I'4?VF/VI_!,?@^3PQIKMX(L9)S<&YEN8"EZ(HMB&$Q;R%SU(^;.TY_M?
M\B.(8W,><\D-QG /)()R#] <DC %1-)E0!@XQP< DY(& >,AA@8R "3QDY^X
MS+Q:SK,<LJY7B9+V5>,85*MZW+I[K>ONQ;3MJ[:Z>7S>7<$X; XE5J<5%Q;<
M%RPYE=]X):/Y-;[+2C;Q1S[U=FP9DOU/(P'S($S@YVY*X]L]#6Y%]UG'1FR
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MN"02.O\ I0_\%R?V%/BW^WA^S1#\/O@OK%G#KNDZQ#=M;EMS;XY$+@[%D/\
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M#[D=."(E3C+=6OH[6_,4:<8MM)W;3O=[H\Y\7>#- \=>%_$/@GQ+;P:CX?\
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M)"%V8+Y Y]CUS_GIZU;.R,;#G<!G[IXY+8P,COVR/U%,D!:)S"K,^TE1&"K
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MX[^F0>:HJERCG:NY%;A"N5X;(*# V] 03SWZYST"V@5F(4'( Z]\DD]3CKP
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M5R,J&W$8+$D!C7]WD9959/*CCC ^4*^Q\9R>% P<],9SU/5J:X,IV17"6N_
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MB4(2Q/&TYQ@Y]SS_ ( _:'^%WQ(F-IX7\6VNH7417Y"R1^;D' A!VESCG)4
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M?@Y/M6T4HI6[)O5[V5]_F ^BD!!Z$'Z?R/H?:@$'D$$>H.:H!:*** "BBB@
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M<[33LD[2C;7NM=+;J_3+.K %9"00#QC STX _ED>],FF58R=^<D#G/'OPO'
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M'_(X)YY2@[QCS6UU3]5V[>6A]@%W+3$9(\F=> ,AUMVX ')R<#CC@<U\'_\
M!/\ WIX4^*XE&#_PM3Q%D$#(S?7!QQGH.0#SP .@KO=/_:/\0:QJ$.ECX/\
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M]MU;[=\.VR6MM;6:VEK:*;*,W4-FD</DW!4>9'\JH-JONQM&>>1S73.C+(@
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MAU;9WBL_"BSR*DKVJL7?RE+@ X(Y*^8>%?V:]5M?^"D'[0OBA[+5=$^ FB>
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M-J7]F6FMG,=O>ZBLQB%I%&9%F:1Y%:,9."1R@[?AQX)\*ZA^T/J?P*T'X6_
MWQ+\&+_X!?#W4]-^*VO:G9-I_P#PE\NGZ=%#?:+%-';VYOY-8GMIVLC.\SEK
MB2+:VQ"<;XT>.8OVD_\ @G_XT^'?@[X5_$70O&WPC^+D,DOA74M,NH;[^S+'
M5BUQJVG1&WC>:#RY/-1T1@P&-R[]M2J&$M'WY*\G%I\MTE==(Z]'>_5;;(>(
MQEFE2@_-<]GHF[)R\^O5=5:_[=^*OVV?V?/!'PX\(?%+QYXKE\">$/'VMV7A
M[PO?:M'*5U/6;[9]@LHHHSOC:]$L;0M(=NTD[QCCLM=_:=^$.@?%/0/A/?\
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MC\:O@_JOQ3\-^/M6AD%II-QI5J)9?#VKWFY+:&[EDW1 R %<%BZ[DKI/A?\
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MM2>D4]>;?M;OTWT.?O\ 48+:*5A*J-;;A*\C8C7 RS;B0N H))).._%?G?\
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M^)18'_A8?P](ZE?^$EM3DCDXP>IZC&<' ^EE/^"=GQ-11_Q7GP^'8 >);4
M8Z @8[9 ')SDU]K&C*G4JU&TU5;:][H]/E\]V?(U,12IQ@Z,:BC)7?N2NW?_
M  _GKZGYY.J1@?ZS!&<\=3CC(!/('?&=I]J8&C)Z2?CTZ<DY7';)Z\@<5^AP
M_P""<WQ/ERW_  G7P]X.T_\ %36H7OC!; /?&">I_!?^'</Q/QG_ (3GX>\$
M?\S+:G/?CJ#Q^?(K5M)79FL9&2<8W3:=[4YWM]S6]OF?GDIX^Z>..V> .3SW
M'UH.2.%S]<8_G7Z(?\.ZOB<.!XY^'^,Y_P"1DM\?^@^U-;_@G7\3L#_BN_AX
M.>_B6SYZ^N/0_KZ&L74=V^:R_P"W7_P3&UW=0>NM^6=_N2OO<_/%<]<8QT(^
MA]3P!STXQG />P(=P,31O%,P!2:1AY 3KEQQC/NWL>.*^_'_ .">'Q,4-_Q7
M7P[R,_\ ,RV?8GKMR?\  \\5Z1\-?^";OB;7/'/AW1_$WQ$\"'0WN()-5CMO
M$EO)=2P>8OF0VT:C=(S*,!%Y<$J,#)&52I)I*-Y/RLOZ_/\ $F57V-GRMMMJ
MWLJKVL][6UU6O?70_+4K"!B.X2:16VN$0@=,9'LI)]0<\'BGNL,8#.QPV1NP
M!R,?7GKTS@]Z_?7_ (*%_L%_ CX*_!2R^(WPOC;2+[1'TW2M5BU,/;/JUS>1
MDO/:).7%Q$'3B6-<$$-@YX_ JTA%[;W(G;8UO*Z1JYV%E!)+#D=6.,\=,8K>
MC4=HW=NRM;9OY_\ !>C5T=-&E+$WFE.FK?:=GJ^NBTWT\QG'\)R.Q.>1^/-%
M)PN%SG  &>^!@=R.W'//:FEE4%B< #D\XY.!TX//'?\ 2NSF5MU?5Z_/<YYP
M<:DX:OEE*-TKWL[?B3%&50Y&!V/N,D]?3!S_ (<U&?D FFREL6,?V@Y*I,3]
MT@ D\<\<  @>UJ653# H!'0$[>#G(SG!SCG.3R#Z8JQ-IM[)-'!IMG/K*Q6X
MO9-.L8&NFE) 7B- Q:1<C**!@ J#GI$YJ,7+>T6^GK^FOGHC?#Q_>0YUR*5X
MJ4FH1O+1:RLE>ZU;MU=D5X(S<$QG$-D-SW.J7&%MELUYG:-7P6D*9*HN6<C:
M&)P:^]_V9OV3]'\7Z<OQS^/EQ>>"_P!FKP66U;24OIDLM>^(EY:JD\-EI!F3
M=+ID\Y9714RRJR*4!)-G]G#]E;PZGAFU_:+_ &NKZ;P7\"M,N%N]"\(,[V.L
M^++NQ87$>F)8$PW$MK>B#R9<2KE7^;(.T^/?M0_M-^,/VEM4>'1[8>$?@YX'
MG2T^'7PZL$%G96.BP.0DD\$>1<3;096\R5N25YP"/-JUG+NK[*U_OM\M^OI8
M]JE3A"Z4HN2M[R=XIM/1/JWJFXW2WV?,:?[3/[67B/\ :+U>#P]INGP^$/@3
MX*+Z9\//AWIJ2V6EM;0#R!J>JPHP^UW\Q\R5I,A0[CY!C%?)=P[A H=G9 $A
M<GYH(0AQ!#U0(0,9(+ ;<'/--EFA:5Y+.Y-U9R6\)9&7:]M/@K,A4= K?<!W
M<,2.AJ)B[8<JVSLQ&0">.O<^W;H,\&MZ$DZ<;N\E=-O3K>UGJ<.*TK26R;C[
MJ^&]K7M_,^_FULE:-F!4J\BLISE@<MSD8(Z<!VQCTXR 0+MJEI&NYIWMB5'E
MSNK2 3'^X%&0S *R\$<YR<8,'^@"S9C(L-S@X,I"EFSC #XR3G"\_-S@9X'M
M/PE_9\^-7QAO(M,\!^#KR]B=#/+K.IVDD.A65IO57NCJ,J-:[H^"%W%MO(&T
M&KJ34(2DM7%726K>L>GS9CR2EHU9/2[T2\V[6LOGT6[1Y+.\R6#]59TGA:_U
M ^7;RB="N^:-PK,JAB0,8 Y)RO']A?\ P:__ +6]M!\(_BE^S1XO&I6>D>$]
M2N/$&C^+)Q-+:73>;Y\L%A)&K*;10I5%0##[ 3@DU^$$O[//[+G[,=M:ZS^T
ME\3T^)_C<H)%^&GA.:2[L1( K265W-"UO#"&96B.]L*6+ <#/U'_ ,$_/^"A
MNE>'OV]O@EX(\)_"?0OA1\#/$UT/"S:3']FEEOXIU<))J,ZL=]Q)*5?9--O7
M PQ) K\P\5LAPV8\/3KNDW)0=1N*<IPE"TU>VFK[JU[WT:/T#@S,<3A<9"A"
MHW'[,DU",K6324K.3MIH]+:*^A_=A>?'CXA_$"]N-*^$'@T&T9?L2^*O%%K.
M=(NFMV*/+;6X>&1CM&Y'P0&P3D'%:_A']G&/7[]?%'Q<\0ZSXBU59EE71)KL
M'0;9OD=DBM]C'8" %5GW;0<8+$U](^';33HM/M(-#MH(M#N(H[NQ6WA$*6RW
M$8D  (!EWEF?J>"!D]:ZM+.( ,868]&4G&3MP3G)!]!GH,KTK^%L4^6K-0BX
M1YI+EE\4)1?*XM=_PZ:[G]/X6E2KTJ4Z\92J.-]%I;NG:SN^WY'.:;X8\/Z3
M#!9:)IEG8Z?$#Y=O:PHL(89!91V9B<%R23R.2U=!_9ELJ^8(8@0/E)C4\Y(Y
M*CU(]/;':U%;@$ 1>6.#M!)& 2>H]0.@].O %6'C(*C!"G@\$< CZ X&,9R2
M1D DURN<[>Z[2^RTMGT_K_,[EE^"DVW3?=IIV_+O:WH83V-L23Y**\OFDR*B
M^8NZVD8LK;3S@X^@Y(Q@?"/[!U@8?#7Q84W$UV#\4->D3[5LD\@->7 ,<1*_
M*F,D*O STSDU^@,P7>F,G8)-P '"FV=58X[':>AZ$#I7PC^P:-WAOXM$ $/\
M3]>*G^'BZGZ'&!@ D@]#D=SG2%3'>RJ7JV>G6_DG^&V_J8SP. 52"]E&/Q+X
M7?:S=_UZ6]#[C2")F"M% /7Y%(/U/3C@?4@9/0/\B,=+=/3F$8_K4X13(<#&
M<'Z%B"3QC/WEQCGC)Y -7/*0=,C\:\Z%7'<]7W[ZI:O56OY]3OG@,"HT_<3]
MW1M7OM_7W&:MM$Q)-O$",'[BCAL\].GTI_V2'_GA%_WRM:"Q("3@GCU[G^7&
M><=QS3]J?W3_ -]?_6K7VN._GOY7NOS,_J.!_P"?</\ P%_Y&8;2$]8(C]56
MC[)#T,$9'IM3_ UI[4_NG_OK_P"M1M3^Z?\ OK_ZU+VV-_F7W+_/3Y6#ZE@?
M^?<?_ 9?Y&;]D@Z>0@'T3C\-M5A;11O<&&-(WD&"Z(H<8.<$CCGN> 2>1FMO
M:G]T_P#?7_UJJ^7'YC%00#S@@G.0.W0>_/4''OI"OB%S*K[T9*UDK/UOKZ:F
ME/!X6,:KI4X\[IN,='J[WMK9ZHY\V;$DLQ=D<LC'.06(P",@$=R,8.1Q5R>*
M2X:*1Y-KQ8 \L@ JHSAL<-SP1WQC&!FM9[9=LF<@;23@<X!!X[]0!P3GGO4"
M6T.QLENAP!G!) &1Q]<]CG@ UC"C.E4=6G*S3N^6Z=NVNC)P6'C3HU(XF/-%
MR3<9>\G9WMIM=+?[SY&_:?\ V==!^.7AF2WGB2V\0Z?;2R:/>V^U'-P/-:*.
MX)5RT.\CY00<@@$8 'X]?"?Q5KW[,&L?$KX7>.K*\@\<^,-/O-)\.300RC36
MW>8EA,@VG-P^8BQ#$%@6/WL5_1A-;Q-,HDC+0RKB-AG<DZ@?>S_"1M'(ZC<#
M7E/B_P""7PX\:Z[IOBOQ=X8LKW6=$N(ELK[RLS%HV'E%MH7."<G*GH<D#&/M
MLEXH=&BZ&)4JE*@K0C.SY7%\\6EHW&]MGHU=Z7/R+C'PLPN=YGA\YP2CAZSG
M>2@HPO%R::<UJM+[Z[KJC\[?V,OV2Y_"Y/Q7^*<%Q?\ BZ_"RV4=TJR6D;R,
M\T=RT!4.9<LFU_N #.,KFOU=\/0($FDE^>^W8E<@82$G=%& 20!'D  '&#QM
MSBK4-JD1-HUE$+2(*;=(U"A0@Q']T#@#&.,8Z#'!OVD0C>4^5L9MNXC&'QPH
MZD@ $ CG^A\O-,ZK9O4G6E)J,6THK1<JO9)?GT>BU/L.%^$,'PE0Y%3A4KX]
MQE4J*]1N4.:4DY+X;73C=;KS186!-@1BT@#%@7*E@21R" .!@X'7L<XS0B$D
MELC&<8Z8!/)]""0=W'OTJ7:3_P LSW]OKV%-)*9RC9]03SGG'']?3UKQ?:R[
M2U_KL?;PJ<T7&SLEI=-;OS5GMZHQ[QO,E4RQ1LD(8HQ!^5RA7*\C)*G@'(..
MA'-9=M;V5K'#%%8VV;82"VD:%?-A\UBTNQL!5+%CDH$(R20<DUUBQ1R#<\1(
M(SRN[D'&3GT &,#GN>!4*P6^_P#U?U^4=!GH1U))_'/&:I3DU>[5O3O;^K_F
M2Z<'=N*;\]M>Z_(YEM,B(C4VD4@AE,MO(T2>9#E@XB#CEXPV25E+YSCIQ4T5
MG-]HN'VL(KN/RY+7:@M5PIRZ1!1AV /F$LVXDD"NF8JIPHP ,C"#N>F,8X]N
M?4=:,D88 Y'(^0#/XCH#T/L3GO6D935I632=[^COW_0XYT*?M$N57;BKI.VO
M]>AR-GX8T335G6TTJTL#=-')>/:6MO"UV8W+)YZ1Q+&^"2"Y3<N=V[).5?3;
M?[26CFFW>8TDQ,4#"\B8G99W2"$">VMP-J(V6"'&[@,O6G##YD(/?C&/92.@
M.,?CSGG,!AB,I/E]%'1?7N.W<Y)R>O;I-6O4:;3M^.[_ ,V:K"4NJOVTM^IQ
M]OX?T>S@^PVEE#;V$EU-=II\=O$EJEU.Y9YXU2-=DA;G*[03R1D$U<ET"RE-
MR1#Y NY89=02(1E=26!&1(;L2(_FQ,APX/);:1C!!Z22",/'\A#!LYQGD8/'
MU]?8#CJ+?V9.Y.?;]/3M[5E2JU;2>BYG?7RTV5]]_+\CZK#I_73L<W;Z/I]M
M$T4-O':V@;]U90PP1V<,. LENL$<:1"&4';(A!SZ ],N70-$GC>UFT;39=/E
ME\YM->QMFLC,5V&18/+V1DJJG*@$.%YQDCN#'%&N&4L#TXSP.V.X[X.1U..M
M,BAB8$[ ",'&.F>0<$G\O09[UK[6INY/TN[?<_ZN/ZM#R_KY''?\(KX?@NK'
M4(-#TZWU#2[86>EW\-K$+G3K,D-]DLW928H"R_<3 VC!&%!JW%91PM>,L8F:
M]G-U,\J*9$<KM*QMC<B#8& W$8)4K@G/3+;OG#D$#(R,<CD_48X'8G!)[4]K
M9".%!; &< 9&<\G\_7)P3TX?M9]U]R_K]/(T]C"R5MM-WKZG,G0=&@NI]9BT
MNQ34IXA;W%U';1*]Q#L!*3;4 8$#!8\_[0%4;6S6W,+>3 PMYI)8?W:!XED9
MG,"N29/+3.%C9F4!<  "NS6-3 RL 00QY4<C'I^! _V<562RMU^9 Q<G=C:0
M"S=3C&WN2><'IG%14JU+*TFM>BMT\KZ;_P!;-4H=G][,![&Q?+&SBM=TPF9H
M;>*%9IQ@Q2RF)5>22%@2GF%D.!E1WBCTC29)[NX-I91WM_ +:[NULK<33Q?*
M TA6)5=OEX,BO@X]P>J6)CA9$#IC&TJN,^N2 ?4D]?KUH\N,-M%LH.>O ]^H
M/T[X!R>]9>UJK[<OZ^0>RAV[=>QS4&B:+IZE+'3+*VC9TF*P6L,4<EPJ[1<&
M-$5%F[AE Z]^H9]AM3.6>%/*EC:W-N(42)8<AV10JJ%#M\Q.,DGYCM&!U?E1
M8&8]H'1<< ^@YP#ZX[YIK1V_WC'R,G[G7(P.<?3Z8 Z"KO5;UJR\[?B<2P<7
M4G)6LVWMHM_Z_IWXU+&*Y-S8EI(;9Y0P6W1("L,?(M%DB59/LVY0Q1F.3G Y
M&-.R@A\TK#:Q6T:R!0L,:Q*^S ,L@4+YCL"2S-EB>YP:V5@AC9I-B[C@Y SC
M))/'7IW/KGG%21P1!\*,?-O.,C&!CU'7/./<CM1[VSDY)[IZ_=][N==.A"%K
M+5==BS'&OEH" ?E7MCMQWXQGM]:EJ"7 "CH,,!C/4;<=*GIFP4444 %%%% !
M6(UO*TLK X5F)&=P&,Y[?GG\>AYVZC*D< _>XQCV/?Z9XZGMTI7:::O;JNC[
M776W3L9U8\T;??\ .Q\@_MJ:I>^'/V6/CAK-KJ$FG26?@K5G-U:W1M+GRS$J
MM%9SK\Z7+Y(A"$%BVT J<'^>SX.Z9\<?!7[+$OQKOKOQ_P"#O@MK)T&Z\O7_
M !#=SZA%.RHS:VMO*L<D5LV[S!(0% 9MK,H&/ZBOB%X-T+XB>%]6\&>*-/34
M-"U>-8K^TE7='.BLS!&&3E=^TCCD  \<UR=W\+_!NH>&I/ >H:!97_@6XT*V
M\-W'A*^ACN-*;2[6W%LD5O:E?)@E6-0RN1O5QG)'3T\/B.5*UFWHU;IHGV5[
M;=['C8C!.HW97NEM^?;[O\S\1_BM\:(_$&I?$CQMX#^(NO>(O#VG_!GP_9)J
MNC:S)-IVA7<D-L]PUS)"62!I=V^4.J'YG)/ SYE_P493QM\;?#/_  3N\)_"
M7XNZOI.K7/B3P]XHGOO".N27=KXBO](T\7E]IFOBSE'F+)9Q3&59GR)"%9<J
MJU^T?P^_8V_9_P#ACX.^(7PY\->#H$\*_$]IXO%UC<?.]S8RP^5]@LIO+0VL
M<<6 F-P4J&P3TM?"[]C#X!_!VSTRT\">&I8TT+5)M2\-MKMRVK2Z!+=VTEK=
MQ:;++'NB26&>=4(#>6)-H. -V\,?@X55SIN2E:5I*STM9QZ6U>M_\LEE"Y5)
MR:;O=7U_#\3\%?B]\7_'OQR_:Q_9W_:6T3XF:]X/^$'PNU&[^%^E>#+66Y6Q
M\:_%/1[-3?2/&DB03/)<V,J(@A8X;86(!S<U+Q?'8:7-^T7H7QP\3R_M6O\
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M9 7'S 8 /(SR20>X] ?K48C(QM.[&,[5/MUQN&2!WQ^7%7< ]0#^%+@#H *
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MQ]WL02#GJ3SP,UG'#SA4YHSO'=)]/E?_ #&N1:J+^]'YO_M\?#GX[?&OP9X
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M^!\0\NQN;Y)5RZC2:E*E.G[3WK.]U=I+1R:5NMV?SR*EM::2M@TOE,D?GL
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MDJ<(,*[$\#:?7(. /7.=W%5(Y_))0Y8!EP?13@GUSWR,XYZ5HBZ\V$Q*I4D
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M-1>3_P!,U_[Z_P#K4 ,,F5QR')Q@@8 &"6S@C.>G. 2,BHXPV?F8DA2=PQG
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M#JWQM_:_[5WP!\ 6]\SV&D^#'U#4K(2,8UO9#B-BF_;O"-CE0=PR#D9K^8*
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MBYCG4D':QD.%YQG^(#;7^75XKMY_[!NO+<J!"VX X++E !UP3Z]1_(_ZD/\
MP1=4K_P3>_9V$JLS?\(Y;A002<FUM@#Q@Y7&<X&3G!&:_GGQ_A*CA,#5B[1J
MXA._+U49:JSZ6MW2;^7[?X6.C4IUJ<HQ<TIIJRT=E;[].A_%/_P<#_LPV_[-
M'_!0?Q!XE\/V%II_@[XV>'W\9:9#; AHM0C:XCUA+K:OEB6>\!: +@[2Q)Z
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M11N?'83C7#TVJ+E*3;:=XPCRR3_O2O+Y6Z[O?_1S6^22-)H6+QLQ0R*  I!
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M,.H&0-WL1DG&.>Q*=&2LIM^=K?E_7IH0I587LEIOJEZ6[W_RW)!&O 4X<\X
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M!X#;XF?\%)/V7?#:VGVSRO%>E:N+<A=H;2-0A>YD+,0@:W.3C/S$#&=PS_K
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MN!CD9("BOZD?^#;_ .*TO[5'A/XZ:1\7@NM^-/"FNVNIN8D6WB2QU-W59@(
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MUK%5;^CMY]#OU^,/PV(7'C;0#D9S_:5H3]1B4_SX(QVJ5?C'\,Q@'QKX>;)
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MI_W]C:Z^T"P+"\4CN&5'BVE?E3$9497B+X>_$;P]^RQXI\*_&7PAK^G?&/\
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M(_X)^^/=;^&'[0/QA\ >)OA/XL\,0?$_7)/$T-[=V-XL%M)K,UU?2H)9(1"
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MZ:B"%2 FT!<EL\'DCGIR1T '; .2!1Y"<80'([''7MR/3KV-6%CVC&&/U8<
M=,<>E.V?[)_[Z'^%:W=K7T(YI]H?<BIY;#K@#HHSC"CMU7.,X[]_7F*2W$J%
M&PPSD@G.1D< !NYR3P1@\@XYT/+4]01CIR/Z"E,2D;3G'3@__6J&Y=%&WG>_
MYE*4DO@A?O?]+6*$=NBYVC P< @?,>>,GKR3P,D]?:LC4T(N([F-26@Q&8@<
M_(ZE<8YX!QC"G)'."1GH?LL?J_/&,CH1@_PYY^OTK(N/+M;V!RC-))^YCR<H
M(]N6DE!'++G(Y/. ><&L:M%UG3<K)4YJ=E?6WHS.<95(.+2BVUJM/R/Y^?\
M@X(_;[O/V)_V.-7\.^%=9-K\5/C4'\(>'98;@Q7FEP7^])IX65A-"&4%5=57
M )8$C&/Y8/\ @GI_P;\_%/\ ;D_9Q\2_'OQOXOUKP3XFU&]NM=\*G4+F[_M+
MQEKMY!/>B59R?,\DW#1[7)*LTNX*"N3_ $+_ /!;?_@C#^TI_P %&/CS\(O'
M_@CXB:/%\._!VO:1/JWA:Z@#2M9VTD/VB. O(?+EVQR LP;<C,&(!!7^A3X+
M?!VR^#/P>^$GPMTBWBV_#+PGI=C(D 7:][964,$LLI4?.TCK-\Y!.%7 )&!]
MSEO$JRG!QHX2%)UY2BYU:M/GC:.^EM6TE#6Z2?,DY)'R^)R&MB*TI3JOV=_=
MBI2TLM'O?[].C/\ +[OOC5_P4,_X)@?&7Q%\(;_XO>/_  CXG\-WC_V'X=U7
M4M5FTO4[8R&"VU.%IY/*:.1$5-J@[1M(W[<UPW[07[?'[:'[6-K:^'_VA?C?
MXDU?PXZI<2>&=*O+Q+9YD!,(O(%989H7R#/N R.#G&1_?E_P6&_X),^#/^"B
MOPH;Q!X;MK+0?VA_"VCR7/A?6[98(+K6(K1I)[>PO79-TPDD54!)7 <!3Z_Y
MW_QL_9[_ &@_V6O$NN> /CS\+?$W@[Q/I=_+9Q^)#IES)I>L:?!-L26WE6,0
MQBZ@$9#[R,G: 02:_??#[.>$\X]A6Q=.C1S)Q_VF#ITE&%1/W94W.*E[-\J<
M97UYI)K2R_*^,L)Q#@55AA[SPW-%4VN:_+RJ]TM+W:NM;:/JT_'X"\:>1& J
M*,;5 P%P^T8[9R"QY)/S'!X$<FH#3Y%6TM7U/5+V!],T_3X8S(\]]>_NK=A'
M\Q<HS%EX)7&!QQ2VFHOJ5Y!9>%M,USQ)J]](D%MH6DZ)>7MP)6PL:M/ ""&.
M,') QG)'!_I@_P"".7_!"GXR_&7XF:%\?_VG?#%WX'^%7AJ^TS6]"T.^<6=_
MXA<?OU#17"NZ1PNP\S]W\Z_*=IQG]#XQX\R?A[)\12PU>"E%1A!4[.<F[MI.
M$E:]UHMK^B/AN'.%LUSO,*4*]",8SE*4IU%.RY6FW?I>UEK:_P S]Q?^#<W]
MA:Z_9A_9/B^*7C327M/B/\8)GOW^TV[QWEEIEW-YT89I56555=@7MM0C'S<?
MTH1H"JQ[@2JX8X!).""<YZ'.<8]#WKE=%T&R\.6MGX<TBUALM TW2[?3M$@M
M8Q&EK':PJD?(4*T@"?,P7DONP",UTMFFU5#%LH,$GEF93ALGJW)!Y]\U_"O%
M.9XO/,TGCG[U.K4<W&4KSC'VDG"+5_LK5]6Y:WL?U%D.5PRC QP[=JB2OR)<
MK:5M6_))+TTZE74#]EC6YC2(JC@RQ2']Y(G0K;9'$V>1@$GC)&:^'?C!^QMX
M"^.'Q9E^*'C:.WUQ(_AA/X(\/:9J$:F_T/6)-2MKVWU2U$JC#V[HFUH1O)7=
MN7-?=5Y:I=1B)T#8<.C#/G1,#CS(R/NLN  2,=1Z5FC18!=P7Y662[M[<VR2
MR98E&ZR-P,R#. >@55 P>:QP^,K8>25",>5)J3D];V2ZWZK_ (?IZ-:DJL&I
M1N^9I;WLF[=>UM3\H=9_8%\?^'OVA?@A\;_ 'BWPZUW\-?#2^'/&FI>)+)[J
M_P!=3SD8O%++OR8[8"*/&P!6 X."?5+C]@3X5RZ'^T#9I8Z>FJ?'NR(UK6M-
MT]H=1LM7=HI+.[LY?F:..&[5)'"\M&2%RR*3^AKZ2DT0AG:YFB63SMDK%PSA
MMP#?*,J#C ]5'&.JRZ?(IGFA:>"2:-$*QL5B1%*[1&,$KE>&+9)7C SQZ,\V
MQ+2<E%M63M;X5KVV\MN]SCIY?"/,FDE*]WUM+L^Z6B['X^?#C_@GU\57^!$_
MP-^./QHN_%VI> ]3FU+X.^*;(SB3PU;V\LLEC;2.P#QO!!*D) ;D DCC:=;P
M-^P!X^TSP!\0X/%GQ8U#6_C=\4I=,T7Q;XPBEN(_[0^'UD[PVNEK(621G2&2
M<RD;0.Y?DC]98;>6W">3'&N&E=A@XF,WRMYHW9.4 QMZL3[54BL+Q+N.6 !/
MLR2&(X;.9^)%.,\+\I0=OF!'S9K+^U:JT4(I;VM'?K]GKYW&\MI/[4_FV_\
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MXGV7Q0^,EW\0_%GQ2\.1^&-6\6>,-1$E]9Z#90S(EJTES<W#>0L,RH=\B*5
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M^(?'?B71H8_L\+SS6ME]JC2\O)$53Y=M.K?ZSY0"0!D<'_6T_9J^#NG?!?\
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M!_4?CQ2>9XAZNC)O_#'_ .1$N&N')*_)72[)5;)_>?)1_9(^&!Y\S7<@<?\
M$RN,\9[;Q36_9'^&#8)?7CU'%_.WZ-(".GX]\X%?6^3_ ,\7_,?_ !5-9P."
MK+SQM;GW!Y_3MSWS4_VA4D[2HRBGO)K1=KV[NR!\-<.07,J=>ZZOVW71]?,^
M2A^R+\+_ .)M?QV_TV<<YXZ2$_T]:/\ AD'X5]WU['/_ "_W!_J>_;\..WUD
M9%/ \W/3DL<_D/\ ZWL::&/<-C/)P_ _EQ^G>G]=]$O3[]TQ+(.'>M&O+O\
MQ=5VUOZ:NVO0^3Q^R9\+K='2,ZRT=XC6TQ?49P!$P8L1AP<CDC'*GG->:?%+
M]G'X<^%OA?XN\4VQU2=_!W@GQ)>Z6)M2G""X@L+R51.K2%3ER%"$[<GC!"U]
MY&58I(E= PED,?SX*C*MD[22#@<Y]3U(S7C'QW\,7>O_  6^)GA>RFBAN]=\
M)Z]:0$'=S/:S@ ]#EN@(/)('>NW*,5*698=TY+^-0UWNG6IW[VT_/I9'#G63
M9;A<LKXC#\U.@H3T<VY)JG4T=^S?SZG^8IJ7_!1/XYV'C'QGIUMHGA);6R\3
M:[:6RSZ1:3S^1#JETD32S,A:5BB(2Y);.3DC@TC_ ,%&?CVYDC;1O!2H>KOH
MMBI&.@/R<= !UR2?H??-3_X) _'/5O&'B_5+7Q/X9CM+[Q%K5W#'>7PCNHXY
MM1N742J6R&YQC.0 2<@"JDG_  1P^/A#[?%?@_KG#:GM0^G5L;B.W4Y'7I7^
M@W"-9K)<'?;V2UZN\W\E??L?QAFF=9'3S3&4:V+I\\7RRC>=TN:25[/XM-=+
M7N>'C_@HG\=&)QIG@KYN"3H^G\;O8H1U&2 #@ '!Q@3I_P %%/CI<A; :%X(
MDFB#3+.VA6*HY )13($48!  Y/3H.E>R_P##G#X_CG_A*O!F">,ZF.<$C^]Q
MZ9'3DYZ"M6T_X(]?M!6\*,OB;P88B[@^7>Q2-D@YP=I(().1U&,$9R:[ZE65
ML547V8S?DUR2NGU_I' LZR"56A3CC(-N<$DY35GSK6ZM>]MGU\C]6/\ @WY^
M+WB+]L_X^?&C3OBGX>TVR3PQHVFB.YT"WCL&8+',FQGM<,"0G!P%R=QSC-?U
MI3?LG?#)(VEB;754[DV#4;DDG.=N"X/<@#G.<L"<5_/+_P &\O[#WC_]D[XJ
M_'?6O%^IZ/=IX@AT>VVVMQO8F6.;_5C!R2V H'#$\GN/ZR "L<>2?FN7QR3M
M 8JN.Q^7&0 !GC%?PSXE9E5J<154Y\T(RA&']U<TG):+O9:MO\3^N>!LMPF8
M91'%8;$1Y+-S:E+W+1C9*^NJ3>NU]--#^0#_ (.%/&FL?L;>"O@9??"/3["\
M'B/Q(S:^OB:V34YHS''((Y(1=AFAC(98V$?[M25)P[#/\UL?_!1?XVR6<BZ;
MH'@FVL[%3<7:S:+8">>:5]_[G<NXK@<*O)#$9Z;?ZT_^#BC]D3XA_M76'P>T
MWP3K.A:9;:+<SK?QZM<B%Y9I)%9'A3[SHH'S$9 ( R,5_,Q=_P#!&SXZV95K
MCQIX-"2O'$/]/4C.S*KP<8  3./7=R#7]&^$-2=3AR@YOFDZ=)W:2>CFK;6M
MMTOHEWO^)^).,RW!9O.E7Q%-*,Y:MS5^=J5O=>C7*[=+;]+>"G_@H]\=I-K)
MH7@9>%*EM%T_YN3@@%,8/< 8SG@8S4\O_!13XZF(SS:'X#FF@#"T1M'T_;YL
MRM&69=H "@[BI&WVQFO<_P#AS-\>R<_\)IX*QV/V^/Y1DX^4$8XQUY')YX-*
MO_!&KX_18*>+_!TOJ+6XBN60D'YI%_A5>NX8SP!S7[$ZKZMVLM$EV6SW^_T/
MSR><<//EYL52M9:N52VR>MFM':S/I_X)_P#!7[P1H/P/U[P]\1?#LL_Q"LK6
M>#3=*TRV^R:#?/-$8U7]V1"5$F"_R@JK-@C K\*_'/C/_A-?&/BOQ@UI'8'Q
M%KM]JXL(^8K,7,A=8(V'WE4=/4GJ>WZ;G_@CC\?R/F\4>&B 00=B8 QC\SU)
M!Y/IDY4?\$=?V@01CQ9X> 7C&Q, #CNX)_'(^N2!=.M)/W83:MU[Z^?IU_R>
M-'.^':<Y<F,I:JSUDTFM>O6_=ZVT\_R->Y-T_G% NW]V%P06!].PY(QWQGD]
M*/, [8/<9&0>1T(X(SV'L1VK]<W_ .".WQ^*8?Q9X?" @'"QALG)& ).<XY]
M!4?_  YW^.XX_P"$LT'CU09_']Y5_6*B^Q+[O\T%3/\ (9?\QU%7[IVMY:6_
M5'Y(>;]?P*_^S9/^>.*/-^O_ 'TG^%?K<?\ @CU\=NA\6:!D<?P@_B-Y[>_3
M%'_#GKXZ_P#0V:!_X[_\51]8J?\ /M_^ Q_^1,/[>X>6CQU"Z\YK\%I]Q^2/
MF_7ZY4_G@9IQ=S&0 I&3W&0,@ D8Z]LY'\A7ZV?\.>OCJ.#XLT#GTVG_ -G'
M'K^&?:1?^"._Q[=28O%GA4H"0?M-[]F<$==B!F!4XQN/T7&:TIUY2=I4VEWL
MOR26Q,\^X?M%PQV'YD[[SN[=%=K7L?DG= FV'&6"\@=CD''4],9Z'IV&0<VW
M4K&=Q ) &"<= <<<8P,#/.<'US7Z^G_@CA^T"V0GBKP=N/;^U,_C@X/)]!U[
MYJ-/^"-_[0414S>)O!A!(X.I=,=>2?<XY'IBNCVOF_Q-7Q#DJHZ8VE&W;F=[
M=[WVVT/QS\1DMHM[CG:HP1Z,Z =.N01@\]>N>!_J9_\ !&3C_@G9^S\'^16\
M)VHRPVY!MK7=@X^K<=NF*_A1US_@C/\ '[4="U1K?Q'X7;[%;F>6.TNC.6"%
M3\X5TVXP2IP3QP<8K^^C_@EK\/-;^$?[$WP2^'7BB2&\U71O#,-M*4(*EH[6
M",G&,_>4J,#(X."3FOYB^D#5YLOIQM+W:Z=W:UN2=[:7ZZ7TMY;_ +KX*9OE
M^)Q\(4JBG>;;:3M9<JNV]'>ZZ67S(_\ @K;:QWO_  3B_:LB<91?AAJKD]0
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M(_AE\./%%EI?AKQ!X/L9+#1[@76BA;:-;.TU /\ :?M@AC5%+SS$.Y=,%9)
MV-Q-3:Q\+_AUXHOM)UCQ/X$T6_UK1(XX;6_EM$2'2/*XCAL&"@1QLH#%46-0
M2 1D<:/,$V^M[K7E>CM==_/KKY:'/_9TK?#YVUWOZ;G\Y7[;^O?'+Q1^VE;_
M !X\!? C7O$^G_LQW&C1>!/%&ERZ@GA^2RU&>&QU>YO=/B(M[LRV=S<1QYV"
M%OGV@E:^C?&GBB\^$'[4/P3_ &D_ EK-\2/%_P"T2-!\/_$+X?Z_+=3O\+++
M;:-J&JZ';C8S3;UF0JY/EH2 N"KG]W#H^F6\!M[:WLK#2I898;G3DL;>2TU4
MR0F.+[2Q02$0-^\#,"01GD;C7)VOPV\#:7KEIXH;PKX<_MG3;"VLK3Q%<0(S
MQS2MM"0Q;,)( NP2(0QP,,6PM1+&4M%[.+25HZK:ST;];O1[/>^AVT,(H+6#
MNGY)[*S5[=5V_$_&[]@^Z'A_]KK]HWPK>0VANK[XB>(];TR3Q#&\NJ16^HS^
M9"89I5!2$*$$,,;%8SN 'I^ZL,=Q#;(MYO,JW*,)+<;DD"D'#A<C:.P'TS7G
M6G?#'X:Z5XKOO&FE^#M%L_'&KR[=2U26(I=W10C]^73<)$8DM$=P^]R">GJH
M<*RP.2'(R4B!* #KU '/S# /H/7/#7Q<'=))-]GKUZO^GZG33@U**Y6KR3OK
MLM>MN^GF23,79$^Z"/,#+D<J=Q7GU!.>!WZ5_"U_P=IZ9=0>-?V:=>$$QBC2
M]4JO%N0VH1)B209"D!PW#;L G(.,_P!T=R=D2W&<8#9(.<J6. =V/QX&"".
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MI]R<8'E,."3T!)[XZ\C']:_HP_8Z_P"2$^#?^P,A_P#(2]/\YYK^=/'6I.>
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M).3'F2.8.H(.P)"^-I'4D 9STQCG%?!7[!V8?!_Q75P=[_$WQ%/A5)90;ZX
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M \ D#(KRJM.HJLU*<N2_N12?NK6_WZ'V.%K0KTE4H64&D[*R2OLDGK?O_P
MO(A#%^/FSQSGDY]?RISMM (]1QCJ._/0?4\5$)@3M4Y  (..W/4\C^6>".]!
MEP0K'J,\@ 8P>O3@X.>_3I6:A)/5R>CTY7]_78Z/:Q6CWVW6^S_$G!R ?4 _
MG2TU2"!CC@<>@[?I3JHU"HFB!)()4GDX[_Y_K4M%1-R5FK6VU5W?7\+("'R?
M]MJ/)_VVJ:BL^:7\S_#_ " HR(1(< .1W)'W3R% X(QG.<]>_:F/O8 ;2,@
MY/)(_P CWX%2RJQD..!@'J,G@#H1Z]_;&*9B7@DC)'!('W3C!X&1WR>WKFLI
MP<Y7>J77JAQDU*TX1<7I%[:6W;];K\B09)4G )'*_@??/7T_'I1UX8YQC .>
M,D;L>V>,C/UINX+C/?<<C)Z<<#&!G( QUZ<<4Y2)#DD  X/?.XD#KCCY2<]>
MG?I5.I!/V:@TY67,ULT[VTU?XZO6PI1M*ZBHQ2Z=$^9)_.Z_ 7:OI^I_QJP1
MD>G'ICT[?@..M0^2O]X^N>,>G7I5@=!CIVKHG",URRV)BK?:YOZ]6-5 O3\/
M\^O)_/I3J**4(1IJT59%!2,-P(R1GN.O7-+152^&7HP(?)_VVIIA;M(0.,#
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MLDLIX 4\+@#H:C>QM-A5K9F  .TXV#!'(4\ \=<<'D$8XT/+<_>]NX.#D<\
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MV/EN%W@,)1G6S:A"$7=QC-07/>$K7UU2;C+1KUNDCWK]D;XE>)_C=^S[X/\
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MW3_P3V0GXNW>>VC']$SD>_ P>_I7PR@/SXQ\L,A.3C(2-B<>YW<=>G2OO/\
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M-996C,?F29C#,7).6X.>/KRUU(S6MM<Z4+;4X+@C=>VTJNK(^UUE)#D$LC#
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MUG'5;581<EA]E+!%N%960N<83 ((+'(&?3)':GG4K-(S)+<11!4WR*[?-$,
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M 7<2<<;CGJ/\DDC/?\Z[OXRV"Z/\7/'5G"@B5?$-UN" J/F).2!T+-(W)Y;
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M+<G)XZCM^Q)6LGNDM?DOZ^1^)X[,?;V345&G'DIQZ14=-KM-NS;;3NWM?12
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MO4O;)[&RU"**.XNE+L82"@B?)BD5AD'S$P>ZD9/%1W%EAYK.>X)M]@9T/"N
M=P!'!^4\D<]??-'WL]'+*>(R6M:LG"2;4FFUK'2_1W;6]TN^FW\^&L?\$\_V
MA_@_XUNOBKH6E6?B?P]X#\2#Q8(;>:2;5-0T^"Z-V=L0C8REXV(QN"XY8@ U
M^X7P;^-'@G]H+P=IWB?X8W?E>)8((=-\<>%M2(.H:1K%E$(+J%809"D)$3.H
M(3  )&17K,&H:IIWFM H>UGA-O<2DAWFM2A5H)%<-E6!VD$9QD#N3\._%W]G
M+Q/HWB2;]H_]D@0^&O'7ABW$WBWX=V<9MM!\=PVY>2^GGM%>-;C4YXTW2,B2
ML?,(7;@&DH\JTO:[_'73YL_0JF>4<WPL</6JQ4H1C&-^6TF[*/-J_)<S:2W>
MB/MD;9=UEYK6=M$Q>>X0DH]PG/E!Q]TNV0%SD]>_$><EASWYP>"2.O'7[K 9
MR22:\0_9^_:!\-_M*Z-=V>F6Z>"OBAIJD>/_ (8:TYM-4M-1M5?SKO1+2<QS
MO;&6*3"QQ'(=5PK#%>T2P-9?9A?>=$N0'<G(.&.-V,<'@YXRI!&:?](^8S3*
MY4(SK4HWLKWBTVNKM:]_57\F]+P:B<V-T,$9A;GMQP<G/..,$\YYZ5_1?^QW
MG_A17@D]SI2''?\ U:Y]/0U_.?K!C-G?/$QV>5\ISP 5!.#QU.<^OJ3FOZ-O
MV/ACX&>!>./[&C8\<9"J><\?4>]?SKXY5$L!;M*;^Z%OZZ>9_2GT7I5)YQ%R
MNY*<&U9W7+)KM?:^O97V/8/B>,^ _$"D<G1+\^F1Y+8Y_$?F,5_+]J4(&L:[
MC )UZ^('TNI0"3SD D8SG/)P<YK^HSQY"\_A+Q#"P+)_9EW& Q/RAK>0D=N
M1CV)].*_ELU1IH;S68I&8RGQ+JX8G!8JM_. HSTPJ]>X!]":\[P(JJ5.LE:\
MI0>ZWM)=^J]=M^WU/TH,.UB8U$GRQIQE=J_VM7=+17>KV[LGMP1/-D'D$CZ
MYS^H_/TJ-<8'Z^Y'&??IQ[8II5RR /L+!03N R.V?Q '';UR5J1\*[KP-K8[
M#L,X_'.??-?U&]]/ZT3/XFC\*^??JW;:_P#6NVI&7"!SQ\R,HSC'[Q-O?OP1
MR.]?H+_P3CA\SXG^-<X/]G>'=)89]7D?(/!P<CZ]\]!7Y]JRJQ++N0 <8SQ@
M\_GW_"OT/_X)LHDOCOXA77F@R/I^E1-T^9!,X$;<_< ) XZ9%?EOBK54>'\1
M"]IRHWCKH[K6_=6VL]S]=\%O^2TPCUM^Z_!03^[R\_0_;>VB,BVTV>'B0_*.
M^5.WV "\')'/'<&[-E(7!!' /S<G!<<Y]?7^O-4(MR&-5.U$ 4(/E5$R0 .V
M",''&>G7FK,^YHF+;CD<=0.&&,#L2 /KC%?Q#BJ3E5<UMS]=-7+HG;J?ZIX9
M-X;#)=:=)?+DC^G_  Q86,!)9!D'[.V,# _U1/4=< CMGT/''P5^P+(LGA#X
MLE@I*?%3Q&IY];N<C.1P03TY QD8R:^]0<+(NXD"!N,]_)<8.>PPI]BP]17P
M1^P,$7PI\51@;7^*/B//HQ^WW())[X4 =3@8QBNVFFJ=1/?E3T[[_P!(5::I
M3C&5K2;5NKVM]]^WH?>8,<O&!D# Y^ZY *M]1Z#D%<]<FN6U*VNY9GAM%ANX
MI2R:I9WR!K::W(*LD:L""3'\K9R7!&<@XKJ8U42'  .#P.Y"_*<=\GY?<X[B
MD%M%/@2HL@&[:'YP@;"Y.=Q/X\@]>!CBHU)TJE11>C:3NK[M^G_ *GAJ6(HK
MGT3ORJRMKOT;['Q#X[^!^H:3K%UXT^!EZ?#7B1%$^K>'II9(])OXEWN5MX"K
M1EY&RP"@@MD]2VWH?A%\?+'Q"U[X;\=V1\'>,M(8V^JOK92UM=4:)S%(^EF0
MH)'=U4I@%@I '%?75YIMM<K"&@@9K=C)$& 'S[6  ).<#&,'OCH#7EGQ#^#_
M ('^)%M!/XNT:W-_8G-EJT,02[LW!)5HIHPK,P(!VL6Z =,UZT*D))>T=M$G
MW^Y[W_#S/GJ^65L/*=3#PNV[Q25T]7RZV:C=6NWWZ&O;_$'PH3Y*^*-'6*/Y
M%#3Q*R*,GY_GSG)&W/4#.!GFS_PG/@QFR?$NC3L ?D6ZC7OUYF XY]N>.]>(
MK^R-\,I0)6NM>9G569S>-E^,*Q4H0#@8XY'.[GJ#]D#X6H2_F:X<@YW7AQR1
MDD[5YSSU ]JTY<$WK-ZVT4/PO9HA8OBR"Y(9?0<5I%RG34FN[7([-[[];Z;'
MM_\ PFW@W.?[:T<]\&]BY]O]8>O3KWYQVS[OXF>"K*1$?Q1ID(9@B0I<1-@G
M *AA+R6)R #GJ3R,UY"?V2/A8<YDUGD?\_I],=B?Y'Z&J$W[)/PNEN%0/KAD
MA*LFZ\9HQW4C"#G &/F Z\<FJY,*D_9Z2\XZ6\]$95L7Q)**CB\'3HTI/E<Z
M4E*SW][E2?GM\^A]-PW%GK5I'=:??V\]F2':2-U;CD[@5/&=I7V&>U97BB_D
MT?3FUZ*,RRV$;,4'S;HPI))QP0%&[W/3DBJWA/PE8>#--&C:;:W,]H4*"6XD
M+J JLREE.XX) ^8$') YSQ?U* 7VFH&YA,<R3Q;=T<J%",,,8*8X(Q@_=KFH
M.C5K."E&]VM8Z62OU\TCT\PJU,'D%2M1C+ZPJ=WRW3O=NSW=[K9V=DNY^67[
M6?[1_P +/%WP_P!5\)A;34M9NW> :6L0EO+*_(<"Y81-N$8< $'J ,Y %?DU
M9WU_9^'SX2OI=.62ZF,MGJ:P[#:V[R%UMVDVAE9$8+G)P%;!R#CT+XSP:7I?
MQ_\ &J6EK!92SZG<VT7 5DCZ@H';:L:[L@J  Q//S5UOP$O/A7X?U+Q./BK&
MFK1'SI;*.^03P*P:-U1 5!+/A@H&!R<#'%?U=P1@\%E'#]#&8?FGB)X:<ZD*
M-G4E.35XI.44WK?=:)VNUK_FQXF\29KF.?XS#8[FC36)22GJDDW9W>NR6[\K
M]#Q:RTG5M81X](TO4=9M]"!>^O[!#-" N<EF0A-N%9CMYZGC!K9^'GBBX\&_
M$#PWX_M;V:[T^RODDFTJ63?Y#V\B +)$<@,,GYN3D8':NZTCXO:G\,-2\<>%
M_ASI\-QI7Q#GEN;2%82ZZ)9R"2,1P;58JJQR-@'&X $KD#'FGA[1(/$'B+3O
M";LNF'Q/>@W.KH-GEW$4A:9$).T&5L @8(+9(QS7J5J=',,)F53%1A!*"]FY
M5)3FXRIZ\ZER\LN:35E=+O>Z/D,IKXG#YSE<</=0>)IM\L5;1Z*Z5K.WEJ]&
M?T[^ _$,/B7PKHNNQ F/Q5I5O.".!#YD*MQG! 7:>.,$\ &O2R6A:"%%++''
M'&6QDD1@KGUR2<Y'4D\'D'P_X%>$;CPE\-/#WAVYOCJCZ?80QV5Y,P9WCP%5
M4/4IC)!&?7/!%>\Q*P +?>'!Z]>0PQWV\<=AZ]:_CO/:='#YUBO9<K4:U5+E
MZ*-6<8[77PI+U5[=_P#47A:K7Q'"V5.LY7=+#<T9/=>RI='JNNO^1F7ZV,$K
MW$TV9$A(2W)PERQ *Q.3PP+ $ YP22 "*^(OVD?VO=$_9YC\-Z3IWA+4/&7Q
M:\6:<;G3O!^AQ-<.FE"[\DW$D(._ 08XC8X8,&(.*^UM1M('NK=I+-K@_:E
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MCX@@\7:'\1?"6C6LL&H:AH_B&PU:/3=0U)U,K736Z7%M& R;1$B@$;MU#PV
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M]$N[_0?5+N-,J,"<D $<'@G/&3G^>#Z#O3UE3!(/3\R!@9[#/M^72JJ#(8'
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MW"BBBCGC_,OZ^0PHHHHYX_S+^OD 4444<\?YE_7R ****.>/\R_KY %5PK@
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MU)("XYSG( JN+^(Q)J$^8+R_8P?87C"M;2,VT';QM();H,#:2.1S*5O8-]Q
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MD>'"B15P<9(RVT %LKJ%IJI-Q);31.K-&L=K%$L4_EPL"0L[C  ^8#&>"-K
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M.9=U]_\ PYG:_P"(5\/:3<ZQ=K/-965K)>SRV4#7$OD1QM*Y6(8R0@W*3QG
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M@N[8DVU]/%ND:+*DDM$$VD'.>HQ7S-X!^#/C;XP:!?ZEX(NK.?2_#7F_:VG
M$B-;;RT1W+RR)$<YR-V<?*./Z-\/N'LOR[!NMCI4:#Q%.G%3KSA!1UBE%RDE
MRN?,M/M-VN?P-XJ\=YSCLWJT<NIXBO'!5YIK#4JE9ZMZ+D;C';23=EO9),^^
M?V"OVD;CR(/A#XKU!EU<S,^AZM=L1'/$"!]GV3$8"J (T#G!)SUP?V$@N9'6
M1_-'EHJP[-A^>9E&9$;NC,02,],]>W\H&C:K<:?KL.JZ7=O:>(O"MZDB7MN6
M2VN/L<H:>.!L*)&8(R.I"C@@$@C']%O[,_QFTOXN_#C1_$4$R7&H6$,>G:M:
MQ.9)ENX52)Y98\Y4L5+D\#\1@?%^)7#-*GB9XO").@YJ3JTTI4KNS4E**Y5U
MO9K6SN?K'@;Q]5QM!9?BZW^T\TE]6K2BL3%/W>54KJ2?-T?ZZ_5,$TZHL;N"
M4&PD*>2HR2O0<$%>WMT(%HR2[0>.=F"#D\KSQZ9YZ]><XK,BFB$B0&1!,0SK
M'R"4.XJPZC!4@@9SU[\5>CN;=@X\V-UB_=R#)RK<+@D<<GCC/H>U?CSG).4?
M=?(^5[ZV;2?G>U_F?U,I)J+=DVK\KT:>ETUTLVUOT:'>;+_>/Y#_ .*H$LIZ
M%L>H4D?H32>;:G&/+P?=OPQZ_I3S<PKW7'; .?R(/'T]O6A2FUI%Z]5&7ZW0
MW)*VVOJ)YDOJW_?#4>9+ZM_WPU*+F$C=N&.>,#/'_ <4"YA;D,!VY4?T6E>I
MVE_X"O\ (7-'O^8GF2^K?]\-1YDOJW_?#4HNH6Z,!]0,?HM'VJ$G;N&>F<#'
M'7^'-%ZG:7_@*_R#FCW$\R7U;_OAJ/,E]6_[X:E-U"#@L,GI@#'/'/RT&ZA7
MJP.?0#^JT7J=I:_W5_D'-'O^8GF2^K?]\-1YDOJQ]MC<^U*;F$#)88]-HR/K
M\O\ DT?:82-VX8ZXVC/'7^'%%ZG:5MOA7^0<\>_]?<03&1ER0Q((. "!@ \_
M,1TSSGH>,4P32_=_AR,?*?[V<\'/J>_7&#FIWFBEZ$ <$<=3SP>#GKZ>HX-,
MWPYSYHSPW3CC@'U_I15J3]G'^[S-+KT:LORZ^NAI"2::LI1E%I/?5]GNMM=;
M'%:SHNE:G'>6=[$LL5U)NN8&4F&<D8(E0@B0?*-P)QP!S\V?A;XB_L"_"_QO
MJ6J:SI"3^&]7U-%WW5BX6R1AU+62A5DR<XRQ;D^F3^B;1()G<^2Z.!@MPQ(
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M@,#CVQUZ?@GCE:%"%U]N;^3@U%_.SU]?,_JCZ+].4LRLGS+FOW2LY_+6^O\
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M).. #GG@#&*;'#YUP]P\31W*J?)E8G88R3A""0N>H;Y>!@9!%;!"Y.[;VXX
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M-KJUN;:ZM>Z35^JLM[&/]D2T?MK[-:-)[6T=G;IKK]Y_.OXP^'OPS^./@?\
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M#7*^)]"L]:TVZT^_M(KRROK>:SNH9(PX,,\;QOD,""<.VTD#! YYX[.%,?\
MV3FE+%\W/[.M3J.*DH2Y$[RBF]&W%M:]K;L^5\1,CEG635<-3>]&<;\G-=M7
MV6NFMM+/J?RL6%_&)?"6KQ0FXF\)ZY!K%XP4NK0V^T-"Q&<%MI7#X.3VZ+^B
MA_X* ^'+/3(E;X5M<[T@7=Y%M(',4:JSL!D')!9/[JY&>U<-^T1^QYXY^'GB
MB_UKX:6+:EX$UMY+O5--AB:26&5]SN@51(40$X4*0"!NQEL#XK-AJNDJ]K-X
M9U*VD+NH1[>0[2"RX!>/ P#CCJ,MT%?U1&MP]QI@,/4S#,Z>%>#BOJR]M[UJ
MG*ZD*EJD8J47MHW'\'_"V(R7/N"<=BZN!R=XU8VI/VC>&4FN1M1<;PDX[*^B
MOTV/8OCM\9+3XX:]H_B#2?#4GAZUTN%H;E71(_M(/! 6+!&%+ '!&W'O7._
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M"<J5&6CJ13YG.UG'F49:<KO>*:Z7>AU%E"8XG2)&@2U18WB*G,T2_*BQ\C:
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M%'M'_+_Y-_P "BBBCVC_ )?_ ";_ ( !103@$^@S41E Y"L<<G@\4>T?\O\
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M@<TZWN7D#."RJ&'RNH5\ DYVD[L\]LCKC&1CGEA\1@_>E%.UE9I^[?9ZVO\
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M@9#1#!YQZ_C@X-?SOXY_PZ27Q.LUTN[T:T8??>*7KKU9_8WT7G?GMJ^=V_\
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MP,#<#^+G'Z*:F?PO^NH[Z-=[?AJ9&HB1@FQRFR9&8@*=R*48J=W&W<<GJ3D
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M?5U:[U;6_COIT&E>)=)G#26#0V^Z"X6.*4[/+(+*<HN1(0W\6?)_@E^Q-=_
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MA+/D 1R1L%&0Q4@ 8'"CD\=<'\E5_9__ &8/B'_P4(^&?QMT7XCZH?CK\%O
M(\&:YX<TH,FC265K (;*>X2)Q$+R[97$[&)V("%B2V!^M\<D=SLNB?.$4SQ*
MJD+M+,NR1E&%;)SCC.,<#FO!Q4%=PMRQ>CNOZVW\]SZ#"3]NDIOFYNJ?];DJ
MH%51OR>KMT.1T[ >H! QWQR*\>^-VGS:M\.O%NGPC$EYX?U&)"NXD,T(^4
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M5;88.#WR3[< ]>E)_P -;?\ !7;_ *,;L_\ P:V_^%/V2\GZ3_X!7M)?U?\
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MN5'3J0AR65TD[.\7;16MJMM3^[HRJ4YJ,FW:,6];M+E6_1^5G9?@?OC!J;7
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ME)/   Y)Z=Z5#$% (3.6Z@=-QQVZ4K&/:=NW..,  [L'&,#.<B@H7$_]T_\
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MV&9+6TCAFWPEDA$(C2 (HC3:1A]X&XR.#E@S$@  C.:T H  P#@ 9('88IV
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M7%?B3#\*?^"P_F%4^+_PY4%%$AN+-)-TAQOD0HFU8P<[$^4JO 4'!IQ^$?\
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M&>:_G">D7;35?F?MQY/\4H=6O_AS\1K:Q<6U^_@SQ#]AF4-O$ZZ5>LN"HZL
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M6-K^R[X.O_$6J>&KC68K&_\ $7B&_P!'%X=0L+5FE>%=3>>20?:T**K(0K!
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M_P"RI<D>WXO_ #%>?\H[ _N?HO\ C1@?W.V.B]/3KT]J;_P'_P <_P#LJ/\
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MW--TX^:\TW?OW_0:<F]8V0ZBBBK2LDNVA04444 %%%% !1110 4444 %%%%
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MM)-25VELM.VNBZZNY_'E^S9_P;*^+/@+^T=\(OC)+\<H-9L_A[X@TS6VM$M
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MIZ*W A$7()V\$$;1@Y!]^V,U-^.>O\^GX=*** "BBB@ HHHH **** "BBB@
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M.F_7-/(R<8W(6 &>_3C@CMQC'XG0 *]PN>#%![\^6HQSU[]1^&.OT?@Q&/\
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M?1O^^36OLI_SK\!_6(?\^:GWK_,D^T+_ '6_(_X4"X7LK=^Q^O<5'YJ^C?\
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M8@ X[$\*.HP#T)ZGZ=^:FT&3S"WRDEL=<^^!R,$G;TSP.<4EQ=1Q/\ZL[=B
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MQ=T_P;?^'OAMJ/CK6?$M_.+9O%UF"UY9I;L'5+A;>*-8F,081QY=\*&9>?\
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MI?57L]/G^;*CF-23TOHN:S=KI;I=6W?3KH?<\]Q/$Y#0O*Y1@MM:LI8(>LK
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MP L4*@%O++G[SE R@*&P<<D5"E\;BREN[*3:9)C;1B[ 5HY5<QL8MP!<\ @
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MGR<[0,G/&#]"#ROB[Q1X;\)^$]=\8>,->TS2?">D:;>:EK>HWUTMMIUMIMA
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M@C/WLYSP,$G'7/?%&\,2 W. >"HXR<<G([CMZ>G/XJM_P75_83/W=?\ %2Y
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M\6'QM=WVM3>,O#%GX-O)3OCC-Y96YM3?;(RHWLRY#;5/&<^OW/\ 8H0;<@2
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MD9K]+#IML2\FYA</$(7NE8+.4#AS\_(R< $@=.W2I)+&WD9'8_O8T"+*" X
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M!'W)%$N)@L9M'G<Y9"S"0XY+$'*C VC&!CODXK2$*IYB<NI?<%<DA<JN O7
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MXBK9]YR]=T"PU.3LE:_6[TZ^I\$?\.U/V&/^C?O!8YYS'J6,?4W0'I_A3O\
MAVE^PW_T;[X+/7_EEJ6.IQS]L''3GTZY.:^],#^\O_?*TI/^T#@=!@9 ^G0G
MV[U:S/-%_P Q%7_P9/\ R&\%!]4_G(^"O^':7[#O;]GWP3ST'DZ@<'OR;W..
M#V[].<AO_#M/]A[.1^S_ ."AR,@0WW('/:\;@]_7IZ"OOA6)XR1_%P<\<#GV
M)S]",8'%/"Y]?H"!_(9'KD\=L9(J99QC$_9U*V(YNJYV[I_"]5U5]/NZW/J\
M(/EY;6\WKZZ_U?7S_/>7_@F3^Q#,TUHGP#\,6MO<H))6MY+U3(W0J$-XS"(<
MY0KM8?*5Q@#Z9^%GP4^'/PDT*U\._#[P;X3\':%9_NK.V\.6+64[[ 4\R^,:
M@3S$9W-(7PV2"#EC[2T$8F:4(OF[!&)",LJ[1]WI@G)RW4X''6HELXEDC,9,
M0#EY%C  G8@DF;^]T/IUQCIB)8B5:[;;EW=[ZZMMOJ[_ #UMM82HQ4KWOY67
MY[F9<:8K%09F)+*"<=>@!.?O9PRG([8P<<;EK MO"L0);!+9.>K=L]\#Z\\G
MFI'A1R"1T(.!TX]NW;\JE P,#H.!6*];^9M^ R0$QL ,DC _&JXB8K@D9QP>
MFXG.<<#IQC/XYSQ:/ )] :0$  ;AQ[C_ !I];]5L^I+G*&W7]-#+D&)%Q(JL
M8R%#8PQ+<D'H.,[AP><\X%95QI_VNUN;*^2*>WG5D9"H*NCY!5U(^;.[D<@J
M3DYSCH9H8V 5U#<<$_?'T/'<9],\GI431HRA,,JJ>"O&WCID''7YC]*N%25.
MTHWYH>]%I7;DFFGTLU9;?(X:^$6+;4E[KC*#=_AC*+C).ZE>-F]&K7L]TC\Y
MOC=^P1X&^(]V^JZ'(GA;4'!?_1 \4;2-R<B([@6Q\QY^\<DU\3:G_P $XOBU
M#=R:?I7B>S33XG++=/O,DR'[HR4+DXX[9[G)X_>_R%= LJARA^0OR0,##9[#
M Q@CUSWJK+9Q"1IL,2P"%&Y13_>"G'()&2,<=1T-?9Y1Q_Q%@*?LX5YQBDHQ
M<ES:1O;5R;\M;_H?D?$7@GPKF]7VKPL+NI*I)Q=VW)J4FTHJ3NVVK?DK'XW>
M!/\ @F:ZE9/''B=[QF!W);23 C@[@,  <,3\V.%Z9 -?H#\)?V=?A_\ "NRA
MM_#^CVUQ/#&D4FH30J]P'3+&3S&(<9)&2,'N/;Z1!5004C(P %/08P.0.?7(
MR?0=\SM9HP0J6A##<RQ$*&)]0/O#NI.>.N:XLYXQSC,8OZ[7G*#DW&,5:-[;
MWYKZ^JT/9R#PMX?R/D^IT8PE'DYMXR2C\-HRA:SN_>\M-49=A:!/W<1+0[6W
M,V?D8= I.2!ANG ./?BU]FE9\>9A 1@+D$9YZ=\Y)QT]!P!6BL:QJ%50$&3C
M@*#SN; '5NYYZ=L"GY79QEF'0XQDEAT^@XX[>A-?$PE*O7=1QUD[W:[O:]VW
M\]M#].H4*&#I*E34;0BDGO*W3FE:+?IZO35K&GM [-%,VV(_ZIQ]Y3NQTZ\X
M!..N23P:X/QY\/\ PYXUTJ;PYXBTF/5+*^A-K)+)&&>!74X9'.61AP?E[8R3
M@@^G'RMV7^;:2 "<J.G*CC!'3IDD57>/8K^6T@\TA=Q;++@!LH3P,YQ@''R]
M:]*GB'@*GMHWC)M-<C:UNO>M=>NO<\_,,#@,XHU,/7A%WC*F^51BO[U_=ES-
MVLY.SU;/QS^+W_!.:YGOKC5/ASXF330HWV^DW!<!V4DJ I5P0HPH.<DGE6XS
M^4?[77_!+?QW^TS967ASXEZ+=+JOA>-)M'\0:6)(Q]DC+JMN7C0!F8,K,&Y^
M5B,G(K^M^XL;6[,4T\"M-%RLI&""I/KP3USC!Y(SQQ5GLK>0>7*H= 0V"%()
MR<9R,L@[KT!SUSQ]WE'BCFV"M0A4<X\MFY12]V*2LM7%:+6379Z'XYF'@IDE
M7,99AAX1A7O*490=1M.2TM.*6L7MKH?R2_ /_@FM<?#'P=%X$T;X06>O75XT
M,%SKFK60GG=TRBR2RSQNQ )\QV)P.,'CC],/@;_P2M^&=M=Z9K_Q3\!>#YKN
MQD29+(6,+HV"K ,#"HV_>'/ Y[@8_::/3K1 1%&(,L.(8T53@X' '0GC /.<
MD=<3QZ?:Q,Y:(3F3M/\ -@GD 8QQD =P/J,GNS?Q.S7,L/*C*K&FFK-\W/)_
MX6K*.GXV%DO@Y@,)F$:\H\SYKR<W**WOM).^_1:==3Y_L/V4/V<X[-+:7X(_
M#V6WMHD2 MX?TXG:J[0%=H]P*C@G=QG!]*NI^RE^S6(SCX&_#Q2225'A_33R
M3GC,> 3W/8^H'/T#!%&RRH8D50#A /E4\GY!T ((/!';MBK$4-N1CR$./0<\
MD^I [<<?4>OYQ+'8VO*56-:HU)N[=2HY-W>MVWIJ]%HKV/V;#9/EV P]+"2I
MTYQHQL[1BXIO575DKI:)[Z>9\\G]DK]F<]/@A\,P#S_R+-@3D]C^Y(R#G)XS
MUZ&FO^R/^S5(,)\#OAB2"#M/ANQZ#()YML'J.*^D!'$!CR\ < 9'] :<%C4@
MA6!'=3S]#@=/\*GZUCE[RJ2YEJFIU$_OOO;J:2P65R3C[*"OI\*2Z>7EW/FC
M_AD/]F[_ *(7\,?_  FM/_\ D:C_ (9#_9N_Z(7\,?\ PFM/_P#D:OI?:A&
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MQM7NK.Q@AU"RDN)99D=D@8J"\N=H7'(VYK^Z^\TMKF[\VU8*<, P & 0$P2
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M'FK_ ,\V_P"^3_A5BBHY:O\ /_7_ ("!!YB-P4(]B",CI_=YZ]/THW)_</\
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M((P/7KCUR.AZ8I8ADG<#R0.5[!CG\3G' ZC//&;BCY0#_=&?KCFEVC.<=?\
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M/VZT3EB48;L\$A<;2K @G/.03[!B,>M>3?%OX)?#'XY^ -9^%OQ0\':9XS\
M:]#-%JVAZK DT#22JZO(D;<9VR'H" P& 03771E&44Y0C%MI->6]NCULMM]M
M#GJ1DG=3DW:ZM;1[?-?UJ?P3?\%#?^#E_P 2_M=?"/\ X5A^S1X:G^&'@_QO
MIIM?$/B;5':WU>V$LSV]W"'<AX[9H2RY*;2Y)+ 8(_G)5?[1N=&\+>"3>>,O
M'?BF]BM1'I,$VJ:GK.N:Q(!#*L$(,TT9O'R[C(5>3A>G^D7X*_X-[O\ @G#X
M<USQ)>W7PT7Q/8:U+*MAHMR6ATK1;9F=Q90P@2Q,T;.7&T+V)48!/T7\$O\
M@D'^PE^SO\0M,^)_PZ^"7AU?&V@O&ND-=6\$RZ8^]#%<0+*"OF6P0.D@5B&4
ML,5^L<.<>87AO+5A\)EU">(<)\U1J<5.<WI/GO=-65V[JZBK[L_,<YX4QV>9
MO'$5LQQ%/#4*B=.C&E&4)03BU#FLKK7=I7=]$CX]_P""/'_!+K2/V%_V3SK'
MBC1%C_:1^.'A^"_\3:I-;)+=^&YKRSDFT[3(RR.UD(9+@>>%.(W4;SA66OOS
M]FW]BS1/A9IWB+4?'NGVOBWX@^*[^_O-=U6[:.[@ALY-C6L%MG,:M@[=J@,"
MH8%1DU^@<ND3S.TS3AF8#<W7+?=XZ#KG  ''0]:EATVYA4A;A@""#RQZ9(R<
M\XX(_$ D=?S[,^)<YQN85,7]=J0=>M.I4A"<G%7NH0IMNZC%671O63O)NWU&
M)X'R#'T:$L3A:4YT(*-G2A>;<>5U):_%)O7IHK'P1H/[$GACPE\9M)^+/A2>
M:VM09)-3TI\*L0)#$6\8ZJ2JJ%7DG)&!U^](+>)LR,S[%&%1_0'A2HY&2QR.
M@(Y);&)SIMT^";DL>.F>![\D>_U]#R)C;XR""3C!.X\XP".F3GUP>G''->=F
M&8XW,E!8BM*;@E'FE.4VTK=UH]-^O4[\@X:RSAUU)9?2C2<[VY(1ARMWNU;>
M]WOM^4<<<;M,R*,+&-F] V#USMSD\YP<$9/<FGB-)K>'[3MNW#$K(860*<9Y
M4*3@?R_&K5M$?,;J,H0>_!/'4#'?!YYJ[Y6.C$?@/\_Y^F.!*4?AG+167I:V
MNI[TX^TBU/WF_M/=&/+;QL=UUM<*?W&U#F)3]W?G()(SU/H,=Z9-'-* LR07
M"EE:-3"59  #@L<?=..IYQT!XK4>,;V&X\D' 7/&!SGG/Z8.:3R_]IO^^?\
MZWY^O>LO93<U)UI633Y>CLUITWZZ"IPA3M:*;LDV^J7H9DB!V2>*&%Q'QAEV
MO'@8)'=N1D=1CC)/%7K=93%^]E\XEOO ;=J[@40#&/DYZ#+8P1TJ0Q#'WF
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M/7GIA_FM_P \_P#QX?X444 2@Y /J ?S&:6BB@ HHHH **** "BBB@ HHHH
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !G /H# 2(  A$! Q$!_\0
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M;W*75M-:G3_+F^@_$WQEUCX\?\$M_B/XZ\3-'-XOC\!ZIX7\7W,,*P0W^O\
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MDO\ Q?J&OW1@?4H=#N-'^_/^#-WC]F[]LLD''_"X/A3R >?^+97/(X.<Y&"
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MX*D0?%/_ ((Z_P#!?#PA_P %$;/P/?>+OA-\8_&-Y\6_#4D@2'3_ !I:^)O
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M^%P_$%2K2E5C.?L\-'%QA)MM2FH^QYE-_P#/M--Q2=OZ7_"'_!-/X(_L2?\
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MT>[T+Q!I$US83VM];1:EI5_<V<DUC<V]S$LV^WFBD5'7Y]_9#_8/_90_8/\
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MAO"L'B-YH]#N]8C\"^))8;#59+<B>*SOHUFM99X/WUMYRSQX,18?HB%4#
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MP-WW\#(&["_* *FI  ,X &22?<GN?>EK-)*_FVW\REL@HHHIC"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )@ X0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/,3^\*<&4\@C\Z.>/?\ /_(!:*3<N0,C)Z<T%E7&2!GIFCGCW_/_ " 6BD)
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M"Q+?<^7&?J1GGL*:+NY='$< ,JA3&68!)5;HZ@G=Q@Y!!/MUQ/LVNMO^W?\
M@E-I=5_7WFG167/>/"WE&1%F=U6")AS(" 6 (&"V3A<>G(Z9DGO)81&_D$QD
M?O6')0\8'4>N><^GJ:<(N+=WII;\>G0$T[VZ&A14,,PF!=2I3.!C.X$<'=R1
MVXQ4U6,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(44B3KJUG;Z1:VEE?R2P,8IK@P 3;WW2,R*=Q=W8_P IO_!!_P#X)/?LU_\
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MN9[S]B#1[N6VN#&GQ#\86EF&&SRT35IEGG4@CS0CY8;@0,KR#EJ_/OXD7_\
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M-A01DY^B3$,9,9P >XZ8YX#=P,$=P #D5 X@98U090N-Q )! ZCH0#T8$<'
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M<Y6Y5'1^=_6W9=!PPRA)2<8NS];:6OY'Q9^V#_P11_8;_;2\8R?$OQUX%O\
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MV$"222G[^)-I<M@\AF8D,.,#(<+8"Y/DW%S#?*0\L[@^3( /F.U@5VD';@
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MI[59K,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -:FB;)QL8?4$#]11[1=G^'^8<\>_P"#)J*A,V#C8W;G!QS[XQ]:=YGM^O\
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MSG)SCWK%UHK;=.SOZM/\MWIWT GHI-PW;>^-WX9Q_.EK5--70!1113 ****
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MN5V=3M&V4 C_ &AC)(]Z]!>%]1J[K+K_ ,N>WZ_U<P_UYH/:%-_/_@G]0?\
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MC.['7&88=2\12,T:>)-98#!60ZC>?-G Q_K=HP>W4]<8(RO^(<8I_P#+Q_\
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M^F223@$YW FY<6&O)+I#I?:T=1>=VO=$@N9)=-E@?!B;[:)L*4+,V$"@_(<
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M%PC2=DDJVMN8H OGRF0".$MC:)"1\N[MD<G@\YIMP=*@@BGDM+58IV'D2-(
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M[XG\9^#/$\_B/XQW'P4U7X,>'=&/PW^'NFHUG:^-H+388)3 KQ;S=+UQ%+N
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M/7C'(_#M7!?#7X;>#?@]H>M:#X+G:^TO6M6^TQQR@XL8BC_<#,^W:[!>H^4
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M'U^#R_)\'CO:^T@^6C/W>>#2ORJ_O-;>5GJ>#BZV98K]W&G4:O>_*XZ*Z?\
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MNH^"K&)M/\%>*#HVHZ&^!MT.*<Q"\DC$1*JT:J060#8 <E>1@\1&WP_^2?\
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MP ,8(K@OAO\ #72O@_H=KX+\%W-S>:,P.W4;UD:_N(R1\D\R%O,$)4(F7;"
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M<!+H_F/R/.2*_A?MV_T>//4V-MCW).">G;'TS^ K^Z?HV-1R/%*]FXXBUO\
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MK^R?\!K?PWH_@K1-(O[2U\%^(['Q=I&N6DS1W%YKL8-Q*LDI==R37!=I$$C
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MSI*JD[P,JZ*!@$8QA^TIO7V<$_\  D_71&+A4;^*7E>3_61]:?"'X)?#_P"
M>GZOH'@"'4K;_A+[LZE=7,<CF6YO@/+^USRNQ=Y&QEAO^9GY8#-5/#WP3^&?
MA/7/B5XR\+>&A8>)_B=8RZ=\0M06-/M&M-*K))<W9#8,C*-OR!5. 0N<[L;X
M2_'S0?C)X6UOQ)J4-WX$OOAMJDN@^*['44 FT34[;=+<6%X(TB4311JQ<)O
MR,$G%9OCK]H[P_H'B'PKX.^&&E:M\7?&/CAKB73M"\,INNGABA\Y[J3S5*+
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M_/=VOA9E*Z=I^OWDIN)=1B1G(9VN'\SYD +,6!V[<>B77P8^&^I:=I7AW4M
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M+)_95]IAEF%NFJ6PD,&\!HR \1"Y/?!KU&#]ESX$6'C"?Q1;>'[J37=/UO\
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MPI\-[(R:,U[-J-_?@2F34=1F<O/>7,K;GGEFD!>1W=VW\D<FO2IHGFMXIK!
MT$]PJSW-P2AA>9\+'&#P I)( 8 ;0 M?)_AO]I?Q-XSA\0^(M#^'-Y;?"O2-
M1O-)LO%@6*'2=4O;*98FMH9G1/F\PE.96+$'')X\3\8?MCW'Q&LK?0/#$3^$
M=6\.^--#T[5]*83+<SV,FI6\?VP-&BH\-Q&S%6!96Y'3KT4J_*VTDM;Z)]?-
M>7R\KZ'.\(YJTI.5UK=M_@Y:>FR/T>9'MKF2UM$%YY82WNI7( A9F$9;<054
MQG+#<>0N,]#3;JT<7%UIMNLSC3H 8KV.1'2_N$(D:/< 1\R!EX9B<D?PUS7Q
M U&TT7X:^(M8\^YMI5L_-OI;97%V5F@3RKB(J P0NW)'8Y)-?$FC?MDMH]I%
MX/\ #WP[\9^-[OPEX;TWQ;K>MZ>IDA2VN+WR)I)YY(6RD40+-N?.,[@N3G:I
MFOLY*+@I7BG=Z/=Z:^E_F*."4+J-TF[Z=_O78_0&.V>2SL[Z.2-;ZXG>ZGTB
M5E,L5LJA?+QG*H&&X?+D]<<TYD-V;:[+QV:K9SQS6P PUSYOR.W3D+P 5R1U
MX(KX-U[]LCX>>#/$&L_$B>6Z&F:_H]O_ ,(_I-W([>=J4I2-K*T41R)YA>0J
M,(JAL9)'!MZ'^WIX3UW39O#MKX&U6X^*SZQ;1V7@%()4U>ZMYXXWB>!7MDCD
M5@6E^7=]TL.G&7]LI_\ +E?<AK"2=]6M.LDM=//?R/N*)8V-[:JSS:@L(O(F
MC1UM$A0 N'D;Y2I+?,2>"><$X+C9W4+Z?%=LADU%E^SW5L5ELPC=5D9"5WDC
M&"<\X(YK\_-+_:E_:#UG]H;Q5\)]=^%4W@SPAHOPOU75O$UU/$HO]&<J[+Y[
M+&K"3 11@@K(IR.M=!X;_:JBCT.3PQ\+O _BGXHWOA6QEUWQ9<VC+,="M(1S
M=S-*CE8]H!_='(Z 9%']LQ_Y\Q^Y?Y&7]GR_G:\O^#S?B?;Y<R1O+#Y96+4!
MI[MC#;@P7?QG@  ''49Z YI;P1B.ZA5A(UL+JWD8 C+K$^2,\C=^A%?#5Y^W
MMH]_=_8OAQ\,-9\8:;IVC_\ "0^+;W38R\6@72QL9EO-UL"3&0I<(0"&YR,$
M?7O@_P <:5\2_!&B^.=%TZ33K/7M*:[EMG4[A<-$XD+':N&)X/4@Y' J*F8+
M$TJU)4U%>RE*Z6K:TM>W5$O".C.C-MO][!:ROU[7Z[G[O_\ !/$@_!*$CI_:
M;XQZ;6K[Y/?\?_:E? W_  3Q4CX)09XSJ<IQ@\85CT.,5]\GO^/_ +4K^;>*
M?^1K7_Z_R_\ 28?YG[5P[_N4/\"_*)/%U?ZC^0J6HHNK_4?R%2UYBV7HOR/<
M77U?Z!1113&%%%% !6>Y=9)W.6X&T>@#$ #I[GZ_0UH5F,P\V8RL$0;5)YQD
M[AC!ZC.,_P )V@GN#A5^*E_BT]=_R ^'_P!MG7=&\)?#S_A.?%=U-:>$_"JS
M:MX@FA($B:?;P"1PFX@9=LJN>/F/&VOPOE_;WM]-L_#WBGXG?!_7/"'PM\;K
MJ4GPT\7PAHUU^RL+CR87E=+6/?\ :"T;.V3C!Y).YOW3_;K\,Z)X\^$^H?#W
M7][:%XRL[C1-5$0_>K;7<1C62,'Y258JQ#?+@>HS7X*:'^PM\3-7T?2_A)\:
MOC)8>,OA3X$M]2MOA=X;M(4_M#PS:ZG*L]K]JDWG:8 (@P!!Q&<$&OTG(+2P
M])V5K.^ENO7[T_4_%N.4I8V[5]4M5?\ I'M7Q!_:E@\'> _"GBNR\$ZGJ.J_
M%3PYXFO_  '!YL;&Z_X1R(F,Q1B%B5RT(? +'YL\C!^>?A7^W?\ $&'X$^"/
M'OQ1^#.L3>.OBE\1=9^'G@OP[8_.VM75E??8;&&XC6W)7S'EB4MY:94DET&6
M%_PQ^PI\7+#QUX/OO&GQM'B#P/\ "C1?%5E\.O#L3"66PLM<4&[=T-VR_P"C
MYY&T?*21RN:\Q^)_[.G[0/P^TOX-_#CP1XQNO$/B*'XC:MX^\$^*Y(5GTWP3
M<7]]%=Q7MV3*PCCLYCYCLKJ0L1VG.#7T3H3FW*-3E3O:*NK6TZ:+N?'3HX)R
M_>N"J.,%)/E33Y(VTMVL_P!3Z@L_VU6F\+?$*XC^'D^B?$?X53W-AXG^&FHN
MD6KQ&UCEDU1M+MY(1+*_V>+*XBDY888DBO!4_P""A?Q$^)WQ$_9^TS]G;X5?
M;?AS\0M6U+P_X_\ [57%]H6KZ5;I/>XC>W$NZ-X[E\;.#L 7)XV?$'_!/?XJ
M>.GE^*-_\;()/VECJM[>>(?%6FDVWA?Q7#>Q"&XANX3=1QW+%(T5=YE(R>,=
M;O@_]@?Q_P#"O3_!VL^$_B5#;_$3PGXMN?&6IK90F/1VFU-1#J08^:JNKPF:
M0! P+,<Y%2L/5BKNHY6L[<S7YA"CE\9QUIOWD]7#1+Y%>Z_;R\ ?"G4/%GAV
MU?4?B9\7?$7B>>&;P1?%YK7PQHEL\J7/V6(Q2B-XBTA'[H-MA&UO2=/^"EO@
M;6M6M-*^$OPHU_QGK^FZ$_B#QE+-'*+7POI]H\<.K91K9U66WD\\1M\A(B4\
M'BL'QQ_P37O9?%__  MOPCXWT#1?B)K_ (BCU?4?$5TOFVDNF3$?VC8HJ3,R
M&XEEEB&['+9*D FO>? W[&<W@7Q3\1?$VDZMH^C1>-_AE>>"]2TO2[6R\V;4
M+^-OM&K.258QW4\LD_R@%E<EFSBES3_FEI_>>GX]#NJ+ J+:E#RM*/7;30\R
M\._MG?%+QO\ M6?"GX9^!O D-]\"OB/X2O\ Q5J.NG$E[87VEJ?MEK</Y)94
M20^6B[U(*'Y>IK]'+H-]HNXT<BW,L\,2*>1 S$% Q(8K@<DGC\P?@?X=_L7>
M+?AAXX^$?CCX=_$-"?AEI.M0>/O#^H@K_;>B:O<>;>?V:9)MI9 &8A=X?@%2
MHX^^Y[RPO+F:6W)C$S&X$)4@013G>B^80$VHK  # ([XKJP\K\W.[IVMS>]M
MV3O;SMY'C8NK3CR>P:D^9W2:<K>=];6O;LM$)"2BK&[D1+'Y2H,\+D;$W DG
M'\)/(/?&:JX(:T1=RII]Q)=62 Y-O-,1YLV3UW@#([$+P,FIID=0RA=SA(I"
M@;>=DV#$P*,V Q([9&&[<U.(@(('9E#SNT< +())'C(W+LSYHPI!;<BX&2>>
M*ZKT^R_\ _X!Q.K*6\?_ "7_ #4OT$\P1R(\08,LQNE<9)6X<;6?D%@" /W8
M(7)8]2 (F<LE[$Q;9J.1>J&*"X )90^""O.<'J?IQ4/F"'8LQV&5V$>0S%L$
MC'R[L'"[B6(ZGY1@T^.5)0#&6<-(8E;RY OF $E02@' 5B<G@ 9(SFL7*"D_
M<AH_^?:O]]KA[2;5O9KEM;5*]ON:_#7L22R&:""V<[HK:(0VZ *ACC4@B-7&
M&(R,Y9B3SG(ZBLPDGE&T2W(3SV\L#S/)XC)7IE01@@9SDYSFH?/C\^&U$@-Q
M<*6AC +%PN"2'&8\CH5)&3W!XJ1F5-NYUR0S<$?=7(8G!.,,O/3I@4KPFU[L
M;_X4OT8E.5U#DM%K=):+M=1CI?5KY][N@:2W,Q@;RS<KMF9E60R+CH=^2N,\
MX.2>1C'$<<2Q9* JQX)&>A.<?,6PN3R.G'!(Q3V)6/SFXA/23^$YZ8XSGIU/
M]*=^8. <'@\C(HY8_P L?_ 8_P"1HFULVO1V(]BA7C51Y<G,B8^5R.F<],$#
M'KGZU([/(]O)(=[VR[(&8 F%,$;5P < $@<C'&***I)+9)7WMI?[K!=]W][_
M ,P))DCE)_>PQB*)QD%(P20@(.2 23R2?>D0M&AC0L$D!60<%F!R<,Y^8KU!
M ZDC&!2T4!=]W][_ ,Q59P$PQ'EY6/I\HY&!D<\$CG/M2#Y=VW@.27  ^8GK
MGCO[8I!T_%OYFEI679?<8.4KOWI;O[4N[\PP#U&:3 ]!^5+1322=TK/NM&+F
MEUE)^LI/\VPHHHIW?=_>PN^[^\*0=!]!2TB]!]!_*AMO=W+@VV[MO1?FR.;[
M@_WT_P#0A3H/]:OU7^4E)(I8  9^8'KCH01^''/?TSTI8LI(&8 <C'(YP'XS
MQCJ!^-&RDW_))+UNG^5]?D:'LOP$_P"2GV/_ %TA_P#1@/\ .OU.4 R\C^ C
M](__ (H_F:_*_P" 1)^*%B!R=T3<<C 9&[<G[V/P_&OU13_6_P# #_**ORSB
M1J-=M]$[_P#@3O\ D?N? #3P4[=X_A%(ER2<$GTSW_C_ ,!4T><$$DX.!GTP
M*@'7\3_-ZGCZ-_O?^RK7SSTE3_P+[[.Y][%*U33[?^9)1115@%%%% !1110
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MA$GGMGRVB8[ 0 <X8?J!^T9$)/CK\1+%IV$;7KR*Y4^:K;I,D28#!2",J3M
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MB+_@GEJ.J^);35_B/\1([KP@O]I7^FVL*1R:C!=7-Q<21&X5KAY #+)$>4'
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MA?MS:GL_[/X_XNQ9_P#7&(?^.Q?E7ZG)_KE_ZYM_Z,8?RQ^0]!7Y2_ "X?\
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M=]]G>_KS6/PX9Y.]E/[]>1W'S;6Z<<CID#@\Q>=(20+*7(QG.XCD<8Y'3O\
MI7[FGX??#P@Y\"Z3D@C_ )!</)[ $IDGT&<^E0_\*Z^'O_0AZ8/^X1&?_91_
M6A^)7/K'!)VT=H==_P"5] ?".&^W-7Z6E;3[^Y^'/FR?\^,N?JW7OQGZ\9X]
M3W3S)#ULIOP+ ?ED_GFOW)_X5U\/O^A$TK_P3P?U%)_PKGX?'_F1-+_\%$(_
ME1_Q$A_] FW_ $[?_P @"X1PE])_?)?Y[GX?1R/M&;2;)&<[6!/YJ./;/U'H
MXO(>/L;]N=K;OS]?Y5^W_P#PK?X??]"/IO' _P")9'P/3_5T'X<?#X G_A!M
M-..<'3(R#CL1Y?/TK5>)EK+ZC_Y(E^#@'^I]![2A;SE]_P!JQ^'^^3_GSD/^
M]O)_/BD+R'I9R ^N)%X],X/Y?X5^WW_"O/A[_P!"'I7_ (+(_P#XW4D?P]^'
MN23X$TH8[_V7%W]]@Y/.?U[4I>)JY7_L26G\B_\ D1?ZH4(_;@N^M[V_[>_0
M_#K>^<&UD+>^_P##G _E2EG'6TD'I_K#_2OW(_X5[\/B<_\ ""Z41QS_ &7'
MG\#LQV]>*4_#SX?'&/ FE'ZZ7'^GR5FO$Z*2_P!B7_@"_P#D1?ZIT?\ G['Y
M=/3WC\-MT@Y%G)CMC>2<].,?CU^N1P7"24C_ (])1]0P-?N*_P /OA\$_P"1
M%TP'C&-+C R.>"4P.!_(=2*KCP#\/R./ ^F$'UTV#Z=X\_RK2/B?&W^YI:_\
M^[]._*'^J6&>LJB;VTDTK?>]=S\0O,F/_+G+^ 8_RR?S_/U#++T-C*<=R&_/
M!(/3J,9],BOW 7X=^ I/G3P3I$8('#Z7;C/H1\A]#GZC/-(WPX\!_-GP9HQX
MY_XEL![>FS./08%5_P 1-5G?!QVT]Q=_\"\Q_P"J6&^S.*?^+_)K\78_$'S)
M#_RZ2C'H)%_F*3?+DYLY@.QS*/U(P<]>/PXK]Q1\//A]@?\ %!Z3N  ;_B4Q
MC)'1N(Q][KSDGKT(IK_#[X?!>? FE@#O_9L0' /0>63TSQZ?2L/^(FQU7U2*
M?;V?Z\MB?]5*%KMP?>[U]=)?DC\/"\@Y%K+QSR9#^?\ ^K'J#WJW=[-'$R#3
MY&06\Q\P_+DM&PP3U !;(XX (&":_<D?#[X?'D>!=*^O]F1D<>H\KGGJ,<U5
MN?AY\.)5BB_X0C34N';:R#3(O+"-U) CP<C (;.<A?4!/Q CCX5<.Z$:3=.3
M4G"RTTM>RU_ (\,4*52G5CRRY9K2[V?5IO5*W0B_X)Z3V\OP-AD*21[=3G!'
MS ]#@GC@$]"V003AB<Y^\HKJ.0]\9.0<XSC'3 (&#GKV(ZG-?(&C6LGAA(M(
M\.+9^']- :4VE@J6=N6!Y8QQ[4WD\'A<DMR>16P->UU"P&IN-K'&)N1@GN''
M/7'4X( XQ7X[G<WB,QJ5;I\TKVU;5Y/9[:W5OQ/TS+,-1HX2--)>ZDW;1)M+
M:^J2VUZ:'UM$8E.\$#)Z%2,'![M@=3QWP. 0,B;S8O5?S7_&OD-_$.OE0&UF
M95Z\3$#(SV/'][L#U/K4/_"0:U_T&YO^_O\ ]:N66Z]%^1KRJ%U':[?S?_#:
MGV%YL7JOYK_C1YL7JOYK_C7Q[_PD&M?]!N;_ +^__6H_X2#6O^@W-_W]_P#K
M5('V%YL7JOYK_C1YL7JOYK_C7Q[_ ,)!K7_0;F_[^_\ UJ>FOZP<[M:G/IB8
MCZ\#;GMWX].: /K_ ,R+L5_';@<]\&J,DN]I=@QA<9 X.&(_$XPQ ]<^IKY2
M_M[5A_S&I^<C_7N,^G\7X_A4;:YKCO#(=:N%A0?>69U#Y .6^923D=2",]>>
ME0^)?/\ )@\-+%0JPA+EDH7UV:OZG/?M<C'AO0FF)$1U%"2!RWW<*O![J"2<
MGN,X)KXE,TES);7%P)H;C3[^RNKA '(N&M\-:(XY61&BZ9)#<' ( K[BOUCU
MR5XM:F.L6X4M#!>AKE$<8):%')PQ R3WX^4G!%!O#?A]\N='MF+K$6WP*69H
ME'EL6(P61>48Y9,XZY)^LRG&*BE"]KO1W5KW7SZ,_-<XX<56JYU*LEY.6O;O
ML?&']JWTPN(W$T-S/J(ND(1V,,:R#; &R,1D-S&&"NNX8P #,U[=W5Y<7@U:
MY%NFU?*>-REO<I@*JAF 4E@,[5 9FR<BOLL^'M"W;ETJ MD'>(5+ @]<D!AC
MU#'L1QP&_P#"-^'U5T&C6BK(P>11;QKO<8PS@*0S<#DYZ<<<5ZM7B!TZDH-2
MDXV5[;Z(\B/AW'%?OH8OEC.S2]K:UO=:MSJVJ?KJ?&:ZAJ4U_(L.HWEB+E=M
MS)=PNUN;V(!X6AWDJHD<,N0,!N<D\53?6[^2[87&LWR82,3W5E:RFUM]4!Q*
M&C0JGSQC#$XR#NW>OVI+X?TJ7Y9-*L)$#957M8B05.0>"#D'YCQN4G)(H3PW
MHZ!XHM(T^-)G,LB):QJLLI4@RL< L[#C<001P6S@'-\1MIKE=W:R:NW^'0?_
M !#/?_;?E[;\O?\ P/C74-1"RA)M0OM-T^[B"Q7.AQRRO<W & US;08 !(4M
MN.XY?)[TV;6]4MH]/M;N^G@BM"(4N[&V9YKFW8KM?4?*.Y)^5P)"6.. 0N3]
MG1^&-(BQY6D6,8&2"EM&,$GD_P"KQDD#) ZX/49I5\.Z&GFF71[,^<RO*%MT
M_>E22K2?*2Y4DXR/EY/4DUE_K%5V]FO+W=?R(_XAQ)-_[=+2ZLZC]/YNA\93
MO-YMZ)]4FU#SHD,L4X9"'==T*L'Y;"?=)4GIC'(JOI]P\<FGE[A;*VTRVNYK
M2!R/)GO =T:/GY6+;< GOG..:^TSX;\-L23H5FSDKES:)R$!"$[U!8HIVJ.H
M'"X'%,?PCHTJJLFB:8Z+EHU:TBPI.2"%.2IY.!UYZ]Z/]8ZO6FO_  #_ (!:
M\-7/66-?+:RO5MJNUY+7;^KGYP^-_AK\./B;?^&=;^(WA2?Q=K>A7=Q=Z#HU
MT VAW#W6W[3=.DR20"XTUF$UKDY1DR@!Y'K:ZA(-+M-#:Z,OA&PB2.VLK:%Y
MM4TX(@VPV]R/WBQ1;50*J[!L9@%/(^R/^$9TI5C#Z39&*'<(U6W3]SO!\PH
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M*C^ VJ%1]%.0/RIP\+:*, :+IX &!BW08'H%*$8'89QQVZ#;_69?\^I?<O\
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MVXZ$\@ 9X.:F7%"DK.+Z_9\AOPZII7^L-K73VSW2OUE:Q\<_NO\ GK_Y$_\
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M&Y:Z+#X>WS_<V^]FC\5>(UI_:%?33XJG3_M[7U/U8_X?B?\ !27_ *'G1O\
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M4YY'0TB_\%Q/^"E##*^/-);Z"]_K,/TS7Y5 9YZ=1D<'J/KTQ@Y]^W-5W:5
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ML,!6'4 <_1G_  J+2SC-R^< $$J3T!QR#S@CIQWQ7R]_P3O.?@':?]A2Z_\
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MI<R;M=M\UM7]VB\[V/5C\:/$P)']FKGW=<XYQVY_H3CKFD'QI\3 @_V:H/\
MOIQGJ.GU_.O+6R'8XSG!XXZ9!ZG'4>O/7UPTD\\8QZD<]O7COUXX]3Q[\<AP
M]DE[ZU]Z2NWKUU5WTVZ'QTN)L?2?*JTHVC&ZC5<5K&,MM7U[:O7J>L#XV^(C
MUT4DJ>3O09;&&(^4]<^O3\RU_C7XB8 ?V04QG!\Q>!UP#MR.0.@[]J\GW,>A
M(SZ.,9]<#^E.SGCYCW'+?3N1Z]O6J_L##JSY=?**T^?,+_6K,'[RKS=NOM7[
MM_-\N_XGJ?\ PN;Q%WL&)_Z[94C'7:5P3[?UJ:'XT^( "6L #DX^8'@X_P!G
MMC]?4<>2$D$C#D \#)QQ[<YYYZTNX_W#^O\ A6O]B4++W>WV8?\ R5_OU[E?
MZVYAI^_^^K*_Y'L'_"ZM?Z?8%.>.2/\ XG\/Z50;XS>(LX%B0.P\P9QC//RY
M_,G%>6EB?X>GKDC^0_/ZTH;C@C@9P 1C]<?H?I2>38>-N9)?]NP_S??[R)<6
M9A)ZU]-/^7L]//1+7KKH>I#XS^(@<_8\\$8=MP.?8#V[T?\ "Z/$9/\ R#T.
M2>C<GKSR0/?KTXZUY9YGM^O_ -:G;O\ =_[Z_P#K4_['P?:7W08?ZTX^6^(F
M_P#N,]/R/4#\9O$W3["![J^/SP/_ *XI?^%S>).UG^4F3_,UY;\ISN(]AG@?
MRS_D=J7Y3U.?^!'_ !IK)L)_)4?_ &Y'^ON,WQ9F,6XK$RLG:SG/3YI-=>C/
M4/\ A<WB3&#9Y]C( ?;C/'Y>_-'_  N7Q(I^:P)&.,R#CIC!V$?D,=J\OPO0
M$>PR2/RSSS2$C Z=><\X[=!@?0#J,G'6IGDF$<6E"IY^[%67?IV$N+<S<DEB
M&U;6]2:]-U?SOMTZGJ'_  N?Q+_SX/\ ]_1_\31_PN?Q+_SX/_W]'_Q->8;O
M9C^%*#GL1]>M8_V'@^TON7^97^MF9?\ /W_R>?\ D>GCXS>)#@-8MR>,R+@^
MV2!CKST[<]*>?C+XD!)_LY<<\;^V3CID<COCMCU->6$\@<Y.>F.GOFEY'\;<
M]!N_ECIC_P"M[4UDF"7\Z;W]V+T^_L1+BG,Y_#5DFK<TE.6J_73R6VOGZC_P
MN7Q*W(T]1VZ@\^O./;C]?0_X7/XC_P"@<O7GYCT[_P /6O+L'^^__?1HP?[[
M_P#?1I_V)@>\O_ (_P"8?ZS9I_T$3_\  Y_Y'J#?&?Q*6PNGMCU60 ?DP!S[
M8]@3Q3?^%S^)?^?!_P#OZ/\ XFO,OQ)]R<FBE_86$>JC.SUORK6_7<K_ %KS
M)67M7IIK.=VUIV/3?^%S^)?^@>Q]C(I'_H-/'QH\2+DG2]^1T9E(4#H>0!C.
M2>O(YKR_\/P_S^=(3CN!Z9H_L'"O11G?_"O\Q_ZUYELZMU_CG_D>H?\ "ZO$
M9_YA$?X%._TJRGQM\1!0/L$:X&-N4X]NE>2Y_P!I>..G0CM][MZ4W'^WCV!X
M'TYIKAW#]=/E^B0?ZU9A_P _4O\ MZ?Z1/76^-GB(HV+&/.?]D^G)P.WIUQS
MG.*B/QJ\2G_F&I^#(#^'S' XY'<X->48P"<AL<Y(R>/?-&X_KTV\_P#H73/?
MUJHY)A*3<91G)OK96TMJD]>OXEQXLS);5[+K^\FON7*SU4_&KQ)_T#T^A=<_
MD.N?KSZ@T'XU>),#.G*!GKN /_H1/Z>G->5;CW! [Y7 _'+&A<$]/I\N,8Q[
MG YS]31+)\&_LS^Y+\F6N+<RYE^_T>_[R>_SCVN_D?4WP9^+.K:OX]LM/N--
M5&N2D8P_+'<JM@''&/F/7/;CBOT/C&9@P; =-I!'0@?=SQST//OZ"OR?^!.?
M^%IZ,<\'<!GK@?9B<GWR#CU'7O7ZOQ<[0/\ GL_Y_,>W^0?6OSW.L/3PN(<*
M<I.'O7YNBYGIZ7T^7D?L/!^,J9A@G5K<JG9-VOK?X97MU:?S=[%O<%Q[#OTY
M(R,\<^_3ZFB-2H.>A.1ZXQCG\ /U]>(L?,Q_VFX_X$?S_(<59'(!]:\6ZT7?
M8^LCO)7O;\^H4444RPHHHH ****3V?H_R8"-T/T/\JIS_?7ZM^A4C\R *N-T
M/T/\JIS'YAWY;]67G^M<%37E2WY5^<29;/\ PR_)G\\/_!R+A?V#+SJ#_P )
M9IA/_?JZ'/7'7^>>.*_A4M(VD:'81G^SXFPV H"F0MUQSSCOGKC'!_NK_P"#
MDG_DPZZ'9O%FF#C.?FBN<G'XY ]J_A1M>8H]S;"--C;/OY9)7C&<EL=NU?WC
M]&6G?*J\I](5I?.,XZ??OUOU/X;^D1'_ (44HK2U*[MUYE?1=[=-RV>8Q.LB
MI!$I,Q<@<+G[O3.<'!^AXP:C,HBS<7]CJEC8SQ9TZYF@D6.Z9F,:M$=G^D('
MR?+BW/A,\Y(JCK'V>XTMXVE:W>TM%NB-I EP68AB.&+#C&<\DX!'/]$5G^SY
M\+-=_8J_9K_:\^(7ANVO?AU\%-&DUK7/"6E6B3:MXE\0:?<73VEWJUK%#+/<
M:+YMJ#-NB*;7^;@DU^R\4<5K**DW?EB\0J$=7&\I-\B5M=6FK=5UOJ_Q;A[A
M]YC%1:33O)]]+/6Z:ZZ_AW7\^2V.MI*]DOA[7-:OHKRW=UT;3;V0-IDT?F%_
M*,+2Q3@,JC>NS(QR,$6+K3=6LKJ'3];TK5O#][=QS2Q#5+*>*"VB5OW0O'$8
M$;F/:WSL,@],X-?OK^PY\7/B3^T#\'_VR/CY\'?A?\+KGXK:EJZVGP^T+4+.
MRCT'0/"UE9S6<+QBZ,4=O>A;>"5XWGA=FSE-VW/@_P &?'GBWXG_ !D^('[*
M7[9?@SP)X;^(/QT\,G3/ /BC34LB-$\43P16UDEI=V[W4,1>1MS;9MAD^8LB
M$BO!P?'<IRJ7<W&$(R;3<E\+E/?;EMW;TOZ^_BN"XP3Y8TTTWY._Y/5)V7WG
MX\(8Y8;22U:XNT\R>UU&[A@G^QVMR&V6[+.R>4(9,[LEONGG'037L+:<T-K/
M%=WFJQNKWMCIZM-)/:7&6LS9HBL[NRJ?,"AL?*-N<&OTY_;7\+>%/V0?A'X/
M_8>TNP\.>(?BU<7]UK'Q/\:VD44NH:3I<<CSZ61=JAP+BSF5E"SL2Z* !C%<
MY_P3/\%Z!<_%[Q9^T;\3_#I\6?"']G?PM/<ZY;/9M?)JDPMWEL%DM_+N6N'6
M2TF.P1R%MX4*,\>S/C%/+IXJ,757)ST^6<8N<7'FCRN;46Y*UGS*/O)MI7:\
M6'"ZCC%1DH:I-NUFM?*Z771*^G7<_.&""YNS=16EI>W.H6\C^9H\5C=2ZE!"
MH8H)X$B+)(>"VY!TXR""7_V9XADB@$7A7Q.EU/(1]GET/4U;RSE4=!]E&<L1
MM)XZ?C^H/[8GB#6OV3?VG_!?[3OP>\+:1'\._P!H#1_#?B;3/!NKZ5#]EM/[
M7GME(%M/'"(PRJW[HPJP+,'"X"U])?M\?MV_&?X/^)O@S#X,\%?"RPU/QE\(
MM+\5SV,^A:>"K7-K;RN5 CV^80Q9%9E^8G ) (\3#<<3J5H*-.HHR7-)N2;B
MVM+)*TK]TU;?6Z1Z6)X7C"-.W+%R44GT>MFW:_?T?WL_"9]-UY5$<GA?Q3;3
M0!I-0GNM&U!;:*+&5=6-J N<$MDGZ#)H:PUFULIM6ET37I=-MP#=:@FD7\5I
M#"S%/,D=[?RPL;<NV\+M4\@@Y_=?]JK]M3XJ^'?V1/V5-=L_AS\/DUSXT7NC
MP^,=3BT*Q,D5O<ZI9V4B"18E #QS2!<%RNXLPPJY_0CQQH'Q5T[XG?#G0U^#
MGP^U+]BB\^#-OK?QB\9OIFD_:],N[GP_%=7%Q$D16]\U)99"K?9'PS;LD ;M
M)>(+HQ<JD9P?/4BK).\8R<8R>EKR23:W3=M3H7 LYJ,U*FHM7W5W:UWW6KTT
ML^E[.W\DK($V_N;J6T,UJSZS#&S:;;VEP@DVSR("JW2A@"C..F,%N*#9:F(+
MJ_DTS58-$BD80ZY+I&H-ITD*G:7:=8/* 88(<2  ,"#C)K]-_#6A_#:7]CG]
MN'Q!X*TVSUGPWI_QYTNV^'7B>XB5UM=%.LW2FRA=HUFCA\I(XVB*1@J H!R,
M_LQI_@CQP- ^&=I>^%/@E>_LP:?^S7IMUXC\#F'3/^$Y\8>)-3\,0RQW&G6S
M'[7-<_:%+<02-ER&;=7++Q+DYPBW-IR5WU^7];?@?ZB.-Y/DT5_=M?=;WOHU
M?^KG\F,>RZA:[M;+48]-7!34KB-EM;M4)6XEM9BBJR1_?"%B0,]3D"K&M[=P
MI'I.E:IJ6HW5Q,-/-MI]W+;7%K&,O(2L)#2*AW$(Q4 @Y( )_4/]I+PYX9TS
M_@FKHWBJP\(CP1J'_"Y_'&GZ9I,T"6WB#3='M]8A2QMYG*+)]G6+RT\M@OR!
M@!@@5V6I?$N^^ G_  3H_9X^,W@3P]H>K>-]2\7W.C7E[J&E6<QEM@EHC"5V
MB);(=F!9N3@-@$FO4J\:1KX=3@YIVW2LW>Z=O-=%Z')/A1PFDE&W,EKHMEJV
MELWNK_-;GY-SZ9K,$8O6\,>)X=/M+.&34I9](OXR+N4A-L+26P7RBPPF<C:V
M<X/#?L>JPV(U>XT36K72[7:=4DN='U)1'&[81UF-LL()&T98XZ'(Y-?N_P#M
M6_M;>/\ 2M?_ &+_  )8^%/AW::)\9_#W@?4/&<-KH=B+V\>^ETV26.(11 ,
M[-(^\$. 'P:W/^"DVH?M4^ [[Q/X<\)_##X?Z3^RTWA[P]<^+M26ST*'Q1]@
ME:R-^]G&LT=R)6C+[2EL6W/C'7/#1XXE2HPC-U/:.53W>K2:M:S5URM>E[=-
M>W#\$\S]HW#EMS?<KVVW?KT5NY_/U96^HZT\LGA_1=;UJ,KYL:66EWT@M[<!
MG\RXG6!H3E%++M<#@CKFEC2.;SV42Q"WS%-%,2)HKE2%:)AQ@!L@#:, D'!X
M']!'C;Q+XP\-_LT?#CQ__P $_/"7PS^)/PGL?!,-G\2=+U&TTZ3XC:#=2V<'
M]HIJ=FYMKIY(YY2\7EQ2;$1B%;)-?S^ZCJD.LZQK6M26,NC7NJZE-=7VG.C0
M1VUZ\A>XA2)@'14D9EVL-P(89 XKZ_(.*XX^/)*]Y/D2G=--Z):/OI^/D?,9
M]D[R]M)1;;NN5O;FZK=:;76Z*FP_WVYSSGUQTY]O\YIRJRDY<L,< _J3_2G
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MUYYQL8\JKL(02^\9R2 ,G /!/09IMV%%M(H?<7M+A9L9^1MC;TY[C.#W. ,
MYKY\^"G[1UM\9/&FL_#_ ,0^"]7^&OQ&\$V\=_9V.H1&,WMEK2H(97 Z!EE&
M,.O7D=J]]G5HX[RWE4I<6[7<%SP</,L;%Y%/1@2  ?7</2LJ^-C7H5H:?PY-
M;_B2H*-2DU_S\CT2\];6/W _X)X #X&00J<JNISD'^+YD8G/Y8%??9.#D<XQ
M^8W_ .37P)_P3N.?@C >F=2E/_CCU]]'O^/_ +4K^9N*%;-<1_V$3_'D1^X\
M.O\ V*"_N)_^2Q1,A+/D\$JW;'=1TR?YU-4*??\ ^ G^:U-7F](_X8_D>VNO
MJ_T"BBB@84444 %52YW3 C^[V/!!(!//&.,>IP>!FK54S]^X_P" ?S%3/X7Z
MK\QK=>J_-'QS^U^=OAO1L#K>E0,_[*@=CTS@?7FO@@K<VL,#$12/.P46T9S+
MC#8X!!#<;AG &>2<&OOO]KTHGAS16EE\I%U.,-(5+!0<#<0 >!U/TZU\-:4M
MK9ZIJ\5PAFE.ERR:5>[@RQ3?9)7CD4') #E'+#"IM(8\<?I_"'^XN+Z)Q_"]
M_P #\)X_?^WI/JTO_2D1RPFRBM=5U>WN+'1+QQ9VTY>-Y)]08E5B^5F$<8D/
MS^9@XSCE6(CELK^P=-+U.RFAUN7?>0S1R0OISZ20'@E,B.W[]HSG!Z,Q#*N#
M7X6_L3_M?_&[PS\4?CWX6_:HUMO$OPF^(_BSQOH7P@U7S))8/!6M:'?SVEBG
MG!YX;-IYBAB#-"S*J$,H9L?0G[._[7NN^ /@/>_\+2LM?^+?QF\<?&7QCX2^
M%^BV#/=S7>@:/J4]O8VT#!Y0Z&!K1559,*<[OER:]F6+]G)PVY6^O=M_J?(K
M+?;Q56S?/&.J\HJ/Z6/U/2$S0>?;(\L /[VY#QB*#&XNCJQWDH 2<# 7!QGK
M"Z.L4/[MPT]VRI<,Z^0;+LX'W_-W!ASA2-IQTS^>FJ_\%'/ ?@GP#\0?$7CW
MX5^*?!_C_P"%^JZ/;ZG\*+B*07>M_P!O7?V.VD:W"R;P[E.AQ^\0="#74>,O
MVWY/A[?>"-$?X&^*-7\:?%[1Y->\*>!_L[2/9Z.+*.\DF(&U(A%:2K,0TB%<
M<+D8I?7EW_%DSR=*$G9JW33K\C[DADMR]Q)-;W1M@WV>U,31M)-<$E0V[)"0
MEL YQM!Y/.1"[FVENH;Y# \$.R)%=)'GU"09M[5'4D9<8W, >20 2,5^:V@_
M\%0/"6HV6EWUQ\)?$EK\)9?&:^ /&?CQK9]OA+Q//=_8Y+65]H=&M9G*K^ZD
M7:I()P,^G?%7]MW2/ /B;7_!OPJ^#7BCXP>%OA@VDZ]\1?B';P&>/1;+5;>*
M]AOIIPJNJV\$F2 I=5BP0*/KR_IO_(Y?[+_Q?=_P#[<:._CCL/-TVYCFOLH4
M:2(BU<YVO+G'RY'H#C.,\XF>"86MQ.BI+-8%4O(DN(20[?<,<>XR;6QSP3UY
MQS7PSJ'_  4+^#.E:S8QZSIOB"6+QUX=.M?#N4+*%\0:HD W:1:LR /)'<2Q
MH(E8E6,>5)-8'AC]IOX9?#VU^,GQ6^(@\3PZAX2N_"Z)X%F,O[_4/%*-)8V7
MDE3F1)"59%8E0" HR )EBG4ZV6W5O[]O333U#^R_\7]?(_05D*?8L0R7#SQF
M6:&*1/,C3'S'G@^2>6Z;>2>U,B6WMW@DU.ZA^SW,D@B%LP:54.1;B5@&4,[A
MA(PX; V8)KP;X!?$_P 7?&33GU/QA\+?$GPQ@GN&U;2]:OT-O#+X5U'?)$,,
MP8+/9@ MM&PN68=*\6NOVUX;_P 0_$:'X9?!#7?&GPK^%NI:WI?B7QR(/M%O
M:W/A]96N)_M!(0#=%N8H64$,!C(-1[5_SR^]C_LM]G^)]Q7%M>6\5M.$54O+
MN2T@A;YIAL4A;EU496%L!BQ  P<D#JZZ^RV$B/\ ;8M:M@!%=_V,PGEL[L@$
M0R^7YH0KYB>8'"L%'3)./E"P_;8\$6/PI^$/QWBTFYOO#GQ=\1ZAX)LK:ZAD
M8V&H"W\LM&'3!\N:08:+)  ()R17Y^ZG^TW\?/V</ WQG\0?#?PS<_$2[\5_
MM%C0=+M[P_:#I^F:C+:M+;PK),IC6*UNY"J#!^4[0Q SU0QO+",='96N[ZVO
MN4LGE+51O?7^NI^U N 5#1V]S< 2?.8MBKY1; *9!W,F1YG;UXP*FMO+ENHK
M29Q;27MRD5AYA0[8RKDRW1S\B*%'S$*,D X%?*GPT_:ST3QS9_$NUUCPEJ?A
M34OV?/!=KKOQ"@:-\M<W%JDTY953.SSR2/O\< '%>=P_MU:9J_B#X/?#[P1\
M*M8\7>)?C_H>IZSHVI1Q,PTSPY822-?ZM'(540B"&"3!R&!. O%$\:IQE#9R
M5DUI;?\ 7N/^QYP3DX:>KW/NIEO(W:)XA)Y+7<<US$R- TL#%4$+ABI5EP<@
M]<YSBI7,4+^3>C[+<>0DKB66)4B9U)1G<D*J-@G)..",# )_.KQ1_P %//@?
MX)^(L7A&+0M5O?AYX1UFU\%^.]<$;S2:?XJGDFM;I28XV=VCF5/F6)UR=P.1
M7G'[5/[;4VN_!WXNV7P2^&WBOQ-X;T<Z>T7QFLX9C:I:W4D8-C]H^1E>R1AO
M5A&!E2P KD52S^-]M%;\43]1?9?^ H_5AR]L]M:W**;B[#2174#QRV*P,,QR
MNR;N0 V?FQM /<DR!8H01-<+>/Q\U@K;.N/FW[O0].!VZ#/E/[/*7.H? +X:
M7MKK$_B'4M7\ ^'=9OYKYR;B*:^B)DB:25B25'RL V.3CJ!73ZU\1?AUX'F6
MS\7>/-$\'7;$*MK=S -(Y) 4[5)(R""0I (SR 2!U&W?G=W_ %NRXX?D>S=N
MFB\_Z\]>B.J9XPKRH&:&%?,G+*5:&,,H+ONX(RRK@=^A^:I)H;R*TCD>+9(]
MPK+*S PR6+!=TR!3N\P;@5&2,G)'.*QH?%'A?7=%U+6_#6L6_CFVTRPGU(Z;
MH\B.^J);1&8Q-]Q0G&Y5D(#=AG-?%.L_\%&/A)X=T#P'XSU/PYJU[<>-OB3_
M ,*CE\&[)?-\/730^<;V6+RCY21[2?-<1QYBP)"2#3]HX[S>O]=+ERIJ6\%\
M[/[KWL?>I@N(F,\]K+#IR6CYG>X@1[B])_=I;*[!GC91D@*6X85(L4:W&F6U
M[NTQKB&26[FOW2*V5CCRHXG<J 9/NC+'.[CH37P'\2OVDOAQXHNM!1#XNTS0
MO WQ)TKPXFK6K2BQ\37U_;&]CM8F  G$1?RI  P&U1N/-?'?Q6_;.^/WQ4^$
MW[4/A_Q1\.-;\#Q?!OQSX?D\)>(+?=#=Z[H,B1,;2&:*YD >[%QN"%E.5"E5
M)Q79'&J,8K1VBEUULEY>1D\$VVTK7=[6774_;"UD,UJ?/,<=\MQ-&L2S*8I(
M"P^RR(V[!:4,F3DKM8D=>+/V>>Y=K6S:%;^&!KB>*X;"I%#S+M)(#,V5"]B.
MN!DU\2_ ']KC3/BCXQ\(_ 7Q9\*O$?@GQ'J?PVT/Q)H'B/4$EC:_ECM(G+N<
MEV!W.&W$G" YS@UTGQW_ &O$^"/Q,T?X-:'\,M4^)7Q:U3P[>>)[73])BD>1
M]#TVW:XU![@C$8!C' ,BLP PK'BFLQC%WNKVV_JVXOJ+[?@CZOCD^VO)<6.G
MW<.E1V$4C7MVT>)-2.%EBC10K^06#;1M)&1\V<"I' A,+26\SVUVPM8;N)T\
MJ"^9L".X5\.%&<L." !ZU\/VW[?_ ,/[_P"&W@#Q9X+\"^(?%/Q)^(NM:CX;
ML/A%;P2FXT_6]/$SF&2 A2")84W^9P-ZA6&2:XS7/^"D7P]\*?#;Q1KGBCX:
M>)M'^*?A;Q#!H6M_"V6WE-Q'XINW:&*..%5.5*-;DLK,!YAWO5?VFNTON']1
M?])?YGZ,SVTDNJSZ%9/!;WD-E]I%[?NHT^:8E6\B,HP928]Q7+99E'J!5$7:
M3Q^;!!,AM)&AO8I619;AU(!:S]4899#AADY/8CXE^(G[9MQX G\"_#[4/@3X
MKU[XK?$#PC%\1E\-6\;M<Z3X>PESNE8.T:K':R*Q3S 0I8%2 *X#PY_P4^\(
M^(+_ ,(>(M6^"'B72?AMXQ\01_#R;Q0MM(D>A>(VN&L7BD?#%Y$G63<57+ 9
M]ZYL1B?;.,TVM&I=[-[M+?97Z;$_V?-NZ;LWI9*R^5O+N?I"T@R$^Q7L4ESC
M[(DI0Y3 #&4KP"2>.Y.>.,T3/Y<=N\<+W2S3K:2S6\T+Q6\[8(678S^61D@[
MB#D' XKX_P#BE^W!HO[-OQC\*_#'QU\/]2O_ (<:]K^A:#'\0':.;;+XMM!>
M6)C,3,ZF&.4X5H0PV@$AABN-_8U\07>H_$_]J#1KSQ-K/BCPO#XJL[WPE:3S
M2L;.WO91-'"AFP(<%F5<K&=F.6W"N?G_ +_X#_LV::=WH[[?+^O,_53X$VJK
M\4M%5G)96</TX^>%>V!@[1SZ8QTY_5&#)QG_ )^''Y!A_GK7Y9_ ;(^)>B*R
MLA^?*L07'[Q,A^200>.X!R,U^IEOV_Z^)/\ V>O@.(O]X;_NO_TI/]3]RX!N
ML!./\JA'UMS._K=M?(L=V_WF_P#0C4Z]!]!_*H.[?[S?^A&IUZ#Z#^5?.=:?
MI^C/N(_%/_$+1116A84444 %%%% !44H'EL> <=<#CD?Y]ZEJ*;_ %; #).
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M_P 0/C!X(2[FTO7=(T>&2]U%YOMGVVRM(81!$)0-T;LCH5RP'3H/F^D?A/\
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MW1XA.2K^2D^X$-OV[9",C-%O3[OG^#7ZZ:%VQZU5)W]7U7^7EW[V/RR\3_\
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MSI^SMXH^!GBOXOZ[KU[INNQ_$"30KZ&QL[B-9(_[(A6-XXC')B/.P*V,\')
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M11DX888YP >.H()Y'3IC/.#4WDJ?O>9G!'"$\<XZC.?\Y-+Y*XX\S\48<?\
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MY\:YRPU5245[KTB^:Z:=[V;MJEK_ ,.9TZ*C6I2B]?:*[;3LF[[+2US]NO\
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M&VH6OH?G?_P4)_8A\)_M^?!6;X/^(]>N_#]N+V*Z-Q;ED(94DC) "/NQO)
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MI:, = !6RY;*]MEO:^P"*<JI]5!_2D;JG^\?_0&IU%)\MG:VW2WD X_ZN/\
MWA_Z*%0Q?ZM?Q_\ 0C4F!Z"BL@"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *CN/^/67_KG<?\ HN;_  J2JUVX$#*2.([G [Y\MSZ=""#W]L8(
M.&(_@5O^O4OR9=/^)#_$OS/VX_X)[?\ )%(/^PC+_P"RU]_!N QXRJG\3FO@
M7_@G><_!&#G.=0G.>Q&,#^5?>]K]R/\ WG_DU?S!Q2[YMB5_+6EKWYH+\K'[
MGPV[9;0]'^$(_P##$\9!;@_PM_-:GJ/_ ):_]L__ &:I*\Q;+T7Y'M!1113
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M[??>Q^%H\$^/6.%\%ZZY_P"N&SCV&X@X]O0YZ$T\>!?B#V\$:[^,:_U:OW/
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M  @GQ"QQX&U\\9R(P0>>#R1U]/QZ=?W/Q/\ ] NU/XK_ %J50^W+:- Q)&2
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M_P#K4?VYI/\ S^P_]]?_ %J^-_-L_P#GXO/_ !__  H\VS_Y^+S_ ,?_ ,*
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M^K*/U/TK[G)8?\N9;W5U(_5QS1\Y_P"71E]V=0#_ ./'G\*T_P!8GVC]S_\
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MD"22?&3$BX/[T<DJ<\=!R#7T/^K.7/>C3N][*WKM'_,\!9MF25N>JG=Z)O\
MX.IZT/CQ\9AC'C*[QN)8E.<8'^UCCD_6E_X7Q\:L ?\ "3]LY\D9SZ9Y)Q^5
M>6%90D\HA(2T -TQ (M<X(:=A]U2I!&P$\^IP*$DD$5J+^62XCL&Y6]<XMR@
M!+-O,@   .<@GT'7"?#66QM>G3CONKW_ "V-89OF6NM26WQ<S[[6[_H>P_\
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M^)O5/U_PKSYS<Y<S=](K[E8ZX-M-O^9_=I_P3C?^$#T#_H'Q?F?\:/\ A ]
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MBM%U7^0O]9,R7QSJ1]>;_.-CJQXZ\5KP=9F7/. %/7N25[X_3K2?\)[XK/\
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MHSCGG&<_YYYLHN-Q[,<CIWR>WU_IVJ'^(_5_U;/XU87H/8 'V/I7A4^OHO\
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M'9/H?T_QHR?0_I_C0L83$=VR6US*0;>W93(9(^,22$/NB# AN> #W'-%T+>
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MC9J?PD_90^%/Q*\+_!K1_"/P<M_$X\8:BT=A%K=T+>298K>=XYA,8'42!44
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M.\*?LS6/P(^%MK<^+?"WB2-;R7Q-=7&A/=ZE]AT]X[AKCSGC=L*R89UC#C)
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MQ48G>1DGYB1G&,=L]><@"KD1;&#CN!C/; /ICC' 'KSC%>%RV2E=:WTZ]O\
M@GVM.K^]E3<6K):][ZHEHHHJ3I"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O(C>8CC
M )R>IR0 #@\<8^F #ZU5NCDKQGYCQGG!5B>G.,X'I^M7F9@V,?*1P><]#Z\9
M![9Z$52F'(R.^5([G 7!]!DC'6BA%PJWE;EL[/OTO\M/3[CDQ]YT.5;Z;=OZ
M^1_-E^T0$B^/WCUY"$$LS)%GHS!I0,'(!/3@YZC.,BO(MLK,\:K$9X88[F..
MXD:(-)$"4&Z/$@<G[B$@,< YXK[&^./[./QA\1?%KQAKMGX=CFLI+YYK67,V
MY[=B3&WRKM <,3D$]CCGCSF;]F'XU?:Y67PW&A:WMV5\L0N&0CY75ACKC ].
M<U^^\*Y]A:67.C5FE>*3Z67+%7]+'Y/FN08K$U^:"D]6TE;N^OS/ KF\O+NR
MMX+W[1>W&I3*]PDBK##I90Y #(%9QM7<-^0<Y%3W3%Y[%3.MW?:<OG113.;/
M2)(%.8X7:WVO-,3U+J[G@< G'NI_9D^.+<'1XL<]C_1,'_@0(_K7E_9?^-[D
M#^Q8MH&,;#C@YS\J9&3S@=,< #K[7]KY1?\ WFGOWTT_K4\K_5G-%HU->6KW
M_P"!V/%+S5&NC+J$ ^Q:SJ;"VGL;:",:1#&F"/,D'[TH^T%C@ @X).YPT4EU
MJ=S>/+)+907MHHCN$A1;;2;NWVK\L*0[07SC/R[E8,"Q/!]M_P"&7?C?C:=&
MC(/4 . PZ;3^ZX&/0CZU:'[,/QL 4?\ ".V>%Z?O)"!QC@%" ,>@W9 ^;&0=
M89SDBO[3$4GM:\K=[]K]#6GD>:8?X:-2=[=]+7MTZWZ'RQX8\$^ O!GBWQ+\
M1M$LM3M?$'BVPET_5HU@CGE:5EC4%9)SE+4[,@@Y4,3]]>.MBO-1M;&VL+N:
M)G:Y2]-]8M)<3_9T8LMG)YW^K+KM#JHV#@;F!&[W=_V8?C<VT?V#:J0>JR2%
MP..YC( ]L'(SZD5#_P ,N?&Y>FAP?,23AINOJ?W?U_,\4WG/#ZU=>FK]I)[O
MU-UEN</_ )AYK7K>WX*YXVMY>W$TEU;:E-IJR2.ZLT,$\ZB( +&ZS[@OF<[0
MB@?-P#A<-6^O&LM0N5N);2_U:6,74B1122LD#,VYX' A43''*J&Z >_M _9:
M^-C?,VB1;L\D/, !VXVY)/T]NAX</V6/C2>1H41YY_>S@>O39QU[?3-4LRX?
MEK[:GKY_CJSCEP[FE24IRC-.3;M:UO)=;>9XU)J5V&M[B\O;W4ENHQ:^6EO;
MVYL$9#&T@CA5%4JI+G!QU;&0#5+%TCM"-1O)A$6C@D=8PB^:&.\D99]H;#*3
MMSP/X<^Y#]ECXTY.W0XLD<_/-R <\C;@\^@!SSVQ2']ECXT\#^P$P..'F.[
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M] '/Y8]J#^R]\;203H<9(Z%A*<>N.&'/X=!CO6W^LV6]X_<7_JSF?:I]\O\
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MFGOKB6^74HFDEOI+9;.V2YW+ AD($TE\H)W8"YR < C@8 /9GX:^.">;<<<
M[2P],@E6Z]BN!TZBE'PR\:G[T"YZ*<$=>#D%,'\<8Z8YIK.\+'1\M]]K?Y?U
MW-*?"^:IVY:K6^[EOIWO_P ,<*)Y;>\62ZC6ZGTZ-O+GM7D: M-T:S!"Y>(D
MC./EP5!X(JI%':62/?:18/!JVH7&W4-0G3_3;E'P))IY3N=F*@<LQ)(VD],^
MD?\ "K_&6!F!,J<C''UZ)@=!Q[XZ5./A5XY8!PB89<#*%CL(QM)"X((]AZC%
M+^W<)_-'[O\ @'6N%<RZ1D_E4C^,FE\MSSEHT%TUJJ%8+>(7*W(R%N+@@[E
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MA/49Z   XY(') 'M@_\ UJ@BD!;)[Y7'H#CD_IQ@\8YZ8GC0AB3G ) SCD8
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M&Q'_ "YVW_?$?^%8.VG+M9>6O7^OP[Q"]GS6OS2>FN[1\<_V>?\ H'7/Z?\
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M+*48QG8QX4C '<#H"1SC/ Y^'?MM^%(_M:Z#$$Y,A& .N??&"/7L,#!^GPF
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MO#3=M1M\M;[/8^W6U",G+:A:(1D "1 -K$\GD$G;Q^@SGAIOHL$#4[09(/\
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M[[;'ZD2?M3?!'3/'3_"[4-7S<3W*6+^)H-MQI<31$+"?[068P)+(7_?(0&!
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MRQ-<"W(B(+7*@;MX4Y&0PR^ ,@GV"6&&VC:*!!'!''<*K1KE)=L;9EZG[Q/
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M<8\H^ 7PZ^+ME^R)\:_#4_A2^O+-_C%I^N_#FS%G<PRW'A2;4S-)>06<\#2
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M "HU_9-^#BL3=:;>2 C(+,5.[C)XD!Z\CGZ@TZ7B#ECFN>G)PNN9>S6J_P#
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MMPS+Q\S%F#8&1GBG-<Q7$KW-D-":\3)U&ZBT^U$ERH(.UY%MP7)'&"VT?='
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M^9Y7^S_+:R?&"W4%RYLK;!(QAOW&?08W=#T].,"OU4A!2W!'7/0]#R%&3U[
M@^G;."/C#X6?#OP_HOC^/6K4S&<Q)#'$RJ(P@*[&!SDDG##C  R/2OLQ?->2
M1<;8X?N(OS!L_+D].03V).>1T('Q.:UE4J.5]')R5_-R?EK:2V]/)?H_"^54
M\!%I)<RC"#UOMOIYO[K7+(.0Q( X8<=#@+C\><?I5B,<D#CH3[YW?UYS_2H8
MX@I'S$[E(Z<88>N<^W&<8 SQBITX_$D?U'Y#CWS7DQFG!^;TVZ:?I^?8^KJ+
MFK1DMDI)^JTN24444%A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6F(W(I!)Y*^Q&,$^
MN.O? SGIQ$R@89L $Y;)[@@C R>BE^GUQGI/,,#/]YE7.!D \'!]Q4#9\N,\
M!3ELXR1@E<$]3G=U/ ]/3!PI5*M.,H7:D]4NJOI]_5&<Y5(PJ2C*W*G**>M]
M]/):7MH?D_\ $S]L#P5X3^)^L:)=^&]6=K&:>VGD56P\D+!9'7"_=9@0,8 V
MD=0:XI?VWOAS=B1D\-:PLD+MC*XPKGMD XY[<'DYKX[_ &C!._QZ^(,L,T4<
M,<\H*L%QNR^\*",Y)^8XZD?B/(HK.WAV7=[++960$#7-[#"6 0#D$,<!90=K
M2#.TC)+9X_;\HX>P>)R[#\[M&45S7BFFFHW35G^*9^:9EQ)B'B*D%!W@[I7_
M )6XZ:]3](1^VKX!!('AS5L]_E&>IY/XYY_#M2_\-J^ O^A:U8D\!0ARWTVC
M/O@=1T.#7YUFWB>2_:ZT>>"RU",)X<U+3)'NFN9MH56FB!PI9R0Q!'=<<8+%
M%PMF[E7&KZ3%;P-<:?"+J1O-G:-H)[4@A9U7YF4J2@PW%>NN#,F:7NKM=I?Y
M:>26QXZXIQO_ #Z>[WEV_P S]%C^VMX#Z?\ "-ZMTY^4CZ\[>@'.1VYZ U)_
MPVS\.LY/A/5^,CKU)YSTY^ZV<<<>H.?SF-I=Q3SZ9+#/!)%?HRZB(=]S*LD:
MY7[-PFT%F)P<!0!C!J*YMVM?/<QD2Z,1!"&0J;I),N9&7CS'5B!_%P"1]X"F
MN!,GJ_#)1Y=_=3O?U72P/BK'=*%O5W^[5_H?I%'^VW\.PPV^%=70\D]<8)P.
M2 /IZDXYP0+'_#;GP\Y_XIK5^.#RO!]#Q7YI26]M%;H9V9WD!DC@C!\QIY1O
M ^7G:JMP,,04)'LU[>&S-FMQ:7 69-TLI9OD).!OY^7A@2"<Y !]W_Q#[*>E
M2-_^O:?Y*_\ D)\4XVUU1=_\22WUMII\_(_2>3]MKX>Y)/AG5SV!+#;ZD=,<
M#G'KCH!4?_#;?P]SC_A&-5SU. "<?@*_-Z2QM&B:VOW+(\F;;RCEI!P%RZY;
MYAE?SR>E2-:SQQ+=2PII6FVJB-)I&65[@G 5&63^+CCD'!&,4/@;+H.T:*FN
M[YHZ^2BFDNNNNI:XKQG_ #X^2:_IGZ2_\-M?#O\ Z%G5_P C37_;<^'3+@^%
M]6;!. QZ ?\  <]ST/L/XJ_-1'\TC:A08XW;AZ^K<@#'( //L,RM:^4\#W"M
M<1[\[8V(,;-RK/@D;3SP>.<;FR"6N!<MO_#4%U;YI*W_ &_=+Y:] _UKQG6@
M_G*/Z:GZ/_\ #;/PZ_Z%75N.O7]?E_#M0/VUOA^<%?#.K@<@+@<'))X '..O
M?&,]J_.1X)]D]_($Q$Y,=JI_>-""2S&,$,<KD_[(*MUP#8WVCQ1ZE/)8V2%E
MM-&MY;ADGG=E!D:2(#! D"I\S$D9/JM:?ZA9.G\<?_ 4_P! _P!:\9_SX^YH
M_1/_ (;7\ A@?^$9U8A<'DD<=>F",?7@]^M/_P"&V?A]_P!"OJOY#W]O8_D:
M_.:XCOD#SZQIJ6TT3);6;6VYTN$G#+O(4;3QR&.0,DYX)JO=Q;Q;  ;H<!BJ
MJH8]0"<8/!].#NZ5,^!,GA%RNG:WV4OT#_6K&/?#_.Z/TA_X;;^'_P#T+.J^
MO4=^_3OG]:!^VU\/O^A8U4\^W/MRIST'Y5^;3KON))  %,<8 Y"$\9P.F1TP
M >%'  H\LDCA">>/E/'/?''I@]>WME2X)R:I)*R2U;>CVZ6<4'^M6,T7U;JM
MW'\%?[GL?I4O[;?P^"C_ (IG5P.>!DC_ +Z"C)YZ?X4']MSX?8.?#.KD8.1@
MG([C[I)S]:_-I4RHR%R,Y&!USZX([=AUZD]:78/[J_DI_38,_F*3X"RKF=DV
MKNS:C^JO;L7_ *VXG7]W:UU9.R37E;]?F?HXW[;'PX<;5\-:OR<A0"!T(R3@
M'/.,9[],T)^VQ\.HAC_A&M7;/) #_+TXSC(SUQQZ]Z_.01J#D)'_ -^Q_P#7
MI0@Q@JA]]B@]?7G_ #^5./ >5W2<7]T1?ZV8G_GV[=;26OWW/T>_X;>^'?0>
M%]8SVX<\GW _^O\ C2#]MKX>GG_A%]8Y_O$]O0,O'OCVSVK\XMB_W5_%1Z].
MGX>OXT;1C&U..F44_7\S6W^H>5)MJ+WTNEI^*%_K5B;NU)?-W_5(_1T_ML_#
M['_(KZL.G(VG'([%/\]J:/VVOA[_ -"SJV,\Y"C(P.@V_6OSDVC^['_W[6DV
M#^ZG_? _QI/@7 KX)*"ZIK=]]$^EEOT#_6O$_P#/M?)V_5GZ.?\ #;7P][>&
MM6_%5'_LOZ4A_;:^'HZ>&M6R,?PKCWYV\CU'<5^<FP?W4_[X'^-&Q?[J?]\#
M_&C_ %%P;WJ1MZ/_ .1#_6O$_P#/O_R;_@GZ-C]MOX>C[WAG5C]$S_):4_MN
M?#X8*^&=5QC^Z3P><< ?B.:_.+RT_N1_]^Q_C2^6,=$'T0?US6?^H.!O_$@E
M?5<FGW6%+BO%R37*[=+R;2_\F_0_1P?MM^ #S_PC6K@'_8X_\>&/KGC\*9-^
MVQ\.O(:4^%+XM;#>)I\AL+G*@;"#QD@@<*"P/:OSF\M>X'X*H_I4%S&C6MX-
MJX^RSCE0>JNH(P!@C.??ICO4UN",+AJ52M1JQYX4Y/X+*VMT]-=C*/%&(C4I
M^T@YQE-0Y4[/7K?1'[N_![4M,^-WA5?&FAEK&-6,2)@D$EMN,A@.AW'Y1QGG
MKGUV'X8:L[+_ *:.<=>"1@$MR<#)R"<<8 SQQ\_?\$\ #\!K7@8.IW0]3\J\
M9;J?;IC\L??"C!PI(VH2#D],].N< X(YZCW)K\3S]1P^-K4;*3C5Y5.*4590
MBY*UN[NET>Q^J9-B98O"PJZJZT5_LM*U_167F>(/\*M5PI6^&>AZCC![ ]C[
M=SSZL_X57K'_ #_#_P >_P :^@'#$#;P<\\XXP?8]\5'ME]3_P!]#_XFO+@F
MHZMN[;U=W9[+^MCUCP/_ (57K'_/\/\ Q[_&C_A5>L?\_P /_'O\:]\VR^I_
M[Z'_ ,31ME]3_P!]#_XFJ \#_P"%5ZQ_S_#_ ,>_QH_X57K'_/\ #_Q[_&O?
M-LOJ?^^A_P#$T;9?4_\ ?0_^)H \#_X57JX_Y?@/^^OZDBH9/A7JTD3QM?J&
M## .<A>O)Y)(Z]20,$=:^@MDAX+$#N<AOTP._O4)',N>2%)SR#D':2.O7CV!
M!'KB)4H5=)W?+JDGI)]FMMNKMZD3E4ARND[2YM;[6\]=3XT^):1?"NQLKB]O
MEN%N)0#%U:0 *'08#'<22!MP<\*1\IKQO_A>6AD9-DN>,@@]>@!)4#.. ",\
M8.3DU['^U^H/AK0G**\@OE"_*221LQCTSSSR.WT^#[90559HT&2IR4&0Q.<G
MU[\' P.#UK[GA_)\-B,/*JU;D3YDTG=I[+3=V>I^4\7<0XK!8VE;WH)IZ-IW
MLU?=>?KH?24?QNT%U)^P X/48&.G!X//MV]JE_X79H6,_P!GD8X.57D_4C.<
M<GCIZ=:^;3;6MP_]G;Q&L^;AA"I:1S%A@JL!E1EOFQ@<@8.!39L VDDL8FG\
MQ+9(XP1Y2AE"O,B\Y+#)W*JCG)ZX]MY%A*K=2SBI:<O;E]U[:6=F_F?-5N-<
MVY_W3E&-H-+FEMRQO>SZZM_TCZ3_ .%V:&.NG$?\!7MU_@I?^%V:(,E=/8<=
M=H&!G))P.@[9.,C)]OG)-/O+K49--E$<EI9QFY:6'!)8#*IN7Y2#N/!=OF'0
MD8JM%NG^TW482--WV<Q3*JN5B.U653@Y)P<C.00:7^KV$\_N,_\ 7;.8M2;>
MG>4FOQ?D?2X^-FC8S_9^1CJ0.G7DD],?I[4?\+LT;_GP(P!T..#G'1N_.*^:
M@2>/W/88+ =  > "/4X/?CGK4-Q]KCMG>W6.9;DI9O$J@R %U_>* 01E0V&&
M,# !S5?ZMX&UW-W>]DM_1/\ 0U_XB!F^FG_D[_+F7W'TR?C7HO06'M@'G@ X
MX)/]TX'/0CM2'XYZ&#C["!C/!SGU.1CJ.O/;'0=?G!XK:YNY-/M(&MI8/L5Q
MYLN-C-"@6558@* 7!W')')X)!IMS%98VL]N]T)2QEB(\H,Q.=V!M!).<;=H'
MJ,9:X<P72:_[>@[_ 'V_4F?'V<NW+?IHI2;OWW/I%OC?HLN(A9 ,>0" #Z<
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M<2N>"J_Y_P" TFP?W$_3_P")IOA["]W]R_R+_P"(@YA_*_Q_S/H__A=FB_\
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M?"<LW_7-OT;%? __  3P_P"2#VG_ &$KG_T&OO=/O-_N/_Z&:_EKBI6S6O\
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M_&N!)I)/LOR/8:<79JS\S>HK!_X2?0/^@K9_]_E_QH_X2?0/^@K9_P#?Y?\
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M#!GY8]J94_+QR*C;PIKGE2PKI%Z$D?<)!$(Y(0W)2*,94KN/&3Q^.0>TP?\
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M?Z,_;GR;HG[MMS_LQ9_ [\Y].X[$TABN?2VZ?Q"%OQ&7X]\?CT%?B(WQ=^+
M&?\ A-;\Y('^MDSV&?\ 7'.,_P"..*G_ .%M_%@)N_X3C4 3C_EM(/7G_6],
MY&<Y/3@9R+A;,]%>2Z6YY?E</]8\OM;W?_ 5^JM^'H?MJ8;OTM\C ^[#CC&<
MKNQV_#M0(;KTM_P$('Y!OUK\0?\ A;_Q<R=OC._."<'SY 2>AZ2G'&.1UR.U
M+_PN#XO_ /0YZAV_Y>)CZ_\ 34>G_P"O%:KA#-VK^]KM:<O\Q?ZQY?Y+_MR'
M^1^W@BNQT%KTZ[(/;GA__K<T>5<Y)Q;=3VBZ^F?,[5^)'_"X/BW_ -#M?_\
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MRQ().#],5(?%GB)1G^T7]/O9Z\=,^A_#KVJ7P_F5O>E*U]/?E_GH1_KME/\
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M .NC .,O9G'/!3C'? .>?T'IS7QFOB_Q/@N=3EVX(Y9L\@]@Q/X'&3QQ2?\
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MP].G7BOC'_A+/%?_ $$Y>_\ ?[_]M.W:C_A+/%?_ $$Y>H_O=C_OFC^Q,?\
MSO\ \"?Y7&N,LH3NH4__  &/37L?9PR.LEB?^_0Q^G^<4?-G/F6./3]UW[9Q
MV_7%?&9\6^*C_P Q*;\S_0C]<^V.<M_X3#Q,.#J4N1U^9QSW_BH_L3'_ ,S_
M / G_F:+C7*7>\:?RC']4?9ZYW\260XR,"/KSDG''0>GY]K!:3L]D/<^61].
M".?TXKXJ7QAXE)_Y"DJGH._ZEMWX#CITR33O^$Q\3MUU&7CG[S'V_B;Z],'I
MS@U<,BQTM')W[\S^]]NQ2XNRFI?EBO[UEO\ )+;;:R/LZ3<2N7LB<'!&SN3V
MR3QW] ,D^D>UO6T)[!=IX[Y&<>G7UKXQE\7^)PH*ZI,I ;(&X@]_[^-QY(."
M.N0:@3QEXH)YU2X;KR <C@GU!.2![<9/2KED&,CHYMWVM)?C<?\ K3EG2-N_
MNO\ R/OSP0TQ\3VZH]J5 0?)LX!*YZ=.-N.2?0'J?IE1'YYW?ZT %"I;:3M4
M$<]"0.3T(QQR*_,OX%^(=9O/B)96UU?32PN8"\9)YW2)GG<1CD#&",'(]_TW
MC53([8&4A&#ZG:AR>/< ?CZU\KG-*5)R@V[I6;TO>+Y6OO3/LN',9#&47*#]
MV3=FDM+ZKL]$UH63_#]?Z&I8^C?[W_LJU#R57&,@ \].F/ZU-'P.>I;MT'RC
MWSV__57C49-Q2\M[ZZ2:/I5:.E];O3KOH24445L4%%%% !1110 @(89!R/\
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MD[5P2<%C$\9",)-M-:;Z^FCNAO#R2:4=^[\_1V+'G#@8(++N3+<LH ^<+G)
M[X!X!/2F&: ^6S9_>'$9WG:Y'54R,Y]1P02*6SU32+C49;'2_$?AR]O[W2+6
M6WTXW-H+JUD$1:\M4C\S?'(FTI@A6&&5LG&(8GE:]D\+Z/JF@:MK.DPIJ=XO
MVNV<Z9%-EFC?+D(T:@EMQ&<$ D*=L0QM"5KRCJE=<L6[]O.W]=C-T9K:E=_X
MW9O9O^D2F6V4.22ACQYFYCF/(SA@!N'ID\<]SQ2&6!=@=V4R(LD89N7C8JJR
M*."5+' (XR#SP<9UGK?AFXN-7CM/%/A_4KFUA'_"0V,5U TELLSNCOA9#_Q[
MNQ;D_(%)/ XO&VMX([&SO=4TYCJ4,=OX(OS/"/[4\J0SM;QEGP^$^4A2W 8C
M&0!U1Q6&BK.<8WU2LEIM?1"]G5_Y\?\ D_\ P"431J[0QRYD WM!D[U7!.XJ
MH) P"1G'!XSFI%>5HVF7<T*KO,H+&-4YRSL#\JJ059L?*W!&2 8;>^M=0UV^
MT?2;S19/&"HL-]8O<0>;"J@AU^9QC*"0Y)'3!.?O>,?&KXZZ1\$K;1[VPUG0
M]?OKG6;;PO>^'([B&0[KMQY_R1[^DA88&X[AQG&*E8G#ZKVL==M?-?=_2#V=
M6Z4J=[_WDM;;W45LKGM7F1$ EV8L PVYQ\P!&W')&.0" 0",]:'*#&T.6Z@$
M-TQUX^H_/'?-,<&2+3+PQ^3]MLK6]\@<+ ;E=_DJ,#B-=J@@!=J@ <@U,W/E
ML>I0\GW"''Z?S]Z%+^7E:ULU&.S;=]O,U7*E_#2?KU*^7Z<YYY*N.N3Z@?3C
M@8'-/:Y>*VN$8,,P3G<=P&#%( %SQ@9!Q[CTJ0C((JGJ!_T-QV,=P",G&-CX
MXSVQQW]2>*YL4_\ 9ZKE9_NY)>ZNMWV*A+EJ4I07*U4B]'O\]+;'[>?\$\69
MO@/&&5D9M3N>I]0O(R1U"G(S[CCK]\Q#Y<8.0<XZ\X7J1U^Z5!YZ8ZX%?!'_
M  3W)_X4;;#/']I70_!=P'Z*,_CVQC[WC_C]A^?+]?7].M?R_P 4)QS3$-=,
M1-?=%?Y,_:,AK2JX"";LW%23LF[.\>O6Z:UZ:WU)(E(EW8XY)/3UY_-ACOCZ
M$U;HP/045Y[ES6;[)?<CVJ</9Q<;N5Y2E=[^\T[?(****184444 (W0_A[=Q
M6<P/FR$#@*#R20!M?\>O3T(].:TJIGAKGIPH_ET^GM^6*BHI6O"3@XN\I+5\
MNUK==7L]!.,)?%!2?2_3[TTO6USXT_:[4'PWH 4!MVH)Q@DD!(QM  X8]0!@
M\'CO7P=;J&&U6RRYW #=Y84DD''W6&0#SD<8 ZU]Y?M;H6\/Z"@D,9;4%Q+W
MC.$.>.W&/;/X'X'TR*75;F.QB/V0"Y*R70)3[2$9B3N'WBX !Z ].PK]%X7A
M4G0515>11O+DM=.UGO?31_H?@W'=2/\ :"C[-7<HI:KL^MO/KU+226K,T8FC
M9T?RW4,K$2$X53@;03D[0"<\X/R'%AX@@1G4JLA=8V8 +(T?^L"MC!*?Q8Y
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ME!?\N[VZ\TM?/?J,^T/_ ',X]<D?CQG\SUQUI//;_GF!]!^O3.?Q'X5)G/\
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MZ(****8!1110 53/WKG_ '1_*KE4S]ZY_P!T?RJ9_!/_  _JAK=>J_-'QO\
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MA,C."N0,UI#3= L+FZFLX;+P\^I2P6T<VG6R1SF$+^Z+/$@/D)C8Q.T8SR<
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MZ^@ZBBBKYUV?X?YFHAZK]?Z&CN#[']<?X4'JOU_H:6FG>[\]/0QJ[K_MV_\
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MIT*W#):J!O!=MWE\.J!\C'K@;JOZU\*?B+\-+* _$CX7^)/ WAO5Y2FFW5_
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M\2_!_P",O@W3;75?&7PD\3>&M/U![.QLIKR!%DFOF98_*"+E_,N'&,,%+97
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M1V\5TA60@HKNN6P0&)PX.#61?_M=_%#X6>(?BM\,OC_X0TRS\1^#_"ND^(]
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MZ8)%1R1))(\K*"\C[W;&,M\W( &!]X],= !C)-2T4N>71^NFY*26RL,$:@Y
MP2.2,9/J2>N3_CZTNWW.?7(S],XSCVZ4ZBAR;=]ON_R*YFMFQNWW8_4^E02
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M_(^]7Q/_  Q):***LH**** "BBB@ JC( 6''>3]'&/RY_,U>JE+]X8YYD_\
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MU XP,] !S2! O*@!L $@ $CG/(VDY]"3G '3&%VL.2T( ()(89P.3C#$YZ\
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M1@TI5R"-N,\=3WX_NT$, 20, 9^]]/;W_/%1*2LU=7:TU7E_P0LUK9W[V?\
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MG_OIO\:-TG_/,_\ ?3?XT+Q\\1UO:7FVK^FE1!_Q [@'_I]]\?\ Y4?P4_\
M$-M^W1_T-O@S_P &EE_\;I/^(;;]NG_H;?!8^NIV7_Q%?WK[I/\ GF?^^F_Q
MHW2?\\S_ -]-_C1_Q'SQ'Z<J]+?_ "T/^('< _\ 3W_R7_Y4?P4?\0VW[=/_
M $-O@O\ \&=G_P#$T?\ $-O^W2.3XM\%X]]3LAUXZE<#VSQFO[U]TG_/,_\
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MPJXZI*\\3)SF];M[.]Y/7SN?I.!RW#95A:6"IJT*<.2"NE[M];6BEO\ U<_
MGX[_   ^+&L?&3XA:WH/A^UF@EN#+$QD7<\+,VQF&0 2I4XYR3R#BO.)/V=/
MC2T5I))X7MA(\";@A5@?ER,?,2 >.,]>G'3]F_$]R_\ :6H-#%())IY8YIHU
M.Z5591ASC) Z#D@=0,<G CFO'\O=]JRJ\84_*.<;<J,X4=_3KDYK[[*.*JN
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MX)^\N3Z<D''7M@')/M3_ -=L4^M=>;<DEZWMI\^PUPS@E_R[@_E_]JC\>O\
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M'4ACC#$D\;BWMG('3J><5\U_9">MI<'VVN,\]SC_ /7T[YI7M]RF*2V:2,8
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M<9RO0'!..<CBOK_S[O\ YYW./]UOYE3BFB:['(2Y';[A_P#B*7^LN*_FJ?\
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M_P"%<>,?^?*4?7</RR!G\*/^%<^,,X^R/G./O'K^5?8 GNQ_RSN<9 )VGC/
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MW?\ VI2\L_\ /$?]]'_XFCRS_P \1_WT?_B:NT4<M7_G_4^\/8T?^?%+[O\
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M=^?0P9M)T^>4.^FQ."<R,0F7/!!(V]?XO7)(SR:E_LG2T(:/3HL_*!\J 9(
M(/!QP>OY$CFMHV^<#;P.!\^,8^@I?(.<[>?]_P!/PJ):ROTL_76W^3_ NE%4
MH\J<FNVEKV,C^S;'_GPA_)/\:/[-L?\ GPA_)/\ &M?R#Z'_ +^'_"CR#Z'_
M +^'_"@HR/[-L?\ GPA_)/\ &C^S;'_GPA_)/\:U_(/H?^_A_P */(/H?^_A
M_P * ,C^S;'_ )\(?R3_ !H_LVQ_Y\(?R3_&M?R#Z'_OX?\ "CR#Z'_OX?\
M"@#(_LVQ_P"?"'\D_P :/[-L?^?"'\D_QK7\@^A_[^'_  H\@^A_[^'_  H
MR/[-L?\ GPA_)/\ &C^S;'_GPA_)/\:U_(/H?^_A_P */(/H?^_A_P * ,C^
MS;'_ )\(?R3_ !I!IVF*!NTV$^I,2$Y]!P./3^5;'D'T/_?P_P"%'D'T/_?P
M_P"% &1_9VF'E=+@[X/EH"#V/3C![T?V;8_\^$/Y)_C6OY!]#_W\/^%'D'T/
M_?P_X4 9']FV/_/A#^2?XT?V;8_\^$/Y)_C6OY!]#_W\/^%'D'T/_?9_PH Q
MQI.E,=QTZ(,1SE5Y(P#CCZ=3V]<Y7^R=*7YCI\/'.-JG/X8(/XC%:_D'T/\
MWW_]:CR#Z'_OO_ZU!+3;NG9:::F/]@TG_H&0_C#'_0"E.D:4<'^SH!@8X5<8
MZCJ ?7T^E:_D'T/_ 'W_ /6H\@^A_P"_A_PH"2;M9V,C^R-*/73X<=_E7\A[
MGM0=-L. -.A YQPG3CZ9(.<G/<<#-:_D'T/_ '\/^%'D'T/?^,]^O;OWH!1:
M>LF_+7]3(_LVQ_Y\(?R3_&C^S;'_ )\(?R3_ !K7\@^A_P"_A_PH\@^A_P"_
MA_PH*,C^S;'_ )\(?R3_ !H_LVQ_Y\(?R3_&M?R#Z'_OX?\ "CR#Z'_OX?\
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M !__ .M07SR[_@C&_L;1_P#H&0?]^E_PI1H^D9XTV ?]LU&?;I^/X5L?9_\
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M_L;1_P#H&0?]^E_PH_L;1_\ H&0?]^E_PK9^S_[/_C__ -:C[/\ [/\ X_\
M_6H#GEW_  1C?V-H_P#T#(/^_2_X4?V-H_\ T#(/^_2_X5L_9_\ 9_\ '_\
MZU'V?_9_\?\ _K4!SR[_ ((QO[&T?_H&0?\ ?I?\*/[&T?G_ (EMOQ_TS7/\
MO7 'J3[&MG[/_L_^/_\ UJ<(=J/VR , [N.03T[ DC'.1Z<$#GEW_!&)_8^D
M'@:;!R".8T'7L/E/)]NG4]*THK2)(T6*VA$0'R(L:84'&0!@ 8P!Z\'/8U*D
M9WX( Y !7C.0<GU!"YP/4]QBKP&.!0'-+O\ @BA]G7_GWC^GEJ!]>AY]\4>0
MO_/K%_WROO\ ['N:OT5,H*5F]T[BO=WZE(6RG/[B!>G5%/7W"_GP,4OV5/\
MGE;_ /?L?_$U<HJ?9KNU\D(S!!%'*TB6T8DZ%@H4=>2NT9&>HZ=>:N1L[$9
M7.2P]<  '/J>...AJ>BJ4$G=7_#_ "&W?HOU_I]0HHHJA!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 A&01Z@C\Z:J;<\DYQU '3/I]:?10 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %(1D$>H(_.EHH C$>"#
GN)QGC [@CM]:DHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>brtx-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaiE+bP9z5Z8SekhvWB/bQlKrycgrmQ/ayEkUB22MTQO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:BRTX="http://biorestorative.com/20241231" elementFormDefault="qualified" targetNamespace="http://biorestorative.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://biorestorative.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical" id="StatementsOfChangesInStockholdersEquityParenthetical">
          <link:definition>00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
          <link:definition>00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperations" id="OrganizationLiquidityGoingConcernAndBusinessOperations">
          <link:definition>999016 - Disclosure - ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999018 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/IntangibleAssets" id="IntangibleAssets">
          <link:definition>999019 - Disclosure - INTANGIBLE ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
          <link:definition>999020 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999021 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999022 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/Leases" id="Leases">
          <link:definition>999023 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/FairValueMeasurement" id="FairValueMeasurement">
          <link:definition>999024 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999025 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999028 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
          <link:definition>999029 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
          <link:definition>999030 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999031 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999032 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999033 - Disclosure - LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
          <link:definition>999034 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative" id="OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative">
          <link:definition>999035 - Disclosure - ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails" id="ScheduleOfRevenueRecognizedDetails">
          <link:definition>999036 - Disclosure - SCHEDULE OF REVENUE RECOGNIZED (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" id="ScheduleOfWeightedAverageDilutiveCommonSharesDetails">
          <link:definition>999037 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999038 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" id="ScheduleOfPropertyPlantAndEquipmentDetails">
          <link:definition>999039 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>999040 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" id="ScheduleOfIntangibleAssetsDetails">
          <link:definition>999041 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" id="ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails">
          <link:definition>999042 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" id="ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails">
          <link:definition>999043 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:definition>999044 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
          <link:definition>999045 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" id="ScheduleOfStockWarrantsDetails">
          <link:definition>999046 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>999047 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails" id="ScheduleOfInformationRelatedToStockOptionsDetails">
          <link:definition>999048 - Disclosure - SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" id="ScheduleOfStockOptionGrantedAssumptionsDetails">
          <link:definition>999049 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" id="ScheduleOfUnvestedRestrictedStockUnitsDetails">
          <link:definition>999050 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" id="ScheduleOfStockOptionExpenseDetails">
          <link:definition>999051 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999052 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>999053 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" id="ScheduleOfIncomeTaxProvisionBenefitDetails">
          <link:definition>999054 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" id="ScheduleOfStatutoryFederalIncomeTaxRateDetails">
          <link:definition>999055 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999056 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" id="ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails">
          <link:definition>999057 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999058 - Disclosure - LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails" id="ScheduleOfFairValueValuationAssumptionsDetails">
          <link:definition>999059 - Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails" id="ScheduleOfFairValueMeasuredOnRecurringBasisDetails">
          <link:definition>999060 - Disclosure - SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" id="ScheduleOfFairValueRecurringBasisDetails">
          <link:definition>999061 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/FairValueMeasurementDetailsNarrative" id="FairValueMeasurementDetailsNarrative">
          <link:definition>999062 - Disclosure - FAIR VALUE MEASUREMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="BRTX_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ATMProgramMember" name="ATMProgramMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_MedicalEquipmentMember" name="MedicalEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ManufacturingEquipmentMember" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ComputerSoftwareAndEquipmentMember" name="ComputerSoftwareAndEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_PatentsAndTrademarksMember" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AccumulatedAmortizationMember" name="AccumulatedAmortizationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_PatentsAndTrademarkMember" name="PatentsAndTrademarkMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_BeneficialOwnershipMember" name="BeneficialOwnershipMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AuctusFundLLCMember" name="AuctusFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_TwoThousandTwentyOneStockIncentivePlanMember" name="TwoThousandTwentyOneStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember" name="TwoThousandAndTwentyOneStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DemandSalesAgreementMember" name="DemandSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_RothCapitalPartnersLLCMember" name="RothCapitalPartnersLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExistingWarrantMember" name="ExistingWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_NewWarrantsMember" name="NewWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceThreeMember" name="ExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceFourMember" name="ExercisePriceFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExercisePriceFiveMember" name="ExercisePriceFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_RangeOneMember" name="RangeOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_RangeTwoMember" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_RangeThreeMember" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" name="ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SectionThreeHundredAndEightyTwoMember" name="SectionThreeHundredAndEightyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_MelvilleLeaseMember" name="MelvilleLeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_BlackScholesOptionMember" name="BlackScholesOptionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DeferredOfferingCost" name="DeferredOfferingCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_GrantIncome" name="GrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_GainOnExchangeOfWarrants" name="GainOnExchangeOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" name="StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" name="StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" name="StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" name="StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharesHeldInAbeyance" name="SharesHeldInAbeyance" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_NoncashLeaseExpense" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1" name="ProceedsFromExchangeAndIssuanceOfWarrantsNet1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_PaymentsForProceedsFromDeferredOfferingCosts" name="PaymentsForProceedsFromDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_IssuanceOfCommonStockHeldInAbeyance" name="IssuanceOfCommonStockHeldInAbeyance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" name="ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_NoInsiderTradingFlag" name="NoInsiderTradingFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DeferredContractCostsPolicyTextBlock" name="DeferredContractCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_WarrantAndOptionValuationPolicyTextBlock" name="WarrantAndOptionValuationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" name="ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ProceedsFromWarrantExercisesNet" name="ProceedsFromWarrantExercisesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AccruedGeneralAndAdministrativeExpenses" name="AccruedGeneralAndAdministrativeExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DeferredTaxAssetsRightOfUseAsset" name="DeferredTaxAssetsRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DeferredTaxLiabilitiesDepreciation" name="DeferredTaxLiabilitiesDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ChangeInValuationAllowance" name="ChangeInValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" name="EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" name="EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_OperatingLeaseLiabilityReduction" name="OperatingLeaseLiabilityReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ChangeInFairValueOfDerivativeLiability" name="ChangeInFairValueOfDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_CommonStockVestRemainderPercentage" name="CommonStockVestRemainderPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AdjustmentForStockbasedCompensation" name="AdjustmentForStockbasedCompensation" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>brtx-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://biorestorative.com/role/Cover" xlink:href="brtx-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheets" xlink:href="brtx-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:href="brtx-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfOperations" xlink:href="brtx-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="brtx-20241231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:href="brtx-20241231.xsd#StatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfCashFlows" xlink:href="brtx-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfCashFlowsParenthetical" xlink:href="brtx-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperations" xlink:href="brtx-20241231.xsd#OrganizationLiquidityGoingConcernAndBusinessOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="brtx-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipment" xlink:href="brtx-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssets" xlink:href="brtx-20241231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="brtx-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquity" xlink:href="brtx-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxes" xlink:href="brtx-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/Leases" xlink:href="brtx-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/FairValueMeasurement" xlink:href="brtx-20241231.xsd#FairValueMeasurement" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEvents" xlink:href="brtx-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="brtx-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="brtx-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:href="brtx-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsTables" xlink:href="brtx-20241231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="brtx-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityTables" xlink:href="brtx-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxesTables" xlink:href="brtx-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesTables" xlink:href="brtx-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/FairValueMeasurementTables" xlink:href="brtx-20241231.xsd#FairValueMeasurementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative" xlink:href="brtx-20241231.xsd#OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails" xlink:href="brtx-20241231.xsd#ScheduleOfRevenueRecognizedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="brtx-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="brtx-20241231.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="brtx-20241231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:href="brtx-20241231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStockWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfInformationRelatedToStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStockOptionExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:href="brtx-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:href="brtx-20241231.xsd#ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:href="brtx-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:href="brtx-20241231.xsd#ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:href="brtx-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFairValueValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFairValueMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFairValueRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/FairValueMeasurementDetailsNarrative" xlink:href="brtx-20241231.xsd#FairValueMeasurementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:href="brtx-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DeferredOfferingCost" xlink:label="loc_BRTXDeferredOfferingCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_BRTXDeferredOfferingCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_GrantIncome" xlink:label="loc_BRTXGrantIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_BRTXGrantIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_GainOnExchangeOfWarrants" xlink:label="loc_BRTXGainOnExchangeOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_BRTXGainOnExchangeOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="loc_us-gaapInterestAndDividendIncomeOperating" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInterestAndDividendIncomeOperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_NoncashLeaseExpense" xlink:label="loc_BRTXNoncashLeaseExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BRTXNoncashLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_GainOnExchangeOfWarrants" xlink:label="loc_BRTXGainOnExchangeOfWarrants" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BRTXGainOnExchangeOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1" xlink:label="loc_BRTXProceedsFromExchangeAndIssuanceOfWarrantsNet1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_BRTXProceedsFromExchangeAndIssuanceOfWarrantsNet1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_PaymentsForProceedsFromDeferredOfferingCosts" xlink:label="loc_BRTXPaymentsForProceedsFromDeferredOfferingCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_BRTXPaymentsForProceedsFromDeferredOfferingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000014 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000015 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperations" xlink:title="999016 - Disclosure - ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipment" xlink:title="999018 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssets" xlink:title="999019 - Disclosure - INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999020 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquity" xlink:title="999021 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxes" xlink:title="999022 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Leases" xlink:title="999023 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurement" xlink:title="999024 - Disclosure - FAIR VALUE MEASUREMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEvents" xlink:title="999025 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:title="999028 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsTables" xlink:title="999029 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999030 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityTables" xlink:title="999031 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesTables" xlink:title="999032 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesTables" xlink:title="999033 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurementTables" xlink:title="999034 - Disclosure - FAIR VALUE MEASUREMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative" xlink:title="999035 - Disclosure - ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails" xlink:title="999036 - Disclosure - SCHEDULE OF REVENUE RECOGNIZED (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:title="999037 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999038 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="999039 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999040 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="999041 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:title="999042 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:title="999043 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999044 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:label="loc_BRTXAccruedGeneralAndAdministrativeExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_BRTXAccruedGeneralAndAdministrativeExpenses" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999045 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999047 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails" xlink:title="999048 - Disclosure - SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:title="999049 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:title="999051 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:title="999052 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999053 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DeferredTaxAssetsRightOfUseAsset" xlink:label="loc_BRTXDeferredTaxAssetsRightOfUseAsset" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_BRTXDeferredTaxAssetsRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_BRTXDeferredTaxLiabilitiesDepreciation" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_BRTXDeferredTaxLiabilitiesDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:title="999054 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ChangeInValuationAllowance" xlink:label="loc_BRTXChangeInValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_BRTXChangeInValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:title="999055 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:label="loc_BRTXEffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_BRTXEffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" xlink:label="loc_BRTXEffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_BRTXEffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:title="999056 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:title="999057 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:title="999058 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails" xlink:title="999059 - Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails" xlink:title="999060 - Disclosure - SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:title="999061 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurementDetailsNarrative" xlink:title="999062 - Disclosure - FAIR VALUE MEASUREMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:title="999063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>brtx-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://biorestorative.com/role/Cover" xlink:href="brtx-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheets" xlink:href="brtx-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:href="brtx-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfOperations" xlink:href="brtx-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="brtx-20241231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:href="brtx-20241231.xsd#StatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfCashFlows" xlink:href="brtx-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfCashFlowsParenthetical" xlink:href="brtx-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperations" xlink:href="brtx-20241231.xsd#OrganizationLiquidityGoingConcernAndBusinessOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="brtx-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipment" xlink:href="brtx-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssets" xlink:href="brtx-20241231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="brtx-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquity" xlink:href="brtx-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxes" xlink:href="brtx-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/Leases" xlink:href="brtx-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/FairValueMeasurement" xlink:href="brtx-20241231.xsd#FairValueMeasurement" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEvents" xlink:href="brtx-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="brtx-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="brtx-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:href="brtx-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsTables" xlink:href="brtx-20241231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="brtx-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityTables" xlink:href="brtx-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxesTables" xlink:href="brtx-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesTables" xlink:href="brtx-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/FairValueMeasurementTables" xlink:href="brtx-20241231.xsd#FairValueMeasurementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative" xlink:href="brtx-20241231.xsd#OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails" xlink:href="brtx-20241231.xsd#ScheduleOfRevenueRecognizedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="brtx-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="brtx-20241231.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="brtx-20241231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:href="brtx-20241231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStockWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfInformationRelatedToStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStockOptionExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:href="brtx-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:href="brtx-20241231.xsd#ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:href="brtx-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:href="brtx-20241231.xsd#ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:href="brtx-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFairValueValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFairValueMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFairValueRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/FairValueMeasurementDetailsNarrative" xlink:href="brtx-20241231.xsd#FairValueMeasurementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:href="brtx-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapAssetsCurrentAbstract_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAssetsCurrent_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DeferredOfferingCost" xlink:label="loc_BRTXDeferredOfferingCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_BRTXDeferredOfferingCost_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapAssets_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapAccountsPayableCurrent_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrent_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilities_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapCommitmentsAndContingencies_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquityAbstract_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapPreferredStockValue_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapCommonStockValue_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapAdditionalPaidInCapital_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_50" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract_60" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract_60" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract_60" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract_60" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:label="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" xlink:label="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" xlink:label="loc_BRTXStockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" xlink:label="loc_BRTXStockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_60" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SharesHeldInAbeyance" xlink:label="loc_BRTXSharesHeldInAbeyance_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesHeldInAbeyance_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000014 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000015 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperations" xlink:title="999016 - Disclosure - ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipment" xlink:title="999018 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssets" xlink:title="999019 - Disclosure - INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999020 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquity" xlink:title="999021 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxes" xlink:title="999022 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Leases" xlink:title="999023 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurement" xlink:title="999024 - Disclosure - FAIR VALUE MEASUREMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEvents" xlink:title="999025 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:title="999028 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsTables" xlink:title="999029 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999030 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityTables" xlink:title="999031 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesTables" xlink:title="999032 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesTables" xlink:title="999033 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurementTables" xlink:title="999034 - Disclosure - FAIR VALUE MEASUREMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative" xlink:title="999035 - Disclosure - ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ATMProgramMember" xlink:label="loc_BRTXATMProgramMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXATMProgramMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_WorkingCapital" xlink:label="loc_BRTXWorkingCapital_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXWorkingCapital_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ProceedsFromWarrantExercisesNet" xlink:label="loc_BRTXProceedsFromWarrantExercisesNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXProceedsFromWarrantExercisesNet_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails" xlink:title="999036 - Disclosure - SCHEDULE OF REVENUE RECOGNIZED (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaapRoyaltyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapRoyaltyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:title="999037 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999038 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_MedicalEquipmentMember" xlink:label="loc_BRTXMedicalEquipmentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXMedicalEquipmentMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ManufacturingEquipmentMember" xlink:label="loc_BRTXManufacturingEquipmentMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXManufacturingEquipmentMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredCosts_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="loc_us-gaapInterestAndDividendIncomeOperating_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInterestAndDividendIncomeOperating_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SharesHeldInAbeyance" xlink:label="loc_BRTXSharesHeldInAbeyance_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_BRTXSharesHeldInAbeyance_140" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="999039 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_MedicalEquipmentMember" xlink:label="loc_BRTXMedicalEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXMedicalEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ComputerSoftwareAndEquipmentMember" xlink:label="loc_BRTXComputerSoftwareAndEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXComputerSoftwareAndEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ManufacturingEquipmentMember" xlink:label="loc_BRTXManufacturingEquipmentMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXManufacturingEquipmentMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_150" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999040 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="999041 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_PatentsAndTrademarksMember" xlink:label="loc_BRTXPatentsAndTrademarksMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarksMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_170" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:title="999042 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_PatentsAndTrademarkMember" xlink:label="loc_BRTXPatentsAndTrademarkMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarkMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_160" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:title="999043 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999044 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999045 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceOneMember" xlink:label="loc_BRTXExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceTwoMember" xlink:label="loc_BRTXExercisePriceTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceThreeMember" xlink:label="loc_BRTXExercisePriceThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceFourMember" xlink:label="loc_BRTXExercisePriceFourMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceFourMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceFiveMember" xlink:label="loc_BRTXExercisePriceFiveMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceFiveMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999047 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails" xlink:title="999048 - Disclosure - SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_RangeOneMember" xlink:label="loc_BRTXRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_RangeTwoMember" xlink:label="loc_BRTXRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXRangeTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_RangeThreeMember" xlink:label="loc_BRTXRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXRangeThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:title="999049 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:title="999051 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:title="999052 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_BeneficialOwnershipMember" xlink:label="loc_BRTXBeneficialOwnershipMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_BRTXBeneficialOwnershipMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_BRTXAuctusFundLLCMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_TwoThousandTwentyOneStockIncentivePlanMember" xlink:label="loc_BRTXTwoThousandTwentyOneStockIncentivePlanMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXTwoThousandTwentyOneStockIncentivePlanMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="loc_BRTXTwoThousandAndTwentyOneStockIncentivePlanMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXTwoThousandAndTwentyOneStockIncentivePlanMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ATMProgramMember" xlink:label="loc_BRTXATMProgramMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXATMProgramMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExistingWarrantMember" xlink:label="loc_BRTXExistingWarrantMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXExistingWarrantMember_320" xlink:type="arc" order="322" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_NewWarrantsMember" xlink:label="loc_BRTXNewWarrantsMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXNewWarrantsMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DemandSalesAgreementMember" xlink:label="loc_BRTXDemandSalesAgreementMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_BRTXDemandSalesAgreementMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BRTXAuctusFundLLCMember_270" xlink:type="arc" order="272" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_280" xlink:type="arc" order="282" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_RothCapitalPartnersLLCMember" xlink:label="loc_BRTXRothCapitalPartnersLLCMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXRothCapitalPartnersLLCMember_300" xlink:type="arc" order="302" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_390" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_390" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference_390" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights_390" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_390" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaapConvertiblePreferredStockTermsOfConversion_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockTermsOfConversion_390" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_390" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_390" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_390" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_390" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_390" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_390" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_390" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_390" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_390" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_390" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_390" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_390" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_390" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_390" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_390" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_390" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_390" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_390" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_390" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_390" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_390" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease_390" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts_390" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_390" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_390" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_390" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_GainOnExchangeOfWarrants" xlink:label="loc_BRTXGainOnExchangeOfWarrants_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_BRTXGainOnExchangeOfWarrants_390" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_390" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_390" xlink:type="arc" order="34" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999053 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:title="999054 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:title="999055 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:title="999056 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:label="loc_BRTXExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_BRTXExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SectionThreeHundredAndEightyTwoMember" xlink:label="loc_BRTXSectionThreeHundredAndEightyTwoMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_BRTXSectionThreeHundredAndEightyTwoMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:title="999057 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:title="999058 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_MelvilleLeaseMember" xlink:label="loc_BRTXMelvilleLeaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_BRTXMelvilleLeaseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLessorOperatingLeaseOptionToExtend_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLessorOperatingLeaseOptionToExtend_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails" xlink:title="999059 - Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExistingWarrantMember" xlink:label="loc_BRTXExistingWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXExistingWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_200" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails" xlink:title="999060 - Disclosure - SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:title="999061 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_90" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurementDetailsNarrative" xlink:title="999062 - Disclosure - FAIR VALUE MEASUREMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExistingWarrantMember" xlink:label="loc_BRTXExistingWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXExistingWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_BlackScholesOptionMember" xlink:label="loc_BRTXBlackScholesOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_BRTXBlackScholesOptionMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:title="999063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ATMProgramMember" xlink:label="loc_BRTXATMProgramMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXATMProgramMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_BRTXAuctusFundLLCMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaapPaymentsForLegalSettlements_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsForLegalSettlements_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_CommonStockVestRemainderPercentage" xlink:label="loc_BRTXCommonStockVestRemainderPercentage_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_BRTXCommonStockVestRemainderPercentage_70" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" order="1000" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>brtx-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="BRTX_SeriesBConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SeriesBConvertiblePreferredStockMember" xlink:to="BRTX_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ATMProgramMember" xlink:label="BRTX_ATMProgramMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ATMProgramMember" xlink:to="BRTX_ATMProgramMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ATMProgramMember_lbl" xml:lang="en-US">ATM Program [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US">Royalty [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_MedicalEquipmentMember" xlink:label="BRTX_MedicalEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MedicalEquipmentMember" xlink:to="BRTX_MedicalEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_MedicalEquipmentMember_lbl" xml:lang="en-US">Medical Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ManufacturingEquipmentMember" xlink:label="BRTX_ManufacturingEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ManufacturingEquipmentMember" xlink:to="BRTX_ManufacturingEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ManufacturingEquipmentMember_lbl" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ComputerSoftwareAndEquipmentMember" xlink:label="BRTX_ComputerSoftwareAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ComputerSoftwareAndEquipmentMember" xlink:to="BRTX_ComputerSoftwareAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ComputerSoftwareAndEquipmentMember_lbl" xml:lang="en-US">Computer Software and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_PatentsAndTrademarksMember" xlink:label="BRTX_PatentsAndTrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatentsAndTrademarksMember" xlink:to="BRTX_PatentsAndTrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_PatentsAndTrademarksMember_lbl" xml:lang="en-US">Patents and Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="BRTX_AccumulatedAmortizationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccumulatedAmortizationMember" xlink:to="BRTX_AccumulatedAmortizationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_AccumulatedAmortizationMember_lbl" xml:lang="en-US">Accumulated Amortization [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_PatentsAndTrademarkMember" xlink:label="BRTX_PatentsAndTrademarkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatentsAndTrademarkMember" xlink:to="BRTX_PatentsAndTrademarkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_PatentsAndTrademarkMember_lbl" xml:lang="en-US">Patents and Trademark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_BeneficialOwnershipMember" xlink:label="BRTX_BeneficialOwnershipMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_BeneficialOwnershipMember" xlink:to="BRTX_BeneficialOwnershipMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_BeneficialOwnershipMember_lbl" xml:lang="en-US">Beneficial Ownership [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Common Class B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AuctusFundLLCMember" xlink:label="BRTX_AuctusFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AuctusFundLLCMember" xlink:to="BRTX_AuctusFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_AuctusFundLLCMember_lbl" xml:lang="en-US">Auctus Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_TwoThousandTwentyOneStockIncentivePlanMember" xlink:label="BRTX_TwoThousandTwentyOneStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_TwoThousandTwentyOneStockIncentivePlanMember" xlink:to="BRTX_TwoThousandTwentyOneStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_TwoThousandTwentyOneStockIncentivePlanMember_lbl" xml:lang="en-US">2021 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:to="BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand And Twenty One Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DemandSalesAgreementMember" xlink:label="BRTX_DemandSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DemandSalesAgreementMember" xlink:to="BRTX_DemandSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DemandSalesAgreementMember_lbl" xml:lang="en-US">Demand Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_RothCapitalPartnersLLCMember" xlink:label="BRTX_RothCapitalPartnersLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RothCapitalPartnersLLCMember" xlink:to="BRTX_RothCapitalPartnersLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_RothCapitalPartnersLLCMember_lbl" xml:lang="en-US">Roth Capital Partners LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExistingWarrantMember" xlink:label="BRTX_ExistingWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExistingWarrantMember" xlink:to="BRTX_ExistingWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExistingWarrantMember_lbl" xml:lang="en-US">Existing Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_NewWarrantsMember" xlink:label="BRTX_NewWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NewWarrantsMember" xlink:to="BRTX_NewWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_NewWarrantsMember_lbl" xml:lang="en-US">New Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceOneMember" xlink:label="BRTX_ExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceOneMember" xlink:to="BRTX_ExercisePriceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceTwoMember" xlink:label="BRTX_ExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceTwoMember" xlink:to="BRTX_ExercisePriceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceThreeMember" xlink:label="BRTX_ExercisePriceThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceThreeMember" xlink:to="BRTX_ExercisePriceThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceFourMember" xlink:label="BRTX_ExercisePriceFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceFourMember" xlink:to="BRTX_ExercisePriceFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceFiveMember" xlink:label="BRTX_ExercisePriceFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceFiveMember" xlink:to="BRTX_ExercisePriceFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_RangeOneMember" xlink:label="BRTX_RangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RangeOneMember" xlink:to="BRTX_RangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_RangeOneMember_lbl" xml:lang="en-US">Range One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_RangeTwoMember" xlink:label="BRTX_RangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RangeTwoMember" xlink:to="BRTX_RangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_RangeTwoMember_lbl" xml:lang="en-US">Range Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_RangeThreeMember" xlink:label="BRTX_RangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RangeThreeMember" xlink:to="BRTX_RangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_RangeThreeMember_lbl" xml:lang="en-US">Range Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:label="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:to="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_lbl" xml:lang="en-US">Expire from 2030 to 2038 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SectionThreeHundredAndEightyTwoMember" xlink:label="BRTX_SectionThreeHundredAndEightyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SectionThreeHundredAndEightyTwoMember" xlink:to="BRTX_SectionThreeHundredAndEightyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SectionThreeHundredAndEightyTwoMember_lbl" xml:lang="en-US">Section 382 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_MelvilleLeaseMember" xlink:label="BRTX_MelvilleLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MelvilleLeaseMember" xlink:to="BRTX_MelvilleLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_MelvilleLeaseMember_lbl" xml:lang="en-US">Melville Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_BlackScholesOptionMember" xlink:label="BRTX_BlackScholesOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_BlackScholesOptionMember" xlink:to="BRTX_BlackScholesOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_BlackScholesOptionMember_lbl" xml:lang="en-US">Black Scholes Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Investments held in marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DeferredOfferingCost" xlink:label="BRTX_DeferredOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredOfferingCost" xlink:to="BRTX_DeferredOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DeferredOfferingCost_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 75,000,000 shares authorized; 6,919,919 and 4,706,917 shares issued and outstanding at December 31, 2024 and 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss From Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_GrantIncome" xlink:label="BRTX_GrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GrantIncome" xlink:to="BRTX_GrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_GrantIncome_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_GainOnExchangeOfWarrants" xlink:label="BRTX_GainOnExchangeOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GainOnExchangeOfWarrants" xlink:to="BRTX_GainOnExchangeOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_GainOnExchangeOfWarrants_lbl" xml:lang="en-US">Gain on exchange of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss Per Share - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss Per Share - Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Common Shares Outstanding - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Common Shares Outstanding - Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:label="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_lbl" xml:lang="en-US">Stock-based compensation:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted share units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted share units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US">Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Conversion of Series B Convertible Preferred Stock into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Conversion of Series B Convertible Preferred Stock into common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance and sale of common stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance and sale of common stock, net of issuance costs, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Common stock issued in connection with warrant exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Common stock issued in connection with warrant exchange, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:label="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:to="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_lbl" xml:lang="en-US">Return and cancellation of shares in lieu of payroll tax withholding</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" xlink:label="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" xlink:to="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_lbl" xml:lang="en-US">Return and cancellation of shares in lieu of payroll tax withholding, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" xlink:label="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_lbl" xml:lang="en-US">Common stock issued in connection with abeyance shares</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" xlink:label="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_lbl" xml:lang="en-US">Common stock issued in connection with abeyance shares, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Aggregate fair value of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SharesHeldInAbeyance" xlink:label="BRTX_SharesHeldInAbeyance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesHeldInAbeyance" xlink:to="BRTX_SharesHeldInAbeyance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharesHeldInAbeyance_lbl" xml:lang="en-US">Shares held in abeyance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDividendIncomeOperating" xlink:to="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xml:lang="en-US">Dividend and interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_NoncashLeaseExpense" xlink:label="BRTX_NoncashLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NoncashLeaseExpense" xlink:to="BRTX_NoncashLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_NoncashLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GainOnExchangeOfWarrants" xlink:to="BRTX_GainOnExchangeOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BRTX_GainOnExchangeOfWarrants_2_lbl" xml:lang="en-US">Gain on exchange of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used In Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Sale of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchase of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided By Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of common stock in at-the-market offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Net proceeds from issuance of common stock in direct-offering</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1" xlink:label="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1" xlink:to="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1_lbl" xml:lang="en-US">Proceeds from exchange and issuance of warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_PaymentsForProceedsFromDeferredOfferingCosts" xlink:label="BRTX_PaymentsForProceedsFromDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PaymentsForProceedsFromDeferredOfferingCosts" xlink:to="BRTX_PaymentsForProceedsFromDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BRTX_PaymentsForProceedsFromDeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Decrease In Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and Cash Equivalents - Beginning of the Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and Cash Equivalents - End of the Year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationRelatedText" xlink:to="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xml:lang="en-US">Cash paid during the year for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_IssuanceOfCommonStockHeldInAbeyance" xlink:label="BRTX_IssuanceOfCommonStockHeldInAbeyance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_IssuanceOfCommonStockHeldInAbeyance" xlink:to="BRTX_IssuanceOfCommonStockHeldInAbeyance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_IssuanceOfCommonStockHeldInAbeyance_lbl" xml:lang="en-US">Issuance of common stock held in abeyance</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:label="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:to="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_lbl" xml:lang="en-US">Return and cancellation of shares in lieu of payroll tax withholding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_NoInsiderTradingFlag" xlink:label="BRTX_NoInsiderTradingFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NoInsiderTradingFlag" xlink:to="BRTX_NoInsiderTradingFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_NoInsiderTradingFlag_lbl" xml:lang="en-US">No insider trading flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="BRTX_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DisclosureLeasesAbstract" xlink:to="BRTX_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Customer and Revenue Concentrations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DeferredContractCostsPolicyTextBlock" xlink:label="BRTX_DeferredContractCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredContractCostsPolicyTextBlock" xlink:to="BRTX_DeferredContractCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DeferredContractCostsPolicyTextBlock_lbl" xml:lang="en-US">Deferred Contract Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DeferredOfferingCostsPolicyTextBlock" xlink:label="BRTX_DeferredOfferingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredOfferingCostsPolicyTextBlock" xlink:to="BRTX_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_WarrantAndOptionValuationPolicyTextBlock" xlink:label="BRTX_WarrantAndOptionValuationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_WarrantAndOptionValuationPolicyTextBlock" xlink:to="BRTX_WarrantAndOptionValuationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_WarrantAndOptionValuationPolicyTextBlock_lbl" xml:lang="en-US">Warrant and Option Valuation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Derivative Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">SCHEDULE OF REVENUE RECOGNIZED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANT ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:label="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:to="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INCOME TAX PROVISION (BENEFIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE RECURRING BASIS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash flows from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_WorkingCapital" xlink:label="BRTX_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_WorkingCapital" xlink:to="BRTX_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ProceedsFromWarrantExercisesNet" xlink:label="BRTX_ProceedsFromWarrantExercisesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ProceedsFromWarrantExercisesNet" xlink:to="BRTX_ProceedsFromWarrantExercisesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ProceedsFromWarrantExercisesNet_lbl" xml:lang="en-US">Proceeds from warrant exercises, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Offering price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Sold shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">FDIC insured limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">FDIC amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred contract costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property plant and equipment estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDividendIncomeOperating" xlink:to="us-gaap_InterestAndDividendIncomeOperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDividendIncomeOperating_2_lbl" xml:lang="en-US">Dividend and interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property plant and equipment gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Gross, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_3_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Net, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Finite Lived Intangible Assets, weighted average amortization period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4_lbl" xml:lang="en-US">Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued bonuses</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:label="BRTX_AccruedGeneralAndAdministrativeExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:to="BRTX_AccruedGeneralAndAdministrativeExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_AccruedGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Accrued general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants, Outstanding Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of Warrants, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Warrants, Outstanding Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Life In Years, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of Warrants, Exercisable Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life In Years, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants outstanding, exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding, number of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants exercisable, weighted average remaining life in years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants exercisable, exercisable number of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options, Outstanding ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Life in Years Outstanding Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value, Outstanding Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Exercisable Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life in Years Exercisable Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic Value, Outstanding Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Options Outstanding, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Options Outstanding, Outstanding Number of Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options Exercisable Weighted Average Remaining Life In Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Options Exercisable, Exercisable Number of Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of shares forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of shares outstanding ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average remaining amortization period (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Preferred stock, liquidation preference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xml:lang="en-US">Preferred stock voting rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred stock voting percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US">Preferred stock conversion term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt conversion, converted instrument, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Number of shares converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Number of shares issued in conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares of common stock authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Common stock authorized to issue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Vested common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Cash fee for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xml:lang="en-US">Net proceeds offering price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Stock issued during period shares new issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of aggregate shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Offering price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">Stock issued during period value new issues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Cash issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Warrants for cash and the payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Stock issued during period value warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average estimated fair value of warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Tax Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credits</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DeferredTaxAssetsRightOfUseAsset" xlink:label="BRTX_DeferredTaxAssetsRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredTaxAssetsRightOfUseAsset" xlink:to="BRTX_DeferredTaxAssetsRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BRTX_DeferredTaxAssetsRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US">Deferred Tax Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DeferredTaxLiabilitiesDepreciation" xlink:label="BRTX_DeferredTaxLiabilitiesDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredTaxLiabilitiesDepreciation" xlink:to="BRTX_DeferredTaxLiabilitiesDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BRTX_DeferredTaxLiabilitiesDepreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total Deferred Tax Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net Deferred Tax Asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Asset, Net of Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Federal:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">State &amp; Local:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ChangeInValuationAllowance" xlink:label="BRTX_ChangeInValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ChangeInValuationAllowance" xlink:to="BRTX_ChangeInValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BRTX_ChangeInValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax, net of valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:to="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_lbl" xml:lang="en-US">Tax return to provision adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in federal valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" xlink:to="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_lbl" xml:lang="en-US">Adjustment for stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Prior year income taxes, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Operating loss carry-forwards subject to expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US">Operating loss carry-forwards not subject to expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Net operating loss description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US">Income tax examination, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DisclosureLeasesAbstract" xlink:to="BRTX_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BRTX_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Net Lease Cost And Other Supplemental Lease Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost (cost resulting from lease payments)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Net lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease - operating cash flows (fixed payments)</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_OperatingLeaseLiabilityReduction" xlink:label="BRTX_OperatingLeaseLiabilityReduction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_OperatingLeaseLiabilityReduction" xlink:to="BRTX_OperatingLeaseLiabilityReduction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_OperatingLeaseLiabilityReduction_lbl" xml:lang="en-US">Operating lease - operating cash flows (liability reduction)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Non-current leases - right of use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Current liabilities - operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current liabilities - operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseOptionToExtend" xlink:to="us-gaap_LessorOperatingLeaseOptionToExtend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lease extension description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average incremental borrowing rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk free interest rate, Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk free interest rate, Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xml:lang="en-US">Balance, January 1, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ChangeInFairValueOfDerivativeLiability" xlink:label="BRTX_ChangeInFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ChangeInFairValueOfDerivativeLiability" xlink:to="BRTX_ChangeInFairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ChangeInFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xml:lang="en-US">Issuance of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_3_lbl" xml:lang="en-US">Balance, december 30, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Marketable securities, fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_2_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Warrant liabilities, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xml:lang="en-US">Fair value of derivative liabilitiy</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xml:lang="en-US">Legal settlements paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Grant options shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Grant options shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Options to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_CommonStockVestRemainderPercentage" xlink:label="BRTX_CommonStockVestRemainderPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_CommonStockVestRemainderPercentage" xlink:to="BRTX_CommonStockVestRemainderPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_CommonStockVestRemainderPercentage_lbl" xml:lang="en-US">Purchase of common shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SeriesBConvertiblePreferredStockMember" xlink:to="BRTX_SeriesBConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SeriesBConvertiblePreferredStockMember_doc" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GrantIncome" xlink:to="BRTX_GrantIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_GrantIncome_doc" xml:lang="en-US">Grant income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GainOnExchangeOfWarrants" xlink:to="BRTX_GainOnExchangeOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_GainOnExchangeOfWarrants_doc" xml:lang="en-US">Gain on exchange of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:to="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_doc" xml:lang="en-US">Return and cancellation of shares in lieu of payroll tax withholding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" xlink:to="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares_doc" xml:lang="en-US">Stock return and cancellation of shares in lieu of payroll tax withholding shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares_doc" xml:lang="en-US">Stock issued during period value common stock issued in connection with abeyance shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" xlink:to="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares_doc" xml:lang="en-US">StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWith abeyance shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesHeldInAbeyance" xlink:to="BRTX_SharesHeldInAbeyance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharesHeldInAbeyance_doc" xml:lang="en-US">Shares held in abeyance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NoncashLeaseExpense" xlink:to="BRTX_NoncashLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_NoncashLeaseExpense_doc" xml:lang="en-US">Noncash Lease Expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1" xlink:to="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1_doc" xml:lang="en-US">Proceeds from exchange and issuance of warrants net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PaymentsForProceedsFromDeferredOfferingCosts" xlink:to="BRTX_PaymentsForProceedsFromDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_PaymentsForProceedsFromDeferredOfferingCosts_doc" xml:lang="en-US">Payments for proceeds from deferred offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_IssuanceOfCommonStockHeldInAbeyance" xlink:to="BRTX_IssuanceOfCommonStockHeldInAbeyance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_IssuanceOfCommonStockHeldInAbeyance_doc" xml:lang="en-US">Issuance of common stock held in abeyance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:to="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_doc" xml:lang="en-US">Return and cancellation of shares in lieu of payroll tax withholding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredOfferingCost" xlink:to="BRTX_DeferredOfferingCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DeferredOfferingCost_doc" xml:lang="en-US">Deferred offering cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NoInsiderTradingFlag" xlink:to="BRTX_NoInsiderTradingFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_NoInsiderTradingFlag_doc" xml:lang="en-US">No insider trading flag.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_WorkingCapital" xlink:to="BRTX_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_WorkingCapital_doc" xml:lang="en-US">Working capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ProceedsFromWarrantExercisesNet" xlink:to="BRTX_ProceedsFromWarrantExercisesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ProceedsFromWarrantExercisesNet_doc" xml:lang="en-US">Proceeds from warrant exercises net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ATMProgramMember" xlink:to="BRTX_ATMProgramMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ATMProgramMember_doc" xml:lang="en-US">ATM Program [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredContractCostsPolicyTextBlock" xlink:to="BRTX_DeferredContractCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DeferredContractCostsPolicyTextBlock_doc" xml:lang="en-US">Deferred contract costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_WarrantAndOptionValuationPolicyTextBlock" xlink:to="BRTX_WarrantAndOptionValuationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_WarrantAndOptionValuationPolicyTextBlock_doc" xml:lang="en-US">Warrant and option valuation [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_doc" xml:lang="en-US">Recently issued accounting pronouncements [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatentsAndTrademarksMember" xlink:to="BRTX_PatentsAndTrademarksMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_PatentsAndTrademarksMember_doc" xml:lang="en-US">Patents and Trademarks [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccumulatedAmortizationMember" xlink:to="BRTX_AccumulatedAmortizationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_AccumulatedAmortizationMember_doc" xml:lang="en-US">Accumulated Amortization [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatentsAndTrademarkMember" xlink:to="BRTX_PatentsAndTrademarkMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_PatentsAndTrademarkMember_doc" xml:lang="en-US">Patents and Trademark [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:to="BRTX_AccruedGeneralAndAdministrativeExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_AccruedGeneralAndAdministrativeExpenses_doc" xml:lang="en-US">Accrued general and administrative expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_BeneficialOwnershipMember" xlink:to="BRTX_BeneficialOwnershipMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_BeneficialOwnershipMember_doc" xml:lang="en-US">Beneficial Ownership [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AuctusFundLLCMember" xlink:to="BRTX_AuctusFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_AuctusFundLLCMember_doc" xml:lang="en-US">Auctus Fund, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_TwoThousandTwentyOneStockIncentivePlanMember" xlink:to="BRTX_TwoThousandTwentyOneStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_TwoThousandTwentyOneStockIncentivePlanMember_doc" xml:lang="en-US">2021 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:to="BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember_doc" xml:lang="en-US">2021 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DemandSalesAgreementMember" xlink:to="BRTX_DemandSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DemandSalesAgreementMember_doc" xml:lang="en-US">Demand Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RothCapitalPartnersLLCMember" xlink:to="BRTX_RothCapitalPartnersLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_RothCapitalPartnersLLCMember_doc" xml:lang="en-US">Roth Capital Partners LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExistingWarrantMember" xlink:to="BRTX_ExistingWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExistingWarrantMember_doc" xml:lang="en-US">Existing Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NewWarrantsMember" xlink:to="BRTX_NewWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_NewWarrantsMember_doc" xml:lang="en-US">New Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">Non option equity instrument exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options granted in period weighted average exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">ShareBased compensation arrangements by share based payment award non options exercised in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price, expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options exercisable weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options outstanding weighted average remaining contractual term2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options exercisable weighted average remaining contractual term1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:to="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_doc" xml:lang="en-US">Schedule of share based compensation warrant outstanding and exercisable by exercise price range [Table text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceOneMember" xlink:to="BRTX_ExercisePriceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceOneMember_doc" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceTwoMember" xlink:to="BRTX_ExercisePriceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceTwoMember_doc" xml:lang="en-US">Exercise PriceTwo [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceThreeMember" xlink:to="BRTX_ExercisePriceThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceThreeMember_doc" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceFourMember" xlink:to="BRTX_ExercisePriceFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceFourMember_doc" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExercisePriceFiveMember" xlink:to="BRTX_ExercisePriceFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExercisePriceFiveMember_doc" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RangeOneMember" xlink:to="BRTX_RangeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_RangeOneMember_doc" xml:lang="en-US">Range One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RangeTwoMember" xlink:to="BRTX_RangeTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_RangeTwoMember_doc" xml:lang="en-US">Range Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_RangeThreeMember" xlink:to="BRTX_RangeThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_RangeThreeMember_doc" xml:lang="en-US">Range Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:to="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_doc" xml:lang="en-US">Expire from 2030 to 2038 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SectionThreeHundredAndEightyTwoMember" xlink:to="BRTX_SectionThreeHundredAndEightyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SectionThreeHundredAndEightyTwoMember_doc" xml:lang="en-US">Section 382 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredTaxAssetsRightOfUseAsset" xlink:to="BRTX_DeferredTaxAssetsRightOfUseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DeferredTaxAssetsRightOfUseAsset_doc" xml:lang="en-US">Deferred tax assets right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredTaxLiabilitiesDepreciation" xlink:to="BRTX_DeferredTaxLiabilitiesDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DeferredTaxLiabilitiesDepreciation_doc" xml:lang="en-US">Deferred tax liabilities depreciation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ChangeInValuationAllowance" xlink:to="BRTX_ChangeInValuationAllowance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ChangeInValuationAllowance_doc" xml:lang="en-US">Change in valuation allowance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:to="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_doc" xml:lang="en-US">Effective income tax rate reconciliation tax return to provision adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MelvilleLeaseMember" xlink:to="BRTX_MelvilleLeaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_MelvilleLeaseMember_doc" xml:lang="en-US">Melville Lease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_BlackScholesOptionMember" xlink:to="BRTX_BlackScholesOptionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_BlackScholesOptionMember_doc" xml:lang="en-US">Black Scholes Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ChangeInFairValueOfDerivativeLiability" xlink:to="BRTX_ChangeInFairValueOfDerivativeLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ChangeInFairValueOfDerivativeLiability_doc" xml:lang="en-US">Change in fair value of derivative liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_CommonStockVestRemainderPercentage" xlink:to="BRTX_CommonStockVestRemainderPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_CommonStockVestRemainderPercentage_doc" xml:lang="en-US">Common stock vest remainder percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_OperatingLeaseLiabilityReduction" xlink:to="BRTX_OperatingLeaseLiabilityReduction_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_OperatingLeaseLiabilityReduction_doc" xml:lang="en-US">Operating lease liability reduction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MedicalEquipmentMember" xlink:to="BRTX_MedicalEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_MedicalEquipmentMember_doc" xml:lang="en-US">Medical Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ManufacturingEquipmentMember" xlink:to="BRTX_ManufacturingEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ManufacturingEquipmentMember_doc" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ComputerSoftwareAndEquipmentMember" xlink:to="BRTX_ComputerSoftwareAndEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ComputerSoftwareAndEquipmentMember_doc" xml:lang="en-US">Computer Software and Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredOfferingCostsPolicyTextBlock" xlink:to="BRTX_DeferredOfferingCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_DeferredOfferingCostsPolicyTextBlock_doc" xml:lang="en-US">Deferred offering costs [Policy Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AdjustmentForStockbasedCompensation" xlink:label="BRTX_AdjustmentForStockbasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AdjustmentForStockbasedCompensation" xlink:to="BRTX_AdjustmentForStockbasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_AdjustmentForStockbasedCompensation_doc" xml:lang="en-US">Adjustment for stock-based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" xlink:to="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_doc" xml:lang="en-US">Adjustment for stock-based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PaymentsForProceedsFromDeferredOfferingCosts" xlink:to="BRTX_PaymentsForProceedsFromDeferredOfferingCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_PaymentsForProceedsFromDeferredOfferingCosts_3_lbl" xml:lang="en-US">PaymentsForProceedsFromDeferredOfferingCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:to="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding_3_lbl" xml:lang="en-US">Return and cancellation of shares in lieu of payroll tax withholding [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_2_lbl" xml:lang="en-US">Deferred Offering Costs [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_3_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredTaxAssetsRightOfUseAsset" xlink:to="BRTX_DeferredTaxAssetsRightOfUseAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DeferredTaxAssetsRightOfUseAsset_3_lbl" xml:lang="en-US">DeferredTaxAssetsRightOfUseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DeferredTaxLiabilitiesDepreciation" xlink:to="BRTX_DeferredTaxLiabilitiesDepreciation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DeferredTaxLiabilitiesDepreciation_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesDepreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ChangeInValuationAllowance" xlink:to="BRTX_ChangeInValuationAllowance_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ChangeInValuationAllowance_3_lbl" xml:lang="en-US">ChangeInValuationAllowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>brtx-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://biorestorative.com/role/Cover" xlink:href="brtx-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheets" xlink:href="brtx-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:href="brtx-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfOperations" xlink:href="brtx-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="brtx-20241231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:href="brtx-20241231.xsd#StatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfCashFlows" xlink:href="brtx-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfCashFlowsParenthetical" xlink:href="brtx-20241231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperations" xlink:href="brtx-20241231.xsd#OrganizationLiquidityGoingConcernAndBusinessOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="brtx-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipment" xlink:href="brtx-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssets" xlink:href="brtx-20241231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="brtx-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquity" xlink:href="brtx-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxes" xlink:href="brtx-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/Leases" xlink:href="brtx-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/FairValueMeasurement" xlink:href="brtx-20241231.xsd#FairValueMeasurement" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEvents" xlink:href="brtx-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="brtx-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="brtx-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:href="brtx-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsTables" xlink:href="brtx-20241231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="brtx-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityTables" xlink:href="brtx-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxesTables" xlink:href="brtx-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesTables" xlink:href="brtx-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/FairValueMeasurementTables" xlink:href="brtx-20241231.xsd#FairValueMeasurementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative" xlink:href="brtx-20241231.xsd#OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails" xlink:href="brtx-20241231.xsd#ScheduleOfRevenueRecognizedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="brtx-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="brtx-20241231.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="brtx-20241231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:href="brtx-20241231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStockWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfInformationRelatedToStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStockOptionExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:href="brtx-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="brtx-20241231.xsd#ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:href="brtx-20241231.xsd#ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:href="brtx-20241231.xsd#ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:href="brtx-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:href="brtx-20241231.xsd#ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:href="brtx-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFairValueValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFairValueMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:href="brtx-20241231.xsd#ScheduleOfFairValueRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/FairValueMeasurementDetailsNarrative" xlink:href="brtx-20241231.xsd#FairValueMeasurementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:href="brtx-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DeferredOfferingCost" xlink:label="loc_BRTXDeferredOfferingCost" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_BRTXDeferredOfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_GrantIncome" xlink:label="loc_BRTXGrantIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_BRTXGrantIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_GainOnExchangeOfWarrants" xlink:label="loc_BRTXGainOnExchangeOfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_BRTXGainOnExchangeOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:label="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" xlink:label="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" xlink:label="loc_BRTXStockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" xlink:label="loc_BRTXStockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXStockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SharesHeldInAbeyance" xlink:label="loc_BRTXSharesHeldInAbeyance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXSharesHeldInAbeyance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="loc_us-gaapInterestAndDividendIncomeOperating" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInterestAndDividendIncomeOperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_NoncashLeaseExpense" xlink:label="loc_BRTXNoncashLeaseExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_BRTXNoncashLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_GainOnExchangeOfWarrants" xlink:label="loc_BRTXGainOnExchangeOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_BRTXGainOnExchangeOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1" xlink:label="loc_BRTXProceedsFromExchangeAndIssuanceOfWarrantsNet1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_BRTXProceedsFromExchangeAndIssuanceOfWarrantsNet1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_PaymentsForProceedsFromDeferredOfferingCosts" xlink:label="loc_BRTXPaymentsForProceedsFromDeferredOfferingCosts" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_BRTXPaymentsForProceedsFromDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="loc_us-gaapSupplementalCashFlowInformationRelatedText" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_IssuanceOfCommonStockHeldInAbeyance" xlink:label="loc_BRTXIssuanceOfCommonStockHeldInAbeyance" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_BRTXIssuanceOfCommonStockHeldInAbeyance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:label="loc_BRTXReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_BRTXReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_NoInsiderTradingFlag" xlink:label="loc_BRTXNoInsiderTradingFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_BRTXNoInsiderTradingFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000014 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock_2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000015 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperations" xlink:title="999016 - Disclosure - ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipment" xlink:title="999018 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssets" xlink:title="999019 - Disclosure - INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999020 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquity" xlink:title="999021 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxes" xlink:title="999022 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Leases" xlink:title="999023 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurement" xlink:title="999024 - Disclosure - FAIR VALUE MEASUREMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaapFinancialInstrumentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapFinancialInstrumentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEvents" xlink:title="999025 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DeferredContractCostsPolicyTextBlock" xlink:label="loc_BRTXDeferredContractCostsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_BRTXDeferredContractCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DeferredOfferingCostsPolicyTextBlock" xlink:label="loc_BRTXDeferredOfferingCostsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_BRTXDeferredOfferingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_WarrantAndOptionValuationPolicyTextBlock" xlink:label="loc_BRTXWarrantAndOptionValuationPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_BRTXWarrantAndOptionValuationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_BRTXRecentlyIssuedAccountingPronouncementsPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_BRTXRecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentTables" xlink:title="999028 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsTables" xlink:title="999029 - Disclosure - INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999030 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityTables" xlink:title="999031 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:label="loc_BRTXScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_BRTXScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesTables" xlink:title="999032 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesTables" xlink:title="999033 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurementTables" xlink:title="999034 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative" xlink:title="999035 - Disclosure - ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ATMProgramMember" xlink:label="loc_BRTXATMProgramMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXATMProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_WorkingCapital" xlink:label="loc_BRTXWorkingCapital" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ProceedsFromWarrantExercisesNet" xlink:label="loc_BRTXProceedsFromWarrantExercisesNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_BRTXProceedsFromWarrantExercisesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails" xlink:title="999036 - Disclosure - SCHEDULE OF REVENUE RECOGNIZED (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaapRoyaltyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapRoyaltyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:title="999037 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999038 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_MedicalEquipmentMember" xlink:label="loc_BRTXMedicalEquipmentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXMedicalEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ManufacturingEquipmentMember" xlink:label="loc_BRTXManufacturingEquipmentMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXManufacturingEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="loc_us-gaapInterestAndDividendIncomeOperating" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInterestAndDividendIncomeOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SharesHeldInAbeyance" xlink:label="loc_BRTXSharesHeldInAbeyance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_BRTXSharesHeldInAbeyance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="999039 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_MedicalEquipmentMember" xlink:label="loc_BRTXMedicalEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXMedicalEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ComputerSoftwareAndEquipmentMember" xlink:label="loc_BRTXComputerSoftwareAndEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXComputerSoftwareAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ManufacturingEquipmentMember" xlink:label="loc_BRTXManufacturingEquipmentMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_BRTXManufacturingEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999040 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="999041 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_PatentsAndTrademarksMember" xlink:label="loc_BRTXPatentsAndTrademarksMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails" xlink:title="999042 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_PatentsAndTrademarkMember" xlink:label="loc_BRTXPatentsAndTrademarkMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails" xlink:title="999043 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999044 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:label="loc_BRTXAccruedGeneralAndAdministrativeExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_BRTXAccruedGeneralAndAdministrativeExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999045 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_BRTXSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockWarrantsDetails" xlink:title="999046 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceOneMember" xlink:label="loc_BRTXExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceTwoMember" xlink:label="loc_BRTXExercisePriceTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceThreeMember" xlink:label="loc_BRTXExercisePriceThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceFourMember" xlink:label="loc_BRTXExercisePriceFourMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExercisePriceFiveMember" xlink:label="loc_BRTXExercisePriceFiveMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999047 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails" xlink:title="999048 - Disclosure - SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_RangeOneMember" xlink:label="loc_BRTXRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_RangeTwoMember" xlink:label="loc_BRTXRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_RangeThreeMember" xlink:label="loc_BRTXRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_BRTXRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails" xlink:title="999049 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails" xlink:title="999051 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:title="999052 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_BeneficialOwnershipMember" xlink:label="loc_BRTXBeneficialOwnershipMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_BRTXBeneficialOwnershipMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_BRTXAuctusFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_TwoThousandTwentyOneStockIncentivePlanMember" xlink:label="loc_BRTXTwoThousandTwentyOneStockIncentivePlanMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXTwoThousandTwentyOneStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="loc_BRTXTwoThousandAndTwentyOneStockIncentivePlanMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXTwoThousandAndTwentyOneStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ATMProgramMember" xlink:label="loc_BRTXATMProgramMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXATMProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExistingWarrantMember" xlink:label="loc_BRTXExistingWarrantMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXExistingWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_NewWarrantsMember" xlink:label="loc_BRTXNewWarrantsMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXNewWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DemandSalesAgreementMember" xlink:label="loc_BRTXDemandSalesAgreementMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_BRTXDemandSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_BRTXAuctusFundLLCMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_RothCapitalPartnersLLCMember" xlink:label="loc_BRTXRothCapitalPartnersLLCMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_BRTXRothCapitalPartnersLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaapConvertiblePreferredStockTermsOfConversion" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockTermsOfConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_GainOnExchangeOfWarrants" xlink:label="loc_BRTXGainOnExchangeOfWarrants" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_BRTXGainOnExchangeOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999053 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DeferredTaxAssetsRightOfUseAsset" xlink:label="loc_BRTXDeferredTaxAssetsRightOfUseAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_BRTXDeferredTaxAssetsRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_BRTXDeferredTaxLiabilitiesDepreciation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_BRTXDeferredTaxLiabilitiesDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" xlink:title="999054 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ChangeInValuationAllowance" xlink:label="loc_BRTXChangeInValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_BRTXChangeInValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails" xlink:title="999055 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:label="loc_BRTXEffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_BRTXEffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" xlink:label="loc_BRTXEffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_BRTXEffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IncomeTaxesDetailsNarrative" xlink:title="999056 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtStatementScenarioAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:label="loc_BRTXExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_BRTXExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_SectionThreeHundredAndEightyTwoMember" xlink:label="loc_BRTXSectionThreeHundredAndEightyTwoMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_BRTXSectionThreeHundredAndEightyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:title="999057 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_OperatingLeaseLiabilityReduction" xlink:label="loc_BRTXOperatingLeaseLiabilityReduction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_BRTXOperatingLeaseLiabilityReduction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:title="999058 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_MelvilleLeaseMember" xlink:label="loc_BRTXMelvilleLeaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_BRTXMelvilleLeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLessorOperatingLeaseOptionToExtend" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLessorOperatingLeaseOptionToExtend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails" xlink:title="999059 - Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExistingWarrantMember" xlink:label="loc_BRTXExistingWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXExistingWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails" xlink:title="999060 - Disclosure - SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_BRTXChangeInFairValueOfDerivativeLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_BRTXChangeInFairValueOfDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:title="999061 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/FairValueMeasurementDetailsNarrative" xlink:title="999062 - Disclosure - FAIR VALUE MEASUREMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ExistingWarrantMember" xlink:label="loc_BRTXExistingWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_BRTXExistingWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_BlackScholesOptionMember" xlink:label="loc_BRTXBlackScholesOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_BRTXBlackScholesOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:title="999063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_ATMProgramMember" xlink:label="loc_BRTXATMProgramMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_BRTXATMProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_BRTXAuctusFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaapPaymentsForLegalSettlements" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsForLegalSettlements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20241231.xsd#BRTX_CommonStockVestRemainderPercentage" xlink:label="loc_BRTXCommonStockVestRemainderPercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_BRTXCommonStockVestRemainderPercentage" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 26, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIORESTORATIVE
THERAPIES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001505497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">30-1341024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">40
    Marcus Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Melville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">760-8100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BRTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,463,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityBankruptcyProceedingsReportingCurrent', window );">Entity Bankruptcy Proceedings, Reporting Current</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,504,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of BioRestorative Therapies, Inc. (the &#8220;Company&#8221;) as of December
31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders&#8217; equity and cash flows for each of
the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024,
in conformity with accounting principles generally accepted in the United States of America.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Marlton,
New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityBankruptcyProceedingsReportingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12, 13, 15d<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityBankruptcyProceedingsReportingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 547,890<span></span>
</td>
<td class="nump">$ 884,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments held in marketable securities</a></td>
<td class="nump">10,184,701<span></span>
</td>
<td class="nump">10,181,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">188,400<span></span>
</td>
<td class="nump">19,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">223,230<span></span>
</td>
<td class="nump">305,231<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">11,144,221<span></span>
</td>
<td class="nump">11,390,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DeferredOfferingCost', window );">Deferred offering costs</a></td>
<td class="nump">148,697<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">362,936<span></span>
</td>
<td class="nump">356,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">151,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">623,945<span></span>
</td>
<td class="nump">713,692<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">12,279,799<span></span>
</td>
<td class="nump">12,611,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">483,070<span></span>
</td>
<td class="nump">189,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">744,485<span></span>
</td>
<td class="nump">711,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">162,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liabilities</a></td>
<td class="nump">2,520,851<span></span>
</td>
<td class="nump">1,543,953<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">3,748,406<span></span>
</td>
<td class="nump">2,607,345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">3,748,406<span></span>
</td>
<td class="nump">2,607,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 75,000,000 shares authorized; 6,919,919 and 4,706,917 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">164,195,434<span></span>
</td>
<td class="nump">156,689,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(155,678,715)<span></span>
</td>
<td class="num">(146,699,334)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">8,531,393<span></span>
</td>
<td class="nump">10,004,375<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">12,279,799<span></span>
</td>
<td class="nump">12,611,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 13,982<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DeferredOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DeferredOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,919,919<span></span>
</td>
<td class="nump">4,706,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">6,919,919<span></span>
</td>
<td class="nump">4,706,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,543,158<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="nump">$ 401,000<span></span>
</td>
<td class="nump">$ 145,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">28,072<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">372,928<span></span>
</td>
<td class="nump">145,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,348,709<span></span>
</td>
<td class="nump">4,034,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,579,413<span></span>
</td>
<td class="nump">11,331,983<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">11,928,122<span></span>
</td>
<td class="nump">15,366,574<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss From Operations</a></td>
<td class="num">(11,555,194)<span></span>
</td>
<td class="num">(15,220,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">616,077<span></span>
</td>
<td class="nump">552,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GrantIncome', window );">Grant income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">83,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">150,850<span></span>
</td>
<td class="nump">169,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GainOnExchangeOfWarrants', window );">Gain on exchange of warrants</a></td>
<td class="nump">1,711,698<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">97,188<span></span>
</td>
<td class="nump">3,997,780<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income</a></td>
<td class="nump">2,575,813<span></span>
</td>
<td class="nump">4,803,070<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (8,979,381)<span></span>
</td>
<td class="num">$ (10,417,704)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss Per Share - Basic</a></td>
<td class="num">$ (1.16)<span></span>
</td>
<td class="num">$ (2.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss Per Share - Diluted</a></td>
<td class="num">$ (1.16)<span></span>
</td>
<td class="num">$ (2.47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Common Shares Outstanding - Basic</a></td>
<td class="nump">7,763,932<span></span>
</td>
<td class="nump">4,218,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Common Shares Outstanding - Diluted</a></td>
<td class="nump">7,763,932<span></span>
</td>
<td class="nump">4,218,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_GainOnExchangeOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on exchange of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_GainOnExchangeOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series B Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15,182<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">$ 146,556,418<span></span>
</td>
<td class="num">$ (136,281,630)<span></span>
</td>
<td class="nump">$ 10,290,339<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,518,158<span></span>
</td>
<td class="nump">3,677,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock-based compensation:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted share units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">4,633,655<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,633,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted share units, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,141,803<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,141,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of Series B Convertible Preferred Stock into common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,200)<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of Series B Convertible Preferred Stock into common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(120,000)<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">2,348,692<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,348,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,417,704)<span></span>
</td>
<td class="num">(10,417,704)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">156,689,256<span></span>
</td>
<td class="num">(146,699,334)<span></span>
</td>
<td class="nump">10,004,375<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">4,706,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Stock-based compensation:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted share units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">985,028<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">985,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted share units, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,827,528<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,827,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,979,381)<span></span>
</td>
<td class="num">(8,979,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued in connection with warrant exchange</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">4,742,043<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,742,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued in connection with warrant exchange, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding', window );">Return and cancellation of shares in lieu of payroll tax withholding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">(48,406)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(48,410)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares', window );">Return and cancellation of shares in lieu of payroll tax withholding, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares', window );">Common stock issued in connection with abeyance shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares', window );">Common stock issued in connection with abeyance shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">$ 164,195,434<span></span>
</td>
<td class="num">$ (155,678,715)<span></span>
</td>
<td class="nump">$ 8,531,393<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">6,919,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents the
aggregate fair value of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpPD4xdmm3mj" title="Aggregate fair value of common stock">3,351,580</span> shares of common stock, which includes <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5nhgzoqroak" title="Warrants exercisable">2,150,000</span> shares that have been issued and <span id="xdx_908_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zTAiLGZkPyDe" title="Shares held in abeyance">1,201,580</span> shares
held in abeyance. See Note 6 - Stockholders&#8217; Equity - Warrant Exercise and Issuance and Note 9 - Fair Value Measurement for additional
details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWith abeyance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common stock issued in connection with abeyance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return and cancellation of shares in lieu of payroll tax withholding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock return and cancellation of shares in lieu of payroll tax withholding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480513/718-10-30-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480843/718-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="nump">3,951,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharesHeldInAbeyance', window );">Shares held in abeyance</a></td>
<td class="nump">1,201,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Aggregate fair value of common stock</a></td>
<td class="nump">3,351,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="nump">2,150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharesHeldInAbeyance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares held in abeyance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharesHeldInAbeyance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (8,979,381)<span></span>
</td>
<td class="num">$ (10,417,704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">189,056<span></span>
</td>
<td class="nump">165,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Dividend and interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(623,801)<span></span>
</td>
<td class="num">(569,068)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,812,566<span></span>
</td>
<td class="nump">7,782,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">151,447<span></span>
</td>
<td class="nump">90,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GainOnExchangeOfWarrants', window );">Gain on exchange of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,711,698)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of warrant liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(97,188)<span></span>
</td>
<td class="num">(3,997,780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(169,100)<span></span>
</td>
<td class="num">(3,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,591<span></span>
</td>
<td class="nump">57,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">293,680<span></span>
</td>
<td class="nump">18,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,799<span></span>
</td>
<td class="nump">581,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(162,317)<span></span>
</td>
<td class="num">(139,328)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,230,346)<span></span>
</td>
<td class="num">(6,430,211)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale of marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,508,641<span></span>
</td>
<td class="nump">20,964,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(20,887,923)<span></span>
</td>
<td class="num">(17,541,287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(106,189)<span></span>
</td>
<td class="num">(171,043)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided By Investing Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">514,529<span></span>
</td>
<td class="nump">3,252,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock in at-the-market offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">494,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance of common stock in direct-offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,853,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1', window );">Proceeds from exchange and issuance of warrants, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,528,027<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_PaymentsForProceedsFromDeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(148,697)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,379,330<span></span>
</td>
<td class="nump">2,348,773<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Decrease In Cash and Cash Equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(336,487)<span></span>
</td>
<td class="num">(829,395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents - Beginning of the Year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">884,377<span></span>
</td>
<td class="nump">1,713,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents - End of the Year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">547,890<span></span>
</td>
<td class="nump">884,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_IssuanceOfCommonStockHeldInAbeyance', window );">Issuance of common stock held in abeyance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding', window );">Return and cancellation of shares in lieu of payroll tax withholding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 48,410<span></span>
</td>
<td class="nump">$ 39,308<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes gross
proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_c20240101__20241231_zSqmWfzB3Fwf" title="Proceeds from debt issuance costs">8,123,391</span>, less issuance costs of $<span id="xdx_908_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231_zFrZALfkTkQg" title="Issuance costs">595,364</span>.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_GainOnExchangeOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on exchange of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_GainOnExchangeOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_IssuanceOfCommonStockHeldInAbeyance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock held in abeyance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_IssuanceOfCommonStockHeldInAbeyance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_PaymentsForProceedsFromDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for proceeds from deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_PaymentsForProceedsFromDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exchange and issuance of warrants net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return and cancellation of shares in lieu of payroll tax withholding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt issuance costs</a></td>
<td class="nump">$ 8,123,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 595,364<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (8,979,381)<span></span>
</td>
<td class="num">$ (10,417,704)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_NoInsiderTradingFlag', window );">No insider trading flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_NoInsiderTradingFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No insider trading flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_NoInsiderTradingFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zWCGyXxRAmw">recognize the importance of assessing, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zrUEszxx1fJa">identifying</span>, and managing cybersecurity risks. These include operational vulnerabilities, intellectual
property theft, fraud, extortion, potential harm to stakeholders, regulatory compliance issues, and associated legal, financial, and
reputational consequences</span>.</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>In
partnership with external consultants, we maintain comprehensive information security processes to identify and mitigate material cybersecurity
risks. Our protective measures include:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technical,
                                            physical, and organizational safeguards</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaster
                                            recovery and business continuity planning</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
                                            encryption and network security controls</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access
                                            restrictions and physical security measures</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
                                            asset management</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuous
                                            systems monitoring</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
                                            security training</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
assessment to date shows that cybersecurity incidents and vulnerabilities have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240101__20241231_zcRFntJBGU59">not</span> materially impacted our business operations, financial
performance, or strategic direction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ongoing monitoring and evaluation have not identified any cybersecurity risks that are expected to significantly affect our operational
capabilities, financial condition, or business objectives in the foreseeable future.</span></p>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">recognize the importance of assessing, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zrUEszxx1fJa">identifying</span>, and managing cybersecurity risks. These include operational vulnerabilities, intellectual
property theft, fraud, extortion, potential harm to stakeholders, regulatory compliance issues, and associated legal, financial, and
reputational consequences<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate IT infrastructure, communication networks, and related systems are essential operational components. These systems manage product
development, internal and external communications, accounting functions, data storage, and other critical operations. Our business depends
on secure handling of proprietary, confidential, and sensitive data.</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zzwvf59E06n5">Our
Chief Financial Officer oversees information security efforts in conjunction with a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zhfkuwQnkeg1">third-party</span> IT services company and reports material
cybersecurity matters to the Chief Executive Officer and Board of Directors</span>.</span></p>

&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our
Chief Financial Officer oversees information security efforts in conjunction with a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zhfkuwQnkeg1">third-party</span> IT services company and reports material
cybersecurity matters to the Chief Executive Officer and Board of Directors<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate IT infrastructure, communication networks, and related systems are essential operational components. These systems manage product
development, internal and external communications, accounting functions, data storage, and other critical operations. Our business depends
on secure handling of proprietary, confidential, and sensitive data.</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zzwvf59E06n5">Our
Chief Financial Officer oversees information security efforts in conjunction with a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zhfkuwQnkeg1">third-party</span> IT services company and reports material
cybersecurity matters to the Chief Executive Officer and Board of Directors</span>.</span></p>

&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zad1yrVgoFC6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
1 - <span id="xdx_82E_zTWJIhlVH5wj">ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#8220;Stem Pearls&#8221;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#8220;BRT&#8221; or the &#8220;Company&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 23, 2022, the Company reincorporated from Delaware to Nevada by filing Articles of Incorporation with the state of Nevada. The
reincorporation was structured as a statutory merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and Going Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which
contemplates realization of assets and satisfying liabilities in the normal course of business. For the year ended December 31, 2024,
the Company had a net loss of $<span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zpyfxt7l3Ml4" title="Net loss">9.0</span> million, negative cash flows from operations of $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zbxaUj3RB9Eg" title="Cash flows from operations">8.2</span> million and working capital of $<span id="xdx_905_ecustom--WorkingCapital_iI_pn5n6_c20241231_zuIvnxRVR3fg" title="Working capital">7.4</span> million.
The Company anticipates that it will continue to incur net losses and negative cash flows from operations as it executes its development
plans for 2025 and beyond, as well as other potential strategic and business development initiatives. These conditions raise substantial
doubt about the Company&#8217;s ability to continue as a going concern for at least twelve months after the issuance date of these financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has previously funded, and plans to continue funding, these losses primarily through current cash on hand, investments in marketable
securities and additional infusions of cash from equity and debt financing. During the year ended December 31, 2024, the Company raised
net proceeds of approximately $<span id="xdx_906_ecustom--ProceedsFromWarrantExercisesNet_pn5n6_c20240101__20241231_zPQQMtfHNcL1" title="Proceeds from warrant exercises, net">7.5</span> million in connection with a warrant exercise program which is further discussed in Note 6 &#8211;
Stockholders&#8217; Equity. On November 6, 2024, the Company entered into an at-the-market offering agreement (the &#8220;2024 ATM&#8221;)
pursuant to which the Company has an ability to issue and sell shares of its common stock up to an aggregate offering price of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241106__20241106_zicrnDnE8Hjb" title="Offering price">3,614,170</span>.
Subsequent to December 31, 2024, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zD3UaD052txg" title="Sold shares of common stock">492,000</span> shares of its common stock under the 2024 ATM and raised approximately $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z22hnIqNkwu3" title="Offering price">1,084,000</span>
of gross proceeds See Note 10 &#8211; Subsequent Events for additional details regarding sales of the Company&#8217;s common under the
2024 ATM subsequent to December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s current funds will not be sufficient to enable the Company to fully complete its development activities or attain profitable
operations. If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its
development, marketing and promotional activities, which would have a material adverse effect on the Company&#8217;s business, financial
condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;), which contemplate continuation of the Company as a going concern and the realization
of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented
in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying consolidated
financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#8217;s
website is at www.biorestorative.com. The information contained in the website or connected thereto is not intended to be incorporated
by reference into this Annual Report. BRT is currently developing a Disc/Spine Program referred to as &#8220;brtxDISC&#8221;. Its lead
cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person&#8217;s own) cultured mesenchymal stem cells collected
from the patient&#8217;s bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral disc disorders
or as a complimentary therapeutic to a surgical procedure. BRT is also engaging in research efforts with respect to a platform technology
utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders and has labeled
this initiative its ThermoStem Program. In addition, in continuation of BRT&#8217;s mission of developing and commercializing cell-based
biologics, it is seeking to develop a biologics-based cosmetic products business. Pursuant to such business, BRT would formulate, manufacture
and sell products designed for cosmetic and aesthetic uses. Further, BRT has licensed a patented curved needle device that is a needle
system designed to deliver cells and/or other therapeutic products or material to the spine and discs or other potential sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zKzKY88P6szc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
2 - <span id="xdx_828_zMyXsBBEEUzi">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zntv9Aiyyqwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zdk4PxG1qrLi">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#8217;s consolidated financial statements. Such consolidated
financial statements and accompanying notes are the representations of Company&#8217;s management, who is responsible for their integrity
and objectivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zxDKCiAlpgg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_z0fNjlbqN8zj">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stem Pearls. All intercompany
accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--UseOfEstimates_zEU1sFsNaugc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z4poG7D1ldXh">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related
notes to the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#8217;s future results to be affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkkM4rTKhXL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z3GH9BVMoxqk">Segment
Reporting</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has one operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#8217;s Chief Executive Officer, serves
as the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial
performance. The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated
expense data beyond what is included in the consolidated statements of operations is not provided to the CODM. Since the Company&#8217;s
operations consist of a single reporting segment, the segment assets are presented on the accompanying consolidated balance sheet as
total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zutuEXoDmQC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zLcOVvLUxfTa">Revenue
Recognition</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue in accordance with ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;).
The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC
606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required
within the revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable
consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company
recognizes revenue primarily from the following different types of contracts:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
    sales</b> - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Royalty
    revenue</b> - Revenue is recognized as a usage-based royalty from customers&#8217; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#8217;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    reason for the bill-and-hold arrangement is substantive</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    customer has requested the product be warehoused</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product has been identified as separately belonging to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product is currently ready for physical transfer to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company does not have the ability to use the product or direct it to another customer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s revenue recognized in its consolidated statements of operations:</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcIh7pV1dQj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z7tV6GJV8wQe" style="display: none">SCHEDULE
OF REVENUE RECOGNIZED</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_z6bGTQxxirwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_zcNhTDyKdqYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zNRTnoVTmbne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Product revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ziVx2XrSPJPj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">101,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">145,800</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zvWAylJpLPRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">401,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">145,800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zucK4GFra5g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z82RXuAQ9m83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zPY8JAe2pUG9">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#8220;FDIC&#8221;) coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zd4LGIJOhtt9" title="FDIC insured limit">250,000</span> per banking institution. The Company had deposits in excess of FDIC coverage of $<span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zkZR8JFpwxA1" title="FDIC amount">252,801</span> and
$<span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_c20231231_zuUVXiGB8vo1" title="FDIC amount">604,226</span> as of December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company has not experienced losses on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zrHslI4Q5v9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zMa1AmFIfaIk">Customer
and Revenue Concentrations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s royalty revenue is derived from one customer. Additionally, all of the Company&#8217;s product sales revenue is
derived from one customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z96cN1ak7Q7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zjqSBcHeCS88">Accounts
Receivable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of December 31, 2024 and 2023, no allowances
for credit losses were determined to be necessary. Management estimates the allowance for credit losses based on existing economic conditions,
the financial conditions of the customers, and the amount and age of past due accounts. Receivables are considered past due if full payment
is not received by the contractual due date. Past due accounts are generally written off against the allowance for credit losses only
after all collection attempts have been exhausted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--DeferredContractCostsPolicyTextBlock_zPwiT9fl58tj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_z9v0S1hZqQUi">Deferred
Contract Costs</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs
relate directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying
performance obligations in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as
cost of revenues in the period when the related revenue is recognized. Deferred contract costs consist of consumables and labor
costs and are included within prepaid &amp; other current assets in the consolidated balance sheets. The Company had $<span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zZfVwr6cQXkb" title="Deferred contract costs">10,250</span>
and $<span id="xdx_905_eus-gaap--DeferredCosts_iI_c20231231_zdJ4p8ov21Hk" title="Deferred contract costs">0 </span>deferred contract
costs as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_842_ecustom--DeferredOfferingCostsPolicyTextBlock_zzmFBpKtS7Q4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_zv1g22C3EyB3">Deferred Offering Costs</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Deferred offering costs, which
primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized as non-current assets
on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the offering proceeds. If
the completion of a contemplated financing was no longer probable, the related deferred offering costs would be charged to general and
administrative expense in the consolidated financial statements. The Company had $<span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_c20241231_zRqgz5xgN36j" title="Deferred offering costs">148,697</span> and $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_c20231231_zQ0rJYVdgKF6" title="Deferred offering costs">0</span> deferred offering costs as of December
31, 2024 and 2023, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrNWYT5nz4ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zheceqDJFsi8">Property
and Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember_zz0rpqtMCv35" title="Property plant and equipment estimated useful lives::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0595">three</span></span> to <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_z9lXBJdFqlhj" title="Property plant and equipment estimated useful lives">fifteen years</span>. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfnq9MSy6d45" title="Property plant and equipment estimated useful lives">3</span> years. Medical equipment costs
are capitalized and depreciated over <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zZ4jRpsDJgA6" title="Property plant and equipment estimated useful lives">5</span> years, while furniture and fixtures are depreciated over <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zjMrGwd0Prad" title="Property plant and equipment estimated useful lives">4</span> years. Office equipment is depreciated
over a period of <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zFxufD0aVXDh" title="Property plant and equipment estimated useful lives">3</span> to <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcK9bTYPatcf" title="Property plant and equipment estimated useful lives">5</span> years, and manufacturing equipment over <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRGoTgdUsUR5" title="Property plant and equipment estimated useful lives">4</span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MaximumMember_zNoLqgQf3lLh" title="Property plant and equipment estimated useful lives">5</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zvYszRC8Li8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zEt2msSsRFC2">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records its intangible assets at cost in accordance with ASC 350, <i>Intangibles - Goodwill and Other</i>. Definite lived intangible
assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over
which the cash flows from the asset are expected to be generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhNRS1Aqq6jc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zFhYORrqYOJc">Impairment
of Long-Lived Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2024 and 2023, the Company determined that
there was <span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20240101__20241231_zkUKhwWoBDvg" title="Impairment of long-lived assets"><span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20230101__20231231_zJwaUYA1d6li" title="Impairment of long-lived assets">no</span></span> impairment charge for its long-lived assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_ecustom--WarrantAndOptionValuationPolicyTextBlock_zIkk7Kjs9Gzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zUd3lVu9E2Sd">Warrant
and Option Valuation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#8220;simplified&#8221;
method to develop an estimate of the expected term of &#8220;plain vanilla&#8221; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry blended with the Company&#8217;s historical
volatility. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining
term consistent with the expected term of the instrument being valued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zQ9biVqlTD72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_86F_z6RhMrU5RzF3">Derivative
Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option pricing model to value the
derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether
such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGbcb7LJWe47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zhJEhRPQrt7k">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of December 31, 2024 and 2023, the carrying amount of cash and cash equivalents,
investments held in marketable securities, accounts receivable, and accounts payable approximate their fair value due to the relatively
short period of time between their origination and their expected realization or payment. The warrant liabilities are measured at fair
value (see Note 9 &#8211; Fair Value Measurement for additional details).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company recognized aggregate dividend and interest income of $<span id="xdx_90C_eus-gaap--InterestAndDividendIncomeOperating_c20240101__20241231_zg5oD0W09dNe" title="Dividend and interest income">623,801</span> and $<span id="xdx_909_eus-gaap--InterestAndDividendIncomeOperating_c20230101__20231231_zU0r2WazoLE7" title="Dividend and interest income">569,068</span> respectively,
on its marketable securities, which was included within other income on its consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zV62cxfcykAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zSfIv1elO46k">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The Company has <span id="xdx_90D_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zZu0Wr23kU3b" title="Shares held in abeyance">1,201,580</span> shares held in abeyance included
in basic loss per share given that they are issuable for no additional consideration (see Note 6 &#8211; Stockholders&#8217; Equity for
additional details). The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding
convertible preferred stock is considered common stock at the beginning of the period or at the time of issuance, if later, pursuant
to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, options, warrants,
restricted stock units (&#8220;RSUs&#8221;) and convertible preferred stock have been excluded from the Company&#8217;s computation of
diluted net loss per common share for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zTOISYbdZzv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z1GIc8cffMY8" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zvW4VkuXWp01" style="width: 18%; text-align: right" title="Total">3,263,467</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNj7qEzjGEDh" style="width: 18%; text-align: right" title="Total">1,466,892</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsnSJJFV0i21" style="text-align: right" title="Total potentially dilutive shares">3,951,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zNev5ZVPtlKh" style="text-align: right" title="Total potentially dilutive shares">4,791,019</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unvested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zeme8xsmLW02" style="text-align: right" title="Unvested"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zigFx6OtpUFa" style="text-align: right" title="Unvested">97,827</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zr441Bl9Y3b4" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_znmyQsqEKWl1" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zfF2OKgWsyX5" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">8,613,259</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zRJKPmUwTj02" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">7,753,896</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zh9UmzbEuc23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4rqRiibYMW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zXmhvArh15nb">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The
fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be
provided in exchange for the award, usually the vesting period, on a straight-line basis. The Company computes the fair value of equity-classified
warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are recorded as incurred as a reduction
of amounts previously expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zyorW7NGWskg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zwBN5Q5WlHH">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes ASC 740, &#8220;Income Taxes,&#8221; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#8220;more likely-than-not&#8221;
that a deferred tax asset will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zUyYKWUBRBq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zvsoDK4W79Yj">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;)
assets and operating lease liabilities in our consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value
of lease payments over the lease term. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental
borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement
date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company&#8217;s lease terms
may include options to extend or terminate the lease when it is reasonably certain that it will exercise the option. Lease expense for
lease payments is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zXTkrjpty3U9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zpKTHgzD4l67">Recently
Adopted Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07,
&#8220;Improvements to Reportable Segments Disclosures (Topic 280)&#8221; (&#8220;ASU 2023-07&#8221;), which updates reportable segment
disclosure requirements, primarily through enhanced disclosures about significant segment expenses on both an annual and interim basis.
The guidance becomes effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after
December 15, 2024, with early adoption permitted. The adoption of this accounting standard on a retrospective basis did not have a material
impact on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_847_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zqqRwAf1WA26" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zNfZlr2uXiec">Recently
Issued Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; (&#8220;ASU
2023-09&#8221;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the impact of this update on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; (&#8220;ASU 2024-03&#8221;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.</span></p>

<p id="xdx_850_zSD8QCfCQlbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zEvV1FTo67xk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
3 - <span id="xdx_829_zsg9IrEIAfo9">PROPERTY AND EQUIPMENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z2ZdwaDNWsb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zRiW19Duyqmj" style="display: none">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zcvb0j2Mshvj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zCrUODQYb0Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zLOXDxjVNdhb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">352,133</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">352,133</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zHKi6c2fM66c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,486</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zTPXuLfpmrf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136,205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136,205</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zdSPeVh24a7d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,779</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zHLEEhyimZOi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Manufacturing equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">501,421</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">395,232</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zb0uKt79Uwyg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">342,048</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">342,048</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzKiZ_z4su14VN8qy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    plant and equipment gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,474,072</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,367,883</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzKiZ_zeJSxm1HRBa4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,111,136</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,011,828</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzKiZ_zPMObeOSxMXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">362,936</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,055</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zZiYqaFLPewe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
depreciation expense for the years ended December 31, 2024 and 2023 was $<span id="xdx_908_eus-gaap--Depreciation_pp0p0_c20240101__20241231_zvtQEHghKRO7" title="Depreciation">99,309</span> and $<span id="xdx_90F_eus-gaap--Depreciation_pp0p0_c20230101__20231231_zi5SeumhaRl8" title="Depreciation">75,989</span>, respectively. Depreciation expense is reflected
in general and administrative expenses and research and development expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--IntangibleAssetsDisclosureTextBlock_z7XcTOpi2I3c" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
4 - <span id="xdx_82E_z8jFnJ0P8vsc">INTANGIBLE ASSETS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a license agreement with the SCTC (as amended) (the &#8220;SCTC Agreement&#8221;). Pursuant to the SCTC Agreement,
the Company obtained, among other things, a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license from the SCTC
to utilize or sublicense a certain method for culturing cells and a worldwide, exclusive, royalty-bearing license from the SCTC to utilize
or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or spine
(and other parts of the body).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2017, the Company received authorization from the Food and Drug Administration (the &#8220;FDA&#8221;) to proceed with a Phase
2 clinical trial. In February 2022, the Company announced that the United States Patent and Trademark Office issued a notice of allowance
for a patent application relating to the Company&#8217;s BRTX-100 clinical program. This patent was issued in March 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zdsSzvPsMxw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zovX5FmRjKn8" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Balance as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zMa8DpLEhmyh" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance">3,676</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgkIpLlGFbo2" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance">1,593,530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zqY3dA0k41Sl" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance">(793,768</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20230101__20231231_z6h1cAws7Od" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance">803,438</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zDUNrjLtHqbj" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,746</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231_zRrGfdmJ09Eb" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,746</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zTRGfffLeNbf" style="text-align: right" title="Beginning Balance">3,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBVozX7VDJlj" style="text-align: right" title="Beginning Balance">1,593,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXRYXWxN8sRe" style="text-align: right" title="Beginning Balance">(883,514</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20240101__20241231_zqwLjk2xJY0j" style="text-align: right" title="Beginning Balance">713,692</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zytthitOTw2k" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,747</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231_zAM5NMN8yS06" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,747</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zQuRKUBmR8mh" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance">3,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zoYjoWDb33X3" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance">1,593,530</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_ztG665tY4AIa" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance">(973,261</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iE_pp0p0_c20240101__20241231_zjzg3CCnlNxd" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, Ending Balance">623,945</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average remaining amortization period at December 31, 2024 (in years)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zFTAQg0U6qf8" title="Finite Lived Intangible Assets, weighted average amortization period"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zWn6aGIbVlz8" title="Finite Lived Intangible Assets, weighted average amortization period">10.3</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zQnJWoLGRUxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zyr8t0Ym6OWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of intangible assets consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_zIE3bG4EPzp9" style="display: none">SCHEDULE OF FINITE LIVED
INTANGIBLE ASSETS AMORTIZATION EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Balance as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zAQRVTNxCnRa" style="width: 14%; text-align: right" title="Beginning Balance">3,676</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zTV1EfXZQxkj" style="width: 14%; text-align: right" title="Beginning Balance">790,092</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zuMtebEZOmgf" style="width: 14%; text-align: right" title="Beginning Balance">793,768</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zY8aapJwfbif" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"><span style="-sec-ix-hidden: xdx2ixbrl0750">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgEjKj6jTWI5" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,746</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2rXVJBGP7il" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,746</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zgRAH3stiYi7" style="text-align: right" title="Beginning Balance">3,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zDe9KaWcOYI7" style="text-align: right" title="Beginning Balance">879,838</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXVvp6oFTRTa" style="text-align: right" title="Beginning Balance">883,514</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zuHhehAQNkik" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"><span style="-sec-ix-hidden: xdx2ixbrl0762">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z6qgnUqvdCNe" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,747</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zygSxwRoDT8e" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,747</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zpDaKpFlcUXl" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">3,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_ziQYvOYoF2Vh" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">969,585</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z21atXqH7Mrd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">973,261</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zXJeZ8EsBx54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zO5E84hy3qC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense for the next five years is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zDxhPMghSJb7" style="display: none">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom">For the Years Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zLqGmLhSvkA" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz89Q_z1vNDKxW98G5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">89,746</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz89Q_za7zLx3utHS9" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz89Q_z9FWK80aZ1L8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz89Q_zCZfaJK7po9f" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz89Q_zlr2Quf6AHf9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">89,746</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz89Q_zivgdmaXPRBi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">448,730</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zRFY1LD10kBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zcCzM4pARQo3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
5 - <span id="xdx_820_zMsUx2ILh5Tl">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z7ve0gvNg4Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z3T5qunqNukl" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zEWk23Yc0nC" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zeM88DjmnpU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zg5ydVfCG0I2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accrued bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">704,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">638,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_z5sQM90mCxFd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">40,485</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">73,686</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zJIAosR1rmQf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">744,485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">711,686</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_ziyjOByjOsNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zJPEBtlN7YIk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
6 - <span id="xdx_82B_zUgzUG841pcg">STOCKHOLDERS&#8217; EQUITY</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
A Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2021, in connection with the Company&#8217;s public offering, the Company&#8217;s Board of Directors adopted a resolution
allowing for the designation and issuance of <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAv4O5ACYYm2" title="Preferred stock, shares issued">1,543,158</span> shares of the Company&#8217;s Preferred Stock, $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQNlJEUEDcQa" title="Preferred stock, par value">.01</span> par value per share, designated
as Series A Preferred Stock (&#8220;Series A&#8221;). The Series A had a liquidation preference of $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3hczMMtKpU8" title="Preferred stock, liquidation preference">0.001</span> per share. On September 8,
2022, the Company issued <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zo0GcvUNCdN2" title="Preferred stock, shares issued">1,543,158</span> shares of Series B Preferred Stock (&#8220;Series B&#8221;) to Auctus Fund, LLC (&#8220;Auctus&#8221;)
in exchange for an equal number of shares of the Company&#8217;s outstanding Series A. Simultaneously, the stock certificate representing
the Series A shares was being returned to the Company for cancellation. On such date and upon such exchange, the Company&#8217;s Board
of Directors cancelled the Series A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
B Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 8, 2022, the Company issued <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYC3O1qRrCy6" title="Preferred stock, shares issued">1,543,158</span> shares of Series B to Auctus in exchange for an equal number of shares of the Company&#8217;s
outstanding Series A. The terms of the Series B are substantially identical to those of the Series A, except that, among other things,
the limitation on beneficial ownership of common stock of the Company upon a conversion of the Series B into Common Stock, and the limitation
on the number of votes attributable to the Series B, is <span id="xdx_90D_eus-gaap--PreferredStockVotingRights_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKAmHWfyKJBh" title="Preferred stock voting rights">9.99</span>% of the then outstanding Common Stock of the Company instead of <span id="xdx_90C_eus-gaap--PreferredStockVotingRights_pid_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuT87XMZHkJ6" title="Preferred stock voting rights">4.99</span>% as
provided for the Series A. The Company is required, at all times, to reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of Common Stock upon the full conversion of the Series B. The Series B is not subject to
redemption by the Company or any Series B holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders
of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Voting
Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders
of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes
for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares
of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law.
The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares
of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled
to vote more than <span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7GqZ3KTuVV4" title="Preferred stock voting percentage">9.99</span>% of the then outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conversion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optional
Conversion - <span id="xdx_902_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zL2VXQ8WU4De" title="Preferred stock conversion term">Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock;</span> provided, however, that in no event shall a Series B holder be entitled to convert any shares of Series B
to the extent that such conversion would result in beneficial ownership by such Series B holder of more than <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_znCDeplQWuW5" title="Preferred stock voting percentage">9.99</span>% of the outstanding
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automatic
Conversion - From time to time, in the event that an event occurs which has the effect of reducing a Series B holder&#8217;s beneficial
ownership of shares of Common Stock to less than <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zphxO48CaFTi" title="Ownership percentage">9.5</span>% of the then publicly disclosed outstanding shares of Common Stock, then, within
five business days, the Series B holder is required to provide notice to the Company to such effect, which notice shall state the number
of shares of Common Stock beneficially owned by the Series B holder and shall provide reasonable detail with regard thereto, including
the number of derivative securities compromising a portion of such beneficial share amount. Such notice shall have the effect of a notice
of conversion with respect to the conversion of such number of shares of Series B as would increase the Series B holder&#8217;s beneficial
ownership of Common Stock to <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zf50yJldC0Qg" title="Preferred stock voting percentage">9.99</span>% of the then publicly disclosed outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 25, 2022, Auctus converted <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_z5AXhJwz8bFi" title="Debt conversion, converted instrument, shares issued">25,000</span> shares of Series B into <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zlLsZqLS1tRe" title="Debt conversion, converted instrument, shares issued">25,000</span> shares of Common Stock. The number of shares of Series B remaining
outstanding after this conversion was <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zLoD9gwPh8vg" title="Conversion of stock shares">1,518,158</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 4, 2023, Auctus converted <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zFD1ODMs5Buk" title="Number of shares converted">120,000</span> shares of Series B into <span id="xdx_90D_eus-gaap--ConversionOfStockSharesIssued1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zUB0LKFisLvh" title="Number of shares issued in conversion">120,000</span> shares of Common Stock. As of December 31, 2024, the number of
shares of Series B remaining outstanding after giving effect to such conversion was <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zveV0mvbGEcl" title="Preferred stock, shares outstanding">1,398,158</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Stock Incentive Plan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, the Company&#8217;s Board of Directors adopted the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &#8220;2021
Plan&#8221;). The 2021 Plan was approved by the Company&#8217;s stockholders on August 17, 2021. Pursuant to the 2021 Plan, a total of
<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210318__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember_zQB2Po9BLkKg" title="Number of shares of common stock authorized">1,175,000</span> shares of common stock were initially authorized to be issued pursuant to the grant of stock options, restricted stock units,
restricted stock, stock appreciation rights and other incentive awards. On December 10, 2021, the Company&#8217;s Board of Directors
approved an amendment to increase the number of shares of Common Stock authorized to be issued from <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20211210__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zVPMbYgrWnQ2" title="Common stock shares authorized">1,175,000</span> to <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20211210__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zncC5eiUPWt1" title="Common stock shares authorized">2,500,000</span>. Such amendment
was approved by the Company&#8217;s stockholders on November 3, 2022. On July 13, 2023, the Company&#8217;s Board of Directors approved
an amendment to the 2021 Plan to increase the number of shares of Common Stock authorized to be issued from <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20230713__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zo1X1po4yASk" title="Common stock shares authorized">2,500,000</span> to <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20230713__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zVCTDa6pQi4" title="Common stock shares authorized">3,850,000</span>. Such
amendment was approved by the Company&#8217;s stockholders on September 13, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 23, 2024, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s 2021 Plan to increase the number of
shares of common stock authorized to be issued under the 2021 Plan from <span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240722__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zVT1EXT7QkA9" title="Common stock authorized to issue">3,850,000</span> to <span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240723__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_z0fNr8c0ddHb" title="Common stock authorized to issue">6,850,000</span>. Such amendment was approved by the Company&#8217;s
stockholders on September 19, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensatory
Common Stock Issuance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company issued <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20230101__20231231_ztpy3rsk930e" title="Vested common stock, shares">1,442</span> shares of immediately vested common stock with a value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20231231_zKuKeGD0i2fd" title="Aggregate common stock services rendered">7,500</span> to a consultant
for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales
of Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, the Company entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (&#8220;JonesTrading&#8221;)
under which the Company had the ability to issue and sell shares of its Common Stock, from time to time, through JonesTrading, up to
an aggregate offering price of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230401__20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--DemandSalesAgreementMember_z2vE6NAiKWPj">6,109,000</span> in what is commonly referred to as an &#8220;at-the-market&#8221; (&#8220;ATM&#8221;)
program. During the year ended December 31, 2023, the Company sold <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zXplo7pD9iOk" title="Sold shares of common stock">132,827</span> shares of its Common Stock at a weighted average price of
$<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zpEUTC3wNX2l" title="Weighted average price">4.68</span> per share and raised $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zunGcHy30dsd">494,782</span> in net proceeds under the JonesTrading ATM program. In November 2024, in connection with the ATM
program with Rodman &amp; Renshaw LLC (&#8220;Rodman&#8221;) discussed below, the Company terminated the Capital on Demand Sales Agreement
with JonesTrading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 13, 2023, the Company sold an aggregate of 	<span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230712__20230713_zGeXKDbsQOZf" title="Sale of aggregate shares">685,033</span> shares of Common Stock to several institutional buyers and accredited investors
in a registered direct offering at an offering price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230713_zcVAT4OtM4yi" title="Offering price">3.03</span> per share. The offering closed on July 13, 2023 with net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230712__20230713_zP7zaht68Fhf" title="Net proceeds offering price">1,853,990</span>.
The Company intends to use the net proceeds from the offering in connection with its clinical trials with respect to its lead cell therapy
candidate, BRTX-100, pre-clinical research and development with respect to its metabolic ThermoStem Program and for general corporate
purposes and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the Company entered into an At The Market Offering Agreement with Rodman, under which the Company currently has the ability
to issue and sell shares of its Common Stock, from time to time, through Rodman, up to an aggregate offering price of approximately $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zH6H9vwuMDQa" title="Sold value of common stock">3,614,000</span>
in an ATM program. See Note 10 - Subsequent Events &#8211; Common Stock Sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Exercise and Issuance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2024, the Company entered into agreements with certain holders of its existing warrants exercisable for an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJLLRuKcXiXh" title="Warrants exercisable">3,351,580</span>
shares of its Common Stock (collectively, the &#8220;Existing Warrants&#8221;), to exercise their warrants at a reduced exercise price
of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWIprX6rqLng" title="Exercise price">2.33</span> per share, in exchange for the issuance of new warrants (the &#8220;New Warrants&#8221;) as described below (the &#8220;Warrant
Exercise and Issuance&#8221;). The aggregate gross proceeds from the exercise of the Existing Warrants and the payment of the New Warrants,
as described below, was approximately $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLxbdAHUuGN7" title="Proceeds from exercise of warrants">8.1</span> million, before deducting cash issuance costs in the amount of $<span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAFNeSFqflDl" title="Cash issuance costs">595,364</span>. The reduction of
the exercise price of the Existing Warrants and the issuance of the New Warrants was structured as an at-market transaction under Nasdaq
rules. Of the <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzsKaWfvjyT2" title="Warrants exercisable">3,351,580</span> shares of Common Stock issuable upon the exercise of the Existing Warrants, through December 31, 2024, the Company
had issued an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z68Q6vqjUh11" title="Warrants exercisable">2,150,000</span> shares of Common Stock. The remaining <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember_zvVWO1PSwBY4" title="Warrants exercisable">1,201,580</span> shares of Common Stock, which are issuable to Auctus
Fund, LLC (&#8220;Auctus&#8221;), are being held in abeyance due to Auctus&#8217; maximum beneficial ownership limitation (the &#8220;Abeyance
Shares&#8221;). Such Abeyance Shares have been fully paid for and are issuable upon notice from Auctus to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the immediate exercise of the Existing Warrants for cash and the payment of $<span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zBxG29Eh8Uv" title="Warrants for cash and the payment">0.125</span> per share underlying the New Warrants,
the exercising holders received the New Warrants to purchase shares of Common Stock in a private placement pursuant to Section 4(a)(2)
of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The New Warrants will be exercisable for a period of five
years into an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNlyN1DFbIFj" title="Warrants exercisable">2,513,686</span> shares of Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zRsdklXiIqW9" title="Exercise price">2.43</span> per share. The securities offered in the private
placement have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not
be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration
requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company agreed to file
a resale registration statement with the SEC to register the resale of the shares of Common Stock underlying the New Warrants issued
in the private placement. Such resale registration statement was filed and was declared effective by the SEC on April 18, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the transaction described above, the Company entered into a financial advisory services agreement, dated February 5,
2024, with Roth Capital Partners, LLC (&#8220;Roth&#8221;), pursuant to which the Company has paid Roth a cash fee of approximately $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240205__20240205__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zzl7n2lB0Vtl" title="Cash fee for services">528,000</span>
for its services, in addition to reimbursement for certain expense. During the year ended December 31, 2024, the Company incurred an
aggregate of $<span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zT0D139u7t1a" title="Issuance costs">595,364</span> of cash issuance costs related to the Warrant Exercise and Issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Warrant Exercise and Issuance, the Existing Warrants were classified as derivative liabilities. Additionally, the Company analyzed
the form of the New Warrants and determined that they should be classified as derivative liabilities in accordance with ASC 815-40, Derivatives
and Hedging &#8212; Contracts in Entity&#8217;s Own Equity. Under the New Warrants, the Company does not control the occurrence of events,
such as a tender offer or exchange, that may trigger cash settlement of the New Warrants and not result in a change of control of the
Company. As a result, such New Warrants do not meet the criteria for equity treatment. Additionally, certain New Warrants contain adjustments
to the settlement amount based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option as defined
under ASC 815-40 and, accordingly, such New Warrants are not considered indexed to the Company&#8217;s own stock and are not eligible
for an exception from derivative accounting. See Note 9&#8211; Fair Value Measurement for details regarding the valuation of the Existing
Warrants and New Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the Warrant Exercise and Issuance to be an exchange by investors of Existing Warrants with an aggregate fair value
of $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zwsYJKgpvCMb" title="Fair value of adjustment">1,115,334</span> along with aggregate cash consideration of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zfFm1YZsZXZc" title="Proceeds from issuance of warrants">8,123,392</span> (consisting of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zCSVqe8YkOf2" title="Proceeds from issuance of warrants">7,809,181</span> paid to exercise the Existing Warrants
and $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_zbHEcEn03OHl" title="Proceeds from issuance of warrants">314,211</span> paid for the New Warrants) for an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zF7lId3Nr2Q7" title="Stock issued during period shares new issues">3,351,580</span> shares of common stock with an aggregate fair value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zefA77ZQfLn9" title="Stock issued during period value new issues">4,742,244</span>,
New Warrants with an aggregate fair value of $<span id="xdx_909_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zk6OWlB7V2rb" title="Stock issued during period value warrants">2,189,420</span> and aggregate cash issuance costs of $<span id="xdx_909_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zWjJHU1kOYy9" title="Issuance costs">595,364</span> and, accordingly, the Company recorded
a gain on exchange of warrants of $<span id="xdx_90D_ecustom--GainOnExchangeOfWarrants_c20240101__20241231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_z8JamcJ6mWz2" title="Gain on exchange of warrants">1,711,698</span> during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Activity Summary</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zSZin8yUZKs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the warrant activity during the year ended December 31, 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zGJJPKtZyAE5" style="display: none">SCHEDULE OF WARRANT ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Outstanding, January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znAqvvT4Qbx9" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding Beginning">4,791,019</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z87TDq6moIv1" style="width: 14%; text-align: right" title="Weighted Average Exercise Price,  Outstanding beginning balance">10.57</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdjrTKuhx9z6" style="text-align: right" title="Number of Warrants, Granted">2,513,686</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAkun9Fl9f26" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzgG1cCZ4vr1" style="text-align: right" title="Number of Warrants, Exercised">(3,351,580</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEztUrDWikmi" style="text-align: right" title="Weighted Average Exercise Price, Exercised">2.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOsoduSVUaRk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired">(1,491</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5TDR39mHj08" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">1,770</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfvfXo0Eesnl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding Ending">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsOAZv5WGZd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding ending balance">5.22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYsjitrPloab" title="Weighted Average Remaining Life In Years, Outstanding">3.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq1vHs0qwAbb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Exercisable Ending">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zegEmgi5jNK" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">5.22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwG8bbAgSYD7" title="Weighted Average Remaining Life In Years, Exercisable">3.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zXSUQ9QnVqc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average estimated fair value of the warrants granted during the year ended December 31, 2024 was $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDO6RUoak3l1" title="Weighted average estimated fair value of warrants granted">0.87 </span>per warrant. See Note
9 &#8211; Fair Value Measurement &#8211; for details regarding the fair value estimates of the Warrants that are classified as derivative
liabilities. The Company did not issue any warrants during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zMwHHKdVRuS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock warrants at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zJhgTLHPR6Ie" style="display: none">SCHEDULE
OF STOCK WARRANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBIP5ZD4QC56" style="width: 22%; text-align: right" title="Warrants outstanding, exercise price">2.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zl2Jku2lXkle" style="width: 22%; text-align: right" title="Warrants outstanding, number of warrants">2,513,686</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zU6Nhvq6d4e2" title="Warrants exercisable, weighted average remaining life in years">4.1</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zC60jbXs1afd" style="width: 21%; text-align: right" title="Warrants exercisable, exercisable number of warrants">2,513,686</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z17wx76SisWa" style="text-align: right" title="Warrants outstanding, exercise price">2.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUseg3QpPL84" style="text-align: right" title="Warrants outstanding, number of warrants">51,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zyTCTVYqM8Mh" title="Warrants exercisable, weighted average remaining life in years">2.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zwoRloxfJKD9" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">51,370</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuBvZFdF9pE2" style="text-align: right" title="Warrants outstanding, exercise price">10.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWunI15vUYcb" style="text-align: right" title="Warrants outstanding, number of warrants">1,150,358</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOE3aHbPJii4" title="Warrants exercisable, weighted average remaining life in years">1.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCyYxBCsyVJe" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">1,150,358</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zroKiGu0kyKh" style="text-align: right" title="Warrants outstanding, exercise price">12.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvBqal267Qf4" style="text-align: right" title="Warrants outstanding, number of warrants">235,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zsRzI4SStm05" title="Warrants exercisable, weighted average remaining life in years">1.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zjlWnxsI3Tue" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">235,970</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcUo7cIEyFd6" style="padding-bottom: 1pt; text-align: right" title="Warrants outstanding, exercise price">60.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4H9FGqoOWtj" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, number of warrants">250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zlijR7PFbo2l" title="Warrants exercisable, weighted average remaining life in years">0.0</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zJksqF3ibGo6" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants exercisable, exercisable number of warrants">250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zMTGD0WHNxH" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, number of warrants">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zfJ2T3TGfPA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, exercisable number of warrants">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_za7feX7DXOtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfNfCP9eNvD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the option activity during the year ended December 31, 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zrN9b2GV9bbk" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding, January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTvM4oSXln82" style="width: 12%; text-align: right" title="Number of Options, Outstanding beginning">1,466,892</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zoDROm8SpfK" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning">4.11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z1Abs0lPnAC2" style="text-align: right" title="Number of Options, Granted">1,934,716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zf56QyHtDan2" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_zBqFaBP2hRrg" style="text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zQdf2naQfNwc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(138,141</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zPDXmZhZIG01" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">1.76</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zcyRTNE1DYVe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding ending">3,263,467</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z6AUvmyFe4hl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending">2.63</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zTVIyvLVQU9e" title="Weighted Average Remaining Life in Years Outstanding Ending">7.5</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231_z0jhmSrRb99" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z6OaUmtzPBzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable Ending">2,499,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zLxmZKqE199h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable Ending">2.95</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zv88ELOpOHR9" title="Weighted Average Remaining Life in Years Exercisable Ending">7.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231_z0nAmGqFN17c" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zoAlkje3gnuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of the stock options granted during the years ended December 31, 2024 and 2023 was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zHbmqifX8bie" title="Weighted average grant date fair value of stock options granted">1.45</span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zRFePEuvUmbe" title="Weighted average grant date fair value of stock options granted">3.00</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zRtaMfXkznRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock options at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_ztcIUlTEysz5" style="display: none">SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zeGpMtvcx146" style="width: 22%; text-align: right" title="Options Outstanding, Exercise Price">1.45</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFR9VoHQVghd" style="width: 22%; text-align: right" title="Options Outstanding, Outstanding Number of Options">1,825,067</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBesCUmhfgB8" title="Options Exercisable Weighted Average Remaining Life In Years">8.1</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zOElztZCIEXk" style="width: 21%; text-align: right" title="Options Exercisable, Exercisable Number of Options">1,138,579</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zlN1nxbD5Qm7" style="text-align: right" title="Options Outstanding, Exercise Price">2.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z5su5TfUL9I1" style="text-align: right" title="Options Outstanding, Outstanding Number of Options">626,215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmxifRgIyVvh" title="Options Exercisable Weighted Average Remaining Life In Years">6.7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrvHndT1tcGc" style="text-align: right" title="Options Exercisable, Exercisable Number of Options">548,368</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGAMtsYhR5eh" style="padding-bottom: 1pt; text-align: right" title="Options Outstanding, Exercise Price">5.08</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zoR8Y98253Y8" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Outstanding Number of Options">812,185</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1xz1zj7zjja" title="Options Exercisable Weighted Average Remaining Life In Years">5.9</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIZKhcRWSsw5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Exercisable Number of Options">812,185</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231_zbocWCIXa5Vc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Outstanding Number of Options">3,263,467</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_ziXBWM6T6LZ" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Exercisable Number of Options">2,499,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zrKbEgsvNC01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zzhvGPbrfrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zZxbFDb2dxqf" style="display: none">SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zGOcrqNV9u6b" title="Risk free interest rate">4.14</span> -<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zlS2vh9EUFd4" title="Risk free interest rate"> 4.30</span>%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoHTrUNaM9yc" title="Risk free interest rate">4.22</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z1KylLmbD0Dj" title="Expected term (years)">2.77</span> - <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zar0bL5bcuah" title="Expected term (years)">5.38</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx5RjK2kIGab" title="Expected term (years)">3.5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zWWPgchvXA8e" title="Expected volatility">101</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_znbbAp1dPtUe" title="Expected volatility">102</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEkATAdzvs76" title="Expected volatility">175.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zauNMGbqKima" style="text-align: right" title="Expected dividends">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0OQS4xjFub7" style="text-align: right" title="Expected dividends">0.00</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AC_zjeFEbC9TUoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the 2021 Plan, the Company may grant restricted stock units (&#8220;RSUs&#8221;) to employees, consultants or non-employee directors
(&#8220;Eligible Recipients&#8221;). The number, terms and conditions of the RSUs that are granted to Eligible Recipients are determined
on an individual basis by the 2021 Plan administrator. On the distribution date, the Company shall issue to the Eligible Recipient one
unrestricted, fully transferable share of the Company&#8217;s common stock (or the fair market value of one such share in cash) for each
vested and nonforfeitable RSU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zbjCRCDfsw47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the unvested RSUs as of December 31, 2024 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z7qX6TjqzmYg" style="display: none">SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%">Non-vested at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z54caD9t4qNf" style="width: 22%; text-align: right" title="Number of shares outstanding beginning">97,827</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7rNzZRrwG7c" style="text-align: right" title="Number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl1085">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE6DHLnyY2Zc" style="text-align: right" title="Number of shares forfeited">(97,827</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVJwCiRoFDV8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z984AZuQj4Zh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending"><span style="-sec-ix-hidden: xdx2ixbrl1091">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zHAVwHeWUTFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zKMX8JsmytWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock-based compensation expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zNmDZQdJkQIj" style="display: none">SCHEDULE OF STOCK OPTION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unrecognized at December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Weighted Average Remaining
    Amortization Period</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8mg1PWdtnvh" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense">2,812,566</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0lPbAx67Oo4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense">7,782,967</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAfZqmoXHmha" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Unrecognized expense">774,470</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbb2sY1Dla3" title="Weighted average remaining amortization period (years)">0.95</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231_zbrAVj7QZ22e" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense">2,812,566</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231_zf5gaaCKHH4l" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense">7,782,967</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231_zZzUIJJBw2k1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense">774,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zOzUVTj3znM8" title="Weighted average remaining amortization period (years)">0.95</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zFWRUvqoB1Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zVozmWE0SJyc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
7 - <span id="xdx_826_zR22wSIZcwLf">INCOME TAXES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company identified its federal and New York tax returns as its &#8220;major&#8221; tax jurisdictions. The Company is no longer subject
to income tax income examinations by these tax authorities for taxable years ended December 31, 2020, and prior. The Company reviewed
the prior New York state income tax filings and concluded that the prior year return will be amended to change the apportionment from
zero to <span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_c20240101__20241231_zUkrmcjJv7h4" title="Prior year income taxes, percentage">100</span>%. The Company believes its income tax filing positions and deductions will be sustained on audit, and it does not anticipate
any adjustments that would result in a material change to its financial position. Therefore, no liabilities for uncertain tax positions
have been recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the Company had approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zePnVp7cedXh" title="Operating loss carry forwards">68,200,000</span> and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zRa5IkvBOzVf" title="Operating loss carry forwards">51,800,000</span>, respectively, of federal and state net operating losses
that may be available to offset future taxable income. As a result of the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;),
certain future carryforwards do not expire. At December 31, 2024, approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_c20241231__srt--StatementScenarioAxis__custom--ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_zDqomiSyERfd" title="Operating loss carry-forwards subject to expiration">7,800,000</span> of federal net operating losses will expire
from 2030 to 2038 and approximately $<span id="xdx_908_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_c20241231_zXc6BzRqcNMd" title="Operating loss carry-forwards not subject to expiration">60,400,000</span> have no expiration but are subject to a utilization limit equal to 80% of current taxable
income. <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseDescription_c20240101__20241231_z84EZ3UauGO9" title="Net operating loss description">The state net operating losses have a 20 year carryforward period and will begin to expire beginning 2035.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zywpKWkgXOba" title="Income tax examination, description">In
accordance with Section 382 of the Internal Revenue Code, the usage of the Company&#8217;s net operating loss carryforwards are subject
to annual limitations due to several greater than 50% ownership changes.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not performed a formal analysis for the year ended December 31, 2024, but it believes its ability to use such net operating
losses and tax credit carryforwards in the future is subject to annual limitations due to change of control provisions under Sections
382 and 383 of the Internal Revenue Code, which will significantly impact its ability to realize these deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit
use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred
over the three-year period ended December 31, 2024. For the period ended December 31, 2024, the Company has recorded a full valuation
allowance against the gross deferred tax asset balance as management believes that it is more likely than not that the results of operations
will not generate sufficient taxable income to realize any of the deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this filing, the Company has not filed its 2024 federal and state corporate income tax returns. The Company expects to
file these documents as soon as practicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOmgaPOBaQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2024 and 2023 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zZUwWPmupGV3" style="display: none">SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_zL9QFC7L3Yig" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zhbF1s19zvl7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zEjIVolmYEU6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred Tax Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGzcBK_zW8G8vTtyQJk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">18,004,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">14,311,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGzcBK_zFIFQbADeNHb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,695,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,788,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTAGzcBK_zdxqp5f1BD88" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,694,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,676,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGzcBK_zOXQBzh1v0Wa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsRightOfUseAsset_i01I_maDTAGzcBK_zBysCmdOR9Q" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1144">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcBK_zwScf9aTi8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">600</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGzcBK_maDTALNz6jW_zRxljnsv5rrj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Deferred Tax Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">29,724,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">32,134,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zlws6xNcz8z3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred Tax Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxLiabilitiesDepreciation_i01NI_pp0p0_di_maDITLz8iB_zLKFtT22d6Pg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(153,200</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(122,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_pp0p0_di_maDITLz8iB_zMvdEk1EX2Mf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41,700</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_i01NI_pp0p0_di_maDITLz8iB_z5JN7o7R2Nk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_di_maDITLz8iB_z626f9pOcRZd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(95,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(86,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pp0p0_di_mtDITLz8iB_msDTALNz6jW_z5ov3kRZfdYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Deferred Tax Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(289,900</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(294,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNz6jW_zDuuMmzJjzh4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Deferred Tax Asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,434,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,840,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8Hs2v6wALU5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(29,434,100</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(31,840,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_z8GkK0NwV2Ph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred Tax Asset, Net of Valuation Allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1178">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Change in valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20240101__20241231_zmS2WbGfj5n6" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">2,405,900</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20230101__20231231_zc9ckzJO7A9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">(4,064,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AC_zgRHuIkbL9D3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zltwcQOflIb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision (benefit) as of December 31, 2024 and 2023 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zewWuR64PcD5" style="display: none">SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zRwhUVQspGih" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zxkSMrPCvzR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zlI2aJg7XIZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maDFSALzNuk_zO5ShPfW6jN4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1189">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1190">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zk51qR840bie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%">Deferred</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3,567,000</td><td style="width: 1%; text-align: left"></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(3,090,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zTDgkAmF6Uzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">State &amp; Local:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maDFSALzNuk_z2FcUaberu53" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1198">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zRDQK8KB7bX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Deferred</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,161,100</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(974,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_maITEBz5Bf_mtDFSALzNuk_zPjhdL5jZTtd" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,405,900</td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,064,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--ChangeInValuationAllowance_i01N_di_msITEBz5Bf_zUa8lJUQV31j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,405,900</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,064,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz5Bf_zTflNXI3Iww2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision (benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1210">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zE62j2LkqvZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbnotrZxBuda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2024 and 2023 is as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zkPZz0PDfa4f" style="display: none">SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zIN1SWuTCKCd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zYoEk77mdqyd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR_zoD8GqfTv0Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR_zBasGeNwUdq5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax, net of valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.7</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maETR_ztCkHqhYvo49" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40D_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_maETR_zPZ9svXk5zz5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax return to provision adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.2</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maETR_zu0T4TNCIfFa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in federal valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">39.7</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-29.7</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_pid_dp_uPure_maETR_zY3qcJ2Patwj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Adjustment for stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">-62.1</p></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1231">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR_z9fAJvH2U32l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    tax rate</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AB_zWRkjNmqbrWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zgcg9trQLw4b" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
8 &#8211; <span id="xdx_82A_zZqO5mhrGS0j">LEASES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a lease for <span id="xdx_902_eus-gaap--AreaOfLand_iI_usqft_c20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_z8CRWSAIBAK3" title="Area of land">6,800</span> square feet of space located in Melville, New York (the &#8220;Melville Lease&#8221;) with respect
to its corporate and laboratory operations. The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option
of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zmpZ4l7IQSC6" title="Rent expense">132,600</span> and
$<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zOjbIvPdVbN8" title="Rent expense">149,260</span>. In June 2019, <span id="xdx_908_eus-gaap--LessorOperatingLeaseOptionToExtend_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_z4SYxbAeZm8h" title="Lease extension description">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zIdUhKaj4omk" title="Rent expense">153,748</span> and $<span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zAvMxkpiKrlg" title="Rent expense">173,060</span>.</span> The lease
expired on December 31, 2024 and the Company is currently leasing the premises on a month-to-month basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zrQlabrxcXu" title="Weighted average incremental borrowing rate">12</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zfhOXOmxfDS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents net lease cost and other supplemental lease information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_8BA_zYd7fINKNxyl" style="display: none">SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zAim7KPlS8Vd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_zJY5zkeqo6Qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease Costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCzEnl_zdxX3SOKOhwd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left; padding-bottom: 1pt">Operating lease cost (cost resulting from lease payments)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">173,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">168,028</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zNJI74DdZmgh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">173,060</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">168,028</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zaVUvxrI8Xgk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease - operating cash flows (fixed payments)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">173,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">168,028</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--OperatingLeaseLiabilityReduction_zHFwZpsBCS1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease - operating cash flows (liability reduction)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">162,317</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">139,328</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current leases - right of use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20241231_zlGR7yPRwte5" style="text-align: right" title="Non-current leases - right of use assets"><span style="-sec-ix-hidden: xdx2ixbrl1266">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_z3Cs3WdUJgzk" style="text-align: right" title="Non-current leases - right of use assets">151,447</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities - operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20241231_zait734oCTT3" style="text-align: right" title="Current liabilities - operating lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1270">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20231231_z5SMTMDgFzqf" style="text-align: right" title="Current liabilities - operating lease liabilities">162,317</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_zZt6kWMqb8m5" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseLiabilityCurrent"><span id="xdx_903_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_ztGyISFv9IYe" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl1273"><span style="-sec-ix-hidden: xdx2ixbrl1274">Non-current liabilities - operating lease liabilities</span></span></span></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20241231_zqhxJYXaknKk" style="text-align: right" title="Non-current liabilities - operating lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1276">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20231231_zSdrEeHsTO37" style="text-align: right" title="Non-current liabilities - operating lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zHFgvhk3iHe6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no future minimum payments under non-cancelable leases following the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zltmBzWqEc73" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
9 &#8211; <span id="xdx_822_zkzDTDJn5Zsa">FAIR VALUE MEASUREMENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the Warrants as liabilities in accordance with the guidance contained in ASC 815-40, Derivatives and Hedging &#8212;
Contracts in Entity&#8217;s Own Equity. For certain Warrants, the Company does not control the occurrence of events, such as a tender
offer or exchange, that may trigger cash settlement of the Warrants and not result in a change of control of the Company. As a result,
such Warrants do not meet the criteria for equity treatment and the Warrants must be recorded as a derivative liability. Additionally,
certain other Warrants contain adjustments to the settlement amount based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221;
option as defined under ASC 815-40 and, accordingly, such Warrants are not considered indexed to the Company&#8217;s own stock and are
not eligible for an exception from derivative accounting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2024, in connection with the Warrant Exercise and Issuance, the Company estimated the aggregate fair value of the Existing
Warrants (see Note 6- Stockholders&#8217; Equity for details) to be $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20240208__20240208__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_ziBScYzZ13xb" title="Fair value of adjustment">1,115,334</span> using the Black-Scholes option pricing model (Level 3
inputs). The following table shows the detail of the valuation assumptions used:</span></p>

<p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-ZMNRFLS_zGWiyj8eGB08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zy4Lx3EQdX9j" style="display: none">SCHEDULE
OF FAIR VALUE VALUATION ASSUMPTIONS</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">February 8, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_z3vjeUokVdy1" title="Risk free interest rate, minimum">4.20</span> - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zsQwgnRfo9ne" title="Risk free interest rate, maximum">4.28</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zqcGcNRJo4Xb" title="Expected term (years)">2.75</span> - <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zMr7mo2LgO82" title="Expected term (years)">2.76</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zT7MOzpWsO63" title="Expected volatility">102</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zByUcEfDP6Vl" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A7_zWTVHDTVNATa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2024, the Company estimated the aggregate issuance date fair value of the warrant liability related to the New Warrants (see
Note 4 - Stockholders&#8217; Equity for details) as $<span id="xdx_909_eus-gaap--DerivativeLiabilities_iI_c20240208_zaZ4oNIOeEXf" title="Derivative liabilities">2,189,420</span> using the Black-Scholes option pricing model (Level 3 inputs). The following
table shows the detail of the valuation assumptions used:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_C0F_gL3FVAALMORAN-ZMNRFLS_zFEXuwxSsfh3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<div id="xdx_C07_gL3FVAALMORAN-ZMNRFLS_z9jIJ08bBYOb"><table cellpadding="0" cellspacing="0" id="xdx_300_zBSJWV5SGvha" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">February 8, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zD3oN4V56Q5b" title="Risk free interest rate">4.12</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8SRKjJEIcZ3" title="Expected term (years)">5.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0OvHJjsBvog" title="Expected volatility">101</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmGV2nd8un74" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C04_gL3FVAALMORAN-ZMNRFLS_zRoWvOb3mFlc">&#160;</span></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2024 and 2023, the Company estimated the aggregate fair value of the warrants classified as derivative liabilities to purchase
an aggregate of <span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zLLHtFGQXIk2" title="Fair value of adjustment">3,900,014</span> and <span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_z5RerJc1v6T2" title="Fair value of adjustment">4,737,908</span> shares of common stock, respectively, to be $<span id="xdx_907_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zC0D4h0jC5k6" title="Fair value of derivative liabilitiy">2,520,851</span> and $<span id="xdx_90D_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zSAOIQsG5Qm9" title="Fair value of derivative liabilitiy">1,543,953</span>, respectively, using the
Black-Scholes option pricing model (Level 3 inputs) using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div id="xdx_C0F_gL3FVAALMORAN-ZMNRFLS_z6Jk0lFnAFsd"><table cellpadding="0" cellspacing="0" id="xdx_307_zKLVcIhIzVE2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zv7eKFqVeiu7" title="Risk free interest rate, Minimum">4.12%</span> - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBHAeic1Mmv" title="Risk free interest rate, Maximum">4.34</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zvyycNHmduL7" title="Risk free interest rate, Minimum">4.04</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zA8LVCxdYpp9" title="Expected term (years)">1.86</span> - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zMhtVWrrmuYj" title="Expected term (years)">4.11</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z570pw5hpvj8" title="Expected term (years)">2.86</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zCRrHeM4Aqyi" title="Expected volatility">97</span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zQRlaizdtMj2" title="Expected volatility">110</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmLHGhk0izj8" title="Expected volatility">87.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1AoHDe9wf58" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4BAeX5Y6SXd" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_C01_gL3FVAALMORAN-ZMNRFLS_zQgLe4Ufswxb">&#160;</span></b></span></p>

<p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zMC0qycoxwah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zKAQQdINnHu1" style="display: none">SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance, January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231_zzGF2dcRpRfi" style="width: 16%; text-align: right" title="Balance, January 1, 2023">5,541,733</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ChangeInFairValueOfDerivativeLiability_c20230101__20231231_zBJbF8pUGFtc" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">(3,997,780</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20240101__20241231_zaG0GkTdbKLk" style="text-align: right" title="Balance, January 1, 2024">1,543,953</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231_zKGDn9WG9Bhf" title="Issuance of warrants">2,189,420</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_iN_di_c20240101__20241231_zGBz4IkSBmC9" title="Exercise of warrants">(1,115,334</span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ChangeInFairValueOfDerivativeLiability_c20240101__20241231_zz1OQhkUhksg" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">(97,188</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20240101__20241231_zDiXGX0BNwLc" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, december 30, 2024">2,520,851</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_z3mL6NzRpPKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities measured at fair value on a recurring basis are as follows:</span></p>

<p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6tGfwS6kgK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z5r5D5GaLK3d" style="display: none"><span>SCHEDULE
OF FAIR VALUE RECURRING BASIS</span></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities (Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%">Marketable securities as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4WzJJjC4wS1" style="width: 12%; text-align: right" title="Marketable securities, fair value">10,184,701</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxeusrZDKjP6" style="width: 12%; text-align: right" title="Marketable securities, fair value">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1363">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2rpFzeBYrv1" style="width: 12%; text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_c20241231_zmKh1dwd0rfe" style="width: 12%; text-align: right" title="Marketable securities">10,184,701</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Marketable securities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zC3pfJMA2Vod" style="text-align: right" title="Marketable securities, fair value">10,181,618</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFxBE74S8NCj" style="text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUaeaX3Cxbrj" style="text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1373">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zkPmSxUWuL6e" style="text-align: right" title="Marketable securities">10,181,618</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrant liabilities as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaDiGqMl6dni" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZUD9addK6D7" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1379">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlzurmG7ynm" style="text-align: right" title="Warrant liabilities, fair value">2,520,851</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_ziSFoXIxNsge" style="text-align: right" title="Warrant liabilities">2,520,851</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrant liabilities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRXvDdOz7IR8" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1385">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWQ1XwDflpwh" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1387">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzV5BGldJR4" style="text-align: right" title="Warrant liabilities, fair value">1,543,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231_zyQUQAE5wWT5" style="text-align: right" title="Warrant liabilities">1,543,953</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zHZFVjyZEVW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zQwk95xqwdn2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE
10 - <span id="xdx_827_z8pGpu2YREya">SUBSEQUENT EVENTS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stock Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to the year ended December 31, 2024, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKg7Zk2AAER1" title="Sold shares of common stock">492,000</span> shares of its common stock under the Rodman ATM program with a weighted-average
gross price of approximately $<span id="xdx_906_eus-gaap--SharePrice_iI_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFw7mnG04Qni" title="Share price">2.20</span> per share and raised approximately $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zus5kgmQYQ7" title="Gross proceeds">1,084,000</span> of gross proceeds. The total commissions and related
legal and accounting fees were approximately $<span id="xdx_904_eus-gaap--PaymentsForLegalSettlements_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuIqcQVJa93f" title="Legal settlements paid">178,000</span> and the Company received net proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zfCSxkZoeUo1" title="Net proceeds">906,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Option
Grants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to December 31, 2024, the Company granted options to purchase an aggregate <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9OxoGbvnv17" title="Grant options shares">2,152,908</span> shares of the Company&#8217;s common stock at an
exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8mtyATWWQi7" title="Exercise price">2.46</span> per share to employees, the Company&#8217;s board of directors and a member of the Company&#8217;s scientific
advisory board. The options had an aggregate grant date fair value of $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zP0528XPAvEi" title="Grant options shares">4,044,250</span> and vest as follows: (i) options to purchase an aggregate
<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zA3ysS42tju2" title="Options to purchase shares">323,459</span> shares of common stock vest monthly over one year, and (ii) options to purchase an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoMpjuVT8AZf" title="Purchase of common shares">1,829,449</span> shares of common stock
vest <span id="xdx_90E_ecustom--CommonStockVestRemainderPercentage_iI_pid_dp_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2ckuWuDozG7" title="Purchase of common shares">50</span>% immediately with the remainder vesting quarterly over two years commencing one year from the date of grant. The Company will
recognize the grant date fair value of the options proportionate to the vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Common Stock Issuance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to the year ended December 31, 2024, the
Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_zn754CUGeFkd" title="Number of shares of common stock">63,525</span> shares of common stock to Auctus Fund, LLC in partial satisfaction of shares held by abeyance.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zntv9Aiyyqwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zdk4PxG1qrLi">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#8217;s consolidated financial statements. Such consolidated
financial statements and accompanying notes are the representations of Company&#8217;s management, who is responsible for their integrity
and objectivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zxDKCiAlpgg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_z0fNjlbqN8zj">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stem Pearls. All intercompany
accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_842_eus-gaap--UseOfEstimates_zEU1sFsNaugc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z4poG7D1ldXh">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related
notes to the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#8217;s future results to be affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkkM4rTKhXL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z3GH9BVMoxqk">Segment
Reporting</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has one operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#8217;s Chief Executive Officer, serves
as the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial
performance. The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated
expense data beyond what is included in the consolidated statements of operations is not provided to the CODM. Since the Company&#8217;s
operations consist of a single reporting segment, the segment assets are presented on the accompanying consolidated balance sheet as
total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zutuEXoDmQC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zLcOVvLUxfTa">Revenue
Recognition</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue in accordance with ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;).
The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC
606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required
within the revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable
consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company
recognizes revenue primarily from the following different types of contracts:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
    sales</b> - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Royalty
    revenue</b> - Revenue is recognized as a usage-based royalty from customers&#8217; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#8217;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    reason for the bill-and-hold arrangement is substantive</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    customer has requested the product be warehoused</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product has been identified as separately belonging to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product is currently ready for physical transfer to the customer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company does not have the ability to use the product or direct it to another customer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s revenue recognized in its consolidated statements of operations:</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcIh7pV1dQj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z7tV6GJV8wQe" style="display: none">SCHEDULE
OF REVENUE RECOGNIZED</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_z6bGTQxxirwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_zcNhTDyKdqYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zNRTnoVTmbne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Product revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ziVx2XrSPJPj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">101,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">145,800</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zvWAylJpLPRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">401,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">145,800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zucK4GFra5g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z82RXuAQ9m83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zPY8JAe2pUG9">Cash
and Cash Equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#8220;FDIC&#8221;) coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zd4LGIJOhtt9" title="FDIC insured limit">250,000</span> per banking institution. The Company had deposits in excess of FDIC coverage of $<span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zkZR8JFpwxA1" title="FDIC amount">252,801</span> and
$<span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_c20231231_zuUVXiGB8vo1" title="FDIC amount">604,226</span> as of December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company has not experienced losses on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Customer and Revenue Concentrations</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zrHslI4Q5v9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zMa1AmFIfaIk">Customer
and Revenue Concentrations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company&#8217;s royalty revenue is derived from one customer. Additionally, all of the Company&#8217;s product sales revenue is
derived from one customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z96cN1ak7Q7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zjqSBcHeCS88">Accounts
Receivable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of December 31, 2024 and 2023, no allowances
for credit losses were determined to be necessary. Management estimates the allowance for credit losses based on existing economic conditions,
the financial conditions of the customers, and the amount and age of past due accounts. Receivables are considered past due if full payment
is not received by the contractual due date. Past due accounts are generally written off against the allowance for credit losses only
after all collection attempts have been exhausted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DeferredContractCostsPolicyTextBlock', window );">Deferred Contract Costs</a></td>
<td class="text"><p id="xdx_84B_ecustom--DeferredContractCostsPolicyTextBlock_zPwiT9fl58tj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_z9v0S1hZqQUi">Deferred
Contract Costs</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs
relate directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying
performance obligations in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as
cost of revenues in the period when the related revenue is recognized. Deferred contract costs consist of consumables and labor
costs and are included within prepaid &amp; other current assets in the consolidated balance sheets. The Company had $<span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zZfVwr6cQXkb" title="Deferred contract costs">10,250</span>
and $<span id="xdx_905_eus-gaap--DeferredCosts_iI_c20231231_zdJ4p8ov21Hk" title="Deferred contract costs">0 </span>deferred contract
costs as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p id="xdx_842_ecustom--DeferredOfferingCostsPolicyTextBlock_zzmFBpKtS7Q4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_zv1g22C3EyB3">Deferred Offering Costs</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Deferred offering costs, which
primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized as non-current assets
on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the offering proceeds. If
the completion of a contemplated financing was no longer probable, the related deferred offering costs would be charged to general and
administrative expense in the consolidated financial statements. The Company had $<span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_c20241231_zRqgz5xgN36j" title="Deferred offering costs">148,697</span> and $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_c20231231_zQ0rJYVdgKF6" title="Deferred offering costs">0</span> deferred offering costs as of December
31, 2024 and 2023, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrNWYT5nz4ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zheceqDJFsi8">Property
and Equipment</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember_zz0rpqtMCv35" title="Property plant and equipment estimated useful lives::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0595">three</span></span> to <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_z9lXBJdFqlhj" title="Property plant and equipment estimated useful lives">fifteen years</span>. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfnq9MSy6d45" title="Property plant and equipment estimated useful lives">3</span> years. Medical equipment costs
are capitalized and depreciated over <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zZ4jRpsDJgA6" title="Property plant and equipment estimated useful lives">5</span> years, while furniture and fixtures are depreciated over <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zjMrGwd0Prad" title="Property plant and equipment estimated useful lives">4</span> years. Office equipment is depreciated
over a period of <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zFxufD0aVXDh" title="Property plant and equipment estimated useful lives">3</span> to <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcK9bTYPatcf" title="Property plant and equipment estimated useful lives">5</span> years, and manufacturing equipment over <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRGoTgdUsUR5" title="Property plant and equipment estimated useful lives">4</span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MaximumMember_zNoLqgQf3lLh" title="Property plant and equipment estimated useful lives">5</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zvYszRC8Li8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zEt2msSsRFC2">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records its intangible assets at cost in accordance with ASC 350, <i>Intangibles - Goodwill and Other</i>. Definite lived intangible
assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over
which the cash flows from the asset are expected to be generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhNRS1Aqq6jc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zFhYORrqYOJc">Impairment
of Long-Lived Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2024 and 2023, the Company determined that
there was <span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20240101__20241231_zkUKhwWoBDvg" title="Impairment of long-lived assets"><span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20230101__20231231_zJwaUYA1d6li" title="Impairment of long-lived assets">no</span></span> impairment charge for its long-lived assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_WarrantAndOptionValuationPolicyTextBlock', window );">Warrant and Option Valuation</a></td>
<td class="text"><p id="xdx_849_ecustom--WarrantAndOptionValuationPolicyTextBlock_zIkk7Kjs9Gzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zUd3lVu9E2Sd">Warrant
and Option Valuation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#8220;simplified&#8221;
method to develop an estimate of the expected term of &#8220;plain vanilla&#8221; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry blended with the Company&#8217;s historical
volatility. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining
term consistent with the expected term of the instrument being valued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Derivative Financial Instruments</a></td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zQ9biVqlTD72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span id="xdx_86F_z6RhMrU5RzF3">Derivative
Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option pricing model to value the
derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether
such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGbcb7LJWe47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zhJEhRPQrt7k">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of December 31, 2024 and 2023, the carrying amount of cash and cash equivalents,
investments held in marketable securities, accounts receivable, and accounts payable approximate their fair value due to the relatively
short period of time between their origination and their expected realization or payment. The warrant liabilities are measured at fair
value (see Note 9 &#8211; Fair Value Measurement for additional details).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company recognized aggregate dividend and interest income of $<span id="xdx_90C_eus-gaap--InterestAndDividendIncomeOperating_c20240101__20241231_zg5oD0W09dNe" title="Dividend and interest income">623,801</span> and $<span id="xdx_909_eus-gaap--InterestAndDividendIncomeOperating_c20230101__20231231_zU0r2WazoLE7" title="Dividend and interest income">569,068</span> respectively,
on its marketable securities, which was included within other income on its consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zV62cxfcykAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zSfIv1elO46k">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The Company has <span id="xdx_90D_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zZu0Wr23kU3b" title="Shares held in abeyance">1,201,580</span> shares held in abeyance included
in basic loss per share given that they are issuable for no additional consideration (see Note 6 &#8211; Stockholders&#8217; Equity for
additional details). The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding
convertible preferred stock is considered common stock at the beginning of the period or at the time of issuance, if later, pursuant
to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, options, warrants,
restricted stock units (&#8220;RSUs&#8221;) and convertible preferred stock have been excluded from the Company&#8217;s computation of
diluted net loss per common share for the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zTOISYbdZzv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z1GIc8cffMY8" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zvW4VkuXWp01" style="width: 18%; text-align: right" title="Total">3,263,467</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNj7qEzjGEDh" style="width: 18%; text-align: right" title="Total">1,466,892</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsnSJJFV0i21" style="text-align: right" title="Total potentially dilutive shares">3,951,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zNev5ZVPtlKh" style="text-align: right" title="Total potentially dilutive shares">4,791,019</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unvested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zeme8xsmLW02" style="text-align: right" title="Unvested"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zigFx6OtpUFa" style="text-align: right" title="Unvested">97,827</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zr441Bl9Y3b4" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_znmyQsqEKWl1" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zfF2OKgWsyX5" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">8,613,259</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zRJKPmUwTj02" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">7,753,896</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zh9UmzbEuc23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4rqRiibYMW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zXmhvArh15nb">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The
fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be
provided in exchange for the award, usually the vesting period, on a straight-line basis. The Company computes the fair value of equity-classified
warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are recorded as incurred as a reduction
of amounts previously expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zyorW7NGWskg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zwBN5Q5WlHH">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes ASC 740, &#8220;Income Taxes,&#8221; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#8220;more likely-than-not&#8221;
that a deferred tax asset will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zUyYKWUBRBq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zvsoDK4W79Yj">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines whether an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;)
assets and operating lease liabilities in our consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value
of lease payments over the lease term. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental
borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement
date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company&#8217;s lease terms
may include options to extend or terminate the lease when it is reasonably certain that it will exercise the option. Lease expense for
lease payments is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zXTkrjpty3U9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zpKTHgzD4l67">Recently
Adopted Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07,
&#8220;Improvements to Reportable Segments Disclosures (Topic 280)&#8221; (&#8220;ASU 2023-07&#8221;), which updates reportable segment
disclosure requirements, primarily through enhanced disclosures about significant segment expenses on both an annual and interim basis.
The guidance becomes effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after
December 15, 2024, with early adoption permitted. The adoption of this accounting standard on a retrospective basis did not have a material
impact on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_847_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zqqRwAf1WA26" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zNfZlr2uXiec">Recently
Issued Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221; (&#8220;ASU
2023-09&#8221;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the impact of this update on its consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; (&#8220;ASU 2024-03&#8221;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DeferredContractCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred contract costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DeferredContractCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_WarrantAndOptionValuationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant and option valuation [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_WarrantAndOptionValuationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">SCHEDULE OF REVENUE RECOGNIZED</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcIh7pV1dQj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_z7tV6GJV8wQe" style="display: none">SCHEDULE
OF REVENUE RECOGNIZED</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_z6bGTQxxirwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_zcNhTDyKdqYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zNRTnoVTmbne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Product revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">300,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ziVx2XrSPJPj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Royalty revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">101,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">145,800</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zvWAylJpLPRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">401,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">145,800</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zTOISYbdZzv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z1GIc8cffMY8" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zvW4VkuXWp01" style="width: 18%; text-align: right" title="Total">3,263,467</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNj7qEzjGEDh" style="width: 18%; text-align: right" title="Total">1,466,892</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsnSJJFV0i21" style="text-align: right" title="Total potentially dilutive shares">3,951,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zNev5ZVPtlKh" style="text-align: right" title="Total potentially dilutive shares">4,791,019</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unvested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zeme8xsmLW02" style="text-align: right" title="Unvested"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zigFx6OtpUFa" style="text-align: right" title="Unvested">97,827</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zr441Bl9Y3b4" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_znmyQsqEKWl1" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zfF2OKgWsyX5" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">8,613,259</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zRJKPmUwTj02" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">7,753,896</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z2ZdwaDNWsb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zRiW19Duyqmj" style="display: none">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zcvb0j2Mshvj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zCrUODQYb0Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zLOXDxjVNdhb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">352,133</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">352,133</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zHKi6c2fM66c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,486</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zTPXuLfpmrf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136,205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136,205</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zdSPeVh24a7d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,779</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zHLEEhyimZOi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Manufacturing equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">501,421</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">395,232</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zb0uKt79Uwyg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">342,048</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">342,048</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzKiZ_z4su14VN8qy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    plant and equipment gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,474,072</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,367,883</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzKiZ_zeJSxm1HRBa4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,111,136</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,011,828</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzKiZ_zPMObeOSxMXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">362,936</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,055</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">SCHEDULE OF INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zdsSzvPsMxw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zovX5FmRjKn8" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Balance as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zMa8DpLEhmyh" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance">3,676</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgkIpLlGFbo2" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance">1,593,530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zqY3dA0k41Sl" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance">(793,768</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20230101__20231231_z6h1cAws7Od" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance">803,438</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zDUNrjLtHqbj" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,746</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231_zRrGfdmJ09Eb" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,746</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zTRGfffLeNbf" style="text-align: right" title="Beginning Balance">3,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBVozX7VDJlj" style="text-align: right" title="Beginning Balance">1,593,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXRYXWxN8sRe" style="text-align: right" title="Beginning Balance">(883,514</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20240101__20241231_zqwLjk2xJY0j" style="text-align: right" title="Beginning Balance">713,692</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zytthitOTw2k" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,747</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231_zAM5NMN8yS06" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense">(89,747</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zQuRKUBmR8mh" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance">3,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zoYjoWDb33X3" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance">1,593,530</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_ztG665tY4AIa" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance">(973,261</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iE_pp0p0_c20240101__20241231_zjzg3CCnlNxd" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, Ending Balance">623,945</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average remaining amortization period at December 31, 2024 (in years)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zFTAQg0U6qf8" title="Finite Lived Intangible Assets, weighted average amortization period"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zWn6aGIbVlz8" title="Finite Lived Intangible Assets, weighted average amortization period">10.3</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES</a></td>
<td class="text"><p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zyr8t0Ym6OWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of intangible assets consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_zIE3bG4EPzp9" style="display: none">SCHEDULE OF FINITE LIVED
INTANGIBLE ASSETS AMORTIZATION EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Balance as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zAQRVTNxCnRa" style="width: 14%; text-align: right" title="Beginning Balance">3,676</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zTV1EfXZQxkj" style="width: 14%; text-align: right" title="Beginning Balance">790,092</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zuMtebEZOmgf" style="width: 14%; text-align: right" title="Beginning Balance">793,768</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zY8aapJwfbif" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"><span style="-sec-ix-hidden: xdx2ixbrl0750">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgEjKj6jTWI5" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,746</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2rXVJBGP7il" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,746</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zgRAH3stiYi7" style="text-align: right" title="Beginning Balance">3,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zDe9KaWcOYI7" style="text-align: right" title="Beginning Balance">879,838</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXVvp6oFTRTa" style="text-align: right" title="Beginning Balance">883,514</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zuHhehAQNkik" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"><span style="-sec-ix-hidden: xdx2ixbrl0762">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z6qgnUqvdCNe" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,747</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zygSxwRoDT8e" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense">89,747</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zpDaKpFlcUXl" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">3,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_ziQYvOYoF2Vh" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">969,585</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z21atXqH7Mrd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance">973,261</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zO5E84hy3qC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense for the next five years is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zDxhPMghSJb7" style="display: none">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom">For the Years Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zLqGmLhSvkA" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz89Q_z1vNDKxW98G5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">89,746</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz89Q_za7zLx3utHS9" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz89Q_z9FWK80aZ1L8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz89Q_zCZfaJK7po9f" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz89Q_zlr2Quf6AHf9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">89,746</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz89Q_zivgdmaXPRBi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">448,730</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z7ve0gvNg4Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z3T5qunqNukl" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zEWk23Yc0nC" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zeM88DjmnpU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zg5ydVfCG0I2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accrued bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">704,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">638,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_z5sQM90mCxFd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">40,485</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">73,686</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zJIAosR1rmQf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">744,485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">711,686</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF WARRANT ACTIVITY</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zSZin8yUZKs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the warrant activity during the year ended December 31, 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zGJJPKtZyAE5" style="display: none">SCHEDULE OF WARRANT ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Outstanding, January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znAqvvT4Qbx9" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding Beginning">4,791,019</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z87TDq6moIv1" style="width: 14%; text-align: right" title="Weighted Average Exercise Price,  Outstanding beginning balance">10.57</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdjrTKuhx9z6" style="text-align: right" title="Number of Warrants, Granted">2,513,686</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAkun9Fl9f26" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzgG1cCZ4vr1" style="text-align: right" title="Number of Warrants, Exercised">(3,351,580</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEztUrDWikmi" style="text-align: right" title="Weighted Average Exercise Price, Exercised">2.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOsoduSVUaRk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired">(1,491</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5TDR39mHj08" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">1,770</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfvfXo0Eesnl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding Ending">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsOAZv5WGZd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding ending balance">5.22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYsjitrPloab" title="Weighted Average Remaining Life In Years, Outstanding">3.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq1vHs0qwAbb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Exercisable Ending">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zegEmgi5jNK" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">5.22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwG8bbAgSYD7" title="Weighted Average Remaining Life In Years, Exercisable">3.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock', window );">SCHEDULE OF STOCK WARRANTS</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zMwHHKdVRuS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock warrants at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zJhgTLHPR6Ie" style="display: none">SCHEDULE
OF STOCK WARRANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBIP5ZD4QC56" style="width: 22%; text-align: right" title="Warrants outstanding, exercise price">2.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zl2Jku2lXkle" style="width: 22%; text-align: right" title="Warrants outstanding, number of warrants">2,513,686</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zU6Nhvq6d4e2" title="Warrants exercisable, weighted average remaining life in years">4.1</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zC60jbXs1afd" style="width: 21%; text-align: right" title="Warrants exercisable, exercisable number of warrants">2,513,686</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z17wx76SisWa" style="text-align: right" title="Warrants outstanding, exercise price">2.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUseg3QpPL84" style="text-align: right" title="Warrants outstanding, number of warrants">51,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zyTCTVYqM8Mh" title="Warrants exercisable, weighted average remaining life in years">2.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zwoRloxfJKD9" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">51,370</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuBvZFdF9pE2" style="text-align: right" title="Warrants outstanding, exercise price">10.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWunI15vUYcb" style="text-align: right" title="Warrants outstanding, number of warrants">1,150,358</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOE3aHbPJii4" title="Warrants exercisable, weighted average remaining life in years">1.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCyYxBCsyVJe" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">1,150,358</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zroKiGu0kyKh" style="text-align: right" title="Warrants outstanding, exercise price">12.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvBqal267Qf4" style="text-align: right" title="Warrants outstanding, number of warrants">235,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zsRzI4SStm05" title="Warrants exercisable, weighted average remaining life in years">1.9</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zjlWnxsI3Tue" style="text-align: right" title="Warrants exercisable, exercisable number of warrants">235,970</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcUo7cIEyFd6" style="padding-bottom: 1pt; text-align: right" title="Warrants outstanding, exercise price">60.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4H9FGqoOWtj" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, number of warrants">250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zlijR7PFbo2l" title="Warrants exercisable, weighted average remaining life in years">0.0</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zJksqF3ibGo6" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants exercisable, exercisable number of warrants">250</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zMTGD0WHNxH" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, number of warrants">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zfJ2T3TGfPA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, exercisable number of warrants">3,951,634</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION ACTIVITY</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfNfCP9eNvD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the option activity during the year ended December 31, 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zrN9b2GV9bbk" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding, January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTvM4oSXln82" style="width: 12%; text-align: right" title="Number of Options, Outstanding beginning">1,466,892</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zoDROm8SpfK" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning">4.11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z1Abs0lPnAC2" style="text-align: right" title="Number of Options, Granted">1,934,716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zf56QyHtDan2" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_zBqFaBP2hRrg" style="text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zQdf2naQfNwc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(138,141</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zPDXmZhZIG01" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">1.76</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zcyRTNE1DYVe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding ending">3,263,467</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z6AUvmyFe4hl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending">2.63</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zTVIyvLVQU9e" title="Weighted Average Remaining Life in Years Outstanding Ending">7.5</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231_z0jhmSrRb99" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z6OaUmtzPBzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable Ending">2,499,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zLxmZKqE199h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable Ending">2.95</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zv88ELOpOHR9" title="Weighted Average Remaining Life in Years Exercisable Ending">7.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231_z0nAmGqFN17c" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zRtaMfXkznRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock options at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_ztcIUlTEysz5" style="display: none">SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">In Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zeGpMtvcx146" style="width: 22%; text-align: right" title="Options Outstanding, Exercise Price">1.45</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFR9VoHQVghd" style="width: 22%; text-align: right" title="Options Outstanding, Outstanding Number of Options">1,825,067</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBesCUmhfgB8" title="Options Exercisable Weighted Average Remaining Life In Years">8.1</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zOElztZCIEXk" style="width: 21%; text-align: right" title="Options Exercisable, Exercisable Number of Options">1,138,579</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zlN1nxbD5Qm7" style="text-align: right" title="Options Outstanding, Exercise Price">2.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z5su5TfUL9I1" style="text-align: right" title="Options Outstanding, Outstanding Number of Options">626,215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmxifRgIyVvh" title="Options Exercisable Weighted Average Remaining Life In Years">6.7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrvHndT1tcGc" style="text-align: right" title="Options Exercisable, Exercisable Number of Options">548,368</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGAMtsYhR5eh" style="padding-bottom: 1pt; text-align: right" title="Options Outstanding, Exercise Price">5.08</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zoR8Y98253Y8" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Outstanding Number of Options">812,185</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1xz1zj7zjja" title="Options Exercisable Weighted Average Remaining Life In Years">5.9</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIZKhcRWSsw5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Exercisable Number of Options">812,185</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231_zbocWCIXa5Vc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Outstanding Number of Options">3,263,467</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_ziXBWM6T6LZ" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Exercisable Number of Options">2,499,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zzhvGPbrfrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zZxbFDb2dxqf" style="display: none">SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zGOcrqNV9u6b" title="Risk free interest rate">4.14</span> -<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zlS2vh9EUFd4" title="Risk free interest rate"> 4.30</span>%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoHTrUNaM9yc" title="Risk free interest rate">4.22</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z1KylLmbD0Dj" title="Expected term (years)">2.77</span> - <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zar0bL5bcuah" title="Expected term (years)">5.38</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx5RjK2kIGab" title="Expected term (years)">3.5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zWWPgchvXA8e" title="Expected volatility">101</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_znbbAp1dPtUe" title="Expected volatility">102</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEkATAdzvs76" title="Expected volatility">175.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zauNMGbqKima" style="text-align: right" title="Expected dividends">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0OQS4xjFub7" style="text-align: right" title="Expected dividends">0.00</td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zbjCRCDfsw47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the unvested RSUs as of December 31, 2024 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z7qX6TjqzmYg" style="display: none">SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%">Non-vested at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z54caD9t4qNf" style="width: 22%; text-align: right" title="Number of shares outstanding beginning">97,827</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7rNzZRrwG7c" style="text-align: right" title="Number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl1085">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE6DHLnyY2Zc" style="text-align: right" title="Number of shares forfeited">(97,827</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVJwCiRoFDV8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z984AZuQj4Zh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending"><span style="-sec-ix-hidden: xdx2ixbrl1091">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">SCHEDULE OF STOCK OPTION EXPENSE</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zKMX8JsmytWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to stock-based compensation expense:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zNmDZQdJkQIj" style="display: none">SCHEDULE OF STOCK OPTION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Unrecognized at December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Weighted Average Remaining
    Amortization Period</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8mg1PWdtnvh" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense">2,812,566</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0lPbAx67Oo4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense">7,782,967</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAfZqmoXHmha" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Unrecognized expense">774,470</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbb2sY1Dla3" title="Weighted average remaining amortization period (years)">0.95</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231_zbrAVj7QZ22e" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense">2,812,566</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231_zf5gaaCKHH4l" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense">7,782,967</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231_zZzUIJJBw2k1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense">774,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zOzUVTj3znM8" title="Weighted average remaining amortization period (years)">0.95</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based compensation warrant outstanding and exercisable by exercise price range [Table text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOmgaPOBaQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2024 and 2023 are summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zZUwWPmupGV3" style="display: none">SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_zL9QFC7L3Yig" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zhbF1s19zvl7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zEjIVolmYEU6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred Tax Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGzcBK_zW8G8vTtyQJk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">18,004,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">14,311,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGzcBK_zFIFQbADeNHb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,695,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,788,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTAGzcBK_zdxqp5f1BD88" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,694,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,676,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGzcBK_zOXQBzh1v0Wa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsRightOfUseAsset_i01I_maDTAGzcBK_zBysCmdOR9Q" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1144">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcBK_zwScf9aTi8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">600</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGzcBK_maDTALNz6jW_zRxljnsv5rrj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Deferred Tax Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">29,724,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">32,134,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zlws6xNcz8z3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred Tax Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxLiabilitiesDepreciation_i01NI_pp0p0_di_maDITLz8iB_zLKFtT22d6Pg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(153,200</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(122,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_pp0p0_di_maDITLz8iB_zMvdEk1EX2Mf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41,700</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_i01NI_pp0p0_di_maDITLz8iB_z5JN7o7R2Nk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_di_maDITLz8iB_z626f9pOcRZd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(95,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(86,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pp0p0_di_mtDITLz8iB_msDTALNz6jW_z5ov3kRZfdYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Deferred Tax Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(289,900</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(294,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNz6jW_zDuuMmzJjzh4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Deferred Tax Asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,434,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,840,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8Hs2v6wALU5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(29,434,100</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(31,840,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_z8GkK0NwV2Ph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred Tax Asset, Net of Valuation Allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1177">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1178">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Change in valuation allowance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20240101__20241231_zmS2WbGfj5n6" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">2,405,900</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20230101__20231231_zc9ckzJO7A9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance">(4,064,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF INCOME TAX PROVISION (BENEFIT)</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zltwcQOflIb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision (benefit) as of December 31, 2024 and 2023 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zewWuR64PcD5" style="display: none">SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zRwhUVQspGih" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zxkSMrPCvzR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zlI2aJg7XIZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maDFSALzNuk_zO5ShPfW6jN4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1189">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1190">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zk51qR840bie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%">Deferred</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3,567,000</td><td style="width: 1%; text-align: left"></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(3,090,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zTDgkAmF6Uzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">State &amp; Local:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maDFSALzNuk_z2FcUaberu53" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1198">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zRDQK8KB7bX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Deferred</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,161,100</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(974,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_maITEBz5Bf_mtDFSALzNuk_zPjhdL5jZTtd" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,405,900</td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,064,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--ChangeInValuationAllowance_i01N_di_msITEBz5Bf_zUa8lJUQV31j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,405,900</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,064,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz5Bf_zTflNXI3Iww2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision (benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1210">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbnotrZxBuda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2024 and 2023 is as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zkPZz0PDfa4f" style="display: none">SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zIN1SWuTCKCd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zYoEk77mdqyd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR_zoD8GqfTv0Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR_zBasGeNwUdq5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax, net of valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.7</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maETR_ztCkHqhYvo49" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40D_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_maETR_zPZ9svXk5zz5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax return to provision adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.2</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maETR_zu0T4TNCIfFa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in federal valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">39.7</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-29.7</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_pid_dp_uPure_maETR_zY3qcJ2Patwj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Adjustment for stock-based compensation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">-62.1</p></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1231">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR_z9fAJvH2U32l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    tax rate</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zfhOXOmxfDS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents net lease cost and other supplemental lease information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_8BA_zYd7fINKNxyl" style="display: none">SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zAim7KPlS8Vd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_zJY5zkeqo6Qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease Costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCzEnl_zdxX3SOKOhwd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left; padding-bottom: 1pt">Operating lease cost (cost resulting from lease payments)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">173,060</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">168,028</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zNJI74DdZmgh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">173,060</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">168,028</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zaVUvxrI8Xgk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease - operating cash flows (fixed payments)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">173,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">168,028</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--OperatingLeaseLiabilityReduction_zHFwZpsBCS1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease - operating cash flows (liability reduction)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">162,317</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">139,328</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current leases - right of use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20241231_zlGR7yPRwte5" style="text-align: right" title="Non-current leases - right of use assets"><span style="-sec-ix-hidden: xdx2ixbrl1266">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_z3Cs3WdUJgzk" style="text-align: right" title="Non-current leases - right of use assets">151,447</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities - operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20241231_zait734oCTT3" style="text-align: right" title="Current liabilities - operating lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1270">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20231231_z5SMTMDgFzqf" style="text-align: right" title="Current liabilities - operating lease liabilities">162,317</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_zZt6kWMqb8m5" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseLiabilityCurrent"><span id="xdx_903_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_ztGyISFv9IYe" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseLiabilityCurrent"><span style="-sec-ix-hidden: xdx2ixbrl1273"><span style="-sec-ix-hidden: xdx2ixbrl1274">Non-current liabilities - operating lease liabilities</span></span></span></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20241231_zqhxJYXaknKk" style="text-align: right" title="Non-current liabilities - operating lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1276">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20231231_zSdrEeHsTO37" style="text-align: right" title="Non-current liabilities - operating lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-ZMNRFLS_zGWiyj8eGB08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zy4Lx3EQdX9j" style="display: none">SCHEDULE
OF FAIR VALUE VALUATION ASSUMPTIONS</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">February 8, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_z3vjeUokVdy1" title="Risk free interest rate, minimum">4.20</span> - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zsQwgnRfo9ne" title="Risk free interest rate, maximum">4.28</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zqcGcNRJo4Xb" title="Expected term (years)">2.75</span> - <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zMr7mo2LgO82" title="Expected term (years)">2.76</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zT7MOzpWsO63" title="Expected volatility">102</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zByUcEfDP6Vl" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><table cellpadding="0" cellspacing="0" id="xdx_300_zBSJWV5SGvha" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">February 8, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zD3oN4V56Q5b" title="Risk free interest rate">4.12</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8SRKjJEIcZ3" title="Expected term (years)">5.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0OvHJjsBvog" title="Expected volatility">101</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmGV2nd8un74" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

&#160;<table cellpadding="0" cellspacing="0" id="xdx_307_zKLVcIhIzVE2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Risk free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zv7eKFqVeiu7" title="Risk free interest rate, Minimum">4.12%</span> - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBHAeic1Mmv" title="Risk free interest rate, Maximum">4.34</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zvyycNHmduL7" title="Risk free interest rate, Minimum">4.04</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zA8LVCxdYpp9" title="Expected term (years)">1.86</span> - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zMhtVWrrmuYj" title="Expected term (years)">4.11</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z570pw5hpvj8" title="Expected term (years)">2.86</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zCRrHeM4Aqyi" title="Expected volatility">97</span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zQRlaizdtMj2" title="Expected volatility">110</span></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmLHGhk0izj8" title="Expected volatility">87.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1AoHDe9wf58" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4BAeX5Y6SXd" title="Expected dividends">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zMC0qycoxwah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zKAQQdINnHu1" style="display: none">SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance, January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231_zzGF2dcRpRfi" style="width: 16%; text-align: right" title="Balance, January 1, 2023">5,541,733</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ChangeInFairValueOfDerivativeLiability_c20230101__20231231_zBJbF8pUGFtc" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">(3,997,780</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20240101__20241231_zaG0GkTdbKLk" style="text-align: right" title="Balance, January 1, 2024">1,543,953</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231_zKGDn9WG9Bhf" title="Issuance of warrants">2,189,420</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_iN_di_c20240101__20241231_zGBz4IkSBmC9" title="Exercise of warrants">(1,115,334</span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ChangeInFairValueOfDerivativeLiability_c20240101__20241231_zz1OQhkUhksg" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">(97,188</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20240101__20241231_zDiXGX0BNwLc" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, december 30, 2024">2,520,851</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUE RECURRING BASIS</a></td>
<td class="text"><p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6tGfwS6kgK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_z5r5D5GaLK3d" style="display: none"><span>SCHEDULE
OF FAIR VALUE RECURRING BASIS</span></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities (Level 1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%">Marketable securities as of December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4WzJJjC4wS1" style="width: 12%; text-align: right" title="Marketable securities, fair value">10,184,701</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxeusrZDKjP6" style="width: 12%; text-align: right" title="Marketable securities, fair value">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1363">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2rpFzeBYrv1" style="width: 12%; text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_c20241231_zmKh1dwd0rfe" style="width: 12%; text-align: right" title="Marketable securities">10,184,701</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Marketable securities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zC3pfJMA2Vod" style="text-align: right" title="Marketable securities, fair value">10,181,618</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFxBE74S8NCj" style="text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUaeaX3Cxbrj" style="text-align: right" title="Marketable securities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1373">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zkPmSxUWuL6e" style="text-align: right" title="Marketable securities">10,181,618</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrant liabilities as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaDiGqMl6dni" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZUD9addK6D7" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1379">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlzurmG7ynm" style="text-align: right" title="Warrant liabilities, fair value">2,520,851</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_ziSFoXIxNsge" style="text-align: right" title="Warrant liabilities">2,520,851</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrant liabilities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRXvDdOz7IR8" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1385">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWQ1XwDflpwh" style="text-align: right" title="Warrant liabilities, fair value"><span style="-sec-ix-hidden: xdx2ixbrl1387">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzV5BGldJR4" style="text-align: right" title="Warrant liabilities, fair value">1,543,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231_zyQUQAE5wWT5" style="text-align: right" title="Warrant liabilities">1,543,953</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 06, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Mar. 27, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,979,381<span></span>
</td>
<td class="nump">$ 10,417,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,230,346<span></span>
</td>
<td class="nump">6,430,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ProceedsFromWarrantExercisesNet', window );">Proceeds from warrant exercises, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Offering price</a></td>
<td class="nump">$ 3,614,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,348,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sold shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sold shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,829,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sold shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | ATM Program [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sold shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ProceedsFromWarrantExercisesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from warrant exercises net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ProceedsFromWarrantExercisesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=BRTX_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=BRTX_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF REVENUE RECOGNIZED (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 401,000<span></span>
</td>
<td class="nump">$ 145,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="nump">$ 145,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">8,613,259<span></span>
</td>
<td class="nump">7,753,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">3,263,467<span></span>
</td>
<td class="nump">1,466,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">3,951,634<span></span>
</td>
<td class="nump">4,791,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">97,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC insured limit</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">FDIC amount</a></td>
<td class="nump">252,801<span></span>
</td>
<td class="nump">$ 604,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred contract costs</a></td>
<td class="nump">10,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">148,697<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Dividend and interest income</a></td>
<td class="nump">$ 623,801<span></span>
</td>
<td class="nump">$ 569,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharesHeldInAbeyance', window );">Shares held in abeyance</a></td>
<td class="nump">1,201,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember', window );">Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Manufacturing Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Manufacturing Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharesHeldInAbeyance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares held in abeyance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharesHeldInAbeyance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">$ 1,474,072<span></span>
</td>
<td class="nump">$ 1,367,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,111,136)<span></span>
</td>
<td class="num">(1,011,828)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">362,936<span></span>
</td>
<td class="nump">356,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember', window );">Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">352,133<span></span>
</td>
<td class="nump">352,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">123,486<span></span>
</td>
<td class="nump">123,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ComputerSoftwareAndEquipmentMember', window );">Computer Software and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">136,205<span></span>
</td>
<td class="nump">136,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">18,779<span></span>
</td>
<td class="nump">18,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ManufacturingEquipmentMember', window );">Manufacturing Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">501,421<span></span>
</td>
<td class="nump">395,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">$ 342,048<span></span>
</td>
<td class="nump">$ 342,048<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ComputerSoftwareAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ComputerSoftwareAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=BRTX_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 99,309<span></span>
</td>
<td class="nump">$ 75,989<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning Balance</a></td>
<td class="nump">$ 713,692<span></span>
</td>
<td class="nump">$ 803,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Finite Lived Intangible Assets, Amortization expense</a></td>
<td class="num">(89,747)<span></span>
</td>
<td class="num">(89,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Finite Lived Intangible Assets, Net, Ending Balance</a></td>
<td class="nump">623,945<span></span>
</td>
<td class="nump">713,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarksMember', window );">Patents and Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Beginning Balance</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite Lived Intangible Assets, Gross, Ending balance</a></td>
<td class="nump">$ 3,676<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite Lived Intangible Assets, weighted average amortization period</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Beginning Balance</a></td>
<td class="nump">$ 1,593,530<span></span>
</td>
<td class="nump">1,593,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="num">(879,838)<span></span>
</td>
<td class="num">(790,092)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Finite Lived Intangible Assets, Amortization expense</a></td>
<td class="num">(89,747)<span></span>
</td>
<td class="num">(89,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite Lived Intangible Assets, Gross, Ending balance</a></td>
<td class="nump">1,593,530<span></span>
</td>
<td class="nump">1,593,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance</a></td>
<td class="num">$ (969,585)<span></span>
</td>
<td class="num">(879,838)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite Lived Intangible Assets, weighted average amortization period</a></td>
<td class="text">10 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember', window );">Accumulated Amortization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="num">$ (883,514)<span></span>
</td>
<td class="num">(793,768)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Finite Lived Intangible Assets, Amortization expense</a></td>
<td class="num">(89,747)<span></span>
</td>
<td class="num">(89,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance</a></td>
<td class="num">$ (973,261)<span></span>
</td>
<td class="num">$ (883,514)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 89,747<span></span>
</td>
<td class="nump">$ 89,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarkMember', window );">Patents and Trademark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Ending Balance</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="nump">879,838<span></span>
</td>
<td class="nump">790,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">89,747<span></span>
</td>
<td class="nump">89,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Ending Balance</a></td>
<td class="nump">969,585<span></span>
</td>
<td class="nump">879,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember', window );">Accumulated Amortization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="nump">883,514<span></span>
</td>
<td class="nump">793,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">89,747<span></span>
</td>
<td class="nump">89,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Ending Balance</a></td>
<td class="nump">$ 973,261<span></span>
</td>
<td class="nump">$ 883,514<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 89,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">89,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">89,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">89,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">89,746<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 448,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Accrued bonuses</a></td>
<td class="nump">$ 704,000<span></span>
</td>
<td class="nump">$ 638,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_AccruedGeneralAndAdministrativeExpenses', window );">Accrued general and administrative expenses</a></td>
<td class="nump">40,485<span></span>
</td>
<td class="nump">73,686<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 744,485<span></span>
</td>
<td class="nump">$ 711,686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_AccruedGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_AccruedGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANT ACTIVITY (Details) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Outstanding Beginning | shares</a></td>
<td class="nump">4,791,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding beginning balance | $ / shares</a></td>
<td class="nump">$ 10.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted | shares</a></td>
<td class="nump">2,513,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 2.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised | shares</a></td>
<td class="num">(3,351,580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">$ 2.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Warrants, Expired | shares</a></td>
<td class="num">(1,491)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired | $ / shares</a></td>
<td class="nump">$ 1,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Outstanding Ending | shares</a></td>
<td class="nump">3,951,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding ending balance | $ / shares</a></td>
<td class="nump">$ 5.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life In Years, Outstanding</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Warrants, Exercisable Ending | shares</a></td>
<td class="nump">3,951,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 5.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life In Years, Exercisable</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non option equity instrument exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ShareBased compensation arrangements by share based payment award non options exercised in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options granted in period weighted average exercise price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercisable weighted average remaining contractual term1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options outstanding weighted average remaining contractual term2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF STOCK WARRANTS (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">3,951,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">3,951,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 2.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">2,513,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">2,513,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 2.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">51,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">51,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceThreeMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">1,150,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">1,150,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFourMember', window );">Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">235,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">235,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFiveMember', window );">Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants outstanding, exercise price | $ / shares</a></td>
<td class="nump">$ 60.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, number of warrants</a></td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable, weighted average remaining life in years</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable, exercisable number of warrants</a></td>
<td class="nump">250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ACTIVITY (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding beginning</a></td>
<td class="nump">1,466,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning | $ / shares</a></td>
<td class="nump">$ 4.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">1,934,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 1.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(138,141)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="nump">$ 1.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding ending</a></td>
<td class="nump">3,263,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending | $ / shares</a></td>
<td class="nump">$ 2.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life in Years Outstanding Ending</a></td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, Outstanding Ending | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable Ending</a></td>
<td class="nump">2,499,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable Ending | $ / shares</a></td>
<td class="nump">$ 2.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life in Years Exercisable Ending</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic Value, Outstanding Ending | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">3,263,467<span></span>
</td>
<td class="nump">1,466,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">2,499,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeOneMember', window );">Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Exercise Price</a></td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">1,825,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">1,138,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeTwoMember', window );">Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Exercise Price</a></td>
<td class="nump">$ 2.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">626,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable Weighted Average Remaining Life In Years</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">548,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeThreeMember', window );">Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Exercise Price</a></td>
<td class="nump">$ 5.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">812,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable Weighted Average Remaining Life In Years</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">812,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=BRTX_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details) - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.22%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">2 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares outstanding beginning</a></td>
<td class="nump">97,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares forfeited</a></td>
<td class="num">(97,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares outstanding ending</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,812,566<span></span>
</td>
<td class="nump">$ 7,782,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense</a></td>
<td class="nump">$ 774,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining amortization period (years)</a></td>
<td class="text">11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense</a></td>
<td class="nump">$ 774,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,812,566<span></span>
</td>
<td class="nump">$ 7,782,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining amortization period (years)</a></td>
<td class="text">11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 06, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Jul. 13, 2023</div></th>
<th class="th"><div>Apr. 04, 2023</div></th>
<th class="th"><div>Oct. 25, 2022</div></th>
<th class="th"><div>Sep. 08, 2022</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 23, 2024</div></th>
<th class="th"><div>Jul. 22, 2024</div></th>
<th class="th"><div>Dec. 10, 2021</div></th>
<th class="th"><div>Nov. 08, 2021</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Cash fee for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,853,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,853,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">494,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">685,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value new issues</a></td>
<td class="nump">$ 3,614,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,348,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,951,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,115,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">595,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,189,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GainOnExchangeOfWarrants', window );">Gain on exchange of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,711,698<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Cash issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 595,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Roth Capital Partners LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Cash fee for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 528,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,513,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrants for cash and the payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Auctus Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,201,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Demand Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Roth Capital Partners LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 595,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember', window );">Existing Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,809,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember', window );">Existing Warrant [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,742,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,115,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,123,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=BRTX_NewWarrantsMember', window );">New Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=BRTX_NewWarrantsMember', window );">New Warrants [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">595,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Stock issued during period value warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,189,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GainOnExchangeOfWarrants', window );">Gain on exchange of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,711,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=BRTX_TwoThousandTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares of common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=BRTX_TwoThousandTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=BRTX_TwoThousandTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember', window );">Two Thousand And Twenty One Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Common stock authorized to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,850,000<span></span>
</td>
<td class="nump">3,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=BRTX_ATMProgramMember', window );">ATM Program [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 906,000<span></span>
</td>
<td class="nump">$ 494,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock voting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Preferred stock conversion term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Beneficial Ownership [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock voting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,518,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Auctus Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member] | Auctus Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Auctus Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_GainOnExchangeOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on exchange of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_GainOnExchangeOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=BRTX_RothCapitalPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=BRTX_RothCapitalPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BRTX_AuctusFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=BRTX_AuctusFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=BRTX_DemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=BRTX_DemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=BRTX_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=BRTX_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=BRTX_TwoThousandTwentyOneStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=BRTX_TwoThousandTwentyOneStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=BRTX_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=BRTX_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=BRTX_BeneficialOwnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=BRTX_BeneficialOwnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=BRTX_AuctusFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=BRTX_AuctusFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 18,004,100<span></span>
</td>
<td class="nump">$ 14,311,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">8,695,100<span></span>
</td>
<td class="nump">15,788,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development costs</a></td>
<td class="nump">2,694,200<span></span>
</td>
<td class="nump">1,676,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">330,000<span></span>
</td>
<td class="nump">330,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DeferredTaxAssetsRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total Deferred Tax Assets</a></td>
<td class="nump">29,724,000<span></span>
</td>
<td class="nump">32,134,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DeferredTaxLiabilitiesDepreciation', window );">Depreciation</a></td>
<td class="num">(153,200)<span></span>
</td>
<td class="num">(122,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(41,700)<span></span>
</td>
<td class="num">(47,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(39,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(95,000)<span></span>
</td>
<td class="num">(86,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total Deferred Tax Liabilities</a></td>
<td class="num">(289,900)<span></span>
</td>
<td class="num">(294,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net Deferred Tax Asset</a></td>
<td class="nump">29,434,100<span></span>
</td>
<td class="nump">31,840,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(29,434,100)<span></span>
</td>
<td class="num">(31,840,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Tax Asset, Net of Valuation Allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">$ 2,405,900<span></span>
</td>
<td class="num">$ (4,064,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DeferredTaxAssetsRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DeferredTaxAssetsRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DeferredTaxLiabilitiesDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DeferredTaxLiabilitiesDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Federal:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">3,567,000<span></span>
</td>
<td class="num">(3,090,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State &amp; Local:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(1,161,100)<span></span>
</td>
<td class="num">(974,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">2,405,900<span></span>
</td>
<td class="num">(4,064,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ChangeInValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(2,405,900)<span></span>
</td>
<td class="nump">4,064,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ChangeInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ChangeInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of valuation allowance</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent differences</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment', window );">Tax return to provision adjustment</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in federal valuation allowance</a></td>
<td class="nump">39.70%<span></span>
</td>
<td class="num">(29.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation', window );">Adjustment for stock-based compensation</a></td>
<td class="num">(62.10%)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment for stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation tax return to provision adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Prior year income taxes, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carry-forwards not subject to expiration</a></td>
<td class="nump">$ 60,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Net operating loss description</a></td>
<td class="text">The state net operating losses have a 20 year carryforward period and will begin to expire beginning 2035.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember', window );">Expire from 2030 to 2038 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carry-forwards subject to expiration</a></td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=BRTX_SectionThreeHundredAndEightyTwoMember', window );">Section 382 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax examination, description</a></td>
<td class="text">In
accordance with Section 382 of the Internal Revenue Code, the usage of the Company&#8217;s net operating loss carryforwards are subject
to annual limitations due to several greater than 50% ownership changes.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 68,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=BRTX_SectionThreeHundredAndEightyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=BRTX_SectionThreeHundredAndEightyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost (cost resulting from lease payments)</a></td>
<td class="nump">$ 173,060<span></span>
</td>
<td class="nump">$ 168,028<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease costs</a></td>
<td class="nump">173,060<span></span>
</td>
<td class="nump">168,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease - operating cash flows (fixed payments)</a></td>
<td class="nump">173,060<span></span>
</td>
<td class="nump">168,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_OperatingLeaseLiabilityReduction', window );">Operating lease - operating cash flows (liability reduction)</a></td>
<td class="nump">162,317<span></span>
</td>
<td class="nump">139,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Non-current leases - right of use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">151,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current liabilities - operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 162,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Current liabilities - operating lease liabilities<span></span>
</td>
<td class="text">Current liabilities - operating lease liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current liabilities - operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_OperatingLeaseLiabilityReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability reduction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_OperatingLeaseLiabilityReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember', window );">Melville Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseOptionToExtend', window );">Lease extension description</a></td>
<td class="text">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $153,748 and $173,060.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember', window );">Melville Lease [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="nump">$ 153,748<span></span>
</td>
<td class="nump">$ 132,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember', window );">Melville Lease [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="nump">$ 173,060<span></span>
</td>
<td class="nump">$ 149,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessor's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 08, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.12%<span></span>
</td>
<td class="nump">4.04%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Existing Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, Minimum</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, Maximum</a></td>
<td class="nump">4.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Existing Warrant [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Existing Warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">2 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Existing Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | Existing Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Balance, January 1, 2024</a></td>
<td class="nump">$ 1,543,953<span></span>
</td>
<td class="nump">$ 5,541,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ChangeInFairValueOfDerivativeLiability', window );">Change in fair value of derivative liability</a></td>
<td class="num">(97,188)<span></span>
</td>
<td class="num">(3,997,780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Issuance of warrants</a></td>
<td class="nump">2,189,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="num">(1,115,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Balance, december 30, 2024</a></td>
<td class="nump">$ 2,520,851<span></span>
</td>
<td class="nump">$ 1,543,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ChangeInFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ChangeInFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE RECURRING BASIS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 10,184,701<span></span>
</td>
<td class="nump">$ 10,181,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liabilities</a></td>
<td class="nump">2,520,851<span></span>
</td>
<td class="nump">1,543,953<span></span>
</td>
<td class="nump">$ 5,541,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities, fair value</a></td>
<td class="nump">10,184,701<span></span>
</td>
<td class="nump">10,181,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warrant liabilities, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warrant liabilities, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Warrant liabilities, fair value</a></td>
<td class="nump">$ 2,520,851<span></span>
</td>
<td class="nump">$ 1,543,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 08, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 2,189,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=BRTX_BlackScholesOptionMember', window );">Black Scholes Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,014<span></span>
</td>
<td class="nump">$ 4,737,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Fair value of derivative liabilitiy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,520,851<span></span>
</td>
<td class="nump">$ 1,543,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember', window );">Existing Warrant [Member] | Black Scholes Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of adjustment</a></td>
<td class="nump">$ 1,115,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=BRTX_BlackScholesOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=BRTX_BlackScholesOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=BRTX_ExistingWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 06, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Mar. 27, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="nump">$ 3,614,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,348,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 494,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,934,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Auctus Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,829,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Grant options shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,152,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Grant options shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,044,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_CommonStockVestRemainderPercentage', window );">Purchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | ATM Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 906,000<span></span>
</td>
<td class="nump">$ 494,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | ATM Program [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sale of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance and sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Legal settlements paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_CommonStockVestRemainderPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock vest remainder percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_CommonStockVestRemainderPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=BRTX_AuctusFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=BRTX_AuctusFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=BRTX_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=BRTX_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>85
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,>H>UI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( ,>H>UJ#*!:T\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( ,>H>UH?E3YSE0D  .PY   8
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M]?V",;F]T6?C[6\AL_\ 4$L#!!0    ( ,>H>UJUS'XX]@(  *\*   8
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ME,"U@7J_8DP^=G3-4M>HT5]02P,$%     @ QZA[6@QL0"/N!   81,  !@
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M=S.;'!9A (,@F/F'4PYC,QA&R8G9&;JH0Q<YT2VY5*:(18O2!K")$)^TC)*
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M00QC]D\.FU59PBI::@M-/,C+90GQ2E<ON^9ZF6W#[TGCBY^)ITOR'5XL*K+
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MKU']/L1_$L:U@PO=0X7SP-:[1K7%H'S[)LZC+R=N*9M$9B=%7K:MPM:^-](
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MMBWT!_'T+[YS*##Z4E&H^B]Z:F2C<(+2K=*BW T&"\J\:OZS+[M [ W =&0
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MO;&D=?B-W0!^*_F&Y=E+K3>9$GK-)5!0*0$Z=RFT6N\/C*(T2/J-U2(61'&
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M_;1K_9AVN'8<73O^4M<N##B="^!*H3S *TZ\!I<[WC?N++=^:TQ:B;&H,J;
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M(*RID/ .5KG@??S\M]/]O9-?W/<WLZON^G(^&)=MW30LH@9\:MH.:(7=T\+
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MWKX1SYN#9\\^F8W6#\NX?BG&$# ]S(B5;UB@:3VYA30UAZ1C>E2^J378UFR
MO#=(39V=3^"[IPM8:(7 &77BW+ W(;"9RYVZ[*TXF1#!Q\I,\G!9K+A6@\UJ
M@MH'\MQR+ESR?*8)"8>MAOY'RC1/A%Y/[S;[CW<KS>_#'4/4U'YC.,NEJ<05
M5GW(]5#\":):KS(P[+9;Q^/>NO$<8'=FV!CN?0\_#=@(@!: 6U%^ZPLR[(.$
M_0/M0<$*-A!$<QJ-^@L'MNX3Z(@Z(]B]!Q";@DCV"Q\3BTK8(U0$$2N!=7$O
M 87UEC#=OQD#IC4 WP<)82HV*R+'J956@"FXS78A%=)CF <KHT?'9_GX^%1]
MTEWV 3LT@;,X]P*8<S?'K>,WM?_&T:,TVPFJ2:O1?0;-U25?S/+H0GETT?2T
M)43K.)$T0-%B!&72@ G./^0RD#&[&=X22 ?X "S1F\WZFR^8#]99SPX[M9?O
MC_?RH]/QC[0N1&'WOH9"/REX!*Q?F;J7X%$8!]:ZQ-0?=5CKV#+.3>J$J@.T
M(:>41?J%8QA88(<*38[6.U&3];@EG$=(4NJU[BK]3=L2N\89C,,QN=@25PHH
MR:@T3 Z![*<<IH<2-#9<IV F$ZW#EHP_KZ[?__[EZE*=_W%U>_[^2EU>?[C_
M<OW'E;JX^?CQYI.Z^_W\]NKN7^G.N&.9$3$XR/>/#_+#XQ,XS,/CX_ST;#_[
MTXO%07YVM)<?'QRJP_SD;"\?[YUE]V32X(!N[^XQ3WEVDI_NGV!=$W;84?+P
ML_7E"UYK+S\X.\WWCD[CI^PT/]Z#M8_.U$E^<@1J=7;,HT=OT<F14]&-VTR\
MB%'QR0RN/(5^U( $UUM&$0UB3Q9A4X*O ^0;/.MF*H=.#U^5!IWM7PXPG\Q#
M>8*("BG6&3;;A8R>F&;17G\/03;%I11N*>4<218ZJS=;8X6@')!G+^4/K?#,
M(@[/.?LPK+90'_E:28'ME=O"%>;AR(<?V.OZ?Y?RDLP;[&>J#<>XPW)24D6D
MACWXT#-DQ\J;W-]98G:E[5V]\L63"I/X:,ZS+\4W'8N<65=\2U/>ZXXL.3'/
M8[F?@B^BX:00C<YJK>CBFU?QN\3A/E&+RV+'_AK0(*L?&C6>HC7X;;S@IAFH
M(HET!2FI4L?]IG$A/D7+1]E/Z7L@,G#7U-"8;V7/6JRCFX+3*3"=I>1'FN #
M],)-!O U,4D<K(3N[,WA#ZXS<VL#EE%;B[<84W8^UP+ ;>$(?J5*YIU%$VNK
MSQPZUV]9JTR3Q9T,U1=S8@/J18WY\A77\B4IBCP)0>(0-X>T)E:"3@['X7X
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M.?]27AS.OS?XL; SO*)8ZRF\.MX].=KA$,[_ ?I/OYL'4*9K%_1QK@&56QP
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MH-\"4;[FRX'BN7E!K[C"][@1M_@#B J] =?7G*MZH!4T/ZE&_P%02P,$%
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M.7)VE.1?T&:I<H+7>SW8YNT6/C&46Y ?I;EAQ5P#_[P;.VUA5!_?-(3#6]>
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M8H\I37.41H'>5T+HK6 <M/^'Z5]02P,$%     @ QZA[6@>H/)(!'@  BEX
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MU0_JV>M??AH?CWX=P/;08WLX!/WUF]1H(ZN9_(2PRR9%%N]#<A!,/Y($6VS
MEI\72J1 H^4J+==(I:PJ#1 J3QN5RYDNTS+3:2$-?*] ;!LC%^F#DE.E2@G
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MY@K@U(RH Y)KDQ65X3WD:0H2<Q9@P!@?]NN&SQ&_H8]@B./\XE@I1"L"VBY
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M2B?8A?0AU47JK()Z2(N6WTW7++D+K6:B<@@!#KR+>RA\M7R.])^,?KVXN?Q
M/\>_ODB0^>+O<-R\KMI5@H*!;\B*+H#\:&2+HLH012!(U=:997:T\R"18('A
M4YB>L 8&WQ>QJ"Q2% 70;1Y!'%M[2EKZR>=O='6K4%Y2].%1W.IT12)^76;[
M+RRY<F#LHEJA-.![U38Z \ZM\C:S[+Y4.4J<:!P V1*&&40%+ \:A$KAH*9"
MUSJ!G\#&M2[6L*:'JG@@+'/@4E  8#=P9%<!>)Z^0.++JV\J:PGKFQGX,JI.
M)'$.2+1A40#BVW4_8,P1J9AXMX.S@[%,5R=/R1MT.M52$^2^\!MI52 S2*3%
M1+PWO I$QZ$"=)B!5L&QH!I-!Z$=:"3(X %9JTN]LD2&]P@"X2ZU2>?S6LU)
MU5H=+0%>"AI@7<'$CZ3:O*WW(#M31[:H,P$.1)4&"WG0.?N%CNC@TFGT0GOT
MD8@@X#SH1Z*D2N260FVS:,*KM/S*QHBDOK-MSDWI]Z&G:4%>,4?CJ1%-U< 6
M,K!!'7CJ=>#IH Z\97L(.C"KP+7>Y<H- NG7@A:RB""3-^$DO>;G_RCCC')?
M*'!^=R$_5RN0VN/1<2*M=G)8DW$!+Y$B,L,C+BA"!N?>JB^OTA 4 '%:C?4.
MS(8[8KU.W%'[6?!1V-<@C8RNC,?;HPT,E"M D5T1<@C1\@$LX+&E1O]A7E6Y
M036*Q-$96^/,82IPX:5U.WB^6LT*,L".KX%5K0L&(UFY\2NF)OL&SDP2J@4+
MAOJ6+=)R[J($<&>VL=G'50M<-9LD8%10" ]J#Q3:"E<!WQ#L%,W' PJ(-INT
M Y7 ]J B*:@2]#[@LQ6H"0I3EOB]\^E8^WB/ 'T!\DZ(Z+G K?1.%Y.YCAC)
MHI18%8 3 H%@U;/UAGF!(*C0<R?Z7D\0QR0. 1<#VAV G4._"JVHV**]"S L
MK,C_1UIDBCT[MH$.[O9' $BEL3WO1[EC1D2/R 1;Y!PMV&>8_)%L.[E@Y%RO
M5QRTN:6;5^*7G\Z.3\Y^A9B>S*$P*89=[NEMM4Z+!N?DB7:(+GC6Q1ZL> ]"
MJ=QC1;B@OXLP>5JS5&A['\#"@*""'ER VXJ^#W""M_Y,-" 2\BJH5N!IB/;A
M*_2&JYRB#[U4HD=1Y, V-@J#'PJ8-P\DV8KMK>3MRRM &*6BG;,\,7ZHIA>J
MV(%=@JC!P@2%X984]"U"6 '[4XH!,05)59;G[)2PN4VJV8@T=56XB,HZ)?NL
MSN YFF^K2NI@I3P8)$&7^B*M:Q1TDBZ<]Y5\KE^$$4 QM6K8GC!ALW0S;(5-
M2F 4#"O _A:2U @Y91$N] 5\TL$'OTF=;1.!@Q'Q%0BWS5&X=9*4/-</# 7<
MW*_&>CS &SF;; C+:[/0*\9O@!B@OO)<LW]30/@._^)[$22ARZ99K<&YUJD%
M3"H35HXT!9["H 60=?O#KP=F#Y*$<W)\Y9?;G3C>(=A?3#G AJ KV('1(2JJ
M1%!3*N^0#U *0M09[+[ L;2G5C%J#C2<PBG6E"(KYZ2CNBOJA8<*OZU1FQ2H
M =*<]W2U6!L*6;W=&P+F1"FO%'MAO .H>BE&7^-H%Q&ZF3'Z(.E&@X)&J.1H
M-VS_Y\YF-Q3^<-:0E%2?"MBP*O^PL=2-^3XO\I6\N_CCZO+^_96X>2MOK[Y<
M?;R_@O\O;MY]O/ZOJTN!.6A,1!^(MY85_J72VB:[Q26HJ.44UG P3J)/K2KV
MR/TL#T:C9#0:P:\]856R?SL>C>G=^/ H.1V-Q*W+;?PL#^VKG]W+(5_QS/N*
M9X.^XD5J%B2D].,*+#4$#TB:/H]Q$%2_QXA@11]\^=8')Z YF[KE#2%':54U
MR-XH^"A/?[F,D.,T]+,JT'EH]GQ^%2)GT!>D=KK.?$9+Y/P>J]@X] )GH6G)
M+'=B5JQTL4X'-[ RFK-?^)_/%!*JK'L<$>F'BA;)OAHZ6M8DO%7H=Q3RDJ%6
M]1IB6]/6I,(OJGI5\9*$\W#?7EY?./<6UO4 H^=D?G^6DR/FH\G1!-AA#![N
M83*9' ^QQ7@4"D:C8<;P)@;6Y7SSBP[5>^M#@U!W\(C3*KNGPH2MZ&9\@]1O
MB!#5!^K@+&#J8<BJ[ #K-!6Y4!%P,0!\B/)1J6X\2/ESQV"WY/.@XNNE]""4
M?DH[T"* EOY9'9ZAKY2!8=/>!=*U=S,Q+6BSJ0FX%,90(&6]?C:S+(J82Z X
MA+@_5H]4S2/.0A69@-4@[_H1I<"(+1#R4=6=9"7;[U*A9*7U>E]^"#GG$'^0
M"7)@MQ&C%"X%[.H;* NT,F W2HCN,EPKLXE)1#<?'-[XO+D+^1*7:W4Q!T4-
M+*VK%-11WH;ZQ7ZTO>R<NJ@$76/WM9[)60L\"MX6I1]MGL-[PRX!&&T-#D,[
MMR\_;<Y)T\Q5B1H(5.LCN$R@: $]4)-S5';-DS2KRF(MTEF#BJ% :A2^\ ZP
MEJM./5!]6Z2M>2JU.YX$R9@,2L:ELMZ:2P_ #]-OJH8A]4N' R^ZX#MA4H[?
MH#^!+U)C*F"*QJ7/8:MFX!M2Y-J8$)?A-G*4SN.6E/D)JB>X.<Z+93>?M]:0
M;!:<($:7J2 +F$8A[W,=?VVW&+[';'&YH*T,B=N-PAF9L4= &T6JM841 VK7
M4-PMGHB[.:6?6-^_BP>R6RAPV%(%V3!D";^;;AW1J#@$,P*?(]J^T&/GMA&D
MC\=L*2>V! '0[@DC;P%_MDLKDY@.3:=5+2Q>*,VU"AE*F\^@4IK.Y2_I<O6K
M=&XL>=4N1=B7R^SD 3>*2XLT1S=OE(")EX-^WC@T/HP'.Q6"\-Q@ @&9;;?P
M_$#/PP[P@>B5>T[43#C?)4*N(]H%9G-*!-6DU$&M88X:"PV4[YXI8@*BLBO&
MEE8/<;7/:>QRGEAKMM( QG(4*-%RK[M'PB9N.]NR+^]756FY8NFKI1WH."CO
M7Z1\I*K9%"W S*#,1UK6?TIY+Y4#"US/A,O_%2I,ANP*JK6("[,P[I'6(3'>
M XX#*%/DVZ0C"4\BEBW2>L[2:0T#UV5S,+3:-+82XQ+V?7S\=*G4<O/A:7)\
M=O($.X?.F/%P:PR$52#^#1?^,:Y8X<R]W/P#S3$.NNA EYW'RC]V&JO.V5]"
M&J.ZH7*JK^+AMK9(,2Y&(7&QEVP/$<)4Q0*380^* TOGQ>#7"NR*+/1#T-VN
M9NW*X<&F-XM:H;L"%AJ4XIK"TP-Y) _MOT?RO0*WAW)+>HGU$A5JE^"VU V)
MB,<#_3O.>SN#Y/&9*8<.H4$516^(0&Z!U7&=!<XGT75#-PV;+DH2,%L#3'5M
M!$EHX$3';FD0\BY'!6EF4XS.1ZVG+6<);+)BJAJ<U5:C5C&_A*TCVV&PYR=\
M+M2W!HOQ@\M%O]86!S G2-:IT;6M?M76#N3:4)QG9;D?B<2;3-=6U"Y;WN \
MYB%GI&&2JI,*[3:O+%R!G4JZ*27 R'U+T \!\B41)*I(L Z-ZW5#(AHZB\;#
MK477H+C+.94)SHEDO=+Y QU% ;!@P%N9;$PW<LSN47#5.A;/776I XBI98!O
MY)Y\5U4Y$0RI>T/;.D2>T.TS'F[WN5XB\SO^? ]J?.\].?4#Q/J!]I\PC>B;
M9H-T7!!&F[)7T%=.Q82B#)63P$VU'_20&"6;5%LUVVN-?\X!LV\"(,4 D#'(
MT %)E$B%ZL?VKV (0L4N[C_2-4B'H90W/L!"?Z/8B24I@JB5RD6A[$/2;5'
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M!_!^5@$%[!\X@;]^_O7_ E!+ P04    " #'J'M: VC@*_T#  "%"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R55FUOXC@0_IY?,<JN5G=2MB3A
MO0M(%-(6J;R(EU9[I_M@PD"B)G'6=DI[O_[&#K!=B:*]+\3VS#SSS(P]0V?/
MQ;.,$!6\IDDFNW:D5'Y=J<@PPI3)*YYC1I(M%RE3M!6[BLP%LHTQ2I.*[[J-
M2LKBS.YUS-E,]#J\4$F<X4R +-*4B;<;3/B^:WOV\6 >[R*E#RJ]3LYVN$"U
MRF>"=I43RB9.,9,QST#@MFOWO>N;NM8W"H\Q[N6[->A(UIP_Z\UHT[5=30@3
M#)5&8/1YP0$FB08B&C\.F/;)I39\OSZBWYK8*98UDSC@R5.\45'7;MFPP2TK
M$C7G^WL\Q&,(ACR1YA?VI6[=MR$LI.+IP9@8I'%6?MGK(0_O#%KN!P;^P< W
MO$M'AN60*=;K"+X'H;4)32],J,::R,69+LI""9+&9*=ZB]5XW)]_A^DM+$9W
MD]'M:-"?+*$_&$Q7D^5H<@>SZ<-H, H6\,>2K1.4?W8JBAQK\TIX<')3.O$_
M<.+Y,.:9BB0$V08WOP)4B/&)MG^D?>-?1!QB> 55SP'?]6L7\*JG-%0-7O4#
MO'X8\B)3<;:#&4_B,$8)?_?74@FZ-O^<B[C$JYW'TT_I6N8LQ*Y-;T6B>$&[
M]^63UW"_76!;.[&M74+O+0;WP7#U$.BJS8/'8+(*Z#N84OW^"H;GV%[$.\\6
MCEZLLUXLG7F=_JI%SP-4A/ =F3B4V*("8;I&H8OT3G4F^*8(%3WG%\P*A,]0
M=5W'=5U:?;7F_(TEZNTD]5S/R+Q:W6FYKC4OSR4IUPZBST<A7,AK_937^F_G
M]2D8W=TO@R'T'X-Y_RZ X>AAM1P]!C"8CL?3"2SN^_-@<2[9%YV<3_8R0FO+
M$VJ1^@HJ_= .?3+^E^+5V948%B)6L=DR!7L4"/@:)@7E&[:"IT9M$R>%HH.<
M<B\C1CHA2\(B8:8)KC%DA42CB=LMM4;@6X@SC6(\1\3(RKE">@PL*1$D[)D$
M1B<&G+HH;*@ZBAN8 4]SEKU]^=3RO>8W"1E-DH1+"3F7L7&JJT:JO-A%I>-7
M%&%,+.C>A#Q[06%:?"[BD-CR(MD03XM:C8DT,S:,M&A(4.L3S^2@U"7J6A;R
M-"7[DNOU+_?V-ZOX?Z[P0O'P&7BN0Y-0=?Q&U:DUFN#1;\-IM7WKB0E!V=+"
M=MUS&M4:U)QFFRZLU[96%*_4!9HO5A*^0KOIM/RF-3!Y4+$N_(P&$PI!.J4O
MSZFV6XY7;_U<62VGX9'O>AN:3K->);^-LR^@\FXTI"AV9@!*,-VNG!*GT].,
M[9>CY:=Z.:#'3.QB"CG!+9FZ5TVZYZ(<>N5&\=P,FC57-+;,,J+_"2BT LFW
MG.[58:,=G/YY]/X#4$L#!!0    ( ,>H>UH'1? $- ,  -H&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;(55;6_;. S^[E\A^(;#"ABU+3N)FR4!
MTC;%!C1KUI<[#,-]4&PZ$69+GB0WW;\_RH[=%$BS#XE(B7SX4*3HR4ZJGWH+
M8,A+60@]=;?&5&/?U^D62J;/904"3W*I2F9051M?5PI8UCB5A4^#8.B7C MW
M-FGV5FHVD;4IN("5(KHN2Z9^7T(A=U,W=+N->[[9&KOASR85V\ #F*=JI5#S
M>Y2,ER TEX(HR*?N/!Q?QM:^,?B'PTX?R,1FLI;RIU6^9%,WL(2@@-18!(;+
M,UQ!45@@I/%KC^GV(:WCH=RAWS2Y8RYKIN%*%O_RS&RG;N*2#')6%^9>[C[#
M/I^!Q4MEH9M_LFMM8XR8UMK(<N^,>LE%N[*7_3T<."3!.PYT[T ;WFV@AN4U
M,VPV47)'E+5&-"LTJ3;>2(X+6Y0'H_"4HY^9K>[O5HO[Q^]D_O6:++X]?5DM
M%U\?R<='MBY GTU\@T&LJ9_N 2];0/H.8$C)4@JSU60A,LC> OC(KJ=(.XJ7
M]"3B-:3G) H]0@,:G\"+^I2C!B]Z+V6%+:W,;X^L"B8,82(CBU\UK[#7#/DQ
M7VNCL%G^.Y9[BQP?1[8/:*PKEL+4Q1>B03V#._O[KW 8?#K!.^YYQZ?09P]7
MGQ?73[<+<G=#^K*M;N=8KC?%.\;[)/)QWMTU.?9^H+^?5.*#U$83F1.S!9++
M A\V%YLQZ0@Z?R#HV$+::D8.UA;*-2A;WX/M)60\9<5!V \D&E OC*)7R;FI
ME>"F5M"4,.<O5M8DI)$7)\-N=:YD6=4&8VB9FQW;F[]"A]'0H\&@6YV[/.<I
M'!HDWFATL5^<)1-UCOU1*TSZP&H0A%Y,0Q)=##P:4><6<%AL99$17E9*/H.U
MTB2*J1?$2;<Z_357?3.^8FZ4U)B0%X]B+QA1E*+AR$N2"-&U'N-,2^NR+IB!
M#$<1UB[EK!EV'T,O#/$7#<F950)4$IJ0LS[>VT@>$=!<\I!Z%^AD+WGH!8,!
M.=:X_L&\*4%MFJFJL35J8=K1T^_V@WO>SJM7\W;J+YG:<*%) 3FZ!N>C@4M4
M.TE;Q<BJF5YK:7 6-N(6/SZ@K &>YU*:3K$!^L_9[']02P,$%     @ QZA[
M6F1H0V3Z P  (0L  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULK59M
M;^(X$/[.KQAE3Z=6RC4A"7GI 1*TL,NI;RIT]UYT'TQBP-HD9FU3NO?K=YR$
ME-[2E'M1I7KLS#PS8S\S3'?+Q6>YHE3!4Y;FLF>LE%J?6Y:,5S0C\HRO:8Y?
M%EQD1.%6+"VY%I0DA5&66HYM^U9&6&[TN\79G>AW^4:E+*=W N0FRXCX.J0I
MW_:,MK$[N&?+E=('5K^[)DLZI>IA?2=P9]4H"<MH+AG/0=!%SQBTSX>^UB\4
M/C*ZE7LRZ$SFG'_6FTG2,VP=$$UIK#0"P>617M TU4 8QI<*TZA=:L-]>8<^
M+G+'7.9$T@N>?F*)6O6,T("$+L@F5?=\^X%6^70T7LQ36?R';:D;. ;$&ZEX
M5AEC!!G+RY4\5?>P9Q#:KQ@XE8%3Q%TZ*J*\)(KTNX)O06AM1--"D6IAC<&Q
M7#_*5 G\RM!.]2<WL\'-^\GP:@2#Z70TF\+)C,Q3*D^[ED)\K67%%=:PQ')>
MP6H[<,USM9(PRA.:O 2P,+ Z.F<7W=!I1+RD\1FX;1,<V_$:\-PZ6[? <U_!
M>\]YLF5I"B1/8)(KDB\9)@L#*:F2<,EDG'*Y$13^&,RE$LB9/P_=0^G%.^Q%
MU]&Y7).8]@PL%$G%(S7Z/[YK^_;/#3EX=0Y>$WI_>O%A=/F [W4[AN]>[U"P
MC7"'@WV^FA8IKR;F6(=2 5^ 6E%8\!3+F>7+<VB,IW5'%,W17E_X3) $6PJV
M&[AB,18VE3"(XTVV25$K@4'&A6)_D:)<9UR1M#4D*<EC"D1JS[^0?(.= TI"
MN/ #N*8?^+BVS4[DFAW71ODD0#'P0SC%36B[IN>&K1?8]&FMO<-/^'<21F;@
M^:A<2W_SBB2DV9R*'1'=RNNSSY,P1*'M(4C0QH^1\Y:_H/87O.G/>RW/*'!-
MQV\7>?J.:T9>I_6I:$-XF>21"NRJV#AU:\:7 K(?TIH*QE%+'7!WPG+X2HF0
MIQAOVSYSH8&VG9JVG:-I.Y[<3&8CN)I\'%U^SQD87-_>SR:_#V:3VQL8_7HW
MNIF.#C*[T>-A9N^_2PLOFSTW@9=,EV]0?3^'UI$Y_.MJ.+H.@L@V[<@II*((
M7B-BQ?5R.9+P81"9H1M"Q?9&Z*!:_@&W(S\R.V%'2Q6Q&VCGU[3S_R_:C1]F
M#_>CX]G7Z/@(]NUN#">K@F@Y?5*PP!FE+#Y@4E]:23_Y3+[6?\ND-:[<_58X
MP5]JW1M>O$O9>O%U]%M4#,&=OR<'>W*X)T<[N<! <\\+S0#;U:&GM/;&EHR*
M93&<Z0+<Y*J<8.K3>OX;E&//LWHY/%X3L62YA)0NT-0^"[ UB'(@*S>*KXLA
M:,X5CE2%N,(9E@JM@-\7G*O=1CNHI^+^-U!+ P04    " #'J'M:O>N>;[L"
M   S!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R=5=N.VC 0?><K
M1FE5M1+:A!!82B$2EZP6:2^(2UNIZH.3#,1J8E/;++M_7]L)*958U/:%S-@S
M9\ZQ/</@P,4/F2$J>"YR)H=.IM2N[[HRR; @\HKOD.F=#1<%4=H56U?N!)+4
M)A6YZWM>URT(94XXL&MS$0[X7N64X5R W!<%$2]CS/EAZ+2<X\*";C-E%MQP
ML"-;7*):[^9">VZ-DM("F:2<@<#-T!FU^N/ Q-N SQ0/\L0&HR3F_(=Q9NG0
M\0PAS#%1!H'HSQ-.,,\-D*;QL\)TZI(F\=0^HM]8[5I+3"1.>/Z%IBH;.CT'
M4MR0?:X6_'"+E9Z.P4MX+NTO',K8SD<'DKU4O*B2-8."LO)+GJMS.$GH>:\D
M^%6";WF7A2S+*5$D' A^ &&B-9HQK%2;K<E19BYEJ83>I3I/A:/)9+&.IA!]
MG4</RV@)HX<I/*YNHP5,UHM%]+""N]EH/+N;K69Z]_V*Q#G*#P-7Z>(&PDVJ
M0N.RD/]*H98/]YRI3$+$4DS_!' UZYJZ?Z0^]B\B3C&Y@G:K";[G!Q?PVO51
MM"U>^Q6\.7FQXH"P%$9)(O8DE_!M%$LE]./Y?DYSB1B<1S0-U9<[DN#0T1TC
M43RA$[Y[T^IZGR[P#6J^P27T<#FYC:;KNP@>;^#?KO&<DHNUSBNQ9X1I Y_U
MB)#5P7&5H= O5PAD"G)*8II31?5NPG4K2P5\TX?_Y]XPMVVNO-W0#P"+6%?3
MC^!DN:(%,6=[P^HM7'M!T_,\;77;/6/5,5MD*$ANF9-4]Q<UEVT&!=2J J\9
M]#IPW6YV>]W&BBL37^7_I71-(0@LBK9:+0,$YUZ >]+(!8JM'5?FY/9,E3U=
MK]83<50.@M_AY3B])V)+F80<-SK5N[KN."#*$54ZBN_L6(BYTD/&FIF>ZBA,
M@-[?<*Z.CBE0_T^$OP!02P,$%     @ QZA[6L7X(EQC!@  /A,  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&ULO5A;<]HX%'[WKSA#VYUDQH#OES1A
MAB2T93>!+)=D.SO[X& !GM@6E44N_?5[)&.;),1E.YU]P9*.SD4ZW_DD=/Q
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M6LO%?S,L?ZS).YRNY /)+>6<)K*Y)$%(F)B \CFEO.@(!^636>=?4$L#!!0
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M1D%I+BC-*VF'G;K5-QJR 3)J $7;98-VL((K)6Q9+,[CPN1-EN\6&U5'=PL
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MEAVC9:  YF0=B3'=7D-FJ*'X?!IQ_8NV:6Q#9O377- X \MY'";IDSQG&W$
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M(4\U@7J,X7@-JOT9/6Z3C'Z?0+0$5IJWRA6NS5M-8 4RG)P,YT,(W:F3L)K
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M/D!_/N=<O9SD":I=5J/_ 5!+ P04    " #'J'M:[I+'KS@$  #^%@  &0
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M!C)/C.\G7V;3A_D,W%Z!Q=WM8G;W[5^PF%]^_08NOT[![*^'Z\7-3*X^3(G
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M?+H@ @<A_PQ.P>/L GSZ_?- %W+:Q%GW\BDFV12H90J(P"V-Q9*#R]@G?A5
ME_$60:.WH"=(B7A!O#-@PA. #-1K"&AZN+NI",<LUM!,\<P6O*L@#@0YO9'G
MT0?7L<#Q(IB'!(PY)X*#[S?2'EP+$O%_FU8O ^\U@R=I?,Y7V"-#3>8I)^R9
M:*,_?H.6\6<3\X[ *NO0*]:AIT(?3<@BB.,@7H )#G'LD2:V&40_A4AJS//(
MAJ;EHH'^O,UCU\PQS)[I%&:5"/M%A'UEA-E.@9:=.@'CB#(1_(?3"D->9*WD
MC22R6:RMZ$X=U^[9-1(M9E8S":L@87V(Q!T1)TFJ[=D(:R<X"YENKU_CL&M6
MVZ\*![O@8"LYW&-!8ID;./;! \.^[$VR;X'OMR2:$]:8)DK ]Z9)1V 5[D[!
MW3EFN7"Z7(>.P"KKX!;KX'Z\7+@[Q\^T;*MV1O<85:*#1MD9C0_EV1=&.2\R
M;=[.(9^GKR:16QW(8JN_PP^QV*1"1W[#SX1)X0;P=@U<$190OY&4<MKFHP.:
MCN"O .T]@Q"5ZX.4ZW,3>$F55Y8>-<1[<ZXKM"KA4JS HZH5V*E<Z0JMNA:E
M8($=*!:XJT5@WS7[IE'/X-Y.!M<-JW&6L@6J=<MA<3;)#=MUMD13'F>#H>T:
M1EM3AZ4R@1^3)H?J*[BK.AH%5IM=6]4LY0E4ZY/N:K^]]TSD5/8;5KF4<@,J
MN_C^3?&\=;0.<=($MC?H$!&93[V=&Z>NY?:=NHS,#56'LTJO5!%0+2..UN#4
MTT(#O!+,.#!!E/UW"QW@XU?>6.:46+]8YE"I9)!:R;3ML++IJ3'?6^B[0JNN
M0*F"$#QFTT,=:91\+8ZA>%"I>)!:\1S43'*,2F([CMF'O5IBYX:U9F+:5DMB
MHU*H(&7S[ZR9Y-/L;29M=BW-!)4J ZE5QC$+,-H5)Z>N;2(+UMDU&-8V-*.G
M;UTF1H0MTCM6#CRZCD5V15>\S>YQ)_!\FEYWUMZ/X?DXO=742YCL<O@6,WD$
M.0C)DX0TSFP9%<ON6[.!H*OTRG).A:!1^K@DV"<L,9#?GR@5;X-D@N+6>_0_
M4$L#!!0    ( ,>H>UI$>'3)_ ,  . 1   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;+58VV[C-A#]%4(MBEV@&XF2K4MJ&_ M70&.8\3.MNBB#[1$
MVT(DTB7I..W7E[I$%T>6LXCR8HO4S-$YPR$Y9.](V2/?82S <Q02WE=V0NRO
M595[.QPA?D7WF,@W&\HB)&23;56^9QCYB5,4JKJFF6J$ J(,>DG?@@UZ]"#"
M@. % _P018C].\(A/?85J+QTW ?;G8@[U$%OC[9XB<7#?L%D2\U1_"#"A >4
M (8W?64(K\?0B1T2BV\!/O+2,XBEK"E]C!NNWU>TF!$.L2=B""3_GO 8AV&,
M)'G\DX$J^3=CQ_+S"_I-(EZ*62..QS3\(_#%KJ_8"O#Q!AU"<4^/7W$FJ!OC
M>33DR2\X9K:: KP#%S3*G"6#*"#I/WK. E%R@.89!SUST$\=.F<<C,S!2(2F
MS!)9$R30H,?H$;#86J+%#TEL$F^I)B#Q,"X%DV\#Z2<&R_'7Z>1A-@5W-^#&
MG;NK*9BYWZ83X,Y7P_GO[DB^&BZ7T]42#&_O[E?N7\.5>S<'TS\7T_ERN@2?
M)EB@(.2?P1?PL)R 3S]_[JE",HOQ52]C,4I9Z&=80!W<4B)V'$R)C_TJ@"HE
MY;KT%UTCO1%Q@KTK8,!?@:[IG1I"X[>[&PUTC#S,1H)GG,&["4@@\)>93%D?
MN$0@L@W6(09#SK'@X/M,V@-7X(C_71>]%+Q3#Q[/]&N^1Q[N*W(J<\R>L#+X
MY2=H:K_5*6\)K!*'3AZ'3A/Z8!A1)H+_4#*%\;-<C#BN$YRB=!.4>"5Z&MB.
MU;%ZZE-92;V5F5M5*'9SBMU&B@LD,)%C@H@/5@SY<MEDC^#[+8[6F-6.3B/>
MCXY.2V 5Z68NW?S(+#7;C$-+8)4X6'D<K,84&.%M0$A MF"$0D2\VA1-(<Q2
M\AFF99YDZ 6C"CL[9V>W,H<:4>HC".I&XOTX%9E.+M-IE"EW@@LCX+QE!"X8
M5:A!K=@UM49RL\"+P]ZX+#1#_.A\: NM*KA4)L"/7!HR]+9BT1):-19Z$0O]
M_<M#AE%./-MR;,,^R<\:.\O1-$<_DZ)%Q0$;-_(W+Q,9C'EAKSUC=FXF%04!
M;*X(+D_S#*#\9<=TNG;WE.%KNY.(5RD6!0%LK@B&GG>(#J&L"WQ0B6KC[&^U
M*F@+K1J!HBZ 'UH8P%8K@[;0JK$H:@/80G$ 7V_\MFUT8><T9U_;68YAF>=R
MMJ@18#M%0@9S<?;7FYV;_<4>#]^[R6< Y2+?L0S=A*<,7]N=1#REJ);.RA%F
MV^0*@0./'HA(CY=Y;WI-,8JO*>*S]DG_$%X/DT.[6L"D=Q^WB,D4X2#$&PFI
M75F2%$NO$]*&H/OD1+ZF0I[OD\<=EB<-%AO(]QM*Q4LC_D!^J3/X'U!+ P04
M    " #'J'M:Z9659X,"  !J!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6R5E5%OFS 4A?^*Q::IDZ9"2$)H1Y"2AK1(;1H%TDV;]N# 36+58&8[
M2??O9P-%44>;]27X8I_SG4NP\0Z,/XHM@$1/&<W%T-A*65R:IDBVD&%QS@K(
MU<R:\0Q+5?*-*0H.."U%&35MRW+,#)/<\+WRWIS['MM)2G*8<R1V68;YGS%0
M=A@:'>/YQH)LME+?,'VOP!N(0"Z+.5>5V;BD)(-<$)8C#NNA,>I<CEV]OESP
M0. @CL9(=[)B[%$783HT+!T(*"12.V!UV<,54*J-5(S?M:?1(+7P>/SL/BU[
M5[VLL( K1K^15&Z'AFN@%-9X1^6"'6Z@[J>O_1)&1?F+#O5:RT#)3DB6U6*5
M("-Y=<5/]7,X$MCV*P*[%MAE[@I4IIQ@B7V/LP/B>K5RTX.RU5*MPI%<_RF1
MY&J6*)WTHZN;8+*\#=#]%$W#61@'Z#9\""8HG,6CV74X5E.C* KB"$V7\7*A
MJKO[11S^&,7A_0P%W^?!+ HB=#8!B0D5GSU3JEC:W$SJ".,J@OU*A DDYZC;
M^8)LR^ZA931!9Q]?V)BJJZ8UNVG-+GV[K_A>,Y8>"*4(YRD*<XGS#5E10",A
M0 HT(2*A3.PXH)^CE9!<O2"_VM)7E%X[16^:2U'@!(:&VA4"^!X,_].'CF-]
M?:.';M-#]RUW7SV2?ENF2M4O57K?[7WW8M!S/'/? NLUL-XIF-,&JU3._\'Z
M#:Q_"C9H@_7? W,:F',*YK;!G/? !@UL< IVT08;O ?F-C#W35C,)*9M-/>?
M-Z37<P==ZP7./#HZ]"E\A_F&Y )16"NA=3Y0#KPZV:I"LJ(\359,JK.I'&[5
MQP"X7J#FUXS)YT(?4,WGQ?\+4$L#!!0    ( ,>H>UH0 +L]I0(  )<&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;*U576^;,!3]*Q:;ID[:"@'R
ML8X@I82JD;HVRL<V:=J# S?!JL&9[23MOY]M"*(+J?JP%_"U[SD^YQI?@@/C
MCR(#D.@IIX486IF4VRO;%DD&.1:7; N%6EDSGF.I0KZQQ98#3@THI[;K.#T[
MQZ2PPL#,37D8L)VDI( I1V*7YY@_7P-EAZ'5L8X3,[+)I)ZPPV"+-S 'N=Q.
MN8KLFB4E.12"L )Q6 ^M4><JZNI\D_"=P$$TQD@[63'VJ(-).K0<+0@H)%(S
M8/7:0P24:B(EXT_%:=5;:F!S?&2_,=Z5EQ46$#'Z@Z0R&UH#"Z6PQCLJ9^QP
M"Y4?(S!A5)@G.I2Y_2\62G9"LKP"*P4Y*<HW?JKJT !T_#, MP*X;P5X%< S
M1DMEQM882QP&G!T0U]F*30],;0Q:N2&%/L6YY&J5*)P,Y]%M/%[>Q>CA!HVB
M:+:,QRC^.8WOY_$<C>['Z&%Q&\]0M)S-XOL%NIN,KB=WD\5$K5Z,06)"Q4?T
M&2WG8W3Q_F-@2Z5),]M)M?]UN;][9O\Q))?(ZWQ"KN/Z+?#H[7#O)=Q6E:C+
MX=;E< V?=X9OBI_QBH) N$C1*$GX#E.!?HU60G+UQ?UN,U@R^NV,^A9>B2U.
M8&BI:R: [\$*/[SK])RO;7;_$]D+\UYMWGN-/31^(44K5NP$B#:O)4'7$.@&
ML0_[CN\X3F#OFRY.TWK>H)GV0I]?Z_/?I&\#!7!,S1GA5%T*HD]'MP,$3ZJ]
MG=%>DO<:HGS''W3_D7Z:U?=Z@UZ[\FZMO/NJ\@636F^E_RC2&& R ZYN.N=0
M2$0)7A%*)&FWT#TMO^^?>FA)ZW1.3=B-MJ%;]C?,-Z00B,): 9W+OF+@91LL
M \FVII.LF%1]R0PS]>< KA/4^IHQ>0QT<ZK_1>%?4$L#!!0    ( ,>H>UK@
MOW$3R0,  &T-   9    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;*57;6_:
M2!#^*R-?=;J3&NRUL0TY0 )"KY&2%I&T457=A\4>P*KMY787"-+]^-NUC7&$
M<4/SA7UA9^:99V=GQKT=XS_$"E'"<Q*GHF^LI%Q?FZ8(5IA0T6)K3-4_"\83
M*M62+TVQYDC#3"B)3=NR/#.A46H,>MG>E ]Z;"/C*,4I![%)$LKW(XS9KF\0
MX[ QBY8KJ3?,06]-E_B \LMZRM7*++6$48*IB%@*'!=]8TBN1\37 MF)KQ'N
M1&4.VI4Y8S_TXC;L&Y9&A#$&4JN@:MCB&.-8:U(X_BV4&J5-+5B='[1_R)Q7
MSLRIP#&+GZ)0KOI&QX 0%W03RQG;?<3"(5?K"U@LLE_8Y6?]K@'!1DB6%,(*
M01*E^4B?"R(J HY]1L N!.P,=VXH0WE#)1WT.-L!UZ>5-CW)7,VD%;@HU;?R
M(+GZ-U)R<O P_CBY^7(W@<\?X&DXFPT_/<)P_'C[]?;Q&_QQ@Y)&L?@3KN")
M<DY3"=_O,9DC_Z=G2F5>*S&#PM0H-V6?,45LN&>I7 F8I"&&+Q68"G<)WCZ
M']F-&F\P:(%#WH-MV6UX!R:(%>4HBJ'!@E/2XV06G'/T:$57(W7M(8Q9HMZ"
MH%DT#34;2U3Q*6&^A^JY*=UGV\,=Y2%\OU,JX59B(FHYR^VWZ^WK-WDMUC3
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M^AY"K@^H_Q>,R<-"&RB_L ;_ U!+ P04    " #'J'M:^M##XG($  "P&0
M&0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6S%F5UOHS@4AO^*Q:Y6NU*G
M8!-HVDTB]5,SVIEIU7:V%Z.]<).3! W@K.TDK;0_?FV@F#;@4II.;Q((^)SW
M&/M]L#-8,_Y#S $DNDOB5 R=N92+ ]<5XSDD5.RR!:3JRI3QA$IURF>N6'"@
MDZQ1$KO$\T(WH5'JC ;9;Q=\-&!+&4<I7' DEDE"^?T1Q&P]=+#S\,-E-)M+
M_8,[&BSH#*Y ?EM<<'7FEE$F40*IB%B*.$R'SB$^./)[ND%VQ]\1K$7E&.E2
M;AG[H4\^38:.IQ5!#&.I0U#UM8)CB&,=2>GXMPCJE#EUP^KQ0_2SK'A5S"T5
M<,SBFV@BYT.G[Z )3.DREI=L_1&*@@(=;\QBD7VB=7[O7N"@\5)(EA2-E8(D
M2O-O>E=T1*6!3QH:D*(!R73GB3*5)U32T8"S->+Z;A5-'V2E9JV5N"C53^5*
M<G4U4NWDZ.KXX^G)M\^GZ/P,75V?'_^%;@XO+P^_7E^AWT] TB@6?PQ<J3+I
M^]UQ$?4HCTH:HI[ >!?Y> <1C_30K\A%8DXYB.+K<4!722YUDU(WR3+X3;IU
MH ]'ZGE,T 6]5^-$HD/.:3H#?;R#SA?ZJ>^@TSO@XT@ NN#1&-"EO@-]_ZS"
MH4\2$O%/775Y[EY];CU1#L2"CF'HJ)D@@*_ &?WV"PZ]/RV5^65EOBWZZ(;J
M,J1 :@X)2=-)E,YV4+I,;H$C-D7KXGJ=[CQRF$76\W$U\O<#'/J]@;NJD=0K
M)?7:28*\,^EM##O5DY;R>B^3%Y3R JN\)X_X7#W:[U] "ZI]N-9@'1]N6$H-
MWW'8AF]0V5Y9V5Z'80L/92RR,OZK>$%= 7F*O<H (;L]OWYT]$MA_3>;3_V-
M 4L"[(?]L%[2?BEIO\-\6F<$40.#KH K(BKH::PJN2B.IH"B%-T#Y;5"[?EZ
M>4.$4<)2.4<AFM![FPMCS^##^RG64*1IW=6X CC\$G>X7C.K.]BC=9Q$V& -
MOR?7\%N #1NRX2YH>Z%'%#D>F\0^:1@F!G&X)>,ZV 3>!)L:NWM>@R;#-6P'
MV_9]XIF$Y,$HO-PI!%*O;\]YA6$?M@)H>UX1OJB[#<&P'6%/G6+.P?XF88_7
M=3H9L.'^>WJ%%:M=BS.(Q"T9^2JOR',$E9&"&X8),<@C+9'7P2G()N8P#CP_
MZ#>H,I@C=LQMWRN>28BSEB^R"E)9W5E)M#6K*-*T[V_#,F)GV9,Y=<:6W.H5
M]G =IQ,Q>".]]UPO6]G:M3C#2=*2DZ_QBB+'(Z]H>*L@!GFD)?*Z>,4FYH@?
M[#=QCAC.D99+M>U9A3UA%ZLP%"0MUW>OM8J:Q9ZMNPW)B)UD3YTB6MG?*NSA
MNNX^&;SYWCLZA6]E:]?B#"7]EI1\C5,4.:I.$3:,$M\0SV])O"[;?IN4(T&3
MHLH^9,O5VM9LXIF$7EW+Q^(-[_R?LV7I;R[M-KO6K>R_Z_\ROE ^BU*!8IBJ
M5MZNWOSG^=\#^8EDBVQ+_I9)R9+L< YT ES?H*Y/&9,/)WJ7O_R39O0_4$L#
M!!0    ( ,>H>UK_7T.[OP,  -(-   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;*V788_:.!"&_\HH5YU:J4=P$@+L 1*P](JN+6C9W:HZW0>3#& U
MB:EM8%>Z'W]V H$]DG!H^X7$P?/.X_'88W=V7'R7*T0%3W&4R*ZU4FI]8]LR
M6&%,98VO,='_++B(J=)-L;3E6B -4Z,XLIUZW;=CRA*KUTF_346OPS<J8@E.
M!<A-'%/Q/,"([[H6L0X?[MARI<P'N]=9TR7.4#VLIT*W[%PE9#$FDO$$!"ZZ
M5I_<#$C+&*0]'AGNY,D[F*',.?]N&N.P:]4-$488*"-!]6.+0XPBHZ0Y?NQ%
MK=RG,3Q]/ZA_2 >O!S.G$H<\^LI"M>I:+0M"7-!-I.[X[B/N!]0P>@&/9/H+
MNZROKSL'&ZEXO#?6!#%+LB=]V@?BQ,"KEQ@X>P,GY<X<I92W5-%>1_ ="--;
MJYF7=*BIM89CB9F5F1+Z7Z;M5&\V_#BZ??@T@LD'F-U/AG_"9'H_GGR!_O!^
M_#B^_P9O;U%1%LEW'5MIA\;,#O;B@TS<*1$G#GSFB5I)&"4AAB\%;$V:XSH'
MW(%3J7B+00U<\AZ<NN/!P^P6WKYY!V_ !KFB N7^4>')S0/CII[<$D^C'QNF
MGN&O_EPJH7/G[Z+A9Q)>L8194#=R30/L6GK%2!1;M'J__D+\^N\5@%X.Z%6I
M][YLXCD*X N8K$V"R_<PV2BI:!*R9 ES7+(DT6]%W)FRGRJ;=;OM$<_W6VVG
M8V\+D!HY4J,2Z6NZ!C"$_A:%7M,P>D(1,(DP%2S EX"# R#\<S*!1;29T^8)
MK5<CI!C5SU']:Z/WAZ")^F^69@3^>;S:KM<D?C%$,X=HOBY>>Z2+$6J>18C4
MO$8Q7"N':UT;H0->88PJU8K7 E0L@W:.V;X64V_7"V0E4]D^F\K?B-LB7DD^
MD?IQ(ZV_;C)SK(O3N??T<CZ;)<E&3K9Z\IH= ]-'(0\Y"YKK^*[G-TN0G".2
M\_-VC%'VN!@]YRQZ3LUW2U"/]8!4[N;GJ'=H3CV&Z!-;(+ $OB$5L@"YD++:
M6Q.>4S$?XK2"5JP4<JP8I+IDC!,EF#Y0!?!(HTUI= MQ*Y6O7][D6%-(=5$I
MWX?H/,*J"#?.LM;QVFWBEE0Y<JP=I+IX7,C: K[+2>L7)&V[9 LGQP)#KJPP
M94G[/T-:[>V0M"1+6IV\(7VN3-UC,2+5U>@UJ?NS*I-]<LR.42S3RX2$@&\2
ME9VX\Z_YA:6?'=./W;/;SF<J].E'0H0+;5JO-76NBNP"D3447Z>']CE7^@J0
MOJ[TI0N%Z:#_7W"N#@WC(+_&]?X%4$L#!!0    ( ,>H>UJO;*;\? 0  )48
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;,59:V_B.!3]*U9VM=J5
M&!([#T(7D"BEFFK;@FAG1ZO1?G")@6B2F'5,:?_]VDE(PLN%3#K]4N+$]]Q[
M+C>'([>SINQ[O""$@Y<PB.*NMN!\>:'K\71!0APWZ9)$XLF,LA!SL61S/5XR
M@KTD* QT9!B.'F(_TGJ=Y-Z8]3ITQ0,_(F,&XE488O9Z20*Z[FI0V]R8^/,%
MES?T7F>)Y^2!\"_+,1,K/4?Q_)!$L4\CP,BLJ_7AQ0"9,B#9\;=/UG'I&D@J
M3Y1^EXL;KZL9LB(2D"F7$%A\/),!"0*)).KX+P/5\IPRL'R]0;].R LR3S@F
M QI\]3V^Z&JN!CPRPZN 3^CZ,\D(V1)O2H,X^0O6Z=Z6K8'I*N8TS()%!:$?
MI9_X)6M$*0 Y1P)0%H!V J!U),#, I+.Z6EE":TKS'&OP^@:,+E;H,F+I#=)
MM&#C1_)K?.!,//5%'.\]##X/K[[<#L'H&MS<7X\F=_W'F]$]F QO^X_#*_ X
M @^/H\%?8#26]Q_ [U>$8S^(_P"?P*] !_$",Q)W="Z*D9#Z-$M\F29&1Q)#
M!.YHQ!<Q&$8>\;8!=,$BIX(V5"Z1$O&*3)O A V #&0=*&AP>KBI*,?,.VLF
M>.:QSLK&?+H4(^:!,7X5H\]!GS$<S8F\;H#14@YR PQ?")OZ,0%CYD\)F,@=
MX-NM@ ,WG(3QOX>:F^:V#N>6[_Y%O,13TM7$RQT3]DRTWF^_0,?X\U!C:@+;
M:I.5M\E2H??2+L1@M.(QQY'G1_-&>0'N5^$388#.LH8=G+4TAY/DD,KUW#.1
M8UI.JZ,_EYGN[X.6X[AME._;(F'G).R32&1?)7X*2*.\.(V$O5<<LMIM:*(=
M$LI:*GY=3L[443)-IW,D9O/;'9&<#DZG$N/<Z:P);(MN*Z?;^L"7N%5GFVH"
MVVJ3F[?)/?\EWF[)(?XI:*O\-C8M>V?:E9DK\FKGO-H_09S:^Z+C(MO8$R=E
M+1690J,P L:Y&@:^)BY(S'[_F3#AZL"$2&LHF=_Z,S':$?B'8';XYU^=S@6O
M,A) $$H; !S@X==#0 ,U4-6^E P2_ G:GB79&@)HNG:KO3,$ZFJJLD4%6W2"
MOC^NJ5+?U2#G*E==:-N4"Y\&/]*HP5J=6EUHVZTJO!JL8-;>UOD,M2STJ-F&
MNY.OS%V56V'AX&D>[L>T'NZ;. <Y".[^JJF+J4JV<'%0;>-J%WMU.B<3>S<5
M>Z'ZZ+C<OX??@X7A@TJC5)?<M_;&P+9<TW%WQ^ ]7!LL;!M4^[9,[1>,J/V\
M&N9L$7L/2P<+3P?;'ZGW-;FXK%7OX0E1X0G1:9[P3+W/4,MZ;S>-W=E7YZ[*
MK?!UZ#1?]V-ZC_9]G0L1='?U7EU,5;*%K4-J6U>WWK^1SMZ8>V,C^,@Z*OAJ
MK*JM*>P?4GJFF@0_2_+V'-1JX/32P6](V#PY#X_!E*XBGIX!YW?S,_=^<M*L
M%]O3 _L[S.:^:$- 9B+4:,H3;I:>@:<+3I?),?(3Y9R&R>6"8(\PN4$\GU'*
M-PN9(/]/1.]_4$L#!!0    ( ,>H>UJ&R?][NP,  # 1   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0V+GAM;*V876_B.!2&_XJ5E58STFX3AZ_2@4@4F)UJ
MAZ$J[<S%:"Y<<@"K29RQ#;3_?FTG!,*F+E2Y@<3Q>7T>&[\YIK=E_$FL "1Z
MCJ-$])V5E.F5ZXKY"F(B+E@*B7JR8#PF4MWRI2M2#B0T07'D^I[7=F-"$R?H
MF;9;'O386D8T@5N.Q#J."7^YAHAM^PYV=@UW=+F2NL$->BE9P@SD0WK+U9U;
MJ(0TAD10EB .B[XSP%=#W-$!IL=W"EMQ<(TTRB-C3_KF)NP[GLX((IA++4'4
MUP:&$$5:2>7Q.Q=UBC%UX.'U3OVS@5<PCT3 D$4_:"A7?>?202$LR#J2=VS[
M!7*@EM:;LTB83[3-^WH.FJ^%9'$>K#*(:9)]D^=\(@X"_-8K 7X>X!\%J)FI
M#FCD 0T#FF5FL$9$DJ#'V19QW5NIZ0LS-R9:T=!$+^-,<O64JC@9S(9?QJ.'
MKV,T_8QF]]/AOVAZ>W\S_8;^N1M\NQ^/T& V>YB8IAGZ, )):"0^HK_1^/>:
MRA<T3<UJ_)Q _ C\5\^5*BDM[<[S!*ZS!/Q7$L ^FK!$K@0:)R&$90%7T11(
M_@[IVK<JCF!^@1KX+^1[?K,BH>'IX0U+.HUBAAM&K_&*WG2Q$" E399H(-25
M0#^_JB[H1D(L*B<LTVM6Z^E]?252,H>^HS:N +X!)_CS#]SV/E7!UB160F\6
MZ$V;>G!'Q1-:< !$$PE*7R).)%0Q6X7.9<[$ND9,^]@F\"Z\IN_WW$T%3:N@
M:5EIQL^I\AX(D4*)T8<7(%Q\K&*QRIS+8L^I@4P:J(UBLXDLB]8N,-NG86Y8
M1"2-U"ZO@K2*G N9B6'O8,7P1:=5O5Z= J1S&DA(-S2$)!15')W_#^T5XV;9
M6;N44KLL4KNTIC:A"8W7L=4VK0KG3G!-8B78;@';K=D NW6BUR160L?>_O7J
MU66!N=*Q;>'FT<_1/N)[B0X*!ER/#;ZAX^?6U<VM"W502%ZJ]NC0KO1>8G]/
M[-?AB+G*D8MY^'CYK(.]%V9?C6#K&S^8D.<WK<<N<>X&K$NM#+RO07"S9OO!
MM18C=:F5\?=%"[97".<84*O2@!K'/^":ZILRT+X\P2?6)V_ZCUVGE?M/<^<_
MV&) -54[9>1](8-/K&3>,*"*0D49D'^\?M;!SH5Q#\Z>,?"E.9(+-&?K1&9G
MMJ(U._9?ZV._/KL>M0_PU< <@MV]3/9?PH3P)4T$BF"A)#U5&#J(9\?S[$:R
MU)QP'YE4YV5SN0(2 M<=U/,%8W)WHP<H_B0)_@-02P,$%     @ QZA[6JKK
M[W[( @  E@<  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULK55M;]HP
M$/XKITR:.FEM(%!@'43BK2KJ&R*E^U#M@TF.Q&IB,]M ^^]G.R%C&T1BVI?X
M;-\]]]SE?-?=<O$J$T0%;UG*9,])E%I=N:X,$\R(O. K9/IFR45&E-Z*V)4K
M@22R1EGJ>K5:R\T(98[?M6=3X7?Y6J64X52 7&<9$>\#3/FVY]2=W<&,QHDR
M!Z[?79$8 U3SU53HG5NB1#1#)BEG('#9<_KUJT''Z%N%9XI;N2>#B63!^:O9
M3**>4S.$,,50&02BEPT.,4T-D*;QH\!T2I?&<%_>H5_;V'4L"R)QR--O-%))
MS^DX$.&2K%,UX]L;+.*Y-'@A3Z7]PK;0K3D0KJ7B66&L&624Y2MY*_*P9^#5
MCQAXA8%G>>>.+,L14<3O"KX%8;0UFA%LJ-9:DZ/,_)1 "7U+M9WR@^'->#2_
M&\/C-<P?GL?!TW@$,[W,)D,C!D^/PUM],WD*X&R$BM!4?H)SF*%4@H8*(P@4
M#U]ASJB2<#8+YOK^Y1ZS!8KO75=ICL:3&Q9\!CD?[PB?N@?WG*E$PIA%&/T.
MX.K@R@B]780#KQ)QA.$%-.J?P:MY39 )$2@K8!MEXAH6MG$L<0;H?* +(H(A
MS_0CD<3665\(PF+4A:M@\0[[>E/R;H_[6R(B>+G3D#!1F,F#B<K]-P_[-X_U
M2JY(B#U'OT:)8H..__%#O57[6A%=LXRN687N/ZS-_P.^+!(&^CU+15A$60P+
MC"EC6CK$.L=M65S3$3;^EW;':W?=S0$ZER6=R]/HQ#K'ZL_RR E4(AU.&U1D
MK%52;)U&43?,)=(C)%M_9>F\(DWMDD/[/W*HQ#H]49V29.??2POM<HAM)>@)
M;-V]7IFAB.U$D!#R-5-YVRQ/RZ'3SWOM+_5\8MT3H1^"A!27VK1VT=:E)_(I
MD&\47]G.N^!*]W$K)GIPHC *^G[)N=IMC(-R%/L_ 5!+ P04    " #'J'M:
M%D[8I$,#  !A"P  &0   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6R]5FUO
MVC 0_BM6-DVMU#8OO'> Q%O7:FM!I:R3IGTPR0%6$SNS#91J/WZV RFTD-$*
M[4MB.[[GGN=\.5]USOB#F !(]!B%5-2LB93QN6T+?P(1%F<L!JJ^C!B/L%13
M/K9%S $'QB@*;<]QBG:$";7J5;/6X_4JF\J04.AQ)*91A/FB"2&;URS76BW<
MDO%$Z@6[7HWQ&/H@!W&/JYF=H@0D BH(HXC#J&8UW/.6ZV@#L^,[@;E8&R,M
M9<C8@YY<!37+T8P@!%]J"*Q>,VA!&&HDQ>/W$M1*?6K#]?$*_<*(5V*&6$"+
MA?<DD).:5;90 ",\#>4MFU_"4E!!X_DL%.:)YLN]CH7\J9 L6AHK!A&AR1L_
M+@.Q9N"6=QAX2P/OI4%^AT%N:9 S0A-F1E8;2URO<C9'7.]6:'I@8F.LE1I"
M]3'V)5=?B;*3]7[KLM,>?.N@[@7JWW5;7U&W=W?5O4&='[W.3;^#CMH@,0G%
M,3I%@WX;'7T\KMI2>=;VMK_TTDR\>#N\N!ZZ9E1.!.K0 ()- %M13GE[*]Y-
M+Q.Q#?X9RKDGR'.\_!9"K?W-<QET<FD8<P8OORN,DOD/ISJ? N2S2/UD ILT
MA4<]AFTA2Q +!E'_;;.Z5W:]0K%8M6?K2E[O*Y7*7J582O=M4,ZGE/.9E >4
M@\_&E#PISADT\UO<Y_,EYP7+3&>Z&)V+&/M0LU2U$<!G8-4_?7"+SN>,Z!=2
M*85,*??F9U4R\ RX*CZJON@*1N@8X8AQ29Z2PXB!$Q:@HP5@+K:F<;8?UT51
MDL8JH0.\$-L2+Q/BG8$HIH$H9J?A!',X;9HT[.&%*K<2-3C'= QZ?(*ZL0G$
MSVN(AL!_;0M!IH?]^2?!.!#81C!*:3!*!TGPTGX)GNGLG5+*J91RII0O0%5B
MAPC3 #4"=0T0(3G6%R#J),+2(T5_T"&R()//6[/@0& ;H:NDH:L<O#)7]JS,
MK_=E5F;7>;Z4G?]4T/[A:*^*EHWQUO.SUYJ5"/C8]'!"G<V4RN3^3U>3/K&I
M^T3=[+Q85_UCPW1-]C-,TGQ>8SXF5* 01@K2.2NI(^))/Y=,)(M-2S1D4C58
M9CA1/3!PO4%]'S$F5Q/M(.VJZW\!4$L#!!0    ( ,>H>UJ*QJ5ZNQX  #M/
M @ 9    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;+W=_6_;R('&\=_OKR#<
M0]$"N42DWK?9 $DX)(=O,]SL=G$H[@?&IFW=VI(KT<ENL7_\42\V18D>B=EO
MKT ;Q38_(T?V4PTY#^?MU\7RE]5M4936K_=W\]7W%[=E^?#=FS>KR]OB/E^]
M7CP4\^HSUXOE?5Y6?UW>O%D]+(O\:G/0_=T;I]<;O;G/9_.+=V\W']/+=V\7
MC^7=;%[HI;5ZO+_/E[]]*.X67[^_L"^>/O##[.:V7'_@S;NW#_E-\:DH?WK0
MR^IO;YZ5J]E],5_-%G-K65Q_?_'>_BZS[<'ZB,V7_'U6?%WM/;;6W\OGQ>*7
M]5_DU?<7O?53*NZ*RW)MY-4?7XJ/Q=W=FJJ>R#]WZL7SH.L#]Q\_Z=[FNZ^^
MF\_YJOBXN/MY=E7>?G\QN;"NBNO\\:[\8?$U*';?T7#M72[N5IO_M;YNOW8\
MN+ N'U?EXGYW</4,[F?S[9_YK[M_B;T#[)<.<'8'..<>T-\=T#_W@,'N@,&Y
M!PQW!PS//6"T.V!T[@'CW0'C<P^8[ Z8'!XP?.& Z>Z Z;DCV+VG5ZYW<,BD
M]](ASR_VV:^V_?1RVV>_WO;3"VZ?_8K;3R^Y??9K;C^]Z/;9K[K]]++;9[_N
M]M,+;V]>^3?;WZO-+Z6;E_F[M\O%5VNY_OK*6S_8_&9OCJ]^%V?S=0I]*I?5
M9V?5<>6[3S^JCU&@8E?\\.G/?YHX]OAOELA^DC_^M_47MRCSV=W*2O/E,E]G
MQ5^M_[)^^N1:?_G/O[Y]4U:CKXTWE[N1Y'8DYX61;"M9S,O;E27F5\55R_'1
MB>,= _"F^K:?OW?GZ7O_X!C%=/'EM=4;O;*<GC-H>4(?S8=[Q6?CX>XYAP]?
M/%R8#P\?[UY;=G]S>+_E<,]\^/N'937ZX,7#??/AZK)\;3G;)^^T'!Z8#_]4
M/%2C3UX\7)[QPO5[+_[3A6=\[[O#V[[WR'RX6UQ6A]LOCAZ??WC;Z,D9K[O3
M?W'T])S#G1</5V<\>7O[3V>W'*[/^8V;O'AX9CX\R:L7SFX]O!$ _>?PZV^\
M_@O>Q[M\M;(6U]:G<G'YB_6/N/J\)<OB?O4_+4_NPQ8;M&/KMXO?K1[RR^+[
MB^K]X*I8?BDNWOWY3_:H][>V;"$QE\0$B7DDYI-80&*2Q$(2BT@L)K&$Q%(2
M4R2F22R#L$9:#I[3<F#2W^EJ>E@LE\65M5K'Y2OK(5]:7_*[QZ(M+(U6U[ D
M,9?$!(EY).:36$!BDL1"$HNVV'B#K<_??'G7>]VKWFE\V0_!<[XH(9]62F**
MQ#2)91#6"+?A<[@-C>'V<7%_OYAOD\U:W>;5"%;^6-XNEK-_M<Y6/QB]K@%'
M8BZ)"1+S2,PGL8#$)(F%)!9ML=%>=HV'O<U_#D+NW"],R*>7DI@B,4UB&80U
M@F[T''0C8]#]O5B5U5NXR[V\>[4+O+:4,V)=4X[$7!(3).:1F$]B 8E)$@M)
M+"*Q>'24A/9@X!RD(#EB2F**Q#2)91#62,'Q<PJ.S6_W\M6M=5T4UO5B::WQ
MV65[_AF9KOE'8BZ)"1+S2,PGL8#$)(F%)!:16+S%A@?O! _RCQPQ)3%%8IK$
M,@AKY-_D.?\FQOQ+B])Z6"XNB^)J?0'DNEC.YC?51ZH8;$M!(]8U!4G,)3$Q
M.?I1MR?#_G1Z\-/ND8/Z)!:0F"2QD,2B;\"LMFR;'+^W:WO!$_+)IR2F2$R3
M6 9AC7B;/L?;],2EBEVT72\7]Y9<K1[S^66QOM*[.\^WN>#;EG1&MVO2D9A+
M8H+$/!+S22P@,4EB(8E%WX"UQN'T* X'T\%XTC](0_*YIR2F2$R36 9AC32T
M>\]QN%Y[:<C#3_G=)OWRFYME<9.7A>&,GYGJ&H&HYJ*:V&G[/^^CR;#7/_AY
M]]!1?50+4$VB6HAJ$:K%J):@6HIJ"M4TJF64UHS%O;7/MC$6U<F)KQGH'(:D
MYJ*:V&G[RQKZKWM'44B.Z:-:@&H2U4)4BU M1K4$U5)44ZBF42VCM&84.G44
M.N9WB)N%+[-JIEQ<65>/VU2LPG%QM5WB9\V+K]M/M[]I=(Y.G?5']L >'YQ)
M^6A^&ITCD-0$JGFHYJ-:@&H2U4)4BU MWFG[,P:G/YB,QX=39'38%-44JFE4
MRRBMF8)U'\0V+J!^]_.ZZ38O5U;Q:[&\G*WRSW?M;PO1*@BJN:@F4,U#-1_5
M E23J!:B6K33]E.L/QW:H_[@8!$@.FR":BFJ*533J)916C,3Z];'NFM\]K64
M73!NSB9^W:5E:T(:T<X)26HNJ@E4\U#-1[4 U22JA:@6[;3&2@#;'O:/$Y(<
M-D&U%-44JFE4RRBMF9!U=<0V=T>>KR]?+E8OI"%:%D$U%]4$JGFHYJ-:@&H2
MU4)4B^SC,LAP.NR/CL*0'#5!M135%*II5,LHK1F&=;W$-O=+FF\79WM+;XQO
M%]&>":JYJ"90S4,U']4"5).H%J):9!]W1!Q[,ATXAZTZ=-@$U5)44ZBF42VC
MM&9"UM43V]P]\?/9W%K,JZGTY6T^OSF=C6@'!=5<5!.HYJ&:CVH!JDE4"U$M
MLH_[(_;8MD?3R6$V?L.P;:L8$_3YIZBF4$VC6D9IS5BL&RFVN9+R\^9^H<65
ME7\IEGD5BS?K1+2NUJL5K_/9[E8SZ[#<WJ1A\;"^B^EJ^V7MMV@PC]@Y.='B
M"JH)5/-0S4>U -4DJH6H%NVT_159]NO!\# VCTM+1Q>CT?H*JBE4TZB645HS
M$.L.BVTNL>Q75:Q_),7]YV+9>E]"L],YYM#6"JH)5/-0S4>U -4DJH6H%J%:
MC&H)JJ6HIE!-HUI&:<W;.M=U%V>[;ARZKZN#-EY0S44U@6H>JOFH%J":1+40
MU2)4BU$M0;44U12J:53+**V9GW4OQC'W8@R+P7>W1C2O!C?SG0/5;CF[/CR^
M%9V+#BM0S4,U']4"5).H%J):A&IQRP_FQ!Y/1H=WCT!'35%-H9I&M8S2FBGH
MU"GX;ZW$F/7.(8CV9E!-H)J':CZJ!:@F42U$M0C58N>X'C8YO&,V.F**:@K5
M-*IEE-9,R;HRXS"5&3/3.0Y;*@S]H3V<'+TG1-LPJ.:AFH]J :I)5 M1+6KY
M46J=7L3HL FJI:BF4$VC6D9IS;BKVS#50U/<B:?^RXNWC# #G8-N<'01T'E]
M>(<:%QU3H)J':CZJ!:@F42U$M0C58E1+4"U%-85J&M4R2FM&85U[<<RUEV\K
M!IK1SO$X;)E8M&Q3X:+#"E3S4,U'M0#5)*J%J!:A6HQJ":JEJ*903:-:1FG-
MA*R[,(ZY"[/996!VLAUH5CI'XN@H$MO:6BXZJD U#]5\5 M03:):B&H1JL6H
MEJ!:BFH*U32J99363,2Z^^*<V'>E;4VC];OUPZ*\M3[F#[,RO[-TOBSGQ7)E
MQ?%'X\)'\V"=@Q-MQJ":0#4/U7Q4"U!-HEJ(:A&JQ:B6H%J*:@K5-*IEE-:,
MU[I#XVR7I%,+']%^#*JYJ"90S4,U']4"5).H%J):A&HQJB6HEJ*:0C6-:AFE
M-?.SKMPX)RHWYVX+:'8Z)R=:N=EIC1, SN3HE*A 1_50S4>U -4DJH6H%J%:
MC&H)JJ6HIE!-HUI&:8U,[-=EFKYY[YB7INQZ.?NR[F;KNVKL^V)>&J?JYD&Z
M!B:JN:@F4,U#-1_5 E23J!:B6H1J,:HEJ):BFD(UC6H9I35CM>[8]&URJMY'
M*S6HYJ*:0#4/U7Q4"U!-HEJ(:A&JQ:B6H%J*:@K5-*IEE-;,3Z?.3W,[Y]QU
MYV:F<W"V;  RM/NCR>C@ZCHZK$ U#]5\5 M03:):B&H1JL6HEJ!:BFH*U32J
M9936S,2ZB],W=W%.+TXW YW3<*LU%Z</#A>GHV,*5/-0S4>U -4DJH6H%J%:
MC&H)JJ6HIE!-HUI&:<THK'LZU<.SWAZNK^1<KB_KY/,KJ[RMLC'_;7VVLC4=
MC6;G=-QJZXT=G^.Q]]IVAH?Y2(XJ4,U#-1_5 E23J!:B6H1J,:HEJ):BFD(U
MC6H9I37SL2[O],WEG9>NZKQ_O"P?5Y;W.+]Z=7+]I7F,SGF);FN#:@+5/%3S
M42U -8EJ(:I%J!:C6H)J*:HI5-.HEE%:,U7KPD]_A%[408L_J.:BFD U#]5\
M5 M03:):B&H1JL6HEJ!:BFH*U32J9936S,^Z'M0WUX/^Z(TGS7SG0!T?7>RQ
MG5[+38;0806J>:CFHUJ :A+50E2+4"U&M0354E13J*91+:.T9E;679^^>;^<
MEV;P;G&_/M7Y*;^KXO+]S;(X8W$FV@-"-1?5!*IYJ.:C6H!J$M5"5(M0+4:U
M!-525%.HIE$MH[1FMM8]H/X4G<>C;2!4<U%-H)J':CZJ!:@F42U$M0C58E1+
M4"U%-85J&M4R2FODYZ#N# W,G:&T**V'I]O#+:ZOB^U,_J5526:M:WZBFHMJ
M M4\5/-1+4 UB6KA3MMOR([LWO2H(ANAP\:HEJ!:BFH*U32J9936C,:Z]S,P
M[ZVS6YADG(^;B<YYB)9]4$V@FH=J/JH%J"91+42U"-5B5$M0+44UA6H:U3)*
M:X:F4X>F0\['!VCG!]5<5!.HYJ&:CVH!JDE4"U$M0K48U1)42U%-H9I&M8S2
MFOE9%X,&)S;I*68WMV5Q9>5?BF5^4UC%JIS=Y^N/7.>SY6X_L[T[MULWZS^*
MJ]9T13M$J.:BFD U#]5\5 M03:):B&K1X+BSUGL]&1_L]8..F:!:BFH*U32J
M99363,VZ0U0][#)5_^;[%)O'Z9R8I.:BFD U#]5\5 M03:):B&H1JL6HEJ!:
MBFH*U32J99363-:Z?308HO-YM&>$:BZJ"53S4,U'M0#5)*J%J!:A6HQJ":JE
MJ*903:-:1FG-_*Q[1@/SQD+RY)Y"9J!S9*+5(E03J.:AFH]J :I)5 M1+1J<
MMX=5C(Z:H%J*:@K5-*IEE-8,P[HT-#"7AL2OLU6Y7E]TUJ5UM"&$:BZJ"53S
M4,U'M0#5)*J%J!:A6HQJ":JEJ*903:-:1FG-]*QK1 -TRZ !6A5"-1?5!*IY
MJ.:C6H!J$M5"5(M0+4:U!-525%.HIE$MH[1F?M95H8%YRZ#F+NC/F_V>V 7=
MC':.4;0QA&H"U3Q4\U$M0#6):B&J18/C':;&D][4GMB'\W.T#(1J*:HI5-.H
MEE%:(R&'=1EH:"X#O3@_MWZWY/Q+L2H72^.<W>QW#4M4<U%-H)J':CZJ!:@F
M42U$M0C58E1+4"U%-85J&M4R2FLF:MTA&J)[!PW1.A&JN:@F4,U#-1_5 E23
MJ!:B6H1J,:HEJ):BFD(UC6H9I37STZGST[QWT!^]S9R9[QRH:+\(U02J>:CF
MHUJ :A+50E2+AL=[6/7[P^/;&L;HL FJI:BF4$VC6D9IS:RLJT-#<W7(D)7;
MUM")J$3+0JCFHII -0_5?%0+4$VB6HAJT4[;/]$Y& \<9W"X$ D=-D&U%-44
MJFE4RRBM&95U7ZAZ:(I*KU&ES*_^]W%5OK35D)GJG(NDYJ*:0#4/U7Q4"U!-
MHEJ(:M%.:]P9V[:'_?Y1+I+#)JB6HII"-8UJ&:4U<[%N^PS->PU]VR5R,]HY
M(='2#ZH)5/-0S4>U -4DJH6H%NVT_82<V$Z_/W4.$Q+M\Z!:BFH*U32J9936
M3,BZSS,T]WG2:@[]O&.E\5(X6NM!-1?5!*IYJ.:C6H!J$M5"5(M0+4:U!-52
M5%.HIE$MH[1F<M;EG^$8O12.UG]0S44U@6H>JOFH%J":1+40U2)4BU$M0;44
MU12J:53+**V9GW7]9VC>1>@;Y^9H"PC57%03J.:AFH]J :I)5 M1+=IIC0O@
M]L"Q#U>OHZ,FJ):BFD(UC6H9I34#LN[W#,W]GM:I^=DKU]&:#ZJYJ"90S4,U
M']4"5).H%J):A&HQJB6HEJ*:0C6-:AFE-=)T5'>!1CURNCY"FS^HYJ*:0#4/
MU7Q4"U!-HEJ(:A&JQ:B6H%J*:@K5-*IEE-;,S[KY,S+O'G3ZQF]FH'-DHF4?
M5!.HYJ&:CVH!JDE4"U$MVFG[4_/6&[^AHR:HEJ*:0C6-:AFE-</0J</PFVL\
MVU68IE.89KMS3J(='E03J.:AFH]J :I)5 M1+1H==W@<>S(=.(<='G38!-52
M5%.HIE$MH[1F4-8=GI&YP^/GL[FUF%O%KY>W^?SFY.4=,]<Y&]'2#JH)5/-0
MS4>U -4DJH6H%NVTQN+TL6V/II/#;$1+.ZB6HII"-8UJ&:4UL[$N[50/3=GH
M]!Q[=S925A/K>3G[4ECZ+I\;+^R8T<X)26HNJ@E4\U#-1[4 U22JA:@6H5J,
M:@FJI:BF4$VC6D9IS1BM.SXC=$>?$5KN0347U02J>:CFHUJ :A+50E2+4"U&
MM0354E13J*91+:.T9G[6#:#1B0;0X_J]YCI =W<@JAY=+N[OJUG[:I.H^6-Y
MNUC._M6^)Z]9[YRG:"\(U02J>:CFHUJ :A+50E2+4"U&M0354E13J*91+=MI
MS5L$C(>]7GV&NAF5=>5G9-[OY_2,W?K=2F;SV?WCO7D2CY:!4,U%-8%J'JKY
MJ!:@FD2U$-4B5(M1+4&U%-44JFE4RRBMF:QU&6B$[@4T0EM J.:BFD U#]5\
M5 M03:):B&H1JL6HEJ!:BFH*U32J9936S,^Z*S0R=X4^[D_8=_/X$_-VM""$
M:BZJB9W66+&RG@WT#E:L>.BP/JH%J"91+42U"-5B5$M0+44UU?)C?CCMW04?
M6NNAM$;PC>M:S]B\Q<]Y4_+\UY-3<O,X7?,0U5Q4$ZCFH9J/:@&J250+42U"
MM1C5$E1+44VAFD:UC-*:R5H7?L;H5C]CM/V#:BZJ"53S4,U'M0#5)*J%J!:A
M6HQJ":JEJ*903:-:1FG-_'3J_#1WA+I/R<U@YPA%BT&H)L8M&\%,ABU3<G18
M']4"5).H%J):A&HQJB6HEJ*::ODQ;SWSI-%A,TIK!E_=^1F;.S\_?EU8/]XN
M'E?Y_,IZ7_WWQZ_5O/PW2U7O'SLO=S>/U3D3T4(0J@E4\U#-1[4 U22JA:@6
MH5J,:@FJI:BF4$VC6D9IS72M6T/50W):/D#SD]1<5!.HYJ&:CVH!JDE4"U$M
M0K48U1)42U%-H9I&M8S2FOE9UX7&YBV!/K8O;;?*Q?9^'JTABG:&4,U%-8%J
M'JKYJ!:@FD2U$-4B5(M1+1D?;U8T:CL1E+9\8>L9(X4^/XUJ&:4UHZ]N^HS-
M39_W/R:67BYNEOG]_M7Q72+NWD^:YN)HU0?57%03J.:AFH]J :I)5 M1+4*U
M&-425$M13:&:1K6,TIJ!6O>!QN@60&.T]8-J+JH)5/-0S4>U -4DJH6H%J%:
MC&H)JJ6HIE!-HUI&:<W\K%L_8_,60(;;:.XNF,^+K]O/M]XMSLQW#E2T!H1J
M M4\5/-1+4 UB6HAJD6H%H^/MQ:R^\[$&3?GQPDZ:HIJ"M4TJF64UHS*NN S
M-A=\?BYF-[=E%9/YEV*9WQ36PW)VV7ZR$BWVH)J+:@+5/%3S42U -8EJ(:I%
MJ!;OM/%>* Y>CR:'D8BV>E!-H9I&M8S2&I$XJ:L_$W/UI[F!I-S;0'+_C&9;
M1)KAKA&):BZJ"53S4,U'M0#5)*J%J!;MM.%>J$U[HZ,K(7'+UPVF@_'$.8@_
M]-FEJ*903:-:1FG-^*O[.1/SACPG]Z PSYW->N<,1/LZJ"90S4,U']4"5),[
M;3\_^B-[<!0T(3ILA&HQJB6HEJ*:0C6-:AFE-:/2J:/RQ'8]52P6*^N]I9?%
M=;%<5H%Y^FJWV>P<D&@;!]4$JGFHYJ-:@&H2U4)4BU M1K4$U5)44ZBF42VC
MM&:*UKV>29^\VCU!FSNHYJ*:0#4/U7Q4"U!-HEJ(:A&JQ:B6H%J*:@K5-*IE
ME-;,S[JY4STTGZ]\>O.Y67S^ZND:]W8*WQJA1K!SA)*:BVH"U3Q4\U$M0#6)
M:B&J1:@6HUJ":BFJ*533.ZVQ+F XZ-O#@ZM@&35L,QWK7L[$W,LY2L>'?+D]
MD=F:C&@C!]5<5!.HYJ&:CVH!JDE4"U$M0K48U1)42U%-H9K>:?N+ WJO>_9A
M+/X[.CN3NK,S,7=VCF+Q;O;/Q]E57LX6<^MA\\EBWKX0R"QWSDBTKH-J M4\
M5/-1+4 UB6HAJD6H%J-:@FHIJBE4TSO-MILA>9R2_XXBSJ0NXDS,&_,<I*3U
M95&N+X<OUVLFVZ]^HU4<5'-13:":AVH^J@4G?D8&KZ?3UA!$.S>H%J%:C&H)
MJJ6HIE!-HUI&:<VHK#LWDQ.=F^VU\ _=KH6C11M4<U%-H)J':CZJ!:@F42U$
MM0C58E1+4"U%-85J&M4R2FNF:%W'F4S1:^%H)P?57%03J.:AFH]J :I)5 M1
M+4*U&-425$M13:&:1K6,TAKY.:V[.]-3W9VNU\+-8-<(1347U02J>:CFHUJP
MTTY>FY3HL"&J1:@6HUJ":BFJ*533J)916C,=ZVK/U%SMZ7PZT^QU#D>TS(-J
M M4\5/-1+3CQ,S)]X70F^B1"5(M0+4:U!-525%.HIE$MH[1F5#IU5)JK/2]$
MY4.Q7&\QD=^T7ADWFYWC$JWVH)I -0_5?%0+4$VB6HAJT4Z;-B_)3M?_=]#H
M?Z.C)JB6HII"-8UJ&:4U\[$N[4S-F_$<YN/E8OZE6*[6JX?*8GG?FHYH<0?5
M7%03J.:AFH]J :I)5 M1+3KQ^R#RR]OMR:;-V?NGBZ'51^[NK,_%[O>CG'V^
M*UY9>6GE\]^L<G9?6.O-K#8WFMG\K5QL_MQ\27E;60^;!7D5N?[;,WN[N+LJ
MEJ^LV;Q<_,=B7M0C[]^BIOW=+5H90K44U12J:53+**V9WG5EJ'KXAR[66[];
M'XIY<3V[G.5WEOHZK[+]=O9@O)AO'K-SOI.:BVH"U3Q4\U$M0#6):B&J1:@6
MHUJ":BFJ*533J)916C-EZ^K1=$A>S)^BW2-4<U%-H)J':CZJ!:@F42U$M0C5
M8E1+4"U%-85J&M4R2FOF9]U1FG;J*)UY#A9M)Z&:BVH"U3Q4\U$M0#6):B&J
M13OM]#E8M'>$:BFJ*533J)916C,?ZW;2U-P\J:?E)R(1+26AFHMJ M4\5/-1
M+4 UB6HAJD4[[3 2AX>)B):04"U%-85J&M4R2FLF8EU"FII+2+NSW]N)]P?S
MV4JT>H1J+JH)5/-0S4>U -4DJH6H%J%:C&H)JJ6HIE!-HUI&:<WLK*M'4[1Z
M-$6K1ZCFHII -0_5?%0+4$VB6HAJ$:K%J):@6HIJ"M4TJF64ULA/NU=WC]:/
M3>\^W>)SN;<0ZM73HH_BRIK-5^7R\;Z:HY]123HQ3M=L93F7Y03+>2SG/W'[
M52)G>+151< .*UDN9+F(Y6*62U@N93G%<IKE,HP[R%![+T/-]9/T<3UC7[\-
MW<7D<X:V)R5:4&(YE^4$RWDLYS]QS=*E/3DJ70;LP)+E0I:+6"YFN83E4I93
M+*=9+L.X@ZQT]K+2W%%ZX6RG];OU_O&R?%Q9WN/\ZI45QQ^-9T)/#-,]1-'>
M$LL)EO-8SF>Y@.4DRX4L%[%<S'()RZ4LIUA.LUR&<0=)V]]+6G2+HB<.2U2T
MZ\1R@N4\EO-9+F YR7(ART4L%[-<PG(IRRF6TRR78=Q!H@[V$G7P_W2NU#A.
M]Z@E.9?E!,MY+.<_<:?/E9+#2I8+62YBN9CE$I9+64ZQG&:Y#.,.,G2XEZ'F
MK8T^/;4X/];EXDZW7SXQ0/?P1#M'+"=8SF,YG^4"EI,L%[)<Q'(QRR4LE[*<
M8CG-<AG&'63L:"]C1^S,'ZT?L9S+<H+E/);S62Y@.<ER(<M%+!>S7,)R*<LI
MEM,LEV'<0:*.]Q*UTYY*9\WQT0(3R[DL)UC.8SF?Y0*6DRP7LESTQ#562/2G
MQRLDXK._,F&?8LIRBN4TRV48=Q"%D[TH-->57HK"Q6.Y*O/YU6Q^TYZ':'>)
MY5R6$RSGL9S/<@'+298+62YZXL[)PS._,F&?8LIRBN4TRV48=Y"'T[T\-"[1
M[W9"L_LR)[2QQ'(NRPF6\UC.9[F Y23+A2P7L5S,<@G+I2RG6$ZS7(9QS?RU
M]PI,=@\]V6FS/264<UE.L)S'<C[+!2PG62YDN8CE8I9+6"YE.<5RFN4RC#M(
MU+TZDXW6F<Q:]T!EZTPH)UC.>^(:<T2G=[3\R&?'#5A.LES(<A'+Q2R7L%S*
M<HKE-,ME&'<0E<Y>5)[59OJ#DWSS(-T3E.TRH9Q@.8_E?)8+6$ZR7,AR$<O%
M+)>P7,IRBN4TRV48=Y"S>UTFF^TRV6R7">5<EA,LY[&<SW(!RTF6"UDN8KF8
MY1*62UE.L9QFN0SC#A)UK\M4/>XTR=\N9;)F\[V&4WNV&N'NV4IR+LL)EO.>
MN#/F^^2X <M)E@M9+F*YF.42EDM93K&<9KD,X[:I^69U6Q2EFY?YN[?WQ?*F
M^%C<W:W/=C[.R_5;T;V/6LOB>OVC]5UL7[PY^KBTOPO;/O[>_NZ]L_[XFYI_
M]_8AORF2?'DSFZ^LN^*Z&JKW>CR\V.YH__27<O%0Y?F%]7E1EHO[S</;(K\J
MENLOJ#Y_O5B43W]9#_!UL?QE\^V\^S]02P,$%     @ QZA[6EG@6$!Q!
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MY9TOZJ"-<>B/3C[MQ,.&>&@E-KM?HBXD!RU@)\4^+1,^B_^B7$;I7[?A#]O
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MWF$/W<O\@"Q_T"*S9TPSH;5([6T,- )I!N#WN1!Z_6 <E,>4H_\ 4$L#!!0
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M(2M(_;J113YFRD#V)Y2*_8<:H/[;$/P+4$L#!!0    ( ,>H>UICL [ H@,
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MH9PLI4(Z)M8$(P-M8>DDMX7@4I<TA8F'F:Y!;<&;XM63X'V;*RHR3$S+9JO
M=AKTPFCL;UL$]AN!_4Z!<^!;QCF03X Y1_Z=0[$$];5-3"?1<\6\$MDCS8-&
M\Z!3\Q6652)7A%.1D>\GGDNEN9/HN9HKLN0H?LDH"-KCES1:DDXM5=A@;^H"
MGH%.%2MM)6[3TTUF<B S6914/" EJ)1I?/K,:"(=(S&R.BHCUO3)V['>Q,0
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M,,=.')0UP/V5E.8PL0<TO?WT!U!+ P04    " #'J'M:[L5:^!4&  "W,@
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M;',O=V]R:V)O;VLN>&UL+G)E;'/-VDMNHT 4A>&M6"P@Y?LB22O.J">91MD
M<LH/Q3:(HI5D]VTY ^>@'O0DJC-"!>+RCSX0\/"<#]VT[T]EMQ_*XN-X.)55
MLYNFX5=*9;W+QZ[<]$,^G8]L^O'83>?EN$U#MW[KMCGI<MFF\?N,YO'A^\S%
MR^>0_V=BO]GLU_EWO_YSS*?I'X/3>S^^E5W.4[-XZ<9MGE9-^CA<=Y=TV<C-
M>7*S>'I=->/3JS2I=I!"D-8/,@BR^D$.05X_*" HZ@>U$-36#[J%H-OZ07<0
M=%<_Z!Z"[NL'R1)E7!(DS; FT%J0:R'P6A!L(1!;D&PA,%L0;2%06Y!M(7!;
M$&XAD%N0;B&P6Q!O(=!;46\ET%M1;R706V</VP1Z*^JM!'HKZJT$>BOJK01Z
M*^JM!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ;01Z&^IM!'K;[&4)@=Z&>AN!
MWH9Z&X'>AGH;@=Z&>AN!WH9Z&X'>AGH;@=Z.>CN!WHYZ.X'>CGH[@=Z.>CN!
MWCY[V4V@MZ/>3J"WH]Y.H+>CWDZ@MZ/>3J"WH]Y.H'>@WD&@=Z#>0:!WH-Y!
MH'>@WD&@=Z#>0:!WS#Y6$N@=J'<0Z!VH=Q#H':AW$.@=J'<0Z-VBWNU/ZEVF
MST,NUYZO-5[_)ZF>SN?FZ^4ORZ^=>+]H+S@G^'?G\2]02P,$%     @ QZA[
M6G32QF+> 0  6B,  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS=I=3\(P% ;@
MOT)V:UCI%WX$N%%OU0O_0-T.L+"M35L0_KW= !.-$@TFOC=;MK;G/6N3YVJ3
MYYVC,-@V=1NFV3)&=\-8*);4F)!;1VT:F5O?F)@>_8(Y4ZS,@I@8C<:LL&VD
M-@YC5R.;3>YH;M9U'-QOT^M0V7::>:I#-KC=3^RRIIEQKJX*$],XV[3EIY3A
M(2%/*_LY85FY<)$F9.S+A&[D^X##NL<->5^5-'@R/CZ8)LUBVYJ%N*LIY*=+
M?-&CG<^K@DI;K)NT) _.DRG#DB@V=;XO>G$Z.:8=IOV5GYW?ESD5F&8^>>M"
M.C%/OX\['DFW>NA2(?*Q.OV)[XFI]-G?1]UIEU3^,#MM[ZOUJ_X\ NMOY^_Q
MQS-^K__+/@1('Q*D#P72AP;I8PS2QR5('U<@?5R#],%'*(V@B,I12.4HIG(4
M5#F*JAR%58[B*D>!E:/(*E!D%2BR"A19!8JL D56@2*K0)%5H,@J4&05*+)*
M%%DEBJP215:)(JM$D56BR"I19)4HLDH4626*K I%5H4BJT*15:'(JE!D52BR
M*A19%8JL"D56A2*K1I%5H\BJ4635*+)J%%DUBJP:15:-(JM&D56CR#K^3UE?
MK%W]]=\>W3UO3-4>\UG_2\WL#5!+ 0(4 Q0    ( ,>H>UI&QTU(E0   ,T
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ QZA[6H,H%K3R    *P(  !$              ( !PP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ QZA[6IE<G",0!@  G"<  !,
M     ( !Y $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #'J'M:
M'Y4^<Y4)  #L.0  &               @($E"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ QZA[6AB4\;?^!0  %QD  !@
M     ("!\!$  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M ,>H>UJUS'XX]@(  *\*   8              " @208  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " #'J'M:#&Q (^X$  !A$P  &
M            @(%0&P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ QZA[6D[II&O%!P  2#,  !@              ("!="   'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ,>H>UI>HR?':P(  ,(%
M   8              " @6\H  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " #'J'M:6Y'5\M4'  "8(@  &               @($0*P
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ QZA[6O*A(7A0
M @  /04  !@              ("!&S,  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( ,>H>UI*HSET3@(  *(%   8              "
M@:$U  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #'J'M:
M3NLOZ0L"  "O!   &0              @($E.   >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,>H>UK'QH26$ (  -P$   9
M      " @6<Z  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ QZA[6AF2$+>?!0  [A$  !D              ("!KCP  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #'J'M:?N/9P/@(  "S%
M&0              @(&$0@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( ,>H>UH:I0YA-!P  %11   9              " @;-+  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ QZA[6JDY+P=?
M P  /0<  !D              ("!'F@  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " #'J'M:DM(E6)P%  !>#0  &0
M@(&T:P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,>H
M>UJ=P521NP(  %8&   9              " @8=Q  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ QZA[6G@7Y[_W#@  #R@  !D
M         ("!>70  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " #'J'M:5?/&GV@(   P%   &0              @(&G@P  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ,>H>UIL$36[8 0  +P)
M   9              " @4:,  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ QZA[6FBF[ WH!@  =Q$  !D              ("!W9
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #'J'M:]1]_
M?KX"   K!@  &0              @('\EP  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( ,>H>UH'J#R2 1X  (I>   9
M  " @?&:  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
MQZA[6@-HX"O] P  A0@  !D              ("!*;D  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " #'J'M:!T7P!#0#  #:!@  &0
M            @(%=O0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( ,>H>UID:$-D^@,  "$+   9              " @<C   !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ QZA[6KWKGF^[ @
M,P8  !D              ("!^<0  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " #'J'M:Q?@B7&,&   ^$P  &0              @('K
MQP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ,>H>UH.
M;^$=7P4  '\-   9              " @87.  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ QZA[6B)4<NXA P  6P<  !D
M     ("!&]0  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,>H>UI*I1X"D04  '$E   9              "
M@2OI  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ QZA[
M6NZ2QZ\X!   _A8  !D              ("!\^X  'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " #'J'M:E-?@!VL"  "F!0  &0
M        @(%B\P  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( ,>H>UJJ0XG7G 0   $7   9              " @03V  !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ QZA[6D1X=,G\ P  X!$
M !D              ("!U_H  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " #'J'M:Z9659X,"  !J!@  &0              @($*_P
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ,>H>UH0 +L]
MI0(  )<&   9              " @<0! 0!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ QZA[6N"_<1/) P  ;0T  !D
M ("!H 0! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #'
MJ'M:^M##XG($  "P&0  &0              @(&@" $ >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ,>H>UK_7T.[OP,  -(-   9
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M970T."YX;6Q02P$"% ,4    " #'J'M:BL:E>KL>   [3P( &0
M    @(%=( $ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M ,>H>UI9X%A <00  $D1   9              " @4\_ 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ QZA[6KP\HT8D P  % L  !D
M             ("!]T,! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    " #'J'M:Y<6G F<#   F"@  &0              @(%21P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( ,>H>UJIV+[,D00
M +(4   9              " @?!* 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ QZA[6CK]N Z8 P  0@P  !D              ("!
MN$\! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #'J'M:
M8[ .P*(#  #G"P  &0              @(&'4P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( ,>H>UKNQ5KX%08  +<R   9
M      " @6!7 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ QZA[6L1NK:HJ P  T@@  !D              ("!K%T! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #'J'M:6/[6K< #   $%@
M&0              @($-80$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( ,>H>UI74\5I' ,  %,+   9              " @01E 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ QZA[6B_ERH0Y
M!P  )$@  !D              ("!5V@! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    " #'J'M:C%W0>3,#  !.$P  #0
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:+GAM;%!+!08     1 !$ ),2  "R?0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>186</ContextCount>
  <ElementCount>346</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999016 - Disclosure - ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperations</Role>
      <ShortName>ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999018 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999019 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999020 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999021 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999022 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999023 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999024 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/FairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999025 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999028 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/PropertyAndEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999029 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/IntangibleAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999030 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999031 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/StockholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999032 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999033 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999034 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/FairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/FairValueMeasurement</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999035 - Disclosure - ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative</Role>
      <ShortName>ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperations</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999036 - Disclosure - SCHEDULE OF REVENUE RECOGNIZED (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails</Role>
      <ShortName>SCHEDULE OF REVENUE RECOGNIZED (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999037 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails</Role>
      <ShortName>SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999038 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999039 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999040 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999041 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999042 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails</Role>
      <ShortName>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999043 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails</Role>
      <ShortName>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999044 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999045 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANT ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999046 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockWarrantsDetails</Role>
      <ShortName>SCHEDULE OF STOCK WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999047 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999048 - Disclosure - SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails</Role>
      <ShortName>SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999049 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999050 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails</Role>
      <ShortName>SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999051 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999052 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/StockholdersEquityTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999053 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999054 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999055 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails</Role>
      <ShortName>SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999056 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/IncomeTaxesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999057 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails</Role>
      <ShortName>SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999058 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/LeasesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999059 - Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999060 - Disclosure - SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999061 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999062 - Disclosure - FAIR VALUE MEASUREMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/FairValueMeasurementDetailsNarrative</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/FairValueMeasurementTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/SubsequentEvents</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>brtx-20241231.xsd</File>
    <File>brtx-20241231_cal.xml</File>
    <File>brtx-20241231_def.xml</File>
    <File>brtx-20241231_lab.xml</File>
    <File>brtx-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="665">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="7">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>92
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "BRTX",
   "nsuri": "http://biorestorative.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "brtx-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "brtx-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "brtx-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "brtx-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "brtx-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    }
   },
   "keyStandard": 308,
   "keyCustom": 38,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 34,
   "memberCustom": 28,
   "hidden": {
    "total": 88,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://biorestorative.com/20241231": 14,
    "http://fasb.org/us-gaap/2024": 71
   },
   "contextCount": 186,
   "entityCount": 1,
   "segmentCount": 68,
   "elementCount": 633,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 665,
    "http://xbrl.sec.gov/dei/2024": 41,
    "http://xbrl.sec.gov/cyd/2024": 7,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://biorestorative.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://biorestorative.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://biorestorative.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://biorestorative.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
     "longName": "00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://biorestorative.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://biorestorative.com/role/StatementsOfCashFlowsParenthetical",
     "longName": "00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "BRTX:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "BRTX:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperations",
     "longName": "999016 - Disclosure - ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS",
     "shortName": "ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://biorestorative.com/role/PropertyAndEquipment",
     "longName": "999018 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://biorestorative.com/role/IntangibleAssets",
     "longName": "999019 - Disclosure - INTANGIBLE ASSETS",
     "shortName": "INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "longName": "999020 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://biorestorative.com/role/StockholdersEquity",
     "longName": "999021 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://biorestorative.com/role/IncomeTaxes",
     "longName": "999022 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://biorestorative.com/role/Leases",
     "longName": "999023 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://biorestorative.com/role/FairValueMeasurement",
     "longName": "999024 - Disclosure - FAIR VALUE MEASUREMENT",
     "shortName": "FAIR VALUE MEASUREMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://biorestorative.com/role/SubsequentEvents",
     "longName": "999025 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://biorestorative.com/role/PropertyAndEquipmentTables",
     "longName": "999028 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://biorestorative.com/role/IntangibleAssetsTables",
     "longName": "999029 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "999030 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://biorestorative.com/role/StockholdersEquityTables",
     "longName": "999031 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://biorestorative.com/role/IncomeTaxesTables",
     "longName": "999032 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://biorestorative.com/role/LeasesTables",
     "longName": "999033 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://biorestorative.com/role/FairValueMeasurementTables",
     "longName": "999034 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
     "longName": "999035 - Disclosure - ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS (Details Narrative)",
     "shortName": "ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "BRTX:WorkingCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails",
     "longName": "999036 - Disclosure - SCHEDULE OF REVENUE RECOGNIZED (Details)",
     "shortName": "SCHEDULE OF REVENUE RECOGNIZED (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_ProductMember",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails",
     "longName": "999037 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)",
     "shortName": "SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999038 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
     "longName": "999039 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)",
     "shortName": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "999040 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails",
     "longName": "999041 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)",
     "shortName": "SCHEDULE OF INTANGIBLE ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
     "longName": "999042 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)",
     "shortName": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_custom_PatentsAndTrademarkMember",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails",
     "longName": "999043 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)",
     "shortName": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "999044 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "shortName": "SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails",
     "longName": "999045 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)",
     "shortName": "SCHEDULE OF WARRANT ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails",
     "longName": "999046 - Disclosure - SCHEDULE OF STOCK WARRANTS (Details)",
     "shortName": "SCHEDULE OF STOCK WARRANTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "999047 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails",
     "longName": "999048 - Disclosure - SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)",
     "shortName": "SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_RangeOneMember",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
     "longName": "999049 - Disclosure - SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
     "longName": "999050 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)",
     "shortName": "SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
     "longName": "999051 - Disclosure - SCHEDULE OF STOCK OPTION EXPENSE (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION EXPENSE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999052 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "999053 - Disclosure - SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "shortName": "SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails",
     "longName": "999054 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)",
     "shortName": "SCHEDULE OF INCOME TAX PROVISION (BENEFIT) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails",
     "longName": "999055 - Disclosure - SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)",
     "shortName": "SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://biorestorative.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999056 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails",
     "longName": "999057 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)",
     "shortName": "SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://biorestorative.com/role/LeasesDetailsNarrative",
     "longName": "999058 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
     "longName": "999059 - Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails",
     "longName": "999060 - Disclosure - SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "BRTX:ChangeInFairValueOfDerivativeLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails",
     "longName": "999061 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
     "longName": "999062 - Disclosure - FAIR VALUE MEASUREMENT (Details Narrative)",
     "shortName": "FAIR VALUE MEASUREMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-08",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-08",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://biorestorative.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2024-11-062024-11-06",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-27_us-gaap_SubsequentEventMember_custom_AuctusFundLLCMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "BRTX_ATMProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ATMProgramMember",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATM Program [Member]",
        "documentation": "ATM Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r676"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "BRTX_AccruedGeneralAndAdministrativeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "AccruedGeneralAndAdministrativeExpenses",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued general and administrative expenses",
        "documentation": "Accrued general and administrative expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other current liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "BRTX_AccumulatedAmortizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "AccumulatedAmortizationMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Amortization [Member]",
        "documentation": "Accumulated Amortization [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r142",
      "r491"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r676",
      "r971"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r833",
      "r834",
      "r835",
      "r837",
      "r909",
      "r972"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r740",
      "r754",
      "r780"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r743",
      "r757",
      "r783"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r733",
      "r744",
      "r758",
      "r775",
      "r784",
      "r788",
      "r796"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r335"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finite Lived Intangible Assets, Amortization expense",
        "label": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r227",
      "r233",
      "r656"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfLand",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r120",
      "r144",
      "r166",
      "r194",
      "r198",
      "r210",
      "r211",
      "r221",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r381",
      "r383",
      "r408",
      "r482",
      "r566",
      "r652",
      "r653",
      "r676",
      "r701",
      "r860",
      "r861",
      "r929"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r148",
      "r166",
      "r221",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r381",
      "r383",
      "r408",
      "r676",
      "r860",
      "r861",
      "r929"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities, fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r668"
     ]
    },
    "BRTX_AuctusFundLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "AuctusFundLLCMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auctus Fund, LLC [Member]",
        "documentation": "Auctus Fund, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r715",
      "r736"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r715",
      "r736"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r715",
      "r736"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "BRTX_BeneficialOwnershipMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "BeneficialOwnershipMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beneficial Ownership [Member]",
        "documentation": "Beneficial Ownership [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_BlackScholesOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "BlackScholesOptionMember",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Black Scholes Option [Member]",
        "documentation": "Black Scholes Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r140",
      "r643"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents - Beginning of the Year",
        "periodEndLabel": "Cash and Cash Equivalents - End of the Year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r81",
      "r164"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Decrease In Cash and Cash Equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r81"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FDIC insured limit",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FDIC amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ChangeInFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ChangeInFairValueOfDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of derivative liability",
        "documentation": "Change in fair value of derivative liability."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ChangeInValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ChangeInValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in valuation allowance",
        "documentation": "Change in valuation allowance.",
        "label": "ChangeInValuationAllowance"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r145",
      "r146",
      "r147",
      "r166",
      "r185",
      "r186",
      "r188",
      "r190",
      "r196",
      "r197",
      "r221",
      "r249",
      "r251",
      "r252",
      "r253",
      "r256",
      "r257",
      "r260",
      "r261",
      "r264",
      "r267",
      "r274",
      "r408",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r554",
      "r575",
      "r593",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r814",
      "r829",
      "r838"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r196",
      "r260",
      "r261",
      "r262",
      "r264",
      "r267",
      "r272",
      "r274",
      "r518",
      "r519",
      "r520",
      "r521",
      "r659",
      "r814",
      "r829"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding, exercise price",
        "verboseLabel": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate fair value of common stock",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable",
        "verboseLabel": "Warrants exercisable, exercisable number of warrants",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding, number of warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r109",
      "r484",
      "r553"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697",
      "r698",
      "r833",
      "r834",
      "r837",
      "r909",
      "r969",
      "r972"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common stock shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r554"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r554",
      "r572",
      "r972",
      "r973"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value; 75,000,000 shares authorized; 6,919,919 and 4,706,917 shares issued and outstanding at December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r486",
      "r676"
     ]
    },
    "BRTX_CommonStockVestRemainderPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "CommonStockVestRemainderPercentage",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of common shares",
        "documentation": "Common stock vest remainder percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ComputerSoftwareAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ComputerSoftwareAndEquipmentMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Software and Equipment [Member]",
        "documentation": "Computer Software and Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer and Revenue Concentrations",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r127"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r645"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued in conversion",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r264",
      "r695",
      "r696",
      "r697",
      "r698"
     ]
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock conversion term",
        "documentation": "Description of conversion terms for preferred stock."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r35",
      "r38",
      "r63",
      "r92",
      "r93"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenues",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r446"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r821",
      "r831",
      "r903"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r821",
      "r831",
      "r903"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r806"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r806"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r808"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r808"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r801"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r802"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r802"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r800"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r803"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r805"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r805"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r806"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r807"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r804"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt conversion, converted instrument, shares issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r23"
     ]
    },
    "BRTX_DeferredContractCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "DeferredContractCostsPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Contract Costs",
        "documentation": "Deferred contract costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred contract costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r822"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r902",
      "r903"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total Deferred Tax Liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r107",
      "r355"
     ]
    },
    "BRTX_DeferredOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "DeferredOfferingCost",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "documentation": "Deferred offering cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred offering costs",
        "label": "Deferred Offering Costs [Default Label]",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "BRTX_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "documentation": "Deferred offering costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r902",
      "r903"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Deferred Tax Assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Deferred Tax Asset",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carry-forwards not subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carry-forwards subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "BRTX_DeferredTaxAssetsRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "DeferredTaxAssetsRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right-of-use assets",
        "documentation": "Deferred tax assets right of use asset.",
        "label": "DeferredTaxAssetsRightOfUseAsset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "BRTX_DeferredTaxLiabilitiesDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "DeferredTaxLiabilitiesDepreciation",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation",
        "documentation": "Deferred tax liabilities depreciation.",
        "label": "DeferredTaxLiabilitiesDepreciation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Lease liability",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "BRTX_DemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "DemandSalesAgreementMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Demand Sales Agreement [Member]",
        "documentation": "Demand Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r31"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r31"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r545",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r581",
      "r582",
      "r583",
      "r584",
      "r587",
      "r588",
      "r589",
      "r590",
      "r609",
      "r610",
      "r613",
      "r615",
      "r691",
      "r693",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeNet",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of derivative liabilitiy",
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liabilities",
        "negatedLabel": "Change in fair value of warrant liabilities",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r104",
      "r543",
      "r545",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r581",
      "r582",
      "r583",
      "r584",
      "r587",
      "r588",
      "r589",
      "r590",
      "r609",
      "r610",
      "r613",
      "r615",
      "r644",
      "r691",
      "r693",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r396",
      "r397",
      "r404",
      "r407",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r567",
      "r569",
      "r570",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r644",
      "r912",
      "r913",
      "r914",
      "r970"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities",
        "periodStartLabel": "Balance, January 1, 2024",
        "periodEndLabel": "Balance, december 30, 2024",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "BRTX_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Net Lease Cost And Other Supplemental Lease Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r715",
      "r736"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r715",
      "r736",
      "r776"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r183",
      "r185",
      "r188",
      "r189",
      "r190",
      "r193",
      "r376",
      "r379",
      "r393",
      "r394",
      "r480",
      "r495",
      "r647"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r185",
      "r188",
      "r189",
      "r190",
      "r193",
      "r376",
      "r379",
      "r393",
      "r394",
      "r480",
      "r495",
      "r647"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r192"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r667"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r343",
      "r366",
      "r667"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in federal valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r667",
      "r832",
      "r895"
     ]
    },
    "BRTX_EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment for stock-based compensation",
        "documentation": "Adjustment for stock-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r667"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r832",
      "r895",
      "r896"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior year income taxes, percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r895",
      "r896"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax, net of valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r667",
      "r832",
      "r895"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r667"
     ]
    },
    "BRTX_EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax return to provision adjustment",
        "documentation": "Effective income tax rate reconciliation tax return to provision adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued bonuses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r938"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining amortization period (years)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized expense",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r136",
      "r154",
      "r155",
      "r156",
      "r168",
      "r169",
      "r170",
      "r172",
      "r177",
      "r179",
      "r181",
      "r195",
      "r222",
      "r223",
      "r240",
      "r276",
      "r364",
      "r365",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r416",
      "r418",
      "r431",
      "r494",
      "r508",
      "r509",
      "r510",
      "r524",
      "r593"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r372",
      "r816",
      "r817",
      "r818",
      "r904",
      "r905",
      "r906",
      "r907"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r740",
      "r754",
      "r780"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r737",
      "r751",
      "r777"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "BRTX_ExercisePriceFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ExercisePriceFiveMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Five [Member]",
        "documentation": "Exercise Price Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ExercisePriceFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ExercisePriceFourMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Four [Member]",
        "documentation": "Exercise Price Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ExercisePriceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ExercisePriceOneMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price One [Member]",
        "documentation": "Exercise Price One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ExercisePriceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ExercisePriceThreeMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Three [Member]",
        "documentation": "Exercise Price Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ExercisePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ExercisePriceTwoMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Two [Member]",
        "documentation": "Exercise PriceTwo [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ExistingWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ExistingWarrantMember",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing Warrant [Member]",
        "documentation": "Existing Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expire from 2030 to 2038 [Member]",
        "documentation": "Expire from 2030 to 2038 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of adjustment",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r6"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r671"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE RECURRING BASIS",
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r406",
      "r437",
      "r438",
      "r439",
      "r657",
      "r658",
      "r662",
      "r663",
      "r664",
      "r668",
      "r671"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r288",
      "r293",
      "r397",
      "r404",
      "r437",
      "r662",
      "r663",
      "r664",
      "r668"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r288",
      "r293",
      "r397",
      "r398",
      "r404",
      "r438",
      "r657",
      "r658",
      "r662",
      "r663",
      "r664",
      "r668"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r397",
      "r398",
      "r399",
      "r400",
      "r404",
      "r439",
      "r657",
      "r658",
      "r662",
      "r663",
      "r664",
      "r668",
      "r671"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r406",
      "r437",
      "r438",
      "r439",
      "r657",
      "r658",
      "r662",
      "r663",
      "r664",
      "r668",
      "r671"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Beginning Balance",
        "negatedPeriodEndLabel": "Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r224",
      "r232",
      "r656"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r639",
      "r656"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r639",
      "r656"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r639",
      "r656"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r639",
      "r656"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r639",
      "r656"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r447",
      "r448",
      "r639"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Finite Lived Intangible Assets, Gross, Ending balance",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r232",
      "r448",
      "r656"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r232",
      "r235",
      "r236",
      "r238",
      "r447",
      "r639",
      "r656"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r639"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r854"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Assets, weighted average amortization period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r744",
      "r758",
      "r784"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r744",
      "r758",
      "r784"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r744",
      "r758",
      "r784"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r744",
      "r758",
      "r784"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r744",
      "r758",
      "r784"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_GainOnExchangeOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "GainOnExchangeOfWarrants",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StatementsOfOperations",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on exchange of warrants",
        "negatedLabel": "Gain on exchange of warrants",
        "documentation": "Gain on exchange of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r577"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_GrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "GrantIncome",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income",
        "documentation": "Grant income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r75",
      "r119",
      "r166",
      "r221",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r408",
      "r649",
      "r652",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r860"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r715",
      "r736"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r87",
      "r669"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r89"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r243",
      "r244",
      "r401",
      "r402",
      "r405",
      "r505",
      "r507",
      "r578",
      "r639",
      "r670",
      "r940"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r401",
      "r402",
      "r405",
      "r505",
      "r507",
      "r578",
      "r639",
      "r670",
      "r940"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r343",
      "r344",
      "r351",
      "r361",
      "r667",
      "r899"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r343",
      "r344",
      "r351",
      "r361",
      "r667",
      "r899"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r339",
      "r343",
      "r348",
      "r349",
      "r350",
      "r352",
      "r359",
      "r367",
      "r369",
      "r370",
      "r371",
      "r523",
      "r667"
     ]
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationDescription",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax examination, description",
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax provision (benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r133",
      "r180",
      "r181",
      "r194",
      "r201",
      "r211",
      "r342",
      "r343",
      "r368",
      "r496",
      "r667"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r340",
      "r341",
      "r352",
      "r353",
      "r358",
      "r363",
      "r517"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r163",
      "r360",
      "r361"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r820",
      "r828"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r744",
      "r758",
      "r775",
      "r784",
      "r788",
      "r796"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r799"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r799"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r799"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r237",
      "r239",
      "r638",
      "r639"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r444",
      "r445",
      "r447",
      "r646",
      "r852"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Finite Lived Intangible Assets, Net, Ending Balance",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r854",
      "r856"
     ]
    },
    "us-gaap_InterestAndDividendIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestAndDividendIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividend and interest income",
        "label": "Dividend and interest income",
        "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r114",
      "r115",
      "r116",
      "r974"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r840"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r161",
      "r162"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r926"
     ]
    },
    "BRTX_IssuanceOfCommonStockHeldInAbeyance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "IssuanceOfCommonStockHeldInAbeyance",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock held in abeyance",
        "documentation": "Issuance of common stock held in abeyance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net lease costs",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r675"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r429"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://biorestorative.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_LessorOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LessorOperatingLeaseOptionToExtend",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease extension description",
        "documentation": "Description of terms and conditions of option to extend lessor's operating lease."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r62",
      "r166",
      "r221",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r382",
      "r383",
      "r384",
      "r408",
      "r552",
      "r648",
      "r701",
      "r860",
      "r929",
      "r930"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r110",
      "r488",
      "r676",
      "r830",
      "r850",
      "r923"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r139",
      "r166",
      "r221",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r382",
      "r383",
      "r384",
      "r408",
      "r676",
      "r860",
      "r929",
      "r930"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities, fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r910"
     ]
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ManufacturingEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ManufacturingEquipmentMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing Equipment [Member]",
        "documentation": "Manufacturing Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments held in marketable securities",
        "verboseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r748"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r749"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r750"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r750"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r750"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r750"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r295",
      "r336",
      "r400",
      "r442",
      "r504",
      "r506",
      "r513",
      "r544",
      "r545",
      "r599",
      "r602",
      "r606",
      "r607",
      "r617",
      "r636",
      "r637",
      "r655",
      "r659",
      "r665",
      "r671",
      "r672",
      "r673",
      "r674",
      "r686",
      "r862",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r913",
      "r914"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r913",
      "r914"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r912",
      "r913",
      "r914"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r913",
      "r914"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r671"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r671"
     ]
    },
    "BRTX_MedicalEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "MedicalEquipmentMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Medical Equipment [Member]",
        "documentation": "Medical Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_MelvilleLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "MelvilleLeaseMember",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Melville Lease [Member]",
        "documentation": "Melville Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r295",
      "r336",
      "r400",
      "r442",
      "r504",
      "r506",
      "r513",
      "r544",
      "r545",
      "r599",
      "r602",
      "r606",
      "r607",
      "r617",
      "r636",
      "r637",
      "r655",
      "r659",
      "r665",
      "r671",
      "r672",
      "r673",
      "r686",
      "r862",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided By Financing Activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided By Investing Activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Investing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Used In Operating Activities",
        "negatedLabel": "Cash flows from operations",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r83"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r83",
      "r113",
      "r137",
      "r151",
      "r152",
      "r156",
      "r166",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r187",
      "r221",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r376",
      "r379",
      "r394",
      "r408",
      "r493",
      "r574",
      "r591",
      "r592",
      "r699",
      "r860"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_NewWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "NewWarrantsMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Warrants [Member]",
        "documentation": "New Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_NoInsiderTradingFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "NoInsiderTradingFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No insider trading flag",
        "documentation": "No insider trading flag."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "BRTX_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Noncash Lease Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Table]",
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss From Operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r649",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost (cost resulting from lease payments)",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r675"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "verboseLabel": "Current liabilities - operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities - operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "BRTX_OperatingLeaseLiabilityReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "OperatingLeaseLiabilityReduction",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease - operating cash flows (liability reduction)",
        "documentation": "Operating lease liability reduction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease - operating cash flows (fixed payments)",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r427"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "verboseLabel": "Non-current leases - right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average incremental borrowing rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r675"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carry forwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r103",
      "r514",
      "r515"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r742",
      "r756",
      "r782"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r745",
      "r759",
      "r785"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r745",
      "r759",
      "r785"
     ]
    },
    "BRTX_PatentsAndTrademarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "PatentsAndTrademarkMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents and Trademark [Member]",
        "documentation": "Patents and Trademark [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_PatentsAndTrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "PatentsAndTrademarksMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents and Trademarks [Member]",
        "documentation": "Patents and Trademarks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal settlements paid",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "BRTX_PaymentsForProceedsFromDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "PaymentsForProceedsFromDeferredOfferingCosts",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred offering costs",
        "documentation": "Payments for proceeds from deferred offering costs.",
        "label": "PaymentsForProceedsFromDeferredOfferingCosts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent expense",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlowsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Table]"
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock voting percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r600",
      "r603",
      "r605",
      "r618"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, liquidation preference",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r63",
      "r829",
      "r863"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r692",
      "r695",
      "r696",
      "r697",
      "r698",
      "r969",
      "r972"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r260"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r554"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r260"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r554",
      "r572",
      "r972",
      "r973"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r485",
      "r676"
     ]
    },
    "us-gaap_PreferredStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockVotingRights",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock voting rights",
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r63"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from debt issuance costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "BRTX_ProceedsFromExchangeAndIssuanceOfWarrantsNet1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ProceedsFromExchangeAndIssuanceOfWarrantsNet1",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exchange and issuance of warrants, net",
        "documentation": "Proceeds from exchange and issuance of warrants net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of common stock in direct-offering",
        "verboseLabel": "Net proceeds offering price",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of common stock in at-the-market offering",
        "verboseLabel": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of warrants",
        "verboseLabel": "Issuance of warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueMeasuredOnRecurringBasisDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "negatedLabel": "Exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "BRTX_ProceedsFromWarrantExercisesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ProceedsFromWarrantExercisesNet",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from warrant exercises, net",
        "documentation": "Proceeds from warrant exercises net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r446",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r641",
      "r660",
      "r685",
      "r686",
      "r687",
      "r689",
      "r690",
      "r858",
      "r859",
      "r865",
      "r939",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails"
     ],
     "auth_ref": [
      "r213",
      "r446",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r641",
      "r660",
      "r685",
      "r686",
      "r687",
      "r689",
      "r690",
      "r858",
      "r859",
      "r865",
      "r939",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r429"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://biorestorative.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r128",
      "r131",
      "r132"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property plant and equipment gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r141",
      "r492"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r429",
      "r481",
      "r492",
      "r676"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r128",
      "r131",
      "r490"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://biorestorative.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r429"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property plant and equipment estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r287",
      "r295",
      "r325",
      "r326",
      "r327",
      "r336",
      "r400",
      "r440",
      "r441",
      "r442",
      "r504",
      "r506",
      "r513",
      "r544",
      "r545",
      "r599",
      "r602",
      "r606",
      "r607",
      "r617",
      "r636",
      "r637",
      "r655",
      "r659",
      "r665",
      "r671",
      "r672",
      "r673",
      "r674",
      "r686",
      "r693",
      "r857",
      "r862",
      "r913",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r287",
      "r295",
      "r325",
      "r326",
      "r327",
      "r336",
      "r400",
      "r440",
      "r441",
      "r442",
      "r504",
      "r506",
      "r513",
      "r544",
      "r545",
      "r599",
      "r602",
      "r606",
      "r607",
      "r617",
      "r636",
      "r637",
      "r655",
      "r659",
      "r665",
      "r671",
      "r672",
      "r673",
      "r674",
      "r686",
      "r693",
      "r857",
      "r862",
      "r913",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ]
    },
    "BRTX_RangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "RangeOneMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range One [Member]",
        "documentation": "Range One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_RangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "RangeThreeMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Three [Member]",
        "documentation": "Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_RangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "RangeTwoMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Two [Member]",
        "documentation": "Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Pronouncements",
        "documentation": "Recently issued accounting pronouncements [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r726",
      "r737",
      "r751",
      "r777"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r294",
      "r432",
      "r433",
      "r483",
      "r489",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r571",
      "r573",
      "r598"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r294",
      "r432",
      "r433",
      "r483",
      "r489",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r571",
      "r573",
      "r598",
      "r928"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r639",
      "r652",
      "r937"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r738",
      "r752",
      "r778"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r739",
      "r753",
      "r779"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r746",
      "r760",
      "r786"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r94",
      "r487",
      "r511",
      "r512",
      "r522",
      "r555",
      "r676"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r168",
      "r169",
      "r170",
      "r172",
      "r177",
      "r179",
      "r181",
      "r222",
      "r223",
      "r240",
      "r364",
      "r365",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r385",
      "r387",
      "r388",
      "r390",
      "r392",
      "r416",
      "r418",
      "r508",
      "r510",
      "r524",
      "r972"
     ]
    },
    "BRTX_ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Return and cancellation of shares in lieu of payroll tax withholding",
        "documentation": "Return and cancellation of shares in lieu of payroll tax withholding.",
        "label": "Return and cancellation of shares in lieu of payroll tax withholding [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails",
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues, net",
        "verboseLabel": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r194",
      "r199",
      "r200",
      "r209",
      "r211",
      "r213",
      "r214",
      "r216",
      "r285",
      "r286",
      "r446"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r640"
     ]
    },
    "BRTX_RothCapitalPartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "RothCapitalPartnersLLCMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roth Capital Partners LLC [Member]",
        "documentation": "Roth Capital Partners LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of aggregate shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "auth_ref": [
      "r182",
      "r296",
      "r815",
      "r836"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION EXPENSE",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INCOME TAX PROVISION (BENEFIT)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF NET DEFERRED TAX ASSETS AND LIABILITIES",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STATUTORY FEDERAL INCOME TAX RATE",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r667",
      "r895"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF REVENUE RECOGNIZED",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r372",
      "r816",
      "r817",
      "r818",
      "r904",
      "r905",
      "r906",
      "r907"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r232",
      "r235",
      "r236",
      "r238",
      "r447",
      "r639",
      "r656"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INTANGIBLE ASSETS",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r853"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r429"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION ACTIVITY",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r95"
     ]
    },
    "BRTX_ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK WARRANTS",
        "documentation": "Schedule of share based compensation warrant outstanding and exercisable by exercise price range [Table text block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r90",
      "r92",
      "r93",
      "r94",
      "r145",
      "r146",
      "r147",
      "r196",
      "r260",
      "r261",
      "r262",
      "r264",
      "r267",
      "r272",
      "r274",
      "r518",
      "r519",
      "r520",
      "r521",
      "r659",
      "r814",
      "r829"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANT ACTIVITY",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r855"
     ]
    },
    "BRTX_SectionThreeHundredAndEightyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "SectionThreeHundredAndEightyTwoMember",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Section 382 [Member]",
        "documentation": "Section 382 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "auth_ref": [
      "r214",
      "r215",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r538",
      "r540",
      "r542",
      "r601",
      "r604",
      "r608",
      "r619",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r642",
      "r661",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r688",
      "r693",
      "r865",
      "r939",
      "r941",
      "r942",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r212",
      "r214",
      "r650",
      "r651",
      "r654"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r825",
      "r864"
     ]
    },
    "BRTX_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Convertible Preferred Stock [Member]",
        "documentation": "Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r825",
      "r864"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average estimated fair value of warrants granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares outstanding beginning",
        "periodEndLabel": "Number of shares outstanding ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividends",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ]
    },
    "BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, Exercisable Ending",
        "documentation": "Non option equity instrument exercisable number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Warrants, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Warrants, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Warrants, Outstanding Beginning",
        "periodEndLabel": "Number of Warrants, Outstanding Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97"
     ]
    },
    "BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non options exercisable weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding beginning balance",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding ending balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares of common stock authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant options shares",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options, Exercisable Ending",
        "label": "Options Exercisable, Exercisable Number of Options",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Exercisable Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Granted",
        "verboseLabel": "Options to purchase shares",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value of stock options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic Value, Outstanding Ending",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options, Outstanding beginning",
        "periodEndLabel": "Number of Options, Outstanding ending",
        "label": "Options Outstanding, Outstanding Number of Options",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average price",
        "verboseLabel": "Exercise price",
        "documentation": "Change in the weighted average exercise price of options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ]
    },
    "BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "ShareBased compensation arrangements by share based payment award non options exercised in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Expired",
        "documentation": "Weighted average exercise price, expired."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "Share based compensation arrangements by share based payment award non options granted in period weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r303",
      "r322",
      "r323",
      "r324",
      "r325",
      "r328",
      "r331",
      "r332",
      "r333",
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock authorized to issue",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding, Exercise Price",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life In Years, Exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non options exercisable weighted average remaining contractual term1."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life In Years, Outstanding",
        "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average remaining contractual term2."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intrinsic Value, Outstanding Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life in Years Exercisable Ending",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life in Years Outstanding Ending",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Grant options shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested common stock, shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfInformationRelatedToStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable Weighted Average Remaining Life In Years",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "BRTX_SharesHeldInAbeyance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "SharesHeldInAbeyance",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares held in abeyance",
        "documentation": "Shares held in abeyance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State &amp; Local:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r145",
      "r146",
      "r147",
      "r166",
      "r185",
      "r186",
      "r188",
      "r190",
      "r196",
      "r197",
      "r221",
      "r249",
      "r251",
      "r252",
      "r253",
      "r256",
      "r257",
      "r260",
      "r261",
      "r264",
      "r267",
      "r274",
      "r408",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r554",
      "r575",
      "r593",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r814",
      "r829",
      "r838"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r67",
      "r68",
      "r136",
      "r154",
      "r155",
      "r156",
      "r168",
      "r169",
      "r170",
      "r172",
      "r177",
      "r179",
      "r181",
      "r195",
      "r222",
      "r223",
      "r240",
      "r276",
      "r364",
      "r365",
      "r373",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r416",
      "r418",
      "r431",
      "r494",
      "r508",
      "r509",
      "r510",
      "r524",
      "r593"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r538",
      "r540",
      "r542",
      "r601",
      "r604",
      "r608",
      "r619",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r642",
      "r661",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r688",
      "r693",
      "r865",
      "r939",
      "r941",
      "r942",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r195",
      "r418",
      "r446",
      "r516",
      "r535",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r573",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r593",
      "r694"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://biorestorative.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r296",
      "r815",
      "r819",
      "r836"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/FairValueMeasurementDetailsNarrative",
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfFairValueValuationAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionExpenseDetails",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r195",
      "r217",
      "r418",
      "r446",
      "r516",
      "r535",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r573",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r593",
      "r694"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r741",
      "r755",
      "r781"
     ]
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued during period value warrants",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options",
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r46"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharebasedCompensationAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation:"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in connection with abeyance shares, shares",
        "documentation": "StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWith abeyance shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series B Convertible Preferred Stock into common stock, shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r35",
      "r63",
      "r64",
      "r94"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance and sale of common stock, net of issuance costs, shares",
        "verboseLabel": "Sold shares of common stock",
        "terseLabel": "Stock issued during period shares new issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r64",
      "r94",
      "r518",
      "r593",
      "r621"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in connection with warrant exchange, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted share units, shares",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r94"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r64",
      "r94"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r64",
      "r94",
      "r309"
     ]
    },
    "BRTX_StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in connection with abeyance shares",
        "documentation": "Stock issued during period value common stock issued in connection with abeyance shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series B Convertible Preferred Stock into common stock",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r67",
      "r68",
      "r94"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash fee for services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance and sale of common stock, net of issuance costs",
        "verboseLabel": "Offering price",
        "terseLabel": "Stock issued during period value new issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r64",
      "r94",
      "r524",
      "r593",
      "r621",
      "r700"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in connection with warrant exchange",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted share units",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r64",
      "r94"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r63",
      "r64",
      "r94"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return and cancellation of shares in lieu of payroll tax withholding",
        "documentation": "Return and cancellation of shares in lieu of payroll tax withholding."
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return and cancellation of shares in lieu of payroll tax withholding, shares",
        "documentation": "Stock return and cancellation of shares in lieu of payroll tax withholding shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r67",
      "r68",
      "r85",
      "r556",
      "r572",
      "r594",
      "r595",
      "r676",
      "r701",
      "r830",
      "r850",
      "r923",
      "r972"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r165",
      "r259",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r276",
      "r391",
      "r596",
      "r597",
      "r625"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r435"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r435"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r435"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r435"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r435"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r436"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationRelatedText": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationRelatedText",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the year for:",
        "documentation": "Additional textual information about cash receipts or disbursements in the period required to be supplementally disclosed."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r927"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r846",
      "r847",
      "r848"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "BRTX_TwoThousandAndTwentyOneStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "TwoThousandAndTwentyOneStockIncentivePlanMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Twenty One Stock Incentive Plan [Member]",
        "documentation": "2021 Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BRTX_TwoThousandTwentyOneStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "TwoThousandTwentyOneStockIncentivePlanMember",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Stock Incentive Plan [Member]",
        "documentation": "2021 Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r125",
      "r126",
      "r129",
      "r130"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "BRTX_WarrantAndOptionValuationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "WarrantAndOptionValuationPolicyTextBlock",
     "presentation": [
      "http://biorestorative.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant and Option Valuation",
        "documentation": "Warrant and option valuation [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants for cash and the payment",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWarrantActivityDetails",
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r692",
      "r695",
      "r696",
      "r697",
      "r698"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable, weighted average remaining life in years",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r913",
      "r914"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Common Shares Outstanding - Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r190"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Common Shares Outstanding - Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r190"
     ]
    },
    "BRTX_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://biorestorative.com/20241231",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://biorestorative.com/role/OrganizationLiquidityGoingConcernAndBusinessOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital",
        "documentation": "Working capital."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480513/718-10-30-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "30",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480843/718-30-35-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-4"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001641172-25-001011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-001011-xbrl.zip
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MZCZT-<:^%^H[F\2E]VM0-G7F.%&\X[FV94***43U"6&%'1S<<,P0 <G7V+=
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MT!7 :APGW 0)<#,/?<_Q4+<KX*)R3/[G40CR2;8@,.PK'[#5=W%+JW-,WK0
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M'K,0. ZC(H=-U_FVK4#QD9!T9995BWN(2ZJ< 6.O/+_P\EQ>]CQ#^8M"R3F
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M[MN>3?]#4\8>39=ZU]IAQ_3]E>,M6-R9L\?(=%<+%P<&7) 7<$%3A>*-Z?]
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M#4V]#,;RP<4KA%C09?A Q2$Z^()=%-51E)Z56)X-[9;O) @MPF:G6>U.B>,
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MZJRHXD4.-"1QU/L2=-5 :FD"U &VIB&5V"."_ W%$O67LCJH\@OGF68'-9E
M1DIW"@.7%6^03=_R$ N?MLYNK.J&5 '!"YB A/Y!F95R%?E$BI&/"']7SC/]
M6R":'W ?5?[WXE-$P(M^WO?A?.Y82'HMRVRN,*NV($PP&Q!"G\I>QTPOFIM6
MR&Y 2JYFG"ZW7QH#@10K$ Q?U,48Z6M5W5ZGY]$ @"T*.V4VOSW7;<\7>8LY
M;$@$?.I':.8Y\OCL-6XF.IE,U.,VSH%--PE'=W# >_1QIUGS\,@@7SN_PYI&
ML@4BGU6MET)DIWESD<E@ SQA:N=0F 5H'KE]9\X)94IT;AYZTDR!IU!56/:6
M#Z;C4U*'\S[V%GWGD:S4\0LU^!)UG>"!1E"'<QA1Z2&:AVM.UL#CKC)TO1#1
MO!/"<]>AU;$\.RYNMBF.Q8%5V+>!>$KR!!Z#RSUC'?MN<7/DSV<!/-/J<2<4
M9)=S$_3@$:_T3=#-4V2C/DO)VGV03'EAG5,*UBD%JP$I6*?8M.K8M'ZY!J?8
M]"DV?8I-U_T>1!DQ3\TLV4(A3QT=FR4'/!5=Z:LDX%E)AB(P1=:I"1,\#Y],
M1HW<=!%W;%">1@Z&0$]9LR/1C4L8@-D G22:1Z(_-P8"*58@&#XKFRCL?6?Z
ME'9O^>#C1V8."?<<3B=BRS0&,EENX(.S?H>J:Y_[O@>_W^VY;MEL(N^'##\0
M?.K*K%A6M(Q<,Z1%OA]\9#GL2BSYNXN8F#T:?_?#Y&%PD$<8YK*^T#R%*)=S
M[4X((+W9;VN(I$F?IV@<Q&)NP(."RAC%FNR,H 3OLOC[M_O1B4U$(CL6D;X8
MOF6W$I:V_LR>%YK>@A:+B".N<+3E_3DOVM(;3-N#Z]XE^5=[,C&FRBML7E&!
M(19+WN?Q0$\S#N=2O56'63A42@=:Q&-H$VK) RD8;)&5F?;A%@XCEZL;\P_L
M=UPS$%26S#6(!N$7:?1P<3:ULQTXU&]IERGVEWL@-0&:(FA)X\V3F$Y!&U6@
MZQS,J5TQ:@WPC,C9QV.5_J>^::.EZ?^ '3KL_3JP@Z) 3]%IAV5YTFYI[CL6
MT6VXCL?:4Y5N5L$,JP,=D!40E))=U"D/0=H3P)TBW#ZJXFPE3!,Q7Z7'W*K<
MT03.3U'/VW-%=P^/.)'(\:2="Y1#-J"3A6 %QGIA0'.YU&ZOVZ=^@,+- S37
M&-M/CIOU!/,V*US8NXGPRO,EX=RL.9R1TKE#3R G2,'MUT0093@"CP$:+L5C
M1 5&'X9*ATS8"[OGA=9CWH!-!/PH5B%-T.0F!6_#2;%D/#]00Y[G\;_@>?RO
M>H/>U&CU>]^,;H;[OWTS'$][_VY/>\-!R_AM9 PFZI_=.@4%3D&!4U#@%!0X
M!05.08%34. 4%&AD4"!O3. %A@1.$0$=P#E%!#0!X@5&!&IQ)BNZ)U*S,YEW
MC41=*G5%OL?F02K#D<0NIZG'Z2IBUP+S^9W>'>%WNII-9V-#Z'ZJ+<&63$L_
M0O:::V+%#,-[Y'<BWV<IT^:=X[+WMCCR>,^31[O3&<^(*#9,TNSBX?2K,6YU
M9N,QS3#N]]J7O7YOVE,C@N3-Q[9%&CCABL/H!QZCW]OC<?RXUK3WK3?]7;4S
M,7Y$U@QHI;\E1=>,EQB?OC(17S'?-AF9*_JC]I/IVQ*NQC+&5NV(%/(00$Q(
M^RF/_H0V;LSRE ET<I:$A_8^T)AD8<69O68:^#'+ @CS^-3NP%R<ZRUGGDWO
M%,DXOJKYFAJ7:#:RN 9^]?.,-E^+=/:QJM(T31]_*?1.NYJ#::7SG_>TNXZ^
MV<)&UH <S1_8X?7/B)Q@>EY #!PFO6$4!N3$2[.]!A%?'>KXNJHR-=69KW4)
MK6P/&:\:[5'\I.G_CIS%/77X/2+?7"#CF5B=3H!&OL.O<5L+ 2]'%Q7([6=8
M.Z_I=K'U*M6R8B;??#FZ68^H0(._YM41M%:VLRPANY?D;%:Q1)9+Q<O1157"
M T\(+VBQ7'-=[W*Y^>K+4=*ZA 4I9=%72"I<,C>$*UXT<]'Q<C12G?@@'57V
MEDHEL_+!\=DP5<3;I+[[<E2U/G%!JEG%ZS!'SSM"N@:+IS05+T<?50D/TLY/
M%6CGG5A@=T6<#IN+;AWLA3ZM?FNZ4^0O+WA*6CLQ+U!7U<B0%[W7R\,)&=8T
MR TZV<OQT8D__0+UL0Z)@=I7<DIX"6[:% -J_.N2!)PT\0BY@?I8A4?SN 4?
M9@M:\+/N^)>T^Q0@Y@7JJ1H9@CJ;\G.J3 .?A-CZD60!\-*9/_*R?"?38>=_
MUKF^R@L&9.M0_,AF.PKOL>_\!]DS(C2?<1\C3-,E@ITU9TRUXT"O9/T0QW]/
MSUQ@*;XN5X><'9D@?.QW-<\:+DL]<V82EX.F]NG%)3//3U*NY&/:ICJ7I$$R
MOLI2\-(^/:/@2E L_?7(CZG)H:Y2.TK30Q%"^B=B-T<1=4[#;K2RUEHV8X>(
MH0>78Z"MLQMKE;!=SC*!97@N>VN306CZA.41VC16539#!42[3-?E3=TE@33-
M,9%2S565U5 "U![;X Y=)517./+ED=JVOLU:AU\H4'M<@SM3I3@YCSEFU+:U
M7B[5BG':Y1I,JU-V]&+%>395#H;^F+IT=_?7]2^#Y+<!IPIOH>%N%97@K=4!
M55PRD-(H.R5ELI**[.=4CU3/GU<3]H6@G8]FK9MMSXZ5,T4QC?((;Y*"/7\*
MT*6$ )I;6LWT.#%B.)\@*_)9]9^.Z;K(OESMKU\Y%P+Y@7\*E2E#1J!AJ%'0
M-1:21(&E3^+0ZW#$:F9E5%FJ\5':.?:73#'&B%6TF^(4G[S8\F?^([57P_%-
M7!-L;/3;4Z/;F@YW^#Y%G$\1YU/$^11Q/D6<3Q'G4\3Y)0?Z3A'G4\19"T4\
M19Q?0L29?5<4:=YM]+(CS(>\UA19CO=G041YM]$+#U!F,%M76#+^M#!RO-_L
MA0>X,MG5+[)5JC1F#\1L3XY]2R>L:8O=^^KMYQ>@5\)C<]4"U"Z<5OBJS^&=
MVLJJ.$*?^HE5\EBIZ7DF/K@<5E"FJ6MBB12.N,"?QD$]@3^/SFLB:^W"HL<N
M"#(E 4I:>PXOM/\TVENZU)H33$UJ$+:#(%H*HXY?I,.JU_1:J]&EKQ7-;O2(
M. [G\P"%(7WQ7/8E;$X7-<O)/D&"<!W07)LHFQ"2O<G*95_[^%87^<XCFY/;
M,B)C)_C!#U3Q>RF+./&AP#E8T,ZZW9*[MC'H\P BCSF_EYH8C)3@(:Q@YG6*
MBI0/ELYQBI(!U?3=D91Y(GI[Y*"IHF"#U+3!8M+K60P#/TSA0/ZUQ8#\XY:7
M/D%^KT/"@]3VLTMK/6=#&=&"2KTF>-V@YETC4UXXF[2:=H(2Q:GENBXO\CK7
M:H'4;XC(EM&2)_>=)G6OR8"N8I@Z+=:&&_-9*-9TD]KO!8OE>D >N)\USR-W
M93K^-].-4,I70FVO*Q\1:RQ$U.<R-D->]FS5G[[]H,;ZR7N.KT<0>H;OBM34
MRV*;OK1MT2L#0"%$KG>^C&\V2MFJDX!V[HM2)]>:WV_8)<.X3KBJ<8G+_GBC
M]*X&4;R<F!>/\:[SZ-C(LQ6H7_K3/[7R'0A"\S#7S'LD#9 ])G_Z#N6 ^5QF
MY&N<*->'M[PHUVSPS9C0R-:8_&?<Z]"_QI&OV:"G:R'7(L6 2YQ<?=5AL]+?
MGL]_,R[')[0)SY6G3#DOO.7&0_O87^;+XH=:M-=,V_MD^0'"/#Z;9T,?\9QX
M@86UT-?4A!RSD<UIG!SS6+M&L<GF:Y&6/G/%FJ9IT#3+R!U/9J( *K>;5C>W
M2EH?<#[VF[<U0;(Y>,%H&-XC?WIOKM_K&.#DO%19IFE>$O2Z'J7R0<E"DM/3
M 5X)^RR--5B_:ZA"=7<I.&GN,8+[B1;=;VS2JE3<70I.BGN,X%Z.+U[(_17V
MY\A1K+L'1)S4]TC9:>[23R5-TJB$%R".(_]<^KJ*\=O(&$P,Y=[[T P9J#+>
M^(RVJM)U$TI$+O*]=OKXN4&Q'Z3L9G&JO?.YYY&9A+9<TH]0*7-=T=Q.ZAS3
MV0A@>=*ULRT!:D7N/D$W-=Y?&<E+8:6O4[<*N'1VLY8,J:;>TVOD(=]TVY[=
MMI=$[,1J8C9(8F2(O*A2W15Y4^5F&"[&CW:K:=,"K3+[F62T5-]#IO9QKE.T
M5/W&VGPMTGD;/T5+=Y3-6#ZX>(50CJNF8)>7'R7ELJ[==M1VV;C(SI908L-P
M; .I_LH>%I%U5N1@0[M X4;AD/_H6"B;@TW(D^ES,,6AZ:9_W\%!.,#A[R@<
M(PLO/%HU:#M2W&G?*2HQ_>LF27M%4RL9[4X@E8DC]M)?83_Y$6W'N?E5+QT_
MKY;"XI#8&17$4N@>?H]=0DD0QXB2F,> O@I%VV:%4BX.0BDT?/)UV.\:X\E?
M__+YXOS3/UK&OV;IEY1:FQ$5A5.29[$8QQ(1%:"Y\BL+E)[+%:-._A+"82=M
MPBU<6."; I 8M ^_;):H-.."UVG@+CK<"0"A ,)E$.,:[=II$D6^@ZRVBAY9
M$4HX\Z' #"YU\@0=AX7.7ICC\=+4GT*L*@<%[1$9#?E^DDTM+-X%=U+D4^',
M#YR'=.V6MYC>RR+X9':JO?9,,8!@VD&$U.U >+DD)PS*X*4(F<.VJLY?TH
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M:(L,UUS\Y3@#45?W5$O*!$R(7K/"S1*%>S4"0S$#(%3J_&+QL6S-XMI@[^"
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M^^?9GK@()S_6O\OXU<Z@Z#E$GKW-6-Z1[IV#?58&PZ1O8;ZQ\/*,"7=;+&J
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M8H)=Y#N/S&>7HEXXTWB]&@::D!6)J%G]GN2L_5OB08"/%_LNU4-_,7W?X/1
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M4VZ:^^T43XBA?]!3"OG)_P=02P,$%     @ QZA[6O%6(L^;?@  77(' !4
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MA_?__(0N+PW*_8+C($D_+V9UN<]YOLU^_/[[U]?7/\3)B_>:I%^S/_C)QJS
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MN'O*\&\[NHI[(?^S))]2+:IETE:7TVK(K86T6-0Y;<SP<9LVM31BXHC*0UE
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MFW02PFM2J"4 AC8B5%VJE#)PJ+# 69Z&?E[>W/A,5DK9XO&S)M)8J6,WX-@
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MK4VU>LCU%"L7=<XF,WQ<!'"AP";2@PJ<D>XN]'&<8?7<V9:Q.EN*X+7FQZ:
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MB:G&SL5Y<M@ NTEV%:AD9EWT.HE?<)H1B^:KS]0%&M#-!64 (+#:/-/1ERL
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MAIFJ\RVK87BY>*N&-J(<CY)LEQ8Q _7A%6J4Y_ZT2F/P D=T)V6)WP8RME4
M(-(*#.O!VX;VN5"7ARP<9=G%QH ]_L#&U#T94Q$IQ#U3JSQ+#P1A(W\%=_^B
M(^4BY54'HBB_52D"ACUB7-R+MZ44 #+0+%E+[PUG.C[P@I9O04F =JX[=:0
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M+8=5D%9Y2C*L"O(9RR SPC3^ G'X&KS'S1\OGR83B?P[[M=S(U33*%%WLH]
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M@3-,VN>9F'V#7W"4;*DG9UJ5VF*<=AI#(Y4=0E,&W!G$#'B7P94P.P4,#N)
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M2WA166?%?84!_#MT1!3MB2Q9/%9GLCB[H ]N^<1Q]M;N?8_>SP9 >26@WZ,
M9_ &0.^4_W-!NG\$-]^_W+['W=/_D'ZW3*9OVS 5;5>,52C09RP4%3#P90M!
MB6"(/HH9)IWALBH&944Y=)L<UR6=4Q>Y3_*3]!)9N4 [BKH:!O85<:'GV%V4
MEO3K,7&2 ^TU- D&QH=*H/G+;G#FI^%6T2>T6C89;VA"D\\:%3!L-<-I\'I1
M<%!R3KE&_*6W"6/6#_24TVHY"HE5F2 )C16I@*&<&4Y%E"P^Z%V8\NY4YULW
M8>83_N]2S+J.\ :E4O#7]U#N]IC!Y$+3_&<<["*,YBN6I*;(3TD?74*3.$ L
M^@<][K;;B*6U]*)28A:3N6L#8XIJ#W^*E\I$@FX6T5V@XL5S)06F[TNA*;P=
M1A?ZGA'Z'?M?@FD7L9]HY92_;XLG33/W\?(Z#CFBCI(Q;HBB/3S4D82.-P=Z
MN-]#:;.[?&57OS'7%G8WGG0!R\>42A+HN-*!IQM;+AN^K.]ESV@5):\9^MTJ
M?,/!>".+)&2H#;W*;KE?D%G5ET4"Z76L!?B8PJ\=(9V"<T[U03F46G7^;C*;
ME24J^65M#% \(V:D ,>=[0>7FUJ2^-(OLB@439F1MDRI,KU]8?:^F+5&J^E9
MYGW0MUI7 WJS2?%*,E_4"?)#UG!)IUM&@')02PPE!/0;&4#H%#1?W9)E;^R'
M7O209"$=-*9O.8XS^EC%76BX:CGR"^[<DU&JQJ!+#"G>^:1U.IOD4QS[Q$6=
MT'U_@0Z?N4#UA^B 67\*5=]"OQR^AJ;Q;E/& ;J/*]%6X="J!]9Y!G6)\R&Z
MR<1^-I/$),7>?'7GQ8&D.IH"-EG& VO2Z? K&-YPD+A >2) ARSRC^YS$U4K
MV=LD7<A''D[*)@,D$)LTZ(B X8(8%_] -1DJ<)')PSDAZ'E=DK8'OSD[_:!'
MR&1"E0T0)HJVSU3-#.D>JZJUP)#+&*KXA2]<>$?$48)TLMHVYR=,%\0XF)#U
MG+?&].R(YGVG09@/1<BDT>1M4HP[S\G<2+DCI2\##&T' N^2N%)$7J%)(VK3
MZ@3P*4G3Y)5Z6B#N\SP^>RF^ZMZC:[S%=[4_B)1SQH2&W=QZ84JOI=*]I-V&
M]=!L$69?;U.,9W&.2=NPJOH4QN%FMY'4N+W/6TU!;+E26ZF*+7T;3*>U;##G
M(1$-M"(JI)<7.JQC7Z!2[>^@AWMO3GMX]?EOJX>W*]5N#R^^_7?4PUL&F_?P
M0NW;ZN$=K^=+$I'2V/&?/)FA30!GV\N-*O9D_5SY=6CG7]8MYRZ%OFVQ3SWX
MEUK:T6'G#4[#%X_>\VN\_:DXZE3)6S[H)(NI,*%9TM-<U=A&B+L-=.5%-)/-
M!?H_7KSSTCUZ=X'HN'CB7-4UO^8K'O9>%$MAJFD]A[69*5P^:[6:<Y>A/U9%
M!B6BSM(G8;HE'M0EF#U ?\I=YS3Q,0ZR6_*O,S+0T9XP7_WDT?%1',&FUH 7
M &&(EXN3+T5I>[V6P@#:J,0]?<.I'V;B^^@J>5OM8_X:IA%:?E(M) "TSJBS
MZ@<'L^HTUCS;;(!7.J<&V,>;)YRB#S^,,ZN*5SA9FC=6-^1OAY4-^<NO#\3S
MHM<DBDW9)+U.]]L\89%KH@1#9BHVIMD^X"G)3.2=3ZP]0'*I)4HU5.E=H$*S
M>-_YM#F"AI/L3I(.R%P- -DX(PP(=P<FST]/H+V)=P<HHT]Q7[IV60]WT62Q
M'')YJS$P.MBMD!B9L'.FF2+L4NR3EW[%.1V_4(;]7<HFVHO&TL&1@W/ ]5C#
M4O@W"G%XBP,3L$;MY+S/-YPS\XZO4[(:R&)D0"N(1:D!9APP@LF=^Q>+FF;P
MI.E08"F'BV!5T&<%83O7B@*N=G4&ADHJ=/R[D-PF$X1QZ@!+N*5VCV6Q3B:*
M;BBE,T3,+YD60+)IH'(O3.DV.T/E;J>=<\[=4X9_VY%Y?OI"_D>59E@L:O7L
M4 &V=<HGD -#)P4X+A=&+8J8+)C4OQT;9,MZO;A#]@B7\3I9J"S2+=MY)D%:
MI[.#YX<TE#[PTA2P'JS0 L8%$[!?X="B"XDC A5 6RKAO-D;UR7N\-J+'G&>
M%UE]9 .)4L/1)149=,F%E:XX&.KH,?(7"];T_<R#'-IZH?*.D_4#W.MDLZ&O
M(R;^5_,SW(:2Y8.H'*=##G%%@$6Y;;:EMO.>/S@8Z7Y'#]'F*_9K-GGQPHAZ
M1(2S'^DVP=BQ3]K/G47DG&&EC1(GI_D6F-'NQ 9V>Q_[#25%]!S*F*ZC@7*P
MY<5ELVR^R[/<BX,P7C^P<_,9O8G#TGP6_^T$!U8A"FHWRA4@>%OQ,*I#&F@"
MPW5D-< ]5<97TI.DDK[@C-3 +"YJJ-[7>:=JDY-\SOH$<L)*XSKU";X%LK>>
MSLYO>!YAIF25Y1_3)!/OQ(S_F6]OS%<9R>?;*<A#GPPFICS3R^%Z(AT3Z'U8
MG5"V+_#&"^, IP_U*SB=6C'6LA?@;6S"(;A;J^+<%^Z'DXL$JLB3K.B+GZ00
M-^,1L^*1$!]G5]=)3'I;3G- /:3ENPG,M$\L^))K)#.U7X/$M]90Y%L[=JU=
MEJNS%V9N^X\IHRO44$>U/F(%H%^*(I3[PJ=J2#:2%;G9N=9J_ :K27A@XGF[
M> 7,2;623CV/IV\^NXDAOMB@% 16X6J47.T3<43&)UPJ-*/E_^!DN*+];('S
M71I/XN":[N)%$;.VVEB8Q7<AWLU79+(G)49+[^VG,']^3B*ZKN/'L>/*@]6X
MXQC#9UVB!2*R,$9^HTA*A6+:HM>3(E(L_9=M43!['>+U4/0Y<J40&9LQA<@W
MQ9N62=R\R2;&= 0.E9+NJ$2/#7!PLTOK#2*VXFSX@87$+"8^0HQ9+FE:39,G
MO*=&JP@U3MD :36J86)RA:P %+!OH.)*4AD]5+G733G"-+_^%",8\LJ/ :18
M8?^).#:H\+,@V3&6"5DV^!,PR,4^_1<<$7B5S3Q)!$+ &EN.4!BND:%G(DM[
M?-4(3FJ?IL+ULF>6QVU:I*_D*E\@ ZONY0 %B7W9"PM%^L12UDG%-P_]JS4/
M\7#X2]SW.'_'-4DO;5B--00Z_PAW44;QN%.] J0^7"BXVHYBG+MIY$/X3=/L
MZO7/^8K\EPS:]/4B?F+LHPRLB?LCYUJX+(*^?5V'N!3-'50;6TE93O&PDY,&
M%H;K:.8R QU8S6D.6)5GHN7O@IC[1MRK^5:V:?[_'9KZS4[!8,4UNT@(5H,J
M$/)WJD3CJB.O=!9G88#39>I1!MQ&'M_G1$*P*E^!D'=,24=@LB@OA-&*2#NI
M_9^2]"NEBK<-<R_BZKW],ZP:%V+CKI\60F1 8E+.W?]N8J#.[3H3>5BM8 96
M[=27OCMQ[DM%9T[\9/F)0%NGWD9RX-P5@-48$G3<BR;+3ZB4<WI67,U"UTG,
MWI1FBX2') K]_1*_Y5=1)^K?6 E6J_1 +)VG_5*W6/^@7PIU1/41*\!) Y8=
MGOB015 2W5-GU:!K1%-%6 W9$[4L%0)UD(L(0'8\4#C)0%IT@6G04+0O-I$G
M/GO=@>XUITE,_N@7]X1TS3NH%%AM?8P)_,*H**LZ^O'JTNAV1Z,X*"QX\'(*
MAQ"=>K-XXZ5?,\F$*!>%U9Y:G/RN%%-@O?6@XG2^)"S<;781340YV21I'OZ-
MF2MS5532L!K'!"KGQ!QT4%/):0L)6&;>;R"VC ZF4:]QW6E2,NA^Q#%.O8@8
M,@DV81QF><IR>93G0OR6O*$>K.;J!UK0I:@V6A?JK!&]5@'5LW=N=N"O"*Y5
M2%^-G;\2A-ESN)7T+JDDK.;2P>2RT=;RJ%9PV[EV?K[+;G=Q<'=W+9N'>!E8
MK2 'R'40)HFHZ 4BPD[K?OF:+)^3749ZZ?*5V+>?Q[@( (FINTEZZP,!+VF4
M/LJP6FL \FXSOO_A_;LR5+Y60E0+2GM.CFQ2$WVPK=H#_'DT[ UQ@N+@T8MP
M-EFGF"WU)&TH%X757%J<_$8654!, ]4J3IMED>3/Y>'!@Y?F=#J53V(J85A-
M8X"4VY\@*JC40962\_EM^D;<SC!>E]MFDH812L%J$15$_II^(8NJS4*7+7"/
M7ZL +4GM<Q*P:EX&C\^M\UI5N-L=GN%939*XV).>_K8+\_TL)BLV5C=9>1I'
M<YP4J4^X1K3Q45B\L&BQ("JUVOS'K P:"U 64AV LI3<,2O%79CV4=733&)B
MFD[&\J>_-4;VM%O[/C?+$X.\'+T^A_XS6M/!$1/GS2?>M.<3ZJ88Y<_5=0)$
M_@^G+T2?!G'6@;F[F$6Y4#'FE9?,WY)/PV1VIJ]G=A7XD/)C7'J/^_TSX_A)
MC!<GT&3I7&B<:HT#>0T@Z&E?$+L4W!9@D$?1H+@>P[.R7[  U_+*UVNW)V'C
MU$N0:5_5K3OB]T+P[5%_B/E"\E^-Q?V*V#W8?[:C_O1M2V8\E^0W_OZW2/V^
MQFO=FS8M+^C!%OT$3'X:#PYTY6#;WS;\])FQ<FR[A[@AO4=BMG $.P(/R;)G
MLKPI4EZQ"P]%D.3.BY8XW;P7L]TZ#(#,=U4'I^T%R0$7WPO2"EH=2TNPH9R"
M.]<N(1^!9.W WRYV ^.;ZQ+#Z\#AQ"#O$N_<= G_&0>[")>7$+GIN=RB;PP_
MDSAHU/S5OC7S+FAUL0=WY)'*I_\D,*K;LI>C=?GA^C:HB.+51:#F0$Z/C9LL
M)M1O.S2(=8OR:27"WC?2/9Q%3K=J9QYCZ:FE2 P65908I>G%F30BXH[/CAO8
MEZ^)23/48H";H8M1W0Q$&E K/*?8J#LT!"&W!(=2TR68 ISFN"7U8](:!SG
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MA^Q*?Z7.$&K\OM@L9>J&N&1CJUO]T)&Z6A-&&-$&ASM"A<1PCK-94A5:8WG
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MR35WK#*]%XSBS'.]<\*RLEQ26P30%;O"CQK"8%Z@:\_XT602A&>S%%9BXO?
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M2W(@'@S[QE0KQJ&$5;K"'$MHXE (Z'3GFT?7%KW^K#@,]D6KIM"*V:,KJ(E
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M>OFT8LHUN4@Y]GUF 0@O4_Y0NDS)'@VF!XL#NU!.1_!<XD6!<Q@,OQ@4"6O
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MJ18PA3(+%U>J0!S#32<XV>U9#48ZX2?;L<.#Q%*I.13N-:Q&4'$15V,CWB$
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MV%5BVI C(+NTU#LC^F\[/-.3&15J*D4X$'9AF9:T!8!9'3FL2K.)X^OSS6-
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M2A4C)5Z@VP<0E;V@I/N_$L-O+2A=/2)RAD*MHWZ-(Z^(G>CR4*>LLLY5E-L
M]1*K*//GO(J>_D59LO;BS8073RJDT-8=%_LLUP;\[?#VDD1DYH5=20EO:.S3
M9,^"(N8PNJQ,"9T_.4V?O<=X2P+3M_=B29!VQ,XQ: -G('?04<QE3QL[VXUI
M Z$H[8B='M &BD#NZ/G\3"QSK.8^/5K$:6^K:+]WXG.^X<2_G+A4U^Q2JKC)
MXS_)'J.9CH>K\6 T7ZWC-VCFZU_&R\'J<;&8CA_&L_5PFK:8S.[FRX?A.BXG
MT2BEG%<(]3C+F#S17=NX2BBW.;9=G2$'L:=/;;'.1F)>2LSE(JGH&A' ?'6>
MMW]VJ<%T$:\OK7;9N0!E[P]#U\NI/=KAH_&B*=+<D=ON_*-9#;S#DNXSIB#/
M4-X-S9I7X3R,%$TTU_E$Y0]>5(I5W0<OVK?&&Z^0M_C2!4<8T\H)4)#+_="L
M]<8H\WCP%F&>T;-+KD9&\H#['3V8T".-X2R\P&9XC=G1(6#ER*<VW(9L^!&T
MV$M[ M2$NYHI_PJ:&L@!8DV +M#5[MB>D 5)UOZY>!:/3];MI6F_S8/U<3E+
M$JN+[9 S,VK(?I$"_.3HXXQ*OC8!_Z>ZI3E72Q"/^=/.$Y:AR6+WQ-OZQO[9
M-@T'D#!6;GX)[!=3T$TJL@P LBW.1I@=QF^N47883YCR./ )Z29#[($X+[;C
M)-I1F$-4V1+-?2?F5=D)(: 3)1UUR2[,\C5*[M<7HD%R,T;))XV_SQ7@;()0
MN>U>*Y0$H,C+;*J=7#B0,//!=NU=M!.QL] $S0]<9%>)F96TH*SY!^-5RM7S
M)F@^7CE7JVA!/\0/?6+,-U/#M2K8FS;*MT'.AN3;]@7+N$P7.JNS\,F=YR^%
MWI%20^QT13#7.22BLY[EQGC^N9MF'B=4L$0GYC\1)P_)^F(G%((!@C,"';/S
M27XB++1"K.$+_>F6,"<%N]G&$FP6Q#<5O(V0D;#S_L!XUF62-H[(4_[0G6'[
MK/@-.57 "8)H%PMG($@6^B!*%KH;3I:#C\/IXSC^;Y()-%RM'A\6[*\K_$*3
M+R2M"S9TG#AG*O\C0+D)6/^K%[3.54X5;*YN40U.U?V[114 >* JFFHH-J^)
MNX_"-?V6N)(#O\<%@<$G KUD0]749$4;1'WT0$4F9P!\="G=4)S;T@X^W_F$
M3-R0,'."63:RD@$J8V ?M.0"*0%/SB!TN[XX959$W62/$1.?[^CAD%O5%_LL
MUAA#/D.TPV[AVR;YZ#F4N2SA014^3G?LVSB-$12R13L0,WF[M5]LBY[@ZBA5
MT1C8UW):6Y!\!J%C>K3$QK]'+#'1V^T]-SZF" U,23<][!DUD[^:DFX"; H
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MR'_ 1AY*#]=BXR?*IK]A_V'JB_[D_P=02P,$%     @ QZA[6D5 9:FU P
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MFP[ TD-.T?*"?2ASA)/:)TV1@(+.NZ(%LJLE DC0+5SD)=N/B<:\-@Y*FPB
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M<9L1SNH+2 J5X[0S9.L'A8$HEH*9R8C_J-5<3\$^COXH-89[*;Y"\1-89(W
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M;#OXJA8_',S'IB#^ "7^[(ZPU>,4G^WFFK C]:;)KBHVI5@JFUW8 .16+(L
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M @6$%7;;!V99(-=%JY!<_NS^!3/3!$I8MSKG] EJ4$E,S/(4WPY;6FP1%;+
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MS,7$V1CCF&S$L!>]X,+=10O  *4E.L?MP-!UX4^G^=+]J%6U E($>UT6[$K
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M]/[/(W>*/+73C^'GSE X 5[Q"N[QTSW6'PY\VB]U&BML_.7PC4[O5'0,=X;
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M1NYL,G3LH\%%%D'%L6]^#<UZ0,$[GD77^%?X_5YO_'X;O]]CI>7UX,@?067
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MA_?.E_Q.?,1R>!N]__[U_GO7PN^?[%\<G![]F_CVE_&O'S_\/U!+ P04
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MW;(PF B 4!E9O*0T<LK6JO!D!#-:%3 <.Y#YV%CW SR)*3T)/\OX5@1C!?#
M)XIZXHGS2VS2RFS>5@]W8'O;+6.GG,T;*H'1^1QKMCYT1%C"&:3B,,E0A<6H
M@0*4GWRT8//L&!5$?)0Z$[_([%85XG<9E2X,#[TU)+[<8&HI@'-2"XW UC-&
MD?C):$>@EVYD@O 6+"=L*;$NKXZA;$PGHGE)D%IY8=Q]4Y,+.7]R:]P%9(2<
M^G$CS5,5P->![8L.7$I9^LR$YWJN3;G=NL^<69X&"@:"'L:%:=<6,=0CV!K4
M%82M$=*X5H69O[,KM5O83_U9MQAA;0JFB>?2LSJSK0J7C/_5^P3-QC?*MSUO
M$E]MGJ (T""9)>7-&$C![BR>$!&:)AP:2+/D)I,3LZ?D>!Y&.A^KT/+_,$MN
M5;9):[-YFQWRJ0!BLF07@EXB)_QT31*%A/7(O>]( IXFU<-+5&Z4BC5!)6]N
M,O*N+0C!)3ATD]9_\PA*,4$AI B2R="+L:!TO03V.L'3>:**<1+F!W X;]#T
M-V\_1ZPA$$0D?$C.:=A.-BC4L\T)#!E3=:.Y@GW76QOT$[<S4&3H'R"^QTD4
MVMSM=@O$<N+0OLZQQ 9;%<P9X8*]_!-A57P'V;TF\A:H!3TI-\9[D@,UY2,9
M%,FBGE(D[58*%(8 F=-S7!2_9X,8*:3)J$/&"(Y)CI( Z'5:34HD@%=N9*UT
M@>F%C2CS(?X\K!GU93MHM[@'C!&A#@KY:4DG@-W1$H)&NF3%*G%IOUDE,6TH
M&^DO6^/)D^%\"LF@.AH4G2@%65%2MLYMTD0W;^>&H$R7@#\R_9>+[O8\J99_
MET5B<.B5\^ OUC=R6)F$I'<$UFHL+80)>T%A-9%PX#(1.V*<3+$T08?/VCA9
M-@;XDN>A(J>0W3'Z_A0HY7S3$_E)3\J)D).D-&5EY"=4"&R\,"5QN)9 .$5R
MND5M3WM"J,,;-8WINWZ&IIFZTTF91W#*3&-3M:",51R0UJ>6$?X6MSUIW#9
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M?#S%=;79. ";_\O::)ZS.YKV=8XT O> , D=<UN/94O(4\ VN(ITUU>*;0P
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MRI8\HT;L<"+E0AWGR^*:4@E;,G[T6>R]Z^)=DR;N36: *<XE.=9@]WV 9>A
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M[DFR49DQ%]M9N!H8XRK*B"9&!1HE]0]CT3E9F$TA7,*!U1AJO6Z9\ MF@19
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MOKW@JVOO7Y_L7QQ?G/Z'^/:GP2]G'_X?4$L#!!0    ( ,>H>UK2O.HZJ1L
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MLE5.D@@8D2J#XJ#=QPX%-R9I54X9I^W.;6*=EVA02UD2^!GQ0Q4K8&F-S;
MM_GNJ]<1HXWFEK%6SWSYVNQPNYA88B6U!5K^.BD6;Y3GR6G^QDI@"C!/ 7WF
M"5L9,3??K_."\T"I!@R]9!,\,4>CJ5>&,?5C8=!Q(D9\O @U&L&<MJ+AT6?Q
MOBM.*5J+F!"1399$VS3[IZE-ON<T^^,@4)&R%;N L?QZVR L"Y2ZJ!62R9_-
MOZ!FYAX(:X9S%D]@4>2,A)B1*2 9V%,@#;6(BEB@<8UE0VP4(L,YH\U6AXM?
M0'F^BG2M#I5%E"0U?$&TI *UC\UH%&A(LO,TT =&JV2 CTT +N.JV)K1*,2"
ML:("!7ZH>P:*-'N6.PQFI+?HV+IMH#8<.ENM@IT$0<GG(9 0EK+@?#\L<DT!
M3JS62G3VY@M(GR2Y:0^OV[ _%<KNR>)&S*-4TA^7*O<451H^7S;?0&O1>T[W
M.)4Y8*++LC#%B+[.@\[ 8RI%3"3SK@84Y&E@I'T@+ $BC)0$( #$+E[NO=X!
MMIWE1NL2,KQC8Q7H1JAN+?H(.B+ )R*?;XV5JLGOB9_9$SD7]X#1QY6FF];O
M-Z.B2(U$*S@FA?1?\\W0!BMY:MN"(N-+LT5!68M6@^4;F7!$$"HF'K%)^C6$
MK]<G2:&/.=69)3=L[L\573 4S.*F7&=32M5(0'@$57QE(_,W4$##'EF-F$9@
M+(K0Y7Q(%X!"&-16-#P>@/G?KC@.L6D*C_*TM27BO-GH8./RJ"7#-A:;.Y.1
M/9MR.O;1X,*ZS*Q2P)[S2FX&3&\:_PJ_W\'6[[?U^SU56MX,COP'J P8-G6N
M+4Q' #0?0=NHC<G GK.5(5=^MAZJ.3,S@@/0AW1,^E AOX ^D@1:XE=YB=J+
MZE!\+(" B']W/B;XM$LAJ"9#QT:HOJR2MV .N]?FD3Y(_[Q>,0S'6$: ?\A7
MYJ8Z,J-:>!O=BB9K#36M!;W&&?9QEH@ZO+7SUP,C+2>T)G$BZE58N# Q"!58
M,[HKK%YYI0!.+%RV-+:U,$AS9]H"J*)KUCI6L^.K 9H#=HT=#YVO)'-!.,J(
M(6+E&;#9B%3&TJ6RT%31BA<F-+L"@W+(6Y((=* $19G5\FT+7("PY&*<"NVH
M*STF]4WRYMYNT>2?[V'^_%'=WNLN.W1ADYQU_%Q.O2S^9GJS[.$B\.D+SPB^
M#!9:[YR'#P/7_T))(=N-K[MQ("G6"*AB[4VH*(?N0Y\F-)X#$@J^9J-6@LA<
MDK2Z)<>P[--7)HU44#U;-)5X0W7DOF3B!OE&FN[K0@?"UU;(.-CF[A$%:;;,
M@4=B&\MZK%@8ERE@5\@MAJF2@+$:Z#T+=,W;Q\8RWBGD7!91C.U=G$>#3Y5N
M;BP0R9=QKJ)%GR<)3CJ,\LI(Y]3CG']'F>LE,9  XE 0CIN>CZ>XJ38;!V#S
M?UD;S7-V1].^SI%&X!X0)J%C;NNQ; EY"M@&5Y'N\Y5B&P. ]O8(W> 5HT8_
M/88--":CN6!R$YFLPKG )$-OC7$00S)O3)%4C)E5AB'075ZU H2' 1#N=K]:
M/$"3M$@SP%' "1AED:6)N6MPA', A?O^PU]@J<8I@'S]^AQJX1W%\D@J?@_5
M]'R<3%W6+COP%[.9>AQN@G;C&9?6=WY*&(<)03)M>D-\R843B-OX(<[:;*I*
MBQWM+!:EW;+FH\]B;[\K?H+=RF+*!? 01HU([5V&5>@.G1_H) ; ;4U$3<Y\
MX[\F'BQ,I8L+=2=#Z4R,C,H9<,0C." 9D*,OW7 AG*??FU8JM?J[[.D]+#5O
MMY::K:7FJ<J1#9&&;]"'9H2:=!<',EX)=9Z6A9HS(NC:XRSJFB$*E_#S#>;>
M>6[,!'/1>EY!=_2;8V:6FC)4A^,XB4K;)YW"=H +U>#=$$8Z-KK74-?NNZE'
MCM8,+-M#^M%GL7?0-;HE:+XWE7Z.'I?&XQH^S+EY*(I#-EX94(.]OD^4"0W=
M0*RMN= 0UK_]9G55V6&"6<]APPT$Z+0T]:301&E =6@#RX9XTYZI2M7DR;;8
MP%6L(O2.HW/I_J0>HFN* YU-PX2EQ>*#WA0Z-MC?:N=-DZX%Q! @NB7@A(^U
M6Y@V*77T?+EE VQF;[OBIJ0BV4F6<ZFR8XI#S"NSF96P2*X<I&@+*J UQ(2#
M-BEJ2S&Q%:4<+D&PF.RR)JJ&(SW=94^Y&R 3)H]O02F[J;-OK5(\RFQKT*LN
MJ65J[\P?/V:4, Y_F,MD?I,^686J:MP >QU*/G<?2NX:X>*R+_,=RBP=4SI\
M/17 R H[BXSET3?$O3Y?-MN<0^D=4*FZ:XH3U_$==!VB9X$\, K+U0?*>AN,
M[?:^D895\H5D Y^)$7(=+#3O5R2Z9R\=CL[#R+_F-YBXER [94N>42-V.)%R
MH8[S97%-J80M&3_Z+/;>=_&N21/W)C/ %!>2'&NP^S[ ,G2@_3 YM"?BEM>Q
MCPUYBQ;B:.:=*'XJTD(,GF$F<C7..7D6KQRO7(3HU%0FA1]C<X.B=+6]G;O7
M)8:9J#AZWD#,ZJGC*2@Z.85[4\1;B>N"B5^T/OPK1[]Q85?F!F.:!/5D14X7
MVU!IP9C])DG(.4XN.Z-^"1^=I;0#E3P@:Y3&>M*(#XT+*,.;5*3.;,1:4<.P
M7E+)BML7O5RR^02R+<L^^BSV,.3-4HYW[%0*[T)]"R(TD/%1@7DK>9FG]!G)
MTV1H(N$L1$%V\#"@& O@D8@.&Z#F+)'F"[_V#OK(.A@(:X+ [0 -O<H0SH@<
M&_%.L2;:P_B)3%N6;<:BM>C,QNQH9 WUO2MT;*FUB5K_P3G!?1 ? =YE:FZL
M/V&]P%--:G'/3:11I4B@]$.'#3Z-E &$.29O;#:1$4>C(-52%IU7QX6L2&F9
MX4U3)  #&06E*3Q'3E5",A@HA(1N_-,@VE4T O6]4P4248ZMAD61F9&62AE-
M84MTCS^+_===$(<EV2:!3*JPX)H4J>X.YCLH*=BI>JG#>!C(9*ZL0HCOHPL(
MJ$#?DDT14P'Q5_=PD=QR]B3! N^D3F)551'/L4R$)I\2Z]C>H 4[(1%JH.T]
M%S;,PDM"0@6R0M0C&1!-*ON#B2B G^@6Q"R)=0"SUA@11R74&:3;6U4$WZHE
M7G;3<+1C2\-7NH3?"-5AH,NY0O;04N!9=L?A5FY= +VEL!YL2M*81X^B7::I
MDIDMD"G=M2X=C-^ Y:+P#K<^)JX!SK1T/,O1:5)5G#?2(I68"^'F,836F:6K
MD;C5W++GH\]B?P\0#)? C<W-+ QA:M>(LZU4!I_C9 JZQ"UE_P-<3YU%-)U]
M14==#.M!: 0J@BWKYL?X&)S,W.G9/0N^8Z#C+J%+"__*(M_4;$3 5S'W/4<+
M0_%G;\.0,N4T+D955%B5( \[2_/%VN/UD$QTE9CZ%_9'6HN([DFR49DQ%]M9
MN!H8XRK*B"9&!1HE]0]CT3E9F$TA7,*!U1AJO6Z9\!MF@19 E:US$G__^]^/
M^A]OK$C$FW,YANP35=3%GU_UG^WL8&IVBQ8FL3K&X-TVQF ;8[ ^DOXN033?
M43I<)/'NOTKHEVZ[X;!@<ZBX0^Q19,=?7^AZNG)%=>;# Q\J_8MVZ[?^X*)W
M<R-^^[EWW;O\U#' -J/X7ZZUQL#8Z2MSVH!T^((J"XPT0!LAAPG6A<M027C&
MIVZS=_9^$O7D\OJL=^T+UYH$_9IPI^_NNSXO/N*P5DG@%U8F@8CTI"5^B6+V
M]!+'?O'/%_MNM \/:$[ZE]>]F\'E]?&@_VM/#( "CZ_ZO9N.Z%^<=FM QPIV
M7O_O,-'Y$^4;NOW*J69'LKQW=]:^^6&=*WXR^^"OY]PX5N.()=46S#@/WKLI
MWN>_:]S.E;1Z[P?7ML3G9%PXCO(B"8OU$^\]"?9><UX$,B\^7H'^1??*D1)V
MVKMD1/,G>."!1W]_6GOH_ZYM=1Y! C-]BK7*]*OCZT'_M \S&7SX;A+\3\BN
MOR3A_]+^-3*>Q#BCS^)35_RFHTA+3/.=8SVCTAAM<ET0ZOG$LCT Z=\G_O_]
MH?70?Q#G6)%GJZH_O*K^X(KSPY/]JY/+L_\0W_X\^.7\X_\#4$L#!!0    (
M ,>H>UI?-:&=CQL  $S    +    97@Q,"TT-2YH=&WM7>MOVSBV_V[ _P.W
MN#-H%H[;I*^[3;9 'NZ,<3-)-O'.8#_2$AUS*TL:44J:^>OO>9 49<MI.N,V
MB>$%=E+;$I_G'/[.D_L_CWXY^=#M[/\\.#B&OP+_MS\:CDX&'_9?\%_X]87]
M>?_P[/@_XG+TGY/!/Y]-LK1\+W9>YJ48Z9DRXE3=B(ML)M,>?]$3EZK0DV?P
M(KQZ[MXKU>=R6R;Z*GTO(I66JM@3]VUK3\QD<:73[3++WPMXW'\QSLHRF]%W
MSS[L?SP['87CW)[(F4YNWW^I=7K6Z#\4#^;9AQ_3L<GW]E]@@[ BYW-S^=IQ
MT_CJ_^^)<#$*?35=Z>#W#S\,/D_U6)?=SL[+_NLW^R\./ZQL+G?N07-FO,TK
MGIK;FA5.Z<[M^2:3.#T[W?[7OP].AA^'@^-NYW)T=O1_XNQ\-#P[%0>_'5P<
MBX.?+@:#7P:GH_W#"YC>OT^/!Q=B]/. /QX.SRX&\-;%P6CXZP"_OS@X'PXN
M>V)X>M3G9W9?[NX(;AF^A);PR?.3@],GOG;?FP#^6YE23VY7.8O15)MNYS1+
MM_]502\3K6)Q66;1)W&6ESI+Q<&-+&)Q<%4H-8,U%,]+>$/\F,2_5]D>K('_
M!9?AQX*^WA+PR$S&2L@T%K3RT*Q.RTQ(([*)^*C&126+6['SNB> .MZ(\2T^
MV^V,57FC5"H.=7:A3)D5LM372HRFJI"YQID,TZC?$Q+F>"UC*:*LR.DI&"N,
M305#.\IFN4QOPX'U:$3'\EK'L$!&SK]R+HM21QI>:\RG_V3WM_WX&!T<G@S$
MT>#DY/S@^'AX^M,_G[U\1I\OSP^.W.?#LPM@=?JG'<J-CLLI-OWRAWL*X:\Y
MH_='%ZZC:X7[(!.W,M#),T('^Z/CMF/<KMR>L"/<??/#BGG]IP)H D=P+$N%
MM/'>+^KH^&N&]FZU0UM@I7!8\)\+N^-_=6E7#@M4$6FCL./S0D=*Y*H0EU-9
M_)G%7>7@_F>W__KMTUC$TVHVAE4#@<K"&@= 2V@>> W?[/;>OMI]&HLX^)QK
M/C_^ G=_0XY^U<;1\ =%.*WHMS^.W"'RU X_1I\[?>'D=\TJN,=/]U1_..QI
MO]1IK+#QE_TW.EWES';ZP7;M=3NCVUS-[1J"06&QG0!<J  [7N'C!B2(0#P7
MH#C >R++V]!AW:)'K?!Z7A715!I%[:0D7[L=Z)_%*HX$>IY!:PR2X7,9C$;]
M#B#:C2*=D\ZN#:-*F'=13H4<9]>*YV,? =P\5CJ]X@D!:(;QF(J0AVT5L/3,
MN'[O1LF"]2X:*'R&#<.'SA.YL!;X70/OSHT)H+N"'8]I%&.%Z'NYQH (>W_X
M(<U*L?]B^ %WH.Z]\>2-!F4BI9G,E$QQWKC4*J)?7^_NUNL;J^_+K=^:SK^G
M6>>[L>YN'TY*4KQ2HV/%I^J>N*S&_X4]1;YPA,8$=N5D<MF@-M(<@2ZBL!EX
M#*@/GC.JN :\2,P.I%@@8:)Z"5)@GO<MRSCN1,*$YDT]G)JA\#?H+];8E^<O
M'&Y?' %/E;"6?T O]'2W4QGLL2H%4GD&CQ8W &9%K"8ZA5]0*L$$IO):A=1M
MQ!7P0&I[G@E+^]3+6I'" U#WBH_7W;ZH591S>"Z+]\2O(&MA&S?8X7%2W6Y_
M!Z6/W:5NYS*:JKA*5"UP_+F3)" [HFRFQ#4\#1Q+ABK><#E.E&B,*E$E\/VV
MR64$#>/(7[[!#C6H#.6-2H#+^>0'8%!.DUM@; ,"(T&SF!'/): 0 5*,@,S.
MBYU=TG7IV2TZ TD*3'1ARO!-&AJ=B2PFLE1MTTLPV!3D2&%026!)U>TPOD7U
MQ<DR>+?"UQ4\>LO=X:.%DA.8C:C@@41,J@3&RXM0T_03)>TU/%3_G=O=#\ZU
M'PN#*,V($1Q&.G7'([:!)R."2X'G'>RTR: +HH\JM92> _2T+Y0++('O3I1V
M'$'?XA$'OP3<L3FL'OF4YB?SM^UM\5&K)'X/='2E )*!O%( RN$%L;UM_:[[
MQ\-?7?=?,NZ^Q>_&60'8RW]WF$C ]CLP:Y,E.H9AW,_.;+NTK459DLC<P-#<
MO[SIE.W.B[.]TZ34W(!$3>@-;\RQ3;]Y^4--"6AG:7NBU5L:OH3&&6>:V7\!
MR]FRLF-@RT_;8P6<!C/(:3O"U7Z[U*=\WMP<^W5MG&GT&&SY"]QSWN:G3MAK
MR*N[_5V,:PCLD.UX1>'ORH&!^FD^\^>,"CT!9X"21:+AI)=&Y$5V#:I4S"H'
M*$&U0P\>W"@ACQ#, $F\ZH='/-NA^(S?J""/D^9>L0K2V#6$8Q<$Q8PX0P .
MK"U3<20K WQZK&0YA3^(K'2BRUOF_N%DP9HQ!3Z6]\-\;)* %B3T;SN*L2/D
M]KJKWD(?,WGK@!Y;+NX"C3VR@&0I*!#6DF>J:(K*#6C+]"@L5K>CTCC08IQ0
MRB;O03/:HN]BE&#E%"02JRD&II,DV0V^]G78E^3>\_'6G(SL=E!(/EV&6<-C
M[Y4]]L)]1"(F:OWS/&")/=!LGM],%7&#)>4,55_^]Y8P4U"VNQT]FZE8 XD
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M&UK-.2B1R9[[<U=O@K!=PQ565Y[ L]HJ&03R=&KS!>![4XT-IVK=H4+W&EC
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MJ"ZB35FLB]K0JZIFL3!5%27Y<CHQ^64"#Z0_7"590P/:/9@X2J)7)DNND]+
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M$PBR CMUSG>X2P<?/GO\[?&CIV#O'GPY.[B:V=T_1T^B :/IG8_'CT[V_DG
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MV%E1-,%3#W&0<QNY.FP" IB%<:DE_"N&Q(/J\0.,;\GZAG])D8YL:<!,M.!
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MC)1/%?'%M[![(9FP/UI/ E3H*%E[*5D!;*\7'C.80;,?:&LV@>*@SZ#@.*,
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M&U EZQYED0C__-+,4U_7W7V"^+D.G$@#; &ND7'8UI O46C8!TD68.LOB9Z
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ME?"NW4Y0TQPU]X( K?;5A)V+TMP#;+:<S=>9&1*U]NFA)(K E'VYK:/+2EQ
MC8T2BF_;_;(C"U[5!KIWSS/*BIV\"RA-)UWLZG#!N=)%@[O^^T!?>%*J%%>$
M#;/4YL0!B4B,CCYMX\=W1^.%E[)M4'T&8?7=X-JO1G#M"*X=P;7[=60?@I/$
MF3 Q2W<Y^-&)K:MY6[IDV7FWC@G;=7"QE2H'(JS"SI=,)_P6=PV@>=!O>Z/E
M&#CA0IZ"B3IE]3C.=3P_SF;:V5F-0)N7TC?$&T:[RK&X0Y>""J8^+GZ HTVJ
MG=0ONE.)?^-T H^Q+DC,M_^22US Z#37 L7LYQUY=G 9&LXMDT)L'HP.[O"'
MO8-$Y5R[O+[8PG-39[+MW!E,>?G=.;KE[H"EU;M6K14?^LB'6\WII*^4"6^;
MBX+H2%H+?*NROLCS@K>1[7%?N> &:[%=6QR%UE6G3GN<=Q%A<8']YO5OC6O,
M$^X,#(>VH\.3Y+W1OM+';6?>O09U3[EH&!I !S8$D.@H"&F?9X^_/7XXAN-#
MN(6>=6ZAXW=$\N2O&6*UM[ W]<FZ_;?!$W;CU1(A#*@G5GQ+QB\_E$ '>O8"
MU'MP&\TH %'Y-&;WNAD.?>^X;RBQNT)%?O!E_SN&:Q^5#M7J?CKIT_>'8 L0
MW@&&8EN[R'H.G#TY<H-Q*P9S*-6%?U"MLT#5]40+J.^""Q;$/1N*FHS5?2 G
MK8K7V^E(3$BTGX<^/:C!M%C:0!,'$*X,U;8[+WWXP2X=KEJ(]?7*"$GP*.K@
M6,\ZH<> ]VW4;I]:NWU)VJV?L^YCT.N,-88?B'/GUS81OF[8VH7"<ME0<! O
MDV$BR1:YLT6EH<+U[)5X%RP;2F<2C6Q$G*V62#;NG'S64+8G)#Q<5-%=U5T;
MRN:B[AUC;X .-$#WN=P K!1<B#G8SE&RJDT9/(GLU?['?8)&N)\>"G+OSLS\
MXY^9.YR%Z>1 H&C*&1,NYM9'/<03T>RN#?L<O,,5? 3S-Y@)=16[9.K8R@=-
M.++S;-D8QQPO?.+79:P<K%1:DS\34+X&!<=T3GC2G>M^=K=3O\NX'#SV[9:J
M=SGUUR:[ZAY[T&OCN7\8YW[QU]R5#O>]O=4QTSQ,^CWMLO]0YJE^U]KBONX6
M/S$H\XIA&CZ-3^#S1TT:P!/T.'15TSN*]GT0[>7LQG!?KBM&/(-1!(8_\S<I
MC]%'OMAKM";@S2;9=#(WVT(>0[?4TOFSMPM5CP)W3_S%K_JB8?\TQ'LQNHO[
MJ2?07;1AR@Z:5%=1<(#H=CF!*VKWFW;*@>CY<[,HUD1OX8TT"CRBIKBI91O'
MV]HQ-06P:UW7A]%9(W$M5'42LYHG>$<6OL^(B\</M^*)(X2",+ $E" "_,CT
MO2BH:EH^+Q3P8!?#\B=2=STPE\/H6!F=WJUTU2%);M%"-_B\_77@_0#B=L02
M"]8P'MPO 6DM<ZBPG>QB ?\N;=37+NI>*?*]0K]\/:)?1O3+B'ZY!^?XWM_C
M_2$L1TIEW4ER'/,BVL#U*>[@[:YTOOY3).'2%S>5.?8$I,"HZ/>'7;MO..YT
MX[$YH*V!!WA-/ 3K_FLN$]9=YG%?A_*#0_53.TR3V/>P-S[TTOL2B954XHCV
M!0QU1,^%0PHA-M#D^0INTLF8?W_Z0_S]%Z<_]"?.\9N[JKT\%XDZ,FU@L:L>
M[E"8X]RD=JNA_[&+8S.T0A",I#9H/)M<ORA6M#Q@HA;,?>/>UL*R$!":>A_9
M#IF$ +LT/:]]6)G9!U:XZHJ4O_J\YOTY[K7,]N3_G;Q[>7IV<H=:Y8=P<._?
M)?J5%"F?^)37$JRGK2>R.@Y4^&T,LS8,)^KI_W$8_<1W5^RM/0IQW( Y$R38
MKMMK53)7/5*7"B.JQ'J[B"8!647<T] V,G!<N;<&+G,KS"3S=]@:=A-'VFGZ
M$.$8ULVZ<[D>VG5WI:[,4%<Y>MOVLX:O^9!L!&SD8[2'X1%?>0M &AG$KHV0
MBT&A(:1 JM,)HU1]!9:#V0WN5EKY_9]Q+$J3J^*#Y@71I50W!=C&8/L]T21<
M)?Y+DN<LUE:GB![),A:#T-&[HVYI-^+T2H:,Z*7)4E J6T+U41'J2G),ML&-
M;6)CT,)'-$)8.MH7NK0=CJ2@E<NYB;:JQ@[42^E5/53A3&H-SF <258S)4#G
MBA.>&H+ZW>AF[ET4 [,1QXY>#'<=8\]ED:<+H4@C%OILZUJYML+_S*J-:)AY
MEE:70UD$S_TH\.?688!1]%P\P8&J;=,ZK7S9X961>MPVK.=@JZ- SFOD\B9)
MSPC1C)SPMP3IR)&UQZ<US+]"4D9AOWO(CK)3I4'"/7ACXHN2E\6B831ZTM-@
M>SB"@IJZ4GR?*+/+*U'Y"/KBQNETBE)7BT+RKMIHWSEP0P&&.OG-"-&[:R8A
MK8PL,PT/3W4X4&/B:(H:V0V=DC>PCGB(,W-A<J(.8!,4'#&0?:).$7,4>SM1
M?7Y=;![9=I%R3*G,+;G@I:8@R 5-N:S&,[-_9P816Z>=WB2WU(WM<%R+)]#B
M7[X]?&H[I,VWFBNGL'JZLOW@7959P)^BQ1O^!<\1LT=ZO=FV()VGW@64Z<MJ
MII.PSHR"=K>@7J1.>*.,[YV,(W3KQP8D=7?C16)^\5I;MT&LD_<2/E8%EFU_
MUO?DN04HD8R?G:8/TW7"2I)#TLD\M0O6AIIG5G#\CFANW[HFFF-":"\]4"[!
M?UW4GJ;L'1$BH0B^2JM-P:U>?"8H:"E)RO@BE9R$)1,"?;F&I=CI D@EW-*_
M@NO*)/ZDVE/I-,]P$2&?A&*Q@,O @K_!%8GJZR(Z>&)+$KMU'XXC\L!9*OUU
M^!^RC+N5L7+UTOH&(B<8.VQC]?K!$<^@9P+.%++/M-U9N\^\WSF?W3"=;T:8
MS@C3>8 PG8]Q\XP)O(^2K/WZ\YKWY[C7,MMW)V?G[TY?GI^@)GKS\O\^C'-Y
M_^S7KR47ZT!&[Z3!B"4._ @5"P]OD_Z:XH1;,7"W]V^(:UOCHL)V97T(^#AJ
MV?:V#TW:;1%%-"[)D#S9!C2]./M;DG-3%6Q_+RF>%J;9TS7Z$6S!ZPXQ'!ER
M?>ZMS=]9MX%([>B%[]\!F?<>$!8FEP1CVIFF7%PF-GC$5:R8@$6AP8L2Q<'&
MF] ;;4O%S5Q"% VMN3PV?!N>6&ZEM+24:^'?76 V+UKL79ND]&S/*IC%C?OL
M8^"Q30O[/)T$(:AV>@.)Y>"5:!? :F?F(LE:78[=F!P[,"X+'7%]A/JTCJ_*
M=:1>?8,8S],^6@6,JQ!D#ZA"Q1\EF.8S7SQEXS1?'SZ+;%"4H!&[1*1+?N)[
M4_8*LBU([Z>5%#R];6Q&Q(.Z]W0?WIA/4=QFK@KN-M5(+J92M.Z=8ULF[2S!
M4S=HR#^!M-D8BZ.+.*6^ATM-B[W$.:;S1FH1DW1)UQ^ULAZ>U"U)S^[8I KO
M7!##,BDPO)D@YB4<WO" +$)OUUH'%8U>J&P>JD6$J=]%-)==)22DC.J=JF;Q
M$6//;/W>0;@_TM7/(<<JV_N;H/9A%226@N."P1&;Q;@D=A>E6K0TO&\.?V_?
MR1)/#<GG\AE,[]IN7>IL]!")T\4P-!UJSNG:H3"=:T6AOAI>5L&T*AJ]A2DZ
M+LK.(E(5ZZBE]U)+<^[AG3I#'O<F.-2^+56BCB=:/BF*B!2L$KW*)KHZA]N]
M83KILYX3_&R3U;Y#A3L8L>7<!VU95V'5L#7#8#C))JUA@?^@0SA32*(62:I6
M(MQIP1ZP@-"P#T(B#Q5-V:/&AUN&'D8OMH+K(,Q'KE(+?CUL80RH(;P-S7*P
M4+FX8T<CL?Z4;Q)'@[7)TB"WLT_$4K2&R8LLX%9X"&-X$Y)#Y>Y?!UAN-5:5
M/^\H1A]UR3[JDF>B2YQ3 GOY8U&N3$K=RX="0XI,U%=<WH"N)K\+RR]#_^<Z
M8?MF.NG!"-HT?M>,Y!:]@_0^0UQA8BC"B6]RX=MJ/YM"';E6-Z&Y0JJ#<C1"
MZ8"CQ 7#4\X$ WUG3NFQLL0D:,D!')T IN./UWJ6H0ZQP*_0.6N1>NTBXHI.
M>QQ2N^!]F,SN>HLFNV'!@UFH;O,MF]>-Q%'<!M8._'S#KCP:VA6JQ<4B \5H
MS]:-P9XH=J'ECSMFW[]Y 3#;EDNH'N/>,&3BK/ZKY":ZCIYP7S^-!;Y5+B^.
M/,CV(/@O@>\0/$R'[WHPA+!>+[F[,GSA)>B)LLB&SXU0\.'[^6)M\?AQ9([O
M<K\8 \(2W/PTUO_HP/H (A?4$&M7O/,8XI/XM!D41[Y3Y1AS;7>^Y#B18FWN
MRKC[-@E[XC!N&/JPLCY>?'MY\3&_[TN%EOWB15'\%IW 04C%X>N_^CHB=5-/
M:$)=D@V\8 5!DLE@,3@WP_:INU /(SU0LK=PK$;&*@\7WW+(_J<Z,=8(1G24
M-2&G$\81P_E>F;)4U2MD[\5!3H"!PH.)@-YC%SN7TQZ@78AJ/#ZDQS:7VPJ1
M#1'8H)6I*E?,LQ570J&=03_4:2;&=,J]J*G\6Q5(Z%'3#3X>SKT\G$RF9F-!
MWSQ%.-=)QC_R(3QM$U&NP1>KJ,Q+/M=JNL@/46 R4?H(%UWV1K"ZWERK++$%
M(NNS4R,XSHX@NOWUDOY;\=7M$:EZ5LQQH.*A/&*2YL[\DE:3P?Y(JX[J$RDO
MU;%1T>1FZPQ*MXHM"Y4ABMD6]!:YO2NX_E'M!-]Q:;M3Q!E@(<0[O.4;XPS3
M>YU:W@VH^W8$U(V N@<(J+O71_:!PZL<E.Z;SVO>G^->@PXY?77R^E5T\M^_
MGO[S^.>3U^=GSQE.%[T]_I]?^.<VTB[Z]?4I_O[MR;L?W[S[Y?CURY/H[*=C
M^-CSZ,WY3R?OHE/XU>OSTW^>1,?_.G[WZNQ!G??[9P1_(Q"]5Y(]B4[ 9KO"
M;MCUQV@_\_#VY^.C\WJP$+!KZ&98.$3?YMF(@(T:](?*34I^0Y)A%8L@#<"%
M-FO;6HJ#9]QK$-P"2ZCBL]!+L\B2DG\+UOL:_F,1&.3X@+.]3&O7[MI^T0&A
MV#>1#EF2=<:4]]S4U\BV%M3ZV(E.)WJFB6K&380T;3ID]PSR'WI7R]/P(P+I
M_0;\EEM1N4AY>>\S==MJM/5X>!0]II)Q5[\M( 9X 0T0;X(F2[CZL-:AAI!6
MF/X0=$+SD>*;QAVB'7J'WR'ZL6R!MT$^3"<V/<A]R4O%".V%)P0NA$E%GI[N
M]OCGH P,*1V&9MP-RL#C&6$+>ZHOY[=IR7##:1TBI[I-Q[Y1)O;2QF' (>^:
M<)(-DJ=VH.\8\HOD?J2&G>%S6#5N^W#P0E4CM&B"LM5UM+:[K7Y@;VO;09[^
M@&V?(GQZI)(B6P1L^I8YWQ'P!^FTA?N[SNM9$O]6F*Z'P?_&BZ>U>AB@!\.B
MX3L"T?DJ;!A3D]2$L3-9:AJB6<-D6)5D]+IYD3<@""O#^0KI#8!7+)*<F+R2
MK*!##]C3;>_/OFT;#_$^'N(0C^9"W[_FZ1T.\T ="SWDEB>906"]0*J^?!@_
M^K:'NF\2_%T^GUMGS-+Q9>LYB.O?, !B E\U6>8:P>$<\B)7:6E?YV)?VBYT
M\3!3,CK[:EFT^E#?=%;@K?64/]>[5!2V ;ZMCD+H A898)R%H'$:<ALF3?#=
ME+=@BAH"XY;RKZKK(;"Q>;<=)=X/@EI0-46?24LIC]A"AYVYFB_[4SM\NTPG
ME+IA(K=;2(:#$/*#^,DA26E2@A(N?>D(=XXFN1\60"3-Q_<X,(0(82ASTBDM
M#>7,3U$[4YVZ+95\);Q*94^C[C%-%Z]+RS&GN7EOUAM/N()XH</HC4Q.@<]Y
M$'W8#%JT/D\$Y;O)2[<8,9\ZD!!)YM%P::NB T'M*([2Z)^V) <?Y)DC+,OI
MS-?*#)[C_AT?Z4?OR87'H,FW2B6R!) /:L'8_??5[JY([=B05L7=UU&U)6@3
MH<GW%UE><,B$T6C*SBT)[Z7H8L1Y5LX]/TS&D:7Y;Q*[R;<W&:T'6GO_!\K[
MIIMXAL/^ @\F[-HC-_32@O/\';0?C+_C ;OS 6-PUANR+3QOD3Y>M[8H^Q^R
MPZ*TU^RQG"X\"@N25NL;EB&LU8%:_=\%#LC%FW#54X&%P[S:FL[8WW5"U%1*
M1)* 3F"M7:6(RXHP5I8(=K4T&;>1+&(>B03QNHY42@Q2UJR+?=V;JH^3H93!
M+TM3-V7>9XV!+?<Q3O3AT"YUU!#W A$]1&6N7:LT//6:C_#/O)MBFBT"\R[+
M.)DPY-U2ZT?YU*A_[JG^^4KIGW/G3[YTYJ^OM]+8QP''D\X0AZ>7I@(QG5NJ
M2L66_\UNL'9,WEP;C(QOC'OCY;GG*_^B!?\/T9HN=!ZK @53#S$73B>]#+BW
MJCH-=)]UF51=@T7E)QU,ODUPN,I]T$/:_=E1-I_P8>R6%D>[2N3'4[F/I_+K
ML'\(^=;]%09R/EF1[SAT='/JO@"%JKR6@$MX[##5119W9CJ.94KXTY/U)BNV
MQF#RK@13GVG]07=@5213Y.I']I=2Z3[L%DK>4T((!^'2-C>YN50D<GV[1!UU
MVJ?HZ9NE2KEQ^G:@G -9>-V &97:6P(3=ZOC7;*9<.?8U<1B2,7&3^]6U()Z
M\@.6M825*C?5M=QO2,9N5.O1XQ'6.L):1UCK?IW9!PYU=+#6;S^O>7^6>^U1
M5YYC0 (^#^B$WC^[^UL!H@:M^H8R9R&GX-J ?496)?^+D'0<7=M8F(%TF0B*
MGCKXMJV+QMG(.)N9KLK2^:Z(25 F8E_SE.^(W]RB_1:7!C&1B-JTW>G4M\7\
MYHBV(XES":M65P(F6A=759Y&9%B4_VI5AVIZ=N>%(W0T6_I"=-O!+Z0;DL)S
MJ@:[J=U3.XQWF3#K1U]**R06L!W.P@KZY *L]POJ[B%;Z'G>8!D7LQ:A2Q^]
M'/*5;.H@!!$.&1G<ES/:^%8KOP SUB.'-C) /7GZI%')H.R02IS0A,4/XJYO
MC)7U?X&?-4O._3;Y'X)R8@39>?(^^I=J H(!,/S="T0AF8\!F+_-Y)]]^1"W
M]*^AO=64*!C7<#"1U!U9QS B>9]ZZQ*:+CFS-,MF05Z][1$3<^\)[L::M $=
MI2&D!VFEZ41#50*@"L8WF .D:K"_8BHQ$L8E;Z.50667Q=1L#[1N5F 5N_"-
M&EA<:5/3HI_K"U%4Q2)-,D31+!J<8QS]8I;@QI72!<<3:5#@B8(8\/"H@%OA
M(F$.+4W$F277HM5H1?"ZZ;MP;94Q=YH"_;TP9<ZPHA#&7Z85#A\#-46>ZPI@
M=V\/=%0;"EG1EN>RED*UU5;][M*A^2;8<[.[F78WF+K%K8<S.FST:6W '@[C
MA+X?UI&KYK@A\(0/M;T_VQU$'%;(D86TD5!*O)RHNHRBBPLZ:\*%V3BD=L ,
M7L4UXYP<Q9#/]<\.HS;^&EZ-[5XN7%S43_J)O9B1$+$DD>\B;##ZWK_RF#7]
MS3!H(*@,3\5N<I7B5-^^2)J*\J5ID:F@FD<(Z;KV,3B_?TI[[I4VY52,"T?K
M+-&0UHXC20Z1;6M["UD,-@MXR]Y'<:]93^%W""-&A 0Q<8)2TO?*L)$_9QN
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M2U?&&N0M3<(PF([*P8O!&:'<-, C:Y1AZV1+<0-<IFM_STPG>-%T'=:6M9C
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M-4\>;KLZM[+!\HI5@_P;1"JN>C^1AQT'OCFZZC9:II'F_NX.VHOI:%F',26
M6X_&VWV9%H9!=QIOOK.&99/)V/I(MO:?V'YB*^T;N\&%+.A&3A:7$0 +%K"T
M  =4Z<:(@Q;2(*#P$_^QFS[O$KX_O#U[J*(HDEB:#?S":"$DH>*X@+?A;80
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M,FGRZ>$M$,9PFUMJQQHXZXN1',^6/O0PQX*--IYERJ8B38E-DPV%U15L#/H
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M#_?P5O:\Z@Z"T^KN]Y#[5J8930*D"\,E)L$<$ ]RDL8QMQHACD^0&JCK@!R
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M#"^S[VM([  8TFQ>4*<2/%L#JI9>F\:RIE.[ V"IHF54D+[9,W<^.#90W@9
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MVCV.%F1[-3K"K$.OQN-<&BF'+Q9MR(W+FUZY.? 7\^BB8S6^:4C?K[@P=![
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MA%0^%,9"!$B,9M4!V9K\UN273.G#5V'R@@4RACV1?<[MIP9[]YE"MJ[DRSC
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M   A+0  "@   &5X,S$M,BYH=&WM6FMOXS86_5Z@_X$UT"(#R.,DTW2QL6O
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M"7;021N=V852 ,ZEB%H4_C/!KTD5>?'N=)$K.]S/9M5Y^J-(4M;H_ISSE@S
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M=E?R:L?&N?NQURH6C'/;M/ 7])_A.F[/;AG5[!='JXMAHSVP+F'L7O;L]Z6
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MSX;_'OYY]-Y<7Y]RW-;)5SR$K^.;_ZHW/_U@FX?T4;U1;[S@ZZV]KQSP +8
M_VL/N&?#_X<G+NM][3)7\&>,U$Z-=.1;$0WD"(NY5SQP?/L$?A-?3_Y\QI#'
MJ2&//;CXT2$,&C#WU+/YPR]\]+4.A'RKOK6YMS/]L-L'<*U'7QM?%4V4X\-/
MSQBB^?6FS^#ROC:_$@>08PCZ[1G#'.%*KM10K;$%?=?8>U^OHH!_W4P/,H1?
MGK4\\7<W_%K_"NBK5@'_E@-T?'MDBG#D\A_6NH!K'\U&?1B:M\X 5GG![\UK
M?\"\FORA!I,$3A=1VG;N]&>V(X8N&WTT/=_C^,QY^(CHR0/ >?J'8]O<0P*
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MQ 1?&!$^MIU6>CN8@[DX*6V-YG;I+H+24MH:S>]P,3]BA9AT3SNMO(UAPE9
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M5<!< ?,*4/%8?FS4UYN;\=^V<EW5"0X.LI#?CJPP$B>19Y^=';X)F!\_BU)
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M.ZE2K+]Z=&Q2?\$&Z9[T^1LH=;[<+8XKYX77/">L4$ [ ZQXT@HX-7Y4&+
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MLE0B8B;K]0"W45P<4-Z%S.W2>'OGD[J%"B4Z>-4_+<H-,Y%5A2,3P(0X#GF
MNR@CPFB":$,42F8$$B,(L,"Z4#"4L1K =$!'E=F!AI0DTX-B((:+(53"=VWR
M%--B@1EA3]6.8TLE5WQ#L9@&@Q53F$9F' IO5GNAX3K*9(UQ69/YHS'P!7$_
MX+4@OY(-A^->0#;W/91DL=F+^7=$%9A7DYZM,/2WR;#Q<^1QLU6OF4@N:^;3
MR% @1RE@$Y0A.0$1QKXFX/YWGD$<9!C$%9D\3ER?A5^=4\4>MEOUK_^<L9TO
M[>#NU\MK'C.%$XKP@87D:7AJF+4,RVB+RZYD&=OKF.6780;-+-OPHH'MAS:W
MG %SUTSU%T%>?6S+3@-^N3G"DEBUS>U6;7MO6_,)O;(XTXO$5C12$<Z[OB!K
M)W-CFB"4U29Y2Z:.Y?+#7@GI5B=!9;8[:5]=G9T>M@_.CHW+B[,_L:?-]?&/
MIS?8\>3VQCR]^.WR[+?C(_B+>="^^.7ZR]7MX9^KL/'5N<*KZ\O#X^.CTXL?
M;XRC+]?P)_4?NKH^/J1?S9/3WXZIY][-2B3PK3"#>[$3 70Z6]FQ!$E84T?T
M-VL%4?U&052_F8[J%U%'P,A<VC0IV ]7Y70B;5),64.E;X&90Q>."9@9.@&4
ML0/^&149^EL9IGK O&]!- RMT57@6YR"A44<Y?YHJ.X@^C4\_&?W^I^?7IYD
M,U6PQ69!]LU4ZWXLI-=0VALJII6-9BFW)F56D'U Q6END]"Z14)KP,U[_,_C
MH"_+>5 ECYL^"[BXC$+R,0, :0%SJ]YJ;G_]YS?6NO[]THK"W[:?%C ?&[=0
MXMQ:K[?6L<AJ!N@WIY0X3R].4C*GG'%M?Z>V5=^L[>S6)TF=IJ WD9YD)'8_
M66PE3R[43CYW]H\N#[^<'X/T:)Q>'%Y>7V%/*) @#_X$R?+D^/KXXO!X59+O
M)QD+M4]))"UJN'TPNM;FE%M8U8$+D%S,M';_$XU^/;CXY[>7-[[EPF)#V%X!
MH]HJ\GX]N=(U535ACF;$U<'!QWC0#* TLZ?_6E\W3QSNVA_)WK]^A8:Y]?7]
MS[9SIZ>;:A.I./^US-<JYI^^5O71-K:RA<WU^G"<PHIJF_K]Y&)@AGWUW]0>
M/F0VL3)W5@"-F:O##7^"KU$&M_ KVCW%J8[?Q,1B=;E];A.T)&DAZ320?)I(
M=H;Q_(Y<'L@X4"9QQ 71P=GCQ3/'+_*9$1+T4H&Z%.JIXSPEK(R?2<#9M_4.
M![D%%C.D<TP#@#R$8185" :2J8:9P=/0^ J 6 1XR<*6EOZ"Y'!Z<73\QZK(
M!BN3<?4]R56%%3T+\3UNL;Y3<HOU6=6/4[KB]'M<U$V]X(X:CE=(H5]Q?T^Q
MMJ+ZLB]/6-%57.,3D$"ZG)0)*"VRJ3RAI0->VAU=^!NY#7U_VE('8*H7^)%G
M(SGU@X]FT.N\:]8W:\W6;JVYM?4^11OA#9SZA[7F"RCXC,G%9V;V U09_S7@
M7^MU4"M/_.">!?;ZF>]_0T_>31S/]OD#*Z4&Z 0:,E^J\?T48+: W"HMY6X<
M=G_O.R'_'F8^:R#MY.&TN;9_U;Z^-4\E3)93FW8*N)R]A;O"J]7!JT=XPJ*A
MV"G0>%I<8V.& O'K,K/6VK[.9]ZH>->*XMBB\ZX$L=JK@UF;:_O7COAFHN?
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MQSSG'\FR-LP;WP7N8V Q7Y 7@<0Z.&4M-9\4!E-3TL+H,OP):AT;#D%[H2/
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M7BTY,I3(T*S5ZW7\?U/T69"D9%BRH[@@&9YL(EB62HDD_ $)BY2P[EF (?A
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M3/EHP'M-^PSS477&%%%UN*JIW9%F6U!\(8IHBMZ)=')G7-0+*^2HF$ CDSP
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M<)D7I)TH((%MR#H^"#94B0] 0 9E651;IL_1H&(P$\W&+FZ/V2K3B(>RW=C
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MFL*9<55Q&]NC"E6N :5BG::NP V.X -"829*.AV#HUZ0B4'ODCKI&%T=-[K
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M6_(]W4V$,%$C5 '>I3IO4^.7N!-)(%VXK*!EN(%;QL_NY4ZD)R,YTW7=?SQ
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M/3FGN49[[L34ME*&9V]C9\@Q[FJ@A%EW<T0G?SA4+B-KM[T:["^TAKR'//Z
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MI5[4G-% 3A2@%?'4.1YFR>[$43^NUYNF6"P[]<ZG",Z=GK$%,7$89VYRYD
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M(?A2ZF*S]("F9L;Q.S"J?Z18J/4W7Z4=G6BM0'Y92]4# UF2]_M' ^C<<.0
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MC-82L9?7=;:D"9W.:?T\"[,6=!V!,WC55T8< E#)<4BF4_IAY<,F$5B"R>]
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M)<[CZHFV;Z9$VS4FVKZ9$FU3HNW.,\0(NQ#.##H3//ADL@AOS"*\[BKAXN]
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MDWKD\M9A;N?ARC*FL$1O#?:$5!-@Y09G\IO >PB7GM]BPYH!444T A2"9TE
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ME"916"C ]CZ#"#0-0V_0C4:*KW>)E&J7F?=)>4&/THU;L_4+!<2O3#?%E[_
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M\<:#&.DIL'5]4>7T-CRE1'Q>EZCN;S9AJ>NB+W)A;7&U<HTIS3GZMFY=QG^
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MD@XF;P?FF@2*?R3$D=MG--_%_DRA>%%E4OK#-*L?&95GM!NU>TI>]S/2J#/
M?K8Z7[E[<T)M47,SKQIHPXH- 44P5;2<<7=A2IH(J;IN&8"TD7H@31AQ\ZUY
M@9[O/VKL3/(<<\VFY&9MZ/_0O<@G#M?]K"PRQJ/W%:_<O$#[7WI(6G @#BM1
MII4 O]=IDRZ:=+T4BX:^:B1G$\PW^KCY'DZ;\9-,;=NAT\GIAP5+Q*>PVZ^P
M.P_C,]YY(I__/WOOVN2VD66+?L>O0,P]]X8= 55;ZO?XQHDHRW:/YMAC'<M]
M^GX%R20)"P0X>%29\^MOKOW(W F")7E:ENJ!#]U659% (I&Y<S_67DMV7W&^
M91OOLO">N\JOR5WXVJW=8>6Z_/?/B_S%%R_^4*CN]G@8V?9O*#\[9+=^J?V/
MYW_\8_&G/_^E^//S/U[1D?#.NAU6Z-R-R+_Q__A];B7J3MX$@-38^>WB9W0C
MF6HFRH?+Y#89[66_1Z^;!E0=/_+VW/IHL[W%I+R"FL[S/^6?25W]6^AP/__B
MV?_*WXP'_TY/4EK_W(#F_?;S6Y+9^C&.5=E7?1IM)%LN2[9<9&%L_+V/-75_
ML')EJ7RS/HAQRKW)WAS[8%%O4&T4NA%Q.R")B3Y212GR;\TL\?QD,R^07OL&
M$K3RNG&1__'7JR]\)%37JO!2!M)0'V;U^WSK9T^LH:PO8IWTW_S+U8OTFV<O
M-$MN?-MV;T5,$?!1NL:?K_Z@U[C*_^$,A_N%20YG1%RS=//W&'16]GSPN#6*
M<UC/E@P31IC/'#_J/])%5^[40@V5OE@3+SU#KR/%-VMH@ZB>OJ".D+VPT6ZZ
MRGV@T+L,K4L5SV175KW[$,<9%6+\G+BRGYYEY79PO$*TR$FG6M9R&69V>^JV
MRG'B5HWL:M@+*IDV&T'7"X43^)?]FW,,<G'<I"5H@=CUZL[G/1.R5 $7^[@(
M;0!&>R6^P/E&6VE=)Z1]XQR&C*26!$[R;)"& =9 $ NTC4/'%[9[AMD=T8-0
M3T=86"0Q]P(<6KE\''Q*R/)^U$*Z7(KX"N+2H'L);(*<C# /' -"T^[ B O3
MI),32RQYYINJ#^N%:%[C]F7R>H1YU+;PT]2;R7Z=-R,M=KUZ="GTXY^R^9FQ
M^:*8[<0 7[S+C/E&JNB \5XVW1-OR4X*71M#*8?BXC/\!JYIVXA-/]_ F;BE
MO.YG@3&T8]FJ,;5#V=&Z&&""L#0'ZIPA/=A^W54K[GC<MNW@-[7+GQ/,_L[+
M9[/S+]JV8D&(9*C<P"WB/[,T 9@@% 84?&T_3=1E1H;)]@59]<__KF\WZZ0]
MCH+-?7RT]Z\$_W6I!'_ 2O!?ETKP?:@$W\<M^10R5NR4.G:!Q#><4.(=X+Q0
M"W1P#K4\I YJX!08X+ZQPU3A[UP;LH06.&&7W,KCRJU0VB2[D#:!;[.C1#=R
M&X$WD:/-<S^;OH. R6VF?Q[V73ONN!I)70.22T3MQCN)$?"9,8VC=R4-")0\
MU+ H0T+A;'&2RXI@8.Q[=O%FTB24XI<42<B0:%Y?$R-%)C1?C.[C).C:5<>!
M/=$0 LH#^%'_KNUXX,E>.X[=>E_V2+Q"CQ,<O_B*A%M!$%&5#CF(0I@TLA16
M-K<_E45#1(5XRF(8KDJ?X:.W"+SUBDF8^0^7)P^:6(\06V;:9?TNXX%9W.7>
M/'WUXT__WS-_&,%:Q+N0<J[>JDS"AVBJ;$@;;QO>/JU5R4VH8%'BU?^W7[DI
M2>(>!^</S19!H'\>P*H/[1M<X37?M<CP;!3%86)YF]3)Y'HWA0KWE(;P4XJ@
M=5?=$$-%R>AG8Z'U625L,_FA*5MJ:+?WBPN:[GU604FEZRC@[BY"!!#,@I"K
MYY[^78M79FH#2!EL_:.A=[EK?V91[?Q5$UY)@:ZS.QXIF[FI'DS-R3R 356@
MYNJZ-8/+6>N%O^MG/ J*8PG36#!0&")Z0HF_Y!XFP]/LLF2Z:*Y7X$;0.4MR
M(OEOFA/)WCLGDG^,G$B6YD0^/A#L41W<'\G?0PHBG'62BCTA![.O_+$*L=S%
M,WM<GIGW\(G/L5WSJ<KB5+W_SUHJ 7K.'SMO"KH*7)'GJN&B$S[692?J6_-J
M:V*_K#- S#108\ZXU-!&GZ,X4R:/9EQ+/M$ZPH&K2!"ZI/7Z#.LUKN*5XY:[
MD%=,3AG-@&:SXYZ>VGZK?.TMW^_>'/U6T;,:.R-HBR:G.?TEGO2K#@IAVW*(
MSE6L:10T.QD1H@E'5')VW51T;GT6?TG[\O,B/9"/'1]?JOJH?"/D56\<>'_P
M,".9?4%945.N'C_;:LAXB?8D0 DY2"(9T5>9T/@$"6[V\7'KX+";=]CGG]5N
M=V'(44R^1G=,@W1!J7VZ&86=0'?Y,9:V7$=T<1P^H%ZEA"<B\XIOH;F&M+_S
M?HVH@-2--?K@$TN=.G]RH]SS63C'TK'.N1[E>E^Y&R=;HF>F>2([<J-WKL+Q
MROL+PI]RZII!4Y(G_ZPG;Q^>L=Y4_2QR@[$]PM[,PCB,9*U,]1URAR@SU'AX
M65NQ,%2@BXB6W6>FS13#X$HBBD3!1-!8JB9#1EVJ7OAHA=8[;ZS&GACY=4[]
MK9KV</(/&*I[<F':L:$;*NW* Y9C;/I1ZE:,M0MZ?0?X>A%_M_@7]_MDG<\G
M49(639M^&^TZ%TJE.64WDX@LC</5JB_NR.-R1[[Y!>FAC)L@E<-.R*SB$N$"
MZ8_6@KZ!Z:23^KOO7A:&8/T01$(IMDHO\;+L!N1+\FMO1O8D%JH7   C+DDB
MI$.\Q_6^P)4J^:'7E'QY,<E4%"9XY&"MB3W.]NK^:2EY0.2I_BZT!8YU&=E6
M0REX.,M19=,<5=@;26J@G\D-S)QF=D<V)Y-/,L.=&5,V(X,:\30_D%-@:K63
MNU":P=[@5]3\9Z-7"CYGXMV/=$P\&3-Q?S16__#%4O3\<$7//WRQ%#WO0]'S
M/F[)QVQMU$EEL)8>,8QPA)?1HB*C_+CR5W.L:1,2QW><D8YU!A^EU3ZV0V[$
M7Z)M&E<O[NOC<E^1/_4OEX1.J$4C0:^!R":@ "6)9C_M79COZ!_7M0]J-P-C
MQ%_N*[?-OPEK\ =>@Q24=\C,CT=_K7UUX(J-1MB9P<ZN#4O)#@EY?Y,0U%.Y
M[%WC^A8^)'+]^9NJOBEY9/\'37FOO0-6;<3M^]$6"[^.+N%5]DT)CN=M_KT?
M$=KEY!'I@W1)F2NE?4,?AW=SVQ.G_E*W?>2:XM2U?NM.S_R(F<6:1GY$OHV0
ML/1460W0,(;A*LJ+:7WX;(/3]5>NELR.HB.9V4@257#2Q>UE4B\DT>@XFT^]
M,*T7DD4()$HEVZ7['MN>"S+DCXOY0>CCE[4C'AA^S;<^2,' ;[DN]KX&A[-I
M(8L:\TQ9-$6Y<A1C&+'XIW_'^P&[D@_$"J6[Z4)U[CR7.I<I.Q]M>H^K#"5X
MA=)3%5\G#TNG2Y8-*N'X%:\>J;XE4<;=LQ.?S"0IJ8W*.PB] [I=X,]).&++
MR0$D_QXA2?Z;A20+,NJ!-'@*R. [)&N_I<:WD#_P]VHWU5J@!$^AVY.G4=?)
M_7O0!YU(?A39\.4A[O?>I7Z%J(@FO2'L&W!;T+:JN:CSOT<D6CO_*\%*^9-2
MVP7_=X#.',D*2G/*]^1'AFZ0P#+RYIN7W*#9:P>E=\4T+2O]-.R*4;,4MX,1
M8JX-0$#MF!,I3KXM/ X_["4D^XB/=A:0?7AT ];@YC=9A-0PU.3_/C8N?RX?
MD8YZY+P*= ^2?XME55#I&!XS0A;M^ZO4851FX(1FQ-XNA&OFZ_Y)?(2RJZAX
MJSH=06#-K^S;LB(*8FT'\M<I,E:1I0ZT:<'5\FI[3W?O!_4,4:!\@;V;W' *
MRP2^>?9[ZC6T#-M;03Q>^&[&A6B://2'>M>>>K)HPE@/%\@YOTQR:.!RL$!\
MWMS?%3HG_>OMM)'Q%J!#AL/V: 1K(FRA:6_IBH$04X%[F5&^HY8I_0:AXQ :
M'OQ^X#[EMF.35KY[0IY?Y7_O^2WH;RY]R<^PCP;%=(7;,]B.A%\,7-:_\KIM
M=M2\AO*XW.(]W@\A[ILUH(]LD_W'F[XD1G5_LW[HBXP1-OZ^A9::1#;J-JZ]
MJ5J@#E@!#F5-+-B"Q?!K$E* D<FW.AP1DDT29VREQ2QG;1?QO\1\VE>A2WJ*
M9ZE,%ZJW"(U?#(_";[AGAOI^!%!&;P;MXS^)LNIK*?6:A%/^#:/6GD(D]>B7
M"CF:D]1;/[&*9PE,L0F4[@K LO? $WH;HVT%G.6L71F ;EE0'8VZ=MZB#@$#
MN>_:QEOQ>CRLRH[0T?@_V-PO11G>-=3K[3I61:5#); _&\S4I*!._09GHTBH
M%) "#2T+$XW48M+&HH+!\3Q,IW-?=@>W67SAQU6>$+!OW"N44V8AT[DM4@3Y
MW<N;95Z3]RK_BIQ@]1S4:^B=>VN$>;-P_8M7BGZ@>APR%/8/ GKXK$N(X) '
M[S90101/67GWLMPZ;J1"SM9_? T08;8?_?0)4,7N]]SLM$F_4<$)\=R5B"AZ
MZ/*1@S*U,(HSQ3LFYYSV%TUE@R:*4L%#DQZL^2XG\LM@<:*I:6^!% ::X0@G
M661P-A8<9>V0:&MN.&1OAXY0S;];C?4.90E\] .@*6<6\H=+5!]_<X+?QVT&
M7LI"RP8FN,1*1MV#]E%AM AH'>%@2/MUN?Z#R@^%)X3$%4*IV+GG8[(#HMJ2
M"3'+7%-%V.D-B<:2\@$QP8%  P%D.,&FFQDW:R&)@Z":(&,JA"G/0/$Q@,14
MP"$L8-Z,WERU(T#/L$4]&$P(%=_[78*8A?#5%$YRR29KM\6Y'4$UBZ,Q.K%9
M[E;0]5,*DKFN19%1+U3??$[>/.>8)YA7;I8%#$:PY*=9TQB[$J@K3:FY_G6A
MW7[JM-L?VWOZ<%S<'V'D#X<'N1][LLOHR*1!QJ"!Q5Y,O !#781.(O31NJ;S
MBY1-]K2Q/>18Q(\+C:P3^_=EP-W*#55+.Z6+"@ &  =L>S>Z2!LF)W4Q Q6&
MC<Q3X$76.R<T<MQ<]65X7@)+*XU1%<;#MGRC-'!#6UA!GL36^O]0$$F67=O0
MF%N-LE<\&$DPVK$HLOK+R20E:FQT5<J6"3J S'0+2TU^:@L7D^_>A(:ADC68
M@W<*<(,ZJ)'U$&=05'ICHE5I/39M],3H/CE\%!^!=N>J"<X[);SY7!$]K81J
M[TM=;M49U"W"ZIV]"C[YGT@A5^'5D.PTSG]D(FER".DC73U;.?8O+K_[R1;_
MH,SK8D_#6(%@JFMOBX($>@>(#FJ"'"E6@5%-?;Q1FB8/Y5MR&2DN*Z8.&S?N
M1XKWNSVW957?^Y7RD%;U(&H)_7B$(H=?F@3]BXH#YRLP4%Y$.AC3[&/J.]-P
MB$^-WLU=T\=?-(Z5(PQFH*^A(T#[5+\\!^HI^X^EO/';[YG>&^6H7ZHU4=@4
M<>3^6+FI;EHY86ZJH6M1.BS94R*RQ2,5>OF&ZA=1HG9R/BX;\MXO\H>T(=EM
M4D_9>[SK?=I]2,0%:'4T)#14[M?,?)+1Q"(]>;>:8GYUXV@KBF?((%P#GXYI
M4>^%MK+P60E;Y$YNL,_3I']Y:/T@8[?\W/UG-DI0)S&9!DX7$*A4E]CQT@?>
MH[GK^=+<]0&;NYXOS5V_77/7I96_)*]^K4%^($)R'WOD#_449/HT W+;Y*\2
M3:X?W4WEK_U56W8;\O)>_?B5K4 ..<[1N5-I\=[N_5IX2.NV.F@VDQ-86T#,
M'*I9\)E0_G'HC$M<)*AH@R?)YAM]6$/-9PPS;D;BMZ=4*^@'D_(-$])WO -P
MPR9_]1]?8_'7H.@/0_$7\O[CAE.Z FCVFX.*S?&SR>>^M!4N?AC0*$FN<5L9
M0DB((U%Y;&P,12+1:"$BU+(A15>4]T1C&O%'^B]]::5.]+*4.>&6//)J(V9@
MLHVM%DJ7.)PI?Q3P"A2(<IJ3@U1'4Z_]=&W'RA=D."P3F7^KPS/ANF*:,:F$
M1WY43@D3&O';KZ]5/Z 7Q0&=B:,?J0@!2LK7V8NLNK;<U/X40&#*259<#'/2
M1U).T1?<E=J/UK5#NVZI% B:6:1)US7#"U@;2,1 #LZ/'_AW GINO&']F0.&
M)8J]_[;E(=G!  0XR6;S/N.J%4DLCE9Y(^1P.H_"ZAV6M=^'RX*\]R_Y(2U(
M@9!PCO'$W?$__E!(.G#85]V&CR0"/'9:T]M0I[(YP>1\L<T6RTJ]]V__H:Y4
M. S,ID"%T/7:!^/4)Q_Z>[QW$,JO6G?^6]MN<D5JY:_1R,Y,I'Y=_^WEZR)9
MO84X/'  R66+7BCX'AR0]#$0DQ:*L2&2QF7EW_O5])!6?AKT[TMJ10L.,U-2
MG,C]MFT^(9"@$($E1C@N@)L^C*+'1QY\1-PSX.W9>%S6\+U?%P]I#>MR9<15
MUQZ/S'LKX3.MS&7)W?O7^)"6'(&;.]1A0LY)Z2YO1.JQ;]<5!?S!;S@KP4?P
M&1))HMDT#K<.]/T5I4!4:'7E&K>M%L?W :R-A[2.)R!1ZBT"JRVT,H&[P-HD
M'BN2F[X ^43V"S+8Q"JO\$<4K16LB01F GI<T(++8OX-<%5HD=^Z3DWR(>&2
M%ABQZS7+??+!7;EQAVIM<F4MM\40D5OWC 4(_#54C#S(#ZQ.2DI7DI0M,9<E
M-Y0*P*YLI/V.HKZ7W_] __7?'_M"N,P4(ZX]-YHL^?Z'/N9%B'(_)7E6C+4*
MU<X^\++)[OW"?4B;;%(EGM%[(]T6VB%[5];>]W$'UTEQ;5F,]_X%/]S%F)B_
M0EL-D7JK7<DP\!L_%N]Y*R2\.@B3S^_<+\KI8T"M/:. 8H?$'0!=T,)@'- L
M\F.YU-&1 &DWK8+0N1^P<Z2#OFR2>[_P'M(F4;@YBMI$"41(5B(M"NY\.93"
M.V6Z:.'\QY)]:1&F*/73,M>T-*ANI;?H+("H3"!;<W$RHE8#V]7?FPJW>3-0
MQP4\HV4;W/>E]9"VP:3&PZ@18^RAM9JTQ,\Y-U>S:U(1U0O5RC_[:)^*8^&:
M).O,T9RHV\6ZA^ER85:%N83(M//3Y#V(N0W7'WOQ/\JJL\V:F>VO$7'MB=PN
M$Q,=A,O!!'R((-ON@%(BL<3%Z/ NKI941YC<HEN7$3<#.N\*VUUDGD3]&O_7
M55=M=KQ=#NU&-!/./23T.91=7?F8&:E2ED-^F=;X)1;F&035?4:TAHZU@IGL
M4>D@)-&4B.<1=POTD;D5>1 0FW91E"A \;XVZ#-^!(Z8^3(4;A/PC#'S&2E#
MI9V]Y^]N;MU$BHA+CJ..#1Q.*>W31;7?3Z*+]*FVYM,S1M_X79_Q+D_(F&9-
MTKLZ\;EV>V'_3T2CSQE/(N-3W!(I'8RM; 2+4DAS4D#Z-+M^83EYBHTB#Z(G
M9&G_0$F3&CZXZ5 W_99Z=3>"4S=A(<61/4.GB0V#4AOQ@]X,].VXVP_W-)=Q
M/U?B4UUZ\-H",E_/J<X=J!\@) CD^.'>B]B>Q+^FK@Q9MLN:6];<.\<:B%TY
M>]SWHYN52IW&6%OCU3.#PWQ9XR.T6;]8VJP_8)OUBZ7->FFS7KSG>S7(AW.<
MK)32)THB&NVZV,E(S9O"XYHTM B-W.*Z+*[+KU]KWF49NFHM#;E-OF]O4YJ_
M'GS2_B.KD5I0@2DBOOA/4<SXV!F:QYTL!$E\(\T8$RU/!.E&S_,\&SUE*S\'
M*%,O_ "2]1[B/3>.F:,7T99[7L$+TM@3CFVIKY >-N5FIUH6S$'+,D6F.!K9
M$$)OT 7TERV1* %WIN2,3/&Z=M61>C,BDG&&][5?Y"P>G:7":IQ8)2'Z<TE_
M6=D3JKP![*0YG:VQ6!L9FW"=#6DDBU@$K>(+2SA3%;:XEHDDH@M65,F.)[<-
M1#BK4V")".R&=@6/P[YEC3;6@8-DM]19PX SU^P0*%W89A/&8@;<6!TOD@1+
M(0E/8 T]V5VS+==$Z5W73FG$HZF^8QW/F6C1'"%"ZO;&U4/"@_N,VCB$#9=:
M\PG412('4NWCV_FPYBA8@UXEQD7AD,OA:[\'_%,1E[0A-]?M1:.98!OZ]F"V
M)9?%;UPD=O&[K.R0%\@2REYR>\BX"*,-Z!%9Y)N%9/P!2*"WP*/-S\;"96<B
M,/R=C5M70"D0<($-BAVYW]O?CATNA4IHD8518S^[+M#IB) +)Q=Q ;06#$FU
MA [I< >!)EA\'M\PQ1^</ZI_@]F<O(69>GG/^@#?Q+^D:^N<1A88C AI46+X
MS03X G2+""2>2_)8HGGCB!AL(,UNN?*_;9LHI36UQ)_ ^WP\<<K'=3UI]XJG
M&;CI5<F FG3/S9/(,*FO$):QO\J!]&3J>G$-']TA=Z?JUIPWEM!?<SF0/+(Y
MQ,H<_.5,(NPJ?U.AH=>O/:J46'-E0JAT <\M7@*3<0BUZ4:0M76HA9\+LA5!
M;FQ/?F4[#KWW8XG<WAM:T+1E5)*B[JXX!@.;D]OBA#6/D^-Y8I W@SJ#])BQ
MW.*=TA[E!)%*3Y#:168)Z0YPR5$1:[M^T31:ZA5+O>(!YI 3S@Q XVD'&Z?Q
M0M#@O=G>?[7?BA1U(#<(-"_P\[P-<^23]H6-D(E'<T%G+"6.7]6L86E:F2&.
M\RO_I2I0ZB=8@@):M<M26Y;:.\<:-=N4L]>J;J6+SR;F0+Y;=MXO@^]U8%&L
M,Z+@"2.M9DZ8S9<S*T9HDWH@N+9726O [PB!:3@ZSY(Z81P*^%8K?F+C_+>7
MK\_)YT@-CF]<:&NJ5?P<.R7LG3(;.#A]DULH"=[Z;]^_?@@TC<L&O$\;T#1Q
M&PZ,&-3%KE/62YHT-+RG$!+EXN;7\[)*EU7Z[BYJ]6_9,,9(.JJ6<\A/N0-O
M0X-@N72K/0REQ&71/<!%9S-5(A2 7[$<[ (K6Q;;>XTU]#]KBSQ.RZKAN!_=
M\>=5H8[^5/D_E51X;%P7/CR3LUVZYQ]G^A[=\XKUL0[<Q602I:9G4O:7>U6E
MZ$G)\C*(8$;63<HV9:W$1E"I1K**,]S<J6_1;]SY.FG=GK;=D\M8R,H&1JJ<
M&=A2B[PWSY$^P5V-,[]?&F<^8./,[Y?&F=^N<>8![;]'CVGX:>\R6S1]/_%P
M@.\-5']$0A GWX"**W$E(J$-*:IV[-.+5<CV[8DGJR8)V KK9P$_/"[OZ1][
MUV1IEZF_\H4UP3ECP8F*7Z/R=P$MA<]'<!XM'"<9,,U 1UFTJ_P-T 6\NMC_
M%YC;G7?II0RN7#WLB"5@-.M<F83;A4<3 'I)WMLS=NBJ&Y>UY'5M*[;^!Z""
M>4PDK&9DF6/C.-H57(XN7HJ*&62WY:X7N4<*KVT[HE52#;J"/FS[?$N_[;+K
MGLE^>SGB^%U,P8,S4':EXN5VB@N;/:0S>4)3- 9C&_T49RL7W.K-)X'^/F(+
M\)'.$0J7JKX;&9 J_%PEL?N$KG.WJ<K\,U-)PEI!HP9V$/WU<UEN$*X<^H"(
M!]'I&8+]PK&5W7%LO=^^5JFDN0BO=^YMOAUIQ&97^,/P4/6]$%DM1]DC.LI>
MLFN3_>K56Z#EXQ8?*I'<O&'M+ WS93F=^L$="(_.36[>AW+-AMGT+H'=BXP!
MW?P--J.A U*P?&KE91,0, ];"<:[VG"_Q]CX]>]7/2N06NFZJ]SOYY#UUYR9
MWSDW957KB1K.3'KVPCSWW0_+)T:H+>>W[Y$%R24+,@,%SW@0RMW')WNZS4%K
M=[[-R_6^<@3$#[-E3W2E19:>';8J;O3!4SC6_#35PQXXR(SA0#(_-3$%=6O'
MS_K?FR7N<JOZT%O P$\_'IS2"K($FMCYXWC$2\P8Y ]GH\B#MP'>/6:&]FNK
M!O_AR O#VSG([P*55P9*03P'Q:RPF[CZ;BR[TG]3B'!'."T\AVV7+ BJ]GNW
M2^8BZKS(7-R?D_W,9CR:CIZ/=-J_E@V0,7G6\>@XC^C/0#FI X*#U2#N0N5R
M*U!5<],W]-6AB8R$18G.#8M/,1=:CMG'=<PB$1'9(*?.'<Y:2E9S(U>(*ZH^
MWU>[?7V*.8BK_/4,3^NE=7KL7$)^2V+7V:]8O7>O7+M@\Z^E^<JT?#%(B5NN
M)L^<S?BO!_02K' 4;$2[LZX.1#'.NL>A. 'R\ZA:]!9AZ!#[HKG[JZ=3KB-U
M+WCJ8\>,F7Y*-I6_[^W>85@9]2_5=:O"[MMP4S]-<LR%5KE?CMY]J?0 M2S!
M/AH>$)8V(8B=\]"IR3_V9&U<KUT$_MG\&9*]ODQ7#,)W?RE,$(ZZSC\(1HG+
M!&KVV_+4<Z4D",73R0A06^WC#&(*%7K:;BJ )JB',IN$VJ8SO.#)(05UTR ^
M6<XSK61^V5(RXL8E:Y(>*K8-2?$2)26\L SNA40CDH\[!]-9S\@T*W?.[P9A
MSFA7O>MN>*[:A@0;<G-EN4#5W+3UC;8XG;^\J\PV#UXJ>C%G<=^&G=,KLX>^
M;"GWTW94P(D?V/N<"KB&7V?4>L/"%X9?UK_-4EION'F%^[3KLZF:-'":."_J
M&G7N9[>.K8XKM"0*^QJUE^3:7I+=T5ZB=-9T8(:;'-NZBA@;ZDYU((DFJ@*9
MT/0D_/C'Q.,X[#Y-J>X/2ZGN Y;J_K"4ZAY,J>XQVI"/%'+]X$_[:4+21DX1
M/>>]M8W?!>S,4<P^<YY>%'U2KY&S,NK#M-+K/$NC/H6BD)^XQ&>/+SX[9U"X
M* #1"1[IG&V6W5#E#4PO(?[_"L0*L;SL'PS-+,@/-INLJW9MATJ37YJ5'[ZI
M3TES2S/ZI8A/[%IO0IETP?#7:#XM$6>2 $K:^J824$EB%E2'67R*2\YP_A6G
MT2*K\QPAE"8(IY4YBA*:N_>IRR@>M#M?/5NP7@Q['XUP1/@+;_Y?CC*/-L)0
MYL8DEK*269=?<>[7Z3Z#>5'CPAE'6Y>DL/B,'X0\[(A!*P)L@,A2[EQ7*4>@
MOO<,S.T5BI <$J!'/5%P8/8XQX+4Z925B-':/DH^\&W\8Q7Y<=25S/E,^VB<
M;3WG/KG*OBFY=VG"/'?VNE 3%UN==U7_ED1D_,(596PN$M=TLXHB.ZQ!Y#_*
M*5L-#9&H[<WG,C_0J_RG/5_\=].K!NZG;1LGVX<>DAJ@&;LI*>JAJ![;M9%L
MM@0S(:CDF 8Q').H4&(!H3#WG&7$LE:A"*'/NQF[D%  /35JT$ F\CDC>Y3Z
MOQP5UA0)(-PS>"E([*.XK0P\V[$)VCB_HR-+!D,I@%[RU/]\O#1C:C^D+5\.
MJG_FB5]Y6Q!"=\IM55R7"&5<LB$SNC,;,A0S98]R"-QHM"E"=DG(_SA?1-4^
MZ%^219]^IZ0^+UK3".\U(:/"@GVHY\%*(\!GC#I ))S=&QM)S%$8<I8NR#27
M4/9]N^::7FAD_ZD;#\?\>N.W8\4=%E0/]*<I*=ZHR*V"-"(I'!]AMXX+W!?/
M JKHR9'F#4XKN<"!TU]E.D^RC^/;R##?H0._Y9XWG3Q<&DUR;2>9LT0;H1:;
M.R?[Q:X#+%?23!*2ED;5/5,"OU"_HP+L)9TPI>QK[,ABO2LXQA?/L05A?9^=
M>PZXC&*5I6NR4N5G5&;!>I@<>L.UUVWT0J1+8 Y4=49I&S+%F2'Y4<<Z?$U6
M/FW#O"F[KKUU5N4&F["A;>S<VR4R^Y2EYM^ 9DK6W(6%8_Q/']14=5PYQZ[B
MUI YED^&%W",)?4EA1(F--RQ@)%](X?MI<2_<TI=.)>1\';ZV%;"PGNVM?@
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M[XUFUQ?I71,5!J9_@>F=WY]R4ZU:<6G^Q^^O?RILIE)*I>8W/E;?$I$N(0I
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M>4:-!#][J]QOA)V%[*%62;E6*&Z!.,":0<EF3AIAN?'.&C(R*N!)Q\OH';3
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M:@1;SY0)_H!;M2.M[H,_C+J3N7Q/5,3XKX!2</91[!<7=R#MT[N2MOTSU-I
M]7>BHI(2+>O^D)&%78&E+[^C<](U#(-.*T_A4;4U-+(X<&!+31Q'H4Z\),5[
MQU-1VB3C0=-U&-93WWU!]B.B<&JAY%A\I-PR+DX!<>]Q>,LPM-O'"-[L1IQH
M@Q-?*'WWP3VX\><KW6:K;:B7%M:9^-_D!KH4,BI,V)L)QB[Z03[6#T6+D)P(
MW=F:>"@6GMU'9])>;;,[+)*R3,1523K7=IFV#1);0\C$\;:\U$IQ>>-D"1,%
MU7I?LZ'(7W?MX-:A-GR-VMR&KO@28U$B@=>OKU]>)R8"B_=5LQ7^@Q\=26LQ
MNVOA343?$\E 0L>3Q0JYV#0VOKVD05VPPI;AA?GVN62VKU;^W]X Q12IDG0H
M.X'AU2&DCL#[9*LA.PO<33?N!.86R#[]#!KC+7G,"8T_[D-M>N>^.V$H@%OH
MZM,DGI( ZYL1\KQ^;?V](35*L0#?_+VPP\LO#*_J+59Q=J33[&7G6#:,M$3G
MOQR3T1E-.4UV;V>[U^D^<_.B>+NV ]^12IT=\R4]6:&&"/JH!:$)N#6(9!<#
M /%R<+<8S@=L.)LL[KESMTG*49K KT^\;+%YJ,B5&%U".<!N,BN0M<!0P/!C
MFMEM9"-/D=;,QR+,WD448D3^H>Z=2!2DW9],?.NM&V >S/T _@UIO%4P\1;
MFCZF$JQ>"O6PLDG+C )N8%HI&X$N1=YV*T.Q(V=%>Z9C^'^57Q-MJ4A'V^S,
MV$2:#^)N[LG,M^JGD?7>M[?Y@62(S]^*$']<<D6K3MD%_*37IT"</3__KV:4
MHJ57,+3ZB9=Z]E[O\DDG @C)F:F3I>7T.PA.@(H"R/D3UW$>;H[C/F0V!!EU
M4M51!NU9:9M.**UI5:I43]L?'*D#3;%9V'P.6)YU7(>P4;1OQP&D+Z'O/QR
MV+J92&ISE55"A0CND>^@$V!> "4H82?(^-\B):(+]%._/EV0'_X9[]E12 0P
M83VR.*[R-NABN&/Y,I&^-=9!7-?[]W[Y]*6!2$;N[4A!<6O)#QSEX?2;\$F#
M^A;YXK(U<H:N^J]^)I'"[.@^5UI/TPM'J6C9'<P?@2/'#JCJ,S;4H(9XQ5I9
M*F<PP\2]<>@2KQKO1 ;BK?-+YGI)/V+#:!;8_.GP_5RJ'!4-(GGRL0G'V6 D
MQOP\?(:OS;<%,!_( 8CMCN60_$C+!EN^'WOB*F%L<\H^(=[%6<M])G%&6!;\
MN9(H.?*.D!,@VS(6JE24C>:A;LN."C&U&QA6#/4BM-!3H]:?OMR 'WW3 MJL
MK5OAHR&ZZZ^R5]OP&J#HU<_<-33BA^7$>"%6:FXD*!5 3A!$&PPJELL6C8)
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M \(B%MW7^A2TN"?2=^EHH%W,;\G-%+(9-Q _"P0_$1OG)>T-YIC1I>(DL;K
MM1[9H]YEJ:BL(>9JSD"5-VT%0[9%RH'H F6YB$5!.IYC?4G54_ODSR.(W*FY
M*.1=-D+38J[5-G'[AAK"0$S>H?UQAAV%6S"1::@'-ZU%AGW:&N7$0@%KHN3(
M1F+-/::JTI)0Q&C5(=Q;\C2"L;1=2*=P5>V\,=:(3'4/@SBS-7_7=F9WOL-:
M6+Z8T#+>^FLSXDE?+[ X_J5UD1B1U?.( O%JPN\O*!34L#.>^=3J*S:A.J &
MQ9FY ]IYCN/*?ZK W9$8Q&G%Y-3=$6140>&%ZD]48/%3 "5Z5W/MIY0W36O
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MHZIOR:8J9L\4,<*:0\P1S1A,)W<ARE0]B70:AM(2T)J;?+4QN?S9"+Z2K5]
MB:>%D*,0ML@RL1ORH*?&"G&J&F+JZC_'%M>@$BF\15ZG*BDAF(60@X#D$";D
MC#PVJ'=EV_I<:H:3M\#)#9/)+/99'<W17 O $WF;'+*=BEONZR>8;(PWD*G
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M+6&:L0;C+- 82)&L !.6W>M!&1/Q)B@2:[ J3H3"0GF^1-PD&6_P,,@&*24
M&DER4@$%=11;0L!?8$8 401"*J$,-,KXAGY:JF]Q2Z6D1O%HL4+%DDHX#)Y-
MA*.Z*RC5EYL9E,8">O2PYC2-N8JV3G=:?:&*;BA9KJR:=\_7FTKSR*BE,Y,Z
M%14;@ %ETC4[TB\@7&M)PK4?@G 9"8=;HB"O5A7I*,*Y^-H JC=O+;U&H@>H
M&6@A[MC]+"5C7=738Z=.$AMR?(F,P0X^+A24*5H$EF;G8&D6YAV]5;@^[U0V
MM:.*,Q<\QAAKN&M7$M;W0@(O'QG8",?#(=8M+C.8=0JZ48 =:M!# 8.!B$KO
MGL:[O/W-I585EIN\ 1"G?H\>F,(SW22)!CX]1JH&/LA8(_8'G_P,>>'R!ESB
M#>)71!>28W'&H:PT<"C)/_;)]C794WYQ^<(JI@3LP=%^G2H6:/ <2C@VLMMS
M9D@ _*SI,>:#R0S-AB58A*L)W:@S1<1^$5/Z4RCG.8TCA ].J?>P*IZ0X^>3
M9Q71>)TU[_N'2298LHHZI"<0I5@H3?;V%=>JY4JLRD3H4D+:E,QL^6*$48=W
M&"RB&E?"%-)LMR@'M>ZM[H&IA_JJ@5^!G+:Y]XL=W<!%3,;^U")[&FPT?E:U
MS5V"YFIU<L79\V=AY750W#RGW"J"P06HSYB]U\$>8]1G+(<[*9"D E6B%'CX
MXZ,; XFV=AV;NYSM.9W&CK.WKP>X$9+BA4?I-XBOE;K449:Z+QLP80D9^%F2
M&+GT39TTKY4OHF_00O0'IBJEOE1U+@0'!-;\$1 UL':8Y(Y*LW<LZ3&0%64L
M"G@[W$*[W*;3;.\[C4YGP:Y09"@'B&+8%PS$8@45#D@ABWR\ I1,":ZMZ-?(
M'5(F*D44DB<6W1S8EYI*#I4KB)P?]#<VI4I<V57.N06_I@37EFI=O.FT#_:=
M9F??>!@I#?[U%L/'0Q$3A(4$FJ.\B;DS[J$TEL]S ^1\]JQRZ_X<?CS()OCD
M@.H:T8T68M8%-C#)D;"JCV CKO,&<:X+B;5B2?7L#&.*2 )PA9O*<1NAVXW\
MP,,RJI<D1YW6HUJ@3S-@6&ZB\<=&HUB,7.Z<WG)V=SJ5W$^ZBEYK3+E[C=MT
M=O>JQY5W)_=2RVLKO#=FL3#=DQMJDV?=^N96N^,<["UZ#_$IE@*AD1O%:#0R
M>]'(30GM$^SWU]MJ5R(+6>@N5D@VRF>N=!LZD?SF<^18SHI^0R5%!IX..]SO
MG(A"8D/L.VS> [8_#F4IS&.F"P6\!TQ13-FA(=\]%@&YT4$+HM1+\D*;4J@B
M[\L86!,<V07&]!7[M5PX=QDRH(@BR3()TF<"\YIL$,2&=)FHPS5)N$Q-[68;
M!.S!(EI"X_R>U+G?V74.VON+1OP^JK>0ZG>=SOZ]J+Y *.4'Y(8H$T_M)DH5
M 6Q+=U"5 &P21PD,.PTU^MKPF6D$)VF'DI/(K:J_SHGEC5.(BF#1:]XKKFC)
M,8P$]\;%,RF[KBC+GTS _%H:N%!\'V@=,EASRZ;01"FRI792WS]U9+2Q5N%Z
M5H\W-PPE2Y*'3!\_YY%)VX/:ORI;0YL1AD&R"<;K[0D6NW6"Q0,F6.S6"1:;
MFV A;YU:ZCJKP 6K#(3+B>C'&>;,H16[4%.13%JS\ >PJJW[6-7?KWQW0+'9
MW=]=I+Q:/R(EN0_.3!>Z%\2B?5^Q:*V>6*Q-UJ=PME'>#.<_WV%>)899L[\0
MN;5@7Y5OS"XH[F5GW;Q#2:N'] HD0K*@*7"#\0Q49F&6%P&N4-Y3^@5^8NC^
M[>:!LW>PIPTIK;SS97]#\%"Y1W#/L=@C&,G^D-AL1EW_CM-J[X&AVKX-59D\
MAX8KR=@D/;\YNU)ZH.9,3.M6$[-X& ML3/M';,S/,C.9\[ 91@ZYEHHM90E'
MB.XT@?>9TR,5Q)XRG//SHORH/(&M@C.JK<$=^0B,'AO1= /8<H_C ST_N';M
MUSG@EF']:$A^/RZ8".J,U<HIEXV0^0LGP[.=Y,#^UYR$;A$$FG:;*H[MHQV,
MR,6]3QA:+(RA4M'5 @U?0][F1WN^BPV#J@P^;.8+$M*"R2N[L.;/:[94V9^"
M_/[S7C#$W!Y^KR]LCE?_9(12)'.3Y8-48BSZJ8$SO6U?S'G"BJFGZN4,JZWI
M&D.#E)-CNJ+H*N0/>)D4'C.[V;*!O0+WX(H1Q\P_DRUX"S)&Q;C1=,59A!%C
M.*=C^%D4BJUT['.?+5*&%CY7U,OF&+WB&MB>VN"9&T&3&W3]T/^DV'4Q%:(J
MN#-')5'\4#$PJV)XS(@3C.=%+>,0<&IFLU160.S2]TMA^SZCD%-Z,AD5AF*O
M%(4$*_P]--B4KD#J \Q)D+RTN-=(1BUJ*E(".'\DPDQRI9BYUZX?N!*%"U6.
MQ2D%]]E.ZZ%#BG+N"],6%B0AJ),QTPLE#+Q:-.8ANJAVJ!9\JJ!M_I2&BN5&
MBOENJ9P?LPU4:&0BVECFFA"T6HJ]!FHFM&9++?A4%K2*1.0[F27!"B?7.RI@
M6,X0:.X[.QVPP'9:QC4HQ\15IWI5@FIP"<N=8ITD)LIA)IML^\7-%/S1.%60
M6SB@H)LM.S-53!@F$ 1YC;:R-KB*@Z<K<7=S%:1X(<RF%PSNARUM1.A'L<J/
M6YRF(#/=<R[.J(%)(157;46N=#NLK$RY.J;8Y0&HX"8=RWS 8AD+Y0?S>R4$
M,O<[TQ4F9"_"'M5QA]V].N[P@'&'O3KNL/%QAW7F)6NP*D[ [8)9L96Z7P4Z
MPRP4LWY2Z%QH0JUC;@8G-Z@R3NTN,LMC*IH7N3;;OU,W9L74'3#(NBY;'8(%
M@;#R(K2X(Z$463)VPYU%25/NHS,U), (-U BM]2&L$[(77W]$V,$,?4?43T;
M*"IW)JY=S]VV"Y1K&Y2K?T,%P-HH0K8ML\?S(14(77]&G5N5*59%Q];R=*R1
MWB5N4-'DI517T$>%SVXD_-7$SR8J]%?HD\DHSICV29GQ*=E]Q?G3TCVEC2[0
M>W$V9OIRJU&1OES2R2EN:F N89,TSAED!=4REF4K'5UVB5'=SLA(=$SEW"DJ
M[; )@1BQSHZW?L'</8%N\BG#H< VP+ZP)]LR5F*8(KPHYWYYN6XL%N;F7A$<
M38E!%OHA4QG#V.?84:S/WIUG9,SG[+OY'#E P-;&YL9%ID=>AP2M^12(E^TS
MFHVU:>E$:[ J%L6%\6@JGAC(2_ZSC,J#R?KJ7U1(:-U=2*BWZ?F;*ZVQ>^8I
M&W(5^R_/HDQBU0F[W'9Y40M*<B/ZH3\!>8.-TSG!THBA((-D,E)T\ZR.O34F
MG.?2J[H!2N_1V%I4UU9P7R7 ?Q)J*$(YZZ%/88A ^O)O)R54:)B65*E,17=S
M2Z.JW3D7(G+9'5<^\U-S&P3_5,B, K"^KT60H\#@#.154#VABOVEW-2<\;95
M75WOL#(#0CC$L!UZOW.$D\AHO)K#U3BJ/0IAQ-SES2\NU]+IZ?;_1 2ZID>-
MXXNN?=P%J@7B'9:EC,GM1U(K!"NQ*ET<NQS !<D$#LP @=Y(F"&BV[PJSI=8
MHTREQD^4L8*C\&V?R;NN<D[FT9T0[5$/L6T?@D),/KX405 )DDDB3>CVR+=.
M7@(AUA)GS27.3:G?7Y3KK$JB( ;G6 13H1HQ8JO&6&!TE"WU.'+1PE+49ZN*
M[:5HG:2052&%9"2:Q &FBY5*G19*+_N>TLNX8):^8!7P::4+5F@3?O_[%0K$
M975C'UL\\EW;V#M6]WI:9AV-[;T'[O6$,HT&\[U_OG+=+XU&4X<*3J^./]*4
MFV^+_/\'H/4?>.Z?SBZ/>^<??C\^H@GUKKHG)_;A^<>/QV=7O;E)UPCW*RVP
MSJ+4RNL:-T)IKMGB2V&+K0JV>/A2V>+A'V^/+WO'AY\N3Z_^J-G@>K%!&@G]
MCMB :12B$X("%AB:&KB$-!C%J:H&&\SZZ.3@."RJTXD[%*/,C24H2YCXY#GQ
M0X(,8\5:>3$(F:+H1?$#0D1S%+ 8=MU :S3!H%\)P$D9 4;$8P/.Y]Y)3OMU
MDM,#)CGMUTE.FYOD].1B0+%CX[\?2HB?YAS9NA*#<0C\:L2YKX<%IL[8J,CP
M"P'%"HZ+![U!;!>6BOK;-^_;EX/]W2]B,/.VM@I[AT%;RFTX'^K,AG.,"F R
MQ!6LY&T0#;Y^\=]^&6"->*/9:'[Y@O]JMMK-+Z.W)X>7;\^/SJ_>;EW^_O9=
M[[<O?QU^.#XY&AW^=G':!F80N$G"$YB.P_3+Y;O@KS]:WZX'[=]G_^UUT]/C
ML\X?D]]G@];O__/^\^O4>_]U]&D2_.7.WI[]\;DS_F_K]_2_GSN-TW<GV7\/
MWUYY[W\=>^]^#T7O[;'[G[/_]=\=_ 7/!=WNER_?808\XK'ZWWX.H_ LF\";
M!A3L@><OQ?"?KT[B:(([N-5HPO^E$?V[V=IJ-U_I^*C73?_YZC */S7@/SO[
M\+M7MD@&[A2E1IR)5W2N)^X@Y1^\LD,0 _]\!0?\\W><[T.2X3G5+\O4*/OT
M"A6KV$U@U@-&Q$-78!9BUA"F"84BO8GBK]+AKZL[5$\A! 9*$H;K*6AB&#.+
M0J$  + GDWQF0IV34#5#F&;+RU$0G+PO!270?]--*HP9)4ZAL6 F^R0XMN>F
M+CHP8QC=,?)LM-Z99\!S>E1? 3%X8BI"+['0 8KG@L6+H1=(V#.CEQ)5$@RY
MSP;6%5 !KM90<0*Y(ED@,(._Z1M_V#BNO*#C#^.;W:__R7[]=<1T*HG.E>T0
M%E!@BVFN2)0;QDS7<JFYG4]RHM&]54X@FKB?ID*<Q[VL/U!_78H$KF."Y6<G
M45PA0:K$QU]_W5P/.P?'C=VP\\2RXGL9]"U,^.!N)OR=F\=,]7#LBR$HIRK
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M#%.2NGD5S0F\_7G"*_5!/TOL9.QBT"04J1U@^QJ*@FPW;'AK@+$ 0N(1(X[
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MB=4F])HME06@+/ZUCK^A=RC9L.*7#3IN$'<GHA]G;CPKE+8P-RIRP0I^M.^
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M!N?'L[WQ@P I#,MFN:!E[(MKW"#<.W*2>/8H@JG*^TOEN!'692!5\+LMG9T
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MQR:"RG*\&09846E'%9J3#=-8@-D.E#X8QQ$F#TYQ-AZW'!ZZ,*I']PE>B(5
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M6RN\&JDNB_U4]235,R'MD6!<[#Y6DRO:5"J$8:)P>S*M,_CA(,BHKZM.E'>
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MJCK8S-=X.L:7N1U=\67N[;-4V )&'\ T8[ 9\+?8FUR*+?A?;-R.#"?Q8;W
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MX+E'PE%G@B@%5;<-^#9'QDJ%DUVE G;7[D]#UE?A04/3>(#76G!$DY,!G^8
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M@*LO995:VJ9L]6</X .MSVL6E5&G\_C7-#AJ/,JF8KV&\[)RNH '+AX4*ZA
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M<7L!'] QIN-5++?;R>GOHFX.MG<]$G*/OO)X#"&=24#;2 JG^KA>O:N:W=$
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M:?N7<":VN]^__TEB_MBB.F0**#>DD&ZU>M:#L9 R%;JQ6JJ*?%WTFYB1BB*
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M*],I =+O"Z>Z ?P<@KX*5^F>^;7B;FZ*2"'5RAKE80ONY6I\O5KGI=KJVL;
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M;[/F]N; Y,!D&AC?N,T[*Z)-[%,='%1RAB,@7FI/QT<WQO"TUTWF8GG!,@J
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MISG\H+J(F"-WFW-@<F!R8#9UFVN+%\AJS>)3:W3V7ZM73<@9GM^@EB^5#09
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M.O]2B3"D%/,?Z1S8.!'JR*ISPIG@5I_^]_\64LG\WP+#</@CQR"ARG"4T O
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M#W_H^6E%WIE7+[H 3)UGUXG *O;_"B_\^(J;,D#ZFB!IDZY"0LVCW'"5X^"
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MC%%.OGTVGCW/^!G0GEAYY ,L9]-+\^ZW=Y+VD,3$'MA6L. ,+6R\*4, U4%
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M[+^._*,"NO"Q@ [D LF]R/A&OR_WR +E2ZU;<C],9<2\M$OQSKY^_ 1NB9U
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MU;Z?O.S]?&7'X;5"(KD01C"UWO,0S&>B&]67B6S.ZII)G+C6LLB9N]%PZ#5
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MJ,\H[0UUM0)HI]%#N314U(E$L4DO.50\ N_.%_!V'1TXT0!ZBL4>+E2;EZ+
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M1R-+Q2(*@46RM()C<"MK:);,\D2X$!H902@;2/%JC&O:H%HCAB#W8!@.\>C
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M$R2QU[#\#SQZL-@725P)#/3J10E8MY?)3ZI0RE/%6IXJE_\V9$1[ENKJERK
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MV1]A>&'Q>WAA L,+J]_#"[\ 6E?)EM(V8+5<C8RJRDQIZX; F#S6LZTEJAQ
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M)V9R:83ZEQAMEV %#8F><--_B1X0/TS,G@CI1];,W_J/]C7X)X,1-2[\[W\
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M@UO-LM%IBGLJ0^TOLT7-U1(X<Z!+3S2#J!"7M+""JD75&H>$4R\F$6ZWWU=
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M:#W?,9=O=]W7H(PX8<>@:3_=MGO#]A^1!J]#%#05" Q:3_UTL@,XDC@^BPN
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MX-\*-^66@&XY^$J:@>H!%2!CMMN(*V!,)!:BX$" %1JH& 6(/!!?C=%$+-1
MF #9P>^U=:'-2&CP:AY))4=/((RC)E<K8<I*<(%H4_IN<G/@#8+EL["J=PK]
M8>:02"W?NCT$,(F2<S0O6;&"YC0#M8\D?G"07_@M\3]VC4.9-$X?"#T05^'E
M6I3E)BU)6\ @R)'VNM33Q;FA:NNM+;O? G\&Q)@VQ96@2%LML\_>"@_+ZI1E
MGN:FL>/JVX'AD&5B"M]/: L(4D+>2P]U>^:Z3)OBB9 5LD;,E5J>*A3R!6^-
M@_2!XVA*D8[&O3;"YVC0!4]#8.#]#G]I,N;:(0WH<O=M?=;?/<P^Y9"<X(*^
M"[8=5^P$1YG,U_R/*P\U\1(;/7Z;AXUK9F<*^Q,"JQ"BA5JLG$/*'"*B06=A
M37,\<FF [A9G,QE\8;8"_@2K^SK8VIP2#6!<-.VO@A"!@R6:*P5;G4MQ(A.-
M*?HC52"KQ$_X$=5Q@Y\$?],@T/(Y3=^K+YN:#P*8)&20V(\E)\$WNS1(YH-T
MBAE$JL7.6$EB&<B(@ 2*[,T$0^PHCL0V?#GR&VQZ!X&"ZQ>30^"@T,"QP'P]
M!4I77 "W":T<NA.CC3B:BRL94&@TYR1E.Q(=OVK#U(?&\*UW<<$-M^W!C/%E
M^!.=6JIOB^#J]$4'B<%^)/'59Y@(X]@TL,E0_&*!(!$RRXR;I&#O"7-A#KK,
M@/.*!4AG\-\:KC'U9\):/";LB4H@'^Z>II6SW>!]VKL)RRA0IM)F%O>EA\\)
M4V&G&3@M7"%?"CAOY$X*YIT3DQ4&5S31A296$&-<33CRW (XR>P[A% $?ZP5
M_H)L,UT!>H! 2E62.4U)^FFA:Q;0CC5(Q](RVV+EJ<2AQ+E[O%0KM9^+]_3J
MO%\W6I4=O KHHC\G=D[4<@R.=LJ U:,HW\?J8-K30')PH&=6^%I2%PJ4&K"\
MP%! /2C6@$F"@E<^#9I^]%4B ]0ERWZ@T/_7?__/R0G1X5B>^8>X!1'QO^"!
M[RM6@*!CP"\D3D[4RPB&6X<M&%)[WK2_5]!R(K7A!3?7@1CW+[==>Y=;*.+2
M+6_M 3J"NQHLK_OQJW-B)I=&J'\)6/KS#]&00/0Y_9?H 0;'Q.R)D'YDW?RM
M_VA?@W\RTN5:KOR__P&$=B&YQ-)O)Q,4ZOY#+-%!J60&^])HK#.GB>6,S/S2
M\G#SDN!:\7),G/$UF#WU/7R!8-MN78IN-P1M(YL99%U"^;)#%AG1T5QBV8N5
MP  _ ,0_R%_; C=.\UNWF^75X]O+4W]BU,EVC425*<>:CVFMG"YFJ*79#)MC
MOF, X7[\Z@HY>@JS3S14!AM.F1/JBXEBC=)B(33U50!.PH!=L\(*YC\8%349
MN+DOGA#'3F-I"X9,W@E,7]." %T1Y):H*6L&HS#+[!JYLB] !8&UP*2= "$^
M"7$CL)(\YY9JGD[^8RSH<8N[^=YD3F/_'7 *=(_A13GVDV&X3_-;B.T]4WNZ
MD8/E?CD!XF;H\0*/UI)1QMG8+>2BE:P":5L8,Z=Z<=!%@^(\!:(&'F+E5 YC
MAZLA/6>)3+W95LT=0Z<:$$ 2>0*$5&M.1I\!0@T6KXJ;G(/R!I=0K!4#Y&XS
MY\ >D#<I@S/C9L##$!00HW& GE/%OFL@,L#C9]6K'T:-=_ =$(IXOO/.V9*-
M&\#U&!XE!P\(,2>ZY](36O@6 08=$/*=?4'5T@2+QHI,$>?!;"N,W &SL+"(
M"?#K#/ )PJYW38+IURDOJ!A;11E90LA])0<%1^5)%AA0I,[=&(EHF#F26')
M1!&"/9(5N$;G8EF(<X_>MZ'Q/J>KQ8K'GT(V RP0AJ1,3ERS6 LHT"J>(%V@
MQE<>*N&4T, @_#]G3^O+^J4,U$4K0!F\2B"I.1H"M2![2;_0G"#C2\L7"<>J
M=J(0$YK''Y8!BVD':Z@HE+$$Z@:HE 7PJX$6>8/I%F3@H%+4;T5Q>A*!H:NJ
M"VH-=&KP<]JQF0_:=L(F70!WJ1[HMT+(O$)HR#GML. )HY^A3407I$[6A>P
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MWVNQE,XT3N<6;UE 7-CT33 <V(4$ 0D^=^AS'&+&$V0J;/%3('-]34$.1>4
M :;"5B0%T+AZ2B4LP"VC3B%<2OICP"HK21B)M]K=G4$;5VF^?:[+ZZ>W\FZ7
MJHV&N'826AI,$1L7B[2^ND_A-'1+O3]E8XIVV(*C0!M=RJ!HGQR>XD%B'C=R
M<A83:(1/6MX[$0VV5F 1!D?73?I7A5%IU&MV9QTZ&]5,VM52"E5-28]V32D4
MC7"D,=5.V+*G +53K(?P5T,2W9%*R.3A>JBT0YYND(J+&_9YJ3@J^4/V4GQ1
M')VNR11T1&FHB-.W"2VS#,2'8@493P]UTWB_B^_32^J65C8)3@0/75QEK!K=
MB<MPW2=HX>"PC94?O&C(MQLL9NF0$]]M?Z<@U+G'4XO%L+"C846G0IV2+J*S
MC%\@%:@ECX(O0I:4%9,H*=LO.>+6K0J+-:UZ14%ZI3YK7*XOJ/LBQ:?:<68[
MZM0Z/W2*H(7 8AY\-Q/^/)(O:DR4#6.8<C=^B*ELPO;3)Y">S;!Z.;)C#7"^
MBHG%\\D?:K1ZVK/Q[G'P]MI;O$^DQWF,LJY/*KGS+JBU[S;I&M5BQ5ZC"H?%
ML*S*4<(+FFDK>U2A6KH$_+\XWKU,7^J*='>]*4UL)P,+"_8^'D6B!1FR\3_$
M:@D6,:5E-O63Z_5'[5R-^-__6Z-(\E_"5N1(-<:[Y_=^>3&7SH>%UQ^_KMN-
M87OH6J=X//6AAZ[^/E#Y,(2NA=XX+6Q1(2\(A21EBPJ#@4J"@YUAY&,]X;IE
M:$M#8NG^[)H6&#BJ926_SQ0\'0%5#HYE25'!1F 4<,Z*+Q*]G$,_J_'!R>.Q
M%D?>L/R:XWD6"= -*G8;[VK-P>.PT3UK7!5U7'OX/GAKS(,W!ED08VU^LX_4
M-8Q=EF!3&Y'B==U.0)*  "-?<VUD0JQ$R.\K6@+$9O&5.*S290F@00#=&)AI
MT]:61V?[6Y3>B)^P1AO*(%7X5_LS@=:.?DG^^S>QX90Y(;'R$MC1'#A33I$!
M':2E"+U#5,'-TQ/X#UC-(^KF])0 ;$%8GTEL:!E805QRST &83^6G(32@#>T
M-)W#8O "\5->35[!V_ '%!#DH:R@@@K*Q25\?$ZM4-?8#C(8X#O H"(#]SX#
M%A_7GO^-EHBN'V -.OH@>)@@P(IU&$@2$!@$_,RL)*![T5,Y0'4.%K2STH*
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M!"4].<6>_:'_Q6@MI&6*Z:J6],;"_-NIZ$,N<E$#LKDD,4%\M7"1UJ:\)@[
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M[F8OI_9M0R;=K<%/9G15;]C%XU&MT]UEG;.*88[V5\OMW7-B4M_KG#SM_T3
M@VC;L)V,K4*BL< %#!F0DQV03<7M$Q[QFYLC8&90(101PRHAQ>E@\B#Z9D/]
MFE [E+:WR_-1*%*W1#_L<F3E5/7$P1EJY%>LAJWGB[\:Q'LV^BDWL;"M>[1
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M62N??S_\4C1 >KKK4//H')TNF4MT2^J]\^ O7C!Y8,1,N:CPRC1<'--X6.Z
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MTJ2^1"Y:!D()]]OX)/B._X!#?\496O-QKO#0%',,:=[(H53I_!;G\B]EKK%
M@<9SAB3X%T22+JU'&[\D0(&#O#1@-(?@RQIXIO:GYNZW/VB[\8G]Q"//T9I0
M+1_3G--G,?^^*-U,BB2%P?F^6-G,W8PKN!5F''08(F_5(I3Y2%$P6H_>,A.X
M@J/+SD_PD@'E7!2KF-),H<O.4CA&U(=0AAN(RA7J0O(L5%^W-A>7BC#1IE.R
M%ZV!J%14F$T,MW*4(;L?M]1)9D3M@^3IV[#_B;HWC6HBB^)]HZB("%&9!"1Q
M8% 1(\J@$!*51@0:(JB@@*1M18:(:44D2DA4A#":%D2Z08B(B,@0E4FF1$@
M;<0HHX"0260,5#F$TE3"#6N]]=9[[\M[[].]]\-A 1^J<BI[__?O7W7.KC5-
M[FI^-I@.L7D)#/#)*RE%;2YT&5'AH&H7+N&>1T.;PF08Q6'U7S5&U_%_=-%%
M>#XW<0&A=YD^E,53;8:RP3HW#O". >H=5M[!H>"_$L0ER=0 '*,2\L"Z O>D
MXKJ;.VNT\7J4,''MG6(*GN_D%XG6Q1X7LY#>-8_97<;^&?LN6;_9YEF]S^^2
MQW%UB4G+8LYM*W9@86?E&8=D1B8^CZ[F9T7X9<4&7#!\TAT1'9=%??KIN>H=
M_8Q@V%GB+M.KH'WL7]QO$K9<F0-C%#NI<2"[E:@#\4(@*3 GP;' HRT%.O&>
M7NR47_EU20]Z+*&@#8%1V95%%>&!<"XGJ]BAT"'_M-3[BH+'L6)Z_!HX! T#
M87S:TB:H5#R7QEH=,Y=D$N>3LX!8^YV,I@0< PS2AKUUFO\+H;1V^+-X_5UD
ME[8FO?*AU/6/"]9_7O7U8=U/'O4:8,4G&,!J3+WY+#('MQ*J QWE7@ :WM G
M%:#4BG^ 8PKKG;J*C9&B!XF\D-U0RA-*YDF]@\T?NN9N?7<>OCI[(7&VE/1X
M N78#%V5DOZUZP,>0DS>SX+MP'@+<3T%H])N 04JK1B@1#+'FX/,F8N&'Y-4
ML)(D(WJ '4FJ-=0#RDH[]&WA$GLSAP6$6,A0;3KEF!)CS=6B>'.LTWHSM1NY
M2_')]H_[;&#[Q:T>QVN+=E^PJ_]Y=JC0YX+#?'W^*ONS4]:*ISY%C 9NFO&A
M71Z7'F:7X +,LRK\<DG'0P.+[=>/'/KJN2H*_S-V:YVEX/L_P'@;-Q%G"^IT
MW*)N 9W%<ZE- 1'B9G1[0,AZ8#P#ZUA)21IN16VJ?=&L9N342KM3>_P:>@N!
MT?JPTHB!:[AZBQ>3N?DURKOR@*-M,1IO)HZKKJE,E4R5AJJ-BZ*+/A"9Q!<+
M"-XV]?2"E:4P6FS*'CK:WK"B41KE[@OEQ4L%"<(J^X&TQ^!O3JKZ\H\1%64E
M'>BT:]XCM5FDHF&D#N4V<;5- W2&1S/IKD9_WUIAI:F?WS,_U5+Y]%BQOK!H
MW#_^_*_ -RY1RH\>N"E/8E;:U'?2VZT/4V\DZOON7_Z_V3!X5'\,]^KOZ(&-
M=V[:]F#!=ROBW;1P<P==&KYE77?^>U]'\!]_:[6%30&>FTAE,2/FGH$GKIN_
M6;_AQ1-%]Z$5^]O']Q\+S=;_5AO8NB_XF?4$4F/C_>M[IWN>!\>M0LS^^OZP
M-"A8:ZGXAI_3^%[L_<OK<9RFK+K"QO_C]"@&+AMR!#(EA'1650<?/2R0NLM
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M!UHY1F .GY4^A)<9*!/$.B0QD8\9^CJJ:*<M_Z!"3//X!1L@TE-*9"<_Q'0
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MC^M>==OF[!QM][/QS>CVP.HY\]Q8I;0.T@*<!*Y 3E(4;@W5K@88O]YT2B)
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M@?% 70I,H/"7I^H8?[ER+.,?^NT^!-T+_RP 7BN0;U36T$5W%Q U';+\8MH
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M3\(?<,F]=$8]V!H^:&?XF.E2=,FUQJ[N=*RDI(*+H-BUHQ&&O7@HN+5S#JW
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MA3)02'/KR$KBVVD&+)-"7'M>@KX,$H#8WF)-L!O LW<^UMX 55^'8C0G>2?
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M1X*:Y+6FG=NH?/K0VM#.01#&3FP$G$C=TF]]CK&V2 @1.*COP"THZ#5V2L9
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MP(4NC"'FI^F@BR6#2D<@6?6$G:R\1!VDK:!%D#4IYZ5'F&"3PE>5A?X<@<4
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M[N.9S(9P_TDK3P1[Y(0;;F00)R/P3L=O5=-I)-F A)R$ GBLC'S+'?WM1=*
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M 4P4L)8#3K 5#2KM7B"M5..:REK.X(G7(W9P;BQHW[XKJML+Q)<F@G,RDQQ
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MLT'<+4RC63B1&(O,]FP#@8C.ZV*KLJ@[$#<X]4$4MVZ!SK&%B8$@,^,[0QO
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MPDTA6[\G>K4V;>8Z?)$3C5[-%,;L%>HD14WT^Y$+]2-=N 7L>6)H@)VQ9_U
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M7;Q45*JV]J#M>/UW8]3>EBM-3Q WZ'&VS,&C*X!09Y%=AC974@=*C"$MW@M
MZRFUNX4V:_V8FU[O<.';<<@R6T7W&:U>/3;QXC/9>6ZP>- [^LOE+S6/YA(H
M_WXF[UO2>%^773R(1L]\#PJ6,;YJJZ67I2JB8B@OIQ4;X42H5!&LRL7K4P[)
MZ(@^[QB<[L1<23E$A#[^^$^0]P! ? J89W:;C<Z>+J/0)0P>37,".:&Z\YV+
M 79#*%<=VUC=3(,0F*XH[%<'!K%\B^ON/"CW&(0)!GLDK.M40_7H=G'/[3^O
M^!D^ -*DY8@A7:8U:U S37NV?^$&6U/"78:Q /Q ;B9GUR>:80*&44"U&*CW
MD1&ONQ)F"K""&$V92GR[K*6PIW-.VN8H92O4'/,;O"E/=4&2E$2]S_CWJ^WN
MK-S<?[M)WWIWCS,<WA=L.4OIR??*!V:[/$-=GIV"?3\>M?6ZZYG<=RJ37;;]
M]/:(!INO95;ESDVM"T4^[**L(*10=<>)E6E6,-.J=#R#=BQIK,.;P\$2&U#=
MT\"2SX3&@ YQ!GZ?JHJ%[EW2Z.1#\<QZM5EN:)C["?D=#I>JL(KT(MDWRM2H
MXL8S+MC(2HY4'G:'MBL47Z8F(N;'R7VDC!)]50FP0AD$D(>X$9C5R 90.+-7
MRH =KM3)YQA:,AS=S:@,%8::JD%%$UU%5]I$,W50&^!WXKI GD3'^BBDU8U9
M3\GT)9G!<_\.D F1. MD[^@<[CU\KXH2X$?ZC*RE^28Q65\7?6\POGTA?MN:
M6U?@F!5?L.MVZ-11Q>U^Y^7OY!:E+XA4K\::W*.^PT[OO@^+[[5.N["<6IJ'
MDN+&:%:D-0Z$\]BUH0 &FIM5IQ/:35?:#.8:V(JN*3VOU'=7'J88>)-2"A-O
M M?4$C&%F+=14_B0E)CB1GY0;-<="M]3&KAT'%'=8:]0UZF['&M$%099IP..
MH/7!5I##E+VSX[HCSI5(!$Q36JG5\1/@"%VV"!V7*:KEXC&O=JYE-<<.)O\"
MA?-MW&+*:1VNM B'\.X3TXL%C/EL&C]T/?QG#*35.04<D.M8+GA HBF]Z*1C
MB_#@=_&ZP"A:T]"MW\YON::K@PF\S+HR[CRVUSGAVF_-A1_;9NYXGW:JKDI,
MJK"//^II[^&]Z:DHY\7+XR+FO]@NLB$Z,H%36V<XLGT(\5*>IKX6;_B.@VU8
MR+J;BGJX#?*3+FEDN#F#>-D>U(D2K?@?O!.B==8A&QK@&/!0Q^(</0;Y'T"6
MTVZ5; 'IQ3(3B'L+.!U3V1N'%9S9.MX]RCR 1*F>S3D%,T7X21X!/,DUHER>
ME++436)Y-!,\9F'2&50PTP&Y#J)KG.4.<1T35J-6T*6TUX#UR!?:1:8)A:E(
MR_11W6T07V?6E3R0S@:TEYB#M-0&+P?'3JP^?CML+_.F$?>L[R;%C>[MH_[]
M=?^G[N;Y*9I0/G+GXZ@_R_G1G8_9LR^'YTSLJ N;[X:0'/TW[WE2%G F-W2N
M9=PG!DC\$!72X&#D5&9J930SN7JW6.J!&!Z2AC8I#Z']7/ 85@N6*\)5!?@]
ME*) T&/VO(Q@"&BKGJ[@WD;71%IN:8##P<MSIV*3,9US6<:%S'0VMNH=,5S:
M>PJK59_8F%W12WX:*?M@/"DGF, LV<*,AY2<*:YC=.%@VX)LV@6Q.=I#>F:2
M\EB5"FS^FY(LU>GZ4QE$F3L),OBL]12F'^B2@M]'\9-C!%S1D=&.4$+3P))&
MF' 551T7X1L5P$$X$BSJ$&,:VKQ.+6FD%D.T=I+A+*W2+9;Q#:6QG,YS"??0
MTX*]NX?N^J84-+0U?$C8<#_$@)S7?SDDY_@ESR#O1W_N#*EQ:'+!AC^MOGK9
MIB)NS%YYG'35X\^MXUG^7[AW,*DD(^=IDBD0#I%R.(2II"6-;F;6DD8]#3%?
MTH!\Q1(RGP'[)7TLEC%3Q<:(NDR6/X1C('/%GZ!UY[OSTJ_1XG/][&M5\+AT
M>ZY:07X870JFVT2_^^';3URC^3,8TN >"PRZ!J>\$H+LACOD:O/, R_<5/[R
M65SG,OL!VJ>@J_YZRK&"$V6,;/7H>^.DF)E1:%* Z@U6TR[0UJ"\$DLH8*8T
M%B3()U)!1D>HCCHO>5+[J3_#)(C9+BI6I97),")'&8W/34'M,I46FJ;O[ROV
M[RVU^ \1?NVSB[)V"2AXFS4TM*E0-7"W5N=(R>T7=I!W0^+,0]FP:A2;<,"Y
M3VYS]+BW\FWM ^.R:.!X9D&U9UP<&?>A'%VS##=K(,&EB/51+4J5HA%60C<[
M:>L)$F8 K1&3 YR5G<%*OF3\6%?$<53=7]*()(Z9C7:K!T2[!HY+,:GSW%6
M T3DS666;!G!;X0] OK9!QY2O'Z!KY9/XPW;P%HV]$X=:U3A"AG$NL7]C:"E
MGB@(#%!\ML3 UY3>;^ Y==(5D+)V 9=4):@EW*UHA!@I5 WTU9+&&O5=34I=
M9@V@<(D6@WN>949I.@3[@7/'A]EZ2NNIT(VJ$F2?TD=8.4W0CR>;3UGJJV<M
MD<>Q01FQ*=<^QZ*7H][_USQS]^JD;56$W'CJ*^]P[HDLJ>%\2YGA3.$''_;5
M[6^;SY5:/9Q$#>X6U=7=?[!WOYGO$U% $/JC';H#WDI'N(=' CV8ZZGO]("-
M3:IBY+325R@C9?Y.%>$Q()8G3/M''"T&CPG'P_U /FF]VS*H<&JA@[H2T@>.
MM((O3\/[!"Y-!7A3^)93L7[7E#ST66T>NNFFS+A"#95=3=5*,[BF6[HPD_T$
M[5_2:'00SAR0EX)>)^%)]=\[=ENJ[R3% ^X13#A"Y!FZ)%8B-H&%P:H"8*_2
M.T+45P>.=XCKG.OQ&^""BM.('YP,I@SRU?/L(<5AI@C#Q=C)KY_=!^X^>EAM
M.W0G5354&7=ZGQ7UL/SE<&%L3-"4S6C^_>#6<K/8RXW/WD>VC3^KF+.U[HT?
M2*P+_UJJIJ?/$"LSGKN:$BQ0-]@3N'6PBR)D@!;Q"V"K/(J^L[2 Y<J-0"Q\
M0+IOG#76+;!T P,Z,6E+&DUT.F<%L@..?$@AR,1\!]>7"]TM3('P!F$5U1'8
M"+$Y!C!.V@ ^SE2ZH\(7)O-&RO7P(XI0D0 2TZN7-"+V1RNJ^ED-Q'1;*4YD
MPB=@XEEIBRP!03,0\( N%4O(ZUX\ALD\5!\D9\X:=%YIP=\K0WZ#DZ5$'<01
M7B@+#$1BX,C2,=B@&\7J?-^*YY80\FW*%H+[SRQRK1Z=]#T%-Q<_/?WN:A)J
M]CVI]5MTF*5_\ET?=\T]N SN&G0]$ 6>4D^NW)K'6(8$P0FR/;,R"'.=NI5R
MB(>Z@:&M%F6O7!IKI_'&T/'BRD])A<&AP1V)EYH:'=,O_9TF^_D9/X<K+)@-
M7])8.4SKL*C!KZ'VT]91+5"^J^X-*$TLQ0A(^@"!_4,%6-$^C]=.S/1\RU6C
M.&3CU;,2B\UR'>:-\\_J($.S>/G_&+Q#!YM_Z2WKNN?\]-G_EC0&_#V<?+P-
M_^@U\U[[I-_;,/U9]S;?G^YX;+EH^EOVZV<MN_+"MJP[((B7U&IK977(/AS)
MW[KGV 4#DVW.E"-E:X_]_IR]W2XP:?Y]F=G=6#W>T=2HRUFEKL[3!WWNAMNP
MJP83G@0\+'<]WK!FR#_H\N\5GL.EI^Y4'(^-\JGP'O;?:--@TW??ROB^'^G#
M7@EC#6S?7K@K,G09R*4CUH]"_C-Q#(IP/5-S'U<6>.500H7W3]?*_=F!C/P"
MT=V%@(,[-G][^:MNH6+^T;'$GV*[#O3M+OE%Z_[EV-$'?3M*FV Y."*7D+OF
MLF@K+MWBA'>2;JOG;,.!+3V;VCXR)7-&42W&?U;@[C5Z- [/9]H[G!J(U M*
M]GIC_7.&?=?WZ/:?8Y__891SX(7U _3S>M'.ZWN$YZ)53WG;VL+6N]YSW^"\
MMJ9&4R>])T*Z8W['\\!?:RE1>]AVI6F=_0\.WK(Z9'KD4K&=D]RT[V&D4'24
MU.G\25:67;TAOM)?P--S#:S,J_2O#DKX[)^WYNWWJ+ZRTPV^6?+>O2]#*G?W
MNWLHKRYIW(RCFM,Z;95:TTL:>N$WJ*,02R[DDPQ$)*?D"P4\=$W3:[SA6.#J
MO;N" F%Z.[JM^;K^L437XD_+;Z:JOK->8>'-F+1S8#EBH*4X."C-/G^&V&XV
MF77OY*].XG6<GRF\[B9]5?AS:$O=SB\#^O^SUIQ?Y/Z+T:];_;%D8VRCZ^6/
MBK?$^YV8,[9G=];U?'(_TVK3WU/1U7-XZ&F>B-"PQT][ W;M^_41V_V)MNTO
MJJSF3CW8<&S\65"S[-%<:POG@;MA +\$#O@:!I$4EJI&P%%YA?J6:>[$@-7Y
M;T:IO(CL@1=D19Z<]5.D>I,<0GAR-J[3)S!R9Z=;L+0:TV6Y'6_;/Y=P^HO.
MXZJ8#53,R"6'^63]PNQ6JVH^EDNK#T ,/10[5+EN<6?!444Z#$E9J>B>83>K
MQY0IWO]&ZADFXI 0F'AZQ.V05.48Y)6MQ2MLN#W^;MK2"%IQ*]8SOL!K^SU'
MSTM_>B[/3::U"T482?GL3DD@9RNP'+XGQ=[FK"SP:>E_-(ILK!14'"J?OK)#
M]';B4]"[QYN&XG62!M0)A-CV_/7WUGTZI^PM/(YS[O3&X&:W%GW?CNF#A3Q
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M3>Q#X:MS>H!I*4H/R"MA0H%R1A";SVA?$'4R>]<5+HR$=>4>S^F6Y:' NC7
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MG"!5H?)$&6J2-1(@T@R>:(@B]A3ZBYS4)X9KD2]-Y:]6+H$ESI]ZA3FV/*T
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MN=R!X*F".8=,R&@I3;U8DZH?,/66DDM9P'^9.VO7?3VX5=7/@-FGZ^&J5CR
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M@H""_5OHL7F>%L\2I@PKSS"P'/#\%U"B2&N(,HU'X9W32HF&_.7VD\MBTRG
MRA(QM%",WM98]3/7+@HE2W[LW7+]G6M?V-N?\'&[1,Q]C:F_=W/KQ:,(#P>#
M.L)R<'5P(N80C-[?T68 DP"FA_O-Z9:?&4VX&SD=MJ[_--+/ELES!&(/(TFJ
MI))2ONZJ67XF_0^TMHY0O<P>P=5,M!^ 9H0I'DL=B&GQ3EU770"!J?1BGV[^
M]I!IQXG'HX,ZY:\&%7NR EF-?S53+M/;3ZMJ'2%6DCTAR1\D\OXP=EDUKU?U
MJ(T%T?"EAPP3^M0#)?Z$ECL6(-3[8*H5(DIU5:1RY_Q /O0/@I\)?X3/NQNH
MM3K:1P^O4J\W-!$43[<_9E5DO9F*.&+7W9\4B',*'+@(Y%/;;KR&3U(",@8O
MK36#5JD^MSN-9;?C!-1\'D7WV!"M8U_;I@DBS@]B+LPW'($VB*\%T85WK('K
M5/S,"#5KIYB3O2581<SSE4P,JVRC:AO&;TD7[Q@&@BA*"54H+G*!#TRLA2T(
M8(I-J7Z^U.-;;/$QB"SIW4_"B6U917GZ 2B^'B&\/)%^ (KK9>#_OJ" 0$6P
M<C&>\]-8:NEZ)/TYNIT@ _4R^<;6![YJI!KD=,RG@H^CCS,=@3R*%S[DN,K:
MM^6<1JE&XKS <=,;W^H(_/;(E$Z,M*$N@JHAZ!OQ"TM!B/6Q#)@(UG,"Y["F
MY#4PB*V'TAIJ^P>E4FLIN*]+G!Z<JT5@WLP"CP:WUL7MZ1LI6FDP2T9"?,MU
M]U++L)+2)$,HWOO36NZ#HO?+M3ZG['VFLUHGL.R^OR%(F"3L*")$7-!?"=S!
M.-Y5M/9PWA6&:7+(+*);#L(P*:,L?;3H:]$5:Z2U^G;91>C&(]3OUGP<0^E2
M-M_^C)C]];)XQ6 L_O6[Y?&<0%>NGIO"942)%HV3 6NU,B-"<J=+7RSH^4MQ
M9GTB4$=#DW1)YL%5'"T(I<-S/']!K^K4Y]_>]_4$RL^^%I U%_U81LH1S25)
M5,N \U2_%C@?O?L!<$0<4M6!E'CFC0\\FK9'B4'2H8=,^:WJG>4,LGW3>TQE
MX:*I>>625TNEASM-L(P?#,UVQP-0&B=<G[+E6?4M'+G.+0V,,)1H/#VDI-RP
M6+02>I"M!52+)['!0'<P-&V'MPAIA :OA%FM&D"[2$>=D)[7@<W253'HU)Y)
M&OU7YQ)Q3HQ>D!"KK8>Z^AY=C#H.-%.QO)SL=9M SH0+AD"3"U7H$T2P"*;C
M+.3PE[E#S8RYYB*F/D,\=5LP'B-S=_A7*3TVMY(0IPT7=K5X[>#DO9LC]7"O
MH/OKL]+IF?]VQ4*?*2T_Y^S&-1B@F-931/,S(WCLW[C/&+W=\=C7C:%+._'2
MC3(I[CK28J8E=ZAV!!7I+4X$_$-DU:='NRF":[$U](5/V!BMUZ7 9?NQ+>F-
M1\ FAR[K67$$;RP/"DS7Z$%$T9'E_P*"Y$%Y"HDH70Z79IK0>Y."X:"?V5(/
M7I8"QE8,3!S*Y0U0U&V@H)-KB<]!4"N='+*G]RQF[WWQ]?.]U3;J#\%>9N")
M W-ISE4-X.2+DK;NB0QP8>5-(7*JZ$W)=@:>]W[X6;/8OIKOM4*Q'8LU%,.;
M-^FC@?:?7J+=$MO'=IH>D@0EK(G&@^UTSY/D)1D;_1_/&7?.T[>+9.8-*@6^
MML'RW"\V33>UF"B+^KK9^EJ(KGN:/_>E4!)OBE[8UE#&_AED:*Q_9&Q2GL_3
M \#=X%BH9(L[U1LER+ F\\1 A'PO 1-VC-ZX-C&O>:$V*,H,\* 6/*:TY93[
M1)0F&.H;-10$[+EB0UXY$-T\J1(HZ+M!1+CO6U.NR/!]691(##FA"SJ)H.G\
M?: SCV%2345,^U(VH@TM&2H[_JQ7;'G=[AG,--0:2/$M=5S9@?+5S5I0'T15
M 1S0<:2T4Z529Z'">+"&'#!Q@Y&-_<<5B-XWR^QN.]',2@?T.7M"8B6P#WO/
M2P=#X^9!3*/7 'PGF3Z70!%,A1P?#<&+(_$=$%5Z;X+:]KZ+DC&<!VCNDMI(
MT%(YYL: U"_U4M9US7V7\9 QU*[N+2>2N/B^#@>("@>@N^ I%6H.4QT;-7^H
MD@EE*(\;6<GR=+6=8?1VP1.% 1,UGR^6NM9_BQGO=A?*5W_;5FG5>3RK##\Y
MXX3IM&1ARU:F__&U*%K)V=&5$PND]H*HO]&G^R^AQ"(S+41CVMV\;1*.(1^G
MEW4C'RHE2 H><_L]=[HL]W:/:G0\'.=AWW:Z./WS[$,7QY=I#Q_(!0=]"KZ8
M0N#O_+BMZLHEG%P9W:-L4SZ6KYBW-'HF:[2\2X\YC4P5N%!;S'IM ,BXJ![Y
M27M^WD0/:54F>?>'U3/F_-\&5) C]@"8NL$4"X,/'X"\YJ>EB-V8&BU<76]T
MB[ GM/NG'P*M_]WT#7M"[A@\"2HK7S>LJHU(/ ")&&H<@(X5$]*U$%)>C7)2
M.<:,<3Q54*CXG4%LZ$Z3[7P];%V1"IN49_/RT*5OL\K8YU!*](WU!$;_3A9]
MMW=^VG6?*I[T ,@1C$?)[EO-(.5-A_PARKY2FT#"?T-K6E"961A&]E>CFT>X
M;Q'@:38:<HXI[$[U4]_8BY[@<$_. >C#1!+D,D#<R6D#I'T]&:6]>X)8IBX-
M+.8%T06>49HM'\. (G*D$V4"^TL=)?\*(-ZDV[1]I.+X?#^U-I13G01/3"/C
ME^ZTY71E^/A1K^36##[FX*>'E:@-FPHC0JM+\'1(K\-?.5*UZGJ.[AE;CY5
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MCW3]$247OZ<N5BC(+!PV#?IV2M 0]\+]V>Y'O?7V_?'A^OG7C-]EL\R<;<P
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M\]9\^>2B8R6SSD8W>M1M3N58<OQQ.].YD0%=2V/TD[L'Z3@'0)^QL^E2^T&
M]P-=MQO/ZV50DG+F6G?O#"J(@DCZ'3_Y3*>S[-._+[#+T80H!* KOY/&48CK
M?\I0\J/U1U,Z"?6ZQ..PSI/O/Q5CF:KXA*.[5$'BS*S)CY=^E,8\H@H#1OQD
M96[K-'\266XR4C%;A3@U3=M?QO,L"Q&S],*ZT?*M^L:"!2WJF+C,E-0'U5MG
M+"2*?A5'.*1SB?(6AQ;?UH=X%[#E%H4&].S4G5=L I1+#M=8ZIM.WK1^M8 /
M(<7CS6_[?[F=1@N.3CZ'[Q)LX#/1 R=CVS_P;&G5I5Z"BD):)<#+5\"?ZW.8
M(B0V7RL5?@@]-5^7$,4^@^YYBCK-2F-K \3VO0-05)L24J/+T32%:5>\#%',
MG3 >J>,J\LD6B]C^\2O/*!TG6\H\6R@R$3+K>#GEN+A!5G>L+N;U7@)3G+3C
M!GB2,5.ECL ?^BX-'--R=?\*>T J;%U2L3=62Y ?*&\OE,D.9BQF<L3@OQ$E
MKVDP0:#_UAC*DH9)R,7&HXZ_PT>+$W>? ;B.3Z3D$ +?SQPYA5&F]F_3M>,<
MJ>4 .#!4>N#U.5@.];\BU&370Y.56.\,_? HH5:&>!=<PDLLET"T]+09K?^,
MR#0%X QYV-"VB\:MT5_3X95,!S>UM>H;JK_4V%VN4VU5P,R^',J,P&',,4P'
M%'(1$";_)[]C#8CNZ_D4'ADS-'V]W"8T@I9%:8UN"?*P1QK0A^AC"7'#.U^7
M++'$O9Q$M-QU2DHD%['&>T]@UU$D6]"#E:]0PVZAFB'%<Y> .7 V+"I-7>8S
M,B%1*3?@QT-<3 #R +2V(=CD*9M-;Q.\W+'(O'I":4#SQ-FRE[;Q[JG]EYB6
MAM<?VMXVU>CIYYMA9JHY!\:WWQX0N]2<[9;63Q?J7+S0O;CM]1A]>N =-<A@
M4GGROS8'/S[)^P&C<W+9_[3J7Q.ISNRZ;2-X'2CG&*9^UG.TU"3J5/T01 X]
MA)%$_X/R!<#T ]!.S-\:  @0TK>G$ IXTW>IL*@M0F*;'%28AI%9+I0=;KE6
M*#3:4UGVTU5JHL4AZ.TR8\;W4^TDTLZ)OI$8@G&(8?,?WS_Y'=TCS/[>1TN+
M1(LZ(0O0<I84TV]WX<GE#.^MR>UW[%,:<=!ZI_\R>VI^6IM2M0JA0M"8WMB7
M+=Y**<(==%)5+UVC%Q9] &HT7?M[Z^8*L+0?P1XDU(S"&\*(N.DP"CJ*G.9.
ME-+%UL&/('LII,2M61Y*?+R?_Z]Z7Q=?YQR3C'W*S8(*8E@1,NC.-_^M-(<Z
M(Y_=SEVVS)#&-CS)GT!.PS3\*N6 A\G0:0RA(+@[_G</Q(8QW'HZU/,<ZBJ%
M!%POHJ_C8UN,*6<!=(X?'ISP%&BPM.Z:*#R; #L Q<YACI=&/UPW%-=(AC:J
MGWV,4.)NA_"Z/V*+]=RKG;S?I#HCVQ%4]J(?6[,6ZI9:7@A++ ]$''\@8Z3:
MH%<H\KI34)#XQQF)ES;18O +VVEV67<;>B@CY=Y/[4I9=3VH\R(KII3'%>7W
M2&#65*_+&!V[FPT7*+U(7.077JMU?%E3GM[54I.:7[9_CD)1AO2XSN^,[#AQ
M0/L%W7< JB.DMP31F^V'(>KL =PI0U[ZKC50_YA\ )K.[,P5)%YFP2G92<5*
MB?4;DEZ-CI@4%*Q4%GJ-WMI=FAPB[?)@PV3T%^JBXD:R%K]:$%'J;'/E<AN,
MH@%HX-9"J @QX-J,%1"X;XWD)^.[P#*S* .ZTKH;@Y_\'2+)RFN!47TMFE-T
MTB=Z+@'O(]$] X/'=)?NT(NSBRF7$?4K$,APRYEB;\=*%H[_=2]G?]4YTTXT
MWC=&"M((:S%TV,X90)Q&F"JBYG2PP-T0_>P-*F)=/)PAW0OA9O#$5(@3(1<X
M:$UIT9=[25\D6C-DQUNI]MOX.-MOKD#8.D3HFS9<> Z9:3N!4OLC3M]D\[;N
M^R$)'0<@?NB] U RYH-=E_2L;J>K^J<4*K@'S-D_7/>L]8Y9#;V@IYEJML8,
MHZ^2-8B$I#GQH6"LT'*N;G*5>WTU/6NNO,IGU^^]\PI$F!XYGVKX[YSPQ%GZ
M;J> Y4,6XZ@2;P8U(*#/J,TT!\ _6ZK^?(EI:U9 W71>52<5")3S<-RTCF?<
MEX#^TUUC)+'#]EEQW:H>_TUP.RGGPT\&ANB1Q8X6.'LHDR3[TO"=36LBU6/+
MM ]W/C2IFG#AA)PTBJSY[<3M]J^=[%#^DEMN.90N57<1VDJH(S#%,G<"6+EM
M&B@KX'H@/6;G+3"HT7X9>L(5_0U^$G*4J3R,<J*3R!G(DJ_2Z^H:8 #OR"B-
MHXU(^E55.JYLJ[T=$EO&UUVV=-WO-M"IINR?R*.1F*(</O &KD;2=:\"&#)V
MFG^GBH%=/TY/, =8]*4.:,U29Q\JDOJ2S;\Z!/_NA3E9[R</'V."PSU+?#[\
M;%.8*G$T?H=,N)%)C/C(L'U&F;%W;\[YK<GF$]P_PYX*8H\19""*3'Y6&EK%
MGGF#\:,MAJ<=-\WY4P56V38FQF"QU2@[L\2;MP0]"N%G8%(WMOH6/HRH:;$T
M7,>84&]ZR4S7^AO6^Z4>@YK5&F= NIG5!+V_,:/;<Y'="Q5J4T7W.9+6-1D6
M'=!:3LX18ES>P;*>M1FY,+E9']#2S( /#6._ME<O6_X'MZ!/],CQ-$V$!''D
MTSJNLS+BN(;].%K1PLV/[*=Y9V3=T#,=3N&$O,U/ ./8</GX>4_)FT9+>M[(
ME&RK;NJFC[-*], YNZY;:3XBEP8:)%D/'PBOO) A)01]P=FQN[,%A5Y25A[8
MKW9Y,IUX/;_%\96OO/C$SW,[8.>?.]YN'KEVKZT*])MLRI*Z6HZ<&]L9^S"5
M?E0=XV131GE/%#3>I>W\RZI$"[!G<(=;SN]?0_&.(^HYM%?H8G$SN]^QKG$$
M94G!"GF%^;E7 ?!N X_B7\7>[I7+8<H5!R"WT7HC):N17\$LQ+6Q$#_^.R/:
METDEOIM8-J\U>7Y&MQU738@VA.Z'^NXU-#/:U(*Z)L3ZJ;A3#DA2;Z[&D\66
M))1*$>H*(RZ.7<^39&@5;V1Z6_<WD-#E6-"64.:5:_NQO+_*>SJMM?'G#PPD
M$ W/_F%HTQ7^P#*9Z/XHGV P$/#27X/GA>$,/YS+6%C/[?VM03EAT"8?NN^=
MJ00=&>8R\OR[="O'2+_RT$N]J:'27ZWWQ>8<E2&A:N1LJ3P9$EM^LV6YU$K[
MPOO*D 2<3E5RN3;LI<GJ#>MS;Y+_C'SCZV# DH(11Y'N7>@+#-%I>R\YD6\A
MV%.K.</N'MG8U]Z[4B6EH?O):=GCMK4#4QX2QAD\VJWPS'FZ(W1:_E^ =Y\/
MV#=M9APM>(U,V7DRID5Z A$WB%L0>S9G3+NAL<'$^ ];:OUS;@%P>(V<F[L<
M[\;G8^?H41?;NG#18IT^9P%/!!(4/@<P,LOS%IMD6A^I?!%A2"0'=MF8G?<V
MYI5Y<*8AUSQNX:-_^,MQ=X&B<P.;YBFY^F@NT91;M?YO?WXK4];*2%N8==P0
M-#M7,E\7.@;NO1Y?_QY8<F:(I]>3H8TM85073,^G*86V$)S8JG@N^[WQ4]G-
M=SZZ"IJ@P:=K1P-=ZFYQW^+M:/\2U<>6H>'ET\E!R=WTV=SBK)9G3QD6,H@C
MB1V4;!U]09'W#HK.K(FTES>X,@2-?+IXN8[\-@6?(Y\,_PJ3R2\LDEUE)?4'
M,#K)'T;/7[4N-<_2LRZ5E;]98!"\;%TJLNYQS*KTYL7]B[%B7WK_X-.[+(22
M\%9!BP7F]4KZ1C_TOUKG%TS7E5K9**HW9DZ^DY?\^ETH)KO/*.#BDPB9X%[7
MCX/__6.X]"S] *2._'KA:(0 [7O 49\O)7J?P5<,EIK=<>B6,"-EFY0JD4<M
M_D:?)7HGC!*,TR/LPC0PJQNU+CJPJ@1A[W V&!I!^@7[W7H $@#B5SM<%>CS
M:5H'H MP0+?+43RE O5&WNTQI<!QQ+GNW-1G3)TW8_V>B83 4Q[P3R61:IB(
M-?&??H&AM]7FL9?,1)+E](42!*HJ)&^0HX_A-[\W/6EM[=37RY \6:@_\/ B
MR7!GF0V>P[57>C"OTTW)2XD*F$N6810X<=9CH>_RO#4]_5D$*;/O^TAF9A])
MF^FT16SO7?E^Z.7;CS1X8DV?^6 C[]"76JF 16^(_=<"[W,SX?K.[,(]G7OS
MC52FH#;UY_VFR6Z=X><J#R3T^^_4/_<TUVT8JM_3N/,F605 L=__CU5K^)\<
MY]/^T9B["[7^<^*QS%[8^QKX3.]3Y_O!"S([VTLS/+C;^=^XIZ]=Z5,J_<-Z
M'%&8->""3)_F_C[\)F9D$413DB^).-$:].08R="VC+;/[W9&5Z6]1V1;3T+?
M4( F5QC]Q,C*HLG]2#:/Y*_+(1ML,]FC-_J;)M0HG[^WG'C[].C%T1T2I&F;
MI+0XBZ"NUQWJ_ _B3/XE25)J=$;_ZRD_TFUHS*B7M]6($%;B?WEX8>F)9H?A
M$]#*%%<E*++@'3#]9=8II//\PK,F3_#+I<(+@3$QZXNYO=V^%I$_%*V?7%'D
MP(HQ$[6UJX_/W9K5I?%@;W#\KJZS3A"W_)UQ>;C@,MJB4"E^R>&Q[NCI(\S!
MXHYWNG/*L>6'?B/6OW-$%VSM(WV&"#]9UZK1T:8TI.WG#^?893L';9;Y3/NG
MN+WK''_3TFC[3#U.<3V^U6!%*F#,_T'MAY'ZR2V_LQ:/_[1<O5\T0VD##R#Q
MAOW(L/-([9</)K'OR=E066/USJ_-I;85WB3Q)*MBWJ]:/LI:HYYV0C8F<7PA
M*G=*></U%T.B*=]+90L6+82W93YAQR_">&++T_!2Y@$Q^0%;,C[F%[)N&&0N
MIIX;>51I&\ Y!O21+TZRS5/H>\ CFUL+^9X*AT8+FW@^RF7]QG3-<Q(QA1 E
MM:@ACKKR+3AOLC$\]TJKGP4<=#^*LXI?Z;GQS=$!483:3D2[JB!LB=;#6;]&
M#R[QL!?3C"$(]Y5^VE$7*19,GWO*T+VA_C!88FMK]+3S 6C !O]#B;LXE,\T
MB3M=*,[FEIG".3[>7S>X9%A&1I>@54C/GW&NKE\;)1@A!A9F=_J;W(^NCBY'
M/!JL31Q^6\":,-2QT1X_/@-?4MU=5C17#V[RC%^R695P#_IN52R]\KPHQZ.J
MV'3HW<2 ^[29R\SV$E6<*=+\KTE3(UTI%G65:L:^;VG1)6[+EAQ."7%X51\5
M4N"Z(]3C]JEQ2%$^8.[)4:@0<F.'Q'J%\AI6@*BG=(3ZS]US1$J1]O]95!7Z
M\?G3]L)T3M*9@D/?SU:/K>4,<(^+='GA5/O.*"GAZ5%_!(GRFX,VS^@W)(W:
M.WZTM:"*HI9)1N5[_/%,/GIM7)8^10_&\Y)*>5#--#W/$8P%#OH]A6[BV4.1
M5D7/'72&0Y,1#.9&-_:D)MN+BDP0CB+>W.U8>!8/2_!N_&5><IP56F$5ZE_E
M%GZYI%&?W\7"#@BD@H\CER@SCLB@;E<>AFT"C<0_-S5U]7AE3@KJ8L4T,L%D
MU/\AV5Z^9:K"OL-HP6IAKG>)>%EB\1&& )_JI^7$8;QA400!M 'RPI\(\2XL
MWY0O86HPH#%,#CR>]6.DY39%9?\%-?[\-IP'^:;7GEZ%5[B8*&T]]&N ^_7D
M.O.XSS/5#S5RQD=YY*$ZPX=Z+MT,,*#);"M,K&&80CP[?2D46!?K;U6)F')3
M;S(N56JP-XDMN"(5UTGT?L6T<Y)X,V$HH>[_Z(,#TW2H;L:)(.A8/U:9C];Y
M5CI2X8=H,6:(&J.]M_+H>_B3 8-R2OT!O\M>!GS")U;>S'=^?^^2P<JI 3>)
M;GUS>ZGG[Q[<2KZYY4U[;O7C-F2SO4TC'59HVQ<XEML1>*3,NM3J;=Z=34=_
M7UZK1WE^D?[:RG=7;EJS%?]3>8[3)JT>3>8Y#79486Y!J_]O;89!6]I,_@-0
M!Y%0OP:N0ZR7E3)YZ-FEL@<@(F9*V&P,)?U8,?]9O\=[IA_CV7 ]--D.[-7P
MK*@5VRF%?L;Q7PE]B%#<P[_N14LC,?2V"-:JZ=0!R %,O[,Q0_B7]01S_P D
MSH35XVXV QU4"I1X 'HB)]9Z>&D?0477NS]Z6-^_;J@BC>-C&GU(W^B%J#DE
MU-2-:JU+:? ;ETVOMBE]>_/Q *33E%Y6!O>1^MI<YF.PV%RY8A!?7[6:V_V]
M<:^AL7)E(M/'\6MM^8HX]R^-;1>[VY\^CFKS+\^6-+=\S*7:A2L\FI_$_7L
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M.A3%!K6GNC_EF<"/U(/04>7_B[G_CFIB"]M \7@L* @!:5*C(M($I+= CG(
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M((8]YA[AU>L(&*$NJYNH7% %#3'I(:C=> V_E[7>2B;>DQM7,&G^)\C_6M8
MQ(R-.=NIR#ET6I^RUM1F8BAJ7_ VC/QZJ6QQ+P]NQ/<NG"_;S714O)N3TYB3
M5?[ YNIG_>>':CQ=6N[L#7B?P=O!RT'1&PEMZ+63,KD,2UFJ,5G!2F@9$]26
M25_H+^+9LA=.CC^6 7E)C";B8XYG!DGYZ8VVL?/+\?_4,$?3?A\7C5(MH+ 2
M+#X2OZ DK3(-2GR=(QE?O,\IV;GV.,L/NL< 'T<Z3 ,/_N)XICJUO[GSU@P
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M%J^<'C/KHU94TZUK&>F*I;*W'\1G9>T_<-U^90=RZ5CSY[M!&SO?J)DNE^Y
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M#"M&U03='WJB3G_0?U=X[X#^M7KGQ&U8$/G"!G14-HMDZ/N5($T(&3'Q@A*
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MX$QIVS YJ[_LF8DZ/_KC[:CA%OYC#1<@@8)0LVN#&,PRD6$Z609B4?WW)+E
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MOP\D4$OEIZM!=!(7#M"P+:.*WBO;,(5%4#8M%BVV&@4%^9"!D1E*5[B[@MW
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M]#V!8[L?=Q-Z?G-IH+ Q4>@$:WEYU,U?53/JGKGRK>LG57)*.@8?KV.L<8'
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MWR<Q@,+&RX'M.>1 U)4-2"-MW9.U#9N#\X7+.<<%_H!^;6G.XN_;Y!CC!>I
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MF7:0Y@"M+A'Q$J>>% F^ /$*>N8LP1(+4FBM09+2[@KFGFCS'+E>=\<U;2K
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M;5E[&>E"XBSAQ+;3H!'A*;@_05N-_= \D*\_Q%S6^I&Y0*JB7Q6X@]4M$,'
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MHC]17QSX44F?5*-ZW7J0_>@/YL0Q=IM*>Q0T5C)-==\/3G7Z*1]S]_1A?@]
MK&R:WCUUDV]A</@TFK-^^)>B<TD)(TMEZWV\XMT$FOI3YZR/7 SI&6A\XC>R
MINAB7:?^H5OM/X+V6>?\K]HJTQM6%[8P,N!:^*<H$(?"HB2G58@H;G0%>KIH
M:X&*:@U6BTMLT,(T?B=Y&7.+Q,D$I"M\&"**#TA1\Q:"], G ]Y;U+1YS$*1
M<6T73S.0ZG6TSOT+N'B*#ESID_WE%B_W1M:".ZA;AZS\JH# VC4 K6/A8(+2
M5$GM!EJPH1!R'V*=!3;*/I2=QSKZ:/0]U<K;%-W\LBDH#FEL.PM@I>YAQ;C
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M<&$O[^L$TQ<;&QMK K9J+VJ7-]:-J(J'_7A2[CRXE0R?Y,UC^JJBTHCIQC5
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MVAH&MT!K.T!W*.5'J*]2VE%^[^M?QQ*2]WOEOI>_])R?HA&4DO'QMJ] C+=
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MQ(X3 M;38R(1L3HAN^=\N64OR*\#Q[RNY_]L0?I\HU\*PV$4Z#G(/S8P!:3
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M0R6D^!G2)F7+E_*WY72]JXAE59J(U[']DBQ5 4U:;3*O?J70I-Z9]0]&!=Y
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MG-82G]M0'M'%VSB_BQ[0_L=+7ZJ\A.6B$(2/'.>W$B5X<?=:R&;H[!L]IC7
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M<.];_6N\<AB-5[BLV=."-&V#^8,2))XMO?EG3WG)H[;]E%O*AZ*YEJH"")7
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M."Y%;[T'<<S6MXQV?3\?_W=*!^IS]/3D;.)8K'A99/S-I;=%1Y356L]OKIE
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MR88$#^FB];TWRZ*''O@SVM66%GW7^3&?+<R#'/H0-\#VC=G?[#JSSZ/DGM5
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MD/$%8?:]T_D(KI, .AP=$'<D?3N31P25#Y[8X\BP&T P-]%Q^U98X,<USAO
MB]LXD]P _O%>;O]__Q&;HK!X_]O-A6*!WK%#V QJ@C$0\TD<ST(\_%P'2+64
M.2 PQE.R(<1&7@I2MP'A%0O1>\ _JFY<%RNU6F\B616X_4+P[E+_'\*+2%:4
M6 Q=_7IXAW";<N:4C[9=N0U'WR[P!D"4FUR#&SI@GSBO5#KKA!6H@.JFU( 8
M<SB#Q T@RXJ,3&OOE_H61H%=Q4 171"!5]D8'L9B^H-O +F;?WS3XNO5=FX
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M6Y>LCI]G);&-XXG3Y%-Z;;)E5B++3,:6R#R''71)J!D185OVYRK7#2T?UFX
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M1^5RP)//]$"T:\DG'!4+QGNBGSMF,R837;L;8^@S.P(AEME9AT3R?!P@RAN
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M%  G]0C[V?.SN>N1 PLA^-PDYHNT+W+^QW3E-S6V+8+S;D0SZVA)W(KYR V
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MH\*I/";=5]S8<Y?_$Z%Z\&?Z0<WC<39S]DP?D^B2KK>C!_:-)0.B]L:8[8;
MS:DCSA*Z@QE<P3<CI\>I6M:0.L*0/SV47Y_DCRKBOM[;S';S[;QTD+OX"N?
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M7(DF? RU:7)W)')7Z":;Z9^$S=OV+&7]_<?&(R#'TLN^<"R"@@A&?=\^_B%
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MNLR) @W:'BDG24+G[R$W,H@4@N3)>V&O;ZV? ^8-BCRU.8)[OQ?X-I#[X8!
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MXB60B&*E/IR6LJ+X+=K9(?\6:G7\:3V24)YDS\Q9S+7MEW#<<B7!8Y'V*S>
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MPSJ1,04)T)B0YAF>;#LGLI+*JB"D(!H1MIG8?1IXD73GP[L +H#<9+EVP%R
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M5@!K4BD0?^'6DHSMM#$!V>Q;P/CK7PN_G$"7-STKJZZ'\3BO"#3=WM(:+/S
M2$G>-6+ROV[?AFAG NV2RYKF]%M-"%9/MW/F;Y [CU3M$90W?G';Y/"$23AM
M0?V1X3O]!/)_\2 #<U:BH_3_7?O"9@50& +19;\(@CCS:LR1X?,6;%E4TVR+
MVZ--P^F,TL[4^RNX@;K!?RQ"CO_(O0PJ_]?52*N'_( )@)A@@^:[<3S#MAII
MHWGHXWB*'"06UQ!FH'S@$ZO3864\0LO6\R)YXJO,:>9-:9*VSU6)S^/MT)"D
M7,<<W O7\Z7)*+Q&V1LHY:_WNC7<I(E-%ADGU5NY:D)B Z(ZYPGA*?<4^PNQ
M1NNL""%<;3CA#IX'B"QUO@9Q;5K$8X*.KK)O4C2&6R>QYOE/OAGM&G_><EJB
M76^F^_R1=I=!<$A?#QMN)!XL\G(=EJL:A7BSQ+=35A8CG*[;%E"-:4UZ)EQ$
MVNRX#!XA>HY?/H5QKQ.H'39, !L($X+D"UQQ4%TU',^%/=<&PF$XH<3B]^R]
M'I4N\Q<1?GXUX\*9N,R#':GVG/]2C.DU.3 F>&:-P1[EZ,'Y3 BG[?'(B-5\
M&4:._9>JI^9[QI[Y[21K5,ER!8M6?0-#(U5C<\AWJ3H@]"8DC:VX6>1BRSI3
MC707D<L-=*$(;+W3M$_%#CO*HM\*-D?H>+8;6IE(B^T8<(7+7=1_$P,%LDWB
MV7@V)&+!O"88 7)+&%@*UW3FG\7M%"K]BL1RG$EQ>?7K:"9C"N([X^XGD 7;
M)039KY.V>::&@QZYX-:^G1M/::IA+B?H[Y%_HXQJY\G7DJ(QI,(/W;<L;8M]
MQ*%YI&%,[A6-9W$:S+3EQSIV;Q0R 7KHW2$HW:)X5,&M*:6?609=/YA)6UL)
M,TUY<C*7_3O2-1]9I/-9^9I7?]YDA^9;F5[[BEZ'5>^A<WZI.64HE\ZF!_/!
MNKW\B'\YG_FRA21Q1\SG^_.77:V.9)1//B;4410?K&.?("/ ])V M6J\#Y0%
M>&@(]+K *O;>?Z^J$^L2/IZ2D\%TT?^[?Y:XPZ:ANR)[=PB1CALC4,,"/7"-
M:"1J/4+=L:0$X!CBX)[H:=W,M_W*0+\FEI]N[*X40.K!D)9OJ'-K+.4:)'G9
M<0WB[MW(MA4&4#A5W5E-/=S[<W, ^GFDI!W[X5N\7)3(C%),DU_C5*X"Z;OL
MJ9)7"H;DPVL&U7)X%H:1I72XW8#_.F>5.&" W3DQ34=G)I[QNJ8YMYX5/,YU
MKWAW/Q,6^4L,E( ?W*(&'>U<E4,<3>),T": 89?D%\233FQM%$4LPF@S3P-^
MW,1 /TK;6,YA>C=3ID$SV"K_([$%2'[E?6U282LD'"^)]=";!3-)TV$2O8T,
M:XE>VEA9M^27+@K7R<M]W5DRT]&OBQ:, D7P>D$H>C?RW^_VF[#O9Q;0 A$C
M&R>#R=$/!Z",>(8:JZ!*<\/1DO;GO3.BH!BT03%S#?HT4B,[#/9=4^HF!^MP
M1LUG%67P2LSE2_P][.K\)P\T3"6RN*.Y*2=_- /E%G_XZY*X9HYS])<SR=XD
M9? ZF*BY%\N @L:J<F<F;Q8R(50@C+7*R][$+N<R)58\JX_F)9 R8VI//C)3
MB%F&@/A[M:ZZ",Q UH9) M*Y\A[)D#P>@KV:(&0%:.(>\G8TG2D&Y2SUA;$V
M#S:^342]^ET0+L"P!\$^BK_LY=[KN;U T'RXF4P#1^KA;J9E0N[N&_\<IZ2[
M1G=GI]4Q4>;(_];BNV]<\:\DV8ZO04W0PTK,)!6R_Q[BV:4F7DI?V<U/*?Z2
MZ:@ZYS_;223=:*%IG++<'8;,-VIOBB2<68E^!3/= &@L0AP'SL)TFVH*86KI
M]L&LV)+:^-+IOSJM2=>@I]CFB8Z5ZKF/'OG+HZD"@@H;%8ZFN6CI:]!&$91L
M-X@&HY*/J38#<^SW</;,;4Y/B:@GEI8XW(UR ^\]-> TD$[<_IRU^G6?\O7O
M'S=C01$60/1&+ST\?!C)R1!-D&E%U5+"H=]^N-DN:*4_;)FJ%IRK^@OGI0C,
M+DX4YAI9]:5)3YUUO@D(DA9XJ-4ZH^S!KU=F;37BY@]O^7Q7R<CX@JMZ,<-Z
M>$!/J;[H):J-_=6C6APC0R6!D;#:2PD&[ZVI+N EG6J65_&*TSL+[EVJ2.?G
M^[EPB8G.%]K(+@^Q<-&$MM7FQA0CL]:;^24$3[2J?YJ2UC04]]!49(BKYBRV
MMNN E;2D:YF-TBCHCR,^13TM9GV):2&P$+XN^0\@XPMD@6H'C&F%#J8P^@8M
MGF#-T]UXK0R:!DU+/WDPON0:=^G1#?J&:PJU$'7"5$+_IV BE*XL#.>5!6(N
M]J6AG,=@<2N98@U9NRFY&NY?</-_7X6:OM:(Z<!3<'5U#Q9)/B[<!+NXTFXS
M40*]$(67K :N04^ 2DRW.\J(/?7(A.QAT:+,'PN+(99S/XQ1S?/_B%09>5)M
MH@\#;A03S118'CZ C+H&,?OD:XU@[("QP0+.*4VC[=N ZXZ,K%(:C7A&@KZ<
MR,M!O^*(KP^$>'R=H<A^#=]+:,S[K$$&$,(@?N"B>S>IN=O]EGO5^-G4GOIP
M!GN.2B&M?JE^]6.B)6DVMV-KT?#.0!02:U*M.+ @0%'2C+-ISD\>J(WM$<:=
MQ#@V-\-E$29?8 8:V2?V#LP&5 5F]F:BS'%>Y ] ?TV8@U<AM(A[N(?# O2$
ML4H@SPCP+5ZQ@7=BZ).IQXH!ZQ=/4R=+;;\6=B;!_/7TR/KU>/QYF1&HL]"K
M+J5[JFC$ 39S7QN(#"K=>S\2S?[73,9WE=_!19E+T&>UPS%"-;-LW*T_^&V:
M2^PES4$/-U"-NP:98<N29=X2*(-G_#C\" K8S*+7TA?#.1@W0Z\5Z*_&#/[G
MQ%I'C,-L][F6=,%^V%T\<Z/-S%]8-E@$@:B?]:$C,6J:ZE)('<_,NE")=TXH
M>?E2;=GG >VTOA_'9JD\T?YZXSF>=0QU$W6E5<<13#)JU6F .RK]"V WH+41
MEN*JGE3BFM.>I,<DL":0HQ5%X$44%;[$E>%9(1L"H<W6'K3=!16^U0\Q/$B&
M$0?^!;?; 3]&=VW_\]H8CSD=:>/[1F&:BS/R)E#U8_(#4;:*TS+!LGM/7"Z^
M-Z*-8'T=VR6?TC C3[';57YGR5_&:%C;X[0MN<TC0]>;:BC("V\<(R!V2."8
M0\\'B\ )RR-62=48*2@+O,BZ)3;-L_+%LJ&+FX? AT.[&7Q%MNI*JI^44[@9
M!^O54;<LOT5#X,F%P$.$RO]7"X0Y6'@5+F(PGQ1=8=4O#5E2Q0B53=SFHJT;
M2?CH>9M-5&4SM.W.WGEF>I4+6&SZ\"\=C6FT9=/OAM:6JE)QE+P$M;Q"?_VP
MWU;!WW_^EZHW%*J,$,/:#1,4/#BL ;OA'LHYI]X.;%*%DD)MK)M[,T^%^U;2
ML:>0#J-TJ"!H(X2UDG0%:8*_@Z9CZ5]2XN:(ELE[/'.$JQ<^2LBD&_TJFH8*
M\Z($URLC0[LO]DJZD;6#S F^5KW*O=4_T9#F<2VY4/[;_\)/9IM:)RD(MA;)
M?>$+V-K7@#D)0A.+_4[B8K[IIQCRQO9=('UI5_A9^Y->(L0CW6#8T9U8"=%T
MWX-0VWYL-@GV$O7JC[I-'>0A<[CV,P.)WO59NCV>[UW-SFZI6TUZNAWM8"LW
MP4K*T8U,+A)1G^]WH.H(M:N,'CK$'6 *!]DL#,5+JL3B&#"1^25E\;XY7W.4
MG[VUOY3[62*N^SQA?,?X"9,(^9K*YG[.H8S[&\9)QC3Y!]3P7P]X:^B)2,*?
M[S2^F-> &^H19_C<?_#<>47)N3B\F6I20J+E./L5XAIT^0@A/!>L%#RY!@'4
M2ESK?NX'RV&/AE-EQMLI..BX-%I2UGWD17;Z2>[VB>!T#PB4HYL06H#%#"L7
MVB-QE6[0UC)5*V \;VL"5/R-EU).VM5/VY'X;52I+ZJ3^!/'74Y-''>%!Y(W
MD0QX9:Q_#,(?HR/U&CVAUDQG#J>"BHL:O]M@">,AX8D5I5?,_<=C>-4:3 .D
MHSJ^5Y=-5%I# ?-Y.M=+E&I=^YSP]/&CQ[E#X0&!+SBW'[)FOQH3%'MG# *3
MS=Q 8 [XWI2R0,3$QBH4)4 GVP1E6(5[#/NK*\^7><+G+<I+?4U5!%]PFWL1
METNH+>G90E$WM-&[),[ $E0[!&'?G,6KH<?:#_\$"3 K=Q_G> =(GWC9V6WG
M:*UH'-]ZT4-^6%$[1??L# L\<VWI$2U\HKX;^O>(Y4C=K3J!F<Y(UNW;O['@
M9<A\Y/!?3J)^T!&F)QLPPSFAH%P$_I?P\[Z%CMR]9_^21+I,_N39.<:=P*AO
MT=9U#.M21_]+MFTB I8Q)H!8\F @D@'Q$JL:):?)Y>^P21=H@LN*]&TU<).3
M.7GM?)XW1:VW:YQP3#3&_*4OK9C\BA,0P#IA3E 9/KBKDW!-O2 )E"$#W;IK
MZH-;;1#[N!>Y_5-HXAVI$&WC!O;[;=*4HO..[9=O$4K8V(+)88Y*_\I5& .L
M:*C8<O5KKF\N>" W?I@SED1(IM,=-TFFX_XR>.D:1.FK$4WH:YO]FZ^(FM=[
MCE.-JW;;,=+0BN(<'UX[LPCYW%2>%+MSERB]Z%4:T2E_X24#7K=SP3>9XV &
M[HU:H@U6F&DVH<"#6^(L?1J5U,-,KC[[G$;-KQD$NUCIH[]*>*F)YB[@. XE
M<8V#!;<7_AQYC-ARS?2P V%GEV;.2NUR(O-_5KV?4O=OI2GKLA_O;CW9T&N/
M-FK^X[![= W"BHG_>'LLVPSW->%X0+>6E%)V\3+7+BUEK:_A$ZV ?41#^5-R
MLP9*[E9D2V^_P$UBV4[Y=GO^N7JHA_V*LQME-D!<$+*VJJ)4PQB/<R/T[Z=D
M+'*ROU/_0='7RXA\?1+[7@]E$L^]UAGTJ351HG[&!QEIP<]EF/TW'9R62-92
M76[(K7TBG$5_JI8>1G+GB>>9;>*EQ"3&XV?EAC\*RK32==YAM)->"?_NHOL[
M($"X>>CP>W7(:=!'2<>WF38EV4R3)M7!:X5$3?%RU ?J266>8@N)QNG\\9]C
M" M!,)=*>[&KJR;/1FO+V_DSFK&,1/KTH!5X8.&RU?+@C:!314$CUAE\:$:P
M\VWN@G.:,+]O/I(YVM4R-1]P"33%4@V:K6N3WYQ)1M_V;A0N6*D.U<: A7O9
M@R6QR#B'*"-ZPW\U9"?1NW5-,&MK#?G(_ZP:*,]OD4@K%GS<M28,"32I9&Q
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MGALW6$GE<@UBE/DKQP %1HPMCYKRTFK]8:*NXJK^Y5^LE)W#LG_.OMI K-P
MTF7PC>JT3N9WSB7O1A]4RSW+&S@_2SW8.<;03!C>[PD[]1))>=QI/7;7G()D
MD=CS;^TBRV9R<H^,)4(+5SO()V(T[7,CJN'1J)8+\9AA'O_&A6KA%C/]'[HJ
M+J.,\@[!]W577C<>$N1NJ"4-H3#5-%;1I?@)UB.SH#3Q='B8Y^[AKG.-=,UQ
M)GE[ZT\2CO;%01$08QNM\=SM=3V\SM5G309L(7H^$J<X[&?1DFO<:P>KM%[J
M^)J5R63[D&]HH@33\-N;NI/JW4>![I 'HB08"!NR7TU9)^J[!]V^NN;9V7O9
M+,<+OR(F9UE9GU=C[#5:4BR^DH.5XL.^;^_LI4?C2 @W\@FW/IAKG(Y>EN,#
MWCEG=40E>WY9YIC5[/0D)A?41O&D).CZ)9P)\M\4A.JE->"QZ32,9$+(8T>B
M?8?JIC4EBN"E#&S23T?>RC1;.V5J2.8Z:SM]9PIEKA@U1]FG)C'<P$732=()
MY&TM<_#W8(G6J2,EBYDW<SY2$YJ;S_U;(L7TW7.RAY\^Z!PW>_R!7KT9%.#6
M>\A1]<+U#HQP"Z=3%O-GD@;0>UH?MM;7.:I2R=?.7M7CS;%*(QQ!L?,X_PL/
MF\G9DZNL8,&RPPP<$KV;_%>C4XX7_W*N62?<='X[?TE&R)<4IN&4IF5_NO9-
M(N9+?MM_9((@J?UKT%(99C*AAPXO.X>P0=L(&(4_:U"81%QT/3,J6;7JES=W
MU.]Y+2[_O&[)GW@C-/QT,A+B,=;+!T?U%7#!\?<^[97N&G7@DAJK_A6^:0G,
MIG6A3WGM\ +M^&I9[ TZ!Z[6#_J.N^&[;Y8$0;CJ8($ 8;P9VY.\82A N?]>
MK&F!:?&%:]V]]KP7890X[D<S(H\=%A-C515?U[^,O!%A=B.Y\XV^I?MKPMA#
M=F[^+P1Q;&W<7,VR9=NL#4/J:W_?IN_SU-K.V*8\T$M2$?+>)\'2\$M]P&4#
MP@C?'>3^C]%%A=MSMOI(,/?6LDTOO/6GM757@F6U+%_1-X8/Y"_31R'I!,F;
MK/R ?S %Y@"0PXD;JS0FW?-X!($MZU'B5E<8#]R>@315&FPW<*IEI\!A$Y*>
M21H'6KMQZJ][ER"/YI!H>]<"::Q_##[@\SZ[^05#9!G',[CKB<F,++,S>-5!
MVG'-P-+"NU-KQ#4,_,9S#AY^1H,32 R^PQ#3,;$6S8@;CIE?DVMMR/Q]J3K
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MLU6A.+P0\.)"(H0P<,YNP2\6IX^>9:>)./TKI+2_L_??X$N^T\.OK[RL/4$
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M 6_&!H/!X:8+/L@816O=-^KB6<Y+Q?-B[V(X4:SUT7>(:^AY/Z?<L]LX.3K
M>=]407*7"#99*P_5R["%O4J.G<&P=V-(V)I[X]S?RHR_]8EN>R/KV);N_67@
MX^ESR>6X*ZX?O8X,H3U$,SX\]M/_.[)*XKR4<56\M!+K&>CT<8)M<:ZHV3LK
M:<6J:T\P\:<IUSF;:!T0/6@K<U,%[PZ6LB**&@N-9KH,(/'%4W@:7_048Z[-
MLR,9MF^C9Y:A2Z?2!%?]%[_3%(Q "*E+C>!I9+/J0&<A:R']?BXTMDL,9X)1
M'12@16A,-Y<O;5HD#UD]GAH1T2/]ERMEIYD:KX1,(>Y_$AIWUFU'H [ H0;5
M::<1<MC(#TLGX9H&Q0@%(.+B@P%=?NT@38NAO\)#W]&$1Z.I3;PAC]X2)>\3
M*B_5$)+-,S)_KA@&>GBF-%^7//P"@](V6]<*TSG*<;MF3H@N+0T$OWK=PW[:
MF9P7-2IMK+E[%G@5%\Q\\VHHQHUEL$P?MU.QF<RU IQC&.)J$&4)P+>UC9?Q
MT?X;/ 8IND-=+7K_0OZ%/F'X[B9"H":ZM )4AS9-@<)2N+E']#J#IB_ZAASP
M3WKK#0/<YR$<RV/PAD71A^-I4J8<F?;W237T;+Z9I. #KSJZS'#T)O&]C81$
MS)]6K.N!E44<@@='\YBV([(@P6,CS8C),9%K.^>4(;5YZVV#B@';95G@I2J"
M<KZJF6VVB^[SVI*KQ?S[J$;/4@/:LZ6,N; F<U75 <7FG,_"NBXT\H(.X19T
MI83^PH;2K(# <BN >!ARU DT\_@\MX@:V!&G#2,FN66>^D R08%MUYT.A&B^
M?! \ X8 %!7!8^QGJGY6R($3;K@NRG@>[R$?9^-Z\.0:%!&(,)+)Y-XJ;@V3
MDX_Q9Y=6#//&T:=?(@G3 E0]W+!66WE<:21.8/@:Q!ZL[KHD$";S>2:G"%L8
M(1*W$W1W?_Q'U?OG"H*19L??R'TIJ42=SA]B& Z7L4681O@]?""Z,TAK!IV=
M '^_ID.N%+?"0AWQK1Q4KN'W[@4]Y3=<UGI]\N'1ER6@AAPKGN]Z8\;=BSHR
M,I<T1\1J9J@B\H_<^S:SQ^W);(W7[D.DE->746<3.+:F)>,L- ,]H&>&+0O]
M<T/P0+Q5#Z.!1^62Z)'"5>ALRO2C>OTXNX$VA.!8*E0G> +:4C@<A'R*^YZ(
M*WHX+2?;]'\<76584V\;'RW='0-)246Z1DB+2#<3D1@PD!XZ-@0!D1(0$! F
M)2#2W35*NF'D!@:]*>*4>OF_UW4^G@_GN>,7YSSG?HYC6<X=\%W-:0&\IO )
M\E2O1^Y)7[_*Z_YM>2HJ^"+I/:I+^"*_FV&4[N&> '\T3*;1U)QJCWF"Y[/7
M@_J@1=^. %#GWPB9I>G N1](\FM79(K.NA2=AK-[<7QJU\$//'"S)3-L!J!5
M1[QSC!Z6 *I-F1YXDQ':-R]IK AY_<"&S.-#(5S""3UB<[A '4Q.!/?;<H @
M\YV,GS5W3@,'<;02;TT_.CD>)D8NX(VTI;\.BW5[$6?.M.$AQ.0R6( 5L2Y4
M;@#$PDAR;FP=0#LY"W$5KR\@5T,TT34G2RLK*SG( %*I5/N$;_8$0Y&/S5?&
MS%L(W].PFMU 8D)$\',</Y_0<TB34UM2PYH.LT'*S:,#O7MU;QZP]P)2HK^?
M6A#9!>*Q0 9?!,OE4C/^-#_\N@/H1<<?>\PU7IC>V-,C_5)7/B1@V+O[_G$4
M2.X*X#F%^8/;2-R6HX33$^)JL"/^FUC9S'*X!,HJ2ZR)$'J0&]DQ&H$SK>^3
ME@6D>PVN) \( K+(@$V7Y%#+[P,\[L3T[V:M!/K#]C&<\4F1Z)QX>^ 9NBZ-
MU@!?G)\@<D^*E%=$ !'1?9%X"4#ZF>&<4%2K+INKD*Q_#"CQS*RF.-%8UB^2
M9\4/V75N/ S=UK!;0'#,2&LHET *@',W?WY6&)/XT))8?N_>:HNX]%/MLW'$
M,1G7!]I*/V'OPCBNK8;D&(.GZ Z &J4X1$55 Z\JKEC]FH;O)W>"1D'$UO<:
M%:J:W4$ZJAP@?WC,D5(*O?%<*0#><@:6W8RZ%"%_E+<NG7;D/_5U2"W0M0O_
MSKU7@$<@UZ/V"C!BZFIXYG8%&+VVLQ<("/*?E6L+/N_2^%J1]1QP^UX!BK*B
M- 4^.3.9W#I[]XOZ.F&] (;@I#?/6(?HG32B-2/5%M23[A@9CCB5Y+_]N&CS
MNV]TN/5FE ;CZ5L\0QW!? N%GHJ_%/BY:4EHB?><W6)A;J="BDC%"KT2=G.+
M'14,G( #L3U$L3-3?(?93.A4@N-@/#ISIO&"=;! LCG4OKH15K5M=))Y,9HP
MN\B%%ET)STK0 ['_4R7(#89U4^"57Y\[E;LD*T"RJJT>3DXK,7\E20=0:EO_
M>W(XP%[SY1!X2:-#H$([WIKN%-K2!+H0JN(3H2>5^PYRCY0L80CK K?RI$K$
M/Z/M%%O+#W&/JMX_B8JDWMHDBM<,H&ZDTCO6O)+[[2+7OS@5\-RK$J6$.:5]
MP^/49'8=BC5Y!SMQU8=W7)/QE5M>J=V<Y]JM<R% )GO,N2PL0"Q5)^'-?<L]
M5=W,*.QKRC3[3,&8.3Z[7A3W%2 @X%K*,YW3%Z[ ;S?.=MZ)"*@<I$H]=CR5
M:S&$>'W2\0W_"/E1F)\8F^U[LT9?=>CN"? P.QA7H:&.9W4@AA/T;/$!*9V0
M4.PZX[WH+P[NK8O5R5U5ZVO*NDIT,\Y"6;=H*P/?R%,+DBW;G4KCGZAE=>$H
M%V1_ARU65P>(-67[I:U\_FET\$9*6.%YT%,J AW=B89,]H%0\8]TWZP-/D+3
M1<V+\PA(I/MV .W:K4PYL:P-CV:!1V8SM!$?O1YY)*KTB:O4*%[#<@8N'W48
M@:_$?HLA1.V+@1F=G,_M\3[K#0.E+L-0WW9JX3')SKF[9K4OQT#WHR4#4H M
MX8-3\9OL</!6 !5<J6Y!89-NTP'":6=% ?)=#)4J:3+$(O:Y21Z%LU :"P:1
M[&N)7KSLI*J&56(#$O7G.3)@M'V+EQ2FWD)I1>]7<RP"4CA]";+;X@]T)BF"
MU*C.6:=T\7]>(P1AF,UA)<?F%EP^PZ\!FG^=+)N8'\WAWFD:MM/D@7R?/LB2
MUI$?#I?1EO___8IG,X=C6'811 FA,/N;MU*.=Y>S2&5[]O#$.W:=,,?^EBJL
M.5U#0G^@3752,O5:5 7T !L=ARJV LCL![=:X:H<M:'QR69S^\%#? J?V%(E
M'1;JC32>=$>,4!5Y _$/4NF)5FA7,H*?EDC+DF(5Z?KG3I/V]<Z?CKX8YQ@_
M1]?\@)OR*RCI^@1N=^9LAE4KQ068U"G?="<K@7%@0ZF>T$7 ]\2=FX;C>,VI
M_P8;-8<OI:^9-.NZ\=Z)%G]W:RR3:X0B[ 6A[J*JQT=*BC%.2[533:EI._G!
ML/-2*)ABY6V&63.>/5%X8\\R*H_CE-=66AE@L2QK2NI[8/X"V6S^2NL6W&>V
MFQ>6I]V('\K[#(/\SK\M)9AAG5/E^I7]E<6?I4?#NI1;#,8/&;[C@ ?9'\YU
M%Q#">[8(B<Z9IAX>'Z5_"SO--'4?"YIG.BW0&5RCE*&14S%OSA+(!!G(>C=K
M#6,TV/T:]EW%%^"FY3Z$KL919+TGK=J-@GLLAIDVHT\"6SSU_,GY(LP3D%N%
MW4)XY4$P^P]72;QM_A6 YD\_0@Y)"::7W6-?$NE '8+<VW+7)+](1Q>)I-?]
M7""DD[':W/S_EV0C_&)>-9#M7'.F"<DTY:<(IICZN,<Q$1" ]>HRROGMF<R8
MJ1'VHB0DLJ36(TRH7ENSIN\*4%M5$R7[>TP.<&ZP>*C!BX.*;1L2*)/+->SN
MZ&F.#V%+FR+<WRF)9'Q=$;+AXK:\X]#^_9SUK']#9 [JF3'<O@?+Z^<X?687
MKV$<*&](G[&R5M5_3TBBHE%K4#6Y3Q"*,><;[K\"8.9P6EV$C$%EGL/OL=7=
MY&4Q(1/!>BD+S+^?+/I_;'[]C6L&!.OG;?/4B>.V$8XJ 8+F07['*5K<A"6T
M:3#VD&SPDGE! ^)>"J,:N+0T_%RSZK]X-S"<.;GD)[-(PM*W#-E6.J-1P#]W
MHXOX<][B:ZH;+"<66_40. K#:S9\U?)>K1XV[)V"/=K=:/6CTC\X\R=,OQF.
M5@/' \DZGV^Y\ YM,H1NLFIN]E^8&N29X6-W)*;*?P29W(CM'RIX?&.L[8=U
MTHND**W0.5# )K,/F"-TD_0*T"]0]V.#,_W;\*#C_(!_8='>TWOIQCP?EP*A
M K__=INUNO39O?XYH7=)PTIPQVFA@CWP8P.YB@4-6+E72O_\.YXK503PIQ1B
MS9O4%"9:Y8LU2(R28E6%8&L29*O=G,@^53@]'H<-4#1G'<69@>T6Q1;]%7?[
M?N7/ZBE0RYMT.VE32PYNJP!N\=8NF**ON\R<VGG=][_C1.%Z2R%*!)>"2F!"
M ..Q(,B_E660/IKKO80@'5>V1D9CBN]XYW]C$NB(,QZXT9!\$-8U\1/L"6]K
MGDU+Y^L(K6'/?O6_,EDJ?;#1=6'5?@DR\1@7V'6)Q<(:7 F'\7%PQBT)17HI
MHX8Y%-@A^C-^;;U/Y,TKAGZ=>]HDMCN$S$D)LOT )L0$@IT 1U(;U,$4%8EZ
M)1@88O+Y2XC8?%6&N5*0\[MIP.P+L>/6VV,CY#LP</05X-%UM1-]!S:9SD4_
M[MDN<;B*SM?\#J#WG=7]N?GCW_KOA<&I[$ FVYQ'46,_T??2HBMC-98F-OZK
M_3BXTR*<>QMV+K65)T>S-[?[K&MIH'+UW;2Y-.9!#7_<1Q%1@_#[8MSWW.K>
M'I&5_?@3U:F_+<=Y.<7#4<=1\P%S_I! %55U+.O9T!:G8IBP4YOBD8)[9-*7
MP)V9&*4SLJH-%&DY9XU_ *8;XX7;+LATBZR9L P,UG<&.3H9('Y7==YX24T:
MTRQ?EF(T=&.O$;BL--SOF-GH*)>T\8W_^<!A"=RT:?&1;P9.];9(V\)A#E,$
M\_W/(Z^J7ZJ_%6&Y0S@>V,2@!J\ #-#?%V2XQ;+PSW!+_/?D8__?^2QC#BE0
M>7IN-T_CPQ(ZIOM?ZI6FWY%3DI.Y=I0B^XSAYJ4.Q"EK8L;6/?Q27-$T0R5^
MR2;.NK65H*;;*YH\5ZYO+.J]?O])MYWTWI<@;4VO_WZBCX0A-OO^Y++W)/@=
M'&TM?NW"4R7(')0HN_+/B,J3/"X>4__N,O/78U%_9(U7=:IB]7(8 31?.;,B
M,E; 4 Z+'+]L.@EVYR*T"H&C2O7?;J65TGPR=KAI*Y7$%,%GUX\ 7K0C9)Q7
MO5'\Y[XER'[U#ZX0Y5D8$KN0P>E4R8U;*=VS(P@F^A3?2Z^[8<3 =IM+\33@
MX.S,DIBQS=E?PP77)VS$0O'_Y&AT1(<R<18W\ZGL66ZVYP@#HN5G^O>.K#/>
M>R >,8*F05L%"-89X=:%T%3V?0$A O0RF?YCCL<MF[HZIDK)M:&BVQEC-( P
MEG$T?,S1E?\BZC&^Y!I0Q%X0W!W-^6'!=I&ZFK9?TTT='/>>M+I(H*??&F6_
MR@ZQWT][8P;KSKON#_$%#9V/+ALH.GVQS _$L0?X[H9M4VAE:1_];W2MDRMD
MV955_3Y:>4.7P<9 309\22-^!;B1V8-.E&.'01%+6*A!_U)?D)/D6X+R:?OD
MJ2-Z'$!7QV8@4ADK'VU>3C5]!6AD/.A $H;1!>0$)^+A.2TNF5<'-7 I:%_E
M: I%#'[?#.3[R54@\?+'Y"=DD%(KS7;N+QFK2^J.K<0>MMTE1V1BM88FMJ2C
M8>D(+N,E707]1,R:G($Z.:C7WQ&".+C;]CDPL#Z55JU$K@[C1 3XB'8UL'WL
M9S67;+3,@VWS9(>WJU_*I_B;!AHDED6UK#OTZ.( 04W95<@^';A^T3*LXK!3
MZB,L<;"YX'8+OB6^4]-#P_;;DFDNYWMPCH/QT]=UA0_)&KH/""-4;WR0M7)#
M].+;'PO%XW,';(DV%6M=*55:'WZD+]NO93N(--^%>H0F+Q_I+6AS^=G]H#I8
M.1/[@6SHJN[R@);;@_7O@@>*G;D<H09S]WJ:824ID"AYXX32G(Q@Y1'MQY2
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MCY;4C(8%E$Y,):#F<TB%AX66\-_4=U]@ZN;<?D\ULR]I]"I\"Q3PP#XG\_B
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M.U7+8"U# A*+U4QFHB<\SFFFD++QGX+2S/<2:YD^<YUW]5+M\0\?C.&OT7[
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M696%O]?@ VG;'*QMWEJG3;7EU94L?HSC_O38C2M[%DT;D3D1A-Y$L"9T_!'
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M0]K6^%?!B.-=_C(E!@8B:4]U>/O)V*^%=0*N\(Q<3FO;>BG5E.I*5( ]$C4
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M;V^MYIT-TRH4U?<E<"#''P$\\?Q"RD6@^Q&()M>!EYM,G%=6!-ISRM8WLPI
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M7P%.$VP(-TZH5\6NV7T$GF[ZYPSZ'LEU6I55??#7UDYBK<"W^,A1B67'LS)
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MUG1K.V<QW6\<8(J,UH<R<3$H_6_NO=0Z5"\[LIV3>-=:5FW;'9N^1NIW5X\
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M7Y<^*)$ZJ,/5CP&)+\L(,Y.X>X0+]T.Y:D:]IEE5TPCBNQX^VF9AM.I9/_0
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M0>K&GQ'##!D2T:A1NLW704-?U.!=?C8.C$6I@6[IE,K+'09[])[X!^RAF(G
M4 <XUEM(F\\IH"CC7"IS*MZN06G;M=_"CZL!\.8 7Z0;S[P&G?Y\S7^4(#<*
MN_YJ6N^N;H'(P#$TCZ0>3".5AG(H_T8:Q-OBL%!X@ !46*6\8AHV/6*80A03
M1"E(?M\8'+T2(+ NY@44":5[EDMB>>4S5+83XN]P08KPG?TV^>!G46!"',M%
M9B=Q_N>+<R^:P+E.DG6;DL+K2@R! %K]&Y(7:&C8^&XCLC"*(H=4+X7A2: \
M/[_>(ZI_; RVQ)4'##;$KIN[9<A:L].83$12+_)F^^YOBE)CY30R=B?#E>G=
M>6,<RUK]+,SN"T42=84\FG%^#>#D2TB=F ]N/EVF%-?/704 ],!\-)#7^(@_
M0WO5)V/F+(NH_"S,AY#4]CW?8@+\+OZ!TW>)\_*JK_&EHU_%:81;Q-QX2HT:
M@H '>J/?W)4)8\;Q@S8& P"P(<RQTH V#CCDVUQ"M6-7*=,Y[ C9;:(]=?>A
ML\D7F="7B-]Z(.J2C?UJRZ'&O?P,S\",$*FC48PZ)8[21&[@_P.&EGS<@7DN
M"VBBXMK$\)Z"L#V]UD#RA_:Z;\*ON9;#PBL#&F/UGQ2LH^.>%2KDA\7J #JJ
MDH%A 6%G)0]B;GIG@O>7BB/A#/__;O,L3*Y",,'4]A_.'VQ1CF@+AGY5USD/
MM_^:+A_.'X$ME?][XZM<&&;*!C?Z!Q[LCAB/[-\_*L.*;G9CVM7N.A3C&0NK
M&.[(0KIF,2\-GJV+1LK  ^$:%<7HB=S_CPQS["_3YS*VA=!WS=>*UWKWMX_
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MXO2/-ISK*7^8\MIX".H](973.WYG8"VSX*T@H<1Q3N!=/6P%3[0Z7$6!--K
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M1 #_ -O.D6/G-P!!FOW97#Q'^D7$#>#SWR4\8 N"3KHBPC[ V"NH$J#@G#>
M$;&)'2 *^'-2"L]D.\ +Q_+8<  OR>MO_0@@0)!>[.*@VM81OR!KJ9>WVO(S
M?AW2B#FHLP)>^W<"K[6Z(X%W55F[_1'B5)PTR-EJ->P%]:=IWY/9PO\[9#>
M<^[VVY5Q[%PE*%S->U_[XZ?K[TS6K2,X:<XYCK-"*=\61$&-?;=6NZ-!=_%L
M=]10P#C,#E[=1+N"*PBX%]$$Z:_&N/X()]W.H-9@F:WN/X%/CJC)DQ:?S$:J
M>G7AFO%$^>XC]FCBWLYYD7(]#PN;#_3*8O5QWHW1*:4Q!8C,J%$D]+AQ.U51
M1\8PT<=M*6\>K] ^;RTFQC>AZ#:@]!$;(Q27[N.!Z-8]B,JT?;R)Y<<$JI27
M>;LC#*EYPT*8%Q'+%G?$R.Y)<$C^!'@XWI&DX7)'VA)B7\VKTH1;H$%]XDET
MJ13]W;R.$!(WYLQJDYS')G9&!DPF]]\+#CI&T]17E:]FP4QRDDZN.,U^A@J/
MN?]VWB,=K%&<'H0TB9\(!**?KYETH+@[RC?!8GC=G^G/=:EF$0<SW8[905RQ
M"&*?W9A1INN*,,1M5F$-,$Q?#KCYHI_,R-@2KU"$B W(3 0+V]\=,7GI3.WX
MV*P]Y2'G'2V0\JTNW%J)&8+00;R@,5 FK(JK;QCJ]Y)FS%-T7#&%!G=LY6II
MUE1-Q+TUXO6R/."63@U//]<U@.FO]DG^]6.,-P(T$#]SSA6L'P-O;X$R9VYO
MT9B%!&>1W;_#&KTF-.9 64N]J^EG1GLW6^8,6<82/]#WH'1;0<GFPNC2*V?S
MSU'W8G?5],!VR(/]@-.U.5/87YSW=M'=K@4[7%:W*-A@#_>?(\])P(>&U"Y9
MQ6,/WA,U-$DPKZOY=$AVRJHCT+;E$/)H8#PWV>/_?#E0<GR\?UW!PUW"Q[-3
MRY'V]U\S8AK@'D&"BPN<U!Y,Y \]2P\<![$=DLNBA<:_K9=6M7%PVXZIK0R3
MCJD-"Y]#$-?D>"Z,1\!#)P]%6I+E$J([:O 7*0[R.VGN^_D='8=A/B9)>DY?
MS@W@Y:.LK#SA;021TX0\.;A'$9'[-2_;P\#SNHW^6H=)K0@VZO7,==^4_1C,
M8AJ)Q(P#,/YI<?CO>W2<CY]%/D4X"P7?D3B4"QR6+0A4T&1CWZPOQX0.WP#,
M%@+) C;X=%K"JO8@HJ]IJR,<0F9EU8RDH%8(1P9;J0-(,_3XLE:F?B[BGFO"
M:O>WJR>)+O9F.<<L9&*OGD<A)2G?93L4O,^9O &L,0S@'Z)-C\_0P@,VU$UY
MUOXV,_>CB6-7G#>?. N.?F(\>:S(D.5'K5XW7K?"<&$YKZQ+U=DMCWH,EASH
MEUAV_7/HS[]G[6R3-?)E4TC! VGZ0/=[C[R'78L@X5]O UQ)!*F;*7L:M (\
MI]G1-O-J158Y"",Q8I]=\U&(S6FCE2FAT<$5SI,?(8:Y1N7VY\D,=R&!'"Y+
MBD&%*EW5:$T_AWF>O%VM'TT)!)_ZJZ&J\ZQ3_C/0R;=R>/)K]#V4Y)$-S^QY
M<AW)H<709<RIZ -P_F#HY,9\KL7+X.IZ:)-EM4XR?S#QC+#DAWVH,AIV7':M
M8ZF-2"X,TZ]'QZ<J.]7I.53F![VHP(0.(=W-Q&M/D&M>>&//CU(E&0!Y8TD
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M&"\/5THW2N(H14U%\1MK+8(</U'2=5;;!ZF:O8[Z0]#=:6M[RWE\P+=Z,'@
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M=D>S))E1>)!5C0/(R0Y?]W=3\0I*2R5T/'S)4\<AM0X@^#0RM:_ TMI\H=C
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MHJ&/P'=#WR/B"+ S"A4X6]QR'$\H(/+X($9,[9I@KN&>F-7.'4*262_^0B_
MZO.D,0 PEE^F]C6F"$3LU?7_[U5./%'/?P,(M;3?&B]^X<TP$RX4_?XC+%6W
MD9#?&-#4SLY.QOZ5U,^JHU1+9F?WZ+<[(\U\>^"B1H]]E7Q"Z$O7'*8<UQ\]
ML)PPRMA(XAMST&IUP=NOV@?<X9.*N[MJ.!"*H'0UA#"3>L>ZRU5!5S'M:5%D
M^R= D7H(F5#AYYG&$:7GS0OI_K[4/;< 11+;KP:(-R$?)U6%2;Y&^ZV*L_]J
MTNR*]KU9T.:X?W&9-RN"Z(S.+GQ1T$$%1?"ING)_H [^M)^<)^[>T0?:F9%P
M,NO1E^57M7*+MYZ2W!0)GN*1=))H?0Z8<WH\3RK^@=(M5R0\C1 Q;"SW)<=X
M?':,=8:0#6L  !(*L8*HRO6'0IKBCT5GN+R(BP(KJ9](/<I!%":^)*H:S3)_
ME 2*\;5+MZAC)IB9\@ZGV@GXZ)\AZQ@[$3&I0\5TO2OLF<$%7<G9YRT7["KZ
M*KV*XA=TC'J3PW#VF:,CFY_JC+%.F/5?9_*1LB+;TP+Y:3*?J^JDEXSW.2CE
MYWX&:[,7VCGI<!>*["]1I3.:2(^QE@D#K.14J>;O$27(:5A_[RX7R6@K8 '8
M%$A2E(<6*<BI':A]!3VG)?D?LOX0%&N^Z#3]XKC_@D\M6[X@H8]\,$G^>MAU
M3U5-K:GP,/2#?@DRCROXNB\0MVPH\.)929_7/^WI S%B=XX'%/S418"_0,I[
M1$)'Q0^#@#8=_(5?!2-I(5TC3J%]9^::%X0U[UX'[JS>^_1EB?ELJ]K-3;ZO
M8R^QFBT)I*9*Q/EG-=RR&J2J88"B:R %K2;(O3(6["M%3'77:Y"G:H.EZ-T?
MD[-["F0.J\Z157-)9_255-@Q?:[>FA Z"7^Q3_^5$#?T=(3_I<KK.PR-W *
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M$V:-&.,V\]?L?LKKLNBK0VI5(RB5-DU)XQ?%='%GII.J<3HW[V /WOW>@.9
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M@I)XV,*_NB*V6!Q?'3;-"I63A@BABT)8MIC4VQRF*6:MNU$U-WIE&PP?AZ8
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M9Z9?.;SP"2KVDT2M??\&ZU+MY1SY*+?VWWN0$M[0/Q?YSW@[^<OC]H:'/FV
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M/=\6,O<T#H+47[@RO&_6,IDD$SSP:*.C+A+G)[;]Z"X^Q-:H,02-@VY[LEP
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M&":.#NB".R>7>(;M'P>GQ;R*1)-I>\I/4IIK8RKM;W!/DY6\2+B+9!>4G>\
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M9Q:LBI;;^%,WX2A5X1],.N-7!GQ6EF/ Z,O$T6^G5\R5QCL;!L!J#_1PK(@
MD5J\K?R3YT44(]_5!7[!:_)7/=R5U()L8V3&6^AM=]_=\F.UMWI3X!3[L4UZ
M<+JW"\==SRJ54T2@0J>C[4W-FO>2D3A>$2PA4JAIK>;P2$4Q?X>NKS?1%WOZ
M ET$.TU(!P7H\/^$E1VT7NV1>>H&S?8+/F5TB"D[&WT>2_BXU2O,WD9A'62(
M^;[DU3PR&R;@,CM3NI'_/Y*N.YK-[__'J+VIO2E:J_:6XF/5:JE1LZI6(Z@9
M%7O6'D71"K6J5M7>*U;MF=H2JW:":DCP\SV_/Y[_GGO.O<_[=5_C/N?<=TC
M_3E]MP?1$;+& I\J1-/_:>PK"O/^8T=$=S%!SI!ER>A\Z^NOA@6\LQ+&G<78
M!(0YG;*&R_T%<D_5#:VFGL<O?6Q87UFQK]/<D.%EL8&!CCMXU]D3DWBO?+-N
MEB[>^,XM2V)B=RV3V#.*"HZ1B0V"/WJD8;1QZF+8S+ZF /EUC@8CV@$&ZQ)1
MCGVJ9/$13:*AUOF1#$.BB#1CUH*5[LA0RIL%9H6E#N5_0QRB^5FQ^GX#H.OA
MT_MP14*/H]>_=#G_*O4.#@TX1#G0W,A!C:8?H%T'VFDIL*E]\L]N :Y_K.V+
M:1<;/VGFG W34&6X4FVY<H(]6R^7!QVHH)(E#MKRI3BCM_+*<'OAG_K@S3GR
M;'&=A[VI1O^=3?S9$?G.PF&,3,?+$NR%TF)#<*]&:[&C_4LY ]?DC?E6XWU_
MCK[]7!/OB,ECZ^C<$O2,L?71H='G:E!GA0*OJV4G&9=7WCK<E^5RZ$.X@.S,
M=4HR3-S].&,CGI>*49)X.'W^QR-2'98(H^GBMK?96^?B0=64;D#$-V?.Q<,&
MY!5*3^3<^1M.WZQ[=61)_%FY+\"!%:S@EBS!,V+-O:$RM5B!BS3$S"U@<"EI
MKTPP+U%5H9EFOV]GATC$ZLV:#@G\V$21B6!O31[[$/<4JSLDB>J.6V<YK_3]
M-FQRX5G[K:WG#Q:G%\_VDF8X*:7%-C(Z:N 5U+#Q^IM?)PG""JTP2$L+23]^
M8#[W=::17-A-B$)])J5H.>9CQYM7!,V4@]KO[YWTXFB3NUARD!G83?B5;DH7
MV]M[QZHOZ;,\&H.#6!XXI2&=J9EB]"W?M5IM?298PO->IWEU,=D^:%@3Z<#(
M9Q\[?S:^<=FCC$MK&2'.[ X@Q+1S/2DDQ@860J$8W;Y.7VU$HZE<LI/ABVDY
MB+U=DW)^I.%,*^^1K2@AV2"ML*+Z\XV31=A%+KJ@TS$8-<ECAVW\VN9>7</;
MVI+'(>LN_1U9^BJ?8! RH0CP=?C&;EZ:DN_%_:7\ORDMLAWIQX5, F6DBL G
MJRG4H#H^IHJAX]\;3L3A*J_.!7%G$T: T#"\SG5>ESA>"V.?CQ)70:D7(:?+
MK>$2O"R6CW("^2Q]!M-_D<Q89C]Z#-D5Y+P%Q*Y3=$GNV4L5W%4D1_FBMG0I
M*)N<:5SUAYU@N=<2 AKS=* _>SF+38F7T>&K*/>6K=0EQ'8CO'A[,Z6<;>*Q
MFN*X7D5JQ]A:X>?4;YN\5QOA(5+A *5.&>THP^;(0;+?NMN5.0( =0(!7JI3
MJ\QFWL^O:$1?D4LK)*59[@ VWZ;I$N]&S#G5ONTB^"M\D/KGGCA &MBB7GT+
M*&(/87I&.MK=)(Q/ZZ:_!2!V<FX!I7('8>1A6S LZ*8WN_OJ(6@$Z &\Y"O@
MOP74CDO> IZ"%FX8;@$C0#3B.DH\[-QTBK1X(;1(+&"/LU1+?^=[F8[-#B]7
MURT@$ A[;GW?XICQD=#\O8P7[]*, 4IJ2N=[*Q2 ';EK+TUT5WX5-@[.@MEK
M$_]2!+/H;'V=W?3XT9G@UC6<]WMFS[:/CGXM^__NF9.,8F_?^VF%U_OY<1]9
M=3[J]B!>EU?LJ]*F)CQK2;H&3I<KS$FQ=OU5G?LM#[,Z'>2@QUIN:%$2K^7$
M];4+L$;9-U:(Z7^DN.([\9[(X;/".MHD,5D =0N(;JSF-BA%:T%4]&?\FU)L
MM8OV+_(\'MNNZ7R'DP9'NU,"E,38ZIH!/*^PL(L:K$8IU&&ZBWEEGUV]N:HC
M;7UE?YQ3DCF=C9QE7,F2T$$J=LN"58!":?S]O_@;*:@4>KOFF_\DSYXW67DL
M)#J'S*AMI*ZZ)Q4BEF0K^:N8*.,Q#5#2Z3K\1G2?6Q;#U7C1^M7:+<"2N@+B
M.L#P6#FV%,2YYMS9<";*QF;PH.7U;Y.UR'=)*:%G%P+7Q8W73W$HKT3_3BY_
M+^JW2R$Y<7A^=IT&#$VJDZ]'M2PFQSG03^(7!<-8=/1R"X!V+BA4%LKD0/]G
M <$M-U6*R8GWFP=3VU4C3&WTS15&2<[:6/&=/W^H6$4J5W@$9>?BC+&B<"!W
M=9@KC'!-_*;"N5CM:*+[=?S%.UFW6X"7?JDVO_Y_-DU<*T^9/G.;#)^%]MV(
MSG7)'G3Q([S$X=Q*D49O*4?U[1A[)J[\.PMGQ/+O56^\G/J8K'<9=1\WFCRY
M6'NAC*U&3VZ.V3_$$%_]9\T3V6!0#32:0[DHQR74'%L@^0O<V7[N,=-O,S"F
MP;?UA<+5^S'_CN30OLC!?!38%5X@'3DSB1S^86>I'Z3Y5CKD)])1H<M2L,?:
M,+M'A>#B/A">NB1CA"[OM?%*::/)#$&=4#FX3X$"2 8!3JE&+<FE*>?9PX+P
M]M^;G+BS2TPPC@#JCG%-[!*\\QB2\;*=4&QOAUZ3?!V9]:"X4G6BFP5";T;1
M)=:7F\"T*(VK,,K!$-*-]!H,GOR]:8CE*7&W8%&7A/57;N!&_R._EPTKL]85
ME/_W3C580UIHT$->6BJY, 'PSX$4'XIU1/'$LIL,)59V*O0I\\3+8H_EDD./
M7C?G"C>DR'B5KSY]/-,0ZY(B\J\)%?!IE(3(IM^AP:$WC/M 6!.]#J\&FLWS
MSVPO>'KP94N*[>GSY/H=4GH\AL?W?JSP#MU;'K[4Y/D].X!8_[G>1QO)+8*H
M.I;H(+^#.BT69ALK76>SMN1.RUE;;N>8ZQJ1H.CWJK>?85\'</J_]E-?V+^4
MQA:Y%V-AQE-0K4J0<FQQ*23.*+?0T5&U6O8]>09_T@]]]LM[I,/W4^VU "%_
MO7!/H2RMLW) !@T,BW;]]+E!\^Q83@XAM;+*)_WDJJ9OHRL,2?LO&!L4QG2-
MA0> C?]ZOM#<'/0QATJS+W1^P_KL#K3Y*7L,FG?_;*(9:_)*'GS\^E$/OCAB
M+@^;J'\=T<6/S3-2EN2TWUM23RW;!Y<M_VD+F/6J?'(_"F0Y_6O9N?7L,>I)
M"KF+X$:6@D?W!NQ&$7T2WW"MI3DO6ZUO^;0+?6Z=W*=YZK[@:S@CWO;XM9-I
M=*& YV.M-^ E@HOF?I.E@PT8W(NP?[.E ^2(1,QZ&J74.H<I#\@&TMO*??;6
MIV<5]^YULMBOV?()JG7 T,(G[^TIW\M)D@/;(XRGMCI/JTZ$QRPNFAD&N0TJ
MT'K.4O(G^2(OTI0>@$[_#=P"T"8.;&%]4B'.&ZL6"PC;-O1JO6T_7>(AXT'3
M54-@HO>OJF\._]Z.3[?\2M.7.PECO_,DZRD%JM>Y-]QW[#'17-R[V:YBQ8L9
M^T= W3'<E AP(]GXZNU-3CT\ 2!B L#HPC8*861^M#S[7=3=;74+79QNZEPS
MC;1,V)IMXCR[/M"L6HG4XKWD;,V2T#]TW9WO9L$AU$A@_"V@?B(JL,0:*VJ.
M+L@/08W3<-D+1Q0VSS%JMVJ]XYK_;36/-())67K0D1IG79XA:['"8<FJP U:
M3K><'&OY1M2XKP:ZM,'HVQ#5@GU 9N@_/DTE?PJ>S#GJHXS""CM:TM >;M69
M4"%L(IQ;<,$4A;!%RUH[9XTW%%KOM14U42Q8O-+KY7W.(>86Q<IZ/DRZ4B!U
M7:%.CS5#AL%-$BS8K]>35471_H)M&  Z5T$"(55YG*"9%*F=8-=G;/=DE#Z)
M<4?]P757%^,?>P"6 $-0W2BN]?3ZJ]R1^FA_ME1?QMK>.WO8^KX7*\UPMN'Q
MRY1!L\^/!3[(3BZ^W=6Y_B0'C&H33\[.J7W;'.:&4>OO9Z0.';?7D@VD/"/O
MFJ8L>?NS,D9 ,/,S=''C%H 5=H5+4K_-FS\NQ1"9+/AQ>#% S.RQKD5V_1PV
MV$>C1DT\R\P6^@*/(T5'(JCJ8DS'"-@FGJAGHT^.#M"W .L9=5%LRUY;)RSZ
MAC4_GU6.6N=^<[[5G/BN@2-AY?VT3G@'G]VOL9YP8Y3*"4GH[)5]([I\ ,C2
M$8:4I,?2:J.K&Y0/%]Y?UR7H-Q@D^BPLE;QK.KH8J^4HQI>F5=XC%>JBQ^0<
MBF.*4=VIJHZH55W[.G18K':'CQ76P%B[>;9QU;K_5[#-:+[5JD!8@RR_BZMM
M_9LWSMHAM4A:4CP84]XSR0FAW#2/BRV:_PM6A+CVRV,&BXW!\AP/Q8^,RQ+T
M3FT?M*8]?K'F R#X2; ,<;HHQBI4N2])-'MMNAT+8Y(3]ZU)<CZR*+SWP8\'
M@4@T'NLH>#I]#G)MO5]:>3/#0[B!SCJNKL3B=&":':W*6B%-2!FYN?;BO,E1
M"9LMBF7,+SH#YR?WT4/18:]O 3Q[/_YT\76;4 V@:LD@PL_17G$-N(!T,=,=
M4.+(#)))BH)*AA^3\D7*7A=]<$/>B3%=>AZ($8:S6W0[5V$S'19J9!/9V,ZO
MV==.9]Z]R>@73=_5]?X%CR;^X:PH#"#ZJV*,[427C3=P$?7;BZ'_-N6"OJX<
M*.2)ETR7CC?'+="+*1>E/"X2_^VI*J&O]+K4&V)"=X, DHLW5-]MS7[EG]@^
MRFL+:N[_9JR,OKD?J!Z!P>_D33[]>+H5_4B++@@0X4  R;P0QFXB0R1^X7K;
MJI./QLMCY/YXG5 EN+36-?T,\I#U^2_\I^'NB-4GZ:8GHFG4KE#&ZX10F8."
M^U.JH(I),%+-)3A$:.>@_YAY57VVS#8WZTWJ^_2S1\VB+5_:.WN IMW(HANF
M?F<4EY8I9B'5I8 I916J4;YF0!<<5)L3$NTKP QTYP.D$:^VNPL+(KB"<+9X
MQF9,;02>BS:IJI%:%V7\Q5\BR_VUA;Y]\.,$?J/OA,-)R*>9IZF?,'E8AJ$+
M<NS(G5C$YR$20_E!%@=%JP[#1\6_R3HZM?D>B6]W)I>(/NHC<.L8"!,[6CX-
MO_<[[%5W C<])C6NXSF22TNOJWT6817"@+I0M/>BO2[[3TK,*'+J%D NQ)]K
MSGL^#, A[FBQL;NGELK-8FFM&K5L,"[AP&(-H7U>S^?<,OMW-$X*WDQ'/:BD
M.OZ==>/L\[F<"^V2&;(IUTN^'M7-N P!&77,@QO6:?<"Q]GMQ5)IQ(]S&8/H
M3.@9"H6I8JPJB!&[/-' 5V%)"\T\C!TVJ&HS_06\P7?LD!Z&.Q]Y69QB)Z$/
MYM7.N%J2%_NZE]!1-#2Y$]Z3 2KKNHX)E5PT 6V&<-C,_ET-M)\3R+1#=\?_
M-G(M?:DJSM9:EU1_F+'T[*N<+1-90*%Q(4\QPJ%!N%<1;UZ,5<('ENFB4AEL
MAH2RJ#M_>;:[4WQ/<_(WW6JC_@EX%V[R?@7C,  DP')8SD#%-V&,O65OEWK/
M&EY*;%GE;7^0JFAZ_5N0LX*X65-O4 \_,=6]4<#]<!H*I.B./S\"#;)P2S5@
M9-=$,@*"H&J.8)\<1K>+G[MC"0^>C6P7EZ^R$1&VG2RM7SS%(G#_0371V=7(
M$X:EO0(>]/R7S];@%1HB:9O!1.^78PG+I5EV(ZH9>!^?)^I_9M75\8*=B+^U
M%.[VP*G!NA)KM:,Y!EM-A*< V4G#2$S81W1'AO*K5XA(K,G%ASN6E1R$W;<T
MGI:U,_6*NF%NQN0DJH:\<_38-&@S;V]UD'=-'=>MES>1$K'[./BTY@GICDTJ
M5E@AB6%I[7AT  Q"!;<$[K^?D04)C+MS.\9L65I(K= Q%4L1<_KXVA?AE&_&
MU%71XZF#6]A,QU+W(XQH3R W<\*D28KB'5X,Y7.>)28V<@X?"@GF:DR<*A(G
M ,Y!P.7ZC8#**JC:K*3_QWKT$'S9H R-2)(@;VZ:]_^B./S&P%VF%>7.YYP:
MF!/.! "P7;V 6F&#@(F,/0)#[\6XQ>?]<)1'"L89^_)M<V#B1S-J#4'7?S@0
MWL,JGTX7";N5\<(X\H.K[AA5/J0#UUZ>8< -;2."#]VX1:@XJYUR,H;C3!/A
MU5(A'54&>WTZFR !]H?]YAD,I;@C@%L -R3*O@/Q>DKP0Y6<;NN9E>9855,,
MOB_@D)7W'I7O:<UC %#S+RQYC10]V%QC!<%9)3[)U"A84"$K]X\[4MD4HP ,
M?.KFO$_D9?IDI!8YN62Y@4C6J0Y& KFPP2_RG]8'KSZKAKL$4U):#(QY_J82
M>,G"P._)L;QCJC\T"N/H=NH$H78'J[50][;/IR&>^P<Z4GO)C\DFRY<[6!B"
M/+$<GV*!P@^>L$Z([GIQWO06B&#!=U\P;RA<W*4-PY6=6K6<S&',)]$XTDCM
M* $N3=.9KN]+Y--GX; !.&U[A(>F:>%TH31=Z.U;0+)XJ*!;L69S![M%JZ>7
M@*C7^ZT2MPMX5<+$B\AALC0I85;>Q9_77V^H]J\&)N)(X=3<"U?]3V,#&U,.
M1M(-C_][6DY?K/>;RLET<461 G1&BC3!,RX/KHDVH[U20H4>HV_J9#3>!2,I
MG;;W:+J=K1; ILL/K)%DIH;I/&LL#YN;'5CPC+LHW0]RXL']7<*(PT-5\2([
MA_T;*D1#)J=R5]&[B\";T1]S+C15%^@U7<]P%0!]X'W'<4!HSCZ06YWECT4?
MV&&(W3S>IF&VV=:V[^=UH?QY=.2BJP_N"=>38U'80IB[5X0Z:[M;(^Q#FW;G
M11&@*T3>YM $[#&Z0WJ:_N/;KY)[U,.L0[7;\R=XQO*A?^S_Z_J*A0V<?,<_
M231EOE&>/O%\Z0?! T&^_'N6V2AAIXO+^[POV7YZ#Q'31^VWW8WJ.K.>$_,7
MMW"@M;5?AD2J5&8*GLD8(/]EB,Q,Y\(">B((.-J[E), H3%O';BZ&-WU[Q!&
M;P<YT$LUP82T2R1SYJ1_[(A]H/YFFE<<_BH4HT=:M@K?:75@O)F]!1!U,+K7
MV.VO,YPGYJ"//RVMH)=7OY8V%JS+63QI,14TR[KW_A5]'OZDY180Z8<MZ!_B
MYEEP1GC*==.ZO^]J5\\L%MNQ <O_.I5COKC8WX[V'BQ,(Q11$J1IV<,[WP*(
M]]LPGC#4G^),'- <0^'^K%>PG9WYYP^]A6!W L?380$*IF9#:'E6(>V=$%#@
M7;#.J),8"QBKF-RU\BAR*SO.#.<\]JPZN6& ^;G_CA[ ZV^L-GU$^[MAH!3G
M11S.$$J! :_E?'6'T3>$:)DM+!Z?__&08%"JI>++ N_0IQ%XB=&QTO4\W#AS
M4%X,_54@-Q_VII8<3XQYL-J5'EB(+5BQZ\KYJ>B)5P++Q!=_H8^\G\' H#U"
M\ST_9]O)W@QTMX!+###Z&*];@Q6UJ&O&,#CL_<2:6N@Q<ZA0!K])L(N@0,(D
M7L;*M,^=$OS+N)E2)VF=$Y=58[1I7/#_+:?4(/Y*2Q9$DF(NU.)>:]OD=.H8
M3R<?:4Q"2](B;G(Q</W%3Y(*5"#8CHUSO([:D">O=&C<K.Y;-WCOD4$)88(U
MDK8)D?4Z=)@!DK*P@;WK/Q0&Q;4&KTX2\/J;3N7](;*SMEKE8WPL"I-N:-E"
M75[QCB:VNL\;,H0@$XN[<OGO!UKSQ.EDRB4N6V-]#!R8W)8B-?>J#\B_YQ_8
M?$C#".8^6UX.=HR=H7U&.UV/^8=LSBD!SX<O=&@5UW[P,Z'1YZ\IK; RHH>4
MRI]*4<I\K8Q^ILEK2D+^=@>O=O>V;CQ4P[E08]-&:I.':5+,=(_!CK=EFJ^!
M+7O"]/AUHA\HMA_,-Z''FWZ)#,31W$S=J&*;RR"W@$%NL>D&Q09):AY:M^EE
MO8M;@$M3BE LV0O-C;HGRW1)5&\X-])+2\-ZE:%.KB5/A3&A6:ZH2W^UI_]A
MN#KG#D*;_MUXJ"PX\CI*#-F5?H;V,)10/2/=D\_'5"*;2L&H@V >3JS'*I;_
M.#B,3DR!7FTPMW1)2IQK]$U]>/B&D%X_@/Q>Y6@HQ<U\P3WL5*@@:(VYM4"2
M!"I90,G<%:NVT)9H*V1_+(O,?58G+&(LO?(JXLZJ1]_EQRZU:;S4)@?KWP\>
M'68$]3<#"YX[HBP);QK<N=_,?RDQ\\Y$2=C%.[]^O/E.O1-->F&#G44/(1T&
MAQ]XT;B',70)B5>Q^S$7D40X49>\EG.D4,BN-TSJ/8L<&VU\MLG+HW6PWD3;
M Z.81"8^5.<5:G^W"7XKSO*TK2Y=&"=1["M 5$Y8:B=,4Z:01/)H6-WA*8PI
M[&TJ)5066XE<CP[(Q;BF=%B).S=/H?B-3#1BG\7G(/1VZ;1Y,\=6 KZ=GIV]
MB;@\09_<D.]A\OOD"V@QQJW?W)5K$_UXXI]#"C:-6_0*?FGCWF36-6C"'RZ]
MC'A&J^J4A$L]>HYCPO^'K<0D+*/B^E=]:&D.0A_/-'33'N3%\TGB%9R)WY4>
M;9<@,_Q/)\Z-2C(4 #Z^3W@"L'$HX=@NKE1*:^S) /U>('ME=5Q^V*-''$<Z
MFNC%+X=:8Y2/1$E?Z=LZ\;[8W%SO>]AA#HP(0TK-""/\1@02]N<EG!A?&@E2
MRCY4I (X$>@#B([3]";ET/^.W'$B>&?L8NE=!/:*[3!QRY.,.#>2-)H_V4F3
M*/IV<)$Q\ @D*?"TI#7VOEC_.UUA):4::TFL<&AED//WU=KXW5FHNV_-R[?K
MZ+3&08YG*0B=FTF(O7EF<%R^^V5^<GAFN!O1(9 B=,&!IHL7[XL(!4"X=W;-
M%\ZY6/>MNS]X-(V6+[9DCCX6S2 :P;4"WH045JAX:RAV\5Q_]_-B@LRB$/TP
M"FS8 '4EGK\AQ.E9AAO;-D96Q&>DY$2P386$C;C"-CUS'(K#B=R,P.Z'WH<Z
M=V,3,12[3U.-IJ&/EIAS)'*W2P?;CE2/Z_?!')FJR[;4NZ&DEDH##VX!?6%+
M/X$)MP#.4%Z()S61+FQ0G>6F'_U6EUWH;]K&^$,J2EFI[D^DQ,K7AQO?2*?#
MZB>/9) .2SP:&-T4V1!^7%]@ <5"[7DMD_O5]LK"T6O9$7O1$9>X[>B@UR1!
MTC1$W$&LA^)A[K7AUH-E>=KE US\5[< N/2*>W::;B!;!A5,O./'&*'.<4]Q
MU/!Y[_V[_%O_KX>'"V)SX8V!]:YS5)?EWJ4#MF7(I_TND=GGKPMV+1:B,L8?
MR?]3^91&F6TZ%I9X'YD7AF<,4)*8GJ^J*LSI91>.]:?,%9*_^LQ>D,LX].Z[
M->LBH9'ZMDMNJ%/X^\_AM%.-V&UT 2WC&E8,JCE5/M^A5-1Y4^GBF6WP<?95
MTHA8LCJTE6)0@4GW#V%2AF_//D^3PB'N3OYHM% <8>POWS8%OC\/Y6EH^/E%
MJ)W]8Z5PED==W8,W:3WPC8TL@:@8(*'U3<\M@%4N60<8MW2]%E6*!Z)GOYAH
M8@8:1Q42&C\@G<24 RJ]'TA/.@FD2E@92#.Y2*9;-L*PPB8)8G_M9&RG&]5(
M]I?U,30YE<MN(!C_R?/()9/S6/.^^J"?,JZ>FUFB4[$ G#"2YZ@2'84RP3]@
M#EC"SLA)DNZ;\="%N7<-&0GQH\ Z3W9];. O*I:''=-DQD-$D>ML?[C5IFCC
M&Z@UUVW0 W][;(Q<IIN75TK C=;,SVC@GQXU\_BG*@KRC":37I NB*LJMBT4
M!3J78-OA+$M]V(RU'L*<R/V7ZI-E$V^(1YAB?>-'Z2B]O4%_)A>CD+J#L(BN
MNTPI6FGB&OS5%MNU#_:<>%;-G5JH)T0O1E&:H3:Y+;4<(WB]UD/4C3W#&;BO
M$S;"R+$N7I2@-2F,0])NKA^ED1!/XSBEM>;LRE,GP1^-= Q,141C@E07C1L.
M2[L;ZXEX'B<,X1U^IK#Z<B%6$/,&L%UQU/.&>?@H0W\0.0%\\"6S3%8/54>X
MM")LJ7EC=Y"6$U*)=(5+1B*LM6L3H-3?[1*W%NX;=>3YCW&P%@5J-,92Q'AK
M;@I^9L3\BP_;^'(CU(P)C.CB?YL7G7=XE5T=&(AA[,\V!/[TJ/$2> ZJ>#GX
M2>,=]?('"W,+YW0B'QH1HO,:W$4L5LX)Y0;E"-R<I+W;4EI4U&IMMBL]KI_$
M-"W-O6T)XS>V/LOK<$2Z>]X"W$RB+$+9\@<L@71X-;"S>[#:IWF!MM31EBX=
M^DD7>=>Q7"O'>6^2F2?/2(#DLB>+9JBP#S<2^&?8L*"-\6"3>3G1WV(=2ILO
MUS8]85\7/[8FG'(4_U-?Y6#E_, D709@N_^/)SKLU7(Y.B?.#W2Y ,1J^ZMT
M'WV1OS)W\P=]^!&)%5729^VRE0GH83TFN%BKQ0A?!,29HM>3_@9/WKO+K34B
M)0WSQZ'PJRA*FE>YG,4M+X!P3CIIO4D[H>NB4 9X6]\R]D;->$G)B3VE]LV(
M>O[7AB+5%I=<FS>&PP  ?;O2;E*HY_XM &U<2[\,.>EO2YZH\$=5TQJGOH@Y
M_UW#:;.76.G\ZG3^#1G,=??UMV6$VI.:]J&P.N$!.\F-V%KT[D;G6E;1&J3X
M.8L]7^?<VD.O_Z0FBO[3+C%KT0TO_/O&U$>! H![-'31B-6HQ:[= GK6Z# ,
M!_8BTT?B>9=@ZX?TYY=T2IVK,'$!"X*2 $5A3N[5P2B<)O1!Q_Q?'NJPOIZI
M3+,I,9C9G)A17]4'UY:&E(&H__93KX=<1E9*)$!G7KT\:)-:'LBC_@%NCEF\
M6?&B]F88Q<N]O)-45_\H&Y9UI_\*N)110F;<(X+.+QC"I<E&S*S> P]),7F!
M=6B=]FIWYBYNM&>FXA3>W%6 .G@@\^E1%^)YJZM% 4.)DJZG5NK'74&BOV$]
MW<RA7'C#N48]/!\*QP5Z/OU?<B#(\7%N=?7'(%"@X%LRJ7HF#2'2L5Z-@Q34
MF;'=:Q&^3JMCO\NMX,3\Y^R'K;V7K[-HMM,#[SVPY=PM8I.[M-SP6EQ'Y1QV
MHXZ$X=S$,\;M/ D>8+P22K%7PBG;H*5FYV/\[XUHG><[= !!'\O[5^.EQ4$!
M9VU!TJL#5&<:GS\)NSW)4B-9,)5/\O'1)0QG<R==1#5'B'UMU+/+&!2%9"AZ
M'.7LB&@"OKW4Z#$7>,?&MG%N3M4)&!EDW51[E^2*8)M40[]/R NG$/D:#A3I
MDKW+\;*8.V*@QP:BY!9*W3<[_[MN?M$5&SQ<=;CX N.)^54YKR39:LE)^*Y
MX@09>)CIN %^[7 /6V^-D!WE&$B$JWC5ECQ^>;S\D9J///:/#H<2\?N;9&S<
MADG?.M.!EC6&);)A^19 ]_;9<,X2;+'W4U5$L^='(32)R;VV9D\0P_K%.ZQ^
M(3;8 MV5O)%H(Z[P,HNFZ!V[5_:VO=W$%_+?Y.)1>^=,!)>]A1#A"T;,6$">
M4=P'J)G;E>U#XIB:FA>DK\Q/!S4U3"E.'TNE#_K.'V1WUY45;02'Q78I+S3^
MFU55^.9@\R>GK70;I1]TK^>_5$G.5JFH[E$BO@]J5R'5I:'#ZX0=JE>Y,ZK4
MGIZ>S^TM18JA20;4U0WT_9_/>C;5FQM-%LTVAA+$-AHPPA$>QTN ,E+Z1Y^R
MC,T#'_:^(542S/!Y3,X?KDZ.(>UQ6)3IZZ)#=\/%=4X&KF!1#>->AC,->QY>
MQ]8+Y%XE_LVV5;T7D:Q</9LK"6']]ZX+;OB@S]$!M1NK)O E06Y&C-I 5@FU
MO^_6?KU85?A; ]G27&ERXE=2XB/"WM?LJ1O"X9E]PCV9?S!VD*=*R#GQ<R64
MI7EGPX-JH7NY/Z>D)HS)??38A+ZYK=>7]TW2 I?Q*D@5(WGO29]*,.&@SE>K
MN$\U/3IO1CU'% 6W:,A(^]25, J'W[J9H)8;Z\QX]86)9N)_.<I#< ,W%RD#
M/VN+QH29S<#LUZ;?,B3'=$R>> ?#HJR;PU6ERC6JH H1C0?59E8A\B?_S9F7
MU=F)M'NV_>Y)5Q9Y7=53@X)3G>."3;%R=Q;:;.;X_(M!OS)X?Y]*T'VK/GZ-
M3<_B8^.TF1#EL6K+I8/7:U&!WFY2*/V&FJ;%E"Q3G45$<0PT_%<&P]#[[ULD
MSL2>HM,_]7@)"="Z Y*4-P.ATMC$FG[4*LAFI@/DY2E'B0.)YL<[U7^2WXED
M77C.KB.H8V[+&%FN1OW6 (VXT&G'O@.F^(L[F3>C\S9U<O..CY6T!UHM6*2&
MJ!([<_787IN0%A!X_6BD7:Q$TE2@0GP'KG+"J_W%7>'/&AL'MNI2I>[_J\OT
MU*'9=1H6I*-5&K?/O/#'@KY!["7OV4'LYR#6_+-&Y1U0@X#?HT<\HLFE+S+(
M!I%I,D]X"K@YHBXXT=G%Y9#C(91+5U.><T?3PA5X_@BW5.>_O".M+YK)?[PB
M38'YE0:@P<:A$R_>8FQO.#"QC2@3^C6L%IQ%:I_Y7T!S,_, :]9'X1PO,?WM
M-&_<QZV'%,J6JS#T,*R^;^^H1*&O4WH?7LGG$DZ532SET*:AID7PK^WH9'X?
M" AE.V"G2=W81++ZC5-JQYC^6A.T2V35E&?,'OFK$DNN"H73T4Y2>_7= NK^
M)?I+!7_%&V"X8H;Z(6!GD.*QJY3-[CVMI+K7FTHNBO<B?J$Z#:PP#H>MJ!/R
MM]QR[""H?KRU]9YU;;Y@W<I+75?V)T(-#P7!.V53XYE)) *LO5>ZFM<9ZB1_
M$,H-V>KDC0DF]/]-'22_8]Z98^:,'_;-*&)]"$AM4U)-LINY2X/KT05LT\<=
M*L583O<VG7+5V,MJS?#E3\BF3-@G/\5A\7!C,@ //UX*<0MXXT5RD-W<)@SG
MR 4[-BDX++(0ZM*SU<NX-]LR\C4)ZM@$/-W,_/P!'X227.S?=$V6/0M#K3KI
MT E?V.=P17:P^\CH#1VIK+[XT/7JR8KB!6OM=X_N-R<1[_D[!U+#&Y"R-;XR
MRR<9QGIKNVQ4_4I$@-T= /T77.UB/Q(\^*DI=6-<3/IICL6DNR=?P<./KH&?
M  \;J @Z=L,!>W=E#WV(AAWFXQ2@.@T8AWA)O!W*X(N3/@?WPYVVAK:F=":6
MSVP4Y)0M&\27/MX4#"'"&Z>A$]GL"O"P#TL2J:$>JMJE*U:V;HRJ!4;'N?RC
M GK\ZYVNKX[E)<:K?-0]7 \[@S=X^FGIEO>67&HWE@W^'*+NN;9%*I4DS+]^
M)+"VC_,5HNG1Y66@Z36>ZB+$JT^)OVZNF\D"?ZKO+\]__4,U).!IKG,_%3/U
M9UK;G7"@J)C =?(QLM5-UH1UKSGG*TCIZUQ)2P(94WT6LYF7-+^G8SW#J\TB
M*NWWZ_VTBQP;J8,A3W>M0&',OU_N67LPLWL>:1ZK!*80_N<;J_"(;837;UO7
M'H+;' @#J-_'3@QR&+GV+K";::E*<BZ%5$G57YJ*BKC&/M8+6&)5VB 8!!#-
M-O!06V'#C)6Y<\MZR]VS?PPQ,=CH5 A^"]^0G[=-(Q7<\I%*^4B &8S W<,K
MH1%)?E[L?ZQO 0EB_M3DZ6#'A+]+E*7)L5NMKKFY,T^*K!A^C68 ]M]/,H;"
M@:10,]0'5><0UQ":ZAW=8*ZJ0 D/1HLH(2[#OAFNV<K[K\O)QHIY:^Z%Q#&]
MC&$,!K\P9R-FC!A14A(\GT2TC), -.YMJ<32FITK#7G"7;F^$>UTW@$(+1C*
ME=J?AVU'R&[-6UJU1-XX2(M61K3\'/7*#M?.?D4X^)B62)7&].!"%ONL#6Y=
M'N?8/<VPM%U36-_P*1^L?J"R8/ @ZT,<E>XH-],N=8%V2'C:$3#4@C1)WH1M
M5_ SLCXSM8:@_%*T0)$8^GLC\[C_<^#5V<@?@D&L4V_3&MNL6,/HRR<XV0+G
M[0,M3R\YW[-PR6T1.P0(\+@G/)PF&F%Y/Z,WG>FG3O16(6_%1HH!81#KI-I[
M)SF^9DZ&8[C?:O:@$F?(^[^LPJTD5:EG@R*$ @P9M)H CG! L^TNIR_B]PU3
M-?L/RF$B-5JGD=W:9S1AJI%OGXH0?&M_(>&;0CJK&OIQ7Z20,.'_']H<H(>.
MP(;#!\"1?QD0E:.2LQY)L('XAN?/S4<.Q7 "J/+N9XV<1.XO/O^,Z0$41"F-
M# 2Y'B6$H0:Q:0 #N<&"^T\>?/Z02)>@Y)3B77CEC^J4V;CD05=W\),#4JGW
MAH/^P*6/U*.YR?:5"Z@![\<M6RR\O]<,ZPOX;*;(9*:9/'GONU!E;E"6+O]S
M%T27)!T6KS ^), U"306(8K&=">=>\45L,QW.*."X753?HI49ZL"H1B$;^V)
M!J\,XV?"=YG))8C1-:+K>G5*_-,\ZD>4JX%/YA\L;,YR].<E%VO+ES37J5[\
MFU'1(:AO33;56U-@BZ^80#VYXD -]5W+H)K[NQFA"@N[F8=Y?RN+_%?DTRRL
M>GK_9 A_ JARIDGK\^3<L%Y'JC\<1X5QN]T\Q%SO&\HN"Z%-4OQ:9M9 DH>_
M32>-9WO,]8EZ7X\3Y(RM],AP,O2%JX\LW +>GD2N,><8*DQ6-,:6U^@C<48:
M^B'J?2BVF/:ED3,6O6Q3?74;R5\E"@#:!YAU/)/-QF3D%J;Q(W"Y[:8.:=D4
MPGUP*.'12.\-CNQU,;>0]Z[!*:JL<Z1XBX;_[UC75:.J-J+JI$L,V\4EVJ_4
MCO"[+#T30#3F?#22F^)V9\O0]K01!HGPHCI!<-B/P$A5;>1BPZB=SDV?>Y[D
M3P=9YA-_XH5JMH0@V\AC^LV79- 351\C0-#N('#Y=/,IUK<,6]N3IYK^=FDM
MMWQMR5VY\V.LV[V#:+^Y)M$V6>?HM*_>3$2?7=6Z8__7?B>NS2M25280(SJ0
MUIWL#QKXD6@R[93669C,K)/CFM/R@8!2RB-5S"ERL(SG1W?<,?\LN,,&0VDW
M)P$^_RWN#*G>/*WE)OS*LOSEFX4LF?& ($%*9(N1S0WY-%('HY.ZF<CE:F9D
MIC'G4M!O,O<DW["SZ<MS"08(4_I97[B.%5=2X*M7KX@L4<"C,^07GB$8>0<]
M>LC@9F56U1\%LF.!6V]/I;E=O7W+(.:9*,/SV+X0^C7+?.7)$''^S8/KIO,P
M0.@,D$Z="OJTKG,:S[/124+M98BYU\&06SN92=5E.-L?OJ?RE)FL7Y1ZL0>0
MT&>"%1Y(A)K,J.JHVE8@Q8E,9_$O5#E 8$&0.%ZZY#+%+$;3CO(5?0_E.FDU
MMA5'.X0)VWP#I)>C95O?Z^*96S;*L44O/:DI-YE6+?9Z*Z@DEI/(/>(4N$1"
M_I>7>W<#MN2+9($G>_7E\40WMB=[/</8?Z@\R+/X-+4BNE3VA4./;V[$7"H(
M7V7PT /6H<??K::+9SH8R%XJAX^*IL996)?"HAXL+/?_W)-',/0RY=U?G-VY
MF<G2L%H4<A%CVF)0CM2X$KYPNL[ZZQ4-9%%7PFO-_Z7\K:JT2<"=B;[DEG5%
M[^02^VJ(6FM%HCFR1,:FOC&P3NSV$]C'(6&_)WNZ&+'/-R4!?V)G=OX-O2^K
M_K:_]JBS\:4_655C97](")6/8I"9-#*@DK9#SY:!C#0;KW+=XI?(0_'G"C9P
M,/P*H]/LRG64G5H^>/JI>&XS97_MWG]FD6F_BHF]5K-4Z5-@S^ZP'04E0I];
M1B]"OJ*D@KE*X82#/OTO(/A9PJA(DD$Q_2'-T"-S(-KD!!#F\2=4,"3,O*MM
MRCCOPGNP<FME:5&#DX/K@5@)OIC(?8D$PDK:NA#FY$5DKU[I+7%BL7,"=T<Y
MQQUF'W$^_Z)4I4GUK5?GP0\ )R&I(< *:X[SA-)BZ[[O6[O&>C8F*Y\8STCX
MNS;-@4N:;08^O"Q)D1<+O/\[]-B*,4.7UY>EN[GY\"^XW%U:[*IZHO0;"'&E
MU) @K\!L^=[^7VMK>\@E\WY=%P>'L4P!J #XPS5.]8O0<G^H&,*/XTA%O\O@
M2^B$8F$!>DUUPM&7>^&1ZDRT"F?$U,,:$Z0#GC&UMXNPK66^PPA%K35(?R!L
MDW)C]%0NS2K9FJW0H/T_E82):E[)TR2T--,STKIQG#^>* ?^GB8\$Z0<??.0
M'2J_%/VHVHGH;7VB@=YV%A?TQRQ=<3%-H6O"P8WTS3R02IT8%,J*=DW^VCTG
M%Q*29T,9PL1F,3/];%BB)E!/R)0^UHHHPT=J?0 J< L@QJ-AT7Z5U^02F<]_
M.!;9NEMW3.=TS2X;=($0=,.7Z20SA(X1PMLC G(HAT:OPW%,):K\B&6#)_X6
M0'MNY>]%_H>;,[4?'*A"P!E(OY3H[N7:G!6H0FH*'3#5G^#T<2/:K\-Y045:
MT),?.MZ5_\;F>=%"K/=%53I-%9^SRY-H> NF^)XM_3>2:_N0ES-S#B:+7<6%
MXH'HN!C'-FQ@Z7ZH&@)O^0T2J$M=]FB\S,VHML2+.(=&'7(!'SNE*]5*RB!C
MFF0([?^);4:29*([H:]5E;Z;J,$+5-MFJNTYU#3D--H/D[Z;C?EH#774DPV[
M3!)Y\MVAT&//FO,]\Y<-+Z[1(O?WT"7SW?AL%)MKB/6F8>IH4SJE#.MD]N-R
M()\PZW AS<SZQ3[6$2DJ264%U9YCWX5;S]KT9;I7"C8QHX>:V*A/,O1B;=PU
MDI,*G6<#R#Q@VM- \&3$C2"VTQ4-T@5[66'LO_^HCNHGA3GZ(>@OOWT0>5U'
MP+8R^"Q?5S!S(.@F!P>  M%_NS]H%Q2#OS<GGN>OBDOX+^NT*CM?G\>B0)4D
MX)UU/PPAQ4?>-!_ <P=>/.]U4K?;2708,]2A"JO9KP]2.A&(TL.$?J]4N\[3
M:+4.D=?5R>!_1L!&T\+)O$M,]%=R,V[@'&L"*MG/RRYW*G-OBQKB&N\<RKHN
M)_QOW^Z(@#BHELUMKIDO52,]M<"/%BO2?'B&HF6=1-+SQ,OF?]!/^&<Q=UB>
M:G#Z*X91+.TR8>#+T!,::6,9^W2,Y04H<;,Y$L_AOOE%<\>$:4^FYRH&)9O(
M,<)1D>D7)K+IOK4E-:(T" KON([&DP?Z!\FR)PZ!W(NUG;ABJDNDY"8J0.R_
MZCO&F.HRW71YPWWG(S?"/;1PGC>3V4OX-<X"L,N0SLS@U_X!%OFS9(J;$\/H
ML3O'6LZ/"D[*^L#*&P@@^(Q**<:%01D:I_W$G[*J&E1IU-IV+'VT]H\>%8X6
M>QEI8P\BHS>4]_AE\NF[3ZMO6M#E$#+L?[^MU?F4<5!+S/RA/44FO&VM%-E-
MID5(7D4--]5V#!+K?6[U!*7$+:T?IFF5=]'-$MJ?6/MVC;4-'9=\K/K0T1<Y
M#NQ=IZMB'A1@23CO9.WR?$[(([&SHW2?7:MQ\>-6<L\4Z7>[T*7N^IKT$EU4
MY7K\E'ZYL>-/Y[H$=R<2*-F7S5>#\BZ*DO\TJ!2'AW(AY1=X+-]7O!R&)]DO
MO]/,;@&OY/3=GO;>TM)*LLO%#&&?FC8_Q?U#JS?#PQ./]1_U8'[!L$(Y?9=0
M#0SSL7B@1>-=ID]1%2^'^#Y!=PP+-J*/CA.IW@'CP:=/!]1&XSY])!CQC=U:
M\/C?^>+(,9X/B>.09#- GG!!3 RZT&,%DC96]D FK,]?IQ2]VE> XW2^^,B9
M%.+?I)%N1,M0&=SSO2,T+;)\Z"CDT"^9$?Z/FJ:<JM*[?MEZ-=>>K#H=;73X
M[ML]CFV)IP"RS3+L0YP=5!A[] V2:8SF6JNZVOE0MJ^<W#I?7<#VEUJ]3_=L
MC++YE]^9@.+ET_2H09V@6OK0 75NC$,O#PF>::[#M::W'&MB7H\P/[HH4<AA
M/AS?Z@#5>Y@VZ1EMB01PO(]%8)_C'D$,D, /Y[4L[O_>9R4O)".33;2"(4[)
M_!VQQ[X<1HKQ,1F:23JL4JHDBFR%M!G'81NE%\W*-9G?W.S)YH\Z),NQ,R=]
MH;))BPRI#ZIBWN3Q9 9<,BO5)Q=NT)70M^^!S2Z.K@MD#6#4;C.@?SZKD#X5
ME6H%P]FO09+G01+.5J8S5X(<A?#P]N/!%^E3[\;<UG]TQ15A<^SGO?"@(.'H
MOT!Z.VRTF[X[\Z*<Z-\@1MZ''%E;9LL[',V$[VS'87C&H7YV2W@R(TH^)L3Y
M8EABP8M.N\I:=G]&@^]32)Y,IP M130'TS=!/Z4>TG<8UXLI&#+N2 MMN6$T
M&66]V0MC4E5O6ZC?W"NE^PVQ9TX0;E8X;2]*LM7;IOM))9UAY434<W(+V"@.
M%659Y_J*'NI=7F?; U)TF(.0XY3P;)@JB\"+5I#VO%=J;F/#<.A+U3]1D04N
M.SY9YPY'E#AVB,U%_/S?(RU+A%RU  [4^]XA]GS5P,")<,^2W7#XX$$30M^1
MX9!T2^KS9UJSD>9#O1L&-$G%QDGLS>..:6>,<(3L"14D8\FM8VBAYNAU.H=5
M@=871'=W>@<B!!F+7C3O(:'J;BP?!+) FGMAE#?T6)D^>P6,]D0BN :",\79
M-*46+:[ 3RE!+[.?)?L2?M>6SLP2#E=.M<,VXZS_ ,F\0CFQ+IO]2[!DN76>
M_05NUGE>]#>;1 ?R S"'CH3GXF?60V3>0ZI"&?E0CR:]6@[T+IYQYQ: K%(G
MAFT,P8]\>Y<ND@D'-I='/(4S=N'O5HJOJZEZOT0J__@O.;?O^Q;=>,S%23SP
M9T%^C7LH9TY?7N=Z%%X;>>V)L&E'O"'<V75H3ZK+)1?232X+A"H]4E(B*@1L
M>W5O%*[73V2"409?=&X!9DE8D*4=S?$"*&B^?$Y\]76[C>QOJGPA1:T&AM'3
MJ"D_=?[K1G4&K($N>CW^Q*-#W]<1I<+&\71N1K$X6X#O;'/6DZ_E3@12?_1U
MF6V3!?#&$HU P7>JC46[)D ?EE@/!%<8H58E![K1Z0>9E]XZ;9GKJXE[%N]B
M&,A^%02J[P0^(-%SP6O>*5Z >X$:9CT"KUV!UT#D]ZNSVSR_!9!9<S5)K6FY
M3.GZU@E:-<&W9*BXPX\\W@#\"SCNQD1 >>95'T/-4>=S'5+^E6]=#6<ZQ"$_
MY4N_NT^ORK7M>_]7^+&?K"3'B=BJQ%/^<XK*)LL1$NE%#1GMY:$-I=MCCTOZ
M:\*,[3><.<$;<+]!3V3=VUR^K M*PFU"H&AO)V*]ZFR!;3:CNP6AFQ+AW(P8
M+D2"V-_V:\*+_7ZCA*OQI:4AXY:VH"5AC2S!9>&,FA<Q4*Y^(HY_#FB3(W:>
M#^RT27@UU"64;Z-3 1YP(Y#?&\F289 ?SRZ4_Z8W]:-PGOS#2(K+J**10EIO
M;";.%OH(&[+IC 6AK.0J5]T]&I:_N%K/'&6#94R",LC3[ Q_OXDW1#X]?>'Z
MK5?5 0Y<;D?R1)Q[L;[-3M^_.JY$?FI(-G2?MB$WKG.O-MKJ!;]AHD8JA&X_
M?G=:STG%\PCC<.BXZ? !UM =K^H8A@+54N$?=,Y6EV1,3!.M02+UBIH_@%U<
M=Z0X-%W8/*4&MR^-:FG">E4:.HE>8B-0/'10+82<'E0?+/\%F>C^6C]3@S[J
M.DJ@6#2.V9(B]4XDF+9HGI"6]N/>01]-R]['#"4V"DY76R\;92SWI=O8*<17
M/UA@':"P?W*_V-)"/,LPBXJ<QX_#YV9]O7Z[.[[!A$:HHM;.Y+NV1+':F97M
M-4Q7__XVW6I+*GWV"Y'"S6PV825U@XI;0*\J6*Z:$-)XPK'/GIJ4P4,YZ5^K
M2M^@P.C.8J**U316A2]R0,N]>3G#[[U/AAT"D?%O\O8WK22Y2\1U"F-_K4]V
MT'VS3%"BV '* *)ZAJAHI %2JFRW@'L$6&?4.,_ TF#I5TAB?YX.#+6)S.=R
M02U8_D"DK<AUR/P>(U@2I(C;"25R E!<::'6A[J)\:SHB434":OJ^->U96L@
M[$V5_=K2.6]SRS"R6)3_LD3&8VG,DO7^J40SCG <&*ZJCVZ;1,G7?L4*/,>(
MJ0O.EA60;7=.EQJD*H'!@JG4C3]UMCU."Y,(&W_?3/'4'5=@-GO6:?#<-VH8
MA;BC4)Z]ICR[^<J?[9!?OQ91^A(UZ-]G]DPN+](8I D?BS[A>GC='DK 0__'
MGK%AH:;ZR+_RDQ7DH^;N?XU!XM2G_<$J$LPNYO3?,\<^"0 0 DB'99 6-A^S
MJW_G':EI7_R8KBGJZ.S$D,97ET6*8ALNK>5AVO1O#!A+G!&BK?]$J2P$P]!&
M)W$L[!:52'VH?JUPK!SE%XF;WZEB#DMOLRW>#?#WJP<*>@D:Z]'^EB"36\#S
M7R?^!<;QL#"B8ALWOYC!V\)B&BZF.QB16IST)>R^O/'Z_GSFM$+RV<1U3G2D
M2@! @-,%\AJ&PH 1T:F)5,I9'1G+Z]H!'(<7ISU6JCVM:_52=H5,/+[AQILO
MOEZW=9':KD\2(ZQ_3$4C D902F!"]]/UO3\SH^Z41Z2^AX]@_OIL$S(.JI#Z
M&_)@]#H\%(A)A:O0LF&SU1P&[,6CX.N+\?\%+##O0.Q/=&*B(Z"1B8_2" >U
MF'IMB1#8J!OR^:*#M<>MG[#++^NP8&Z8:A,W1823+4@A.Y$8$=/SA#;OS<>-
MXQ%6WG WHMF.AS@/*!DV'26'?KW?-EY0')H8Y.CJZ^X+IERV9A@7LXR52VJH
M_,%5[TT)4%F W@*::P\G09(?/"0Z3(+O3\;6KBWL&H! >^HKZ!_<=J5]44P_
M=88>?36$%BH)Y%77AL(O['EO 3%VY>X%?& 63;1$CD3J=UNK)6T02F7FM=[B
M5L<3ME\?>3W3+T>(*9 =2G>4=8;NBG.O_!-XM3?G9[-.9U*QE_,O.WVTJM][
MQDOON*:I74\(U[K>X-K-1+ '1*_!ZK?4V9LP7VY:*Y;[@X.8OY2XF2Y-+%4)
MWAP<Z2S(KO$]""1-XTEC4%*IC,'6XH(@/+J(&TY(<(^%=7=B*<8R"0\LVK<7
M3I"S8^CCTH_/GMBNWQ&LV(G@!SN(YPA*(7WP9G>3ND#/+U1^Q;9K($X.Y:ZE
M;T0:.4##?#"#E 'ILIVU.>K\-:F(^,6<($]6TU2L\%%6.3R$<2!/,C'?$/T6
MDJF/H1Z*R&.!2/IS,#LT.!3[_&A<@74^CZ'/)JXYI",XYE:__JK*A0X>N.J$
MP3FBY9=<8O-*>!:-Q,[LV1#O!31I=AS)'[6. D@4>Q25FX^:T2$W (>;J3RC
M@LY:B'"_\A@[<U')HO6*1)U7Y<KP:YQJ.E5]3VVO5ZZ.AJ HO748(_!-&!E>
M%]-X"T@Z\3?2\#SF;V1F?\';X-GD3%_MRE"7U/M(X.'$"ZHDHMYVEL-2),B!
M &J,=2\V"49>,PZ=6N^? &(7CZK\]2QX)?CC19)<]/ +% 3KD<:ZO-P"93?K
M:W0SH>)[,%IUOC^6:VSH]42HN",JC!J;K2?!WJ]KIZE-_Q*28#GFK?=!S&,1
M/#H\/$@[Q4U__>.&$G*":L6:(+^X@+ULXTQ E=1O)QX^F'%Q8FR<7"PQS/C1
M1Z3W4F]00_%>Y40C[>_!Y>=HZ!5IDG\E#VM(N6;C=.V)Q*'Y7_UL!7+.:=MP
M=NGTGS^LAI^9Q_/*.4/O72?@)7&*V L<_#UWQ751F>!__UG,P\QFMEJTD\5>
MY9D]E++//N6D$M%]%TX-> ]&'/FC<_U-6-U" XK5\S=<G.=4[?D<2^P@V4*.
MUQ] HL[)>Q\;C#C ]C1/-_(VNI$;8<1%4[+5+L>T]$O8.)NY_#N[/S!?$O5B
MFK>!C\>\/8;D]^$#TYGEKI>VHEL1D?CC<ARM@:\"W$X=R'(@?Q?T;QY OG2$
M 6,__N>*7D_ GP6R#XBP92SNO.;2(N;K$6TJ1.<<LA1;O;7.25)U0G4ZP-7E
MYOAP]__V1O+\M'>W9+53GZ;_$8\F[-/YS>%;GRWH3? ];*,(2#*4T*%58N=V
MP]>.OHA#[LE]@[[T\I*Q<="E<A>\>,5LM?1J]Q?@4?CZ<SOY:EP@E'E&PF]4
MY2.&.'-_R3FERDM,C-+:K>DJIGRIH;E+D/:117B4!!&=%EA--+'K?QVH]G*4
MJ]-F5=]5O(0$23%7(&,C&6KO]8ME, I1M&43A'MJ\6>0/[> @G'D[FVW@-0:
M?SN9@:OLS(TC,[U9OZ,PXU.DDZRUW4_KGA_.NCFX$N)[/1QDMIX# /\UBNLJ
MOU(L;044C*V__@(J<5_Z>P-SDDC[&5'1X1-5;MN7W* O^L3LG5GR1L%C@L$?
M=[,)QU,O-(20OG@IU]" * ZNS&Z-KLIXN=Q>-K_4KY3UN! \8LM,5$N..;LP
M6#@&NG X1-P"*-01*- X[8#404#%][1*KMH<;MX-Z6%6 &O3(6-C. !5WM/]
MN\N@-NZ]2PXFLS_@O7S%5ZPG3C=Z:;!ZVW;%\$PCX+XYI:RTM$%+&FMR>5$/
M:=.?L&;)GDF&U7'G!X.E)0[6WUV-Y\'ES1V=LUMA0FL[<SKR;0W15,<3_=F3
M@H[8Y8MC+!>2;6NJL'7!'W1@9Z]B9SIK%*M%\\'3T$/"_V49&UW6Q&J-SK;G
MICCJ_\A[KZBFNJAM=%,$E-X[00."5.F=4*2)=*47%90FO04$0N\0BL(+4@4$
ME")*[ST@0F@"4A- :2()-4 (/^_7SG_QCW'.Q;DZYV+?9.PYUUIS/7/.YQE9
M8^W9(HQ18,MD0$+ ?L)Y^6F:<I8KRH&NG_Q-U0?-P,/^&R-"U=1M9Q*W7Q5,
MQHFG.'YO1.+N;J:]0[3=J*E+?7D-@=97,J"$A1\+9#D67>G! H;QOY981,A'
MI1\&<1$#?"3'_7TKO)C]U",E&"O4<X=RE]IW?&%MT1RZ;M4U'M/:)/7^$TC0
MTY0R,_ P(](N?>J5YWJ<%=$;!096G1=Z9-/-?]_R SWV.-5-B$HH(V:\';/9
MGXJRL]!E":?'-.TIZ;20=LS]-JVLWJ!"?Z^XD1M5A6 ;"Y-P9Q@DE1CJLG5E
MHV3G^V-+_2G3:-E>Q<ALW)?(>-N\]Z5EZ# I*OB# LB/"?SL1B+8$Q(3/4W*
MXR;U_F<NZ8 N/YGRYVRC?W3RXVXTI9^='2CPAIAW,A$EG7,WC$I;4!TN-HS*
M=%!'9+\B0F8^)M:4&*%M(9HFJQ5-6!@5F7KD=U$1UOZ>;8C1A6T=R)@#CL?L
MWT=(61@DWDU[\G+@D9-E;O+02U[Q_*"_7E*>X4_[LTQMYG6\^*; "H<?)-._
MZYI%]Z7U9$V$MJ"H#BTJB\F^"#MZCTNEZ>X>@:<*M)@ $RTF(FPBCA/;D )*
M"8D\;PI3T3OBFKQ&GM*ZRS8VV1B$$9_.(N@PGT!^UEP!FYGAC\/R5@G! K_4
M0%RPOE3<8@JL;WU&6RF.EQ",#-]D@O6EX1:O "VXR?'%'ZGCVY%U]80QKRM
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MRR73NWIDYM^B=QN[[%O&;RK[1*JQ5,5IF5.$%,*(O2$..Z_-=CI6C)7*P!$
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M-B7L4FE*W)+4?7Y=$R9X%!E7X+*T6M<:5@O0^J4Y<O!\';.[HWB.G9,N?"Q
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M1<CTH\KHR%AV]KUT;Y^4S3EI(D$ (%>3T']$<XL<2%?CI3&\.003<Q/XIU(
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M_&DY6+'TL&PHBR3VA0B%<(3\G0['AY=1'9S%6ROW,,WQ>*-J*YS?T J' >/
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M6S]S_-J&EF&; $N1IC3MF[,K^LZCA7JI](1%D_=>JVVIO+&>DMI]F*-7VA7
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M?+$-B_SUG BZHCOL\4<RA@3)"WJ^W?8FJ.GD--""Q'CZ0Y+"G6XV,FW?ZC*
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M=)"_D20KP@E'CP&A]=AVPJTGZQ".4/9)QZ^XL#589$CS0!W#EG51OSC=TNH
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MAI/ASDT7*Y3SCP1_VJV9MWJ\]*SH$C;[8.UOJKALH\#K.P86A;@0J-JTDA'
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M((#_K,:Q;HKAGG@?YMAR_I1,]_-]:9$85\8A6^$S(4@A>.^6*D(J(/ '73>
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MD=RS7DIW'[7GTN$9C*@U("O<3:,LMN3VZE$\'F=+(YM<<WC'<EN<L7UKS@W
M:(D%T<OZRT2/J)^6AMQ$?X(T-F%\]:D1= K\*G/E[]+]1;R\AH20<:V]]9ZH
MQ=M5+T?GMO%XJ:/!.,N$(R?JI^LDK5AM$/\Z81W."+572:KU)O#>  ;%$#<
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MPQ)RD=.4$."C%@RA<G9U?;^@[O13B;1T0)#$9F^)C7E.BV.PK@(CW3H]N@"
M+\+Y73V!%"*5:[!5]W$UZ&7//J%=E>[$) TUGYK-B _?=K3;NXHKFY-:HUF2
M@\P>**>)GPW\A3-';FPJ86'I?7?PSMUS5O.(K83 +RUH$'"EI;)@LX+TP*N>
M44B=4Z63VL#OK=U[&Y++XL^$$7N CY>&,6L7DFSI&*_GOU20][7.]E%0W?*J
M$;^;9^ON3_*4E?>E<LV-?VQ*8C\W7>?WT;AV:]RSK1J:5"\6-9Y?>SC_KR<;
MM/*KJ43^.'CO!6M7VJ_8'/D7T-[;2/;RSTYQ)^BOADCGG1@\1SG$8H@@AC4Z
M*JS>V -V:^J.2E@GMD=S_(?R$79 <$LDF&U;+-@3@SW ..O2.QKVF*.U0676
M#AAM8%=]K]=GS6\7RB&LAZ+'S$?J@F]_QMM1TA/1T@-;_]P FK<&)8"T$/O'
MG$S351#[8;9(R;G>7]_;E^:I7EAG?2ZL0[MQ$#O]UNYTD,OP050=C"%!L;P"
M.#@JL"-CWQ2W4+MWKZ3%=\>K."]7T=2K&;*<D]<T2N(I!/A&.< ! /'8P08,
M@CR,/,8(7/.!4FPCEQGQRL>T-BN=8H(;^F=G64^T':S4S)H!JFK<9"S)Z.FU
M+=2/X\%2MC]Y=APS>#FLR^,9U,]3\"&51H_?Q^E$>:M2*9(G I %[6UO(6YB
MC\-;H=Q\?K!0E9K^?$"+8S;H)*+6@+4IPD72@GCU<NY1T</ZM(=VAIW?\D3)
M,@Z*2GI&P2WV \ D;\G>1X@!R7.+-V)!E.C7\!6/_I:^(ND)Q24S*F9+]HO(
M5UU6@ OUI]=?H#J8+V<.. D49!'$!KD!H$9^M'U]WULZ.>=I%63>XU;_2T@R
M6R&:U'OE%7'2>(-X[_6'W@A,SQB,X3<V_J@<!>+<V.=E+!P*(PVK-*I(M7['
MO/Z(]??R'=O"K"B K/Z4WJY]<B0IE!]K/[1FGV U'5N;.[#)6;*X\V"V%O&Z
M>WY[7CDZR$4\9D*HRY3'OS)/E.]N;0WLS7%,.GTIRWD<W\^TOB=Y86W?O92_
MT*S)'"T>.;;9ZCY&NVK((TJT*78:DF\ /D"6]2_+4$-,*LYJT;!3)M#0B]&B
MQ#"OP^23>D^2+K7^.J*1&L!]TM$]>P/P K&[@^DT[+%6?\$4$/4'F.OJ]AE%
ME>ZDO>Y_C?X3=R6I>[&ZVB94M(@\CI&(E9"K>WCN!6A[%^9M92K7W0PYZHO'
MLS6ZRQFU ]9"C>NPN Q*I4%W>)//P6&-]1Z#/43B>UN?G^3B*W/6<60TD)E/
MH$:((2#KO@: #@"-O=*,_+DZ-MJ0SAHI%6O:B3F/D]8@JO9@ZZ,5C_Q1O1<&
M99N^JKUSYZ0RBDQU^GL1P^^*EO^-H(+T#1O7[MG1=< Q(T>?/>OJ CV26&\
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M\Q&E>D*_0D8O+[/?T1#'-EIS'$ MQ?\L"LPT?;I35!*P^-G&:HW#0/SJ6QJ
M?BC*&(-X':3*'?R[X0)[ PB_@*4_VM%]#596I> [&=73N"I9IR]J,2%C[7@/
M#ZY.$ '<*R(7UR<E7MGK)"4Y;]HJ:,W#7#P@(I;D#T9DCP;DJ$W=GX;#P][^
M3C\##)%NG^\.D'#LD!)4+^=*134MKV*,+\8> VKS&,J'^3Z\/B+=9CJ<T)2E
M0I3:< ;F.:1A .J-5*I\OD-\M W@4C6.+ZZS4<&-).!A;;7^TT-CZ7=@^7\$
M3!F]OY'XVO<3;Z$2)#P.#0'P:HO&#SCB!:M8-,R59_6=TV4_LCQN<8S:DU?(
MZG(<&-B[ES+W$IV;]*UZ.TM5Z&0]<*R*)UJ@PB5%OE9_\K6*?;?\A@+>UC\B
M/,>5N&5MU/I'1\<SOCW+**JKH36UM27LKCFC2I"][!U1O]'UPSUZN2CYBB:
M \F/)^DT"$:%&8:5G9G+X%'5";[ JH 9!:(<<B [11KO4[F,'44B._W"(^!;
M0[$_0)TBWBTY45+>JE)'KU1NET\DP>,3_?UC)"7OIA\8WY<CF]#>$:3X[33V
MA/@>]P[X"<;O6]0WBN\& Z0956YH-701)K)+M Y@FC=!6_A1$EO-GI8;$Q!%
MA-2>&%NJ'E&2XM<CYV*VW/DV+=YUPO;_J/K.=SB_[^L1O8[>&5U$BUZ"28@6
M$1'1RP01+0S11HP2O0N"A"B)'F6B]]Z"(+J,.J,D^@S"'09//M\7SW7]7MQ_
MP-[GG+77.O=9>R_1#B7^X9&5]1FSS30]BGW!00*I5B$\DLDC4\U_8"&2,KJV
M<>!)WB($]GQ'9"E@6>B5N6*MXR^1%/9(YEA,19 O/37QN>/2!>6_J.O>$O.,
MI3?S1GAWDSBG)CHGWSK[J [%;_ZK(TAX.^M^&OETRC7(^(R9R&!O,NIFYA>R
M5QS1@>1W4H2.U$$;)^P#EA::?^[4#>_Y)/+J*'>O!?N83/YOU#!DO'0H!;@)
MZX='0QN>X7[UHIAUL9 H5>W&<LPJ,\+Y24V@U(FZVTHO=@MM[1XM8-#MM&!*
MX_0TC5S9#;MUV1SJ/A%N=L6(-^_G<8-R2N^#/X\J1?STC8E>Q>169ID(L;V.
M-%:+9U5.]1;":#@TOP!]NHS#_^J&_PSHS;+Z-0AE!:C[%,><795B_W@\@$F:
MF[;(Z*5]?_:R/4H@A4.&G@C$% ZVQ,"BKT&@3AD$6!//$A-S(LV,L+::HOJ=
M^H:YPK50+85Q 4W 5!+*'^9\M5?A5Q&Z001<@R[(W#K%YJ#P0^8=7AF@W!GO
M&:R%R4@NR3I]-.%1M!/0G*;'2BI-PWB?/;P[G"H#Q)V^_CJK'YJ\2@%UA:'K
MUF/ZI#GOE0)W^JY!+$CIM4,6A!6V!U4R=X@T_B*9%-LHL5CXW%ESESXX+(N+
MDN0*($A=YH=0(-D[9OQ0T2&D/]J9L#Q>N1K'CS-W5/S$8P4S$H3;#-4V<4?<
M16YWQT&"RBW!.'.,3$2_A]_:*MA._0\A1'Y&RJ!O:W=%>'*#;2[K[!1[3]#
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M]%"U?57AJDE668:?U@ <F$-Z6P3\*9#NY%%F->'LB;=]6&/9,?XIM=1:V[]
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MD#J7 :S>/<#\M6G;F!#<GE,>;_W-Q-THC"K3Z>61QFN@Z8+>?>7VS)6H:W9
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M'!4>1)5JR>=Q/]O\^5YAV' /K"-\Y*5KA%E=D!OJY 0@6&C,"O>,O*%2?Z=
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MU-^IW#E5.O.2(%G8\9N5T#[P]$8DS0;CZ#']7="O&22+Z/XJ1ES]CA&0]66
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M:J4"U5/L9L7LI:4\)6]=$="68OJ!_6LZ_?[;@R?4C :9XH;Y5U1<N/-12Z6
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MB*N!WOJL#X[>\/3A+)#%$B/Y]DR)F:=G#IC@?O$X?<1D67M85:&>F960@57
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M;6USII6NH7W30@6M-N-M)LX8(MH!4M\9R #_:( 3%P@R0!3;X."C=IR<?Y)
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M?',".UTHXG3BJ_KO^+8XY<^5R\V51@(ET$IMH6X'HOXZ"\^>1Q1" AF*?FK
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MMPU3DPH;8%P52NR7J'X#Z<SQ]!7X_%T\?WGO5_^'>OW^&#W^O8,'GVN>7;=
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M"(IB5;.8 ^2WA,I_GP_6SIK$R_2]!8:,A4'+I'KY4D2/QDVH50'49I'T-U^
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M$$*CV_33&!]SL*?^P.+Y[VY9I1[XA'<AN*RGO2#,X6$H <?$UR<@VO +NO6
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M:;@<Y\=$Q! Q/<G$-%#[%;\MFT#(WQJOPA5M>86LQDNU-:_46>UE-2&JJ."
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M5C [FGL)#,]##Z'>XF4\:[HOF1SYCD)OB4ZJMG\JP?EW@O_4]:T,2[\S#)\
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MR4>@O3&:-W< &/V0*__[S1O0*BCI#B R;WAU!\C17=Q_Y%,XOKW/_/.,C#O
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MH_+W?L*NC=_C1B$)FB+V##:2WD:>26!__\C_G)=GZQO863,AF.XWFFNM4G]
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M:8QJI#N40G!MXK?G^P;?]%WK1VXBNDJ"\I8&8]:%BOW23E;-E.Q=AW%_E'Z
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MJ-1R@S[<0GC/)0A7;"Q;S"3K>%CY;!7N<FGEL"L 8/24?SS=J 2D[&W0'_Q
MS+A&<"/0B3I-.@9NZG3JO[H%#,('ZL^]\4=X(OA0K]7?6\ P?(TP].]5^"T@
ML9*')55K0&MX4"_,_\K K)):_U,JF#OJ M_&\5,+7P%5[T(1<COD+8?A].5*
MI%\,72 N<;< %K\Q#HV4D(8!<:UQ%45TH!(F#7+]>-%.YOYA^;CEOBO,_E3W
MW-3E1*H@4VIK7K@8=%ZWX!O\SMU)J_Y=#+<-*1G+)A-WJCS[U[S5I))##QQS
M>!FBZ&ZF:A;&ZZ7,L>KT]/.1>MX;=N*4Y?":CD3FB8V!&&+Z7BZ^\&_=__+:
MMJZ1CA:E2!.V+*MX,7A*>0MX,(R5#<C$DY)OD'^4+0[ \:\-.\PP/9]4%:O]
MAAR$L]Q;5S%(2U;W5 /9;%0ZO]5C&M1@Y3GX9;W[RTO[ E7"G:G?\.RBYAS$
M%FR7TYNN!7-BH,_+\+5Q:SP(%6Z"70F9_^*4_S%\PAU(2921[*TG.^SZZ90/
MDK,W.-L9CUNLJ<2>T ( "M].1IX_#4<Q'C:S)SDO_.]J&ACP;%S/7<LJ3QLW
MO,RO/0_*P#?AAWHM7I?X.HS@U6V;3-#(,5_O#S41TB$C_IQ]WXB.==Q(*7QR
M,)!Y!>(XW+,3G;J^3O9'A ^HG/U@SRX'0OI370F2Q5\0^Q'[F#W!?RD)@&JV
M3YP!E5W,BQR7-VU8RMNXU\K^ RB_UD GAAV#_.//@5@@2]TPS\\ZQ32Q0-8&
MG7ZW_KJ+5UT <0V/]6&^R@%R+2N7W6GXFGLH\2V 1#^Z>Q@CD@C8:S.8QA[\
MOES8!:?D8WM[5",WW!BX(O&YML%IL_:#(2"6$TLBL"TX<B3RG/4#X<#DKQ4'
M^']+(.7<6GW:R'-]K,AWHY(])D,5/N-VHCR*@)R@I%ZZII85*T\VG*+-.E>R
MHDZ![4E:J$.> N6J_U'W59P3QB&J]4X5= K/;@'YZ?DL5Y022=:6#X"V=Z M
MVN-TU;GYQWD^YVKS8@%1PO5/GQ;<RQ/",B@MWPJ])EW) ?EL)OH,;NO*"G98
M_6I!R!FCMJ.,VYKL+FX!%HA ,"-678AFPXW*(<S<H,Y^;]?>**GW,DXKQ'I=
MC,1F0YCZQ>;GN:L1\6.*R>O]D\3O<GPY-DFY,* M/)*F_K54574M=9!S9C,R
M5:X/RX@P&-"Z3.2?!@W= H@G"KY)O7J^GN\W>WA^F9-J+I$,8+%A026F"W10
M./:W24^91"\C:ZU >99^O)9S['U:&@?!P^5*K*T=BDG^V7V=S('D"!QWZ_,8
M9F^UE!FA]EE98N*+2X/( 8*M",%<#'&\I))@KY%+ZF[C%6^NV]]EW=*&40DR
MJ* 7O8%FE=;)U</C(FAK$6 0!6?"(]@)<5+K-SZF<YGOZZ.%MC@#I%R@3<O:
MU1(T)1I_&\^'C9E,6,)\!D#&-]\Z&5=QYNC#,A__RE5G(#E[O[]ZKWI;6\KA
M0:9><T"!KIJE[HC@KZ?'/;^J/?5\+%.+LCK/&W=\+:0[;P&!QRUY=O&%1@L?
MS+[RC##+_-ZDFQTLV',O<PY62KA( CH?48T]\EM,NIO$D5?<M:H^/@09<ZA^
MZJ>V-%U=+U@T55(8B7L>IW7Q3:6=2V+!5'WRMX"X\_47RV7C2S8<:WH2"S[=
M+'%723I3GPZH$?]-?1JB)F.57N",F'HV^_%Q+V."ORN 7N#YPG;X\M*\@=-C
MII?Y*3F^7$1Y),. !]U;*)8@@A$C9G,RD?\4;01O =3G"97HW>G.1 O0=6Z
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M"0I+P]VNOU\IM94[FS[_+J:TM/(ZV_\90S*9PW7)!,4E8U6>E +55R;!C '
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M"C9:;]HTLXWU1^#UWS'0_5O ->,_-@&TQX NV'(.)!< [?6[\'GG7*,?#/:
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MX,.216G&<$'&[($FA;U3R@\[ 6]NDX1O]^6,IEDB]?GZVV'/B[]-NV31\<]
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MK3+]DGINO,GXICQHJ36X<N^PO_Z@O+$U,&3%HEO6E8+'I(2.@7Z)04@N?36
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MI0+?I"=SY[ZG#H<UC%VJKBY#>P($$JZ;S/_E5H+U!:&CQ!$X&DQPWRI:'Y8
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M,5="MYI>N@!E'$,W,C./25P_.+#)=<B2XXD3C+9]0: 6R\$6"CRWNTG"^5?
M#_BN5;%E%P&F>'KB)$4?M,LZS\]XD;2*OJR2V,/UYH997P;2BY@-+<4B>WMC
MNY/XK5+@A-"B<-JRT"A/W*K'E521WJ">2R.'9*U9%=>(V(>^\.:<'+9&=NU<
MW6\QAZNZFI-K+F0N8($Y^P_&)]0"98^*[!*]F9D8A_?P$ZE3I%1(QY5A[[;
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M%N8U7?-&GZP]DW^ARWE$D/Y"-46/B?3;#5 PF5"-3[!M*Y%(+3M,1?K&/5(
M'ALBQ3$I=ER ?GBE$"ATG8]CQ(2C)CNR2;::>0[H/O%SC>[MG?+9NPA60E9U
M'LOTB[\>3V<J;,7_%QV?8A;O6UZ'<A'J<LL2UF]=YB(5L-.6C!'PM)"=3-&8
M%U_/F:E8X.$JC4M:_AE.CAC2SZ25_EVO9^+TSBEOU"Y +C!#H;N=_RSZ#6>"
M\E:ALY/#HZ\VT=\X[GCLU J"9"1EJ</A7-R)#^X\ZZ7Z41)IW"43OY$BZ[G(
M,"AV]? &N/OD%E8Y@H=O@%\2,:>#C(&/A\1</R/OG#[TDXO9&IJ;,\<H0&P3
M8LU"*2E^4*ZFLM ($H/B.IR9]'^E+(RMRY38"IG-B.^+SRR+&-ESDN*[JNF5
MQRM35L83JI_3D1Q&JF2_.]F(;!^!/Z))WADP3%R/=93N='X]+U>_Y33_9 WW
M&(5MP_]TEES8SS/FILUCFB)A,VEJON/LFCO\P/:=HC%7\Q9 %N[&Z<\ZU8,*
M\,J??C,6X@9B>*BF@;++\I-3*-O].Z/[J9,+M#;(#CO.$A(^0JVB8 D=AD)L
M.M]F?MA-V7&P1)](K3)>3HT7Z"UTNA5GOVH2V [\\:OJUV!J*8^G>I $KO+Z
MQ<D<@(=O+6D=FA4D(C40W,@:)<9+S/G0VZI9<6/J=/!B:\=HH+NS+;/%;B]+
M2@!&"K^N4-!]$?\@^A_OORN(+CUO2WA22\_ /0KIP$:4WME0FV<?K0D)<?7W
MO.4R=%!6IBH)K;!>S'?5.O&DQ><S@]7EU6E/9I]U>H52@5V3:[[R=H2?QW2^
M"EF]XPZOI>]I*:Z?^"Z8Z>3N.Z&F)<]@'7/4)>.R]USZT\A??C[SQG_B!-&6
M'*'A8>S#'P8I?-O:I>T^-K(L7=T K+[9^O61(Q.#*L8INV7@!&O8G#HKA%**
M?UJ9A$QCD&V2#DO%A+M_.NDJJ[^$G DX.XR44X<,;42]Q#@?Q'-4+,SS0-[O
M5>W81E,Y?:"LWD1()T[AK]M9]M=VM0<6<+5,9#*6CJU_R"GJ93Y.A"5]Y  '
M^\EPECJ=0?[L8US#A%\AM'B6N9&VISXCV]O]9Q7-]=B!'=S]L=L@,_0-?S%&
MCJZ[4O65XQ<X-36]EQV:Q3*._NOH[_7=+M,+LO3A^)$2?42RQ+\19I[W0I:[
MZ\,O$J/\J SM?!( 3GFU1]Q )X45"K7R[>3O 2Z"+"V_R]FAH#77Y-6,2L&6
M]-V/PJ9;]88P;HXP)E-?:SA]M5I) F-(C! A,*B3][JIF#LY=8-]-8QX@-"W
M12ZTA15KA_&$^:91MW]-_FU8XFE0N-)'7UO;29E<]]"^P9,+JY[C86(?MZ7-
MTJM0<7""^DY+U,%74 PQN0$\MDW#)"*I$C4JD!D<('Q0W[L+VJ8NI3&O3L^D
MDO_MSUST:"EZA5,8_ZJ6!"0'929_8Y2SO7#E?_T*JAVTT_XC_UOR C(OX93Q
M@X\Y]@9 ;6N]_.=6[*;3/P2MG[L*"O#J+BHFGN,V"U,"%Q2"@!/4QLE6OSUN
M7V@R?PTJ>IW*(@66\T51@39&CW[X9;LPD+ #^[()4TFP$'&$R^E.>/CS]:(-
M!(+9^A=ZL<!LY0AMM&P4QF,B8F=K77N'ODP1(%VU.F>)EONLPX>S.V<OD=2-
MDAV9-(?^*W[W(NUKFTGYO]U7JY)+:A-RLP!Y/DAL#4F-X\7H+UG$*43+&A:7
M_M!OG[B4R\G5"O#Q:$WES@W%UU215)T#&.04"8B:>0)U#C;:Y(A/62 F^[K)
M:M6,G/RDYS5Z;/- %$;WXBT>N^=((WX+&RA0Z9"C_3#0%--IK%</5P)'RCZ4
M$G$PBG?G?")0$L=93Z!F:..>.=U)%L ]&F:<L9X^7^*_6VER>N&/K185*I6J
M=TNKWZTOG<]$7YNM![,&*APJ=+E2F00:8?K>^+W+,5GH7@!A@F2$[+^%'CJ5
M.98S$=1&GE#S>W<J#Z,(+8C+FZQ&";PW.>$/:8B*"%YV/HHA2B-)Z(PA'#=D
M(L+?*P[QS?G;CU[1$7[3RP[GC#90=68$'M7 [K9H&."UL)!/5.:EFG^9#5&Z
MGS0D2.;OH4VN+05<ZNHY>WHT\&V]<Q9T#>U+42O0$]22M_,^]49B6>2"3!N<
M^ACO&E @>W,!/.+9T"Z5:]%TC,X9P2Q;1# O7KSI<MHGR [LNGD%/K>:52#Y
MN'E;5DL(Q*Z,D>R$?B!TGY5DMFVFN0Z#KAIC;K7:.YUVA4NWVD)X9;%\-1*'
M7[[LWSA 2Z,'$5]Q$J :W9<_N_^U=P7DSL%\0!.Z)W.).IPS2%![CE=+65-C
M]LXSJS&A0X7M\NP2B>LS?K1S P"6ZTZ1:5W&@VDW@,L-((I,'#;939JMDZ/1
M-4W\KW_X0Q3UYOVG=0P$GI<?;@ %2T>_5<H=".Q<H0#S\EE=Y=HU4>/^&6.<
MS'7D#2#?G")&<(=(CJCUDO$>7Z)Y!6T4/;.-'6<6PC_X53[Z/8*'V1HY1 D[
MZ:K2H6>G@#:Z[TFNDDU+*>@YG&;D@<!@[X6M)OF]F?><"%.'IL!*2SA289@F
MG67N%SB$#-\N;G#J9 -9*K$['-_RT$*X6SX*5%!WOH%X6SZL[?99XT@+S,((
MX3JHG.@S3S ;7==;G\U+R&;Y O*3;R17@8<SLRD+^;(XMH9DX0- RR59=AST
ML(3&8"*/\1#&>S4<KLWW0Z\JK7<6!\RZH.<^*X&R"Q@ZA73,_%<.^R&JM#D0
MSM0>SB:JWSPF.&=D(W=.C#4)=T[(_XEQ3+-QV($*9^:N?3<."W\\0T4 OWA]
MR$A6AE!9W@=$70PE8M1%[]T1U'!U#V%X4,,D>'S1F*W^!OB64969<0(Y">K-
M$:EEL$RC!ZQ6V*W+@1/9MS_5:91%OE. F#*50XA=(%;"F8L=VY*R>LG@PIT]
MA<XL/,"M+41R=K9 SY^,3T-WK;DYU7(=?7%25?4&S=S,W7!2@<MV>S5LP/T2
M )Q9".5 [[U/\IE\O2,H']/&%LX(,2?ZW !-B=K^QWJ>N$F<E+H"VHO%^V10
M3FK+>/<&:,2M"KKN]>WQ5EH)X]$-(4Y!]^%9!;('VI">_$]=#)\U@.*3)6UB
MAOTA3_2>ITQG1S3]^\M5ZR/V@"!@\.D@SPU0C_QZ S#&O6THQV;< (EL_ '!
M_'%]RJW_-,T-BG^W/M06J9-JV=F4)M?,>@I*C$U6>*RFB2!%P4,.6\Y/\_UT
MKL>Q@YBQX2)#]A I<'A6VT1Z3E+3%3JXN;2\A>9ME>:BQ.6GAW'QUF:B:>PA
M'G,4;4.K^HV5<@:L/FQ:74675Z<%PX:[D\<*+=;B(9ZPC7)9^,6I%%B^;K!4
MD&X8>;CM/D FO1)7*I%]ACSL[1AR;A!SVO*^E;);-<Y/(0T?7(<I17*^&;[,
M=4/=H4N:HH0=$'<%.V8]%_+07HDG@UQX)H)^G\B&07IVC.>?DWV,]Q"M86#H
MTG:D1[%C412$('!1IX?<#<#K^#%)2RQ@I\3$J3K,N9<J3$O*R[&'SU3K=-M0
MU=#0P)"DZ9,"SX#OUH"?//9T/:U/T#"&ASM8&?KQ1/):34TT3IOW!DAA.X?J
MXY[ZW6H+GU/7PU(SKOGW]<U]6-@U3*$$EVB9>-4K;PH2<7ZY>E>0O+^& Q\\
M>G2VG!PU9PK4V)(V1'UCW@!.V"(L*+])W1L<RQY"Z/^2 ZWR! R/6EP^O@&8
MY#LZ$7I5Y<?!%J['/!$#;8_X?O6&37$2$\U),=L!S-8%%NM>,9(Y/(S\U@1H
M58"0(RET46[3Q@IB\;4;OU"^\?#SW$I<7TQ*I-)I:Z=\U,5)47*Q1X/E7LT%
MM'5F>\TC+T @^ 88_!?S6(H[P(/<<P>1-,I.7E E\N8</I<$L_)04SR7D[X!
M(C2*6T.[7BK)NLG)>6C+0<GL$U[_KL2'UW$&"8?)[?"HS^K'B;HGNY0[B>/Z
MS'U,T,[OY1;2+0,V&W''!+/\I/TNL91N)BJ,O%\A4OSM&^O86DXK:MWOR:G\
M1/<&B,!@F(>:_R5;L!MD3DAXLY@,I0,F\$R H>S@(>X)HV'Y=UI62;.5E5A
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MF8F!CS%.,LYO _O.HXEDM#U9ODLIP?!AQW"?M[=+'5Z =-&YY$#>9@VT&LR
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M1=-;+FV%*\]J3IP^] OZ89]>7410VCQS.3!BI$)IN"[RR<#:@2D$C*1?=O@
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M.I.<=\MP%GV1O];US'A Q,V^L56T=>'K.\E7CIOAQ>22X<%N)&(Z"99#737
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MD:C_Z\NN2)U; "!#"^<U-(_LVLU"2S=OG^W9MXT<*&D*JH#>:SYTWS_BV2C
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MOY^%/M63_L:F'^0OC=5:]"YKR6;65QO(#\77R1%&'WT\_,V1P+!<HAP^.>8
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MR::R_IVJ&.:^8! J@5'F;/>LY#H%>(FDO3YI^%[#RKZ6*^N?MSGH.^0Z!G*
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MCTML]EX(P8-$T.&]CU#'^:7>E7>D?%LI^C"O$)0!?79WE6KJZ#NDI8WU/1?
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M/F!8^*?QK)2T(GL>63Y;EO2Y?=C)B#5)FNI(\;%G((R\'T^#[<# AKJ8NB#
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M]4S$OJ(-Z23;UP42PFQ6G_KH#IG,0"OX-8XZ'G[[.< W>V4%(3Y=^:@Q36-
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M*7SRHF1[W'>ZYM.)6Z,I_^024F]GW65G8Q*5NE6:K?:]B0 G,I,'O/@R/PF
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MD==>?@F+X7D<7P>SYVB2L&(+/CX4_?A2@294$4^%8,3O@G!.\]JD(\AIWR6
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M(<=DY+2I(%<JH"C$#Q,>?YCT^?:P&-^CW3JD7R,+1X@^<Z\/K=1,_/+YCTM
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M_C?V RG1@%3#AF_KO$*/#O#/;W]%3B,%WL']7A UYZRO9$IZBPAIB,U!5UQ
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M^7HS@;VY-%\GSLZO)7]T:R!HY/NXC(S1WZE%*0$LHS!V CP9\;4Q:7(^9J;
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M7CMD'L^@GA+9/A0VT:)M&M2[-\Z%V-$"+>1N4,;R6YI"^'2?K@@?I1EE'G9
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MT]*A;M/7[48!?'8':^GI;2?JWR&)W:!'^"=8V#DQAJFOXSZ[5M^5<IMCP&8
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MB!T1^V]!X_KEGZ.R:FZ]L7MDS,&E?_[0QY>*DAU@NAZ.5-3G>/ &9/QGT_P
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M5:=WEC4,BA-N)[Z;P#&0IS%G6.OI;%6=0-?#8?J6-%\SVQR]/T38 ELA1B8
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M89M+A1^U),8Z(D1(AS9OC'?\D;T!* ;04M=F22!-<__F]6&SUYY]0Y,MW,O
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M'V^"[+)T5&!V:7K'?"1FA)[7G-T/"]A_9F5P/G$CF=&BM9>F6(JJ#?F[E8.
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MRP1$P!V-GQDK4W;RK]R*:PZ\&];>[?->KG7-)-K_O[/7\^*[KDGFGVX7)XX
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M^YM'P<L/$LMDU@]_&&_>&L1+>+>#[;IE8OZI27G^C.V!A'^(Y\_PFN@/FY+
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M639US;6LW&NIG9N\\-<M[A@0'#&/<!$!%%HHH<,_/M=,#VAY'[^9\VO-_W;
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M2:9!9S9=P7"-_O;9U=OOF+VK\D3AG.;H1FFPRR_UG#AU##^=>PR DX740RZ
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MG.\J59&66%$CL_S LB4:(Q@*I9+A%"'#\1RBC5T2FA</YI"IFC%,T<^6J07
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MI <>#X"1R^=Y3V]^Z$1HZ-^$Q[3*L('@-GE7[0;LI<8=A$SDIEGOV>8\D['
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MMCJQJ?+!0J'VK2=;#AC;6L&Z$(&'1=+^ZA?M<9$R0,/]?0I?HDJ*SZ:(" E
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M]R/HE!#A2_7^:^KV93O-ZI'M=PBCEY >$:W>="*@5NR+LIB6\Y6IB555I7N
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M]]A#=,HD(J*M !NFB?H'Y:R?6'-P-1SGO=)0O,LD3!<N3-+)YHZT0'; 22W
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MU*-SE;"TNSE2?#Z9I2VUQTQR[]'4\B-;"7HAC8X'+^,W/J7+DKPX>O^GP$%
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MF0" 3]L+GL*_"[4?=)U['BN\Q8\"B6\L3/I3)UD03UYQ_;Q!GDSP#?Y^:".
MV/NF!,"1)*KPB-, L@L>6]72MJYNL-S'&T (@"?V H$M)6 A&*E_TG_CJ![
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M)^DNTZAF&FRJN354DR<%)>&R+SCBW']\9/,&@T3 Z#"<?7B6226.CRMWG]S
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MV&Q4]()O\B9^0U9=_LVSIEYC*%:$8" ;82'T8Z+ 5K[_TLK5$9T:*/Q?^><
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M+[60(@' C6<P\^)([&</Y-3UF(3/'HL_";TF6@D?FR3-(0!R6%SYG?QAJ@0
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M4>8GMU#&'1AY*/MEJJK/>Z\B51NG6ZB1>&IN'NG-IT6-61JC9P$L^GX9O^_
M;'7G[;O;[V-LCFPL, 4_G3A)VQ^ '*7!%(?(C.6]5VC\E]]]XRK%_+[N*)M
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MJ!7_QUAX_[*O^+6BH.&G;//60<^2X5^.AX;U]L<S6GF&Z'ZED<(D RUVO=]
MN<F+X"'])#&_[>D&W_:2 _7^,0YC?ZW5&^CZ6+PX7F*7:)G;[TG\-:GYN#6&
MYA&O]R?7P07R/N6.JNZJ>6&=QJ-9%$/A[AOA!8EL;;6]-WF[]' VZ<??9_@3
MB0SR/G\$?"572![&=/?#F-JE]V;HEG;EDF(^2-]R.657W S2D\BV\?U.\S+4
MQ+PRA*@K/@OW'A<'L\O$Z/U8QI2;-&@!:3 94M\KGNR47/YF-R;.%[0"A+YP
M#PP\LG:?D@$)EV?.5G Z\#4.\<.77XUK?6]C6+J^_/CY14 5ZY&=0C^YFO[G
M>L,R'3&W#+H2*?BK0;AJZ.P<[GYU$S6E:PE?^,,/,GI;\<$04;+2#L4[G>SD
M+-:>H_GQ?*20[QJ#7'SKO#MYFAUD)/&/$QZ1.TXR'PC]'B[BW4P\0-%$0+^]
M.G@*5Y<1^NKINP9C5WJ(GX*@WXY18PV.U*/Q;/C>9N$OH>RFYD/-]G'1I0];
M<_62DJ_+7GK(#<7]#C5:T.RDE,7&!5>VJ4$D[)ZLS8QX21$ M\&FJQ:O_)TE
M^7_^TN_6+Y% ^?"](%\I7JR$9+GVH^)=&?S?#\H,0;D )=6GLFLETC0D$;XT
M4S:0'IL;585OQ@J!%B;Q%!M*A_O")91T\;OGB).5?W0KG$F.-J$S$+31 QX"
MH/ON7(3'K&$][T_93H[(IK6&37TW+:6*%A>W9S-8G739CX?'-:!4;-+2>P\:
M&:J>*P Y_FV[)SB  #A,PO?!;NC8ZN\;VEVIDGQ-:6SKS?VN@4E&\5@7"CC;
MT;PA)B[_Q5LC  I9:V]<:P4,8W"N-7BEBR>RG/CO3=E?W/Q)ZO48 1 ,/I=8
MD5)"0()EQMI%>T-O5%*W&;C3@@#8[OL-0[N1$0!TZEA)*)9A!1_O.'RS-FCP
M$3TNY?C&ZA=LK'&L4&X[&*V[E"0%/( ,$@"8+(4Y J 9S$L K#FA(7@6.)[B
MD !0D[0C "+]@9@XX&K%__Q@?VIC",)(1Q( ,87SSPB RS=*M4J'-STC0O<#
MJ@D ;[PN = SOM6/F[P$WHP!](D 0,^LH(W 5Z+EPEC6SIM6O?\U3;^;:;+4
MW RHCA.K\;^L@4T@?A?_1?[WR3+&O=H(DU'("_I#OU+'/["<<]3!+2NS\96,
MYT(A3TP\"RO@MC"+I]A57KJ^9\QPP/KN$Q)_"0*=;%,OC.$IUAMMSIDFF^,A
M*)E 2KH!RS:-SEW H>9DW(K9Y0J>7)CNF:N1[_[^TC7\,OFJZNAP#=E-'0ZZ
MBPTZLEEGC'G:*HJ>[%RP71B+D0RZ+(X^4(,.]Y;L9-,/>PFM]V_TNCAMZ8R.
MQ(S[B6(-<1GM#/Y[> J_HUH='!3LD$!\T0VN%8XZ>*\[+XQH+Z0SN;EMU5V<
M/"V!+'M7-@V7:RV)$\M:N@T\G@,'PU'Z1<8$0/0[7"40401D:A6JN)G]"P49
M)6K\".PNRZPQNJHCA%KOF\H1=?_,"5RDZ>ACPH^X"XUCV@\/+H0\6-ECN"S"
MDI9 MQR:GV4M^,86+9@Y&'*P3:"\0X!=679%A@O"T>O5"58)WAW)/W[K$O]"
M4>3?.MO-&YL\!3_*;\H]GP9:@/(@,RVY"C/ZET"[^D_*=FYNQ)T4:LE";;G-
M^XE]$Y(=,;\=N<V]*>3L$X;O6,<M/([@MXH-?T\:B8R-E54??$J1F$\WT+FM
MK;MQL7")0"KVA[:UO(OY5PJ(Q_[U#."BP9RD1J)2 F?(M")#C-;4$/NNU$NN
M_?^F7+"<9S?0M&>PMB+5>0Y8+UTO ^!M(M] $ 1 I?:52*^=P5HQ 0!BW+2V
M8WWQJ_T4?OT_H8[S>?'WV:@OP=_ ZTC8.A:W=YSG8R-Y2>%Q_NWRE.)3ZM[D
M\<X,S/#FE/T$G3P$SV)A5\S8\N-?!E^^]/.R"M-OK),*M--'R)(BV)";5T;G
MNI'E^/O;ET\(@&.[ KPECFNI<9C^HMX4\ADK2M[X>?@$&DXG+_Q-Y18S#R)%
MC!S5V4=.-F'RKH"O)B)JG8ZO(]7;_X/P=5L_T^##AKQ&LGC1+",GG_8HGKJ9
M2GU6X_PW/Z6>OI7I0$20<5':9F%LSIMP+5C@-;<_3!LM]/F3[9%PS(=XK5"W
M/_K+W8?/)KD?&+H/<S(Q#8LBPJ^?*6EZ-OR7;]5_/M3I%/ADP%,]QR"[1'NH
MR.S58)/TAU/'F8G#D*K%ZV*IP?<<9:S<.\>O&P:]F=]17D\%!)'31IY09L13
M)B>*O=RF:"FWDF:S9;/ZLRNC8'6T%S^;$$R)J5YU2[SAXD^5A/V]E#^Z5%7V
M_BQ?O<B)^7W(1"UF&PG.:/2DD,L7C/Q'2U:-$*PBI:3DE^5C)7K+X55'I:.C
MR=O4)^+[UA '4:O,PH[120SOV4WTC9<_:)NF7TDK\5EIF[D0KQI88MJ)3:,.
M_3\H>\^HII[H;?0("J((2D=*4$"D29<6"*@T$1"I4E60*KVWA"(@O0DH4E0Z
M"*$'*0D]% $% >F]MX0:2+O\[O^^[UUWO9_NA_ER9LZ:O6;V>?;S[#DS0X#-
M/T(5Y4TNOH0R^G.9OJH,<Z#_.LLN%,!SV"Q'=#Y+^PN94"4#EOD"I//79]BD
MK]SI1(7_[E%-?;FPCP<N &HCS'H(J;"MFT8&BLL@OJPW]W%Y_^;5$NX/#Q63
M+NH5\]AA[;J:;A&^=(W"1)2=W 4B18PJ2:1MYGJ,HVXSBKJX58<K=%^EG;GR
M2[N/[Z8JNGAB!&4'62A2@76DURX7?Z@(/7]C!5$],UGF?!+G@-$D_@6=7V#V
MI3.3W_X7X'BWI_F1,QFXI]$1PE>_?"Y&@)P[D8&2P^84X1B/]NOM)+%GWD/B
M"FDS8P%O3-[ZL_8_;S:%&(.S%YLH)#V5:B2%VK9Q9,"D@,M_&$PYK,:WO!E_
M"8=?/YF"=56L"N8-_HG+QK;$&5G/!<U:0G-ZEV-^?W[Q9#Z>YX[F,&6NN+K&
MX8[3*(WA]%/F.RTN2)_N["B6(8]HT]['R50+ABL,!=@N%0;5-O1ECW9>-^KX
ML+^!Q^<&[[]Z_U.P3XN//S[F_7NXN=^5@]6?AR^=DW)A'F-/C;[5UJ<B$^;W
M6I&!V=87]#PZ%\"5+LYJJ.(2%HBLW;Z0MQD<[ \JOH>;3GE3!/"U1!I[W!]Z
M'-6?$LE)H5R,H\13D\9@M:!.MQN$I\1PY$,GA=;"M<\GY? P,G +?F,^XBF0
M6I&;(]JG_2D?_9G)><U&V6KUG<G0>5W\>.K[A7?!Z6 ?*X_MX7Z-$K2^]9_Y
MG1!V""6893'4)K]8Z-?[-]+MP\\P>I5ZI3*XI$3FU[0LW ]-TK4$!>RR+95,
M?"I0C.>'&Y,OZH/1Z0]WON_DY,8^/0TTMT3UXL06D@C,\,42K%)T)VB:LJUI
M?J<9J^M<_\>&6W)41@XL"W>6>.I2^:!N5G=\;JU=>KHYW?'=:F.CV@&[I $;
MI%KA07/!UGB54].]_-<5FQ,GW_=Z+@+BSUB\3N[?]SZIBG$:J0RFDKO\!^XS
M/O";N#Z,V"+][HW%Z8O(%NR$>[L(X\ %&2.<':5WO33KR<#[J+'D2.T*69,H
MOI:&Y*@ &W^QNV^GOAX.0C6=\JH$=MWPS$ZG5O\=V.M'\!WS@4??M."8AD_:
M+#TH]*EP++>_9Y^&IS?Z6X#Z&;M%#;&K0\C>[*I2Z*$HD2'\U!\MO>KYTI)O
M9Y_5A;FB;-H WR1YH70D7:8DW,SK?AH30>DYF0M07'MI?9ND*D<?0]K/\%VU
M83X6U\>4_^RY6X5>^R9ZUO#0_EOAM$^\A!Z,#]7<G\B>6)9MA^%$6#OC]IG,
M@KF(/UJ8E]PF8<O6V5G!YWIQ.[9)'6;=?3:T" 6KJN8WM^J*O:'ORLJ:_3SE
MB2Z_CP<A%J/>NR:="E&?ET(8=E\$B6KH-"%^&K@],-5N8K_J,]ROR;<0ZO7;
M9L<D<YEDAYP](23^[OT1_SPB(CYE/C%T(=L>3(D[$GG0YOD/H'L9Q'UI>QYS
M?JV"MFI8*#O&-B9;(GY!1>52>EM;+TE299@G4<+8]KXF&SN80E?C<BK]BG\[
ML+!>J'<W8A0.WYILX1_FMJTH-X9J*8?RO9'D<@^)'AU/V)W\F-8&T&EMSJ73
MJJK<D<K8HM9!<S6]J$YRG$;(+0.4S=1L;4.>]^];Z!%'+T@7G PPJPN0-LD
MTH0,Q):@+EB=4@&!# Q!6_%_\/-GNP+K*@Q+L+T\_"H,5R8!.=4C'J (1FK_
M4Z6Q#UNOR\L!M&/^HUK[Z1=<J^3BBYN%G/:3 :P1Z_]4@UK)0.X(U/O2@_^W
MI_P+?N=-!N:%R4"WH?7_TP!Z2@K2.OM]N4 G(EUNO^/HHFT)P[OG[ V[0QJ/
M4STE57BPPY2E"^=J^/;AG#MHN;[U:7B@,8]0N*JO %]V*M6.JTU?CP9U2E*A
MFDXF?*/MTT^A:8OL</' E?AX=WGEA14&N6W]B'MR>.2B!M=A!BB)4AK7\>X-
M(&]!>]RW\(K^XZN5%>^^S4'P I8,;/&!2 C>^,,DLVX4&GN KZ=,G:CD3SS4
M".VCX)_]D^3L(5W(G),J^2U4)]^+H8V"+O BR,M<D$,O^J[AF/EK9."M6/34
M?@><PQD*C-W#19TT)>876VI3AJ1J!R7=ETZ14^3W_/:06P5(]LC;M+8$M%UO
MRYTPY?G\BE2I3O@N*-,A17O']#1XAI-"]PJ,!H3Q) ,$INMM*,9@K078O^G%
MD".K>]6XH-*&XN40*'OJ$F]Y/=*F1I+*3M19I/&5)OOCT$L4R,-."\2M+(\'
MMQ.>R2J#<OH:/GXO*6GLT3V-_U(J?'^O8O#W&;=(]Y^.M\=;3Q%\J<X9FP]7
M68Z"A.]O;T$UH1V0^HG=UTMZTWHG3AA$C+(\;L#B3R54T/_%L/'(_G%03^+Y
MR+IQ7:)ALO3J;7GF3P\]K[JJ"Q/UI$?  YEG*;E&.O'HLOB,:] M!#@^7,\@
MF1JW1%# [L<@&8+U<(Y8B,;!^/[B7.MW7-')[L.8?XZG[A8_5*--B!.*R%/*
MQ!NPLGD"X^E))\X-[T$:1M[$S6/PE@CD7[AWW U(=Z""'H>%X^W5+(&I[JZK
MELDSM>KM'ZYUAH46(?$]NK?+/RZY^V?)09_=CB_]^_'U +/@0;^DQ]-Q5S!B
MCM T#?N"P4L4QB>8]L"E'.M^YE?DENN-:APH'S/<H9U<#%RYE>@Q/_,"\HL)
M/GCHB\ZGPY5)6CX2WYMFUM@WY/3J[:3,I7PHS]V2.W&'YQOO7@8_;+:-\H@9
MYW&>HO7I_IW$ARXB>I0.ZY#D(87$''7!*/\PRE^JJ?TT2B\-J_6'3)-I.HXH
MY==CS\N[F4RD=.[U+AKPAKO'QT+\^5: 4#\E\;EH;K_OP:JXH*7=1V1 #Y/W
M@2"_I..F.KA_XONE1%5IK* <'Q>5)5=D9_>AF5?0(**]?2FS*D<O0+AR%V;Y
MJS"V6%V7P3=-ZVA[9(K[&_,OD92/*9J9'H^@SU5L<MGB?2@OARL>=C^U-!?B
M>DRG]TN.RY-F(=O=7?>20+;7ZKE&4C#UDHLNOK,)$N-]P\NPQD\!F>,2=+5Y
MU/YR2\I02M^GEQ9R*5=?T(9H43+\\R<#;=QW_KJ!E?)Q28_'ZUUN%,AF0?."
M:_2* K2:-)H$Q>5B'UZ)\U3$O^@P:CJ%T>7Y;>E-E)(!20+DUY%Q!G],D>/$
M@"X["6OA]9L6'Q$Q75+*HOGYL4A*T\?#2[-YF;RI[A2I6KT\GN+NSOT[I/L$
M^;^[/DK:FEAXE!WBM_W#J9."TS]<"AT.?1J(GRFKIODY%I('VF^OKF>-PQ@W
M;BKG1EC]J6#M8CG85H#B>UO*!^^UOU@C[?V)CS2;>;(I+,E5]L-K(O;\1[/V
M7N#Q[DKG]M^Y ^V1 >CIH2*Z$?%!W<KAHU8:J!_MSJ79H\>%MC@IQ#_A?O-D
M1)T_A;:4VT]1_2N5!_I:Z^$Q\ZH[01\75+*151SK#6?9 /TSNYDA:F"2L<=2
M4V7TBCN LY?IBAV0K.:X,2>)2404R,9(PV]MG!=ENKP:T5XR=ZX+NK]K3Z&6
M-DBGK_]=?N"A;[CZ)4#PM5!EUKDB7 !W2\1'>++A? \%Q]W.C3H4><?H\0(=
MFE]N([?9SD,Y03F::\XUTF]K.M-KPV^K>II\W,[6QV?[5I5[X>B :+Z$[AQD
M[33.%1\/]EK<E>TX/:A(R/S CPI]J>=M*_%-:Y: >+-PA_-@(#=?P<PM@<!:
M4CB>7^"?]"3'9?=NQAK.B67SW4G->]MFWL$IYCX5OAZ:=ZY]%,5;Z=P9B"PS
M>%[0AL:$H[6/ZY3U/JE.B?)7/&4FAXJ(9\!5*ET-"PKE1NZ/W_UOK@S<OA&+
M1]SGL/PHN/(J7&_!7V[0@]5*%',<]F1,QH5E3&QBL"[@P;*^<@96JF+%!B:>
MP4=S:4KC\C)[YY]@@T44:Z=7R.*L+MIRM"XN<_1>G-Y/!F)A<DE\.2]G,EK^
M9+:MVPZ3SC&G5U2Q#<OM@;.J'2!=8UR;+(X]O&C2OS%$W/WJ^1/8%0#676<8
MZ-5E*']]V(%7O7X6.9FN/J)%+5#-&1\BD:RR8-VMP/1F\^VXMX,WD6+N\1)[
M07.,P @-6ZQP],QE?Y'RAD<TBIJ7%\:MHK'TBWEQ1]JS)EK8Z&B"QK>- <$Q
MMUWXLEMUR^NX'VNRQM3N/.7+N?+=<HM"ZB?-?V"=I+#C,NM!7/Y?FY\Q*SXO
M>>G9C'G$KS!'6^2R:X%MXCF)3#,]O(?/%M1RD/9S+R9[_H1E)RHE!IGDH9?T
M:&?F5(NGG,RXUO)/'. ,_3<>@>J*(CT+B$A;A@QQ]#5V\/B9RED[V[T:GZ0X
MU/5@R4W''_[#G2PN'G>G'<?%2J?9Q>S</HJH: 9/S+A3:?4J;>N5&8W.$L2:
MCT@_\->W#6&??;::A$^58A_V4XE<!4>,\B*."0HCM< /5?9K>OJ;IE/!,1[V
M;C)U6#TW!9JE5$'F9=MD"@JYV38N8!G^.*MUI>'W:I)\&SM:OD>=NE]=TG^[
MMS) K4=7S+\!N?Q->L39#GZ:&HX.W=%[1D%_M(PEU2O8.\QF'T[ #>));&6_
M?=@66" I\9S05Z"2<F^-I23X1@^3OIKK_]Y4;-BR9I(&@#[%WVP+I>$M!N_M
M48-]R^MO):7ZW4K54R40FU\X;5; _UUCZ#[YF'7/3E7D761Z@(IFNTIGJCRO
M4N!QD>A'E9[NR8)$^EKVJY9#C;Q>@1*\'I24/&'):@XU+AP(QG@?@$X3U#LJ
MB<P_9,ZL#O=;#9$Q-A<7O!#W:G>[M*N> ZGBS!EJH+89>\Z%7=ZPB-[B!,E_
M#Y^SC?*WU)TQ_;SB5\UF]ZHP4T3O\FFW==(>?3EL0SW/;-+W@EO]HMV4WI@#
MW:&)?"RLCBVC3EJ;V7H?;A+ ;K="0+.U%;>FIG=H_DG%K_B/&<U3?GL+Y'K-
M(Q6OM:IQENNP9"*&H:TJ^3)9_9:?9\%=*JO72JW%4E*5[;C4+Q%"7J=.R74.
M,S+R"@S)!E=*$!SH9FYJ\3R@ >>F%ZFK<DE>+4O U[ Z\EV* CP!M #B=6^/
MGI74XUC'2N(75-^\.PE50?]?\DQ(HW.6M1M%*8UBVX8*-F-.X)CB+A:H*"8Z
MVF!0 1(OH\W1:!^M,?;]0X3'E<ZO"3;KEV_5IW^!W")-F)DDH1S@_T"+ KM2
MWW$/MR]8$1H4A9#0^+X9:,$Z/O#VU2F5<-SL@YY;3$O7C]P@[V+N:?5-_93!
MDR^\APIGWV/<H* 1"Y8MQL%U&0O;_ARST59'QZKT>?_H?F/-']Z 7L6V\2WE
ME?A[/?[[X]6?O:/K[-[:FOFUHS_LZXU'3\H^C _NJJ S;T=>Z_:]41C!<".0
M28))T*"HD..IY)JGBV6ASP"T]'AS+>!3MI)3.O]]6;9FAWK= 3^7^HV)!1@8
M=8MTU0)7O 3:06&OM\_=FF!= G4DA9]:,QYS.8C^\LT5GTC30R!1#>-&CPJJ
M9RS9=<>4'24!ND?KW=Z@F#D&K%^;V'MK%I)LL-!X/LZMA&"'O8E+6%1L%MX7
M/#9]4/E-FPB6YG9/B.NJ;@G]3G^?<^_1_-]@*-O(;D'XG<*7CT5;XQS'4]%N
M-Z\7/6MLK+["N(*X8RP>KS*5KZ3CGG7:00: >?^0%JDR@O)OUV!V&]^G&]][
M[B$0\SRYEB^$O2F]=Q7B/QHGA_6VK[?:U8TX.F35/G4VFG8E(NVO#_!-NRBV
MSL#+C]V*5V!25E(X@V40%T$2YU@8S(5QF45$DH1)O[.RR4#MZ?M@'^ZO)]PL
MF"5_/R,IFC?<YIW.7HV[=!14;Q<D*_V*,59I%S,;D5?[PK]8$TM7CO%:..W>
MU05-H3H?5L_W+5Y7<M1ITL[7L*F;LW ,6VK,8J9X5ENRT C?; !=Q7FY1CBZ
M?=]4MH[*$M5H]]!X]2JN,V/S74.'J425FN)TW8>MK_W/WE?U4I7I+8"N6$]M
M(3FMKSK4;)K]W5WB,AX)48+4U.<\>L-<Z6/ZE P46"KV_/JE\:OP95@I::P8
M\2 'I%3A<[;K.MQG :GEJZ\-/*L[MO(-@>ZM'X8L0:+GZ'"[F(F32,Q)V,+P
M3?_')TJXSQ=VF=U+XO3#:)?-30Z^%:U'1RXM:<LS[-UY.!D1TJ.B*<>9&7[!
M[Q:Q'"?VF L%$\RZ-'S=W_Q$!FL)CVQA#O&Y<C"P]$54P=2EHFC"RC]#,3H%
M:B(>2B>NRG.-]$4$RH;3UAU=^/VCSO+>M%H6QKKO:\5W,F W;?DX*ES[:BI/
M%;./\4J5<+*>JMGP0A+]P,EGO6AO?GGM=(<CW/=D)TVZZ2A;M9G%_E35/F'B
M<NRX? 7$+C76Q74F?=_9:M_D8#[$U=.D;\L0SKY]M4)TP'MLKV'2<FJZN!*]
M:+VC\!:"H-Z]XR$6ZSU,-[,U)X]JB>M \HRZVF#-S.)R3O8= _$\+K<7&,9C
M$-=D:1N,42'+)F_]LO@:O'QNSJ<+2@JR>1OU2,K+]U&7+C6:B[TG44=W&?B/
MZU'Y.P8[EIBKL10OL8F\$#5['ON(]]D7DUOK5P/CW\;T\?ZN$!UA<C;-?5Q]
MFB+'1V]KD^RNLHD&Y47$=#\JR ZPJ#=Q?%G>ZA-"!A:/E5JXN;WO,%<L5Q*/
MZD^<6^.2;DXIGZHK!::+QF/H^4X65GR4G)[I,P\\V<<WT!HDS=)25*#9N=_;
M^BPS?UV7"(<TD0'K3XACRD."4W;R_DOVU13F?(E=_7 M]&"\/5O;=KQ'HI>%
M[D?E6IV#6:L3LX!][Q;"D6(AS-[8\0'TI?#Q6C.BH@FJ,33/@N3S9UU,#T?$
M'IOKW$/KB]YH31CM<=EKZ3 *>]DHHM7>HW*F2KIE'4D&ZJ.:%R",_MM:<8OO
MW3E>+J?";M5GM-.^?.MYU_1AI#W_\%Q[.V"[:SU&/^UW\FH<YC#+^KCFSX.5
MVK1'Z6_M7A(B!(;8TO'-)^7KC>!PA8D5UN[A\*;,G;.R#2NNQF;S06VCB"%D
M8^[S%?3M2D-YX;XK49(>?5O^I%!,?P-#SM,]T_1'WXL^E@[5Q#OS.\NK-FMU
M[B J]FUP>3T[]VQ$7.GJ[AM6$BN@9BF%@IY%\Y(O5D=K&\A WC2JQJ3;+11Y
M"2.Y94:8>A@)YR<#_P8'%R,?%#T'$E(*\3],D>9R?1:<R?3;Z&@9'=FN++H<
M^"8K9GZ3=7Q;FO7J8RH3(/S:P\Z>W_\(FFW#ARC,\(D"DOB-('KA9)\%$+5)
M)MIJ=8PRR.DOCK=6<PP_7GDJ<3G4'\P)AR!15,' /#WT-LZM7?;!WI1:O'M+
M9-;C5F!&-BR#EZU/@'>:_0S.L+%ZB#;*!;'N%@N6#@K-_(F:VTK89PXQ&=R"
M)BT\JVX,YA.(;3?4::]_87AF43@(M=N9/C48WQK0^+GE/M5YXD^8,*;M,/W<
MZ-]S]>!/^^4K&]\2?4.EVLMI.-W#L5H?YOE#_=Y5M]'F!]FX_CG5O,PISEO&
M(>>Z&/,X_9+6<UG*B9Q9<4WYMLOV80:B96J@Y,J7)!5)NH>EPY0IO7NZDEI*
M-Z!FJ<;U=9-PI:GC&5+JQ]</5P>PRBX,>L93.ILUZ4ASV@?%/T9H ZG6E5M.
MT-M/+[U.SWH&0^H=D('M45(O&5CA?YEXH^P2WZO<;WI<0;1T6@N<(4(_"V=3
M=KX1X/MJ.DED0,F6P$8&#&)5$N8<FPX/Z3[M1FP3E0YA?:"YB[AJ0KA_H'&*
MPHZ1@6M.GE;0;SNO"7 R0$$&HJ3ZE>6S;-HV9E9R(ZBS_002<5QI U!8$.0Q
M 3H#8X'E+9LI:Y).20JH18U42"L92(3C#-9#,I=);TZ84&EDX!YLS?[LG0=^
M$V^_#BD1S<T)#/30O'5AM3G$@& ;&)@R+[<\OYF_DK0/6RXG,07PXN=Q6V0@
MDG._A@#[I10IMD(&^O+./D^#4M:&>R#QIUPQ<LJX#8>#>9Z T?B(M,9LG].>
M0)N\SD3OX!3B/L$'UI'$]]\5F%S6F/R<,^JJ0D+>F109D (_:>.<T8460XHT
M#@K_VT TI3=,>=0#&0Y$_1^=/W!4NN@6GDQ,$)Y/LSJ=.)!:J8U:$M":_?)+
MI?!S37]SA(L17_R*IT>VQS\[;7/-Q2_!_*FWKB;P7/TN/:4.\N>(3Z0SE6(
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MGOL<EWB+E*32VY3H2Y2(YW]=F<(]58<Y$E6'K:T"<ZF+=87>/J-ET+-8+A8
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M&U1@-;6S7_?Y;.IWESU=*4:?F@G+S,D8P13%9.PPHA=%E(*0.8L?4^$LD2Q
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MK.2.:'*;UD<M5K!@%L2^)*5'X=Z2ISJ -4!TG&]=,;EW(V=Z ]SM)?1&14)
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M[Q[DHV W]]K:V41<'=0COCFN5F7X"XI]:RGFKU2;R_44V+ B>U+G1<TP (L
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M?('0[)I4N]1A9Z5PZ+PCCC+#KB A[1Z)I'OY*:Z*2ZYKI4^GC@ZP8Q3D-O?
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M#J2)O]?[+K("U#3C[,H7CS?,SG(M@_MF-D^"_= 9J'G$R"W;YPRDC5"$(98
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M_$O,(+@E2NJ3]VKP45_@?"NC$XN*5QCN-L=BIZ;T5=\Y:'+Y>AAP$UA[S"\
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M#R0I1D5&+U'3!QYNO9 ;P]5=O<(UR3&&$:1HI<013R5+Z^.=?7=JO!PL^GW
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M9/WC'D0XL13H4JWC;U4-6HX]+*$#*B>5>Y[&;:)^/BH97,"TPWO")8#8_UO
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M^#?!"%%CY.O@IKM+3Z+\"=2 V:DUWF%CN['-$-!Y/@-4)JZD55ZCW=AY30V
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MO P!_0YT7$ZA\)@Q8JX=<:WYR2Z$ODV@AO_]T%)>9-Z<L\8[,CV_&;I3]T$
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M.\[@YUX@Q!#!5/ DW_=Y<TW=5(DERD4P@:/*Z]V%R&&-7F 6NB*W6GJ2L8Y
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MO;E@P^L9*,ET'8E(23O#,SESR+>N\ SF]7V_YV/;GXW.T>?/ZSSU-!Q_[?F
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M7CSY(\'R1<CB%<Z2\4%C1I7O$/HZU+WY$1,3G##!Y2=7LH)[<4DJ;>U^472
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M \C#U(032?_WF]G_T-;'_P!02P,$%     @ QZA[6DAD^Z]5,0, #T(# !
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MX5B#=N"ZIW]?CZBXNV'#7SP?5"/O^L'/6<\59"9B",6722E#N6QH-W@M?.J
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MWI/IK-D>7O=[8&+1O/J1YXFF: Y2;MK#*TFC2J_C# @;!2ZQ8^QG<>&"/:'
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M9"-0QSXD0V?[Z"(:)4/1Q;;)6\DZH'Y>[93@$YS4;'<?<[)T-/VSUX&B2M]
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M'24Q5ZTD1J<:].^H2U=,8N"I)%W>UXO'(!3P,^DM8ZF<)\P<!PH;B8_/#XF
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M6[D0[EAJ<WA&K]I&5PC$TOJ 2=I)+PZ^"CJN-(?7)Q*NDMK9 :A8$HV\00_
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M?;NT\/5*\U/CJ7J!<=V-.W/CR$3F-+3$9+9>T/QC@>S*,L,=]Z*:$%M5(_=
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MT'+'T7"H%:;?X.=-,R.4KFQ:VIA<F=:DHZ*_D&H 2?LR.PO,U1,!=%\N8H@
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M3DWAY= .R/8R;K[4\#@JW.1-'/37IKO1OS]P>_+=_WM+E,[TG3J3$V2PON>
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M_N?FM!]Q)3=JQ_2/_>)L_\&Y%LV#+/_1Z3T7C?SO'Q^[1J\4'UD7HO%_!/>
MG<-@^%,3^B]_%.;B2ZF)IGFS;0Z9.G;%XV]M,$]Z2$D?S&^Y/CD+Z:>*Q@'.
M.3ZJR(RN_U;8-/*2+(JXYJ]V6.;,I"&,*5IHYW;+^L3L/5CN>PEE=42V62XL
MKVA7(R]B@WD#0;,*]Y'UO7O%&LC)'F14@A=&@!SZD#%M8D81!WQXS"IO@R!.
MT=FZF;QINA;_X7NRIO0=>6&Y/,\87WHHH:W_#.Q?-^O.-*/><:EAR-\M/12Z
M*VX9E@G:?XP2-QH_A4? 6-K$C'V'UG1#'Y\)N$8NL]9$@FL4Q!V+!ZOG;WYI
M;]N'D(0#*MUVA"PWO)PUOT]STDJ/"IK.,)-G8 ;$YX*$9J/IQP8X(#_ J!LT
MGTY%[$O5F2M0A=0I^KD+IU>077?$ 7@=6[V]>UCJ_ICX'J;(&+.:^TAR4)9"
M/"@WF!Y[FW[O6:%I5Z$<UWIH\5)M1$6L);47+#J7''D '9F?GDZ[^.MDU9#@
M/& INAFCY6>?QIVADLYX+8HA"S3[C9H-/VJQ1]7XAK?C #()2_HW@7+(_1<\
MZ9U#9B]=EL:6JG! WG9R36!^\N!62]\Z9'\'HWRM-(&]>RV#5(MW:7FZ_BB8
MRV%9":D;NQ%I-QE(ZPX)HE\TJK<9[)39WU*RKFI*JF0ODI$\U8G86LQ[G28_
MS[\[,UD8UXB:S OSN-D+^XFXPWWY6C=%:F*I% >\WB4'+Q@4(NN[!3YA.71_
M!*JA#12';^&:Q4$HV0'%:KR9JN\LM*S^K H^MSZXSB=K%<4=B]3' 6&1U\_0
M.2C:\^!)L)UKI*4SVA-%;CC5 KZ-V0.#GO/(DAW#'<5#K@!WH7_+\AF](Y3M
MC+P)L'N0#D4LO^_.)CH/@JHB!=M;_UI>]HWN,;&76F9$F4E7DKC<;XY84F,?
MHDN@]_FJ/H!@=T&#SXEO%5%G*[AC?C0"R_/4%47;&?RX$95>6/?RRZEWUFL]
MRGRFRU_E%:29RO=$!/MDZ06H#/D/\])*#_[,;MW+R^AUG\FZ2)WN>M;V/*!B
M8:@=1.9%Q>#K/7T&BH$Q!CY?]UO+ZF#LV:I%]L8X'1>,SKT3U>3RC5-7.PQW
MCG!VU9C$DIFN.CL:UDRTT5P_FKVVJ]AIHD6'][X:9OLQVWD5E-='6?;9T<X@
M?5E7077E_@,>!0X!XCX04CM@+M 2!Y"[=BI)CTE8?LK$ 9_R;BNE-A?.LA?Z
M*@J:EWI4+"[&&F.;?K^9K4XSB;3"#RF];R<=&O@:Q=@]KU.6]V_<=V4M;3OL
M[+&P5FW5R?LI881KC<.(AJ'HDJY@ZO4W!B.>+)F"8?!6.FS9/UB1<C<._\?\
M9X6R1V<+VE1BR*.#')16[VT6L>N$1043(;FE5_#;N-"WJ-)CDMCDSG,0>9Y>
M=)!>3[61KJ]!E1[7JOXHV*(0KB84'O3C4,+C\9_J+AJ^#>4_*LK=40*A [S0
M/Z!0+#NV9_DQV@H!C0B60?N@[I*B;?/W7OIBNJX^"=S4_W"XX'#>/K=/<2Y(
M(GK'Z!N,]RH/VK;=\KNE,=/4PYI6M.%>&J<*W;:_\!=E[9^E  &0B"XO5:@8
M'CG,*1L^<IZ37QA95DN(*]%1R.TH5K+[F.E1GW-66^$R](R;^T>IR\:SRDO-
M< 4AU>Y%4EY0IR[G1:]#.8GC,_/!S*#N#$-U2NV62>JMX=197P*N2O+V@>)"
MM9>#C)X1L4]"ZW-2WW:WYTD1T,C;6#5[OOX4$D;\_N5)LQH@&*;!(28M].<R
MCTS%N;^!F3=7X-<I1OB: (O7O3OXWV1V/#A 4GA,5T3M@8)*N&#OCIE-6H-[
M+2S)&!^X^7O?P_B,D^3K$,_^"]/W><G^WV/)0TAMJ<+(3K(YBG9ZGFZ1> OV
M6:7]54OZ8TH8']C\VZTYYIT<[//;240:#]#[IDO]G>'Q!OD6H/%2$Z_=D)<W
MA$A]Q)'Q$1_8@P5\>5YQ,;]V\'"Z-7.SME;S')-Y+;FO(1CU@;/.LTG@0X34
M/_SOB9*<GZ9[F>+C-[^DCGC(Q?[ASM6KT?*@'745I!(?6!<S*M2G#B/R3,W>
M^GZ".%FKI2%P=ROX'H_?T[F:PO9>(3%2@UFQ8SW_O?Y"XRRWN)O:DED4+R&"
MHN5T)U03F66Q[XJE@ZORR)H_31EW_)@>5SME77#FN+U\&)I?+\[$.B0M4/?>
M]@U%7&)TL"9"874C5U6TV[V[TN8;?U^8JC]M=F#/[T:%Q&PW]1[%&./KK77:
M"=TUV9U$\=P<W=.BX+>K;!Q47 \2;_6+( 3)A .2?S@[S9]Z<_W];B&IMSGP
M)P::UK^3?=I!P-%X-94XRK4P<'_Y?*B*Z"UII(CJ=#LQ0$/,Q?8NEC]%RR;M
MHBX#4\H8M+*, _Z0/E3?Y+WXW?L@IE=%O8.;DW,C1$,A)6CG7LT'ZR<=W'=L
MV!C>>KB-!+]K52$HYF*BJWGYOQ<:V.&)=/OY&5\%YB6')H\2)GH>J"N9+_A2
M:K@!ES%[N?*8=TD?KTTO,TT,S3,6WVX*P/U-X;5"1W]$J/0R7U"I7+X:U^;.
MF:@^K'FWE?%&XVI0]\3IT8]8G]O2.X^:,9U)'T$J6NJMQ&,0?E97'X_5!9>#
M5L:M_BU,^,TI#AB+E*,Z*SFSW.3ACC4&B(+?^B.^$P:S>:Y,*O*]&U1G#F&+
M]Y!M#Q;OE0M%CU>E0@:X6UU@FT'!JM%5UX0X( 5FC0/,[^. \1 <('>C\Y*B
M!;K*=7H+.K'@KQ6#."#D&2R6@=/#Y]FBAP@S:SWOD37RVO'L.?A6V[53'<?"
M!==5\\SKQV\EQJK.K3,P,$ "^;K>%TNMGL&=31,DOH*^/5%_?)N01H>2*$B$
M'V\6!1[>];V2QJQ@^&='%7ETK\F/JALO*C6G)3"0+8WG= 8A>L_I@/\V ^8V
M) [PPP%JQ&?_%%%&O^+S!/-NZ@[5.-YM%]7IUEM,Y:YLPI4#P&J7X+U#<"X8
M+<N(?2%U1+B!KM=0E&G7:CG9&^@_%+7L+'WSX0>9'X:"FT/NW0N??DQ;[I>*
MHR,L>2.2"\%[P([AU+ZM:!4: >O!"L*ZO6?MWX*&7J57+D;>J><;JA:>XD!7
M(&96L*3F.. .@ZFI%VSUSN NJ1V;3UT2^,O8_BA?S.>!U/1>W]$7@.,5IMWE
M<;\816$KQ:38]Z@R:8/G.AH/"R1R)ZMJ9\Y7IBL0NJPR6HKK;(,RV=7")1;9
M;$((XCR=F9H?]4:WF:O)! >0^#EWG)">LKEGXTT%H');3Y:>L;:](_A]1SP^
MIX@UE(N0(_^C[*Z\T3(7EM3ROZD65B%=8 >U0E4F#MF!GBZV^(_ Z; "I$,0
MOIHG&EY][CW+3:%%2^?QF[D73WZ$E"T1[81X"/?*B&D!148:"*X02_-G!I]3
M+7W>A-0=%.1DVJVE(!%Q#IHY,ILR/V5,CE_ZES'L"M0'R<$(R[Z8'=0ED(*D
M^J<U-C;8\))T]6"ODYYK$?*1M?WE>J)#9LW,U4:J2 I^Z2$WNPQ&[KFB'ZU8
MHNVT(>## !PPZP1%G?;_7,"2VMZVF]4%LI93N[^Z<?F,S1K;S)8BTT]<1Z3\
MRT+0[;E$CN DT:FFH;NVQ)GSB@6<IW$Z#CD:]TLU,]$RKD7?8N+R %ZXAU2B
M=/2U<!73^M"!O5165VQ0E-U@PV"FHW_7V\B'R ))?_=ZQ>,]<\$LF'1=- _D
MFLXJ;X%W_Z3BR5?"P7=!WTYJW6Q?2MO<+*;6)_H5\5[3#&')N,-A<Y@W[J$#
M&B$W#WG9Y>SVIJ:G45IACI*/MF08&E\%GTD>>?D/6:P@MYB@E V%8H4%(3U2
MQ;W#KW,3_.;V-C\&/LP,:LJ[$R7-DTABWDTILZ@NVQ=,PN[[;Z,F@GW(F26Y
M_8$D,6_BM_ QF$4+Q>P2+Y;4_M8:C K"[7?-C2I(%D%HMH5&!!=3X6V#1K%D
M(M'0$)..0[R$D'U*C2_G![/%["+N%KQ(DQ0<$,E&5KV2FU6/F)TMCKY^NOP(
M<B+4@P-B>KW/:J$1F[5Q(1VFK@)P8B!$1TS$[VI; 1'K,X<@87^@QGE*)L(H
MRTM F)TDI@9*"UK$ 4@M2_2C.%C6N=\T<25Q/ 7HTDF'4N9,AD#A]2VIA9E"
M.I[+\>ZC2J6(!>AL^]E2W,]#V_NXO.77FR'K_,AG5CB 2X'^"C.&.1@^9D$B
M8@IGE<CI4L:%-+#>ZFB)G^^T3"E52?\NR6'-_!%PDR3Q1R\?M\_+*.*?8UK5
M&@B2SRI:H-<T"U@R41R@BJIX>PS^J+;6T^6Y"Q;?C?X?&[%L0+ID'?MRRRBB
MP69:B51PIITW8'H9H8+/U2_H)3+3+G=6M';R*_Z[75O[^UH&3:M52(^F(=J6
MM$RNU?_@OVD)N1I'=#^WDLBPJW0HI"@2^7M"'<('^P;?/LE/!PNS;6Q^OD#P
MMOGM] 3]M[)[[>VWC@^!(-@EQR>9(OLYX,=38^#5= A2KY0&8J?M]'&/(IR)
M"W0\%M[7R"[B4.);UD&9&B&>S3Z_]RC0\-]EC?FM#OMDW6,*L5TWW3D<*+G-
M,N!BI%;G!G]!T^K-P4_1^D)?=O5]%02[+-&S^D2J7!DNM>T( T/>U/A$DC[%
MH-O&+D.0>Q7H1]W,*QA9QXHM85:KSX@Z8U=V59EM!;Q1334LZ:T*N<,LY@*N
MKO_4J^Y<./^"8+)<5<Z+G;A0I3P0'!L(NLMA%^JNZV=0N-!Z9H&%^5AR\?EZ
M];BY"#SN%7#],#A[6G6R<J+$]%Q,TZR=X)XTC1S40C3[+6K$3Q&I\:/+#V9G
M\%9ET7., A:82"([0A7L>/C]5H0VWQHG@>@=V YT+_MV)%+]3!$:FL+<'.*F
M<=JCOH+4@J$?314889GAW00*M!N:XCL=3OZ) =9 ;M.Z@O[JI0Q&80B/WC9
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M@WQ'M.7[ZZVZU$7$<^4\@L1'+X^4'\DU<K%_<P(%Y^--6>],Y$I5KJ%V31Z
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MCR?<BDZ%U^1XES98O_]O-<M;JSV;@"-UB<_H8,CR8!#H,ED"?DWW!)P&0M&
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M!2<&/5[AH_%W^ [7X ^/\L$UY1VLL"5M;H&!.H$3LHU%SU\>UTO&]+P(:8V
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MY7[&F]_#J%?JY"FX-RQAB,2V_\N'='2*6'^<-! FCO$%WR/^RNI>Y3_Q&,^
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M;UJW#K@1,!=@FZEB-.U#E5XZ:.#2?"P%X-$4#.V#U$ BU!D6D3%@?G597Q1
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M/.]<I>?98LHK>43>:3=YVY?!O+7,*S5(/W_@3\>WJ#_E-0K.^5I.O.S3$LJ
M9>L L0<<+T+BH"!JT42>EB5Y_"3>K(W3]B^E !ZVI,0I7023*';7/+=[[Y*O
M(-H4(ST=:A*-F+LX#%KPB%. 78/:#2^C&V\MP"JKDISR/MS<$_D<7BW$;O6@
M\M+(=1O/.NZ"HY5YW"N4V ..MV]FY;?V-9>C#+V/.8P\?-TB0G+&.H:K4FTX
M'BMN?_R8WJ+2-12HOGQWUZV@/NJ$F8U634C'-WEM3(0'4:UGIFMC[P,$B@#Z
MG:$NK\'8QVP,;Q2M;(^ZVR <5L0;&5TN"VP\!%PIW.-]HXG&_+_EZC1\M&[U
ME[[RW7S;7_IB-)K9. O\[(@ZS9(;K!7)V,P2D(>ACVSF5DPMA^H0HCW.Y6A<
MZ7^"B,/S;A0QEA5[T'X1O.5G^5LK;ZO_U(.8"-E&XD+FL6R(:VH$S.\#W^G/
MJ\U]EYV%A,8'WS;6=?<GK[/*Q1_$YC!$EG:L_[P]<<%L7Z3V_<>=8V:O75DW
M5Y]6C<!N!>Q@+M7&,1'D"EP49;94/6)N?.BVXU=%M]?=[;O:<>V[EI+SE9(>
MFE[^CHIOL99I]@*/4RT%N$F%9!ZH1C6A%V>])(A35XU^7T:4BEUX%H]$CJF;
M)=Q(R$AYO'K_8]JKIS>T!&_VG'>(\U.==!M'(CV,Y(_8J''#(,*'7!^+_E4P
M9["I.S[+C;M_(/P0VIW#EA+HGADH5BU[ X$($!G;S3W3&$BY&%E)E_9HV3K6
MDN[1X.+[>&57EL^BC;P+5SLHP%7HJU&X.2ZZ;9X#*O,N.&J\JND-B:51EF!A
M.B]RC[GU'<H1D*QRE7H6_0#G4CYMQTL!+A%UHQ<S6EG\N^",Y"N;5G,92Q"^
M&,UA#Q>?Q:.T,K$S[>O [)75F\^TF>ED6?2J82CIIJ0S23PL]IBKLWJE\>GH
M^R>&_762@I'-SE&=U]UM'SN\<*6[K45#+\):5G\F^3Z& KA]L*H!=/Q)\6V!
MKKL]M/>D,U;?2ZR*?>:3N, O:ZSYZ#>I1IW='ENTR-8=4)69N<<*M<4)Y"YD
M2KC\>&7_X@<3[';5BU'Z_J_:41]$@(MB(A9KNT5G1D0H*4N=!0?O +$0Y7QP
M''N=L"K+(=^&X'9\1-'&U_B:4LE&"9$^>\M2]V7Q"/H5M7N7Y,:9/6X+\_.G
ME>V5EM<9BGVJ-FTZ(M?#J\\O<+'P-_UMX8"N2L8UF[J>_T+O(ZKW91H=S_AU
MNC]]4\(@R]H@V#O9,C"2]5]?G>PL'S$F5V_@;OQ'U@O0G]A1?.6PNH\33@IM
MB4TO6C0RQ$.QMF4-.$:ZA'VTTI6?\BMIYFKJ^_IG1,]SG8$S8,33+\6$B(7C
M]CU:J/B$NNT2).E4H*AD?>J3EQR+7'LZAS[ZM,J;R_3B.VZ1UI[GQN=Q]W&_
MO#XI>C\U<G:C '88<G<69VI43KG/;J%US^SW@/<YAK;="@,/$V@,:;BTF:+$
MGV30"QX-^L2E#3Q"I@9I]GLMBY3=2+^A_V7LDY/WW5^*#+W*"_',YV&JC:;4
MBE<G@!;@,14!NI),3YH(@8O\CNC64#4TK8?\5UA<48J+=8&H\N1LWA?S5<ML
M;W^:9#NOL\?D:7,7)'VHU"24@^"VA.0,\-!3#=;!?1WD2?AE-6O K0A^?<)C
MU\OM\90]/.TV4*9CAL*$5#TEFH)-0S+(YY/&HZ5=\1.(FX5+V_+)MEJX_I>_
M[PQX-XCN:K' ,WFU-'IE+\1=NH]F"B!")QBG53&K\PU#APMOU^56P)5]-IL@
MH/F:W=06)R':;)Q(LSCK2'99$UVZ5?Y=5/^K@67*8V@)C7UJXC<+DU*J>O@M
M!*:C.N?4A]7YWW:(3\T.T.@O?[R\8Z;?(_@Q_[Q<#VWXF-M\]BP%L/Z#B5X.
M5G+_*@W>0MG%;'[!,.Y_<XSB.A"[76#%W7Y3ZJQ6^'9Q^'SNR2^#W,:X$14!
MR12-MC]] \RREK]M1P7-&P9XPTU39+WUE$M>0TT70_QUQJJ1+"Y7R"HUH[?%
MQA(S\WH23[];WW>449IYE.7^Y&/8;)0/Y/(6&&N:]#Z'?TB='J-ATOZU>J<[
MH5F$ K3E9;0VW#B :O@.G73A+1OS5D2"#0YL] 1>MGQ,80%33<L<$FV8(?[&
MNA6Z3=Z:ZYXK9(KYC-(H^;W1^_HD>U=0K[9)[-C9M:PU1]$TY7SZ8J1^A2[B
MFD/U[HY,V?44Z[KR6:&:I\K[>;$S/^A,ZF6[U6K7C:#T. E\"L%KZ4/IA4N$
MAH=#C2PXL0?8I3<3I3<K< I'I(JFQ E1@*%#A_@38*8;YTU2P,UW>DRK88X[
M3=[/5[-%$TVQ&&NL.H2.Z+-XHGYCB2ED:':KGCF6DU??,6Y52V#;QOWB,^/'
MMYZ(<4WRO8E_6?4VSM;OCYV=K@GMM)N$[=R$K1_85?*5G!5<O9M_?\;H6D?E
MK3A])K8_/0D-%PJ8OZA(5,?R!U3B W=M2UVGN)!1=+4Y$E%M^8\.I$;TF?^F
M,?U+K.51P$FW@*8P#PEY&-!%X@6<4ULY.T&L(PC>[L;6\94^YH@V71&9KJ:?
MU9"5\=Q?V:TC2U!ED,47SD\!7#H(PC@Y/8)"+E%V7/,&U&I<72UP*=@6;!"G
MEWRHH3A;ID!?*\P>9L]'(U0)W"D)**SD[IS;Q$^?UBR=?M@A"&\2EL]<>KWL
MBV;;"_1>7$X(?CN\9*2_Z! G_ZA\^0I+E9O(*^ADRT^^BP\E;S2BW-ZV3?#6
M9JO_D/[R6[C6HCV2IY_U(A"$;L?/(RA ^QD%B)H#<$Y4W[\$NDPT('PH?:/)
M^YN@XT%;B#&9.,3)?7X5%BD8^\*([$03%/DBQ24>#5[(A[!!;V&G.Z^MQ6E>
M"\C4(Q0M>EQJS76!,3D@/LWH+64B7K],5'YB_#C/.J5O@/ZS?Y,%_NN.="W,
M%#8"60V-1[F)U)><<J6V>@2R9$SI[)S]&%W]G.8A)!O/8Y#D95/S[%-0^&.=
M*1-0)BWG]:KDW*:XISKIBV-A5JAQ;H>/BU'&)B\U;Q!BSQQG L[#SA,UQS1I
M">5VA%(<39L,5!?"8MVUXY-/"&;PJ7_*.ORKVT6HPN3.I8)P,Z",IAV.-=^[
M2'A'K7\!H?'FBP$9!@0W#.B2'G;?X[)D5:Q Y))BK<O5.+WVJ\EBSY2X;'[S
M')>YZHI-*_]5K'ICNSVW(XFWV*@ 3QZX;S0H%:3\.;'NKSN].\+\_HQKV\P&
MLQU[Z]ZG%F8'B1:1'+74'.6_G. ,_H9NIMG;HZ7YE=9_F3H]U)Y'9MB#TW7U
MU6)4Z&GB"!1@*6.G]3OY+Y*;*('M[H:P'4E0@.AK>&3N:QFBUMM$MS^$FB$[
MR\\##P<+N5>4G[Z_,W7N>I1$ BD!JNW_@VA"^B'O@N)TT;R);=04KVS"IN4?
M/.@:G,.;RGOF9I[GN^)@4^+DJ.+65G=" 9 $MC-%YR+_O.9YZ:T!TF,"YYMB
MG*'.4^]GS]H/,6N1P<^?[_"=VO.KD$PCQ'@H #P:]/$%.0B] F]Q38H-$OKS
M!P07[[@*:GP8O?Q1&U-++ZQP^L5CFOR?HDQN+2A_("TB=Y&D6^ Q4G^8^V_.
MI/T?>A,S@V2$&_0#_S1IE0(,)1C_ST%^$0VPQOE3]I_H;Z=L*Q"5"7C1.JHV
MJ1.,8]*Y_#3R?P[C_>_2N2E@+7"NVX95!;0V5_"CD (\;6%.#:-O]DGJYB8Z
M/WMKLDL!!/\[_T[NY!\%H-(1^/GT< YX47R$C-S<"V+?9H4QDB_O+%OF14XJ
M15;6]&%XH_#<]$.L=?CRW08RJ^Y#<FN&I3KHJK/P/ O_/W6GWV+)0W'_AZ6S
MC&OJ_>/^$!"1DE Z%!25[@81:6$BTC$5D!C=,9@TTB'PHY44B8%TC@Y!D.[8
M1DAOQ!@PMIO_?=\/SH/SX%P/ON?Z?CZ?]^N<Z[H(]P4WQ 1I:FW=:C2DFU:&
MK95^D?!WTBKX$$XN19'O?W%8\=]9G9DYO7K;6A>X,_>7P'KY\JJE1$J@XNKQ
MN=.2W^(P$6 BX(2V=/+UD_Y![\**R-#[1@GYOMFX]K:(X9,RI2S9":C:&(1^
MTP:-5J:_SH7PH[%4>:#>?,XIS2B"J+_5?E1)D17N[4&VDD: Y,*,B][DH&2.
M6<8;JL-N7HICT^\1?+5RXG5->:0/CG_';V_)D:%D!Y24G3F&*=(_U75\!IL=
MYL9]2<FA<?+-_%RMNKBB1<&#F3;9;X'1:DKY%R-;[$#Y!_R?<JO Y<$55;/9
M%]S1=EG]KV^5R0L?)\QD_-%_)M,Z.PR9L\%J(@H&X?/ [GSFZ^^=U/[<_6L,
MRNS^_"BC"0RU>6>6HU#";%[E<M\?'["-APN8?<F\WT,Q-H7GN,MTF'\#%GYV
MT<D$>7K]C7#/_P2QG=2NC3'LR0=@;B>5[\H36KP\ JJZ:G2I)YGRW811GN2>
M%*L/55\_O7^\?4AR2S<H8)W]<RC"B#YJF(&B6W#TQ6.OP9#<4;:G9@PSJ?3/
M^KL3R;7^/KESZS&+YS>/M"@YTO#!@LAU4\,Z'05SO:FM"2&?"9\I/<6Q41-F
MF[(@UY5#[(R/'Z$3]6]M20!9$*VL0)BXB:G*HOX/A;<FSU9X-:-T5]2WKNR7
MG*L>1JC>^THST<;[W;*&4YXN9X<[@@AH3"RX$@\9$$)?K3])^" RX,:-2_N#
MR0%+?X$Z"-',=-,OJ\H/<B3_5VQ5V];Z@SI25+I@[%TV7[;&<<0D9:K6I\6'
M;QD%R3+^,8F.B>IK;?-M&&F\;&+V*G59_9>QQM+U5FN81%]3$7-R+S#MCQ]2
M5IGA6\UXJF/QI/M;;6^/IN= ]16'2O</N.QV#[%RLR>G'5CP<+G5O[,EH)6*
M)A'@P+VDJWE=2038!9/VP-E/VRA#E/"/,8+,G5QM?UUX:W^EJ3?E_L[V%EL:
M>*?J]"CRE=BOPK.[,@P0"^PL;AQ!E]2:V=UAV"/&4@UA19MH_I5:BJ;Y3XK]
MZ2/M#\8^+.XU-?,YG^4ND@R/G3^N;3??>]RQDDWZL2L@BN!H*CCNN:W@_HV^
MK8XC7^\!QF)I .OQPT+W3^K:>-/Y\-./J^_>K[,TB1DFLM#^=W\\8OTWBYF9
M8:P^MIU9N.E*^G!I3>/(JXZS[^1GX72#MFR_4H/^R.J:WH.#G5;E!=P*9JIK
MC3$$$#*P1E=OD1,Y'4*WMQCR'3G$RIIU('@D6/U$<SFN5?J8XWGK+X[<\+&0
M=$P9GLF%Y[JLDQ-7UV/>V/(C9!R#HQU'# X J8:5EA>E!L*%TCLBS[HF%B9G
MME6Q\1(60R%&EN_C";K/FLPVFY-L^>TS.3QZFE.D]Y<U5BE)E6K<N^Y6D.G2
M-/37>U9*SR6:7PY_,$[<D6%XH.&629:+XB!-]K^5SQ]:;A27^J[![U=A/A&@
M )YQJ9U2BZO%Q+^#.12G[H$/SU:7O#L3/-NX"]F(@,&DA?-N(H!"Q4DD''1'
MZ B%+NB'QW&Q8]P^'VQ&J2=X_SAD.S*FI$MG\JA\C1"]12Y'JJ!F,FN/S;V.
M+L.%HF6P7S&@OK4O&2$*.%UT]9KJ5 BCPQHXLY=M[0M>ID35QDE$,&-AO5F[
M.CG#V#V"EV)9/H3[UZ# (MW*PM*.6#V;D_K=EGM_,KXV=_,<WO7TU >R=I%1
MNMUO_,Y25P_>RV*PT-,^^#O^_AUD[P$B72+1-'Z]EO-/@ %ZC28F+<%T(#?
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MI#H;["0$?L0.F"1 _LT^C?#\F7'5+PV7VEZ5PP&O#/W+D#)1<,<."@-T7M)
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MG<:E7X'PO4^RL^TFA< 5BRKY0W]8;"<G6/Y\?U"EZXJJ.2E&BH[44?Y^?]_
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M%!S/'>?__3B2DUJY]%DZDG?Q6C>)5T&4$&CQ/G$6D_5$ !5>&O=^E77:!>F
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M03$%-"+<O:U_\Q8X\4K<7PM-J3Y/9?B!D!?A3P62R06$1PY!&PSZ"FMZ@42
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M_,;DA4"BXG@_R\U+)B&%<4(9+9!BWO8C^[4X&;#TIH'Z6F<=*!//:BI_4('
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MJ3'8:Y"SP@=$9>?L2OD/]L?@:'8V?R6B!E=P>?L&C-Q>NEQC$CKDDS?A;41
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MT2[;/Y=A2]IOE(\LV<K[L1/HLYKB&24SX>J2JB<H$:_XQ2V9P7AP='WS"RD
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M!3,2WKF?*$7L-EH.^[NX<MJ\-2]UYX@?>DRHIO*&@*Y 514XT$O=6>]Z&4S
M842TZ6_-U#9/U64F6]*YLD"<YX'/6?V<R>OY2S1:N84(N/.QEIT-XY*S_^2E
M]J/W_3<TPN#>IG7_7.4@F#\=<437..TN]32<+_SIBSL:B/ VV LZV:X_$':F
M'+,2,WN&VVL<WX?\TRT/$GD'Y@.C7B>J1"MR3_D;"\M*EAS)E0U/"']1<-FK
M4+F+H:TTEJ=S,72Z.KHA/X(Y]UA(00E>;)I  Y[$_:*+881V:PJ%R$O-1;_M
MAI%_^\MHO7*W/=^"IR[U[T^M)(^4%E:)AM"==B B+PAT75:OQ-BW".S3@GX\
MXOS7RA]-4)!DL,KID$'1+%HLJOE]9 \<!,QL9&AF_OY*?I$U@U/Y:S>0@Z#*
M Q$8H+B7D,=@9-)#7BZ>AHE)H8]J#Y;U7?MRXE&;:7\6X.XT!1K+SZT=SU%:
M4_5##9H)\SN7Z85ZWU=!S^EOE_DXAF[MWJL5Y]M5-1/CX;N5OE?YV$$G4./X
M*^QHQ:R#84H=K-SHLE=^/%WWW+U,GR-V(M:X$>97X>>R!W>AZQF_Y< EB:$8
M.+ A4&XJ'7UIT.JDL71:8X90('4=/XEW9OU8T@Y8O^9_TXQ@G=S<GT&(%=WK
M8'K4X$_7+R2QO@RJ<^M3 J,&$C *VM?5E9T*.X&NWX/</+PS*-WL8&HT\3&0
M,N57P]34O^MH%CYU49">,V*#K_,+<10PB!FN  EE B*3XM;8A5/'CBP:V;?0
MV'"RR<8"F[*A>\-.0J]1/.WPML07\C^36' )5U0X&(J_SWXV1 AO--4@$N'X
MLQLI@7!YLFSF7V<Y_;XY\7C&K<$D455 S8=-,3*=ZM9(\IVBW9D@$3P5@:3H
M3_F.@_G8974']QF.^VN^ "X  T4V#0 9<7Y(6)^>9G>CE^/J_>D0:MPON2?:
M@I4?:J<6G\K@1TV+WT3W#$9_%?NTV'75F7(E/>]?T;W6R/R%\*@I$>*!@I'Z
MNVDWXKP"F.8 X,"\AJ)B^3\_GHZ^_$,M;"[SXJK[[K?W!.0R#M2=V9C]./_[
M.IS&*0ZQI*LK]'SO[=1;)$$AZ.GWJ 6[',_Z^"\NM-L]&Z7N[C1@O@?)R^,^
MCC;V[UT?6@14N?"8'E#?^?[*C?GAUY])[99HDGV'RP;KB2LB8)WNZJ.2X]K1
M'($#IVDPK?Q\MP"MJ_1@K=< /((I'4?T7Y?FE-.K+)TJ]$7-RO+FC5#Z16K+
MW/XP^)O%6R4%3JE,[[^%0FP2 0GM2AA>J[0^.+K:IP(:L\I<DVW7THE16P@-
MD.ACAN:?@QRZEP>]&+2[[U]+F \YO\^8_"L8"-EL7Y%[5Q7_LY<ZX=:Z,P2_
M>^OPC?880$[:F@/MFNY1N?*ODQR=\<4#=B"?VVJ<SEDQ-G2'X9FQ'=VS##6!
M^^R_+EAD9:B57JU<&.?99JXTG9W'75ESGQP0 2 )C)W*IW%:G&8?]R^:S)X]
M(+NC>=G 6O1B9C1!Q'IY6?_<V'RUJ5BH72:H3PMS86(XPN/X*D>?]AT'FPK9
M 8$?;X!+QP"Q9A@5_!.L//^^7;'_Q2F,_K=K"N2#9*#=1N"[CP'W)_<@Z(<:
MB;(:LT;L+WA"4 '& \BQ?POFUQ7Z$6JERQ=B%Y?N;VY)I45>]SX%W'Y-'UI/
M+6T;8[Z4DR4DN<<NL(<5^;G;.#NA6>ZTF:BSFZGS;25:;I6]>@OPV7]J'MAN
M4EPD\K]5"T1  [*S]ZKQ*@LG@VY"$+YC(@@#V:"^/1"'<B9=GU4@]/ZBQCD]
M>>+3)P_*^K@%BZ[DBA.E@?7277[DKG+[(8\=0"2GH"25^K((*-A%8-#$6-XU
M29*[CCP_]5S/-E-G+%L5O2<H_M3VJUD6&TWT)T*H/A3L_/[7E&MQ6\V4LXM=
M\N\^3><P*4:!APGW7Z:_(KM7G,N1_]]]\RMM-+8FVP-#%XE70H*K6,(+=\VQ
MN9F+48F0<5%V]JCG?W\F__Q&&O%6;GU6O/>=R^(?&;A46X"#[8FL]!KOS-KI
M_O\"=L$Z<Q?P'MX)1P2@VWI4&H+A"6?!W+TJ=7YQ/D)4.MJ'#P0$8@P-,WN/
MG<@+F^D@/%$CC[_*^@PM3=81[D*49Y6?PO;GT$U(YTYI+M+)$'[_D=?^LQ81
MZ7@Q^Q]KUVGZ'2DS,[.JU,\CBXR>,^U3L%QCDXL3 L2[R=@B<5J;,XA(0^/8
M&0V:"!F><,[X< $^LX=?TWDI,C1=2@=<%M<T)YTW?O7-IBZ9%;^U&(MG/7ST
MX81O2MI<DT*X+]4X,NIGX^;4'V@RO!XU28<F D3^$H)Y_K<'13%>_+H*#^7*
M0EU9^:T3 0>4A6;XQW[9F_ Z29)*38ZHI]F\6ZH;C9;JM3JRPRRH4-P<8CP>
M1 ]U&&FC2U@5QMP.1[B $'/A, ++[IR([)1^@Q_3V+?*_(^"2*,O^LRLBB[4
MTC=6G"J56V=)Z1W\Q")H5+FLK./KIY%WN1S790;AY*[5[](%'O((DY#-NI9]
M]P=9-EBHT/L#>T/XPE@_Y ]>N;VVF)ML#X-1R]MD:C1%\38-J\%= 5T;QC\C
MYHQ$!):.M53J47C8Y05W!)R."+!SP^FVNUUIXBQ0_7-QRCRX3-7K_/H5>T1U
M@X<G2JUA5K!JLSG,XDD6]4M_[91DS=KP7Y]-JRGD$'24>,D9B"X10(;&E5]I
MW\@_6U1Y(=7X'9DO#\VH2OKK32;FEYU ;5_%O[")=/H/DFZQ$,(>U=?&O/XX
MM6\C0Z_I(F;APU[%J_(X63$%7/_508M7L)>/(_L\6R,4ZO@@+PB1=WL/V-C,
M;![\=?8.VM&/:M)%B?W1RC#?I@69[_CCH!MF&DE_,G-]X+TZW('OO+Y]<E?J
MX6,#261V9 9^>/5(3_C,[5WC_#^AV16(:ME#0Q^PFU0[VW-1<MZIY2)5R5R2
MK8C@ZCYA,\]WM\A#O" T^1;<2R?8H=K4G:IVQQ^X6_X$+LNU0S%-\*,^Z-^\
M)0>2)@!341AP&/0=*/B+1RV"YU%1G[2BXX.[/SEJWO317@QM<YAD@]<H\:Q(
ME2\WE)O3IELAPK[#]A!]:G+Y;@1,LY5M*TX$]/7?$?+Q:#[P%60ZN]5:Q&74
ML;2VN3D%+2C%<\W>A>Q4@ZP+H+N0R&\0JNM.R9$]=FY:B,V$FZ(<2LD(!@EX
M '=N8L#I]^EEQ.EFO&4)2/F,>70$Z)P4%85D8NNO?^)54$1 [.+<OH4/"DCO
MSXB@B*@/%G:+ ]VS19\A"[@</0;B?CH$2NT6/<L_B_C$62NM4^?-8[*[?\[L
MM<*:C;1=CJ,:^"4:973AL:VA?+'(E+>P'3^K7WXSV4G\(X4M^D( Z*B6Q]-_
MK=H7\U,X1RH;AQX\2@38*6C0>HHO=&W5I%/*:9\X+ 7+MV%E+ON9V[-#\H*=
M0YSVN(1P5E>"A+G.V[B1TH6]#%#=@S*T!ATM7@5C;JZTU>#AX5)6K*:5S:>>
MP=_LD"W3QY.A"N?!;*U1=-+X:W O+"'I#DA1UP(#7"1S9["85=%I M..,;TE
M$>"ZEZ'\W,_T>VN3UD:^0M ,V?/:>,"]FN[^D YKAWRVZ5,%*(T3@0&]6OO=
M=#FXZ/64CY*<Z[?)3?(L"R#M;Z%T*M$7[1Q-O\7!QCLN9[)OY][\:FBN;WA@
M VSP-SHX/:H5 ]O8T;/SB-EL]C2*'9^$O_T!!)<U5AL #WVO#BHD2^*+]"%S
M:5,7;I>.%P7C?F&GW''07W/QPB[>=AA0+X@#K-;+)8"6E_32$TFPG962C5AE
MFH[WM]5]\U8[)4_YM0#C,&PB*<*\JAI^!8&\FCY=4;AZ?@@-6[0E A@J#U[H
MWE'T/"IKF$1(<)TP>4C4"O:O'*N2<;?Y4($Y-0WK9J7^B  QTK!2K:D=^:08
MEPS"D6Y6&&*?;X7]!4:8S)[/KH6%0I&B=RTRGPYG7^E_TF?-VM3FXH6TW=KN
ME\^H$%^QJJNE&*E)?\EB0V+HQ-#]LC#>91W+2' ;P<? $DK>[M[5/J]K*/BY
MPI48.TLP64P\JE]ZG5+3#5+Y\UB3=7U 2987QD(#H*4E&0A@Q4NT-0%[LE,B
MFV+G!"<LAFPC<P_3M<=(Q0Y;+CTU%*;G*7[\ >M/5Y?Y^10E5#>L6 0'*A$T
MLT2"5_W\]@^JJD*6'D9S_0QTI^!G6?<,1'$JE;-3J,APNLMMP\LX"2V26K[4
MD1S))%WKJ0 4W%HA<()Y=,G4TR,>():WP+5-"D!+S-V'U1>U^:@<_-,<&5Y@
M*._-@EA)>9[,@5X%<7>1$@','\<5/]WID"4"DKQ.]RE0!Z#RG]"@F]G-?^PK
M=6&'IB-%!L?G68@.!.SFI+C[[[Y@;V.0^T<>4L8AT"1[/=D8F$Q!L_1_2'O/
MJ";^MEUT$*2)%%$!*4% 01 1$.D$5)H(L5&D!06E29=>0A%!6B@"BI H((@(
M47H/2 F($CI*,4! .B34 "EG_L_SO.\^Z^Q]SEIG[P_S89(UU_SF+M=]79G,
MFGKQ5(U<5-/8?)-ID02L(<.XU.Z"\52@A;OC'IY'@ACY<6*0#-<,IR661SAH
MKN&7W6ZHW^E2Q&$>FIO_CE/#ZZJO1/K@S;"8T<\W?'E$N967=8$%0A*J0#K:
M?>']QL=A:YD/IQNKGX4//RV6*FML:&FI60HPUC]I\2+JG[^^@AO+W?!%&I[^
MXT5^0U\?JYEPDO/[NZ$IK72ATOL01/%"I[#;Z9:X!03UI/3N61)Z;9]DX15#
MEQPKIT(]%1XUJ)Z>3WUQ/UU)E_WP:U,JX)BJI B/S8*0W G?W%V(%;!D'1FK
MIPMA[%(/9:/5.*WQ;DD9N9=6F28=&,"#V<F7=B\N=ZRIBW/Y=4OF?L4#6ZC?
MWT_"WL3?O<\4E9;NZ]/3UM:'N)Z1L*>DHX)7$E$QC.RT:.]ZFWZ3SW/%KG%_
MHT%',YZB*CW+92O],K\XPJ[>LGE]JK'SS^B0EP'B C/].()RP\"P"R,<?GQP
M07#1SS%WFRBT@U.[S@!86ZGGI9')J*NV/L@J9LK\4RP:^AZS/*JDFE'%Y;_6
M-OT,Y\NQA/.[Y[%UO\DQ=M^HSUA\,UPQQ4#3$F/8F7*YX]XKE&-"<DX-$NO_
M!%-0TUP>-*(E,Q-?=S?K3,Y XWC>G^R);#SV#?4]2-27(1S8Q=J@"3H#8 ![
MQR%D+K9O7@?R?\ !C64 M';X""%; MW@:S:P[H.",J&WVK90G+G.;)RX%I[K
MXR64]UT<_SPWP.]%[ETH5H22.8(<_6.+Q@)*,.VOZ'=XJ,),I+=L= 7G9+QD
MFC>K!@,82EU9#<(U0\C'&,"WIXB>I^0NQ,H2(OL7 RA#6(;:',;0*5ZD0CGI
M]\P3XA$ 2N<5 YB]X.-,XR+#%A2V$*\1'>=F4*]=#'\:Y&(80'K!OCX#B(?3
M^0,IOXE(*N<=!E#S)(-^%D$Q)1"=DT%E=L&0/GZ&7K[;LTA ,P#[5QQL:M(I
MRAG[CCJ3 PR #Y:(6'1..)RG/V0 O-DOL L=$=Y%6#$[GGG^?U!@#$"_%@>A
M\ O13-.T$=^0E%@&,*.#F*NA$(NO^T&6CZ;2T8/84CSZ$$M980"Q$.@>@CS&
M #CAY).46OH+-6P+G)J*G>7W)M"8APY+$)O2FW'@J5K#SC. _"FBU^$_H9^\
M@OA_Y@)AB?XO*-<'/+H(+F3_)O3LB@E=(EO _P?9?:27 62<(66_T)AQI6:J
M4F0@WQ6HUYE)N<\H$T3$MS#$6FKAOT.#@G41A+?PU' F,#BY$>8TN[6, 2R4
MWBSLM.V%9P 8TZ /G=AMY4YH+O9G'/6:O=!27 (#J+W  ,#%)O]KL=*B.E<I
MTSP'^_?P=*;!_\5B;?Z#9?!;6WB+ :ST4^_.@FM7OG5WOY?:#R;Q! EG>P7^
M^2Q8+VAPI=? U+QF #\]R&TZ6#<@PN"'&)1V']&AP  XXJBC!&&Z*H@LIYQ
M+Z_Y3^J2*T)4%QC 6#&8-I-$#P8@J65)4-@2^&?%H-L(FJB5@NZ+Q6TF_K^'
MMX;ROUJQ9LQ&;AHE,O@@</L#B&T(EH0K6!(,H(>->LU, ,2V0DSS,H YV+P
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MAIFFHP<<DU)B#?26EA7W+:<02_99Z#W0;)QQWU_FD/A!3&+1F]#*2(5R[R\
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M]8^ZMK_GNK>4ZZA-W*$[B\>E=_U[%&.K\I*H>M5FYSQG.-17_1I%CH0<N?[
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M1M?RMQ<F/-V_YA37'QYH7D4DP!GQ^%;Q,DA0.W<%3,(ES:WY[GY2=$YKAJ)
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MM<\!SC%6?I;2Q>7K-8N#DY.K;PHI5T0)=WLT8WN EUP-K)+13PF8N H*#ZD
MNSULCK/Z;HE+$GX_]^/]\<+C2TJB>)^2C)QCBR6UWNJXYJ:S NA]7#7_!NO4
MIA6Z1Y[TT/\#SZBK/YC%AH/]!31.(\DLV_ER.H,C=8 IZ>8Y@.:0>!0I*Z?+
M1MKIT!4D"L8N04@/ C#,T-N-!3NGIH/&I[/Q:9YKYHF&9G&S'L6-+Q*79$/1
M7:!I/NPY($H.QK+@EG7BA62)$"9%WV@KL6&W>#ZJ;2V16S2U0&LXPDC[.%/J
M;T1G:LZ_3RMS>>.YQIDZ\I[X4'?''8ICXQ.K+B/=YI;95?SZYP.NCIV9R0Y0
M74D"V6X)$;W V%Q+@$>H7&VA)=:E%=X[:J@6&>1=TGYGY?SHV53^<,= ;Y@L
M4VN@,_A[.DC1K#T=%S$D]I /U#5\](B*9VTRXKCD5(F"6>339CDUW*1HVZAB
MEM4Z5-O'G?[H<KL\>/J0R/P9MAN&>))6Y:#&(F(XI#"M_GB)D4,L912O>HP_
ML)/D2]W8Z[[Z'9U-D_BM5 F1;:=Q_+K0B\54:]DVT;[>Z-B:2*F?TQDJ-PG>
M:#A%'%25=$T@ZE+BY-N5H' BI:E,+O-4&S8R<X7):T;R'#!:U6KZ*F?TOC[?
MW>#:MTFL SP_8S7Z>Q??@I"83F B[QDJ9KM"^RYA=]-VK IZ_U-00H^JB9-3
MJ:MYF<K0D*?,:'1 UHSHC\*YRP%4N=S5"#D8+RGE,=$9WW(J-> 0YNY'[#*6
M%R 9]$B]G8+\;/Z!\N0U&O34O7-OVX&/\,;S^-'&/B@)41/;(Y_ "]FJ73Y[
MIHQB^K=XE0)4BVBU*UU7N._ND\WFNN/N+K8[>Y<_\2O^Y:M7+RTM:_,\JS3K
MU_ 2DG[J>[JVPY8>E9O%(U,R2HE>X_B*K,E)LW- 5<FS+_#.^S"ZC0*9/V1Y
MWV66ZU,D#>\=Y3-JK-/?A%G7D,-BA]6BA@;DZ(.T0?'&I$LRGAFKI=0T@,5I
MT</I"UJNCD/P4 0PA 1+@FH*8>B9N[$\EY&'K'[]UQY'MN'KN_DULH-?,E_J
M/\/0?C>(+MF:/+4(FEQ&=8.GN;#.L:W"G\F\I)LX,+X%''=RSQ@8!P6[(5\O
MN Z%*ON4:^GVDR?W '"%"7T[=JI]Y-8.81;GW<7R#L)5!^*==E%#, 0<U#43
MD''^_\95N-RE7[U;?-3T432Q9J[BR65C+:6R$:K-C&IS7U^W)Y/^!8MO=@@S
M6TA&F8RHC+KT%F^P2ACL3-<:J 1;A->Q))+53LU@PT J;=E"$A;7<5*W7KJ)
MS#'>3DH7?;W'F7[+S-'Z"W2DD;ZT7^4 & 7R@D?J*HV3 SA3EC'7U@MH24_$
M9N )4$A%7]?$GN7HM$,"V/WSS0;7>U5T?9G<"D(%ER86>Q<C"]2)U7@U@O?%
M''P[_%Z7DP")"3 1M?Q=\GSEG?7F/WG1NJ;,!8TKP9Z*DD-E &9FC=V+D1[0
M589/!QY&G.575>V'LK"3P:2D*M*.<5J::/Q*2VM#<\,[ZZ(D,;Y$QHK(.Q_Y
M'E\78YQ_<&I-. =(<X=!Z)&:!V0U5%K]DO?LV#(P&7J_,LB]=X&=".K^09=1
M%E3=:2O]!\^4GQ)7=RJ9XSZU?QJ;X=2M;;A!$_KK.PY 7@@L@7>:PIW;7LU,
MFL O![7/&A'%_S1[1]2'5JK>2[ D,GT6ZZ2),1FM%2AT\[*_DL%-&X_3UCO5
MIHPO LD@PN)%LD(ST7>B6,BBA*N=.24Q4-GJ(!BHUG9SLN1AUD3O6HZD0S#[
MMA%U?\J-T6G[Z.)4Y)W%&F O=SLW!2W(WAI[40* M.TWYH+0/?1;J?'B8\7<
MB2^TWY2+WCSM,!Q\NV]_N83GSXRO=ZBT:O,YH /E7/O+M'M)U%D>3K! &ANO
M[/A30L*\":*':00+O&S1YDEV3$65?W4<D&4'1\A.: 65Z<NN1:H$Q;<:VB"/
MAZ^O9TG27<_D#]>.Q:+Q:$+"!9GW5 N2:4:A5W'R\;:JOY6G BI]Z\J-O'&_
M*H;TO<3?]_W]G'RKLK%&[A>SGH1HW1F"0A^$6?;&*YP:0<TG0=^+?\&D25]G
M>P3Y1F6Y'*U59ZR;T8R&46YQ'PG1\:;&;^BQ=!,H%PC3.:#S/LC#\J*R(!A(
MWGV*9!,2_"RZ EPYA?:3B,'+F4M6_:UQK2SIN,<N^!RW:MKA+)\#'URDT&2=
M;9T#JFVX:H8@T\A-$L*1K']6#Q,@62Q[Q^HJN @R3<*$@I1Z%*V[Z0\#>MA0
MT<O1]S037G#FOZE3RI:I%)XIC@)TX#JA=A<A17ST"VF(D+ULT)42(RA/G.RJ
M3A;D:ID,8.'X<E^>+**X7BEC<73+EC[MX40UUY4:K?)^/JK;5Y=@HF<1(#<@
M79 \F.#=?19J1(3'U'M2/_O5:K2<T%0<)M+=0Q%J3#\QT0>(RM3..&4^XU5Y
MH?",AWL_)092 \%+$)0Z435S@EQCK:+864Q,#CP1JH,S4=S_*"B,U3IM>ALO
MG#(B[\5-LV?S!.(RF\@;*S53E&,C4#"O28F%\5W.?OK@D87IBYGZXO'1"1L^
MW7>$$KPS ;&$Z4H*11<(CZN< WC#:GNY3BS>*B<]V)VQGJZV_U!FB,UR<I9Z
M%CO(O:+N)$;,#+AX !)G!<KG #J27V]S?DKB01B\-V2\+UH^0KF0]F]O>^ES
MM#=_P_='HP;-8!DA1W[#(&W>8P,LD'QM#(N.(U,MH5C_B4Q:$"_(0?>F6X%"
M"\%S92Q)><K6UMA'F$VH6]\AS8Q%YB;MK@_ VXRPN.6)#=9V)D"P,,22-V/0
M-3/"6D]I*YCH;!SME&?SW&I.[!#EU-!D9']E]?J>3]P'2:KC#U?>;O99N)G:
M5!:>;OVWTX_=+2G;B;Q"'G2AVVC;J>H%%Y/R(3W>I)N86/)-0F@/G%^;FH#L
MFUE+A/$$I0]UP6X2&(EW#S?#E)XTNCNZ5LR8^Z+8EEK=ZVWNA)L$ NG;-2\2
MUV/2SC*&D31[K_%7JP9QK5,UY,*S6J6AN5YUP4ZJ1_(>G6FJ(]_$L]D^ DR#
M.WJ#P3W@:5&<_+M6RU.'H*-NKARZ[ !B;D_.A:B[DP#Z99ZEX/]6M( S>&CA
M==_^P^Z?NYGOR7,./'BR;" 1A,7@$P@/CM"Z[#6$/A3AZD7)%R"^F+GGS?F>
M(E1G[-28-7 HHEXPY7D<;OID5__Z).0B@*WUM/]WI@)/*&IO%QA\PK%&6T )
M=7&(&=4_E?N]^SV+7>1E*R+3DD'L[X^QM)R$X7. ZSF %?Z52:7H'7F#7?)4
M^]:F(K<0]5]X*T_,:^8UQBT]W9XH_3_\[[GQ:-TS-/BQUN&ZQ94_.+A+,8]*
MJ$O#F,G^?AA&GN>17QF729>;=/$LZE55<TBRH@*]J\:* U-&QXBNW4:0SH_U
MGZG>])$ FFN=2WZ=9[ F- ^@A^>V5"%5DVC#4I &AAK@S+VF4S9X&DP3LZTW
MXILVMZMQ#M@<RQ*)>C0WKP79I7P<++/GFDJ!M5R0IC7,H)Z"Z4$DL$:1S0EK
M.@V))P6X@M97*%.L#GW8AN^!)'C#?;?\$.X,NEZ9C+7,HAK1X$O%S?[8Z<?G
MI8S?M^?['4F'@2SW:?H-",3<7GF%4L:4::IG\I6,_%4>FQANLMS_;22Q!PI<
MXH9W01&*CZ074EZ]#X3 ;8N&4\&/2LHNK%H ?L7?$D#L=$ \R:2O?NB<LM>K
M+Q',([$JYLR-]CA8$[K2Q.;Q$M?(C?&@7D]6Z!!LQ7$LOYZ^:>,>IGEX#H@,
MJ]1$M66J<59DM>U\$__R3NI1ZO_WR\^X!7OU#D!>08D8@)F%WV$]G*7R6;.&
M=!_,H2^XTURB1'V$OF33XN,'587=M,XU'99J'OJ&$#:SK_R)R<>F6GFTG?L\
MH@(NG[FN(#.;/+9.]U%#8'#C"GK!7\/\Q'/VY!@XG(UG99=/6= )9M"3^9GF
M7'C+]79G/\W^TEKIB*)T?\/@3^*W'N<8[FV'9*Q^G'+:I<=>*>ST$MO"0@H=
M&MCV/A+N5)UL1^3JK>9V;X ))+O?E"]PM_1374/:/_3<K?K%KZ!!<ZB^EJ*1
M>VA'&C]LLH2J\7(BD4[0'U=C[NA:F'-O)K(\\H.T$ZK"HHNS-55>96(SUIV&
M..#&P(S5)CKI:Y"<*V#S4?/M$S+F4E-K:TL-,O((SX7D?3]X=%FDXM:Z$_-M
MQ@C+OO$YM17^%;.CA[:A'$J5\X=Y[?Y/'JYB#--I-9*YW,.JE7L.Y*K6(CHD
M!#?@K\#)LIV_L6B=E/V'0!*KZ,ED]B&$M+#"LO6\(2+10WUI#23EZ+@7,<8/
MT#R%S/QW7,Z"Z\ZB":@2+'UF.<R99!+L=G0.B)@B&@\_J4IL?DN]937RM6LF
ME,]%E/>>PE>&/3%@F^2IGD,X@[K8ML]OHX"RN07M&F,G6OR7N&WVZ]:>-[87
MW<C?B[3TH#B0W-^7'3^T@9[G@!@;TF)2B7YBU!_ TJWU.LIF1,H=W7H7V$\0
M'^#).8 !7\!5LB,FY)M,=0> _C2?JNOA*&"7M_*.,L9FA'<?G-^9.6-R70G^
M"EPN- U$ALF&^F_"8H<$N0G@\%8>["([6?^W3+T6A#6HH<L&9)[T,CG8ROSY
M'XYTO_?U6HH,&H][S@YPE>_VGM3_:/C>DG/C39/Q6)C]Z OPH;_]D+-$/J6B
M&<_\3969;I7&ZRCP[ -,3?7W691;D6"Y6'0'KBDQ7.?[:Z6-^W?/ 8Q-Q*80
M%Q]H3T9,;G79V>+DGO;38 Q+I4V(VUE1P<Z?>:>F[G/ A^#*D(7%R":<>W"H
MKW*V^<S[&;<!T>;:NS1[I7& '\V81OF/([_>T0]WJ+]0\:[F'7K<9!WO*7_@
MZL!E*O;$2%J,<;AIR4?XB0):ZG,SU0Z>^M"*-+6HY)+FA1'3[J":36H2.]-I
M%N0'.:4D2:1]OA>\=E0;L3GF+! :IF16*P?,:I\I:(<G5^"RF5<SQ6\.*CTR
M:;&:V+7Q7 WZDY,YY1Z:,#0[;^15R-EN93T[FTOCJ% 7J?Z,XT&9G(_O^(]4
M)M/>4:T[*GP#;^\71AH\[Y+/X=X1<T*X>"AF(+59EC%-+-,.N$>/YIEETC 8
M-2'^7=6EO7]4&)T?AO"+#FFS;-%TX&(_;'?T^>A1E]C=JY6)OH&SR@G;09+5
M<+\@&Q..)V:4-C;<KPW-X<2)'TQW>,R'C/-GMJ\:.^6L!EL#G15EW+INUZCJ
M&W&_9+@:$1>S,&'':*S29;,@)BYGK3 MOKSGY<43\^*+QDKBEE9X!UW;/F4(
MQ O_1\]^^DJ/1(@2W5PH!-7L]&VE*C\_/+GET!?"?DWB4^< NEIEI-8CWS,N
M$GF4?4Q_4O_Q$'$L>//K!M<;R2RUYN*>[U.Y_5N%D0P2,7K2:5<&=V\ZF7PV
M\@ED74M.>&:?M>F_A70T+I/Y38HNXBML1?)%O^4TH)&V*E>3^D3=9S3?,D^_
MU41L9&3BU&:.<@?0V_7<C2 WK^R:P886^=#D3F$0Y"*;X*6 ;'\_>+_AL%,!
M!1];S]=3 ED.G)7P(/2^06S;,*Z3-GN&#5_WU5)Y>(-7GRV_3SK2K.X#4*3<
M"U<Z0R>AUOP^,$6G[K",L_)R\B'=_5GWW;0F8^$9:S'^I2/^B!0/\'0@SMUK
MOO!>^SF@[8 ?7KY."@U<7B0,07C/ ?_8N) GBQ25IY0&IY/07R'5F^"-CD9W
M1:O&X7]';2ELR);F,?;!F9EUV7- ;;43JCYK@L&+IOH&E75,GD#%((>U0(0'
MY_$[O;#0Z[7Q.\;#.C@;_7=Q)Q[1&;1R5UGF);5OQM$Q]0OH'0%)%TIX"9UY
MZ'A"V:/^IRKHVQ=VL^3P.6F"%;$5EY>WQ$HNN+V$3O9-^8RQFCQ[-635XNLU
MG^UMG$:I7G5;WPL[!Q#@5?D8-ILW> \Y_ZG"YU4J5VL#OKF-2ND,ZE<B:J9>
M:,A=__(^)?.8_V5>8H-&]G#T9[9NAYL,:0_4YOHVOFK(R7,D+#5PO"][?,L2
ML(+PNC A6]+LXIV46=H.]'<A6#@+6AE!N!@9/1!1-,%WPX>D^W;9<$03!R".
M&*@PBPUYOUFJ]$2H4,X!8Y!&+I97KUWEG/_-(.<P# 78C6<U[[:#5F]A0D:-
M>$MU+4&-M)';SWRN5RF$^^1=J>?\)/A\!SKP=UQY;-5JWA;->T]V5J,N1HC1
MCX:?35B\<9#@/@M:SJ:HP7^QRRUVR\'WJ3!_4]Q8MMJ(=:F/8GE$/]O=1%>I
MVV&6?SFT>5)JG=IP1UR4BM6P;V&[YP EM(5I:\YV*++=^D.U_M_O30V1ZA6.
MJ3%IA3$J;*QFF8RO?:@=TQI[_8)+7WP.T\&-K48NX\\!(5\4E*T#@_M%N:7F
M] VI$3;3NG\0-4=]OV:3W^8MI9O?5O_GAP1]#<UC'(\ZO47VE4BZHOVF(^,<
M$,=_1*EGQ\HT>%%V[M=0FJ/ZE7A=Q[(U5RW&6V9W=C>";*H^^SINRF4>AFGB
M1:3?(+^C?;U?:RR*-WWD/_YY&1#]F"4 ;VH\K+MJT8S,-5MX[1U3Q,93Y+#'
M!TA\T\- >QOPJ5/T^U'AJ2S4HW$(%/OE=<E?L8%PC:5E:W4TS<N#%68&N)-W
MDE B*81QY277^[1P=;Y"T3RXOX-ZA7BOAK^X_U)VSF^)\;IJ;V&#F+T;>+F
MR<"3AI3+[*),'9%%EUI&^(5I/H4MHA.W=_K%THV^&@[5^:""_)W0^IMGTG/G
M@/]&(M+@\#KDII2ZWYC (7,^Z IH^8.NVCG@UQ7Y@7, *6?>N4G:(NB;6@@J
M1#K,<[>M_7YKK5+"7Y^,OV.& R6>U\:,_[4[1VU#[IT#VK,^-3L<!OO0L=\<
MNL5X)^J:@Z^V_$\?1=^,2*7)Q?_;6D'.=0,"?*,15ZT=,B9V]K%=,YCK38EQ
M [(^2\1:"B/DD/H(VEX0#OP*5AE*PC)^Y0Y)3K(*N('%N=0MM%56GO(^&:SE
MS73M,UL;&JF6,T\_;GLVZ;!_#J!<WGQ/$J;;&WO\<60GFV=@[:M2JH&7@>TY
M 'Z)05W'2%2W55"ACXI\MKFT,\WU('O9N=M2&<QU*5O0U^='5/BCWM/*[XD<
M@D6[.B9A]C 1DJ>&D;67GE!$(W54]'&RH42)P%[>*JJ@,;E-ZCCF1K%$T4:?
M[QN+M@KL&2_9 ]:9_E+*CN"S9J*,]#XM;\\YN)AS.FS,S+A,/L.! _&@$^)8
MI=&JQ%%T\#"J!\[T\Z]V5_B-G;PEGV<^BO,^!GIC#50J@91K.XSG $S7.6#1
MF**RVKD@/01NW,]X=/AOYKBP:>_::5>* JA5.N:":$Z[07OS\)WB"SH$+>L2
M,.0CR.DZO*_4V>^_1@3MX4$6%P1S^2@&OM;\/Y=3AG>%+2..MU%'H^> )$"@
M[L57GMW\FBR[O<7QW'-@@ J9\8O5B":YH*T\XW^N+XJHDT2+KMH6(IX4Y&N=
MCBOAV@ )A6*#A(JWGSR+'#2VP+X[OS)F:G*@^S.>[NXP->I5Q,R__TX^V ZW
MG^&'E L[O*5Y&2OF&VX@D3:P-KD<\-YC3^*XJE"ZKDM]\*!#S#&=+X^1L[]#
M%!A$^>W2KCFJ'%3'PY@^\T+F1^F2DL"'AU6&F,;UO&0 2 P1LZ J&CB=J4\%
MNMEQ\ _U%/$0Z'9V3?3GS66?'TG&-_773VR/\"?!B$3?*J,$M(/%C\3,E?J$
MP!F;Q1PRLTX C_ANSC\3K7O)#O%3Z,L^ZDK1+P7Z3]_FQ6"('%?U5=MB1A<6
MP:WI6O'R7]LGG)NS3&JMC6Z0/+8&).@X9*[;O6'7H"ZYL.4K8WTE&N',^NJB
M.J\-J$5+UG8Z+LCTYTJPT H5V:9) %1RHPV#KY!I6UFB&'_-G5GK-XY6NG=8
M]L48ZPJ5+AZUT.#Q%DAJ6ZF=[^>H$HT<O\4[_Y'+<<PA,I!QVRZC4V.',9#+
M/) S(3@TH(S*27RXKO2G?7USXT(EXZ("WY];_>JS2"')D=#?A-F^S41KX6,#
MJ0K8QZ4E' _PC@N(J=5-CVZ:XWFD3_4D]\@501_-2-V/J['Y=K;D\H9XBOON
M]2!KE5I(:VW#WD5!"&U:.QR-JTSOM[2L+_^Y>F@T/_RS8FTU\SG=JRN6[^QJ
MM_1=WTVJ>LOFN%G$@N_<K[NED$9347)MVV$@\9:I7U[$KW?[\B1SP5O:<>]3
MCIQ$D[6$GV)*]DISEQ%)UU,;-O_=-E!?TS@MI"'V8P0_C5)FNOS_[O]-.>:@
M?'LE7[0S;@/O5.<L6!'0'>$[NQ>6I:]6.YS!L:^H6=NW9;WZ,%$QBUIL?Z"<
MT<KEP#IH1X4O=/CUK<W0Q@I58Q?Z:7R_["Y]WY_9J(&1C2W4LG70%(#VVY=D
MPRM30/![5K!#VDF& 5D:SILV7!,.VTV,2.L0>^E 3>.7Z)"64[JJSG_W;YF*
M2=>P\B@XMS#$HP7:??;T9[,^Y,+Q '_EO:IN6$L;Y^:65V_E6M^S?,TYL^L0
M(93A*MQ0.K!U6<LW66K(_X9[J7W*X/-"-<[=%?F/ZL^$Y(+G=\/IA3(2KW5N
M6RPCDRY?(0!:\Q+7I@*T^4^($>%:DB0G+"[R);>$#U"A4T/CG^:US/5(JC7N
M\L,FYS.:^]!1\N)Q[$G9ATH<2!8^S,\>]W;&ME8UWUFWTK.QNTR*NFS66.38
M0RQW:/[OEU3<*L"I@]^L6!3I:6N0?G(RH:^&/*P*%'B )]VOQPQ>,NR<8V2]
M]N-2BP$)@HO1>$=+[4*S% G6D) RPGE_Z@"8.2][IV@>&Z?J\2N@5UKW-_1U
MO@FZORV:5W^D^/C('@\,EGW:CIP_4HN]LJJ:TJ)E'8K2[<>9NP_E)FE/+9C0
M_GPPNE%>;BPQ5?4%</Q$W\)'44H@*OJ*H9#=^S]^RK/RD2/#KC)8TE3+1Y89
MX;ZISTQ[W!^5?M!1 ;M\W%M C*TN>G3SAF+\'+C/ @RBV@7Z2@4%<3#>H/';
MT@ ),0 7=5[&[Y#] ] XW&,9U;+I1('$_I-JO?GQ=3VMKN<^BDR=Y-[HT+20
MY"][$%L?6KJ\0)MK73H'R;JBY6/F>.DV]@->I!/ND2'V^\6C1?NV=$O]8H_<
M>)D1[M0**M'5#=\#//Q",CBQL]R, 2U#,<K5$_]B("/9S<>D9DT#=$.=/N(H
M:"F _,/XU/WJ&89,3Z$:H)0Y _>VJQ?. 3]QSBV65GWBH0DMH=+.1MCV=(@<
M%L=(4ZHG'@<*]&-OPN4D"XNXI6O7]!S.5*4W*#9E@>4&,OQ6\'/74_]R"7'2
MTSB4>%\8";HOMN(J^B*)0U%@6_"OI^ +S^=:2A$.UG#J?MVQIA.^XHP$I;IK
M=KGD)NV/_MZ<A/PL)12XH>)YCF\L($(I#>KN=P-HWE3R3^AOWHN7\9]LS$Q\
M]*,I]6''ZW\]:5L=CB^C+#D%N7_YIW"X+X (^.*J:!SJNG582D].'<_S>CY[
M<,Z[X('4U]Q+VTN$U^T%,"Y2QT$X/R-+-K=@'ANB;.#@(B"6D^U#NF(IIYO'
M3X-'V )2YH&[\F=F/T%9)4NO67S]KJM.Y-Q'3\F:[FI]_/C7SU=Y^4K=*&L@
M?UXR]Y+#2YZ.<"FC0+CKVKP56N;;ZB'/HL>HZN4 K3C0+:WXG4T;-%F:A2<B
M.L)W*AJ$X5DZZM?]<%',HIUP3Q+UQM1'MLD%:-3#-<&V#7B#S^PIBG3E'""J
MUM54/)]I# &'5<K/YIIH\LMD-R<VQ#YN:&W^WER?:L70X=3:@KQS_>%C)D1K
MGY[ZDF]:3D[H9KQWMFE\4=:)L5-M@W'^T"4>AFM&T$_Y4U?SPGT8EEY23R-B
MVM4E<GW1 +R,CN)E\\VI*OI'7]Y#%8EEI[_D0FYV"@1IT-Z"\SM\U?A:VRKC
M#T4NNL.S#^9&$5=7RV:SRJVW_[;G[UP LL^78,\=3N/2B8TP3=7=M?I@WDMC
M_NZW[OS%BB7B_G8^#A+Y=E^@.%WG,.TEP6TFNF_^[N-\T)C7$X)83O"CM5=2
M]#(]Z:H98[II%PI!]3WGB5 L$>4/"[E!KX=NUS3#+5LD/Z=G^.#4,<BIQ= W
M>F<I4B>VM%<>/R>Q9[!]#@@/J.*X,#+P7U-08@Y$%J/A\LM&Y=OGY[)8+NG7
MBIS8I:BFVS2.D8:BZ6 O6G4D@+E];4RGD_I@;;3M&H7#(IG-Y[?PDX%GIJUA
MJ@5%@93(0A CU)X.VKBW3S_Y'7H. (]\L8R!Q*?G;>C+2KL=/UTTRZR>P8 [
ML#T^VY[ZOHDW'Q2/SS<AI/&%@<<%81EX]*G!.>!=H2\W!D;'G:J#&>XX!VP6
M]+4<DIQPNJH])54^%YCV-%G'+[E1B+!(,K=5Z;LG32K3.'DIJ'/6I_FZ0/2"
MQ!"$X\'%LG?]M5GX [><PZ<H[$C*89C3A5)*'!6IO$5=*#>ZRSJY^:G'_CAH
M#& V:A+[?2X?TVV%1N..!0M15N0IDN@2R[5U")M,=;7LM'!2H3AA2ECL\4]F
M3?9'S*]U^M?V"U>8+80&?Y?-\-'@^)UGJ7D$? QY. @:VR(J1(65P">>$@MR
M)O+D3-F4F49Y>@OZB#+>LJ]_@C-^?RWDP[?E.%SYL7#GQW$N#2/Q3P P,&*L
MFKK-^NT!SS\  )=.+T:%CSH'3)2*I'(.[&2B/ZFO4/)>$I-#[(-^Q8BM 5*5
MDO4!F+%DZ<'<MJP<L?T]8W#'R<:CO/=S >D%U>.;1];@]6M/[G/0??[_W&2=
M1DZ1I#-N,.;'1@%FFJ7%#2(?&^C^!0,C.G&_D X))AF2:XDEZUG TF\9+Q^8
M';SJIX[JG^JA,((%CK6?8-S>XT9-;9%69Q/@B:VUWM"ZX_S6]M!S0+<;M 2;
M;\^M??^_'XR]&E33?4Y;SV&1]"91^ 7!XNOE#@GNM437 &-1A60@ZW,%SE]>
MBV7"U+2&]#QK&GT&L!B4\#G Q<;Y12P.G"Q32;Y;=N\KQ9P-K?763 9W19%A
M]KN#:$0>?YJMP1D2^WAR VKR+3M&^H7DQR' @[PU"9H#;G5<!*3**4_G*5MX
M45F?[R&QKJAZ>U[6?UJN8;L%R)*(^1Q=Z2RI!?GBVM(&HCYZOL'F?Q%NHQZ2
M5:Z#2GG(&RT;A[\-.5KUOEZR$+KHBKY?WIH.O=XBO0K)3 7%D9:&-7%&6L?#
MY3.;=S4+0MY5ZM9C/9<&L+(O4C\YSAD"UN8[USZCH=0Y6^> )]*SI''!W/GR
MLT7$TX_$)+[-!_D3"/$OH<#6N^8-'@X](1#1MGT;7\2.[^3BANNHC>MFWN8$
M4Y^^RD/F3XR)9WK:OGU&FZ3[G/58T7#M^Q6^Z0P?9Y-!LYN4?AS_RV2IGN;)
M=ZITND(3#U(?+6M'^_Z)/HX8N>7WBUDI74J\(V"^VLIMLK[H'##,Q7SKR\YI
MJ?]%GU2.@<W2I=-]?H(M)5'AG_)-GK-UZCQ?62GP,=39I>.?J;L+)#Y>'YJD
MV%_Q.\X8.P=,0M[&5Y/B7R@7"(]'OBQU4$KG^[1AX->YY@5 <SA0V&4]4EGB
M#NS!X(4F:OZ5707$'_^#,BCMDW*-@?;MHOJ]Q35/XW. ];\+BBEU_\L',P?Y
MS3ZMZZIUGQ!OHG<ZB4A6Z+?+V]583PY?S5'1NK%"BNP!W@V)/1BXA&(RB&N]
M=YV6*/?M>CI@+Y?:BT5#@A[)3QTQHL=0($KDHZ/OF?E$GW@\W*<AP/*T_QR@
M<?7L7N]&EDAEUNSZWZJ3 X5L/CO[&7\'_ZVS?G^0'[Q.%O4/5 )?&@51Y-Y#
M9A70AQ3$F/:&:]1^]\N,?SJ7ERR6 \EB(6OS%XK(-I__0SEK/.RD/C:%>Y/>
MF7("V39ZHUY#5[UWF 'T&6E/*84.HL[:)@;7#Q^9PUHL@[<?X#RD4=N?*A?8
M(*NPC:NS7KY5ZV>A;@DGIQ>4X-(((1GZCZNOO?G,8V\$".CH6,>/A.((>6X4
M&>?G8SU6W5IGOVZ\A-.*YAVBJ=O,PP)[GK08R,<=5"M8K]&Y,L]%]'&G[6_K
M_=.H!/UI1F'$4+WRFR>[-XD-7)0P@^V$TWI0< YES-47ZZD4;@A!WA]ZB:<O
MH%*G.13$?H.[=X!6[48Q8Z:)<$VRO D< K\@_2Z#BDL=W\_V_NHS:'5T4$MD
MX'?"F0QZ-*B@QN7\)R82MO0:3 ,8 :K.HTJ[3A7'_&]&EM7U<@N![#BH7$,Q
M,,\>A:%</BT7K*87/0U\D.H@\::8&^#;@3:]S-.O'1G6TVV.7./MRQAK^(HH
M &SN0-Y6EKM_3Q<CJE;RV*%W5E<2V=%_ 5%1B]3?OR;Y65Z,W[MR<XU^ZI&,
M JV0$Z(Y2; ^_]O((=SU')!ZH4,/Z7- ]I-Q:Y<M&$&NF#H<WE#W$[&]<=MY
M=W8R(SF(/_F]ZF?F"\%>J]3V\8'71: %?(PX2/HJ&/;28ZA115I4W=F7NTVA
M@D9H#>!MS2.@+5%_@KHG9^1-.LN,^#\Z9EV/EP$C"B\PD7LTB[+!XK]M4&?U
M.QMW<3*T%X44D5]Y#D#Z@P)T%X%G]!>.0>86O_GG<02"U35*FWP268K3H$YN
MPHWM<I#NGK5@JY2P.L[G@$OB!^BC;VJ3T >->ZU/*_I\4T@G&3P2D1H\W$QS
M!VL%EU[PI#2O]CQ:5#NAQCVD47GN/S,MN7@.\'+>8?@CVH^.JRN8@[O>\,//
MKF,F<L_*F0TOA!D+QE63'UJTP9CR0WM>G -ZK<N/T"</4>,M@3A">6%/SI+9
MA=+J[7U>+[IDRQCHJ"FLY?ECN#'<OPE>JFKNU^3!&YV4MB5/RN95\@ZL&=B,
MFOGAC&!=)QVA;%N/M)D[\DX.EZ9.H8X73/@VPT14YU$)D-]Y\CLY=%<!\M85
M*Q "SH0:E.^(.9P)#QR ;O9K._,[+&J/=U:0\N0OS$A=0OT]<>NU^C\CB44*
M+6CCJR*O\37EA6;7K_,#%T9 "$H)>YQH>B0[V.P>%@:>2RN]W<%",MP?WS9S
M,V0 Z2]1[V/ (3[M41*"-\9@MH:4T8=+#CH,W+IMM7\LEN]NPD3-+X%9-ZWC
M9Y2T=H..];5.D@M+AC)2-]N%_WL8=RN2Z>"PA;P FM>7M5=.B9;P;P%_VYP#
MVZN]+5 #-EF-#8G^9O:37\C><%3UTR.[ $EKGXO[3##IVD/@.23*Z-4E1'7T
MUA-#1ID>W+!'$=)<*R,5+D3%L:VOH>VO?43_CBR18DL4&F)AW50?H%92UR S
MT(MJ.PB]/!WCLR4J*>R2[U<Z:V!FQ/;7PL/.;M&WF2[-9(WZ9>>\/@> 4O_V
MOM?PWA+*M9*6AF# OQ$M44]2+MJ/I^2G^B+P#!@AW/'XAP!I4XK-".HK^FI1
MT4_OPM</'UASBX4R7L/H#<.8F )[!5CB51*/;F ?1FR2 C9 FAFGH3UX+RSH
MNEN[_^.16=Y QMM&#!)YC!'[)P=54,CEB<]WG@FMKM35_R5L!AY=%(%K4B\L
M'E0^?YJDZ7N4\<9(PGF\J!T2?%KBJ=T<712H*AZ@%>S%*^&BOT_%[)?93R\$
M?%]@N.5F_KU $3SM!710 !3>I,G8S8A \RL<[G/T4SJRY<N@UV)-)R34QI+T
M5U6R_ATG,UQI"SX0<N81;Z\_TK2<436JK1=+7'-9:>!F5?A%';4SY_]_2/O.
MH":Z\-\@( A($$% 2E":2@?I55%Z1WH)"H@TZ1T2.BHE% &E1:6)E" M]-"K
M@%*E$ZKTA!H@Y?+>._=^O_/_L#-G9^?LV7W./K^RLWL>Q%"-HFA5]T3,Q_2D
MYVS2B .^P+:FDL %>,FR]V]$5/Q]6"O30CYR/<$-JZRAH_[Z(7^>'.V9M0/=
M\NU$LCZ*H[G(_$:3DK4UEVE9V5XJ3J4)^*_IZ3];]=Q9E\P- E\>1"=Z3]B?
MR/5!BPQ.V6^1 "(!2V?=4+2%@LM0759F*Q31U?+T-&P*]3@_>_\/=O0TF 3X
MXC^Z10)T&Q'RH?\X?2^@6.93F;_NT,V1.2(.AG]P>1.&/Y^#+EV=+/;^:#*T
M9I1 7@DU(-Z'[1Z1 *H[\"OX>8?XV=;E0 (H_Y_1--UW6=AJD)O%/(G$,#I#
MJC[PS)H]">!L@]%X3I5XU&XTM[33(U5AR>@G'>C\RYW72=\P/3W*-Y^>FK/I
M OY3KSC_R;41AO"PCR=<\$VD57=358VH8(XLBT/EF(.=:H<L>>- 'Y42)(TH
M'QH&GC[9]GWE=DG=:=.R-3+?[+?0EG"@;'%=27F1HNW]7KXYE]J(-*7/]?E]
M<G(J!=C"KGQV:N5'QNL%;I'MRHY!H[HGRJUR[6MTWJ8JKBY.57_\G,?7=$R$
MBEA[ \31FNV<[?]N<*PJTD,X+SUPQBIUE=$,^KHQ]O2-9[W4)[MB8A#XC8B*
M=P7#-[3J+T2RM\?&U8[VN5>R687<F:UNN7T6#FC-4?XG\RAD.S/7F6@ML#J!
M*'$G<LYMEA H/8!(.!M!0N58M/L,9[_DRDY-G&K:INY"J6H)'(1$)BMIV+T3
M/;E.IE[BYW-=SL=[.AW^ZZP2YQB4P3S\*Q^I=>91,?UBA*8E-.MA[;_QUH)0
M/K?#@@/*UD0 ?<EKS3Y\70(,'SH-[\,6R0QJX&/*DX-6- E/B)BS;=7-1D1T
MS_XWLMY2_^@E7ZC2XD19Z/=K%JY9$62P;/7V$85*[_1M[PM3Z,L5A:$#\+J#
MRLF9B%O&RZTZX>,/KK.>1\0\6-/P[ GQ]T^\K0'Q%Y"HT#>>3?EW[_M?(GW!
M>1,)(-K;QB(?BUO>1JI>T9CYQ2;(("RPZ!)20 (\L49<XE;/5]+[L9SK9XA#
MX,F<J YA 0+:"!\]';UX]_=D\RS"/E"Q:N#TP.C\ZM%\H@.^W(5B33&;<W6B
M%S17)+[4M[HSBCZY#T.Z@H^9&Q57WX,17,15F+9*U<Y9VK$;/I;8XD00NQJ9
M2!'>_=I83,H:?+FG#Y4F?@FYY#]1\K=6#K=3)J)DP#M@^BO!ZPHZOM-X<5Z1
M'!)X<4D"2(2CC*[RHN+/A6(\=A79*KMFFC4'7R0!#&T\(Z!']&T>T,]G\L/K
MB5#7V<2\OXR]!2G7-0<V$T'V#Y=<^E?-Z@5^#\;/_5Q%K&?C3"[57E"M3XE\
MI)-T2A;3E\_W[16'Z0<7R2=_#XBLT%^+/CQ/I*6CJUZE8* 7W_9-C30G)!BY
M"$AGGFUH7303XWQ6<^4]U!.-#9Y-'A,KPX<V - U47LJ0IBZBEX#TU0C0\3F
MBUHO?>G"[: 3=-!>])+*[C)>1$KPX/P2U>NEFGIZO&9/!C,914P5)1BW"3U=
M6.0"+J6>)FL(\*[F)BXO<VGN3^E([WZ$%\+/Z3G\U3Z+.C&=30H&-$^K[1WL
M69  _^YYXG0;B1KGKW.1=F^.;ALA9\.=C(.6C\&>NJ>(]W$%W^DV+J &+5<$
M38&] !51&4Y0"US:!46 ?'^Y1RBD)A-"0KQ-";$FYXZM3J*'\N8<AM##[>P3
M(R1>[O1W7K7X]SEG6=ZF5= [\B,JS(%L$[?O#\M5@+UV7E,@IW(!EADS[GHW
M3F5-SLM'>?^4,G(7R#I:&8HUHATV^#(I E"2V/R"'^4D :RR/_-9\WX[6]!"
M(G*LYFKX;5RBTUNV.F9'!D3RF.M;FT'^A!+BMTP'XJPZ- >TJ2<C4%_R1F6O
M\$JSN)IW+KE/7-VKL H![XDY ^7=:YN@TK-:%?@BT@6SR9_,.N6_!U490!P*
M$/S;H;_E+U'+()\<>$Z>\?CWT0,'KKSJ4.^S1LYMHT<>BTUYG[G?/G)42T\F
MDQN1/]N:+F7&C,Y*/96Y^2J, ;CT3QR&,(1FN=I/2#VI@GKHJ^6&X[TDJ$?H
MM?#AH5.W!HN+Q_W9];4JC-O*0N<,]*]LLYV8#M%FO/H?FKDDI^[X:*GT3*PU
M;'-O"M*NGP=\6PB<+E;:4IYNYJNC5565O>:G7+B9++ZT,U<1INJ)Z".W;)!E
MY?'>FW<\X2I)EC<.+S-, 4@EQ/)P0[!QZO++# KYP433L</@AJ4TZ_V<NF89
MPML'WOO@83R-2V637]TQZLH8D!L@(6.H*[CW( '"$20 LPGM%("LM!/ 028/
M'%<T[\I_7725I\VP2QRT%R9I?)4\"WT$O,JJ94N^P>X<<='S6 -\<9Z%.O<V
MV"<!]F -Q-G=IWG:=!SD34Z/-+[>BY3=5G">7^-9>G0H1<O/&7>B\J3/AFQ4
MEU'A+LYKM)1;F(#T3I%0"?(]V09^W^GUS1T++S!-#\3K.\M>%@1SCH30Y2\9
MROL]1J=,EP;2APIX++19J73V,LL>B: N6QXOU+&'U;6-.NQ-3? ("'^WNL<&
MN,%PL]Q ($5KKN^?9/Y=SV\=Y":U;%?FMUR7PQFA?(*E[)DJ(5/UM\X2*LSE
MB*#RZ9M.3\2.RW),$?],1%Z)\[P.<CGVMH8UX%O?Y*Y6\XO&]UK-!L\#$08-
MP][[MOZN3/L+F0GAP#]+U[9I9=Y[K"08QYG/W3$62VR_#JC\?6-M6;R#\WRE
M+>?YTX.&VX]^K(\HQ-J)I]S85IA>-]\E0$N1/8*TUDG:6L8&]Z+N")#_,KY^
MHP\0^=MQM=('^B*%>(KV36-4#$F-<8<;*QF\4G+;E-2^%6O!#Y>2'3QKV_J^
M5#/I?C5O![*A+!QO:?QY'(OXQVR9<EQ<_CP4;7[YIR]>24+^*+)7<KI$U4#W
M>/>FC89H;J(#ZYF  *J>^OM]D.3MCL75?-EV$+%@9\>XZ_?EU<S_]K9SFL^8
M:ULT,W Z!$^.NL8P.4@C-\S_E9, R[>-GC.Q4S(9J?Y/-N:U_K#H1$J>QE%N
M[_'T%R4;S]?(AT()\SY*D# BU8=F0<JW^A)E,!_67.#XT0^?7MLN@&K'MMQV
M8>2H6OHT.>#2(<\4-O6FY %R9+<2X5%KW1R(3'>6EF?,!RV8:[F.N\Z>@X:=
M^X[^6UC<DNR6I5WK+_<OYUDW-]X&:9\X/FUWH-J_,GA"*%<28)8$6!%M'TT"
MWU1FQ\O_/O:\%<1BW#"^3Q38D>BCFTV.:>KZE2DV)*Z>1FGVO+/Q.2#Q&K74
M!0I[>L$I>AJ+B_\Q1-U '& QMII)!"%MQ#,R!2B\;*,$ )@"0(0;)A)J#_N
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M<C[MP(&\*8M+/;&;76*XG"YY$B!.F&NP2W_2O4AEUDHJC:^)%^1:5?-1X.-
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ML_-&HPS^\=S$8 F%/A8G3!1%[87PK)5NQ$B\,O:A#Z+BD;U(G0AUB)XM^UQ
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M3(;_\S>YKV3NIVBM(7ZR=B@W["R1RVUUZWYYF0.XG3FP3\U#+O M:^ND-\1
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M%VGO&=34%_U['XJ@@$20WH+2>T=*("A*$6DBH+0H(!B1+M(3BA2I H)2I(B
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MSXU/7H]+SY$!9$[Q 8PH[<I=7+5>[N6=-!PBUT7K-GOU!J$O/\YI>(3Q/.#
M^/:I#^KS&]"_O-,B I>->-9VW#('MX?J<DIR8#@A<&"/Y^8&XE2&0,$GUZ4J
MN"A#O#IMN76.$)G$7"$)P^=NXJNK"QH6,^V9ZIX_2=<]OMW" 3CB O8N!;<R
MWBU*3/W +.\O<E'3D>Q+N@\<]E!'2#I-L;_W643AW(CY#W+R-WKX6A8"?+ O
MS\W>R@ED7^FZ6+T'W?L<U %QXZW.!/?OYAYK#QNKK"Q6#3?V[_= S0[=6+H>
M_?D6^#S@366.@I?;[UO6Z&/;,H<'E+*6"<H'&PD$#;77?/5;G8+:%%'Y200
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M05:X]9AG]<]_!V<,/ZIM3-:E=I45/;&I!=BY]83+[!6HFW_U=6[YN!MA*\B
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MSWR6.9XR(,T@U^BRX<-73<E #!M,0J&CZ<FB%+>).SNAL@T!'O39?0?#)8)
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M?%G"Z_2=/+PA":1RAM%3WS8@CDF(_D2B[@''"<LT#8!9I0&N,'@:F4/PJ?]
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M3*\TY\:=3ZLFRPJ2BM";STYK*BM:US;X3V$<9&K$(0)_@5J<J8$W4:1:4$-
M9V:U2Y-Z+JCQ*("2=[BMMASU(71I]Q+L'L%_*L8PTI^UN&6\[F-KLL-;JW7[
M%"VQL3>C2-;^(Q&[CACB'[Q9-_3* 9IMFGSO82N"GIC_B* 3F51)7$2.F63-
M9UT+ $D-:"TTJ:S@E+:K@Y[U[EMG#PVK&;?-7V+F065>$^OQ*2]-JGY:D/,"
M!Z3GX\LE2R[??\V69;+5*(- B!9R/P!2+=B9;K8S=V(UZ\8Z-<+:_"?G!OH6
M:\T'Z\-+#P..=[;#- ?7H'SD"R\)Z.[R18[+WUV^;$ =PI)Z?UA%5;,G#ZX^
MN"S=%2-L%S]'GZZ>?X,X>'J;+$N<+PK2\)?6M\;W8MA>^]$ ;$3[/DVA)C<-
M3T-]DQ3^*S/K8E%+4_9IUYU0/PM5JLJNXZ=BA-[8W#KH8Q"0OB^QS_,W+EVE
M$[H,")/O["Z)\@_*DGQ98*/Q3F_,0YX&*&(](L5]OGOSIZX(Z1U6I'1EJ23<
M\MM_=)4Q7^;5[;27UE%HK G;Q!T9Q@*WKN//&49UR!+=*QXNTP 7B:D6[=$F
M#434MZ%+!)GLFYYR^IY!>P*COZ.N\\VEMLC==RX6LC]B(T*7D4"7!?Z)#C$B
M#= K?/N/,1\93 @UZ;!*O/AJLH&T5[%=TM0<;*R"RN"[]E2!J3LYK:K)$8][
M?SU%\GU=ZV;9F'QUBJPT&S_)?B;SV1YAH'2V.PN7)B599/LN^9B9X1[XZH7!
M1X7\QJV)_.IP,+#NK+.B!P*(R5.'@A/KAQ8TP&+?&<KSKQ#11ZIX&N #7&@=
MPE;9<9,X8#X=_#1HR#CFWA3THN+B5HTYM"1+F=&,"2IP5 !58)'/Q,K^Y5@2
M_]"FO(2.2@Y*[>VX3%18 G'4IY?C%UACBNL(-LF9,AZV*T,2*?-KV5YS;W!>
MBXMFLP%P[DEL+]>K0(FW_6I-A4XM&2+8D0L? <)>''Q'8)CF)0)/7>A83\V<
M]0\W\*BWQ-LPC>G,"$Y6YH2[@', M+CHY>H@5=>%";4#8TM-&B Z4U_ZE^O#
MLI>W;&]-^?/D4_6)),&2:,4*@9X.;OQ4E+J$6ZF+,#-^)_=RVI+-N1.M6RZ7
M+WL7-ULYCZQ9Y7[;;151+#835?H6+'8(\))'/S70$B)T[FY/-N1W9QT8#_Q9
M5ZZV&B@["A4IZG.ZF#MXZ6I-#>A31&)[OWSL_3-V1_R^L86=!:_GQ/D$;6.2
M=_3Y([T#RBN.UJP\9P=6RE+7W,M?K$S=1NY>'JHRP'S^!Z73/?.X^24)7I9S
M%U6P(8&"^27>6Y*'%LP*]I\O)N0D+FZ/D0^KAM#AJI?K70C"/W=P>BU1#$%:
M4G&LL,UT8S/@JQY_H+J#,'"#^W6'TQ;YU_MW=FP?^KW?0.3S,'<A&LLL264V
M34IBC=Z!C>U35" 9LF4M%%T>U:5B$BU6X9>[ZY>1;?B-)/.OK@3H^84KO^!:
MB6W$/TB:V;]I#98TL@$"O63<KPO4H.ND 2"/?7?")#MKX<,5[CR!T]/Y]N=;
M=\OWW3>)*48/>1PC_]^#(!-=!__793MD3N]($7:Z _ (,WKI+ES8_C'*FU]#
M6]N<!Q1.#H8\ZRP)SNPF]PH'@U'WP"N'N*JQV)'DG8A'/)=^PK8LIK5PR*<J
MUKB"];\FYK)%G';!TMRM<O'7,H8_AB<%R(8U\P/B\(:"1@;?7;]BM7U6895Z
MS//%[=L-N0LX:4N?HM3TVSEVLP$^M9;;K;-[ZY];^P$H !MN_21_U2A33U#F
M-Q-:W3E%97-]^^";-BY0.RD'*VS+&!+RPA^]M/NVPX5AYSQIL9$A)#S)AVX7
M]5MP2N/QDZ#G1D$6/V6S'_75?QU>#YUM-"[[QBY3,GGUQO?F]B_Z-ENKDJY4
M:B2Z#O*-HC,\%]"Y20U]OORP\[27D$+7U87CP^:%E2N,@/9_P1$45RT%NOA"
M$OQCWK6Z^I-BD]&YE,85JE/L<PB. B$+Z=, *4H6$U$+VB$.(2\.!K!3DUER
M &%[O/RQ(1&T!J_/NCZGI>XO> <H GJ<IR,$T/"=IMKMHXT-,1K#BMB;56[:
MWGO/5PYI@$;CT$ 2S_9-_XJSF(QCB(_)"%%J")*RAR!FW8;@"D%V%8DKD&>Q
MP\ZID*N)'D!,*E"#*$+XYXLNUG9J$OP1C<\H&\#EQ!U2P@8\%"N*62I/+6]#
MLUM($671]91Z <34C!L-X/E[0LHG)!5E] ;QB>^ 6I<].\:'BZ(G8(7*)=&?
M#O:JJ>-O0 ,29#"Y;%T]DT3^;E^0)$@)>G9""?K>;%^Q;HJ YUF*DZCGCOXB
M2#2 #@T ?$:Y=>7A7P2'K0KJ@/\K_R=..MMY0[!(J' NA*48AZA![!:2J\,/
M<&-9ZG]0.UW'<X6;4_G4>FN!=\V?[Q45351(UKL+;;70 )_:*X5#;AU4=:1=
M:]C/J=B;:Q+WN?LS+GE H 6W'N>/2YS\'ORA2X &N 'F@U!<AVX3>MWR;7YZ
MDY83P6] MPY O<!#U*;)K;3Y,]E2E-:PFH:TH=H;%]0?G>D8?)CLT*>)_8N'
MZ-]E(YJ?U)\%BA<B,/0TP/OO:,5#R0$T(?R CV&%O2UN/R$7NB9+\C50B$_-
MO97L^>4=%7'.UHH<>:N.!SDCH7T\XY5[%H^W!.U[WR=$F8*'$+.4_U\P&D >
M,92E?D;0,B[[HU0])/&\75@]QPE+\?]L<9_YN5E#@$H$D9\(I/Y![H:?-9!)
MQ"?DZK"P'0V0H>C[OR->'(U#_MW*H.I3G<(=MUL)=Q$%I3^8(?*#XF^\Y[ )
M<P';)NI=_PS_G(V.M;?NYSU?K-+9^52'X1P=NE(NS-N$7\?,(-Y"S37GEGN8
MIH;RV)/[LR];ELM(;CR!LW!,LE]N08JNH+V4#K3@$"U>J7+LXKTC%]PE%<(U
M1G9-;K['/G9[Y452]J?D%!]ECEUZ=-.NR0S.84";))K/\LT>K-U)>@]6/]?#
MP,X>8JK0.\). SPO/9S\/64POTL-"[_/\2R3XL1R0G:1^5"NZWY\4F@6DL+$
M\$.%GW]Q?WP%)\2TXF _WEB>VIK<"DI@603=NYCHI>&:%1S3YY#FX.4#P+*8
M_QC@QWD &-X:J!+,F/_^[(._%EQY&RH<<B *.!56C1WQD^<K^UU:M%[IX:'O
MQE=2V]ZR<$P2,. N'3/&1>A7[.3G+DQA&G C'6*QC\A&I:P?&Z^GQ4FAA9=+
M@#FYG0XX=><2,>_^^VQ?%UZSOAB6'0CLGW-(NFW^XI21X0CM^1.=B."!WUC'
M")"]B_\2OU%9627?7RAB]98SY_D47_[^[DT&A_-\8+OY#L^;9XVAB_!X5>>#
MTD7U.B^V?;;J+O3)0J!CAIJ.6.C45J8G*U:>WP,TK=NPG 4;GI^VJK):V+0*
M!O%F.IN'\ 0[++G5[<[L%K<AN8ZZ)=W:2OO*EK1(A4 :X+YZ<I>0+YJO'.+<
M@EMIW/#=UYE"$LR6Y8A=!'-A=:NR4+ME;Y0A:9=R'D+E!?7EGPC4&Y*9LL],
M@)GA248VI!Y"/G.8F6N([\$A5+..,DGX97+BK&?M/,('0SV)0VR-[][ G:8C
MCW\AR '(2ZA^R =P%P'^E?&V;G-^0GO;KH?&/P@O7 KQ>[O4(62$!B '/1^*
MV+<T12JL[8H7MWK.@2ZM[GZ!'FT@"B$>L.PO\.U&R%9??N?N2)A:0N\H7V68
M= OB8B3R4@86 TK4@L;$$P*7._EI@'>3Y)5P:L/CH[/_UKYQ-$""2AD-L.1.
M-F=NI7+%W^5*)+F+'.(HGH]7G,$:*OP#358*?VSUBYM72=:02?6.R6,$GN>D
M'"X<O5T6M3N*$:7?Z4F0SZG<"B"K/;W:<M!(9A"!:R$MR5K_O=!%\!7WC-L=
M8>[:7V'(BRXJ$;1/GA*MER7+<'R@ 0[ &T+(U67[31K@B4X)#5#%\VV);;[\
M=&;;98C<1ZU>/</@7#0)U/A6LOJWY<%F#8='$(+:J!AL!A:_/&_XJN7$^=<V
M]#T(WZ0I30/\WD;0 .$7: "4!&+)@VRA L%G0\_()V]4V!"R/R;<WKR9\WQ\
MB6U&S@<VK&/C+!FPTT.Q'\(8DE-8_]N*R;VMO';@5 7;F$&*&W!YK*Q3WX1K
M0%/5H#'#!-_E?FV8&RSH+-J.6OZ)BQZ&5U,*FW\%DX? U2;:4AU]$>7@K%,%
MN*L!1OH^Q6Z(C,3ST0#)IQY_;!9Q6^WR^XHB?E@1Y&/VX!7?I\'*T,,SW'84
M_'?\ 4&9>AG7%[&7?P7*H_["@,)A1*W-\SWQ[I,CFQ)+(6M^2+$XT,%['?H2
M<KV@3] _^=^F'XGZBM\I&!?N.OC^9E4 :%,8.@TY]8&LP.=B/ P!%HT <B)S
MYW%/&%"XXR/2N86ZC;2F_*.T4\H)0IK2,+.8'4-^UPM-;,MK+]]ZKU\5YZ,7
MG:K\8XSH7B+6G]5^U.>S/)J!R#8NU.*UF4U-#"_Y$@WP/=-G7I9\'IZ F1J@
M5$GX'NN.]7-H!^FH',A."9-0E4'GYO+3GH3;>=W19?0Q? TQ6L\K+-TFIL.E
M8<:OTPEI>/=I5+ZRH)^:HR 5$OV8?GFJ3ZD+R@]-IUX4_\0YC07^0AO(SYDB
M-FQ]ZIZEY>N7;W8TMD=0'(9.S_H<7?R9"C^$N*N7[YX$G&7N"PV 39.+W2TY
M459?^81@NS!TYK]/,#%GK:&QX[]:F"_E*!K=WT($J1QN;_^W/R1B^2<V,$X6
MKP-"?A2,./9=.SH880Q[E<'H-/YE0\]Z4*E$S=-V$FYC6T@#6-S>&=K1V6Z*
MVO(1QB0$R3DGA.R*:Q(UZSXU;=_)4\4_?MRS&;&Y.4M?#Q>C ;J7B94<FC+C
M,=A\33OY?M_3L1P_==!C80*B>Y+X#:-,OJ%,$EL)'I40 I(/<2HGWIT[+_&3
M3@>4U7SM^8JUW=^(36'+R89]ZV3G[5GI?LBDN3PVKE=A8#U/9?- T#?620:Q
MWK,?078CB,!,B>5Y,/M2^YSE9>.04#T$R#60+.T9"SE#$CUUUI#"-UE'?*;P
MT4IW9AOFL]5Z&WK)L?U:_G<[I!A\UOVLRY<B*(>>B=;.*NAZ9??^X#!U7S0:
MZ"'G-8WC&^A7W8>^A^+KJ;=D@.0;5R(<');=WM)I .@25=!@_OZ[(G' 972?
M;6'?3&+UOC,6A)>*"\460T]*LMR=JB@DY>/_Z*%9_%6?FLNK"E@]=!*U/97F
M<U=\*XX#?(%9B-$;33^39M>,8W49$$U_Q[YP2$Q!7J9*)D&6&\<9&>77'M^)
M&! <4-WS17G<1'S(O\SM$#1KY)OS0O]., W0$#TVTXR<@ W;J S7S;1XS'94
MT "/NP@WKIQ*!JQ:^?V#3PV>_S-  ]SCPUU=!@H%HZPY]OO,9OW,MC;O9%SF
M4X]"B/VXYSMH)]?N/<*XZ V-O7 &ZB'!?+X-:_I)W42^KI'K*W3;*'6G(NB'
M?)Z']4.(;JN0V8*FUYDW%E@>;+5E,GIA[@#Y-H $\1[S?]I%Y=H&+#G93S F
M%+C31^+;=SBF'EWPP^M#0@B. 4I^;F7GK.*7Y4'#:ZAS<G\E_]PN7,.!1[0-
M;Y2YO]M?G0]UGV.4'^,;5/?QS<E[^!+>W<BK>9L(IK0N9PJ83MA2@QR:F]Q7
M>M\J/Q!HI(\8/-+04CIZ@\^/'GDT]GE0](M.1!/]H,1N D"0+1SZR>F'G_Q8
MT?$'?9O=L+IMQTW? _66EO(HD\L)NM")XG5<V/;L_17TG*RFS5\TWYR/:O[.
M*0+2B>$XEH4HG&F8J<F>;EMA%STA54YV[^XW<LS4'=\-C;W@OB<T )-G-.2?
M ,<*I+LZ?7-$'A%>DZ^QNC8U!XON .W8PIW/-%<A##+71D;3 %Q06T2WP!+Z
MA+&'Q($OI%[$L"-^WP$-("(?H9..>RA#Z%\T $'1,_HT(S_SC/C<-M'$^S P
M#7#W+^(JE?O_&UO D73<#7F[O[^Y_C<0A2A1$JSNJW;(DVQ.!0[&*62PR(61
M<&/\_4S#86]@_/\-ZB(F0(1O,9&E"ZP>4VVSF463VX!&>XWSUEYR[1HA1^*J
M'S=,:DK$<J *DS/!P>W&U\=+])ZF/2AJ;@C475^!%3M+<?XX)W%5H+_+KPG%
MX$&'9\*!P@?_N5EO"6:^KL[9XU+WC?-% S'B)=;.U/';R&A%Z5LT@-:E]2FS
M0'VVO=[85NRM=Y4 @',U'[:!;ZKO$G&L#\8XX61+1]*]6CO8"02KYV>H"YY.
M33A,F\I>8GKRO-5CQ@7S99OXE[P;ZTL6YA)@:BKO*OD>:/F/!ACVTYGS\.+(
MD,[''YJC;',-"[I$#OIU2\DH8'1M?Y!*G%<H3H,21I%<3L;*<B<@ZF7DYQC!
MG?PKO.#-L5*1M50J%X3[/ V0E-M_%]3K.YM7=+RAA>87G"JSBJK5?9X=5^PT
M42'NGI&)0U2 7X]^G%"Z4>BWD_7'JL1^:\\\M?G[?FK$IWZ=99]@M.8GH3*F
MX]HCM2^'V_G[Q*G^PGYAL<[YLA%#V("6,":TD832 \:IZXZ[^N;_.@G8AQ0[
M-'DJQ5<9!VP&0R:A:Z#-.\^/_::^(K,TAU@,S6I09$#^[\7\ M1H2<--GD9=
M)W:M?E'AB$J.U\?"A<GH?OI^8='=,C2FFOJ.!M!TY8=!EV%<PA6J6+:0N#SM
MX!<A?O1E%9 ?WJVJB;6MH90E:LTJ9)BC&:XSV]D?M"_-'@:K 39W\@F7J'MY
MCW&SWY>;=\[)H0'*-=#\78*!(E0EPD=-*8(10,C6CMZ>7S2O>2!55#@ZPACR
M ::?<Z.([*7[.H=^/+?S1+C-.R'M]H "L!@\5+RU/35UTLRYO/4U(B$I)>VP
M9OM?6,IW9E+6+[80G0T-S>83^BE!R&N;P!GGRL"[:O;T.6^ =+J+]J,=TL(R
M!&V]W(>Q*4!3%0V5(4YF%<CCY]%]>=>,\K=Y#TZG-U&/3T ]5:X9/:2T]G6]
MJ3%,!NF?SLGV1QI &I("70FKN'BWA-,BK@'\ZKTZQST@/#<L]/F[*I?7+8*^
M_+A2=:[U<;S:26*T55_'3?3.H9E)YZ(@;&[E$+P]$M;Z#+$D33!?+V]" Y/'
MD"6-(6XW?F&+-Q3K+!NR#I&?9.[\1*;G(KN1 Z?Z;-Z9KPUM6^DV[@K=I>=#
M"8&Q-4G/<;^JT=7W45YWQ1.'"&L=BL)R!'YZZ@UCKLTF#E2IZ$G(<9&F/$&.
MWT;O7MC<2IBF[U0'>'VJF$/\UXSK/@W067423_AJ<!RG>5;4>^+3V58EF<[)
M_YZ"4'DZI<L9;@CX$&$&465HJ-4'LU1_N9Q\YMZ4T;!,!2*9TL*A!R4^AIFD
MYAK<951U!C8#:G=&--C#5$T0+YST3;-MP%9(;/%[&L#&)R\V?R[_7UC!?3;'
MK>C%-NSZ.@VP60C RCIYH\^KH&#T>0BM]6&84X<L09,UU\"F233]]1['BUXJ
MD%_=6Y<&8(Y^WQ*O[<,AFB$8, (=RZ_4T8/\J-Y<_OBE;18Y;".-$('9?#0S
MK0,7SLC;NFY+M^Z$%;.4^>A/+[+M__#Q_>^01N'IM8J8ST!-QQ+-0?24F_-4
M5=EAU7O>?N&;X/Y"%>P$FHH^6!]6HW)Q<!V/KX$/G3SANYO]0=B]:P/5^?M[
M4'%/2E/B8;:D&14T=[8:)C^^WQMZ=;=?\Y_@&R^?,%V@^C/^A,FAZ;A$\Y$S
M8Z^9X[P)Y0'Q!14=C.>P>^=.+V+K(IH4$=TVR[5CSQ P3]SF>XCLQFT)Q$ML
MQ@S<,'/[./H$\U''P%Q92'9(P,9E!C=M#P34Y\G=]HF&5$%PH[E[1Z%RH9Q<
M]&.:/6,EMI)8$%%?W>R,X<"A-  "2:G;GDG\OU="$G<#(+M9D&IY&N#,EN#%
M2=9N<37O=CX;GJFTQ">A(&>VA!KS_-,#^1-$CM&^LZ9C@@;$']/@/7O8!W."
M62V?Z2MY":0"A8GBNYW@@R$^5G^LHOJQ60CN+'A,O?4_<7_]%Y?J]"'>)R.T
M/_^G/,7H* 2'X+1@ORTGNCFBBQ("EN!FNES4-)*.-2U !DRX@^6.6U"^H(_Y
M)!:]DH+=D_1Y(KNJWZ#B[ED-&<S[\P?A=N6/J#=.#KK61RY8WY;RJ_,)W/U%
M/9ZMUO]0DY6Q&DL]3*<!Q!IFW42WUI4YFT.O>7EICZP<#:H''M"+G>C4M[LS
M;_&Z8#NTO=>G)COD,_JHXBPL&ZD2=#6,RQR(7:SW2L1;U94KX>J.RV^#)V0$
MJD0$$Y@/&5;"M_L-]9H=^ ;^K<T?U65@O6F "K#SHUGDF18;.-WONB!/T&@I
MG$FC P[6OM'#E1C<P::$T6W ,XU >8&("@#W+2L7M>>7T/?NKAR("OI([LLN
M0F/\L]$QZ:939F/ZK)]8^W5Q?N_S B\EW.UGZAHXIBC'/Q_8#O_X[L5);JE/
MT#$ KEF_USPL8>P3X;%NT2X;U&':<8"N6?KE(/_1NH RK>R4,GI2B7XP&9E*
MAD#_N9J?*)]B3F^-JZ=9VXO0HPT^4>L58>PAZ=N_8848#23%!&N4ZJT_%+I9
ME*699JD*M6I7W?U\G=O(BIO;Z"'@OY_(U2BM,QW&4BR[ #TNPDZM"8(\<'^O
MU%[L\O[[ OXP8_\_$\I^JZV348CJM'$;[(C>/S-IF^F&.K6N%-4OXC+FC9,C
M"V5WX#8T0)<1Q&,8>G2>>$Y39CV/QY-[[DFY3);[<<WW4&S6 XR(6?\^G\DS
MM-@Y=F_R/@<1C%E^O>FH#JG-+4J6.N?BX&Y4D-NSUR<JT>:LP2UX/,B(/"O2
MQ95K]I1(&8=GD<+2HUVL;\ )6^> <.U00D[(%'Z,.3W8'=;&F>7G,?>&[6FE
M-6>P6#\[G=CE%39OZ)@P!S$XA0!G-R'\E%O)==K5S[24^?E3O7P0@QR@6A \
M>]FPD=6V/4SM1:YZZADY7Y:_Z5JJZNV&[A97K"'TG:GLX<0T+I0 ?*1:=)A:
M ;)\X3BH]N!%O^[*BKV&CM<32T,B>'?9BG<?Z42,Z ]HN=,R\.QM0)(=@W")
M6 !]7"S5@;W8Q?FUYR&S:-X,U;1A5+I7.*#XPL^<X*1K\1NM429OU!)_,OK>
M7["Y9_>63V:G4L9L %F/K$O!/'7)U>>-Y>_^^>?[X]M+CQCH4T<0CK;,7IZ3
MXD]:E&-=^LU=GQ)-LHWCS30S)FRA+J"D*MZF;\_MA76U<[(]]"ITODV(-:>X
M*+N=F%//^NFR.#1FU2CCR//=>P-11P*K2FJ.4.9=/OJ)#)% E*(R67"3<-W.
M(OO(\_W+L%E'U4VF63?WL$I1T54P4#!1C_K"N;DA>Z"VNFY\>]MO(MC#G]\N
M7<4=BQWINOG-1,!K (SB$Q53,?04T!$J7CG.>E;>Y[!7R&KAX;B*W][C:DLR
M$^-*#A^1I8I4,>S[S$3 GZ],[*1UJ"E/SJ=ZVD&6I;QOKVN>HB?<MH60:GZ0
MDC,W"U2'/?0S@T[_Y([_0'=S2BQ9UY9=X4H<FU O ;/)3 -$Y%%%;A4V;M$
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M4X">A^F?Z?<8(G2II _$!U,;TV1T6]"H)MIS\U(A!.'W/)V)#W[(D]"ET+:
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MC],:4W;!G[4_?7<,^VVY&Z09J3^3'.Y]I,FZA@Q1I0(>DQAZ,O*X@"%2JC'
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MJKJZ.D_S.N,MC(2\_% 1B2;R0.6!C::81P>%G_@K)9?W^:G]X;C+T%L]NOF
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M=901:G(3!P4$J\C);.>@+7ZY@ZJV+W@KU1"$0B#E%:'H''3#'Z7\;)&BC=I
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MZ70]=[X.1HK+T0=KK[;U($%DF=H)_$0)$1Q1&^QF(E(ZMZB:X3HKL4H3)!+
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M*POCMQF,)LF\I$?3^*+2IF#<PIRUE@?S&/.'L-B=QC>WV'+DY663D:<VY.>
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M2_S33%R%6MBMA^SMO8KT%8%9[AW;QV#* Y3&9?G'NW?.3,]!DI\9VZG_\9Z
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MUS3MKZBZMB?WZ96<2$I(->E1V#;Z*ISP8JK9./^N_XW6*W.-"ZZ4/RXKD0Y
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M@641@L*_W &]3A9@J"N$%2I@E;;D9#=*!>"@\0!X-_0+1C"[8J05J3H1IU0
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M9H ,:1IL-;U/'Z4G:L0P95!N&(,^]]=2-_.Q]1'FY73+K>Q\K0!?)S);!8R
M#?!T) OUM+LJ,./K)&N@[DT,1:0"J?G;%BD60_+H2U\C+B;KUBS6GCR3M1%>
M&6BA.]9JK1P^%C!*^$"7W-N10[J7PF=@<IB\3^>0])P7%TU%FJ3Q%M8I7X0$
M;E !TA4!\@.*14@HUK,JYJB :U6U5+AO78C4!(ZI^X'\[IN"OC$-]CA ?ZR?
M(I[GVA3E30S2SY>WC?<)#PAMX"V[,K95C";?T7(+3UN<T)TPTHIR(GY:F!S-
M26]:71;KMO$9=OANWG4WZY(]*=:*6HE1G6\);M8B:M4#+[I?\>0$>.H (H>#
M[\Z>;R*(2!L_WZL>]RG"<%FBH6:A+8#*"-'C3V>^5 %IQZ"(62Q-ZU.*3?RB
MI.NG"\(./2N;-SP/;78I.O5^ZLW<>CLV9NS6@8S+]DDCWZY+1_6",]B:(5G2
M[#<S&W2<[^YTXNL$.GEM,![7UJU!HXI*'2(RDG<1*(T^NN])Y1DKME;?*!TJ
M:Q'O-4>SOVX\4\3U.&T4<B]JA_&+ZAO/1<_;)-'P#*[<*9XV>4AY&;\XV4#P
ME-\3?_%5(M0Y1JF(#5Y]WV#W6D7F6\MDZF(?E,Z'E,9Y9SM]<DY-YY9^U(HF
MC#YT3)1_W$0S2:=>8NA;#D2Y-;#[R444K]IS-MC(!ATC@!A-FF%KI-N@QY^-
M#[G(.&BI]ZK4[@[-83OQNZ@JR?XK+L">?(<=U;UNSQG*J;LE,X_WGWKN/R(J
MNWU%!;0S:\A9*@!P6AF&T75:$I:H?6[D\"F?M)7;@_V8LRR/'M8%YE$\;!L=
MTM(G+H AN,Q5"^]<BO?O=.4O9Y_9A\DWPE@8&M@P_8DQRNL"QW<J(/3(;$VO
M&<M)^[X76-M3]AS2B<[(MM-RU=_ P$ZSI6'>]4P^N"<X YIP%T<5VGBR6DL]
MPL8>9ZVXGUK;5)#7]FS5L6/-,2F<[O%'R8XXS'FJYQN;XKMCQQ#*,CHF&<:#
M%<.#@CN<B#.]>D0NO;6+X)L82P&?4.M+D%;^M+\F6U/0I3]!:I?/_NZG O 2
M/(:<Z/"./L;"!R@36<H3;T+C_*JP\1-=;[\XD0[3SJX)_?QJ1LEP/L+;X$0R
MP4QNEWP$19Y5D] P.#(VXDI_0JZ_Z9%LH::C K03E><F5JL >HH4$@W\' U"
MI9UDV7F$OB*80'"P=PWT#O,,&D=S:I5$V'JT@?]:IV%LD)"X>#):TA9)F%5C
M)]/&;1X)> @?8HG'Z.9PM<$_!QA>.1:^#8Y#\!:P/0,SSA@-4)R4C$.(VWV0
MIF_Z"]T:74ZY/=>Q*.!S*V>GGL0?U>2"BX".*,_^!\V02N[W"!3-_?%8AO$E
M\(- %7 %C%(!_=J,,U.Z38ON/3^=(4E":JDF5W#_!.ZLH1&60./\7U4;UQ8%
MH16/Y(C+#/'V%<-<01')P0+@Z$<J"+Q/:7(;Q9&#KORV,-*F*SL!!_XSG287
M#QM:)V'MF%S,0A;Y7PTWWYT]C\TFOWCF1,R.["A7:W1J0SK:H[MX?@D5QODE
M(U3FPPY-=KZB*DT*318I$E7 V>.23QI0K]Y%E"1.*Z422^-\RL,W0;\E,,_T
M.EHP[Z8HD39TH7SZZ@@WX Y[?L896]U11T9$(G0M3BD?0[*2YB+CI?N\??J"
MW=\BJEA'O\G29-.YW4[?$(Y-SN(@H6FO OD7ZRJP&3*NOCQ$8?%FMMQ6<02+
MQ$MC350*\Y98Q*2[*\__JY\)OO@4>:2T&:XZ2!\R&KND^+A:IW9]1(@V0JS+
M0'W&<)?@SC?FV9%%D6S+S)K$0"ZAYN!)^3ID9U1=>8*#]@U(4J \&QI>O[;"
M ;#U)Z7=<C1]&=O /<KMO+MQTK!T]C;.T3W#%&]*;FXU+*+O4..7SY/M.E.]
MB'E+@ABMV2YX I^IPLE'P%?7D+<L0;%6:^^[0!QH=LMKAKJ080O[=](ZP:<(
M&J;N,*9O1KJX8J?V>!<SF\%F;6IR,9<F[2O@;/=_T5*"V8N0M,9L>GOR8LD!
MC..B=[=!?>8PTJP[Q)_0$S3G"Z5G3*?R)ANM,)HC(+GUPW<$6<]L=6B=D=$)
M.2<CB8)Q\4B[R3S_N/47:T"3H229EIVF5L('<Q%K?E+TATG/XH1!Y9LX/&_O
MI8Z-T'T=1Z(1_ODJY$1'"3BP+I,3H"[Q_Y41Z QI9CO:9^5!=7:*4.3D]0+E
M@Y#D&_YU1!6L%",1Z[C3@Q 3EKP?RM3.C-2./3_%)VP(RGVUL:<QRBK$S'(,
MP64R1M)*D"Z\!>ZX"3\ ;V#X3>3?$! M?>HHL8^6CAH-,K\%/*PJI5<GJ8!D
M@J PMD-,@\9R$")2>C6K'1Z$?D &NH21:()2E&  CZQ/4 'I>^>*5D K+>"\
M>B7)R:JX@7]GRVBMNN9<TINKYHZ/F$+E^9Y8WC_VO/GN!'FMLN3\\-#,K,]C
M3"J'>0_!I(6C_E;8;'#HJ1(-WP\LH!NO@G6FGN3,^:B\ 5N70WW9Y88QMAE<
M%6#0=]\7;L(LMM!SJ:.'S-_JU'8^8D.]Z0S#4X"QYHV;9YR(,Y69\O!;GP]S
M<JYV5#B>F"^9I"I?2K--UZ-T:[[4]),2@, Y"2A=M%[_P<(WHGO%FTK<3-Q7
M!?A$.^:VPRZ.X3IU1::>.STL,T@7#]'&2]_W@T%^EKLD$?RLUKJO:TS#8CK$
M\^Z5KS?YHC5]I2V@-](4%=E-+@T4,,[6LR,6&&PR(&;<<B#G'4@TB+=%%4MO
M[RWP79G]ON'!NOMFPUZXE0!JV3G??H,:STEKM%F0G<BF4])H?&E=EBT6& ?U
MO%]_C]YWKY6VV"ETPJUT\ML)W.X"MZ&N#K^5*08:^>T#S@4#EU^,%@[RJ.]E
M\?'<NAL[VI*>ZV6[R2X?U#ZJU:DPA7KM^"R%<JNT0)HV3+65&[,Y>L;DWF%P
MA=-;U@0/B7:R&[R0V^-8[93B43B($#B/%^M5 .B)/TSX:_@R4&X&,4L82@%6
MXCFY5P60?0CR/AS_IC95!?R4 /Y=5HD*<*K B%^3>UT^^\ IX>#8!?!5JM--
M UM^K\TBSQ">%+[LP6&0]%S[+X7F;=%W#<JP,!945I1'H3VH1.\/4#"VA%([
M^87C(+91 2+A6(%W1?==TU4%KO5 9OOY>KLYW8+41%%_T/)[,VS-[H\/5<<X
MQ_ID+ LO#\!2A[;*W<P5RPL,LF4SUFOK576\XR1ETU>OF8&J<,2A]?'@Q5YN
MAH#PJ$'[O0Y0%^Z&U:UWY66(;/2"P."5X>=S2IZL<*[-^=WGR)QUHYY9VOBH
MM6Z\]/RF%^AOO]OEOD)@+5(?=QO,>G%BX5!O=.)5J\NF]MB8RV*IXTN_LF[I
M _SF;9;>Q3I5U3YE)6&A,?)!B3"$<8S/J]^2>O2P#4I'TXVYJY6*0G6W0*\J
M!02%Y)TL5ZI)E&4$QPV$#6-)_)&WOM"B+9'*KW1S/&LSJ8WUU$_X>2I6ZR>Z
M"GC)VRXF3C0A[%DL)5FRD]<^W_V'3^&1L;&] 2?'T0HS @(59EX:KS)FT@BI
M!)L4MH+T[!T9G?V8RY7JD43:AN,>M@U]+^D3HRJ >Z,)[(GXOKNO8'F5WNEG
M^B][$4IL"CVHI'TOGOJ8_FIA[8*E8\.#M&WF+P40M.U)/UGB[;\6C0G,1WA%
M'!?DMA3F]G9D$):^VGYRP"-!9O!YD%FQ]&75HD7GLBN0P!U7 ;OO6/J1BJ.G
MOM:"EQ)$N8L4$_+O,:LUZRC\771EE6R+=#Z\D)E1]=F-$ S'>RJ00_E,-,=<
M.IZ+&8T>4]C*HH4TFJ8X.)#"4"+YM6-:TD.+QQP]%8"*4P&IS?#C/CJ)"F_'
M#!W&2$WQ&,6%<8S"C*RK=<4+<P^:1%HV;R<+WJ1I-,PU4 %UK:WI,OZ.$\]>
M^4X,92+4O&5&:6W3.^*$ DU7:/S03@2.1_"0,WR]MB(/X33PG_KA?$PA=17P
MBQ["!69RZUU*\LBGH$G$5$N_W$OYH!AI9_I"M_^E)H:WW%PZ!/5_@0+6J(!=
MB",:<7R$6>"R$<CX2M[!R7<8<J)<!6CAB4J3'S8O:7F[682#7W=TG/HO-GY<
M7N7;NSI!Y/R/KOEW"XB)=)'+.V12M.SZ.=@]X!Q2M)//_=#+B))'3X?227_\
MV-& ?C ?'(T<43@ZQHMHI:\[ ON7,95\Y$35[ CF'FJ*AU%=,,I%UG@1X7;2
M-5!Q)=1/E4#CV(:07D9&EF40EGT'G[0;_Y0I\3:P0'"OFY+$)4E0#MQ6AXFL
M,-Z$=;-AWC/U$!TO.TY1%].&8:0[YKJLJNF$+Y?:[?AHX&4=*QW\Y.L]@="7
M1OK[)MHO![[X?W-,##TVHJCHZ&B0SH(7,C(@[EM/43=X52])J"A"]([D8*3C
M>2F;"=\+QVD/G9I/@*<XL"1(\2F7686IG<JD9_!!@BA_(1(KS 2BEF<1Q+P'
MQBE0_=I_ZFF*ISN!CI6R"48BV.L;SX"3*> .QD2-C2*,AU2FL=)W9#ER3EZQ
M< ^I G]L^1#>YB)[ES[%<:7G9)F;X11/.9V-P:B 'QB5-@H77U"D,CM:J\T5
M9M /C+V8M#^I.,]L[2A+@28OOKR^&AP["R=%NY#CE%/;TR4%_[!= ;T'VXZ"
M"EFA&*IQ O^R,$[[G6$(OW JO2P)CYVB"2\2X3V3 &D8>F=/#)YV@F19(^]4
MKCA4_BG8(/A$149&5$G]=(>,V9WUV@NF0,HM1CK.JU!1&\AMQU1*V C4$9J=
M;VL7HW9!45,CP_#<\7H2!O%S8P9;V;=1S";[?[U&>_2&5.FQ@\+680C42+C
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M":RCTLF'J\K&-UFJSW4Q<[W2?,'NUYD+8OM+FW-(A53_(_U'AYTW^/8_%-4
M>C*2#>=6\<"]G6X] 4A EE3@+XI@\L[;Z2M.3SVE]O_G6J*KGG@*M#MRMWO<
M([)-K=6)O#_EQV/:_E=<7G.S78J,)BBW4XWFLM,JB2$96NPLUOY+Z2; [?]\
MH52?_P]02P$"% ,4    " #'J'M:+Z)3F- 0  #3L   $0
M@ $     8G)T>"TR,#(T,3(S,2YX<V102P$"% ,4    " #'J'M:R/@R$J(5
M  !W"0$ %0              @ '_$   8G)T>"TR,#(T,3(S,5]C86PN>&UL
M4$L! A0#%     @ QZA[6K/W0T#V-P  ":X# !4              ( !U"8
M &)R='@M,C R-#$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( ,>H>UKQ5B+/FWX
M %UR!P 5              "  ?U>  !B<G1X+3(P,C0Q,C,Q7VQA8BYX;6Q0
M2P$"% ,4    " #'J'M:=2%I@[]<  !H&@8 %0              @ '+W0
M8G)T>"TR,#(T,3(S,5]P<F4N>&UL4$L! A0#%     @ QZA[6D5 9:FU P
M-0\   D              ( !O3H! &5X+3(S+FAT;5!+ 0(4 Q0    ( ,>H
M>UHT4[I/OAT  -G-   +              "  9D^ 0!E>#$P+30P+FAT;5!+
M 0(4 Q0    ( ,>H>UI8*TCMO!T  (?.   +              "  8!< 0!E
M>#$P+30Q+FAT;5!+ 0(4 Q0    ( ,>H>UJ*H>2TE!T  "C)   +
M      "  65Z 0!E>#$P+30R+FAT;5!+ 0(4 Q0    ( ,>H>UH6RRLWD!L
M *K    +              "  2*8 0!E>#$P+30S+FAT;5!+ 0(4 Q0    (
M ,>H>UK2O.HZJ1L  "G    +              "  =NS 0!E>#$P+30T+FAT
M;5!+ 0(4 Q0    ( ,>H>UI?-:&=CQL  $S    +              "  :W/
M 0!E>#$P+30U+FAT;5!+ 0(4 Q0    ( ,>H>UHXUNJYLF4  %7$ @ *
M          "  67K 0!E>#$P+3<N:'1M4$L! A0#%     @ QZA[6B3M]8L<
M)@  %4<!  @              ( !/U$" &5X,3DN:'1M4$L! A0#%     @
MQZA[6C-$N@(;"   IT$   H              ( !@7<" &5X,S$M,2YH=&U0
M2P$"% ,4    " #'J'M:S$1>W)T'   A+0  "@              @ '$?P(
M97@S,2TR+FAT;5!+ 0(4 Q0    ( ,>H>UH=1"I5T 0  '\D   (
M      "  8F' @!E>#,R+FAT;5!+ 0(4 Q0    ( ,>H>UJ1(1.=(PT# (N#
M'  ,              "  7^, @!F;W)M,3 M:RYH=&U02P$"% ,4    " #'
MJ'M:!Y[/;77, 0#[[P$ $               @ ',F04 9F]R;3$P+6M?,# Q
M+FIP9U!+ 0(4 Q0    ( ,>H>UJ?WHA0\50# &E> P 0              "
M 6]F!P!F;W)M,3 M:U\P,#(N:G!G4$L! A0#%     @ QZA[6NBO?!W))0,
M?BT# !               ( !CKL* &9O<FTQ,"UK7S P,RYJ<&=02P$"% ,4
M    " #'J'M:$M['[:A-  "%3P  $               @ &%X0T 9F]R;3$P
M+6M?,# T+FIP9U!+ 0(4 Q0    ( ,>H>UI(9/NO53$#  ]" P 0
M      "  5LO#@!F;W)M,3 M:U\P,#4N:G!G4$L%!@     7 !< 7 4  -Y@
$$0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:BRTX="http://biorestorative.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="brtx-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2025-03-26</instant>
        </period>
    </context>
    <context id="From2024-10-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-11-062024-11-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2024-11-06</startDate>
            <endDate>2024-11-06</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-27</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ComputerSoftwareAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ComputerSoftwareAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ComputerSoftwareAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ManufacturingEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ManufacturingEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">BRTX:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PatentsAndTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PatentsAndTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PatentsAndTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-08</instant>
        </period>
    </context>
    <context id="From2022-09-082022-09-08_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-08</startDate>
            <endDate>2022-09-08</endDate>
        </period>
    </context>
    <context id="From2022-09-082022-09-08_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-08</startDate>
            <endDate>2022-09-08</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-242022-10-25_us-gaap_CommonClassBMember_custom_AuctusFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-25</endDate>
        </period>
    </context>
    <context id="From2022-10-242022-10-25_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-25</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-04_custom_AuctusFundLLCMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-04</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-04_custom_AuctusFundLLCMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-04</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-18_custom_TwoThousandTwentyOneStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-10</instant>
        </period>
    </context>
    <context id="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-10</instant>
        </period>
    </context>
    <context id="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-13</instant>
        </period>
    </context>
    <context id="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-13</instant>
        </period>
    </context>
    <context id="AsOf2024-07-22_custom_TwoThousandAndTwentyOneStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-22</instant>
        </period>
    </context>
    <context id="AsOf2024-07-23_custom_TwoThousandAndTwentyOneStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-23</instant>
        </period>
    </context>
    <context id="From2023-04-012023-04-30_us-gaap_CommonStockMember_custom_DemandSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">BRTX:DemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-122023-07-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2023-07-12</startDate>
            <endDate>2023-07-13</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2023-07-13</instant>
        </period>
    </context>
    <context id="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-06_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="From2024-02-062024-02-06_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="From2024-02-062024-02-06_us-gaap_CommonStockMember_custom_AuctusFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="From2024-02-062024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="From2024-02-052024-02-05_us-gaap_CommonStockMember_custom_RothCapitalPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember_custom_RothCapitalPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">BRTX:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExistingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_NewWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:NewWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:NewWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember29065375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember29065765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">BRTX:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember29066796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SectionThreeHundredAndEightyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">BRTX:SectionThreeHundredAndEightyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MelvilleLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_custom_ExistingWarrantMember_custom_BlackScholesOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2024-02-08</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BlackScholesOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BlackScholesOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_BlackScholesOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_BlackScholesOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">BRTX:BlackScholesOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ExistingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_custom_ExistingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_custom_ExistingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_custom_ExistingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ExistingWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">BRTX:ExistingWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-27</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">BRTX:ATMProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-27</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-27</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-27_us-gaap_SubsequentEventMember_custom_AuctusFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000005">0001505497</dei:EntityCentralIndexKey>
    <BRTX:DeferredOfferingCost
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0087"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0113"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0125"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0126"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0195"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GrantIncome
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0221"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GainOnExchangeOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0228"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GainOnExchangeOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:PaymentsForProceedsFromDeferredOfferingCosts
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:IssuanceOfCommonStockHeldInAbeyance
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_us-gaap_ProductMember"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MinimumMember"
      id="xdx2ixbrl0595">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl0645"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="AsOf2024-12-31_custom_PatentsAndTrademarksMember"
      id="xdx2ixbrl0738"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31_custom_PatentsAndTrademarkMember"
      id="xdx2ixbrl0750"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_custom_PatentsAndTrademarkMember"
      id="xdx2ixbrl0762"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1001"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1013"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1021"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember29066796"
      id="xdx2ixbrl1085"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember29066796"
      id="xdx2ixbrl1089"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1091"
      unitRef="Shares"
      xsi:nil="true"/>
    <BRTX:DeferredTaxAssetsRightOfUseAsset
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1144"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1177"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1178"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1189"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1190"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1198"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1199"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1210"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1211"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1231"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="AsOf2023-12-31" id="xdx2ixbrl1273">http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="AsOf2024-12-31" id="xdx2ixbrl1274">http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1387"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000012">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000013">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000014">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000015">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000016">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000018">001-37603</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000019">BIORESTORATIVE THERAPIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000020">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000021">30-1341024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000022">40     Marcus Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-12-31" id="Fact000023">Suite 1</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000024">Melville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000025">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000026">11747</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000027">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000028">760-8100</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-12-31" id="Fact000029">Common     Stock $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-12-31" id="Fact000030">BRTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-12-31" id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000032">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000033">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000034">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000035">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000036">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000037">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000038">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000039">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000040">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000041">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000042"
      unitRef="USD">11463696</dei:EntityPublicFloat>
    <dei:EntityBankruptcyProceedingsReportingCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000043">true</dei:EntityBankruptcyProceedingsReportingCurrent>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-26"
      decimals="INF"
      id="Fact000044"
      unitRef="Shares">7504780</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000045">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000048">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
corporate IT infrastructure, communication networks, and related systems are essential operational components. These systems manage product
development, internal and external communications, accounting functions, data storage, and other critical operations. Our business depends
on secure handling of proprietary, confidential, and sensitive data.&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zzwvf59E06n5"&gt;Our
Chief Financial Officer oversees information security efforts in conjunction with a &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zhfkuwQnkeg1"&gt;third-party&lt;/span&gt; IT services company and reports material
cybersecurity matters to the Chief Executive Officer and Board of Directors&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&#160;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000049">Our
Chief Financial Officer oversees information security efforts in conjunction with a &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zhfkuwQnkeg1"&gt;third-party&lt;/span&gt; IT services company and reports material
cybersecurity matters to the Chief Executive Officer and Board of Directors</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000050">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000053">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zWCGyXxRAmw"&gt;recognize the importance of assessing, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zrUEszxx1fJa"&gt;identifying&lt;/span&gt;, and managing cybersecurity risks. These include operational vulnerabilities, intellectual
property theft, fraud, extortion, potential harm to stakeholders, regulatory compliance issues, and associated legal, financial, and
reputational consequences&lt;/span&gt;.&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;In
partnership with external consultants, we maintain comprehensive information security processes to identify and mitigate material cybersecurity
risks. Our protective measures include:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Technical,
                                            physical, and organizational safeguards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disaster
                                            recovery and business continuity planning&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Data
                                            encryption and network security controls&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Access
                                            restrictions and physical security measures&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
                                            asset management&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Continuous
                                            systems monitoring&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee
                                            security training&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
assessment to date shows that cybersecurity incidents and vulnerabilities have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240101__20241231_zcRFntJBGU59"&gt;not&lt;/span&gt; materially impacted our business operations, financial
performance, or strategic direction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
ongoing monitoring and evaluation have not identified any cybersecurity risks that are expected to significantly affect our operational
capabilities, financial condition, or business objectives in the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&#160;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000054">recognize the importance of assessing, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zrUEszxx1fJa"&gt;identifying&lt;/span&gt;, and managing cybersecurity risks. These include operational vulnerabilities, intellectual
property theft, fraud, extortion, potential harm to stakeholders, regulatory compliance issues, and associated legal, financial, and
reputational consequences</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000055">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000056">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <BRTX:NoInsiderTradingFlag contextRef="From2024-01-01to2024-12-31" id="Fact000058">true</BRTX:NoInsiderTradingFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact000059">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000060">688</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000061">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have audited the accompanying consolidated balance sheets of BioRestorative Therapies, Inc. (the &#x201c;Company&#x201d;) as of December
31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders&#x2019; equity and cash flows for each of
the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024,
in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000062">Marcum LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000063">Marlton, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">547890</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">884377</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">10184701</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">10181618</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">188400</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">19300</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">223230</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">305231</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000083"
      unitRef="USD">11144221</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000084"
      unitRef="USD">11390526</us-gaap:AssetsCurrent>
    <BRTX:DeferredOfferingCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">148697</BRTX:DeferredOfferingCost>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">362936</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">356055</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">151447</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000095"
      unitRef="USD">623945</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">713692</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">12279799</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">12611720</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">483070</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">189389</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">744485</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000111"
      unitRef="USD">711686</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000114"
      unitRef="USD">162317</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000116"
      unitRef="USD">2520851</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000117"
      unitRef="USD">1543953</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000119"
      unitRef="USD">3748406</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000120"
      unitRef="USD">2607345</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000122"
      unitRef="USD">3748406</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">2607345</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000134"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000136"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000138"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000140"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000149"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000151"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000153"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000155"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000142"
      unitRef="USD">13982</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000143"
      unitRef="USD">13982</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000157"
      unitRef="USD">13982</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000158"
      unitRef="USD">13982</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000163"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000165"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000167"
      unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000169"
      unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000171"
      unitRef="Shares">6919919</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000173"
      unitRef="Shares">6919919</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000175"
      unitRef="Shares">4706917</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000177"
      unitRef="Shares">4706917</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000160"
      unitRef="USD">692</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000161"
      unitRef="USD">471</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000179"
      unitRef="USD">164195434</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">156689256</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000182"
      unitRef="USD">-155678715</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000183"
      unitRef="USD">-146699334</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000185"
      unitRef="USD">8531393</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000186"
      unitRef="USD">10004375</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000188"
      unitRef="USD">12279799</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">12611720</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000191"
      unitRef="USD">401000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">145800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000194"
      unitRef="USD">28072</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">372928</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">145800</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000203"
      unitRef="USD">5348709</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">4034591</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000206"
      unitRef="USD">6579413</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">11331983</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000209"
      unitRef="USD">11928122</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">15366574</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000212"
      unitRef="USD">-11555194</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000213"
      unitRef="USD">-15220774</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000218"
      unitRef="USD">616077</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">552293</us-gaap:InterestIncomeExpenseNet>
    <BRTX:GrantIncome
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000222"
      unitRef="USD">83333</BRTX:GrantIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000224"
      unitRef="USD">150850</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000225"
      unitRef="USD">169664</us-gaap:OtherNonoperatingIncomeExpense>
    <BRTX:GainOnExchangeOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">1711698</BRTX:GainOnExchangeOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000230"
      unitRef="USD">97188</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000231"
      unitRef="USD">3997780</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000233"
      unitRef="USD">2575813</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000234"
      unitRef="USD">4803070</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000236"
      unitRef="USD">-8979381</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">-10417704</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000239"
      unitRef="USDPShares">-1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000241"
      unitRef="USDPShares">-1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000243"
      unitRef="USDPShares">-2.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000245"
      unitRef="USDPShares">-2.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000247"
      unitRef="Shares">7763932</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000249"
      unitRef="Shares">7763932</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000251"
      unitRef="Shares">4218347</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000253"
      unitRef="Shares">4218347</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000261"
      unitRef="Shares">1518158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000255"
      unitRef="USD">15182</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000263"
      unitRef="Shares">3677775</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000256"
      unitRef="USD">369</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000257"
      unitRef="USD">146556418</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000258"
      unitRef="USD">-136281630</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000259"
      unitRef="USD">10290339</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000277"
      unitRef="Shares">89840</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000272"
      unitRef="USD">9</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000273"
      unitRef="USD">4633655</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000275"
      unitRef="USD">4633664</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000281"
      unitRef="USD">3141803</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000283"
      unitRef="USD">3141803</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">1442</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000287"
      unitRef="USD">7500</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000289"
      unitRef="USD">7500</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000299"
      unitRef="Shares">-120000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000293"
      unitRef="USD">-1200</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000301"
      unitRef="Shares">120000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000294"
      unitRef="USD">12</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000295"
      unitRef="USD">1188</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000309"
      unitRef="Shares">817860</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000304"
      unitRef="USD">81</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000305"
      unitRef="USD">2348692</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000307"
      unitRef="USD">2348773</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000314"
      unitRef="USD">-10417704</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000315"
      unitRef="USD">-10417704</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000323"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000317"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000325"
      unitRef="Shares">4706917</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000318"
      unitRef="USD">471</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000319"
      unitRef="USD">156689256</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000320"
      unitRef="USD">-146699334</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000321"
      unitRef="USD">10004375</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000333"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000327"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000335"
      unitRef="Shares">4706917</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000328"
      unitRef="USD">471</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000329"
      unitRef="USD">156689256</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000330"
      unitRef="USD">-146699334</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000331"
      unitRef="USD">10004375</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000343"
      unitRef="Shares">2000000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000338"
      unitRef="USD">200</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">4742043</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000341"
      unitRef="USD">4742243</us-gaap:StockIssuedDuringPeriodValueOther>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000351"
      unitRef="Shares">-34825</BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholdingShares>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000346"
      unitRef="USD">-4</BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000347"
      unitRef="USD">-48406</BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding>
    <BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000349"
      unitRef="USD">-48410</BRTX:StockReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding>
    <BRTX:StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000359"
      unitRef="Shares">150000</BRTX:StockIssuedDuringPeriodSharesCommonStockIssuedInConnectionWithAbeyanceShares>
    <BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000354"
      unitRef="USD">15</BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares>
    <BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">-15</BRTX:StockIssuedDuringPeriodValueCommonStockIssuedInConnectionWithAbeyanceShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000373"
      unitRef="Shares">97827</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000368"
      unitRef="USD">10</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">985028</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000371"
      unitRef="USD">985038</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000377"
      unitRef="USD">1827528</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000379"
      unitRef="USD">1827528</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000384"
      unitRef="USD">-8979381</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000385"
      unitRef="USD">-8979381</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000393"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000387"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000395"
      unitRef="Shares">6919919</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000388"
      unitRef="USD">692</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000389"
      unitRef="USD">164195434</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000390"
      unitRef="USD">-155678715</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000391"
      unitRef="USD">8531393</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000403"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      id="Fact000397"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000405"
      unitRef="Shares">6919919</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000398"
      unitRef="USD">692</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000399"
      unitRef="USD">164195434</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000400"
      unitRef="USD">-155678715</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000401"
      unitRef="USD">8531393</us-gaap:StockholdersEquity>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000408"
      unitRef="Shares">3351580</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000410"
      unitRef="Shares">2150000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <BRTX:SharesHeldInAbeyance
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000412"
      unitRef="Shares">1201580</BRTX:SharesHeldInAbeyance>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000417"
      unitRef="USD">-8979381</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000418"
      unitRef="USD">-10417704</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000423"
      unitRef="USD">189056</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000424"
      unitRef="USD">165735</us-gaap:DepreciationAndAmortization>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000426"
      unitRef="USD">623801</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000427"
      unitRef="USD">569068</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000429"
      unitRef="USD">2812566</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000430"
      unitRef="USD">7782967</us-gaap:ShareBasedCompensation>
    <BRTX:NoncashLeaseExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000432"
      unitRef="USD">151447</BRTX:NoncashLeaseExpense>
    <BRTX:NoncashLeaseExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000433"
      unitRef="USD">90313</BRTX:NoncashLeaseExpense>
    <BRTX:GainOnExchangeOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000435"
      unitRef="USD">1711698</BRTX:GainOnExchangeOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000438"
      unitRef="USD">97188</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000439"
      unitRef="USD">3997780</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000444"
      unitRef="USD">169100</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000445"
      unitRef="USD">3300</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000447"
      unitRef="USD">-33591</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000448"
      unitRef="USD">-57851</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000450"
      unitRef="USD">293680</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000451"
      unitRef="USD">18487</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000453"
      unitRef="USD">32799</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000454"
      unitRef="USD">581616</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000456"
      unitRef="USD">-162317</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000457"
      unitRef="USD">-139328</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000459"
      unitRef="USD">-8230346</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000460"
      unitRef="USD">-6430211</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000465"
      unitRef="USD">21508641</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000466"
      unitRef="USD">20964373</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000468"
      unitRef="USD">20887923</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000469"
      unitRef="USD">17541287</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000471"
      unitRef="USD">106189</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000472"
      unitRef="USD">171043</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000474"
      unitRef="USD">514529</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000475"
      unitRef="USD">3252043</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000481"
      unitRef="USD">494783</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000484"
      unitRef="USD">1853990</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000486"
      unitRef="USD">7528027</BRTX:ProceedsFromExchangeAndIssuanceOfWarrantsNet1>
    <BRTX:PaymentsForProceedsFromDeferredOfferingCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000489"
      unitRef="USD">148697</BRTX:PaymentsForProceedsFromDeferredOfferingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000492"
      unitRef="USD">7379330</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000493"
      unitRef="USD">2348773</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000495"
      unitRef="USD">-336487</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000496"
      unitRef="USD">-829395</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000498"
      unitRef="USD">884377</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000499"
      unitRef="USD">1713772</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000501"
      unitRef="USD">547890</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000502"
      unitRef="USD">884377</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <BRTX:IssuanceOfCommonStockHeldInAbeyance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000519"
      unitRef="USD">15</BRTX:IssuanceOfCommonStockHeldInAbeyance>
    <BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000522"
      unitRef="USD">48410</BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding>
    <BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000523"
      unitRef="USD">39308</BRTX:ReturnAndCancellationOfSharesInLieuOfPayrollTaxWithholding>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000526"
      unitRef="USD">8123391</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000528"
      unitRef="USD">595364</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000530">&lt;p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zad1yrVgoFC6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
1 - &lt;span id="xdx_82E_zTWJIhlVH5wj"&gt;ORGANIZATION, LIQUIDITY, GOING CONCERN AND BUSINESS OPERATIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Corporate
History&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#x201c;Stem Pearls&#x201d;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#x201c;BRT&#x201d; or the &#x201c;Company&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 23, 2022, the Company reincorporated from Delaware to Nevada by filing Articles of Incorporation with the state of Nevada. The
reincorporation was structured as a statutory merger.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which
contemplates realization of assets and satisfying liabilities in the normal course of business. For the year ended December 31, 2024,
the Company had a net loss of $&lt;span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20241231_zpyfxt7l3Ml4" title="Net loss"&gt;9.0&lt;/span&gt; million, negative cash flows from operations of $&lt;span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20241231_zbxaUj3RB9Eg" title="Cash flows from operations"&gt;8.2&lt;/span&gt; million and working capital of $&lt;span id="xdx_905_ecustom--WorkingCapital_iI_pn5n6_c20241231_zuIvnxRVR3fg" title="Working capital"&gt;7.4&lt;/span&gt; million.
The Company anticipates that it will continue to incur net losses and negative cash flows from operations as it executes its development
plans for 2025 and beyond, as well as other potential strategic and business development initiatives. These conditions raise substantial
doubt about the Company&#x2019;s ability to continue as a going concern for at least twelve months after the issuance date of these financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has previously funded, and plans to continue funding, these losses primarily through current cash on hand, investments in marketable
securities and additional infusions of cash from equity and debt financing. During the year ended December 31, 2024, the Company raised
net proceeds of approximately $&lt;span id="xdx_906_ecustom--ProceedsFromWarrantExercisesNet_pn5n6_c20240101__20241231_zPQQMtfHNcL1" title="Proceeds from warrant exercises, net"&gt;7.5&lt;/span&gt; million in connection with a warrant exercise program which is further discussed in Note 6 &#x2013;
Stockholders&#x2019; Equity. On November 6, 2024, the Company entered into an at-the-market offering agreement (the &#x201c;2024 ATM&#x201d;)
pursuant to which the Company has an ability to issue and sell shares of its common stock up to an aggregate offering price of $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241106__20241106_zicrnDnE8Hjb" title="Offering price"&gt;3,614,170&lt;/span&gt;.
Subsequent to December 31, 2024, the Company sold &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zD3UaD052txg" title="Sold shares of common stock"&gt;492,000&lt;/span&gt; shares of its common stock under the 2024 ATM and raised approximately $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z22hnIqNkwu3" title="Offering price"&gt;1,084,000&lt;/span&gt;
of gross proceeds See Note 10 &#x2013; Subsequent Events for additional details regarding sales of the Company&#x2019;s common under the
2024 ATM subsequent to December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s current funds will not be sufficient to enable the Company to fully complete its development activities or attain profitable
operations. If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its
development, marketing and promotional activities, which would have a material adverse effect on the Company&#x2019;s business, financial
condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the
United States of America (&#x201c;U.S. GAAP&#x201d;), which contemplate continuation of the Company as a going concern and the realization
of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented
in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying consolidated
financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Business
Operations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#x2019;s
website is at www.biorestorative.com. The information contained in the website or connected thereto is not intended to be incorporated
by reference into this Annual Report. BRT is currently developing a Disc/Spine Program referred to as &#x201c;brtxDISC&#x201d;. Its lead
cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person&#x2019;s own) cultured mesenchymal stem cells collected
from the patient&#x2019;s bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral disc disorders
or as a complimentary therapeutic to a surgical procedure. BRT is also engaging in research efforts with respect to a platform technology
utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders and has labeled
this initiative its ThermoStem Program. In addition, in continuation of BRT&#x2019;s mission of developing and commercializing cell-based
biologics, it is seeking to develop a biologics-based cosmetic products business. Pursuant to such business, BRT would formulate, manufacture
and sell products designed for cosmetic and aesthetic uses. Further, BRT has licensed a patented curved needle device that is a needle
system designed to deliver cells and/or other therapeutic products or material to the spine and discs or other potential sites.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000532"
      unitRef="USD">-9000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000534"
      unitRef="USD">-8200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <BRTX:WorkingCapital
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000536"
      unitRef="USD">7400000</BRTX:WorkingCapital>
    <BRTX:ProceedsFromWarrantExercisesNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000538"
      unitRef="USD">7500000</BRTX:ProceedsFromWarrantExercisesNet>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-11-062024-11-06"
      decimals="0"
      id="Fact000540"
      unitRef="USD">3614170</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000542"
      unitRef="Shares">492000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000544"
      unitRef="USD">1084000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000546">&lt;p id="xdx_80B_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zKzKY88P6szc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
2 - &lt;span id="xdx_828_zMyXsBBEEUzi"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zntv9Aiyyqwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_861_zdk4PxG1qrLi"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#x2019;s consolidated financial statements. Such consolidated
financial statements and accompanying notes are the representations of Company&#x2019;s management, who is responsible for their integrity
and objectivity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zxDKCiAlpgg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86E_z0fNjlbqN8zj"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stem Pearls. All intercompany
accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zEU1sFsNaugc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_z4poG7D1ldXh"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related
notes to the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#x2019;s future results to be affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkkM4rTKhXL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_z3GH9BVMoxqk"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has one operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#x2019;s Chief Executive Officer, serves
as the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial
performance. The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated
expense data beyond what is included in the consolidated statements of operations is not provided to the CODM. Since the Company&#x2019;s
operations consist of a single reporting segment, the segment assets are presented on the accompanying consolidated balance sheet as
total assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zutuEXoDmQC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zLcOVvLUxfTa"&gt;Revenue
Recognition&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue in accordance with ASC Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;ASC 606&#x201d;).
The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC
606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required
within the revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable
consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company
recognizes revenue primarily from the following different types of contracts:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Product
    sales&lt;/b&gt; - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Royalty
    revenue&lt;/b&gt; - Revenue is recognized as a usage-based royalty from customers&#x2019; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#x2019;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    reason for the bill-and-hold arrangement is substantive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    customer has requested the product be warehoused&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    product has been identified as separately belonging to the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    product is currently ready for physical transfer to the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    Company does not have the ability to use the product or direct it to another customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s revenue recognized in its consolidated statements of operations:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcIh7pV1dQj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z7tV6GJV8wQe" style="display: none"&gt;SCHEDULE
OF REVENUE RECOGNIZED&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_z6bGTQxxirwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_zcNhTDyKdqYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zNRTnoVTmbne" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Product revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0561"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ziVx2XrSPJPj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Royalty revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;101,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;145,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zvWAylJpLPRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;401,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;145,800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zucK4GFra5g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z82RXuAQ9m83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zPY8JAe2pUG9"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#x201c;FDIC&#x201d;) coverage of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zd4LGIJOhtt9" title="FDIC insured limit"&gt;250,000&lt;/span&gt; per banking institution. The Company had deposits in excess of FDIC coverage of $&lt;span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zkZR8JFpwxA1" title="FDIC amount"&gt;252,801&lt;/span&gt; and
$&lt;span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_c20231231_zuUVXiGB8vo1" title="FDIC amount"&gt;604,226&lt;/span&gt; as of December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company has not experienced losses on this account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zrHslI4Q5v9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_868_zMa1AmFIfaIk"&gt;Customer
and Revenue Concentrations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of the Company&#x2019;s royalty revenue is derived from one customer. Additionally, all of the Company&#x2019;s product sales revenue is
derived from one customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z96cN1ak7Q7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zjqSBcHeCS88"&gt;Accounts
Receivable&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of December 31, 2024 and 2023, no allowances
for credit losses were determined to be necessary. Management estimates the allowance for credit losses based on existing economic conditions,
the financial conditions of the customers, and the amount and age of past due accounts. Receivables are considered past due if full payment
is not received by the contractual due date. Past due accounts are generally written off against the allowance for credit losses only
after all collection attempts have been exhausted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--DeferredContractCostsPolicyTextBlock_zPwiT9fl58tj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_z9v0S1hZqQUi"&gt;Deferred
Contract Costs&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs
relate directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying
performance obligations in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as
cost of revenues in the period when the related revenue is recognized. Deferred contract costs consist of consumables and labor
costs and are included within prepaid &amp;amp; other current assets in the consolidated balance sheets. The Company had $&lt;span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zZfVwr6cQXkb" title="Deferred contract costs"&gt;10,250&lt;/span&gt;
and $&lt;span id="xdx_905_eus-gaap--DeferredCosts_iI_c20231231_zdJ4p8ov21Hk" title="Deferred contract costs"&gt;0 &lt;/span&gt;deferred contract
costs as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--DeferredOfferingCostsPolicyTextBlock_zzmFBpKtS7Q4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86C_zv1g22C3EyB3"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Deferred offering costs, which
primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized as non-current assets
on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the offering proceeds. If
the completion of a contemplated financing was no longer probable, the related deferred offering costs would be charged to general and
administrative expense in the consolidated financial statements. The Company had $&lt;span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_c20241231_zRqgz5xgN36j" title="Deferred offering costs"&gt;148,697&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_c20231231_zQ0rJYVdgKF6" title="Deferred offering costs"&gt;0&lt;/span&gt; deferred offering costs as of December
31, 2024 and 2023, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrNWYT5nz4ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zheceqDJFsi8"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember_zz0rpqtMCv35" title="Property plant and equipment estimated useful lives::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0595"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_z9lXBJdFqlhj" title="Property plant and equipment estimated useful lives"&gt;fifteen years&lt;/span&gt;. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfnq9MSy6d45" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt; years. Medical equipment costs
are capitalized and depreciated over &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zZ4jRpsDJgA6" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt; years, while furniture and fixtures are depreciated over &lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zjMrGwd0Prad" title="Property plant and equipment estimated useful lives"&gt;4&lt;/span&gt; years. Office equipment is depreciated
over a period of &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zFxufD0aVXDh" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt; to &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcK9bTYPatcf" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt; years, and manufacturing equipment over &lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRGoTgdUsUR5" title="Property plant and equipment estimated useful lives"&gt;4&lt;/span&gt; to &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MaximumMember_zNoLqgQf3lLh" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zvYszRC8Li8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zEt2msSsRFC2"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records its intangible assets at cost in accordance with ASC 350, &lt;i&gt;Intangibles - Goodwill and Other&lt;/i&gt;. Definite lived intangible
assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over
which the cash flows from the asset are expected to be generated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhNRS1Aqq6jc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zFhYORrqYOJc"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2024 and 2023, the Company determined that
there was &lt;span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20240101__20241231_zkUKhwWoBDvg" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20230101__20231231_zJwaUYA1d6li" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment charge for its long-lived assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--WarrantAndOptionValuationPolicyTextBlock_zIkk7Kjs9Gzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zUd3lVu9E2Sd"&gt;Warrant
and Option Valuation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#x201c;simplified&#x201d;
method to develop an estimate of the expected term of &#x201c;plain vanilla&#x201d; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry blended with the Company&#x2019;s historical
volatility. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining
term consistent with the expected term of the instrument being valued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zQ9biVqlTD72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span id="xdx_86F_z6RhMrU5RzF3"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option pricing model to value the
derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether
such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGbcb7LJWe47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zhJEhRPQrt7k"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of December 31, 2024 and 2023, the carrying amount of cash and cash equivalents,
investments held in marketable securities, accounts receivable, and accounts payable approximate their fair value due to the relatively
short period of time between their origination and their expected realization or payment. The warrant liabilities are measured at fair
value (see Note 9 &#x2013; Fair Value Measurement for additional details).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2024 and 2023, the Company recognized aggregate dividend and interest income of $&lt;span id="xdx_90C_eus-gaap--InterestAndDividendIncomeOperating_c20240101__20241231_zg5oD0W09dNe" title="Dividend and interest income"&gt;623,801&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--InterestAndDividendIncomeOperating_c20230101__20231231_zU0r2WazoLE7" title="Dividend and interest income"&gt;569,068&lt;/span&gt; respectively,
on its marketable securities, which was included within other income on its consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zV62cxfcykAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zSfIv1elO46k"&gt;Net
Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The Company has &lt;span id="xdx_90D_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zZu0Wr23kU3b" title="Shares held in abeyance"&gt;1,201,580&lt;/span&gt; shares held in abeyance included
in basic loss per share given that they are issuable for no additional consideration (see Note 6 &#x2013; Stockholders&#x2019; Equity for
additional details). The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding
convertible preferred stock is considered common stock at the beginning of the period or at the time of issuance, if later, pursuant
to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, options, warrants,
restricted stock units (&#x201c;RSUs&#x201d;) and convertible preferred stock have been excluded from the Company&#x2019;s computation of
diluted net loss per common share for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zTOISYbdZzv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z1GIc8cffMY8" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zvW4VkuXWp01" style="width: 18%; text-align: right" title="Total"&gt;3,263,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNj7qEzjGEDh" style="width: 18%; text-align: right" title="Total"&gt;1,466,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsnSJJFV0i21" style="text-align: right" title="Total potentially dilutive shares"&gt;3,951,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zNev5ZVPtlKh" style="text-align: right" title="Total potentially dilutive shares"&gt;4,791,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unvested RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zeme8xsmLW02" style="text-align: right" title="Unvested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zigFx6OtpUFa" style="text-align: right" title="Unvested"&gt;97,827&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zr441Bl9Y3b4" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes"&gt;1,398,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_znmyQsqEKWl1" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes"&gt;1,398,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zfF2OKgWsyX5" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;8,613,259&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zRJKPmUwTj02" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;7,753,896&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zh9UmzbEuc23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4rqRiibYMW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zXmhvArh15nb"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The
fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be
provided in exchange for the award, usually the vesting period, on a straight-line basis. The Company computes the fair value of equity-classified
warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are recorded as incurred as a reduction
of amounts previously expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zyorW7NGWskg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_zwBN5Q5WlHH"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes ASC 740, &#x201c;Income Taxes,&#x201d; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#x201c;more likely-than-not&#x201d;
that a deferred tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
uncertain tax positions that meet a &#x201c;more likely than not&#x201d; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#x2019;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zUyYKWUBRBq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zvsoDK4W79Yj"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines whether an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;)
assets and operating lease liabilities in our consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value
of lease payments over the lease term. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental
borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement
date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company&#x2019;s lease terms
may include options to extend or terminate the lease when it is reasonably certain that it will exercise the option. Lease expense for
lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zXTkrjpty3U9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zpKTHgzD4l67"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07,
&#x201c;Improvements to Reportable Segments Disclosures (Topic 280)&#x201d; (&#x201c;ASU 2023-07&#x201d;), which updates reportable segment
disclosure requirements, primarily through enhanced disclosures about significant segment expenses on both an annual and interim basis.
The guidance becomes effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after
December 15, 2024, with early adoption permitted. The adoption of this accounting standard on a retrospective basis did not have a material
impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zqqRwAf1WA26" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zNfZlr2uXiec"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU No. 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d; (&#x201c;ASU
2023-09&#x201d;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the impact of this update on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU No. 2024-03, &#x201c;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#x201d; (&#x201c;ASU 2024-03&#x201d;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_850_zSD8QCfCQlbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000548">&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zntv9Aiyyqwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_861_zdk4PxG1qrLi"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#x2019;s consolidated financial statements. Such consolidated
financial statements and accompanying notes are the representations of Company&#x2019;s management, who is responsible for their integrity
and objectivity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000550">&lt;p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_zxDKCiAlpgg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86E_z0fNjlbqN8zj"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stem Pearls. All intercompany
accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000552">&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zEU1sFsNaugc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_z4poG7D1ldXh"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related
notes to the financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends
and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision,
actual results could differ from these estimates which may cause the Company&#x2019;s future results to be affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000554">&lt;p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkkM4rTKhXL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_z3GH9BVMoxqk"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief
operating decision-maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance.
The Company has one operating and reporting segment (BioRestorative Therapies, Inc.) which develops therapeutic products and medical
therapies using cell and tissue protocols, primarily involving adult stem cells. The Company&#x2019;s Chief Executive Officer, serves
as the CODM and reviews financial information presented on a consolidated basis to make operational decisions and evaluate financial
performance. The CODM reviews profit and loss information on a consolidated basis, as presented in the statement of operations. Disaggregated
expense data beyond what is included in the consolidated statements of operations is not provided to the CODM. Since the Company&#x2019;s
operations consist of a single reporting segment, the segment assets are presented on the accompanying consolidated balance sheet as
total assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000556">&lt;p id="xdx_848_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zutuEXoDmQC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zLcOVvLUxfTa"&gt;Revenue
Recognition&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue in accordance with ASC Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;ASC 606&#x201d;).
The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC
606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required
within the revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable
consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company
recognizes revenue primarily from the following different types of contracts:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Product
    sales&lt;/b&gt; - Revenue is recognized at the point in time the customer obtains control of the goods and the Company satisfies its performance
    obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Royalty
    revenue&lt;/b&gt; - Revenue is recognized as a usage-based royalty from customers&#x2019; usage of intellectual property pursuant to a license
    agreement at the point in time in which the underlying sale occurs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes bill-and-hold revenue from its sale of cosmetic vials warehoused at a Company location for a specified period of time
in accordance with directions received from the Company&#x2019;s customer. Even though the vials are held at a Company location, a sale
is recognized at the point in time when the customer obtains control of the product. Control is transferred to the customer in a bill-and-hold
arrangement when: (i) customer acceptance specifications have been met, (ii) legal title has transferred, (iii) the customer has a present
obligation to pay for the product and (iv) the risks and rewards of ownership have transferred to the customer. Additionally, all the
following bill-and-hold criteria have to be met in order for control to be transferred to the customer:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    reason for the bill-and-hold arrangement is substantive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    customer has requested the product be warehoused&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    product has been identified as separately belonging to the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    product is currently ready for physical transfer to the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    Company does not have the ability to use the product or direct it to another customer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s revenue recognized in its consolidated statements of operations:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcIh7pV1dQj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z7tV6GJV8wQe" style="display: none"&gt;SCHEDULE
OF REVENUE RECOGNIZED&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_z6bGTQxxirwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_zcNhTDyKdqYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zNRTnoVTmbne" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Product revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0561"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ziVx2XrSPJPj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Royalty revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;101,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;145,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zvWAylJpLPRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;401,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;145,800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zucK4GFra5g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000558">&lt;p id="xdx_89E_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcIh7pV1dQj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_z7tV6GJV8wQe" style="display: none"&gt;SCHEDULE
OF REVENUE RECOGNIZED&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_z6bGTQxxirwg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_zcNhTDyKdqYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zNRTnoVTmbne" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Product revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0561"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--RoyaltyMember_ziVx2XrSPJPj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Royalty revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;101,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;145,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zvWAylJpLPRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;401,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;145,800&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_us-gaap_ProductMember"
      decimals="0"
      id="Fact000560"
      unitRef="USD">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_us-gaap_RoyaltyMember"
      decimals="0"
      id="Fact000563"
      unitRef="USD">101000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_us-gaap_RoyaltyMember"
      decimals="0"
      id="Fact000564"
      unitRef="USD">145800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000566"
      unitRef="USD">401000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000567"
      unitRef="USD">145800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000569">&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z82RXuAQ9m83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zPY8JAe2pUG9"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its accounts that hold cash and cash equivalents in excess of the Federal Depository Insurance Corporation
(&#x201c;FDIC&#x201d;) coverage of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zd4LGIJOhtt9" title="FDIC insured limit"&gt;250,000&lt;/span&gt; per banking institution. The Company had deposits in excess of FDIC coverage of $&lt;span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_c20241231_zkZR8JFpwxA1" title="FDIC amount"&gt;252,801&lt;/span&gt; and
$&lt;span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_c20231231_zuUVXiGB8vo1" title="FDIC amount"&gt;604,226&lt;/span&gt; as of December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company has not experienced losses on this account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000571"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000573"
      unitRef="USD">252801</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000575"
      unitRef="USD">604226</us-gaap:CashUninsuredAmount>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-12-31" id="Fact000577">&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zrHslI4Q5v9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_868_zMa1AmFIfaIk"&gt;Customer
and Revenue Concentrations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of the Company&#x2019;s royalty revenue is derived from one customer. Additionally, all of the Company&#x2019;s product sales revenue is
derived from one customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000579">&lt;p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z96cN1ak7Q7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zjqSBcHeCS88"&gt;Accounts
Receivable&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are carried at their contractual amounts, less an estimate for credit losses. As of December 31, 2024 and 2023, no allowances
for credit losses were determined to be necessary. Management estimates the allowance for credit losses based on existing economic conditions,
the financial conditions of the customers, and the amount and age of past due accounts. Receivables are considered past due if full payment
is not received by the contractual due date. Past due accounts are generally written off against the allowance for credit losses only
after all collection attempts have been exhausted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <BRTX:DeferredContractCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000581">&lt;p id="xdx_84B_ecustom--DeferredContractCostsPolicyTextBlock_zPwiT9fl58tj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_z9v0S1hZqQUi"&gt;Deferred
Contract Costs&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company defers costs associated with fulfilling its contracts if those costs meet all of the following criteria: (i) the costs
relate directly to a contract, (ii) the costs generate or enhance resources of the Company that will be used in satisfying
performance obligations in the future, and (iii) the costs are expected to be recovered. Deferred contract costs are recognized as
cost of revenues in the period when the related revenue is recognized. Deferred contract costs consist of consumables and labor
costs and are included within prepaid &amp;amp; other current assets in the consolidated balance sheets. The Company had $&lt;span id="xdx_903_eus-gaap--DeferredCosts_iI_c20241231_zZfVwr6cQXkb" title="Deferred contract costs"&gt;10,250&lt;/span&gt;
and $&lt;span id="xdx_905_eus-gaap--DeferredCosts_iI_c20231231_zdJ4p8ov21Hk" title="Deferred contract costs"&gt;0 &lt;/span&gt;deferred contract
costs as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</BRTX:DeferredContractCostsPolicyTextBlock>
    <us-gaap:DeferredCosts
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000583"
      unitRef="USD">10250</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000585"
      unitRef="USD">0</us-gaap:DeferredCosts>
    <BRTX:DeferredOfferingCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000587">&lt;p id="xdx_842_ecustom--DeferredOfferingCostsPolicyTextBlock_zzmFBpKtS7Q4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86C_zv1g22C3EyB3"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Deferred offering costs, which
primarily consist of direct, incremental professional fees incurred in connection with a financing, are capitalized as non-current assets
on the balance sheet. Upon consummation of a financing, the deferred offering costs would be offset against the offering proceeds. If
the completion of a contemplated financing was no longer probable, the related deferred offering costs would be charged to general and
administrative expense in the consolidated financial statements. The Company had $&lt;span id="xdx_90D_eus-gaap--DeferredOfferingCosts_iI_c20241231_zRqgz5xgN36j" title="Deferred offering costs"&gt;148,697&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_c20231231_zQ0rJYVdgKF6" title="Deferred offering costs"&gt;0&lt;/span&gt; deferred offering costs as of December
31, 2024 and 2023, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</BRTX:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000589"
      unitRef="USD">148697</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000591"
      unitRef="USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000593">&lt;p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zrNWYT5nz4ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zheceqDJFsi8"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Depreciation is computed using straight-line method over the estimated useful lives of the related
assets, generally &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__srt--RangeAxis__srt--MinimumMember_zz0rpqtMCv35" title="Property plant and equipment estimated useful lives::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0595"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_z9lXBJdFqlhj" title="Property plant and equipment estimated useful lives"&gt;fifteen years&lt;/span&gt;. Expenditures that enhance the useful lives of the assets are capitalized and depreciated. Computer
equipment costs are capitalized, as incurred, and depreciated on a straight-line basis over a range of &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfnq9MSy6d45" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt; years. Medical equipment costs
are capitalized and depreciated over &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zZ4jRpsDJgA6" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt; years, while furniture and fixtures are depreciated over &lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zjMrGwd0Prad" title="Property plant and equipment estimated useful lives"&gt;4&lt;/span&gt; years. Office equipment is depreciated
over a period of &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zFxufD0aVXDh" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt; to &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcK9bTYPatcf" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt; years, and manufacturing equipment over &lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRGoTgdUsUR5" title="Property plant and equipment estimated useful lives"&gt;4&lt;/span&gt; to &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember__srt--RangeAxis__srt--MaximumMember_zNoLqgQf3lLh" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
improvements are amortized over the lesser of (i) the useful life of the asset, or (ii) the remaining lease term. Maintenance and repairs
are charged to expense as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment
extends the useful life of the assets. At the time of retirement or other disposition of property and equipment, the cost and accumulated
depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      id="Fact000597">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember"
      id="Fact000599">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_MedicalEquipmentMember"
      id="Fact000601">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      id="Fact000603">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember"
      id="Fact000605">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember"
      id="Fact000607">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MinimumMember"
      id="Fact000609">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_ManufacturingEquipmentMember_srt_MaximumMember"
      id="Fact000611">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000613">&lt;p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zvYszRC8Li8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zEt2msSsRFC2"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records its intangible assets at cost in accordance with ASC 350, &lt;i&gt;Intangibles - Goodwill and Other&lt;/i&gt;. Definite lived intangible
assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over
which the cash flows from the asset are expected to be generated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000615">&lt;p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zhNRS1Aqq6jc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zFhYORrqYOJc"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews long-lived assets, including definite-lived intangible assets and right-of-use assets from operating leases, for impairment
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of
these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the
carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written
down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows
or appraised values, depending on the nature of the assets. For the years ended December 31, 2024 and 2023, the Company determined that
there was &lt;span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20240101__20241231_zkUKhwWoBDvg" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20230101__20231231_zJwaUYA1d6li" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment charge for its long-lived assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000617"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000619"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <BRTX:WarrantAndOptionValuationPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000621">&lt;p id="xdx_849_ecustom--WarrantAndOptionValuationPolicyTextBlock_zIkk7Kjs9Gzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zUd3lVu9E2Sd"&gt;Warrant
and Option Valuation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#x201c;simplified&#x201d;
method to develop an estimate of the expected term of &#x201c;plain vanilla&#x201d; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry blended with the Company&#x2019;s historical
volatility. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining
term consistent with the expected term of the instrument being valued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</BRTX:WarrantAndOptionValuationPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000623">&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zQ9biVqlTD72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span id="xdx_86F_z6RhMrU5RzF3"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes option pricing model to value the
derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether
such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000625">&lt;p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGbcb7LJWe47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zhJEhRPQrt7k"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date and is measured using inputs in one of the following three categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 measurements are based on unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to
access. Valuation of these items does not entail a significant amount of judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 measurements are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar
assets or liabilities in markets that are not active or market data other than quoted prices that are observable for the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 measurements are based on unobservable data that are supported by little or no market activity and are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers cash and cash equivalents, investments held in marketable securities, accounts receivable, accounts payable and warrant
liabilities to meet the definition of financial instruments. As of December 31, 2024 and 2023, the carrying amount of cash and cash equivalents,
investments held in marketable securities, accounts receivable, and accounts payable approximate their fair value due to the relatively
short period of time between their origination and their expected realization or payment. The warrant liabilities are measured at fair
value (see Note 9 &#x2013; Fair Value Measurement for additional details).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2024 and 2023, the Company recognized aggregate dividend and interest income of $&lt;span id="xdx_90C_eus-gaap--InterestAndDividendIncomeOperating_c20240101__20241231_zg5oD0W09dNe" title="Dividend and interest income"&gt;623,801&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--InterestAndDividendIncomeOperating_c20230101__20231231_zU0r2WazoLE7" title="Dividend and interest income"&gt;569,068&lt;/span&gt; respectively,
on its marketable securities, which was included within other income on its consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000627"
      unitRef="USD">623801</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000629"
      unitRef="USD">569068</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000631">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zV62cxfcykAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zSfIv1elO46k"&gt;Net
Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.
All outstanding options and warrants are considered potential common stock. The Company has &lt;span id="xdx_90D_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zZu0Wr23kU3b" title="Shares held in abeyance"&gt;1,201,580&lt;/span&gt; shares held in abeyance included
in basic loss per share given that they are issuable for no additional consideration (see Note 6 &#x2013; Stockholders&#x2019; Equity for
additional details). The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding
convertible preferred stock is considered common stock at the beginning of the period or at the time of issuance, if later, pursuant
to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, options, warrants,
restricted stock units (&#x201c;RSUs&#x201d;) and convertible preferred stock have been excluded from the Company&#x2019;s computation of
diluted net loss per common share for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zTOISYbdZzv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z1GIc8cffMY8" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zvW4VkuXWp01" style="width: 18%; text-align: right" title="Total"&gt;3,263,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNj7qEzjGEDh" style="width: 18%; text-align: right" title="Total"&gt;1,466,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsnSJJFV0i21" style="text-align: right" title="Total potentially dilutive shares"&gt;3,951,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zNev5ZVPtlKh" style="text-align: right" title="Total potentially dilutive shares"&gt;4,791,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unvested RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zeme8xsmLW02" style="text-align: right" title="Unvested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zigFx6OtpUFa" style="text-align: right" title="Unvested"&gt;97,827&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zr441Bl9Y3b4" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes"&gt;1,398,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_znmyQsqEKWl1" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes"&gt;1,398,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zfF2OKgWsyX5" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;8,613,259&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zRJKPmUwTj02" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;7,753,896&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zh9UmzbEuc23" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <BRTX:SharesHeldInAbeyance
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000633"
      unitRef="Shares">1201580</BRTX:SharesHeldInAbeyance>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000635">&lt;p id="xdx_894_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zTOISYbdZzv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z1GIc8cffMY8" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zvW4VkuXWp01" style="width: 18%; text-align: right" title="Total"&gt;3,263,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNj7qEzjGEDh" style="width: 18%; text-align: right" title="Total"&gt;1,466,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zsnSJJFV0i21" style="text-align: right" title="Total potentially dilutive shares"&gt;3,951,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zNev5ZVPtlKh" style="text-align: right" title="Total potentially dilutive shares"&gt;4,791,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unvested RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zeme8xsmLW02" style="text-align: right" title="Unvested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zigFx6OtpUFa" style="text-align: right" title="Unvested"&gt;97,827&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zr441Bl9Y3b4" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes"&gt;1,398,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_znmyQsqEKWl1" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible notes"&gt;1,398,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231_zfF2OKgWsyX5" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;8,613,259&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zRJKPmUwTj02" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities"&gt;7,753,896&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000637"
      unitRef="Shares">3263467</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000639"
      unitRef="Shares">1466892</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000641"
      unitRef="Shares">3951634</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000643"
      unitRef="Shares">4791019</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000647"
      unitRef="Shares">97827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000649"
      unitRef="Shares">1398158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000651"
      unitRef="Shares">1398158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000653"
      unitRef="Shares">8613259</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000655"
      unitRef="Shares">7753896</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000657">&lt;p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z4rqRiibYMW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zXmhvArh15nb"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The
fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be
provided in exchange for the award, usually the vesting period, on a straight-line basis. The Company computes the fair value of equity-classified
warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are recorded as incurred as a reduction
of amounts previously expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000659">&lt;p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zyorW7NGWskg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_zwBN5Q5WlHH"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss
and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes ASC 740, &#x201c;Income Taxes,&#x201d; which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been included in the consolidated financial statements or tax returns. The Company accounts
for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and
the related financial amounts, using currently enacted tax rates. A valuation allowance is recorded when it is &#x201c;more likely-than-not&#x201d;
that a deferred tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
uncertain tax positions that meet a &#x201c;more likely than not&#x201d; threshold, the Company recognizes the benefit of uncertain tax
positions in the consolidated financial statements. The Company&#x2019;s practice is to recognize interest and penalties, if any, related
to uncertain tax positions in income tax expense in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000661">&lt;p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zUyYKWUBRBq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zvsoDK4W79Yj"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines whether an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;)
assets and operating lease liabilities in our consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value
of lease payments over the lease term. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental
borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement
date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company&#x2019;s lease terms
may include options to extend or terminate the lease when it is reasonably certain that it will exercise the option. Lease expense for
lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000663">&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zXTkrjpty3U9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zpKTHgzD4l67"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07,
&#x201c;Improvements to Reportable Segments Disclosures (Topic 280)&#x201d; (&#x201c;ASU 2023-07&#x201d;), which updates reportable segment
disclosure requirements, primarily through enhanced disclosures about significant segment expenses on both an annual and interim basis.
The guidance becomes effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after
December 15, 2024, with early adoption permitted. The adoption of this accounting standard on a retrospective basis did not have a material
impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <BRTX:RecentlyIssuedAccountingPronouncementsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000665">&lt;p id="xdx_847_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zqqRwAf1WA26" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zNfZlr2uXiec"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU No. 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d; (&#x201c;ASU
2023-09&#x201d;). The amendments in ASU 2023-09 are designed to enhance the transparency of income tax disclosures by requiring consistent
categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently
evaluating the impact of this update on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU No. 2024-03, &#x201c;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses,&#x201d; (&#x201c;ASU 2024-03&#x201d;), which is intended to require more
detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included
in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after
December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The
amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of ASU
2024-03 or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the potential
impact of this update on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

</BRTX:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000667">&lt;p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zEvV1FTo67xk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
3 - &lt;span id="xdx_829_zsg9IrEIAfo9"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z2ZdwaDNWsb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zRiW19Duyqmj" style="display: none"&gt;SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zcvb0j2Mshvj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_zCrUODQYb0Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zLOXDxjVNdhb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Medical equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;352,133&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;352,133&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zHKi6c2fM66c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zTPXuLfpmrf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer software and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zdSPeVh24a7d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zHLEEhyimZOi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Manufacturing equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;501,421&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;395,232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zb0uKt79Uwyg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;342,048&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;342,048&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzKiZ_z4su14VN8qy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
    plant and equipment gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,474,072&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,367,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzKiZ_zeJSxm1HRBa4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,111,136&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,011,828&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzKiZ_zPMObeOSxMXd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;362,936&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;356,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zZiYqaFLPewe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
depreciation expense for the years ended December 31, 2024 and 2023 was $&lt;span id="xdx_908_eus-gaap--Depreciation_pp0p0_c20240101__20241231_zvtQEHghKRO7" title="Depreciation"&gt;99,309&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--Depreciation_pp0p0_c20230101__20231231_zi5SeumhaRl8" title="Depreciation"&gt;75,989&lt;/span&gt;, respectively. Depreciation expense is reflected
in general and administrative expenses and research and development expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000669">&lt;p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_z2ZdwaDNWsb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zRiW19Duyqmj" style="display: none"&gt;SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zcvb0j2Mshvj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_zCrUODQYb0Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zLOXDxjVNdhb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Medical equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;352,133&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;352,133&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zHKi6c2fM66c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareAndEquipmentMember_zTPXuLfpmrf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer software and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zdSPeVh24a7d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zHLEEhyimZOi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Manufacturing equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;501,421&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;395,232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zb0uKt79Uwyg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;342,048&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;342,048&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzKiZ_z4su14VN8qy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
    plant and equipment gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,474,072&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,367,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzKiZ_zeJSxm1HRBa4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,111,136&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,011,828&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzKiZ_zPMObeOSxMXd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;362,936&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;356,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact000671"
      unitRef="USD">352133</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact000672"
      unitRef="USD">352133</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000674"
      unitRef="USD">123486</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000675"
      unitRef="USD">123486</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_ComputerSoftwareAndEquipmentMember"
      decimals="0"
      id="Fact000677"
      unitRef="USD">136205</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_ComputerSoftwareAndEquipmentMember"
      decimals="0"
      id="Fact000678"
      unitRef="USD">136205</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="Fact000680"
      unitRef="USD">18779</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="Fact000681"
      unitRef="USD">18779</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_ManufacturingEquipmentMember"
      decimals="0"
      id="Fact000683"
      unitRef="USD">501421</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_ManufacturingEquipmentMember"
      decimals="0"
      id="Fact000684"
      unitRef="USD">395232</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000686"
      unitRef="USD">342048</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000687"
      unitRef="USD">342048</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000689"
      unitRef="USD">1474072</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000690"
      unitRef="USD">1367883</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000692"
      unitRef="USD">1111136</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000693"
      unitRef="USD">1011828</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000695"
      unitRef="USD">362936</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000696"
      unitRef="USD">356055</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000698"
      unitRef="USD">99309</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000700"
      unitRef="USD">75989</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000702">&lt;p id="xdx_80E_eus-gaap--IntangibleAssetsDisclosureTextBlock_z7XcTOpi2I3c" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
4 - &lt;span id="xdx_82E_z8jFnJ0P8vsc"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a party to a license agreement with the SCTC (as amended) (the &#x201c;SCTC Agreement&#x201d;). Pursuant to the SCTC Agreement,
the Company obtained, among other things, a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license from the SCTC
to utilize or sublicense a certain method for culturing cells and a worldwide, exclusive, royalty-bearing license from the SCTC to utilize
or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or spine
(and other parts of the body).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2017, the Company received authorization from the Food and Drug Administration (the &#x201c;FDA&#x201d;) to proceed with a Phase
2 clinical trial. In February 2022, the Company announced that the United States Patent and Trademark Office issued a notice of allowance
for a patent application relating to the Company&#x2019;s BRTX-100 clinical program. This patent was issued in March 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zdsSzvPsMxw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zovX5FmRjKn8" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Patents and Trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Licenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Balance as of January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zMa8DpLEhmyh" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance"&gt;3,676&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgkIpLlGFbo2" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance"&gt;1,593,530&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zqY3dA0k41Sl" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance"&gt;(793,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20230101__20231231_z6h1cAws7Od" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance"&gt;803,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zDUNrjLtHqbj" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231_zRrGfdmJ09Eb" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zTRGfffLeNbf" style="text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBVozX7VDJlj" style="text-align: right" title="Beginning Balance"&gt;1,593,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXRYXWxN8sRe" style="text-align: right" title="Beginning Balance"&gt;(883,514&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20240101__20241231_zqwLjk2xJY0j" style="text-align: right" title="Beginning Balance"&gt;713,692&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zytthitOTw2k" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231_zAM5NMN8yS06" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zQuRKUBmR8mh" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance"&gt;3,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zoYjoWDb33X3" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance"&gt;1,593,530&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_ztG665tY4AIa" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance"&gt;(973,261&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iE_pp0p0_c20240101__20241231_zjzg3CCnlNxd" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, Ending Balance"&gt;623,945&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average remaining amortization period at December 31, 2024 (in years)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zFTAQg0U6qf8" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0738"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zWn6aGIbVlz8" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;10.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zQnJWoLGRUxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zyr8t0Ym6OWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
of intangible assets consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B1_zIE3bG4EPzp9" style="display: none"&gt;SCHEDULE OF FINITE LIVED
INTANGIBLE ASSETS AMORTIZATION EXPENSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Patents and Trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Licenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Balance as of January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zAQRVTNxCnRa" style="width: 14%; text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zTV1EfXZQxkj" style="width: 14%; text-align: right" title="Beginning Balance"&gt;790,092&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zuMtebEZOmgf" style="width: 14%; text-align: right" title="Beginning Balance"&gt;793,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zY8aapJwfbif" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0750"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgEjKj6jTWI5" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2rXVJBGP7il" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zgRAH3stiYi7" style="text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zDe9KaWcOYI7" style="text-align: right" title="Beginning Balance"&gt;879,838&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXVvp6oFTRTa" style="text-align: right" title="Beginning Balance"&gt;883,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zuHhehAQNkik" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0762"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z6qgnUqvdCNe" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zygSxwRoDT8e" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zpDaKpFlcUXl" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;3,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_ziQYvOYoF2Vh" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;969,585&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z21atXqH7Mrd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;973,261&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zXJeZ8EsBx54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zO5E84hy3qC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense for the next five years is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zDxhPMghSJb7" style="display: none"&gt;SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom"&gt;For the Years Ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zLqGmLhSvkA" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz89Q_z1vNDKxW98G5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; width: 80%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz89Q_za7zLx3utHS9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz89Q_z9FWK80aZ1L8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz89Q_zCZfaJK7po9f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz89Q_zlr2Quf6AHf9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 1pt"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz89Q_zivgdmaXPRBi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;448,730&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zRFY1LD10kBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000704">&lt;p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zdsSzvPsMxw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zovX5FmRjKn8" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Patents and Trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Licenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Balance as of January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zMa8DpLEhmyh" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance"&gt;3,676&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgkIpLlGFbo2" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance"&gt;1,593,530&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zqY3dA0k41Sl" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance"&gt;(793,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20230101__20231231_z6h1cAws7Od" style="width: 12%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance"&gt;803,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zDUNrjLtHqbj" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20231231_zRrGfdmJ09Eb" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zTRGfffLeNbf" style="text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBVozX7VDJlj" style="text-align: right" title="Beginning Balance"&gt;1,593,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXRYXWxN8sRe" style="text-align: right" title="Beginning Balance"&gt;(883,514&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iS_pp0p0_c20240101__20241231_zqwLjk2xJY0j" style="text-align: right" title="Beginning Balance"&gt;713,692&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zytthitOTw2k" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20240101__20241231_zAM5NMN8yS06" style="border-bottom: Black 1pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;(89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zQuRKUBmR8mh" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance"&gt;3,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zoYjoWDb33X3" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance"&gt;1,593,530&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_ztG665tY4AIa" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance"&gt;(973,261&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iE_pp0p0_c20240101__20241231_zjzg3CCnlNxd" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, Ending Balance"&gt;623,945&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average remaining amortization period at December 31, 2024 (in years)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zFTAQg0U6qf8" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0738"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zWn6aGIbVlz8" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;10.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_custom_PatentsAndTrademarksMember"
      decimals="0"
      id="Fact000706"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact000708"
      unitRef="USD">1593530</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact000710"
      unitRef="USD">793768</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000712"
      unitRef="USD">803438</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact000714"
      unitRef="USD">89746</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000716"
      unitRef="USD">89746</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_PatentsAndTrademarksMember"
      decimals="0"
      id="Fact000718"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact000720"
      unitRef="USD">1593530</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact000722"
      unitRef="USD">883514</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000724"
      unitRef="USD">713692</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact000726"
      unitRef="USD">89747</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000728"
      unitRef="USD">89747</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_custom_PatentsAndTrademarksMember"
      decimals="0"
      id="Fact000730"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact000732"
      unitRef="USD">1593530</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact000734"
      unitRef="USD">973261</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000736"
      unitRef="USD">623945</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="AsOf2024-12-31_us-gaap_LicenseMember"
      id="Fact000740">P10Y3M18D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000742">&lt;p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zyr8t0Ym6OWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
of intangible assets consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B1_zIE3bG4EPzp9" style="display: none"&gt;SCHEDULE OF FINITE LIVED
INTANGIBLE ASSETS AMORTIZATION EXPENSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Patents and Trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Licenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Balance as of January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zAQRVTNxCnRa" style="width: 14%; text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zTV1EfXZQxkj" style="width: 14%; text-align: right" title="Beginning Balance"&gt;790,092&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zuMtebEZOmgf" style="width: 14%; text-align: right" title="Beginning Balance"&gt;793,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zY8aapJwfbif" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0750"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zgEjKj6jTWI5" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z2rXVJBGP7il" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zgRAH3stiYi7" style="text-align: right" title="Beginning Balance"&gt;3,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zDe9KaWcOYI7" style="text-align: right" title="Beginning Balance"&gt;879,838&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zXVvp6oFTRTa" style="text-align: right" title="Beginning Balance"&gt;883,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zuHhehAQNkik" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0762"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z6qgnUqvdCNe" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zygSxwRoDT8e" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization expense"&gt;89,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zpDaKpFlcUXl" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;3,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_ziQYvOYoF2Vh" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;969,585&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_z21atXqH7Mrd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending Balance"&gt;973,261&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_custom_PatentsAndTrademarkMember"
      decimals="0"
      id="Fact000744"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact000746"
      unitRef="USD">790092</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact000748"
      unitRef="USD">793768</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact000752"
      unitRef="USD">89746</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact000754"
      unitRef="USD">89746</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_custom_PatentsAndTrademarkMember"
      decimals="0"
      id="Fact000756"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact000758"
      unitRef="USD">879838</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact000760"
      unitRef="USD">883514</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact000764"
      unitRef="USD">89747</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact000766"
      unitRef="USD">89747</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_custom_PatentsAndTrademarkMember"
      decimals="0"
      id="Fact000768"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_us-gaap_LicenseMember"
      decimals="0"
      id="Fact000770"
      unitRef="USD">969585</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      id="Fact000772"
      unitRef="USD">973261</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000774">&lt;p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zO5E84hy3qC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense for the next five years is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zDxhPMghSJb7" style="display: none"&gt;SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS FUTURE AMORTIZATION EXPENSES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; vertical-align: bottom"&gt;For the Years Ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zLqGmLhSvkA" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz89Q_z1vNDKxW98G5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; width: 80%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz89Q_za7zLx3utHS9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz89Q_z9FWK80aZ1L8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz89Q_zCZfaJK7po9f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANz89Q_zlr2Quf6AHf9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 1pt"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;89,746&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz89Q_zivgdmaXPRBi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: bottom"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;448,730&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000776"
      unitRef="USD">89746</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000778"
      unitRef="USD">89746</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000780"
      unitRef="USD">89746</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000782"
      unitRef="USD">89746</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000784"
      unitRef="USD">89746</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000786"
      unitRef="USD">448730</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000788">&lt;p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zcCzM4pARQo3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
5 - &lt;span id="xdx_820_zMsUx2ILh5Tl"&gt;ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z7ve0gvNg4Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consist of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_z3T5qunqNukl" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zEWk23Yc0nC" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231_zeM88DjmnpU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zg5ydVfCG0I2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Accrued bonuses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;704,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;638,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_z5sQM90mCxFd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;40,485&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;73,686&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zJIAosR1rmQf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;744,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;711,686&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_ziyjOByjOsNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000790">&lt;p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z7ve0gvNg4Wl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consist of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_z3T5qunqNukl" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zEWk23Yc0nC" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231_zeM88DjmnpU4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zg5ydVfCG0I2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Accrued bonuses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;704,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;638,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_z5sQM90mCxFd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;40,485&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;73,686&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zJIAosR1rmQf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;744,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;711,686&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000792"
      unitRef="USD">704000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000793"
      unitRef="USD">638000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <BRTX:AccruedGeneralAndAdministrativeExpenses
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000795"
      unitRef="USD">40485</BRTX:AccruedGeneralAndAdministrativeExpenses>
    <BRTX:AccruedGeneralAndAdministrativeExpenses
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000796"
      unitRef="USD">73686</BRTX:AccruedGeneralAndAdministrativeExpenses>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000798"
      unitRef="USD">744485</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000799"
      unitRef="USD">711686</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000801">&lt;p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zJPEBtlN7YIk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Note
6 - &lt;span id="xdx_82B_zUgzUG841pcg"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
A Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 8, 2021, in connection with the Company&#x2019;s public offering, the Company&#x2019;s Board of Directors adopted a resolution
allowing for the designation and issuance of &lt;span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAv4O5ACYYm2" title="Preferred stock, shares issued"&gt;1,543,158&lt;/span&gt; shares of the Company&#x2019;s Preferred Stock, $&lt;span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQNlJEUEDcQa" title="Preferred stock, par value"&gt;.01&lt;/span&gt; par value per share, designated
as Series A Preferred Stock (&#x201c;Series A&#x201d;). The Series A had a liquidation preference of $&lt;span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3hczMMtKpU8" title="Preferred stock, liquidation preference"&gt;0.001&lt;/span&gt; per share. On September 8,
2022, the Company issued &lt;span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zo0GcvUNCdN2" title="Preferred stock, shares issued"&gt;1,543,158&lt;/span&gt; shares of Series B Preferred Stock (&#x201c;Series B&#x201d;) to Auctus Fund, LLC (&#x201c;Auctus&#x201d;)
in exchange for an equal number of shares of the Company&#x2019;s outstanding Series A. Simultaneously, the stock certificate representing
the Series A shares was being returned to the Company for cancellation. On such date and upon such exchange, the Company&#x2019;s Board
of Directors cancelled the Series A.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
B Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
September 8, 2022, the Company issued &lt;span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYC3O1qRrCy6" title="Preferred stock, shares issued"&gt;1,543,158&lt;/span&gt; shares of Series B to Auctus in exchange for an equal number of shares of the Company&#x2019;s
outstanding Series A. The terms of the Series B are substantially identical to those of the Series A, except that, among other things,
the limitation on beneficial ownership of common stock of the Company upon a conversion of the Series B into Common Stock, and the limitation
on the number of votes attributable to the Series B, is &lt;span id="xdx_90D_eus-gaap--PreferredStockVotingRights_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKAmHWfyKJBh" title="Preferred stock voting rights"&gt;9.99&lt;/span&gt;% of the then outstanding Common Stock of the Company instead of &lt;span id="xdx_90C_eus-gaap--PreferredStockVotingRights_pid_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuT87XMZHkJ6" title="Preferred stock voting rights"&gt;4.99&lt;/span&gt;% as
provided for the Series A. The Company is required, at all times, to reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of Common Stock upon the full conversion of the Series B. The Series B is not subject to
redemption by the Company or any Series B holder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Dividends&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders
of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Voting
Rights&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders
of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes
for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares
of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law.
The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares
of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled
to vote more than &lt;span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7GqZ3KTuVV4" title="Preferred stock voting percentage"&gt;9.99&lt;/span&gt;% of the then outstanding shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Conversion&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Optional
Conversion - &lt;span id="xdx_902_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zL2VXQ8WU4De" title="Preferred stock conversion term"&gt;Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock;&lt;/span&gt; provided, however, that in no event shall a Series B holder be entitled to convert any shares of Series B
to the extent that such conversion would result in beneficial ownership by such Series B holder of more than &lt;span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_znCDeplQWuW5" title="Preferred stock voting percentage"&gt;9.99&lt;/span&gt;% of the outstanding
shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Automatic
Conversion - From time to time, in the event that an event occurs which has the effect of reducing a Series B holder&#x2019;s beneficial
ownership of shares of Common Stock to less than &lt;span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zphxO48CaFTi" title="Ownership percentage"&gt;9.5&lt;/span&gt;% of the then publicly disclosed outstanding shares of Common Stock, then, within
five business days, the Series B holder is required to provide notice to the Company to such effect, which notice shall state the number
of shares of Common Stock beneficially owned by the Series B holder and shall provide reasonable detail with regard thereto, including
the number of derivative securities compromising a portion of such beneficial share amount. Such notice shall have the effect of a notice
of conversion with respect to the conversion of such number of shares of Series B as would increase the Series B holder&#x2019;s beneficial
ownership of Common Stock to &lt;span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zf50yJldC0Qg" title="Preferred stock voting percentage"&gt;9.99&lt;/span&gt;% of the then publicly disclosed outstanding shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 25, 2022, Auctus converted &lt;span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_z5AXhJwz8bFi" title="Debt conversion, converted instrument, shares issued"&gt;25,000&lt;/span&gt; shares of Series B into &lt;span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zlLsZqLS1tRe" title="Debt conversion, converted instrument, shares issued"&gt;25,000&lt;/span&gt; shares of Common Stock. The number of shares of Series B remaining
outstanding after this conversion was &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20221024__20221025__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zLoD9gwPh8vg" title="Conversion of stock shares"&gt;1,518,158&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 4, 2023, Auctus converted &lt;span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zFD1ODMs5Buk" title="Number of shares converted"&gt;120,000&lt;/span&gt; shares of Series B into &lt;span id="xdx_90D_eus-gaap--ConversionOfStockSharesIssued1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zUB0LKFisLvh" title="Number of shares issued in conversion"&gt;120,000&lt;/span&gt; shares of Common Stock. As of December 31, 2024, the number of
shares of Series B remaining outstanding after giving effect to such conversion was &lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zveV0mvbGEcl" title="Preferred stock, shares outstanding"&gt;1,398,158&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2021
Stock Incentive Plan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 18, 2021, the Company&#x2019;s Board of Directors adopted the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the &#x201c;2021
Plan&#x201d;). The 2021 Plan was approved by the Company&#x2019;s stockholders on August 17, 2021. Pursuant to the 2021 Plan, a total of
&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210318__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember_zQB2Po9BLkKg" title="Number of shares of common stock authorized"&gt;1,175,000&lt;/span&gt; shares of common stock were initially authorized to be issued pursuant to the grant of stock options, restricted stock units,
restricted stock, stock appreciation rights and other incentive awards. On December 10, 2021, the Company&#x2019;s Board of Directors
approved an amendment to increase the number of shares of Common Stock authorized to be issued from &lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20211210__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zVPMbYgrWnQ2" title="Common stock shares authorized"&gt;1,175,000&lt;/span&gt; to &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20211210__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zncC5eiUPWt1" title="Common stock shares authorized"&gt;2,500,000&lt;/span&gt;. Such amendment
was approved by the Company&#x2019;s stockholders on November 3, 2022. On July 13, 2023, the Company&#x2019;s Board of Directors approved
an amendment to the 2021 Plan to increase the number of shares of Common Stock authorized to be issued from &lt;span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20230713__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zo1X1po4yASk" title="Common stock shares authorized"&gt;2,500,000&lt;/span&gt; to &lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20230713__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zVCTDa6pQi4" title="Common stock shares authorized"&gt;3,850,000&lt;/span&gt;. Such
amendment was approved by the Company&#x2019;s stockholders on September 13, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 23, 2024, the Company&#x2019;s Board of Directors approved an amendment to the Company&#x2019;s 2021 Plan to increase the number of
shares of common stock authorized to be issued under the 2021 Plan from &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240722__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_zVT1EXT7QkA9" title="Common stock authorized to issue"&gt;3,850,000&lt;/span&gt; to &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20240723__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneStockIncentivePlanMember_z0fNr8c0ddHb" title="Common stock authorized to issue"&gt;6,850,000&lt;/span&gt;. Such amendment was approved by the Company&#x2019;s
stockholders on September 19, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Compensatory
Common Stock Issuance&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company issued &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20230101__20231231_ztpy3rsk930e" title="Vested common stock, shares"&gt;1,442&lt;/span&gt; shares of immediately vested common stock with a value of $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20231231_zKuKeGD0i2fd" title="Aggregate common stock services rendered"&gt;7,500&lt;/span&gt; to a consultant
for services rendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sales
of Common Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2023, the Company entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (&#x201c;JonesTrading&#x201d;)
under which the Company had the ability to issue and sell shares of its Common Stock, from time to time, through JonesTrading, up to
an aggregate offering price of approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230401__20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--DemandSalesAgreementMember_z2vE6NAiKWPj"&gt;6,109,000&lt;/span&gt; in what is commonly referred to as an &#x201c;at-the-market&#x201d; (&#x201c;ATM&#x201d;)
program. During the year ended December 31, 2023, the Company sold &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zXplo7pD9iOk" title="Sold shares of common stock"&gt;132,827&lt;/span&gt; shares of its Common Stock at a weighted average price of
$&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zpEUTC3wNX2l" title="Weighted average price"&gt;4.68&lt;/span&gt; per share and raised $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zunGcHy30dsd"&gt;494,782&lt;/span&gt; in net proceeds under the JonesTrading ATM program. In November 2024, in connection with the ATM
program with Rodman &amp;amp; Renshaw LLC (&#x201c;Rodman&#x201d;) discussed below, the Company terminated the Capital on Demand Sales Agreement
with JonesTrading.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 13, 2023, the Company sold an aggregate of 	&lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230712__20230713_zGeXKDbsQOZf" title="Sale of aggregate shares"&gt;685,033&lt;/span&gt; shares of Common Stock to several institutional buyers and accredited investors
in a registered direct offering at an offering price of $&lt;span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230713_zcVAT4OtM4yi" title="Offering price"&gt;3.03&lt;/span&gt; per share. The offering closed on July 13, 2023 with net proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230712__20230713_zP7zaht68Fhf" title="Net proceeds offering price"&gt;1,853,990&lt;/span&gt;.
The Company intends to use the net proceeds from the offering in connection with its clinical trials with respect to its lead cell therapy
candidate, BRTX-100, pre-clinical research and development with respect to its metabolic ThermoStem Program and for general corporate
purposes and working capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the Company entered into an At The Market Offering Agreement with Rodman, under which the Company currently has the ability
to issue and sell shares of its Common Stock, from time to time, through Rodman, up to an aggregate offering price of approximately $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zH6H9vwuMDQa" title="Sold value of common stock"&gt;3,614,000&lt;/span&gt;
in an ATM program. See Note 10 - Subsequent Events &#x2013; Common Stock Sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrant
Exercise and Issuance&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 6, 2024, the Company entered into agreements with certain holders of its existing warrants exercisable for an aggregate of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJLLRuKcXiXh" title="Warrants exercisable"&gt;3,351,580&lt;/span&gt;
shares of its Common Stock (collectively, the &#x201c;Existing Warrants&#x201d;), to exercise their warrants at a reduced exercise price
of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWIprX6rqLng" title="Exercise price"&gt;2.33&lt;/span&gt; per share, in exchange for the issuance of new warrants (the &#x201c;New Warrants&#x201d;) as described below (the &#x201c;Warrant
Exercise and Issuance&#x201d;). The aggregate gross proceeds from the exercise of the Existing Warrants and the payment of the New Warrants,
as described below, was approximately $&lt;span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLxbdAHUuGN7" title="Proceeds from exercise of warrants"&gt;8.1&lt;/span&gt; million, before deducting cash issuance costs in the amount of $&lt;span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAFNeSFqflDl" title="Cash issuance costs"&gt;595,364&lt;/span&gt;. The reduction of
the exercise price of the Existing Warrants and the issuance of the New Warrants was structured as an at-market transaction under Nasdaq
rules. Of the &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzsKaWfvjyT2" title="Warrants exercisable"&gt;3,351,580&lt;/span&gt; shares of Common Stock issuable upon the exercise of the Existing Warrants, through December 31, 2024, the Company
had issued an aggregate of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z68Q6vqjUh11" title="Warrants exercisable"&gt;2,150,000&lt;/span&gt; shares of Common Stock. The remaining &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AuctusFundLLCMember_zvVWO1PSwBY4" title="Warrants exercisable"&gt;1,201,580&lt;/span&gt; shares of Common Stock, which are issuable to Auctus
Fund, LLC (&#x201c;Auctus&#x201d;), are being held in abeyance due to Auctus&#x2019; maximum beneficial ownership limitation (the &#x201c;Abeyance
Shares&#x201d;). Such Abeyance Shares have been fully paid for and are issuable upon notice from Auctus to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration for the immediate exercise of the Existing Warrants for cash and the payment of $&lt;span id="xdx_90A_eus-gaap--WarrantExercisePriceIncrease_c20240206__20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zBxG29Eh8Uv" title="Warrants for cash and the payment"&gt;0.125&lt;/span&gt; per share underlying the New Warrants,
the exercising holders received the New Warrants to purchase shares of Common Stock in a private placement pursuant to Section 4(a)(2)
of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The New Warrants will be exercisable for a period of five
years into an aggregate of &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNlyN1DFbIFj" title="Warrants exercisable"&gt;2,513,686&lt;/span&gt; shares of Common Stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240206__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zRsdklXiIqW9" title="Exercise price"&gt;2.43&lt;/span&gt; per share. The securities offered in the private
placement have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not
be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration
requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company agreed to file
a resale registration statement with the SEC to register the resale of the shares of Common Stock underlying the New Warrants issued
in the private placement. Such resale registration statement was filed and was declared effective by the SEC on April 18, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the transaction described above, the Company entered into a financial advisory services agreement, dated February 5,
2024, with Roth Capital Partners, LLC (&#x201c;Roth&#x201d;), pursuant to which the Company has paid Roth a cash fee of approximately $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240205__20240205__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zzl7n2lB0Vtl" title="Cash fee for services"&gt;528,000&lt;/span&gt;
for its services, in addition to reimbursement for certain expense. During the year ended December 31, 2024, the Company incurred an
aggregate of $&lt;span id="xdx_906_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--RothCapitalPartnersLLCMember_zT0D139u7t1a" title="Issuance costs"&gt;595,364&lt;/span&gt; of cash issuance costs related to the Warrant Exercise and Issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to the Warrant Exercise and Issuance, the Existing Warrants were classified as derivative liabilities. Additionally, the Company analyzed
the form of the New Warrants and determined that they should be classified as derivative liabilities in accordance with ASC 815-40, Derivatives
and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity. Under the New Warrants, the Company does not control the occurrence of events,
such as a tender offer or exchange, that may trigger cash settlement of the New Warrants and not result in a change of control of the
Company. As a result, such New Warrants do not meet the criteria for equity treatment. Additionally, certain New Warrants contain adjustments
to the settlement amount based on a variable that is not an input to the fair value of a &#x201c;fixed-for-fixed&#x201d; option as defined
under ASC 815-40 and, accordingly, such New Warrants are not considered indexed to the Company&#x2019;s own stock and are not eligible
for an exception from derivative accounting. See Note 9&#x2013; Fair Value Measurement for details regarding the valuation of the Existing
Warrants and New Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined the Warrant Exercise and Issuance to be an exchange by investors of Existing Warrants with an aggregate fair value
of $&lt;span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zwsYJKgpvCMb" title="Fair value of adjustment"&gt;1,115,334&lt;/span&gt; along with aggregate cash consideration of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zfFm1YZsZXZc" title="Proceeds from issuance of warrants"&gt;8,123,392&lt;/span&gt; (consisting of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zCSVqe8YkOf2" title="Proceeds from issuance of warrants"&gt;7,809,181&lt;/span&gt; paid to exercise the Existing Warrants
and $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_zbHEcEn03OHl" title="Proceeds from issuance of warrants"&gt;314,211&lt;/span&gt; paid for the New Warrants) for an aggregate of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zF7lId3Nr2Q7" title="Stock issued during period shares new issues"&gt;3,351,580&lt;/span&gt; shares of common stock with an aggregate fair value of $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zefA77ZQfLn9" title="Stock issued during period value new issues"&gt;4,742,244&lt;/span&gt;,
New Warrants with an aggregate fair value of $&lt;span id="xdx_909_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zk6OWlB7V2rb" title="Stock issued during period value warrants"&gt;2,189,420&lt;/span&gt; and aggregate cash issuance costs of $&lt;span id="xdx_909_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zWjJHU1kOYy9" title="Issuance costs"&gt;595,364&lt;/span&gt; and, accordingly, the Company recorded
a gain on exchange of warrants of $&lt;span id="xdx_90D_ecustom--GainOnExchangeOfWarrants_c20240101__20241231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementEquityComponentsAxis__custom--NewWarrantsMember_z8JamcJ6mWz2" title="Gain on exchange of warrants"&gt;1,711,698&lt;/span&gt; during the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrant
Activity Summary&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zSZin8yUZKs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the warrant activity during the year ended December 31, 2024 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zGJJPKtZyAE5" style="display: none"&gt;SCHEDULE OF WARRANT ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Outstanding, January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znAqvvT4Qbx9" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding Beginning"&gt;4,791,019&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z87TDq6moIv1" style="width: 14%; text-align: right" title="Weighted Average Exercise Price,  Outstanding beginning balance"&gt;10.57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdjrTKuhx9z6" style="text-align: right" title="Number of Warrants, Granted"&gt;2,513,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAkun9Fl9f26" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzgG1cCZ4vr1" style="text-align: right" title="Number of Warrants, Exercised"&gt;(3,351,580&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEztUrDWikmi" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;2.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOsoduSVUaRk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired"&gt;(1,491&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5TDR39mHj08" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;1,770&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfvfXo0Eesnl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding Ending"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsOAZv5WGZd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding ending balance"&gt;5.22&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYsjitrPloab" title="Weighted Average Remaining Life In Years, Outstanding"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq1vHs0qwAbb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Exercisable Ending"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zegEmgi5jNK" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;5.22&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwG8bbAgSYD7" title="Weighted Average Remaining Life In Years, Exercisable"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zXSUQ9QnVqc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average estimated fair value of the warrants granted during the year ended December 31, 2024 was $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDO6RUoak3l1" title="Weighted average estimated fair value of warrants granted"&gt;0.87 &lt;/span&gt;per warrant. See Note
9 &#x2013; Fair Value Measurement &#x2013; for details regarding the fair value estimates of the Warrants that are classified as derivative
liabilities. The Company did not issue any warrants during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zMwHHKdVRuS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock warrants at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zJhgTLHPR6Ie" style="display: none"&gt;SCHEDULE
OF STOCK WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBIP5ZD4QC56" style="width: 22%; text-align: right" title="Warrants outstanding, exercise price"&gt;2.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zl2Jku2lXkle" style="width: 22%; text-align: right" title="Warrants outstanding, number of warrants"&gt;2,513,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zU6Nhvq6d4e2" title="Warrants exercisable, weighted average remaining life in years"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zC60jbXs1afd" style="width: 21%; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;2,513,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z17wx76SisWa" style="text-align: right" title="Warrants outstanding, exercise price"&gt;2.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUseg3QpPL84" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;51,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zyTCTVYqM8Mh" title="Warrants exercisable, weighted average remaining life in years"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zwoRloxfJKD9" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;51,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuBvZFdF9pE2" style="text-align: right" title="Warrants outstanding, exercise price"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWunI15vUYcb" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;1,150,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOE3aHbPJii4" title="Warrants exercisable, weighted average remaining life in years"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCyYxBCsyVJe" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;1,150,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zroKiGu0kyKh" style="text-align: right" title="Warrants outstanding, exercise price"&gt;12.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvBqal267Qf4" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;235,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zsRzI4SStm05" title="Warrants exercisable, weighted average remaining life in years"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zjlWnxsI3Tue" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;235,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcUo7cIEyFd6" style="padding-bottom: 1pt; text-align: right" title="Warrants outstanding, exercise price"&gt;60.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4H9FGqoOWtj" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, number of warrants"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zlijR7PFbo2l" title="Warrants exercisable, weighted average remaining life in years"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zJksqF3ibGo6" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zMTGD0WHNxH" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, number of warrants"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zfJ2T3TGfPA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_za7feX7DXOtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfNfCP9eNvD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the option activity during the year ended December 31, 2024 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zrN9b2GV9bbk" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding, January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTvM4oSXln82" style="width: 12%; text-align: right" title="Number of Options, Outstanding beginning"&gt;1,466,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zoDROm8SpfK" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning"&gt;4.11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z1Abs0lPnAC2" style="text-align: right" title="Number of Options, Granted"&gt;1,934,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zf56QyHtDan2" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;1.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_zBqFaBP2hRrg" style="text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zQdf2naQfNwc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(138,141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zPDXmZhZIG01" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;1.76&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zcyRTNE1DYVe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding ending"&gt;3,263,467&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z6AUvmyFe4hl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending"&gt;2.63&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zTVIyvLVQU9e" title="Weighted Average Remaining Life in Years Outstanding Ending"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231_z0jhmSrRb99" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1013"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z6OaUmtzPBzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable Ending"&gt;2,499,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zLxmZKqE199h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable Ending"&gt;2.95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zv88ELOpOHR9" title="Weighted Average Remaining Life in Years Exercisable Ending"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231_z0nAmGqFN17c" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1021"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zoAlkje3gnuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average grant date fair value of the stock options granted during the years ended December 31, 2024 and 2023 was $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zHbmqifX8bie" title="Weighted average grant date fair value of stock options granted"&gt;1.45&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zRFePEuvUmbe" title="Weighted average grant date fair value of stock options granted"&gt;3.00&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zRtaMfXkznRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock options at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_ztcIUlTEysz5" style="display: none"&gt;SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zeGpMtvcx146" style="width: 22%; text-align: right" title="Options Outstanding, Exercise Price"&gt;1.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFR9VoHQVghd" style="width: 22%; text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;1,825,067&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBesCUmhfgB8" title="Options Exercisable Weighted Average Remaining Life In Years"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zOElztZCIEXk" style="width: 21%; text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;1,138,579&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zlN1nxbD5Qm7" style="text-align: right" title="Options Outstanding, Exercise Price"&gt;2.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z5su5TfUL9I1" style="text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;626,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmxifRgIyVvh" title="Options Exercisable Weighted Average Remaining Life In Years"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrvHndT1tcGc" style="text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;548,368&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGAMtsYhR5eh" style="padding-bottom: 1pt; text-align: right" title="Options Outstanding, Exercise Price"&gt;5.08&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zoR8Y98253Y8" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;812,185&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1xz1zj7zjja" title="Options Exercisable Weighted Average Remaining Life In Years"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIZKhcRWSsw5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;812,185&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231_zbocWCIXa5Vc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;3,263,467&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_ziXBWM6T6LZ" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;2,499,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zrKbEgsvNC01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zzhvGPbrfrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zZxbFDb2dxqf" style="display: none"&gt;SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zGOcrqNV9u6b" title="Risk free interest rate"&gt;4.14&lt;/span&gt; -&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zlS2vh9EUFd4" title="Risk free interest rate"&gt; 4.30&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoHTrUNaM9yc" title="Risk free interest rate"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z1KylLmbD0Dj" title="Expected term (years)"&gt;2.77&lt;/span&gt; - &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zar0bL5bcuah" title="Expected term (years)"&gt;5.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx5RjK2kIGab" title="Expected term (years)"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zWWPgchvXA8e" title="Expected volatility"&gt;101&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_znbbAp1dPtUe" title="Expected volatility"&gt;102&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEkATAdzvs76" title="Expected volatility"&gt;175.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zauNMGbqKima" style="text-align: right" title="Expected dividends"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0OQS4xjFub7" style="text-align: right" title="Expected dividends"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zjeFEbC9TUoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the 2021 Plan, the Company may grant restricted stock units (&#x201c;RSUs&#x201d;) to employees, consultants or non-employee directors
(&#x201c;Eligible Recipients&#x201d;). The number, terms and conditions of the RSUs that are granted to Eligible Recipients are determined
on an individual basis by the 2021 Plan administrator. On the distribution date, the Company shall issue to the Eligible Recipient one
unrestricted, fully transferable share of the Company&#x2019;s common stock (or the fair market value of one such share in cash) for each
vested and nonforfeitable RSU.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zbjCRCDfsw47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the unvested RSUs as of December 31, 2024 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_z7qX6TjqzmYg" style="display: none"&gt;SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%"&gt;Non-vested at January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z54caD9t4qNf" style="width: 22%; text-align: right" title="Number of shares outstanding beginning"&gt;97,827&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7rNzZRrwG7c" style="text-align: right" title="Number of shares granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE6DHLnyY2Zc" style="text-align: right" title="Number of shares forfeited"&gt;(97,827&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVJwCiRoFDV8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1089"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-vested at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z984AZuQj4Zh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1091"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zHAVwHeWUTFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-Based
Compensation Expense&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zKMX8JsmytWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock-based compensation expense:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zNmDZQdJkQIj" style="display: none"&gt;SCHEDULE OF STOCK OPTION EXPENSE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;Unrecognized at December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;Weighted Average Remaining
    Amortization Period&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8mg1PWdtnvh" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense"&gt;2,812,566&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0lPbAx67Oo4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense"&gt;7,782,967&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAfZqmoXHmha" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Unrecognized expense"&gt;774,470&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbb2sY1Dla3" title="Weighted average remaining amortization period (years)"&gt;0.95&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231_zbrAVj7QZ22e" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense"&gt;2,812,566&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231_zf5gaaCKHH4l" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense"&gt;7,782,967&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231_zZzUIJJBw2k1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense"&gt;774,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zOzUVTj3znM8" title="Weighted average remaining amortization period (years)"&gt;0.95&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zFWRUvqoB1Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000803"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000805"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000807"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000809"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000811"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockVotingRights
      contextRef="From2022-09-082022-09-08_us-gaap_SeriesBPreferredStockMember"
      id="Fact000813">9.99</us-gaap:PreferredStockVotingRights>
    <us-gaap:PreferredStockVotingRights
      contextRef="From2022-09-082022-09-08_us-gaap_SeriesAPreferredStockMember"
      id="Fact000815">4.99</us-gaap:PreferredStockVotingRights>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000817"
      unitRef="Pure">0.0999</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      id="Fact000819">Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock;</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000821"
      unitRef="Pure">0.0999</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember"
      decimals="INF"
      id="Fact000823"
      unitRef="Pure">0.095</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember"
      decimals="INF"
      id="Fact000825"
      unitRef="Pure">0.0999</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember_custom_AuctusFundLLCMember"
      decimals="INF"
      id="Fact000827"
      unitRef="Shares">25000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000829"
      unitRef="Shares">25000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-10-242022-10-25_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000831"
      unitRef="Shares">1518158</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-04-032023-04-04_custom_AuctusFundLLCMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000833"
      unitRef="Shares">120000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2023-04-032023-04-04_custom_AuctusFundLLCMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000835"
      unitRef="Shares">120000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000837"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-03-18_custom_TwoThousandTwentyOneStockIncentivePlanMember"
      decimals="INF"
      id="Fact000839"
      unitRef="Shares">1175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000841"
      unitRef="Shares">1175000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000843"
      unitRef="Shares">2500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000845"
      unitRef="Shares">2500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000847"
      unitRef="Shares">3850000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-07-22_custom_TwoThousandAndTwentyOneStockIncentivePlanMember"
      decimals="INF"
      id="Fact000849"
      unitRef="Shares">3850000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-07-23_custom_TwoThousandAndTwentyOneStockIncentivePlanMember"
      decimals="INF"
      id="Fact000851"
      unitRef="Shares">6850000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000853"
      unitRef="Shares">1442</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000855"
      unitRef="USD">7500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-04-012023-04-30_us-gaap_CommonStockMember_custom_DemandSalesAgreementMember"
      decimals="0"
      id="Fact000856"
      unitRef="USD">6109000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember"
      decimals="INF"
      id="Fact000858"
      unitRef="Shares">132827</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember"
      decimals="INF"
      id="Fact000860"
      unitRef="USDPShares">4.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember"
      decimals="0"
      id="Fact000861"
      unitRef="USD">494782</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-07-122023-07-13"
      decimals="INF"
      id="Fact000863"
      unitRef="Shares">685033</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-07-13"
      decimals="INF"
      id="Fact000865"
      unitRef="USDPShares">3.03</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-07-122023-07-13"
      decimals="0"
      id="Fact000867"
      unitRef="USD">1853990</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_ATMProgramMember"
      decimals="0"
      id="Fact000869"
      unitRef="USD">3614000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000871"
      unitRef="Shares">3351580</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000873"
      unitRef="USDPShares">2.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact000875"
      unitRef="USD">8100000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000877"
      unitRef="USD">595364</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000879"
      unitRef="Shares">3351580</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000881"
      unitRef="Shares">2150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember_custom_AuctusFundLLCMember"
      decimals="INF"
      id="Fact000883"
      unitRef="Shares">1201580</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2024-02-062024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000885"
      unitRef="USDPShares">0.125</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000887"
      unitRef="Shares">2513686</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-06_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000889"
      unitRef="USDPShares">2.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-02-052024-02-05_us-gaap_CommonStockMember_custom_RothCapitalPartnersLLCMember"
      decimals="0"
      id="Fact000891"
      unitRef="USD">528000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember_custom_RothCapitalPartnersLLCMember"
      decimals="0"
      id="Fact000893"
      unitRef="USD">595364</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember"
      decimals="0"
      id="Fact000895"
      unitRef="USD">1115334</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember"
      decimals="0"
      id="Fact000897"
      unitRef="USD">8123392</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-12-31_custom_ExistingWarrantMember"
      decimals="0"
      id="Fact000899"
      unitRef="USD">7809181</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember"
      decimals="0"
      id="Fact000901"
      unitRef="USD">314211</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember"
      decimals="INF"
      id="Fact000903"
      unitRef="Shares">3351580</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_InvestorMember_custom_ExistingWarrantMember"
      decimals="0"
      id="Fact000905"
      unitRef="USD">4742244</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact000907"
      unitRef="USD">2189420</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact000909"
      unitRef="USD">595364</us-gaap:PaymentsOfDebtIssuanceCosts>
    <BRTX:GainOnExchangeOfWarrants
      contextRef="From2024-01-012024-12-31_custom_NewWarrantsMember_us-gaap_InvestorMember"
      decimals="0"
      id="Fact000911"
      unitRef="USD">1711698</BRTX:GainOnExchangeOfWarrants>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000913">&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zSZin8yUZKs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the warrant activity during the year ended December 31, 2024 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zGJJPKtZyAE5" style="display: none"&gt;SCHEDULE OF WARRANT ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Outstanding, January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znAqvvT4Qbx9" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding Beginning"&gt;4,791,019&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z87TDq6moIv1" style="width: 14%; text-align: right" title="Weighted Average Exercise Price,  Outstanding beginning balance"&gt;10.57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdjrTKuhx9z6" style="text-align: right" title="Number of Warrants, Granted"&gt;2,513,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAkun9Fl9f26" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzgG1cCZ4vr1" style="text-align: right" title="Number of Warrants, Exercised"&gt;(3,351,580&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEztUrDWikmi" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;2.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOsoduSVUaRk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired"&gt;(1,491&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5TDR39mHj08" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;1,770&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfvfXo0Eesnl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding Ending"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsOAZv5WGZd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding ending balance"&gt;5.22&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYsjitrPloab" title="Weighted Average Remaining Life In Years, Outstanding"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq1vHs0qwAbb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Exercisable Ending"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zegEmgi5jNK" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;5.22&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwG8bbAgSYD7" title="Weighted Average Remaining Life In Years, Exercisable"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000915"
      unitRef="Shares">4791019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000917"
      unitRef="USDPShares">10.57</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765"
      decimals="0"
      id="Fact000919"
      unitRef="Shares">2513686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765"
      decimals="INF"
      id="Fact000921"
      unitRef="USDPShares">2.43</BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765"
      decimals="INF"
      id="Fact000923"
      unitRef="Shares">3351580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765"
      decimals="INF"
      id="Fact000925"
      unitRef="USDPShares">2.33</BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765"
      decimals="INF"
      id="Fact000927"
      unitRef="Shares">1491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765"
      decimals="INF"
      id="Fact000929"
      unitRef="USDPShares">1770</BRTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000931"
      unitRef="Shares">3951634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000933"
      unitRef="USDPShares">5.22</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765"
      id="Fact000935">P3Y3M18D</BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000937"
      unitRef="Shares">3951634</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000939"
      unitRef="USDPShares">5.22</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065765"
      id="Fact000941">P3Y3M18D</BRTX:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember29065375"
      decimals="INF"
      id="Fact000943"
      unitRef="USDPShares">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000945">&lt;p id="xdx_89B_ecustom--ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock_zMwHHKdVRuS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock warrants at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zJhgTLHPR6Ie" style="display: none"&gt;SCHEDULE
OF STOCK WARRANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBIP5ZD4QC56" style="width: 22%; text-align: right" title="Warrants outstanding, exercise price"&gt;2.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zl2Jku2lXkle" style="width: 22%; text-align: right" title="Warrants outstanding, number of warrants"&gt;2,513,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zU6Nhvq6d4e2" title="Warrants exercisable, weighted average remaining life in years"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zC60jbXs1afd" style="width: 21%; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;2,513,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z17wx76SisWa" style="text-align: right" title="Warrants outstanding, exercise price"&gt;2.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUseg3QpPL84" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;51,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zyTCTVYqM8Mh" title="Warrants exercisable, weighted average remaining life in years"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zwoRloxfJKD9" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;51,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zuBvZFdF9pE2" style="text-align: right" title="Warrants outstanding, exercise price"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWunI15vUYcb" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;1,150,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOE3aHbPJii4" title="Warrants exercisable, weighted average remaining life in years"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCyYxBCsyVJe" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;1,150,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zroKiGu0kyKh" style="text-align: right" title="Warrants outstanding, exercise price"&gt;12.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvBqal267Qf4" style="text-align: right" title="Warrants outstanding, number of warrants"&gt;235,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zsRzI4SStm05" title="Warrants exercisable, weighted average remaining life in years"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zjlWnxsI3Tue" style="text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;235,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zcUo7cIEyFd6" style="padding-bottom: 1pt; text-align: right" title="Warrants outstanding, exercise price"&gt;60.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4H9FGqoOWtj" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, number of warrants"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zlijR7PFbo2l" title="Warrants exercisable, weighted average remaining life in years"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zJksqF3ibGo6" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_zMTGD0WHNxH" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, number of warrants"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zfJ2T3TGfPA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, exercisable number of warrants"&gt;3,951,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BRTX:ScheduleOfShareBasedCompensationWarrantOutstandingAndExercisableByExercisePriceRangeTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact000947"
      unitRef="USDPShares">2.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact000949"
      unitRef="Shares">2513686</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember"
      id="Fact000951">P4Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact000953"
      unitRef="Shares">2513686</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact000955"
      unitRef="USDPShares">2.92</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact000957"
      unitRef="Shares">51370</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember"
      id="Fact000959">P2Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact000961"
      unitRef="Shares">51370</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact000963"
      unitRef="USDPShares">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact000965"
      unitRef="Shares">1150358</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember"
      id="Fact000967">P1Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact000969"
      unitRef="Shares">1150358</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact000971"
      unitRef="USDPShares">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact000973"
      unitRef="Shares">235970</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember"
      id="Fact000975">P1Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact000977"
      unitRef="Shares">235970</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact000979"
      unitRef="USDPShares">60.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact000981"
      unitRef="Shares">250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember"
      id="Fact000983">P0Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact000985"
      unitRef="Shares">250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000987"
      unitRef="Shares">3951634</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000989"
      unitRef="Shares">3951634</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000991">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfNfCP9eNvD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the option activity during the year ended December 31, 2024 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zrN9b2GV9bbk" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding, January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zTvM4oSXln82" style="width: 12%; text-align: right" title="Number of Options, Outstanding beginning"&gt;1,466,892&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zoDROm8SpfK" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning"&gt;4.11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z1Abs0lPnAC2" style="text-align: right" title="Number of Options, Granted"&gt;1,934,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zf56QyHtDan2" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;1.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_zBqFaBP2hRrg" style="text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231_zQdf2naQfNwc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(138,141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20241231_zPDXmZhZIG01" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;1.76&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zcyRTNE1DYVe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Outstanding ending"&gt;3,263,467&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z6AUvmyFe4hl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Ending"&gt;2.63&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zTVIyvLVQU9e" title="Weighted Average Remaining Life in Years Outstanding Ending"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20241231_z0jhmSrRb99" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1013"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z6OaUmtzPBzj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable Ending"&gt;2,499,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zLxmZKqE199h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable Ending"&gt;2.95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zv88ELOpOHR9" title="Weighted Average Remaining Life in Years Exercisable Ending"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20241231_z0nAmGqFN17c" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding Ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1021"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000993"
      unitRef="Shares">1466892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000995"
      unitRef="USDPShares">4.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000997"
      unitRef="Shares">1934716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000999"
      unitRef="USDPShares">1.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001003"
      unitRef="Shares">138141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001005"
      unitRef="USDPShares">1.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001007"
      unitRef="Shares">3263467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001009"
      unitRef="USDPShares">2.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-01-01to2024-12-31" id="Fact001011">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001015"
      unitRef="Shares">2499132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001017"
      unitRef="USDPShares">2.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-01to2024-12-31" id="Fact001019">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001023"
      unitRef="USDPShares">1.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001025"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001027">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zRtaMfXkznRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock options at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_ztcIUlTEysz5" style="display: none"&gt;SCHEDULE OF INFORMATION RELATED TO STOCK OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Remaining Life&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;In Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zeGpMtvcx146" style="width: 22%; text-align: right" title="Options Outstanding, Exercise Price"&gt;1.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFR9VoHQVghd" style="width: 22%; text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;1,825,067&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBesCUmhfgB8" title="Options Exercisable Weighted Average Remaining Life In Years"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zOElztZCIEXk" style="width: 21%; text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;1,138,579&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zlN1nxbD5Qm7" style="text-align: right" title="Options Outstanding, Exercise Price"&gt;2.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z5su5TfUL9I1" style="text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;626,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zmxifRgIyVvh" title="Options Exercisable Weighted Average Remaining Life In Years"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrvHndT1tcGc" style="text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;548,368&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGAMtsYhR5eh" style="padding-bottom: 1pt; text-align: right" title="Options Outstanding, Exercise Price"&gt;5.08&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zoR8Y98253Y8" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;812,185&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z1xz1zj7zjja" title="Options Exercisable Weighted Average Remaining Life In Years"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIZKhcRWSsw5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;812,185&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231_zbocWCIXa5Vc" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Outstanding Number of Options"&gt;3,263,467&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_ziXBWM6T6LZ" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Exercisable Number of Options"&gt;2,499,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact001029"
      unitRef="USDPShares">1.45</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact001031"
      unitRef="Shares">1825067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_RangeOneMember"
      id="Fact001033">P8Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact001035"
      unitRef="Shares">1138579</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001037"
      unitRef="USDPShares">2.91</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001039"
      unitRef="Shares">626215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_RangeTwoMember"
      id="Fact001041">P6Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001043"
      unitRef="Shares">548368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-12-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001045"
      unitRef="USDPShares">5.08</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001047"
      unitRef="Shares">812185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_RangeThreeMember"
      id="Fact001049">P5Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001051"
      unitRef="Shares">812185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001053"
      unitRef="Shares">3263467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001055"
      unitRef="Shares">2499132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001057">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zzhvGPbrfrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zZxbFDb2dxqf" style="display: none"&gt;SCHEDULE
OF STOCK OPTION GRANTED ASSUMPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zGOcrqNV9u6b" title="Risk free interest rate"&gt;4.14&lt;/span&gt; -&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zlS2vh9EUFd4" title="Risk free interest rate"&gt; 4.30&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoHTrUNaM9yc" title="Risk free interest rate"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z1KylLmbD0Dj" title="Expected term (years)"&gt;2.77&lt;/span&gt; - &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zar0bL5bcuah" title="Expected term (years)"&gt;5.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx5RjK2kIGab" title="Expected term (years)"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zWWPgchvXA8e" title="Expected volatility"&gt;101&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_znbbAp1dPtUe" title="Expected volatility"&gt;102&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEkATAdzvs76" title="Expected volatility"&gt;175.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zauNMGbqKima" style="text-align: right" title="Expected dividends"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0OQS4xjFub7" style="text-align: right" title="Expected dividends"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001059"
      unitRef="Pure">0.0414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001061"
      unitRef="Pure">0.0430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001063"
      unitRef="Pure">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember"
      id="Fact001065">P2Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember"
      id="Fact001067">P5Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember"
      id="Fact001069">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001071"
      unitRef="Pure">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001073"
      unitRef="Pure">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001075"
      unitRef="Pure">1.7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001077"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001079"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001081">&lt;p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zbjCRCDfsw47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the unvested RSUs as of December 31, 2024 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_z7qX6TjqzmYg" style="display: none"&gt;SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%"&gt;Non-vested at January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z54caD9t4qNf" style="width: 22%; text-align: right" title="Number of shares outstanding beginning"&gt;97,827&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7rNzZRrwG7c" style="text-align: right" title="Number of shares granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE6DHLnyY2Zc" style="text-align: right" title="Number of shares forfeited"&gt;(97,827&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVJwCiRoFDV8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1089"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-vested at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z984AZuQj4Zh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1091"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001083"
      unitRef="Shares">97827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember29066796"
      decimals="INF"
      id="Fact001087"
      unitRef="Shares">97827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001093">&lt;p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zKMX8JsmytWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to stock-based compensation expense:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zNmDZQdJkQIj" style="display: none"&gt;SCHEDULE OF STOCK OPTION EXPENSE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;Unrecognized at December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;Weighted Average Remaining
    Amortization Period&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8mg1PWdtnvh" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense"&gt;2,812,566&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0lPbAx67Oo4" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Stock-based compensation expense"&gt;7,782,967&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAfZqmoXHmha" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Unrecognized expense"&gt;774,470&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzbb2sY1Dla3" title="Weighted average remaining amortization period (years)"&gt;0.95&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20241231_zbrAVj7QZ22e" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense"&gt;2,812,566&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231_zf5gaaCKHH4l" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation expense"&gt;7,782,967&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20241231_zZzUIJJBw2k1" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized expense"&gt;774,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231_zOzUVTj3znM8" title="Weighted average remaining amortization period (years)"&gt;0.95&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact001095"
      unitRef="USD">2812566</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact001097"
      unitRef="USD">7782967</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact001099"
      unitRef="USD">774470</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_EmployeeStockOptionMember"
      id="Fact001101">P0Y11M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001103"
      unitRef="USD">2812566</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001105"
      unitRef="USD">7782967</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001107"
      unitRef="USD">774470</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2024-01-01to2024-12-31" id="Fact001109">P0Y11M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001111">&lt;p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zVozmWE0SJyc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
7 - &lt;span id="xdx_826_zR22wSIZcwLf"&gt;INCOME TAXES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company identified its federal and New York tax returns as its &#x201c;major&#x201d; tax jurisdictions. The Company is no longer subject
to income tax income examinations by these tax authorities for taxable years ended December 31, 2020, and prior. The Company reviewed
the prior New York state income tax filings and concluded that the prior year return will be amended to change the apportionment from
zero to &lt;span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_c20240101__20241231_zUkrmcjJv7h4" title="Prior year income taxes, percentage"&gt;100&lt;/span&gt;%. The Company believes its income tax filing positions and deductions will be sustained on audit, and it does not anticipate
any adjustments that would result in a material change to its financial position. Therefore, no liabilities for uncertain tax positions
have been recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024, the Company had approximately $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zePnVp7cedXh" title="Operating loss carry forwards"&gt;68,200,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zRa5IkvBOzVf" title="Operating loss carry forwards"&gt;51,800,000&lt;/span&gt;, respectively, of federal and state net operating losses
that may be available to offset future taxable income. As a result of the Tax Cuts and Jobs Act of 2017 (the &#x201c;Tax Act&#x201d;),
certain future carryforwards do not expire. At December 31, 2024, approximately $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_c20241231__srt--StatementScenarioAxis__custom--ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember_zDqomiSyERfd" title="Operating loss carry-forwards subject to expiration"&gt;7,800,000&lt;/span&gt; of federal net operating losses will expire
from 2030 to 2038 and approximately $&lt;span id="xdx_908_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_c20241231_zXc6BzRqcNMd" title="Operating loss carry-forwards not subject to expiration"&gt;60,400,000&lt;/span&gt; have no expiration but are subject to a utilization limit equal to 80% of current taxable
income. &lt;span id="xdx_90A_eus-gaap--LesseeOperatingLeaseDescription_c20240101__20241231_z84EZ3UauGO9" title="Net operating loss description"&gt;The state net operating losses have a 20 year carryforward period and will begin to expire beginning 2035.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231__srt--StatementScenarioAxis__custom--SectionThreeHundredAndEightyTwoMember_zywpKWkgXOba" title="Income tax examination, description"&gt;In
accordance with Section 382 of the Internal Revenue Code, the usage of the Company&#x2019;s net operating loss carryforwards are subject
to annual limitations due to several greater than 50% ownership changes.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not performed a formal analysis for the year ended December 31, 2024, but it believes its ability to use such net operating
losses and tax credit carryforwards in the future is subject to annual limitations due to change of control provisions under Sections
382 and 383 of the Internal Revenue Code, which will significantly impact its ability to realize these deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit
use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred
over the three-year period ended December 31, 2024. For the period ended December 31, 2024, the Company has recorded a full valuation
allowance against the gross deferred tax asset balance as management believes that it is more likely than not that the results of operations
will not generate sufficient taxable income to realize any of the deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the date of this filing, the Company has not filed its 2024 federal and state corporate income tax returns. The Company expects to
file these documents as soon as practicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOmgaPOBaQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2024 and 2023 are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zZUwWPmupGV3" style="display: none"&gt;SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zL9QFC7L3Yig" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zhbF1s19zvl7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zEjIVolmYEU6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred Tax Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGzcBK_zW8G8vTtyQJk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;18,004,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;14,311,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGzcBK_zFIFQbADeNHb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,695,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,788,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTAGzcBK_zdxqp5f1BD88" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,694,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,676,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGzcBK_zOXQBzh1v0Wa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsRightOfUseAsset_i01I_maDTAGzcBK_zBysCmdOR9Q" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1144"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcBK_zwScf9aTi8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;600&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGzcBK_maDTALNz6jW_zRxljnsv5rrj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Total Deferred Tax Assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;29,724,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;32,134,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zlws6xNcz8z3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred Tax Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxLiabilitiesDepreciation_i01NI_pp0p0_di_maDITLz8iB_zLKFtT22d6Pg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(153,200&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_pp0p0_di_maDITLz8iB_zMvdEk1EX2Mf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(41,700&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(47,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_i01NI_pp0p0_di_maDITLz8iB_z5JN7o7R2Nk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1162"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_di_maDITLz8iB_z626f9pOcRZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(95,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(86,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pp0p0_di_mtDITLz8iB_msDTALNz6jW_z5ov3kRZfdYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Total Deferred Tax Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(289,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(294,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNz6jW_zDuuMmzJjzh4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net Deferred Tax Asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,434,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,840,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8Hs2v6wALU5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29,434,100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(31,840,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_z8GkK0NwV2Ph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Deferred Tax Asset, Net of Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1177"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1178"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20240101__20241231_zmS2WbGfj5n6" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance"&gt;2,405,900&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20230101__20231231_zc9ckzJO7A9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance"&gt;(4,064,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zgRHuIkbL9D3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zltwcQOflIb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income tax provision (benefit) as of December 31, 2024 and 2023 consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zewWuR64PcD5" style="display: none"&gt;SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231_zRwhUVQspGih" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zxkSMrPCvzR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zlI2aJg7XIZg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Federal:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maDFSALzNuk_zO5ShPfW6jN4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1189"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1190"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zk51qR840bie" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 64%"&gt;Deferred&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,567,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(3,090,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zTDgkAmF6Uzj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;State &amp;amp; Local:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maDFSALzNuk_z2FcUaberu53" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1198"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zRDQK8KB7bX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Deferred&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,161,100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(974,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_maITEBz5Bf_mtDFSALzNuk_zPjhdL5jZTtd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,405,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,064,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ChangeInValuationAllowance_i01N_di_msITEBz5Bf_zUa8lJUQV31j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,405,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,064,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz5Bf_zTflNXI3Iww2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income tax provision (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1210"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zE62j2LkqvZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbnotrZxBuda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2024 and 2023 is as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zkPZz0PDfa4f" style="display: none"&gt;SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_zIN1SWuTCKCd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zYoEk77mdqyd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR_zoD8GqfTv0Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR_zBasGeNwUdq5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State tax, net of valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maETR_ztCkHqhYvo49" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_maETR_zPZ9svXk5zz5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax return to provision adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maETR_zu0T4TNCIfFa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in federal valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;39.7&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;-29.7&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_pid_dp_uPure_maETR_zY3qcJ2Patwj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Adjustment for stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;-62.1&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1231"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR_z9fAJvH2U32l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
    tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zWRkjNmqbrWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001113"
      unitRef="Pure">1</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact001115"
      unitRef="USD">68200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact001117"
      unitRef="USD">51800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="AsOf2024-12-31_custom_ExpireFromTwoThousandThirtyToTwoThousandThirtyEightMember"
      decimals="0"
      id="Fact001119"
      unitRef="USD">7800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001121"
      unitRef="USD">60400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2024-01-01to2024-12-31" id="Fact001123">The state net operating losses have a 20 year carryforward period and will begin to expire beginning 2035.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:IncomeTaxExaminationDescription
      contextRef="From2024-01-012024-12-31_custom_SectionThreeHundredAndEightyTwoMember"
      id="Fact001125">In
accordance with Section 382 of the Internal Revenue Code, the usage of the Company&#x2019;s net operating loss carryforwards are subject
to annual limitations due to several greater than 50% ownership changes.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001127">&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zOmgaPOBaQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s net deferred tax assets, liabilities and valuation allowance as of December 31, 2024 and 2023 are summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zZUwWPmupGV3" style="display: none"&gt;SCHEDULE
OF NET DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zL9QFC7L3Yig" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zhbF1s19zvl7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zEjIVolmYEU6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred Tax Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGzcBK_zW8G8vTtyQJk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;18,004,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;14,311,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTAGzcBK_zFIFQbADeNHb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,695,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,788,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTAGzcBK_zdxqp5f1BD88" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,694,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,676,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pp0p0_maDTAGzcBK_zOXQBzh1v0Wa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsRightOfUseAsset_i01I_maDTAGzcBK_zBysCmdOR9Q" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1144"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcBK_zwScf9aTi8J9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;600&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGzcBK_maDTALNz6jW_zRxljnsv5rrj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Total Deferred Tax Assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;29,724,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;32,134,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zlws6xNcz8z3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred Tax Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxLiabilitiesDepreciation_i01NI_pp0p0_di_maDITLz8iB_zLKFtT22d6Pg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(153,200&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_pp0p0_di_maDITLz8iB_zMvdEk1EX2Mf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(41,700&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(47,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_i01NI_pp0p0_di_maDITLz8iB_z5JN7o7R2Nk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1162"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_di_maDITLz8iB_z626f9pOcRZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(95,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(86,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pp0p0_di_mtDITLz8iB_msDTALNz6jW_z5ov3kRZfdYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Total Deferred Tax Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(289,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(294,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNz6jW_zDuuMmzJjzh4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net Deferred Tax Asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,434,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,840,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_z8Hs2v6wALU5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29,434,100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(31,840,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_z8GkK0NwV2Ph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Deferred Tax Asset, Net of Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1177"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1178"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20240101__20241231_zmS2WbGfj5n6" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance"&gt;2,405,900&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pp0p0_di_c20230101__20231231_zc9ckzJO7A9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Change in valuation allowance"&gt;(4,064,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001132"
      unitRef="USD">18004100</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001133"
      unitRef="USD">14311000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001135"
      unitRef="USD">8695100</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001136"
      unitRef="USD">15788000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001138"
      unitRef="USD">2694200</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001139"
      unitRef="USD">1676000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001141"
      unitRef="USD">330000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001142"
      unitRef="USD">330000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <BRTX:DeferredTaxAssetsRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001145"
      unitRef="USD">25000</BRTX:DeferredTaxAssetsRightOfUseAsset>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001147"
      unitRef="USD">600</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001148"
      unitRef="USD">4000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001150"
      unitRef="USD">29724000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001151"
      unitRef="USD">32134000</us-gaap:DeferredTaxAssetsGross>
    <BRTX:DeferredTaxLiabilitiesDepreciation
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001156"
      unitRef="USD">153200</BRTX:DeferredTaxLiabilitiesDepreciation>
    <BRTX:DeferredTaxLiabilitiesDepreciation
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001157"
      unitRef="USD">122000</BRTX:DeferredTaxLiabilitiesDepreciation>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001159"
      unitRef="USD">41700</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001160"
      unitRef="USD">47000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001163"
      unitRef="USD">39000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001165"
      unitRef="USD">95000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001166"
      unitRef="USD">86000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001168"
      unitRef="USD">289900</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001169"
      unitRef="USD">294000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001171"
      unitRef="USD">29434100</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001172"
      unitRef="USD">31840000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001174"
      unitRef="USD">29434100</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001175"
      unitRef="USD">31840000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001180"
      unitRef="USD">-2405900</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001182"
      unitRef="USD">4064000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001184">&lt;p id="xdx_899_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zltwcQOflIb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income tax provision (benefit) as of December 31, 2024 and 2023 consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zewWuR64PcD5" style="display: none"&gt;SCHEDULE
OF INCOME TAX PROVISION (BENEFIT)&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231_zRwhUVQspGih" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zxkSMrPCvzR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zlI2aJg7XIZg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Federal:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maDFSALzNuk_zO5ShPfW6jN4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1189"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1190"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zk51qR840bie" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 64%"&gt;Deferred&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,567,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(3,090,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zTDgkAmF6Uzj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;State &amp;amp; Local:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maDFSALzNuk_z2FcUaberu53" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1198"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzNuk_zRDQK8KB7bX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Deferred&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,161,100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(974,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_maITEBz5Bf_mtDFSALzNuk_zPjhdL5jZTtd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,405,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,064,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ChangeInValuationAllowance_i01N_di_msITEBz5Bf_zUa8lJUQV31j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,405,900&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,064,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBz5Bf_zTflNXI3Iww2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income tax provision (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1210"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001192"
      unitRef="USD">3567000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001193"
      unitRef="USD">-3090000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001201"
      unitRef="USD">-1161100</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001202"
      unitRef="USD">-974000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001204"
      unitRef="USD">2405900</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001205"
      unitRef="USD">-4064000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <BRTX:ChangeInValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001207"
      unitRef="USD">2405900</BRTX:ChangeInValuationAllowance>
    <BRTX:ChangeInValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001208"
      unitRef="USD">-4064000</BRTX:ChangeInValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001213">&lt;p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbnotrZxBuda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the statutory federal income tax benefit to actual tax benefit for the years ended December 31, 2024 and 2023 is as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zkPZz0PDfa4f" style="display: none"&gt;SCHEDULE
OF STATUTORY FEDERAL INCOME TAX RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_zIN1SWuTCKCd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zYoEk77mdqyd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR_zoD8GqfTv0Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR_zBasGeNwUdq5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State tax, net of valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maETR_ztCkHqhYvo49" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment_pid_dp_uPure_maETR_zPZ9svXk5zz5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax return to provision adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maETR_zu0T4TNCIfFa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in federal valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;39.7&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;-29.7&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation_pid_dp_uPure_maETR_zY3qcJ2Patwj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Adjustment for stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;-62.1&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1231"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR_z9fAJvH2U32l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
    tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001215"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001216"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001218"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001219"
      unitRef="Pure">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001221"
      unitRef="Pure">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001222"
      unitRef="Pure">0.072</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001224"
      unitRef="Pure">0.004</BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment>
    <BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001225"
      unitRef="Pure">-0.002</BRTX:EffectiveIncomeTaxRateReconciliationTaxReturnToProvisionAdjustment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001227"
      unitRef="Pure">0.397</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001228"
      unitRef="Pure">-0.297</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <BRTX:EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001230"
      unitRef="Pure">-0.621</BRTX:EffectiveIncomeTaxRateReconciliationInAdjustmentForStockbasedCompensation>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001233"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001234"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001236">&lt;p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zgcg9trQLw4b" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
8 &#x2013; &lt;span id="xdx_82A_zZqO5mhrGS0j"&gt;LEASES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a party to a lease for &lt;span id="xdx_902_eus-gaap--AreaOfLand_iI_usqft_c20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_z8CRWSAIBAK3" title="Area of land"&gt;6,800&lt;/span&gt; square feet of space located in Melville, New York (the &#x201c;Melville Lease&#x201d;) with respect
to its corporate and laboratory operations. The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option
of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $&lt;span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zmpZ4l7IQSC6" title="Rent expense"&gt;132,600&lt;/span&gt; and
$&lt;span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zOjbIvPdVbN8" title="Rent expense"&gt;149,260&lt;/span&gt;. In June 2019, &lt;span id="xdx_908_eus-gaap--LessorOperatingLeaseOptionToExtend_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_z4SYxbAeZm8h" title="Lease extension description"&gt;the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $&lt;span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zIdUhKaj4omk" title="Rent expense"&gt;153,748&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zAvMxkpiKrlg" title="Rent expense"&gt;173,060&lt;/span&gt;.&lt;/span&gt; The lease
expired on December 31, 2024 and the Company is currently leasing the premises on a month-to-month basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was &lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zrQlabrxcXu" title="Weighted average incremental borrowing rate"&gt;12&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zfhOXOmxfDS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents net lease cost and other supplemental lease information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_8BA_zYd7fINKNxyl" style="display: none"&gt;SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_zAim7KPlS8Vd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20231231_zJY5zkeqo6Qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease Costs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCzEnl_zdxX3SOKOhwd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left; padding-bottom: 1pt"&gt;Operating lease cost (cost resulting from lease payments)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;173,060&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;168,028&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zNJI74DdZmgh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net lease costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;173,060&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;168,028&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasePayments_zaVUvxrI8Xgk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating lease - operating cash flows (fixed payments)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;173,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;168,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--OperatingLeaseLiabilityReduction_zHFwZpsBCS1k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease - operating cash flows (liability reduction)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;162,317&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;139,328&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-current leases - right of use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20241231_zlGR7yPRwte5" style="text-align: right" title="Non-current leases - right of use assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1266"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_z3Cs3WdUJgzk" style="text-align: right" title="Non-current leases - right of use assets"&gt;151,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities - operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20241231_zait734oCTT3" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1270"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20231231_z5SMTMDgFzqf" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;162,317&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_zZt6kWMqb8m5" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseLiabilityCurrent"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_ztGyISFv9IYe" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseLiabilityCurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1273"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1274"&gt;Non-current liabilities - operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20241231_zqhxJYXaknKk" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1276"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20231231_zSdrEeHsTO37" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1278"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zHFgvhk3iHe6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
are no future minimum payments under non-cancelable leases following the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="AsOf2024-12-31_custom_MelvilleLeaseMember"
      decimals="INF"
      id="Fact001238"
      unitRef="sqft">6800</us-gaap:AreaOfLand>
    <us-gaap:PaymentsForRent
      contextRef="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MinimumMember"
      decimals="0"
      id="Fact001240"
      unitRef="USD">132600</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2024-01-012024-12-31_custom_MelvilleLeaseMember_srt_MaximumMember"
      decimals="0"
      id="Fact001242"
      unitRef="USD">149260</us-gaap:PaymentsForRent>
    <us-gaap:LessorOperatingLeaseOptionToExtend
      contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember"
      id="Fact001244">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $153,748 and $173,060.</us-gaap:LessorOperatingLeaseOptionToExtend>
    <us-gaap:PaymentsForRent
      contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember"
      decimals="0"
      id="Fact001246"
      unitRef="USD">153748</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember"
      decimals="0"
      id="Fact001248"
      unitRef="USD">173060</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001250"
      unitRef="Pure">0.12</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001252">&lt;p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zfhOXOmxfDS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents net lease cost and other supplemental lease information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_8BA_zYd7fINKNxyl" style="display: none"&gt;SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_zAim7KPlS8Vd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20231231_zJY5zkeqo6Qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease Costs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCzEnl_zdxX3SOKOhwd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: left; padding-bottom: 1pt"&gt;Operating lease cost (cost resulting from lease payments)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;173,060&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;168,028&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zNJI74DdZmgh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net lease costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;173,060&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;168,028&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasePayments_zaVUvxrI8Xgk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating lease - operating cash flows (fixed payments)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;173,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;168,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--OperatingLeaseLiabilityReduction_zHFwZpsBCS1k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease - operating cash flows (liability reduction)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;162,317&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;139,328&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-current leases - right of use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20241231_zlGR7yPRwte5" style="text-align: right" title="Non-current leases - right of use assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1266"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_z3Cs3WdUJgzk" style="text-align: right" title="Non-current leases - right of use assets"&gt;151,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities - operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20241231_zait734oCTT3" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1270"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20231231_z5SMTMDgFzqf" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;162,317&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_zZt6kWMqb8m5" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseLiabilityCurrent"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20241231_ztGyISFv9IYe" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseLiabilityCurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1273"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1274"&gt;Non-current liabilities - operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20241231_zqhxJYXaknKk" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1276"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20231231_zSdrEeHsTO37" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1278"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001254"
      unitRef="USD">173060</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001255"
      unitRef="USD">168028</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001257"
      unitRef="USD">173060</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001258"
      unitRef="USD">168028</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001260"
      unitRef="USD">173060</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001261"
      unitRef="USD">168028</us-gaap:OperatingLeasePayments>
    <BRTX:OperatingLeaseLiabilityReduction
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001263"
      unitRef="USD">162317</BRTX:OperatingLeaseLiabilityReduction>
    <BRTX:OperatingLeaseLiabilityReduction
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001264"
      unitRef="USD">139328</BRTX:OperatingLeaseLiabilityReduction>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001268"
      unitRef="USD">151447</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001272"
      unitRef="USD">162317</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001280">&lt;p id="xdx_80B_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zltmBzWqEc73" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
9 &#x2013; &lt;span id="xdx_822_zkzDTDJn5Zsa"&gt;FAIR VALUE MEASUREMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the Warrants as liabilities in accordance with the guidance contained in ASC 815-40, Derivatives and Hedging &#x2014;
Contracts in Entity&#x2019;s Own Equity. For certain Warrants, the Company does not control the occurrence of events, such as a tender
offer or exchange, that may trigger cash settlement of the Warrants and not result in a change of control of the Company. As a result,
such Warrants do not meet the criteria for equity treatment and the Warrants must be recorded as a derivative liability. Additionally,
certain other Warrants contain adjustments to the settlement amount based on a variable that is not an input to the fair value of a &#x201c;fixed-for-fixed&#x201d;
option as defined under ASC 815-40 and, accordingly, such Warrants are not considered indexed to the Company&#x2019;s own stock and are
not eligible for an exception from derivative accounting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 8, 2024, in connection with the Warrant Exercise and Issuance, the Company estimated the aggregate fair value of the Existing
Warrants (see Note 6- Stockholders&#x2019; Equity for details) to be $&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20240208__20240208__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_ziBScYzZ13xb" title="Fair value of adjustment"&gt;1,115,334&lt;/span&gt; using the Black-Scholes option pricing model (Level 3
inputs). The following table shows the detail of the valuation assumptions used:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-ZMNRFLS_zGWiyj8eGB08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zy4Lx3EQdX9j" style="display: none"&gt;SCHEDULE
OF FAIR VALUE VALUATION ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;February 8, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_z3vjeUokVdy1" title="Risk free interest rate, minimum"&gt;4.20&lt;/span&gt; - &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zsQwgnRfo9ne" title="Risk free interest rate, maximum"&gt;4.28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zqcGcNRJo4Xb" title="Expected term (years)"&gt;2.75&lt;/span&gt; - &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zMr7mo2LgO82" title="Expected term (years)"&gt;2.76&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zT7MOzpWsO63" title="Expected volatility"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zByUcEfDP6Vl" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zWTVHDTVNATa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 8, 2024, the Company estimated the aggregate issuance date fair value of the warrant liability related to the New Warrants (see
Note 4 - Stockholders&#x2019; Equity for details) as $&lt;span id="xdx_909_eus-gaap--DerivativeLiabilities_iI_c20240208_zaZ4oNIOeEXf" title="Derivative liabilities"&gt;2,189,420&lt;/span&gt; using the Black-Scholes option pricing model (Level 3 inputs). The following
table shows the detail of the valuation assumptions used:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_C0F_gL3FVAALMORAN-ZMNRFLS_zFEXuwxSsfh3"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C07_gL3FVAALMORAN-ZMNRFLS_z9jIJ08bBYOb"&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_300_zBSJWV5SGvha" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;February 8, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zD3oN4V56Q5b" title="Risk free interest rate"&gt;4.12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8SRKjJEIcZ3" title="Expected term (years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0OvHJjsBvog" title="Expected volatility"&gt;101&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmGV2nd8un74" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_C04_gL3FVAALMORAN-ZMNRFLS_zRoWvOb3mFlc"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 31, 2024 and 2023, the Company estimated the aggregate fair value of the warrants classified as derivative liabilities to purchase
an aggregate of &lt;span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zLLHtFGQXIk2" title="Fair value of adjustment"&gt;3,900,014&lt;/span&gt; and &lt;span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_z5RerJc1v6T2" title="Fair value of adjustment"&gt;4,737,908&lt;/span&gt; shares of common stock, respectively, to be $&lt;span id="xdx_907_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20241231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zC0D4h0jC5k6" title="Fair value of derivative liabilitiy"&gt;2,520,851&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--BlackScholesOptionMember_zSAOIQsG5Qm9" title="Fair value of derivative liabilitiy"&gt;1,543,953&lt;/span&gt;, respectively, using the
Black-Scholes option pricing model (Level 3 inputs) using the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C0F_gL3FVAALMORAN-ZMNRFLS_z6Jk0lFnAFsd"&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_307_zKLVcIhIzVE2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zv7eKFqVeiu7" title="Risk free interest rate, Minimum"&gt;4.12%&lt;/span&gt; - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBHAeic1Mmv" title="Risk free interest rate, Maximum"&gt;4.34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zvyycNHmduL7" title="Risk free interest rate, Minimum"&gt;4.04&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zA8LVCxdYpp9" title="Expected term (years)"&gt;1.86&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zMhtVWrrmuYj" title="Expected term (years)"&gt;4.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z570pw5hpvj8" title="Expected term (years)"&gt;2.86&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zCRrHeM4Aqyi" title="Expected volatility"&gt;97&lt;/span&gt;% - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zQRlaizdtMj2" title="Expected volatility"&gt;110&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmLHGhk0izj8" title="Expected volatility"&gt;87.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1AoHDe9wf58" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4BAeX5Y6SXd" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_C01_gL3FVAALMORAN-ZMNRFLS_zQgLe4Ufswxb"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zMC0qycoxwah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zKAQQdINnHu1" style="display: none"&gt;SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Balance, January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231_zzGF2dcRpRfi" style="width: 16%; text-align: right" title="Balance, January 1, 2023"&gt;5,541,733&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value of derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ChangeInFairValueOfDerivativeLiability_c20230101__20231231_zBJbF8pUGFtc" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;(3,997,780&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance, January 1, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20240101__20241231_zaG0GkTdbKLk" style="text-align: right" title="Balance, January 1, 2024"&gt;1,543,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231_zKGDn9WG9Bhf" title="Issuance of warrants"&gt;2,189,420&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_iN_di_c20240101__20241231_zGBz4IkSBmC9" title="Exercise of warrants"&gt;(1,115,334&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ChangeInFairValueOfDerivativeLiability_c20240101__20241231_zz1OQhkUhksg" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;(97,188&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20240101__20241231_zDiXGX0BNwLc" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, december 30, 2024"&gt;2,520,851&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z3mL6NzRpPKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets
and liabilities measured at fair value on a recurring basis are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6tGfwS6kgK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_z5r5D5GaLK3d" style="display: none"&gt;&lt;span&gt;SCHEDULE
OF FAIR VALUE RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements at reporting date using:&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets for identical liabilities (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant unobservable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%"&gt;Marketable securities as of December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4WzJJjC4wS1" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;10,184,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxeusrZDKjP6" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1363"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2rpFzeBYrv1" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1365"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_c20241231_zmKh1dwd0rfe" style="width: 12%; text-align: right" title="Marketable securities"&gt;10,184,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Marketable securities as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zC3pfJMA2Vod" style="text-align: right" title="Marketable securities, fair value"&gt;10,181,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFxBE74S8NCj" style="text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1371"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUaeaX3Cxbrj" style="text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1373"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zkPmSxUWuL6e" style="text-align: right" title="Marketable securities"&gt;10,181,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrant liabilities as of December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaDiGqMl6dni" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1377"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZUD9addK6D7" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1379"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlzurmG7ynm" style="text-align: right" title="Warrant liabilities, fair value"&gt;2,520,851&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_ziSFoXIxNsge" style="text-align: right" title="Warrant liabilities"&gt;2,520,851&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrant liabilities as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRXvDdOz7IR8" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1385"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWQ1XwDflpwh" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1387"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzV5BGldJR4" style="text-align: right" title="Warrant liabilities, fair value"&gt;1,543,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231_zyQUQAE5wWT5" style="text-align: right" title="Warrant liabilities"&gt;1,543,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zHZFVjyZEVW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-02-082024-02-08_custom_ExistingWarrantMember_custom_BlackScholesOptionMember"
      decimals="0"
      id="Fact001282"
      unitRef="USD">1115334</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001289">&lt;p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-ZMNRFLS_zGWiyj8eGB08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zy4Lx3EQdX9j" style="display: none"&gt;SCHEDULE
OF FAIR VALUE VALUATION ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;February 8, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_z3vjeUokVdy1" title="Risk free interest rate, minimum"&gt;4.20&lt;/span&gt; - &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zsQwgnRfo9ne" title="Risk free interest rate, maximum"&gt;4.28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zqcGcNRJo4Xb" title="Expected term (years)"&gt;2.75&lt;/span&gt; - &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zMr7mo2LgO82" title="Expected term (years)"&gt;2.76&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zT7MOzpWsO63" title="Expected volatility"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__custom--ExistingWarrantMember_zByUcEfDP6Vl" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_300_zBSJWV5SGvha" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;February 8, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zD3oN4V56Q5b" title="Risk free interest rate"&gt;4.12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8SRKjJEIcZ3" title="Expected term (years)"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0OvHJjsBvog" title="Expected volatility"&gt;101&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240208__20240208__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmGV2nd8un74" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&#160;&lt;table cellpadding="0" cellspacing="0" id="xdx_307_zKLVcIhIzVE2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE VALUATION ASSUMPTIONS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zv7eKFqVeiu7" title="Risk free interest rate, Minimum"&gt;4.12%&lt;/span&gt; - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBHAeic1Mmv" title="Risk free interest rate, Maximum"&gt;4.34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zvyycNHmduL7" title="Risk free interest rate, Minimum"&gt;4.04&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zA8LVCxdYpp9" title="Expected term (years)"&gt;1.86&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zMhtVWrrmuYj" title="Expected term (years)"&gt;4.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z570pw5hpvj8" title="Expected term (years)"&gt;2.86&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zCRrHeM4Aqyi" title="Expected volatility"&gt;97&lt;/span&gt;% - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zQRlaizdtMj2" title="Expected volatility"&gt;110&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmLHGhk0izj8" title="Expected volatility"&gt;87.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1AoHDe9wf58" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z4BAeX5Y6SXd" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&#160;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ExistingWarrantMember"
      decimals="INF"
      id="Fact001291"
      unitRef="Pure">0.0420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ExistingWarrantMember"
      decimals="INF"
      id="Fact001293"
      unitRef="Pure">0.0428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_custom_ExistingWarrantMember"
      id="Fact001295">P2Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_custom_ExistingWarrantMember"
      id="Fact001297">P2Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_custom_ExistingWarrantMember"
      decimals="INF"
      id="Fact001299"
      unitRef="Pure">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ExistingWarrantMember"
      decimals="INF"
      id="Fact001301"
      unitRef="Pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-02-08"
      decimals="0"
      id="Fact001303"
      unitRef="USD">2189420</us-gaap:DerivativeLiabilities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact001305"
      unitRef="Pure">0.0412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedTermMember_us-gaap_FairValueInputsLevel3Member"
      id="Fact001307">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact001309"
      unitRef="Pure">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-02-082024-02-08_us-gaap_MeasurementInputExpectedDividendRateMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact001311"
      unitRef="Pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_custom_BlackScholesOptionMember"
      decimals="0"
      id="Fact001313"
      unitRef="USD">3900014</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_custom_BlackScholesOptionMember"
      decimals="0"
      id="Fact001315"
      unitRef="USD">4737908</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="AsOf2024-12-31_custom_BlackScholesOptionMember"
      decimals="0"
      id="Fact001317"
      unitRef="USD">2520851</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="AsOf2023-12-31_custom_BlackScholesOptionMember"
      decimals="0"
      id="Fact001319"
      unitRef="USD">1543953</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001321"
      unitRef="Pure">0.0412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001323"
      unitRef="Pure">0.0434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001325"
      unitRef="Pure">0.0404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember"
      id="Fact001327">P1Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember"
      id="Fact001329">P4Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001331">P2Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001333"
      unitRef="Pure">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001335"
      unitRef="Pure">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001337"
      unitRef="Pure">0.8700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001339"
      unitRef="Pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001341"
      unitRef="Pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001343">&lt;p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zMC0qycoxwah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth a summary of the changes in the fair value of Level 3 liabilities that are measured at fair value on a recurring
basis during the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zKAQQdINnHu1" style="display: none"&gt;SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Balance, January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231_zzGF2dcRpRfi" style="width: 16%; text-align: right" title="Balance, January 1, 2023"&gt;5,541,733&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value of derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ChangeInFairValueOfDerivativeLiability_c20230101__20231231_zBJbF8pUGFtc" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;(3,997,780&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance, January 1, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20240101__20241231_zaG0GkTdbKLk" style="text-align: right" title="Balance, January 1, 2024"&gt;1,543,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20241231_zKGDn9WG9Bhf" title="Issuance of warrants"&gt;2,189,420&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_iN_di_c20240101__20241231_zGBz4IkSBmC9" title="Exercise of warrants"&gt;(1,115,334&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ChangeInFairValueOfDerivativeLiability_c20240101__20241231_zz1OQhkUhksg" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;(97,188&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20240101__20241231_zDiXGX0BNwLc" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, december 30, 2024"&gt;2,520,851&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001345"
      unitRef="USD">5541733</us-gaap:DerivativeLiabilitiesCurrent>
    <BRTX:ChangeInFairValueOfDerivativeLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001347"
      unitRef="USD">-3997780</BRTX:ChangeInFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001349"
      unitRef="USD">1543953</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001351"
      unitRef="USD">2189420</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001353"
      unitRef="USD">1115334</us-gaap:ProceedsFromWarrantExercises>
    <BRTX:ChangeInFairValueOfDerivativeLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001355"
      unitRef="USD">-97188</BRTX:ChangeInFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001357"
      unitRef="USD">2520851</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001359">&lt;p id="xdx_891_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6tGfwS6kgK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_z5r5D5GaLK3d" style="display: none"&gt;&lt;span&gt;SCHEDULE
OF FAIR VALUE RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements at reporting date using:&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets for identical liabilities (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant unobservable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%"&gt;Marketable securities as of December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z4WzJJjC4wS1" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;10,184,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxeusrZDKjP6" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1363"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2rpFzeBYrv1" style="width: 12%; text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1365"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_c20241231_zmKh1dwd0rfe" style="width: 12%; text-align: right" title="Marketable securities"&gt;10,184,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Marketable securities as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zC3pfJMA2Vod" style="text-align: right" title="Marketable securities, fair value"&gt;10,181,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFxBE74S8NCj" style="text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1371"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUaeaX3Cxbrj" style="text-align: right" title="Marketable securities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1373"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zkPmSxUWuL6e" style="text-align: right" title="Marketable securities"&gt;10,181,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrant liabilities as of December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaDiGqMl6dni" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1377"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZUD9addK6D7" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1379"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlzurmG7ynm" style="text-align: right" title="Warrant liabilities, fair value"&gt;2,520,851&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20241231_ziSFoXIxNsge" style="text-align: right" title="Warrant liabilities"&gt;2,520,851&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrant liabilities as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zRXvDdOz7IR8" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1385"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWQ1XwDflpwh" style="text-align: right" title="Warrant liabilities, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1387"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXzV5BGldJR4" style="text-align: right" title="Warrant liabilities, fair value"&gt;1,543,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231_zyQUQAE5wWT5" style="text-align: right" title="Warrant liabilities"&gt;1,543,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001361"
      unitRef="USD">10184701</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001367"
      unitRef="USD">10184701</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001369"
      unitRef="USD">10181618</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001375"
      unitRef="USD">10181618</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001381"
      unitRef="USD">2520851</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001383"
      unitRef="USD">2520851</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001389"
      unitRef="USD">1543953</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001391"
      unitRef="USD">1543953</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001393">&lt;p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zQwk95xqwdn2" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTE
10 - &lt;span id="xdx_827_z8pGpu2YREya"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Common
Stock Sales&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to the year ended December 31, 2024, the Company sold &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKg7Zk2AAER1" title="Sold shares of common stock"&gt;492,000&lt;/span&gt; shares of its common stock under the Rodman ATM program with a weighted-average
gross price of approximately $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFw7mnG04Qni" title="Share price"&gt;2.20&lt;/span&gt; per share and raised approximately $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zus5kgmQYQ7" title="Gross proceeds"&gt;1,084,000&lt;/span&gt; of gross proceeds. The total commissions and related
legal and accounting fees were approximately $&lt;span id="xdx_904_eus-gaap--PaymentsForLegalSettlements_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuIqcQVJa93f" title="Legal settlements paid"&gt;178,000&lt;/span&gt; and the Company received net proceeds of approximately $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--ATMProgramMember_zfCSxkZoeUo1" title="Net proceeds"&gt;906,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Option
Grants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to December 31, 2024, the Company granted options to purchase an aggregate &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9OxoGbvnv17" title="Grant options shares"&gt;2,152,908&lt;/span&gt; shares of the Company&#x2019;s common stock at an
exercise price of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8mtyATWWQi7" title="Exercise price"&gt;2.46&lt;/span&gt; per share to employees, the Company&#x2019;s board of directors and a member of the Company&#x2019;s scientific
advisory board. The options had an aggregate grant date fair value of $&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zP0528XPAvEi" title="Grant options shares"&gt;4,044,250&lt;/span&gt; and vest as follows: (i) options to purchase an aggregate
&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zA3ysS42tju2" title="Options to purchase shares"&gt;323,459&lt;/span&gt; shares of common stock vest monthly over one year, and (ii) options to purchase an aggregate of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoMpjuVT8AZf" title="Purchase of common shares"&gt;1,829,449&lt;/span&gt; shares of common stock
vest &lt;span id="xdx_90E_ecustom--CommonStockVestRemainderPercentage_iI_pid_dp_c20250327__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2ckuWuDozG7" title="Purchase of common shares"&gt;50&lt;/span&gt;% immediately with the remainder vesting quarterly over two years commencing one year from the date of grant. The Company will
recognize the grant date fair value of the options proportionate to the vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Common Stock Issuance&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Subsequent to the year ended December 31, 2024, the
Company issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250327__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--AuctusFundLLCMember_zn754CUGeFkd" title="Number of shares of common stock"&gt;63,525&lt;/span&gt; shares of common stock to Auctus Fund, LLC in partial satisfaction of shares held by abeyance.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001395"
      unitRef="Shares">492000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001397"
      unitRef="USDPShares">2.20</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001399"
      unitRef="USD">1084000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_custom_ATMProgramMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001401"
      unitRef="USD">178000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_ATMProgramMember"
      decimals="0"
      id="Fact001403"
      unitRef="USD">906000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001405"
      unitRef="Shares">2152908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001407"
      unitRef="USDPShares">2.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001409"
      unitRef="USD">4044250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001411"
      unitRef="Shares">323459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001413"
      unitRef="Shares">1829449</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <BRTX:CommonStockVestRemainderPercentage
      contextRef="AsOf2025-03-27_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001415"
      unitRef="Pure">0.50</BRTX:CommonStockVestRemainderPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-03-27_us-gaap_SubsequentEventMember_custom_AuctusFundLLCMember"
      decimals="INF"
      id="Fact001417"
      unitRef="Shares">63525</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#xdx2ixbrl0337"
          xlink:label="xdx2ixbrl0337"
          xlink:type="locator"/>
        <link:footnote id="Footnote000406" xlink:label="Footnote000406" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the
aggregate fair value of <xhtml:span
  id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpPD4xdmm3mj"
  title="Aggregate fair value of common stock">3,351,580</xhtml:span> shares of common stock, which includes <xhtml:span
  id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5nhgzoqroak"
  title="Warrants exercisable">2,150,000</xhtml:span> shares that have been issued and <xhtml:span
  id="xdx_908_ecustom--SharesHeldInAbeyance_iI_pid_c20241231_zTAiLGZkPyDe"
  title="Shares held in abeyance">1,201,580</xhtml:span> shares
held in abeyance. See Note 6 - Stockholders&#x2019; Equity - Warrant Exercise and Issuance and Note 9 - Fair Value Measurement for additional
details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0337"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000338"
          xlink:label="Fact000338"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000338"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000339"
          xlink:label="Fact000339"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000339"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0340"
          xlink:label="xdx2ixbrl0340"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0340"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000341"
          xlink:label="Fact000341"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000341"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000343"
          xlink:label="Fact000343"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000343"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000486"
          xlink:label="Fact000486"
          xlink:type="locator"/>
        <link:footnote id="Footnote000524" xlink:label="Footnote000524" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes gross
proceeds of $<xhtml:span
  id="xdx_90B_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_c20240101__20241231_zSqmWfzB3Fwf"
  title="Proceeds from debt issuance costs">8,123,391</xhtml:span>, less issuance costs of $<xhtml:span
  id="xdx_908_eus-gaap--PaymentsOfDebtIssuanceCosts_c20240101__20241231_zFrZALfkTkQg"
  title="Issuance costs">595,364</xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000486"
          xlink:to="Footnote000524"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0487"
          xlink:label="xdx2ixbrl0487"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0487"
          xlink:to="Footnote000524"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
